<SEC-DOCUMENT>0000950123-23-011145.txt : 20240506
<SEC-HEADER>0000950123-23-011145.hdr.sgml : 20240506
<ACCEPTANCE-DATETIME>20231208180134
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-23-011145
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20231211
<PUBLIC-REL-DATE>20240506
DATE AS OF CHANGE:		20231208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRAIL, LLC
		CENTRAL INDEX KEY:			0001699031
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				475117880
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06991
		FILM NUMBER:		231476562

	BUSINESS ADDRESS:	
		STREET 1:		1525 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-771-9796

	MAIL ADDRESS:	
		STREET 1:		1525 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Grail, Inc.
		DATE OF NAME CHANGE:	20170227
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>As confidentially submitted to the Securities and Exchange Commission on December&nbsp;8, 2023. This draft
registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>File No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington,&nbsp;D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 10
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL FORM </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>FOR
REGISTRATION OF SECURITIES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;12(b) or (g) of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to be converted as described herein into a corporation named </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name
of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>86-3673636</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation&nbsp;or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1525 O&#146;Brien Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94025</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(833) 694-2553 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Illumina, Inc.<BR>5200 Illumina Way<BR>San Diego, CA 92122<BR>(858) <FONT STYLE="white-space:nowrap">202-4500</FONT><BR>Attn: Charles E. Dadswell,<BR>General Counsel and Secretary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cravath,&nbsp;Swaine&nbsp;&amp;&nbsp;Moore&nbsp;LLP<BR>Worldwide Plaza<BR>825 Eighth Avenue<BR>New York, New
York 10019<BR>(212) <FONT STYLE="white-space:nowrap">474-1000</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attn: Andrew J. Pitts<BR>Ting S. Chen<BR>Daniel J.
Cerqueira</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1525&nbsp;O&#146;Brien&nbsp;Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo&nbsp;Park,&nbsp;California</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(833) 694-2553</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attn:&nbsp;Abram&nbsp;Barth,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Counsel</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins&nbsp;LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>355&nbsp;South&nbsp;Grand&nbsp;Avenue,&nbsp;Suite&nbsp;100 Los&nbsp;Angeles,&nbsp;California&nbsp;90071<BR>(213) <FONT
STYLE="white-space:nowrap">485-1234</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attn: W.&nbsp;Alex&nbsp;Voxman<BR>Andrew Clark<BR>Ross McAloon</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alexa Berlin</B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title of Each Class&nbsp;to be so
Registered</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Which Each Class&nbsp;is to be Registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common stock, par value $0.001 per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be registered pursuant to Section&nbsp;12(g) of the Act: None. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in <FONT
STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GRAIL, LLC, the registrant whose name appears on the cover of this Form 10 registration statement, is a Delaware limited liability company. Prior to the
completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> GRAIL, LLC will be converted into a Delaware corporation and will be renamed GRAIL, Inc. References to &#147;GRAIL&#148; in this Form 10 registration statement are to GRAIL, LLC
prior to the effective time of such conversion and to GRAIL, Inc. on and after the effective time of such conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GRAIL is a wholly owned subsidiary
of Illumina, Inc. (&#147;Illumina&#148;). On August&nbsp;18, 2021, Illumina acquired GRAIL. The acquisition is subject to ongoing legal proceedings and, on September&nbsp;6, 2022, the European Commission adopted an order prohibiting Illumina&#146;s
acquisition of GRAIL. On October&nbsp;12, 2023, the European Commission adopted a decision requiring Illumina to divest GRAIL and imposing transitional measures providing that GRAIL must be held and operated separately and independently from
Illumina. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information Required in Registration Statement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cross-Reference Sheet Between the Information Statement and Items of Form&nbsp;10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Registration Statement on Form 10 incorporates by reference information contained in our Information Statement filed as Exhibit&nbsp;99.1 to this
Form&nbsp;10. For your convenience, we have provided below a cross-reference sheet identifying where the items required by Form&nbsp;10 can be found in the Information Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Item <BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Caption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Location in Information Statement</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Summary,&#148; &#147;Risk Factors,&#148; &#147;Cautionary Statement Concerning Forward-Looking Statements,&#148; &#147;The <FONT STYLE="white-space:nowrap">Spin-Off,&#148;</FONT> &#147;Business,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Where You Can Find More Information&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">1A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Risk Factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Summary,&#148; &#147;Risk Factors,&#148; and &#147;Cautionary Statement Concerning Forward-Looking Statements&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Financial Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Summary,&#148; &#147;Risk Factors,&#148; &#147;Capitalization,&#148; &#147;Selected Historical Financial Data,&#148; &#147;Unaudited Pro Forma Condensed Consolidated Financial Information,&#148; &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Index to Consolidated Financial Statements&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Properties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Business&#151;Properties&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Security Ownership of Certain Beneficial Owners and Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Security Ownership of Certain Beneficial Owners and Management&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Directors and Executive Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Management&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Compensation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Management&#148; and &#147;Executive Compensation&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certain Relationships and Related Transactions, and Director Independence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Risk Factors,&#148; &#147;The <FONT STYLE="white-space:nowrap">Spin-Off,&#148;</FONT> &#147;Management,&#148; and &#147;Certain Relationships and Related Party Transactions&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Legal Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Business&#151;Legal Proceedings&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Market Price of and Dividends on the Registrant&#146;s Common Equity and Related Stockholder Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Summary,&#148; &#147;The <FONT STYLE="white-space:nowrap">Spin-Off,&#148;</FONT> &#147;Dividend Policy,&#148; &#147;Security Ownership of Certain Beneficial Owners and Management,&#148; and &#147;Description of Our Capital
Stock&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recent Sales of Unregistered Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Description of Our Capital Stock&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Description of Registrant&#146;s Securities to be Registered</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Description of Our Capital Stock&#148;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Item <BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Caption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Location in Information Statement</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">12.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Indemnification of Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Description of Our Capital Stock&#148; and &#147;Certain Relationships and Related Party Transactions&#151;Agreements with Illumina&#151;Separation and Distribution Agreement&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">13.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Financial Statements and Supplementary Data</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Summary,&#148; &#147;Selected Historical Financial Data,&#148; &#147;Unaudited Pro Forma Condensed Consolidated Financial Information,&#148; and &#147;Index to Consolidated Financial Statements&#148; and the consolidated
financial statements referenced therein</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">14.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not applicable</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">15.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Financial Statements and Exhibits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(a)&#8194;&#8201;&#8202;Consolidated Financial Statements</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">See &#147;Unaudited Pro Forma Consolidated Condensed Financial
Information&#148; and &#147;Index to Consolidated Financial Statements&#148; and the consolidated financial statements referenced therein</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(b)&#8194;&#8201;&#8202;Exhibits</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">See below</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are filed as exhibits hereto: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Separation and Distribution Agreement between GRAIL, Inc. and Illumina, Inc.*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Incorporation of GRAIL, Inc.*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Bylaws of GRAIL, Inc.*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Tax Matters Agreement between GRAIL, Inc. and Illumina, Inc.*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Stockholder and Registration Rights Agreement between GRAIL, Inc. and Illumina, Inc.*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Agreement and Plan of Merger, dated as of September&nbsp;20, 2020, among Illumina, Inc., SDG Ops, Inc., SDG Ops, LLC and GRAIL,
Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to the Agreement and Plan of Merger, dated as of September&nbsp;20, 2020, among Illumina, Inc., SDG Ops, Inc., SDG Ops, LLC and GRAIL, Inc., dated as of February&nbsp;4, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Supply and Commercialization Agreement, dated as of February&nbsp;28, 2017, by and between Illumina, Inc. and GRAIL, Inc., as amended on September&nbsp;27, 2017 and on August&nbsp;18, 2021*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 2024 Incentive Award Plan+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Long-term Incentive Award Agreement+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between GRAIL, LLC and each of its directors and executive officers+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of 2024 Employee Stock Purchase Plan+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Offer Letter, between GRAIL, LLC and Robert Ragusa, dated October 14, 2021+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement, between GRAIL, Inc. and Aaron Freidin, dated July 5, 2018+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Offer Letter, between GRAIL, Inc. and Josh Ofman, dated May 13, 2019+*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between The Chinese University of Hong Kong and Cirina Limited (No.&nbsp;TC1510005), dated as of April&nbsp;7, 2016, as amended May&nbsp;29, 2017*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between The Chinese University of Hong Kong and Cirina Limited (No.&nbsp;TC1510006), dated as of April&nbsp;7, 2016, as amended May&nbsp;29, 2017*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between The Chinese University of Hong Kong and Cirina Limited (No.&nbsp;TC1711655), dated as of May&nbsp;29, 2017*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between The Chinese University of Hong Kong and Cirina Limited (No.&nbsp;TC1711656), dated as of May&nbsp;29, 2017*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement by and between The Chinese University of Hong Kong and Cirina Limited (No.&nbsp;TC1711657), dated as of May&nbsp;29, 2017*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease by and between MENLO PREHC I, LLC, MENLO PREPI I, LLC, TPI Investors&nbsp;9, LLC and GRAIL, Inc., dated as of May&nbsp;5, 2016*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Lease among MENLO PREHC I, LLC, MENLO PREPI I, LLC, TPI Investors&nbsp;9, LLC and GRAIL, Inc., dated as of June&nbsp;8, 2017*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement by and between PP Office Owner&nbsp;1, L.P. and GRAIL, Inc., dated as of June&nbsp;4, 2020*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of subsidiaries of GRAIL, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preliminary Information Statement of GRAIL, LLC, subject to completion, dated December&nbsp;8, 2023</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;12 of the Securities Exchange Act of 1934, the registrant has duly caused this Registration Statement on Form 10
to be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GRAIL, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AGREEMENT AND PLAN OF MERGER </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ILLUMINA, INC., </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SDG OPS, INC., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SDG OPS, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GRAIL, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of September&nbsp;20, 2020 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.50pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE I DEFINED TERMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Defined Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation; Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE II THE MERGERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing; Effective Times</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the First Merger; Conversion of Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of the Second Merger; Conversion of Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Incorporation; Bylaws; Certificate of Formation; Operating Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Directors and Officers of the Surviving Corporation and the Surviving Entity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intended Tax Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III DELIVERY OF MERGER CONSIDERATION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Election Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange of Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stock Transfer Books</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Equity Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Capitalization Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority Relative to This Agreement; Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Conflict; Required Filings and Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permits; Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Registration Statement; Financial Statements; Undisclosed Material Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Certain Changes or Events</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Labor and Employment Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real Property; Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prohibited Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights Agreement; State Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion of Financial Advisor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE V REPRESENTATIONS AND WARRANTIES OF PARENT, FIRST MERGER SUB AND SECOND MERGER
SUB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Incorporation and Bylaws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority Relative to This Agreement; Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Conflict; Required Filings and Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings; Financial Statements; Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Operations of First Merger Sub and Second Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI CONDUCT OF BUSINESS PENDING THE MERGERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business by the Company Pending the Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business by Parent Pending the Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VII ADDITIONAL AGREEMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration Statement; Consent Solicitation Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Solicitation of Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Access to Information; Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Benefits Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Directors&#146; and Officers&#146; Indemnification and Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notification of Certain Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reasonable Best Efforts; Further Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Obligations of First Merger Sub and Second Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents of Accountants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Drag-Along; Stockholder Agreements and Communications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Anti-Takeover Statutes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stockholder Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financing Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignations of Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII CONDITIONS TO THE MERGERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to the Obligations of Each Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to the Obligations of Parent, First Merger Sub and Second Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to the Obligations of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX TERMINATION, AMENDMENT AND WAIVER</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees and Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Continuation Payments; Additional Termination Payment; Equity Issuance Fees and Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Procedure for Termination or Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE X CVR HOLDER REPRESENTATIVE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Designation and Replacement of CVR Holder Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority and Rights of the CVR Holder Representative; Limitations on Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE XI GENERAL PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Survival of Representations, Warranties, Covenants and Agreements; Exclusive Remedy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parties in Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;11.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>WAIVER OF JURY TRIAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Assertion of Attorney-Client Privilege</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Release by Equityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Schedules</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Selling Investors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Exhibits</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of Selling Investor Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of Drag-Along Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit C</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Treatment Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit E</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of Drag-Along Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">AGREEMENT AND PLAN OF MERGER, dated as of September&nbsp;20, 2020 (this
&#147;<U>Agreement</U>&#148;), among Illumina, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), SDG Ops, Inc., a Delaware corporation and direct, wholly owned subsidiary of Parent (&#147;<U>First Merger Sub</U>&#148;), SDG Ops, LLC, a
Delaware limited liability company and a direct, wholly owned subsidiary of Parent (&#147;<U>Second Merger Sub</U>&#148;), and GRAIL, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, upon the terms and subject to the conditions of this Agreement and in accordance with the DGCL (as defined below) and the DLLCA (as
defined below), Parent, First Merger Sub, Second Merger Sub and the Company have agreed to enter into a business combination transaction pursuant to which (a)&nbsp;First Merger Sub will merge with and into the Company (the &#147;<U>First
Merger</U>&#148;), with the Company being the surviving corporation (the Company, in its capacity as the surviving corporation of the First Merger, is sometimes referred to as the &#147;<U>Surviving Corporation</U>&#148;), and (b)&nbsp;immediately
following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Corporation will merge with and into Second Merger Sub (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the
&#147;<U>Mergers</U>&#148;), with Second Merger Sub being the surviving company of the Second Merger (Second Merger Sub, in its capacity as the surviving company of the Second Merger, is sometimes referred to as the &#147;<U>Surviving
Entity</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, for U.S. federal income tax purposes, each of the parties hereto intends that the First Merger and the Second
Merger, taken together, will constitute an integrated transaction that qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code, and that this Agreement be, and hereby is, adopted as a &#147;plan of
reorganization&#148; for the purposes of Section&nbsp;368 of the Code and Treasury Regulations Sections 1.368-2(g) and 1.368-3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company Board (as defined below), including both Preferred Directors (as defined in the Company&#146;s certificate of
incorporation), has (i)&nbsp;determined that this Agreement and the Transactions are fair to, and in the best interests of, the Company and its stockholders; (ii)&nbsp;approved and declared advisable this Agreement and the Transactions;
(iii)&nbsp;approved the Transactions as a &#147;Sale of the Company&#148; pursuant to Section&nbsp;2.2 of the Voting Agreement and specified that Section&nbsp;2 of the Voting Agreement shall apply to the Transactions (the &#147;<U>Drag-Along
Resolutions</U>&#148;); (iv)&nbsp;resolved to recommend that the stockholders of the Company adopt this Agreement; and (v)&nbsp;directed that this Agreement be submitted to the stockholders of the Company for adoption; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parent Board (as defined below) has (i)&nbsp;determined that this Agreement and the Transactions are fair to, and in the best
interests of, Parent and its stockholders and (ii)&nbsp;approved this Agreement and the Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of
First Merger Sub has (i)&nbsp;approved this Agreement and declared its advisability and (ii) resolved to recommend the adoption of this Agreement by the sole stockholder of First Merger Sub; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent, as the sole stockholder of First Merger Sub, shall adopt this Agreement immediately following the execution of this Agreement
upon the approval of the Board of Directors of First Merger Sub; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent, as the sole member of Second Merger Sub, has (i)&nbsp;determined that this
Agreement and the Transactions are advisable, fair to, and in the best interests of, Second Merger Sub and its sole member and (ii)&nbsp;approved this Agreement and the Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the execution and delivery of this Agreement, each holder of Company Stock listed on <U>Schedule A </U>(the
&#147;<U>Selling Investors</U>&#148;) will enter into a Selling Investor Support Agreement in the form attached hereto as <U>Exhibit A,</U> with such changes and modifications as may be mutually agreed by Parent and the Company (the &#147;<U>Selling
Investor Support Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the execution and delivery of this Agreement, the Selling Investors will
execute and deliver a consent in the form attached hereto as <U>Exhibit B </U>(the &#147;<U>Drag-Along Consent</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS,
as of or prior to the Closing, Parent and a trustee mutually agreeable to Parent and the Company (the &#147;<U>Trustee</U>&#148;) will enter into a Contingent Value Rights Agreement, substantially in the form attached hereto as <U>Exhibit C</U>,
with such changes as may be mutually agreed by Parent and the Company or as the Trustee shall reasonably request (the &#147;<U>CVR Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements contained in this
Agreement, and intending to be legally bound hereby, Parent, First Merger Sub, Second Merger Sub and the Company hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINED
TERMS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01 <U>Certain Defined Terms</U>. For purposes of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acceptable Confidentiality Agreement</U>&#148; means a customary confidentiality agreement between the Company and a Person who has
made a proposal satisfying the requirements of <U>Section&nbsp;7.02(c) </U>that contains terms no less favorable to the Company than those contained in the Confidentiality Agreement and does not include provisions requiring exclusive negotiations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Action</U>&#148; means any litigation, suit, claim, action, proceeding or investigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of a Person means a Person who, directly or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with, such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Aggregate Option Exercise Price</U>&#148; means the aggregate
exercise price of all Company Stock Options that are outstanding as of immediately prior to the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Aggregate Stock Consideration</U>&#148; means, subject to adjustment pursuant to
<U>Section&nbsp;3.02(f)</U>, the following: (a)&nbsp;if the Average Parent Stock Price is an amount greater than $399, then the Aggregate Stock Consideration shall be 11,278,195 shares of Parent Common Stock; (b)&nbsp;if the Average Parent Stock
Price is an amount greater than or equal to $295 but less than or equal to $399, then the Aggregate Stock Consideration shall be a number of shares of Parent Common Stock equal to the quotient obtained by dividing (x)&nbsp;$4,500,000,000 by
(y)&nbsp;the Average Parent Stock Price; or (c)&nbsp;if the Average Parent Stock Price is an amount less than $295, then the Aggregate Stock Consideration shall be 15,254,237 shares of Parent Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Alternative Consideration</U>&#148; means a number of shares of Parent Common Stock and/or an amount of cash (which may be set by
reference to the Company Fully Diluted Share Count), such number and/or amount to be determined by Parent in its sole discretion prior to the mailing of the Election Form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Average Parent Stock Price</U>&#148; means the volume weighted average trading price of Parent Common Stock on the NASDAQ (as
reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the parties) for the 20 consecutive Trading Days ending on (and including) the Trading Day that is 10 Trading Days prior to the Closing Date
(rounded to four decimal places). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>beneficial owner</U>&#148;, with respect to any shares of Company Stock, has the meaning
ascribed to such term under Rule 13d-3 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blue Sky Laws</U>&#148; means state securities or &#147;blue
sky&#148; Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day on which banks are not required or authorized to close in the City of New
York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>CARES Act</U>&#148; means the Coronavirus Aid, Relief and Economic Stability Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cash Consideration</U>&#148; means the quotient obtained by dividing (a)&nbsp;$3,500,000,000 plus the Aggregate Option Exercise Price
by (b) the Company Fully Diluted Share Count. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class A Restricted Stock Award</U>&#148; means an award of restricted shares of
Company Class&nbsp;A Common Stock granted pursuant to the Company Stock Plan or otherwise (including as a result of any early exercise of Company Stock Options), whether subject to service- and/or performance-based vesting criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the date on which the Closing occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the United States Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Collaboration Partner</U>&#148; means any third party that manufactures, co-develops or co-markets (or has a license to manufacture,
develop, market or sell) any product of the Company or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commitment Letter</U>&#148; has the meaning set forth in the definition of
Financing Sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Board</U>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Class&nbsp;A Common Stock</U>&#148; means Class&nbsp;A Common Stock, par value $0.001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Class B Common Stock</U>&#148; means Class B Common Stock, par value $0.001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Common Stock</U>&#148; means, collectively, the Company Class&nbsp;A Common Stock and the Company Class B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Disclosure Letter</U>&#148; means the disclosure letter dated as of the date of this Agreement and delivered by the Company
to Parent, First Merger Sub and Second Merger Sub simultaneously with the signing of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Equity
Awards</U>&#148; means, collectively, the Company Restricted Stock Awards, the Company RSU Awards and the Company Stock Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Fully Diluted Share Count</U>&#148; means, in each case as of immediately prior to the Effective Time, (a)&nbsp;the aggregate
number of shares of Company Class&nbsp;A Common Stock issued and outstanding, including all Class&nbsp;A Restricted Stock Awards; (b)&nbsp;the aggregate number of shares of Company Class&nbsp;A Common Stock issuable upon conversion of all issued and
outstanding shares of Company Class B Common Stock and Company Preferred Stock in accordance with the Company&#146;s certificate of incorporation; and (c)&nbsp;except as otherwise included in the foregoing clause (b), the aggregate number of shares
of Company Class&nbsp;A Common Stock issuable in respect of all outstanding options and other direct or indirect rights to acquire shares of Company Class&nbsp;A Common Stock or securities ultimately convertible into or exchangeable for shares of
Company Class&nbsp;A Common Stock, including all Company RSU Awards and Company Stock Options; <U>provided</U> that, for the avoidance of doubt, any equity securities which may be issuable by the Company pursuant to the terms of the contract
disclosed at item 35 of <U>Section&nbsp;4.09(a) of the Company Disclosure Letter </U>shall not be included in &#147;Company Fully Diluted Share Count&#148; unless such equity securities are issued and outstanding as of immediately prior to the
Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IP</U>&#148; means all Company Owned IP together with all Intellectual Property licensed by the Company
or any of its Subsidiaries and used, held for use or planned for use in the Company&#146;s business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company IP Agreements</U>&#148; means any and all contracts relating in whole or in
part to the Company IP or IT Assets, to which the Company or any of its Subsidiaries is a party or beneficiary or by which the Company or any of its Subsidiaries, or any Company IP or IT Assets may be bound, which contracts are used, held for use or
planned for use in the Company&#146;s business, including all (a)&nbsp;licenses or covenants, including covenants not to sue, to Intellectual Property granted by the Company or any of its Subsidiaries to any third party, (b)&nbsp;licenses or
covenants, including covenants not to sue, to Intellectual Property granted to the Company or any of its Subsidiaries by any third party, (c)&nbsp;other contracts between the Company or any of its Subsidiaries and any third party relating to the
transfer, development, maintenance or use of Intellectual Property or IT Assets and (d)&nbsp;consents, settlements, and Orders governing the use, validity or enforceability of Intellectual Property or IT Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Material Adverse Effect</U>&#148; means any event, occurrence, state of facts, development, circumstance, change or effect
that, individually or in the aggregate with all other events, occurrences, state of facts, developments, circumstances, changes and effects, (a)&nbsp;has had or would reasonably be expected to have a material adverse effect on the business,
financial condition or results of operations of the Company and its Subsidiaries taken as a whole; <U>provided</U>, <U>however</U>, that any event, occurrence, state of facts, development, circumstance, change or effect to the extent resulting from
the following shall not be taken into account in determining whether a Company Material Adverse Effect has occurred: (i)&nbsp;any failure, in and of itself, to meet internal projections or forecasts for any period ending on or after the date of this
Agreement (<U>provided</U> that the facts or causes underlying or contributing to such change or failure shall be considered in determining whether a Company Material Adverse Effect has occurred); (ii)&nbsp;changes in U.S. or non-U.S. general
economic or political conditions, or in the financial, credit or securities markets in general, including any shutdown of any Governmental Authority; (iii)&nbsp;changes in applicable Law or GAAP or in any interpretation thereof; (iv)&nbsp;changes in
the industries in which the Company and its Subsidiaries operate regardless of geographic region (including legal and regulatory changes); (v)&nbsp;acts of civil unrest or war (whether or not declared), armed hostilities or terrorism, or any
escalation or worsening of any acts of civil unrest or war (whether or not declared), armed hostilities or terrorism; (vi)&nbsp;earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, volcanic eruptions or other natural disasters or any
epidemic or pandemic (including the COVID-19 pandemic); (vii)&nbsp;FDA and other regulatory actions, enforcement, requirements or directives (including delay, clinical hold, rejection or additional clinical requirements with respect to any premarket
approval application or investigational device exemption application), the scope of marketing approval or intended use statement(s), issuance of warning letters, audit findings, and other exercise or enforcement discretion, pre- or post-approval
requirements, limitations or restrictions or rejection or revocation of any accreditations, authorizations, certifications, permits licenses related to the Company&#146;s businesses and products (<U>provided</U> that the exception in this clause
(vii)&nbsp;shall only apply to the definition of &#147;Company Material Adverse Effect&#148; for the purposes of <U>Section&nbsp;8.02(a)</U> as applied to the representations and warranties in <U>Section&nbsp;4.18 </U>if the representations and
warranties in <U>Section&nbsp;4.18 </U>were true as of the date hereof, disregarding the exceptions set forth in this clause (vii)&nbsp;and clause (viii)); (viii)&nbsp;data and other results from clinical trials (including PATHFINDER, STRIVE and
SUMMIT) (<U>provided</U> that the exception in this clause (viii)&nbsp;shall only apply to the definition of &#147;Company Material Adverse Effect&#148; for the purposes of <U>Section&nbsp;8.02(a)</U> as applied to the representations and warranties
in <U>Section&nbsp;4.18</U> if the representations and warranties in <U>Section&nbsp;4.18</U> were true as of the date hereof, disregarding the exceptions set forth in clause (vii)&nbsp;and this clause (viii)); (ix)&nbsp;any disruptions in
Parent&#146;s supply of sequencers and associated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reagents to the Company and its Subsidiaries; or (x)&nbsp;the public announcement of this Agreement or the pendency of the Transactions; <U>provided</U> that, in each of clauses (ii)&nbsp;through
(vi), the Company and its Subsidiaries, taken as a whole, are not affected disproportionately relative to other participants in the industries in which they operate; or (b)&nbsp;would reasonably be expected to prevent or materially delay the
consummation of the Transactions by the Company. Notwithstanding the foregoing, in the case of clauses (a)(vii) and (a)(viii), any event, occurrence, state of facts, development, circumstance, change or effect resulting from intentional fraud by the
Company or any of its Subsidiaries may be taken into account in determining whether the condition set forth in <U>Section&nbsp;8.02(a) </U>has been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Owned IP</U>&#148; means all Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries
(whether solely or jointly with one or more other Persons) as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Permits</U>&#148; means
franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, consents, concessions, registrations, clearances, exemptions, certificates, filings, notices, approvals and orders of any Governmental Authority necessary for
each of the Company and its Subsidiaries to own, lease and operate their respective properties and assets or to carry on their respective businesses as they are now being conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Preferred Stock</U>&#148; means, collectively, the Company Series A Preferred Stock, the Company Series B Preferred Stock,
the Company Series C Preferred Stock and the Company Series D Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Recommendation</U>&#148; means the
recommendation of the Company Board that the Company stockholders adopt this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Registration Statement</U>&#148;
means the registration statement on Form S-1 (File No.&nbsp;333-248672) filed by the Company with the SEC on September&nbsp;9, 2020, including all exhibits thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Restricted Stock Awards</U>&#148; means, collectively, the Class&nbsp;A Restricted Stock Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company RSU Award</U>&#148; means an award of restricted stock units with respect to shares of Company Class&nbsp;A Common Stock
granted pursuant to the Company Stock Plan or otherwise, whether subject to service- and/or performance-based vesting criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Series A Preferred Stock</U>&#148; means the Series A Preferred Stock, par value $0.001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Series B Preferred Stock</U>&#148; means the Series B Preferred Stock, par value $0.001 per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Series C Preferred Stock</U>&#148; means the Series C Preferred Stock, par value $0.001 per share, of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Series D Preferred Stock</U>&#148; means the Series D Preferred Stock, par
value $0.001 per share, of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stock</U>&#148; means, collectively, the Company Common Stock and Company
Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stock Option</U>&#148; means an award of unexercised options to purchase shares of Company Class&nbsp;A
Common Stock granted pursuant to the Company Stock Plan or otherwise, whether subject to service- and/or performance-based vesting criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stock Plan</U>&#148; means the Company&#146;s 2016 Equity Incentive Plan, as amended and/or amended and restated from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Stockholder Approvals</U>&#148; means the adoption of this Agreement and approval of the Transactions by the
affirmative vote of, or the execution and delivery to the Company of a written consent by, (a)&nbsp;holders of a majority of the total voting power of Company Common Stock and Company Preferred Stock, voting together as a single class, and
(b)&nbsp;holders of a majority of the Company Preferred Stock, voting together as a single class on an as-converted to Class&nbsp;A Common Stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Competing Proposal</U>&#148; means any inquiry, proposal or offer from any Person (other than Parent or its Affiliates) relating to,
or that would reasonably be expected to lead to, in one transaction or a series of related transactions (other than the Mergers), (a)&nbsp;any merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or
other similar transaction involving the Company or any of its Subsidiaries pursuant to which any Person or the shareholders of any Person would own 15% or more of any class of equity securities of the Company or of any resulting parent company of
the Company; (b)&nbsp;any sale, lease, license, exchange, transfer or other disposition of, or joint venture involving, assets or businesses that constitute or represent more than 15% of the total revenue, operating income, EBITDA or fair market
value of the assets of the Company and its Subsidiaries, taken as a whole (other than sales of inventory and dispositions of non-material assets or licenses, in each case, in the ordinary course of the Company&#146;s business); (c)&nbsp;any sale,
exchange, transfer or other disposition of more than 15% of any class of equity securities, or securities convertible into or exchangeable for equity securities, of the Company; (d)&nbsp;any tender offer or exchange offer that, if consummated, would
result in any Person becoming the beneficial owner of more than 15% of any class of equity securities of the Company; or (e)&nbsp;any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Competing Transaction Agreement</U>&#148; means a binding letter of intent, binding memorandum of understanding, binding agreement in
principle, merger agreement, acquisition agreement, option agreement or other contract or agreement which would reasonably be expected to lead to any Competing Proposal (other than an Acceptable Confidentiality Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidentiality Agreement</U>&#148; means the Confidentiality Agreement, dated as of August&nbsp;11, 2020, between the Company and
Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>contract</U>&#148; means any loan or credit agreement, bond, debenture, note,
mortgage, indenture, lease, supply agreement, license agreement, development agreement or other contract, agreement, obligation, commitment or instrument, in each case, that is legally binding and including all amendments, supplements, restatements
or other modifications thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>control</U>&#148; (including the terms &#147;<U>controlled by</U>&#148; and &#147;<U>under
common control with</U>&#148;) means the possession, directly or indirectly, or as trustee or executor, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as
trustee or executor, by contract or credit arrangement or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Designated Investments</U>&#148; means one or more of the
following: (a)&nbsp;direct obligations of, or obligations fully guaranteed as to principal and interest by, the United States or any agency or instrumentality thereof, <U>provided</U> such obligations are backed by the full faith and credit of the
United States; or (b)&nbsp;a deposit account of Exchange Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; means the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>DLLCA</U>&#148; means the Delaware Limited Liability Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Drag-Along</U>&#148; means the requirement of the Voting Agreement Parties to take certain actions upon the approval of a &#147;Sale
of the Company&#148;, as such term is defined in the Voting Agreement, to comply with the requirements of Section&nbsp;2 of the Voting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Encumbrances</U>&#148; means mortgages, pledges, liens, security interests, hypothecations, conditional and installment sale
agreements, encumbrances, charges or other claims to title of third parties or restrictions on ownership or use of any kind, including any easement, reversion interest, right of way or other encumbrance to title, limitations on voting rights or
disposition rights, or any option, right of first refusal or right of first offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Law</U>&#148; means any Law
relating to pollution or protection of the environment, natural resources, threatened or endangered species or, as it relates to exposure to hazardous or toxic materials, human health and safety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Permits</U>&#148; means all permits, licenses and other authorizations required under any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Ratio</U>&#148; means the number (rounded to four decimal places) obtained by dividing (x)&nbsp;the Aggregate Stock
Consideration by (y)&nbsp;the Company Fully Diluted Share Count. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Expenses</U>&#148; means all out-of-pocket fees and expenses (including all fees
and expenses of counsel, accountants, investment banking firms and other financial institutions, experts and consultants to a party hereto and its Affiliates) actually incurred or accrued by a party hereto or its Affiliates or on its or their behalf
or for which it or they are liable in connection with or related to the authorization, preparation, negotiation, execution and performance of the Transactions, the solicitation of stockholder approvals, the filing of any required notices under
applicable foreign, federal or state antitrust, competition, fair trade or similar Laws or other similar regulations and all other matters related to the closing of the Transactions, including the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FFCRA</U>&#148; means the Families First Coronavirus Response Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Financing Sources</U>&#148; means the Persons that have committed to provide or have otherwise entered into agreements to provide
(such agreements, a &#147;<U>Commitment Letter</U>&#148;) any part of the Financing and any joinder agreements, indentures, credit agreements or other definitive agreements entered into pursuant thereto or relating thereto, and any arrangers,
underwriters, initial purchasers, placement agents or administrative agents in connection with the Financing, together with their current and future Affiliates and their and such Affiliates&#146;, officers, directors, employees, attorneys, partners
(general or limited), controlling parties, advisors, members, managers, accountants, consultants, agents, representatives and funding sources of each of the foregoing, and their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; means common law intentional fraud under Delaware law in the making of the representation and warranties contained in
this Agreement or in the certificates contemplated by <U>Section&nbsp;8.02(c) </U>or <U>Section&nbsp;8.03(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148;
means United States generally accepted accounting principles in effect from time to time, applied consistently throughout the periods involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authority</U>&#148; means any federal, national, foreign, supranational, state, provincial, county, local or other
government, governmental, regulatory or administrative authority, agency, instrumentality or commission or any court, tribunal, or judicial or arbitral body of competent jurisdiction. For purposes of <U>Section&nbsp;4.19</U>, the term
&#147;<U>Governmental Authority</U>&#148; shall also include any entity controlled by a Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hazardous
Materials</U>&#148; means any petroleum or petroleum products, radioactive materials, medical wastes, asbestos, polychlorinated biphenyls, hazardous or toxic substances and any other chemical, material, substance or waste that is regulated or that
forms the basis of liability under any Environmental Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Authority</U>&#148; means the Governmental Authorities that
administer Health Laws, including the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Health Law</U>&#148; means any Law applicable to the Company&#146;s products and
activities, including any Law the purpose of which is to ensure the safety, efficacy and quality of medical, biotechnology, diagnostic and similar products by regulating the research, development, manufacturing and distribution of these products,
including applicable Law relating to good laboratory practices, good clinical practices, investigational use, product marketing authorization, manufacturing facilities compliance and approval, good manufacturing practices, labeling, advertising,
promotional practices, safety surveillance, record keeping and filing of required reports, including, without limitation, the FDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; means, with respect to any Person, all obligations or undertakings by such Person (i)&nbsp;for borrowed money
(including deposits or advances of any kind to such Person); (ii)&nbsp;evidenced by bonds, debentures, notes or similar instruments; (iii)&nbsp;under swaps, options, derivatives and other hedging contracts or arrangements that will be payable upon
termination thereof (assuming termination on the date of determination); (iv)&nbsp;letters of credit, bank guarantees, and other similar contracts or arrangements entered into by or on behalf of such Person to the extent they have been drawn upon;
(v)&nbsp;pursuant to a guarantee of any Indebtedness of a type referred to in clauses (i)&nbsp;through (iii)&nbsp;above, and (v)&nbsp;all Indebtedness of a type referred to in clauses (i)&nbsp;through (iii)&nbsp;above of any Person secured by (or
for which the holder of such Indebtedness has a right, contingent or otherwise, to be secured by) any Encumbrance (other than a Permitted Encumbrance) (other than those set forth in clauses (h)&nbsp;and (i)&nbsp;of the definition thereof) on any
property or assets owned by the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means all rights in or to
(a)&nbsp;patents, utility models, statutory invention registrations, registered designs and equivalent thereof, and all applications and pre-grant and post-grant forms of any of the foregoing, including, in each case, any provisionals,
substitutions, divisionals, continuations, continuations-in-part, re-examinations, renewals, extensions, reissues, and equivalents thereof in any jurisdiction; (b)&nbsp;registered or unregistered trademarks, trade dress, trade names, brand names,
corporate names, service marks, certification marks, designs, logos, slogans and other indications of origin, the goodwill associated with the foregoing and registrations in any jurisdiction of, and applications in any jurisdiction to register, the
foregoing, including any extension, modification or renewal of any such registration or application; (c)&nbsp;copyrightable works (including copyrights in Software and Internet websites), whether published or unpublished and copyright registrations,
applications for registration, and extensions thereof; (d)&nbsp;rights associated with domain names, uniform resource locators, Internet Protocol addresses, social media handles, and other names, identifiers, and locators associated with Internet
addresses, sites, and services; (e)&nbsp;trade secrets, confidential know-how (including all ideas, concepts, research and development) and other proprietary confidential information, whether or not patentable, including inventions, discoveries,
prototypes, results, data (including clinical data, pre-clinical data, and post-clinical data), testing procedures, testing results, methods, designs, specifications, know-how and other forms of technology, in each case, that derives economic value,
whether actual or potential, from not being generally known to other persons (collectively, &#147;<U>Trade Secrets</U>&#148;); (f)&nbsp;Software; and (g)&nbsp;any and all other similar or equivalent intellectual property rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intentional Breach</U>&#148; means, with respect to any agreement or covenant of a
party in this Agreement, an action or omission taken or omitted to be taken by such party in material breach of such agreement or covenant that the breaching party intentionally takes (or fails to take) with knowledge that such action or omission
would, or would reasonably be expected to, cause such material breach of such agreement or covenant; <U>provided</U>, that (a)&nbsp;as it applies to the Company, knowledge means the actual knowledge of any of the individuals listed in
<U>Section&nbsp;1.01(a) of the Company Disclosure Letter </U>or of the Company Board and (b)&nbsp;as it applies to Parent, First Merger Sub or Second Merger Sub, knowledge means the actual knowledge of Francis A. deSouza, Sam A. Samad and/or Charles
E. Dadswell or of the Parent Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investor Agreements</U>&#148; means, collectively, (a)&nbsp;the Voting Agreement;
(b)&nbsp;the Amended and Restated Investors&#146; Rights Agreement dated November&nbsp;27, 2019, by and among the Company and certain stockholders of the Company party thereto; and (c)&nbsp;the Amended Right of First Refusal and Co-Sale Agreement
dated November&nbsp;27, 2019, by and among the Company and certain stockholders of the Company party thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IRS</U>&#148;
means the United States Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>IT Assets</U>&#148; means all (a)&nbsp;computers (including, servers,
firewalls, workstations, desktops, laptops and handheld devices), Software, hardware (whether general or special purpose), networks, firmware, middleware, routers, hubs, switches, data communications lines, data storage devices, information security
and telecommunications capabilities, data centers, operating systems and all other information technology equipment and other similar or related items of information technology hardware and infrastructure, including any
&#147;Infrastructure-as-a-Service&#148; or &#147;Platform-as-a-Service&#148; or other cloud or hybrid cloud services, and (b)&nbsp;any business systems software or applications (including, CRM, ERP, HR, IT support, and accounting systems), whether
hosted in &#147;on prem&#148; and/or in the cloud, or provided as a service (e.g., &#147;Software-as-a-Service&#148;), in each case of both (a)&nbsp;and (b), owned, licensed or used by the Company or any of its Subsidiaries and the documentation,
reference and resource materials relating thereto and all contracts and contractual rights required in connection with the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge of Parent</U>&#148; means the actual knowledge of Francis A. deSouza, Sam A. Samad and/or Charles E. Dadswell. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>knowledge of the Company</U>&#148; means the actual knowledge of the individuals listed in <U>Section&nbsp;1.01(b) of the Company
Disclosure</U> Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any federal, state, local, national, supranational, foreign or administrative law
(including common law), statute, ordinance, regulation, requirement, rule, code or Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Consideration</U>&#148; means
the CVR Consideration or the Cash&nbsp;&amp; Stock Consideration, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>NASDAQ</U>&#148; means The NASDAQ Global Select
Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Non-U.S. Benefit Plan</U>&#148; means a Plan that is not subject exclusively to United States Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, judgment, injunction, award, decision,
determination, stipulation, ruling, subpoena, writ, decree or verdict entered by or with any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Outside
Date</U>&#148; means September&nbsp;20, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Board</U>&#148; means the Board of Directors of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Common Stock</U>&#148; means the common stock, par value $0.01 per share, of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent IP</U>&#148; means all Parent Owned IP together with all Intellectual Property licensed by Parent or any of its Subsidiaries
and used, held for use or planned for use in Parent&#146;s business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Material Adverse Effect</U>&#148; means any event,
occurrence, state of facts, development, circumstance, change or effect that, individually or in the aggregate with all other events, occurrences, state of facts, developments, circumstances, changes and effects, (a)&nbsp;has had or would reasonably
be expected to have a material adverse effect on the business, financial condition or results of operations of Parent and its Subsidiaries taken as a whole; <U>provided</U>, <U>however</U>, that any event, occurrence, state of facts, development,
circumstance, change or effect to the extent resulting from the following shall not be taken into account in determining whether a Parent Material Adverse Effect has occurred: (i)&nbsp;any change in the market price or trading volume of the Parent
Common Stock or any failure, in and of itself, to meet internal projections or forecasts or published revenue or earnings predictions for any period ending (or for which revenues or earnings are released) on or after the date of this Agreement
(<U>provided </U>that the facts or causes underlying or contributing to such change or failure shall be considered in determining whether a Parent Material Adverse Effect has occurred); (ii)&nbsp;changes in U.S. or non-U.S. general economic or
political conditions, or in the financial, credit or securities markets in general, including any shutdown of any Governmental Authority; (iii)&nbsp;changes in applicable Law or GAAP or in any interpretation thereof; (iv)&nbsp;changes in the
industries in which Parent and its Subsidiaries operate regardless of geographic region (including legal and regulatory changes); (v)&nbsp;acts of civil unrest or war (whether or not declared), armed hostilities or terrorism, or any escalation or
worsening of any acts of civil unrest or war (whether or not declared), armed hostilities or terrorism; (vi)&nbsp;earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, volcanic eruptions or other natural disasters or epidemic or pandemic
(including the COVID-19 pandemic); (vii)&nbsp;FDA and other regulatory actions, enforcement, requirements or directives (including delay, clinical hold, rejection or additional clinical requirements with respect to any premarket approval application
or investigational device exemption application), the scope of marketing approval or intended use statement(s), issuance of warning letters, audit findings, and other exercise or enforcement discretion, pre- or post-approval requirements,
limitations or restrictions or rejection or revocation of any accreditations, authorizations, certifications, permits licenses related to Parent&#146;s businesses and products; (viii)&nbsp;data and other results from clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials, or (ix)&nbsp;the public announcement of this Agreement or the pendency or consummation of the Transactions; <U>provided</U> that in each of clauses (ii)&nbsp;through (vi), Parent and its
Subsidiaries, taken as a whole are not affected disproportionately relative to other participants in the industries in which they operate; or (b)&nbsp;would reasonably be expected to prevent or materially delay the consummation of the Transactions
by Parent, First Merger Sub or Second Merger Sub. Notwithstanding the foregoing, in the case of clauses (a)(vii) and (a)(viii), any event, occurrence, state of facts, development, circumstance, change or effect resulting from intentional fraud by
Parent or any of its Subsidiaries may be taken into account in determining whether the condition set forth in <U>Section&nbsp;8.03(a) </U>has been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Owned IP</U>&#148; means all Intellectual Property owned or purported to be owned by Parent or any of its Subsidiaries
(whether solely or jointly with one or more other Persons) as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Permits</U>&#148; means
franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, consents, concessions, registrations, clearances, exemptions, certificates, filings, notices, approvals and orders of any Governmental Authority necessary for
Parent and each of its Subsidiaries to own, lease and operate their respective properties and assets or to carry on their respective businesses as they are now being conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>PBGC</U>&#148; means the Pension Benefit Guaranty Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance-Vesting Award</U>&#148; means any Company Equity Award that, as of immediately prior to the Closing, is outstanding and
subject to performance-based vesting criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Encumbrances</U>&#148; means (a)&nbsp;statutory Encumbrances for
current Taxes, special assessments or other governmental charges not yet due and payable or the amount or validity of which is being contested in good faith by appropriate proceedings and for which appropriate reserves have been established in
accordance with GAAP, (b)&nbsp;mechanics&#146;, materialmen&#146;s, carriers&#146;, workers&#146;, repairers&#146; and similar Encumbrances arising or incurred in the ordinary course of business, (c)&nbsp;zoning, entitlement, building and other land
use Laws imposed by governmental agencies having jurisdiction over any real property which are not violated in any material respect by the current use and operation of such real property, (d)&nbsp;deposits or pledges made in connection with, or to
secure payment of, worker&#146;s compensation, unemployment insurance, old age pension programs mandated under applicable Laws, (e)&nbsp;covenants, conditions, restrictions, easements, and other similar non-monetary matters of record affecting title
to, but not adversely affecting current occupancy or use of, the owned real property in any material respect, (f)&nbsp;restrictions on the transfer of securities arising under federal and state securities Laws, (g)&nbsp;any Encumbrances caused by
state statutes or specific provisions of Real Property Leases, in each case, with respect to tenant&#146;s personal property, fixtures and/or leasehold improvements at the subject leased real property, (h)&nbsp;other Encumbrances incurred in the
ordinary course of business and which would not reasonably be expected to have an adverse impact on the use of the property so encumbered, and (i)&nbsp;Encumbrances listed in <U>Section&nbsp;1.01(c) of the Company Disclosure Letter</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, corporation, partnership, limited
partnership, limited liability company, syndicate, person (as defined in Section&nbsp;13(d)(3) of the Exchange Act), trust, association, entity or Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Data</U>&#148; means (a)&nbsp;any information defined as &#147;personal data&#148;, &#147;personally identifiable
information&#148; or &#147;personal information&#148; under any Privacy and Data Security Requirement, (b)&nbsp;any information that, alone or in combination with other information, can reasonably be used to identify an individual natural person or
relating to an identified or identifiable natural person, directly or indirectly, including name, a unique identification number, government-issued identifier (including Social Security number and driver&#146;s license number) physical address,
gender and date of birth; and (c)&nbsp;individually identifiable health information constituting &#147;protected health information&#148; as defined under 45 C.F.R. &#167; 160.103. Personal Data that has been pseudonymized shall also be considered
Personal Data to the extent treated as such under any Privacy and Data Security Requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Plan</U>&#148; means each
(a)&nbsp;&#147;employee benefit plan&#148; as that term is defined in Section&nbsp;3(3) of ERISA (whether or not subject to ERISA) and (b)&nbsp;each other employment, individual independent contractor, individual consulting, pension, retirement,
profit sharing, deferred compensation, stock option, change in control, retention, equity or equity-based compensation, stock purchase, employee stock ownership, severance, vacation, bonus, incentive, disability, medical, vision, dental, health,
life insurance, fringe benefit or other compensation or benefit plan, program, agreement, arrangement, policy or contract, in each case, sponsored, maintained or contributed to, or required to be sponsored, maintained or contributed to, by the
Company or any of its Subsidiaries, or to which the Company or any of its Subsidiaries is a party or with respect to which the Company or any of its Subsidiaries have any obligation or liability, whether actual or contingent to provide compensation
and/or benefits to or for the benefit of any Service Provider (or spouse, dependent or beneficiary thereof), other than any multiemployer plan (within the meaning of Section&nbsp;3(37) of ERISA) and any statutory plan to which contributions are
mandated by a Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Privacy and Data Security Requirements</U>&#148; means (a)&nbsp;any Laws regulating the
Processing of Personal Data, (b)&nbsp;obligations under all contracts to which the Company or any of its Subsidiaries is a party that relate to Personal Data or protection of the IT Assets and (c)&nbsp;all of the Company&#146;s and its
Subsidiaries&#146; internal and publicly posted policies (including if posted on the Company&#146;s or its Subsidiaries&#146; products and services) regarding the Processing of Personal Data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Process</U>&#148; or &#147;<U>Processing</U>&#148; with regard to Personal Data means the collection, use, storage, maintenance,
retention, transmission, access, processing, recording, distribution, transfer, import, export, protection (including security measures), deletion, disposal or disclosure or other activity regarding data (whether electronically or in any other form
or medium). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Software</U>&#148; means (a)&nbsp;any Software used under a license identified as an open source license by
the Open Source Initiative (www.opensource.org), and (b)&nbsp;any other Software that is distributed as freeware, or under similar licensing or distribution models. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Real Property Leases</U>&#148; means all leases, subleases, licenses, occupancy
agreements and other agreements under which the Company or any of its Subsidiaries uses or occupies or has the right to use or occupy, now or in the future, any real property (including all guaranties thereof and all material modifications,
amendments, supplements, waivers and side letters thereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registered Company IP</U>&#148; means all Intellectual Property:
(a)&nbsp;included in the Company Owned IP or (b)&nbsp;that is exclusively licensed to the Company, in each case (a)&nbsp;and (b), that is the subject of an application, certificate, filing, registration, or other document issued, filed with or
recorded by any Governmental Authority or Internet domain name registrar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registered Parent IP</U>&#148; means all Intellectual
Property: (a)&nbsp;included in the Parent Owned IP or (b)&nbsp;that is exclusively licensed to Parent, in each case (a)&nbsp;and (b), that is the subject of an application, certificate, filing, registration, or other document issued, filed with or
recorded by any Governmental Authority or Internet domain name registrar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the S-4
Registration Statement and/or a registration statement on another appropriate form for the registration under the Securities Act of all of the shares of Parent Common Stock to be issued in connection with the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; means a Person&#146;s officers, directors, employees, accountants, consultants, legal counsel, investment
bankers, advisors, agents and other representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Service Provider</U>&#148; means each director, officer, employee or independent contractor of the Company and each of its
Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Service-Vesting Award</U>&#148; means each Company Equity Award that is outstanding immediately prior to the
Closing other than a Performance-Vesting Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Software</U>&#148; means all computer software, programs (whether in source
code, object code, human readable form or other form), applications, algorithms, user interfaces, application programming interfaces, diagnostics, software development tools and kits, templates, menus, analytics and tracking tools, compilers,
library functions, version control systems, operating system virtualization environments, databases and compilations, including data and collections of data, whether machine-readable or otherwise, technology supporting the foregoing, together with
all boot, compilation, configuration, debugging, performance analysis and runtime files, libraries, data, documentation, including user manuals and training materials, related to any of the foregoing, and any cloud storage containing any of the
foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>SOX</U>&#148; means the Sarbanes-Oxley Act of 2002, and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; or &#147;<U>Subsidiaries</U>&#148; of any specified Person
means an Affiliate controlled by such Person, directly or indirectly, through one or more intermediaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Superior
Proposal</U>&#148; means an unsolicited written bona fide offer made by a third party with respect to a Competing Proposal which the Company Board reasonably determines, in its good faith judgment, after having received the advice of a financial
advisor of nationally recognized reputation and outside legal counsel, to be (a)&nbsp;more favorable to the stockholders of the Company from a financial point of view (after taking into account all of the terms and conditions of such proposal,
including the sources and terms of any financing, financing market conditions and the existence of a financing contingency) than the Mergers (after taking into account any changes to the financial terms of this Agreement proposed by Parent in
response to such offer or otherwise) and (b)&nbsp;reasonably expected to be consummated on the terms so proposed. For the purposes of the definition of &#147;Superior Proposal&#148;, each reference to &#147;15%&#148; in the definition of
&#147;Competing Proposal&#148; shall be replaced with &#147;66 %&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means any return, declaration,
report, election, claim for refund or information return or other statement or form filed or required to be filed with any Governmental Authority relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Sharing Agreement</U>&#148; means all existing agreements or arrangements (whether or not written) binding the Company or
any of its Subsidiaries that provide for the allocation, apportionment, sharing or assignment of any Tax liability or benefit, or the transfer or assignment of income, revenues, receipts or gains for the purpose of determining any Person&#146;s Tax
liability, in each case, excluding (i)&nbsp;any such agreement or arrangement between or solely among the Company and its Subsidiaries or (ii)&nbsp;any agreement or arrangement entered into in the ordinary course of business and not primarily
related to Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means all taxes or similar duties, fees or charges or assessments thereof imposed by any
Governmental Authority, in each case in the nature of a tax, including any interest, penalties and additions imposed with respect to such amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on which shares of Parent Common Stock are traded on the NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means, collectively, (a)&nbsp;this Agreement, (b)&nbsp;the Selling Investor Support Agreement,
(c)&nbsp;the CVR Agreement, (d)&nbsp;the Drag-Along Consent and (e)&nbsp;the Support Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transactions</U>&#148; means
the Mergers and the other transactions contemplated by this Agreement and by the CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Indenture Act</U>&#148;
means the Trust Indenture Act of 1939. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Voting Agreement</U>&#148; means the Amended and Restated Voting Agreement dated as
of November&nbsp;27, 2019, by and among the Company and the Voting Agreement Parties, as amended by Amendment No.&nbsp;1 to the Voting Agreement dated as of April&nbsp;17, 2020, by and among the Company and the Voting Agreement Parties, and
Amendment No.&nbsp;2 to the Voting Agreement dated as of May&nbsp;11, 2020, by and among the Company and the Voting Agreement Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Voting Agreement Parties</U>&#148; means those certain holders of Company Stock that are party to the Voting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.02 <U>Other Defined Terms</U>. The following terms have the meanings set forth in the Sections set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Defined Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Location of Definition</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Additional Termination Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alternative Capital Raise</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(f)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alternative Cash-Out Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alternative Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.18(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alternative Rollover Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anti-Corruption Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.19(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Antitrust Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.07(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Appraisal Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.05(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Book-Entry Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash&nbsp;&amp; Stock Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash&nbsp;&amp; Stock Election Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash-Out Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash-Out Award Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash-Out Deductions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificates of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Change in the Company Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.02(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.11(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Capitalization Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.06(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Year VCP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.04(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Related Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.03(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Consent Solicitation Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Continuation End Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Continuation Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Continuing Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Cash-Out Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(i)</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Defined Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Location of Definition</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Election Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Holder Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 10.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CVR Rollover Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Designated Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drag-Along Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drag-Along Resolutions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Election Deadline</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.01(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Election Form</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Election Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.01(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Award Ratio</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Election Form</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Issuance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Issuance End Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(f)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equityholder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equityholder Released Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.11(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equityholder Releasing Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.11(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Existing Representation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Export Control Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.19(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.18(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDA Fraud Policy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.18(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FDCA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.18(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Filed Parent SEC Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Article V</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.06(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Financing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 5.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Financing Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 5.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Financing Offering Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.19(a)(v)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 10.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intended Tax Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.08(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Letter of Transmittal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mailing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.15(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Money Laundering Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.19(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No Election Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No Election Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Notice of Adverse Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.02(d)</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Defined Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Location of Definition</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(g)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Equity Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.04(e)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Related Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.03(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Restricted Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent SEC Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 5.09(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stock Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(d)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permitted Restrictions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.07(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Post-Closing Bonus Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Post-Closing Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pre-Closing Designated Persons</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pre-Closing Privileges</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Prior Company Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">R&amp;D Sponsor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.12(j)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reduction Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Regulatory Termination Fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.03(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Released Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.11(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Required Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.19(a)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Restraint</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 8.01(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rollover Awards</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rollover Performance-Based Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Rollover Service-Based Award</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S-4 Effectiveness Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.01(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S-4 Registration Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sanctioned Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.19(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sanctions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.19(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;1542</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 11.11(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Selling Investor Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Selling Investors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Social Security Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.18(f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 2.04(a)(i)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 7.13(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surviving Entity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 9.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.03 <U>Interpretation; Headings</U>. Whenever the words &#147;include&#148;,
&#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation&#148;. The definitions contained in this Agreement are applicable to the singular as well as the
plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. As used herein, the term &#147;made available&#148; means, with respect to any document, that such document was in the Company&#146;s
electronic data room relating to the transactions contemplated by this Agreement prior to 5:00 pm Pacific Daylight Time on the day prior to the date of this Agreement or otherwise provided via electronic means. When reference is made to an Article,
Section, Schedule or Exhibit, such reference is to an Article or Section of, or Schedule or Exhibit to, this Agreement unless otherwise indicated. The table of contents and descriptive headings contained in this Agreement are included for
convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. All terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered
pursuant hereto, unless otherwise defined therein. The words &#147;hereof&#148;, &#147;herein&#148; and &#147;hereunder&#148; and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular
provision of this Agreement. Any contract, instrument or Law defined or referred to herein or in any contract or instrument that is referred to herein means such contract, instrument or Law as from time to time amended, modified or supplemented,
including (in the case of contracts or instruments) by waiver or consent and (in the case of Laws) by succession of comparable successor Laws and references to all attachments thereto and instruments incorporated therein. References to a Person are
also to its permitted successors and assigns. Each of the parties has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement must be construed as if it is
drafted by all the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authorship of any of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE MERGERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01 <U>The Mergers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon the terms and subject to the satisfaction or written waiver (where permissible) of the conditions set forth in <U>Article VIII</U>,
and in accordance with the applicable provisions of the DGCL and this Agreement, at the Effective Time, First Merger Sub shall be merged with and into the Company. As a result of the First Merger, the separate corporate existence of First Merger Sub
shall cease and the Company shall continue as the Surviving Corporation and, following the First Merger, shall be a wholly owned Subsidiary of Parent (<U>provided</U>, that references to the Company for periods after the Effective Time until the
Second Effective Time shall include the Surviving Corporation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon the terms and subject to the satisfaction or written waiver
(where permissible) of the conditions set forth in <U>Article VIII</U>, and in accordance with the applicable provisions of the DGCL, the DLLCA and this Agreement, at the Second Effective Time, the Surviving Corporation shall be merged with and into
Second Merger Sub. As a result of the Second Merger, the separate corporate existence of the Surviving Corporation shall cease and Second Merger Sub shall continue as the Surviving Entity and, following the Second Merger, shall be a wholly owned
Subsidiary of Parent (<U>provided</U>, that references to the Company for periods after the Second Effective Time shall include the Surviving Entity). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02 <U>Closing; Effective Times</U>. The closing of the Transactions (the
&#147;<U>Closing</U>&#148;) shall take place on the third Business Day after the satisfaction or written waiver (where permissible) of the conditions set forth in <U>Article VIII</U> (other than those conditions that by their terms are to be
satisfied at the Closing, but subject to the satisfaction or written waiver (where permissible) of those conditions at the Closing), unless another date is agreed to in writing by Parent and the Company; <U>provided</U>, <U>however</U>, that if all
the conditions set forth in <U>Article VIII</U> shall no longer be satisfied or waived (where permissible) on such third Business Day, then the Closing shall take place on the first Business Day on which all such conditions shall again have been
satisfied or waived (where permissible) unless another time is agreed to in writing by Parent and the Company. The Closing shall be effected by the electronic exchange of signatures by electronic transmission, or by such other means or at such other
place as the parties shall agree. Subject to the terms and conditions of this Agreement, as soon as practicable on the Closing Date, the parties hereto shall cause the First Merger to be effected by filing a certificate of merger (the &#147;<U>First
Certificate of Merger</U>&#148;) with the Secretary of State of the State of Delaware, in such form and containing such information as is required by, and executed in accordance with, the relevant provisions of the DGCL. The First Merger shall
become effective at the date and time of such filing of the Certificate of Merger, or such later time as may be agreed by each of the parties hereto and specified in the First Certificate of Merger (such time being the &#147;<U>Effective
Time</U>&#148;). As soon as practicable following the Effective Time and in any case on the same day as the Effective Time, the parties hereto shall cause the Second Merger to be effected by filing a certificate of merger (the &#147;<U>Second
Certificate of Merger</U>&#148; and, together with the First Certificate of Merger, the &#147;<U>Certificates of Merger</U>&#148;) with the Secretary of State of the State of Delaware, in such form and containing such information as is required by,
and executed in accordance with, the relevant provisions of the DGCL and the DLLCA. The Second Merger shall become effective at the date and time of such filing of the Second Certificate of Merger, or such later time as may be agreed by each of the
parties hereto and specified in the Second Certificate of Merger (such time being the &#147;<U>Second Effective Time</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03 <U>Effect of the Mergers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At the Effective Time, the effect of the First Merger shall be as provided in this Agreement, the First Certificate of Merger and in the
applicable provisions of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties and obligations of
First Merger Sub and the Company shall become the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties and obligations of the Surviving Corporation, which shall include the assumption by the Surviving
Corporation of any and all agreements, covenants, duties and obligations of First Merger Sub and the Company set forth in this Agreement to be performed after the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Second Effective Time, the effect of the Second Merger shall be as provided in
this Agreement, the Second Certificate of Merger and in the applicable provisions of the DGCL and the DLLCA. Without limiting the generality of the foregoing, and subject thereto, at the Second Effective Time, all the property, rights, privileges,
agreements, powers and franchises, debts, liabilities, duties and obligations of Second Merger Sub and the Surviving Corporation shall become the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties and
obligations of the Surviving Entity, which shall include the assumption by the Surviving Entity of any and all agreements, covenants, duties and obligations of the Surviving Entity and the Surviving Corporation set forth in this Agreement to be
performed after the Second Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04 <U>Effect of the First Merger; Conversion of Securities</U>. (a)&nbsp;At the
Effective Time, by virtue of the First Merger and without any action on the part of Parent, First Merger Sub, the Company or any holders of Company Stock, each share of Company Class&nbsp;A Common Stock, Company Class B Common Stock, Company Series
A Preferred Stock, Company Series B Preferred Stock, Company Series C Preferred Stock and Company Series D Preferred Stock issued and outstanding immediately prior to the Effective Time (other than Appraisal Shares, Company Restricted Stock Awards
and any shares of Company Stock to be canceled pursuant to <U>Section&nbsp;2.04(c)</U>) shall be converted automatically into the right to receive, in accordance with Section&nbsp;251(b)(5) of the DGCL and the terms of this Agreement, the following
consideration at the election of the holder thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Each share of Company Stock with respect to which an election to
receive a combination of cash, Parent Common Stock and a CVR has been effectively made and not revoked pursuant to <U>Section&nbsp;3.01 </U>(each, a &#147;<U>CVR Election Share</U>&#148;) shall be converted into the right to receive (A)&nbsp;the
Cash Consideration, without interest, (B)&nbsp;the number of validly issued, fully paid and non-assessable shares of Parent Common Stock equal to the Exchange Ratio (the &#147;<U>Stock Consideration</U>&#148;), subject to
<U>Section&nbsp;3.02(e)</U>, and (C)&nbsp;one contingent value right issued by Parent subject to and in accordance with the CVR Agreement (a &#147;<U>CVR</U>&#148;) (collectively, the &#147;<U>CVR Consideration</U>&#148;). Each CVR issued as Merger
Consideration hereunder will be substantially in the form attached as Annex A to the CVR Agreement (the &#147;<U>CVR Certificate</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Each share of Company Stock with respect to which an election to receive the Alternative Consideration in lieu of
receiving a CVR has been effectively made and not revoked pursuant to <U>Section&nbsp;3.01</U> (each, a &#147;<U>Cash&nbsp;&amp; Stock Election Share</U>&#148;) shall be converted into the right to receive (A)&nbsp;the Cash Consideration, without
interest, (B)&nbsp;the Stock Consideration, subject to <U>Section&nbsp;3.02(e)</U>, and (C)&nbsp;the Alternative Consideration (collectively, the &#147;<U>Cash&nbsp;&amp; Stock Consideration</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Each share of Company Stock with respect to which no election has been effectively made in accordance with
Section&nbsp;3.01 (the &#147;<U>No Election Shares</U>&#148;) shall be converted into the right to receive the CVR Consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as set forth in <U>Section&nbsp;2.04(c)</U>, by virtue of the First Merger, each
share of Company Stock, when converted in accordance with <U>Section&nbsp;2.04(a)</U>, shall cease to be outstanding and shall automatically be cancelled and cease to exist, and each holder of a certificate or certificates that immediately prior to
the Effective Time represented outstanding shares of Company Stock (&#147;<U>Certificates</U>&#148;) and each holder of shares of Company Stock outstanding immediately prior to the Effective Time that are not represented by Certificates
(&#147;<U>Book-Entry Shares</U>&#148;) shall thereafter cease to have any rights with respect to such shares of Company Stock except (i)&nbsp;the right to receive, as applicable, the Merger Consideration, any dividends pursuant to
<U>Section&nbsp;3.02(c)</U> and cash in lieu of any fractional shares payable pursuant to <U>Section&nbsp;3.02(e)</U>, in each case to be issued or paid, without interest, in consideration therefor upon surrender of such Certificate or transfer of
the Book-Entry Shares in accordance with <U>Section&nbsp;3.02(b)</U> (or in the case of a lost, stolen or destroyed Certificate, <U>Section&nbsp;3.02(j)</U>) or (ii)&nbsp;as provided by Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At the Effective Time, by virtue of the First Merger and without any action on the part of Parent, First Merger Sub, the Company or any
holders of Company Stock, each share of Company Stock held in the treasury of the Company immediately prior to the Effective Time shall automatically be cancelled and retired and cease to exist without any conversion thereof, and no payment shall be
made with respect thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each issued and outstanding share of capital stock of First Merger Sub, par value $0.01 per share, shall,
by virtue of the First Merger and without any action on the part of Parent, First Merger Sub or the Company, be converted into and become one validly issued, fully paid and non-assessable share of Class&nbsp;A Common Stock, par value $0.001 per
share, of the Surviving Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05 <U>Effect of the Second Merger; Conversion of Securities</U>. Upon the terms and
subject to the conditions of this Agreement, at the Second Effective Time, by virtue of the Second Merger and without any action on the part of any party hereto or any holders of Company Stock or the holders of any shares of capital stock of Parent,
the Surviving Corporation or Second Merger Sub: (a)&nbsp;each share of Class&nbsp;A Common Stock of the Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be cancelled and shall cease to exist without
any conversion thereof or payment therefor; and (b)&nbsp;each limited liability company interest of Second Merger Sub issued and outstanding immediately prior to the Second Effective Time shall not be affected and shall remain outstanding as a
limited liability company interest of the Surviving Entity, which shall constitute one hundred percent (100%)&nbsp;of the outstanding equity of the Surviving Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06 <U>Certificate of Incorporation; Bylaws; Certificate of Formation; Operating Agreement</U>. (a)&nbsp;At the Effective Time,
the Company&#146;s certificate of incorporation in effect immediately prior to the Effective Time shall continue to be the certificate of incorporation of the Surviving Corporation until thereafter amended as provided therein or by applicable Law.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Effective Time, the bylaws of Company as in effect immediately prior to the Effective Time shall be amended and restated to
read in their entirety as the bylaws of First Merger Sub as in effect immediately prior to the Effective Time, except that all references therein to First Merger Sub shall be replaced by references to the Surviving Corporation, until thereafter
amended as provided therein or by applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At the Second Effective Time, the certificate of formation and operating agreement of
Second Merger Sub in effect immediately prior to the Second Effective Time shall continue to be the certificate of formation and operating agreement of the Surviving Entity until thereafter amended as provided therein or by applicable Law, except
that the name of the Surviving Entity shall be &#147;GRAIL, LLC&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07 <U>Directors and Officers of the Surviving
Corporation and the Surviving Entity</U>. The parties shall take all requisite action so that, from and after the Effective Time, the directors of First Merger Sub immediately prior to the Effective Time shall be the directors of the Surviving
Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the Surviving Corporation and until their respective successors are duly elected and qualified or until such director&#146;s earlier death,
resignation or removal, and the officers of First Merger Sub immediately prior to the Effective Time shall be the officers of the Surviving Corporation, each until their respective successors are duly elected and qualified or until such
officer&#146;s earlier death, resignation or removal. The parties shall take all requisite action so that, from and after the Second Effective Time, the officers of Second Merger Sub immediately prior to the Second Effective Time shall be the
officers of the Surviving Entity, as set forth in the operating agreement of the Surviving Entity, each until their respective successors are duly elected and qualified or until such officer&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08 <U>Intended Tax Treatment</U>. (a)&nbsp;For U.S. federal income tax purposes (and for purposes of any applicable state or
local Tax that follows the U.S. federal income tax treatment), the parties hereto intend that (i)&nbsp;the First Merger and the Second Merger, taken together, will constitute an integrated transaction that qualifies as a &#147;reorganization&#148;
within the meaning of Section&nbsp;368(a) of the Code, and (ii)&nbsp;this Agreement will constitute a &#147;plan of reorganization&#148; for the purposes of Section&nbsp;368 of the Code and Treasury Regulations Sections 1.368-2(g) and 1.368-3(a)
(clauses (i)&nbsp;and (ii)&nbsp;collectively, the &#147;<U>Intended Tax Treatment</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) So long as the conditions set forth on
<U>Exhibit D</U> are satisfied, then (i)&nbsp;each party hereto will agree to prepare and file all Tax Returns consistent with the position that the Mergers qualify for the Intended Tax Treatment, and (ii)&nbsp;no party shall take any position on
any Tax Return or during the course of any audit, litigation or other proceeding with respect to Taxes that is inconsistent with the Intended Tax Treatment, except, in each case, as otherwise required by a final determination by a taxing authority
or a change in applicable Law after the date of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties shall cooperate with each other and their respective
counsel and use their reasonable best efforts to cause the conditions set forth on <U>Exhibit D</U> to be satisfied. Neither the Company nor Parent shall, or shall cause or permit any of their respective Subsidiaries to, take or omit to take any
reasonable action not required or contemplated by this Agreement, as a result of which the Mergers would reasonably be expected to fail to qualify for the Intended Tax Treatment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent shall reasonably promptly notify the Company, and the Company shall reasonably promptly notify the Parent, in each case if such
party becomes aware of any non-public fact or circumstance that would reasonably be likely to prevent or impede the Mergers from qualifying for the Intended Tax Treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELIVERY OF MERGER CONSIDERATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01 <U>Election Procedures</U>. (a)&nbsp;Not less than 30 days prior to the anticipated Effective Time (the &#147;<U>Mailing
Date</U>&#148;), Parent will cause to be mailed to each record holder of shares of Company Stock (other than shares of Company Stock cancelled pursuant to <U>Section&nbsp;2.04(c)</U>) as of five Business Days prior to the Mailing Date: (x)&nbsp;an
election form in such form consistent with the terms of this Agreement as Parent shall specify (which such form shall be reasonably acceptable to the Company) (the &#147;<U>Election Form</U>&#148;) and (y)&nbsp;a letter of transmittal which shall
specify that delivery shall be effected, and risk of loss and title to the shares of Company Stock shall be deemed to pass, only upon proper delivery of the Certificates (or affidavits of loss in lieu thereof together with the required indemnity) or
transfer of the Book-Entry Shares to the Exchange Agent, and shall be in a customary form and have such other provisions as are reasonably acceptable to the Company and Parent, including instructions for use in effecting the surrender or transfer
(the &#147;<U>Letter of Transmittal</U>&#148;). The Election Form shall state the procedures for electing the Merger Consideration and shall specify the number of shares of Parent Common Stock and/or amount of cash that comprise the Alternative
Consideration as determined by Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Election Form will permit each holder of shares of Company Stock to specify (i)&nbsp;the
number of shares of Company Stock with respect to which such holder elects to receive the CVR Consideration, (ii)&nbsp;the number of shares of Company Stock with respect to which such holder elects to receive the Cash&nbsp;&amp; Stock Consideration
or (iii)&nbsp;that such holder makes no election with respect to such holder&#146;s shares of Company Stock. Any shares of Company Stock with respect to which the Exchange Agent does not receive a properly completed Election Form during the period
(the &#147;<U>Election Period</U>&#148;) from the Mailing Date to 5:00 p.m., Eastern time, on the date which Parent and the Company shall agree is as near as practicable to three Business Days preceding the Closing Date, or such other date as Parent
and the Company will, prior to the Closing, mutually agree (the &#147;<U>Election Deadline</U>&#148;), will be deemed to be No Election Shares. Parent and the Company shall publicly announce the date of the Election Deadline at least three Business
Days prior to the Election Deadline. If the Closing Date is delayed to a subsequent date, the Election Deadline shall be similarly delayed to a subsequent date, and Parent and the Company shall promptly announce any such delay and, when determined,
the rescheduled Election Deadline. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall direct the Exchange Agent to make Election Forms available as may be reasonably
requested from time to time by all Persons who become holders of record of Company Stock between the date that is five Business Days prior to the Mailing Date and the Election Deadline, and the Company shall provide to the Exchange Agent all
information reasonably necessary for the Exchange Agent to perform as specified in this Agreement and as specified in any agreement between Parent and/or the Company and the Exchange Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any election made pursuant to this <U>Section&nbsp;3.01</U> will have been properly made
only if the Exchange Agent will have actually received a properly completed Election Form during the Election Period. Any Election Form may be revoked or changed by the Person submitting it, by written notice received by the Exchange Agent during
the Election Period. In the event an Election Form is revoked during the Election Period, the shares of Company Stock represented by such Election Form will be deemed to be No Election Shares, except to the extent a subsequent election is properly
made during the Election Period. Any termination of this Agreement in accordance with <U>Article IX</U> shall result in the revocation of all Election Forms delivered to the Exchange Agent on or prior to the date of such termination. Subject to the
terms of this Agreement and of the Election Form, the Exchange Agent will have reasonable discretion to determine whether any election, revocation or change has been properly or timely made and to disregard immaterial defects in the Election Forms,
and any good faith decisions of the Exchange Agent regarding such matters will be binding and conclusive. None of Parent, First Merger Sub, Second Merger Sub, the Company or the Exchange Agent will be under any obligation to notify any Person of any
defect in an Election Form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02 <U>Exchange of Certificates</U>. (a)&nbsp;<U>Exchange Agent</U>. Prior to the Mailing Date,
Parent shall designate a commercial bank or trust company reasonably acceptable to the Company to act as agent (the &#147;<U>Exchange Agent</U>&#148;) for the exchange of shares of Company Stock in accordance with this <U>Article III</U>. Parent
shall deposit, or shall cause to be deposited, with the Exchange Agent, for the benefit of the holders of shares of Company Stock (other than shares of Company Stock cancelled pursuant to <U>Section&nbsp;2.04(c), </U>Company Restricted Stock Awards
and Appraisal Shares), for exchange in accordance with this <U>Article III</U> at or prior to the Effective Time, (i)&nbsp;book-entry shares representing the aggregate Stock Consideration and any shares of Parent Common Stock included in the
aggregate Alternative Consideration (excluding any portion of the aggregate Stock Consideration or Alternative Consideration deliverable in respect of shares of Company Stock owned directly or indirectly by Parent, First Merger Sub or Second Merger
Sub and any part of the aggregate Stock Consideration in respect of which cash is to be paid in lieu of fractional shares pursuant to <U>Section&nbsp;3.02(e)</U>), and (ii)&nbsp;cash in an amount sufficient to pay the aggregate Cash Consideration
and the cash portion, if any, of the Alternative Consideration (excluding any Cash Consideration and the cash portion, if any, of the Alternative Consideration payable in respect of shares of Company Stock owned directly or indirectly by Parent,
First Merger Sub or Second Merger Sub), plus any cash to be paid in lieu of any fractional shares pursuant to <U>Section&nbsp;3.02(e)</U>, and (iii)&nbsp;CVR Certificates representing the aggregate number of CVRs issuable pursuant to the CVR
Agreement, in the case of each of clauses (i), (ii)&nbsp;and (iii), payable or deliverable pursuant to <U>Section&nbsp;2.04(a)</U>. In addition, Parent shall deposit, or cause to be deposited, with the Exchange Agent, as necessary from time to time
at or after the Closing any dividends or distributions payable pursuant to <U>Section&nbsp;3.02(c)</U>. All shares of Parent Common Stock, cash (including any cash to be paid in lieu of any fractional shares pursuant to <U>Section&nbsp;3.02(e)</U>)
and CVR Certificates, together with any dividends or distributions with respect thereto pursuant to <U>Section&nbsp;3.02(c)</U>, deposited with or provided to the Exchange Agent by or on behalf of Parent, shall be referred to in this Agreement as
the &#147;<U>Exchange Fund</U>&#148;. For avoidance of doubt, Parent shall not be required to deposit any funds related to any CVR with the Trustee unless and until such deposit is required pursuant to the terms of the CVR Agreement. The cash
portion of the Exchange Fund shall be invested by the Exchange Agent as directed by Parent; <U>provided</U> that the Exchange Fund shall only be invested into Designated Investments. Any interest or other income from such investments shall be paid
to and become income of Parent. Except as contemplated by <U>Section&nbsp;3.02(g)</U>, the Exchange Fund shall not be used for any purpose other than as specified in this <U>Section&nbsp;3.02(a)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange Procedures</U>. (i)&nbsp;As promptly as practicable after the Effective
Time, the parties shall cause the Exchange Agent to mail to each holder of record of shares of Company Stock as of the Effective Time who is entitled to receive the Merger Consideration pursuant to <U>Section&nbsp;2.04(a)</U>, as set forth on the
Closing Capitalization Schedule if such holder of shares of Company Stock has not already returned a valid, duly completed Letter of Transmittal: (A)&nbsp;a Letter of Transmittal and (B)&nbsp;instructions for use in effecting the surrender of the
Certificates or transfer of the Book-Entry Shares pursuant to such letter of transmittal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Promptly following the
later of (x)&nbsp;the Effective Time and (y)&nbsp;(A)&nbsp;delivery to the Exchange Agent of a letter of transmittal properly completed and validly executed in accordance with the instructions thereto and (B)&nbsp;with respect to holders of
Certificates, surrender to the Exchange Agent of a Certificate for cancellation, in each case, together with such other documents as may be reasonably requested, the holder of such shares of Company Stock shall be entitled to receive in exchange
therefor (I)&nbsp;cash in the amount equal to the Cash Consideration and, if applicable, the cash portion, if any, of the Alternative Consideration that such holder has the right to receive pursuant to <U>Section&nbsp;2.04(a)</U> and this <U>Article
III</U> (in each case, rounded to the nearest cent); (II) book-entry shares representing the Stock Consideration and, if applicable, any shares of Parent Common Stock included in the Alternative Consideration that such holder has the right to
receive pursuant to <U>Section&nbsp;2.04(a)</U> and this <U>Article III</U>; (III) if applicable, CVRs in the amount that such holder has the right to receive pursuant to <U>Section&nbsp;2.04(a)</U> and this <U>Article III</U> (subject to and in
accordance with the CVR Agreement); (IV) cash in lieu of any fractional shares of Parent Common Stock such holder is entitled to receive pursuant to <U>Section 3.02(e)</U> (rounded to the nearest cent) and (V)&nbsp;any dividends or other
distributions such holder is entitled to receive pursuant to <U>Section&nbsp;3.02(c)</U>; and the Certificates or Book-Entry Shares so surrendered shall forthwith be cancelled. In the event of a transfer of ownership of shares of Company Stock which
is not registered in the transfer records of the Company, (I)&nbsp;cash in the amount equal to the Cash Consideration and, if applicable, the cash portion, if any, of the Alternative Consideration that such holder has the right to receive pursuant
to <U>Section 2.04(a)</U> and this <U>Article III</U> (in each case, rounded to the nearest cent); (II) book-entry shares representing the Stock Consideration and, if applicable, any shares of Parent Common Stock included in the Alternative
Consideration that such holder has the right to receive pursuant to <U>Section&nbsp;2.04(a)</U> and this <U>Article III</U>; (III), if applicable, CVRs in the amount that such holder has the right to receive pursuant to <U>Section&nbsp;2.04(a)</U>
and this <U>Article III</U> (subject to and in accordance with the CVR Agreement); (IV) cash in lieu of any fractional shares of Parent Common Stock such holder is entitled to receive pursuant to<U> Section&nbsp;3.02(e)</U> (rounded to the nearest
cent) and (V)&nbsp;any dividends or other distributions such holder is entitled to receive pursuant to <U>Section&nbsp;3.02(c)</U> may be issued to a transferee if the Certificate or Book-Entry Shares representing such shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of Company Stock are presented to the Exchange Agent, accompanied by all documents required to evidence and effect such transfer and by evidence that any applicable stock transfer Taxes have been
paid. Until surrendered as contemplated by <U>Section&nbsp;2.04(a)</U> and this <U>Section&nbsp;3.02</U>, each Certificate or Book-Entry Share shall be deemed at all times after the Effective Time to represent only the right to receive upon such
surrender, in each case, without interest, the Merger Consideration, cash in lieu of any fractional shares of Parent Common Stock the holder of such Certificate or Book-Entry Share is entitled to receive pursuant to <U>Section 3.02(e)</U> and any
dividends or other distributions such holder is entitled to receive pursuant to <U>Section&nbsp;3.02(c)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Distributions with
Respect to Unexchanged Shares of Parent Common Stock</U>. No dividends or other distributions declared or paid with a record date after the Effective Time with respect to the Parent Common Stock (and no cash payment in lieu of fractional shares of
Parent Common Stock pursuant to <U>Section&nbsp;3.02(e)</U>) shall be paid to the holder of any unsurrendered Certificate or Book-Entry Share until the holder of such Certificate or Book-Entry Share shall surrender such Certificate or Book-Entry
Share in accordance with <U>Section&nbsp;3.02(b)</U>. Subject to the effect of escheat, Tax or other applicable Laws, following surrender of any such Certificate or Book-Entry Share in accordance with <U>Section&nbsp;3.02(b)</U>, there shall be paid
to the record holder of shares of Parent Common Stock issued in exchange therefor, without interest, at the appropriate payment date (or, if previously paid, promptly), the amount of dividends or other distributions with a record date after the
Effective Time but prior to surrender payable with respect to such shares of Parent Common Stock and the amount of any cash payable in lieu of fractional shares of Parent Common Stock pursuant to <U>Section&nbsp;3.02(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No Further Rights in Company Stock</U>. All Merger Consideration issued or paid upon surrender of Certificates or transfer of
Book-Entry Shares in accordance with the terms of this <U>Article III</U> (including any cash paid pursuant to <U>Section&nbsp;3.02(c)</U> or <U>Section&nbsp;3.02(e)</U>) shall be deemed to have been issued or paid, as the case may be, in full
satisfaction of all rights pertaining to the shares of Company Stock formerly represented by such Certificates or Book-Entry Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
<U>No Fractional Shares</U>. No fractional shares of Parent Common Stock shall be issued as Stock Consideration or Alternative Consideration, but in lieu thereof each holder of Company Stock otherwise entitled to a fractional share of Parent Common
Stock will be entitled to receive, from the Exchange Agent in accordance with the provisions of this <U>Section&nbsp;3.02(e)</U>, a cash payment in lieu of such fractional share of Parent Common Stock in an amount equal to the amount of such
fractional share (expressed as a decimal) multiplied by the Average Parent Stock Price. The parties hereto acknowledge that payment of such cash consideration in lieu of issuing fractional shares of Parent Common Stock was not separately
bargained-for consideration but merely represents a mechanical rounding off for purposes of avoiding the expense and inconvenience to Parent that would otherwise be caused by the issuance of fractional shares of Parent Common Stock. Such amounts
payable to holders of shares of Company Stock shall be without interest, rounded down to the nearest whole cent and subject to the amount of any withholding Taxes as contemplated in <U>Section&nbsp;3.02(i)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Adjustments to Stock Consideration</U>. The calculation of the Aggregate Stock
Consideration and aggregate shares of Parent Common Stock, if any, payable as Alternative Consideration shall be equitably adjusted to reflect appropriately the effect of any stock split, reverse stock split, stock dividend (including any dividend
or distribution of securities of a Subsidiary of Parent or the Company or of securities convertible into Parent Common Stock or Company Stock), recapitalization, reclassification, combination, exchange of shares or other like change with respect to
Parent Common Stock or Company Stock with a record date occurring on or after the date hereof and prior to the Effective Time; <U>provided</U> that nothing in this <U>Section&nbsp;3.02(f)</U> shall be construed to permit the Company or Parent to
take any of the foregoing actions with respect to Company Stock or Parent Common Stock, as applicable, to the extent otherwise prohibited by the terms of this Agreement, including <U>Section&nbsp;6.01</U> and <U>Section</U><U> </U><U>6.02</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Termination of Exchange Fund</U>. Any portion of the Exchange Fund (including proceeds of any investment thereof) that remains
undistributed to the holders of shares of Company Stock on the date that is 12 months after the Effective Time shall be delivered to Parent, upon demand, and any holders of shares of Company Stock who have not theretofore complied with this
<U>Article III </U>shall thereafter look only to Parent for the Merger Consideration to which they are entitled pursuant to <U>Section&nbsp;2.04(a)</U>, any cash in lieu of fractional shares of Parent Common Stock to which they are entitled pursuant
to <U>Section&nbsp;3.02(e)</U> and any dividends or other distributions with respect to the Parent Common Stock to which they are entitled pursuant to <U>Section&nbsp;3.02(c)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>No Liability</U>. None of the Exchange Agent, Parent, the Surviving Corporation or the Surviving Entity shall be liable to any holder of
shares of Company Stock for any Merger Consideration from the Exchange Fund (or dividends or other distributions with respect to Parent Common Stock) or other cash delivered to a public official pursuant to any abandoned property, escheat or similar
Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Withholding Rights</U>. Each of the Surviving Corporation, the Surviving Entity, the Exchange Agent, Parent, First Merger Sub
and Second Merger Sub shall be entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement or the CVR Agreement such amount as it is required to deduct and withhold with respect to the making of such payment under
the Code, the rules or regulations promulgated thereunder, any provision of applicable state, local or foreign Tax Law or any other Law. To the extent that amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for
purposes of this Agreement and the CVR Agreement as having been paid to the Person in respect of which such deduction and withholding was made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Lost Certificates</U>. If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the
Person claiming such Certificate to be lost, stolen or destroyed and, if required by Parent, providing an indemnity agreement in customary form reasonably acceptable to Parent against any claim that may be made against Parent with respect to such
Certificate, the Exchange Agent will issue in exchange for such lost, stolen or destroyed Certificate the Merger Consideration with respect to the shares of Company Stock formerly represented by such Certificate to which the holder thereof is
entitled pursuant to <U>Section&nbsp;2.04(a)</U>, any cash in lieu of fractional shares of Parent Common Stock to which the holder thereof is entitled pursuant to <U>Section&nbsp;3.02(e)</U> and any dividends or other distributions to which the
holder thereof is entitled pursuant to <U>Section&nbsp;3.02(c)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03 <U>Stock Transfer Books</U>. At the Effective Time, the stock transfer
books of the Company shall be closed and there shall be no further registration of transfers of shares of Company Stock thereafter on the records of the Company. On or after the Effective Time, any Certificates or Book-Entry Shares presented to the
Exchange Agent or Parent for any reason shall be cancelled and exchanged for the Merger Consideration with respect to the shares of Company Stock formerly represented by such Certificates or Book-Entry Shares to which the holders thereof are
entitled pursuant to <U>Section&nbsp;2.04(a)</U>, any cash in lieu of fractional shares of Parent Common Stock to which the holders of such Certificates or Book-Entry Shares are entitled pursuant to <U>Section&nbsp;3.02(e)</U> and any dividends or
other distributions to which the holders thereof are entitled pursuant to <U>Section&nbsp;3.02(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.04 <U>Company
Equity Awards</U>. (a)&nbsp;Immediately prior to, and contingent on, the Effective Time, a number of options, shares of Company Stock or restricted stock units, as applicable, subject to each Service-Vesting Award that is unvested as of immediately
prior to the Effective Time equal to the number of options, shares or units, as applicable, that would have vested on or prior to the third anniversary of the Effective Time if the applicable holder of such Service-Vesting Award satisfied all
applicable service-based vesting criteria through such third anniversary shall vest, with such vesting applied to the options, shares or units, as applicable, that have the longest remaining vesting periods (<I>i.e.</I>, in reverse chronological
order, as illustrated in the examples set forth on <U>Section&nbsp;3.04(a) of the Company Disclosure Letter</U>). Any Service-Vesting Award (or portion thereof) that remains unvested following the application of the accelerated vesting provided for
in this <U>Section&nbsp;3.04(a)</U>, shall be referred to as a &#147;<U>Rollover Service-Based Award</U>&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Immediately prior to,
and contingent on, the Effective Time, a number of options, shares of Company Stock or restricted stock units, as applicable, subject to each Performance-Vesting Award that is unvested as of immediately prior to the Effective Time equal to the
number of options, shares or units, as applicable, (rounded up to the nearest whole option, share or unit, as applicable) that would have vested based on achievement of the performance-based vesting criteria applicable to such Performance-Vesting
Award shall vest as set forth on <U>Section&nbsp;3.04(b)(i) of</U><U> </U><U>the Company Disclosure Letter</U>. Any Performance-Vesting Award (or portion thereof) that remains unvested following the application of the vesting described in this
<U>Section&nbsp;3.04(b)</U>, shall be referred to as a &#147;<U>Rollover Performance-Based Award</U>&#148; and, together with the Rollover Service-Based Awards, the &#147;<U>Rollover Awards</U>&#148;. For purposes of this Agreement, the term
&#147;<U>Cash-Out Award</U>&#148; shall mean any Company Equity Award (or portion thereof) that is outstanding and vested as of immediately prior to the Effective Time (including, for the avoidance of doubt, any such Company Equity Award (or portion
thereof) that (x)&nbsp;vests as a result of the application of <U>Sections 3.04(a)</U> or <U>(b)</U>, or (y)&nbsp;vested in the ordinary course prior to the application of <U>Sections 3.04(a) </U>and <U>(b)&nbsp;</U>or on an accelerated basis in
connection with (and on or prior to) the Effective Time (a &#147;<U>Single-Trigger Award</U>&#148;)). <U>Section&nbsp;3.04(b)(ii) of the Company Disclosure Letter</U> sets forth, to the Company&#146;s knowledge, all Single-Trigger Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On the Mailing Date, Parent will cause to be provided to each holder of Company Equity
Awards an election form in such form consistent with the terms of this Agreement as Parent shall specify (which such form shall be reasonably acceptable to the Company) (the &#147;<U>Equity Election Form</U>&#148;). The Equity Election Form shall
state the procedures for electing among the options for the treatment of Rollover Awards and Cash-Out Awards described herein and shall specify the number of shares of Parent Common Stock and/or amount of cash that comprise the Alternative
Consideration as determined by Parent. Each Equity Election Form will permit each holder of Company Equity Awards to specify: (i)&nbsp;which Cash-Out Awards such holder elects to treat as &#147;<U>CVR Cash-Out Awards</U>&#148;; (ii)&nbsp;which
Cash-Out Awards such holder elects to treat as &#147;<U>Alternative Cash-Out Awards</U>&#148;; (iii)&nbsp;which Rollover Awards such holder elects to treat as &#147;<U>CVR Rollover Awards</U>&#148;; (iv)&nbsp;which Rollover Awards such holder elects
to treat as &#147;<U>Alternative Rollover Awards</U>&#148;; and/or (v)&nbsp;that such holder makes no election with respect to some or all of such holder&#146;s Company Equity Awards (any Company Equity Awards described in this clause (v)&nbsp;and
any other Company Equity Awards for which Parent does not receive a properly completed Equity Election Form during the Election Period, the &#147;<U>No Election Awards</U>&#148;). The treatment of each of the CVR Cash-Out Awards, Alternative
Cash-Out Awards, CVR Rollover Awards and Alternative Rollover Awards is described below. Any No Election Award shall be treated for all purposes, except as set forth below, as a CVR Cash-Out Award or a CVR Rollover Award, as applicable.
Notwithstanding anything else in this Agreement or any Election Form to the contrary, any Company Stock Option that is a Rollover Award and that has an exercise price that is greater than or equal to the sum of (x)&nbsp;the Cash Consideration and
(y)&nbsp;an amount equal to the product of (I)&nbsp;the Stock Consideration and (II) the Average Parent Stock Price shall be treated as an Alternative Rollover Award. <U>Section&nbsp;3.01(d)</U> shall apply to the Equity Election Forms <I>mutatis
mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Immediately prior to, and contingent on, the Effective Time, each Company Stock Option (or portion thereof) that is a
Rollover Award shall be canceled in exchange for the right to receive (i)&nbsp;in the case of a CVR Rollover Award only, a number of fully vested CVRs equal to the number of shares of Company Class&nbsp;A Common Stock subject to such Rollover Award
immediately prior to such cancelation and (ii)&nbsp;an option to acquire a number of shares of Parent Common Stock equal to the product (rounded down to the nearest whole share) of (A)&nbsp;the number of shares of Company Class&nbsp;A Common Stock
subject to such Rollover Award immediately prior to such cancelation, and (B)&nbsp;the applicable Equity Award Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (x)&nbsp;the
exercise price per share of Company Class&nbsp;A Common Stock of such Rollover Award immediately prior to such cancelation by (y)&nbsp;the Equity Award Ratio (such options, &#147;<U>Parent Stock Options</U>&#148;); <U>provided</U> that the exercise
price and the number of shares of Parent Common Stock purchasable pursuant to such Parent Stock Option shall be determined in a manner consistent with the requirements of Section&nbsp;409A of the Code and Section&nbsp;422 of the Code (to the extent
applicable); <U>provided further</U>, that the parties intend that the actions provided for in the foregoing with respect to CVR Rollover Awards shall be implemented by means of a deemed partial exercise of the Company Stock Option in exchange for
Company Restricted Stock Awards covering a number of shares with an aggregate value equal to the aggregate value of the CVRs to be received in exchange for such Rollover Award, with such Company Restricted Stock Awards immediately thereafter
canceled in exchange for the fully vested CVRs provided for above in accordance with the election of the holder of such CVR Rollover Awards (and, for clarity, the remainder of the Company Stock Option converted into the Parent Stock Option provided
for above in a manner consistent with the requirements of Section&nbsp;409A of the Code and Section 422 of the Code (to the extent applicable)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For purposes of this Agreement, the &#147;<U>Equity Award Ratio</U>&#148; shall mean:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the case of a CVR Rollover Award, a fraction (A)&nbsp;the numerator of which is the sum of (x)&nbsp;the Cash
Consideration and (y)&nbsp;an amount equal to the product of (I)&nbsp;the Stock Consideration and (II) the Average Parent Stock Price and (B)&nbsp;the denominator of which is the Average Parent Stock Price </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) in the case of an Alternative Rollover Award, a fraction (A)&nbsp;the numerator of which is the sum of (x)&nbsp;the cash
portion of the Cash&nbsp;&amp; Stock Consideration (which includes the cash portion of the Alternative Consideration (if any)) and (y)&nbsp;an amount equal to the product of (I)&nbsp;the stock portion of the Cash&nbsp;&amp; Stock Consideration
(which includes the stock portion of the Alternative Consideration (if any)) and (II) the Average Parent Stock Price and (B)&nbsp;the denominator of which is the Average Parent Stock Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Immediately prior to, and contingent upon, the Effective Time, each Company Restricted Stock Award (or portion thereof) that is a Rollover
Award shall be canceled in exchange for the right to receive (i)&nbsp;in the case of a CVR Rollover Award only, a number of fully vested CVRs equal to the number of shares of Company Class&nbsp;A Common Stock subject to such Rollover Award
immediately prior to such cancelation and (ii)&nbsp;a number of restricted shares of Parent Common Stock equal to the product (rounded down to the nearest whole share) of (A)&nbsp;the number of shares of Company Class&nbsp;A Common Stock subject to
such Rollover Award immediately prior to such cancelation and (B)&nbsp;the applicable Equity Award Ratio (such restricted shares, &#147;<U>Parent Restricted Stock</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Immediately prior to, and contingent upon, the Effective Time, each Company RSU Award (or portion thereof) that is a Rollover Award shall
be canceled in exchange for the right to receive (i)&nbsp;in the case of a CVR Rollover Award only, a number of fully vested CVRs equal to the number of shares of Company Class&nbsp;A Common Stock subject to such Rollover Award immediately prior to
such cancelation and (ii)&nbsp;a restricted stock unit with respect to a number of shares of Parent Common Stock equal to the product (rounded down to the nearest whole share) of (A)&nbsp;the number of shares of Company Class&nbsp;A Common Stock
subject to such Rollover Award immediately prior to such cancelation, and (B)&nbsp;the applicable Equity Award Ratio (such restricted stock units, collectively with the Parent Stock Options and Parent Restricted Stock, the &#147;<U>Parent
Awards</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as specifically provided in this <U>Section&nbsp;3.04</U>, following the Effective Time, each Parent Award
shall continue to be governed by the terms and conditions that applied to the applicable Rollover Award immediately prior to the applicable cancelation, including, for the avoidance of doubt, any service-based and performance-based vesting criteria
that are not satisfied or deemed satisfied prior to the Effective Time (including pursuant to <U></U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Sections 3.04(a)</U> and <U>(b)</U>). Notwithstanding the foregoing, solely to the extent set forth on <U>Section&nbsp;3.04(b) of the Company Disclosure Letter</U>, Parent Awards in respect of
Rollover Awards that are Performance-Vesting Awards shall no longer be subject to any performance-vesting criteria following the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Immediately prior to, and contingent on, the Effective Time, each Cash-Out Award shall be canceled and converted into the right to receive
for each share of Company Stock subject to such Cash-Out Award as of immediately prior to such cancelation, in full satisfaction of the rights of the applicable holder with respect thereto, (i)&nbsp;in the case of a CVR Cash-Out Award, the CVR
Consideration or (ii)&nbsp;in the case of an Alternative Cash-Out Award, the Cash&nbsp;&amp; Stock Consideration, in each case, less (A)&nbsp;in the case of any Cash-Out Award that is a Company Stock Option, the applicable exercise price for such
share and (B)&nbsp;in the case of all Company Equity Awards, any required withholding Taxes ((A) and (B)&nbsp;together, the &#147;<U>Cash-Out Deductions</U>&#148;, and the net consideration payable hereunder in respect of a Cash-Out Award, the
&#147;<U>Cash-Out Award Consideration</U>&#148;). Any Cash-Out Deductions shall be satisfied by reducing the cash portion of the applicable consideration by the amount of such Cash-Out Deductions, but not below zero. In the event such cash portion
has a value that is less than such Cash-Out Deductions, such cash portion shall be reduced to zero and in addition Parent shall retain a portion of the stock portion of the applicable consideration that has a value equal to the amount by which the
Cash-Out Deductions exceed such cash portion. The Cash-Out Award Consideration shall be paid as promptly as practicable following the Effective Time (and in no event later than five (5)&nbsp;Business Days thereafter) through Parent&#146;s, the
Surviving Entity&#146;s or the applicable Subsidiary of the Surviving Entity&#146;s payroll. Notwithstanding the foregoing, to the extent that any Cash-Out Award Consideration relates to a Company RSU Award that is nonqualified deferred compensation
subject to Section&nbsp;409A of the Code, Parent, the Surviving Entity or the applicable Subsidiary shall pay such amounts at the earliest time, as applicable, that will not trigger a Tax or penalty under Section&nbsp;409A of the Code, but no later
than five (5)&nbsp;Business Days after such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Notwithstanding the foregoing, in the event any Cash-Out Award Consideration would
result in the payment of a fractional share of Parent Common Stock, all such fractional shares a holder of Company Equity Awards in respect of Company Equity Awards would be entitled to shall be aggregated and paid in (i)&nbsp;a number of shares of
Parent Common Stock equal to such aggregated number rounded down to the nearest whole share and (ii)&nbsp;an amount in cash equal to the product of (A)&nbsp;such aggregated number minus the number of whole shares determined in clause (i)&nbsp;and
(B)&nbsp;the Average Parent Stock Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) No later than the Effective Time, Parent shall, if registration of the shares of Parent
Common Stock issuable under the Company Stock Plan or other Plan is required under the Securities Act and such registration is not covered by any Form S-4 filed in connection with the Transactions, file with the SEC a registration statement on Form
S-8, as the case may be (or any successor form), or another appropriate form with respect to such Parent Common Stock and shall use commercially reasonable efforts to have such registration statement declared effective no later than the Effective
Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) At or prior to the Effective Time, the Company, the Company Board or a committee of the
Company Board, as applicable, shall adopt any resolutions and take any actions which are necessary to effectuate the provisions of this <U>Section&nbsp;3.04</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Notwithstanding anything in this Agreement to the contrary, any Taxes required to be withheld in connection with CVRs issued in respect of
any Company Equity Award pursuant to this <U>Section&nbsp;3.04</U> (other than in respect of any Cash-Out Awards, which are covered solely by <U>Section&nbsp;3.04(i)</U>) shall be satisfied by reducing the cash portion of the applicable
consideration that would otherwise be received by the holder of the applicable Company Equity Award by the amount of such required Tax withholding, but not below zero and, in the event such cash portion has a value that is less than such required
Tax withholding, such cash portion shall be reduced to zero and in addition Parent shall retain a portion of the stock portion of the applicable consideration that would otherwise be received by the holder of the applicable Company Equity Award that
has a value equal to the amount by which the required Tax withholding exceeds such cash portion. In the event the cash and stock portion has a value that is less than such required Tax withholding, the Company shall determine an alternative means of
satisfying such Tax withholding that is reasonably acceptable to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.05 <U>Appraisal Rights</U>.
(a)&nbsp;Notwithstanding anything in this Agreement to the contrary, shares of Company Stock that are outstanding immediately prior to the Effective Time and that are held by any holder who has not voted in favor of the Mergers or consented thereto
in writing, has not waived appraisal rights in connection with the Mergers, and properly demands appraisal of such shares pursuant to, and in accordance with, Section&nbsp;262 of the DGCL (&#147;<U>Appraisal Shares</U>&#148;) shall not be converted
into the right to receive the Merger Consideration as provided in <U>Section&nbsp;2.04(a)</U>, but instead shall be entitled to only those rights as are granted by Section&nbsp;262 of the DGCL; <U>provided</U>, <U>however</U>, that if any such
holder shall fail to perfect or otherwise shall waive, withdraw or lose the right to appraisal under Section&nbsp;262 of the DGCL, or a court of competent jurisdiction shall determine such holder is not entitled to the relief provided by
Section&nbsp;262 of the DGCL, then the right of such holder to be paid the fair value of such holder&#146;s Appraisal Shares under Section&nbsp;262 of the DGCL shall cease and such Appraisal Shares shall thereupon be treated as if they were No
Election Shares and shall be deemed to have been converted as of the Effective Time into, and shall represent only the right to receive, the CVR Consideration as provided in <U>Section&nbsp;2.04(a)</U> upon the surrender of such shares in the manner
provided in <U>Section&nbsp;3.02</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall give prompt notice to Parent of any demands received by the Company for
appraisal of any shares of Company Stock, any attempted withdrawals of such demands and any other instruments served pursuant to the DGCL and received by the Company relating to be paid the &#147;fair value&#148; of the Appraisal Shares, as provided
in Section&nbsp;262 of the DGCL, and Parent shall have the right to participate in and direct all negotiations and Actions with respect to such demands. Prior to the Effective Time, the Company shall not, without the prior written consent of Parent,
make any payment with respect to, or settle or offer to settle, any such demands, or agree to do any of the foregoing. Parent shall not, except with the prior written consent of the Company, require the Company to make any payment with respect to
any demands for appraisal or offer to settle or settle any such demands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.06 <U>Closing Capitalization Schedule</U>. (a)&nbsp;No less than five
Business Days prior to the Closing, the Company shall deliver to Parent and the Exchange Agent a schedule (the &#147;<U>Closing Capitalization Schedule</U>&#148;), setting forth, as of the Effective Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) a list, substantially in the form of <U>Section&nbsp;3.06 of the Company Disclosure Letter</U>, of all holders of Company
Stock and Company Equity Awards and each such holder&#146;s address and: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) the number of shares of each class or series
of Company Stock held by such holder immediately prior to the Closing Date, indicating whether any such shares are Company Restricted Stock Awards (and if so, whether or not such Company Restricted Stock Awards are subject to any performance-based
vesting conditions and, if so, the target number of shares of Company Stock that may be issued under such award) and with respect to any shares of Company Class B Common Stock or Company Preferred Stock of any series, (I)&nbsp;the conversion rate to
Company Class&nbsp;A Common Stock applicable thereto, (II) the liquidation preference applicable thereto and (III) the amount of any accrued but unpaid dividends applicable thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) the number of Company RSU Awards held by such holder immediately prior to the Closing Date, indicating whether or not such
Company RSU Awards are subject to any performance-based vesting conditions and, if so, the target number of shares of Company Stock that may be issued under such award; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) the number of all Company Stock Options held by such holder immediately prior to the Closing Date, indicating
(I)&nbsp;whether such Company Stock Options are vested or unvested, (II) the number of shares of Company Stock issuable upon exercise of such Company Stock Options, as applicable, (III) the exercise price with respect to each Company Stock Option
and (iV) whether or not such Company Stock Options are subject to any performance-based vesting conditions and, if so, the target number of shares of Company Stock that may be issued under such award; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) (A)&nbsp;the calculation of the Company Fully Diluted Share Count and Cash Consideration and Stock Consideration payable
in respect of a share of each class or series of Company Stock, (B)&nbsp;the aggregate Merger Consideration to be paid to Company stockholders pursuant to Section&nbsp;2.04(a) and (C)&nbsp;the aggregate consideration to be paid in respect of Company
Equity Awards pursuant to <U>Section&nbsp;3.04</U>, in each case calculated in accordance with this Agreement, the Company&#146;s certificate of incorporation, and any applicable Plan (including the Company Stock Plan and any other Plans governing
the terms of any Company Stock Options, Company Restricted Stock Awards or Company RSU Awards) and accompanied with detailed calculations to arrive at the amounts set forth in the Closing Capitalization Schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall (i)&nbsp;take all necessary actions to freeze all exercises of Company
Stock Options as of immediately prior to delivery of the Closing Capitalization Schedule, and (ii)&nbsp;promptly, but in no event later than the Closing Date, provide Parent and the Exchange Agent an updated Closing Capitalization Schedule
reflecting any forfeiture, vesting or settlement (as applicable) of Company Restricted Stock Awards, Company RSU Awards and Company Stock Options that occur between the delivery of the Closing Capitalization Schedule and the Closing Date. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As an inducement to Parent, First Merger Sub and Second Merger Sub to enter into this Agreement, except (i)&nbsp;as disclosed in the Company
Registration Statement (including exhibits) filed by the Company and publicly available prior to the date of this Agreement (but excluding any forward-looking disclosures set forth in any &#147;risk factors&#148; section, any disclosures in any
&#147;forward-looking statements&#148; section and any other disclosures included therein to the extent they are predictive or forward-looking in nature, in each case other than statements of historical fact) or (ii)&nbsp;as set forth in the Company
Disclosure Letter (it being agreed that disclosure of any item in any section of the Company Disclosure Letter shall be deemed disclosure with respect to any other section of this Agreement to which the relevance of such disclosure is reasonably
apparent on its face), the Company hereby represents and warrants to Parent, First Merger Sub and Second Merger Sub that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01 <U>Organization and Qualification; Subsidiaries</U>. (a)&nbsp;The Company is a corporation duly incorporated, validly
existing and in good standing under the Laws of the State of Delaware and has the requisite corporate or similar power and authority to own, lease and operate its properties and assets and carry on its business as it is now being conducted. The
Company has made available to Parent, prior to the execution of this Agreement, a true and complete copy of the Company&#146;s certificate of incorporation and bylaws, as amended to the date of this Agreement, which are in full force and effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Subsidiary of the Company is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction
of its organization and has the requisite corporate or similar power and authority to own, lease and operate its properties and assets and to carry on its business as it is now being conducted, except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect. The Company and each of its Subsidiaries is duly qualified or licensed as a foreign corporation to do business, and is in good standing, in each jurisdiction where the character of
the properties or assets owned, leased or operated by it or the nature of its business makes such qualification or licensing necessary or desirable, except where the failure to be so qualified or licensed and in good standing would not, individually
or in the aggregate, be reasonably expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Section&nbsp;4.01(b) of the Company
Disclosure Letter</U> sets forth, as of the date hereof, a true and complete list of each Subsidiary of the Company, the jurisdiction of incorporation or formation of each such Subsidiary and the ownership interest of the Company and any third
parties in each such Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company has made available to Parent, prior to the execution of this Agreement, a
true and complete copy of the organizational documents of each of its Subsidiaries, in each case, as amended to the date of this Agreement. Such certificates of incorporation, bylaws and equivalent organizational documents are in full force and
effect, except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. None of the Company&#146;s Subsidiaries is in violation of any of the provisions of its certificate of incorporation,
bylaws or equivalent organizational documents except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. The Company is not in violation of any of the provisions of its certificate of
incorporation or bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02 <U>Capitalization</U>. (a)&nbsp;The authorized capital stock of the Company consists of
(i)&nbsp;898,203,200 shares of Company Common Stock and (ii)&nbsp;534,145,027 shares of Company Preferred Stock. As of the date hereof, (i)&nbsp;120,746,694 shares of Company Class&nbsp;A Common Stock were issued and outstanding, including 592,442
shares subject to Company Restricted Stock Awards (with zero (0)&nbsp;additional shares of Company Class&nbsp;A Common Stock issued and held in the treasury of the Company and 6,804,539 shares of Company Class&nbsp;A Common Stock reserved for future
issuance pursuant to the Company Stock Plan); (ii)&nbsp;24,989,397 shares of Company Class B Common Stock, which are convertible into 26,179,367 shares of Company Class&nbsp;A Common Stock, were issued and outstanding, none of which are subject to
Company Restricted Stock Awards (with an additional zero (0)&nbsp;shares of Company Class B Common Stock issued and held in the treasury of the Company and zero (0)&nbsp;shares of Company Class B Common Stock reserved for future issuance pursuant to
the Company Stock Plan); (iii)&nbsp;85,000,000 shares of Company Series A Preferred Stock, which are convertible into 85,000,000 shares of Company Class&nbsp;A Common Stock, were issued and outstanding; (iv)&nbsp;309,256,591 shares of Company Series
B Preferred Stock, which are convertible into 309,256,591 shares of Company Class&nbsp;A Common Stock, were issued and outstanding; (v)&nbsp;63,144,600 shares of Company Series C Preferred Stock, which are convertible into 63,144,600 shares of
Company Class&nbsp;A Common Stock, were issued and outstanding; and (vi)&nbsp;76,743,836 shares of Company Series D Preferred Stock, which are convertible into 76,743,836 shares of Company Class&nbsp;A Common Stock, were issued and outstanding, in
each case duly authorized and validly issued, fully paid and non-assessable. As of the date hereof, 96,320,592 shares of Company Class&nbsp;A Common Stock are subject to outstanding Company Stock Options, and 30,343,670 shares of Company
Class&nbsp;A Common Stock are subject to outstanding Company RSU Awards. With respect to Company Equity Awards, the foregoing assumes 100% achievement of all applicable performance criteria. Except as set forth in this <U>Section&nbsp;4.02</U> or as
set forth in <U>Section 4.02(a) of the Company Disclosure Letter</U>, there are no authorized, issued, reserved for issuance or outstanding (i)&nbsp;shares of capital stock, voting securities or other equity interests of the Company;
(ii)&nbsp;options, calls, warrants, convertible debt, other convertible or exchangeable instruments or rights, agreements, arrangements or commitments of any character made or issued by the Company or any of its Subsidiaries obligating the Company
or any of its Subsidiaries to issue, deliver or sell any shares of capital stock, voting securities or other equity interests of the Company or any of its Subsidiaries; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii) &#147;phantom&#148; stock, &#147;phantom&#148; stock rights, stock appreciation rights, stock-based units or any other similar interests issued by the Company or any of its Subsidiaries, or
rights to acquire such interests from the Company or any Subsidiary. All shares of Company Stock subject to issuance as aforesaid, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be,
and each outstanding share of Company Stock has been and is, (i)&nbsp;duly authorized, validly issued, fully paid and non-assessable; and (ii)&nbsp;not subject to or issued in violation of any preemptive rights purchase option, call option, right of
first refusal, anti-dilutive right, subscription right or any similar right created by applicable Law, the organizational documents of the Company or any agreement to which the Company is a party or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) There are no outstanding contractual obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any
capital stock, voting securities or other equity interests or securities convertible into or exchangeable or exercisable for capital stock, voting securities or other equity interests of the Company or any of its Subsidiaries or to provide funds to,
or make any investment (in the form of a loan, capital contribution or otherwise) in, any Subsidiary of the Company or any other Person. All Company Stock Options, Company Restricted Stock Awards and Company RSU Awards are evidenced by award
agreements, in each case, in substantially the forms made available to Parent by the Company, and no award agreement contains terms that are materially inconsistent with the applicable forms. There are no declared or accrued unpaid dividends with
respect to any Company Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each outstanding share of capital stock of, or other equity interests in, each Subsidiary of the
Company is duly authorized, validly issued, fully paid and non-assessable; each such share or interest is owned by the Company or another of its wholly owned Subsidiaries free and clear of all Encumbrances and free of any restriction on the right to
vote, sell or otherwise dispose of such capital stock or other equity interests (in each case, other than any Encumbrance or restriction arising under applicable securities Laws); and each such share or interest was not issued in violation, in any
material respect, of any preemptive rights, purchase option, call option, right of first refusal, anti-dilutive right, subscription right or any similar right under applicable Law, the organizational documents of any applicable Subsidiary or any
agreement to which the Company or any Subsidiary is a party or otherwise bound. Except for the capital stock of, or other equity interest in, its Subsidiaries, the Company does not own, directly or indirectly, any capital stock of, or other equity
or similar interest in, any corporation, partnership, joint venture, association or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) As of the date of this Agreement,
no bonds, debentures, notes or other Indebtedness of the Company having the right to vote (or convertible into or exercisable for securities having the right to vote) on any matters on which stockholders of the Company may vote are issued or
outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as provided in the Investor Agreements, the Selling Investor Support Agreement and the Support Agreements, none
of the Company or any of its Subsidiaries is party to any stockholder agreements, voting trusts, proxies or other similar agreements, arrangements or understandings with respect to the voting or transfer, or requiring registration, of the Company
Common Stock or the Company Preferred Stock or other voting or equity interests in the Company or any of its Subsidiaries. The Company has made available to Parent a true and complete copy of the Investor Agreements (including any amendments
thereto). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Section&nbsp;4.02(f) of the Company Disclosure Lette</U>r sets forth a true and
complete list as of the date hereof of each registered holder of Company Stock, showing the number of shares of each class or series of such capital stock held by each such holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Closing Capitalization Schedule will, as of the Closing Date, be true and complete in all respects and the amounts set forth therein
will be calculated pursuant to and in accordance with this Agreement, the Company&#146;s certificate of incorporation and any applicable Plan (including the Company Stock Plan and any other Plans governing the terms of any Company Equity Awards). As
of the Closing, (i)&nbsp;the number of shares of Company Stock set forth in the Closing Capitalization Schedule as being owned by a Person, or subject to Company Equity Awards owned by such Person, will constitute the entire interest of such Person
in the issued and outstanding capital stock of, or any other equity or ownership interests in, the Company, and record ownership of such shares of Company Stock set forth in the Closing Capitalization Schedule is held by such Person and (ii)&nbsp;no
Person not disclosed in the Closing Capitalization Schedule will be the record owner of, or have a right to acquire from the Company any shares of capital stock of, or any other equity or ownership interests in, the Company or options in respect of
the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03 <U>Authority Relative to This Agreement; Vote Required</U>. (a)&nbsp;The Company has all necessary
corporate power and authority to execute and deliver this Agreement, and, subject to, with respect to the Mergers, obtaining the Company Stockholder Approvals and filing the Certificates of Merger with the Secretary of State of the State of Delaware
as required by the DGCL and the DLLCA, as applicable, to perform its obligations hereunder and to consummate the Transactions. The execution and delivery of this Agreement by the Company and the consummation by the Company of the Transactions have
been duly and validly authorized by all necessary corporate action, and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement or to consummate the Transactions (other than, with respect to the Mergers,
obtaining the Company Stockholder Approvals and filing the Certificates of Merger with the Secretary of State of the State of Delaware as required by the DGCL and the DLLCA, as applicable). This Agreement has been duly and validly executed and
delivered by the Company and, assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance
with its terms, subject to the effect of any applicable bankruptcy, insolvency (including all Laws relating to fraudulent transfers), reorganization, moratorium or similar Laws affecting creditors&#146; rights generally and subject to the effect of
general principles of equity (regardless of whether considered in a proceeding at law or in equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company Board, by
resolutions duly adopted by the Company Board (by the unanimous vote of all directors, including both Preferred Directors (as defined in the Company&#146;s certificate of incorporation), present) at a meeting duly called and held on the date hereof
and not subsequently rescinded, modified or withdrawn in any way prior to the date of this Agreement, has (i)&nbsp;determined that this Agreement and the Transactions are fair to, and in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the best interests of, the Company and its stockholders; (ii)&nbsp;approved and declared advisable this Agreement and the Transactions; (iii)&nbsp;adopted the Drag-Along Resolutions;
(iv)&nbsp;resolved to recommend that the stockholders of the Company adopt this Agreement and (v)&nbsp;directed that this Agreement be submitted to the stockholders of the Company for adoption, which resolutions have not, as of the date hereof, been
subsequently rescinded, modified or withdrawn in any way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The only votes of the holders of any class or series of capital stock of
the Company necessary to adopt this Agreement and approve the Transactions are the Company Stockholder Approvals. The Selling Investors collectively hold a sufficient number of shares of Company Common Stock and Company Preferred Stock to deliver
the Company Stockholder Approvals without further stockholder support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Voting Agreement is in full force and effect and has not
been amended in any manner. To the knowledge of the Company, there is no contract or other agreement in effect that would prevent or disable the effectiveness of the Drag-Along or restrict the exercise or effectiveness of the Drag-Along, in each
case, with respect to the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) (i)&nbsp;The distribution of Merger Consideration to the stockholders of the Company pursuant
to <U>Article II</U> and <U>Article III </U>will satisfy the requirements of Section&nbsp;2.1 and Section&nbsp;2.2 of Part B Article Fourth and Section&nbsp;7 of Part A Article Fourth of the Company&#146;s certificate of incorporation and
(ii)&nbsp;the Mergers will constitute a Deemed Liquidation Event (as defined in the Company&#146;s certificate of incorporation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04 <U>No Conflict; Required Filings and Consents</U>. (a)&nbsp;The execution and delivery of this Agreement by the Company do
not, and the performance of this Agreement by the Company, and the consummation of the Transactions, will not, (i)&nbsp;conflict with or violate the certificate of incorporation, bylaws or other equivalent organizational documents of (A)&nbsp;the
Company or (B)&nbsp;any of its Subsidiaries, (ii)&nbsp;assuming all consents, approvals, authorizations and other actions described in <U>Section&nbsp;4.04(b)</U> have been obtained or taken and all filings and obligations described in
<U>Section&nbsp;4.04(b)</U> have been made or satisfied, conflict with or violate any Law applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound, or
(iii)&nbsp;violate, conflict with, require consent under, result in any breach of, result in loss of benefit under, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others
any right of termination, amendment, acceleration or cancellation of, or result in the creation of an Encumbrance on any property or asset of the Company or any of its Subsidiaries pursuant to, any contract, Company Permit or other instrument or
obligation to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries or any of their respective assets or properties is bound, except, with respect to clauses (i)(B), (ii)&nbsp;and (iii)&nbsp;of
this <U>Section&nbsp;4.04(a)</U>, for any such conflicts, violations, breaches, defaults or other occurrences which would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery of this Agreement by the Company do not, and the performance
of this Agreement by the Company and the consummation of the Transactions will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority, except (i)&nbsp;applicable requirements of
the Securities Act (including in connection with the Registration Statement) or any Blue Sky Laws, (ii)&nbsp;the pre-merger notification requirements of the HSR Act, the requirements of any other Antitrust Laws and the filing of the Certificates of
Merger with the Secretary of State of the State of Delaware as required by the DGCL or the DLLCA, as applicable, or (iii)&nbsp;where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications,
would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.05
<U>Permits; Compliance</U>. (a)&nbsp;Since January&nbsp;1, 2018, the Company and its Subsidiaries have operated and conducted their businesses in compliance with all Laws of any Governmental Authority applicable to their respective businesses or
operations, except where such non-compliance would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Since January&nbsp;1, 2018, neither the Company nor any of the Subsidiaries has received any
written notice alleging, or been charged by a Governmental Authority with, any violation of any Laws, except where such violation would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company and each of its Subsidiaries has obtained and holds all Company Permits and all such Company Permits are valid and in full
force and effect, except where the failure to hold the same or to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. In addition, (i)&nbsp;the Company and each
of its Subsidiaries have not been in default under, or violation of, any such Company Permit, (ii)&nbsp;no suspension or cancellation of any of the Company Permits is pending or, to the knowledge of the Company, threatened, and (iii)&nbsp;the
Company has taken all measures reasonably necessary (including by making all applications or filings required by applicable Law or the applicable Governmental Authority) to extend any Company Permit to prevent the expiration thereof, except, with
respect to clauses (i), (ii)&nbsp;and (iii)&nbsp;of this <U>Section&nbsp;4.05(b)</U>, as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.06 <U>Company Registration Statement; Financial Statements; Undisclosed Material Liabilities</U>. (a)&nbsp;The Company has made
available to Parent true and complete copies of all written correspondence with the SEC related to the Company Registration Statement. The Company Registration Statement, at the time it was filed and, if amended, as of the date of such amendment,
complied in all material respects with all applicable requirements of the Securities Act and the rules and regulations promulgated thereunder, and did not, at the time it was filed and, if amended, as of the date of such amendment, contain any
untrue statement of material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the consolidated financial statements (including, in each case, any notes
thereto) contained in the Company Registration Statement (collectively, the &#147;<U>Financial Statements</U>&#148;) was prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in
the notes thereto) and each fairly presents, in all material respects, the consolidated financial condition, results of operations, changes in stockholders&#146; equity and cash flows of the Company and its consolidated Subsidiaries as of the
respective dates thereof and for the respective periods indicated therein (subject, in the case of unaudited financial statements, to normal year-end adjustments). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company and its Subsidiaries maintain a system of internal controls over financial reporting that are effective to ensure (i)&nbsp;the
reliability of financial reporting, including policies and procedures that mandate the maintenance of records that in reasonable detail accurately and fairly reflect the material transactions and dispositions of the assets of the Company and its
Subsidiaries, (ii)&nbsp;that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP, consistently applied, (iii)&nbsp;that transactions are executed only in accordance with the authorization of
management and (iv)&nbsp;the prevention or timely detection of the unauthorized acquisition, use or disposition of assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither
the Company nor any of its Subsidiaries has any liabilities or obligations of any nature (whether accrued, absolute, contingent or otherwise), except liabilities (i)&nbsp;reflected or reserved against in the consolidated balance sheet (or the notes
thereto) of the Company as of December&nbsp;31, 2019, included in the Financial Statements, (ii)&nbsp;incurred after December&nbsp;31, 2019 in the ordinary course of business, (iii)&nbsp;incurred in connection with the negotiation, execution,
delivery or performance of, or pursuant to the terms of, this Agreement or the other Transaction Documents (for clarity, any liability caused by or resulting from a breach by the Company of this Agreement shall not be deemed a liability
&#147;incurred in connection with the negotiation, execution, delivery or performance of, or pursuant to the terms of, this Agreement&#148;) or (iv)&nbsp;that would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since January&nbsp;1, 2018, none of the Company, the Company&#146;s independent accountants, the Company
Board or its audit committee has received any written, or to the knowledge of the Company, oral notification of any (i)&nbsp;&#147;significant deficiency&#148; in the internal controls over financial reporting of the Company;
(ii)&nbsp;&#147;material weakness&#148; in the internal controls over financial reporting of the Company; or (iii)&nbsp;fraud, whether or not material, that involves management or other employees of the Company who have a significant role in the
internal controls over financial reporting of the Company. Since January&nbsp;1, 2018, there have been no material internal investigations regarding accounting, auditing or revenue recognition discussed with, reviewed by or initiated at the
direction of the Chief Executive Officer, Chief Financial Officer or General Counsel of the Company or the Company Board or any committee thereof. For purposes of this Agreement, the terms &#147;significant deficiency&#148; and &#147;material
weakness&#148; shall have the meanings assigned to them in the Statement of Auditing Standard FAS 115 - Communicating Internal Control Related Matters Identified in an Audit, as in effect on the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Since January&nbsp;1, 2018, (i)&nbsp;neither the Company nor any of its Subsidiaries has received any written or, to the knowledge of the
Company, oral complaint, allegation, assertion or claim regarding accounting, internal accounting controls or auditing practices, procedures, methodologies or methods of the Company or any of its Subsidiaries, or unlawful
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounting or auditing matters with respect to the Company or any of its Subsidiaries, and (ii)&nbsp;no attorney representing the Company or any of its Subsidiaries, whether or not employed by
the Company or any of its Subsidiaries, has reported evidence of a breach of fiduciary duty or similar violation by the Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents to the Company Board or
any committee thereof or to the General Counsel or Chief Executive Officer of the Company, except as, in each of (i)&nbsp;and (ii), has not had and would not, individually or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.07 <U>Absence of Certain Changes or Events</U>. Since December&nbsp;31, 2019, there has not been any
Company Material Adverse Effect. From June&nbsp;30, 2020 to the date of this Agreement, (a)&nbsp;the Company and its Subsidiaries have conducted their businesses in all material respects in the ordinary course and (b)&nbsp;neither the Company nor
any of its Subsidiaries has taken any action that, if taken after the date of this Agreement, would constitute a breach of any of the covenants set forth in <U>Section&nbsp;6.01(b)</U> (with the exception of those set forth in clauses (i), (ii),
(iv), (viii), (xii), (xiv), (xv), (xix), (xx)&nbsp;and (xxii)&nbsp;(to the extent related to the foregoing)), except where such action has not had, and would not, individually or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.08 <U>Absence of Litigation</U>. Except as set forth on Section&nbsp;4.08 of the Company Disclosure
Letter, there is no Action pending or, to the knowledge of the Company, threatened (i)&nbsp;against or involving the Company, any of its Subsidiaries or any of their respective assets, officers, directors or key employees (in the case of officers,
directors or key employees, arising out of such officer&#146;s, director&#146;s or key employee&#146;s relationship with the Company) that, individually or in the aggregate, has or would reasonably be expected to have a Company Material Adverse
Effect, or (ii)&nbsp;that seeks to restrain or enjoin the consummation of the Transactions. There is not any Order of any Governmental Authority or arbitrator outstanding against, or, to the knowledge of the Company, investigation by any
Governmental Authority involving, the Company, any of its Subsidiaries or any of their respective assets, officers, directors or key employees (in the case of such officers, directors or key employees, such as would affect the Company or any of its
Subsidiaries) that, individually or in the aggregate, has or would reasonably be expected to have a Company Material Adverse Effect. There is no material Action pending by the Company or any of its Subsidiaries, or which the Company or any of its
Subsidiaries intends to initiate, against any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.09 <U>Employee Benefit Plans</U>.
(a)&nbsp;<U>Section&nbsp;4.09(a) of the Company Disclosure Letter</U> lists each material Plan as of the date hereof. To the extent applicable, with respect to each material Plan, true and correct copies of the following have been delivered or made
available to Parent by the Company: (i)&nbsp;all Plan documents (including all amendments and attachments thereto), or written summaries of any such Plan not in writing; (ii)&nbsp;all related trust documents, insurance contracts or other funding
arrangements and the most recent actuarial report; (iii)&nbsp;the most recent annual report (Form 5500) filed with the IRS or comparable report filed with any other applicable Governmental Authority; (iv)&nbsp;the most recent determination, opinion
or advisory letter from the IRS or other applicable Governmental Authority; and (v)&nbsp;the most recent summary plan description and any summary of material modification thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, (i) the terms of each Plan comply with applicable Law and each Plan has been operated and funded in accordance with its terms and applicable Law and (ii)&nbsp;the Company and its Subsidiaries are in compliance with
all Laws relating to the Plans. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, no Action is pending or, to the knowledge of the Company, threatened with respect to any Plan
(other than claims for benefits in the ordinary course), and, to the knowledge of the Company, there are not any facts that would be reasonably expected to give rise to any such Action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code either has received a favorable determination letter from
the IRS or may rely upon a favorable prototype opinion letter from the IRS as to its qualified status and, to the knowledge of the Company, there are no facts or circumstances that could reasonably be expected to adversely affect such qualification.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither the Company nor any of its Subsidiaries has incurred or reasonably expects to incur any liability (actual or contingent)
under, arising out of or by operation of Title IV of ERISA (other than liability for premiums to the PBGC arising in the ordinary course), except as would not, individually or in the aggregate, reasonably be expected to have a Company Material
Adverse Effect. Neither the Company nor any of its Subsidiaries has, during the six-year period ending on the date hereof, maintained, contributed to or been required to contribute to any &#147;multiemployer plan&#148; as defined in
Section&nbsp;3(37) or 4001(a)(3) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as provided in this Agreement or as set forth on <U>Section&nbsp;4.09(e) of the
Company Disclosure Letter</U>, neither the execution of this Agreement nor the consummation of the Transactions will (either alone or in connection with any other event, including a termination of employment or service of any current or former
Service Provider in connection with the Transactions): (i)&nbsp;entitle any current or former Service Provider to severance pay or benefits or any increase in severance pay or benefits upon any termination of employment or service with the Company
or any of its Subsidiaries; and (ii)&nbsp;accelerate the time of payment or vesting or trigger any payment or funding (through a grantor trust or otherwise) of compensation or benefits under, or increase the amount payable pursuant to, any of the
Plans to any current or former Service Provider. No payment or benefit that will or may be made by the Company or its Subsidiaries to any of their respective current or former Service Providers is reasonably expected to, individually or in
combination with any other such payment or benefit, constitute an &#147;excess parachute payment&#148;, as defined in Section&nbsp;280G(b)(1) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its Subsidiaries has any obligation to provide health or other welfare benefits to any current or former
Service Provider following any termination of employment under any Plan (other than continuation coverage required under Section 4980(B)(f) of the Code or other applicable Law or for which the Service Provider bears the full cost). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) No current or former Service Provider is entitled to any gross-up, make-whole or
reimbursement payment from the Company or any of its Subsidiaries in respect of any Tax imposed on such Service Provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Neither the
Company nor any of its Subsidiaries has (i)&nbsp;applied for or received any loan under the Paycheck Protection Program under the CARES Act or (ii)&nbsp;deferred any Taxes under Section&nbsp;2302 of the CARES Act or claimed any Tax credit under
Section&nbsp;2301 of the CARES Act or Sections 7001-7003 of the FFCRA or I.R.S. Notice 2020-65. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) With respect to each Non-U.S. Benefit
Plan, except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all contributions to each Non-U.S. Benefit Plan required to be made by the Company or its Subsidiaries by Law or by the
terms of such Non-U.S. Benefit Plan or pursuant to any mandatory provident fund schemes have been made or, if applicable, accrued in accordance with generally accepted accounting practices in the applicable jurisdiction applied to such matter; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) each Non-U.S. Benefit Plan required to be registered has been so registered and has been maintained in good standing with
applicable Governmental Authorities; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) each Non-U.S. Benefit Plan is in compliance with any funding requirements
mandated by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section 4.10 <U>Labor and Employment Matters</U>. (a)&nbsp;Neither the Company nor any of its Subsidiaries is
a party to any collective bargaining agreement or similar contract applicable to any current or former Service Provider. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect,
(i)&nbsp;from January&nbsp;1, 2018 through the date of this Agreement, there have not been any strikes or other labor disputes or work stoppages or organizational campaigns, petitions or other unionization activities seeking recognition of a
collective bargaining unit relating to any current or former Service Provider, (ii)&nbsp;there are no strikes or other labor disputes or work stoppages or campaigns, petitions or other activities ongoing or, to the knowledge of the Company,
threatened, and (iii)&nbsp;neither the Company nor any of its Subsidiaries is the subject of any proceeding alleging that the Company or any of its Subsidiaries has engaged in any unfair labor practice under any applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the Company and
each of its Subsidiaries are currently in compliance with all applicable Laws related to the engagement of service providers, employment practices and labor relations, including those related to wages, hours, classification, immigration, health,
safety and collective bargaining. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, no current or former individual independent contractor that provides personal services to the
Company or its Subsidiaries (other than any current or former director) is entitled to any fringe or other benefits (other than cash consulting fees or other consulting payments) pursuant to any Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, no Action by or before any Governmental Authority with respect to the Company or any of its Subsidiaries in relation to the employment or alleged employment of any individual is ongoing or, to the knowledge of the
Company, pending or threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect and except as set forth in <U>Section&nbsp;4.10(d) of the Company Disclosure Letter</U>, since January&nbsp;1, 2018, the Company and its Subsidiaries have not been subject to any Actions alleging sexual harassment, sexual
misconduct, bullying or unlawful discrimination committed by any director, officer or other managerial employee of the Company or any of its Subsidiaries related to his or her directorship or employment with the Company or any of its Subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section 4.11 <U>Real Property; Title to Assets</U>. (a)&nbsp;Neither the Company nor any of its Subsidiaries owns any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i)&nbsp;each
Real Property Lease is valid and binding on the Company or the Subsidiary of the Company that is a party thereto and, to the knowledge of the Company, each other party thereto and is full force and effect, (ii)&nbsp;all rent and other sums and
charges payable by the Company or any of its Subsidiaries as tenants thereunder are current and all obligations required to be performed or complied with by the Company or any of its Subsidiaries thereunder have been performed, (iii)&nbsp;no
termination event or condition or uncured default of a material nature on the part of the Company or, if applicable, its Subsidiaries or, to the knowledge of the Company, the landlord thereunder, exists under any Real Property Lease, (iv)&nbsp;the
Company and each of its Subsidiaries has a good and valid leasehold interest in each parcel of real property leased by it free and clear of all Encumbrances, except Permitted Encumbrances, (v)&nbsp;neither the Company nor any of its Subsidiaries has
received any written notice from any landlord under any Real Property Lease that such landlord intends to terminate such Real Property Lease and (vi)&nbsp;neither the Company nor any of its Subsidiaries has received written notice of any pending
and, to the knowledge of the Company, there is no threatened, condemnation with respect to any property leased pursuant to any of the Real Property Leases. The Company and its Subsidiaries have not subleased or licensed any portion of any real
property that is leased pursuant to any Real Property Lease to any Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company or one of its Subsidiaries, as the case may
be, has valid title to, or valid leasehold or comparable contractual rights in or relating to, all material personal property owned or leased by it, free and clear of all Encumbrances, except Permitted Encumbrances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12 <U>Intellectual Property</U>. (a)&nbsp;<U>Section&nbsp;4.12(a) of the
Company Disclosure Letter</U> sets forth, as of the date of this Agreement, a true and complete list of all (i)&nbsp;Registered Company IP, indicating for each such item, as applicable, the owner, the application, publication or registration number,
and date and jurisdiction of filing or issuance; and (ii)&nbsp;material Software included in the Company Owned IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would
not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the Registered Company IP is subsisting and, to the knowledge of the Company, valid and enforceable. The Company and its Subsidiaries possess
all rights, title and interests in and to the Company Owned IP, free and clear of any Encumbrances other than Permitted Encumbrances, except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse
Effect. To the knowledge of the Company, the Registered Company IP owned by the Company is currently in compliance with any and all formal legal requirements necessary to record, perfect and maintain the Company or any of its Subsidiaries&#146;
interest therein and the chain of title thereof, except where any non-compliance would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect and to the
knowledge of the Company, since January&nbsp;1, 2018, the operation of the Company&#146;s business has not infringed, misappropriated or otherwise violated (including with respect to the development, clinical testing, manufacture, distribution,
marketing, use or sale by the Company or any of its Subsidiaries of their respective products or of their respective Intellectual Property) the Intellectual Property of any third party (other than such rights determined and documented in writing by
Company counsel and/or outside counsel to be invalid, not infringed or unenforceable) and to the knowledge of the Company, no other Person has infringed, diluted, misappropriated or otherwise violated, or is infringing, diluting, misappropriating or
otherwise violating the Company IP. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect and except as set forth in <U>Section&nbsp;4.12(c) of the Company Disclosure Letter</U>,
there are currently no pending Actions or Actions threatened in writing regarding: (i)&nbsp;the licensing or use by the Company or any of its Subsidiaries of any other Person&#146;s Intellectual Property; (ii)&nbsp;any actual or potential
infringement, dilution, misappropriation, or other violation by any other Person of the Company IP; (iii)&nbsp;any actual or potential infringement, dilution, misappropriation, or other violation of any other Person&#146;s Intellectual Property by
the Company or any of its Subsidiaries; or (iv)&nbsp;the ownership, validity, registrability, enforceability or use of any Company IP, and to the knowledge of the Company (and except as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect), no valid basis exists for any Action in connection with any of the foregoing items (i)&nbsp;through (iv)&nbsp;of this <U>Section&nbsp;4.12(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company Owned IP constitutes all of the material Intellectual Property owned by the Company and its Subsidiaries that is used, held
for use or planned for use in the operation or conduct of the Company&#146;s business as currently conducted; and the Company IP constitutes all of the Intellectual Property that is used, held for use or planned for use in the conduct of the
Company&#146;s business in the manner in which it is currently being conducted, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except where failure to own or otherwise possess rights to any such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse
Effect. To the knowledge of the Company, except as set forth in Section&nbsp;4.12(d) of the Company Disclosure Letter, the consummation of this Agreement and compliance by the Company and its Subsidiaries with the provisions of this Agreement will
not conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of
a benefit under, or result in the creation of any Encumbrance (other than a Permitted Encumbrance) in or upon, any Company IP. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect,
after the Effective Time, Parent will own all right, title and interest in and to or otherwise have valid rights and licenses to use all Company IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To the knowledge of the Company, each of the Company and its Subsidiaries have used commercially reasonable efforts to maintain, preserve
and protect the secrecy and confidentiality of their Trade Secrets and other confidential information and prevent the misuse or misappropriation of the Trade Secrets and other confidential information included in the Company IP, including through
the development of policies for the protection of Intellectual Property, except any failure to maintain, preserve or protect that would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. To the
knowledge of the Company, each current and former employee, consultant or independent contractor of the Company who has had access to Trade Secrets or confidential information included in the Company IP has entered into a written agreement with the
Company that requires such employee, consultant or contractor to protect the secrecy and confidentiality of such Trade Secrets and information, except any failure to enter into such agreements would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect. To the knowledge of the Company, there has been no misappropriation or unauthorized disclosure or use of any of the Company&#146;s Trade Secrets or other confidential information, except any
misappropriation or unauthorized disclosure would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, no current or
former director, officer, employee, contractor or consultant of the Company or its Subsidiaries owns any rights in or to any Company Owned IP. To the knowledge of the Company, all current and former directors, officers, employees, contractors and
consultants of the Company and its Subsidiaries who contributed to the business or to the discovery, creation or development of any Company Owned IP did so (i)&nbsp;within the scope of his or her employment such that it constituted a work made for
hire and all Company Owned IP arising therefrom became the exclusive property of the Company or any of its Subsidiaries or (ii)&nbsp;pursuant to an executed, enforceable, valid written agreement, assigned all of his or her rights in Company Owned IP
to the Company or any of its Subsidiaries, except any failure to assign would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. No current or former directors, officers, employees, contractors
or consultants of the Company or any of its Subsidiaries has made a written claim, or threatened in writing to make any claim, of ownership or right, in whole or in part, to any Company Owned IP or asserted in an Action against the Company or any of
its Subsidiaries such claim of ownership or right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, the IT Assets operate and perform as required to permit the operation of the Company&#146;s business as currently conducted. To the knowledge of the Company, since January&nbsp;1, 2018, except as would not,
individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i)&nbsp;there has been no actual or threatened security breach or unauthorized access to or use of any of the IT Assets and (ii)&nbsp;the IT Assets
do not contain any material viruses, worms, trojan horses, bugs, or faults, and have not experienced breakdowns, errors, contaminants, or continued substandard performance that has caused or reasonably could be expected to cause any material
disruption or interruption in or to the use of any such IT Assets or to the business of the Company. The Company and its Subsidiaries have implemented reasonable backup, security and disaster recovery technology reasonably consistent with industry
practices and are in compliance in all material respects with applicable Privacy and Data Security Requirements for the IT Assets used in the business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, there is no
Public Software included in the Company IP that is subject to any open source, public source, freeware or other third party license agreement that: (i)&nbsp;requires the Company or its Subsidiaries to license, disclose or distribute any proprietary
source code, IT Asset or Company IP to licensees or any other Person, (ii)&nbsp;prohibits or limits the receipt of consideration in connection with licensing, sublicensing or distributing any Software included in the Company Owned IP,
(iii)&nbsp;except as specifically permitted by Law, allows any Person to decompile, disassemble or otherwise reverse-engineer any Software included in the Company Owned IP, (iv)&nbsp;requires the licensing of any Software included in the Company
Owned IP to any other Person for the purpose of making derivative works or (v)&nbsp;otherwise materially limits the Company&#146;s or its Subsidiaries&#146; right to require royalty payments for the use or restrict further distribution of such
Software. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the Company and its Subsidiaries are in compliance with all of the terms and conditions of any licenses applicable to
any Public Software used by the Company and its Subsidiaries in the operation of the business as currently conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) All Company
proprietary Software has been created, and the associated source code written, only by individuals, who, at the time they created and developed such Software, were Company employees, contractors or consultants of the Company or any of its
Subsidiaries. To the knowledge of the Company, the Company and its Subsidiaries have not disclosed, delivered or licensed to any Person, or obligated themselves to disclose, deliver or license to any Person, any Software source code included in
Company Owned IP other than to a current or former employee, contractor or consultant who has executed, enforceable, valid written confidentiality obligations to the Company or any of its Subsidiaries restricting the use and disclosure of such
source code. To the knowledge of the Company, there has been no unauthorized use, reverse engineering, decompiling, disassembling, or other unauthorized disclosure of or access to any source code owned by the Company and its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Schedule 4.12(j) of the Company Disclosure Letter </U>lists, as of the date hereof,
all agreements pursuant to which a university, or other educational institution, research institution or agency, Governmental Authority, or other organization (each, an &#147;<U>R&amp;D Sponsor</U>&#148;) has sponsored research or development
conducted in connection with the businesses of the Company and its Subsidiaries. Except as set forth in <U>Schedule 4.12(j) of the Company Disclosure Letter, </U>no R&amp;D Sponsor has any claim of right or license to, ownership of, or other
Encumbrance (other than a Permitted Encumbrance) on, any Company IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect, since January&nbsp;1, 2018, the Processing of any Personal Data by the Company and its Subsidiaries has not violated, and does not violate, any applicable Privacy and Data Security
Requirements. Without limiting the foregoing the Company and its Subsidiaries have ensured that all appropriate consents required by applicable Privacy and Data Security Requirements have been obtained from data subjects or other Persons whose
Personal Data is Processed thereby, except where such failure to obtain a consent would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect, the Company and its Subsidiaries have further obtained all rights and licenses necessary to Process Personal Data in the manner it is now Processed thereby or by any Person on its
behalf. There is no Action pending, asserted in writing or threatened in writing against the Company or any of its Subsidiaries alleging a violation of any Privacy and Data Security Requirement or any Person&#146;s right of privacy or publicity,
and, to the knowledge of the Company, no valid basis exists for any such Action. Neither the Company nor its Subsidiaries has (i)&nbsp;received any written communications from or (ii)&nbsp;to the knowledge of the Company, been the subject of any
investigation by a data protection authority or any other Governmental Authority, in each of (i)&nbsp;and (ii), regarding the Processing of Personal Data. Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, the execution and performance of this Agreement will not breach or otherwise cause any violation on the part of the Company or any of its Subsidiaries of any applicable Privacy and Data Security Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, with respect to
all Personal Data Processed by the Company and its Subsidiaries, the Company and its Subsidiaries have taken commercially reasonable measures designed to protect such information against loss and unauthorized access, use, disclosure or other misuse.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, to the
extent required by applicable Privacy and Data Security Requirements, each of the Company and its Subsidiaries has contractually obligated all data processors to contractual terms relating to the protection and use of IT Assets, or Personal Data or
confidential information thereon, no less protective than those implemented and maintained by the Company. The Company is not aware of any material violations of such contractual obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) To the knowledge of the Company, no Person has gained unauthorized access to, engaged in
unauthorized Processing, disclosure, use, or access to, or accidentally or unlawfully destroyed, lost or altered (i)&nbsp;any Personal Data related to the business of the Company and its Subsidiaries; or (ii)&nbsp;any IT Assets that Process Personal
Data related to the business of and owned or maintained by the Company and its Subsidiaries, its respective personal data processors, customers, subcontractors or vendors, or any other Persons on its behalf. Neither the Company nor its Subsidiaries
has notified or, as of the date hereof, plans to notify, either voluntarily or as required by any Privacy and Data Security Requirements, any affected individual, any third party, any Governmental Authority, or the media of any breach or
non-permitted use or disclosure of Personal Data of the Company and its Subsidiaries. Neither the Company nor its Subsidiaries does, or permits any third party to, sell, rent, or otherwise make available to any Person any Personal Data, except in
compliance with the applicable Privacy and Data Security Requirements. To the knowledge of the Company, the Personal Data Processed by the Company and its Subsidiaries can be used after the Closing in a manner substantially the same as currently
used by the Company and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13 <U>Taxes</U>. Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All Tax Returns required to be filed by or with respect to the
Company or any of its Subsidiaries have been timely filed (taking into account any extension of time within which to file) and all such Tax Returns are true, complete and accurate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Taxes due and payable by the Company and its Subsidiaries have been timely paid, whether or not required to be shown on a Tax Return,
or, in the case of Taxes not yet due or that are being contested in good faith, have been accrued or reserved, in accordance with GAAP, on the Financial Statements. There are no Tax Encumbrances on the assets of the Company or any of its
Subsidiaries other than Permitted Encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of the Company and its Subsidiaries has timely paid or withheld all Taxes
required to be paid or withheld with respect to their employees, independent contractors, creditors and other third parties (and timely paid over such Taxes to the appropriate Governmental Authority to the extent required by applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither the Company nor any of its Subsidiaries has executed any outstanding waiver of any statute of limitations for the assessment or
collection of any Tax and there is no pending request by a Governmental Authority in writing to execute such a waiver or extension. No material audit or other examination or administrative, judicial or other proceeding of, or with respect to, any
Tax Return or Taxes of the Company or any of its Subsidiaries is currently in progress. No deficiency for any material amount of Tax has been asserted or assessed by a Governmental Authority in writing against the Company or any of its Subsidiaries
that has not been settled, paid or withdrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Within the two (2)-year period ending on the date hereof, neither the Company nor any
of its Subsidiaries has been a party to any transaction treated by the parties as a distribution to which Section&nbsp;355 or 361 of the Code applies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its Subsidiaries has participated in a &#147;listed
transaction&#148; within the meaning of Treasury Regulation &#167; 1.6011-4, or any similar provision of state, local or foreign Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
Neither the Company nor any of its Subsidiaries (i)&nbsp;is a party to or is bound by any Tax Sharing Agreement, (ii)&nbsp;has liability for payment of any amount as a result of being party to any Tax Sharing Agreement, (iii)&nbsp;has been a member
of an affiliated group filing a consolidated United States federal income Tax Return (other than an affiliated group the common parent of which was the Company) or (iv)&nbsp;has liability for the Taxes of any Person (other than the Company or any of
its Subsidiaries) under Treasury Regulation &#167; 1.1502-6 (or any similar provision of state, local or foreign Law), as a transferee or successor, or by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Section&nbsp;4.13(h) of the Company Disclosure Letter</U> contains a list, as of the date of this Agreement, of all jurisdictions in
which the Company or any of its Subsidiaries files any income Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) To the knowledge of the Company, no claim has been made in
writing by any Governmental Authority in a jurisdiction where the Company or any of its Subsidiaries do not file Tax Returns that any such entity is, or may be, subject to taxation by that jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Neither the Company nor any of its Subsidiaries has an outstanding request for a ruling or similar determination from a Governmental
Authority with respect to Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Neither the Company nor any of its Subsidiaries will be required to include any item of income in,
or exclude any item of deduction from, taxable income for any taxable period ending after the Closing Date as a result of any: (i)&nbsp;adjustment pursuant to Section&nbsp;481 of the Code (or similar provision under any federal, state, local or
foreign Law) associated with a change of accounting method that was made on or before the date of this Agreement; (ii)&nbsp;closing agreement or other agreement with any Governmental Authority executed on or before the date of this Agreement;
(iii)&nbsp;transaction entered into on or before the date of this Agreement and treated under the installment method, long-term contract method, cash method or open transaction method of accounting; or (iv)&nbsp;inclusion, other than in the ordinary
course of business, under Section 951(a) of the Code or similar provision of state, local or foreign law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14
<U>Environmental Matters</U>. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect: (a)&nbsp;the Company is and, since January&nbsp;1, 2018, has been in compliance with all
Environmental Laws and possesses and is and, since January&nbsp;1, 2018, has been in compliance with all Environmental Permits, (b)&nbsp;there is no Action, Order or notice of violation or liability, in each case pursuant to Environmental Law
pending or, to the knowledge of the Company, threatened in writing against the Company or any of its Subsidiaries; (c)&nbsp;there has been no release, spill, discharge or disposal of or exposure to any Hazardous Material, nor are there any other
facts or conditions, in each case that would reasonably be expected to form the basis of any Action or Order pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Environmental Law involving the Company or its Subsidiaries; (d)&nbsp;neither the Company nor any of its
Subsidiaries has retained or assumed, either contractually or by operation of Law, any liabilities or obligations that would reasonably be expected to form the basis of any Action or Order pursuant to Environmental Law involving the Company or its
Subsidiaries; and (e)&nbsp;there are no underground or aboveground storage tanks containing Hazardous Materials or any known or suspected asbestos-containing materials on, at or under any real property leased pursuant to any of the Real Property
Leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15 <U>Material Contracts</U>. (a)&nbsp;Other than any contracts described in, or included as exhibits to, the
Company Registration Statement, <U>Section&nbsp;4.15(a) of the Company Disclosure Letter</U> contains a true and complete list of the following types of contracts to which the Company or any of its Subsidiaries is a party and that are in effect, or
pursuant to which the Company or any Subsidiary has material ongoing obligations, in each case as of the date of this Agreement (such contracts, including those described in, or included as exhibits to, the Company Registration Statement, whether or
not set forth on <U>Section&nbsp;4.15(a) of the Company Disclosure Letter</U> and including any contract entered into after the date hereof in accordance with the terms of this Agreement that would have been required to be set forth on
<U>Section&nbsp;4.15(a) of the Company Disclosure Letter</U> if it had been entered into as of the date of this Agreement, the &#147;<U>Material Contracts</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) all contracts that would, if the Company were an issuer of securities registered pursuant to Section&nbsp;12 of the
Exchange Act, be required to be filed by the Company as a &#147;material contract&#148; pursuant to Item&nbsp;601(b)(10) of Regulation S-K under the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) (A)&nbsp;all joint venture contracts or partnership arrangements or (B)&nbsp;similar agreements involving a sharing with
any third party of profits, losses, costs or liabilities by the Company or any of its Subsidiaries, pursuant to which, in the case of this clause (B), the Company would reasonably expect its share of such profits, losses, costs or liabilities in any
fiscal year to exceed $2,000,000 (or its equivalent in another currency); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) all contracts involving the payment of
royalties or other amounts calculated based upon the revenues or income of the Company or any of its Subsidiaries or income or revenues related to any product of the Company or any of its Subsidiaries and requiring payments by the Company in any
fiscal year in excess of $500,000 (or its equivalent in another currency); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) all contracts (A)&nbsp;relating to the
acquisition or disposition of any assets or properties (whether by merger, sale of stock, sale of assets or otherwise) for aggregate consideration in excess of $2,000,000 or (B)&nbsp;pursuant to which any earn-out, indemnification or deferred or
contingent payment obligations remain outstanding that would reasonably be expected to involve payments by or to the Company or any of its Subsidiaries of more than $2,000,000 after the date hereof (in each case, excluding, for the avoidance of
doubt, acquisitions or dispositions of supplies, products or other assets in the ordinary course of business or of supplies, products or other assets that are obsolete, worn out, surplus or no longer used or useful in the conduct of business of the
Company or its Subsidiaries); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) all contracts relating to Indebtedness for borrowed money (including
commitments to provide such Indebtedness) of the Company or any of its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) all contracts that limit, or
purport to limit, in any material respect, the ability of the Company or any of its Affiliates to compete in any line of business or with any Person or entity or in any geographic area or during any period of time or in any customer segment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) all material Company IP Agreements, except for shrink-wrap or click-wrap licenses for off the shelf computer software,
pursuant to which the Company or any of its Subsidiaries would reasonably be expected to make or receive payments of more than $500,000 during any fiscal year; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) all contracts with respect to any Intellectual Property that contain a covenant not to sue; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) each contract between or among (A)&nbsp;the Company or any of its Subsidiaries, on the one hand, and (B)&nbsp;any
Affiliate, stockholder, employee, officer or director of the Company or of any Subsidiary, or, to the knowledge of the Company, any of their respective Affiliates or family members, on the other hand, but excluding, for the avoidance of doubt,
(I)&nbsp;any contracts or arrangements between the Company and any of its Subsidiaries or between any Subsidiary of the Company and another Subsidiary of the Company, (II) any Plan, (III) any contract providing for indemnification or reimbursement
of expenses for officers or directors of the Company or any of its Subsidiaries (in such individual capacity as such), and (IV) any contract entered into in the ordinary course of business and on arms&#146; length terms; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) all contracts (other than purchase orders under a master agreement) for the purchase of materials, supplies, goods,
services, equipment or other assets pursuant to which the Company or any of its Subsidiaries would reasonably be expected to make payments of more than $1,000,000 during any fiscal year; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) all contracts relating to research services or clinical trials or pilot or other testing programs in respect of products
(including products under development) of the Company or any of its Subsidiaries pursuant to which the Company or any of its Subsidiaries would reasonably be expected to make or receive payments of more than $500,000 during any fiscal year or which
are otherwise material; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) all contracts that relate to collaboration or joint development or other similar agreement
or arrangement with respect to any products (including products under development) or services of the Company or any of its Subsidiaries pursuant to which the Company or any of its Subsidiaries would reasonably be expected to make or receive
payments of more than $2,000,000 during any fiscal year or which are otherwise material; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) all contracts that limit in any material respect the research,
development, manufacture, distribution, sale, supply, license, marketing or manufacturing of products (including products under development) or services of the Company or any of its Subsidiaries pursuant to which the Company or any of its
Subsidiaries would reasonably be expected to make or receive payments of more than $2,000,000 during any fiscal year or which are otherwise material; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) all contracts granting any put, call, right of first refusal, right of first negotiation, right of first offer,
redemption or similar right in favor of any Person other than the Company or its Subsidiaries, in each case, with respect to any asset that is material to the Company; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) all contracts that provide for &#147;exclusivity&#148; or any similar requirement or &#147;most favored nation&#148; or
similar rights, in each case in favor of any Person other than the Company or any of its Subsidiaries, and, in the case of contracts with suppliers or vendors, (A)&nbsp;the current term of which is longer than two years (not including any renewal
terms) and (B)&nbsp;pursuant to which the Company or any of its Subsidiaries would reasonably be expected to make or receive payments of more than $1,000,000 during any fiscal year, which are otherwise material, other than, in each case, any such
contract that is terminable without penalty by the Company or its Subsidiaries on no more than 6 months&#146; notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as would
not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, each Material Contract is in full force and effect, and is legal, valid, binding and enforceable in accordance with its terms against the
Company and its Subsidiaries (as applicable) and, to the knowledge of the Company, the other parties thereto. True and complete copies of each Material Contract (and a written summary of the terms of any oral Material Contracts) have been made
available to Parent. None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any other party thereto is in violation of or in default under (nor does there exist any condition which upon the passage of time or the giving of
notice or both would cause such a violation of or default under) any Material Contract to which it is a party or by which it or any of its properties or other assets is bound, nor have any of them given or received any notice alleging any of the
same, except, in each case, as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16 <U>Insurance</U>. Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a
Company Material Adverse Effect, all insurance policies and all self-insurance programs and arrangements relating to the business, assets and operations of the Company and its Subsidiaries are in full force and effect, and all premiums thereon have
been timely paid or, if not yet due, accrued. As of the date of this Agreement, there is no claim pending under the Company&#146;s or any of its Subsidiaries&#146; insurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">policies or fidelity bonds as to which coverage has been questioned, denied or disputed by the underwriters
of such policies or bonds, except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. The Company and its Subsidiaries are in compliance with the terms of such policies and bonds and the
Company has no knowledge of any threatened termination of, or premium increase with respect to, any of such policies or bonds, except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17 <U>Brokers</U>. No broker, finder, financial advisor or investment banker (other than Morgan Stanley&nbsp;&amp; Co.
LLC, the fee payable to whom will not exceed the amount set forth in the engagement letter dated September&nbsp;13, 2020, as made available to Parent prior to the date hereof) is entitled to any brokerage, finder&#146;s or other fee or commission in
connection with the Transactions based upon arrangements made by or on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18 <U>Regulatory
Compliance</U>. (a)&nbsp;Since January&nbsp;1, 2018, except as would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect, none of the Company, any of its Subsidiaries or, to the knowledge of
the Company, any of their respective directors, officers, employees or Collaboration Partners (solely with respect to such Collaboration Partners&#146; activities with the Company and its Subsidiaries) have (i)&nbsp;made an untrue statement of a
material fact or fraudulent statement to the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;) or any other Health Authority, (ii)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or any other Health
Authority, or (iii)&nbsp;committed any other act, made any statement or failed to make any statement, that (in the case of any of (i), (ii)&nbsp;or (iii)) establishes a reasonable basis for the FDA to invoke the policy respecting &#147;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities&#148; set forth in 56 Fed. Reg. 46191 (September 10, 1991) (the &#147;<U>FDA Fraud Policy</U>&#148;) or for any other Health Authority to invoke a similar policy that may be applicable to
the Company or any of its Subsidiaries in another jurisdiction. None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any of their respective directors, officers, employees or Collaboration Partners (solely with respect
to such Collaboration Partners&#146; activities with the Company and its Subsidiaries) are the subject of any pending or, to the Company&#146;s knowledge, threatened investigation by the FDA under the FDA Fraud Policy, or the subject of any similar
investigation by any other Health Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company has made available to Parent true and complete copies of all correspondence,
pre-submissions, submissions and other communications with the FDA since January&nbsp;1, 2018, other than immaterial correspondence of an administrative nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect, since
January&nbsp;1, 2018, (i)&nbsp;the Company and each of its Subsidiaries and, to the knowledge of the Company, each Collaboration Partner (solely with respect to such Collaboration Partner&#146;s activities with the Company and its Subsidiaries), has
been in compliance with all Health Laws, including those relating to laboratory developed tests, and without limiting the generality of the foregoing, (ii)&nbsp;all products under development by or on behalf of the Company or any of its Subsidiaries
have been researched, developed, tested, manufactured, handled, labeled, packaged, stored, supplied, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">distributed, imported, and exported, as applicable, in compliance with applicable Health Laws as presently
enforced with respect to laboratory developed tests and (iii)&nbsp;all clinical trials conducted by or on behalf of the Company or any of its Subsidiaries have been conducted in compliance in all material respects with applicable protocols,
procedures and applicable Health Laws. Except as would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect, none of the Company, any of its Subsidiaries or, to the knowledge of the Company,
any Collaboration Partner (solely with respect to such Collaboration Partner&#146;s activities with the Company and its Subsidiaries) (A)&nbsp;has received any written notice or other written communication from any Health Authority (including a
warning, untitled or notice of violation letter or Form FDA-483) alleging any violation of any Health Law, including any failure to maintain systems and programs adequate to ensure compliance with any such Health Laws or any violation of or failure
to comply with any such Health Laws with respect to clinical trials, or contesting the premarket clearance or approval of, the uses of or the labeling and promotion of any product subject to any Health Law, or (B)&nbsp;is subject to any enforcement,
regulatory or administrative proceedings against or affecting the Company relating to or arising under any Health Law and, to the knowledge of the Company, no such enforcement, regulatory or administrative proceeding has been threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect, Company and
its Subsidiaries have, since January&nbsp;1, 2018, (i)&nbsp;filed with the applicable Health Authority all required filings, including adverse event reports, and (ii)&nbsp;all such filings were in material compliance with applicable Law when filed,
and no deficiencies have been asserted in writing by any applicable Health Authority with respect to any such filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither the
Company nor any of its Subsidiaries, nor, to the knowledge of the Company, any director, officer, employee or agent of the Company or any of its Subsidiaries, has been convicted of any crime or engaged in any conduct for which debarment is mandated
by Section&nbsp;306 of the Federal Food, Drug, and Cosmetic Act (including the rules and regulations promulgated thereunder, the &#147;<U>FDCA</U>&#148;), (21 U.S.C. &#167; 335a(a)) or any other Health Law or authorized by Section&nbsp;306 of the
FDCA (21 U.S.C. &#167; 335a(b)) or any other Health Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither the Company nor any of its Subsidiaries, nor, to the knowledge of
the Company, any officer, employee or agent of the Company or any of its Subsidiaries, has been convicted of any crime or engaged in any conduct for which such Person or entity could be excluded from participating in the federal health care programs
under Section&nbsp;1128 of the Social Security Act of 1935 (the &#147;<U>Social Security Act</U>&#148;), or any similar Law in any foreign jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Except as would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect, to the
knowledge of the Company, there are no facts, circumstances or conditions that would reasonably be expected to form the basis for any Action against or affecting the Company or any of its Subsidiaries, in each case relating to or arising under
(i)&nbsp;the FDCA or any other Health Law or (ii)&nbsp;the Social Security Act or any similar Law in any foreign jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19 <U>Prohibited Payments</U>. (a)&nbsp;Except as would not, individually or
in the aggregate, reasonably be expected to result in a Company Material Adverse Effect, none of the Company, any of its Subsidiaries, any of their respective officers or employees, and, to the knowledge of the Company, any supplier, distributor,
licensee or agent or any other Person acting on behalf of the Company or any of its Subsidiaries, directly or indirectly, has (i)&nbsp;made or offered to make or received any direct or indirect payments in violation of the United States Foreign
Corrupt Practices Act, the U.K. Bribery Act 2010, the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions or any other applicable anti-corruption or anti-bribery Law (collectively,
&#147;<U>Anti-Corruption Laws</U>&#148;), including any contribution, payment, commission, rebate, promotional allowance or gift of funds or property or any other economic benefit or thing of value to or from any employee, official or agent of any
Governmental Authority where either the contribution, payment, commission, rebate, promotional allowance, gift or other economic benefit or thing of value, or the purpose thereof, was illegal under any Law (including the Anti-Corruption Laws), or
(ii)&nbsp;provided or received any product or services in violation of any Law (including the Anti-Corruption Laws). Except as would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect,
neither the Company nor any of its Subsidiaries has received any written or, to the knowledge of the Company, other communication from any Governmental Authority regarding any material violation of, or failure to comply with, any Anti-Corruption
Laws or to the knowledge of the Company, is the subject of any internal complaint, audit or review process regarding a material violation of, or failure to comply with, any Anti-Corruption Laws. Since January&nbsp;1, 2018, neither the Company nor
any of its Subsidiaries has made any disclosure (voluntary or otherwise) to any Governmental Authority with respect to any alleged irregularity, misstatement or omission or other potential violation or liability arising under or relating to any
Anti-Corruption Laws, except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all respects with applicable
financial recordkeeping, reporting and internal control requirements of the Currency and Foreign Transactions Reporting Act of 1970, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority (collectively, the &#147;<U>Money Laundering Laws</U>&#148;) and of the United States Foreign Corrupt Practices Act, except, in each case, where such
non-compliance would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. No action, claim, suit or proceeding by or before any Governmental Authority involving the Company or any of its
Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened, nor, to the knowledge of the Company, is any investigation by or before any Governmental Authority involving the Company or any of its
Subsidiaries with respect to the Money Laundering Laws pending or threatened, in each case except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any of
their respective Representatives or Affiliates (nor, to the knowledge of the Company, any Person or entity acting on behalf of any of the foregoing) is currently a Person that is, or is owned or controlled by a Person that is (&#147;<U>Sanctioned
Person</U>&#148;), (i)&nbsp;the subject or the target of any sanctions administered or enforced by the U.S. Government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department
of State), the United Nations Security Council, the European Union, or Her Majesty&#146;s Treasury (collectively, &#147;<U>Sanctions</U>&#148;), or (ii)&nbsp;located, organized, or resident in a country or territory subject to comprehensive
Sanctions. The Company is not knowingly engaged in any dealings or transactions with any Sanctioned Person. No action, claim, suit or proceeding by or before any Governmental Authority involving the Company or any of its Subsidiaries with respect to
any Sanctions is pending or, to the knowledge of the Company, threatened, nor, to the knowledge of the Company, is any investigation by or before any Governmental Authority involving the Company or any of its Subsidiaries with respect to any
Sanctions pending or threatened, in each case except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company and its Subsidiaries have conducted their transactions in compliance with all applicable export and re-export control Laws,
including the International Traffic in Arms Regulations and the Export Administration Regulations (collectively, &#147;<U>Export Control Laws</U>&#148;), except, in each case, where such non-compliance would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect. No action, claim, suit or proceeding by or before any Governmental Authority involving the Company or any of its Subsidiaries with respect to the Export Control Laws is pending or, to
the knowledge of the Company, threatened, nor, to the knowledge of the Company, is any investigation by or before any Governmental Authority involving the Company or any of its Subsidiaries with respect to the Export Control Laws pending or
threatened, in each case except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company has and has implemented policies and procedures reasonably designed to ensure compliance with the Anti-Corruption Laws, Money
Laundering Laws, Sanctions and Export Control Laws except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20 <U>Rights Agreement; State Takeover Statutes</U>. (a)&nbsp;The Company is not party to any rights agreement, &#147;poison
pill&#148; or similar agreement or plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company Board, including both Preferred Directors (as defined in the Company&#146;s
certificate of incorporation) has approved unanimously by all directors present at a meeting of the Company Board held on the date hereof the terms of this Agreement, the consummation of the Transactions, including the Mergers, the terms of the
Support Agreements and the terms of the Selling Investor Support Agreement and such approval is sufficient to render inapplicable to this Agreement, the Transactions, including the Mergers, the Support Agreements and the Selling Investor Support
Agreement the restrictions on &#147;business combinations&#148; set forth in Section&nbsp;203 of the DGCL, to the extent such restrictions would otherwise be applicable to this Agreement, the Transactions, including the Mergers, the Support
Agreements and the Selling Investor Support Agreement. Assuming the accuracy of the representations and warranties of Parent, First Merger Sub and Second Merger Sub set forth in <U>Section&nbsp;5.14</U>, no &#147;business combination&#148;,
&#147;control share acquisition&#148;, &#147;fair price&#148;, &#147;moratorium&#148; or other anti-takeover or similar Laws apply to this Agreement, the CVR Agreement or the Transactions, including the Mergers. To the knowledge of the Company, the
Company and its Subsidiaries are not subject to Section&nbsp;2115(b) of the California Corporations Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21 <U>Opinion of Financial Advisor</U>. The Company has received the opinion
of Morgan Stanley&nbsp;&amp; Co. LLC, dated the date of this Agreement, to the effect that, as of the date of this Agreement, the Merger Consideration is fair, from a financial point of view, to the Company&#146;s stockholders, a signed copy of
which opinion has been, or will promptly be, delivered to Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22 <U>Information Supplied</U>. The information supplied
by the Company for inclusion or incorporation by reference in the Registration Statement and the Consent Solicitation Statement will not when supplied contain any untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.23 <U>No Other Representations and Warranties</U>. Notwithstanding anything herein to the contrary, the representations and
warranties of the Company expressly set forth in this Article IV and in the certificate delivered by the Company pursuant to <U>Section&nbsp;8.02(c</U>) are and shall constitute the sole and exclusive representations and warranties made with respect
to the Company and its Subsidiaries in connection with this Agreement or the Transactions. Except for the representations and warranties referred to in previous sentence, none of the Company, its Subsidiaries or any other Person has made or is
making any express or implied representations or warranty, statutory or otherwise, of any nature, including with respect to any express or implied representation or warranty as to the merchantability, quality, quantity, suitability or fitness for
any particular purpose of the business or the assets of the Company and its Subsidiaries. Except for the representations and warranties expressly set forth in <U>Article IV</U> and in the certificate delivered pursuant to
<U>Section&nbsp;8.02(c</U>), all other warranties, express or implied, statutory or otherwise, of any nature, including with respect to any express or implied representation or warranty as to the merchantability, quality, quantity, suitability or
fitness for any particular purpose of the business or the assets of the Company and its Subsidiaries, are hereby expressly disclaimed. The Company hereby acknowledges and agrees that, except for the representations and warranties set forth in
<U>Article V</U> and in the certificate delivered by Parent, First Merger Sub or Second Merger Sub pursuant to <U>Section 8.03(c</U>), (a)&nbsp;none of Parent or any of its Subsidiaries, or any of its or their respective Affiliates, stockholders or
Representatives, or any other Person, has made or is making any express or implied representation or warranty with respect to Parent or any of its Subsidiaries or their respective business or operations, including with respect to any information
provided or made available to the Company or any of its Affiliates, stockholders or Representatives, or any other Person, or, except as otherwise expressly set forth in this Agreement, had or has any duty or obligation to provide any information to
the Company or any of its Affiliates, stockholders or Representatives, or any other Person, in connection with this Agreement, the transactions contemplated hereby or otherwise, and (b)&nbsp;to the fullest extent permitted by law, none of Parent or
any of its Subsidiaries, or any of its or their respective Affiliates, stockholders or Representatives, or any other Person, will have or be subject to any liability or other obligation of any kind or nature to the Company or any of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Affiliates, stockholders or Representatives, or any other Person, resulting from the delivery, dissemination
or any other distribution to the Company or any of its Affiliates, stockholders or Representatives, or any other Person, or the use by the Company or any of its Affiliates, stockholders or Representatives, or any other Person, of any such
information provided or made available to any of them by Parent or any of its Subsidiaries, or any of its or their respective Affiliates, stockholders or Representatives, or any other Person, including any information, documents, estimates,
projections, forecasts or other forward-looking information, business plans or other material provided or made available to the Company or any of its Affiliates, stockholders, or Representatives, or any other Person, in &#147;data rooms,&#148;
confidential information memoranda, management presentations or otherwise in anticipation or contemplation of the Mergers or any other Transaction, and (subject to the express representations and warranties of Parent, First Merger Sub and Second
Merger Sub set forth in <U>Article V</U> and the certificate delivered by Parent, First Merger Sub or Second Merger Sub pursuant to <U>Section&nbsp;8.03(c)</U>) none of the Company or any of its Affiliates, stockholders or Representatives, or any
other Person, has relied on any such information (including the accuracy or completeness thereof). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF PARENT, FIRST MERGER SUB AND SECOND MERGER SUB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">As an inducement to the Company to enter into this Agreement, except as disclosed in the Parent SEC Reports (including exhibits and other
information incorporated by reference therein) filed by Parent and publicly available prior to the date of this Agreement (&#147;<U>Filed Parent</U> <U>SEC Reports</U>&#148;) (but excluding any forward-looking disclosures set forth in any &#147;risk
factors&#148; section, any disclosures in any &#147;forward-looking statements&#148; section and any other disclosures included therein to the extent they are predictive or forward-looking in nature, in each case other than statements of historical
fact), Parent, First Merger Sub and Second Merger Sub hereby, jointly and severally, represent and warrant to the Company that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01 <U>Organization</U>. Each of Parent, First Merger Sub and Second Merger Sub is a company duly organized, validly existing
and in good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has the requisite corporate or limited liability company power and authority and all necessary governmental approvals to own, lease and
operate its properties and assets and to carry on its business as it is now being conducted, except where the failure to possess such governmental approvals would not, individually or in the aggregate, reasonably be expected to have a Parent
Material Adverse Effect. Each of Parent, First Merger Sub and Second Merger Sub is duly qualified or licensed as a foreign corporation or limited liability company to do business, and is in good standing, in each jurisdiction where the character of
the properties or assets owned, leased or operated by it or the nature of its business makes such qualification or licensing necessary, except where the failure to be so qualified or licensed and in good standing would not, individually or in the
aggregate, be reasonably expected to have a Parent Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02 <U>Certificate of Incorporation and Bylaws</U>. Parent has made available
to the Company, prior to the execution of this Agreement, a true and complete copy of the certificate of incorporation and bylaws of Parent and of First Merger Sub and a true and complete copy of the certificate of formation and operating agreement
of Second Merger Sub, each as amended to the date of this Agreement. Such certificates of incorporation and bylaws and such certificate of formation and operating agreement are in full force and effect. None of Parent, First Merger Sub nor Second
Merger Sub is in violation of any of the provisions of its certificate of incorporation, certificate of formation, bylaws, operating agreement or equivalent organizational documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03 <U>Capitalization</U>. (a)&nbsp;The authorized capital stock of Parent consists of (i)&nbsp;320,000,000 shares of Parent
Common Stock and (ii)&nbsp;10,000,000 shares of preferred stock, par value $0.01 per share. As of September&nbsp;11, 2020, (A)&nbsp;146,360,372 shares of Parent Common Stock are issued and outstanding, all of which are duly authorized, validly
issued, fully paid and non-assessable, (B)&nbsp;47,967,116 shares of Parent Common Stock are held in the treasury of Parent, (C)&nbsp;1,817,350 shares of Parent Common Stock are subject to outstanding equity-based awards granted pursuant to
Parent&#146;s stock incentive plans and (D)&nbsp;there are no outstanding shares of preferred stock. Except as set forth in this <U>Section 5.03</U> and except for stock options granted pursuant to the stock option plans of Parent, there are no
options, calls, warrants, convertible debt or other convertible or exchangeable instruments or other rights, agreements, arrangements or commitments of any character made or issued by Parent, First Merger Sub or Second Merger Sub relating to the
issued or unissued capital stock of Parent, First Merger Sub or Second Merger Sub or obligating Parent, First Merger Sub or Second Merger Sub to issue, deliver or sell any shares of capital stock, voting securities or other equity interests or
securities convertible into or exchangeable or exercisable for capital stock, voting securities or other equity interests of Parent, First Merger Sub or Second Merger Sub. All shares of Parent Common Stock subject to issuance as aforesaid, upon
issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be duly authorized, validly issued, fully paid and non-assessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The authorized capital stock of First Merger Sub consists of 1,000 shares of common stock, par value $0.01 per share, all of which are
duly authorized, validly issued, fully paid and non-assessable and free of any preemptive rights in respect thereof and all of which are owned by Parent. Each outstanding share of capital stock of First Merger Sub is owned by Parent free and clear
of all Encumbrances, except where failure to own such shares free and clear would not, individually or in the aggregate, materially adversely affect Parent&#146;s ability to consummate the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All outstanding limited liability company interests of Second Merger Sub have been duly authorized, validly issued and are free of any
preemptive rights in respect thereof and all of which are owned by Parent. All limited liability company interests of Second Merger Sub are owned by Parent free and clear of all Encumbrances, except where failure to own such limited liability
company interests free and clear would not, individually or in the aggregate, materially adversely affect Parent&#146;s ability to consummate the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04 <U>Authority Relative to This Agreement; Vote Required</U>. (a)&nbsp;Each
of Parent, First Merger Sub and Second Merger Sub has all necessary corporate or limited liability company power and authority to execute and deliver this Agreement and the CVR Agreement (as applicable) and, subject to adoption of this Agreement by
Parent, as sole stockholder of First Merger Sub (which such adoption will occur on the date hereof), to perform its obligations hereunder and thereunder and to consummate the Transactions. The execution and delivery of this Agreement and the CVR
Agreement (as applicable) by Parent, First Merger Sub and Second Merger Sub and the consummation by Parent, First Merger Sub and Second Merger Sub of the Transactions have been duly and validly authorized by all necessary corporate or limited
liability company action, and no other corporate or limited liability company proceedings on the part of Parent, First Merger Sub or Second Merger Sub are necessary to authorize this Agreement or the CVR Agreement or to consummate the Transactions
(other than, with respect to the Mergers, the adoption of this Agreement by Parent, as sole stockholder of First Merger Sub (which such adoption will occur on the date hereof), and the filing of the Certificates of Merger with the Secretary of State
of the State of Delaware as required by the DGCL, and the DLLCA, as applicable). This Agreement has been duly and validly executed and delivered by Parent, First Merger Sub and Second Merger Sub and, assuming due authorization, execution and
delivery by the Company, constitutes a legal, valid and binding obligation of each of Parent, First Merger Sub and Second Merger Sub, enforceable against each of Parent, First Merger Sub and Second Merger Sub in accordance with its terms, subject to
the effect of any applicable bankruptcy, insolvency (including all Laws relating to fraudulent transfers), reorganization, moratorium or similar Laws affecting creditors&#146; rights generally and subject to the effect of general principles of
equity (regardless of whether considered in a proceeding at law or in equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No vote of the stockholders of Parent is required by
Law, Parent&#146;s certificate of incorporation or bylaws or otherwise in order for Parent to execute and deliver this Agreement, and to perform its obligations hereunder and to consummate the Transactions. The adoption of this Agreement by Parent,
as sole stockholder of First Merger Sub, is the only vote of stockholders required in order for First Merger Sub to consummate the Transactions to perform its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.05 <U>No Conflict; Required Filings and Consents</U>. (a)&nbsp;The execution and delivery of this Agreement and the CVR
Agreement (as applicable) by each of Parent, First Merger Sub and Second Merger Sub do not, and the performance of this Agreement and the CVR Agreement (as applicable) by each of Parent, First Merger Sub and Second Merger Sub, and the consummation
of the Transactions, will not, (i)&nbsp;conflict with or violate the certificate of incorporation, certificate of formation, bylaws, operating agreement or other equivalent organizational documents of either Parent, First Merger Sub or Second Merger
Sub, (ii)&nbsp;assuming all consents, approvals, authorizations and other actions described in <U>Section&nbsp;5.05(b</U>) have been obtained or taken and all filings and obligations described in <U>Section 5.05(b</U>) have been made or satisfied,
conflict with or violate any Law applicable to Parent, First Merger Sub or Second Merger Sub or by which any property or asset of either of them is bound, or (iii)&nbsp;violate, conflict with, require consent under, result in any breach of, result
in loss of benefit under, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation of, or result in the
creation of an Encumbrance (other than a Permitted Encumbrance) on any property or asset of Parent, First Merger Sub or Second Merger Sub pursuant to, any loan or credit agreement, note, bond, debenture, mortgage, indenture, deed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of trust, contract, agreement, lease, Parent Permit or other instrument or obligation to which Parent, First Merger Sub or Second Merger Sub is a party or by which Parent, First Merger Sub or
Second Merger Sub or any of their respective assets or properties is bound, except, with respect to clauses (ii)&nbsp;and (iii)&nbsp;of this <U>Section 5.05(a</U>), for any such conflicts, violations, breaches, defaults or other occurrences which
would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and
delivery of this Agreement and the CVR Agreement (as applicable) by each of Parent, First Merger Sub and Second Merger Sub do not, and the performance of this Agreement by each of Parent, First Merger Sub and Second Merger Sub, and the consummation
of the Transactions, will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority, except (i)&nbsp;for applicable requirements, if any, of the Securities Act (including in
connection with the Registration Statement), the Exchange Act, the Trust Indenture Act, Blue Sky Laws and state takeover Laws, any filings required to be made with the NASDAQ, the HSR Act, the requirements of any other applicable Antitrust Laws and
the filing of the Certificates of Merger with the Secretary of State of the State of Delaware as required by the DGCL and the DLLCA, as applicable, or (ii)&nbsp;where the failure to obtain such consents, approvals, authorizations or permits, or to
make such filings or notifications, would not, individually or in the aggregate, prevent or materially delay consummation of any of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.06 <U>Compliance</U>. Since January&nbsp;1, 2018, Parent and its Subsidiaries have operated and conducted their businesses in
compliance with all Laws of any Governmental Authority applicable to their respective businesses or operations, except where such non-compliance would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse
Effect. Since January&nbsp;1, 2018, neither Parent nor any of its Subsidiaries has received any written notice from any Governmental Authority alleging, or been charged by a Governmental Authority with, any violation of any Laws, except where such
violation would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.07
<U>Intellectual Property</U>. (a)&nbsp;The Registered Parent IP owned by Parent is subsisting and, to the knowledge of Parent, valid and enforceable, except as would not, individually or in the aggregate, reasonably be expected to have a Parent
Material Adverse Effect. Parent and its Subsidiaries possess all rights, title and interests in and to the Parent Owned IP, free and clear of any Encumbrances other than Permitted Encumbrances, except as would not, individually or in the aggregate,
reasonably be expected to have a Parent Material Adverse Effect. To the knowledge of Parent, the Registered Parent IP owned by Parent is currently in compliance with any and all formal legal requirements necessary to record, perfect and maintain
Parent or any of its Subsidiaries&#146; interest therein and the chain of title thereof, except where any non-compliance would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Parent Owned IP constitutes all of the material Intellectual Property owned by
Parent and its Subsidiaries that is used, held for use or planned for use in the operation or conduct of Parent&#146;s business as currently conducted; and the Parent IP constitutes all of the Intellectual Property that is used, held for use or
planned for use in the conduct of Parent&#146;s business in the manner in which it is currently being conducted, except where failure to own or otherwise possess rights to any such Intellectual Property would not, individually or in the aggregate,
reasonably be expected to have a Parent Material Adverse Effect. To the knowledge of Parent, the consummation of this Agreement and compliance by Parent and its Subsidiaries with the provisions of this Agreement will not conflict with, or result in
any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit under, or result in
the creation of any Encumbrance (other than a Permitted Encumbrance) in or upon, any Parent IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.08 <U>Financing</U>.
Parent has delivered to the Company complete and correct copies of executed commitment letters from Goldman Sachs Bank USA, together with related fee letters (with respect to such fee letters, complete copies with only the fee amounts, interest
rates, original issue discount, and economic and other &#147;market flex&#148; terms redacted, none of which redacted provisions would adversely affect the amount or availability of the Financing on the Closing Date) of which have been provided to
the Company (collectively, the &#147;<U>Financing Commitments</U>&#148;), pursuant to which the Financing Sources party thereto have committed, subject to the terms and conditions set forth therein, to lend the amounts set forth therein for the
purposes of financing the Transactions and related Expenses (together with any Alternative Financing and any capital markets debt or equity financing in replacement thereof or supplemental thereto, the &#147;<U>Financing</U>&#148;). Subject to
Parent&#146;s rights with respect to Alternative Financing pursuant to and subject to the terms and conditions of <U>Section&nbsp;7.18</U>, as of the date hereof, (i)&nbsp;none of the Financing Commitments has been amended or modified as of the date
hereof in any material respect and (ii)&nbsp;the respective commitments contained in the Financing Commitments have not been withdrawn or rescinded in any material respect (it being understood that the exercise of &#147;market flex&#148; provisions
under any fee letter shall not be deemed an amendment, modification, withdrawal or rescission). Except for engagement letters with respect to the Financing, there are no side letters or contracts, agreements or understandings to which Parent, First
Merger Sub or Second Merger Sub is a party related to the funding or investing, as applicable, of the Financing other than as expressly set forth in the Financing Commitments. Parent has fully paid any and all commitment fees or other fees in
connection with the Financing Commitments that are payable on or prior to the date of this Agreement. As of the date hereof, the Financing Commitments are in full force and effect and are the legal, valid, binding and enforceable obligations of
Parent, First Merger Sub and Second Merger Sub, as the case may be, and, to the knowledge of Parent, First Merger Sub and Second Merger Sub, each of the other parties thereto, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar Laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles. There are no conditions precedent or other contingencies related to the funding of the full amount of the
Financing Commitments, other than as expressly set forth in the Financing Commitments. Assuming the accuracy of the representations and warranties of the Company set forth in this Agreement, compliance by the Company with the covenants set forth in
this Agreement and the satisfaction of the conditions set forth in <U>Article VIII</U>, no event has occurred as of the date hereof which, with or without notice, lapse of time or both, would constitute, or would reasonably be expected to
constitute, a default or breach of the Financing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commitments on the part of Parent, First Merger Sub or Second Merger Sub or, to the knowledge of Parent,
First Merger Sub and Second Merger Sub, any other party thereto. Subject to the accuracy of the representations and warranties of the Company set forth in this Agreement and compliance by the Company with the covenants set forth in this Agreement,
as of the date hereof, Parent has no reason to believe that any of the conditions to the Financing contemplated by the Financing Commitments will not be satisfied. Assuming the Financing is funded in accordance with the Financing Commitments (and
assuming the accuracy of the representations and warranties of the Company set forth in this Agreement, compliance by the Company with the covenants set forth in this Agreement and the satisfaction of the conditions set forth in <U>Article
VIII</U>), Parent, First Merger Sub and Second Merger Sub will have on the Closing Date sufficient funds to (i)&nbsp;pay the Merger Consideration; (ii)&nbsp;pay any and all Expenses required to be paid by Parent, First Merger Sub, Second Merger Sub,
the Surviving Corporation and the Surviving Entity in connection with the Mergers and the Financing; and (iii)&nbsp;satisfy all of the other payment obligations of Parent, First Merger Sub, Second Merger Sub, the Surviving Corporation and the
Surviving Entity contemplated hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.09 <U>SEC Filings; Financial Statements; Absence of Changes</U>. (a)&nbsp;Parent
has filed all forms, reports, statements, schedules and other documents required to be filed by it, including all contracts required to be filed by Parent as a &#147;material contract&#148; pursuant to Item&nbsp;601(b) (10)&nbsp;of Regulation S-K
under the Securities Act, with the SEC since January&nbsp;1, 2018 (collectively, the &#147;<U>Parent SEC Reports</U>&#148;). The Parent SEC Reports (i)&nbsp;at the time they were filed and, if amended, as of the date of such amendment, complied in
all material respects with all applicable requirements of the Securities Act, the Exchange Act or SOX, as the case may be, and the rules and regulations promulgated thereunder, and (ii)&nbsp;did not, at the time they were filed, and, if amended, as
of the date of such amendment, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the consolidated financial statements (including, in each case, any notes thereto) contained
(or incorporated by reference) in the Parent SEC Reports was prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto or, in the case of unaudited statements, as
permitted by Form 10-Q of the SEC) and each fairly presents, in all material respects, the consolidated financial condition, results of operations, changes in stockholders&#146; equity and cash flows of Parent and its consolidated Subsidiaries as of
the respective dates thereof and for the respective periods indicated therein (subject, in the case of unaudited financial statements, to normal year-end adjustments). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent maintains disclosure controls and procedures required by Rule 13a-15 or Rule 15d-15 under the Exchange Act and such controls and
procedures are effective to ensure that all material information concerning Parent and its Subsidiaries is made known on a timely basis to the individuals responsible for the preparation of Parent&#146;s SEC filings and other public disclosure
documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor any of its Subsidiaries has any liabilities or obligations of any
nature (whether accrued, absolute, contingent or otherwise), except liabilities (i)&nbsp;reflected or reserved against in the consolidated balance sheet (or the notes thereto) of Parent as of December&nbsp;31, 2019, included in the Filed Parent SEC
Reports, (ii)&nbsp;incurred after December&nbsp;31, 2019 in the ordinary course of business, (iii)&nbsp;incurred in connection with the negotiation, execution, delivery or performance of, or pursuant to the terms of, this Agreement or the other
Transaction Documents (for clarity, any liability caused by or resulting from a breach by the Parent of this Agreement shall not be deemed a liability &#147;incurred in connection with the negotiation, execution, delivery or performance of, or
pursuant to the terms of, this Agreement) or (iv)&nbsp;that would not, individually or in the aggregate, reasonably be expected to have a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Since December&nbsp;31, 2019, (i)&nbsp;there has not been any Parent Material Adverse Effect and (ii)&nbsp;neither Parent nor any of its
Subsidiaries has taken any action that, if taken after the date of this Agreement, would constitute a breach of any of the covenants set forth in <U>Section&nbsp;6.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10 <U>Information Supplied</U>. The information supplied by Parent for inclusion or incorporation by reference in the
Registration Statement and the Consent Solicitation Statement does not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11 <U>Absence of Litigation</U>. There is no Action pending
or, to the knowledge of Parent, threatened (i)&nbsp;against or involving Parent, First Merger Sub or Second Merger Sub, any of their respective Subsidiaries or any of their respective assets, officers, directors or key employees (in the case of
officers, directors or key employees, arising out of such officer&#146;s, director&#146;s or key employee&#146;s relationship with Parent, First Merger Sub or Second Merger Sub, as applicable) that, individually or in the aggregate, had or would
reasonably be expected to have a Parent Material Adverse Effect, or (ii)&nbsp;that seeks to restrain or enjoin the consummation of the Transactions or that would reasonably be expected to affect the ability of Parent, First Merger Sub or Second
Merger Sub to perform its obligations under this Agreement or prevent or materially impede or delay the consummation of the Transactions. There is no Order of any Governmental Authority or arbitrator outstanding against, or, to the knowledge of
Parent, investigation by any Governmental Authority involving, Parent, any of its Subsidiaries or any of their respective assets, officers, directors or key employees (in the case of such officers, directors or key employees, such as would affect
Parent or any of its Subsidiaries) that would reasonably be expected to affect the ability of Parent, First Merger Sub or Second Merger Sub to perform its obligations under this Agreement or prevent or materially impede or delay the consummation of
the Transactions. There is no material Action pending by Parent, First Merger Sub or Second Merger Sub or any of their respective Subsidiaries, or which Parent, First Merger Sub or Second Merger Sub or any of their respective Subsidiaries intends to
initiate, against any other Person, except where the failure of which would not have, or would not reasonably be expected to have, a Parent Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12 <U>Operations of First Merger Sub and Second Merger Sub</U>. Each of First
Merger Sub and Second Merger Sub is a direct, wholly owned Subsidiary of Parent, was formed solely for the purpose of engaging in the Transactions, has engaged in no other business activities and has conducted its operations only as contemplated by
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13 <U>Brokers</U>. No broker, finder, financial advisor or investment banker (other than Goldman
Sachs&nbsp;&amp; Co. LLC) is entitled to any brokerage, finder&#146;s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Parent, First Merger Sub or Second Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14 <U>No Other Representations and Warranties</U>. Notwithstanding anything herein to the contrary, the representations and
warranties of Parent, First Merger Sub and Second Merger Sub expressly set forth in this <U>Article V</U> and in the certificate delivered by Parent, First Merger Sub or Second Merger Sub pursuant to <U>Section 8.03(c</U>) are and shall constitute
the sole and exclusive representations and warranties made with respect to Parent and its Subsidiaries in connection with this Agreement or the Transactions. Except for the representations and warranties referred to in previous sentence, none of
Parent, its Subsidiaries or any other Person has made or is making any express or implied representations or warranty, statutory or otherwise, of any nature, including with respect to any express or implied representation or warranty as to the
merchantability, quality, quantity, suitability or fitness for any particular purpose of the business or the assets of Parent and its Subsidiaries. Except for the representations and warranties expressly set forth in this <U>Article V</U> and in the
certificate delivered by Parent, First Merger Sub or Second Merger Sub pursuant to <U>Section&nbsp;8.03(c</U>), all other warranties, express or implied, statutory or otherwise, of any nature, including with respect to any express or implied
representation or warranty as to the merchantability, quality, quantity, suitability or fitness for any particular purpose of the business or the assets of Parent and its Subsidiaries, are hereby expressly disclaimed. Parent, First Merger Sub and
Second Merger Sub hereby acknowledge and agree that, except for the representations and warranties set forth in <U>Article IV</U>, in the certificate delivered by the Company pursuant to <U>Section 8.02(c</U>) (in each case as qualified and limited
by the Company Disclosure Letter), (a)&nbsp;none of the Company or any of its Subsidiaries, or any of its or their respective Affiliates, stockholders or Representatives, or any other Person, has made or is making any express or implied
representation or warranty with respect to the Company or any of its Subsidiaries or their respective business or operations, including with respect to any information provided or made available to Parent, First Merger Sub, Second Merger Sub or any
of their respective Affiliates, stockholders or Representatives, or any other Person, or, except as otherwise expressly set forth in this Agreement, had or has any duty or obligation to provide any information to Parent, First Merger Sub, Second
Merger Sub or any of their respective Affiliates, stockholders, members or Representatives, or any other Person, in connection with this Agreement, the transactions contemplated hereby or otherwise, and (b)&nbsp;to the fullest extent permitted by
law, none of the Company or any of its Subsidiaries, or any of its or their respective Affiliates, stockholders or Representatives, or any other Person, will have or be subject to any liability or other obligation of any kind or nature to Parent,
First Merger Sub, Second Merger Sub or any of their respective Affiliates, stockholders, members or Representatives, or any other Person, resulting from the delivery, dissemination or any other distribution to Parent, First Merger Sub, Second Merger
Sub or any of their respective Affiliates, stockholders or Representatives, or any other Person, or the use by Parent, First Merger Sub, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Second Merger Sub or any of their respective Affiliates, stockholders, members or Representatives, or any other Person, of any such information provided or made available to any of them by the
Company or any of its Subsidiaries, or any of its or their respective Affiliates, stockholders or Representatives, or any other Person, including any information, documents, estimates, projections, forecasts or other forward-looking information,
business plans or other material provided or made available to Parent, First Merger Sub, Second Merger Sub or any of their respective Affiliates, stockholders, members or Representatives, or any other Person, in &#147;data rooms,&#148; confidential
information memoranda, management presentations or otherwise in anticipation or contemplation of the Mergers or any other Transaction, and (subject to the express representations and warranties of the Company set forth in <U>Article IV</U> and the
certificate delivered by the Company pursuant to <U>Section 8.02(c</U>) (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, First Merger Sub, Second Merger Sub or any of their respective Affiliates,
stockholders, members or Representatives, or any other Person, has relied on any such information (including the accuracy or completeness thereof). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDUCT OF
BUSINESS PENDING THE MERGERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01 <U>Conduct of Business by the Company Pending the Mergers</U>. (a)&nbsp;The Company
covenants and agrees that, between the date of this Agreement and the Effective Time or such earlier date as this Agreement may be terminated in accordance with its terms, except (i) as set forth in <U>Section&nbsp;6.01 of the Company Disclosure
Letter</U>, (ii)&nbsp;as expressly contemplated by this Agreement or (iii)&nbsp;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), the Company shall, and shall cause each of its
Subsidiaries to, conduct its business in the ordinary course. Without limiting the generality of the foregoing, the Company shall, and shall cause its Subsidiaries to, use its reasonable best efforts to preserve intact its present business
organization and maintain the goodwill and existing relationships with its suppliers, licensors, licensees and others having significant business relationships with them. In addition, notwithstanding anything to the contrary contained in herein
(including the foregoing sentences of this <U>Section&nbsp;6.01(a)</U>), the Company and its Subsidiaries shall be permitted, without the prior consent of Parent, to take or refrain from taking all actions, whether or not in the ordinary course of
business, that the Company or its Subsidiaries reasonably believe necessary or appropriate in response to the COVID-19 pandemic, including complying with orders, directives or recommendations of any Governmental Authority; <U>provided</U> that the
Company shall, to the extent reasonably practicable in the circumstances, reasonably consult with Parent prior to taking or refraining from taking any such action to the extent it would otherwise constitute a breach of this
<U>Section&nbsp;6.01(a</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) By way of amplification and not limitation, except (v)&nbsp;as set forth in <U>Section&nbsp;6.01 of the
Company Disclosure Letter</U>, (w)&nbsp;as expressly contemplated by this Agreement (including pursuant to <U>Section&nbsp;9.04</U>) or the other Transaction Documents, (x)&nbsp;with the prior written consent of Parent (which consent shall not be
unreasonably withheld, delayed or conditioned), (y)&nbsp;as required by Law, or (z)&nbsp;as the Company reasonably believes necessary or appropriate in response to the COVID-19 pandemic, including complying with orders, directives or recommendations
of any Governmental Authority (<U>provided</U> that the Company shall, to the extent reasonably practicable in the circumstances, reasonably consult with Parent prior to taking or refraining from taking any action in reliance on this clause
(z)&nbsp;to the extent it would otherwise constitute a breach of this <U>Section&nbsp;6.01(b)</U>), neither the Company nor any of its Subsidiaries shall, between the date of this Agreement and the Effective Time, do any of the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) amend or otherwise change its certificate of incorporation or bylaws, or
equivalent organizational documents, or the equivalent organizational documents of any of its Subsidiaries or create any new Subsidiaries other than direct or indirect wholly owned Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) amend or otherwise change the Investor Agreements in a manner adverse to Parent or that would materially to prevent or
materially delay the consummation of the Transactions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) merge or consolidate the Company with any other Person or
restructure, reorganize or completely or partially liquidate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) issue, deliver, sell, grant, pledge, dispose of or
grant an Encumbrance (other than any Encumbrance arising under applicable securities Laws) on any shares of any class of capital stock of the Company or any of its Subsidiaries, any other voting securities or other ownership interests, or any
options, warrants, convertible securities or other rights of any kind to acquire any shares of such capital stock, voting securities or equity interests, or any &#147;phantom&#148; stock, &#147;phantom&#148; stock rights, stock appreciation rights,
stock-based units or other similar interests of the Company or any of its Subsidiaries (except (i)&nbsp;for the issuance of shares of Company Stock issuable pursuant to the exercise of Company Stock Options or the settlement of Company RSU Awards,
in each case, outstanding on the date hereof in accordance with their terms on the date hereof and (ii)&nbsp;as set forth in <U>Section&nbsp;6.01(b) of the Company</U> <U>Disclosure Letter</U>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) other than in the ordinary course of business, (A)&nbsp;sell, lease, license, pledge or dispose of or (B)&nbsp;grant an
Encumbrance on any properties or assets or any interests therein of the Company or any of its Subsidiaries, other than Permitted Encumbrances; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) sell, lease, sublease, license, sublicense, assign or otherwise grant rights under any Company IP (except for
non-exclusive licenses or exclusive licenses for therapeutics granted in fields other than the Field (as defined in the CVR Agreement), in each case, granted in the ordinary course of business, consistent with past practice) or transfer, cancel,
abandon, or fail to renew, maintain or diligently pursue applications for or otherwise dispose of any Company IP (except for patent and trademark portfolio management in the ordinary course of business, consistent with past practices, but excluding
abandonment of patent applications); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) declare, set aside, make or pay any dividend, payable in cash, stock, property
or otherwise, with respect to any of its capital stock, except for dividends by any of the Company&#146;s direct or indirect wholly owned Subsidiaries to the Company or any of its other wholly owned Subsidiaries; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) adjust, reclassify, combine, split, subdivide or redeem, or purchase
or otherwise acquire, directly or indirectly, any of its capital stock, voting securities or other ownership interests or any securities convertible into or exchangeable or exercisable for capital stock, voting securities or other ownership
interests; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) acquire any assets outside the ordinary course of business from any other Person for consideration in
excess of $5,000,000 in any individual transaction or series of related transactions or $25,000,000 in the aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x)
make any loans, advances, guarantees or capital contributions to or investments in any Person, other than (A)&nbsp;advances to employees of the Company or any of its Subsidiaries in respect of travel or other related business expenses in the
ordinary course of business or (B)&nbsp;advance payments or prepayments under any contract in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) incur any Indebtedness for borrowed money with a principal amount in excess of $10,000,000 or guarantee such Indebtedness
of another Person, or issue or sell any debt securities or warrants or other rights to acquire any debt security of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) make or authorize any capital expenditure in excess of $25,000,000 in the aggregate during any 12-month period beginning
on or after the date hereof (excluding any capital expenditures referenced on <U>Section&nbsp;6.01(b) of the Company</U> <U>Disclosure Letter)</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) modify in any material respect any accounting policies, other than as required by GAAP or Law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) except as required by applicable Law, (A)&nbsp;make any material change (or file any such change) in any method of Tax
accounting, (B)&nbsp;make, change or rescind any material Tax election; (C)&nbsp;settle or compromise any material Tax liability for an amount materially in excess of the amount accrued or reserved therefor in the Financial Statements or enter into
any closing agreement relating to a material amount of Taxes; or (D)&nbsp;other than in the ordinary course of business, waive or extend the statute of limitations in respect of any material Tax claim or assessment, unless requested by the
appropriate Governmental Authority; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) except as required by applicable Law or the terms of any Plan in effect
on the date hereof or adopted or entered into after the date hereof in accordance with, or as set forth on, <U>Section&nbsp;6.01(b) of the Company Disclosure Letter</U>, (A)&nbsp;adopt, enter into, terminate, materially modify or materially amend
any collective bargaining agreement or similar contract or any Plan; (B)&nbsp;other than annual base cash compensation raises (x)&nbsp;that are merit-based and do not exceed 4%&nbsp;per annum in the aggregate or (y)&nbsp;in connection with
promotions for employees below the level of Vice President, in each case, in the ordinary course of business and in a manner consistent with past practice, increase the compensation or benefits of any current or former Service Provider;
(C)&nbsp;grant or pay any change-in-control, retention, severance or termination pay to, or increase in any manner the change-in-control, retention, severance or termination pay of any current or former Service Provider; (D)&nbsp;accelerate the
vesting or payment of any compensation or benefit to any Service Provider under any Plan; or (E)&nbsp;terminate or hire any Service Provider, other than terminations in the ordinary course of business consistent with past practice (which, for the
avoidance of doubt, shall include terminations for &#147;cause&#148;, as reasonably determined by the Company); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi)
apply for any loan under the Paycheck Protection Program under the CARES Act or make any election pursuant to Sections 2301-2308 of the CARES Act, Sections 7001-7005 of the FFCRA, IRS Notice 2020-65 or any other similar Law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) except as required by Law or any judgment by a court of competent jurisdiction, (A)&nbsp;settle or compromise any Action
which involves payment to or by the Company or any of its Subsidiaries (exclusive of attorney&#146;s fees) in excess of $10,000,000 in any single instance or involves any non-<I>de minimis </I>injunctive or equitable relief or the imposition of any
non-<I>de minimis </I>restrictions on the business activities of the Company and its Subsidiaries; (B)&nbsp;cancel or compromise any Indebtedness in excess of $2,000,000 in the aggregate; or (C)&nbsp;waive or assign any claims or rights in excess of
$250,000 individually or $2,000,000 in the aggregate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) (A)&nbsp;(1)&nbsp;enter into new clinical trial contracts or
(2)&nbsp;terminate, cancel, fail to renew, or modify or amend, or waive, release or assign any material rights or claims under any existing clinical trial contract, other than in the ordinary course of business, or (B)&nbsp;enter into, terminate,
cancel, fail to renew, or modify or amend, or waive, release or assign any material rights or claims under, (x)&nbsp;any Material Contract described in clause (iii)&nbsp;of the definition thereof, or any contract that, if existing on the date
hereof, would have been such a Material Contract; or (y)&nbsp;any Material Contract (other than of the type described in clause (A)&nbsp;or clause (B)(x)) or Real Property Lease, or any contract or lease that, if existing on the date hereof, would
have been a Material Contract or Real Property Lease, other than in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix) other than in
the ordinary course of business, amend any material Company Permit in any material respect, or allow any material Company Permit to lapse, expire or terminate, other than (A)&nbsp;amendments, renewals or extensions of material Company Permits or
(B)&nbsp;non-renewal or non-extension of material Company Permits that are not necessary to conduct the Company&#146;s business as then conducted; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx) authorize, apply for, or cause to be approved, the listing of shares of
Company Common Stock or Company Preferred Stock on any stock exchange; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxi) file any amendment to the Company
Registration Statement, or cause, request or seek to have the Company Registration Statement declared effective under the Securities Act other than any such actions taken in connection with the withdrawal of the Company Registration Statement; or
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxii) authorize, commit or agree to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Agreement is intended to give Parent, directly or indirectly, the right to control or direct the operations of
the Company or its Subsidiaries prior to the Effective Time in violation of applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02 <U>Conduct of Business by
Parent Pending the Mergers</U>. Parent covenants and agrees that, between the date of this Agreement and the Effective Time, except (a)&nbsp;as expressly contemplated by this Agreement or the other Transaction Documents or (b)&nbsp;with the prior
consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), Parent shall not, and shall cause its Subsidiaries not to, do any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) amend or otherwise change, including by merger, consolidation or otherwise, Parent&#146;s certificate of incorporation or
bylaws, except for any amendments or changes that would not (x)&nbsp;materially delay, materially impede or prevent the consummation of the Transactions or (y)&nbsp;adversely affect the stockholders of the Company in any material respect differently
than the stockholders of Parent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) declare, set aside, make or pay any dividend, payable in cash, stock, property or
otherwise, with respect to any of Parent&#146;s capital stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) liquidate, dissolve, reorganize or otherwise wind up
the business and operations of Parent, First Merger Sub or Second Merger Sub; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) authorize, commit or agree to do any
of, the foregoing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL AGREEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01 <U>Registration Statement; Consent Solicitation Statement</U>. (a)&nbsp;As promptly as practicable after the execution of
this Agreement, Parent and the Company shall cooperate in preparing and shall prepare (i)&nbsp;a consent solicitation statement (such consent solicitation statement, as amended or supplemented from time to time, the &#147;<U>Consent Solicitation
Statement</U>&#148;) to be sent to the stockholders of the Company relating to the solicitation of consents from the Company&#146;s stockholders in connection with obtaining the Company Stockholder Approvals and (ii)&nbsp;a registration statement on
Form S-4 to register the shares of Parent Common Stock and CVRs to be issued in connection with the Mergers (together with all amendments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereto, the &#147;<U>S-4 Registration Statement</U>&#148;), and Parent shall file with the SEC the S-4 Registration Statement, in which the Consent Solicitation Statement shall be included as
part of the prospectus, in connection with the registration under the Securities Act of the shares of Parent Common Stock to be issued to the stockholders of the Company pursuant to the Mergers and CVRs to be issued in connection with the Mergers.
Parent shall use its reasonable best efforts to cause the Registration Statement to become effective as promptly as practicable and to keep the Registration Statement effective as long as necessary to consummate the Transactions, and, if required by
Law, each of Parent and the Company shall use its reasonable best efforts to have the CVR Agreement become qualified under the Trust Indenture Act as promptly as practicable. Each of Parent and the Company shall furnish all information concerning
itself as the other may reasonably request in connection with such actions and the preparation of the Registration Statement and the Consent Solicitation Statement. The Registration Statement and the Consent Solicitation Statement shall include all
information reasonably requested by such other party to be included therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Company shall use its reasonable best efforts to cause
the Consent Solicitation Statement to be mailed to the stockholders of the Company and shall use commercially reasonable efforts to solicit and obtain the Company Stockholder Approvals via written consent, in each case as promptly as practicable
after the S-4 Registration Statement is declared effective under the Securities Act (the &#147;<U>S-4 Effectiveness Time</U>&#148;); <U>provided</U> that, notwithstanding the foregoing, in no event shall the Company or any of its Subsidiaries be
obligated to bear any expense or pay any fee (other than the payment of nominal administrative, processing or similar fees or charges) or grant any concession in connection with obtaining the Company Stockholder Approvals following such
solicitation. The Company shall include the Company Recommendation in the Consent Solicitation Statement (unless there has been a Change in the Company Recommendation in accordance with <U>Section 7.02(d)</U> prior to the date of distribution of the
Consent Solicitation Statement in accordance with this <U>Section&nbsp;7.01(b)</U>). Notwithstanding anything to the contrary in this Agreement, the Company&#146;s obligations pursuant to the first sentence of this <U>Section&nbsp;7.01(b)</U> shall
not be affected by the commencement, public proposal, public disclosure or communication to the Company of any Competing Proposal or any Change in the Company Recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No amendment or supplement to the Consent Solicitation Statement or the S-4 Registration Statement will be made by Parent or the Company
without providing the other party a reasonable opportunity to review and comment thereon. Each party will advise the other promptly after receiving oral or written notice of any oral or written request by the SEC for amendment of the S-4
Registration Statement or Consent Solicitation Statement or SEC comments thereon or requests by the SEC for additional information. Parent will advise the Company promptly after receiving oral or written notice of the issuance of any stop order or
the suspension of the qualification for offering or sale in any jurisdiction of the Parent Common Stock issuable in connection with the Mergers. Each party shall promptly provide the other with copies of any written communication from the SEC and
shall cooperate on the preparation of appropriate responses thereto (and will provide the other with copies of any such responses given to the SEC) and modifications to the S-4 Registration Statement or Consent Solicitation Statement as shall be
reasonably appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If, at any time prior to the Effective Time, any information relating to (i)&nbsp;the
Company or any of its Subsidiaries, or their respective Affiliates or Representatives, or (ii)&nbsp;Parent, First Merger Sub or Second Merger Sub, or their respective Affiliates or Representatives, shall be discovered by the Company or Parent which
should be set forth in an amendment or a supplement to the S-4 Registration Statement or the Consent Solicitation Statement so that either such document would not include any misstatement of a material fact or omit to state any material fact
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, the party which discovers such information shall promptly inform the other party and the parties will cooperate to prepare an
appropriate amendment or supplement describing such information which shall promptly be filed with the SEC and, to the extent required by Law, disseminated to the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company will not call or convene any meeting of its stockholders in connection with the Company Stockholder Approvals. The only
corporate actions to be set forth in the Consent Solicitation Statement are (i)&nbsp;the adoption of this Agreement and approval of the Transactions, including the Mergers, by the holders of Company Common Stock and Company Preferred Stock and
(ii)&nbsp;any other matters contemplated by this Agreement that may be required to be approved by the holders of Company Common Stock and/or the holders of Company Preferred Stock under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Following receipt of the Company Stockholder Approvals via written consent, the Company shall promptly provide any notices required by
Section&nbsp;228 of the DGCL in accordance therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Company shall, as promptly as practicable and (i)&nbsp;no later than 45
days after the end of any fiscal quarter (other than any fourth fiscal quarter) ending after the date hereof, prepare and furnish to Parent copies of the unaudited consolidated financial statements of the Company and its Subsidiaries as of the end
of and for such fiscal quarter, together with the comparable period of the prior fiscal year, reviewed by the Company&#146;s independent accountants as provided in the procedures specified by the Public Company Accounting Oversight Board in AU 722
and (ii)&nbsp;no later than 90 days after the end of any fiscal year ended after the date hereof, prepare and furnish to Parent copies of the annual consolidated financial statements of the Company and its Subsidiaries as of the end of and for such
fiscal year, accompanied by an audit report, on such annual financial statements from the Company&#146;s independent accountants, in the case of each of clauses (i)&nbsp;and (ii)&nbsp;together with the notes thereto, and prepared from the books and
records of the Company and its Subsidiaries and in accordance with GAAP applied on a consistent basis through the periods involved (except as may be otherwise required under GAAP) and the rules and regulations of the SEC, including the requirements
of Regulation S-X. When delivered pursuant to this <U>Section&nbsp;7.01(g)</U>, such financial statements shall present fairly in all material respects the consolidated financial position and results of operations of the Company and its Subsidiaries
as of the dates and for the periods shown therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02 <U>No Solicitation of Transactions</U>. (a)&nbsp;The Company agrees that
it will not, and that it will cause each of its Subsidiaries not to and will direct each of its and its Subsidiaries&#146; Representatives not to, directly or indirectly, (i)&nbsp;solicit, initiate, seek or take any other action to facilitate or
knowingly encourage the making, submission or announcement of any proposal that constitutes, or would be reasonably be expected to lead to any Competing Proposal, (ii)&nbsp;enter into, maintain, continue or participate in any discussions or
negotiations with any Person or entity in furtherance of, or furnish to any Person any information or otherwise cooperate in any way with respect to, any Competing Proposal, (iii)&nbsp;agree to, approve, endorse, recommend or consummate any
Competing Proposal, (iv)&nbsp;enter into, or propose to enter into, any Competing Transaction Agreement, or (v)&nbsp;resolve, propose or agree, or authorize or permit any Representative to do any of the foregoing. The Company shall, and shall cause
its Subsidiaries to and will direct its and its Subsidiaries&#146; Representatives to, immediately cease and cause to be terminated all existing discussions or negotiations with any Persons conducted prior to the execution of this Agreement by the
Company, any of its Subsidiaries or its or any of their respective Representatives with respect to any Competing Proposal, request the prompt return or destruction of all confidential information previously furnished and terminate access to any
physical or electronic data rooms related to a potential Competing Proposal previously granted to such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall
promptly, and in any event within 24 hours of the Company obtaining knowledge of the receipt thereof, advise Parent in writing of any Competing Proposal, the financial and other material terms and conditions of any such Competing Proposal (including
any changes thereto) and the identity of the Person making any such Competing Proposal. The Company shall (i)&nbsp;keep Parent reasonably informed of the status and material details (including any change to the terms thereof) of any such Competing
Proposal and (ii)&nbsp;provide to Parent, as soon as practicable after receipt or delivery thereof (and in any event, within 24 hours of such receipt or delivery), copies of all correspondence (other than non-substantive written correspondence) and
other written material (including all draft and final versions (and any amendments thereto) of agreements (including schedules and exhibits thereto) and any comments thereon) relating to any such Competing Proposal exchanged between the Company or
any of its Subsidiaries (or their Representatives), on the one hand, and the Person making such Competing Proposal (or its Representatives), on the other hand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary in this Agreement, at any time prior to the receipt of the Company Stockholder Approvals, the
Company may, subject to compliance with <U>Section&nbsp;7.02(b)</U>, furnish information to, and enter into discussions with, a Person who has made, after the date hereof, an unsolicited, written, bona fide Competing Proposal so long as such
Competing Proposal did not result from a breach of this <U>Section&nbsp;7.02</U> and, prior to furnishing such information and entering into such discussions, the Company Board has (i)&nbsp;reasonably determined, in its good faith judgment (after
having received the advice of a financial advisor of nationally recognized reputation and outside legal counsel) that (A)&nbsp;such Competing Proposal constitutes, or could reasonably be expected to lead to, a Superior Proposal and (B)&nbsp;the
failure to furnish such information to, or enter into such discussions with, the Person who made such Competing Proposal would be inconsistent with the Company Board&#146;s fiduciary duties to the Company and its stockholders under applicable Law,
(ii)&nbsp;previously provided all such information to Parent (or provides such information to Parent substantially concurrent with the time it is provided to such Person), and (iii)&nbsp;obtained from such Person an Acceptable Confidentiality
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth in this <U>Section 7.02(d)</U>, neither the Company Board nor any
committee thereof shall (i)&nbsp;(A)&nbsp;fail to make, withdraw, qualify, modify or amend, or propose publicly to fail to make, withdraw, qualify, modify or amend, the Company Recommendation or fail to include the Company Recommendation in the
Consent Solicitation Statement, (B)&nbsp;adopt or recommend, or propose publicly to adopt or recommend, any Competing Proposal, or (C)&nbsp;enter into any agreement relating to a Competing Proposal (other than an Acceptable Confidentiality
Agreement), or (ii)&nbsp;make any public statement inconsistent with the Company Recommendation (any of the actions described in the foregoing clauses (i)&nbsp;and (ii), a &#147;<U>Change in the Company Recommendation</U>&#148;). Notwithstanding the
foregoing, if at any time prior to the receipt of the Company Stockholder Approvals and subject to compliance with <U>Section&nbsp;7.02(b)</U> the Company Board determines in its good faith judgment (after having received the advice of a financial
advisor of nationally recognized reputation and outside legal counsel) that the failure of the Company Board to make a Change in the Company Recommendation would be inconsistent with the fiduciary duties of the Company Board to the Company and its
stockholders under applicable Law, then the Company Board may make a Change in the Company Recommendation; <U>provided</U>, <U>however</U>, that no Change in the Company Recommendation may be made that relates to a Competing Proposal unless such
Competing Proposal constitutes a Superior Proposal; <U>provided</U>, <U>further</U>, that the Company shall not be entitled to exercise its right to make a Change in the Company Recommendation until after the fourth Business Day following
Parent&#146;s receipt of written notice from the Company advising Parent that the Company Board intends to make a Change in the Company Recommendation (a &#147;<U>Notice of Adverse Recommendation</U>&#148;) and specifying the reasons therefor,
including the terms and conditions of any Superior Proposal and including an unredacted copy of any proposed agreement (including schedules and exhibits thereto) relating to such Superior Proposal (it being understood and agreed that any subsequent
amendment to the financial terms or any other material term of such Superior Proposal shall require a new Notice of Adverse Recommendation and a three Business Day notice period). The Company agrees that, during the applicable four or three Business
Day notice period prior to the Company Board making a Change in the Company Recommendation, the Company and its Representatives shall negotiate in good faith with Parent and its Representatives regarding any revisions to the terms of this Agreement
proposed by Parent. In determining whether to make a Change in the Company Recommendation, the Company Board shall take into account any changes to the financial or other terms of this Agreement proposed by Parent in response to a Notice of Adverse
Recommendation or otherwise. At the end of the four Business Day notice period (or three Business Day notice period with respect to any amendment to the financial terms or any other material term of such Superior Proposal) the Company Board may
effect a Change in the Company Recommendation if the Company Board shall again make a determination in good faith after consultation with its outside legal counsel and financial advisors (and taking into account any adjustment or modification of the
terms of this Agreement proposed by Parent), that the Competing Proposal continues to be a Superior Proposal and that the Change in the Company Recommendation is required to comply with the fiduciary duties of the Company Board to the Company and
its stockholders under applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything in this Agreement to the contrary, (i)&nbsp;neither the Company
Board nor any committee thereof shall withdraw, revoke, rescind, modify or amend in any manner the Drag-Along Resolution and (ii)&nbsp;in no event shall any Change in the Company Recommendation (A)&nbsp;affect the validity and enforceability of this
Agreement or the other Transaction Documents, including the obligations of the Company and the Company&#146;s stockholders that are party to the Transaction Documents to consummate the Mergers or the other Transactions and to deliver (or cause to be
delivered) the written consent contemplated by Section&nbsp;3(b) of the Selling Investor Support Agreement, or (B)&nbsp;cause any state corporate takeover statute or other similar statute to be applicable to the Mergers or the other Transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03 <U>Access to Information; Confidentiality</U>. (a)&nbsp;Except as otherwise prohibited by applicable Law, from the date
of this Agreement until the Effective Time, the Company shall, and shall cause its Subsidiaries to, provide to Parent and Parent&#146;s Representatives reasonable access during normal business hours upon reasonable prior notice to the officers,
employees and other personnel, agents, properties, offices and other facilities of the Company and its Subsidiaries and to the books and records thereof (including for purposes of conducting regulatory compliance reviews and audits to allow Parent
to be in compliance with its policies and procedures and any applicable Law at the Effective Time); <U>provided</U>, <U>however</U>, that (x)&nbsp;the Company shall not be required to provide access to or disclose any such information to the extent
such access or disclosure would result in the loss of attorney-client privilege of the Company or any of its Subsidiaries (<U>provided</U> that the Company and its Subsidiaries shall use their reasonable best efforts to allow for such access or
disclosure in a manner that does not result in a loss of attorney-client privilege) and (y)&nbsp;the Company may limit physical access to the properties, offices and other facilities of the Company and its Subsidiaries to the extent the Company
reasonably determines, in light of COVID-19, that such access would jeopardize the health and safety of any employee of the Company or its Subsidiaries or to the extent necessary to comply with applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without limiting the generality of the foregoing, the Company covenants and agrees that, between the date of this Agreement and the
Effective Time, the Company shall keep Parent reasonably informed as to the Company&#146;s FDA regulatory strategy with respect to non-immaterial communications with FDA, pre-submissions to FDA, submissions to FDA, and any other regulatory issues
under consideration for presentation to FDA, including IDEs, clinical trials (whether new or on-going), and medical technology, including by providing copies of material information to Parent; <U>provided</U>, that the Company shall not be required
to provide such information to the extent providing such information would result in the loss of attorney-client privilege of the Company or any of its Subsidiaries (<U>provided</U> that the Company and its Subsidiaries shall use their reasonable
best efforts to provide such information in a manner that does not result in a loss of attorney-client privilege). In order to keep Parent reasonably informed regarding the Company&#146;s regulatory relationship with FDA, the Company also agrees to
in a reasonably timely manner provide Parent with any and all material communications with FDA with respect to its pre-submissions, submissions, and other non-immaterial regulatory issues such as IDEs, clinical trials (whether new or on-going),
medical technology and any other subject which would likely have a material impact on the Company&#146;s current or future business. Nothing contained in this <U>Section&nbsp;7.03(b)</U> is intended to give Parent, directly or indirectly, the right
to control or direct the FDA regulatory strategy of the Company or its Subsidiaries prior to the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as otherwise prohibited by applicable Law, from the date of this Agreement until
the Effective Time, Parent shall, and shall cause its Subsidiaries to, provide to the Company and the Company&#146;s Representatives reasonable access during normal business hours upon reasonable prior notice to Parent&#146;s personnel and records
on a basis consistent with the Company&#146;s access to such personnel and records prior to the date hereof in connection with the Company&#146;s due diligence review of Parent and its Subsidiaries in connection with the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All information obtained by the parties hereto pursuant to this <U>Section&nbsp;7.03</U> shall be kept confidential in accordance with the
Confidentiality Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No investigation pursuant to this <U>Section&nbsp;7.03</U> shall affect any representation, warranty,
covenant or agreement in this Agreement of any party hereto or any condition to the obligations of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04
<U>Employee Benefits Matters</U>. (a)&nbsp;From and after the Effective Time, Parent shall (or shall cause its Affiliates, including the Surviving Entity and its Subsidiaries to), honor in accordance with their terms, all Plans and all other
contracts, agreements, arrangements, policies, plans and commitments of the Company and its Subsidiaries, in each case, as in effect immediately prior to the Effective Time that are applicable to current or former Service Providers. For the period
beginning on the Closing Date and continuing through the first anniversary of the Closing Date (or, if shorter, during the period of employment), Parent shall, or shall cause the Surviving Entity and its Subsidiaries to, provide each employee of the
Company or its Subsidiaries who continues to be employed by the Company or the Surviving Entity or their respective Affiliates after the Closing Date (collectively, the &#147;<U>Continuing Employees</U>&#148;) with (i)&nbsp;an annual base salary or
hourly wage rate, as applicable, and annual cash target bonus or other recurring cash incentive opportunity that is no less favorable, in the aggregate, than the annual base salary or hourly wage rate, as applicable, and annual target cash bonus or
other recurring cash incentive opportunity provided to such Continuing Employee immediately prior to the Effective Time, in the aggregate, and (ii)&nbsp;health, welfare and retirement benefits that are substantially comparable, in the aggregate, to
either, in Parent&#146;s sole discretion, (A)&nbsp;the health, welfare and retirement benefits provided to such Continuing Employee immediately prior to the Effective Time or (B)&nbsp;the health, welfare and retirement benefits provided to similarly
situated employees of Parent and its Affiliates, in each case and for the avoidance of doubt, excluding defined benefit pension benefits. Without limiting the foregoing, the Chief Executive Officers of each of Parent and the Company, or each of
their respective designees, shall cooperate to design and implement an annual bonus program, including performance goals, for the benefit of the Continuing Employees for the first full calendar year commencing after the Closing Date (the
&#147;<U>Post-Closing Bonus Plan</U>&#148;), with the bonus payouts to be based on the attainment of performance goals applicable to the business of the Company and its Subsidiaries for such year (and not, for the avoidance of doubt, performance
goals applicable to the business of Parent or any of its Subsidiaries other than the Company and its Subsidiaries). Each Continuing Employee shall be entitled to participate in the Post-Closing Bonus Plan with an annual bonus target equal to the
greater of (x)&nbsp;such Continuing Employee&#146;s annual bonus target under the Closing Year VCP (as defined below) and (y)&nbsp;the annual bonus target of a similarly-situated employees of Parent (as reasonably determined by Parent where such
targets constitute a range). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For all purposes under the employee benefit plans of Parent and its Subsidiaries
providing benefits to any Continuing Employee after the Effective Time (including the Plans), but excluding any retiree health or welfare plans or programs and (solely for purposes of vesting) any equity compensation arrangements (the &#147;<U>New
Plans</U>&#148;), Parent shall credit each Continuing Employee with his or her years of service with the Company and its Subsidiaries and their respective predecessors before the Effective Time, to the same extent as such Continuing Employee was
entitled, immediately prior to the Effective Time, to credit for such service under any similar Plan in which such Continuing Employee participated or was eligible to participate immediately prior to the Effective Time; <U>provided </U>that the
foregoing shall not apply to the extent that its application would result in a duplication of benefits with respect to the same period of service. In addition, and without limiting the generality of the foregoing, Parent shall (or shall cause its
Subsidiaries, including the Surviving Entity and its Subsidiaries, to) cause (i)&nbsp;each Continuing Employee to become immediately eligible to participate, without any waiting time, in any and all New Plans to the extent coverage under such New
Plan is replacing coverage under a Plan in which such Continuing Employee participated immediately prior to the Effective Time, and (ii)&nbsp;for purposes of each New Plan providing medical, dental, pharmaceutical and/or vision benefits to any
Continuing Employee, all pre-existing condition exclusions or limitations, evidence of insurability requirements, required physical examinations and actively-at-work requirements of such New Plan to be waived for such Continuing Employee and his or
her covered dependents, to the extent such conditions were inapplicable or waived under the comparable Plans in which such Continuing Employee participated immediately prior to the Effective Time. Parent shall (or shall cause its Subsidiaries,
including the Surviving Entity and its Subsidiaries, to) cause any eligible expenses incurred by any Continuing Employee and his or her covered dependents during the portion of the Plan year ending on the date such Continuing Employee&#146;s
participation in the corresponding New Plan begins to be taken into account under such New Plan for purposes of satisfying all applicable deductible, coinsurance and maximum out-of-pocket requirements applicable to such Continuing Employee and his
or her covered dependents for the applicable plan year as if such amounts had been paid in accordance with such New Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the
extent any payments to &#147;disqualified individuals&#148; of the Company or its Subsidiaries (within the meaning of Section 280G of the Code) could be characterized as &#147;excess parachute payments&#148; within the meaning of
Section&nbsp;280G(b)(1) of the Code in connection with the Transactions, the Company shall (i)&nbsp;no later than the Closing (and in any event prior to obtaining the consent of any recipient of such payment in accordance with (ii)&nbsp;below),
disclose its calculations with respect to the potential excess parachute payments to Parent, and provide any other information reasonably requested by Parent that is necessary in order for Parent to review and understand such calculations (it being
understood that the Company shall not be required to provide documents and information not in the Company&#146;s possession or to prepare or draft any calculations or documents (other than the waivers, disclosure and solicitation documents and
calculations of excess parachute payments otherwise referenced in this <U>Section&nbsp;7.04(c)</U>)), (ii)&nbsp;use commercially reasonable efforts to obtain from any disqualified individual a waiver of his or her rights to any such potential excess
parachute </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment absent approval by the Company&#146;s shareholders in accordance with this <U>Section&nbsp;7.04(c</U>), and (iii)&nbsp;prior to the Closing, submit such payments for approval or
disapproval by a vote of the stockholders of the Company entitled to vote on such matters in a manner intended to meet the requirements of Section&nbsp;280G of the Code and the applicable treasury regulations thereunder. Parent shall have the right
to review and comment on any waiver required by clause (ii)&nbsp;and any disclosure and solicitation documents required by clause (iii)&nbsp;before such waiver or consent is sought or document is distributed, as applicable, and the Company shall
consider any such comments in good faith. Parent shall, no later than ten (10)&nbsp;Business Days prior to the Closing, provide to the Company any Parent plans or arrangements that could result in the payment of any excess parachute payment that
would be subject to the foregoing; <U>provided</U> that, in any event, the Company&#146;s failure to include such Parent plans or arrangement in the stockholders voting materials described herein due to Parent&#146;s failure to provide such plans
and arrangements as contemplated hereby will not result in a breach of the covenants set forth in this <U>Section&nbsp;7.04(c</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
Parent shall maintain (or cause its Subsidiaries, including, following the Closing, the Surviving Entity and its Subsidiaries, to maintain) the Company&#146;s annual Variable Compensation Plan for the year in which the Closing Date occurs (the
&#147;<U>Closing Year VCP</U>&#148;) until at least December&nbsp;31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the year in which the Closing Date occurs, and shall pay (or cause its Subsidiaries, including, following the Closing, the
Surviving Entity or its Subsidiaries, to pay) to each Continuing Employee who was a participant in the Closing Year VCP immediately prior to the Closing an award thereunder for the calendar year in which the Closing occurs based on the greater of
(x)&nbsp;actual performance under the Closing Year VCP (which, for the avoidance of doubt, may be up to 150%) and (y) target performance (each, a &#147;<U>VCP Bonus</U>&#148;), subject to each such Continuing Employee&#146;s continued employment
with the Surviving Entity or its Subsidiaries through the applicable payment date and otherwise in accordance with the terms of the Closing Year VCP. If any such Continuing Employee&#146;s employment is involuntarily terminated prior to the payment
of his or her VCP Bonus, he or she will remain eligible to receive his or her VCP Bonus following the end of the applicable calendar year (but in no event later than March&nbsp;15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the year
following the year in which the Closing Date occurs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Following the Closing, Parent shall provide each Continuing Employee with
equity-based compensation (&#147;<U>Parent Equity Awards</U>&#148;) in accordance and consistent with Parent&#146;s standard incentive equity grant practices, which shall include (without limitation), grants of Parent Equity Awards no less
frequently than, in amounts and values that are no less than, and with terms and conditions (including vesting conditions) that are no less favorable than, Parent Equity Awards granted to similarly-situated Parent employees from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Without limiting the generality of <U>Section&nbsp;11.05</U>, the provisions of this <U>Section&nbsp;7.04</U> are for the sole benefit of
the parties to this Agreement and nothing herein, express or implied, is intended or shall be construed as to confer upon or give any Person (including for the avoidance of doubt, any Continuing Employee or other current or former Service Provider),
other than the parties hereto and their respective permitted successors and assigns, any legal or equitable or other rights or remedies (including with respect to the matters provided for in this <U>Section&nbsp;7.04</U>) under or by reason of any
provision of this Agreement. Nothing contained in this Agreement, express or implied, shall (i)&nbsp;be treated as an amendment to any Plan, New Plan or other compensation or benefit plan, program, policy, agreement, arrangement or understanding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for any purpose, (ii)&nbsp;obligate Parent or the Surviving Entity or any of their Subsidiaries to (A)&nbsp;maintain any particular benefit plan or arrangement or (B)&nbsp;retain the employment
of any particular employee or (iii)&nbsp;prevent Parent or the Surviving Entity or any of their Subsidiaries from amending or terminating any benefit plan or arrangement, in each case, subject to compliance with the other provisions of this
<U>Section&nbsp;7.04</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05 <U>Directors&#146; and Officers&#146; Indemnification and Insurance</U>. (a)&nbsp;Parent
shall cause the Surviving Entity to assume, and shall cause the Surviving Entity to comply with (including by providing the Company with sufficient funds to comply with), the obligations with respect to all rights to indemnification, advancement of
expenses, and exculpation from liabilities, for acts or omissions occurring at or prior to the Effective Time now existing in favor of the current or former directors or officers of the Company as provided in the certificate of incorporation and
bylaws of the Company or any indemnification contract between such directors or officers and the Company (in each case, as in effect on the date hereof), without further action, as of the Effective Time, and such obligations shall survive the
Mergers and shall continue in full force and effect in accordance with their terms. For the avoidance of doubt, the applicable rights of indemnification, advancement of expenses, and exculpation contemplated by this <U>Section&nbsp;7.05</U> and
pursuant to the terms of the certificate of incorporation or bylaws of the Company as in effect at or prior to the Effective Time shall not be impaired by any modification of such terms in any amendment or restatement of such certificate of
incorporation or bylaws following the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Parent shall obtain, at the Effective Time, a prepaid (or &#147;tail&#148;)
directors&#146; and officers&#146; liability insurance policy in respect of acts or omissions occurring at or prior to the Effective Time for six years from the Effective Time, covering each Person currently covered by the Company&#146;s
directors&#146; and officers&#146; liability insurance policies (a true and complete copy of which has been heretofore made available to Parent), on terms with respect to such coverage and amounts no less favorable than those of such policy in
effect on the date hereof; <U>provided</U>, <U>however</U>, that in no event shall the Surviving Entity be required to expend pursuant to this <U>Section&nbsp;7.05(b</U>) an aggregate amount in excess of 300% of the last annual premium paid by the
Company for such insurance; <U>provided</U>, <U>further</U>, that, if the aggregate amount necessary to procure such insurance coverage exceeds such maximum amount, Parent shall only be obligated to provide as much coverage as may be obtained for
such maximum amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event the Surviving Entity or any of their respective successors or assigns (i)&nbsp;consolidates with or
merges into any other Person and shall not be the continuing or surviving limited liability company or entity of such consolidation or merger or (ii)&nbsp;transfers all or substantially all of its properties and assets to any Person, then, and in
each such case, proper provision shall be made so that the successors and assigns of the Surviving Entity, as the case may be, or at Parent&#146;s option, Parent, shall assume the obligations set forth in this <U>Section&nbsp;7.05</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.06 <U>Notification of Certain Matters</U>. (a)&nbsp;The Company shall give prompt notice to Parent, and Parent shall give
prompt notice to the Company, of (i)&nbsp;the occurrence, or non-occurrence, of any change, event, fact or development which would reasonably be expected to cause any of their respective representations or warranties contained in this Agreement to
become untrue or inaccurate such that the conditions set forth in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section&nbsp;8.02(a</U>) or <U>Section 8.03(a</U>) would not be satisfied and (ii)&nbsp;any failure of the Company, Parent, First Merger Sub or Second Merger Sub, as the case may be, to comply
with or satisfy any covenant, condition or agreement to be complied with or satisfied by it under this Agreement such that the conditions set forth in <U>Section&nbsp;8.02(b</U>) or <U>Section&nbsp;8.03(b</U>) would not be satisfied;
<U>provided</U>, <U>however</U>, that the delivery of any notice pursuant to this <U>Section&nbsp;7.06</U> shall not limit or otherwise affect the remedies available hereunder to the party receiving such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall give prompt notice to Parent, and Parent shall give prompt notice to the Company, of any notice or other communication
from any Governmental Authority in connection with the Transactions or from any Person alleging that the consent of such Person is or may be required in connection with the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.07 <U>Reasonable Best Efforts; Further Action</U>. (a)&nbsp;Upon the terms and subject to the conditions set forth in this
Agreement, each of the parties hereto agrees to use its reasonable best efforts to take, or cause to be taken, all actions that are necessary, proper or advisable to consummate and make effective the Transactions, including using its reasonable best
efforts to accomplish the following: (i)&nbsp;the satisfaction of the conditions precedent set forth in Article VIII, (ii)&nbsp;the obtaining of all necessary consents, approvals or waivers from third parties, including pursuant to the contracts set
forth on <U>Section&nbsp;4.04 of the Company Disclosure Letter</U>; <U>provided</U> that, notwithstanding the foregoing, in no event shall the Company or any of its Subsidiaries be obligated to bear any expense or pay any fee (other than the payment
of nominal administrative, processing or similar fees or charges) or grant any concession in connection with obtaining the consents, approvals or waivers referred to in this clause (ii), (iii)&nbsp;the obtaining of all necessary actions or
nonactions and consents from, and the giving of any necessary notices to, Governmental Authorities and third parties and the making of all necessary registrations, declarations and filings under the HSR Act, which shall be made as soon as reasonably
practicable following the date hereof and in any event no later than fifteen (15)&nbsp;Business Days following the date hereof, or are required or advisable under other applicable antitrust, competition or pre-merger notification Laws of any
jurisdiction (collectively, &#147;<U>Antitrust Laws</U>&#148;), if any, (iv)&nbsp;the taking of all reasonable steps to provide any supplemental information requested by any Governmental Authority, including participating in meetings with officials
of such entity in the course of its review of this Agreement or the Transactions, including the Merger, (v)&nbsp;the taking of all reasonable steps as may be necessary to avoid any Action by any Governmental Authority or third party that would
otherwise have the effect of materially delaying or preventing the consummation of the Merger and (vi)&nbsp;the defending or contesting of any Actions challenging this Agreement or the consummation of the Merger, including seeking to have any stay
or temporary restraining order entered by any court or other Governmental Authority vacated or reversed. In connection with and without limiting the generality of the foregoing, reasonable best efforts shall include (and with respect to remedies,
shall be limited to) Parent and its Subsidiaries offering and agreeing to undertake Permitted Restrictions as reasonably necessary to obtain pre-merger clearance in as timely a manner as reasonably possible from Governmental Authorities under
Antitrust Laws in the United States and, if applicable, the UK and Germany (specifically, for (1)&nbsp;any waiting period applicable to the Mergers under the HSR Act to have been terminated or expired and the avoidance of an Action in the US seeking
to prohibit consummation of the Merger, and (2)&nbsp;any antitrust clearance required to be obtained in the UK and Germany (if applicable)). Notwithstanding the foregoing or any other provision of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement to the contrary, in no event shall Parent or its Subsidiaries (including First Merger Sub and Second Merger Sub and, after the Effective Time, the Surviving Corporation and its
Subsidiaries and, after the Second Effective Time, the Surviving Entity and its Subsidiaries) be required to agree to or accept (A)&nbsp;any commitment, undertaking or Order to divest, hold separate or otherwise dispose of any portion of its or
their respective businesses or assets, including after giving effect to the Transactions, or (B)&nbsp;any limitation on the ability of Parent or its Subsidiaries to acquire or hold or exercise full rights of ownership of any capital stock of the
Company or its Subsidiaries, including after giving effect to the Transactions; <U>provided</U>, however, it being understood that Permitted Restrictions affecting the operations of Parent or its Subsidiaries (including, for this purpose, the
Company and its Subsidiaries) shall be deemed not to be a limitation on the ability to exercise full rights of ownership. In no event shall the Company or any of its Subsidiaries be permitted to commit or agree to any remedy (including any matter
described in clauses (A)&nbsp;and (B)&nbsp;and any Permitted Restriction) without Parent&#146;s prior written consent. Nothing in this <U>Section&nbsp;7.07(a</U>) shall require any party to take or agree to take any action with respect to its
business or operations pursuant to this <U>Section&nbsp;7.07(a</U>) unless the effectiveness of such agreement or action is conditioned upon the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, &#147;<U>Permitted Restrictions</U>&#148; shall mean the actions described in <U>Section&nbsp;7.07 of the
Company</U> <U>Disclosure Letter</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent and the Company shall (i)&nbsp;reasonably cooperate with each other in
connection with any filing or submission with any Governmental Authorities in connection with the Transactions and any consents from any Governmental Authority in connection therewith and any investigation or other inquiry related thereto and in
connection with resolving any such investigation or inquiry with respect to any such filing or the Mergers, (ii)&nbsp;not extend any waiting or suspension period under any applicable Antitrust Laws or enter into any agreement with any Governmental
Authority not to consummate the Mergers, except with the prior written consent of the other party (such consent not to be unreasonably withheld, conditioned or delayed), (iii)&nbsp;respond as promptly as practicable to any applicable inquiries or
requests received from any Governmental Authority for additional information or documentation, (iv)&nbsp;promptly make any applicable further filings or information submissions pursuant thereto that may be necessary or advisable and
(v)&nbsp;promptly make any requisite filings or submissions required or advisable under any applicable Antitrust Laws. Each of Parent and the Company shall (A)&nbsp;promptly notify the other party of any written or oral communication to that party
or its Subsidiaries or Representatives from any Governmental Authority regarding the parties&#146; collaborative efforts to obtain consents to the Mergers under Antitrust Laws, (B)&nbsp;subject to applicable Law and to the extent reasonably
practicable, permit the other party to review and comment on any substantive written communication regarding such efforts prior to providing such communication to any Governmental Authority and (C)&nbsp;to the extent reasonably practicable, not
agree to participate, or permit its Subsidiaries or Representatives to participate, in any substantive meeting or discussion with any Governmental Authority in respect of any filings, investigation or inquiry concerning consents to the Mergers under
Antitrust Laws unless it consults with the other party in advance and, to the extent permitted by such Governmental Authority and reasonably practicable, gives the other party the opportunity to attend and participate. For the avoidance of doubt,
subject to the proviso in the following sentence, Parent and the Company shall jointly control all communications with any Governmental Authority </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to Antitrust Laws, and determine and direct the strategy and process by which the parties will seek required approvals relating to Antitrust Laws. If the parties hereto initially
disagree upon any such proposed communication, strategy or process, the parties agree to work together in good faith to resolve the disagreement and endeavor to implement such communication, strategy or process in a mutually acceptable manner;
provided that to the extent that a disagreement is unresolved after good faith discussions between Parent and the Company, the implementation of such communication, strategy or process will be controlled by Parent after good faith consideration of
the views of Company. Without limiting the foregoing, neither party shall make any filings, submissions or substantive written communications to any Governmental Authority to obtain consents to the Mergers under Antitrust Laws without first
providing a written copy of such filing, submission or communication to the other party (or as appropriate to such party&#146;s outside counsel) and allowing the other party a reasonable opportunity to provide comments on such filing, submission or
communication prior to submission. Parent and the Company covenant and agree to incorporate all reasonable comments of the other party (or as appropriate such party&#146;s outside counsel) with respect to such filings, submissions and communications
prior to delivery of the same to any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.08 <U>Obligations of First Merger Sub and Second Merger
Sub</U>. Parent shall take all action necessary to cause each of First Merger Sub and Second Merger Sub to perform its obligations under this Agreement and to consummate the Mergers on the terms and subject to the conditions set forth in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.09 <U>Consents of Accountants</U>. Parent and the Company will each use their respective reasonable best
efforts to cause to be delivered to each other consents from their respective independent auditors, in form reasonably satisfactory to the recipient and customary in scope and substance for consents delivered by independent public accountants in
connection with registration statements on Form S-4 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10 <U>Listing</U>. Parent shall cause the
shares of Parent Common Stock to be issued in the Mergers to be approved for listing on the NASDAQ, subject to official notice of issuance, and the Company shall cooperate with Parent to the extent reasonably necessary with respect to such listing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11 <U>Public Announcements</U>. The initial press release relating to the Transactions shall be a joint press release, the
text of which has been agreed to by each of Parent and the Company. Thereafter, unless otherwise required by applicable Law or the requirements of applicable stock exchanges, each of Parent and the Company shall each use its reasonable best efforts
to consult with the other before issuing, and give each other the opportunity to review and comment upon, any press release or notice to stockholders, or otherwise making any public statements with respect to this Agreement, the Mergers or any of
the other Transactions; <U>provided</U>, <U>however</U>, that each of Parent and the Company may make public statements that do not contain any information relating to the Transactions that has not been previously announced or made public in
accordance with this Agreement and do not reveal material, nonpublic information regarding the other party; <U>provided</U>, <U>further</U>, that the Company may make public statements regarding a Change in the Company Recommendation pursuant to
<U>Section&nbsp;7.02(d</U>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12 <U>Certain Tax Matters</U>. (a)&nbsp;During the period from the date of
this Agreement to the Closing Date, the Company and its Subsidiaries shall: (i)&nbsp;prepare and timely file all Tax Returns that are due on or before the Closing Date in accordance with, to the extent applicable and, except as required by Law, past
practice, (ii)&nbsp;pay all Taxes due and payable in respect of such Tax Returns, except in the case of clauses (i)&nbsp;and (ii), where failure to file or pay would not, individually or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, (iii)&nbsp;accrue a reserve in the applicable books and financial statements in accordance with past practices for all Taxes payable for which no Tax Return is due prior to the Closing Date for which failure to pay would,
individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect and (iv)&nbsp;promptly notify Parent of any suit, claim, action, investigation, proceeding or audit (in each case with respect to a material amount of
Taxes) that becomes pending against or with respect to the Company or any of its Subsidiaries that would, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall deliver to Parent on or prior to the Closing Date a properly executed statement signed by the Company to the effect that
the shares of Company Stock are not &#147;United States real property interests&#148; within the meaning of Section&nbsp;897 of the Code; provided, however, that notwithstanding the foregoing, the sole remedy under this Agreement in respect of any
Person for the failure of the Company to deliver such certification specified in this <U>Section&nbsp;7.12(b</U>) to Parent shall be to withhold in accordance with <U>Section&nbsp;3.02(i</U>) any Taxes that are required to be withheld by such Person
pursuant to Section&nbsp;1445 of the Code by reason of such failure from any payment otherwise payable pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13 <U>Drag-Along; Stockholder Agreements and Communications</U>. (a)&nbsp;Following the execution of the Drag-Along Consent by
the Selling Investors, the Company shall promptly send a notice to the its stockholders (in the form attached hereto as <U>Exhibit E</U>) regarding the approval of this Agreement and the Transactions for purposes of the Drag-Along and the exercise
of the Drag-Along and informing the Voting Agreement Parties of their obligations pursuant to Section&nbsp;2 of the Voting Agreement with respect to the Drag-Along. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Promptly following the S-4 Effectiveness Time and prior to the Effective Time, and in consideration of, among other things, the entry into
this Agreement by the Company, Parent, First Merger Sub and Second Merger Sub and the anticipated consummation of the Transactions, the Company shall, pursuant to Section&nbsp;2.2(c) of the Voting Agreement, use commercially reasonable efforts to
cause each Voting Agreement Party to duly execute and deliver to the Company and Parent a support agreement in the form attached hereto as <U>Exhibit F</U> (with such changes and modifications as may be mutually agreed by Parent and the Company,
each, a &#147;<U>Support Agreement</U>&#148;); <U>provided</U> that, notwithstanding the foregoing, in no event shall the Company or any of its Subsidiaries be obligated to bear any expense or pay any fee (other than the payment of nominal
administrative, processing or similar fees or charges) or grant any concession in connection with the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Unless otherwise required by Law or a Governmental Authority, the Company (i)&nbsp;shall
recognize the proxy granted to Parent in respect of all shares of Company Stock held by the Voting Agreement Parties pursuant to the Drag-Along Consent and the proxy granted to Parent pursuant to the Selling Investor Support Agreement and each
Support Agreement and (ii)&nbsp;shall not register transfers of Company Stock that do not comply with the terms of the Selling Investor Support Agreement and the Support Agreements (as applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything in this Agreement to the contrary, in no event shall any Change in the Company Recommendation affect the validity
and enforceability of the obligations of the Company pursuant to this <U>Section&nbsp;7.13</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14 <U>Anti-Takeover
Statutes</U>. The Company and the Company Board shall: (a)&nbsp;grant such approvals and take all actions necessary so that no &#147;business combination&#148;, &#147;control share acquisition&#148;, &#147;fair price&#148;, &#147;moratorium&#148; or
other anti-takeover or similar Laws become applicable to this Agreement, the CVR Agreement, the Support Agreements and the Selling Investor Support Agreement or the Transactions, including the Mergers, and (b)&nbsp;if any such anti-takeover or
similar Law becomes applicable to the Transactions, grant such approvals and take all actions necessary so that the Transactions may be consummated as promptly as practicable and otherwise to take all such other actions as are reasonably necessary
to eliminate or minimize to the greatest extent possible the effects of any such Law on the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.15
<U>Stockholder Litigation</U>. From and after the date hereof, the Company shall promptly advise Parent orally and in writing of any Actions (including derivative claims) commenced or, to the knowledge of the Company, threatened against the Company
and/or its directors or officers relating to this Agreement, the Mergers and/or the other Transactions contemplated hereby and shall keep Parent promptly and reasonably informed regarding any such Action. The Company shall give Parent the
opportunity to participate in the defense or settlement of any such Action and shall give due consideration to Parent&#146;s views with respect thereto. The Company shall not agree to any settlement of any such Action without Parent&#146;s prior
written consent (such consent not to be unreasonably withheld, conditioned or delayed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.16 <U>Section&nbsp;16 Matters</U>.
Prior to the Effective Time, the Parent Board (or a duly formed and duly authorized committee thereof) shall take all such actions as may be necessary or appropriate to cause any acquisitions of Parent Common Stock (including derivative securities
related to Parent Common Stock) by any individual who shall become subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act as a result of the Transactions to be exempt under Rule 16b-3 under the Exchange Act, to the extent
permitted by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.17 <U>CVR Agreement</U>. At or prior to the Effective Time, Parent will duly adopt, execute
and deliver, and each of Parent and the Company shall use its commercially reasonable efforts to cause the Trustee to execute and deliver, the CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.18 <U>Financing</U>. (a)&nbsp;Each of Parent, First Merger Sub and Second Merger Sub shall use its reasonable best efforts to
take, or cause to be taken, all actions and do, or cause to be done, all things necessary or advisable to arrange and obtain the Financing on the terms and conditions described in or contemplated by the Financing Commitments prior to when the
conditions to the Mergers set forth in <U>Article VIII</U> (other than those conditions that by their terms must be satisfied at the Closing) are satisfied, including using reasonable best efforts to (i)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintain in effect the Financing Commitments; (ii)&nbsp;satisfy on a timely basis all conditions and covenants applicable to Parent, First Merger Sub and Second Merger Sub in the Financing
Commitments and otherwise comply with its obligations in each case thereunder; (iii)&nbsp;enter into definitive agreements with respect to the Financing Commitments on the terms and conditions (including the &#147;market flex&#148; provisions)
contemplated thereby; (iv)&nbsp;in the event that all conditions in the Financing Commitments have been satisfied, cause the Persons providing Financing under the Financing Commitments to fund the Financing and consummate the Financing contemplated
by such Financing Commitments on or prior to the date the Closing is required to occur pursuant to <U>Section&nbsp;2.02</U>; and (v)&nbsp;enforce its rights under the Financing Commitments, except, in the case of clauses (i)&nbsp;through
(v)&nbsp;above, to the extent (and solely to the extent) Parent or one or more of its Subsidiaries has issued in one or more offerings any debt or equity securities in lieu of the Financing on or prior to the Closing Date or otherwise will have
sufficient cash at the Closing, in each case in an amount such that Parent, First Merger Sub, Second Merger Sub, the Surviving Corporation and the Surviving Entity will be able to satisfy all of the payment obligations of Parent, First Merger Sub,
Second Merger Sub, the Surviving Corporation and the Surviving Entity contemplated hereunder in connection with the Closing. Notwithstanding the foregoing, in no event shall Parent be required to pursue litigation against the Financing Sources in
respect of this clause (a)&nbsp;or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) None of Parent, First Merger Sub or Second Merger Sub shall agree to any amendment or
modification to be made to, or any waiver of any provision or remedy under the Financing Commitments, without the prior written consent of the Company if such amendments, modifications or waivers would, or would reasonably be expected to,
(i)&nbsp;reduce the aggregate amount of the Financing; (ii)&nbsp;impose new conditions (or expand any existing conditions) to the receipt of the Financing (in the case of each of (i)&nbsp;and (ii), only if such amendments, modifications or waivers
would reasonably be expected to (x)&nbsp;interfere with Parent&#146;s ability to make available to the Exchange Agent at or immediately prior to the Closing funds sufficient for the satisfaction of all of Parent&#146;s, First Merger Sub&#146;s and
Second Merger Sub&#146;s obligations under this Agreement, including the payment of the Merger Consideration and the payment of all associated costs and Expenses or (y)&nbsp;prevent, materially delay or materially impair the ability of Parent, First
Merger Sub and Second Merger Sub to consummate the Mergers or its other obligations under the Agreement); (iii)&nbsp;prevent or materially delay the consummation of the Transactions; or (iv)&nbsp;adversely impact the ability of Parent, First Merger
Sub or Second Merger Sub to enforce its rights against the other parties to the Financing Commitments (<U>provided</U>, <U>however</U>, that, for the avoidance of doubt, Parent, First Merger Sub and Second Merger Sub may amend or modify the
Financing Commitments to add lenders, lead arrangers, underwriters, initial purchasers, bookrunners, syndication agents or similar entities, if the addition of such additional parties, individually and in the aggregate, would not prevent or
materially delay the Financing or the consummation of the Transactions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent, First Merger Sub and Second Merger Sub shall keep
the Company reasonably informed on a timely basis of the status of its efforts to arrange the Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Parent, First Merger Sub and Second Merger Sub shall give the Company prompt notice of
Parent&#146;s receiving any notice of any material breach or material default by any party to any Financing Commitment or definitive document related to the Financing of which Parent, First Merger Sub or Second Merger Sub become aware;
<U>provided</U>, <U>however</U>, that in no event will Parent, First Merger Sub and Second Merger Sub be under any obligation to disclose any information that is subject to attorney-client or similar privilege. If any portion of the Financing
becomes unavailable on the terms and conditions (including the &#147;market flex&#148; provisions) contemplated in the Financing Commitments and such portion is necessary to consummate the Mergers, Parent shall use its reasonable best efforts to
arrange and obtain alternative financing from alternative sources in an amount sufficient to consummate the transactions contemplated by this Agreement upon terms and conditions not materially less favorable to Parent than those in the Financing
Commitments (including, as necessary, the &#147;market flex&#148; provisions contained in any fee letter related to the Financing Commitments) (the &#147;<U>Alternative Financing</U>&#148;) as promptly as practicable following the occurrence of such
event and prior to when the conditions to Mergers set forth in <U>Article VIII</U> (other than those conditions that by their terms must be satisfied at the Closing) are satisfied. Any replacement commitment letters and related fee letters (which
may be redacted) in connection with an Alternative Financing shall constitute Financing Commitments under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.19 <U>Financing Cooperation</U>. (a)&nbsp;Prior to the Closing, the Company shall, and shall cause its Subsidiaries and each of
its and their respective officers, employees, consultants and representatives to, use reasonable best efforts to cooperate with Parent, First Merger Sub and Second Merger Sub in connection with Parent&#146;s obtaining the Financing; <U>provided</U>,
<U>however</U>, that nothing herein shall require such cooperation to the extent it would interfere unreasonably with the business or operations of the Company or its Subsidiaries in any material respect; <U>provided</U>, <U>further</U>, that
neither the Company nor any of its Subsidiaries shall be required to commit to take any action that is not contingent upon the Closing (including the entry into any agreement) or that would be effective prior to the Effective Time other than as
specifically set forth herein. Such cooperation shall include, without limitation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) furnishing Parent, First Merger Sub
and Second Merger Sub and their Financing Sources, promptly following Parent&#146;s request, with such pertinent and customary (as compared to other transactions of this size and nature) information (other than financial information, which is
covered by clause (ii)&nbsp;below), to the extent reasonably available to the Company, regarding the Company and its Subsidiaries as may be reasonably determined by Parent to be necessary in order to consummate the Financing, including all
information necessary to satisfy the conditions set forth in the Financing Commitments; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) furnishing Parent and its
Financing Sources as promptly as practicable (but no earlier than (i)&nbsp;90 days after the end of the relevant final fiscal year end in the case of paragraph (1), and (ii)&nbsp;45 days after the end of the relevant fiscal quarter in the case of
paragraph (2))&nbsp;with: (A)(1) audited consolidated balance sheets and related statements of income, stockholders&#146; equity and cash flows of the Company prepared in accordance with GAAP for the three most recently completed fiscal years ended
at least 90 days before the Closing Date, and (2)&nbsp;unaudited consolidated balance sheets and related statements of income, and cash flows of the Company prepared in accordance with GAAP and reviewed by the Company&#146;s independent accountants
in accordance with the procedures set forth in AS 4105 (<I>Reviews of Interim Financial</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<I>Information</I>) for each subsequent fiscal quarter ended at least 45 days prior to the then expected Closing Date and (B)&nbsp;financial information of the type that would be required by
Regulation S-X and Regulation S-K under the Securities Act for an offering of securities registered on Form S-3 under the Securities Act, including all information required to be incorporated by reference therein and audit reports of annual
financial statements to the extent so required or otherwise reasonably necessary to permit Parent to prepare pro forma financial statements customary for Financings of the applicable type (all such information in clauses (A)&nbsp;and this clause
(B), the &#147;<U>Required Information</U>&#148;); <U>provided</U>, <U>however</U>, that the Required Information shall not include, and Parent shall be solely responsible for, the preparation of pro forma financial information, including pro forma
cost savings, synergies, capitalization, ownership or other pro forma adjustments desired to be incorporated into any pro forma financial information; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) cooperating with Parent&#146;s Financing Sources&#146; due diligence investigation of the Company and its Subsidiaries;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;participating in and assisting with the syndication, underwriting, placement or other marketing of the
Financing, including participating in a reasonable number of meetings, presentations, road shows, due diligence sessions, drafting sessions and sessions with rating agencies, including direct contact between senior management of the Company and its
Subsidiaries and representatives of the Company with prospective investors, lenders and rating agencies in connection with a Financing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) assisting with the preparation of customary materials for registration statements, rating agency presentations, offering
documents, private placement memoranda, bank information memoranda, prospectuses and supplements related thereto and similar documents required in connection with the Financing (all such documents and materials, collectively, the &#147;<U>Financing
Offering Documents</U>&#148;), providing customary authorization letters authorizing the distribution of information to prospective Financing Sources and containing customary 10b-5 representations and representations that the public side versions of
such documents, if any, do not include material non-public information regarding the Company or its Subsidiaries or securities and management representation letters and delivering and consenting to the inclusion or incorporation in any SEC filing
related to the Financing of the historical audited consolidated financial statements and unaudited consolidated interim financial statements of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) executing and delivering any currency or interest hedging arrangements, other definitive financing documents
(<U>provided</U>, <U>however</U>, that the effectiveness of such documents will be conditioned upon the occurrence of the Effective Time), and obtaining and delivering certificates or documents required to satisfy the conditions in the Financing
Commitments; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) obtaining from the Company&#146;s registered public accounting firm
that has audited the Company&#146;s most recent financial statements customary comfort letters, consents, and other documentation and items required in connection with the Financing with respect to financial information provided pursuant to clause
(a)(ii) of this Section&nbsp;7.19 that is included or incorporated by reference in any prospectus, prospectus supplement, private placement memorandum or other offering document for which such comfort is customarily required, including customary
confirmations (in customary form and scope and delivered at such customary times) of such accountants that they are prepared to issue any such comfort letter or consent subject to the completion of its customary procedures related thereto and
obtaining customary legal opinions, in each case as reasonably requested by Parent (including those requested by Parent on behalf of a Financing Source); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) delivering notices of prepayment within the time periods required by the relevant agreements governing indebtedness and
arranging for customary payoff letters, lien terminations and instruments of discharge to be delivered at Closing to allow for the payoff, discharge and termination in full on the Closing Date of all indebtedness and Encumbrances under indebtedness
of the Company required to be repaid as of the Effective Time by the terms of any Financing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) taking all corporate and
other actions, subject to the occurrence of the Effective Time, reasonably requested by Parent to (A)&nbsp;permit the consummation of the Financing, (B)&nbsp;the distribution or payment of the proceeds of the Financing, if any, obtained by any
Subsidiary of the Company to the Surviving Entity, and (C)&nbsp;cause the direct borrowing or incurrence of all of the proceeds of the Financing, by the Surviving Entity or any Subsidiary of the Company concurrently with or immediately following the
Effective Time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) furnishing Parent and its Financing Sources promptly and in any event at least 3 Business Days before
the Closing Date with all documentation and other information which any Financing Source providing or arranging the Financing has reasonably requested at least 10 Business Days prior to the Closing Date that such Financing Source has determined is
required by Governmental Authorities under applicable &#147;know your customer&#148; and anti-money laundering rules and regulations, including, without limitation, the USA PATRIOT Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) procuring consents to the reasonable use of all of the Company&#146;s logos in connection with the Financing
(<U>provided</U>, <U>however</U>, that such logos are used solely in a manner that is not intended to and is not reasonably likely to harm or disparage the Company or its Subsidiaries or the reputation or goodwill of the Company or any of its
Subsidiaries); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) furnishing customary information reasonably available to the Company regarding the Company and
its Subsidiaries required for Parent to obtain corporate and facilities ratings and ratings on any debt securities issued in connection with the Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At Parent&#146;s reasonable request, the Company shall or shall cause its Subsidiaries
to use their respective reasonable best efforts to amend or supplement any information supplied in writing by or on behalf of the Company or any of its Subsidiaries to Parent, First Merger Sub, Second Merger Sub or any Financing Source on a
reasonably current basis to the extent such information (excluding any projections, forecasts, pro forma financial information and other forward-looking information), to the knowledge of the Company, taken as a whole, is not correct in all material
respects, contains any untrue statement of material fact or omits to state any material fact necessary to make such information supplied in writing by or on behalf of the Company or any of its Subsidiaries not materially misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Nothing in this <U>Section&nbsp;7.19</U> shall require such cooperation to the extent it would (i)&nbsp;require the Company to agree to
pay any fees, reimburse any expenses or give any indemnities prior to the Effective Time, (ii)&nbsp;require the Company to incur any other liability or obligation prior to the Effective Time (it being understood, however, that the Company shall bear
all costs and expenses of its annual audit and quarterly reviews of its financial statements but not the costs of any comfort letter (which shall be borne by Parent)), or (iii)&nbsp;cause any condition to the Mergers set forth in <U>Article VIII</U>
to fail to be satisfied or otherwise cause any breach of this Agreement that would give Parent the right to terminate this Agreement (unless, in each case, waived in writing by Parent). Parent shall promptly, upon request by the Company, pay all
reasonable and documented out-of-pocket third party costs incurred by the Company or any of its Subsidiaries in connection with cooperation pursuant to this <U>Section&nbsp;7.19</U> except for the costs of the Company&#146;s registered public
accounting firm described in the prior sentence. All confidential information provided by the Company or its Subsidiaries to Parent or its Affiliates pursuant to this <U>Section&nbsp;7.19</U> shall be kept confidential in accordance with the
Confidentiality Agreement, except that Parent shall be permitted to disclose such information to its Financing Sources and prospective Financing Sources, subject to ordinary and customary confidentiality undertakings. Notwithstanding the foregoing,
Parent shall be permitted to disclose such confidential information upon prior written notice to the Company if such disclosure is required in order to comply with applicable laws (including any securities Law or the rules of a securities exchange)
and with judicial process. Parent, First Merger Sub and Second Merger Sub shall indemnify and hold harmless the Company, its Subsidiaries and their respective Representatives from and against any and all losses, damages, claims, costs or expenses
suffered or incurred by any of them in connection with the Financing (other than arising from fraud, willful misconduct or misrepresentations, misstatements or omissions) and any information utilized in connection therewith (other than written
information directly provided by the Company and its Subsidiaries). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) For the avoidance of doubt and notwithstanding anything to the
contrary in this Agreement, Parent acknowledges and agrees that its obligation to consummate the transactions contemplated by this Agreement on the terms and subject to the conditions set forth herein are not conditioned upon the availability or
consummation of the Financing or any other debt financing, the availability of any equity financing or the receipt of the proceeds therefrom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Without limiting in any respect the liabilities of the Financing Sources to Parent,
First Merger Sub, Second Merger Sub or their Affiliates, or the remedies of Parent, First Merger Sub, Second Merger Sub or their Affiliates against the Financing Sources under any other agreement to which they are both parties, none of the Financing
Sources shall have any liability to the parties or their Affiliates relating to or arising out of this Agreement, whether at law or equity, in contract, in tort or otherwise, and neither the parties nor any of their Affiliates will have any rights
or claims against the Financing Sources in respect of the Financing under this Agreement. Notwithstanding anything herein to the contrary, in no event shall the Company or its Affiliates be entitled to seek any remedy, including specific performance
of this Agreement, against any of the Financing Sources (it being expressly agreed that the Financing Sources in their capacities as such shall be third party beneficiaries of this Section&nbsp;7.19(e) and shall be entitled to enforce the provisions
contained in this Section&nbsp;7.19(e) as if they were a party to this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything to the contrary herein,
it is understood and agreed that the condition precedent set forth in <U>Section</U><U> </U><U>8.02(b)</U>, as applied to the Company&#146;s obligations under this <U>Section&nbsp;7.19</U>, shall be deemed to be satisfied unless the financing
contemplated by the Debt Commitment Letter has not been obtained as a direct result of the Company&#146;s Intentional Breach of its obligations under this <U>Section 7.19.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Company and Parent agree to the matters set forth on <U>Section&nbsp;7.19(g) of the Company Disclosure Letter</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.20 <U>Resignations of Directors and Officers</U>. At or prior to the Closing, the Company shall request that each director and
officer of the Company deliver to Parent written resignation and release letters, effective as of the Closing Date, of each of the directors and officers of the Company requested by Parent in writing at least five Business Days prior to the Closing,
effectuating his or her resignation from such position as a member of the Company Board or as an officer (although not as an employee, if applicable, unless otherwise so requested by Parent), in form and substance reasonably satisfactory to Parent.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO THE MERGERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01 <U>Conditions to the Obligations of Each Party</U>. The respective obligations of the Company, Parent, First Merger Sub and
Second Merger Sub to consummate the Mergers are subject to the satisfaction or written waiver (where permissible under applicable Law) at or prior to the Effective Time of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Registration Statement shall have become effective under the Securities Act and no stop order
suspending the effectiveness of the Registration Statement shall have been issued by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholder Approval</U>. The
Company Stockholder Approvals shall have been obtained in accordance with the DGCL and the Company&#146;s certificate of incorporation and bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Order</U>. No Governmental Authority shall have enacted, issued, promulgated,
enforced or entered any Law, whether temporary, preliminary or permanent (collectively, a &#147;<U>Restraint</U>&#148;), which is then in effect and has the effect of enjoining, restraining, prohibiting or otherwise preventing the consummation of
the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Regulatory Approvals</U>. (i)&nbsp;Any waiting period (and any extension thereof) applicable to the consummation
of the Mergers under the HSR Act shall have expired or been terminated and (ii)&nbsp;any approval or waiting period with respect to those jurisdictions set forth in <U>Section&nbsp;8.01(d) of the Company Disclosure Letter</U> shall have been
obtained or terminated or shall have expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>NASDAQ Listing</U>. The shares of Parent Common Stock to be issued in the Mergers
shall have been authorized for listing on the NASDAQ, subject to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02 <U>Conditions to the
Obligations of Parent, First Merger Sub and Second Merger Sub</U>. The obligations of Parent, First Merger Sub and Second Merger Sub to consummate the Mergers are subject to the satisfaction or written waiver (where permissible under applicable Law)
at or prior to the Effective Time of the following additional conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. In each case as of
the date of this Agreement and as of the Closing Date, except to the extent any such representations and warranties expressly relate to an earlier date, in which case as of such earlier date, (i)&nbsp;the representations and warranties of the
Company set forth in the first sentence of <U>Section&nbsp;4.07</U> (Absence of Certain Changes or Events) shall be true and correct in all respects, (ii)&nbsp;the representations and warranties of the Company set forth in
<U>Section&nbsp;4.01(a)</U> (Organization and Qualification; Subsidiaries) (only as it relates to the Company), <U>Section&nbsp;4.02 </U>(Capitalization) (except with respect to <U>Section&nbsp;4.02(b)</U> and <U>Section&nbsp;4.02(e)</U>),
<U>Section&nbsp;4.03</U> (Authority Relative to This Agreement) (except with respect to <U>Section&nbsp;4.03(d) </U>and <U>Section&nbsp;4.03(e)</U>), and <U>Section&nbsp;4.17 </U>(Brokers) shall be true and correct in all material respects and
(iii)&nbsp;the other representations and warranties of the Company set forth in <U>Article IV </U>shall be true and correct (without giving effect to any &#147;material&#148;, &#147;materiality&#148; or &#147;Company Material Adverse Effect&#148;
qualification contained therein) except where the failure of any such representations and warranties to be so true and correct has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Agreements and Covenants</U>. The Company shall have performed or complied, in each case, in all material respects with
the agreements and covenants required by this Agreement to be performed by it or complied with at or prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Officer&#146;s Certificate</U>. The Company shall have delivered to Parent a certificate, dated the Closing Date, signed by the Chief Executive Officer or Chief Financial Officer of the Company, certifying as to the satisfaction of the conditions
specified in <U>Section&nbsp;8.02(a)</U> and <U>Section&nbsp;8.02(b)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Restrictions</U>. No Restraint shall be in effect, in each case, under any Antitrust
Law which imposes any remedies on Parent and its Subsidiaries (including First Merger Sub and Second Merger Sub and, after the Effective Time, the Surviving Corporation and its Subsidiaries and, after the Second Effective Time, the Surviving Entity
and its Subsidiaries), (a)&nbsp;other than Permitted Restrictions or (b)&nbsp;unless such Restraint is part of an agreement between Parent and its Subsidiaries and a Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Stockholder Agreements</U>. The Selling Investors shall have duly executed and delivered, or caused to be delivered, to Parent, First
Merger Sub or Second Merger Sub the Selling Investor Support Agreement and the Drag-Along Consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03 <U>Conditions to the
Obligations of the Company</U>. The obligations of the Company to consummate the Mergers are subject to the satisfaction or waiver (where permissible under applicable Law) at or prior to the Effective Time of the following additional conditions:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Representations and Warranties</U>. In each case as of the date of this Agreement and as of the Closing Date, except to the extent
any such representations and warranties expressly relate to an earlier date, in which case as of such earlier date, (i)&nbsp;the representations and warranties of Parent, First Merger Sub and Second Merger Sub set forth in
S<U>ection&nbsp;5.09(e)(i)</U> (Absence of Changes) shall be true and correct in all respects, (ii)&nbsp;the representations and warranties of Parent, First Merger Sub and Second Merger Sub set forth in <U>Section&nbsp;5.01</U> (Corporate
Organization), <U>Section&nbsp;5.03</U> (Capitalization) and <U>Section&nbsp;5.04 </U>(Authority Relative to This Agreement; No Vote Required) shall be true and correct in all material respects and (iii)&nbsp;the other representations and warranties
of Parent, First Merger Sub and Second Merger Sub set forth in <U>Article V</U> shall be true and correct (without giving effect to any &#147;material&#148;, &#147;materiality&#148; or &#147;Parent Material Adverse Effect&#148; qualification
contained therein) except where the failure of any such representations and warranties to be so true and correct has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Agreements and Covenants</U>. Parent, First Merger Sub and Second Merger Sub shall have performed or complied, in each case, in all
material respects with the agreements and covenants required by this Agreement to be performed by them or complied with at or prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Officer&#146;s Certificate</U>. Parent shall have delivered to the Company a certificate, dated the Closing Date, signed by the Chief
Executive Officer or Chief Financial Officer of Parent, certifying as to the satisfaction of the conditions specified in <U>Section&nbsp;8.03(a) </U>and <U>Section</U><U> </U><U>8.03(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>CVR Agreement</U>. The CVR Agreement shall be in full force and effect at or prior to the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION, AMENDMENT AND WAIVER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01 <U>Termination</U>. This Agreement may be terminated and the transactions contemplated by this Agreement may be abandoned at
any time prior to the Effective Time, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Parent and the Company, duly authorized by the Parent
Board and the Company Board, respectively; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by either Parent or the Company if: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Effective Time shall not have occurred on or before 11:59 p.m., Eastern time, on the Outside Date; <U>provided</U>,
<U>however</U>, that if on the Outside Date all of the conditions set forth in <U>Section&nbsp;8.01</U>, <U>Section&nbsp;8.02</U> and <U>Section&nbsp;8.03</U> have been satisfied (or, with respect to the conditions that by their terms must be
satisfied at the Closing, would have been so satisfied if the Closing would have occurred) other than the conditions set forth in <U>Section&nbsp;8.01(c)</U> (to the extent such Restraint arises under the HSR Act or any other Antitrust Laws),
<U>Section&nbsp;8.01(d)</U> or <U>Section&nbsp;8.02(d)</U>, then either Parent or the Company may extend the Outside Date to 11:59 p.m., Eastern time, on December&nbsp;20, 2021 by delivering written notice to the other party, which notice shall
expressly reference extension of the Outside Date to December&nbsp;20, 2021 pursuant to this <U>Section&nbsp;9.01(b)(i)</U>; <U>provided</U>, <U>further</U>, that the right to terminate this Agreement under this <U>Section&nbsp;9.01(b)(i)</U> shall
not be available to any party whose breach of any provision of this Agreement has been the proximate cause of, or resulted in, the failure of the Effective Time to occur on or before such time; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any Restraint having the effect set forth in <U>Section&nbsp;8.01(c)</U> hereof shall have become final and
nonappealable; <U>provided</U>, <U>however</U>, that the party seeking to terminate this Agreement shall have complied in all material respects with its obligations under <U>Section&nbsp;7.07</U>; <U>provided</U>, <U>further</U>, that an Initial
Enforcement Order made by the Competition and Markets Authority pursuant to section 72(2) of the UK Enterprise Act 2002 is not considered a Restraint for the purposes of this <U>clause</U> <U>9.01(b)(ii)</U>; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by Parent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) upon a breach by the Company of, or failure by the Company to perform, any representation, warranty, covenant or agreement
set forth in this Agreement such that the conditions set forth in <U>Section&nbsp;8.02(a)</U> or <U>Section&nbsp;8.02(b)</U> would not be satisfied and such breach or failure is incapable of being cured by the Outside Date or, if curable by the
Outside Date, is not cured by the Company within thirty (30)&nbsp;days of receipt by the Company of written notice of such breach or failure; <U>provided</U>, <U>however</U>, that Parent shall not have the right to terminate this Agreement pursuant
to this <U>Section&nbsp;9.01(c)(i)</U> if either of Parent, First Merger Sub or Second Merger Sub is in breach of its representations, warranties or covenants such that the conditions in <U>Section&nbsp;8.03(a)</U> and <U>Section&nbsp;8.03(b)</U>
would not be satisfied; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If any Restraint having the effect set forth in
<U>Section&nbsp;8.02(d)</U> hereof shall have become final and nonappealable; <U>provided</U>, <U>however</U>, that Parent shall have complied in all material respects with its obligations under <U>Section&nbsp;7.07</U>; <U>provided</U>,
<U>further</U>, that an Initial Enforcement Order made by the Competition and Markets Authority pursuant to section 72(2) of the UK Enterprise Act 2002 is not considered a Restraint for the purposes of this <U>clause 9.01(c)(ii)</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if the Selling Investors fail to duly execute and deliver, or cause to be delivered, to Parent, First Merger Sub or
Second Merger Sub the Selling Investor Support Agreement and the Drag-Along Consent within 24 hours following the execution and delivery of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by the Company upon a breach by any of Parent, First Merger Sub or Second Merger Sub of, or a failure by any of Parent, First Merger Sub
or Second Merger Sub to perform, any representation, warranty, covenant or agreement set forth in this Agreement such that the conditions set forth in <U>Section&nbsp;8.03(a)</U> or <U>Section&nbsp;8.03(b)</U> would not be satisfied and such breach
or failure is incapable of being cured by the Outside Date or, if curable by the Outside Date, is not cured by Parent, First Merger Sub or Second Merger Sub, as applicable, within 30 days of receipt by Parent, First Merger Sub or Second Merger Sub,
as applicable, of written notice of such breach or failure; <U>provided</U>, <U>however</U>, that the Company shall not have the right to terminate this Agreement pursuant to this <U>Section&nbsp;9.01(d)</U> if the Company is in breach of its
representations, warranties or covenants such that the conditions in <U>Section&nbsp;8.02(a) </U>and <U>Section&nbsp;8.02(b)</U> would not be satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02 <U>Effect of Termination</U>. In the event of termination of this Agreement pursuant to <U>Section&nbsp;9.01</U>, written
notice thereof shall be given to the other parties hereto, specifying the provision or provisions hereof pursuant to which such termination shall have been made, and this Agreement shall forthwith become void, and there shall be no liability under
this Agreement on the part of any party hereto or their respective Subsidiaries or Representatives, except (a)&nbsp;with respect to this <U>Section&nbsp;9.02</U>, <U>Section&nbsp;4.17</U>, <U>Section&nbsp;5.13</U>, <U>Section&nbsp;7.03(d)</U>,
<U>Section&nbsp;7.19(c)</U>, <U>Section&nbsp;9.03</U>, <U>Section&nbsp;9.04</U>, <U>Section&nbsp;9.05</U>, the tenth and eleventh sentences of <U>Section&nbsp;10.02</U> and <U>Article XI</U>, each of which shall survive any termination of this
Agreement and remain in full force and effect and (b)&nbsp;nothing in this <U>Section&nbsp;9.02</U> or <U>Section&nbsp;9.03</U> shall relieve any party from liability for fraud committed prior to such termination or for any Intentional Breach prior
to such termination of any of its representations, warranties, covenants or agreements set forth in this Agreement; <U>provided</U>, <U>however</U>, that the Confidentiality Agreement shall survive any termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03 <U>Fees and Expenses</U>. (a)&nbsp;In the event that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Parent or the Company terminates this Agreement pursuant to <U>Section&nbsp;9.01(b)(i)</U> and, at the time of such termination, one or
more of the conditions set forth in <U>Section&nbsp;8.01(c)</U> (if the failure of such condition to be satisfied is a result of a Restraint arising under Antitrust Laws), <U>Section&nbsp;8.01(d)</U> or <U>Section&nbsp;8.02(d)</U> were not satisfied
or waived; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Parent or the Company terminates this Agreement pursuant to <U>Section&nbsp;9.01(b)(ii)</U> as a result of a Restraint
arising under Antitrust Laws; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Parent terminates this Agreement pursuant to <U>Section&nbsp;</U><U>9.01(c)(ii)</U>, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and, in the case of each of clauses (i), (ii)&nbsp;and (iii), at the time of such termination (A)&nbsp;all of the other conditions set forth in <U>Article
VIII</U> have been satisfied or validly waived (except for those conditions that by their terms must be satisfied at the Closing, <U>provided </U>that such conditions would have been so satisfied if the Closing would have occurred) and (B)&nbsp;the
Company and the Selling Investors are not in breach in any material respect of its obligations under this Agreement or Selling Investor Support Agreement, as applicable, in any manner that shall be the proximate cause of the failure of any of the
conditions referred to in clause (i)&nbsp;above or the imposition of the Restraint in clause (ii)&nbsp;above or the imposition of any remedies (x)&nbsp;other than Permitted Restrictions or (y)&nbsp;unless such remedy is part of an agreement between
Parent and its Subsidiaries and a Governmental Authority, as applicable, then Parent shall pay to the Company a fee equal to $300,000,000 (the &#147;<U>Regulatory Termination Fee</U>&#148;), by wire transfer on the second Business Day following the
date of termination of this Agreement. In no event shall Parent be required to pay the Regulatory Termination Fee on more than one occasion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Expenses incurred in connection with this Agreement and the Transactions shall be paid by the party incurring such Expenses, whether
or not the Mergers or any other Transaction is consummated, except Expenses incurred in connection with filing, printing and mailing of the Registration Statement and the Consent Solicitation Statement (including filing fees) shall be borne by
Parent, whether or not the Mergers or any other Transaction is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties hereto acknowledge and agree that the
agreements contained in <U>Section&nbsp;9.03(a)</U> are an integral part of the Transactions, and that, without these agreements, the parties hereto would not enter into this Agreement; accordingly, if Parent fails promptly to pay the Regulatory
Termination Fee, and, in order to obtain such payment, the Company commences a suit that results in a judgment against Parent for the Regulatory Termination Fee, Parent shall pay to the Company its costs and expenses (including attorneys&#146; fees
and expenses) in connection with such suit, in each case, together with interest on the amount of the Regulatory Termination Fee, as applicable, from the date such payment was required to be made until the date of payment at the prime rate set forth
in <I>The Wall Street Journal</I>, in effect on the date such payment was required to be made. Each party further acknowledges that the Regulatory Termination Fee is not a penalty, but rather is a reasonable amount that will compensate the receiving
party in the circumstances in which such payment is payable for the efforts and resources expended and opportunities forgone while negotiating this Agreement and in reliance on this Agreement and on the expectation of the consummation of the
Transactions contemplated hereby, which amounts would otherwise be impossible to calculate with precision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to the proviso at the end of this sentence, in the event the Regulatory
Termination Fee is required to be paid and is paid to the Company pursuant to <U>Section&nbsp;9.03(a)</U>, such payment of the Regulatory Termination Fee shall constitute liquidated damages and be the sole and exclusive monetary remedy of the
Company and its Subsidiaries and the Company&#146;s and its Subsidiaries&#146; respective current or future stockholders, employees, directors, officers or Affiliates (collectively, the &#147;<U>Company Related Parties</U>&#148;) against Parent,
First Merger Sub and Second Merger Sub and their respective current, former or future Representatives (collectively, the &#147;<U>Parent Related Parties</U>&#148;) for all losses, damages, costs or expenses in respect of this Agreement (or the
termination thereof) or the Transactions (or the failure of such transactions to occur for any reason or for no reason) or any breach of any covenant or agreement or otherwise in respect of this Agreement or any oral representation made or alleged
to be made in connection herewith, and upon payment of the Regulatory Termination Fee, none of the Parent Related Parties shall have any further monetary liability or obligation relating to or arising out of this Agreement or the Transactions, and
none of the Company, its Subsidiaries or any other Company Related Party shall seek to recover any other monetary damages; <U>provided</U>, <U>however</U>, that (x)&nbsp;<U>Section&nbsp;7.19(c)</U> shall survive any such termination and (y)&nbsp;in
the event of any Intentional Breach by Parent, First Merger Sub or Second Merger Sub prior to such termination, the Company shall be entitled to the payment of the Regulatory Termination Fee (to the extent owed pursuant to
<U>Section&nbsp;9.03(a)</U>) and to seek any damages (including, for the avoidance of doubt, damages of the type referred to in <U>Section&nbsp;11.05(ii)</U>), to the extent proven, resulting from or arising out of such Intentional Breach (as
reduced by any Regulatory Termination Fee paid by Parent). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.04 <U>Continuation Payments; Additional Termination Payment;
Equity Issuance Fees and Expenses</U>. (a)&nbsp;In the event (i)&nbsp;the Effective Time has not occurred on or before 11:59 p.m., Eastern Time, on December&nbsp;20, 2020, and (ii)&nbsp;the Company is not in breach in any material respect of its
obligations under this Agreement in any manner that shall have proximately caused the failure of the Effective Time to occur prior to the date on which a Continuation Payment (as defined below) is due, Parent shall make a payment to the Company of
$35 million (each, a &#147;<U>Continuation Payment</U>&#148;), by wire transfer on the next Business Day following such date and on the 20<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of each month thereafter until the earlier of
(a)&nbsp;the Closing Date or (b)&nbsp;the termination of this Agreement by either Parent or the Company pursuant to <U>Section&nbsp;9.01</U> (such date, the &#147;<U>Continuation End Date</U>&#148;); <U>provided</U>, <U>however</U>, that Parent
shall have no obligation to make any Continuation Payment which is an Excess Continuation Payment unless and until the Company Conditions have been satisfied (it being understood that any Excess Continuation Payment(s) that would have been required
to be paid if the Company Conditions have been satisfied will be paid by Parent to the Company promptly following satisfaction of the Company Conditions); <U>provided</U>, <U>further</U>, that the Company may waive Parent&#146;s obligation to make
any Excess Continuation Payment. For the avoidance of doubt, no additional Continuation Payments shall be payable by Parent in relation to periods after the Continuation End Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that this Agreement is terminated in a circumstance where the Regulatory
Termination Fee becomes payable by Parent in accordance with <U>Section&nbsp;9.03</U> and subject to the satisfaction (or waiver by Parent) of the Company Conditions (unless Parent&#146;s material breach of this <U>Section&nbsp;9.04</U> is the
proximate cause of the failure of such Company Conditions to be satisfied), at the Company&#146;s election, by written notice to Parent no later than the date which is ten (10)&nbsp;Business Days after such termination, Parent shall pay to the
Company an additional amount specified by the Company up to $300 million (the &#147;<U>Additional Termination Payment</U>&#148;) on or prior to the date which is three (3)&nbsp;Business Days after the later of: (i)&nbsp;the date of the
Company&#146;s written election referred to in this <U>Section&nbsp;9.04(b)</U>, and (ii)&nbsp;the satisfaction of the Company Conditions (unless Parent&#146;s breach of this <U>Section&nbsp;9.04</U> is the proximate cause of the failure of such
Company Conditions to be satisfied, in which case the Additional Termination Payment shall be payable upon the date specified in clause (i)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon the date which is the later of (i)&nbsp;sixty (60)&nbsp;days after the date of termination of this Agreement (the
&#147;<U>Termination Date</U>&#148;), and (ii)&nbsp;three (3)&nbsp;Business Days after satisfaction or waiver (where permissible) of the Issuance Conditions, as consideration for any Excess Continuation Payments and the Additional Termination
Payment, in each case, actually made by Parent, as applicable, the Company shall (x)&nbsp;issue and deliver to Parent a number of validly issued, fully paid and non-assessable shares of Series E-1 Preferred Stock equal to (I)&nbsp;(A)&nbsp;the
aggregate amount of Excess Continuation Payments actually paid by Parent to the Company, plus (B)&nbsp;the amount of the Additional Termination Payment actually paid by Parent to the Company ((A) plus (B)&nbsp;being the &#147;<U>Investment
Amount</U>&#148;), minus (C)&nbsp;an amount (if any) specified by the Company in its sole discretion (the &#147;<U>Reduction Amount</U>&#148;), divided by (II) the Issue Price (the &#147;<U>Equity Issuance&#148;</U>), and (y)&nbsp;pay to Parent the
Reduction Amount (if any); <U>provided that</U>, prior to consummation of the Equity Issuance, the Company may elect (in its sole discretion) to pay to Parent an amount of cash equal to the Investment Amount, and, upon such payment being made to
Parent, the Company shall have no further liability pursuant to this <U>Section&nbsp;9.04 </U>and, for the avoidance of doubt, will not be obliged to consummate the Equity Issuance or follow the process set forth in <U>Section</U><U>
</U><U>9.04(f)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall use its reasonable best efforts to cause the Company Conditions to be satisfied prior to the
earlier to occur of (i)&nbsp;in circumstances where the Regulatory Termination Fee is payable, the Termination Date, and (ii)&nbsp;prior to the date that the first payment by Parent to the Company of any Excess Continuation Payment is payable.
Parent irrevocably agrees that it shall (and shall cause its Subsidiaries to), upon the written request of the Company, vote any shares of capital stock of the Company held by it to approve all matters and execute any written consents and/or
amendments or restatements of the Investor Agreements, in each case as are reasonably necessary to satisfy the Company Conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As used in this <U>Section&nbsp;9.04</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Class A-1 Common Stock</U>&#148; shall mean a series of common stock of the Company having substantially the same
terms as the Class&nbsp;A Common Stock, except that (1)&nbsp;shares of Class&nbsp;A-1 Common Stock shall have no voting rights and (2)&nbsp;upon the transfer by the holder thereof to a third party, a share of Class&nbsp;A-1 Common Stock shall
automatically convert into a share of Class&nbsp;A Common Stock if such conversion satisfies the Regulatory Condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Company Conditions</U>&#148; shall mean: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A) The Company shall have received all necessary stockholder and other corporate approvals and adopted and filed with the
Secretary of State of the State of Delaware an amendment to its certificate of incorporation, in a form consistent with this <U>Section&nbsp;9.04</U>, creating and authorizing the issuance of the Series E-1 Preferred Stock and the Series E Preferred
Stock, Class&nbsp;A-1 Common Stock and Class&nbsp;A Common Stock into which such Series E-1 Preferred Stock may be converted </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B) The Company shall have either (x)&nbsp;received such waivers as are reasonably required under its certificate of
incorporation, bylaws and the Investor Agreements to permit the consummation of the Equity Issuance, including the waiver of any preemptive rights, rights of first offer, rights of first refusal or similar rights of any stockholder of the Company
with respect to the Equity Issuance, or (y)&nbsp;notified the Parent that it has complied, or intends to comply, with any such preemptive rights, rights of first offer, rights of first refusal or similar rights of any stockholder of the Company with
respect to the Equity Issuance (it being understood that the Company may, at its election, issue additional shares of Series E-1 Preferred Stock to such stockholders above and beyond the amount of shares to be issued to Parent in the Equity Issuance
(assuming there is no Reduction Amount) or adjust the number of shares to be issued to Parent in the Equity Issuance by specifying a Reduction Amount). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C) Amendments to each of the Investor Agreements to include the Series E-1 Preferred Stock and the Series E Preferred Stock in
the definition of &#147;Preferred Stock&#148; and to define &#147;Class A Common Stock&#148; to include shares of Class&nbsp;A-1 Common Stock in each such Investor Agreement, in each case in a consistent with this <U>Section&nbsp;9.04</U>, shall
have been approved and adopted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<U>Excess Continuation Payments</U>&#148; shall mean Continuation Payments
actually paid to the Company in excess of $315 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) &#147;<U>Issuance Conditions</U>&#148; shall mean the
Regulatory Condition and the Company Conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Issue Price</U>&#148; shall mean $8 billion divided by the
Company Fully Diluted Share Count (with the reference to the Effective Time in the definition of &#147;Company Fully Diluted Share Count&#148; deemed to be a reference to the date of the Equity Issuance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) &#147;<U>Regulatory Condition</U>&#148; shall mean (A)&nbsp;no
Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law, whether temporary, preliminary or permanent, which is then in effect and has the effect of enjoining, restraining, prohibiting or otherwise preventing the
Equity Issuance, (B)&nbsp;no Action by a Governmental Authority seeking such Law shall be pending, and (C)&nbsp;any waiting period under the HSR Act, if applicable, shall have expired or been terminated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) &#147;<U>Series E Preferred Stock</U>&#148; shall mean a series of preferred stock of the Company having substantially
the same terms as the Series A Preferred Stock, except that the Original Issue Price (as defined in the Restated Certificate of Incorporation) shall be equal to the Issue Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) &#147;<U>Series E-1 Preferred Stock</U>&#148; shall mean a series of preferred stock of the Company having substantially
the same terms as the Series A Preferred Stock, except that (i)&nbsp;the Original Issue Price (as defined in the Restated Certificate of Incorporation) of the Series E-1 Preferred Stock shall be equal to the Issue Price, (ii)&nbsp;shares of Series
E-1 Preferred Stock shall have no voting rights (including with respect to a vote on mandatory conversion in connection with a Qualified IPO (as defined in the Restated Certificate of Incorporation)), other than the right to approve (x)&nbsp;the
amendment, alteration or repeal of any provision of the certificate of incorporation or bylaws of the Company in a manner that alters or changes the powers, preferences or rights of the shares of Series E-1 Preferred Stock so as to adversely affect
them disproportionately to any other series or class of stock (it being understood that the creation of a new series of preferred stock shall not be deemed to alter or change the powers, preferences, or rights of the Series E-1 Preferred Stock or
otherwise require the affirmative vote or written consent of the holders of the Series E-1 Preferred Stock), and (y)&nbsp;any waiver of any adjustment to the conversion price for the Series E-1 Preferred Stock, (iii)&nbsp;holders of Series E-1
Preferred Stock will have no rights to designate a member of the Company Board, (iv)&nbsp;upon transfer by the holder thereof to a third party, a share of Series E-1 Preferred Stock shall automatically convert into a share of Series E Preferred
Stock if such conversion satisfies the Regulatory Condition and (v)&nbsp;the Series E-1 Preferred Stock shall otherwise be convertible into shares of Class&nbsp;A-1 Common Stock on substantially the same terms on which the Series A Preferred Stock
is convertible into Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) In the event that a Governmental Authority shall, pursuant to any applicable Antitrust
Law, have enacted, issued, promulgated, enforced or entered any Law, which shall have become final and nonappealable, that has the effect of enjoining, restraining, prohibiting or otherwise preventing the satisfaction of the Regulatory Condition or
the consummation of the Equity Issuance on or before the date which is 180 days after the Termination Date (the &#147;<U>Equity Issuance End Date</U>&#148;), then Parent shall nonetheless be obligated to make the Excess Continuation Payments and the
Additional Termination Payment to the extent otherwise payable pursuant to this <U>Section&nbsp;9.04</U>; <U>provided</U> that: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for a period of 60 days after the Equity Issuance End Date, the parties
hereto shall use reasonable best efforts to structure the Equity Issuance in a manner that is in compliance with applicable Law (including arranging for the Equity Issuance to be made in favor of a nominee of Parent or such other arrangement as is
mutually agreed between the Company and Parent); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) if, after such 60 day period, neither the Equity Issuance nor an
alternative structure contemplated by clause (i)&nbsp;have been consummated, the Company shall (subject to the proviso at the end of this sentence of this clause (ii)) (x)&nbsp;from such date until the date which is 24 months after the Termination
Date (the &#147;<U>Alternative Financing End Date</U>&#148;), use its commercially reasonable efforts to carry out one or more bona fide equity capital raises (each, an &#147;<U>Alternative Capital Raise</U>&#148;) in respect of shares of Company
Capital Stock, and (y)&nbsp;if any Alternative Capital Raise is consummated prior to the Alternative Financing End Date, pay to Parent an amount equal to the lesser of (A)(I) the lesser of (a)(1) the number of shares of Series E-1 Preferred Stock
that would have been issued pursuant to the Equity Issuance (and have not yet been covered by an Alternative Capital Raise pursuant to this <U>Section&nbsp;9.04(f)(ii)</U>), and (2)&nbsp;the actual number of shares issued on the Alternative Capital
Raise, multiplied by (II) the price per security obtained by the Company on the Alternative Capital Raise minus (b)&nbsp;the costs and expenses incurred by Company in connection with such Alternative Capital Raise, and (B)&nbsp;the Investment
Amount; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that, notwithstanding the foregoing provisions of this <U>Section&nbsp;9.04(f)</U>, at any time between the
Equity Issuance End Date and the Alternative Financing End Date, the Company may elect (in its sole discretion) to pay to Parent an amount of cash equal to the Investment Amount, and, upon such payment being made to Parent, the Company shall have no
further obligations or liability pursuant to this <U>Section&nbsp;9.04 </U>in respect of the Excess Continuation Payments and the Additional Termination Payment. Notwithstanding the foregoing provisions of this <U>Section&nbsp;9.04</U>, except in
the event of an Intentional Breach of this <U>Section&nbsp;9.04 </U>by the Company, with effect from the Alternative Financing End Date, the Company shall have no obligations or liability pursuant to this <U>Section&nbsp;9.04 </U>or in respect of
the Excess Continuation Payments and the Additional Termination Payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Until the Equity Issuance End Date, solely in connection
with the Equity Issuance and/or the alternative structure contemplated by <U>Section&nbsp;9.04(f)(i)</U>, the Company will use its commercially reasonable efforts to reasonably cooperate with Parent to obtain any required approvals under Antitrust
Laws in connection with the Equity Issuance and/or such alternative structure by: (i)&nbsp;providing Parent with such information as Parent reasonably requests in writing in connection with making any filings required under Antitrust Laws,
(ii)&nbsp;at Parent&#146;s reasonable request (and at Parent&#146;s sole cost and expense) making such administrative filings with Governmental Authorities that are required by Antitrust Law to be made by the Company in connection with the Equity
Issuance or such alternative structure, (iii)&nbsp;at Parent&#146;s reasonable request (and at Parent&#146;s sole cost and expense), attending and participating in meetings with any Governmental Authorities which are reasonably required in
connection with obtaining clearance under Antitrust Laws, (iv)&nbsp;promptly notifying Parent of any written or material oral communication from any Governmental Authority relating to such approvals or clearance, (v)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to applicable Law and to the extent reasonably practicable, permit Parent to review and comment on any substantive written communication regarding the Equity Issuance or such alternative
structure prior to providing such communication to any Governmental Authority and (vi)&nbsp;to extent reasonably practicable, not agree to participate, or permit its Subsidiaries or Representatives to participate, in any substantive meeting or
discussion with any Governmental Authority with respect to the Equity Issuance or such alternative structure unless it consults with Parent in advance and, to the extent permitted by such Governmental Authority and reasonably practicable, gives
Parent the opportunity to attend and participate. For the avoidance of doubt, and notwithstanding any provision in this <U>Section&nbsp;9.04(g)</U>, nothing in this <U>Section&nbsp;9.04(g)</U> shall obligate the Company or any of its Subsidiaries to
offer, agree to or accept any commitment, remedy, undertaking or Order of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.05 <U>Amendment</U>. This Agreement
may be amended by the parties hereto by action taken by or on behalf of their respective boards of directors at any time prior to the Effective Time; <U>provided</U>, <U>however</U>, that, after the Company Stockholder Approvals have been obtained,
no amendment may be made that under applicable Law or in accordance with the rules of any relevant stock exchange requires further approval by the stockholders of the Company without such approval having been obtained. This Agreement may not be
amended except by an instrument in writing signed by each of the parties hereto. Notwithstanding anything to the contrary in this <U>Section&nbsp;9.05</U>, none of <U>Section&nbsp;5.08</U>, <U>Section&nbsp;7.18</U>, <U>Section&nbsp;7.19</U>,
<U>Section&nbsp;9.05</U>, <U>Section&nbsp;11.05</U>, <U>Section&nbsp;11.07</U> and <U>Section&nbsp;11.09</U> (or any other provision of this Agreement the amendment or waiver of which has the effect of modifying such Sections) may be amended,
modified, terminated or waived in a manner that is adverse to the Financing Sources without the prior written consent of such Financing Sources (it being expressly agreed that the Financing Sources in their capacities as such shall be third party
beneficiaries of this <U>Section&nbsp;9.05</U> and shall be entitled to the protections of the provisions contained in this <U>Section&nbsp;9.05</U> as if they were a party to this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.06 <U>Waiver</U>. At any time prior to the Effective Time, any party hereto may (a)&nbsp;extend the time for the performance of
any obligation or other act of any other party hereto, (b)&nbsp;to the extent permitted by applicable Law, waive any breach of or inaccuracy in the representations and warranties of any other party contained in this Agreement or in any document
delivered pursuant hereto and (c)&nbsp;to the extent permitted by applicable Law, waive compliance with any agreement of any other party or any condition to its own obligations contained in this Agreement. No extension or waiver by the Company shall
require the approval of the stockholders of the Company, unless required by applicable Law. Notwithstanding the foregoing, no failure or delay by the Company or Parent, First Merger Sub or Second Merger Sub in exercising any right hereunder shall
operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or future exercise of any other right hereunder. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the party
or parties to be bound thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.07 <U>Procedure for Termination or Amendment</U>. A termination of this Agreement pursuant
to <U>Section&nbsp;9.01</U> or an amendment of this Agreement pursuant to <U>Section&nbsp;9.04</U> shall, in order to be effective, require, in the case of Parent or the Company, action by its board of directors or, with respect to any amendment of
this Agreement pursuant to <U>Section&nbsp;9.04</U>, the duly authorized committee of its board of directors to the extent permitted by applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVR HOLDER REPRESENTATIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01 <U>Designation and Replacement of CVR Holder Representative</U>. The parties have agreed that it is desirable to designate
a representative to act on behalf of those holders of Company Stock and Company Equity Awards who receive CVRs pursuant to the terms of this Agreement (each, a &#147;<U>Holder</U>&#148;) for all purposes under the CVR Agreement (the &#147;<U>CVR
Holder Representative</U>&#148;). The Company (and, upon execution of a Letter of Transmittal, each Holder) will, promptly following the date hereof, subject to the prior written consent of Parent (not to be unreasonably withheld, conditioned or
delayed), designate an initial CVR Holder Representative, and appoint the CVR Holder Representative as agent and attorney-in-fact for and on behalf of the other Holders for all purposes under the CVR Agreement; <U>provided</U> that notwithstanding
the foregoing, the Company may appoint Fortis Advisors LLC (or any of its Affiliates) or Shareholder Representative Services LLC (or any of its Affiliates) as the CVR Holder Representative without Parent&#146;s consent. The CVR Holder Representative
may resign at any time by five days&#146; prior written notice to Parent. The CVR Holder Representative may be removed pursuant to the terms of the CVR Agreement. In the event that the CVR Holder Representative has resigned or been removed, a new
CVR Holder Representative, as applicable, shall concurrently be appointed pursuant to the CVR Agreement. All power, authority, rights and privileges conferred in this Agreement and the CVR Agreement to the initial CVR Holder Representative will
apply to any successor CVR Holder Representative. The designation of any Person as a CVR Holder Representative is and shall be coupled with an interest, and, except as set forth in this <U>Article X</U>, such designation is irrevocable and shall not
be affected by the death, incapacity, illness, bankruptcy, dissolution or other inability to act of any of the stockholders of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02 <U>Authority and Rights of the CVR Holder Representative; Limitations on Liability</U>. The CVR Holder Representative shall
have such powers and authority as are necessary to carry out the functions, on behalf of the Holders, assigned to it under the CVR Agreement, as applicable; <U>provided</U>, <U>however</U>, that the CVR Holder Representative shall have no obligation
to act, except as expressly provided herein. Without limiting the generality of the foregoing, each Holder agrees that the CVR Holder Representative has full power, authority and discretion, on behalf of each Holder and his, her or its successors
and assigns, to (a)&nbsp;interpret the terms and provisions of the CVR Agreement and the documents to be executed and delivered by the Holders in connection therewith, (b)&nbsp;execute and deliver and receive deliveries of all agreements,
certificates, statements, notices, approvals, extensions, waivers, undertakings, amendments and other documents required or permitted to be given in connection with the consummation of the transactions contemplated by the CVR Agreement, as
applicable, (c)&nbsp;receive service of process in connection with any claims under the CVR Agreement or any document or agreement contemplated to be executed or delivered in connection with the CVR Agreement, (d)&nbsp;agree to, negotiate and enter
into settlements and compromises of, and assume the defense of, claims, and demand arbitration and comply with Orders and awards of arbitrators </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to such claims, and take all actions necessary or appropriate in the judgement of the CVR Holder Representative for the accomplishment of the foregoing, (e)&nbsp;give and receive
notices and communications, and (f)&nbsp;take all actions necessary or appropriate in the judgment of the CVR Holder Representative in connection with the CVR Agreement. All actions taken by the CVR Holder Representative under the CVR Agreement
shall be binding upon the Holders and their successors as if expressly confirmed and ratified in writing by each of them. The CVR Holder Representative shall not, in its capacity as such, have any liability to any Holder with respect to actions
taken or omitted to be taken in its capacity as the CVR Holder Representative, except that the CVR Holder Representative will be liable for its willful misconduct or actual fraud, as finally determined by a court of competent jurisdiction from which
no further appeal may be taken. The CVR Holder Representative shall at all times be entitled to rely on any directions received from the Majority Holders (as defined in the CVR Agreement); <U>provided</U>, <U>however</U>, that the CVR Holder
Representative shall not be required to follow any such direction, and shall be under no obligation to take any action in its capacity as the CVR Holder Representative, unless the CVR Holder Representative has been provided with other funds,
security or indemnities which, in the sole determination of the CVR Holder Representative are sufficient to protect the CVR Holder Representative against the costs, expenses and liabilities which may be incurred by the CVR Holder Representative in
responding to such direction or taking such action. At no cost to the Parent, First Merger Sub, Second Merger Sub or the Company, the CVR Holder Representative shall be entitled to engage such counsel, experts and other agents and consultants as it
shall deem necessary in connection with exercising its powers and performing its function hereunder and (in the absence of bad faith on the part of the CVR Holder Representative) shall be entitled to conclusively rely on the opinions and advice of
such Persons. The CVR Holder Representative shall be entitled to reimbursement from the Holders or the holders of the CVRs, as applicable, for all reasonable expenses, disbursements and advances (including fees and disbursements of their counsel,
experts and other agents and consultants) incurred by the CVR Holder Representative in such capacity, and shall be entitled to indemnification from the Holders against any loss, liability or expenses arising out of actions taken or omitted to be
taken in its capacity as the CVR Holder Representative (except in each case for those arising out of the CVR Holder Representative&#146;s, as applicable, gross negligence or willful misconduct), including the costs and expenses of investigation and
defense of claims. Parent and the Company shall be able to rely conclusively (without liability) on any instructions given and actions taken by the CVR Holder Representative as the instruction and decision of each Holder in all matters referred to
therein, including instructions with respect to the payment and distribution of any amounts payable pursuant to or in relation to the CVR Agreement. No Holder shall have any cause of action against Parent or the Company for any action taken by
Parent or the Company in reliance upon the written instructions or decisions of the CVR Holder Representative, or otherwise on account of payments or distributions made by or on behalf of Parent in accordance with the instructions of the CVR Holder
Representative. The annual administration or retainer fees payable to the CVR Holder Representative shall be borne by Parent. Other than such annual administration or retainer fees, none of Parent, the Company or their respective Subsidiaries shall
be responsible for or pay any other fees, expenses or other costs of the CVR Holder Representative. Notwithstanding anything to the contrary in this <U>Article X</U>, in the event of a conflict between the terms of the CVR Agreement and this
<U>Article X</U>, the CVR Agreement shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01 <U>Non-Survival of Representations, Warranties, Covenants and Agreements; Exclusive Remedy</U>. The representations,
warranties, covenants and agreements in this Agreement and in any certificate delivered pursuant hereto shall terminate at the Effective Time, except for those covenants and agreements contained in this Agreement (including, without limitation,
<U>Article II</U>, <U>Article III</U>, <U>Section&nbsp;7.04</U>, <U>Section</U> <U>7.05</U>, <U>Article X </U>and this <U>Article XI</U>) that by their terms are to be performed in whole or in part after the Effective Time (the &#147;<U>Post-Closing
Covenants</U>&#148;). Effective as of the Effective Time, except for claims for Fraud or in respect of the Post-Closing Covenants, following the Effective Time, none of Parent, First Merger Sub, Second Merger Sub, the Company or any holder of
Company Stock or Company Equity Awards (each, an &#147;<U>Equityholder</U>&#148;) shall have any other rights or remedies in connection with any breach of this Agreement or any other liability arising out of the negotiation, entry into or
consummation of the Transactions, whether at law or in equity or based on contract, tort, statute or otherwise. The provisions of and the limited remedies provided in this <U>Section&nbsp;11.01</U> were specifically bargained for among the parties
and were taken into account by the parties in arriving at the Merger Consideration. After the Closing, no party or its Affiliates may seek the rescission of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02 <U>Notices</U>. All notices, requests, claims, demands and other communications under this Agreement shall be in writing
and shall be deemed to have been duly given (a)&nbsp;when delivered in person, (b)&nbsp;upon confirmation of receipt after transmittal by facsimile (to such number specified below or another number or numbers as such Person may subsequently specify
by proper notice under this Agreement), (c)&nbsp;upon confirmation of receipt after transmittal by email (to such email address specified below or another email address or addresses as such Person may subsequently specify by proper notice under this
Agreement) and (d)&nbsp;on the next Business Day when sent by national overnight courier (providing proof of delivery), in each case to the respective parties at the following addresses (or at such other address for a party as shall be specified in
a notice given in accordance with this <U>Section&nbsp;11.02</U>): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to Parent, First Merger Sub or Second Merger Sub: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Illumina,&nbsp;Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">5200 Illumina Way</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">San Diego, California 92122</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Charles E. Dadswell, Senior Vice President and General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">858-202-4500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">858-202-4545</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CDadswell@illumina.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">legalnotices@illumina.com</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Cravath, Swaine &amp; Moore LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Worldwide Plaza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">825 Eighth Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, New York 10019-7475</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Faiza J. Saeed</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ting S. Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">212-474-1000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">212-474-3700</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">fsaeed@cravath.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">tchen@cravath.com</TD></TR></TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">if to the Company: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAIL, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">1525 O&#146;Brien Drive</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Menlo Park, California 94025</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">650-863-1024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">msong@grailbio.com</TD></TR></TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">W. Alex Voxman, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Andrew Clark, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">213-485-1234</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">213-891-8763</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">alex.voxman@lw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">andrew.clark@lw.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03 <U>Severability</U>. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by virtue of any rule of Law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the
Transactions is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the Transactions be consummated as originally contemplated to the fullest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.04 <U>Entire Agreement; Assignment</U>. This Agreement (including the exhibits and schedules hereto, including the Company
Disclosure Letter), the other Transaction Documents and the Confidentiality Agreement constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both
written and oral, among the parties, or any of them, with respect to the subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matter hereof and thereof. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties, in whole or in part (whether pursuant to a
merger, by operation of Law or otherwise), without the prior written consent of the other parties, except that Parent, First Merger Sub and Second Merger Sub may assign all or any of their rights and obligations under this Agreement to any Affiliate
of Parent, <U>provided</U> that no such assignment shall relieve the assigning party of its obligations under this Agreement if such assignee does not perform such obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.05 <U>Parties in Interest</U>. This Agreement shall be binding upon, inure solely to the benefit of, and be enforceable by,
only the parties hereto, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except (i)&nbsp;as
specifically provided in <U>Section&nbsp;7.05</U>, <U>Section&nbsp;7.18</U>, <U>Section 7.19</U>, <U>Section&nbsp;9.05</U>, <U>Section&nbsp;11.05</U>, <U>Section&nbsp;11.07</U> and <U>Section&nbsp;11.09</U> (which is intended to be for the benefit
of the Persons expressly covered thereby and may be enforced by such Persons) and (ii)&nbsp;that the Company shall have the right to pursue damages on behalf of its stockholders in the event of Parent&#146;s, First Merger Sub&#146;s or Second Merger
Sub&#146;s Intentional Breach of this Agreement, which right is hereby acknowledged by Parent, First Merger Sub and Second Merger Sub. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.06 <U>Specific Performance</U>. The parties hereto agree that the parties hereto would be irreparably damaged if any provision
of this Agreement was not performed in accordance with its specific terms or was otherwise breached. Accordingly, the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the
performance of the terms of this Agreement, in addition to any other remedy at law or in equity. The parties further agree that no party to this Agreement shall be required to obtain, furnish or post any bond or similar instrument in connection with
or as a condition to obtaining any such legal or equitable relief and each party waives any objection to the imposition of such relief or any right it might have to require the obtaining, furnishing or posting of any such bond or similar instrument.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.07 <U>Governing Law</U>. (a)&nbsp;This Agreement shall be governed by, and construed in accordance with, the laws of the
State of Delaware, without giving effect to any choice or conflict of law provisions or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of
Delaware. All Actions arising out of or relating to this Agreement or the Transactions shall be heard and determined exclusively in the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware
(or in the event, but only in the event, that the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over
the action or proceeding is vested exclusively in the federal courts of the United States of America, the United States District Court for the District of Delaware, and, in each case, the appellate court(s) therefrom). The parties hereto hereby
(i)&nbsp;irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware (or in the event, but only in the event, that the Court of Chancery of
the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or, if subject matter jurisdiction over the action or proceeding is vested exclusively in the federal courts of the United States of America, the United States District Court for the District of
Delaware and, in each case, the appellate court(s) therefrom) for the purpose of any Action arising out of or relating to this Agreement or the Transactions brought by any party hereto, (ii)&nbsp;irrevocably waive, and agree not to assert by way of
motion, defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an
inconvenient forum, that the venue of the Action is improper, or that this Agreement or the Transactions may not be enforced in or by the above-named courts, and (iii)&nbsp;agree that such party will not bring any Action arising out of or relating
to this Agreement or the Transactions in any court other than the Court of Chancery of the State of Delaware (or in the event, but only in the event, that the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the
Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action or proceeding is vested exclusively in the federal courts of the United States of America, the United States District Court for
the District of Delaware). Service of process, summons, notice or document to any party&#146;s address and in the manner set forth in <U>Section&nbsp;11.02</U> shall be effective service of process for any such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the parties hereto and each Affiliate of Parent acknowledges and irrevocably agrees (i)&nbsp;that any Action (whether at law, in
equity, in contract, in tort or otherwise) arising out of, or in any way relating to, the Financing or the performance of services thereunder or related thereto against or by any Financing Source in its capacity as such shall be subject to the
exclusive jurisdiction of any state or federal court sitting in the Borough of Manhattan, New York, New York, and any appellate court therefrom, and each party hereto submits for itself and its property with respect to any such Action to the
exclusive jurisdiction of such courts, (ii)&nbsp;not to bring or permit any of its Affiliates to bring or support anyone else in bringing any such Action in any other court, (iii)&nbsp;to waive and hereby waive, to the fullest extent permitted by
Law, any objection which any of them may now or hereafter have to the laying of venue of, and the defense of an inconvenient forum to the maintenance of, any such Action in any such court, (iv)&nbsp;that a final judgment in any such Action shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law and (v)&nbsp;that any such Action shall be governed by, and construed in accordance with, the Laws of the State of New York (it
being expressly agreed that the Financing Sources in their capacities as such shall be third party beneficiaries of this Section&nbsp;11.07 and shall be entitled to enforce the provisions contained in this Section&nbsp;11.07 as if they were a party
to this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.08 <U>Counterparts</U>. This Agreement may be executed and delivered (including by facsimile
transmission or .pdf) in counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">SECTION 11.09 <U>WAIVER OF JURY TRIAL</U>. EACH PARTY HERETO AND EACH AFFILIATE OF PARENT
ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, EACH OF THE PARTIES HERETO AND EACH AFFILIATE OF PARENT HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS (INCLUDING THE COMMITMENT LETTER
AND ANY FINANCING CONTEMPLATED BY PARENT OR ANY OF ITS AFFILIATES IN CONNECTION WITH THIS AGREEMENT). EACH OF THE PARTIES HERETO CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY MAKES THIS
WAIVER VOLUNTARILY, AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS IN THIS <U>SECTION 11.09</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.10 <U>Non-Assertion of Attorney-Client Privilege</U>. Parent acknowledges that Latham&nbsp;&amp; Watkins LLP and other legal
counsel (&#147;<U>Prior Company Counsel</U>&#148;) have, on or prior to the Closing Date, represented one or more of the Selling Investors, Equityholders, the Company, and its Subsidiaries and other Affiliates, and their respective officers,
employees and directors (each such Person, other than the Company and its Subsidiaries and their respective officers and employees, a &#147;<U>Designated Person</U>&#148;) in one or more matters relating to this Agreement or any other agreements or
transactions contemplated hereby (including any matter that may be related to a litigation, claim or dispute arising under or related to this Agreement or such other agreements or in connection with such transactions) (excluding, for the avoidance
of doubt, the Company&#146;s planned initial public offering) (each, an &#147;<U>Existing Representation</U>&#148;). Each of Parent and the Company (on behalf of itself and its Affiliates) waives and shall not assert, and agrees after the Closing to
cause its Affiliates to waive and to not assert, any attorney-client privilege, attorney work-product protection or expectation of client confidence with respect to any communication between any Prior Company Counsel, on the one hand, and any
Designated Person or the Company or any of its Subsidiaries (collectively, the &#147;<U>Pre-Closing Designated Persons</U>&#148;), or any advice given to any Pre-Closing Designated Person by any Prior Company Counsel, occurring during one or more
Existing Representations in connection with any representation by one or more Prior Company Counsel of one or more Designated Persons, in each case, in connection with one or more post-Closing matters relating to this Agreement or any other
agreements or transactions contemplated hereby (including any matter that may be related to a litigation, claim or dispute arising under or related to this Agreement or such other agreements or in connection with such transactions) (collectively,
&#147;<U>Pre-Closing Privileges</U>&#148;), it being the intention of the parties hereto that all rights to such Pre-Closing Privileges, and all rights to waiver or otherwise control such Pre-Closing Privilege, shall be retained by such Designated
Persons and shall not pass to or be claimed or used by Parent or the Company, except as provided in the last sentence of this <U>Section&nbsp;11.10</U>. Furthermore, each of Parent and the Company (on behalf of itself and its Affiliates)
acknowledges and agrees that any advice given to or communication with any of the Designated Persons in connection with any Existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Representation shall not be subject to any joint privilege (whether or not the Company or one more of its Subsidiaries also received such advice or communication) and shall be owned solely by
such Designated Persons. Notwithstanding the foregoing, (i)&nbsp;in the event that a dispute arises between Parent or the Company or any of its Subsidiaries, on the one hand, and a third party other than a Designated Person, on the other hand, the
Company may assert the Pre-Closing Privileges on behalf of the Designated Persons to prevent disclosure to such third party, <U>provided</U>, <U>however</U>, that such privilege may be waived only with the prior written consent of the Designated
Persons, acting on behalf of the applicable Designated Persons (such consent not to be unreasonably withheld, conditioned or delayed) and (ii)&nbsp;the foregoing provisions of this <U>Section&nbsp;11.10</U> shall not extend to any communication or
materials not involving the negotiation, documentation and consummation of the transactions contemplated by this Agreement or any claims brought in connection with such transactions or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.11 <U>Release by Equityholders</U>. (a)&nbsp;Effective as of the Effective Time, upon execution of a Letter of Transmittal,
each Equityholder, on behalf of himself, herself or itself and each of his, her or its past, present and future controlled Affiliates, parent(s) and subsidiary companies, representatives, and assigns (each, an &#147;<U>Equityholder Releasing
Party</U>&#148; and, collectively, the &#147;<U>Equityholder Releasing Parties</U>&#148;) will absolutely, unconditionally and irrevocably release, acquit and forever discharge the Company and each of its respective past, present and future
controlled Affiliates, parent(s) and subsidiary companies, joint ventures, predecessors, successors and assigns, and their respective past, present and future representatives, investors, equityholders, insurers and indemnitees, firms, corporations,
limited liability companies, partnerships, trusts, associations, organizations, stockholders, members, managers, directors, officers, employees, partners, trustees, principals, consultants, contractors, family members, heirs, executors,
administrators, predecessors, successors and assigns (collectively the &#147;<U>Released Parties</U>&#148;), of and from any and all manner of action or inaction, cause or causes of action, Actions, Encumbrances, contractual obligations, promises,
liabilities or damages (whether for compensatory, special, incidental or punitive damages, equitable relief or otherwise) of any kind or nature whatsoever, past, present or future, at law, in equity or otherwise (including with respect to conduct
which is negligent, grossly negligent, willful, intentional, with or without malice, or a breach of any duty, applicable Law or rule), whether known or unknown, whether fixed or contingent, whether concealed or hidden, whether disclosed or
undisclosed, whether liquidated or unliquidated, whether foreseeable or unforeseeable, whether anticipated or unanticipated, whether suspected or unsuspected (&#147;<U>Claims</U>&#148;), which such Equityholder Releasing Parties, or any of them,
ever have had or ever in the future may have against the Released Parties, or any of them, in each case, to the extent arising solely as a result of the ownership or purported ownership of any of Company Stock, Company Stock Options or other
security or interest of the Company and which, in each case, are based on acts, events or omissions occurring prior to or contemporaneously with the Effective Time (the &#147;<U>Equityholder Released Claims</U>&#148;); <U>provided</U>,
<U>however</U>, that the foregoing release shall not release, impair or diminish, and the term &#147;Equityholder Released Claims&#148; shall not include, in any respect (i)&nbsp;an <U>Equityholder&#146;s</U> right pursuant to the Transaction
Documents, including the right to receive its respective portion of the Merger Consideration; (ii)&nbsp;any Claims for indemnification, insurance benefits, reimbursement or advancement of expenses in such <U>Equityholder&#146;s</U> capacity as a
director, officer or employee of the Company under the Company&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organizational documents or any indemnification agreement in effect as of the date hereof (or any fiduciary insurance policy maintained by the Company or the Surviving Entity for the benefit of
the <U>Equityholder</U>, or any indemnification agreements with the <U>Equityholder </U>or its board designee) with respect to any act, omission, event or transaction occurring prior to or contemporaneously with the Effective Time; or (iii)&nbsp;the
rights of any <U>Equityholder</U> Releasing Party in his or her capacity as an employee of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon execution of a Letter of
Transmittal, each <U>Equityholder</U> shall represent and acknowledge that he, she or it has read this release and the Merger Agreement and other Transaction Documents and understands their terms and has been given sufficient opportunity to review
this release and the Transaction Documents and to ask questions of the Company&#146;s Representatives. Each <U>Equityholder </U>will further represent that, in signing the Letter of Transmittal, he, she or it does not rely, and has not relied, on
any representation or statement made by any Representative of the Company or any other Person with respect to the subject matter, basis or effect of this release or otherwise, except such express representations and warranties set forth in the
Merger Agreement or this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Without limiting the generality of <U>Section&nbsp;11.11(a)</U>, with respect to the Equityholder
Released Claims, each <U>Equityholder</U>, upon execution of a Letter of Transmittal, will acknowledge that he, she or it is familiar with Section&nbsp;1542 of the Civil Code of the State of California (&#147;<U>Section 1542</U>&#148;) and expressly
waive all rights under Section&nbsp;1542 and any similar applicable Law or common law principle in any applicable jurisdiction prohibiting or restricting the waiver of unknown claims. Section&nbsp;1542 reads as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the provisions of Section&nbsp;1542 or any similar applicable Law or common law principle in any applicable jurisdiction,
upon execution of a Letter of Transmittal, each <U>Equityholder</U> will expressly acknowledge that the foregoing release is intended to include in its effect all claims within the scope of such release which any <U>Equityholder</U> does not know or
suspect to exist in his, her or its favor against any of the Released Parties (including, without limitation, unknown and contingent claims), and that the foregoing release expressly contemplates the extinguishment of all such claims (except to the
extent expressly set forth in this <U>Section&nbsp;11.11</U>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Parent, First Merger Sub, Second Merger Sub and the Company have caused
this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ILLUMINA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francis deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Francis deSouza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SDG OPS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francis deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Francis deSouza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &nbsp;&nbsp;President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SDG OPS, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Francis deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Francis deSouza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &nbsp;&nbsp;President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GRAIL, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Bishop</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Hans Bishop</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Agreement and Plan of Merger</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SELLING INVESTOR SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SELLING INVESTOR SUPPORT AGREEMENT (hereinafter referred to as this &#147;<U>Agreement</U>&#148;), dated as of [&#9679;], among Illumina,
Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;) and each of the undersigned stockholders (the &#147;<U>Selling Investors</U>&#148;) of GRAIL, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), set forth on Schedule&nbsp;1(b)
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Parent, SDG Ops, Inc., a Delaware corporation and wholly owned subsidiary of Parent (&#147;<U>First Merger
Sub</U>&#148;), and SDG Ops, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (&#147;<U>Second Merger Sub</U>&#148;), have entered into an Agreement and Plan of Merger dated as of September&nbsp;20, 2020 (as it may be
amended from time to time, the &#147;<U>Merger Agreement</U>&#148;), which provides for, among other things, the merger of First Merger Sub with and into the Company, with the Company continuing as the surviving corporation (the &#147;<U>Surviving
Corporation</U>&#148;) (the &#147;<U>First Merger</U>&#148;), and immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Corporation will merge with and into Second Merger Sub, with
Second Merger Sub being the surviving company of the Second Merger (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the &#147;<U>Mergers</U>&#148;), and pursuant to which all shares of Company Stock issued and outstanding
immediately prior to the Effective Time (other than as provided in Section&nbsp;2.04(c) of the Merger Agreement and Appraisal Shares) will be converted into the right to receive the Merger Consideration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each Selling Investor Beneficially Owns and is entitled to vote (or direct the voting of) the number of shares of Company Stock set
forth opposite such Selling Investor&#146;s name on Schedule&nbsp;1(b) attached hereto; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent desires that the Selling
Investors agree, and the Selling Investors are willing to agree, on the terms and subject to the conditions set forth herein, (i)&nbsp;to not Transfer (as defined below) the Covered Shares (as defined below), and (ii)&nbsp;to vote or consent with
respect to all of the Covered Shares in a manner so as to facilitate the consummation of the Mergers and the other Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Definitions</U>. Capitalized terms used but not defined herein shall have the respective meanings ascribed
to them in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following respective meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Beneficially Own</U>&#148; means, with respect to any securities, (i)&nbsp;having &#147;beneficial
ownership&#148; of such securities for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> or <FONT STYLE="white-space:nowrap">13d-5</FONT> under the Exchange Act (or any successor statute or regulation) or (ii)&nbsp;having the right
to become the Beneficial Owner of such securities (whether such right is exercisable immediately or only after the passage of time or the occurrence of conditions) pursuant to any agreement, arrangement or understanding, or upon the exercise of
conversion rights, exchange rights, rights, warrants or options, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Covered
Shares</U>&#148; means, with respect to any Selling Investor, (i)&nbsp;all shares of Company Stock set forth opposite such Selling Investor&#146;s name on Schedule&nbsp;1(b) attached hereto, and (ii)&nbsp;all shares of Company Stock that such
Selling Investor comes to Beneficially Own during the period from the date of this Agreement through the Expiration Date, together with any voting securities or instruments of the Company, or other securities or interests exercisable for or
convertible into shares of Company Stock or voting securities or instruments of the Company, that such Selling Investor comes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Beneficially Own during the period from the date of this Agreement through the Expiration Date (including by way of bonus issue, share dividend or distribution, subdivision, reclassification,
recapitalization, consolidation, exchange, readjustment or other similar transaction or other change in the capital structure of the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Expiration Date</U>&#148; means the earlier to occur of (i)&nbsp;the Effective Time and (ii)&nbsp;the
termination of the Merger Agreement in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transfer</U>&#148; means, with
respect to any Selling Investor, that such Selling Investor sells, pledges, Encumbers, exchanges, assigns, grants an option with respect to, transfers, tenders or otherwise disposes of its Beneficial Ownership of Covered Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement Not to Transfer or Encumber</U>. Each Selling Investor hereby agrees that, from the date hereof until
the Expiration Date, it shall not Transfer any Covered Shares, cause the conversion of any Covered Shares or deposit any Covered Shares into a voting trust or enter into any tender, voting or other agreement or arrangement with any Person with
respect to any Covered Shares or grant a proxy or power of attorney with respect thereto (other than pursuant to this Agreement or the Drag-Along Consent) or give instructions with respect to the voting of the Covered Shares in any manner that is
inconsistent with this Agreement or otherwise take any other action with respect to the Covered Shares that would in any way restrict, limit or interfere with the performance by the Selling Investors of their obligations hereunder or the
transactions contemplated hereby, including the execution and delivery of the Written Consent approving the adoption of the Merger Agreement and approving the Transactions; <U>provided</U>, however, that the Stockholder may Transfer all or any
portion of the Shares to one or more of its controlled Affiliates or a family member that, prior to such Transfer, executes and delivers to the Parent a written agreement, in form and substance reasonably acceptable to Parent, to assume all of the
Selling Investor&#146;s obligations hereunder and to be bound by the terms of this Agreement to the same extent as the Selling Investor is bound hereunder and to make each of the representations and warranties hereunder in respect of the Covered
Shares transferred as the Selling Investor shall have made hereunder. Notwithstanding the foregoing, following the receipt of the Company Stockholder Approvals, a Selling Investor may cause the conversion of any shares of Company Class&nbsp;B Common
Stock into shares of Company Class&nbsp;A Common Stock in accordance with the Company&#146;s certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement to Consent and Approve</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor agrees to execute and deliver the Drag-Along Consent in such Selling Investor&#146;s capacity
as a holder of Company Preferred Shares, and (ii)&nbsp;to refrain from (x)&nbsp;withdrawing, revoking, rescinding, modifying or amending in any manner the Drag-Along Consent or (y)&nbsp;modifying or amending in any manner, or waiving compliance of,
the Voting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor hereby irrevocably and unconditionally agrees, promptly after the
Registration Statement (which shall include the Consent Solicitation Statement) is declared effective by the SEC (and in any event within five Business Days after notification thereof to such Selling Investor), to execute and deliver, or cause to be
executed and delivered, a written consent substantially in the form attached hereto as <U>Exhibit A</U> (the &#147;<U>Written Consent</U>&#148;) approving the adoption of the Merger Agreement and approving the Transactions, including the Mergers,
with respect to all of such Selling Investor&#146;s Covered Shares. The Selling Investor&#146;s execution and delivery of the Written Consent shall be carried out in accordance with the DGCL and the organizational documents of the Company, so as to
ensure that it is duly counted for purposes of recording the results of such consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor
hereby irrevocably and unconditionally agrees that, from the date hereof until the Expiration Date, it shall vote or cause to be voted (including by written consent) all of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Selling Investor&#146;s Covered Shares (i)&nbsp;in favor of (A)&nbsp;the adoption of the Merger Agreement and the approval of the Transactions and (B)&nbsp;any amendment to the
Company&#146;s certificate of incorporation or Investor Agreements to the extent contemplated in <U>Section</U><U></U><U>&nbsp;9.04</U> of the Merger Agreement and otherwise as is reasonably necessary to permit to, or assist the Company in,
complying with its obligations under <U>Section</U><U></U><U>&nbsp;9.04</U> of the Merger Agreement and (ii)&nbsp;against (A)&nbsp;any Competing Proposal; (B)&nbsp;any amendment of the organizational documents of the Company which would prevent or
materially delay the consummation of the Transactions, including the Mergers; or (C)&nbsp;any other action, agreement or transaction involving the Company that would reasonably be expected to prevent or materially delay the consummation of the
Transactions, including the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor agrees that, from the date hereof until the
Expiration Date, in the event that a meeting of the stockholders of the Company is held regarding the Merger Agreement, the Transactions or any of the matters referred to in Section&nbsp;3(c), it shall, or shall cause the holder of record of any of
the Covered Shares of such Selling Investor on any applicable record date to, be present in person or represented by proxy at such meeting or otherwise cause all Covered Shares of such Selling Investor to be counted as present thereat for purposes
of establishing a quorum, and shall vote all of such Selling Investor&#146;s Covered Shares at such meeting in accordance with Section&nbsp;3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Except for the delivery of the Written Consent expressly contemplated by this Agreement, prior to the Expiration
Date, no Selling Investor shall call, seek to call or request the call of any meeting of stockholders of the Company with respect to any matter relating to the Mergers or any other Transaction, or take any action by consent relating to the Mergers
or any other Transaction, other than as expressly contemplated by Section&nbsp;3(c), whether pursuant to the DGCL, the organizational documents of the Company or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein, in no event shall this Section&nbsp;3 require or be construed so
as to require any Selling Investor to vote or cause to be voted (including by written consent) such Selling Investor&#146;s Covered Shares in favor of or against any stockholder vote to approve &#147;parachute payments&#148; (within the meaning of
Section 280G of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations thereunder) solicited in connection with the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein, in the event that a vote or consent of the stockholders of the
Company is required in order to effect an amendment to the Merger Agreement that reduces the amount or changes the form of consideration payable in respect of each share of Company Capital Stock in the Mergers or otherwise amends the Merger
Agreement in a manner adverse to the Selling Investor (any such amendment, an &#147;<U>Adverse Amendment</U>&#148;), the provisions of this Section&nbsp;3 shall not apply with respect to the Selling Investor&#146;s vote or consent with respect to
such Adverse Amendment (and Selling Investor shall not be required to vote or consent to such Adverse Amendment); <U>provided</U>, <U>however</U>, that the term &#147;Adverse Amendments&#148; shall not include the amendments contemplated in
Section&nbsp;3(c)(i)(B). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voided Acts</U>. Any (i)&nbsp;Transfer (or purported Transfer) in breach of this
Agreement or (ii)&nbsp;attempt by any Selling Investor to vote, or express consent or dissent with respect to (or otherwise to utilizing the voting power of), its Covered Shares in contravention of this Agreement shall be null and void <I>ab
initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement Not to Solicit</U>. Each Selling Investor agrees that it shall not, and shall cause
each of such Selling Investor&#146;s controlled Affiliates not to, and shall instruct such Selling Investor&#146;s and such Selling Investor&#146;s controlled Affiliates&#146; Representatives not to, directly or indirectly, (a)&nbsp;solicit,
initiate seek, or take any other action to facilitate or encourage the making, submission or announcement of any proposal that constitutes, or would be reasonably be expected to lead to, any Competing Proposal, (b)&nbsp;enter into, maintain,
continue or participate in any discussions or negotiations with any Person or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entity in furtherance of, or furnish to any Person any information or otherwise cooperate in any way with respect to, any Competing Proposal, (c)&nbsp;agree to, approve, endorse, recommend or
consummate any Competing Proposal, (d)&nbsp;enter into, or propose to enter into, any Competing Transaction Agreement, or (e)&nbsp;resolve, propose or agree, or authorize or permit any Representative to do any of the foregoing. Each Selling Investor
shall, and each Selling Investor shall cause such Selling Investor&#146;s controlled Affiliates and use such Selling Investor&#146;s reasonable best efforts to cause such Selling Investor&#146;s Representatives to, immediately cease and cause to be
terminated any discussions and negotiations with any Person conducted heretofore with respect to any Competing Proposal or proposal that would reasonably be expected to lead to a Competing Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Commencement or Participation in Actions</U>. Each Selling Investor hereby agrees not to commence or join in, and
to take all reasonable actions necessary to opt out of (if applicable), any Action against the Company and/or its directors and officers (for the avoidance of doubt, participating in the defense of such Action or any Action to enforce the Drag-Along
is not prohibited by this Section&nbsp;6) with respect to, any litigation (a)&nbsp;challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement or the Merger Agreement or the exercise of the Drag-Along in
connection with the Transactions or (b)&nbsp;alleging a breach of any fiduciary duty of the Company Board or its members or any stockholder of the Company in connection with the Merger Agreement, the Transactions or the transactions contemplated
hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Appraisal Rights or Rights of Dissent</U>. Each Selling Investor hereby waives, and agrees not to
exercise or assert, any appraisal or dissenters&#146; rights it may have or could potentially have or acquire in connection with the Mergers under Section&nbsp;262 of the DGCL and otherwise, whether or not such Selling Investor has previously made a
written demand upon the Company and otherwise complied with the appraisal rights provisions of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. Each Selling Investor agrees that, for a period of two years following the Expiration Date,
such Selling Investor shall not, and shall cause its Affiliates, directors, officers, employees and agents not to divulge or convey to any third party, any of the Company&#146;s confidential information, other than: (i)&nbsp;any of the
Company&#146;s confidential information that is or becomes generally available to the public other than as a result of an act or omission by such Selling Investor or its Affiliate, director, officer, employee or agent, (ii)&nbsp;any information that
has been independently developed or conceived by the Selling Investor or its Affiliates, director, officer, employee or agent, (iii)&nbsp;is or has been made known or disclosed to the Selling Investor by a third party without a breach of any
obligation of confidentiality such third party may have to the Company. Notwithstanding the foregoing, each Selling Investor shall be permitted to make any such disclosure (a)&nbsp;to its directors, officers, employees and agents who reasonably need
to know such information and who agree to keep such information confidential and are made aware of the Selling Investor&#146;s obligations of confidentiality under this Agreement and (b)&nbsp;to the extent requested by a Governmental Authority or
required by Law or legal process (in which case the Selling Investor will, to the extent reasonably practicable and legally permissible, provide Parent with advance notice of such required or requested disclosure, shall use commercially reasonable
efforts to resist such disclosure, and, at the request of Parent, shall cooperate with Parent to, at Parent&#146;s sole cost and expense, limit or prevent such disclosure). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Directors and Officers</U>. Each Selling Investor is entering into this Agreement solely in its capacity as a
Beneficial Owner of Covered Shares, and in this regard, such Selling Investor shall not be deemed to make any agreement or understanding in this Agreement in such Selling Investor&#146;s capacity as a director or officer of the Company, including
with respect to Section&nbsp;7.02 of the Merger Agreement. The parties acknowledge and agree that nothing in this Agreement shall (i)&nbsp;restrict in any respect any actions taken by a Selling Investor or its designee who is a director or officer
of the Company in his or her capacity as a director or officer of the Company or (ii)&nbsp;be construed to prohibit, limit or restrict the Selling Investor or its designee from exercising its fiduciary duties as a director or officer of the Company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Irrevocable Proxy</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor hereby irrevocably grants to, and appoints, Parent, and any individual designated in writing
by Parent, and each of them individually, as such Selling Investor&#146;s proxy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> (with full power of substitution), for and in the name, place and
stead of such Selling Investor, to vote such Selling Investor&#146;s Covered Shares, or execute a written consent or grant approval in respect of such Covered Shares, in a manner consistent with this Agreement from the date hereof until the
Expiration Date,<I> </I><U>provided</U>,<I> </I><U>however</U>, for the avoidance of doubt, that such proxy and voting and related rights are limited to those matters set forth in clauses (b)-(d) of Section&nbsp;3, and each Selling Investor shall
retain at all times the right to vote such Selling Investor&#146;s Covered Shares (or to direct how such Covered Shares shall be voted) in such Selling Investor&#146;s sole discretion and without any other limitation on any matters not connected
with the Transactions. Each Selling Investor understands and acknowledges that Parent has entered into the Merger Agreement in reliance upon such Selling Investor&#146;s execution and delivery of this Agreement. Each Selling Investor hereby affirms
that the irrevocable proxy set forth in this Section&nbsp;10(a) is given to secure the performance of the duties of such Selling Investor under this Agreement. Each Selling Investor hereby further affirms that the irrevocable proxy is coupled with
an interest sufficient in law and such irrevocable proxy is executed and intended to be irrevocable in accordance with applicable Law and Section&nbsp;2.09 of the Company&#146;s bylaws<B> </B>until, and shall not be terminated by operation of Law or
upon the occurrence of any other event other than, the termination of this Agreement pursuant to Section&nbsp;19. Each Selling Investor shall, upon written request by Parent, as promptly as practicable, execute and deliver to Parent a separate
written instrument or proxy that embodies the terms of this irrevocable proxy set forth in this Section&nbsp;10(a). Each Selling Investor agrees not to grant any proxy that conflicts with or is inconsistent with the proxy granted to Parent in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor hereby revokes (or agrees to cause to be revoked) any proxies that conflict
with or are inconsistent with the proxy granted to Parent in this Agreement that such Selling Investor has heretofore granted with respect to the Covered Shares Beneficially Owned by such Selling Investor, other than any such proxy granted to Parent
pursuant to the Drag-Along Consent and Voting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>[Reserved]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of Parent</U>. Parent hereby represents and warrants as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization and Qualification</U>. Parent is a legal entity duly organized, validly existing and in good
standing under the Laws of the jurisdiction of its incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority; Binding Agreement</U><I>.</I>
(i)&nbsp;Parent has all requisite power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby, and (ii)&nbsp;the execution and delivery by Parent of this
Agreement and the performance of Parent&#146;s obligations and the consummation of the transactions contemplated hereby by Parent have been duly authorized by all necessary action, and no other actions on the part of Parent (or its board of
directors or stockholders) are necessary to authorize or adopt this Agreement or to consummate the transactions contemplated by this Agreement. This Agreement has been duly executed and delivered by Parent, and, assuming this Agreement constitutes a
valid and binding obligation of the Selling Investors, constitutes a valid and binding obligation of Parent, enforceable against Parent in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency (including all Laws
relating to fraudulent transfers), reorganization, moratorium or similar Laws affecting creditors&#146; rights generally and subject to the effect of general principles of equity (regardless of whether considered in a proceeding at law or in
equity). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Conflicts</U><I>.</I> None of the execution and delivery by
Parent of this Agreement, the performance by Parent of its obligations hereunder or the consummation by Parent of the transactions contemplated hereby does or would reasonably be expected to conflict with or result in a violation or breach of
(i)&nbsp;Parent&#146;s certificate of incorporation or bylaws, (ii)&nbsp;any other contract to which Parent is a party or by which Parent may be bound, except for violations, breaches or defaults that, individually or in the aggregate, would not
reasonably be expected to in any material respect impair or adversely affect the ability of Parent to perform its obligations under this Agreement, or (iii)&nbsp;any Law applicable to Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Litigation</U>. There are no Actions pending or, to the knowledge of Parent, threatened against Parent, or
any Order to which Parent is subject, except, in each case, for those that, individually or in the aggregate, would not reasonably be expected to prevent or materially and adversely impair or otherwise affect the ability of Parent to fully perform
its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Selling Investors</U>. Each
Selling Investor (severally and not jointly) hereby represents and warrants as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization and
Qualification</U>. If such Selling Investor is not an individual, such Selling Investor is a legal entity duly formed or organized (as applicable), validly existing and in good standing under the Laws of the jurisdiction in which it is formed or
organized, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority; Binding Agreement</U><I>.</I> If such Selling Investor is an
individual, he or she has full legal capacity, right and authority to execute and deliver this Agreement and to perform his or her obligations hereunder and consummate the transactions contemplated hereby. If such Selling Investor is not an
individual, (i)&nbsp;such Selling Investor has all requisite power and authority to execute and deliver this Agreement, to perform such Selling Investor&#146;s obligations hereunder and to consummate the transactions contemplated hereby and
(ii)&nbsp;the execution and delivery by such Selling Investor of this Agreement and the performance of such Selling Investor&#146;s obligations and the consummation of the transactions contemplated hereby by such Selling Investor have been duly
authorized by all necessary action, and no other actions on the part of such Selling Investor (or its governing body, board of directors, members, partners, stockholders or trustees, as applicable) are necessary to authorize or adopt this Agreement
or to consummate the transactions contemplated by this Agreement. This Agreement has been duly executed and delivered by such Selling Investor, and, assuming this Agreement constitutes a valid and binding obligation of Parent, constitutes a valid
and binding obligation of such Selling Investor, enforceable against such Selling Investor in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency (including all Laws relating to fraudulent transfers),
reorganization, moratorium or similar Laws affecting creditors&#146; rights generally and subject to the effect of general principles of equity (regardless of whether considered in a proceeding at law or in equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Conflicts</U><I>.</I> None of the execution and delivery by such Selling Investor of this Agreement, the
performance by such Selling Investor of such Selling Investor&#146;s obligations hereunder or the consummation by such Selling Investor of the transactions contemplated hereby does or would reasonably be expected to conflict with or result in a
violation or breach of, or in default under, (i)&nbsp;if such Selling Investor is not an individual, such Selling Investor&#146;s articles or certificate of formation, incorporation or organization, operating agreement, bylaws or comparable
organizational documents, as applicable, each in its currently effective form as amended from time to time, (ii)&nbsp;any other contract to which such Selling Investor is a party or by which such Selling Investor may be bound, including any voting
agreement or voting trust, or (iii)&nbsp;any Law applicable to such Selling Investor, except, in each case, for violations, breaches or defaults that, individually or in the aggregate, would not reasonably be expected to (x)&nbsp;in any material
respect impair or adversely affect the ability of such Selling Investor to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
perform such Selling Investor&#146;s obligations under this Agreement on a timely basis or (y)&nbsp;prevent or materially delay the consummation of the Transactions. The execution, delivery and
performance by such Selling Investor of this Agreement, and the consummation by such Selling Investor of the transactions contemplated hereby, require no consent or action by or in respect of, or filing with, any Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership of Shares</U><I>.</I> Such Selling Investor (i)&nbsp;is the lawful record and Beneficial Owner of the
shares of Company Stock set forth opposite such Selling Investor&#146;s name on Schedule&nbsp;1(b) attached hereto and has, and at all times prior to the Expiration Date will have, the sole power to vote (or cause to be voted), Transfer, or demand
or waive any appraisal rights with respect to, such shares of Company Stock, all of which are free and clear of, and not subject to, any Encumbrances (other than those (A)&nbsp;created by this Agreement, (B)&nbsp;applicable to such Selling
Investor&#146;s Covered Shares that may exist pursuant to securities Laws or (C)&nbsp;any proxies that are not required by Section&nbsp;10(b) to be revoked and which do not relate to the Mergers, the Transactions or Competing Proposals) and
(ii)&nbsp;as of the date hereof, does not Beneficially Own or have the right to vote (or cause the voting of) any shares of any class of Company Stock or other securities of the Company or any interest therein or any voting rights with respect to
any securities of the Company other than the shares of Company Stock set forth opposite such Selling Investor&#146;s name on Schedule 1(b) attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>[Reserved]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Litigation</U>. As of the date hereof, there are no Actions pending or, to the knowledge of such Selling
Investor, threatened against such Selling Investor, or any Order to which such Selling Investor is subject, except, in each case, for those that, individually or in the aggregate, would not reasonably be expected to (i)&nbsp;prevent or impair or
materially delay the ability of such Selling Investor to fully perform such Selling Investor&#146;s obligations under this Agreement on a timely basis or (ii)&nbsp;prevent or materially delay the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Finder&#146;s Fees</U>. No broker, investment banker, financial advisor, finder, agent or other Person is
entitled to any broker&#146;s, finder&#146;s, financial advisor&#146;s or other similar fee or commission payable by the Company in connection with this Agreement based upon arrangements made by or on behalf of such Selling Investor in his, her or
its capacity as a stockholder of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure and Communications</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor hereby consents to and authorizes the publication and disclosure of such Selling
Investor&#146;s identity and ownership, this Agreement and the nature of such Selling Investor&#146;s commitments, arrangements and understandings pursuant to this Agreement and such other information pertinent to such disclosure, including the
filing of this Agreement, by Parent and the Company in the Registration Statement, Consent Solicitation Statement or other disclosure document required by applicable Law to be filed with the SEC or other Governmental Authority in connection with
this Agreement, the Merger Agreement or the Transactions, and agrees to reasonably cooperate with Parent in connection with such filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Selling Investors shall not issue or make any press release or public announcement related to this Agreement,
the Merger Agreement or the Transactions, or any other announcement or communication to the employees, customers or suppliers of the Company or any of its Subsidiaries, in each case without the approval of Parent, unless required by applicable Law;
<U>provided</U>, that, each Selling Investor may make public statements that do not contain any information relating to the Transactions that has not been previously announced or made public in accordance with this Agreement or the Merger Agreement
so long as no such public statement (i)&nbsp;disparages the Transactions, (ii)&nbsp;encourages other holders of capital stock of the Company to vote against, or withhold their vote or consent on, the Transactions, including the adoption of the
Merger Agreement, or (iii)&nbsp;encourages other holders of capital stock of the Company to exercise appraisal rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Ownership Interest</U>. Nothing contained in this Agreement
shall be deemed to vest in Parent any direct or indirect ownership or incidence of ownership of or with respect to any Covered Shares. All ownership and economic benefits of and relating to the Covered Shares shall remain vested in and belong to the
applicable Selling Investor, and, except as otherwise provided herein, Parent shall not have any authority to direct any Selling Investor in the voting or disposition of any Covered Shares. For the avoidance of doubt, each Selling Investor shall be
entitled to any dividends or other distributions declared by the Company Board with respect to such Selling Investor&#146;s Covered Shares having a record date prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>[Reserved]</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Stop Transfer Instructions</U>. Each Selling Investor shall not request that the Company register the Transfer
(book-entry or otherwise) of any certificated or uncertificated interest representing any of such Selling Investor&#146;s Covered Shares, unless such Transfer is made in compliance with this Agreement. Each Selling Investor hereby authorizes Parent
to direct the Company to impose stop orders to prevent the Transfer of any Covered Shares on the books of the Company in violation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<U>[Reserved</U>.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. This Agreement, and all rights and obligations of the parties hereunder, shall terminate and
shall have no further force or effect upon the termination of the Merger Agreement in accordance with its terms; <U>provided</U>, <U>however</U>, that (i)&nbsp;this Section&nbsp;19 and Sections 1, 14 and 23 shall survive any termination of the
Agreement and (ii)&nbsp;Sections 2, 3, 4, 5, 10 and 17 shall terminate and shall have no further force or effect as of the Expiration Date. Notwithstanding the foregoing, nothing set forth in this Section&nbsp;19 or elsewhere in this Agreement shall
relieve either party hereto from liability, or otherwise limit the liability of a Selling Investor, for any intentional breach of this Agreement prior to such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transaction Documents</U>. Each Selling Investor acknowledges that the Merger Agreement and the other
Transaction Documents may be amended in accordance with the terms and conditions set forth in the Merger Agreement and the other Transaction Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. Each Selling Investor hereby waives any and all notice, information and consent requirements, as
well as any right of first refusal, right of first offer, right of first negotiation, right restricting share transfers, redemption right, <FONT STYLE="white-space:nowrap">co-sale</FONT> right, registration right, preemptive right and other similar
rights, that may be applicable to, or triggered by, the Transactions, including the Mergers, the Merger Agreement, the other Transaction Documents and any of the transactions contemplated thereby that are contained in the Company&#146;s
organizational documents or any contractual obligation between the Company and such Selling Investor, or under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;<U>Release by Selling Investors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Effective as of the Effective Time, each Selling Investor, on behalf of himself, herself or itself and each of
his, her or its past, present and future controlled Affiliates, parent(s) and subsidiary companies, representatives, and assigns (each, a &#147;<U>Selling Investor Releasing Party</U>&#148; and, collectively, the &#147;<U>Selling Investor Releasing
Parties</U>&#148;) hereby absolutely, unconditionally and irrevocably releases, acquits and forever discharges the Company and each of its respective past, present and future controlled Affiliates, parent(s) and subsidiary companies, joint ventures,
predecessors, successors and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assigns, and their respective past, present and future representatives, investors, equityholders, insurers and indemnitees, firms, corporations, limited liability companies, partnerships, trusts,
associations, organizations, stockholders, members, managers, directors, officers, employees, partners, trustees, principals, consultants, contractors, family members, heirs, executors, administrators, predecessors, successors and assigns
(collectively the &#147;<U>Selling Investor Released Parties</U>&#148;), of and from any and all manner of action or inaction, cause or causes of action, Actions, Encumbrances, contractual obligations, promises, liabilities or damages (whether for
compensatory, special, incidental or punitive damages, equitable relief or otherwise) of any kind or nature whatsoever, past, present or future, at law, in equity or otherwise (including with respect to conduct which is negligent, grossly negligent,
willful, intentional, with or without malice, or a breach of any duty, applicable Law or rule), whether known or unknown, whether fixed or contingent, whether concealed or hidden, whether disclosed or undisclosed, whether liquidated or unliquidated,
whether foreseeable or unforeseeable, whether anticipated or unanticipated, whether suspected or unsuspected (&#147;<U>Claims</U>&#148;), which such Selling Investor Releasing Parties, or any of them, ever have had or ever in the future may have
against the Selling Investor Released Parties, or any of them, in each case, to the extent arising solely as a result of the ownership or purported ownership of any of Company Stock, Company Stock Options or other security or interest of the Company
and which, in each case, are based on acts, events or omissions occurring prior to or contemporaneously with the Effective Time (the &#147;<U>Selling Investor Released Claims</U>&#148;); <U>provided</U>, <U>however</U>, that the foregoing release
shall not release, impair or diminish, and the term &#147;Selling Investor Released Claims&#148; shall not include, in any respect (i)&nbsp;the Selling Investor&#146;s right pursuant to the Transaction Documents, including the right to receive its
respective portion of the Merger Consideration; (ii)&nbsp;any Claims for indemnification, insurance benefits, reimbursement or advancement of expenses in such Selling Investor Releasing Party&#146;s capacity as a director, officer or employee of the
Company under the Company&#146;s organizational documents or any indemnification agreement in effect as of the date hereof (or any fiduciary insurance policy maintained by the Company or the Surviving Corporation for the benefit of the Selling
Investor, or any indemnification agreements with the Selling Investor or its board designee) with respect to any act, omission, event or transaction occurring prior to or contemporaneously with the Effective Time; or (iii)&nbsp;the rights of any
Selling Investor Releasing Party in his or her capacity as an employee of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Selling Investor
Releasing Party represents and acknowledges that he, she or it has read this release and the Merger Agreement and other Transaction Documents and understands their terms and has been given sufficient opportunity to review this release and the
Transaction Documents and to ask questions of the Company&#146;s Representatives. Each Selling Investor Releasing Party further represents that, in signing this release, he, she or it does not rely, and has not relied, on any representation or
statement made by any Representative of the Company or any other Person with respect to the subject matter, basis or effect of this release or otherwise, except such express representations and warranties set forth in the Merger Agreement or this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of Section&nbsp;22(a), with respect to the Selling Investor
Released Claims, each Selling Investor Releasing Party acknowledges that he, she or it is familiar with Section&nbsp;1542 of the Civil Code of the State of California (&#147;<U>Section</U><U></U><U>&nbsp;1542</U>&#148;) and hereby expressly waives
all rights under Section&nbsp;1542 and any similar applicable Law or common law principle in any applicable jurisdiction prohibiting or restricting the waiver of unknown claims. Section&nbsp;1542 reads as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT
THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the provisions of Section&nbsp;1542 or any
similar applicable Law or common law principle in any applicable jurisdiction, each Selling Investor Releasing Party expressly acknowledges that the foregoing release is intended to include in its effect all Claims within the scope of such release
which any Selling Investor Releasing Party does not know or suspect to exist in his, her or its favor against any of the Selling Investor Released Parties (including, without limitation, unknown and contingent Claims), and that the foregoing release
expressly contemplates the extinguishment of all such Claims (except to the extent expressly set forth in this Section&nbsp;22). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous and General</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments; Waivers, Etc</U>. This Agreement may not be amended, changed, supplemented or otherwise modified
with respect to any Selling Investor, except upon the execution and delivery of a written agreement executed by each of Parent and such Selling Investor. Any agreement on the part of any party to any waiver or any extension of time for performance
shall be valid only if set forth in an instrument in writing signed on behalf of such party. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial
exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. Except as otherwise herein provided, the rights and remedies herein provided shall be cumulative and not exclusive of any rights
or remedies provided by applicable Law or equity, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts; Effectiveness</U><I>.</I> This Agreement may be executed in any number of counterparts (including
by facsimile or by attachment to electronic mail in portable document format (PDF)), each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement, and shall become effective
when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; </U><U>WAIVER OF JURY TRIAL</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without
giving effect to any choice or conflict of law provisions or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. All Actions arising out
of or relating to this Agreement or the transactions contemplated hereby shall be heard and determined exclusively in the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware ((or in the
event, but only in the event, that the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action
or proceeding is vested exclusively in the federal courts of the United States of America, the United States District Court for the District of Delaware, and, in each case, the appellate court(s) therefrom). The parties hereto hereby
(A)&nbsp;irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware ((or in the event, but only in the event, that the Court of Chancery of
the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action or proceeding is vested exclusively in the federal courts
of the United States of America, the United States District Court for the District of Delaware, and, in each case, the appellate court(s) therefrom) for the purpose of any Action arising out of or relating to this Agreement or the transactions
contemplated hereby brought by any party hereto, (B)&nbsp;irrevocably waive, and agree not to assert by way of motion, defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the <FONT
STYLE="white-space:nowrap">above-named</FONT> courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Action is improper, or that this Agreement or the transactions contemplated hereby may not be enforced in or by the <FONT STYLE="white-space:nowrap">above-named</FONT> courts, and (C)&nbsp;agree
that such party will not bring any Action arising out of or relating to this Agreement or the transactions contemplated hereby in any court other than the Court of Chancery of the State of Delaware (or in the event, but only in the event, that the
Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action or proceeding is vested exclusively in
the federal courts of the United States of America, the United States District Court for the District of Delaware). Service of process, summons, notice or document to any party&#146;s address and in the manner set forth in
<U>Section</U><U></U><U>&nbsp;23(d)</U> shall be effective service of process for any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES HERETO
CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER,
(B)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS, AS
APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS IN THIS SECTION&nbsp;23(C)(II). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U><I>.</I>
Notices, requests, instructions or other documents to be given under this Agreement shall be in writing and shall be deemed given, (i)&nbsp;on the date sent by <FONT STYLE="white-space:nowrap">e-mail</FONT> of a PDF document if sent during normal
business hours of the recipient, and on the next business day if sent after normal business hours of the recipient, (ii)&nbsp;when delivered, if delivered personally to the intended recipient, and (iii)&nbsp;one Business Day later, if sent by
overnight delivery via a national courier service (providing proof of delivery), and in each case, addressed to a party at the following address for such party: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">if to Parent:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Illumina, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">5200 Illumina Way</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">San Diego, California 92122</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Charles E. Dadswell, Senior Vice President and General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Telephone:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-202-4500</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Facsimile:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-202-4545</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CDadswell@illumina.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">legalnotices@illumina.com</TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">with copies to (which shall not constitute notice):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Cravath, Swaine&nbsp;&amp; Moore LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Worldwide Plaza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">825 Eighth Avenue</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10019</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Faiza J. Saeed, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ting S. Chen, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">fsaeed@cravath.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">tchen@cravath.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">if to a Selling Investor, to such Selling Investor at the address corresponding to such Selling Investor&#146;s name on Schedule 1(b) with copies (which shall not constitute notice) to the Company (in accordance with
<U>Section</U><U></U><U>&nbsp;11.02</U> of the Merger Agreement) and to its counsel:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">355 South Grand Avenue, Suite 100</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Los Angeles, California 90071-1560</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Attention:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Alex W. Voxman, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Clark, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Email:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">alex.voxman@lw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">andrew.clark@lw.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice may be given to such other persons or addresses as may be designated in writing by the party to receive such
notice as provided above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U><I>.</I> This Agreement (including any Schedules hereto) and
the Merger Agreement constitute the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties both written and oral, among the parties hereto, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Parties in Interest; No Third Party Beneficiaries</U><I>.</I> Subject to Section&nbsp;23(i), and without
relieving any party of any obligation hereunder, this Agreement shall be binding upon and inure solely to the benefit of each party hereto and their respective successors and permitted assigns. This Agreement is not intended to, and does not, confer
upon any Person other than the parties hereto any rights or remedies hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U><I>.</I>
The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application
thereof to any Person or any circumstance, is invalid or unenforceable, (i)&nbsp;a suitable and equitable provision negotiated in good faith by the parties hereto shall be substituted therefor in order to carry out, so far as may be valid and
enforceable, the intent and purpose of such invalid or unenforceable provision and (ii)&nbsp;the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not, subject to clause (i)&nbsp;above, be
affected by such invalidity or unenforceability, except as a result of such substitution, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Section headings or captions herein are for convenience of reference only, do not constitute part of this
Agreement and shall not be deemed to limit or otherwise affect any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provisions hereof. Where a reference in this Agreement is made to a Section or Schedule, such reference shall be to a Section of or Schedule to this Agreement unless otherwise indicated. Whenever
the words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation&#148;. The words &#147;hereof&#148;, &#147;herein&#148; and
&#147;hereunder&#148; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word &#147;or&#148; when used in this Agreement is not exclusive. The
word &#147;extent&#148; in the phrase &#147;to the extent&#148; shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply &#147;if&#148;. All terms defined in this Agreement shall have the defined
meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to
the masculine as well as to the feminine and neuter genders of such term. Any statute defined or referred to herein means such statute as from time to time amended, modified or supplemented, including by succession of comparable successor statutes.
Any agreement or instrument defined or referred to herein includes all attachments thereto and instruments incorporated therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity
or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U><I>.</I> This Agreement shall not be assignable by operation of
law or otherwise without the prior written consent of each of the parties. Any purported assignment in contravention of the preceding sentence shall be null and void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>. All costs and expenses incurred in connection with this Agreement shall be paid by the party
incurring such cost or expense, whether or not the transactions contemplated by this Agreement or the Merger Agreement are consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U><I>.</I> The parties hereto acknowledge and agree that irreparable damage would occur
and that the parties would not have any adequate remedy at law if any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an
adequate remedy therefor. It is accordingly agreed that Parent shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the performance of the terms and provisions hereof in any court
referred to in Section&nbsp;23(c), without proof of actual damages (and each party hereby waives any requirement for the security or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are
entitled at law or in equity. The parties further agree not to assert that a remedy of specific enforcement is an unenforceable, invalid, contrary to applicable Law or inequitable remedy for any reason, and not to assert that a remedy of monetary
damages would provide an adequate remedy for any such breach or that Parent otherwise has an adequate remedy at law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ILLUMINA, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ F<SMALL>RANCIS</SMALL> <SMALL>DE</SMALL>S<SMALL>OUZA</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: &nbsp;&nbsp;&nbsp;&nbsp;Francis deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;President and Chief Executive
Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Parent Signature Page to
Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>6 Dimensions Capital, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">6 Dimensions Capital GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">General Partner</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ L<SMALL>EON</SMALL> C<SMALL>HEN</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leon Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR></TABLE></DIV>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>6 Dimensions Affiliates Fund, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">6 Dimensions Capital GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ L<SMALL>EON</SMALL> C<SMALL>HEN</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leon Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Absolute Partners Master Fund Limited</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H<SMALL>ENRY</SMALL> L<SMALL>I</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Li</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Arch Venture Fund IX Overage, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ARCH Venture Partners IX Overage, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ARCH Venture Partners IX, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ M<SMALL>ARK</SMALL> M<SMALL>C</SMALL>D<SMALL>ONNELL</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Mark McDonnell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Arch Venture Fund VIII, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ARCH Venture Partners VIII, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ARCH Venture Partners VIII, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ M<SMALL>ARK</SMALL> M<SMALL>C</SMALL>D<SMALL>ONNELL</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Mark McDonnell</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:300pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H<SMALL>AL</SMALL> B<SMALL>ARRON</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hal Barron</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Biomatics Capital Partners, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ B<SMALL>ORIS</SMALL> N<SMALL>IKOLIC</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Boris Nikolic</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H<SMALL>ANS</SMALL> B<SMALL>ISHOP</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hans Bishop</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Bristol-Myers Squibb Company</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ D<SMALL>AVID</SMALL> E<SMALL>LKINS</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Elkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President&nbsp;&amp; CFO</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ B<SMALL>ROOK</SMALL> B<SMALL>YERS</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brook Byers</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Celgene Switzerland LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ D<SMALL>AVID</SMALL> E<SMALL>LKINS</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Elkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President&nbsp;&amp; CFO</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b)</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Creekstone Investment, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ P<SMALL>AUL</SMALL> <SMALL>DAUBER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Dauber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Decheng Capital China Life Sciences<BR>USD Fund I, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">By its General Partner, Decheng Capital China Management&nbsp;I (Cayman)</TD></TR></TABLE></DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ X<SMALL>IANGMIN</SMALL> C<SMALL>UI</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Xiangmin Cui</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Decheng Capital China Life Sciences USD Fund II, L.P.</B> (as stockholder, and as Proxyholder for Denlux Diagnostics Invest
Inc. and Denlux Capital Inc.)</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By its
General Partner,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decheng Capital China Management II</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Cayman)</P></TD></TR></TABLE></DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ X<SMALL>IANGMIN</SMALL> C<SMALL>UI</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Xiangmin Cui</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deepbay Holdings Ltd.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ A<SMALL>LEXANDER</SMALL> W<SMALL>EST</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander West</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denlux Capital Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ X<SMALL>IANGMIN</SMALL> C<SMALL>UI</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Xiangmin Cui</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denlux Diagnostics Invest Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ X<SMALL>IANGMIN</SMALL> C<SMALL>UI</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Xiangmin Cui</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>The Duane Family Trust</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ C<SMALL>ATHY</SMALL> F<SMALL>RIEDMAN</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cathy Friedman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Explore Investments LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ P<SMALL>AUL</SMALL> D<SMALL>AUBER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Dauber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K<SMALL>AYE</SMALL> F<SMALL>OSTER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kaye Foster</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ C<SMALL>ATHY</SMALL> F<SMALL>RIEDMAN</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cathy Friedman</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ M<SMALL>AYKIN</SMALL> H<SMALL>O</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maykin Ho</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Huber Family QTIP Trust U/A/D 09/19/2012</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>EFF</SMALL> H<SMALL>UBER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Huber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Huber Vossough 2020 GRAT U/A/D</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>08/18//2020</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>EFF</SMALL> H<SMALL>UBER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Huber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maywood Trust U/A/D 09/19/2012</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>EFF</SMALL> H<SMALL>UBER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Huber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>The Jeffrey T. Huber 2018 Grantor Retained</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annuity Trust U/A/D 3/12/2018</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/<SMALL>S</SMALL>/ J<SMALL>EFF</SMALL> H<SMALL>UBER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Huber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Illumina, Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ F<SMALL>RANCIS</SMALL> <SMALL>DE</SMALL>S<SMALL>OUZA</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Francis deSouza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; CEO</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Johnson&nbsp;&amp; Johnson UK Treasury Company</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Limited</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ L<SMALL>UC</SMALL> F<SMALL>REYNE</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luc Freyne</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K<SMALL>WAN</SMALL> C<SMALL>HEE</SMALL> C<SMALL>HAN</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kwan Chee Chan</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Madrone Opportunity Fund, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Madrone Capital Partners, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">General Partner</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ G<SMALL>REG</SMALL> P<SMALL>ENNER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Penner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Merck Sharp&nbsp;&amp; Dohme Corp.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ B<SMALL>ENJAMIN</SMALL> T<SMALL>HORNER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benjamin Thorner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVP&nbsp;&amp; Head of BD&amp;L, MRL</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Milky Way Investments Group Limited</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ D<SMALL>ESPOINA</SMALL> Z<SMALL>INONOS</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Despoina Zinonos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Rainbow Horizon Limited</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jackson Law</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jackson Law</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Partner</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ W<SMALL>ILLIAM</SMALL> R<SMALL>ASTETTER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Rastetter</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>The Rastetter Family Trust DTD Sept. 2, 2010,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>William and Marisa Rastetter, Trustees</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ W<SMALL>ILLIAM</SMALL> R<SMALL>ASTETTER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Rastetter</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee</P></TD></TR></TABLE></DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ M<SMALL>ARISA</SMALL> R<SMALL>ASTETTER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marisa Rastetter</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trsutee</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>The Investment 2002 Trust dated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>November&nbsp;11, 2002</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ W<SMALL>ILLIAM</SMALL> R<SMALL>ASTETTER</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Rastetter</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman, Neurocrine</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:300pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sutter Hill Associates, LLC, a California</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>limited liability company</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J<SMALL>EFF</SMALL> B<SMALL>IRD</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Bird</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director, Sutter Hill</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ventures</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Sutter Hill Ventures, a California Limited</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Partnership</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J<SMALL>EFF</SMALL> B<SMALL>IRD</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeff Bird</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director, Sutter Hill</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ventures</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ W<SMALL>AI</SMALL> K<SMALL>WUN</SMALL> R<SMALL>OSSA</SMALL> C<SMALL>HIU</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wai Kwun Rossa Chiu</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Waycross Ventures, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ B<SMALL>ROOK</SMALL> B<SMALL>YERS</SMALL></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brook Byers</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Partner</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:500pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Selling Investor Signature Page to Selling Investor Support Agreement]</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Selling Investor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class A<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class B<BR>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted<BR>Stock&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Company<BR>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Form of] Written Consent </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE
PREFERRED STOCKHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND CLASS A COMMON STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF GRAIL, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned (the &#147;<U>Selling Investors</U>&#148;), being the holders of a majority of the shares of Class&nbsp;A Common Stock, par value $0.001 per share (the &#147;<U>Company Class&nbsp;A Common Stock</U>&#148;), of GRAIL, Inc., a Delaware
corporation (the &#147;<U>Company</U>&#148;), issuable or previously issued upon conversion of the shares of the Company&#146;s Series A Preferred Stock, par value $0.001 per share, Series B Preferred Stock, par value $0.001 per share, Series C
Preferred Stock, par value $0.001 per share, and Series D Preferred Stock, par value $0.001 per share (collectively, the &#147;<U>Company Preferred Stock</U>&#148;), hereby consent to, adopt and approve the following resolutions and each and every
action effected thereby: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company, Illumina, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), SDG Ops, Inc.,
a Delaware corporation and wholly owned subsidiary of Parent (&#147;<U>First Merger Sub</U>&#148;), and SDG Ops, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (&#147;<U>Second Merger Sub</U>&#148;), have entered
into an Agreement and Plan of Merger dated as of September&nbsp;20, 2020 (as it may be amended from time to time, the &#147;<U>Merger Agreement</U>&#148;; capitalized terms used but not defined herein shall have the respective meanings ascribed to
them in the Merger Agreement), which provides for, among other things, the merger of First Merger Sub with and into the Company, with the Company continuing as the surviving corporation (the &#147;<U>Surviving Corporation</U>&#148;) (the
&#147;<U>First Merger</U>&#148;), and immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Corporation will merge with and into Second Merger Sub, with Second Merger Sub being the
surviving company of the Second Merger (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the &#147;<U>Mergers</U>&#148;), and pursuant to which all shares of Company Stock issued and outstanding immediately prior to the
Effective Time (other than as provided in Section&nbsp;2.04(c) of the Merger Agreement and Appraisal Shares) will be converted into the right to receive the Merger Consideration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, each Selling Investor holds and is entitled to vote (or direct the voting of) the number of shares of Company Preferred Stock
set forth opposite such Selling Investor&#146;s name on<U> Schedule 1</U> attached hereto, collectively constituting a majority of the shares of Company Class&nbsp;A Common Stock issuable or previously issued upon conversion of the shares of Company
Preferred Stock; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, each Selling Investor is a party to the Amended and Restated Voting Agreement dated as of
November&nbsp;27, 2019 (the &#147;<U>Voting Agreement</U>&#148;), by and among the Company and the Voting Agreement Parties thereto, as amended by Amendment No.&nbsp;1 to the Voting Agreement dated as of April&nbsp;17, 2020, by and among the Company
and the Voting Agreement Parties thereto, and Amendment No.&nbsp;2 to the Voting Agreement dated as of May&nbsp;11, 2020, by and among the Company and the Voting Agreement Parties thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Section&nbsp;2.2 of the Voting Agreement provides that, in the event that each of (a)&nbsp;the Company Board and (b)&nbsp;the
holders of a majority of the shares of Company Class&nbsp;A Common Stock then issuable or previously issued upon conversion of the shares of Company Preferred Stock approves a Sale of the Company (as defined therein) in writing, specifying that
Section&nbsp;2 of the Voting Agreement shall apply to such transaction, then each Voting Agreement Party shall be obligated to vote all shares of Company Stock held by such Voting Agreement Party in favor of, and adopt, such Sale of the Company and
take such other actions as set forth in Section&nbsp;2 of the Voting Agreement; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company Board has approved the Transactions in writing as a Sale of the
Company pursuant to Section&nbsp;2.2 of the Voting Agreement and has specified that Section&nbsp;2 of the Voting Agreement shall apply to the Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the Transactions, each Selling Investor has entered into the Selling Investor Support Agreement, dated as
of [&#149;], by and among Parent and certain other stockholders of the Company party thereto (the &#147;<U>Selling Investor Support Agreement</U>&#148;), pursuant to which, among other things, each Selling Investor has agreed to vote or execute and
deliver consents with respect to all shares of Company Stock held by such Selling Investor in accordance with the terms of the Selling Investor Support Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, each Selling Investor desires, pursuant to Section&nbsp;2.2 of the Voting Agreement, to approve the Transactions as a Sale of
Company and to specify that the Drag-Along apply to the Transactions, including the Mergers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, BE IT</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Merger Agreement and the Transactions, including the Mergers, are and each hereby is, approved, authorized and
confirmed in all respects for purposes of Section&nbsp;2.2(ii) of the Voting Agreement; and be it further </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the
Transactions constitute, and are hereby approved as, a Sale of the Company pursuant to Section&nbsp;2.2 of the Voting Agreement and that Section&nbsp;2 of the Voting Agreement applies to the Transactions; and be it further </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the exercise of the Drag-Along pursuant to Section&nbsp;2.2 of the Voting Agreement in connection with the Transactions
is approved, authorized and confirmed in all respects; and be it further </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that each Voting Agreement Party shall be
(x)&nbsp;notified of its obligation to (i)&nbsp;vote all shares of Company Stock held by such Voting Agreement Party in favor of, and adopt, the Merger Agreement and the Transactions, including the Mergers, by executing a written consent in the form
attached hereto as<U> Exhibit A</U> and delivering such written consent to the Company after the Registration Statement is declared effective by the SEC as specified in the Consent Solicitation Statement, (ii)&nbsp;vote against any and all proposals
that could delay or impair the ability of the Company to consummate the Transactions, including the Mergers, and (iii)&nbsp;refrain from exercising any dissenters&#146; rights or rights of appraisal under applicable law (including, without
limitation, appraisal rights pursuant to Section&nbsp;262 of the General Corporation Law of the State of Delaware) with respect to the Transactions, including the Mergers, and (y)&nbsp;requested to execute and deliver the Support Agreement as
promptly as practicable following the date hereof, pursuant to Section&nbsp;2.2(c) of the Voting Agreement (provided, however, that the foregoing shall not require or be construed so as to require any Voting Agreement Party to vote the shares of
Common Stock held by such Voting Agreement Party in favor of any stockholder vote to approve &#147;parachute payments&#148; (within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations
thereunder) solicited in connection with the Transaction); and be it further </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that promptly after the Registration Statement (which shall include the
Consent Solicitation Statement) is declared effective by the SEC, each Selling Investor will execute and deliver, or cause to be delivered, a written consent in the form attached hereto as <U>Exhibit A</U> pursuant to and in accordance with the
Selling Investor Support Agreement; and be it further </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that, pursuant to Section&nbsp;3.2 of the Voting Agreement, Parent
be, and hereby is, appointed as the Selling Investors&#146; designee to hold and have the sole power to exercise the proxy and power of attorney contemplated by Section&nbsp;3.2 of the Voting Agreement in connection with the Transactions, which
designation shall not be revoked or rescinded prior to the earlier of the Effective Time or the termination of the Merger Agreement in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[Selling Investor]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Drag-Along Consent] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Schedule 1 </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Form of] Written Consent </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT
VALUE RIGHTS AGREEMENT<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and among </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ILLUMINA, INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[TRUSTEE] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[HOLDER REPRESENTATIVE] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of [&#149;] </B></P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to review by trustee and Holder Representative. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance and Opinions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of Documents Delivered to Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acts of Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices, etc., to Trustee and Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice to Holders; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conflict with Trust Indenture Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Headings and Table of Contents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Benefits of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Holidays</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Separability Clause</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Recourse Against Others</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acceptance of Trust</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 1.16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">CONTINGENT VALUE RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Forms Generally</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title and Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registrable Form</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution, Authentication, Delivery and Dating</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Temporary CVRs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration, Registration of Transfer and Exchange</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutilated, Destroyed, Lost and Stolen CVRs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payments with Respect to CVRs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Persons Deemed Owners</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cancellation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ability to Abandon CVR; Certain Acquisitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 2.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CUSIP Numbers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">THE TRUSTEE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Duties and Responsibilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Rights of Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Not Responsible for Recitals or Issuance of CVRs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Money Held in Trust</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compensation and Reimbursement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disqualification; Conflicting Interests</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corporate Trustee Required; Eligibility</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignation and Removal; Appointment of Successor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acceptance of Appointment of Successor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger, Conversion, Consolidation or Succession to Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 3.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preferential Collection of Claims Against Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">HOLDERS&#146; LISTS AND REPORTS BY THE TRUSTEE AND PARENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 4.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent to Furnish Trustee with Names and Addresses of Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 4.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preservation of Information; Communications to Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 4.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports by Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 4.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports by Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">AMENDMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 5.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments Without Consent of Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 5.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendments with Consent of Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 5.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution of Amendments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 5.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Amendments; Notice to Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 5.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conformity with Trust Indenture Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 5.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reference in CVRs to Amendments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">COVENANTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Amounts, if any, to Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maintenance of Office or Agency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Money for Covered Revenues Payments to Be Held in Trust</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Books and Records</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Audits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Covenants and Acknowledgements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 6.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Use of Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">REMEDIES OF THE TRUSTEE AND HOLDER ON EVENT OF DEFAULT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Event of Default Defined; Waiver of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Collection by the Trustee; the Trustee May Prove Payment Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Application of Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Suits for Enforcement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Restoration of Rights on Abandonment of Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limitations on Suits by Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Unconditional Right of Holders to Institute Certain Suits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Control by Holders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Past Defaults</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Trustee to Give Notice of Default, But May Withhold in Certain Circumstances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 7.12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Right of Court to Require Filing of Undertaking to Pay Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">CONSOLIDATION, MERGER, SALE OR CONVEYANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 8.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent May Consolidate, etc., on Certain Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 8.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successor Person Substituted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 8.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Opinion of Counsel to the Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 8.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">REDEMPTION OF SECURITIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 9.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice to Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 9.2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Redemption</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 9.3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Notice of Redemption</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 9.4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Deposit of Redemption Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 9.5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Optional Redemption by Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">ARTICLE 10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">HOLDER REPRESENTATIVE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 10.1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority and Rights of the Holder Representative; Limitations on Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annex A - Form of CVR Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: This Table of Contents shall not, for any purpose, be deemed to be a part of this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reconciliation and tie between Trust Indenture Act of 1939 and Contingent Value Rights Agreement, dated as
of [&#149;]. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Trust Indenture Act Section</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Agreement Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;310(a)(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(5)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.8</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.7, 3.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;311(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;312(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.1, 4.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.2(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;313(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;314(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(e)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;315(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.1(a), 3.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.11</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.1(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(d)(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.1(a), 3.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(d)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.1(c)(ii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(d)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.1(c)(iii)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(e)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;316(a)(last sentence)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.1 (Definition of &#147;Outstanding&#148;)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(1)(A)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(1)(B)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Not Applicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;317(a)(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">6.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;318(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1.7</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: This reconciliation and tie shall not, for any purpose, be deemed to be a part of this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [&#149;] (this &#147;<U>CVR
Agreemen</U>t&#148;), by and among Illumina, Inc., a Delaware corporation (the &#147;<U>Parent</U>&#148;), [&#149;], a national banking association, as Trustee (the &#147;<U>Trustee</U>&#148;), and [&#149;], a [&#149;], as Holder Representative (the
&#147;<U>Holder Representative</U>&#148;), in favor of each person who from time to time holds one or more Contingent Value Rights (the &#147;<U>CVRs</U>&#148; and, each individually, a &#147;<U>CVR</U>&#148;) to receive cash payments in the amounts
and subject to the terms and conditions set forth herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>W I T N E S S E T H: </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this CVR Agreement is entered into pursuant to the Agreement and Plan of Merger, dated as of September&nbsp;20, 2020 (as amended
prior to the effective time thereof, the &#147;<U>Merger Agreemen</U>t&#148;), by and among Parent, SDG Ops, Inc., a Delaware corporation and direct, wholly owned Subsidiary of Parent (&#147;<U>First Merger Sub</U>&#148;), SDG Ops, LLC, a Delaware
limited liability company and a direct, wholly owned subsidiary of Parent (&#147;<U>Second Merger Sub</U>&#148;), and GRAIL, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Merger Agreement, Parent, First Merger Sub, Second Merger Sub and the Company have agreed to enter into a business
combination transaction pursuant to which (a)&nbsp;First Merger Sub will merge with and into the Company (the &#147;<U>First Merger</U>&#148;), with the Company being the surviving corporation (the Company, in its capacity as the surviving
corporation of the First Merger, is sometimes referred to as the &#147;<U>Surviving Corporation</U>&#148;), and (b)&nbsp;immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving
Corporation will merge with and into the Second Merger Sub (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the &#147;<U>Mergers</U>&#148;), with Second Merger Sub being the surviving company of the Second Merger (Second
Merger Sub, in its capacity as the surviving company of the Second Merger, is sometimes referred to as the &#147;<U>Surviving Entity</U>&#148; or the Company); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the CVRs shall be issued in accordance with and pursuant to the terms and conditions of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the consummation of the transactions contemplated by the Merger Agreement, it
is covenanted and agreed, for the equal and proportionate benefit of all Holders, as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1. <U>Definitions</U>. For all purposes of this CVR Agreement, except as otherwise expressly provided or unless the context
otherwise requires: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the terms defined in this Article 1 have the meanings assigned to them in this Article 1, and include the plural
as well as the singular; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) all accounting terms used herein and not expressly defined herein shall, except as otherwise noted, have the
meanings assigned to such terms in accordance with applicable Accounting Standards, where &#147;<U>Accounting Standards</U>&#148; means GAAP; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) all capitalized terms used in this CVR Agreement without definition shall have the respective meanings ascribed to them in the Merger
Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) all other terms used herein which are defined in the Trust Indenture Act (as defined
herein), either directly or by reference therein, have the respective meanings assigned to them therein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the words
&#147;<U>herein</U>,&#148; &#147;<U>hereof</U>&#148; and &#147;<U>hereunder</U>&#148; and other words of similar import refer to this CVR Agreement as a whole and not to any particular Article, Section or other subdivision; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are deemed to be followed by the words &#147;without
limitation&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of a Person means a Person who, directly or indirectly through one or more intermediaries,
controls, is controlled by, or is under common control with, such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Percentage</U>&#148; means, as of a
specified date, (a)&nbsp;a percentage equal to 30% (measured by the projected Covered Revenues of Applicable Products of Parent and its Subsidiaries for the period from such specified date through the End Date) less (b)&nbsp;the percentage of
projected Covered Revenues of Applicable Products of Parent and its Subsidiaries that have been sold, transferred, conveyed, leased, exclusively licensed (or licensed pursuant to another licensing arrangement or arrangements involving Intellectual
Property that operate to transfer a substantial portion of the value of such Intellectual Property) or otherwise disposed of in connection with prior Minority Transactions (measured in accordance with immediately foregoing clause (a)&nbsp;as of the
date of such Disposition). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Products</U>&#148; means the Products referred to in clauses (a), (b)&nbsp;and (e)&nbsp;of
the definition of Covered Revenues. If a Product that was a Bundled Product or Service ceases to be a Bundled Product or Service, then effective as of the date on which such Product ceases to be a Bundled Product or Service, it will not be an
Applicable Product for any purpose under this CVR Agreement for so long as it is not a Bundled Product or Service and does not and would not generate Covered Revenues on a standalone basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board of Directors</U>&#148; means the board of directors of Parent or any other body performing similar functions, or any duly
authorized committee of that board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board Resolution</U>&#148; means a copy of a resolution certified by the Secretary or an
Assistant Secretary of Parent, to have been duly adopted by the Board of Directors or a written consent signed by the requisite directors serving on the Board of Directors and, in either case, that is in full force and effect on the date of such
certification, and delivered to the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bundled Product or Service</U>&#148; means any Product or Service of Parent and its
Subsidiaries included within Covered Revenues as a result of the application of the final sentence of the definition of &#147;Field&#148; and does not generate Covered Revenues on a standalone basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day on which banks are not required or authorized to close in the City of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commencement Date</U>&#148; means the later of (a)&nbsp;the Closing Date and (b)&nbsp;(i)&nbsp;the date that the Company&#146;s
Galleri early detection test first becomes commercially available in the United States as a laboratory developed test, based on the date of any press release or other public announcement related to such event, or (ii)&nbsp;such earlier date (on or
after the Closing Date) that the Holder Representative specifies in writing to Parent upon five days&#146; prior notice; <U>provided</U> that in any event the Commencement Date shall be no later than December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidential Information</U>&#148; shall have the meaning set forth in Section&nbsp;6.8 of this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consideration</U>&#148; means (a)&nbsp;the total value of all cash, securities and
other property paid or payable, directly or indirectly, by a purchaser to Parent or its Subsidiaries in connection with a transaction, plus, without duplication, (b)&nbsp;the aggregate principal amount of all indebtedness for borrowed money
(including capitalized leases and preferred equity obligations) of Parent or its Subsidiaries, directly or indirectly, assumed by the transferee or acquiror in such transaction or refinanced (including any premiums paid) or extinguished by the
transferee or acquiror in connection with such transaction. If any portion of Consideration is subject to increase by payments related to future events contingent or otherwise (including amounts paid into escrow), then the amount of such
Consideration will be calculated based on the present value of such payments as mutually agreed upon in good faith by Parent and the Holder Representative. Non-cash consideration consisting of publicly traded securities shall be valued as set forth
in the definitive agreement for the transaction or, if not so specified, at the average of their closing prices for the five trading days immediately prior to the closing of the transaction and any other non-cash consideration shall be valued at the
fair market value thereof as determined in good faith by Parent and the Holder Representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>control</U>&#148; (including the
terms &#147;<U>controlled by</U>&#148; and &#147;<U>under common control with</U>&#148;) means the possession, directly or indirectly, or as trustee or executor, of the power to direct or cause the direction of the management and policies of a
Person, whether through the ownership of voting securities, as trustee or executor, by contract or credit arrangement or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Corporate Trust Office</U>&#148; means the office of the Trustee at which at any particular time its corporate trust business shall
be principally administered, which office at the date of execution of this CVR Agreement is located at [&#149;]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered
Products and Services</U>&#148; means the Products and Services referred to in clauses (a)&nbsp;and (b)&nbsp;of the definition of Covered Revenues, the Samples referred to in clause (d)&nbsp;of the definition of Covered Revenues and the Products,
Services and Data referred to in the definition of &#147;Sale of Data&#148; referenced in clause (e)&nbsp;of the definition of &#147;Covered Revenues&#148;. If a Product or Service that was a Bundled Product or Service ceases to be a Bundled Product
or Service, then effective as of the date on which such Product or Service ceases to be a Bundled Product or Service, it will not be a Covered Product and Service for any purpose under this CVR Agreement for so long as it is not a Bundled Product or
Service and does not and would not generate Covered Revenues on a standalone basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Revenues</U>&#148; means, for any
Covered Revenues Measuring Period or any Threshold Measuring Period (including, for the avoidance of doubt, the First Threshold Measuring Period and the Final Threshold Measuring Period), without duplication: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Net Sales of any Products or Services designed and Sold for use in the Field, in each case utilizing any Methylation-based Technology,
whether in whole or in part; <U>plus</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Net Sales of the Minimal Residual Disease Test for Therapy Selection; <U>plus</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Other Covered Revenue of Parent and its Subsidiaries on a consolidated basis; <U>plus</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) other revenue of Parent and its Subsidiaries on a consolidated basis in connection with the use or license of Samples, and Net Sales of
Samples, in each case for any purpose so long as such Samples were generated or collected by the Company or its Subsidiaries or (following the Closing) Parent or its Subsidiaries from activities within the Field; <U>plus</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Net Sales from the Sale of Data; <U>plus</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the portion of the Consideration attributable to the Applicable Products or any other
assets or rights, including Intellectual Property, Data, and Samples, in each case that generate Covered Revenues (other than in connection with a Specified Asset Sale), in each case Disposed of in a Minority Transaction; <U>less</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) any Permitted Deductions to the extent not already deducted in calculating any of the foregoing clauses (a)&nbsp;through (f); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that Covered Revenues shall exclude payments received in the form of grants for research from governmental entities or non-profit
organizations. Notwithstanding anything to the contrary set forth herein, Covered Revenues shall exclude in all cases any revenue of Parent and its Subsidiaries to the extent generated from (A)&nbsp;Parent&#146;s and its Subsidiaries&#146; general
purpose instruments and reagents used for nucleic acid clustering and sequencing-by-synthesis or (B)&nbsp;Parent&#146;s and its Subsidiaries&#146; general purpose analysis software for DNA base calling and sequence alignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, any dollar of revenue that is included within the calculation of Covered Revenues shall only be counted once for
purposes of calculating Covered Revenues under this CVR Agreement. For example, if a Product is Sold to a non-wholly owned Subsidiary and included in the calculation of Net Sales, including subject to clauses 2 and 3 of the definition of Net Sales,
a Sale of such Product by such non-wholly owned Subsidiary to a third party shall only be included in the calculation of Net Sales for the purpose of the calculation of Covered Revenues to the extent the Net Sales in such second transaction exceeds
the Net Sales included in Covered Revenues in the first transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event that Parent or any
Subsidiary of Parent directly or indirectly, by a sale or swap of assets or other rights, merger, reorganization, joint venture, lease, license or any other transaction or arrangement, sells, transfers, conveys, licenses or otherwise disposes of
their respective rights in and to the business of Parent and its Subsidiaries that would generate Covered Revenues after the Closing Date and prior to the Commencement Date, the Consideration received in connection with such sale or swap of assets
or other rights, merger, reorganization, joint venture, lease, license or any other transaction or arrangement attributable to the business of Parent and its Subsidiaries that would generate Covered Revenues shall be included in Covered Revenues in
the First Threshold Measuring Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Revenues Measuring Period</U>&#148; means each fiscal quarter of Parent during the
Covered Revenues Term; <U>provided</U> that (a)&nbsp;if the Commencement Date does not fall on the first day of Parent&#146;s fiscal quarter, the first Covered Revenues Measuring Period shall commence on the Commencement Date and end on the last day
of Parent&#146;s fiscal quarter during which the Commencement Date falls and (b)&nbsp;the final Covered Revenues Measuring Period shall end on the End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Revenues Payment</U>&#148; means, subject to any reductions pursuant to Sections 6.5(a) or 6.5(b), (I)&nbsp;(x)&nbsp;with
respect to any Covered Revenues Measuring Period within a Threshold Measuring Period (other than the First Threshold Measuring Period and the Final Threshold Measuring Period), an amount equal to (i)&nbsp;for any Covered Revenues recognized in the
applicable Threshold Measuring Period up to and including $1,000,000,000, 2.5% of such Covered Revenues for such Covered Revenues Measuring Period <U>plus</U> (ii)&nbsp;for any Covered Revenues recognized in the applicable Threshold Measuring Period
in excess of $1,000,000,000, 9.0% of such Covered Revenues recognized in such Covered Revenues Measuring Period and (y)&nbsp;with respect to any Covered Revenues Measuring Period within the First Threshold Measuring Period or the Final Threshold
Measuring Period, an amount equal to (i)&nbsp;for any Covered Revenues recognized in the applicable Threshold Measuring Period up to and including amount equal to $2,737,850.79 <U>multiplied</U> <U>by</U> the total number of days in such Threshold
Measuring Period, 2.5% of such Covered Revenues recognized in such Covered Revenues Measuring Period <U>plus</U> (ii)&nbsp;for any Covered Revenues recognized in the applicable Threshold Measuring Period in excess of an amount equal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to $2,737,850.79 <U>multiplied</U> <U>by</U> the number of days in such Threshold Measuring Period, 9.0% of such Covered Revenues recognized in such Covered Revenues Measuring Period, in the case
of each of (x)&nbsp;and (y), <U>multiplied</U> <U>by</U> (II) a fraction, the numerator of which is the aggregate number of CVRs Outstanding as of the applicable Covered Revenues Payment Date, and the denominator of which is the Total Equity Count;
<U>provided</U> that in no event will any Covered Revenues Payment become payable on account of Covered Revenues recognized in the period after the End Date; <U>provided</U>, <U>further</U>, that if Parent or any of its Subsidiaries enters into an
agreement (including any license, settlement, covenant not to sue or other similar agreement and including any agreement with collaboration, licensing, asset sale, intellectual property enforcement or other similar terms) that requires payment to a
third party for any significant know how, trade secrets, patents or other Intellectual Property after the Closing Date that is utilized to generate any Covered Revenue (&#147;<U>Specified Covered Revenue</U>&#148;), 9.0% of the amounts payable under
such agreement shall be deducted from the Covered Revenues Payments payable in respect of Specified Covered Revenue under clauses (x)(ii) and (y)(ii) above, provided that the total amount deducted shall not exceed 1.0% of all Covered Revenues for
which Covered Revenues Payments are payable under clauses (x)(ii) and (y)(ii) above (i.e., in no event will a Covered Revenues Payment with respect to a Covered Revenues Measuring Period under clauses (x)(ii) and/or (y)(ii) above be less than 8.0%
of Covered Revenues recognized in the applicable Threshold Measuring Period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Revenues Payment Date</U>&#148; means the
15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day after the date Parent is required to provide the Covered Revenues Statement pursuant to Section&nbsp;4.4(b) for the Covered Revenues Measuring Period in respect of which a Covered
Revenues Payment is due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Revenues Statement</U>&#148; means, with respect to each Covered Revenues Measuring Period, the
written statement of Parent, certified by the Chief Financial Officer of Parent and setting forth the calculation of the Covered Revenues Payment due, if any, and identifying any Covered Product and Service, if applicable, in respect of the
applicable Covered Revenues Measuring Period in accordance with this CVR Agreement, including (a)&nbsp;for any Covered Products and Services for all countries in the aggregate, (x)&nbsp;the aggregate gross amount invoiced or otherwise charged for
the sale and distribution of such Covered Products and Services by Parent and its Subsidiaries to third parties (other than Parent or its Affiliates) during the applicable period and (y)&nbsp;an itemized calculation of Net Sales for such Covered
Products and Services showing deductions for such Covered Revenues Measuring Period provided for in accordance with the definition of Net Sales and (b)&nbsp;to the extent that any Covered Revenue for an applicable period is recorded in currencies
other than United States dollars, the exchange rates used for conversion of such foreign currency into United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Revenues Term</U>&#148; means the period beginning on the Commencement Date and ending on the End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR</U>&#148; and &#147;<U>CVRs</U>&#148; shall have the meaning set forth in the Preamble of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR Agreement</U>&#148; means this instrument as originally executed and as it may from time to time be supplemented or amended
pursuant to the applicable provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR Certificate</U>&#148; means a certificate representing any of the CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR Register</U>&#148; shall have the meaning set forth in Section&nbsp;2.6(a) of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR Shortfall</U>&#148; shall have the meaning set forth in Section&nbsp;6.5(e) of this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Data</U>&#148; means any data, metadata or information in any form whatsoever
(including computational data, validation data, genomics data, genotype data, phenotype data, sequencing data, assay and related data, epigenomics data (including methylation data), other -omics data (including proteomics, metabolomics and
transcriptomics data), data generated or derived from biological samples, in vitro and in vivo data, stability data, other study data, nonclinical and clinical data (including preclinical and clinical broad data sets, and safety databases), business
and commercial data, manufacturing data, and regulatory data), whether or not raw, processed, analyzed, compiled, aggregated, organized, preliminary or final, technical, scientific, in hard copy or electronic form or in a database to the extent
generated, created, aggregated or collected from or in the course of: (i)&nbsp;any Parent or Company research, development, clinical study, regulatory, manufacturing or commercial activities; or (ii)&nbsp;other activities or sources, including
(a)&nbsp;knowledge, know-how, trade secrets, practices, procedures, methods (including any applicable reference standards), processes, expertise, techniques, methods, results, inventions (whether or not patentable), developments, specifications,
formulations, formulae, materials or compositions of matter, (b)&nbsp;software, algorithms, blueprints, marketing reports, or engineering reports; or (c)&nbsp;nonclinical and clinical results (including pharmacological, biological, chemical,
biochemical, toxicological, pharmaceutical, physical, analytical preclinical and clinical study and investigator reports, statistical analyses, expert opinions and reports). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Default Interest Rate</U>&#148; means a rate equal to the sum of 3.0% plus the prime rate of interest quoted in the Money Rates
section of<I> The Wall Street Journal</I>, or similar reputable data source, calculated daily on the basis of a 365-day year or, if lower, the highest rate permitted under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Diligent Efforts</U>&#148; means, with respect to any Product or Service, efforts of a Person to perform diligently its obligations
using such effort and employing such resources normally used by such Person in the exercise of its commercially reasonable business discretion relating to the research, development or commercialization of a Product or Service, that is of similar
market potential at a similar stage in its development or product life, taking into account issues of market exclusivity (including patent coverage, regulatory and other exclusivity), safety and efficacy, product profile, the competitiveness of
alternate Products or Services in the marketplace or under development, the launch or Sales of a similar Product or Service by such Person or third parties, the regulatory structure involved and likelihood of obtaining regulatory approval or
clearance, the profitability of the applicable Product or Service (including pricing and reimbursement status achieved) and other relevant factors, including technical, commercial, legal, scientific and/or medical factors. Factors beyond the
reasonable control of a Person, including regulatory delays, safety findings, unforeseen technical challenges, the failure of a Product or Service to meet necessary scientific or regulatory endpoints, and force majeure events shall be taken into
account when evaluating whether a Person&#146;s efforts hereunder constitute Diligent Efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disposition</U>&#148; means any,
direct or indirect, sale or swap of assets or other rights, merger, reorganization, joint venture, lease, exclusive license (or another licensing arrangement or arrangements involving Intellectual Property that operate to transfer a substantial
portion of the value of such Intellectual Property) or any other transaction or arrangement or series of related transactions or arrangements entered into by Parent or any of its Subsidiaries to sell, transfer, convey, lease, exclusively license (or
license pursuant to another licensing arrangement or arrangements involving Intellectual Property that operate to transfer a substantial portion of the value of such Intellectual Property) or otherwise dispose of its or their respective rights in
and to applicable assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>End Date</U>&#148; means the date that is 12 years after the Commencement Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Event of Default</U>&#148; shall have the meaning set forth in Section&nbsp;7.1 of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act Documents</U>&#148; shall have the meaning set forth in
Section&nbsp;4.4(a) of this CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Existing IP</U>&#148; means the Company&#146;s know-how or other Intellectual
Property as in existence as of the Closing Date, including all modifications, derivations, continuations, and improvements thereto following the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Existing Products</U>&#148; means all Products referred to in clauses (a), (b)&nbsp;and (e)&nbsp;in the definition of Covered
Revenues as in existence as of the Closing Date, to the extent regulatory approval and clearance is applicable, including Galleri multi-cancer early detection test, DAC diagnostic aid for cancer test and the Minimal Residual Disease Test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Field</U>&#148; means (i)&nbsp;detection, screening or diagnosis of or for cancer or nonalcoholic steatohepatitis
(&#147;<U>NASH</U>&#148;) in all populations, including through use of the Company&#146;s Galleri multi-cancer early detection test and/or DAC diagnostic aid for cancer test, and/or (ii)&nbsp;surveillance or monitoring of individuals with or
suspected of cancer or NASH in order to determine the probability of whether an individual likely has cancer or NASH, disease prognosis, risk assessment, staging, monitoring of such disease, progression or recurrence, including through use of the
Company&#146;s Minimal Residual Disease Test. For the avoidance of doubt, the Field excludes (i)&nbsp;applications, Products and Services to the extent consisting solely of Therapy Selection and (ii)&nbsp;any Products of Parent or its Subsidiaries
in existence as of the Closing Date and improvements, future versions, iterations and natural extensions thereof (including the TruSight Oncology 500 Product (&#147;<U>TSO500</U>&#148;)) used for solely Therapy Selection. If a Product or Service
utilizing any Methylation-based Technology, whether in whole or in part (including any Product or Service of Parent or its Subsidiaries in existence as of the Closing Date (including TSO500)) is used for an application in the Field alone and/or also
Therapy Selection, it shall be included in its entirety in the calculation of Covered Revenues. If a Product or Service utilizing any Methylation-based Technology, whether in whole or in part (including Products or Services of Parent or its
Subsidiaries in existence as of the Closing Date (including TSO500)), is bundled, combined or Sold together with another Product or Service, regardless of whether such other Product or Service utilizes any Methylation-based Technology (including
Products of Parent or its Subsidiaries in existence as of the Closing Date (including TSO500)) for an application in the Field alone and/or also Therapy Selection, such bundled or combined Product or Service shall be deemed included within the Field
and included in its entirety in the calculation of Covered Revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Final Threshold Measuring Period</U>&#148; means the final
Threshold Measuring Period of the Covered Revenues Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Merger</U>&#148; shall have the meaning set forth in the Recitals
of this CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Merger Sub</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Threshold Measuring Period</U>&#148; means the first Threshold Measuring Period of the Covered Revenues Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles in effect from time to time, applied consistently by the
Company in the preparation of its financial statements throughout the periods involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Authority</U>&#148; means
any federal, national, foreign, supranational, state, provincial, county, local or other government, governmental, regulatory or administrative authority, agency, instrumentality or commission or any court, tribunal, or judicial or arbitral body of
competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holder</U>&#148; means a Person in whose name a CVR is registered in the CVR
Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holder Representative</U>&#148; means the Person identified in the preamble of this CVR Agreement, who shall initially
be the representative of the Holders appointed in accordance with Article X of the Merger Agreement, as such representative may be replaced from time to time by the request of the Majority Holders upon such Holders&#146; written notice to the then
current Holder Representative, Parent and Trustee and subject to the prior written consent of Parent (not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Independent Accountant</U>&#148; shall have the meaning set forth in Section&nbsp;6.5(a) of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means all worldwide rights in or to (a)&nbsp;patents and patent applications, including, in each
case, any provisionals, substitutions, divisionals, continuations, continuations-in-part, re-examinations, renewals, extensions, reissues, and equivalents thereof in any jurisdiction, (b)&nbsp;copyrightable works (including copyrights in Software),
whether published or unpublished and copyright registrations, applications for registration, and extensions thereof and (c)&nbsp;trade secrets and other proprietary information, whether or not patentable, including inventions, discoveries,
prototypes and Data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any federal, state, local, national, supranational, foreign or administrative law
(including common law), statute, ordinance, regulation, requirement, rule, code or Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Majority Holders</U>&#148; means, at
the time of determination, Holders (other than Parent and its Affiliates and their respective successors) of at least a majority of the Outstanding CVRs held by Holders (other than Parent and its Affiliates and their respective successors). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Agreement</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Mergers</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Methylation-based Technology</U>&#148; means detection or assessment of methylation status at one or more genomic locations derived
from a Sample by methylation-aware methods, including sequencing-based methods for assessment of methylation status of nucleic acid molecules. Methylation-based Technology includes reagents, protocols and methods for extraction, chemical (including
bisulfite treatment) or enzymatic conversion, DNA library preparation or reagents for use with any methylation-aware method, enrichment kits, panels and/or methods for the enrichment of nucleic acids derived from one or more differentially
methylated genomic regions informative for determining presence of disease or tissue of origin, and analysis software including for example, bioinformatics, pipelines, machine learning, algorithms and classifiers, for determining methylation status
at one or more genomic locations, detecting presence of a disease state, type of disease, disease burden, or disease tissue of origin based on methylation status at one or more genomic regions, and any clinical implications thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Minimal Residual Disease Test</U>&#148; means the Company&#146;s or any of its Subsidiaries&#146; Products utilizing
Methylation-based Technology, whether in whole or in part, including wet lab, software analysis and bioinformatics pipeline, classifier and machine learning and components thereof (including all improvements, future versions, iterations and natural
extensions thereto and thereof) for detection of residual disease in cancer patients following initial diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Minority
Transaction</U>&#148; means any bona fide Disposition of (a)&nbsp;the rights in and to any Applicable Products of Parent and its Subsidiaries that generated less than the Applicable Percentage as of the consummation of such transaction, or
(b)&nbsp;any immaterial non-Product assets, in each case, to any third party. Notwithstanding the foregoing, for purposes of the immediately preceding clause (a), no Disposition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(or series of related Dispositions) of Applicable Products of Parent or its Subsidiaries that would cause
the Applicable Percentage to be less than 10%, or during any period that the Applicable Percentage is less than 10%, shall be a Minority Transaction under such clause (a)&nbsp;if such Disposition would cause the Applicable Percentage to decrease by
5% or more, unless the Holder Representative provides its prior written consent to treat such Disposition as a Minority Transaction. For purposes of clarification, a Minority Transaction shall not include (A)&nbsp;Sales of Products or Services made
by Parent or its wholly owned Subsidiaries or (B)&nbsp;ordinary course licensing arrangements between Parent and its Subsidiaries, on the one hand, and third party licensees, on the other hand, in each case of clauses (A)&nbsp;and (B)&nbsp;in the
ordinary course of business and which are taken into account in the calculation of Net Sales in accordance with the terms of this CVR Agreement. The Disposition of assets that are ancillary to and are not required for the generation of Covered
Revenues (e.g., real property) shall not be a Minority Transaction; <U>provided</U>, <U>however</U>, Covered Products and Services, Data described in the definition of &#147;Sale of Data&#148;, Samples described in clause (d)&nbsp;of the definition
of &#147;Covered Revenues&#148;, and any assets in the Field utilizing Existing IP (and, in each case, any rights therein) and/or any assets that are integral thereto shall not be deemed or considered ancillary for this purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales</U>&#148; means the gross amount invoiced or otherwise charged by Parent and its Subsidiaries for Sales of Covered Products
and Services, less Permitted Deductions to the extent actually taken or incurred and separately accounted for in the invoice with respect to such Sale, in each case, in accordance with standard allocation procedures, allowance methodologies, and
accounting methods consistently applied in accordance with GAAP at the time in question (except as otherwise expressly provided below): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarity, no deductions shall be made for sales commissions. For purposes of calculating Covered Revenue for a Covered Product or Service
in question, a Sale will be deemed to occur upon the Company and/or Parent and/or its Subsidiaries invoicing or otherwise charging the customer for the Covered Product or Service in question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Net Sales shall be calculated as follows under the following circumstances: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Products and Services provided to third parties without charge in connection with (x)&nbsp;research and development or
clinical trials in the ordinary course of business provided without charge (provided that neither Parent nor any of its Subsidiaries provide such Products or Services for the purpose of receiving revenue related or unrelated to the Products or
Services provided (other than Covered Revenues) and Parent and its Subsidiaries act in good faith in connection therewith) (y)&nbsp;compassionate use, humanitarian and charitable donations, or indigent programs or for use as samples (in accordance
with applicable Law) shall be excluded from the computation of Net Sales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Parent&#146;s or its Subsidiary&#146;s Sale
of Covered Products or Services to a wholly owned Subsidiary of Parent shall be excluded from the computation of Net Sales unless such Product or Service (i)&nbsp;is thereafter sold to a third party, <U>provided</U>, <U>however</U>, that in such
event, Net Sales will be calculated on the gross amount invoiced or otherwise charged to such third party on an arm&#146;s-length basis, or (ii)&nbsp;is used or distributed to a wholly owned Subsidiary of Parent in connection with any Plan of Parent
or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) If (i)&nbsp;a Covered Product or Service is Sold in a manner that is not an
arm&#146;s-length transaction, (ii)&nbsp;a Covered Product or Service is provided to a Subsidiary in connection with any Plan of Parent or any Subsidiary of Parent, or (iii)&nbsp;a Covered Product or Service is Sold in-kind or for non-cash
consideration, Net Sales for such Covered Product or Service will equal the average for such Covered Product or Service in the applicable country during the preceding calendar quarter. If there is not sufficient information available to determine
such average Net Sales price, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the Holder Representative and the Parent will negotiate in good faith and mutually agree
upon the Net Sales value, taking into consideration the fair market value of such Covered Product or Service and the Net Sales of similar Covered Products or Services in similar countries (provided that if Parent and the Holder Representative are
unable to agree on such Net Sales value after negotiating in good faith for 30 days, the Parties shall engage a Subject Matter Expert to resolve the dispute in accordance with the procedures set forth in Section&nbsp;6.5(b),<I> mutatis
mutandis</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Officer&#146;s Certificate</U>&#148; means a certificate signed by a duly authorized executive officer of Parent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Opinion of Counsel</U>&#148; means a written opinion of counsel, who may be counsel for Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Order</U>&#148; means any order, judgment, injunction, award, decision, determination, stipulation, ruling, subpoena, writ, decree or
verdict entered by or with any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Other Covered Revenue</U>&#148; means all revenue of Parent and its
Subsidiaries (including the Company) on a consolidated basis recognized in connection with any activities in or directed to the Field, or otherwise to the extent arising from or attributable to the Field, in each case that utilize Existing IP, other
than revenue recognized in connection with Net Sales, which activities include licensing (or granting of similar rights, including option, distribution rights and/or enforcing intellectual property rights) under the intellectual property of Parent
and its Subsidiaries (including the Company) (other than intercompany licenses), collaboration, asset sale, intellectual property enforcement or other activities (including any settlements, awards, penalties, damages or other recoveries), in each
case in or directed to the Field, or otherwise to the extent arising from or attributable to the Field that utilize the Company&#146;s Existing IP. If Parent and its Subsidiaries (including the Company) receive non-cash consideration (including
shares of equity or in-kind contribution of goods or services), or consideration in a transaction that is not at arm&#146;s length (including any transfer of technology or intellectual property rights to an Affiliate, other than a wholly owned
Subsidiary), from any activities in or directed to the Field, or otherwise arising to the extent from or attributable to the Field (other than from or in connection with Net Sales) that utilize the Company&#146;s Existing IP such consideration will
be included in Other Covered Revenue based on the fair market value of such consideration, as determined in good faith by Parent. Notwithstanding the foregoing, Other Covered Revenue shall exclude any consideration received by Parent or its
Subsidiaries in connection with any Minority Transaction (to the extent included in clause (f)&nbsp;of the definition of Covered Revenues), any transaction subject to Section&nbsp;8.1 or any Specified Asset Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Outstanding</U>&#148; when used with respect to CVRs means, as of the date of determination, all CVRs theretofore authenticated,
issued and delivered under this CVR Agreement, except (i)&nbsp;CVRs theretofore cancelled by the Trustee or delivered to the Trustee for cancellation and (ii)&nbsp;CVRs in exchange for or in lieu of which other CVRs have been authenticated and
delivered pursuant to this CVR Agreement, other than any such CVRs in respect of which there shall have been presented to the Trustee proof satisfactory to it that such CVRs are held by a bona fide purchaser in whose hands the CVRs are valid
obligations of Parent; <U>provided</U>, <U>however</U>, that in determining whether the Holders of the requisite Outstanding CVRs have given any request, demand, authorization, direction, consent, waiver or other action hereunder, CVRs owned by
Parent or any Affiliate of Parent (or any successor thereof), whether held as treasury securities or otherwise, shall be disregarded and deemed not to be Outstanding, except that for the purposes of determining whether the Trustee shall be protected
in relying on any such request, demand, authorization, direction, consent, waiver or other action, only CVRs that a Responsible Officer of the Trustee actually knows are so owned shall be so disregarded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent</U>&#148; means the Person (as defined herein) named as Parent in the first paragraph of this CVR Agreement, until a successor
Person shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter Parent shall mean such successor Person. To the extent necessary to comply with the requirements of the provisions of Trust Indenture Act
Sections 310 through 317, inclusive, to the extent that they are applicable to Parent, the term &#147;Parent&#148; shall include any other obligor with respect to the CVRs for the purposes of complying with such provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Request</U>&#148; or &#147;<U>Parent Order</U>&#148; means a written request
or order signed in the name of Parent by a duly authorized officer of Parent, and delivered to the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Party</U>&#148;
means the Trustee, the Holder Representative and Parent, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Paying Agent</U>&#148; means any Person authorized by
Parent to pay the amounts determined pursuant to Section&nbsp;2.2, if any, with respect to any CVRs on behalf of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Payment
Date</U>&#148; means any Covered Revenues Payment Date and any such date as shall be required for any CVR Shortfall payment pursuant to the review procedure set forth in Section&nbsp;6.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Deductions</U>&#148; means the following items, all in accordance with standard allocation procedures, allowance
methodologies and accounting methods consistently applied in accordance with GAAP (except as otherwise provided below): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) credits or
allowances for defects, returns, rejections, recalls or billing corrections; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) reasonable reserves made for uncollectible amounts on
previously sold or distributed Products and Services and deductions for bad debts (which adjustment shall be based on actual bad debts incurred and written off as uncollectible by Parent in a quarter, net of any recoveries of previously written off
bad debts from current or prior quarters); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) separately itemized and invoiced freight, postage, shipping and insurance, handling, and
other transportation costs, <U>provided</U> that such items are passed on to the purchaser (or other acquirer) at cost; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) sales, use,
value added, and other similar Taxes (excluding income Taxes), tariffs, customs duties, surcharges, and other governmental charges levied on the production, Sale, transportation, delivery, use, or performance of any Product or Service (as
applicable) that are incurred at time of the transaction, are directly related to the transaction, and are actually paid to a Governmental Authority; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) any reasonable and customary quantity, cash, rebates, or charge backs; <U>provided</U> that the aggregate deductions under this clause
(e)&nbsp;and clause (a)&nbsp;above shall not exceed, in any calendar year, 5.0% of the gross amount invoiced or otherwise received for the Sale of any Products or Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Transfer</U>&#148; means (a)&nbsp;a transfer by a Holder of all, but not less than all, CVRs held by such Holder to a
single transferee, (b)&nbsp;a transfer by a Holder of any or all of the CVRs held by such Holder to a single transferee, <U>provided</U> that such transfer does not result in such Holder or such transferee holding less than 0.5% of the total number
of CVRs then Outstanding or (c)&nbsp;a transfer as provided in Section&nbsp;2.11 of this CVR Agreement. Notwithstanding any other provision in this CVR Agreement to the contrary, any transfer that results in a number of Holders that would require
the registration of the CVRs as a class of equity securities under the Exchange Act shall be deemed to not be a Permitted Transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, corporation, partnership, limited partnership, limited liability company, syndicate, person (as
defined in Section&nbsp;13(d)(3) of the Exchange Act), trust, association, entity or Governmental Authority. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Pro Rata Portion</U>&#148; means, with respect to a Holder, a fraction, the
numerator of which is the sum of the aggregate number of CVRs that such Holder holds, and, the denominator of which is the total number of CVRs Outstanding, in each case, as of the applicable Payment Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product</U>&#148; means any tangible or intangible item, material, composition, or device, including kits, nucleotides, buffers,
reagents, equipment, instruments, hardware, software, and any component of any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Redemption Eligibility
Date</U>&#148; means the date that at least 90% of the CVRs issued pursuant to the terms of the Merger Agreement either (a) are no longer Outstanding and/or (b)&nbsp;have been repurchased, acquired, redeemed or retired by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Redemption Price</U>&#148; means (i)&nbsp;the fair market value of a CVR as determined by an independent nationally recognized
valuation firm mutually acceptable to Parent and the Holder Representative, the expenses of which will be borne by Parent or (ii)&nbsp;in the event that Holders (other than Parent and its Affiliates and their respective successors) of more than 50%
of Outstanding CVRs accept a tender offer by Parent or any of its Affiliates that is undertaken by Parent or any of its Affiliates in connection with the redemption after the Redemption Eligibility Date, the price accepted in such tender offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; shall have the meaning set forth in Section&nbsp;6.8 of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Responsible Officer</U>&#148; when used with respect to the Trustee means any officer assigned to the Corporate Trust Office and also
means, with respect to any particular corporate trust matter, any other officer of the Trustee to whom such matter is referred because of his or her knowledge of and familiarity with the particular subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Review Request Period</U>&#148; shall have the meaning set forth in Section&nbsp;6.5(a) of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sale of Data</U>&#148; means (i)&nbsp;Sales of a Product or Service accessing Data or databases containing Data, generated, created,
aggregated or collected by the Company or (following the Closing) Parent or any Subsidiary of Parent from activities within the Field and subjecting it to analysis, data mining or similar information technology processes for any purpose to create or
improve such Product or Service for any purpose (including outside the Field) or (ii)&nbsp;Sales of Data or databases containing Data generated, created, aggregated or collected by the Company or (following the Closing) Parent or any Subsidiary of
Parent from activities within the Field to a third party for any purpose (including outside the Field); provided that in each case of (i)&nbsp;and (ii), if any such Data or databases containing such Data is amalgamated with other Data of Parent
wherein 50% or more of the value of such combined Data is derived from the other Data of Parent, then 50% of the Net Sales generated shall be deemed to be &#147;Covered Revenues&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sales</U>&#148; means any sale, distribution, lease, license, provision, performance, making available or exploitation of any Covered
Products or Services (with the terms &#147;Sell&#148; and &#147;Sold&#148; having correlative meanings) (it being understood, for the avoidance of doubt, that a &#147;Sale&#148; shall not include any transaction subject to Section&nbsp;8.1 or a
Minority Transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sample</U>&#148; means a non-tissue biopsy sample including a sample of blood (and any components thereof
including whole blood, blood fraction, plasma, serum, blood mononuclear cells (PBMCs) and white blood cells (WBC)), urine, pleural fluid, pericardial fluid, cerebrospinal fluid, peritoneal fluid, cervical swab, fecal, saliva or any other bodily
fluid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the Securities and Exchange Commission. </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Second Merger</U>&#148; shall have the meaning set forth in the Recitals of this
CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Second Merger Sub</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Services</U>&#148; means any work or service of any kind for use in the Field utilizing any Methylation-based Technology, whether in
whole or in part, and all ancillary, wrap-around or support services that are reasonably related to, provided in connection with or customarily billed together to support such work or services, including services for genotyping, sequencing,
screening, diagnostics and testing (including by using the Galleri multi-cancer early detection test, the DAC diagnostic aid for cancer, or the Minimal Residual Disease Test), Data interpretation, clinical trial, research, collaboration,
development, and software or Data provided as a service, in each case for use in the Field utilizing any Methylation-based Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shortfall Interest Rate</U>&#148; means a rate equal to the prime rate of interest quoted in<I> The Wall Street Journal</I>, or
similar reputable data source, calculated daily on the basis of a 365-day year or, if lower, the highest rate permitted under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shortfall Report</U>&#148; shall have the meaning set forth in Section&nbsp;6.5(b) of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; or &#147;<U>Subsidiaries</U>&#148; of any specified Person means an Affiliate controlled by such Person,
directly or indirectly, through one or more intermediaries, and, for the avoidance of doubt, after the Closing, the Company and its Subsidiaries are Subsidiaries of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Surviving Corporation</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Surviving Entity</U>&#148; shall have the meaning set forth in the Recitals of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means all taxes or similar duties, fees or charges or assessments thereof imposed by any Governmental Authority, in
each case in the nature of a tax, including any interest, penalties and additions imposed with respect to such amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Therapy
Selection</U>&#148; means (i)&nbsp;determining whether, or the probability of whether an individual is likely to respond to a therapy or intervention, (ii)&nbsp;determining whether an individual would likely not respond to therapy or intervention,
(iii)&nbsp;determining the manner in which a specific therapy is applied with respect to dose, frequency, means of administration, or co-administration with another therapy; (iv)&nbsp;determining where administration of a therapeutic treatments is
contraindicated; and/or (v)&nbsp;identification of patients who may be eligible for adjuvant cancer therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Threshold Measuring
Period</U>&#148; means each fiscal year of Parent during the Covered Revenues Term; <U>provided</U> that (i)&nbsp;if the Commencement Date does not fall on the first day of Parent&#146;s fiscal year, the First Threshold Measuring Period shall
commence on the Commencement Date and end on the last day of Parent&#146;s fiscal year during which the Commencement Date falls and (ii)&nbsp;the Final Threshold Measuring Period shall end on the End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Total Equity Count</U>&#148; means, in each case as of immediately prior to the Effective Time, (a)&nbsp;the aggregate number of
shares of Company Class&nbsp;A Common Stock issued and outstanding, including all Class&nbsp;A Restricted Stock Awards; (b)&nbsp;the aggregate number of shares of Company Class&nbsp;A Common Stock issuable upon conversion of all issued and
outstanding shares of Company Class B Common Stock, including all Class B Restricted Stock Awards, and Company Preferred Stock in accordance with the Company&#146;s certificate of incorporation; and (c)&nbsp;except as otherwise included in the
foregoing clause (b), the aggregate number of shares of Company Class&nbsp;A Common Stock issuable in respect of all outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options and other direct or indirect rights to acquire shares of Company Class&nbsp;A Common Stock or securities ultimately convertible into or exchangeable for shares of Company Class&nbsp;A
Common Stock, including all Company RSU Awards and Company Stock Options; provided that, for the avoidance of doubt, any equity securities which may be issuable by the Company pursuant to the terms of the contract disclosed at item 35 of
Section&nbsp;4.09(a) of the Company Disclosure Letter shall not be included in &#147;Total Equity Count&#148; unless such equity securities are issued and outstanding as of immediately prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trust Indenture Act</U>&#148; means the Trust Indenture Act of 1939, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trustee</U>&#148; means the Person named as the &#147;Trustee&#148; in the first paragraph of this CVR Agreement, until a successor
Trustee shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter &#147;Trustee&#148; shall mean such successor Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2. <U>Compliance and Opinions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon any application or request by Parent to the Trustee to take any action under any provision of this CVR Agreement, if requested by the
Trustee, Parent shall furnish to the Trustee (i)&nbsp;an Officer&#146;s Certificate stating that, in the opinion of the signor, all conditions precedent, if any, provided for in this CVR Agreement relating to the proposed action have been complied
with and (ii)&nbsp;an Opinion of Counsel stating, subject to customary exceptions, that in the opinion of such counsel all such conditions precedent, if any, have been complied with, except that, in the case of any such application or request as to
which the furnishing of such documents is specifically required by any provision of this CVR Agreement relating to such particular application or request, no additional certificate or opinion need be furnished. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Every certificate or opinion with respect to compliance with a condition or covenant provided for in this CVR Agreement shall include:
(i)&nbsp;a statement that each individual signing such certificate or opinion has read such covenant or condition and the definitions herein relating thereto; (ii)&nbsp;a brief statement as to the nature and scope of the examination or investigation
upon which the statements or opinions contained in such certificate or opinion are based; (iii)&nbsp;a statement that, in the opinion of each such individual, he or she has made such examination or investigation as is necessary to enable him or her
to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv)&nbsp;a statement as to whether, in the opinion of each such individual, such condition or covenant has been complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3. <U>Form of Documents Delivered to Trustee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In any case where several matters are required to be certified by, or covered by an opinion of, any specified Person, it is not necessary
that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so certified or covered by only one document, but one such Person may certify or give an opinion with respect to some matters and one or more
other such Persons as to other matters, and any such Person may certify or give an opinion as to such matters in one or several documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any certificate or opinion of an officer of Parent may be based, insofar as it relates to legal matters, upon a certificate or opinion of,
or representations by, counsel. Any such certificate or Opinion of Counsel may be based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of Parent stating that the information
with respect to such factual matters is in the possession of Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any certificate, statement or opinion of an officer of Parent or
of counsel may be based, insofar as it relates to accounting matters, upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of Parent. Any certificate or opinion of any independent firm of public
accountants filed with the Trustee shall contain a statement that such firm is independent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Where any Person is required to make, give
or execute two or more applications, requests, consents, certificates, statements, opinions or other instruments under this CVR Agreement, they may, but need not, be consolidated and form one instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4. <U>Acts of Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Any request, demand, authorization, direction, notice, consent, waiver or other action provided by this CVR Agreement to be given or taken
by Holders may be embodied in and evidenced by one or more instruments of substantially similar tenor signed by such Holders in person or by an agent duly appointed in writing; and, except as herein otherwise expressly provided, such action shall
become effective when such instrument or instruments are delivered to the Trustee and, where it is hereby expressly required, to Parent. Such instrument or instruments (and the action embodied therein and evidenced thereby) are herein sometimes
referred to as the &#147;Act&#148; of the Holders signing such instrument or instruments. Proof of execution of any such instrument or of a writing appointing any such agent shall be sufficient for any purpose of this CVR Agreement and (subject to
Section&nbsp;3.1) conclusive in favor of the Trustee and Parent, if made in the manner provided in this Section&nbsp;1.4. Parent may set a record date for purposes of determining the identity of Holders entitled to vote or consent to any action by
vote or consent authorized or permitted under this CVR Agreement. If not previously set by Parent, (i)&nbsp;the record date for determining the Holders entitled to vote at a meeting of the Holders shall be the date preceding the date notice of such
meeting is mailed to the Holders, or if notice is not given, on the day next preceding the day such meeting is held, and (ii)&nbsp;the record date for determining the Holders entitled to consent to any action in writing without a meeting shall be
the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to Parent. If a record date is fixed, those Persons who were Holders of CVRs at such record date (or their duly designated proxies),
and only those Persons, shall be entitled to take such action by vote or consent or, except with respect to clause (d)&nbsp;below, to revoke any vote or consent previously given, whether or not such Persons continue to be Holders after such record
date. No such vote or consent shall be valid or effective for more than 120 days after such record date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The fact and date of the
execution by any Person of any such instrument or writing may be proved in any reasonable manner which the Trustee deems sufficient. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
The ownership of CVRs shall be proved by the CVR Register. Neither Parent nor the Trustee nor any agent of Parent or the Trustee shall be affected by any notice to the contrary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) At any time prior to (but not after) the evidencing to the Trustee, as provided in this Section&nbsp;1.4, of the taking of any action by
the Holders of the CVRs specified in this CVR Agreement in connection with such action, any Holder of a CVR the serial number of which is shown by the evidence to be included among the serial numbers of the CVRs the Holders of which have consented
to such action may, by filing written notice at the Corporate Trust Office and upon proof of holding as provided in this Section&nbsp;1.4, revoke such action so far as concerns such CVR. Any request, demand, authorization, direction, notice,
consent, waiver or other action by the Holder of any CVR shall bind every future Holder of the same CVR or the Holder of every CVR issued upon the registration of transfer thereof or in exchange therefor or in lieu thereof, in respect of anything
done, suffered or omitted to be done by the Trustee, any Paying Agent or Parent in reliance thereon, whether or not notation of such action is made upon such CVR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Holders, including any permitted transferee (in each case by their acceptance of the CVRs hereby), shall be deemed to have acknowledged
the rights and privileges of the Holder Representative set forth in this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5. <U>Notices, etc., to Trustee and Parent</U>. Any request, demand,
authorization, direction, notice, consent, waiver or Act of Holders or other document provided or permitted by this CVR Agreement to be made upon, given or furnished to, or filed with: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Trustee by any Holder or by Parent shall be sufficient for every purpose hereunder if made, given, furnished or filed, in writing, to
or with the Trustee at its Corporate Trust Office; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Parent by the Trustee or by any Holder shall be sufficient for every purpose
hereunder if in writing and mailed, first-class postage prepaid, to Parent addressed to it at 5200 Illumina Way, San Diego, California 92122, or at any other address previously furnished in writing to the Trustee by Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6. <U>Notice to Holders; Waiver</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Where this CVR Agreement provides for notice to Holders of any event, such notice shall be sufficiently given (unless otherwise herein
expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder&#146;s address as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest date,
prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice
with respect to other Holders. Where this CVR Agreement provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and such waiver shall be the equivalent
of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in reliance upon such waiver. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In case by reason of the suspension of regular mail service or by reason of any other cause, it shall be impracticable to mail notice of
any event as required by any provision of this CVR Agreement, then any method of giving such notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7. <U>Conflict with Trust Indenture Act</U>. If any provision hereof limits, qualifies or conflicts with another provision
hereof which is required to be included in this CVR Agreement by any of the provisions of the Trust Indenture Act, such required provision shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8. <U>Effect of Headings and Table of Contents</U>. The Article and Section headings herein and the Table of Contents are for
convenience only and shall not affect the construction hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9. <U>Benefits of Agreement</U>. Nothing in this CVR
Agreement or in the CVRs, express or implied, shall give to any Person (other than the Parties hereto and their successors and permitted assigns and, solely in accordance with the express terms of this CVR Agreement and subject to Sections 1.4,
1.13, 2.2 and 7.6, the Holders) any benefit or any legal or equitable right, remedy or claim under this CVR Agreement or under any covenant or provision herein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.10. <U>Governing Law</U>.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> This CVR Agreement shall be governed by, and
construed in accordance with, the Laws of the State of Delaware, without giving effect to any choice or conflict of Law provisions or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of
any jurisdiction other than the State of Delaware. All litigation, suits, actions or proceedings (collectively, &#147;<U>Actions</U>&#148;) arising out of or relating to this CVR Agreement shall be heard and </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Trustee to confirm Delaware law is acceptable. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">determined exclusively in the Court of Chancery of the State of Delaware and any state appellate court
therefrom within the State of Delaware (or if the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, any state or federal court within the State of Delaware and the appellate court(s) therefrom). Each of Parent,
the Trustee, the Holder Representative and each of the Holders by their acceptance of the CVRs hereby (a)&nbsp;irrevocably submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and any state appellate court
therefrom within the State of Delaware (or if the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, any state or federal court within the State of Delaware and the appellate court(s) therefrom) for the purpose of
any Action arising out of or relating to this CVR Agreement brought by any party hereto, (b)&nbsp;irrevocably waives, and agrees not to assert by way of motion, defense or otherwise, in any such Action, any claim that it is not subject personally to
the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this CVR Agreement may not be
enforced in or by the above named courts, and (c)&nbsp;agrees that such party will not bring any Action arising out of or relating to this CVR Agreement in any court other than the Court of Chancery of the State of Delaware (or if the Court of
Chancery of the State of Delaware does not have subject matter jurisdiction, any state or federal court within the State of Delaware and the appellate court(s) therefrom). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.11. <U>Legal Holidays</U>. In the event that a Payment Date shall not be a Business Day, then (notwithstanding any provision of
this CVR Agreement or the CVRs to the contrary) payment on the CVRs need not be made on such date, but may be made, without the accrual of any interest thereon, on the next succeeding Business Day with the same force and effect as if made on such
Payment Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.12. <U>Separability Clause</U>. In the event any provision in this CVR Agreement or in the CVRs shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.13. <U>No Recourse Against Others</U>. No current or former director, officer or employee, as such, of Parent or the Trustee or
of their respective Affiliates shall have any liability for any obligations of Parent or the Trustee under the CVRs or this CVR Agreement or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a
CVR, each Holder waives and releases all such liability. The waiver and release are part of the consideration for the issue of the CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.14. <U>Counterparts</U>. This CVR Agreement shall be signed in any number of counterparts with the same effect as if the
signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.15. <U>Acceptance of Trust</U>. [&#149;], the Trustee named herein, hereby accepts the trusts in this CVR Agreement declared
and provided, upon the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.16. <U>Termination</U>. This CVR Agreement shall
automatically terminate and be of no further force or effect and shall be deemed satisfied and discharged, and the Parties hereto shall have no liability hereunder (other than with respect to monies due and owing by Parent to the Trustee)
(i)&nbsp;on the expiration of the final Review Request Period following the End Date or (ii)&nbsp;in the event that all of the CVR Certificates not previously cancelled shall have become due and payable pursuant to the terms hereof, in each case,
provided that all disputes with respect to amounts payable to the Holders brought pursuant to the terms and conditions of this CVR Agreement have been resolved, and Parent has paid or caused to be paid or deposited with the Trustee all amounts
payable to the Holders under this CVR Agreement (including any amounts determined in accordance with Section&nbsp;6.5). Notwithstanding the satisfaction and discharge of this CVR Agreement, the obligations of Parent under Section 3.6(c) shall
survive. For the avoidance of doubt, in no event will any Covered Revenues Payment become payable on account of Covered Revenues recognized after the End Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT VALUE RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1. <U>Forms Generally</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs and the Trustee&#146;s certificate of authentication shall be in substantially the forms set forth in Annex A, attached hereto and
incorporated herein by this reference, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this CVR Agreement and may have such letters, numbers or other marks of identification and such
legends or endorsements placed thereon as may be required to comply with the rules of any securities exchange or as may be required by Law or any rule or regulation pursuant thereto, all as may be determined by the officers executing such CVRs, as
evidenced by their execution of the CVRs. Any portion of the text of any CVR may be set forth on the reverse thereof, with an appropriate reference thereto on the face of the CVR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The definitive CVRs shall be typewritten, printed, lithographed or engraved on steel engraved borders or produced by any combination of
these methods or may be produced in any other manner permitted by the rules of any securities exchange on which the CVRs may be listed, all as determined by the officers executing such CVRs, as evidenced by their execution of such CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2. <U>Title and Terms</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs represent the rights of Holders to receive contingent cash payments pursuant to this CVR Agreement. The aggregate number of CVRs
in respect of which CVR Certificates may be authenticated and delivered under this CVR Agreement is limited to a number equal to [&#149;]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>. The initial Holders shall be determined pursuant to the
terms of the Merger Agreement and this CVR Agreement, and a list of the initial Holders shall be furnished to the Trustee by or on behalf of Parent in accordance with Section&nbsp;4.1. From and after the Effective Time, no CVRs shall be issued
except as provided in, and in accordance with the terms and conditions of, the Merger Agreement or as otherwise expressly permitted by this CVR Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The CVRs shall be known and designated as the &#147;Contingent Value Rights&#148; of Parent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in
part, other than through a Permitted Transfer in compliance with applicable United States federal and state securities Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) On or
prior to each Covered Revenues Payment Date, Parent shall pay to the Trustee, by wire transfer to the account designated by the Trustee, the Covered Revenues Payment due, if any, in respect of the Covered Revenues Measuring Period ended immediately
preceding such Covered Revenues Payment Date, and, promptly following such payment, and in any event within five Business Days, the Trustee shall pay each Holder a Pro Rata Portion of such Covered Revenues Payment; <U>provided</U> that Parent may
retain any Covered Revenues Payment due to Parent or any of its Affiliates with respect to any CVRs owned by Parent or such Affiliates. The final such Covered Revenues Measuring Period shall end on the End Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert number of CVRs issued at Closing pursuant to the terms of the Merger Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Holders of the CVRs, by acceptance thereof, agree that no joint venture, partnership
or other fiduciary relationship is created hereby or by the CVRs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Other than in the case of interest on amounts due and payable after
the occurrence of an Event of Default or with respect to any CVR Shortfall, no interest shall accrue on any amounts payable in respect of the CVRs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The rights of the Holders of CVRs are limited to those contractual rights expressed in this CVR Agreement and the CVR Certificate. A Holder
of any CVR or CVR Certificate is not, and shall not, by virtue thereof, be, entitled to any rights of a holder of any other equity security or other ownership interest of Parent or in any constituent company to the Mergers or any of their respective
Affiliates, either at Law or in equity. The CVRs shall not have any voting or dividend rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Except as provided in this CVR
Agreement (including Section&nbsp;6.5), none of Parent or any of its Affiliates shall have any right to set-off any amounts owed or claimed to be owed by any Holder to any of them against such Holder&#146;s CVRs or any Covered Revenues Payment or
other amount payable to such Holder in respect of such CVRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3. <U>Registrable Form</U>. The CVRs shall be issuable only
in registered form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4. <U>Execution, Authentication, Delivery and Dating</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The CVRs shall be executed on behalf of Parent by its chairman of the Board of Directors or its president or any vice president or its
treasurer, but need not be attested. The signature of any of these officers on the CVRs may be manual or facsimile. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) CVRs bearing the
manual or facsimile signatures of individuals who were, at the time of execution, the proper officers of Parent shall bind Parent, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the authentication and
delivery of such CVRs or did not hold such offices at the date of such CVRs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At any time and from time to time after the execution and
delivery of this CVR Agreement, Parent may deliver CVRs executed by Parent to the Trustee for authentication, together with a Parent Order for the authentication and delivery of such CVRs; and the Trustee, in accordance with such Parent Order, shall
authenticate and deliver such CVRs as provided in this CVR Agreement and not otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each CVR shall be dated the date of its
authentication. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) No CVR shall be entitled to any benefit under this CVR Agreement or be valid or obligatory for any purpose unless
there appears on such CVR a certificate of authentication substantially in the form provided for herein duly executed by the Trustee, by manual or facsimile signature of an authorized officer, and such certificate upon any CVR shall be conclusive
evidence, and the only evidence, that such CVR has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5. <U>Temporary CVRs</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Pending the preparation of definitive CVRs, Parent may execute, and upon Parent Order, the Trustee shall authenticate and deliver,
temporary CVRs which are printed, lithographed, typewritten, mimeographed or otherwise produced, substantially of the tenor of the definitive CVRs in lieu of which they are issued and with such appropriate insertions, omissions, substitutions and
other variations as the officers executing such CVRs may determine with the concurrence of the Trustee. Temporary CVRs may contain such reference to any provisions of this CVR Agreement as may be appropriate. Every temporary CVR shall be executed by
Parent and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive CVRs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If temporary CVRs are issued, Parent will cause definitive CVRs to be prepared without
unreasonable delay. After the preparation of definitive CVRs, the temporary CVRs shall be exchangeable for definitive CVRs upon surrender of the temporary CVRs at the office or agency of Parent designated for such purpose pursuant to
Section&nbsp;6.2, without charge to the Holder. Upon surrender for cancellation of any one or more temporary CVRs, Parent shall execute and the Trustee shall authenticate and deliver in exchange therefor a like amount of definitive CVRs. Until so
exchanged, the temporary CVRs shall in all respects be entitled to the same benefits under this CVR Agreement as definitive CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6.<U> Registration, Registration of Transfer and Exchange</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent shall cause to be kept at the office of the Trustee a register (the &#147;<U>CVR Register</U>&#148;) in which, subject to reasonable
regulations as it may prescribe, Parent shall provide for the registration of the CVRs and any Permitted Transfers of CVRs. The Trustee is hereby initially appointed &#147;CVR Registrar&#148; for the purpose of registering the CVRs and any Permitted
Transfers of CVRs as herein provided. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to the restrictions on transferability set forth in Section&nbsp;2.2(c), every request
made to transfer a CVR must be in writing and accompanied by a written instrument of transfer and other requested documentation in form reasonably satisfactory to the Trustee and Parent, duly executed by the Holder thereof, setting forth in
reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice and surrender for registration of transfer of the CVR Certificates, the Trustee shall, subject to its reasonable determination that the transfer
instrument is in proper form, notify Parent that it has received such written notice. Upon receipt of such notice from the Trustee, Parent shall determine, in good faith, whether the transfer otherwise complies with the other terms and conditions of
this CVR Agreement (including the provisions of Section 2.2(c)), and if it determines that it does so comply, Parent shall instruct the Trustee in writing to, and the Trustee shall, upon surrender for registration of transfer of such CVR Certificate
at the Corporate Trust Office, authenticate and deliver, in the name of the designated transferee or transferees, one or more new CVR Certificates representing the same aggregate number of CVRs represented by the CVR Certificate so surrendered that
are to be transferred and Parent shall execute and the Trustee shall authenticate and deliver, in the name of the transferor, one CVR Certificate representing the aggregate number of CVRs represented by such CVR Certificate that are not to be
transferred. If Parent determines in good faith that the proposed transfer does not comply with the other terms and conditions of this CVR Agreement (including the provisions of Section&nbsp;2.2(c)), Parent shall provide the Trustee with written
notice of such determination, which notice shall include, in reasonable detail, the rationale for such determination, including which provisions of this CVR Agreement the proposed transfer does not comply. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At the option of the Holder, CVR Certificates may be exchanged for other CVR Certificates that represent in the aggregate the same number
of CVRs as the CVR Certificates surrendered at the Corporate Trust Office. Every CVR presented or surrendered for exchange shall (if so required by Parent or the Trustee) be duly endorsed, or be accompanied by a written instrument of exchange in
form satisfactory to Parent and the Trustee. Whenever any CVR Certificates are so surrendered for exchange, Parent shall execute, and the Trustee shall authenticate and deliver, the CVR Certificates which the Holder making the exchange is entitled
to receive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Parent and the Trustee may require payment of a sum sufficient to cover any stamp or
other Tax or governmental charge that is imposed in connection with any such registration of transfer or exchange, other than pursuant to Sections 2.7 and 5.6, not involving a transfer. The Trustee shall have no duty or obligation to take any action
under any section of this CVR Agreement that requires the payment of applicable Taxes or governmental charges unless and until the Trustee is satisfied that all such Taxes or governmental charges have been paid or otherwise not due and owing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) All CVRs issued upon any registration of transfer or exchange of CVRs as provided for herein shall be the valid obligations of Parent,
evidencing the same rights, and entitled to the same benefits under this CVR Agreement, as the CVRs surrendered upon such registration of transfer or exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) A Holder may make a written request to the Trustee to change such Holder&#146;s address of record in the CVR Register. The written request
must be duly executed by the Holder. Upon receipt of such written request, the Trustee is hereby authorized to record the change of address in the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.7. <U>Mutilated, Destroyed, Lost and Stolen CVRs</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If (i)&nbsp;any mutilated CVR is surrendered to the Trustee, or (ii)&nbsp;Parent and the Trustee receive evidence to their satisfaction of
the destruction, loss or theft of any CVR, and there is delivered to Parent and the Trustee such security or indemnity as may be required by them to save each of them harmless, then, in the absence of notice to Parent or the Trustee that such CVR
has been acquired by a bona fide purchaser, Parent shall execute and, upon delivery of a Parent Order, the Trustee shall authenticate and deliver, in exchange for any such mutilated CVR or in lieu of any such destroyed, lost or stolen CVR, a new CVR
Certificate of like tenor and amount of CVRs, bearing a number not contemporaneously Outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In case any such mutilated,
destroyed, lost or stolen CVR has become or is to become finally due and payable within 15 days, Parent in its discretion may, instead of issuing a new CVR Certificate, pay to the Holder of such CVR on the applicable Payment Date, as the case may
be, all amounts due and payable with respect thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Every new CVR issued pursuant to this Section&nbsp;2.7 in lieu of any destroyed,
lost or stolen CVR shall constitute an original additional contractual obligation of Parent, whether or not the destroyed, lost or stolen CVR shall be at any time enforceable by anyone, and shall be entitled to all benefits of this CVR Agreement
equally and proportionately with any and all other CVRs duly issued hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The provisions of this Section&nbsp;2.7 are exclusive
and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen CVRs </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.8. <U>Payments with Respect to CVRs</U>. Payment of any amounts with respect to the CVRs shall be made in such coin or currency
of the United States of America as at the time is legal tender for the payment of public and private debts. Parent may, at its option, pay such amounts by wire transfer or check payable in such money. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.9. <U>Persons Deemed Owners</U>. Prior to the time of due presentment for registration of transfer, Parent, the Trustee and any
agent of Parent or the Trustee may treat the Person in whose name any CVR is registered as the owner of such CVR for the purpose of receiving payment on such CVR and for all other purposes whatsoever, whether or not such CVR be overdue, and neither
Parent, the Trustee nor any agent of Parent or the Trustee shall be affected by notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10. <U>Cancellation</U>. All CVRs surrendered for payment, registration of
transfer or exchange shall, if surrendered to any Person other than the Trustee, be delivered to the Trustee and shall be promptly canceled by it. Parent may at any time deliver to the Trustee for cancellation any CVRs previously authenticated and
delivered hereunder which Parent may have acquired in any manner whatsoever, and all CVRs so delivered shall be promptly canceled by the Trustee. No CVRs shall be authenticated in lieu of or in exchange for any CVRs canceled as provided in this
Section&nbsp;2.10, except as expressly permitted by this CVR Agreement. All cancelled CVRs held by the Trustee shall be destroyed and a certificate of destruction shall be issued by the Trustee to Parent, unless otherwise directed by a Parent Order.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.11. <U>Ability to Abandon CVR; Certain Acquisitions</U>. A Holder may at any time, at such Holder&#146;s option, abandon
all of such Holder&#146;s remaining rights in a CVR by transferring such CVR to Parent or any of its Affiliates without consideration therefor. Nothing in this CVR Agreement shall prohibit Parent or any of its Affiliates from offering to acquire or
acquiring any CVRs from the Holders, in private transactions or otherwise, in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.12. <U>CUSIP
Numbers</U>. Parent in issuing the CVRs may use &#147;CUSIP&#148; numbers (if then generally in use), and, if so, the Trustee shall use &#147;CUSIP&#148; numbers in any Call Notice as a convenience to Holders; <U>provided</U> that any such notice
may state that no representation is made as to the correctness of such numbers either as printed on the CVRs or as contained in any Call Notice and that reliance may be placed only on the other identification numbers printed on the CVRs, and such
Call Notice shall not be affected by any defect in or omission of such numbers. Parent shall promptly notify the Trustee in writing of any change in the &#147;CUSIP&#148; numbers. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE TRUSTEE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1. <U>Certain Duties and Responsibilities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) With respect to the Holders, the Trustee, prior to the occurrence of an Event of Default with respect to the CVRs and after the curing or
waiving of all Events of Default which may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this CVR Agreement and no implied covenants shall be read into this CVR Agreement against the Trustee.
In the event that an Event of Default with respect to the CVRs has occurred (which has not been cured or waived), the Trustee shall exercise such of the rights and powers vested in it by this CVR Agreement, and use the same degree of care and skill
in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his or her own affairs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the
absence of bad faith or willful misconduct on its part, prior to the occurrence of an Event of Default and after the curing or waiving of all such Events of Default which may have occurred, the Trustee may conclusively rely, as to the truth of the
statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee which conform to the requirements of this CVR Agreement; but in the case of any such certificates or opinions which by any
provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this CVR Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) No provision of this CVR Agreement shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent
failure to act, or its own bad faith or willful misconduct, except that (i)&nbsp;this subsection (c)&nbsp;shall not be construed to limit the effect of subsections (a)&nbsp;and (b)&nbsp;of this Section&nbsp;3.1; (ii)&nbsp;the Trustee shall not be
liable for any error of judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and (iii)&nbsp;the Trustee shall not be liable with respect to any action
taken or omitted to be taken by it in good faith in accordance with the direction of the Holders pursuant to Section&nbsp;7.9 relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising
any trust or power conferred upon the Trustee, under this CVR Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Whether or not therein expressly so provided, every provision of this CVR Agreement relating to the conduct or affecting the liability of
or affording protection to the Trustee shall be subject to the provisions of this Section&nbsp;3.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2. <U>Certain Rights of Trustee</U>. Subject to the provisions of
Section&nbsp;3.1, including the duty of care that the Trustee is required to exercise upon the occurrence of an Event of Default: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the
Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness
or other paper or document reasonably believed by it to be genuine and to have been signed or presented by the proper party or parties and the Trustee need not investigate any fact or matter stated in the document; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) any request or direction or order of Parent mentioned herein shall be sufficiently evidenced by a Parent Request or Parent Order and any
resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution and the Trustee shall not be liable for any action it takes or omits to take in good faith reliance thereon; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) whenever in the administration of this CVR Agreement the Trustee shall deem it desirable that a matter be proved or established prior to
taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith or willful misconduct on its part, rely upon an Officer&#146;s Certificate and the Trustee
shall not be liable for any action it takes or omits to take in good faith reliance thereon; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the Trustee may consult with counsel and
the written advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such advice or Opinion of
Counsel; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this CVR Agreement at the
request or direction of any of the Holders pursuant to this CVR Agreement, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in compliance
with such request or direction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the Trustee shall not be bound to make any investigation into the facts or matters stated in any
resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document, but the Trustee in its discretion may make such further
inquiry or investigation into such facts or matters as it may see fit, and if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of Parent, personally or by
agent or attorney, as reasonably necessary for such inquiry or investigation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) the Trustee shall not be liable for any action taken, suffered or omitted to be taken by it in good faith and reasonably believed
by it to be authorized or within the discretion or rights or powers conferred upon it by this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3. <U>Notice of Default</U>. If a default occurs hereunder with respect to
the CVRs, the Trustee shall give the Holders notice of any such default actually known to it as and to the extent applicable and provided by the Trust Indenture Act; <U>provided</U>, <U>however</U>, that in the case of any default of the character
specified in Section&nbsp;7.1(b) with respect to the CVRs, no notice to Holders shall be given until at least 30 days after the occurrence thereof. For the purpose of this Section&nbsp;3.3, the term &#147;default&#148; means any event that is, or
after notice or lapse of time or both would become, an Event of Default with respect to the CVRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4. <U>Not Responsible
for Recitals or Issuance of CVRs</U>. The Trustee shall not be accountable for Parent&#146;s use of the CVRs or the proceeds from the CVRs. The recitals contained herein and in the CVRs, except the Trustee&#146;s certificates of authentication,
shall be taken as the statements of Parent, and the Trustee assumes no responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this CVR Agreement or of the CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.5. <U>Money Held in Trust</U>. Money held by the Trustee in trust hereunder need not be segregated from other funds except to
the extent required by Law or as otherwise agreed by the Trustee in writing with Parent. The Trustee shall be under no liability for interest on any money received by it hereunder, except as otherwise agreed by the Trustee in writing with Parent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.6. <U>Compensation and Reimbursement</U>. Parent agrees: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to pay to the Trustee from time to time reasonable compensation for all services rendered by it hereunder in such amount as Parent and the
Trustee shall agree from time to time (which compensation shall not be limited by any provision of Law in regard to the compensation of a Trustee of an express trust); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) except as otherwise expressly provided herein, to reimburse the Trustee upon its request for all reasonable expenses, disbursements and
advances incurred or made by the Trustee in accordance with any provision of this CVR Agreement (including the reasonable compensation and the reasonable expenses and disbursements of its agents and counsel), except any such expense, disbursement or
advance as may be attributable to the Trustee&#146;s negligence, bad faith or willful misconduct; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to indemnify the Trustee and
each of its agents, officers, directors and employees for, and to hold it harmless against, any loss, liability or expense (including attorneys&#146; fees and expenses) incurred without negligence, bad faith or willful misconduct on its part,
arising out of or in connection with the acceptance or administration of this trust and the performance of its duties hereunder, including the reasonable costs and expenses of defending itself against any claim or liability in connection with the
exercise or performance of any of its powers or duties hereunder. Parent&#146;s payment obligations pursuant to this Section&nbsp;3.6 shall survive the termination of this CVR Agreement. If the Trustee incurs expenses after the occurrence of an
Event of Default specified in Sections 7.1(c) or 7.1(d) with respect to Parent, such expenses are intended to constitute administrative expenses under bankruptcy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.7. <U>Disqualification; Conflicting Interests</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If applicable, to the extent that the Trustee or Parent determines that the Trustee has a conflicting interest within the meaning of the
Trust Indenture Act, the Trustee shall immediately notify Parent of such conflict and, within 90 days after ascertaining that it has such conflicting interest, either eliminate such conflicting interest or resign to the extent and in the manner
provided by, and subject to the provisions of, the Trust Indenture Act and this CVR Agreement. Parent shall take prompt steps to have a successor appointed in the manner provided in this CVR Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event the Trustee shall fail to comply with the foregoing subsection 3.7(a), the
Trustee shall, within 10 days of the expiration of such 90-day period, transmit a notice of such failure to the Holders in the manner and to the extent provided in the Trust Indenture Act and this CVR Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In the event the Trustee shall fail to comply with the foregoing subsection 3.7(a) after written request therefore by Parent or any Holder,
any Holder of any CVR who has been a bona fide Holder for at least six months may on behalf of himself or herself and all others similarly situated, petition any court of competent jurisdiction for the removal of such Trustee and the appointment of
a successor Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.8. <U>Corporate Trustee Required; Eligibility</U>. There shall at all times be a Trustee hereunder
which satisfies the applicable requirements of Sections 310(a)(1) and (5)&nbsp;of the Trust Indenture Act and has a combined capital and surplus of at least $150,000,000. If such corporation publishes reports of condition at least annually, pursuant
to Law or to the requirements of a supervising or examining authority, then for the purposes of this Section&nbsp;3.8, the combined capital and surplus of such corporation shall be deemed to be its combined capital and surplus as set forth in its
most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section&nbsp;3.8, it shall resign immediately in the manner and with the effect hereinafter specified in
this Article 3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.9. <U>Resignation and Removal; Appointment of Successor</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to this Article 3 shall become effective until
the acceptance of appointment by the successor Trustee under Section&nbsp;3.10. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Trustee, or any Trustee or Trustees hereafter
appointed, may resign at any time by giving written notice thereof to Parent. If an instrument of acceptance by a successor Trustee shall not have been delivered to the Trustee within 30 days after the giving of such notice of resignation, the
resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor Trustee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Trustee may be
removed at any time by an act of the Majority Holders, delivered to the Trustee and to Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;If at any time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the Trustee shall fail to comply with Section&nbsp;3.7 after written request therefor by Parent or by any Holder who has
been a bona fide Holder of a CVR for at least six months, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the Trustee shall cease to be eligible under
Section&nbsp;3.8 and shall fail to resign after written request therefor by Parent or by any such Holder, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) the
Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or
affairs for the purpose of rehabilitation, conservation or liquidation, then, in any case, (i)&nbsp;Parent, by a Board Resolution, may remove the Trustee, or (ii)&nbsp;the Holder of any CVR who has been a bona fide Holder of a CVR for at least six
months may, on behalf of himself or herself and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy
shall occur in the office of Trustee for any cause, Parent, by a Board Resolution, shall promptly appoint a successor Trustee. If, within one year after any removal by Holders of a majority of the Outstanding CVRs, a successor Trustee shall be
appointed by act of the Majority Holders, as applicable, delivered to Parent and the retiring Trustee, the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment in accordance with Section&nbsp;3.10, become the
successor Trustee and supersede the successor Trustee appointed by Parent. If no successor Trustee shall have been so appointed by Parent or the Holders and accepted appointment within 60 days after the retiring Trustee tenders its resignation or is
removed, the retiring Trustee may, or any Holder who has been a bona fide Holder for at least six months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the appointment of a successor
Trustee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Parent shall give notice of each resignation and each removal of the Trustee and each appointment of a successor Trustee by
mailing written notice of such event by first-class mail, postage prepaid, to the Holders of CVRs as their names and addresses appear in the CVR Register. Each notice shall include the name of the successor Trustee and the address of its Corporate
Trust Office. If Parent fails to send such notice within 10 days after acceptance of appointment by a successor Trustee, it shall not be a default hereunder, but the successor Trustee shall cause the notice to be mailed at the expense of Parent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.10. <U>Acceptance of Appointment of Successor</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Every successor Trustee appointed hereunder shall execute, acknowledge and deliver to Parent and to the retiring Trustee an instrument
accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and
duties of the retiring Trustee; but, upon request of Parent or the successor Trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor Trustee all the rights, powers and
trusts of the retiring Trustee, and shall duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring Trustee hereunder. Upon request of any such successor Trustee, Parent shall execute any and all
instruments for more fully and certainly vesting in and confirming to such successor Trustee all such rights, powers and trusts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No
successor Trustee shall accept its appointment unless at the time of such acceptance such successor Trustee shall be qualified and eligible under this Article 3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.11. <U>Merger, Conversion, Consolidation or Succession to Business</U>. Any corporation into which the Trustee may be merged or
converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all of the corporate trust
business of the Trustee, by sale or otherwise, shall be the successor of the Trustee hereunder; <U>provided</U> such corporation shall be otherwise qualified and eligible under this Article 3, without the execution or filing of any paper or any
further act on the part of any of the Parties hereto. In case any CVRs shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion, sale or consolidation to such authenticating Trustee may
adopt such authentication and deliver the CVRs so authenticated with the same effect as if such successor Trustee had itself authenticated such CVRs; and such certificate shall have the full force which it is anywhere in the CVRs or in this CVR
Agreement provided that the certificate of the Trustee shall have the same; <U>provided</U>, <U>further</U>, that the right to adopt the certificate of authentication of any predecessor Trustee shall apply only to its successor or successors by
merger, conversion or consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.12. <U>Preferential Collection of Claims Against Parent</U>. If and when the Trustee
shall be or shall become a creditor, directly or indirectly, secured or unsecured, of Parent (or any other obligor upon the CVRs), excluding any creditor relationship set forth in Section&nbsp;311(b) of the Trust Indenture Act, if applicable, the
Trustee shall be subject to the applicable provisions of the Trust Indenture Act regarding the collection of claims against Parent (or any such other obligor). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HOLDERS&#146; LISTS AND REPORTS BY THE TRUSTEE AND PARENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1. <U>Parent to Furnish Trustee with Names and Addresses of Holders</U>. Parent will furnish or cause to be furnished to the
Trustee (a)&nbsp;promptly after the issuance of the CVRs, and semi-annually thereafter, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a recent date, and (b)&nbsp;at such times as the
Trustee may request in writing, within 30 days after receipt by Parent of any such request, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a date not more than 15 days prior to the time
such list is furnished; <U>provided</U>, <U>however</U>, that if and so long as the Trustee shall be the CVR Registrar, no such list need be furnished. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2. <U>Preservation of Information; Communications to Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Trustee shall preserve, in as current a form as is reasonably practicable, the names and addresses of Holders contained in the most
recent list furnished to the Trustee as provided in Section&nbsp;4.1 and the names and addresses of Holders received by the Trustee in its capacity as CVR Registrar. The Trustee may destroy any list furnished to it as provided in Section&nbsp;4.1
upon receipt of a new list so furnished. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The rights of the Holders to communicate with other Holders with respect to their rights
under this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as provided by Section&nbsp;312(b)(2) of the Trust Indenture Act, if applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Every Holder of CVRs, by receiving and holding the same, agrees with Parent and the Trustee that neither Parent nor the Trustee shall be
deemed to be in violation of Law or held accountable by reason of the disclosure of any such information as to the names and addresses of the Holders made pursuant to the Trust Indenture Act (if applicable) regardless of the source from which such
information was derived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3. <U>Reports by Trustee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within 60 days after December&nbsp;31 of each year, commencing with the December&nbsp;31 following the date of this CVR Agreement, the
Trustee shall transmit to all Holders such reports concerning the Trustee and its actions under this CVR Agreement as may be required pursuant to the Trust Indenture Act to the extent and in the manner provided pursuant thereto. The Trustee shall
also comply with Section&nbsp;313(b)(2) of the Trust Indenture Act, if applicable. The Trustee shall also transmit by mail all reports as required by Section&nbsp;313(c) of the Trust Indenture Act, if applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) A copy of each such report shall, at the time of such transmission to the Holders, be filed by the Trustee with each stock exchange, if
any, upon which the CVRs are listed, with the SEC and also with Parent. Parent will promptly notify the Trustee when the CVRs are listed on any stock exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4. <U>Reports by Parent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent shall: (i)&nbsp;file with the Trustee, (A)&nbsp;within 15 days after Parent is required to file the same with the SEC, copies of the
annual reports filed on Form 10-K and quarterly reports filed on Form 10-Q and of the information, documents and other reports (or copies of such portions of any of the foregoing as the SEC may from time to time by rules and regulations prescribe)
which Parent is required to file with the SEC pursuant to Section&nbsp;13 or Section 15(d) of the Exchange Act (such annual and quarterly reports and required information, documents and other reports, together the &#147;<U>Exchange Act
Documents</U>&#148;), and (B)&nbsp;if Parent is not required to file Exchange Act Documents under Section&nbsp;13 or 15(d) of the Exchange Act, within 45 days after each calendar quarter of Parent (other than the last quarter of each calendar year),
quarterly financial information and, within 90 days after each calendar year of Parent, annual financial information that would be required pursuant to Section&nbsp;13 of the Exchange Act in respect of a security listed and registered on a national
securities exchange as may be prescribed from time to time in such rules and regulations (<U>provided</U> that Parent also delivers with, or includes within, the annual and quarterly reports referred to in (A)&nbsp;and (B)&nbsp;the amount of Covered
Revenues for the annual or quarterly period to date (as applicable)); (ii)&nbsp;file with the Trustee such additional information, documents and reports with respect to compliance by Parent with the conditions and covenants of this CVR Agreement as
may be required from time to time by the rules and regulations of the SEC; and (iii)&nbsp;make available to the Holders on Parent&#146;s website as of an even date with the filing of such materials with the Trustee, the information, documents and
reports required to be filed by Parent pursuant to subsections (i)&nbsp;and (ii)&nbsp;of this Section&nbsp;4.4(a). If Parent has timely electronically filed with the SEC&#146;s EDGAR system (or any successor system) the reports described above,
Parent shall be deemed to have satisfied the requirements of this Section&nbsp;4.4(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Parent shall file with the Trustee, within 60
days following the end of any Covered Revenues Measuring Period, a Covered Revenues Statement with respect to such Covered Revenues Measuring Period. For the avoidance of doubt, the Covered Revenues Statements shall be treated as Confidential
Information pursuant to Section&nbsp;6.8, and no public filing of such Covered Revenues Statements shall be required pursuant to this Section&nbsp;4.4. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1. <U>Amendments Without Consent of Holders</U>. Without the consent of any Holders, Parent and the Trustee, at any
time and from time to time, may enter into one or more amendments hereto or to the CVRs, for any of the following purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to convey,
transfer, assign, mortgage or pledge to the Trustee, as security for the CVRs, any property or assets; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to evidence the succession of
another Person to Parent, and the assumption by any such successor of the covenants of Parent herein and in the CVRs; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to add to the
covenants of Parent such further covenants, restrictions, conditions or provisions as the Board of Directors and the Trustee shall consider to be for the protection of the Holders, and to make the occurrence, or the occurrence and continuance, of a
default in any such additional covenants, restrictions, conditions or provisions an Event of Default permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as herein set forth; <U>provided</U>, that in
respect of any such additional covenant, restriction, condition or provision, such amendment may provide for a particular period of grace after default (which period may be shorter or longer than that allowed in the case of other defaults) or may
provide for an immediate enforcement upon such an Event of Default or may limit the remedies available to the Trustee upon such an Event of Default or may limit the right of the Majority Holders to waive such an Event of Default; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) to cure any ambiguity, or to correct or supplement any provision herein or in the CVRs which may be defective or inconsistent with any
other provision herein; <U>provided</U> that such provisions shall not materially reduce the benefits of this CVR Agreement or the CVRs to the Holders; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) to make any amendments or changes necessary to comply or maintain compliance with the
Trust Indenture Act, if applicable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) to make any other provisions with respect to matters or questions arising under this CVR
Agreement; <U>provided</U>, that such provisions shall not adversely affect the interests of the Holders; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) to make any change that
does not adversely affect the interests of the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promptly following any amendment of this CVR Agreement or the CVRs in accordance with this
Section&nbsp;5.1, the Trustee shall notify the Holders of the CVRs of such amendment; <U>provided</U> that any failure so to notify the Holders shall not, in itself, affect the validity of such amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2. <U>Amendments with Consent of Holders</U>. With the consent of the Majority Holders, by Act of said Holders delivered to
Parent and the Trustee (including consents obtained in connection with a purchase of, or tender offer or exchange offer for, the CVRs), Parent (when authorized by a Board Resolution) and the Trustee may enter into one or more amendments hereto or to
the CVRs for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this CVR Agreement or to the CVRs or of modifying in any manner the rights of the Holders under this CVR Agreement or to the CVRs;
<U>provided</U>, <U>however</U>, that no such amendment shall, without the consent of the Holder of each Outstanding CVR affected thereby: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) modify in a manner adverse to the Holders any provision contained herein with respect to the termination of this CVR Agreement or the CVRs
or the time for payment and amount of any Covered Revenues Payment, or otherwise extend the time for payment of the CVRs or reduce the amounts payable in respect of the CVRs or modify any other payment term or payment date. Notwithstanding the
foregoing, each Holder of a CVR, by acceptance thereof, including any permitted transferee, consents to the optional redemption provisions set forth in Article 9 hereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) reduce the number of CVRs, the consent of whose Holders is required for any such amendment; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) modify any of the provisions of this Section&nbsp;5.2, except to increase any such percentage or to provide that certain other provisions
of this CVR Agreement cannot be modified or waived without the prior consent of the Holder of each CVR affected thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall not be
necessary for any Act of Holders under this Section&nbsp;5.2 to approve the particular form of any proposed amendment, but it shall be sufficient if such Act shall approve the substance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3. <U>Execution of Amendments</U>. In executing any amendment permitted by this Article 5, the Trustee (subject to
Section&nbsp;3.1) shall be fully protected in relying upon an Opinion of Counsel stating that the execution of such amendment is authorized or permitted by this CVR Agreement. The Trustee shall execute any amendment authorized pursuant to this
Article 5 if the amendment does not adversely affect the Trustee&#146;s own rights, duties or immunities under this CVR Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4. <U>Effect of Amendments; Notice to Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon the execution of any amendment under this Article 5, this CVR Agreement and the CVRs shall be modified in accordance therewith, and
such amendment shall form a part of this CVR Agreement and the CVRs for all purposes, and every Holder of CVRs shall be bound thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the execution by Parent and the Trustee of any amendment pursuant to the
provisions of this Article 5, Parent shall mail a notice thereof by first class mail to the Holders of CVRs at their addresses as they shall appear on the CVR Register, setting forth in general terms the substance of such amendment. Any failure of
Parent to mail such notice, or any defect therein, shall not, in itself, however, in any way impair or affect the validity of any such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5. <U>Conformity with Trust Indenture Act</U>. Every amendment executed pursuant to this Article 5 shall conform to the
applicable requirements of the Trust Indenture Act, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6. <U>Reference in CVRs to Amendments</U>. If an amendment
changes the terms of the CVRs, the Trustee may require the Holders of the CVRs to deliver it to the Trustee. CVRs authenticated and delivered after the execution of any amendment pursuant to this Article 5 may, and shall if required by the Trustee,
bear a notation in form approved by the Trustee as to any matter provided for in such amendment. If Parent shall so determine, new CVRs so modified as to conform, in the opinion of the Trustee and the Board of Directors, to any such amendment may be
prepared and executed by Parent and authenticated and delivered by the Trustee in exchange for Outstanding CVRs. Failure to make the appropriate notation or to issue a new CVR shall not affect the validity of such amendment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1. <U>Payment of Amounts, if any, to Holders</U>. Parent will duly and punctually pay or cause to be paid the amounts,
if any, owed with respect to the CVRs in accordance with the terms of the CVRs and this CVR Agreement. Such amounts shall be considered paid on or prior to the applicable Payment Date if on such date, the Trustee or the Paying Agent holds in
accordance with this CVR Agreement money sufficient to pay all such amounts then due. Each of the Surviving Entity, Parent (or any of its Affiliates), the Trustee and the Paying Agent shall be entitled to deduct and withhold from any amounts
otherwise payable pursuant to this CVR Agreement or the Merger Agreement such amount as it is required to deduct and withhold with respect to the making of such payment under the Code, the rules or regulations promulgated thereunder, any provision
of applicable state, local or foreign Tax Law or any other Law. To the extent that amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for purposes of this CVR Agreement and the Merger Agreement as having been
paid to the Person in respect of which such deduction and withholding was made. The consent of the Holders shall not be required for any such withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2. <U>Maintenance of Office or Agency</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) As long as any of the CVRs remain Outstanding, Parent will maintain in the Borough of Manhattan, the City of New York, an office or agency
(i)&nbsp;where CVRs may be presented or surrendered for payment, (ii)&nbsp;where CVRs may be surrendered for registration of transfer or exchange and (iii)&nbsp;where notices and demands to or upon Parent in respect of the CVRs and this CVR
Agreement may be served. Parent hereby initially designates the Corporate Trust Office as such office or agency of Parent, unless Parent shall hereafter designate and maintain some other office or agency for one or more of such purposes. Parent or
any of its Subsidiaries may act as Paying Agent, registrar or transfer agent; <U>provided</U> that such Person shall take appropriate actions to avoid the commingling of funds. Parent will give prompt written notice to the Trustee of any change in
the location of any such office or agency. If at any time Parent shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and
Parent hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Parent may from time to time designate one or more other offices or agencies (in or
outside of the City of New York) where the CVRs may be presented or surrendered for any or all such purposes, and may from time to time rescind such designation; <U>provided</U>, <U>however</U>, that no such designation or rescission shall in any
manner relieve Parent of its obligation to maintain an office or agency in the Borough of Manhattan, the City of New York for such purposes. Parent will give prompt written notice to the Trustee of any such designation or rescission and any change
in the location of any such office or agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3. <U>Money for Covered Revenues Payments to Be Held in Trust</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If Parent shall at any time act as the Paying Agent, it will, on or before the Payment Date, as the case may be, segregate and hold in
trust for the benefit of the Holders all sums held by such Paying Agent for payment on the CVRs until such sums shall be paid to the Holders as herein provided, and will promptly notify the Trustee of any failure of Parent to make payment on the
CVRs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Whenever Parent shall have one or more Paying Agents for the CVRs, it will, on or before a Payment Date, deposit with a Paying
Agent a sum in same day funds sufficient to pay the amount, if any, so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Parent will cause each Paying Agent other than the Trustee to execute and deliver to the Trustee an instrument in which such Paying Agent
shall agree with the Trustee, subject to the provisions of this Section&nbsp;6.3, that (i)&nbsp;such Paying Agent will hold all sums held by it for the payment of any amount payable on CVRs in trust for the benefit of the Persons entitled thereto
until such sums shall be paid to such Persons or otherwise disposed of as herein provided, and will notify the Trustee of the sums so held, and (ii)&nbsp;that it will give the Trustee notice of any failure by Parent (or by any other obligor on the
CVRs) to make any payment on the CVRs when the same shall be due and payable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Any money deposited with the Trustee or any Paying
Agent, or then held by Parent, in trust for the payment on any CVR and remaining unclaimed for one year after the Payment Date shall be paid to Parent on Parent Request, or (if then held by Parent) shall be discharged from such trust, and the Holder
of such CVR shall thereafter, as an unsecured general creditor, look only to Parent for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money shall thereupon cease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.4. <U>Books and Records</U>. Parent shall keep, and shall cause its Subsidiaries to keep, true, complete and accurate records
in sufficient detail to enable the Holders and their consultants or professional advisors to determine the amounts payable hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.5. <U>Audits</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon the written request of the Holder Representative or the Majority Holders, as the case may be (the &#147;<U>Requesting
Party</U>&#148;), provided to Parent within 120 days following the date on which Parent delivers a Covered Revenues Statement with respect to a Covered Revenues Measuring Period ending upon the last day of any Threshold Measuring Period pursuant to
Section&nbsp;4.4(b) (the &#147;<U>Review Request Period</U>&#148;), Parent shall permit, and shall cause its Subsidiaries to permit, an independent certified public accounting firm of nationally recognized standing selected by the Requesting Party
and Parent (failing agreement on which each shall designate an independent public accounting firm of its own selection, which firms shall in turn appoint an independent public accounting firm for such purpose) (the &#147;<U>Independent
Accountan</U>t&#148;) to have access during normal business hours to such of the records of Parent as may be reasonably necessary to verify the accuracy of any Covered Revenues Statements delivered with respect to the Threshold Measuring Period most
recently ended and the figures underlying the calculations set forth therein for any period within such Threshold Measuring Period, and subject to customary confidentiality provisions (it being understood that such review shall not include any
matter addressed in Section&nbsp;6.5(b) below). Parent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall pay, or cause to be paid, the fees charged by the Independent Accountant; <U>provided</U>, that, in the event that the Independent Accountant determines that the Covered Revenues included
in the Covered Revenues Statements is either at least 95.5% of the Covered Revenues that should have been included in the Covered Revenues Statement or within $10,000,000 of the Covered Revenues that should have been included in the Covered Revenues
Statement, the Holders shall pay, or cause to be paid, the fees charged by such Independent Accountant, which amount Parent may deduct from any future Covered Revenues Payments payable to Holders pursuant to this CVR Agreement. The Independent
Accountant, acting as an expert and not as an arbitrator, shall be charged to come to a final determination as promptly as practicable (and in any event within 30 days) with respect to those specific items in the applicable Covered Revenues
Statement that the Requesting Party and Parent disagree on and submit to it for resolution, and the scope of the disputes to be resolved by the Independent Accountant shall be limited to such specific items. If issues are submitted to the
Independent Accountant for resolution, Parent shall, and shall cause its Subsidiaries to, furnish to the Independent Accountant such access, work papers and other documents and information related to those disputed issues as the Independent
Accountant may request and as are available to Parent and subject to customary confidentiality provisions. The Independent Accountant shall disclose to the Requesting Party the amounts that the Independent Accountant believes to be due and payable
by Parent and details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. The Independent Accountant shall provide Parent with a copy of all disclosures made to the
Requesting Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During the Review Request Period, the Requesting Party may also provide notice in writing to Parent challenging
Parent&#146;s determination that a given activity does not generate Covered Revenue recognized in any Covered Revenues Measuring Period for which any Covered Revenues Statement has been delivered with respect to the Threshold Measuring Period most
recently ended, which notice shall (i)&nbsp;identify in reasonable detail why the Requesting Party believes such activity generated Covered Revenue recognized in such Covered Revenues Measuring Period, including identifying the activity and the
clause of &#147;Covered Revenue&#148; at issue (the &#147;<U>Specified Dispute</U>&#148;), including with respect to challenges regarding Intellectual Property, identifying in reasonable detail the item(s) of Intellectual Property at issue and
alleged infringing items (it being understood that such Specified Dispute shall not include any matter addressed in Section&nbsp;6.5(a) above), and (ii)&nbsp;propose a relevant subject matter expert of nationally recognized standing to be appointed
to resolve the Specified Dispute pursuant to the terms of this Section&nbsp;6.5(b). Within 10 Business Days of the receipt of such notice, Parent shall either accept the appointment of such expert or shall propose in writing to the Requesting Party
a different independent relevant subject matter expert of nationally recognized standing. For the next 15 Business Days thereafter, Parent and the Requesting Party shall discuss the selection of such expert and failing agreement, the experts
proposed by Parent and the Requesting Party shall in turn appoint an independent relevant subject matter expert to resolve such dispute pursuant to the terms of this Section 6.5 (the &#147;<U>Subject Matter Expert</U>&#148;), which expert shall be
selected no later than the end of such 15-Business Day period. Within one month after the appointment of the Subject Matter Expert, each of Parent and the Requesting Party shall submit in writing to the Subject Matter Expert its arguments regarding
the Specified Dispute. The Subject Matter Expert, acting as an expert and not as an arbitrator, shall be charged to come to a final determination with respect to the Specified Dispute as promptly as practicable (and in any event within one month) by
adopting the position of either Parent or the Requesting Party. The Subject Matter Expert shall not be permitted to make any determination other than adopting the position of either Parent or the Requesting Party, and the scope of the disputes to be
resolved by the Subject Matter Expert shall be limited to the Specified Dispute. Parent shall permit, and shall cause its Subsidiaries to permit, the Subject Matter Expert to have access during normal business hours to such of the records of Parent
as may be reasonably necessary to resolve the Specified Dispute, subject to customary confidentiality provisions. Parent shall pay, or cause to be paid, the fees charged by the Subject Matter Expert; provided, that, in the event that the Subject
Matter Expert determines that the Covered Revenues included in the Covered Revenues Statements is either at least 95.5% of the Covered Revenues that should have been included in the Covered Revenues Statement or within $10 million of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Covered Revenues that should have been included in the Covered Revenues Statement, the Holders shall pay, or cause to be paid, the fees charged by such Subject Matter Expert, which amount Parent
may deduct from any future Covered Revenues Payments payable to Holders pursuant to this CVR Agreement. Parent shall, and shall cause its Subsidiaries to, furnish to the Subject Matter Expert such reasonable access, work papers and other documents
and information related to disputed issues as the Subject Matter Expert may request and as are available to Parent, and subject to customary confidentiality provisions. The Subject Matter Expert shall disclose to the Requesting Party only the
amounts that the Subject Matter Expert believes to be due and payable by Parent, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. The Subject Matter Expert
shall provide Parent with a copy of all disclosures made to the Requesting Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the contrary, only one,
and not both, of the Holder Representative or the Majority Holders may provide notice requesting an audit pursuant to Sections 6.5(a) or 6.5(b) during each Review Request Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) All other items in the Covered Revenues Statement that the Requesting Party and Parent do not submit, prior to the end of the Review
Request Period, to the Independent Accountant or to the Subject Matter Expert for resolution shall be deemed to be agreed by the Requesting Party and Parent and neither the Independent Accountant nor the Subject Matter Expert shall be charged with
calculating or validating those agreed upon items. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If the Independent Accountant or Subject Matter Expert concludes that any Covered
Revenues Payment amount should have been greater than the Covered Revenues Payment set forth in an applicable Covered Revenues Statement (the difference being the &#147;<U>CVR Shortfall</U>&#148;), Parent shall pay the CVR Shortfall within 60 days
of the date the Requesting Party deliver to Parent the Independent Accountant&#146;s or Subject Matter Expert&#146;s written report (the &#147;<U>Shortfall Report</U>&#148;); <U>provided</U> that the CVR Shortfall amount shall bear interest at the
Shortfall Interest Rate beginning from 30 days after the date the Requesting Party delivers to Parent the Shortfall Report until payment is made to the Trustee. The decision of such Independent Accountant and Subject Matter Expert shall be final,
conclusive and binding on Parent and the Holders, shall be non-appealable and shall not be subject to further review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If, upon the
expiration of the Review Request Period, neither the Holder Representative nor the Majority Holders have requested a review of the applicable Covered Revenues Statement in accordance with this Section&nbsp;6.5, the calculation of the Covered
Revenues Payment payable with respect to all Covered Revenues Measuring Periods within the applicable Threshold Measuring Period shall be conclusive and binding on each Holder, and Parent shall be released from any liability or accountability with
respect to payments in respect of such Covered Revenues Measuring Periods in excess of such Covered Revenues Payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each Person
seeking to receive information from Parent in connection with a review pursuant to this Section&nbsp;6.5 shall enter into, and shall cause its accounting firm to enter into, a reasonable and mutually satisfactory confidentiality agreement with
Parent or any Subsidiary obligating such party to retain all such financial information disclosed to such party in confidence pursuant to such confidentiality agreement and not use such information for any purpose other than the completion of such
review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Parent shall use, and shall cause its Affiliates to use, its (and their) commercially reasonable efforts to include a
provision in any license or distribution agreement with any third party with respect to any Covered Product or Service that would allow any Independent Accountant appointed pursuant to this Section&nbsp;6.5 such access to the records of the other
party to such license or distribution agreement as may be reasonably necessary to perform its duties pursuant to this Section&nbsp;6.5 provided, that this provision shall not apply if the underlying license agreement with Parent or Affiliates would
not customarily include audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights. The parties hereto agree that, if Parent or its Affiliates have exercised audit rights under any collaboration, license, sublicense or distribution agreement, or any agreement referred to
in the final proviso of the definition of &#147;Covered Revenues Payment&#148;, prior to the Requesting Party&#146;s request for an audit under this Section&nbsp;6.5 and under such collaboration, license, sublicense, distribution or other agreement
Parent and its Affiliates cannot request another audit, the results of Parent&#146;s prior audit of the counterparty shall be used for purposes of the audit requested by the Requesting Party under this Section&nbsp;6.5 and that Parent shall not have
any further obligation to provide access to the Independent Accountant or Subject Matter Expert with respect to such counterparty until such time as Parent may again exercise its rights of audit under the collaboration, license, sublicense,
distribution or other agreement with such counterparty. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each of the Requesting Party and Parent shall bear its own costs and expenses
in connection with the reviews and audits provided for in this Section&nbsp;6.5, except that the fees and expenses of the Independent Accountant and/or the Subject Matter Expert will be borne as provided in Section&nbsp;6.5(a) and
Section&nbsp;6.5(b), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.6. <U>Certain Covenants and Acknowledgements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Covered Revenues Term, Parent shall operate its business and its Subsidiaries&#146; businesses in good faith and shall not take
any action, and shall cause its Subsidiaries not to take any action, for the primary purpose of avoiding or reducing the amount of Covered Revenues Payments payable to the Holders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) So long as any of the CVRs remain Outstanding, Parent shall not enter into any binding agreement, arrangement or understanding, which
would, or would reasonably be expected to, delay or prevent Parent&#146;s ability to timely make any Covered Revenues Payment that becomes due under this CVR Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Parent shall use, and shall cause its Subsidiaries to use, Diligent Efforts to obtain regulatory approval and clearance for the Existing
Products;<U> provided</U>, however, that such obligation to use Diligent Efforts shall terminate upon the earlier of (i)&nbsp;the End Date and (ii)&nbsp;such time as the data generated in an appropriate clinical trial does not support further
development of such Product. Parent shall use, and shall cause its Subsidiaries to use, Diligent Efforts to Sell and commercialize Products of Parent and its Subsidiaries that are included in the definition of Covered Products and Services, in each
case in the Field utilizing any Methylation-based Technology; <U>provided</U>, <U>however</U>, that such obligation to use Diligent Efforts shall terminate upon the End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without limiting the provisions of this Section&nbsp;6.6, each of the Trustee and Holder Representative (by execution of this CVR Agreement) and the Holders
(by their acceptance of the CVRs hereby) shall be deemed to have acknowledged that (i)&nbsp;Parent may make decisions regarding the operation of the businesses of Parent and its Subsidiaries, including the investment and allocation of resources, on
the basis of the strategic objectives of Parent and its Affiliates taking into account any relevant factors (including technical, commercial, legal, scientific and/or medical factors), and that such decisions may adversely affect the amount of
Covered Revenues Payments payable to the Holders, and (ii)&nbsp;it is Parent&#146;s present intention to operate the Company business as a stand-alone division within Parent and Parent may in its discretion develop, package, distribute and sell
products and services separately, in each case of (i)&nbsp;and (ii), so long as such actions taken or not taken do not conflict with or breach the provisions of this CVR Agreement, including this Section&nbsp;6.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.7. <U>Notice of Default</U>. Parent shall file with the Trustee written notice of the occurrence of any Event of Default or
other default under this CVR Agreement within five Business Days of its becoming aware of any such default or Event of Default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.8. <U>Confidentiality</U>. The Trustee, the Holder Representative and the
Holders hereby agree that any confidential or non-public information (including Covered Revenues Statements) they receive from or on behalf of Parent or any Affiliate of Parent, which receipt arises out of the transactions contemplated by this CVR
Agreement (the &#147;<U>Confidential Information</U>&#148;), shall: (a)&nbsp;not be used for any purpose other than for purposes permitted under this CVR Agreement; (b)&nbsp;not be used directly or indirectly in any way that is for competitive
purposes; and (c)&nbsp;not be disclosed by, and be kept confidential by, the Trustee, the Holder Representative and the Holders and its directors, officers, members, managers, employees, affiliates, and agents (collectively,
&#147;<U>Representatives</U>&#148;); <U>provided</U>, <U>however</U>, that any such Confidential Information may be disclosed only to their Representatives (including the Independent Accountant) who (i)&nbsp;need to know such Confidential
Information and (ii)&nbsp;are bound in writing to a non-disclosure agreement no less restrictive than this Section&nbsp;6.8. It is understood that such Representatives shall be informed by the Trustee, the Holder Representative or the applicable
Holder of the confidential nature of such Confidential Information, and that the Trustee, the Holder Representative or such Holder, as applicable, shall be responsible for any disclosure or use made by its Representatives in breach of obligations
under this CVR Agreement to the same extent as if such disclosure or use had been made directly by the Trustee or such Holder, as applicable. Each of the Trustee, the Holder Representative and the Holders will promptly notify Parent of any breach of
this CVR Agreement of which they become aware, and will use reasonable efforts to assist and cooperate with Parent in minimizing the consequences of such breach. &#147;Confidential Information&#148; shall not include any information that is
(A)&nbsp;publicly available other than because of disclosure by the Trustee, the Holder Representative or the Holders or any of their respective Representatives or (B)&nbsp;is lawfully disclosed to the Trustee, the Holder Representative or Holders
by sources (other than Parent or its Affiliates) rightfully in possession of the Confidential Information. If the Trustee, the Holder Representative, the Holders or their respective Representatives are legally required or requested to disclose any
Confidential Information, they will in advance of such disclosure, unless otherwise prohibited by Law, promptly notify Parent of such request or requirement so that Parent may seek to avoid or minimize the required disclosure and/or obtain an
appropriate protective order or other appropriate relief to ensure that any Confidential Information so disclosed is maintained in confidence to the maximum extent possible by the Person receiving the disclosure, or, in Parent&#146;s discretion, to
waive compliance with the provisions of this CVR Agreement. In any such case, the Trustee, the Holder Representative and the Holders agree to cooperate and use reasonable efforts to avoid or minimize the required disclosure and/or obtain such
protective order or other relief. If, in the absence of a protective order or the receipt of a waiver hereunder, the Trustee, the Holder Representative, Holders or their respective Representatives are legally obligated to disclose any Confidential
Information, they will disclose only so much thereof to the party compelling disclosure as they reasonably believe in good faith, on the basis of advice of counsel, is required by Law. The Trustee, the Holder Representative and Holders shall give
Parent prior written notice of the specific Confidential Information that they believe they are required to disclose under such circumstances. All Confidential Information disclosed by or on behalf of Parent or any of its Affiliates shall be, and
shall remain, the property of Parent or such Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.9. <U>Non-Use of Name</U>. None of the Trustee, the Holder
Representative or the Holders shall use the name, trademark, trade name, or logo of Parent, its Affiliates, or their respective employees in any publicity or news release relating to this CVR Agreement or its subject matter, without the prior
express written permission of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REMEDIES OF THE TRUSTEE AND HOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ON EVENT OF DEFAULT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1. <U>Event of Default Defined; Waiver of Default</U>. &#147;<U>Event of Default</U>&#148; with respect to the CVRs, means each
one of the following events which shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of Law or pursuant to any judgment, decree or order
of any court or any order, rule or regulation of any administrative or governmental body): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) default in the payment of all or any part
of any Covered Revenues Payment after a period of 10 Business Days after such Covered Revenues Payment shall become due and payable on a Payment Date or otherwise; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) material default in the performance, or breach in any material respect, of any covenant or warranty of Parent in respect of the CVRs (other
than a covenant or warranty in respect of the CVRs, a default in whose performance or whose breach is elsewhere in this Section&nbsp;7.1 specifically dealt with), and continuance of such default or breach for a period of 90 days after there has been
given, by registered or certified mail, to Parent by the Trustee or to Parent and the Trustee by the Majority Holders, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a &#147;Notice
of Default&#148; hereunder; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) a court having jurisdiction in the premises shall enter a decree or order for relief in respect of
Parent in an involuntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian, Trustee or sequestrator (or similar official) of Parent or for any
substantial part of its property or ordering the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of 90 consecutive days; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Parent shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or
consent to the entry of an order for relief in an involuntary case under any such Law, or consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, Trustee or sequestrator (or similar official) of Parent or
for any substantial part of its property, or make any general assignment for the benefit of creditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where authorization and/or
appearance of each of the Holders is required by applicable Law, if an Event of Default described above occurs and is continuing, then, and in each and every such case, either the Trustee or the Trustee upon the written request of the Majority
Holders by notice in writing to Parent (and to the Trustee if given by the Majority Holders), shall bring suit to protect the rights of the Holders, including to obtain payment for any amounts then due and payable, which amounts shall bear interest
at the Default Interest Rate until payment is made to the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing provisions, however, are subject to the condition that
if, at any time after the Trustee shall have begun such suit, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, Parent shall pay or shall deposit with the Trustee a sum
sufficient to pay all amounts which shall have become due (with interest upon such overdue amount at the Default Interest Rate to the date of such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the
Trustee, its agents, attorneys and counsel, and all other expenses and liabilities incurred and all advances made, by the Trustee, and if any and all Events of Default under this CVR Agreement shall have been cured, waived or otherwise remedied as
provided herein, then and in every such case the Majority Holders, by written notice to Parent and to the Trustee, may waive all defaults with respect to the CVRs, but no such waiver or rescission and annulment shall extend to or shall affect any
subsequent default or shall impair any right consequent thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2. <U>Collection by the Trustee; the Trustee May Prove
Payment Obligations</U>. Parent covenants that in the case default shall be made in the payment of all or any part of the CVRs when the same shall have become due and payable, whether at a Payment Date or otherwise, then upon demand of the Trustee,
Parent will pay to the Trustee for the benefit of the Holders the whole amount that then shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have become due and payable on all CVRs (with interest from the date due and payable to the date of such payment upon the overdue amount at the Default Interest Rate); and in addition thereto,
such further amount as shall be sufficient to cover the costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their respective agents, attorneys and counsel, and any expenses and liabilities
incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence, bad faith or willful misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders by such appropriate judicial
proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this CVR Agreement or in aid of the exercise of any power granted herein, or to enforce
any other remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case Parent shall fail forthwith to pay such amounts upon such demand, the Trustee, in its own name and as Trustee
of an express trust, shall be entitled and empowered to institute any action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceedings to judgment or final decree, and may
enforce any such judgment or final decree against Parent or other obligor upon such CVRs and collect in the manner provided by Law out of the property of Parent or other obligor upon such CVRs, wherever situated, the moneys adjudged or decreed to be
payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any judicial proceedings relative to Parent or other obligor upon the CVRs, irrespective of whether any amount is then due
and payable with respect to the CVRs, the Trustee is authorized: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to file and prove a claim or claims for the whole amount owing and
unpaid in respect of the CVRs, and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for reasonable compensation to the Trustee and each predecessor Trustee, and
their respective agents, attorneys and counsel, and for reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of negligence, bad faith or willful misconduct)
and of the Holders allowed in any judicial proceedings relative to Parent or other obligor upon the CVRs, or to their respective property; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) unless prohibited by, and only to the extent required by, applicable Law, to vote on behalf of the Holders in any election of a Trustee or
a standby Trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or a Person performing similar functions in comparable proceedings; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to collect and receive any moneys or other property payable or deliverable on any such claims, and to distribute all amounts received with
respect to the claims of the Holders and of the Trustee on their behalf; and any Trustee, receiver, or liquidator, custodian or other similar official is hereby authorized by each of the Holders to make payments to the Trustee, and, in the event
that the Trustee shall consent to the making of payments directly to the Holders, to pay to the Trustee such amounts as shall be sufficient to cover reasonable compensation to the Trustee, each predecessor Trustee and their respective agents,
attorneys and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence, bad faith or willful misconduct, and all other amounts due to the
Trustee or any predecessor Trustee pursuant to Section&nbsp;3.6. To the extent that such payment of reasonable compensation, expenses, disbursements, advances and other amounts out of the estate in any such proceedings shall be denied for any
reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, moneys, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation
or under any plan of reorganization or arrangement or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to
or vote for or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the CVRs, or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any
Holder in any such proceeding except, as aforesaid, to vote for the election of a Trustee in bankruptcy or similar person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All rights of
action and of asserting claims under this CVR Agreement, or under any of the CVRs, may be enforced by the Trustee without the possession of any of the CVRs or the production thereof and any trial or other proceedings instituted by the Trustee shall
be brought in its own name as Trustee of an express trust, and any recovery of judgment, subject to the payment of the expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall
be for the ratable benefit of the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any proceedings brought by the Trustee (and also any proceedings involving the
interpretation of any provision of this CVR Agreement to which the Trustee shall be a party) the Trustee shall be held to represent all the Holders, and it shall not be necessary to make any Holders of such CVRs parties to any such proceedings
(unless required by applicable Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3. <U>Application of Proceeds</U>. Any monies collected by the Trustee pursuant to
this Article 7 in respect of any CVRs shall be applied in the following order at the date or dates fixed by the Trustee upon presentation of the several CVRs in respect of which monies have been collected and stamping (or otherwise noting) thereon
the payment in exchange for the presented CVRs if only partially paid or upon surrender thereof if fully paid: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST: To
the payment of costs and expenses in respect of which monies have been collected, including reasonable compensation to the Trustee and Holder Representative and each predecessor Trustee and predecessor Holder Representative, as applicable, and their
respective agents and attorneys and of all expenses and liabilities incurred, and all advances made, by the Trustee and Holder Representative and each predecessor Trustee and predecessor Holder Representative, as applicable, except as a result of
their respective negligence, bad faith or willful misconduct, and all other amounts due to the Trustee and Holder Representative or any predecessor Trustee or predecessor Holder Representative pursuant to Section&nbsp;3.5; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND: To the payment of the whole amount then owing and unpaid upon all the CVRs, with interest at the Default Interest Rate
on all such amounts, and in case such monies shall be insufficient to pay in full the whole amount so due and unpaid upon the CVRs, then to the payment of such amounts without preference or priority of any security over any other CVR, ratably to the
aggregate of such amounts due and payable; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD: To the payment of the remainder, if any, to Parent or any other
Person lawfully entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4. <U>Suits for Enforcement</U>. In case an Event of Default has occurred, has not been
waived and is continuing, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this CVR Agreement by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of
such rights (unless authorization and/or appearance of each of the Holders is required by applicable Law), either at Law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this
CVR Agreement or in aid of the exercise of any power granted in this CVR Agreement or to enforce any other legal or equitable right vested in the Trustee by this CVR Agreement or by Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5. <U>Restoration of Rights on Abandonment of Proceedings</U>. In case the
Trustee or any Holder shall have proceeded to enforce any right under this CVR Agreement and such proceedings shall have been discontinued or abandoned for any reason, or shall have been determined adversely to the Trustee or to such Holder, then
and in every such case Parent and the Trustee and the Holders shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of Parent, the Trustee and the Holders shall continue as though no such
proceedings had been taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6. <U>Limitations on Suits by Holders</U>. Subject to the right of the Holder Representative
and the Majority Holders under Section&nbsp;6.5, no Holder of any CVR shall have any right by virtue or by availing itself of any provision of this CVR Agreement to institute any Action at law or in equity or in bankruptcy or otherwise upon or under
or with respect to this CVR Agreement, or for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy hereunder, unless (a)&nbsp;such Holder previously shall have given to the Trustee written
notice of default and of the continuance thereof, as hereinbefore provided; (b)&nbsp;the Majority Holders shall have made written request upon the Trustee to institute such action or proceedings in its own name as Trustee hereunder and shall have
offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby; and (c)&nbsp;the Trustee for 15 days after its receipt of the latter of such notice, request and offer
of indemnity shall have failed to institute any such action or proceeding and no direction inconsistent with such written request shall have been given to the Trustee pursuant to Section&nbsp;7.9. For the protection and enforcement of the provisions
of this Section&nbsp;7.6, each and every Holder and the Trustee shall be entitled to such relief as can be given either at Law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7. <U>Unconditional Right of Holders to Institute Certain Suits</U>. Notwithstanding any other provision in this CVR Agreement
and any provision of any CVR, the right of any Holder of any CVR to receive payment of the amounts payable in respect of such CVR on or after the respective due dates expressed in such CVR, or to institute suit for the enforcement of any such
payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.8.
<U>Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as provided in Section&nbsp;7.6, no right or
remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every other right
and remedy given hereunder or now or hereafter existing at Law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate
right or remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No delay or omission of the Trustee or of any Holder to exercise any right or power accruing upon any Event of
Default occurring and continuing as aforesaid shall impair any such right or power or shall be construed to be a waiver of any such Event of Default or an acquiescence therein; and, subject to Section&nbsp;7.6, every power and remedy given by this
CVR Agreement or by Law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.9. <U>Control by Holders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Majority Holders shall have the right to direct the time, method, and place of conducting any proceeding for any remedy available to
the Trustee, or exercising any power conferred on the Trustee with respect to the CVRs by this CVR Agreement; <U>provided</U> that such direction shall not be otherwise than in accordance with Law and the provisions of this CVR Agreement; and
<U>provided</U>, <U>further</U>, that (subject to the provisions of Section&nbsp;3.1) the Trustee shall have the right to decline to follow any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
direction if (i)&nbsp;the Trustee, being advised by counsel, shall determine that the action or proceeding so directed may not lawfully be taken or if the Trustee in good faith by its board of
directors, the executive committee, (ii)&nbsp;a committee of directors or Responsible Officers of the Trustee shall determine that the action or proceedings so directed would involve the Trustee in personal liability or (iii)&nbsp;the Trustee in
good faith shall so determine that the actions or forbearances specified in or pursuant to such direction would be unduly prejudicial to the interests of Holders not joining in the giving of said direction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Nothing in this CVR Agreement shall impair the right of the Trustee in its discretion to take any action deemed proper by the Trustee and
which is not inconsistent with such direction or directions by Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10. <U>Waiver of Past Defaults</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the case of a default or an Event of Default specified in clause (b), (c)&nbsp;or (d)&nbsp;of Section&nbsp;7.1, the Majority Holders may
waive any such default or Event of Default, and its consequences except a default in respect of a covenant or provisions hereof which cannot be modified or amended without the consent of the Holder of each CVR affected. In the case of any such
waiver, Parent, the Trustee and the Holders shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair any right consequent thereon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Upon any such waiver, such default shall cease to exist and be deemed to have been cured and not to have occurred, and any Event of Default
arising therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this CVR Agreement; but no such waiver shall extend to any subsequent or other default or Event of Default or impair any right consequent thereon.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11. <U>The Trustee to Give Notice of Default, But May Withhold in Certain Circumstances</U>. The Trustee shall transmit to
the Holders, as the names and addresses of such Holders appear on the CVR Register (as provided under Section&nbsp;313(c) of the Trust Indenture Act, if applicable), notice by mail of all defaults which have occurred and are known to the Trustee,
such notice to be transmitted within 90 days after the occurrence thereof, unless such defaults shall have been cured before the giving of such notice (the term &#147;default&#148; for the purposes of this Section 7.11 being hereby defined to mean
any event or condition which is, or with notice or lapse of time or both would become, an Event of Default); <U>provided</U> that, except in the case of default in the payment of the amounts payable in respect of any of the CVRs, the Trustee shall
be protected in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of directors or Trustees and/or Responsible Officers of the Trustee in good faith determines that the withholding of such
notice is in the interests of the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12. <U>Right of Court to Require Filing of Undertaking to Pay Costs</U>. All
Parties to this CVR Agreement agree, and each Holder of any CVR by his or her acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this CVR
Agreement or in any suit against the Trustee for any action taken, suffered or omitted by it as the Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion
assess reasonable costs, including attorneys&#146; fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section&nbsp;7.12
shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder or group of Holders holding in the aggregate more than 10% of the CVRs Outstanding or to any suit instituted by any Holder for the enforcement of the payment
of any CVR on or after the due date expressed in such CVR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATION, MERGER, SALE OR CONVEYANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1. <U>Parent May Consolidate, etc., on Certain Terms</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Parent shall not merge or consolidate with or into any other Person, or sell or convey all of its assets to any Person (other than a wholly
owned Subsidiary of Parent), unless (i)&nbsp;Parent shall be the continuing Person, or the successor Person or the Person which acquires by sale or conveyance all the assets of Parent (including the shares of the Company), Parent shall be a Person
organized under the Laws of the United States of America or any State thereof and shall expressly assume by an instrument supplemental hereto, executed and delivered to the Trustee, in form satisfactory to the Trustee, the due and punctual payment
of the CVRs, according to their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this CVR Agreement to be performed or observed by Parent and (ii)&nbsp;Parent, or such successor Person, as the case
may be, shall not, immediately after such merger or consolidation, or such sale or conveyance, be in default in the performance of any such covenant or condition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise provided in Section&nbsp;8.1(a) or in a Minority Transaction, Parent and its Subsidiaries shall not consummate a
Disposition of their respective rights in and to Applicable Products to any third party (including the sale of substantially all, but not all, the assets of Parent), except in a bona fide transaction and unless Parent obtains the agreement of the
transferee to (i)&nbsp;(x)&nbsp;at all times after any such Disposition, include such Applicable Products (or Services or other assets and rights included in such Disposition, if applicable) in the calculation of Covered Revenues, in accordance with
the terms hereunder (with the transferee substituted for Parent as necessary) as if such transferee was Parent and (y)&nbsp;include in the contract for such Disposition appropriate provisions for such treatment and a requirement that the transferee
comply with the covenants in this Section&nbsp;8.1(b) to the same extent as Parent, and (ii)&nbsp;adjust the dollar amounts set forth in the definition of &#147;Covered Revenues Payment&#148; as agreed upon by Parent and the Holder Representative as
a result of such transaction to apportion such thresholds between the portion of the business retained by Parent and its Subsidiaries and the portion of the business attributable to the Applicable Products (and Services and such other assets and
rights, if applicable) acquired by the transferee (which apportionment shall be based on the relative percentage of projected Covered Revenues transferred and the percentage of projected Covered Revenues retained for the period from the closing of
the transaction to the End Date) (any transaction in which the transferee agrees to such inclusions, a &#147;<U>Specified Asset Sale</U>&#148;). For purposes of clarification, this Section&nbsp;8.1(b) will not apply to (A)&nbsp;Sales of Products or
Services made by Parent or its wholly owned Subsidiaries or (B)&nbsp;ordinary course licensing arrangements between Parent and its Subsidiaries, on the one hand, and third party licensees, on the other hand, in each case of clauses (A)&nbsp;and
(B)&nbsp;in the ordinary course of business and which are taken into account in the calculation of Net Sales in accordance with the terms of this CVR Agreement. If any transaction covered by this Section&nbsp;8.1(b) also involves the Disposition of
assets or other rights other than Applicable Products, any commercial arrangement between Parent or any of its Affiliates, on the one hand, and the acquirer or any Affiliate of the acquirer on the other hand, or any other consideration paid or
deemed paid by Parent to the transferee in such Disposition, then the Consideration allocated to the Applicable Products, assets or other rights included in Covered Revenues shall be calculated based on their actual value in proportion to the
aggregate value of such Applicable Products, assets or other rights taking into account the value of all components of such transaction (the &#147;<U>Appropriate Allocation</U>&#148;). If a Product or Service that was a Bundled Product or Service
ceases to be a Bundled Product or Service, then effective as of the date on which such Product or Service ceases to be a Bundled Product or Service, it will not be an Applicable Product for purposes of this Section&nbsp;8.1(b) for so long as it is
not a Bundled Product or Service and does not and would not generate Covered Revenues on a standalone basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except as otherwise provided in Section&nbsp;8.1(a), Section&nbsp;8.1(b), this
Section&nbsp;8.1(c) or in a Minority Transaction, Parent and its Subsidiaries shall not consummate a Disposition of their respective assets or rights in and to the business of Parent and its Subsidiaries that generate Covered Revenues to any third
party without the prior written consent of the Majority Holders or the Holder Representative, such consent not to be unreasonably withheld, conditioned or delayed. Section&nbsp;8.1(b) and this Section&nbsp;8.1(c) shall not apply with respect to the
Disposition of assets that are ancillary to and are not required for the generation of Covered Revenues (e.g., real property); <U>provided</U>, <U>however</U>, Covered Products and Services, Data described in the definition of &#147;Sale of
Data&#148;, Samples described in clause (d)&nbsp;of the definition of &#147;Covered Revenues&#148;, and any assets in the Field utilizing Existing IP (and, in each case, any rights therein) and/or any assets that are integral thereto, shall not be
deemed or considered ancillary for this purpose and shall be covered by Section&nbsp;8.1(b) and the first sentence of this Section&nbsp;8.1(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the event Parent and Holder Representative are unable to agree on any matters that are the subject of Section&nbsp;8.1(b) (including
(i)&nbsp;whether a given transaction is a &#147;Minority Transaction&#148;, (ii)&nbsp;whether a particular transaction is subject to Section&nbsp;8.1(b), (iii)&nbsp;whether the proceeds of any particular transaction constitute Covered Revenues
(including any Appropriate Allocation, as applicable) or (iv)&nbsp;the applicable adjustments described in Section&nbsp;8.1(b)(ii)), within 30 days of notice from one party to the other, either Parent or Holder Representative may provide written
notice to the other of its (x)&nbsp;election to have such disagreement resolved by a Subject Matter Expert and (y)&nbsp;its proposal of the applicable Subject Matter Expert. Within 10 Business Days of the receipt of such notice, the receiving party
shall either accept the proposal of such Subject Matter Expert or shall propose in writing to the other party a Subject Matter Expert. For the next 15 Business Days thereafter, Parent and the Holder Representative shall discuss the selection of such
expert and failing agreement, the experts proposed by Parent and the Holder Representative shall in turn appoint an independent relevant Subject Matter Expert to resolve such dispute, which expert shall be selected no later than the end of such
15-Business Day period. Within one month after the appointment of the Subject Matter Expert, each of Parent and the Holder Representative shall submit in writing to the Subject Matter Expert its arguments for such disputed matter(s). The Subject
Matter Expert, acting as an expert and not as an arbitrator, shall be charged to come to a final determination with respect to the proposed adjustment as promptly as practicable (and in any event within one month) by adopting the position of either
Parent or the Holder Representative. The Subject Matter Expert shall not be permitted to make any determination other than adopting the position of either Parent or the Holder Representative, and the scope of the disputes to be resolved by the
Subject Matter Expert shall be limited to the disputed matter(s). Parent shall permit, and shall cause its Subsidiaries to permit, the Subject Matter Expert to have access during normal business hours to such of the records of Parent as may be
reasonably necessary to resolve the disputed matter(s). The person whose position was not adopted by the Subject Matter Expert shall pay, or cause to be paid, the fees charged by the Subject Matter Expert. Parent shall, and shall cause its
Subsidiaries to, furnish to the Subject Matter Expert such access, work papers and other documents and information related to the adjustment dispute as the Subject Matter Expert may request and as are available to Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2. <U>Successor Person Substituted</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In case of any such consolidation, merger, sale or conveyance, and following such an assumption by the successor Person in accordance with
the terms of this CVR Agreement, Parent shall be discharged from all obligations and covenants under this CVR Agreement solely with respect to the business and assets transferred in such bona fide consolidation, merger, sale or conveyance, but, for
the avoidance of doubt, Parent will remain bound by all obligations and covenants with respect to any business or assets retained by Parent or its Subsidiaries that generate Covered Revenues, and such successor Person shall succeed to and be
substituted for Parent with the same effect as if it had been named herein (it being understood, for the avoidance of doubt, that the calculations of Covered Revenues and Net Sales shall not include any revenue or Sales of any Affiliates of the
successor Person other than the revenue and Sales of the business and assets of Parent and its Subsidiaries). Such successor Person may cause to be signed, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may issue either in its own name or in the name of Parent prior to such succession any or all of the CVRs issuable hereunder which theretofore shall not have been signed by Parent and delivered
to the Trustee, and, upon the order of such successor corporation instead of Parent and subject to all the terms, conditions and limitations in this CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any CVRs which previously
shall have been signed and delivered to the Trustee for authentication, and any CVRs which such successor corporation thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the CVRs so issued shall in all respects
have the same legal rank and benefit under this CVR Agreement as the CVRs theretofore or thereafter issued in accordance with the terms of this CVR Agreement as though all of such CVRs had been issued at the date of the execution hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In case of any such consolidation, merger, sale or conveyance, such changes in phraseology and form (but not in substance) may be made in
the CVRs thereafter to be issued as may be appropriate. The successor entity to such consolidation, merger, sale or conveyance may satisfy the obligations of Section&nbsp;4.4(a)(i)(A) and (B)&nbsp;of this CVR Agreement by providing copies of such
successor entity&#146;s Exchange Act Documents in the case of Section&nbsp;4.4(a)(i)(A) or such successor entity&#146;s financial information in the case of Section&nbsp;4.4(a)(i)(B). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In the event of any such sale, transfer or conveyance (other than a conveyance by way of lease) Parent or any Person which shall
theretofore have become such in the manner described in this Article 8 shall be discharged from all obligations and covenants under this CVR Agreement and the CVRs and may be liquidated and dissolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3. <U>Opinion of Counsel to the Trustee</U>. The Trustee, subject to the provisions of Sections 3.1 and 3.2, shall receive an
Officer&#146;s Certificate and Opinion of Counsel, prepared in accordance with Sections 1.3 and 1.4, as conclusive evidence that any such consolidation, merger, sale or conveyance, and any such assumption, and any such liquidation or dissolution,
complies with the applicable provisions of this CVR Agreement, and if a supplemental agreement is required in connection with such transaction, such supplemental agreement complies with this Article 8 and that there has been compliance with all
conditions precedent herein provided for or relating to such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4. <U>Successors</U>. All covenants, provisions
and agreements in this CVR Agreement by or for the benefit of Parent, the Trustee, the Holder Representative or the Holders shall bind and inure to the benefit of their respective permitted successors, assigns, heirs and personal representatives,
whether so expressed or not. Parent may assign this CVR Agreement without the prior written consent of the other Parties to this CVR Agreement to one or more of its direct or indirect Subsidiaries; <U>provided</U>, <U>however</U>, that in the event
of any such assignment Parent shall remain subject to its obligations and covenants hereunder, including, but not limited to, its obligation to make any Covered Revenues Payments. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REDEMPTION
OF SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1. <U>Notice to Trustee</U>. If Parent elects to redeem CVRs pursuant to the optional redemption
provisions of Section&nbsp;9.5 hereof, it shall furnish to the Trustee, at least 45 days (unless a shorter period shall be agreed to by the Trustee) but not more than 60 days before a redemption date (but in any event prior to the notice provided
pursuant to Section&nbsp;9.2 hereof), an Officer&#146;s Certificate setting forth (i)&nbsp;the clause of this CVR Agreement pursuant to which the redemption shall occur, (ii)&nbsp;the redemption date, (iii)&nbsp;the amount of CVRs to be redeemed and
(iv)&nbsp;the Redemption Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2. <U>Notice of Redemption</U>. At least 30 days but not more than 60 days
before a redemption date, Parent shall mail or cause to be mailed, by first-class mail, a notice of redemption to each Holder whose CVRs are to be redeemed at its registered address. The notice (the &#147;<U>Call Notice</U>&#148;) shall identify the
amount of CVRs to be redeemed and shall state: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the redemption date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;the Redemption Price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the name and address of the paying agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) that CVRs called for redemption must be surrendered to the Paying Agent to collect the Redemption Price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) that, unless Parent defaults in making such redemption payment, all right title and interest in and to the CVRs and any Covered Revenues
Payment or any other amounts due under this CVR Agreement, if any, on CVRs called for redemption ceases to accrue on and after the redemption date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the clause of this CVR Agreement pursuant to which the CVRs called for redemption are being redeemed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN number, if any, listed in such notice or printed on
the CVRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Parent&#146;s request, the Trustee shall give the notice of redemption in Parent&#146;s name and at its expense; <U>provided</U>,
<U>however</U>, that Parent shall have delivered to the Trustee at least 45 days (unless a shorter period shall be agreed to by the Trustee) but not more than 60 days prior to the redemption date, an Officer&#146;s Certificate requesting that the
Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.3. <U>Effect of Notice of Redemption</U>. Once notice of redemption is mailed in accordance with Section&nbsp;9.2 hereof, CVRs
called for redemption shall become irrevocably due and payable on the redemption date at the Redemption Price. A notice of redemption shall be deemed to be given when mailed, whether or not the Holder receives the notice. In any event, failure to
give such notice, or any defect in such notice, shall not affect the validity of the proceedings for the redemption of the CVRs held by Holders to whom such notice was properly given. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.4. <U>Deposit of Redemption Price</U>. On or one Business Day prior to the redemption date, Parent shall deposit with the
Trustee or with the Paying Agent (if different from the Trustee) money sufficient to pay the Redemption Price of all CVRs to be redeemed on that date. The Trustee or the paying agent shall promptly return to Parent any money deposited with the
Trustee or the paying agent by Parent in excess of the amounts necessary to pay the Redemption Price of all CVRs to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Parent complies with
the provisions of the preceding paragraph, on and after the redemption or purchase date, as applicable, all right title and interest of a Holder to any Covered Revenues Payment, if any, shall cease to accrue on the CVRs called for redemption or
subject to purchase. If any CVR called for redemption or subject to purchase shall not be so paid upon surrender for redemption or purchase because of the failure of Parent to comply with the preceding paragraph, interest shall be paid on the unpaid
redemption price from the redemption date or purchase date, as applicable, until such redemption price is paid at the Default Interest Rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.5. <U>Optional Redemption by Parent</U>. Parent may, at any time on and after the Redemption Eligibility Date, redeem all (but
not less than all) of the outstanding CVRs at the Redemption Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HOLDER REPRESENTATIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.1. <U>Authority and Rights of the Holder Representative; Limitations on Liability</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Holder Representative shall have such powers and authority as are necessary to carry out the functions, on behalf of the Holders,
assigned to it under this CVR Agreement; <U>provided</U>, <U>however</U>, that the Holder Representative shall have no obligation to act, except as expressly provided herein. Without limiting the generality of the foregoing, each Holder agrees that
the Holder Representative has full power, authority and discretion, on behalf of each Holder and his, her or its successors and assigns, to (a)&nbsp;interpret the terms and provisions of this CVR Agreement and the documents to be executed and
delivered by the Holders in connection herewith, (b)&nbsp;execute and deliver and receive deliveries of all agreements, certificates, statements, notices, approvals, extensions, waivers, undertakings, amendments and other documents required or
permitted to be given by it under this CVR Agreement, (c)&nbsp;receive service of process in connection with any claims under this CVR Agreement or any document or agreement contemplated to be executed or delivered in connection with this CVR
Agreement, (d)&nbsp;agree to, negotiate and enter into settlements and compromises of, and assume the defense of, claims, and demand arbitration and comply with Orders and awards of arbitrators with respect to such claims, and take all actions
necessary or appropriate in the judgement of the Holder Representative for the accomplishment of the foregoing (e)&nbsp;give and receive notices and communications as provided under this CVR Agreement and (f)&nbsp;take all actions necessary or
appropriate in the judgment of the Holder Representative on behalf of the Holders in carrying out the provisions of this CVR Agreement applicable to the Holders. All actions taken by the Holder Representative under this CVR Agreement shall be
binding upon the Holders and their successors as if expressly confirmed and ratified in writing by each of them. The Holder Representative shall, in its capacity as such, have no liability to any Holder with respect to actions taken or omitted to be
taken in their capacity as the Holder Representative, except that the Holder Representative will be liable for its willful misconduct or actual fraud, as finally determined by a court of competent jurisdiction from which no further appeal may be
taken. The Holder Representative shall at all times be entitled to rely on any directions received from the Majority Holders; <U>provided</U>, <U>however</U>, that the Holder Representative shall not be required to follow any such direction, and
shall be under no obligation to take any action in its capacity as the Holder Representative, unless the Holder Representative has been provided with other funds, security or indemnities which, in the sole determination of the Holder Representative,
are sufficient to protect the Holder Representative against the costs, expenses and liabilities which may be incurred by the Holder Representative in responding to such direction or taking such action. At no cost to Parent, the Company or the
Trustee, the Holder Representative shall be entitled to engage such counsel, experts and other agents and consultants as it shall deem necessary in connection with exercising its powers and performing its function hereunder and the Holders
(including any permitted transferees) agree by their acceptance of the CVRs that the Holder Representative shall be entitled to (in the absence of bad faith on the part of the Holder Representative) conclusively rely on the opinions and advice of
such Persons. The Holder Representative shall be entitled to reimbursement for all reasonable expenses incurred or reasonably estimated to be incurred, disbursements and advances (including fees and disbursements of their counsel, experts and other
agents and consultants) incurred by the Holder Representative in such capacity, and in the event of an Event of Default, and upon notice to the Trustee, such reimbursement shall be paid to the Holder Representative in accordance with
Section&nbsp;7.3 (it being understood that none of Parent, the Company or their respective Affiliates shall be responsible for such reimbursement). The Holder Representative shall be entitled to indemnification from the Holders against any loss,
liability or expenses arising out of actions taken or omitted to be taken in its capacity as the Holder Representative (except for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">those arising out of the Holder Representative&#146;s gross negligence or willful misconduct), including the
costs and expenses of investigation and defense of claims. Parent and the Company shall be able to rely conclusively (without liability) on any instructions given and actions taken by the Holder Representative as the instruction and decision of each
Holder in all matters applicable to the Holder referred to herein. No Holder shall have any cause of action against Parent, the Company or the Trustee for any action taken by Parent, the Company or the Trustee in reliance upon the written
instructions or decisions of the Holder Representative, or otherwise on account of payments or distributions made by or on behalf of Parent or the Trustee in accordance with the instructions of the Holder Representative. Each Holder by accepting the
CVR, including any permitted transferee, acknowledges and agrees to the terms and conditions of this Section&nbsp;10.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Notwithstanding anything to the contrary herein, any action that may be taken by the Holder Representative (including the making of any consents or other agreements) under this CVR Agreement may instead by taken by the Majority Holders and in such
case Parent shall be entitled to conclusively rely on the agreement or consent of the Majority Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally
left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed,
all as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ILLUMINA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;],</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as the
Trustee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;],</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">as the Holder
Representative</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CVR MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR IN ANY OTHER MANNER TRANSFERRED OR DISPOSED OF, IN WHOLE OR IN PART,
OTHER THAN THROUGH A &#147;PERMITTED TRANSFER&#148; (AS DEFINED IN THE CVR AGREEMENT REFERRED TO HEREIN) IN COMPLIANCE WITH THE TERMS OF THE CVR CERTIFICATE AND APPLICABLE UNITED STATES FEDERAL AND STATE SECURITIES LAWS. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ILLUMINA, INC. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Certificate for</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Contingent Value Rights</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This certifies that
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, or registered assigns (the &#147;Holder&#148;), is the registered holder of the number of Contingent Value Rights (&#147;<U>CVRs</U>&#148;) set
forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in the CVR Agreement referred to on the reverse hereof, to payments from Illumina, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), in an amounts and
in the forms determined pursuant to the provisions set forth on the reverse hereof and as more fully described in the CVR Agreement referred to on the reverse hereof. Such payments shall be made on a Payment Date, as defined in the CVR Agreement
referred to on the reverse hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment of any amounts pursuant to this CVR Certificate shall be made only to the registered Holder
(as defined in the CVR Agreement) of this CVR Certificate. Such payment shall be made in the Borough of Manhattan, The City of New York, or at any other office or agency maintained by Parent for such purpose, in such coin or currency of the United
States of America as at the time is legal tender for the payment of public and private debts; <U>provided</U>, <U>however</U>, Parent may pay such amounts by wire transfer or check payable in such money. [TRUSTEE] has been initially appointed as
Paying Agent at its office or agency in the Borough of Manhattan, The City of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further
provisions of this CVR Certificate set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been duly executed by the Trustee referred to on the reverse hereof by manual signature,
this CVR Certificate shall not be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS
WHEREOF, Parent has caused this instrument to be duly executed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#149;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Attest:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Authorized Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Form of Reverse of CVR Certificate] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. This CVR Certificate is issued under and in accordance with the Contingent Value Rights Agreement, dated as of [&#149;] (the &#147;<U>CVR
Agreement</U>&#148;), among Parent and [&#149;], a national banking association, as trustee (the &#147;<U>Trustee</U>,&#148; which term includes any successor Trustee under the CVR Agreement), and [&#149;], a [&#149;], as Holder Representative (the
&#147;<U>Holder Representative</U>&#148;), and is subject to the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder of this CVR Certificate consents by acceptance hereof. The CVR Agreement is hereby
incorporated herein by reference and made a part hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective rights, limitations of rights, duties, obligations and immunities thereunder of Parent, the Trustee and the
Holders of the CVRs. All capitalized terms used in this CVR Certificate without definition shall have the respective meanings ascribed to them in the CVR Agreement. Copies of the CVR Agreement can be obtained by contacting the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. On each Covered Revenues Payment Date, Parent shall pay to the Holder hereof, for each CVR represented hereby, a Pro Rata Portion of the
Covered Revenues Payment, if any, with respect to the Covered Revenues Measuring Period ended immediately prior to such Covered Revenues Payment Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. In the event of any conflict between this CVR Certificate and the CVR Agreement, the CVR Agreement shall govern and prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Each Covered Revenues Payment, if any, and interest thereon, if any, shall be payable by Parent in such coin or currency of the United
States of America as at the time is legal tender for the payment of public and private debts; provided, however, Parent may pay such amounts by its check or wire transfer payable in such money. [TRUSTEE] has been initially appointed as Paying Agent
at its office or agency in the Borough of Manhattan, The City of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Except where authorization and/or appearance of each of the
Holders is required by applicable Law, if an Event of Default described above occurs and is continuing, then, and in each and every such case, either the Trustee or the Trustee upon the written request of the Majority Holders by notice in writing to
Parent (and to the Trustee if given by the Majority Holders), shall bring suit to protect the rights of the Holders, including to obtain payment for any amounts then due and payable, which amounts shall bear interest at the Default Interest Rate
until payment is made to the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. The CVRs may not be sold, assigned, transferred, pledged, encumbered or in any other manner
transferred or disposed of, in whole or in part, other than through a Permitted Transfer in compliance with the terms of the CVR Agreement and applicable United States federal and state securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. As provided in the CVR Agreement and subject to certain limitations therein set forth, every request made to transfer a CVR must be in
writing and accompanied by a written instrument of transfer and other requested documentation in form reasonably satisfactory to the Trustee and Parent, duly executed by the Holder thereof, and setting forth in reasonable detail the circumstances
relating to the transfer. Upon receipt of such written notice and surrender for registration of transfer of the CVR Certificates, the Trustee shall, subject to its reasonable determination that the transfer instrument is in proper form, notify
Parent that it has received such written notice. Upon receipt of such notice from the Trustee, Parent shall determine whether the transfer otherwise complies with the other terms and conditions of the CVR Agreement (including the provisions of
Section&nbsp;2.2(c) of the CVR Agreement), and if it determines that it does so comply, Parent shall instruct the Trustee in writing to, and the Trustee shall, upon surrender for registration of transfer of such CVR Certificate at the Corporate
Trust Office, authenticate and deliver, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the name of the designated transferee or transferees, one or more new CVR Certificates representing the same aggregate number of CVRs represented by the CVR Certificate so surrendered that are
to be transferred and Parent shall execute and the Trustee shall authenticate and deliver, in the name of the transferor, one new CVR Certificate representing the aggregate number of CVRs represented by such CVR Certificate that are not to be
transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. At the option of the Holder, CVR Certificates may be exchanged for other CVR Certificates that represent in the aggregate
the same number of CVRs as the CVR Certificates surrendered at the Corporate Trust Office. Every CVR presented or surrendered for exchange shall (if so required by Parent or the Trustee) be duly endorsed, or be accompanied by a written instrument of
exchange in form satisfactory to Parent and the Trustee. Whenever any CVR Certificates are so surrendered for exchange, Parent shall execute, and the Trustee shall authenticate and deliver, the CVR Certificates which the Holder making the exchange
is entitled to receive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Parent and the Trustee may require payment of a sum sufficient to cover any stamp or other Tax or charge that
is imposed in connection with any such registration of transfer or exchange as provided for in Sections 2.6(b) and 2.6(c) of the CVR Agreement and described in clauses (7)&nbsp;and (8)&nbsp;above. The Trustee shall have no duty or obligation to take
any action under any section of the CVR Agreement that requires the payment of applicable Taxes or charges unless and until the Trustee is satisfied that all such Taxes or charges have been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. All CVRs issued upon any registration of transfer or exchange of CVRs as provided for in the CVR Agreement shall be the valid obligations
of Parent, evidencing the same rights, and entitled to the same benefits under the CVR Agreement, as the CVRs surrendered upon such registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. Neither Parent nor the Trustee has any duty or obligation to the holder of this CVR Certificate, except as expressly set forth herein or
in the CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Redemption</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Notice to Trustee</U>. If Parent elects to redeem CVRs pursuant to the optional redemption provisions of Section&nbsp;9.5 of the CVR
Agreement, it shall furnish to the Trustee, at least forty five (45)&nbsp;days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60)&nbsp;days before a redemption date (but in any event prior to the notice provided
pursuant to Section&nbsp;9.2 of the CVR Agreement), an Officer&#146;s Certificate setting forth (i)&nbsp;the clause of the CVR Agreement pursuant to which the redemption shall occur, (ii)&nbsp;the redemption date, (iii)&nbsp;the amount of CVRs to be
redeemed and (iv)&nbsp;the redemption price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notice of Redemption. At least thirty (30)&nbsp;days but not more than sixty
(60)&nbsp;days before a redemption date, Parent shall mail or cause to be mailed, by first-class mail, a notice of redemption to each Holder whose CVRs are to be redeemed at its registered address. The notice shall identify the amount of CVRs to be
redeemed and shall state: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the redemption date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;the redemption price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the name and address of the paying agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) that CVRs called for redemption must be surrendered to the Paying Agent to collect the redemption price; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) that, unless Parent defaults in making such redemption payment, all
right title and interest in and to the CVRs and any Covered Revenues Payment or any other amounts due under this CVR Agreement, if any, on CVRs called for redemption ceases to accrue on and after the redemption date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) the clause of this CVR Agreement pursuant to which the CVRs called for redemption are being redeemed; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN number, if any, listed in such
notice or printed on the CVRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Parent&#146;s request, the Trustee shall give the notice of redemption in Parent&#146;s name and at its expense;
<U>provided</U>, <U>however</U>, that Parent shall have delivered to the Trustee at least forty five (45)&nbsp;days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60)&nbsp;days prior to the redemption date, an
Officer&#146;s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Effect of Notice of Redemption</U>. Once notice of redemption is mailed in accordance with Section&nbsp;9.2 of the CVR Agreement, CVRs
called for redemption shall become irrevocably due and payable on the redemption date at the redemption price. A notice of redemption shall be deemed to be given when mailed, whether or not the Holder receives the notice. In any event, failure to
give such notice, or any defect in such notice, shall not affect the validity of the proceedings for the redemption of the CVRs held by Holders to whom such notice was properly given. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Deposit of Redemption Price</U>. On or one (1)&nbsp;Business Day prior to the redemption date, Parent shall deposit with the Trustee or
with the Paying Agent (if different from the Trustee) money sufficient to pay the redemption price of all CVRs to be redeemed on that date. The Trustee or the paying agent shall promptly return to Parent any money deposited with the Trustee or the
paying agent by Parent in excess of the amounts necessary to pay the redemption price of all CVRs to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Parent complies with the provisions
of the preceding paragraph, on and after the redemption or purchase date, as applicable, all right title and interest of a Holder to any Covered Revenues Payment, if any, shall cease to accrue on the CVRs called for redemption or subject to
purchase. If any CVR called for redemption or subject to purchase shall not be so paid upon surrender for redemption or purchase because of the failure of Parent to comply with the preceding paragraph, interest shall be paid on the unpaid redemption
price from the redemption date or purchase date, as applicable, until such redemption price is paid at the Default Interest Rate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
<U>Optional Redemption by Parent</U>. Parent may, at any time on and after the Redemption Eligibility Date, redeem all (but not less than all) of the outstanding CVRs at a cash redemption price equal to the Redemption Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. The Holders, including any permitted transferee, (by their acceptance of this CVR hereby) shall be deemed to have acknowledged the rights
and privileges of the Holder Representative set forth in the CVR Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRUSTEE&#146;S CERTIFICATE OF AUTHENTICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is one of the CVR Certificates referred to in the within-mentioned CVR Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">[&#149;],</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Signatory</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Conditions for Reporting Intended Tax Treatment </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of Parent and the Company has provided to Tax Counsel representations and warranties that the parties
agree are customarily provided in connection with an opinion that a transaction is more likely than not to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(A) of the Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Share Consideration Percentage is equal to or greater than 40%. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Exhibit D: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Consideration
Percentage</U>&#148; means the fraction, expressed as a percentage, the numerator of which is the Total Share Consideration and the denominator of which is the Total Consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Total Share Consideration</U>&#148; means the Parent-owned Stock Consideration Value<I> plus</I> the Shareholder-owned Stock Consideration Value.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Total Consideration</U>&#148; means (i)&nbsp;the Total Share Consideration,<I> plus</I> (ii)&nbsp;the number of CVRs issued pursuant to
Section&nbsp;2.04(a) in respect of Shareholder-owned Company Stock times the CVR Value,<I> plus</I> (iii)&nbsp;the aggregate Cash Consideration issued pursuant to Section&nbsp;2.04(a) in respect of Shareholder-Owned Company Stock,<I> plus</I>
(iv)&nbsp;the value of Alternative Consideration (other than the Parent Common Stock, if any, included in the Alternative Consideration) issued pursuant to Section&nbsp;2.04(a) in respect of Shareholder-owned Company Stock,<I> plus</I> (v)&nbsp;the
number of Parent-owned New Stock<I> multiplied by</I> the Deemed Company Stock Value,<I> plus</I> (vi)&nbsp;the number of Appraisal Shares<I> multiplied by</I> the Deemed Company Stock Value,<I> plus</I> (vii)&nbsp;the aggregate amount of the
Continuation Payments made pursuant to Section&nbsp;9.04. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Outstanding Company Stock</U>&#148; means the Company Stock issued and outstanding
immediately prior to the Effective Time (other than any shares of Company Stock to be canceled or converted pursuant to Section&nbsp;2.04(c)).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent-owned Company Stock</U>&#148; means the Company Stock owned by Parent immediately prior to the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent-owned New Stock</U>&#148; means 11,746,280 shares of Company Series D Preferred Stock purchased by Parent from the Company on April&nbsp;17,
2020, and owned by Parent immediately prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent-owned Old Stock</U>&#148; means the Parent-owned Company Stock other
than the Parent-owned New Stock. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This term is intended to exclude any shares of Company Stock owned or deemed to be owned or received by any
person by reason of holding any Company Equity Award. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Shareholder-owned Company Stock</U>&#148; means the Outstanding Company Stock other than the
Parent-owned Company Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent-owned Stock Consideration Value</U>&#148; means the number of shares of Parent-owned Old Stock<I> multiplied
by</I> the Deemed Company Stock Value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Shareholder-owned Stock Consideration Value</U>&#148; means (i)&nbsp;the aggregate number of shares of
Parent Common Stock issued pursuant to Section 2.04(a) (including shares of Parent Stock, if any, issued as Alternative Consideration) in respect of Shareholder-owned Company Stock, without regard to Section&nbsp;3.02(e),<I> multiplied by</I>
(ii)&nbsp;the Parent Stock Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Deemed Company Stock Value</U>&#148; means the value of the Cash&nbsp;&amp; Stock Consideration (valuing
Parent Common Stock at the Parent Stock Price), without regard to Section&nbsp;3.02(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR Value</U>&#148; means the fair market value of a CVR
as of the Closing Date, as determined by Parent for purposes of Parent&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Stock Price</U>&#148; means the
average of the volume weighted averages of the trading prices of Parent Common Stock on the NASDAQ (as reported by Bloomberg L.P. or, if not reported therein, in another authoritative source mutually selected by the parties) on the Closing Date
(rounded to four decimal places). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Counsel</U>&#148; means Cravath, Swaine&nbsp;&amp; Moore LLP or any other nationally recognized law firm
or accounting firm retained by Parent. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT E </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[GRAIL LETTERHEAD] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2020
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF EXERCISE OF THE DRAG-ALONG RIGHT</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PURSUANT TO SECTION 2 OF THE</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AMENDED AND RESTATED VOTING AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice is hereby given to stockholders of GRAIL, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) that at a meeting held on September&nbsp;20,
2020, the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), including both Preferred Directors (as defined in the certificate of incorporation of the Company), approved and declared advisable the entry by the Company into an
Agreement and Plan of Merger (the &#147;<U>Merger Agreement</U>&#148;) with Illumina, Inc. (&#147;<U>Illumina</U>&#148;), a Delaware corporation, SDG Ops, Inc. (&#147;<U>First Merger Sub</U>&#148;), a Delaware corporation and a wholly owned
subsidiary of Illumina, and SDG Ops, LLC (&#147;<U>Second Merger Sub</U>&#148;), a Delaware limited liability company and wholly owned subsidiary of Illumina, pursuant to which, subject to the satisfaction or waiver of certain conditions, First
Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation (the &#147;<U>Surviving Corporation</U>&#148;) and as a wholly owned subsidiary of Illumina (the &#147;<U>First Merger</U>&#148;), and
immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Corporation will merge with and into Second Merger Sub, with Second Merger Sub continuing as the surviving entity and as a wholly
owned subsidiary of Illumina (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the &#147;<U>Mergers</U>&#148;). All of the members of the Board who were present at the meeting voted in favor of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with such approval, the Board approved the transactions contemplated by the Merger Agreement (the &#147;<U>Transactions</U>&#148;), including
the Mergers, as a &#147;Sale of the Company&#148; pursuant to Section&nbsp;2.2 of the Amended and Restated Voting Agreement dated as of November&nbsp;27, 2019 (as amended, the &#147;<U>Voting Agreement</U>&#148;), by and among the Company and
certain stockholders of the Company party thereto, and specified that Section 2 of the Voting Agreement shall apply to the Transactions, including the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the execution and delivery of the Merger Agreement by the Company, certain stockholders of the Company (such holders, the &#147;<U>Selling
Investors</U>&#148;), collectively owning a majority of the shares of Class&nbsp;A Common Stock of the Company then issuable or previously issued upon conversion of the shares of Preferred Stock (as defined in the Company&#146;s certificate of
incorporation), approved in writing (a)&nbsp;the Merger Agreement and the Transactions, including the Mergers, for purposes of Section&nbsp;2.2(ii) of the Voting Agreement, (b)&nbsp;the Transactions, including the Mergers, as a &#147;Sale of the
Company&#148; pursuant to Section&nbsp;2.2 of the Voting Agreement and the application of Section&nbsp;2 of the Voting Agreement to the Transactions, including the Mergers, and (c)&nbsp;the appointment of Illumina as the Selling Investors&#146;
designee to hold and have the sole power to exercise the proxy and power of attorney contemplated by Section&nbsp;3.2 of the Voting Agreement in connection with the Transactions, including the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter constitutes notice in accordance with Section&nbsp;6.7 of the Voting Agreement that, as of [&#149;], 2020, the conditions specified in
Section&nbsp;2 of the Voting Agreement have been satisfied and Section&nbsp;2 applies to the Transactions, including the Mergers. All parties to the Voting Agreement are obligated thereunder to, among other things, (i)&nbsp;vote all shares of
capital stock of the Company held by such party in favor of, and to adopt, the Transactions, including the Mergers, and in opposition to any and all other proposals that could delay or impair the ability of the Company to consummate the
Transactions, including the Mergers, (ii)&nbsp;execute and deliver all related documentation and take such other action in support of the Transactions, including the Mergers, as shall reasonably be requested by the Company or the Selling Investors
to carry out the terms and provision of Section&nbsp;2 of the Voting Agreement and (iii)&nbsp;refrain from exercising any dissenters&#146; rights or rights of appraisal under applicable law in connection with the Transactions, including the Mergers.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Please be advised that the Company intends to request stockholders&#146; adoption of the Merger Agreement
and approval of the Transactions, including the Mergers, by consent. A Consent Solicitation Statement containing further details will be provided to stockholders at a later date. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#149;]</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McDonald Hopkins LLC, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">300 N. LaSalle St., Ste. 1400, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago, IL 60654 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jordan H. Koss </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jkoss@mcdonaldhopkins.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proskauer Rose LLP, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One International Place, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Ori Solomon </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">osolomon@proskauer.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1900 University Avenue, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">East Palo Alto, CA 94303 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jason Freedman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jason.freedman@ropesgray.com]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included for all Investors listed on Schedule A to the Voting Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT F </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SUPPORT AGREEMENT</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUPPORT AGREEMENT (hereinafter referred to as this &#147;<U>Agreement</U>&#148;), dated as of [&#149;], among Illumina, Inc., a Delaware
corporation (&#147;<U>Parent</U>&#148;) and the undersigned stockholder (the &#147;<U>Stockholder</U>&#148;) of GRAIL, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company, Parent, SDG Ops, Inc., a Delaware corporation and wholly owned subsidiary of Parent (&#147;<U>First Merger
Sub</U>&#148;), and SDG Ops, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (&#147;<U>Second Merger Sub</U>&#148;), have entered into an Agreement and Plan of Merger dated as of September&nbsp;20, 2020 (as it may be
amended from time to time, the &#147;<U>Merger Agreement</U>&#148;), which provides for, among other things, the merger of First Merger Sub with and into the Company, with the Company continuing as the surviving corporation (the &#147;<U>Surviving
Corporation</U>&#148;), and immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Corporation will merge with and into Second Merger Sub, with Second Merger Sub being the surviving
company of the Second Merger (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the &#147;<U>Mergers</U>&#148;), and pursuant to which all shares of Company Stock issued and outstanding immediately prior to the Effective Time
(other than as provided in Section&nbsp;2.04(c) of the Merger Agreement and Appraisal Shares) will be converted into the right to receive the Merger Consideration; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Stockholder Beneficially Owns and is entitled to vote (or direct the voting of) the number of shares of Company Stock set forth
on Schedule 1(b) attached hereto; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent desires that the Stockholder agree, and the Stockholder is willing to agree, on the
terms and subject to the conditions set forth herein, (i)&nbsp;to not Transfer (as defined below) the Covered Shares (as defined below), and (ii)&nbsp;to vote or consent with respect to all of the Covered Shares in a manner so as to facilitate the
consummation of the Mergers and the other Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, and of the representations,
warranties, covenants and agreements contained herein, and intending to be legally bound hereby, the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Certain Definitions</U>. Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following
respective meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Beneficially Own</U>&#148; means, with respect to any securities, (i)&nbsp;having &#147;beneficial
ownership&#148; of such securities for purposes of Rule 13d-3 or 13d-5 under the Exchange Act (or any successor statute or regulation) or (ii)&nbsp;having the right to become the Beneficial Owner of such securities (whether such right is exercisable
immediately or only after the passage of time or the occurrence of conditions) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, rights, warrants or options, or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Covered Shares</U>&#148; means (i)&nbsp;all shares of Company Stock set forth
opposite the Stockholder&#146;s name on Schedule 1(b) attached hereto and (ii)&nbsp;all shares of Company Stock that the Stockholder comes to Beneficially Own during the period from the date of this Agreement through the Expiration Date, together
with any voting securities or instruments of the Company, or other securities or interests exercisable for or convertible into shares of Company Stock or voting securities or instruments of the Company, that the Stockholder comes to Beneficially Own
during the period from the date of this Agreement through the Expiration Date (including by way of bonus issue, share dividend or distribution, subdivision, reclassification, recapitalization, consolidation, exchange, readjustment or other similar
transaction or other change in the capital structure of the Company). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Expiration Date</U>&#148; means the earlier to occur of
(i)&nbsp;the Effective Time and (ii)&nbsp;the termination of the Merger Agreement in accordance with its terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
&#147;<U>Transfer</U>&#148; means that the Stockholder sells, pledges, Encumbers, exchanges, assigns, grants an option with respect to, transfers, tenders or otherwise disposes of its Beneficial Ownership of Covered Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Agreement Not to Transfer or Encumber</U>. The Stockholder hereby agrees that, from the date hereof until the Expiration Date, it shall
not Transfer any Covered Shares, cause the conversion of any Covered Shares or deposit any Covered Shares into a voting trust or enter into any tender, voting or other agreement or arrangement with any Person with respect to any Covered Shares or
grant a proxy or power of attorney with respect thereto (other than pursuant to this Agreement) or give instructions with respect to the voting of the Covered Shares in any manner that is inconsistent with this Agreement or otherwise take any other
action with respect to the Covered Shares that would in any way restrict, limit or interfere with the performance by the Stockholder of its obligations hereunder or the transactions contemplated hereby, including the execution and delivery of the
Written Consent approving the adoption of the Merger Agreement and approving the Transactions; <U>provided</U>, however, that the Stockholder may Transfer all or any portion of the Shares to one or more of its controlled Affiliates or a family
member that, prior to such Transfer, executes and delivers to the Parent a written agreement, in form and substance reasonably acceptable to Parent, to assume all of the Stockholder&#146;s obligations hereunder and to be bound by the terms of this
Agreement to the same extent as the Stockholder is bound hereunder and to make each of the representations and warranties hereunder in respect of the Covered Shares transferred as the Stockholder shall have made hereunder. Notwithstanding the
foregoing, following the receipt of the Company Stockholder Approvals, a Stockholder may cause the conversion of any shares of Company Class B Common Stock into shares of Company Class&nbsp;A Common Stock in accordance with the Company&#146;s
certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Agreement to Consent and Approve</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Stockholder hereby agrees to refrain from modifying or amending in any manner, or waiving compliance of, the Voting Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Stockholder hereby irrevocably and unconditionally agrees, promptly after the Registration Statement (which shall include the Consent
Solicitation Statement) is declared effective by the SEC (and in any event within five Business Days after notification thereof to the Stockholder), to execute and deliver, or cause to be executed and delivered, a written consent substantially in
the form attached hereto as <U>Exhibit A</U> (the &#147;<U>Written Consent</U>&#148;) approving the adoption of the Merger Agreement and approving the Transactions, including the Mergers, with respect to all of the Stockholder&#146;s Covered Shares.
The Stockholder&#146;s execution and delivery of the Written Consent shall be carried out in accordance with the DGCL and the organizational documents of the Company, so as to ensure that it is duly counted for purposes of recording the results of
such consent. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Stockholder hereby irrevocably and unconditionally agrees that, from the date hereof
until the Expiration Date, it shall vote or cause to be voted (including by written consent) all of the Stockholder&#146;s Covered Shares (i)&nbsp;in favor of (A)&nbsp;the adoption of the Merger Agreement and the approval of the Transactions and
(B)&nbsp;any amendment to the Company&#146;s certificate of incorporation or Investor Agreements to the extent contemplated in Section&nbsp;9.04 of the Merger Agreement and otherwise as is reasonably necessary to permit to, or assist the Company in,
complying with its obligations under Section&nbsp;9.04 of the Merger Agreement and (ii)&nbsp;against (A)&nbsp;any Competing Proposal; (B)&nbsp;any amendment of the organizational documents of the Company which would prevent or materially delay the
consummation of the Transactions, including the Mergers; or (C)&nbsp;any other action, agreement or transaction involving the Company that would reasonably be expected to prevent or materially delay the consummation of the Transactions, including
the Mergers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Stockholder agrees that, from the date hereof until the Expiration Date, in the event that a meeting of the
stockholders of the Company is held regarding the Merger Agreement, the Transactions or any of the matters referred to in Section&nbsp;3(c), it shall, or shall cause the holder of record of any of the Covered Shares of the Stockholder, as
applicable, on any applicable record date to, be present in person or represented by proxy at such meeting or otherwise cause all of the Stockholder&#146;s Covered Shares to be counted as present thereat for purposes of establishing a quorum, and
shall vote all of the Stockholder&#146;s Covered Shares at such meeting in accordance with Section&nbsp;3(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except for the delivery
of the Written Consent expressly contemplated by this Agreement, prior to the Expiration Date, the Stockholder shall not call, seek to call or request the call of any meeting of stockholders of the Company with respect to any matter relating to the
Mergers or any other Transaction, or take any action by consent relating to the Mergers or any other Transaction, other than as expressly contemplated by Section&nbsp;3(c), whether pursuant to the DGCL, the organizational documents of the Company or
otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything to the contrary herein, in no event shall this Section&nbsp;3 require or be construed so as to
require the Stockholder to vote or cause to be voted (including by written consent) its Covered Shares in favor of or against any stockholder vote to approve &#147;parachute payments&#148; (within the meaning of Section&nbsp;280G of the Internal
Revenue Code of 1986, as amended, and the Treasury Regulations thereunder) solicited in connection with the Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
Notwithstanding anything to the contrary herein, in the event that a vote or consent of the stockholders of the Company is required in order to effect an amendment to the Merger Agreement that reduces the amount or changes the form of consideration
payable in respect of each share of Company Capital Stock in the Mergers or otherwise amends the Merger Agreement in a manner adverse to the Stockholder (any such amendment, an &#147;<U>Adverse Amendment</U>&#148;), the provisions of this
Section&nbsp;3 shall not apply with respect to the Stockholder&#146;s vote or consent with respect to such Adverse Amendment (and the Stockholder shall not be required to vote or consent to such Adverse Amendment); <U>provided</U>, <U>however</U>,
that the term &#147;Adverse Amendments&#148; shall not include the amendments contemplated in Section&nbsp;3(c)(i)(B). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Voided Acts</U>. Any (i)&nbsp;Transfer (or purported Transfer) in breach of this
Agreement or (ii)&nbsp;attempt by the Stockholder to vote, or express consent or dissent with respect to (or otherwise to utilizing the voting power of), its Covered Shares in contravention of this Agreement shall be null and void<I> ab initio</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Agreement Not to Solicit</U>. The Stockholder agrees that it shall not, and shall cause each of the Stockholder&#146;s controlled
Affiliates not to, and shall instruct the Stockholder&#146;s and the Stockholder&#146;s controlled Affiliates&#146; Representatives not to, directly or indirectly, (a)&nbsp;solicit, initiate seek, or take any other action to facilitate or encourage
the making, submission or announcement of any proposal that constitutes, or would be reasonably be expected to lead to, any Competing Proposal, (b)&nbsp;enter into, maintain, continue or participate in any discussions or negotiations with any Person
or entity in furtherance of, or furnish to any Person any information or otherwise cooperate in any way with respect to, any Competing Proposal, (c)&nbsp;agree to, approve, endorse, recommend or consummate any Competing Proposal, (d)&nbsp;enter
into, or propose to enter into, any Competing Transaction Agreement, or (e)&nbsp;resolve, propose or agree, or authorize or permit any Representative to do any of the foregoing. The Stockholder shall, shall cause its controlled Affiliates and use
its reasonable best efforts to cause its Representatives to, immediately cease and cause to be terminated any discussions and negotiations with any Person conducted heretofore with respect to any Competing Proposal or proposal that would reasonably
be expected to lead to a Competing Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Commencement or Participation in Actions</U>. The Stockholder hereby agrees not to
commence or join in, and to take all reasonable actions necessary to opt out of (if applicable), any Action against the Company and/or its directors and officers (for the avoidance of doubt, participating in the defense of such Action or any Action
to enforce the Drag-Along is not prohibited by this Section&nbsp;6) with respect to, any litigation (a)&nbsp;challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement or the Merger Agreement or the exercise
of the Drag-Along in connection with the Transactions or (b)&nbsp;alleging a breach of any fiduciary duty of the Company Board or its members or any stockholder of the Company in connection with the Merger Agreement, the Transactions or the
transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Appraisal Rights or Rights of Dissent</U>. The Stockholder hereby waives, and agrees not to
exercise or assert, any appraisal or dissenters&#146; rights it may have or could potentially have or acquire in connection with the Mergers under Section&nbsp;262 of the DGCL and otherwise, whether or not the Stockholder has previously made a
written demand upon the Company and otherwise complied with the appraisal rights provisions of the DGCL. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Confidentiality</U>. The Stockholder agrees that, for a period of two years following
the Expiration Date, it shall not, and shall cause its Affiliates, directors, officers, employees and agents not to, divulge or convey to any third party any of the Company&#146;s confidential information, other than: (i)&nbsp;any of the
Company&#146;s confidential information that is or becomes generally available to the public other than as a result of an act or omission by the Stockholder or its Affiliate, director, officer, employee or agent, (ii)&nbsp;any information that has
been independently developed or conceived by the Stockholder or its Affiliates, director, officer, employee or agent, as applicable; or (iii)&nbsp;is or has been made known or disclosed to the Stockholder by a third party without a breach of any
obligation of confidentiality such third party may have to the Company. Notwithstanding the foregoing, the Stockholder shall be permitted to make any such disclosure (a)&nbsp;to its directors, officers, employees and agents, as applicable, who
reasonably need to know such information and who agree to keep such information confidential and are made aware of the Stockholder&#146;s obligations of confidentiality under this Agreement and (b)&nbsp;to the extent requested by a Governmental
Authority or required by Law or legal process (in which case the Stockholder will, to the extent reasonably practicable and legally permissible, provide Parent with advance notice of such required or requested disclosure, shall use commercially
reasonable efforts to resist such disclosure, and, at the request of Parent, shall cooperate with Parent to, at Parent&#146;s sole cost and expense, limit or prevent such disclosure). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>[Directors and Officers</U>. The Stockholder is entering into this Agreement solely in its capacity as a Beneficial Owner of Covered
Shares, and in this regard, the Stockholder shall not be deemed to make any agreement or understanding in this Agreement in the Stockholder&#146;s capacity as a director or officer of the Company, including with respect to Section&nbsp;7.02 of the
Merger Agreement. The parties acknowledge and agree that nothing in this Agreement shall (i)&nbsp;restrict in any respect any actions taken by the Stockholder or its designee who is a director or officer of the Company in his or her capacity as a
director or officer of the Company or (ii)&nbsp;be construed to prohibit, limit or restrict the Stockholder or its designee from exercising its fiduciary duties as a director or officer of the
Company.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Irrevocable Proxy</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Stockholder hereby irrevocably grants to, and appoints, Parent, and any individual designated in writing by Parent, and each of them
individually, as the Stockholder&#146;s proxy and attorney-in-fact (with full power of substitution), for and in the name, place and stead of the Stockholder, to vote the Stockholder&#146;s Covered Shares, or execute a written consent or grant
approval in respect of such Covered Shares, in a manner consistent with this Agreement from the date hereof until the Expiration Date, <U>provided</U>, <U>however</U>, for the avoidance of doubt, that such proxy and voting and related rights are
limited to those matters set forth in clauses (b)-(d)&nbsp;of Section&nbsp;3, and the Stockholder shall retain at all times the right to vote the Stockholder&#146;s Covered Shares (or to direct how such Covered Shares shall be voted) in the
Stockholder&#146;s sole discretion and without any other limitation on any matters not connected with the Transactions. The Stockholder understands and acknowledges that Parent has entered into the Merger Agreement in reliance upon the
Stockholder&#146;s execution and delivery of this Agreement. The Stockholder hereby affirms that the irrevocable proxy set forth in this Section&nbsp;10(a) is given to secure the performance of the duties of the Stockholder under this Agreement. The
Stockholder hereby further affirms that the irrevocable proxy is coupled with an interest sufficient in law and such irrevocable proxy is executed and intended to be irrevocable in accordance with applicable Law and Section&nbsp;2.09 of the
Company&#146;s bylaws until, and shall not be terminated by operation of Law or upon the occurrence of any other event other than, the termination of this Agreement pursuant to Section&nbsp;16. The Stockholder shall, upon written request by Parent,
as promptly as practicable, execute and deliver to Parent a separate written instrument or proxy that embodies the terms of this irrevocable proxy set forth in this Section&nbsp;10(a). The Stockholder agrees not to grant any proxy that conflicts
with or is inconsistent with the proxy granted to Parent in this Agreement. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included if applicable to the Stockholder. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that
conflict with or are inconsistent with the proxy granted to Parent in this Agreement that the Stockholder has heretofore granted with respect to the Covered Shares Beneficially Owned by the Stockholder, other than any such proxy granted to Parent
pursuant to the Voting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Representations and Warranties of Parent</U>. Parent hereby represents and warrants as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization and Qualification</U>. Parent is a legal entity duly organized, validly existing and in good standing under the Laws
of the jurisdiction of its incorporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authority; Binding Agreement</U><I>.</I> (i)&nbsp;Parent has all requisite power and
authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby, and (ii)&nbsp;the execution and delivery by Parent of this Agreement and the performance of Parent&#146;s
obligations and the consummation of the transactions contemplated hereby by Parent have been duly authorized by all necessary action, and no other actions on the part of Parent (or its board of directors or stockholders) are necessary to authorize
or adopt this Agreement or to consummate the transactions contemplated by this Agreement. This Agreement has been duly executed and delivered by Parent, and, assuming this Agreement constitutes a valid and binding obligation of the Stockholder,
constitutes a valid and binding obligation of Parent, enforceable against Parent in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency (including all Laws relating to fraudulent transfers), reorganization,
moratorium or similar Laws affecting creditors&#146; rights generally and subject to the effect of general principles of equity (regardless of whether considered in a proceeding at law or in equity). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Conflicts</U><I>.</I> None of the execution and delivery by Parent of this Agreement, the performance by Parent of its obligations
hereunder or the consummation by Parent of the transactions contemplated hereby does or would reasonably be expected to conflict with or result in a violation or breach of (i)&nbsp;Parent&#146;s certificate of incorporation or bylaws, (ii)&nbsp;any
other contract to which Parent is a party or by which Parent may be bound, except for violations, breaches or defaults that, individually or in the aggregate, would not reasonably be expected to in any material respect impair or adversely affect the
ability of Parent to perform its obligations under this Agreement, or (iii)&nbsp;any Law applicable to Parent. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Representations and Warranties of the Stockholder</U>. The Stockholder hereby
represents and warrants as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>[Organization and Qualification</U>. The Stockholder is a legal entity duly formed or organized
(as applicable), validly existing and in good standing under the Laws of the jurisdiction in which it is formed or organized, as applicable.]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authority; Binding Agreement</U><I>.</I> [The Stockholder has full legal capacity, right and authority to execute and deliver this
Agreement and to perform his or her obligations hereunder and consummate the transactions contemplated hereby.]<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> [(i) the Stockholder has all requisite power and authority to execute and deliver
this Agreement, to perform the Stockholder&#146;s obligations hereunder and to consummate the transactions contemplated hereby and (ii)&nbsp;the execution and delivery by the Stockholder of this Agreement and the performance of the
Stockholder&#146;s obligations and the consummation of the transactions contemplated hereby by the Stockholder have been duly authorized by all necessary action, and no other actions on the part of the Stockholder [(or its governing body, board of
directors, members, partners, stockholders or trustees, as applicable)] are necessary to authorize or adopt this Agreement or to consummate the transactions contemplated by this Agreement.]<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> This
Agreement has been duly executed and delivered by the Stockholder, and, assuming this Agreement constitutes a valid and binding obligation of Parent, constitutes a valid and binding obligation of the Stockholder, enforceable against the Stockholder
in accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency (including all Laws relating to fraudulent transfers), reorganization, moratorium or similar Laws affecting creditors&#146; rights generally and subject to
the effect of general principles of equity (regardless of whether considered in a proceeding at law or in equity). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No
Conflicts</U><I>.</I> None of the execution and delivery by the Stockholder of this Agreement, the performance by the Stockholder of its obligations hereunder or the consummation by the Stockholder of the transactions contemplated hereby does or
would reasonably be expected to conflict with or result in a violation or breach of, or in default under, [(i) the Stockholder&#146;s articles or certificate of formation, incorporation or organization, operating agreement, bylaws or comparable
organizational documents, as applicable, each in its currently effective form as amended from time to time,]<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> (ii)&nbsp;any [other] contract to which the Stockholder is a party or by which the
Stockholder may be bound, including any voting agreement or voting trust, or (iii)&nbsp;any Law applicable to the Stockholder, except, in each case, for violations, breaches or defaults that, individually or in the aggregate, would not reasonably be
expected to (x)&nbsp;in any material respect impair or adversely affect the ability of the Stockholder to perform its obligations under this Agreement on a timely basis or (y)&nbsp;prevent or materially delay the consummation of the Transactions.
The execution, delivery and performance by the Stockholder of this Agreement, and the consummation by the Stockholder of the transactions contemplated hereby, require no consent or action by or in respect of, or filing with, any Governmental
Authority. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included if the Stockholder is not an individual. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included if the Stockholder is an individual. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included if the Stockholder is not an individual. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included if the Stockholder is not an individual. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Ownership of Shares</U><I>.</I> The Stockholder (i)&nbsp;is the lawful record and
Beneficial Owner of the shares of Company Stock set forth opposite the Stockholder&#146;s name on Schedule 1(b) attached hereto and has, and at all times prior to the Expiration Date will have, the sole power to vote (or cause to be voted),
transfer, or demand or waive any appraisal rights with respect to, such shares of Company Stock, all of which are free and clear of, and not subject to, any Encumbrances (other than those (A)&nbsp;created by this Agreement, (B)&nbsp;applicable to
the Stockholder&#146;s Covered Shares that may exist pursuant to securities Laws or (C)&nbsp;any proxies which do not relate to the Mergers, the Transactions or Competing Proposals) and (ii)&nbsp;as of the date hereof, does not Beneficially Own or
have the right to vote (or cause the voting of) any shares of any class of Company Stock or other securities of the Company or any interest therein or any voting rights with respect to any securities of the Company other than the shares of Company
Stock set forth opposite the Stockholder&#146;s name on Schedule 1(b) attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Disclosure and Communications</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Stockholder hereby consents to and authorizes the publication and disclosure of its identity and ownership, this Agreement and the
nature of the Stockholder&#146;s commitments, arrangements and understandings pursuant to this Agreement and such other information pertinent to such disclosure, including the filing of this Agreement, by Parent and the Company in the Registration
Statement, Consent Solicitation Statement or other disclosure document required by applicable Law to be filed with the SEC or other Governmental Authority in connection with this Agreement, the Merger Agreement or the Transactions, and agrees to
reasonably cooperate with Parent in connection with such filings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Stockholder shall not issue or make any press release or public
announcement related to this Agreement, the Merger Agreement or the Transactions, or any other announcement or communication to the employees, customers or suppliers of the Company or any of its Subsidiaries, in each case without the approval of
Parent, unless required by applicable Law; <U>provided</U>, that, the Stockholder may make public statements that do not contain any information relating to the Transactions that has not been previously announced or made public in accordance with
this Agreement or the Merger Agreement so long as no such public statement (i)&nbsp;disparages the Transactions, (ii)&nbsp;encourages other holders of capital stock of the Company to vote against, or withhold their vote or consent on, the
Transactions, including the adoption of the Merger Agreement, or (iii)&nbsp;encourages other holders of capital stock of the Company to exercise appraisal rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>No Ownership Interest</U>. Nothing contained in this Agreement shall be deemed to vest in Parent any direct or indirect ownership or
incidence of ownership of or with respect to any Covered Shares. All ownership and economic benefits of and relating to the Covered Shares shall remain vested in and belong to the Stockholder, and, except as otherwise provided herein, Parent shall
not have any authority to direct the Stockholder in the voting or disposition of any Covered Shares. For the avoidance of doubt, the Stockholder shall be entitled to any dividends or other distributions declared by the Company Board with respect to
the Stockholder&#146;s Covered Shares having a record date prior to the Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Stop Transfer Instructions</U>. The
Stockholder shall not request that the Company register the Transfer (book-entry or otherwise) of any certificated or uncertificated interest representing any of its Covered Shares, unless such Transfer is made in compliance with this Agreement. The
Stockholder hereby authorizes Parent to direct the Company to impose stop orders to prevent the Transfer of any Covered Shares on the books of the Company in violation of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Termination</U>. This Agreement, and all rights and obligations of the parties
hereunder, shall terminate and shall have no further force or effect upon the termination of the Merger Agreement in accordance with its terms; <U>provided</U>, <U>however</U>, that (i)&nbsp;this Section&nbsp;16 and Sections 1, 13 and 20 shall
survive any termination of the Agreement and (ii)&nbsp;Sections 2, 3, 4, 5, 10 and 15 shall terminate and shall have no further force or effect as of the Expiration Date. Notwithstanding the foregoing, nothing set forth in this Section&nbsp;9 or
elsewhere in this Agreement shall relieve either party hereto from liability, or otherwise limit the liability of the Stockholder, for any breach of this Agreement prior to such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Transaction Documents</U>. The Stockholder acknowledges that the Merger Agreement and the other Transaction Documents may be amended in
accordance with the terms and conditions set forth in the Merger Agreement and the other Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Waiver</U>. The
Stockholder hereby waives any and all notice, information and consent requirements, as well as any right of first refusal, right of first offer, right of first negotiation, right restricting share transfers, redemption right, co-sale right,
registration right, preemptive right and other similar rights, that may be applicable to, or triggered by, the Transactions, including the Mergers, the Merger Agreement, the other Transaction Documents and any of the transactions contemplated
thereby that are contained in the Company&#146;s organizational documents or any contractual obligation between the Company and the Stockholder, or under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Release by the Stockholder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Effective as of the Effective Time, the Stockholder, on behalf of itself and each of its past, present and future controlled Affiliates,
parent(s) and subsidiary companies, representatives, and assigns, as applicable (collectively, the &#147;<U>Stockholder Releasing Parties</U>&#148;), hereby absolutely, unconditionally and irrevocably releases, acquits and forever discharges the
Company and each of its respective past, present and future Affiliates, parent(s) and subsidiary companies, joint ventures, predecessors, successors and assigns, and their respective past, present and future controlled representatives, investors,
equityholders, insurers and indemnitees, firms, corporations, limited liability companies, partnerships, trusts, associations, organizations, stockholders, members, managers, directors, officers, employees, partners, trustees, principals,
consultants, contractors, family members, heirs, executors, administrators, predecessors, successors and assigns (collectively the &#147;<U>Stockholder Released Parties</U>&#148;), of and from any and all manner of action or inaction, cause or
causes of action, Actions, Encumbrances, contractual obligations, promises, liabilities or damages (whether for compensatory, special, incidental or punitive damages, equitable relief or otherwise) of any kind or nature whatsoever, past, present or
future, at law, in equity or otherwise (including with respect to conduct which is negligent, grossly negligent, willful, intentional, with or without malice, or a breach of any duty, applicable Law or rule), whether known or unknown, whether fixed
or contingent, whether concealed or hidden, whether disclosed or undisclosed, whether liquidated or unliquidated, whether foreseeable or unforeseeable, whether anticipated or unanticipated, whether suspected or unsuspected
(&#147;<U>Claims</U>&#148;), which such Stockholder Releasing Parties, or any of them, ever have had or ever in the future may have against the Stockholder Released Parties, or any of them, in each case, to the extent arising solely as a result of
the ownership or purported ownership of any of Company Stock, Company Equity Awards or other security or interest of the Company and which, in each case, are based on acts, events or omissions occurring prior to or contemporaneously with the
Effective Time, at law or in equity, whether known or unknown, matured or unmatured, absolute or contingent, relating to or arising from the Transactions (the &#147;<U>Stockholder Released</U> <U>Claims</U>&#148;); <U>provided</U>, <U>however</U>,
that the foregoing release shall not release, impair or diminish, and the term &#147;Stockholder Released Claims&#148; shall not include, in any respect [(i)] the Stockholder&#146;s right pursuant to the Transaction Documents, including the right to
receive its respective portion of the Merger Consideration; [(ii) any Claims for indemnification, insurance benefits, reimbursement or advancement of expenses in such Stockholder Releasing Party&#146;s capacity as a director, officer or employee of
the Company under the Company&#146;s organizational documents or any indemnification agreement in effect as of the date hereof (or any fiduciary insurance policy maintained by the Company or the Surviving Corporation for the benefit of the
Stockholder, or any indemnification agreements with the Stockholder or its board designee) with respect to any act, omission, event or transaction occurring prior to or contemporaneously with the Effective Time; or (iii)&nbsp;the Stockholder&#146;s
in his or her capacity as an employee of the Company.]<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include if applicable. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Stockholder represents and acknowledges that it has read this release and the
Merger Agreement and other Transaction Documents and understands their terms and has been given sufficient opportunity to review this release and the Transaction Documents and to ask questions of the Company&#146;s Representatives. The Stockholder
further represents that, in signing this release, it does not rely, and has not relied, on any representation or statement made by any Representative of the Company or any other Person with respect to the subject matter, basis or effect of this
release or otherwise, except such express representations and warranties set forth in the Merger Agreement or this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Without
limiting the generality of Section&nbsp;19(a), with respect to the Stockholder Released Claims, the Stockholder acknowledges that it is familiar with Section&nbsp;1542 of the Civil Code of the State of California (&#147;<U>Section 1542</U>&#148;)
and hereby expressly waives all rights under Section&nbsp;1542 and any similar applicable Law or common law principle in any applicable jurisdiction prohibiting or restricting the waiver of unknown Claims. Section&nbsp;1542 reads as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the provisions of Section&nbsp;1542 or any similar applicable Law or
common law principle in any applicable jurisdiction, the Stockholder expressly acknowledges that the foregoing release is intended to include in its effect all Claims within the scope of such release that a Stockholder Releasing Party does not know
or suspect to exist in his, her or its favor against any of the Stockholder Released Parties (including, without limitation, unknown and contingent Claims), and that the foregoing release expressly contemplates the extinguishment of all such Claims
(except to the extent expressly set forth in this Section&nbsp;19). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Miscellaneous and General</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendments; Waivers, Etc</U>. This Agreement may not be amended, changed, supplemented or otherwise modified except upon the execution
and delivery of a written agreement executed by each of Parent and the Stockholder. Any agreement on the part of any party to any waiver or any extension of time for performance shall be valid only if set forth in an instrument in writing signed on
behalf of such party. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the
exercise of any other right, power or privilege. Except as otherwise herein provided, the rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by applicable Law or equity, and the exercise by a
party of any one remedy will not preclude the exercise of any other remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Counterparts; Effectiveness</U><I>.</I> This Agreement
may be executed in any number of counterparts (including by facsimile or by attachment to electronic mail in portable document format (PDF)), each such counterpart being deemed to be an original instrument, and all such counterparts shall together
constitute the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Governing Law; WAIVER OF JURY TRIAL</U><I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any
choice or conflict of law provisions or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. All Actions arising out of or relating to
this Agreement or the transactions contemplated hereby shall be heard and determined exclusively in the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware (or in the event, but only in the
event, that the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action or proceeding is
vested exclusively in the federal courts of the United States of America, the United States District Court for the District of Delaware, and, in each case, the appellate court(s) therefrom). The parties hereto hereby (a)&nbsp;irrevocably submit to
the exclusive jurisdiction of the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware (or in the event, but only in the event, that the Court of Chancery of the State of Delaware does not
have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action or proceeding is vested exclusively in the federal courts of the United States of America,
the United States District Court for the District of Delaware and, in each case, the appellate court(s) therefrom) for the purpose of any Action arising out of or relating to this Agreement or the transactions contemplated hereby brought by any
party hereto, (b)&nbsp;irrevocably waive, and agree not to assert by way of motion, defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or
immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement or the transactions contemplated hereby may not be enforced in or by the above named courts,
and (c)&nbsp;agree that such party will not bring any Action arising out of or relating to this Agreement or the transactions contemplated hereby in any court other than the Court of Chancery of the State of Delaware (or in the event, but only in
the event, that the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or, if subject matter jurisdiction over the action or proceeding is
vested exclusively in the federal courts of the United States of America, the United States District Court for the District of Delaware). Service of process, summons, notice or document to any party&#146;s address and in the manner set forth in
Section&nbsp;20(d) shall be effective service of process for any such action. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER
THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE, EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY
WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH OF THE PARTIES HERETO CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER,
(C)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS IN THIS SECTION 20(C)(II). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U><I>.</I> Notices, requests, instructions or other documents to be given under this Agreement shall be in writing and shall be
deemed given, (i)&nbsp;on the date sent by e-mail of a PDF document if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient, (ii)&nbsp;when delivered, if delivered
personally to the intended recipient, and (iii)&nbsp;one Business Day later, if sent by overnight delivery via a national courier service (providing proof of delivery), and in each case, addressed to a party at the following address for such party:
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to Parent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Illumina, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">5200 Illumina
Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, California 92122 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charles E. Dadswell, Senior Vice President and General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;858-202-4500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Facsimile: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;858-202-4545 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CDadswell@illumina.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;legalnotices@illumina.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with copies to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cravath, Swaine&nbsp;&amp; Moore LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Worldwide Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">825 Eighth
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Faiza J. Saeed, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Ting S. Chen, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fsaeed@cravath.com
</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;tchen@cravath.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Stockholder, to the address listed on Schedule 1(b) with copies (which shall not constitute notice)
to the Company (in accordance with Section&nbsp;11.02 of the Merger Agreement) and to its counsel: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">355 South Grand Avenue, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Los Angeles, California 90071-1560 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alex W. Voxman, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Andrew Clark, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;alex.voxman@lw.com
</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;andrew.clark@lw.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice may be given to such other persons or addresses as may be designated in writing by the party to receive such notice
as provided above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire Agreement</U><I>.</I> This Agreement (including any Schedules hereto) and the Merger Agreement constitute
the entire agreement, and supersedes all other prior agreements, understandings, representations and warranties both written and oral, among the parties hereto, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Parties in Interest; No Third Party Beneficiaries</U><I>.</I> Subject to Section&nbsp;20(i), and without relieving any party of any
obligation hereunder, this Agreement shall be binding upon and inure solely to the benefit of each party hereto and their respective successors and permitted assigns. This Agreement is not intended to, and does not, confer upon any Person other than
the parties hereto any rights or remedies hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Severability</U><I>.</I> The provisions of this Agreement shall be deemed severable
and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid or
unenforceable, (i)&nbsp;a suitable and equitable provision negotiated in good faith by the parties hereto shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or
unenforceable provision and (ii)&nbsp;the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not, subject to clause (i)&nbsp;above, be affected by such invalidity or unenforceability, except as
a result of such substitution, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Interpretation</U><I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Section headings or captions herein are for convenience of reference only, do not constitute part of this Agreement and shall not be
deemed to limit or otherwise affect any of the provisions hereof. Where a reference in this Agreement is made to a Section or Schedule, such reference shall be to a Section of or Schedule to this Agreement unless otherwise indicated. Whenever the
words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without limitation&#148;. The words &#147;hereof&#148;, &#147;herein&#148; and
&#147;hereunder&#148; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The word &#147;or&#148; when used in this Agreement is not exclusive. The
word &#147;extent&#148; in the phrase &#147;to the extent&#148; shall mean the degree to which a subject or other thing extends, and such phrase shall not mean simply &#147;if&#148;. All terms defined in this Agreement shall have the defined
meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to
the masculine as well as to the feminine and neuter genders of such term. Any statute defined or referred to herein means such statute as from time to time amended, modified or supplemented, including by succession of comparable successor statutes.
Any agreement or instrument defined or referred to herein includes all attachments thereto and instruments incorporated therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The
parties have participated jointly in negotiating and drafting this Agreement. In the event that an ambiguity or a question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties, and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)
<U>Assignment</U><I>.</I> This Agreement shall not be assignable by operation of law or otherwise without the prior written consent of each of the parties. Any purported assignment in contravention of the preceding sentence shall be null and void.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Expenses</U>. All costs and expenses incurred in connection with this Agreement shall
be paid by the party incurring such cost or expense, whether or not the transactions contemplated by this Agreement or the Merger Agreement are consummated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Specific Performance</U><I>.</I> The parties hereto acknowledge and agree that irreparable damage would occur and that the parties would
not have any adequate remedy at law if any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an adequate remedy therefor. It is
accordingly agreed that Parent shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the performance of the terms and provisions hereof in any court referred to in Section&nbsp;20(c),
without proof of actual damages (and each party hereby waives any requirement for the security or posting of any bond in connection with such remedy), this being in addition to any other remedy to which they are entitled at law or in equity. The
parties further agree not to assert that a remedy of specific enforcement is an unenforceable, invalid, contrary to applicable Law or inequitable remedy for any reason, and not to assert that a remedy of monetary damages would provide an adequate
remedy for any such breach or that Parent otherwise has an adequate remedy at law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ILLUMINA, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Parent Signature Page to Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have executed and caused to be effective this Agreement
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[Stockholder]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Stockholder Signature Page to Support Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1(b) </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Form of] Written Consent </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO
AGREEMENT AND PLAN OF MERGER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This AMENDMENT, dated as of February&nbsp;4, 2021 (this &#147;<U>Amendment</U>&#148;) to the Agreement
and Plan of Merger (the &#147;<U>Agreement</U>&#148;), dated as of September&nbsp;20, 2020, among Illumina, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), SDG Ops, Inc., a Delaware corporation and direct, wholly owned subsidiary of Parent
(&#147;<U>First Merger Sub</U>&#148;), SDG Ops, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Parent (&#147;<U>Second Merger Sub</U>&#148;) and GRAIL,&nbsp;Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;, and together with Parent, First Merger Sub and Second Merger Sub, the &#147;<U>Parties</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
subject to the terms and conditions set forth in this Amendment, and pursuant to Section&nbsp;9.05 of the Agreement, the Parties desire to amend certain terms of the Agreement by entering into, and as set forth in, this Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for and in consideration of the aforesaid premises and of the mutual representations, warranties and covenants contained
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the Parties hereby agree as set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Definitions</B>. Capitalized terms used herein without definition shall have the meanings ascribed to
such terms in the Agreement unless otherwise indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B> <B>Amendment to Agreement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> Section 1.01 of the Merger Agreement is hereby amended to add the following definitions in the proper lexicographical ordering:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <FONT STYLE="white-space:nowrap">&#147;Non-Stock</FONT> Tax Deductions&#148; means, with respect to any <FONT
STYLE="white-space:nowrap">Cash-Out</FONT> Award, the required withholding Taxes in connection with the CVR Consideration or the Cash&nbsp;&amp; Stock Consideration, as applicable, payable with respect to such
<FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award, excluding any Stock Tax Deductions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;Stock Tax Deductions&#148; means,
with respect to any <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award, any required withholding Taxes in connection with the stock portion of the CVR Consideration or the Cash&nbsp;&amp; Stock Consideration, as applicable, payable with respect
to such <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> Section 1.02 of the Merger Agreement is hereby amended to
delete <FONT STYLE="white-space:nowrap">&#147;Cash-Out</FONT> Deductions&#148; and to add &#147;Exercise Price Deduction&#148; with the appropriate cross-reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> Section 3.04(i) of the Agreement is hereby amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Immediately prior to, and contingent on, the Effective Time, each <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award shall be
canceled and converted into the right to receive for each share of Company Stock subject to such <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award as of immediately prior to such cancelation, in full satisfaction of the rights of the applicable
holder with respect thereto, (i)&nbsp;in the case of a CVR <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award, the CVR Consideration or (ii)&nbsp;in the case of an Alternative <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award, the
Cash&nbsp;&amp; Stock Consideration, in each case, less (A)&nbsp;in the case of any <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award that </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
is a Company Stock Option, the applicable exercise price for such share (the &#147;Exercise Price Deduction&#148;) and (B)&nbsp;in the case of all Company Equity Awards, any required withholding
Taxes (the net consideration payable hereunder in respect of a <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award, the <FONT STYLE="white-space:nowrap">&#147;Cash-Out</FONT> Award Consideration&#148;). Any Exercise Price Deduction and any <FONT
STYLE="white-space:nowrap">Non-Stock</FONT> Tax Deductions shall be satisfied by reducing the cash portion of the applicable consideration by the amount of such deductions, but not below zero. In the event such cash portion has a value that is less
than the sum of the Exercise Price Deduction and the <FONT STYLE="white-space:nowrap">Non-Stock</FONT> Deductions, such cash portion shall be reduced to zero and in addition Parent shall retain a portion of the stock portion of the applicable
consideration that has a value equal to the amount by which the sum of the Exercise Price Deduction and the <FONT STYLE="white-space:nowrap">Non-Stock</FONT> Tax Deductions exceeds such cash portion. Any Stock Tax Deductions shall be satisfied by
Parent retaining a portion of the stock portion of the applicable consideration that has a value equal to the amount of the Stock Tax Deductions. The <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award Consideration shall be paid as promptly as
practicable following the Effective Time (and in no event later than five (5)&nbsp;Business Days thereafter) through Parent&#146;s, the Surviving Entity&#146;s or the applicable Subsidiary of the Surviving Entity&#146;s payroll. Notwithstanding the
foregoing, to the extent that any <FONT STYLE="white-space:nowrap">Cash-Out</FONT> Award Consideration relates to a Company RSU Award that is nonqualified deferred compensation subject to Section&nbsp;409A of the Code, Parent, the Surviving Entity
or the applicable Subsidiary shall pay such amounts at the earliest time, as applicable, that will not trigger a Tax or penalty under Section&nbsp;409A of the Code, but no later than five (5)&nbsp;Business Days after such time.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Representations and Warranties. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> Each Party hereto hereby represents and warrants that: (i)&nbsp;it has all necessary corporate or limited liability company power
and authority to execute and deliver this Amendment and to perform its obligations hereunder, (ii)&nbsp;the execution and delivery of this Amendment by such Party has been duly and validly authorized by all necessary corporate or limited liability
company action, and no other corporate or limited liability company proceedings on the part of such Party are necessary to authorize this Amendment and (iii)&nbsp;this Amendment has been duly and validly executed and delivered by such Party and,
assuming due authorization, execution and delivery by all other Parties, constitutes a legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms, subject to the effect of any applicable
bankruptcy, insolvency (including all Laws relating to fraudulent transfers), reorganization, moratorium or similar Laws affecting creditors&#146; rights generally and subject to the effect of general principles of equity (regardless of whether
considered in a proceeding at law or in equity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> Each Party hereto further represents and warrants that the execution and
delivery of this Amendment by such Party does not, and the performance of this Amendment by such Party, will not, (i)&nbsp;conflict with or violate the certificate of incorporation, certificate of formation, bylaws, operating agreement or other
equivalent organizational documents of such Party, (ii)&nbsp;conflict with or violate any Law applicable to such Party or by which any property or asset of either of them is bound, or (iii)&nbsp;violate, conflict with, require consent under, result
in any breach of, result in loss of benefit under, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation
of, or result in the creation of an Encumbrance (other than a Permitted Encumbrance) on any property or asset of such Party pursuant to, any loan or credit agreement, note, bond, debenture, mortgage, indenture, deed of trust, contract, agreement,
lease, Parent Permit, Company Permit or other instrument or obligation to which such Party is a party or by which such Party or any of their respective assets or properties is bound. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B> <B>General Provisions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> All of the provisions of this Amendment shall be effective as of the date of this Amendment. Except to the extent specifically
amended hereby, all of the terms of the Agreement shall remain unchanged and in full force and effect, and, to the extent applicable, such terms shall apply to this Amendment as if it formed a part of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> After giving effect to this Amendment, each reference in the Agreement to &#147;this Agreement&#148;, &#147;hereof&#148;,
&#147;hereunder&#148; or words of like import referring to the Agreement shall refer to the Agreement as amended by this Amendment. All references in the Agreement to &#147;the date hereof&#148; or &#147;the date of this Agreement&#148; shall refer
to September&nbsp;20, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> This Amendment and the Agreement, (including the exhibits and schedules thereto, including the
Company Disclosure Letter), the other Transaction Documents and the Confidentiality Agreement constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and
undertakings, both written and oral, among the Parties, or any of them, with respect to the subject matter hereof and thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B>
The provisions of Article XI (General Provisions) of the Agreement shall, to the extent not already set forth in this Amendment, apply <I>mutatis mutandis</I> to this Amendment, and to the Agreement as modified by this Amendment, taken together as a
single agreement, reflecting the terms as modified hereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature Page Follows] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Amendment to be duly executed
and delivered as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ILLUMINA, INC.,</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joydeep Goswami</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Joydeep Goswami</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Senior Vice President of Corporate Development and Strategic Planning</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SDG OPS, INC.</B>,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott M. Davies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Scott M. Davies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President and Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SDG OPS, LLC</B>,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott M. Davies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Scott M. Davies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President and Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GRAIL, INC.</B>,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hans Bishop</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Hans Bishop</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: CEO</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>List of Subsidiaries </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><U>Name of Entity</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Jurisdiction</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GRAIL Bio UK Limited</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United Kingdom</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>Information contained herein is subject to completion or amendment. A Registration Statement on Form 10 relating to these securities has
been confidentially submitted to the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>PRELIMINARY AND SUBJECT TO COMPLETION, DATED
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION STATEMENT
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">1525
O&#146;Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">Menlo Park, California 94025 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">(par value
$0.001) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are sending you this Information Statement in connection with Illumina, Inc.&#146;s partial <FONT STYLE="white-space:nowrap">spin-off</FONT>
of its wholly owned subsidiary, GRAIL, LLC, or &#147;GRAIL.&#148; GRAIL must be held and operated separately and independently from Illumina pursuant to the transitional measures ordered by the European Commission, following the prohibition of
Illumina&#146;s acquisition of GRAIL on September 6, 2022. Prior to the completion of the <FONT STYLE="white-space:nowrap">spin-off,</FONT> GRAIL will be converted into a Delaware corporation and will be renamed GRAIL, Inc. To effect the <FONT
STYLE="white-space:nowrap">spin-off,</FONT> Illumina, Inc., or &#147;Illumina,&#148; will distribute at least 85.5% of the shares of GRAIL&#146;s common stock owned by Illumina as of the close of business on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, which is the record date for the distribution, on a pro rata basis to the holders of Illumina common stock. Immediately after the distribution
becomes effective, Illumina may retain up to 14.5% of GRAIL&#146;s common stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend that the distribution of GRAIL common stock
will be <FONT STYLE="white-space:nowrap">tax-free</FONT> to Illumina stockholders for U.S. federal income tax purposes, except for cash that stockholders receive in lieu of fractional shares and subject to the discussion below under &#147;The <FONT
STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT> U.S. Federal Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off&#151;Consequences</FONT> to Holders of Illumina Common
<FONT STYLE="white-space:nowrap">Stock&#151;Non-U.S.</FONT> Holders&#151;Distribution of Our Common Stock.&#148; You should consult your own tax advisor as to the tax consequences of the distribution to you, including potential tax consequences
under state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a record holder of Illumina common stock as
of the record date, for every &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of Illumina common stock you hold on that date, you will be entitled to receive
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of GRAIL common stock. Illumina will distribute the shares of GRAIL common stock in book-entry form, which means that we will not issue
physical stock certificates. The distribution agent will not distribute any fractional shares of GRAIL common stock. Instead, the distribution agent will aggregate fractional shares into whole shares, sell the whole shares in the open market at
prevailing market prices and distribute the aggregate cash proceeds of the sales, net of brokerage fees and other costs, pro rata to each holder (net of any required withholding for taxes applicable to each holder) who would otherwise have been
entitled to receive a fractional share in the distribution. As discussed in the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Trading</FONT> Prior to the Distribution Date&#148; beginning on page&nbsp;105 of this
Information Statement, if you sell your Illumina common stock in the <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> market after the record date and on or before the distribution date, you also will be selling your right to receive
shares of GRAIL common stock in connection with the distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the distribution will be effective as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, New York City time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024. Immediately after the
distribution becomes effective, GRAIL will be an independent, publicly traded company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Illumina&#146;s stockholders are not required to
vote on or take any other action in connection with the <FONT STYLE="white-space:nowrap">spin-off.</FONT> We are not asking you for a proxy, and request that you do not send us a proxy. Illumina&#146;s stockholders will not be required to pay any
consideration for the shares of GRAIL common stock they receive in the <FONT STYLE="white-space:nowrap">spin-off,</FONT> and they will not be required to surrender or exchange their common stock of Illumina or take any other action in connection
with the <FONT STYLE="white-space:nowrap">spin-off.</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina currently owns all outstanding shares of GRAIL common stock.
Accordingly, no public trading market for GRAIL common stock currently exists. We expect, however, that a limited trading market for GRAIL common stock, commonly known as a &#147;when-issued&#148; trading market, will develop on or shortly before
the record date for the distribution, and we expect <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> trading of GRAIL common stock will begin on the first trading day after the distribution date. We intend to list the GRAIL common
stock on the Nasdaq Global Select Market under the ticker symbol &#147;GRAL.&#148; Following the distribution, Illumina will continue to trade on the Nasdaq Global Select Market under the ticker symbol &#147;ILMN.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In reviewing this Information Statement, you should carefully consider the matters described in the section entitled &#147;<A HREF="#toc556103_5">Risk
 Factors</A>&#148; beginning on page&nbsp;28 of this Information Statement. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved these securities or determined if this Information Statement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This Information Statement is not an offer to sell, or a solicitation of an offer to buy, any securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this Information Statement is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_1">INDUSTRY AND MARKET DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_2">TRADEMARKS AND COPYRIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_3">BASIS OF FINANCIAL PRESENTATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_4">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_6">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_7">THE <FONT STYLE="white-space:nowrap">SPIN-OFF</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_10">SELECTED HISTORICAL FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_11">UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL
INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_12">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_13">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_14">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_15">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_16">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_17">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_18">DESCRIPTION OF OUR CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_19">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc556103_20">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_1"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this Information Statement concerning our industry and the markets in which we operate,
including our general expectations and market position, market opportunity, and market size, is based on information from various sources on assumptions that we have made that are based on such information and other, similar sources and on our
knowledge of, and expectations about, the markets for our products. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market
opportunity, and market size information included in this Information Statement is generally reliable, such information is inherently imprecise. In addition, projections, assumptions, and estimates of our future performance and the future
performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled &#147;Risk Factors&#148; and elsewhere in this Information
Statement. These and other factors could cause results to differ materially from those expressed in the estimates made by independent third parties and by us. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_2"></A>TRADEMARKS AND COPYRIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;GRAIL,&#148; the GRAIL logos, &#147;Galleri&#148; and other trade names, trademarks or service marks of GRAIL appearing in this
Information Statement are the property of GRAIL. GRAIL also owns or has the rights to copyrights that protect the content of its products. Other trade names, trademarks, service marks or copyrights appearing in this Information Statement are the
property of their respective holders. Solely for convenience, trade names, trademarks, service marks, and copyrights referred to in this Information Statement appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, <SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>, and <SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> symbols, but those references are not intended to indicate, in any way,
that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, service marks, and copyrights. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_3"></A>BASIS OF FINANCIAL PRESENTATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina acquired the common stock of GRAIL that it did not own and completed its acquisition of GRAIL on August&nbsp;18, 2021. Our
consolidated balance sheets as of December 31, 2023, January 1, 2023, and January 2, 2022, and our consolidated statements of operations, comprehensive loss, and cash flows for the period from January 2, 2022 to January 1, 2023, the period from
January 2, 2023 to December 31, 2023, and the period from August 19, 2021 to January 2, 2022 (the &#147;Successor&#148;) reflect the new basis of accounting established in connection with the acquisition of GRAIL on August&nbsp;18, 2021 and for the
period from January 1, 2021 to August&nbsp;18, 2021 (the &#147;Predecessor&#148;) reflect the predecessor activity of GRAIL prior to the acquisition. A black line distinguishes the periods before and after the acquisition of GRAIL because these
periods are not comparable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the acquisition, we had a fiscal year end of December 31, which we will revert back to upon the
closing of the Spin-Off. Illumina, and, by proxy, us following the acquisition and prior to the Spin-Off, use a <FONT STYLE="white-space:nowrap">52-53</FONT> week fiscal year-end calendar that ends on the Sunday closest to the quarter-end, so the
exact year-end date may change from year to year. In this Information Statement when we discuss our financial results: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">references to 2023 refer to the fiscal year ended December&nbsp;31, 2023, which was 52 weeks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">references to 2022 refer to the fiscal year ended January&nbsp;1, 2023, which was 52 weeks; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">references to 2021 refer either to the Predecessor period from January&nbsp;1, 2021 to August&nbsp;18, 2021 (the
&#147;2021 predecessor period&#148;), or the Successor period from August&nbsp;19, 2021 to January&nbsp;2, 2022 (the &#147;2021 successor period&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_4"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this Information Statement and provides an overview of our company, our separation from
Illumina and Illumina&#146;s distribution of our common stock to its stockholders. For a more complete understanding of our business and the <FONT STYLE="white-space:nowrap">spin-off,</FONT> you should read the entire Information Statement
carefully, particularly the discussion of &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operation&#148; beginning on pages 28 and 168, respectively, of this Information Statement,
and our historical consolidated financial statements and the notes to those financial statements appearing elsewhere in this Information Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this Information Statement, unless the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;GRAIL,&#148; &#147;we,&#148; &#147;our,&#148; and &#147;us&#148; refer to GRAIL, LLC and its consolidated
subsidiaries prior to the effective time of its conversion to a corporation and to GRAIL, Inc. and its consolidated subsidiaries on and after the effective time of such conversion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Illumina&#148; refers to Illumina, Inc. and its consolidated subsidiaries other than, for all periods
following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> (as defined below), GRAIL; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the &#147;Distribution&#148; refers to the transaction in which Illumina will distribute to its stockholders at
least 85.5% of the shares of our common stock owned by Illumina; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the &#147;Distribution Date&#148; refers to the date on which the Distribution occurs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">&#147;Spin-Off&#148;</FONT> refers to the transaction in which we will be
separated from Illumina. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our mission is to detect cancer early, when it can be cured. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative commercial-stage healthcare company focused on saving lives and shifting the paradigm in early cancer detection. We
believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our Galleri test is a clinically-validated, commercially available test for early detection of
multiple types of cancer, which we termed multi-cancer early detection (&#147;MCED&#148;). Galleri detects a shared cancer signal across more than 50 types of cancer and can predict with high accuracy the specific organ or tissue type where the
cancer signal originated, all from a simple blood draw. We launched Galleri in the United States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold more than 125,000 commercial tests and established over
100 commercial partnerships, including leading healthcare systems, employers, payors, and life insurance providers. Commercial use of Galleri has detected some of the most aggressive cancers in early stages including, among others, endometrial,
esophageal, gastrointestinal stromal, head and neck, liver, pancreatic, and rectal cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is a major public health crisis. It is
the second leading cause of death both in the United States and worldwide. Most cancers that result in death are diagnosed too late, in advanced stages when they are most challenging to treat. Approximately 67% of cancer deaths result from cancers
that have no recommended screening guidelines. In the United States, we consider standard of care screening for cancer to consist of the grade A and B recommendations published by the United States Preventive Services Task Force
(&#147;USPSTF&#148;), which currently recommend broad population screening for only four types of cancer using single-cancer screening tests (breast, cervical, colorectal, and lung cancer), and prostate cancer screening, which is USPSTF grade C and
is widely implemented in the United States. We believe that expanding upon these current guidelines to screen individuals for many types of cancer with a single test represents a significant opportunity to reduce cancer mortality and the cost of
cancer care. Based on our published modeling data, we estimate that adding Galleri to these five standard of care single-cancer screening tests could detect many more cancers at an earlier </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage and potentially avert approximately 100,000 deaths per year in the United States as measured by five-year survival. In addition, a recent analysis demonstrated that diagnosing cancer early
could result in an estimated $26&nbsp;billion in annual cost-savings in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed Galleri to detect cancer early,
when it can be cured. Galleri works by detecting DNA fragments shed into the bloodstream by tumor cells. DNA from cancer has specific methylation patterns that can be used to both identify a general cancer signal and localize that signal to a
specific organ or tissue type. In clinical studies, Galleri identified a shared cancer signal across more than 50 types of cancer, often at an early stage. If a cancer signal is detected, Galleri predicts the tissue type or organ associated with the
cancer signal (the cancer signal origin) with high accuracy. Test results are then used by healthcare providers to guide <FONT STYLE="white-space:nowrap">follow-up</FONT> diagnostic testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an early leader in MCED testing, we have established strong relationships within the cancer and primary care community, including through
partnerships with academic and community medical centers, key opinion leaders, and governmental policy and advocacy partners. We have shared evidence supporting our MCED testing at renowned medical conferences, such as the American Association of
Cancer Research (&#147;AACR&#148;), American Society of Clinical Oncology (&#147;ASCO&#148;), European Society of Medical Oncology (&#147;ESMO&#148;), and American Academy of Family Physicians (&#147;AAFP&#148;). We have also published results from
our studies in leading scientific and medical journals, including <I>The Lancet</I>,<I> Nature</I>,<I> Nature Medicine</I>,<I> Cancer Cell</I>,<I></I> and <I>The Lancet Oncology</I>. Our industry leadership has been recognized with multiple national
high profile accolades, including being acknowledged by <I>Time Magazine</I> as one of the Best Inventions of 2022 and <I>The Atlantic</I> as one of the top breakthroughs of 2022, and being named in <I>Fast Company</I> World Changing Ideas of 2022
and in the <I>Fortune</I> Change the World List in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To support broad access for Galleri in the United States, we plan to complete a
premarket approval application (&#147;PMA&#148;) submission with the U.S. Food and Drug Administration (the &#147;FDA&#148;) in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We seek to use data from
the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, together with data from our PATHFINDER 2 study, as well as supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States. We
believe that FDA approval could unlock broad coverage by large commercial payors in the United States and we are working with stakeholders to advance and shape the public reimbursement landscape to cover MCED screening for FDA-approved MCED tests.
Following FDA approval, we also expect to pursue inclusion of Galleri in the USPSTF&#146;s guideline recommendation. In the United Kingdom, we are working with NHS England to complete our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial.
Subject to results of an early analysis from the first screening test (the prevalent screening round) representing one year of results out of the three-year trial period, the NHS may commence phased commercial implementation in England, beginning
with a two-year pilot, and with the potential for further expansion subject to final results from the trial. We believe our work with the NHS and the data generated from our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial could facilitate
adoption in other single-payor systems around the world and support evidence of clinical utility worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding, we have
undertaken a rigorous approach to identify in a blood sample the most informative markers of cancer through what we believe is the largest clinical program in genomic medicine to date. We have collected population-scale clinical data from more than
300,000 participants across eight clinical studies, with more than 21,000 of these participants included in the studies that supported the development and launch of Galleri, and over 165,000 individuals enrolled in interventional studies (NHS
Galleri and PATHFINDER 2) to support our PMA submission. These studies include our foundational case-control Circulating Cell-free Genome Atlas (&#147;CCGA&#148;) study to develop and validate our MCED technology, multiple large-scale observational
studies in asymptomatic individuals, and multiple large-scale interventional studies in intended use populations. Our interventional studies include our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, which is the first and largest
randomized controlled trial of an MCED test, and which enrolled more than 140,000 individuals in just over 10 months. Through these studies and our ongoing collection of real-world data, we have built what we believe is an unprecedented longitudinal
dataset of high quality, linked clinical and genomic data. Our clinical studies, including our early discovery work, have demonstrated robust and reproducible test performance. Notably, key results from our interventional
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PATHFINDER study were generally consistent with data from our case-control CCGA study, which is evidence supporting the generalizability and robustness of Galleri. We expect to continue to report
ongoing and long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> clinical data from these studies over many years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our
extensive discovery work, we believe that targeted methylation is the best approach for detecting a cancer signal and identifying a cancer signal origin. In our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> analyses, methylation exhibited stronger performance when compared to interrogating mutations, chromosomal alterations, fragment lengths, and other genomic
features, either alone or in combination. In contrast to well-established cancer mutations that only affect a handful of genomic locations, there are nearly 30&nbsp;million methylation sites across the human genome, making them a ubiquitous and rich
signal for cancer detection. After comprehensive analysis of whole-genome methylation patterns, we refined and developed a targeted methylation approach focused on highly informative and <FONT STYLE="white-space:nowrap">low-noise</FONT> methylation
regions for cancer signal and cancer signal origin detection. Our targeted methylation approach can detect lower levels of cancer signal in blood compared to the other approaches, enabling early cancer detection in asymptomatic individuals more
efficiently compared to whole-genome methylation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary targeted methylation platform, as well as our growing body of clinical
and real-world data, have provided us with unique insights into cancer biology that enable development of products beyond asymptomatic screening. We are leveraging our proprietary platform for additional applications, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Precision oncology portfolio: </I>We are developing our precision oncology portfolio and launched our research
use only (&#147;RUO&#148;) targeted methylation platform with customizable classifiers in 2023. We have partnered with a number of leading oncology therapeutics companies to test applications of biomarkers with the goal of optimizing the use of
therapeutic interventions. Some of our partnerships also include development of customized applications to support clinical studies and companion diagnostic development and commercialization. Potential applications for our technology in a precision
oncology setting include <FONT STYLE="white-space:nowrap">pre-treatment</FONT> prognosis, post-treatment prognosis or minimal residual disease (&#147;MRD&#148;), biomarker discovery, detection of recurrence, and clinical monitoring. We believe the
research and clinical development settings represent significant opportunities with biopharmaceutical companies given the large number of ongoing oncology studies and the significant need to identify residual disease or recurrence early and help
inform treatment decisions. In addition to companion diagnostic opportunities, we believe that our methylation platform could enable standalone clinical products and support patient care across the cancer care continuum. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Diagnostic aid for cancer test</I>: We are developing our diagnostic aid for cancer (&#147;DAC&#148;) test to
accelerate diagnostic resolution for patients with <FONT STYLE="white-space:nowrap">non-specific</FONT> signs and symptoms, but with a clinical suspicion of cancer. Through a simple blood test, DAC is designed to provide physicians with a powerful
decision-making tool to aid diagnosis, achieve resolution more quickly, and avoid unnecessary workups. Symptomatic detection of cancer is a significant unmet need; we estimate that approximately 16 million patients in the United States present with <FONT
STYLE="white-space:nowrap">non-specific</FONT> signs and symptoms each year. Data published in <I>The Lancet Oncology</I> showed that, in a symptomatic patient population, our methylation technology was able to detect many cancer types and identify
where the cancer signal origin was located in the body with high accuracy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these products and other future
products in development present significant market opportunities and patient care solutions across the cancer care continuum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our continued growth will be driven by the following strengths: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our clinically-validated, commercially available, MCED test, Galleri.</B> Galleri is a clinically-validated,
commercially available, MCED test that is setting the standard for multi-cancer early </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
detection. From a simple blood draw, Galleri can detect a cancer signal shared by over 50 types of cancer, over 45 of which do not have recommended screening guidelines. Galleri has demonstrated
high positive predictive value (&#147;PPV&#148;) and low false positive rate, improves the opportunity for early detection of cancer in asymptomatic individuals by screening for multiple types of cancer, and predicts the location of the suspected
cancer with high accuracy to help guide an efficient diagnostic evaluation. Further, as Galleri relies on a blood draw, the test can be integrated into existing care pathways, such as annual health checks, which can enable wide scale implementation
and increase access to cancer screening, thus helping to address well-known disparities in cancer care. Our industry leadership in MCED testing has been recognized with multiple national high profile accolades, including being acknowledged by
<I>Time Magazine</I> as one of the Best Inventions of 2022 and <I>The Atlantic</I> as one of the top breakthroughs of 2022, and being named in <I>Fast Company</I> World Changing Ideas of 2022 and in the <I>Fortune</I> Change the World List in 2023.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our established commercial leadership is driving the development of a significant market.</B> The commercial
opportunity for Galleri is significant, with more than 300&nbsp;million individuals globally over the age of 50 (our intended use population), including more than 100&nbsp;million individuals in the United States. We launched Galleri in the United
States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold more than 125,000 commercial tests and established over 100 commercial partnerships, including leading healthcare systems, employers, payors, and
life insurance providers. In this real-world setting, Galleri is detecting deadly cancers in early stages. As an early leader in MCED testing, we have established strong relationships within the cancer and primary care community, including through
partnerships with academic and community medical centers, key opinion leaders, and governmental policy and advocacy partners. Our partnership with the NHS presents an opportunity to drive further adoption of Galleri, including by payors and health
systems around the world. Subject to the results of an early analysis from the first screening test (the prevalent screening round) in the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, the NHS may commence phased commercial
implementation in England, beginning with a two-year pilot, and with the potential for further expansion subject to final results from the trial. Our commercial leadership is further supported by our high-capacity laboratories to enable population
screening volumes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Clinical validation through unprecedented clinical studies and real-world experience.</B> We designed and
executed what we believe is the largest clinical program in genomic medicine to date. We have collected population-scale clinical data from more than 300,000 participants across eight clinical studies, with more than 21,000 of these participants
included in the studies that supported the development and launch of Galleri, and over 165,000 individuals enrolled in interventional studies (NHS Galleri and PATHFINDER 2) to support our PMA submission. These studies include our foundational
case-control CCGA study to develop and validate our MCED technology, multiple large-scale observational studies in asymptomatic individuals, and multiple large-scale interventional studies. Our interventional studies include our <FONT
STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, which is the first and largest randomized controlled trial of an MCED test, and which enrolled more than 140,000 individuals in just over 10 months. Through these studies and our ongoing
collection of real-world data, we have built what we believe is an unprecedented longitudinal dataset of high quality, linked clinical and genomic data. Our clinical studies, including our early discovery work, have demonstrated robust and
reproducible test performance. Notably, key results from our interventional PATHFINDER study were generally consistent with data from our case-control CCGA study, which is evidence supporting the generalizability and robustness of Galleri. Together
with our partners at leading community and academic medical centers in the United States and United Kingdom, we expect to continue to report ongoing and long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> clinical data from these studies
over many years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our highly-differentiated methylation platform, which enables product opportunities across the cancer care
continuum.</B> We have taken a scientifically rigorous approach to develop a deep and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
comprehensive understanding of cancer biology. We built an atlas to characterize the landscape of cell-free nucleic acids (&#147;cfDNA&#148;) across a broad and diverse population and in
individuals with and without cancer. We then used this atlas and other data to train our machine learning algorithms to recognize methylation patterns indicative of cancer and accurately predict the cancer signal origin. These efforts supported the
development of our proprietary methylation platform on which Galleri is based, and which we will continue to leverage to advance a number of clinical applications across the cancer care continuum. For example, we developed and launched our
post-diagnosis RUO offering and are working closely with biopharmaceutical companies to develop products and services to optimize treatment once a cancer has been diagnosed. Potential applications for our technology in a post-diagnosis setting
include <FONT STYLE="white-space:nowrap">pre-treatment</FONT> prognosis, <FONT STYLE="white-space:nowrap">post-treatment</FONT> prognosis or MRD, biomarker discovery, detection of recurrence, and clinical monitoring. We are also developing our DAC
test to enable faster diagnosis and care for patients presenting with <FONT STYLE="white-space:nowrap">non-specific</FONT> symptoms that are suspicious for cancer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our intellectual property portfolio.</B> We own or license exclusive worldwide commercial rights to
intellectual property covering Galleri and our products in development. Specifically, we have exclusive licenses to more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;granted patents globally,
and own more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued patents, with more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pending
patent applications covering methylation and other technologies. In addition, our patents, trade secrets, and <FONT STYLE="white-space:nowrap">know-how</FONT> provide broad intellectual property coverage for our products, including chemistry,
bioinformatics, and machine learning algorithms used in Galleri and our product development pipeline. Our patents will begin to expire in 2028. Our patent applications, if issued as patents, would begin to expire in 2037. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our highly experienced and multidisciplinary team.</B> Since our founding, we have built an entrepreneurial
culture driven to improve outcomes for cancer patients. We are led by a multidisciplinary team with extensive experience across biotechnology, life sciences, public health, genomics, computer science, data science, biostatistics, clinical
development, medical affairs, government and regulatory affairs, quality assurance, and laboratory and commercial operations. We believe this confluence of talent from multiple disciplines has enabled us to make significant progress in improving
cancer care and will enable us to remain at the forefront of our industry. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Establishing Galleri as the population multi-cancer screening standard and extending commercial leadership in
large global markets.</B> We believe we have an unprecedented opportunity to establish a new standard of care by adding Galleri to existing single-cancer screenings, and establish and maintain the market leading position in cancer detection. The
commercial opportunity for Galleri is significant, with more than 300&nbsp;million individuals globally over the age of 50, including over 100&nbsp;million individuals in the United States. Our goal is to address cancer screening globally, beginning
in large markets with established health systems, such as the United States and United Kingdom, and thereafter extending to other markets. We will continue to engage with key opinion leaders, healthcare providers, advocacy organizations, regulators,
and payors to help drive broader scientific and commercial endorsement worldwide. In addition, we believe Galleri&#146;s performance will drive clinical outcomes and high patient and provider satisfaction that will lead to further awareness and
adoption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expanding access to our products by pursuing reimbursement and coverage from payors.</B> Our ability to impact
cancer outcomes will be accelerated in markets where we secure reimbursement for our products. Prior to broad reimbursement in the United States, we will continue our work with clinics and health systems to accelerate utilization, and with
self-insured employers and health insurers to offer and cover Galleri. In the United States, we have established private reimbursement from over 70 self-insured employers and multiple payors and health systems as of September&nbsp;30, 2023. To
support broad access for Galleri in the United States, we plan to complete a PMA submission with the FDA in </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We seek to use data from the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, together
with data from our PATHFINDER 2 study, as well as supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States. We believe that FDA approval could unlock large commercial payors in the United
States and we are working with stakeholders to advance and shape the public reimbursement landscape in the United States to enable coverage of FDA-approved MCED tests by Medicare. Following FDA approval, we also expect to pursue inclusion of Galleri
in the USPSTF&#146;s guideline recommendation. In the United Kingdom, we are working with NHS England to complete our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial. Subject to results of an early analysis from the first screening test
(the prevalent screening round) representing one year of results out of the three-year trial period, the NHS may commence phased commercial implementation in England, beginning with a two-year pilot, and with the potential for further expansion
subject to final results from the trial. We believe our work with the NHS and the data generated from our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial could facilitate adoption in other single-payor systems around the world and support
evidence of clinical utility worldwide. We will continue to invest in clinical evidence generation and work with regulatory bodies and payors in our target markets to expand coverage for early cancer screening and to increase access.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Defining, leading, and expanding adoption of MCED.</B> We coined the term &#147;multi-cancer early
detection&#148; and will continue to drive MCED as a solution to one of healthcare&#146;s most important challenges. Since our inception in 2016, we have established and maintained a leading voice regarding the early detection of multiple cancer
types in peer-reviewed literature. As of September&nbsp;30, 2023, we have published more than 45 manuscripts, including in high profile journals like <I>The Lancet</I>, <I>Nature</I>, <I>Nature Medicine</I>, <I>Cancer Cell</I>, and <I>The Lancet
Oncology</I>. We have also presented our data in more than 20 podium and 135 poster presentations at renowned medical conferences, including AACR, ASCO, ESMO, and AAFP. We fund medical education programs for MCED and intend to continue to educate
healthcare providers, as well as key opinion leaders, regulators, professional societies, and policymakers on the clinical benefits and public health impact of MCED. In addition, we believe this market development strategy will drive adoption of our
products and further awareness of the benefits of MCED testing generally. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Driving cutting edge science and technology to continuously improve existing products and develop new
products.</B> Our methylation platform and extensive technological infrastructure, together with expansive ongoing data collection, will continue to drive improvements to Galleri and enable the development of additional products. Our technology has
broad applicability in cancer detection and management, and findings from our SYMPLIFY study demonstrated the potential of our platform to extend beyond asymptomatic screening, into symptomatic detection. We launched our RUO offering, a part of our
precision oncology portfolio, in 2023, which has formed the basis of additional biopharmaceutical partnerships to enable further discovery and execution of new development programs. In addition, these partnerships have generated findings that
support expansion into precision oncology applications, including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment prognosis, recurrence detection, and clinical monitoring. We continually seek to enhance the performance of our
products through a comprehensive, rigorous approach to ongoing classifier training, improvement of features, and reduced processing time and cost. We will continue to improve our technologies and launch innovative products across the cancer care
continuum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leveraging our existing infrastructure to enable and scale our growing business.</B> Over the last several
years, we have made significant investments to build a scalable infrastructure capable of meeting significant demand while satisfying stringent certification parameters. Our high-capacity laboratories are accredited by the College of American
Pathologists (&#147;CAP&#148;) and certified by the Clinical Laboratory Improvement Amendments of 1988 (&#147;CLIA&#148;) and the New York Department of Health, which represent one of the most rigorous levels of validation required for laboratory
developed </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
tests. Our facilities are able to process a substantial number of tests per year. In addition, we engineered custom technology infrastructure and cloud-based tools to enable scalable data
collection and analysis capabilities. Our ability to collect, manage, and integrate high-quality genomic and clinical data is central to our business, and our automated laboratory workflows and processes enable high volumes of tests and samples to
be processed automatically with high efficiency and speed and low failure rates. As demand for our products increases, we expect to leverage the scale efficiencies of our infrastructure and platform technology, which we believe will positively
impact margins over time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Sustaining a patient-first corporate culture that champions diversity.</B> We have built a multi-disciplinary
organization of leading scientists, engineers, and clinicians driven to improve outcomes for cancer patients. We are on an urgent mission to detect cancer early, when it can be cured. In our pursuit to improve cancer care and solve one of
healthcare&#146;s most important challenges, we intend to grow our diversity among employees and will continue to foster an agile and inclusive environment that is a destination for world-class talent. We believe our mission, values, and leadership
attributes all contribute to this vibrant and inclusive culture and serve as a powerful magnet for talent. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of GRAIL common stock is subject to numerous risks, including risks relating to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT>
The following list of risk factors is not exhaustive. Please read the information in the section entitled &#147;Risk Factors&#148; beginning on page&nbsp;28 of this Information Statement for a more thorough description of these and other risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Business and Industry </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We operate in a rapidly evolving field and have a limited operating history, which make it difficult to evaluate
our current business and predict our future performance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant net losses in each period since our inception and anticipate that we will continue
to incur net losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our products or future products may not perform as expected, and the results of our clinical studies may not
support the launch or use of our products or future products and may not comply with the requirements, or be replicated in later studies or in the post-market or real-world setting. This could materially and adversely affect our business, financial
condition, results of operations, and growth prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The clinical study process is lengthy and expensive with uncertain outcomes. We have encountered delays and may
encounter future delays in, or unexpected data from, our clinical studies, and may therefore be unable to complete our clinical studies on the timelines we expect, if at all. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A substantial majority of our revenue is generated from sales of Galleri and we are highly dependent on it for
our success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our products do not receive adequate coverage and reimbursement from third-party payors, if at all, our
ability to expand access to our products beyond our existing sales channels will be limited and our overall commercial success will be limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercial products may fail to achieve the degree of market acceptance necessary for commercial success.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to generate sufficient revenue to offset our ongoing operating expenses and achieve and
maintain profitability. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to develop and commercialize new products, including enhanced versions of current products.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If similar third-party products are developed and do not perform as intended or cause harm or injury to patients,
the market for our products could be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to obtain additional financing, we may be unable to expand our commercialization efforts with respect
to Galleri and any other products that we successfully develop and commercialize, or to develop additional products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our products result in direct or indirect participant or patient harm or injury, we could be subject to
significant reputational and liability risks, and our reputation, business, financial condition, results of operations, and growth prospects could be materially adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on Illumina as a sole supplier for our next-generation sequencers and associated reagents, Madison
Industries (&#147;Madison&#148;) (who acquired our blood collection tube manufacturer Streck, Inc. in 2023) as a sole supplier of our blood collection tubes, and Twist Bioscience Corporation (&#147;Twist&#148;) as a sole supplier of our DNA panels.
Additionally, we rely on a limited number of suppliers for some of our laboratory instruments and reagents, and we may not be able to immediately find replacements if necessary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have launched Galleri as a laboratory developed test (&#147;LDT&#148;), and plan to launch DAC as an LDT in
the United States. If the FDA modifies its current policy of enforcement discretion on LDTs, as it has recently proposed through rulemaking, or if Congress enacts legislation that changes the current requirements or oversight for LDTs, we may lose
the ability to commercialize any LDTs unless we have obtained FDA marketing authorization, which could require us to incur substantial costs and delays. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory clearance, approval, or certification processes of the FDA and comparable foreign regulatory
authorities or notified bodies are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable regulatory approvals, clearances, or certifications, or if such approvals, clearances, or certifications
are significantly delayed, our business will be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our operations and business depend on various third parties, including information technology, sample collection,
processing, transfer facilities, and other patient-facing service providers. Any disruption, failure, or interruption at any of these third parties could materially adversely affect our business, results of operations, financial condition, and
growth prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to scale our operations successfully to support demand for our products, our business could
suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our multi-cancer detection tests are a new approach to cancer screening, which present a number of novel and
complex issues for FDA review. Because the FDA has never cleared or approved a multi-cancer detection test, it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a proposed intended use, or
if we will be able to obtain such approval on a timely basis or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of
the intellectual property protection we obtain is not sufficiently broad, third parties could develop and commercialize technology and tests similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights
from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Distribution does not qualify as a transaction that is <FONT STYLE="white-space:nowrap">tax-free</FONT>
for U.S. federal income tax purposes, Illumina and its stockholders could be subject to significant tax liability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We could have an indemnification obligation to Illumina if the Distribution were determined not to qualify for <FONT
STYLE="white-space:nowrap">non-recognition</FONT> treatment for U.S. federal tax purposes, which could materially adversely affect our business, financial condition and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to agree to numerous restrictions to preserve the
<FONT STYLE="white-space:nowrap">non-recognition</FONT> treatment of the Distribution, which may reduce our strategic and operating flexibility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to achieve some or all of the benefits that we expect to achieve from the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> which could materially adversely affect our business, financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No market for our common stock currently exists and an active trading market may not develop or be sustained
after the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> our stock price may fluctuate significantly. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If securities analysts do not publish research or reports about our business or if they publish negative
evaluations of our stock, the price of our stock could decline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require
us to relinquish rights to our technologies or our products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an emerging growth company and the information we provide shareholders may be different from information
provided by other public companies, which may result in a less active trading market for our common stock and higher volatility in our stock price. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Substantial sales of our common stock may occur in connection with the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including the disposition by Illumina of the shares of our common stock that it retains after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> which could cause our stock price to decline.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina acquired the common stock of GRAIL that it did not own and completed its acquisition of GRAIL on August&nbsp;18, 2021 (the
&#147;Acquisition&#148;). The Acquisition has been subject to various legal challenges, including by the U.S. Federal Trade Commission and the European Commission. Pursuant to the binding Hold Separate Commitments (as defined in the section entitled
&#147;The Spin-Off&#151;Background&#148; beginning on page&nbsp;96 of this Information Statement) that Illumina put in place and the various orders of the European Commission related to its review of the Acquisition, Illumina and GRAIL have operated
as independent legal entities that transact at arms&#146; length and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of GRAIL has remained the sole responsibility of GRAIL&#146;s management.
On July&nbsp;12, 2023, the European Commission adopted a final decision finding that Illumina breached the EU Merger Regulation (as defined in the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Background&#148;</FONT>
beginning on page&nbsp;96 of this Information Statement) by, in its view, acquiring the possibility to exert decisive influence over GRAIL and exerting such influence during the pendency of the European Commission&#146;s review. On
September&nbsp;26, 2023, Illumina sought the annulment of this decision. On October&nbsp;12, 2023, the European Commission adopted a decision (the &#147;EC Divestment Decision&#148;) requiring Illumina to (among other things) divest GRAIL. On
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, Illumina applied for the suspension of the execution of certain provisions of the EC Divestment Decision, and sought the annulment of the EC Divestment Decision. On
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , the European Commission approved a divestment plan (the &#147;Divestment Plan&#148;) submitted by Illumina pursuant to which Illumina agreed to divest
GRAIL on specified terms. The EC Divestment Decision permits Illumina to retain up to a 14.5% ownership interest in GRAIL. See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Background&#148;</FONT> beginning on
page&nbsp;96 of this Information Statement for more detail. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, Illumina announced plans for the separation of GRAIL from Illumina via the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To effect the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina will distribute at
least 85.5% of the shares of GRAIL&#146;s common stock owned by Illumina to Illumina&#146;s stockholders, and GRAIL will become an independent, publicly traded </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company. Immediately after the Distribution becomes effective, Illumina may retain up to 14.5% of GRAIL&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we intend to enter into a Separation and Distribution Agreement
and several other agreements with Illumina related to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> These agreements will govern the relationship between Illumina and us after completion of the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> and allocate between Illumina and us various assets, liabilities and obligations, including <FONT STYLE="white-space:nowrap">tax-related</FONT> assets and liabilities. See the section entitled
&#147;Certain Relationships and Related Party Transactions&#148; beginning on page&nbsp;202 of this Information Statement for more detail. No approval of Illumina&#146;s stockholders is required in connection with the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> and Illumina&#146;s stockholders will not have any appraisal rights in connection with the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is subject to the satisfaction, or the waiver by Illumina&#146;s board of
directors (the &#147;Illumina Board&#148;), of a number of conditions. If the Illumina Board waives any condition prior to the effectiveness of the Registration Statement on Form&nbsp;10, of which this Information Statement is a part, and the result
of such waiver is material to Illumina stockholders, Illumina will file an amendment to the Registration Statement to revise the disclosure in this Information Statement accordingly. In the event that the Illumina Board waives a condition after the
Registration Statement on Form 10, of which this Information Statement is a part, becomes effective and such waiver is material to Illumina stockholders, Illumina will communicate such change to Illumina stockholders by filing a Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> describing the change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Illumina has the right not to complete the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> if, at any time, the Illumina Board determines, in its sole and absolute discretion, that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not in the best interests of Illumina or its stockholders or
is otherwise not advisable. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, Illumina and GRAIL will have incurred significant costs related to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including
fees for consultants, financial and legal advisors, accountants and auditors, that will not be recouped. Total <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs associated with the <FONT STYLE="white-space:nowrap">Spin-Off</FONT>
are preliminarily estimated to range from $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is completed. If the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, the <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs will generally be limited to the transaction costs incurred for services rendered as of the date the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> is abandoned, which will be less than the range noted above. Our management will also have devoted significant time to manage the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> process, which will
decrease the time they will have to manage our business. See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;105 of
this Information Statement for more detail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the EC Divestment Decision and with the goal of enhancing stockholder value, the Illumina Board conducted a process through
which it considered a range of potential divestment transactions. After evaluating various factors and other considerations, including the input of various outside advisors, the Illumina Board concluded that the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> presented the most attractive alternative for enhancing long-term stockholder value while complying with the requirements of the EC Divestment Decision and that proceeding with the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> would be in the best interests of Illumina and its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other things, the
Illumina Board considered a number of potential benefits of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Opportunity for continued ownership of GRAIL by Illumina stockholders.</I></B> The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will provide Illumina stockholders the opportunity to determine whether they wish to continue to own an interest in GRAIL despite GRAIL&#146;s required separation from Illumina. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Distinct and clear financial profiles and compelling investment cases</I></B>. Investment in one or the
other company may appeal to investors with different goals, interests and expectations. The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will allow investors to make independent investment decisions with respect to Illumina and GRAIL and
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
may result in greater alignment between the interests of each company&#146;s stockholder base and the characteristics of its respective business, capital structure, and financial results.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Separate capital structures and allocation flexibility</I></B>. The
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> will permit each of Illumina and GRAIL to allocate its financial resources to meet the unique needs of its own businesses, which will allow each company to focus on its distinct strategic priorities
and individual business risk and return profiles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Creation of independent equity securities and increased strategic opportunities</I></B>. The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will afford Illumina and GRAIL the ability to offer their independent equity securities to the capital markets and enable each standalone company to use its own industry-focused stock to pursue portfolio
enhancing acquisitions or other strategic opportunities that are more closely aligned with each company&#146;s strategic goals and expected growth opportunities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Illumina Board also considered a number of potentially negative factors in evaluating the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Notwithstanding these costs and risks, the anticipated costs of which are not reasonably quantifiable, and considering the factors discussed above, the Illumina Board determined that the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> provided the best opportunity to achieve the above benefits and enhance stockholder value. Neither Illumina nor GRAIL can assure you that, following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> any
of the benefits described above or otherwise will be realized to the extent anticipated or at all. For additional information, see the sections entitled &#147;Risk Factors&#148; and &#147;The
<FONT STYLE="white-space:nowrap">Spin-Off&#151;Reasons</FONT> for the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on pages&nbsp;28 and 97, respectively, of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined by the Jumpstart Our Business Startups Act of 2012. We will continue to be an emerging growth company until the earliest to occur of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which our total annual gross revenues first meet or exceed $1.235&nbsp;billion
(as adjusted for inflation); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which we have, during the prior three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which we (i)&nbsp;have an aggregate worldwide market value of common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700&nbsp;million or more (measured at the end of each fiscal year) as of the last business day of our most recently completed second fiscal quarter and (ii)&nbsp;have been a
reporting company under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), for at least one year (and have filed at least one annual report under the Exchange Act); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock
pursuant to an effective registration statement under the Securities Act of 1933. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For as long as we are an emerging
growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with
the auditor attestation requirements in the assessment of our internal control over financial reporting under Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, exemption from new or revised financial accounting standards applicable to public
companies until such standards are also applicable to private companies, reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, and exemptions from the requirement of
holding a nonbinding advisory vote on executive compensation and stockholder approval on golden parachute compensation not previously approved. We may choose to take advantage of some or all of these reduced burdens. For example, we have taken
advantage of the reduced disclosure obligations regarding executive compensation in this Information Statement. For as long as we take advantage of the reduced reporting </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations, the information we provide stockholders may be different from information provided by other public companies. In addition, it is possible that some investors will find our common
stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to not take advantage of the extended transition period that allows an emerging growth company to delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies, which means that the financial statements included in this Information Statement, as well as financial statements we file in the future, will be subject
to all new or revised accounting standards generally applicable to public companies. Our election not to take advantage of the extended transition period is irrevocable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Delaware
limited liability company. Prior to the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will be converted into a Delaware corporation and change our name to GRAIL, Inc. Our headquarters are located in Menlo Park and our
principal executive offices are located at 1525 O&#146;Brien Drive, Menlo Park, California 94025. Our telephone number is (833) 694-2553. Our website address is https://grail.com. Information contained on, or connected to, our website or
Illumina&#146;s website does not and will not constitute part of this Information Statement or the Registration Statement on Form 10, of which this Information Statement is a part, or any other filings with, or any information furnished or submitted
to, the Securities and Exchange Commission (the&nbsp;&#147;SEC&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for Furnishing This Information Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are furnishing this Information Statement solely to provide information to Illumina&#146;s stockholders who will receive shares of our
common stock in the Distribution. Illumina&#146;s stockholders are not required to vote on the Distribution. Therefore, you are not being asked for a proxy and you are not required to send a proxy to Illumina. You do not need to pay any
consideration, exchange or surrender your existing shares of Illumina common stock or take any other action to receive your shares of GRAIL common stock to which you are entitled in the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> You should
not construe this Information Statement as an inducement or encouragement to buy, hold or sell any of our securities or any securities of Illumina. We believe that the information contained in this Information Statement is accurate as of the date
set forth on the cover. Changes to the information contained in this Information Statement may occur after that date, and neither we nor Illumina undertake any obligation to update the information except in the normal course of our and
Illumina&#146;s respective public disclosure obligations and practices. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUESTIONS AND ANSWERS ABOUT THE <FONT STYLE="white-space:nowrap">SPIN-OFF</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provides only a summary of certain information regarding the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> You should read
this Information Statement in its entirety for a more detailed description of the matters described below. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Why am I receiving this Information Statement? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina is making this Information Statement available to you because you are a holder of shares of Illumina
common stock. If you are a holder of shares of Illumina common stock as of the Record Date (as defined below), for every&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share[s] of Illumina common stock
that you hold as of the Record Date, you will be entitled to receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share[s] of GRAIL common stock. This Information Statement is intended to help you
understand how the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will affect your post-Distribution ownership in each of Illumina and GRAIL. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT> </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is the method by which we will separate from Illumina. In
the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina will distribute to its stockholders at least 85.5% of the outstanding shares of our common stock owned by Illumina in a transaction (the &#147;Distribution&#148;). Following the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> we will be an independent, publicly traded company, and Illumina may retain up to 14.5% ownership interest in us. Illumina will continue as an independent, publicly traded company. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Will the number of Illumina shares I own change as a result of the
<FONT STYLE="white-space:nowrap">Spin-Off?</FONT> </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No, the number of shares of Illumina common stock you own will not change as a result of the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the reasons for the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT>
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the EC Divestment Decision and with the goal of enhancing stockholder value, the Illumina
Board conducted a process through which it considered a range of potential divestment transactions. After evaluating various factors and other considerations, including the input of various outside advisors, the Illumina Board concluded that the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> presented the most attractive alternative for enhancing long-term stockholder value while complying with the requirements of the EC Divestment Decision and that proceeding with the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> would be in the best interests of Illumina and its stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Among other
things, the Illumina Board considered a number of potential benefits of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Opportunity for continued ownership of GRAIL by Illumina stockholders.</I></B> The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will provide Illumina stockholders the opportunity to determine whether they wish to continue to own an interest in GRAIL despite GRAIL&#146;s required separation from Illumina. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Distinct and clear financial profiles and compelling investment cases</I></B>. Investment in one or the
other company may appeal to investors with different goals, interests and expectations. The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will allow investors to make independent investment decisions with respect to Illumina and GRAIL and may
result in greater alignment between the interests of each company&#146;s stockholder base and the characteristics of its respective business, capital structure, and financial results. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Separate capital structures and allocation flexibility</I></B>. The
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> will permit each of Illumina and GRAIL to allocate its financial resources to meet the unique needs of its own businesses, which will allow each company to focus on its distinct strategic priorities
and individual business risk and return profiles. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Creation of independent equity securities and increased strategic opportunities</I></B>. The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will afford Illumina and GRAIL the ability to offer their independent equity securities to the capital markets and enable each standalone company to use its own industry-focused stock to pursue portfolio
enhancing acquisitions or other strategic opportunities that are more closely aligned with each company&#146;s strategic goals and expected growth opportunities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Illumina Board also considered a number of potentially negative factors in evaluating the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT>
Notwithstanding these costs and risks, the anticipated costs of which are not reasonably quantifiable, and considering the factors discussed above, the Illumina Board determined that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> provided the
best opportunity to achieve the above benefits and enhance stockholder value. Neither Illumina nor GRAIL can assure you that, following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> any of the benefits described above or otherwise will be
realized to the extent anticipated or at all. For additional information, see the sections entitled &#147;Risk Factors&#148; and &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Reasons</FONT> for the
<FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on pages&nbsp;28 and 97, respectively, of this Information Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Why is the separation of GRAIL structured as a <FONT STYLE="white-space:nowrap">spin-off?</FONT>
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina believes that a <FONT STYLE="white-space:nowrap">tax-free</FONT> distribution of our shares is the
most efficient way to separate our business from Illumina in a manner that will achieve the above benefits. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will I receive in the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> in respect of my shares of
Illumina common stock? </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a holder of Illumina common stock, for
every&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share[s] of Illumina common stock you hold on the Record Date, you will receive a dividend
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share[s] of GRAIL common stock. The distribution agent will distribute only whole shares of our common stock in the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> See &#147;&#151;How will fractional shares be treated in the Distribution?&#148; beginning on page&nbsp;18 of this Information Statement for more information on the treatment of the fractional shares
you may be entitled to receive in the Distribution. Your proportionate interest in Illumina will not change as a result of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is being distributed in the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT>
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina will distribute
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> based on the
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of Illumina common stock outstanding as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024. The actual number of shares of our common stock that Illumina will distribute will depend on the total number of shares of Illumina common
stock outstanding on the Record Date. The shares of our common stock that Illumina distributes will constitute at least 85.5% of the issued and outstanding shares of our common stock immediately prior to the Distribution. For more information on the
shares being distributed in the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> see the section entitled &#147;Description of Our Capital Stock&#151;Common Stock&#148; beginning on page&nbsp;206 of this Information Statement.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is the record date for the Distribution? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina will determine record ownership as of the close of business
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024 (the &#147;Record Date&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>When will the Distribution occur? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Distribution will be effective as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, New York City time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024 (the &#147;Distribution
Date&#148;). On or shortly after the Distribution Date, the whole shares of our common stock will be credited in book-entry accounts for Illumina stockholders entitled to receive the shares in the
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Distribution. See &#147;&#151;How will Illumina distribute shares of our common stock?&#148; beginning on page&nbsp;17 of this Information Statement for more information on how to access your
book-entry account or your bank, brokerage or other account holding the GRAIL common stock you receive in the Distribution on and following the Distribution Date. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What do I have to do to participate in the Distribution? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All holders of Illumina common stock as of the Record Date will participate in the Distribution. You are not
required to take any action in order to participate, but we urge you to read this Information Statement carefully. Holders of Illumina common stock on the Record Date will not need to pay any cash or deliver any other consideration, including any
shares of Illumina common stock, in order to receive shares of our common stock in the Distribution. In addition, no stockholder approval of the Distribution is required. We are not asking you for a vote and request that you do not send us a proxy
card. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>If I sell my shares of Illumina common stock on or before the Distribution Date, will I still be entitled
to receive shares of GRAIL common stock in the Distribution? </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you sell your shares of Illumina common stock before the Record Date, you will not be entitled to receive
shares of GRAIL common stock in the Distribution. If you hold shares of Illumina common stock on the Record Date and decide to sell them on or before the Distribution Date, you may be able to choose to sell your Illumina common stock with or without
your entitlement to the GRAIL common stock to be distributed in the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> You are encouraged to consult with your bank, broker or other nominee, as applicable, and your financial advisor regarding your
options and the specific implications of selling your shares of Illumina common stock prior to or on the Distribution Date. See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Trading</FONT> Prior to the Distribution
Date&#148; beginning on page&nbsp;105 of this Information Statement for more information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Is the completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> subject to the satisfaction or
waiver of any conditions? </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes, the completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is subject to the satisfaction, or
the Illumina Board&#146;s waiver, of the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Illumina Board shall have authorized and approved the Distribution and not withdrawn such authorization and
approval, and shall have declared the dividend of our common stock to Illumina stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ancillary agreements contemplated by the Separation and Distribution Agreement shall have been executed by
each party to those agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock shall have been accepted for listing on the Nasdaq Global Select Market (&#147;Nasdaq&#148;), or
another national securities exchange approved by Illumina, subject to official notice of issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the SEC shall have declared effective our Registration Statement on Form 10, of which this Information Statement
is a part, under the Exchange Act, and no stop order suspending the effectiveness of the Registration Statement shall be in effect and no proceedings for that purpose shall be pending before or threatened by the SEC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina shall have received a private letter ruling from the U.S. Internal Revenue Service (&#147;IRS&#148;) and
the written opinion of Cravath, Swaine&nbsp;&amp;&nbsp;Moore LLP, each of which shall remain in full force and effect, that, subject to the limitations specified therein and the accuracy of and compliance with certain representations, warranties and
covenants, the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Illumina Board shall have received one or more opinions (which have not been withdrawn or adversely modified)
in customary form from one or more nationally recognized valuation, appraisal or accounting firms, or investment banks, as to the solvency and financial viability of Illumina prior to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and each of
Illumina and GRAIL after the consummation of the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal
restraint or prohibition preventing consummation of the Distribution shall be in effect, and no other event outside the control of Illumina shall have occurred or failed to occur that prevents the consummation of the Distribution;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no other events or developments shall have occurred prior to the Distribution Date that, in the judgment of the
Illumina Board, would result in the Distribution having a material adverse effect on Illumina or its stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the Distribution Date, notice of Internet availability of this Information Statement or this Information
Statement shall have been mailed to the holders of Illumina common stock as of the Record Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina shall have duly elected as members of our post-Distribution Board of Directors (the &#147;Board&#148;),
the individuals listed in this Information Statement, and such individuals shall be the members of our Board immediately after the Distribution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately prior to the Distribution Date, our Certificate of Incorporation and Bylaws, each in substantially
the form filed as an exhibit to the Registration Statement on Form 10, of which this Information Statement is a part, shall be in effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Illumina and GRAIL cannot assure you that any or all of these conditions will be met, or that the Distribution will be consummated even if all
of the conditions are met. Illumina may at any time prior to the Distribution Date decide to abandon the Distribution or modify or change the terms of the Distribution. If the Illumina Board waives any condition prior to the effectiveness of the
Registration Statement on Form 10, of which this Information Statement is a part, and the result of such waiver is material to Illumina stockholders, Illumina will file an amendment to the Registration Statement to revise the disclosure in this
Information Statement accordingly. In the event that the Illumina Board waives a condition after the Registration Statement on Form 10, of which this Information Statement is a part, becomes effective and such waiver is material to Illumina
stockholders, Illumina will communicate such change to Illumina stockholders by filing a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> describing the change. For a complete discussion of the conditions to the Distribution, see
the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;105 of this Information Statement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Can Illumina decide to cancel the Distribution even if all the conditions have been satisfied?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. The Illumina Board may, in its sole discretion and at any time prior to the Distribution Date, decide to
terminate or abandon the Distribution even if all the conditions to the Distribution have been satisfied if the Illumina Board determines that the Distribution is not in the best interests of Illumina or its stockholders or is otherwise not
advisable. For a more detailed description, see the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;105 of this
Information Statement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>How will Illumina distribute shares of our common stock? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Registered stockholders.</I> If you are a registered stockholder (meaning you own your shares of Illumina
common stock directly through Illumina&#146;s transfer agent, Computershare Trust Company, N.A. (&#147;Computershare&#148;)), our distribution agent will credit the whole shares of our common stock you receive in the Distribution to a new book-entry
account with our transfer agent, Computershare, on or shortly after the </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Distribution Date. Our distribution agent will mail you a book-entry account statement that reflects the number of whole shares of our common stock you own. You will be able to access information
regarding your book-entry account holding the GRAIL shares at
www.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.com or by calling
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Street name&#148; or beneficial stockholders.</I> If you own your shares of Illumina common stock beneficially through a bank, broker
or other nominee, your bank, broker or other nominee will credit your account with the whole shares of our common stock you receive in the Distribution on or shortly after the Distribution Date. Please contact your bank, broker or other nominee for
further information about your account. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We will not issue any physical stock certificates to any stockholders, even if requested. See the
section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;When</FONT> and How You Will Receive GRAIL Shares&#148; beginning on page&nbsp;99 of this Information Statement for a more detailed explanation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>How will fractional shares be treated in the Distribution? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The distribution agent will not distribute any fractional shares of our common stock in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> Instead, the distribution agent will aggregate all fractional shares into whole shares and sell the whole shares in the open market at prevailing market prices on behalf of Illumina stockholders entitled
to receive a fractional share. The distribution agent will then distribute the aggregate cash proceeds of the sales, net of brokerage fees and other costs, pro rata to these holders (net of any required withholding for taxes applicable to each
holder). We anticipate that the distribution agent will make these sales in the &#147;when-issued&#148; market, and &#147;when-issued&#148; trades will generally settle within two trading days following the Distribution Date. See &#147;&#151;How
will GRAIL common stock trade?&#148; beginning on page&nbsp;19 of this Information Statement for additional information regarding &#147;when-issued&#148; trading and the section entitled &#147;The
<FONT STYLE="white-space:nowrap">Spin-Off&#151;Treatment</FONT> of Fractional Shares&#148; beginning on page&nbsp;100 of this Information Statement for a more detailed explanation of the treatment of fractional shares. The distribution agent will,
in its sole discretion, without any influence by Illumina or us, determine when, how, through which broker-dealer and at what price to sell the whole shares of GRAIL common stock. The distribution agent is not, and any broker-dealer used by the
distribution agent will not be, an affiliate of either Illumina or us. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the U.S. federal income tax consequences to me of the Distribution?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is conditioned upon Illumina&#146;s receipt
of a private letter ruling from the IRS and a written opinion of Cravath, Swaine&nbsp;&amp; Moore LLP, each of which shall remain in full force in effect, that, subject to the limitations specified therein and the accuracy of and compliance with
certain representations, warranties and covenants, the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections 355 and 368 of the Code. If the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> qualifies for such treatment, for U.S. federal income tax purposes, no gain or loss will be recognized by, or be includible in the income of, a U.S. Holder (as defined in the section entitled &#147;The <FONT
STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT> U.S. Federal Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement) as a result of the Distribution,
except with respect to any cash received by Illumina stockholders in lieu of fractional shares. After the Distribution, Illumina stockholders generally should allocate their aggregate tax basis in their Illumina common stock held immediately before
the Distribution between their Illumina common stock and our common stock in proportion to their relative fair market values on the date of the Distribution (subject to certain adjustments). See the section entitled &#147;The <FONT
STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT> U.S. Federal Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement for more information regarding the
potential tax consequences to you of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We urge you to consult your
tax advisor as to the specific tax consequences of the Distribution to you, including the effect of any U.S. federal, state, local or foreign tax laws and of changes in applicable tax laws. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Does GRAIL intend to pay cash dividends? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not anticipate paying any cash dividends in the foreseeable future. We currently anticipate that we will
retain all available funds for use in the operation and expansion of our business. Any future determination to pay dividends on our common stock will be made at the discretion of the Board and will depend upon, among other factors, our financial
condition, results from operations, current and anticipated cash needs, plans for expansion, and other factors that our Board may deem relevant. We cannot assure you that we will pay a dividend in the future or continue to pay any dividend if we do
commence paying dividends. See the section entitled &#147;Dividend Policy&#148; beginning on page&nbsp;108 of this Information Statement for more information. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>How will GRAIL common stock trade? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Currently, there is no public market for our common stock. We intend to list our common stock on Nasdaq under
the ticker symbol &#147;GRAL.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We anticipate that trading in our common stock will begin on a
&#147;when-issued&#148; basis on or shortly before the Record Date for the Distribution and will continue up to and including the Distribution Date. &#147;When-issued&#148; trading in the context of a <FONT STYLE="white-space:nowrap">spin-off</FONT>
refers to a sale or purchase made conditionally on or before the Distribution Date because the securities of the <FONT STYLE="white-space:nowrap">spun-off</FONT> entity have not yet been distributed. &#147;When-issued&#148; trades generally settle
within two trading days after the Distribution Date. On the first trading day following the Distribution Date, any &#147;when-issued&#148; trading of our common stock will end and <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT>
trading will begin. <FONT STYLE="white-space:nowrap">&#147;Regular-way&#148;</FONT> trading refers to trading after the security has been distributed and typically involves a trade that settles on the second full trading day following the date of
the trade. See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Trading</FONT> Prior to the Distribution Date&#148; beginning on page&nbsp;105 of this Information Statement for more information. We cannot predict the
trading prices for our common stock before, on or after the Distribution Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will happen to the listing of Illumina&#146;s common stock? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina&#146;s common stock will continue to trade on Nasdaq under the ticker symbol &#147;ILMN&#148; after
the Distribution. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Will the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> affect the trading price of my Illumina common
stock? </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We expect the trading price of shares of Illumina common stock immediately following the Distribution to be
lower than the trading price immediately prior to the Distribution because the trading price will no longer reflect the value of GRAIL. Furthermore, until the market has fully analyzed the value of Illumina without GRAIL, the trading price of shares
of Illumina common stock may fluctuate and result in a higher volatility in the price of our common stock. There can be no assurance that, following the Distribution, the combined trading prices of the Illumina common stock and the GRAIL common
stock will equal or exceed what the trading price of Illumina common stock would have been in the absence of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">It is possible that, after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the combined equity value of Illumina and GRAIL will be less
than Illumina&#146;s equity value before the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will happen to Illumina&#146;s equity incentive awards in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off?</FONT> </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We expect that each Illumina equity incentive award outstanding as of the Distribution Date held by directors
and employees that will continue at Illumina will remain outstanding and continue to be subject to the same terms and conditions following the Distribution Date, but with adjustments to the number of shares of Illumina common stock subject to such
award in order to preserve its value. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will happen to GRAIL&#146;s cash-based equity incentive awards in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off?</FONT> </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each GRAIL cash-based equity incentive award (each, a &#147;Cash-Based Equity Award&#148;) outstanding as of
the Distribution Date may convert into an equity-based award that settles in shares of GRAIL common stock. If converted, we expect that the number of shares subject to such award will be based on the value of the award at the time of the
Distribution compared to the value of the GRAIL shares in the Distribution, and will otherwise continue to be subject to the same terms and conditions following the Distribution Date (each such converted award, a &#147;GRAIL RSU&#148;).
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will GRAIL&#146;s relationship be with Illumina following the
<FONT STYLE="white-space:nowrap">Spin-Off?</FONT> </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the Distribution, GRAIL and Illumina will be separate companies with separate management teams and
separate boards of directors and Illumina may retain up to 14.5% of the outstanding shares of our common stock. GRAIL will enter into a separation and distribution agreement with Illumina to effect the separation and provide a framework for the
relationship between GRAIL and Illumina after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> (the &#147;Separation and Distribution Agreement&#148;), and will enter into certain other agreements, including a Tax Matters Agreement (as defined
below), and a Stockholder and Registration Rights Agreement (as defined below) with respect to Illumina&#146;s continuing ownership of GRAIL common stock. These agreements will allocate between GRAIL and Illumina the obligations of Illumina and its
subsidiaries attributable to periods prior to, at and after the Distribution and govern the relationship between GRAIL and Illumina following the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> In addition to the aforementioned agreements, we are
also currently party to, or intend to enter into, various other agreements with Illumina and its subsidiaries, including a supply and commercialization agreement and license agreements. For additional information regarding the Separation and
Distribution Agreement, Tax Matters Agreement, and Stockholder and Registration Rights Agreement, see the sections entitled &#147;Risk Factors&#151;Risks Relating to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> and &#147;Certain
Relationships and Related Party Transactions&#148; beginning on pages&nbsp;84 and 202, respectively, of this Information Statement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>How will Illumina vote any shares of GRAIL common stock it retains? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina is expected to agree to vote any shares of GRAIL common stock that it retains in proportion to the
votes cast by GRAIL&#146;s other stockholders and is expected to grant GRAIL a proxy to vote its shares of GRAIL common stock in such proportion. For additional information on these voting arrangements, see &#147;Certain Relationships and Related
Party Transactions&#151;Agreements with Illumina&#151;Stockholder and Registration Rights Agreement&#148; beginning on page&nbsp;203 of this Information Statement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What does Illumina intend to do with any shares of GRAIL common stock it retains?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Illumina intends to hold for investment purposes any GRAIL common stock that it retains after the Distribution.
Illumina expects that the IRS private letter ruling will require that all retained shares be sold or otherwise disposed of by Illumina as soon as warranted consistent with the business reasons for the retention of those shares, but in no event later
than five years after the Distribution. Such dispositions could include a sale of its shares for cash, distributions of GRAIL common stock to Illumina stockholders or securityholders as dividends or in exchange for outstanding shares of Illumina
common stock, indebtedness or other securities, or any combination thereof. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who will manage GRAIL following the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT>
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">GRAIL is led by Robert Ragusa, who is GRAIL&#146;s Chief Executive Officer, and Aaron Freidin, who is
GRAIL&#146;s Chief Financial Officer. For more information regarding GRAIL&#146;s directors and management, see the section entitled &#147;Management&#148; beginning on page&nbsp;187 of this Information Statement. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Do I have appraisal rights in connection with the <FONT STYLE="white-space:nowrap">Spin-Off?</FONT>
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. Holders of Illumina common stock are not entitled to appraisal rights in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who is the transfer agent and registrar for GRAIL common stock? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Computershare is the transfer agent and registrar for GRAIL common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Are there risks associated with owning shares of GRAIL common stock? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. Our business faces both general and specific risks and uncertainties. Our business also faces risks
relating to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will also face risks associated with being an independent, publicly traded company. Accordingly, you should read
carefully the information set forth in the section entitled &#147;Risk Factors&#148; beginning on page&nbsp;28 of this Information Statement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Where can I get more information? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have any questions relating to the mechanics of the Distribution, you should contact the distribution
agent at: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">150 Royall Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Canton, MA
02021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Phone: <FONT STYLE="white-space:nowrap">(877)&nbsp;373-6374</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: web.queries@computershare.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Before the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> if you have any questions relating to the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> you should contact Illumina at: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Illumina, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">5200 Illumina Way </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA
92122 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Phone: <FONT STYLE="white-space:nowrap">(858)&nbsp;202-4500</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: ir@illumina.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">After
the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> if you have any questions relating to GRAIL, you should contact us at: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">GRAIL, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1525 O&#146;Brien Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Phone: (833) 694-2553 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A link to our investor relations website
and additional contact information will be made available at https://grail.com. Information contained on, or connected to, our website does not and will not constitute part of this Information Statement or the Registration Statement on Form 10, of
which this Information Statement is a part, or any other filings with, or any information furnished or submitted to, the SEC. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY OF THE <FONT STYLE="white-space:nowrap">SPIN-OFF</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Distributing Company </P></TD>
<TD>Illumina, Inc., or &#147;Illumina,&#148; a Delaware corporation that holds all of our common stock issued and outstanding prior to the Distribution. After the Distribution, Illumina will own up to 14.5% of the shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Distributed Company </P></TD>
<TD>GRAIL, LLC, or &#147;GRAIL,&#148; a Delaware limited liability company and a wholly owned subsidiary of Illumina. Prior to the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> GRAIL will be converted into a Delaware
corporation and will be renamed GRAIL, Inc. After the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will be an independent, publicly traded company. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Distributed Securities </P></TD>
<TD>At least 85.5% of the shares of our common stock owned by Illumina, which will be at least 85.5% of our common stock issued and outstanding immediately prior to the Distribution. Illumina may retain up to 14.5% of the outstanding shares of
GRAIL&#146;s common stock and expects to hold any retained shares for investment purposes. Illumina expects that the IRS private letter ruling will require that all retained shares be sold or otherwise disposed of by Illumina as soon as warranted
consistent with the business reasons for the retention of those shares, but in no event later than five years after the Distribution. Such dispositions could include a sale of its shares for cash, distributions of GRAIL common stock to Illumina
stockholders or securityholders as dividends or in exchange for outstanding shares of Illumina common stock, indebtedness or other securities, or any combination thereof. Based on the approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Illumina common stock outstanding on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024,
and applying the distribution ratio pursuant to which, for every &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of Illumina common stock outstanding,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of GRAIL common stock will be distributed, approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of GRAIL common stock will be distributed in the aggregate. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> each Cash-Based Equity Award outstanding as of the Distribution Date may convert into GRAIL RSUs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Record Date </P></TD>
<TD>The Record Date is the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Distribution Date </P></TD>
<TD>The Distribution Date is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Distribution Ratio </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For every &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of Illumina common stock each
Illumina stockholder holds on the Record Date, such stockholder will receive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of our common stock. The distribution agent will distribute only
whole shares of our common stock in the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Treatment</FONT> of Fractional Shares&#148; beginning on page&nbsp;100 of
this Information Statement for more detail. Please note that if you sell your shares of Illumina common stock on or before the Distribution Date, the buyer of those shares may in some circumstances be entitled to receive the shares of our
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
common stock to be distributed in respect of the Illumina shares that you sold. For more information, see the section entitled &#147;The
<FONT STYLE="white-space:nowrap">Spin-Off&#151;Trading</FONT> Prior to the Distribution Date&#148; beginning on page 105 of this Information Statement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">The Distribution </P></TD>
<TD>On the Distribution Date, Illumina will release the shares of our common stock to the distribution agent to distribute to Illumina stockholders. Illumina will distribute our shares in book-entry form and thus we will not issue any physical stock
certificates. You will not be required to make any payment, surrender or exchange your shares of Illumina common stock or take any other action to receive your shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Fractional Shares </P></TD>
<TD>The distribution agent will not distribute any fractional shares of our common stock to Illumina stockholders. Instead, the distribution agent will first aggregate fractional shares into whole shares, then sell the whole shares in the open
market at prevailing market prices on behalf of Illumina stockholders entitled to receive a fractional share, and finally distribute the aggregate cash proceeds of the sales, net of brokerage fees and other costs, pro rata to these holders (net of
any required withholding for taxes applicable to each holder). If you receive cash in lieu of fractional shares, you will not be entitled to any interest on the payments. The cash you receive in lieu of fractional shares generally will, for U.S.
federal income tax purposes, be taxable as described under the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT> U.S. Federal Income Tax Consequences of the
<FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Conditions to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </P></TD>
<TD>Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is subject to the satisfaction, or the Illumina Board&#146;s waiver, of the following conditions: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Illumina Board shall have authorized and approved the Distribution and not withdrawn such authorization and
approval, and shall have declared the dividend of our common stock to Illumina stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ancillary agreements contemplated by the Separation and Distribution Agreement shall have been executed by
each party to those agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock shall have been accepted for listing on Nasdaq or another national securities exchange approved
by Illumina, subject to official notice of issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the SEC shall have declared effective our Registration Statement on Form&nbsp;10, of which this Information
Statement is a part, under the Exchange Act, and no stop order suspending the effectiveness of the Registration Statement shall be in effect and no proceedings for that purpose shall be pending before or threatened by the SEC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina shall have received a private letter ruling from the IRS and the written opinion of Cravath,
Swaine&nbsp;&amp;&nbsp;Moore LLP, each </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="43%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of which shall remain in full force and effect, that, subject to the limitations specified therein and the accuracy of and compliance with certain representations, warranties and covenants, the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Illumina Board shall have received one or more opinions (which have not been withdrawn or adversely modified)
in customary form from one or more nationally recognized valuation, appraisal or accounting firms, or investment banks, as to the solvency and financial viability of Illumina prior to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and each of
Illumina and GRAIL after the consummation of the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no order, injunction or decree issued by any governmental authority of competent jurisdiction or other legal
restraint or prohibition preventing consummation of the Distribution shall be in effect, and no other event outside the control of Illumina shall have occurred or failed to occur that prevents the consummation of the Distribution;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no other events or developments shall have occurred prior to the Distribution Date that, in the judgment of the
Illumina Board, would result in the Distribution having a material adverse effect on Illumina or its stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the Distribution Date, notice of Internet availability of this Information Statement or this Information
Statement shall have been mailed to the holders of Illumina common stock as of the Record Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina shall have duly elected the individuals to be listed as members of our post-Distribution Board in this
Information Statement, and such individuals shall be the members of our Board immediately after the Distribution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately prior to the Distribution Date, our Certificate of Incorporation and Bylaws, each in substantially
the form filed as an exhibit to the Registration Statement on Form 10, of which this Information Statement is a part, shall be in effect. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The fulfillment of the foregoing conditions will not create any obligation on the part of Illumina to complete the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> If the Illumina Board waives any condition prior to the effectiveness of the Registration Statement on Form&nbsp;10, of which this Information Statement is a part, and the result of such waiver is material
to Illumina stockholders, Illumina will file an amendment to the Registration Statement to revise the disclosure in this Information Statement accordingly. In the event that the Illumina Board waives a condition after the Registration Statement on
Form 10, of which this Information Statement is a part, becomes effective and such waiver is material to Illumina stockholders, Illumina will communicate such change to Illumina stockholders by filing a Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> describing the change. For a complete discussion of the </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
conditions to the Distribution, see the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT>
beginning on page&nbsp;105 of this Information Statement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition, Illumina has the right not to complete the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> if, at any time, the Illumina Board determines, in its sole and absolute discretion, that the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> is not in the best interests of Illumina or its stockholders, or is otherwise not advisable. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, Illumina and GRAIL will
have incurred significant costs related to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including fees for consultants, financial and legal advisors, accountants and auditors, that will not be recouped. Total
<FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs associated with the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> are preliminarily estimated to range from $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is completed. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, the
<FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs will generally be limited to the transaction costs incurred for services rendered as of the date the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is abandoned, which will be less
than the range noted above. Our management will also have devoted significant time to manage the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> process, which will decrease the time they will have to manage the business of GRAIL.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Trading Market and Ticker Symbol </P></TD>
<TD>We intend to file an application to list our common stock on Nasdaq under the ticker symbol &#147;GRAL.&#148; We anticipate that, on or shortly before the Record Date, trading of shares of our common stock will begin on a &#147;when-issued&#148;
basis and will continue up to and including the Distribution Date, and we expect that <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> trading of our common stock will begin the first trading day after the Distribution Date.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We also anticipate that, on or shortly before the Record Date, there will be two markets in Illumina common stock: (i)&nbsp;a <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> market on which shares of
Illumina common stock will trade with an entitlement for the purchaser of Illumina common stock to receive shares of our common stock to be distributed in the Distribution, and (ii)&nbsp;an
<FONT STYLE="white-space:nowrap">&#147;ex-distribution&#148;</FONT> market on which shares of Illumina common stock will trade without an entitlement for the purchaser of Illumina common stock to receive shares of our common stock. For more
information, see the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Trading</FONT> Prior to the Distribution Date&#148; beginning on page&nbsp;105 of this Information Statement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Tax Consequences to Illumina Stockholders </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is conditioned upon Illumina&#146;s receipt of a private letter ruling from the IRS
and a written opinion of Cravath, Swaine&nbsp;&amp; Moore LLP, each of which shall remain in full force and effect, that, subject to the limitations specified therein and the accuracy of and compliance with certain representations, warranties and
covenants, the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code. If the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> qualifies for such treatment, for U.S. federal income tax purposes, no </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
gain or loss will be recognized by, or be includible in the income of, a U.S. Holder (as defined in the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT>
U.S. Federal Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement) as a result of the Distribution, except with respect to any cash received by Illumina
stockholders in lieu of fractional shares. After the Distribution, Illumina stockholders generally should allocate their aggregate tax basis in their Illumina common stock held immediately before the Distribution between their Illumina common stock
and our common stock in proportion to their relative fair market values on the date of the Distribution (subject to certain adjustments). See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT> U.S. Federal
Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement for more information regarding the potential tax consequences to you of the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We urge you to consult your tax advisor as to the specific tax consequences of the Distribution to you, including the effect of any U.S. federal, state, local or foreign tax laws and of changes in applicable tax laws.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Relationship with Illumina After the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </P></TD>
<TD>Following the Distribution, Illumina may retain up to 14.5% of the outstanding shares of our common stock. Illumina intends to hold any retained shares for investment purposes. Illumina expects that the IRS private letter ruling will require
that all retained shares be sold or otherwise disposed of by Illumina as soon as warranted consistent with the business reasons for the retention of those shares, but in no event later than five years after the Distribution. Such dispositions could
include a sale of its shares for cash, distributions of GRAIL common stock to Illumina stockholders or securityholders as dividends or in exchange for outstanding shares of Illumina common stock, indebtedness or other securities, or any combination
thereof. We intend to enter into several agreements with Illumina related to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> which will govern the relationship between Illumina and us after completion of the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> and allocate between Illumina and us various assets, liabilities, rights and obligations. These agreements include: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Separation and Distribution Agreement that will set forth Illumina&#146;s and our agreements regarding the
principal actions that both parties will take in connection with the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and aspects of our relationship following the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Tax Matters Agreement that will govern the respective rights, responsibilities and obligations of Illumina and
us after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> with respect to all tax matters and will include restrictions to preserve the <FONT STYLE="white-space:nowrap">tax-free</FONT> status of the Distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Stockholder and Registration Rights Agreement that will govern the respective rights, responsibilities and
obligations of Illumina and us after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> with respect to Illumina&#146;s continuing ownership of GRAIL common stock. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition to the above agreements, we are also currently party to, or intend to enter into, various other agreements with Illumina and its subsidiaries, including a supply and commercialization agreement and license
agreements. We describe these arrangements in greater detail under the section entitled &#147;Certain Relationships and Related Party Transactions&#148; beginning on page&nbsp;202 of this Information Statement and describe some of the risks of these
arrangements under the section entitled &#147;Risk Factors&#151;Risks Relating to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;84 of this Information Statement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend Policy </P></TD>
<TD>We do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends on our common stock will be made at the discretion of our Board and will depend upon certain factors. For more information, see
the section entitled &#147;Dividend Policy.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Transfer Agent </P></TD>
<TD>Computershare Trust Company, N.A. (&#147;Computershare&#148;). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>Our business faces both general and specific risks and uncertainties. Our business also faces risks relating to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will also
face risks associated with being an independent, publicly traded company. Accordingly, you should read carefully the information set forth under the section entitled &#147;Risk Factors&#148; beginning on page&nbsp;28 of this Information Statement.
</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the following risks and other information in this Information Statement in evaluating GRAIL and GRAIL common
stock. Any of the following risks and uncertainties could materially adversely affect our business, financial condition, and results of operations. The following risks have generally been separated into five groups: risks relating to our business
and industry, risks relating to regulation and legal compliance, risks relating to intellectual property, risks relating to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> and risks relating to our common stock. References to &#147;we,&#148;
&#147;our,&#148; &#147;us,&#148; and words of similar import in this section refer to GRAIL and, unless otherwise specified, its consolidated subsidiaries. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Business and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We operate in a rapidly evolving field and have a limited operating history, which makes it difficult to evaluate our current business
and predict our future performance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate in a rapidly evolving field and, having commenced operations in January 2016, have
a limited operating history. We completed our first sale of our multi-cancer early detection test, Galleri, in <FONT STYLE="white-space:nowrap">mid-2021</FONT> and our other products and products in development have an even more limited history,
with most still not in commercial distribution. We have funded our operations to date primarily with the proceeds from the sale of equity securities and capital contributions from Illumina and, to a lesser extent, revenue derived from sales of
Galleri and biopharmaceutical business revenue. Our short operating history as a company, evolving business strategies, and rapid growth may make it difficult to evaluate our current business or our future success and the risks and challenges we may
encounter, and may increase the risk that we will not continue to grow at or near historical rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to address the risks and
difficulties that we face, including those described elsewhere in this &#147;Risk Factors&#148; section, our business, financial condition, results of operations, and growth prospects could be materially adversely affected. We have encountered in
the past, and expect to encounter in the future, risks and difficulties frequently experienced by companies with limited operating histories in new and rapidly evolving fields. If our assumptions regarding these risks and difficulties, which we use
to plan and operate our business, are incorrect or change, or if we do not address these risks and difficulties, our results of operations could differ materially from our expectations and our business, financial condition, results of operations,
and growth prospects could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses in each period since our inception and
anticipate that we will continue to incur net losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant
net losses. Our net loss was $5.4&nbsp;billion for fiscal year 2022, $911.5&nbsp;million for the 2021 successor period, and $336.2&nbsp;million for the 2021 predecessor period. Substantially all of our net losses since inception have resulted from
our research and development programs, commercialization efforts, investments in our facilities, payments to licensors, and general and administrative costs associated with our operations, as well as intangible asset amortization and goodwill
impairment of $4.7&nbsp;billion related to the intangibles and goodwill recorded by Illumina upon the acquisition of GRAIL and application of pushdown accounting and other costs. As of January&nbsp;1, 2023, we had an accumulated deficit of
$6.3&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested significant financial resources in research and development activities, including to develop our
methylation platform, and to develop our products, such as Galleri and our precision oncology portfolio. We have also invested significant resources to conduct large scale clinical studies to improve Galleri and current and future products,
including our diagnostic aid for cancer (&#147;DAC&#148;) test, and to commercialize Galleri and plan for potential commercial launches of our future and current products in other markets. The amount of our future net losses will depend, in part, on
the level of our future expenditures and our ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generate additional revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good or reliable indication of our future performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and operating losses for the foreseeable future if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire, and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing clinical studies and initiate and conduct additional clinical studies to support the
development and commercialization of our products and future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to expand our laboratory capacity and enhance operating capabilities for greater commercial scale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals, clearances, or certifications, or coverage and reimbursement, that may be necessary or
desired for our products and future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and expand sales, marketing, and distribution infrastructure for purchases of our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional intellectual property and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under any license or collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property
obtained through license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide additional infrastructure to support our continued research and development operations and any planned
commercialization efforts in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against any litigation, including but not limited to any patent disputes, employment matters, product
liability claims or other lawsuits related to our products, our marketing, advertising, or labeling, or our clinical research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">support international commercial expansion of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to engage the medical community and others to drive awareness and adoption of multicancer early
detection (&#147;MCED&#148;) testing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet the requirements and demands of being a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our products or future products may not perform as expected, and the results of our clinical studies may not support the launch or use
of our products or future products and may not comply with the requirements, or be replicated in later studies or in the post-market or real-world setting, required to support a commercial opportunity or for any necessary or desirable regulatory
clearances, approvals, or certifications, or reimbursement or coverage. This could materially and adversely affect our business, financial condition, results of operations, and growth prospects.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to provide reliable, high-quality products that perform as indicated in our product labeling,
marketing, and advertising material, as well as our ability to complete clinical studies and comply with applicable regulatory requirements that enable us to commercialize our products and future products. Our commercial product, Galleri, which we
have launched as a laboratory developed test (&#147;LDT&#148;) in the United States and for which we are pursuing a premarket approval application (&#147;PMA&#148;) with the U.S. Food and Drug Administration (the &#147;FDA&#148;) and our precision
oncology portfolio, which we currently offer on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">research-use-only</FONT></FONT> basis, and our future products in development, including DAC, may not perform as expected. Results
from our ongoing or future studies, or from the post-market or real-world setting, involving current or future products or our methylation platform may be inconsistent with certain results obtained from our previous
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies, or from interim results initially reported on those studies. For example, certain results of an early analysis from the first screening test (the prevalent screening round) in the
NHS-Galleri Trial will impact the extent to which NHS commences a potential two-year commercial pilot in England. These results represent limited information from only one year of results out of the three-year trial period, and final results from
the full three-year period, which will inform the extent to which NHS commences broad commercial implementation, may differ from these initial results results for a variety of reasons. It is possible that the results of the early analysis or final
results will be unsuitable to the NHS, which could have a significant adverse impact on the success of our commercial efforts for Galleri, our ability to achieve FDA authorization at all or within our anticipated timelines, our brand and reputation,
our business, and our growth prospects. Furthermore, other studies have been or may be conducted in populations (such as our SUMMIT study which was conducted in a population of tobacco users) or under other circumstances which make their results
more complicated to interpret or result in data that is more difficult to compare. In addition, as Galleri and our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">research-use-only</FONT></FONT> offering are currently available to
customers and others, any studies, including those conducted by third parties, that use our current or future products, or that examine elements of our methylation platform, may produce results that are inconsistent to evaluate independently or
comparatively from our own studies. If any such inconsistent results were to be produced, either before or after launch of a product or future product, our reputation, business, financial condition, results of operations, and growth prospects would
suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products require a number of complex and sophisticated biochemical and bioinformatics processes, which could be adversely
impacted by a number of different factors. An operational or technological failure in one of these complex processes or fluctuations in external variables may result in performance characteristics, such as sensitivity or specificity rates, that are
lower than we anticipate or that vary between test runs or in a higher than anticipated number of tests that fail to produce results. In addition, we continue to evaluate and refine our algorithms and other processes under development. These
refinements may inadvertently result in unanticipated issues that may reduce our performance characteristics, such as sensitivity or specificity rates, or otherwise adversely affect the performance of our tests and their results. Galleri was
launched in the United States as an LDT in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> We plan to complete a PMA submission for Galleri, for which the FDA has granted breakthrough device designation. Additionally, following the future launch
of DAC as an LDT, we may voluntarily decide to seek clearance or approval from the FDA. The FDA and other regulators may require that we generate additional clinical data to support such clearance, approval, or certification, which could result in
delays, increased costs, or other limitations on our ability to receive such clearance, approval, or certification, if at all, including narrowed indication or labeling than expected or desired. For additional information, see &#147;&#151;The
regulatory clearance, approval, or certification processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable regulatory
approvals, clearances, or certifications, or if such approvals, clearances, or certifications are significantly delayed, our business will be substantially harmed.&#148; Our stakeholders include certain third parties, including telemedicine and
phlebotomy providers, couriers, storage and data collection management providers, and ordering and results delivery providers, among others, which we refer to as patient-facing service providers. Other important third parties are clinical study
providers and collaborators, including clinical research organization (&#147;CRO&#148;) and partners. Negative results experiences or outcomes, including those published by third parties, such as patient-facing service providers and other partners,
that use our methylation platform, our products, or our offerings may harm our reputation, business, and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we
plan to improve our products to enhance performance, offerings, scalability, and/or cost of goods. However, we may not be successful in transitioning our products to a new or enhanced version or iteration. Product development involves a lengthy and
complex process and we may be unable to commercialize, validate, or improve performance of any of our products on a timely basis, or at all. Our failure to successfully develop new and/or improved products (including new versions of existing
products) on a timely basis could have a material adverse effect on our results of operation and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, generating the
clinical data necessary to validate and support the launch of our products as LDTs and enhanced versions of products and subsequently obtain regulatory clearance, approval, or certification, or coverage and reimbursement, is time-consuming and
carries with it the risk of not yielding the desired results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The performance achieved in published studies may not be replicated in later studies that may be required to obtain or maintain premarket clearance, approval, or certification, or coverage and
reimbursement. Limited results from earlier-stage studies may not predict results from studies in larger numbers of participants or participants drawn from different populations. Unfavorable results from ongoing or future clinical studies could
result in delays in, modifications to, or abandonment of ongoing or future clinical studies, or abandonment of a product development program, or may delay, limit, or prevent regulatory clearances, approvals, or certifications, or coverage and
reimbursement of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The clinical study process is lengthy and expensive with uncertain outcomes. We have encountered
delays and may encounter future delays in, or unexpected data from, our clinical studies, and may therefore be unable to complete our clinical studies on the timelines we expect, if at all, which could materially and adversely impact our ability to
launch our products and seek regulatory clearance or approval, or coverage and reimbursement. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive,
time-consuming, and subject to uncertainty. Initiating and completing clinical studies necessary to validate and market our products, and to support regulatory authorizations or certifications and coverage and reimbursement, will be time-consuming
and expensive and the outcomes are inherently uncertain. Clinical studies must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities&#146; legal requirements and regulations, and are subject
to oversight by governmental agencies and institutional review boards (&#147;IRBs&#148;) or ethics committees at the medical institutions where the clinical studies are conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of our development efforts and clinical studies of our products conducted to date and ongoing or future studies of our current or
future products may not be predictive of the results of later clinical studies, and interim results of a clinical study do not necessarily predict final results. Our interpretation of data and results from our clinical studies do not ensure that we
will achieve similar or favorable results in future clinical studies. In addition, clinical data are often susceptible to various interpretations, analyses, and methodological limitations, and many companies that have believed their products
performed satisfactorily in earlier clinical studies have nonetheless failed to replicate results in later clinical studies. Products in later future clinical studies may fail to show the desired safety and efficacy despite having success in
previous clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we cannot guarantee that any clinical studies will be conducted as planned or completed on
schedule, if at all, or within the anticipated budget. The timely completion of clinical studies in accordance with their protocols and applicable requirements depends, among other things, on our ability to enroll a sufficient number of participants
who remain in the study until its conclusion. Many of our clinical studies require enrolling a large number of asymptomatic participants (i.e., individuals without symptoms of cancer) who may not see value in enrollment. Additionally, we may
encounter delays as a result of the administrative complexities in managing and recruiting for studies of this scope and size. If we are unable to recruit sufficient participants for our clinical studies, including PATHFINDER 2, or if we are unable
to maintain sufficient participation of enrolled participants to maintain statistical power for our endpoints, our product development, commercialization activities, and our ability to seek regulatory clearance or approval for our products could be
delayed, require modification, or be prevented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our PMA submission for Galleri requires clinical data, including certain
data from our ongoing PATHFINDER 2 study and the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, both of which we are conducting under an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> Investigational Device Exemption
(&#147;IDE&#148;) application. We may encounter difficulties enrolling or maintaining a sufficient number of participants in our current or future studies, including our PATHFINDER 2 study or <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT>
Trial. Delays in our studies would cause us to delay completion of our PMA submission for Galleri, which would negatively impact our business, financial condition, results of operations, and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initiation and completion of clinical studies may be prevented, delayed, or halted for
numerous reasons, including as a result of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to generate sufficient data to support the initiation or continuation of clinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to rely on previously-collected data on earlier versions of our products, such as Galleri, in
support of the launch or submission for marketing authorization (or certification) of the later or enhanced versions of our products, including Galleri, or our other products and future products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement to submit an IDE or comparable foreign application to the FDA or comparable foreign regulatory
authorities, which must become effective prior to commencing certain human clinical studies of medical devices, and which the FDA or comparable foreign regulatory authorities may disapprove; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays caused by participants withdrawing from clinical studies or failing to return for <FONT
STYLE="white-space:nowrap">follow-up</FONT> or by institutions failing to submit data, including <FONT STYLE="white-space:nowrap">follow-up</FONT> data, to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failure in reaching a consensus or agreement, if required, with regulatory agencies on study design or
feedback from regulatory agencies necessitating changes to ongoing or planned clinical study design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failure in reaching agreement on acceptable terms with CROs, service providers, and clinical study
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failure in obtaining any required IRB approval or ethics committee approval for our clinical study
sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in amending, or the inability to amend, our <FONT STYLE="white-space:nowrap">IRB-</FONT> or ethics
committee-approved protocols at clinical study sites when necessary or desired; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty or delays in collaborating with sites, institutions, and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, investigators, sites, or participants to comply with the applicable study protocol or applicable
regulatory requirements and standards for data collection, reporting, records maintenance, or data integrity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us or any CROs or other third parties to adhere to clinical study requirements, including the
applicable protocol; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with good clinical practice (&#147;GCP&#148;) and good laboratory practice
(&#147;GLP&#148;) requirements, and/or other applicable regulations and requirements of the FDA or other applicable governmental authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with applicable data privacy and security laws, including laws related to clinical studies such
as the European Union&#146;s (&#147; EU&#148;) or United Kingdom&#146;s General Data Protection Regulation (&#147;GDPR&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges caused by transferring personal information or biological samples from the EU, United Kingdom, or
other countries to our systems or facilities in the United States for processing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our products and future products to achieve acceptable performance metrics, such as sensitivity,
specificity, positive predictive value, and/or safety endpoints; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unacceptable safety findings, including findings related to the risk, such as higher likelihood, of false
positive test results (which could lead to unnecessary confirmatory testing, such as biopsy, or anxiety) or false negative test results (which could lead to foregoing standard of care screening, a delay in diagnosis or disease progression);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or suspension of a study or site by us or the data safety monitoring board (or independent data
monitoring committee), suspension or termination of a study or site by an IRB, ethics committee, or institution, or clinical hold or termination of a study or site by a regulatory authority, including the FDA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to collaborate with clinical investigators, including if they are disqualified, terminated,
suspended, or change affiliated institutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse inspections of our clinical study sites or results by any applicable regulatory authority, including the
FDA, NHS, or United Kingdom Medicines and Healthcare products Regulatory Agency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in statutory or regulatory requirements or guidance, or clinical guidelines, that require amending
existing or designing new clinical protocols, obtaining new IRB or ethics committee approvals, modifying our clinical studies, modifying our consent process or obtaining additional consent from study participants, or altering the pathway to
clearance, approval, or certification of our products and future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical studies of our products and future products being greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">destruction or compromise of, or other inability to access or receive, clinical study samples processed, stored,
managed, or otherwise in the control of a clinical site or other third party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determination that data from research conducted outside the United States does not meet the FDA&#146;s
requirements for submission and support of a marketing authorization or future clinical study IDE application, for example because the foreign data are not applicable to the U.S. population and U.S. medical practice, the studies have been performed
by clinical investigators of unsuitable competence, or the FDA cannot validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies of our products and future products producing negative or inconclusive results, which may result
in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon development programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such delays could adversely affect the costs, timing, or successful completion of our clinical studies. Moreover, we depend on our
collaborators and on medical and clinical institutions and CROs to conduct our clinical studies in compliance with applicable GCP and other regulatory requirements, and while we have agreements governing their committed activities, we have limited
influence over their actual performance. To the extent we, our collaborators or the CROs fail to enroll participants for our clinical studies, fail to conduct the study according to applicable GCP or other regulatory requirements, or are delayed for
a significant time in the execution of studies, including achieving full enrollment, we may be affected by increased costs, program delays, enforcement actions, or a determination that the data are unusable for regulatory or product development
purposes. In addition, clinical studies that are conducted in countries outside the United States may subject us to further delays and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to initiate or complete clinical studies successfully could result in additional costs to us, slow down or prevent our product
development and receipt of positive reimbursement coverage decisions, or impair our ability to generate revenue. Delays in initiating or completing our planned clinical studies could also allow third parties to bring products to market sooner than
expected, which could impair our ability to successfully commercialize our products and future products, if launched, and may harm our business, financial condition, results of operations, and growth prospects. In addition, many of the factors that
may cause, or lead to, a delay in initiation or completion of clinical studies may also ultimately lead to the delay or the narrowing or denial of any regulatory clearance, approval, or certification we may seek with respect to our products and
future products. Delays in the initiation or completion of any clinical study of our products or future products in development, such as Galleri, our precision oncology portfolio, or DAC, or seeking coverage and reimbursement, will increase our
costs, slow down or jeopardize our product development and regulatory clearance, approval, or certification process, and delay or potentially jeopardize broad adoption of our products and future products and their ability to generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial products may fail to achieve the degree of market acceptance necessary
for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of any of our marketed products, including Galleri and our precision oncology
portfolio, or future products will depend on the degree of market acceptance by consumers, including self-insured employers, health systems, healthcare providers, life insurance companies, patients, and, over the longer-term, third-party payors. The
degree of market acceptance of our products will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance, validation, and clinical utility of such products as demonstrated in clinical studies, from
real-world use, and published in peer-reviewed journals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate the clinical validation and utility of our products and their potential advantages to
the medical community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our products to demonstrate comparable or <FONT STYLE="white-space:nowrap">non-inferior</FONT>
performance in real-world intended use populations as in clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of consumers, including self-insured employers, health systems, healthcare providers, life
insurance companies, patients, and others in the medical community to utilize our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of commercial third-party payors and government payors to cover and reimburse our products, the
scope and amount of which will affect an individual&#146;s or entity&#146;s willingness or ability to pay for our products and likely heavily influence healthcare providers&#146; decisions to recommend our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">willingness of providers, patients, and others to learn about our products, including Galleri and DAC, and
establish a sense of understanding and confidence in the use of our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to Galleri, which was launched as an LDT in the United States for use in an asymptomatic population,
the concern that the product could lead to unnecessary medical screening procedures or a high false positive rate and the associated costs of unnecessary workups resulting from false positives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief of providers, patients, and others that the use of Galleri in its intended use population is
clinically appropriate, and not restricting its use to a narrower intended population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction or market acceptance of future third-party products, including the expansion of the capabilities
of existing products and tests that are reimbursed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our partners and our employees and contractors to ensure the safety and privacy of our patient
data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity (adverse or positive) concerning our products or operations (including third-party partners,
patient-facing service providers, vendors, or suppliers) or future third-party products, including adverse publicity resulting from the use of our products or offerings by third parties, including partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of our marketing and distribution support and patient-facing service providers.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of our products, once introduced, to be listed in physician guidelines or of our studies to produce
favorable and consistent results or to be published in peer-reviewed journals could limit the adoption of our products. In addition, healthcare providers and third-party payors, including the Centers for Medicare and Medicaid Services
(&#147;CMS&#148;), may rely on physician guidelines issued by industry groups, medical societies, and other key organizations, such as the United States Preventive Services Task Force (&#147;USPSTF&#148;), an independent, volunteer panel of experts
in the field of prevention, evidence-based medicine and primary care, before utilizing or reimbursing the cost of any diagnostic or screening test. Although we have a number of clinical studies underway designed to evaluate the clinical validity of
Galleri, our product is not yet, and may never be, listed in any such guidelines, even if approved by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if our products or the technology underlying them do not receive sufficient
favorable exposure in peer-reviewed publications, the rate of physician and market acceptance of our products and positive reimbursement coverage decisions for our products could be negatively affected. The publication of clinical data in
peer-reviewed journals is a crucial step in commercializing and helping obtain reimbursement for products, and our inability to control when, if ever, results are published, if positive, may delay or limit our ability to derive sufficient revenues
from any product that is developed using data from a clinical study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we believe that FDA approval for Galleri may provide
clinical and regulatory credibility and validation in the view of providers, third-party payors, and others, and our failure to achieve FDA approval, at all or within our anticipated timelines, could limit adoption of Galleri, even if we continue to
publish data on its clinical validity and utility in peer-reviewed journals. Our PMA submission and a potential subsequent rejection or material delay (including a requirement to conduct additional studies) may reflect negatively on Galleri and the
ongoing and planned clinical studies used to support our PMA submission, which could lead healthcare providers, payors, and others to lose confidence in the utility or benefit of Galleri and our other products and future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to achieve broad market acceptance of our products would materially harm our business, financial condition, and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to generate sufficient revenue to offset our ongoing operating expenses and achieve and maintain profitability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate future revenue growth from product sales and achieve profitability depends on our ability to continue
commercializing our products. We completed our first sale of Galleri in <FONT STYLE="white-space:nowrap">mid-2021</FONT> and as of September&nbsp;30, 2023 we have sold approximately 125,000 Galleri tests through our existing market channels. We also
launched our precision oncology portfolio in 2023, which currently comprises a research use only (&#147;RUO&#148;) offering, and have partnered with several biopharmaceutical companies to deploy this offering. While we plan to commercially launch
DAC in the United States as an LDT, we cannot assure you that we will successfully be able to do so as planned, if at all, and our failure to do so may prevent us from generating increased revenue. Furthermore, even if we are able to launch any
future products in a timely manner, we may not be able to generate sufficient revenue to offset our costs and achieve profitability. Our ability to generate future revenue growth from product sales depends heavily on our success in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing clinical development, validation, and demonstration of the clinical utility of our products and future
products and continuing to improve product performance and expand product features over time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking, obtaining, and maintaining marketing authorizations or certifications that may be necessary or desired
for any versions of Galleri, DAC, and any future products that we develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and commercializing our products by maintaining and expanding our sales force, marketing, medical
affairs, and distribution infrastructure, and collaborating with commercialization partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investing in and enhancing our proprietary methylation platform, and enhancing later versions of our existing and
future products and offerings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance by consumers, including self-insured employers, health systems, healthcare providers,
life insurance companies, patients, and third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and maintaining supply and manufacturing relationships with third parties that can timely and
consistently provide adequate, in both amount and quality, products and services to support clinical development and the market demand for Galleri, our precision oncology portfolio, and, if launched, future versions of Galleri and DAC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving adequate coverage and reimbursement from government healthcare programs, health insurance
organizations, and other third-party payors for products that we launch; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving sufficient efficiencies and cost management strategies in our laboratory, supply chain, and elsewhere
to maintain an appropriate cost of goods sold to offer our products at an acceptable price in a <FONT STYLE="white-space:nowrap">pre-reimbursement</FONT> environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and
maintaining such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade
secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and trademarks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our
existing and future products and offerings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defending against third-party interference, invalidation, or infringement claims, if any; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring, and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate incurring significant costs to continue commercializing our products. Our expenses could increase beyond expectations if we are
required by the FDA or other regulatory agencies, or notified bodies to delay the launch of any new products, narrow or change our intended use or product claims, and modify or expand our clinical studies or to perform additional clinical studies,
either <FONT STYLE="white-space:nowrap">pre-</FONT> or post-approval (or certification), in addition to those that we currently anticipate. Additionally, it may be difficult for us to offset the costs of the high-single-digit royalty that we will be
required to pay under our agreement with Illumina. For more information, see &#147;Business,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Material Cash Requirements,&#148; and
&#147;Certain Relationships and Related Party Transactions&#151;Agreements with Illumina&#148; beginning on pages&nbsp;113, 182, and 202, respectively, of this Information Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to generate significant additional revenue to achieve and maintain profitability and will need to obtain additional funding to
continue operations. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. We may never be able to generate sufficient revenue to achieve or maintain profitability and our recent and
historical growth should not be considered indicative of our future performance. If we do not achieve or maintain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which could
have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>A substantial
majority of our revenue is generated from sales of Galleri and we are highly dependent on it for our success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began selling
Galleri in the United States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> Sales of Galleri accounted for a substantial majority of our revenue to date and we expect that such sales will continue to account for the substantial majority of our
revenue for the foreseeable future. Our ability to execute our growth strategy and become profitable will therefore depend upon the adoption of Galleri as a widely used MCED test. Continued adoption and use of Galleri will depend on several factors
discussed in these risk factors, including, among others, the prices we charge for our tests, the scope of coverage and amount of reimbursement available from third-party payors, including managed care organizations, private health insurers, and
government healthcare programs, such as Medicare and Medicaid in the United States and similar programs in other countries, the availability of clinical and real-world data that supports the value and impact of our tests, and the extent to which our
tests receive FDA authorization or a USPSTF grade A or B recommendation. We cannot assure you that Galleri will continue to maintain or gain market acceptance, and any failure to do so would harm our business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>One of the key elements of our strategy is to expand access to our tests by pursuing
coverage and reimbursement from third-party payors, both private and government payors. If our products do not receive adequate coverage and reimbursement, if at all, from third-party payors, our ability to expand access to our products beyond our
existing sales channels will be limited and our overall commercial success will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have coverage and
reimbursement from third-party payors, either private or government, for Galleri. However, a key element to our strategy is to expand access to our tests by pursuing coverage and reimbursement by third-party payors, including government payors.
Coverage and reimbursement by third-party payors, including managed care organizations, private health insurers, and government healthcare programs, such as Medicare and Medicaid in the United States and similar programs in other countries, for
early detection tests we offer or are planning to offer, can be limited and uncertain. Healthcare providers may not order our products unless third-party payors cover and provide adequate reimbursement rates for a substantial portion of the price of
our products. If we are not able to obtain adequate coverage and an acceptable level of reimbursement for our products from third-party payors, there could be a greater <FONT STYLE="white-space:nowrap">co-insurance</FONT> or <FONT
STYLE="white-space:nowrap">co-payment</FONT> obligation for any individual for whom a test is ordered. The individual may be forced to pay the entire cost of a test
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket,</FONT></FONT> which could dissuade physicians from ordering our products and, if ordered, could result in delay in or decreased likelihood of our collection of payment.
We believe our revenue and revenue growth will depend on our success in achieving coverage and adequate reimbursement for our products from third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare is the single largest U.S. payor and a particularly important payor for many cancer-related laboratory services given the
demographics of the Medicare population. Traditional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicare generally does not cover screening tests, which are considered preventive services, that
are performed in the absence of signs or symptoms of illness or injury, unless there is a statutory provision that explicitly authorizes coverage of the test. The Medicare Improvements for Patients and Providers Act of 2008 authorizes the CMS to
cover additional preventive services that are not expressly covered by the statute if the service is (a)&nbsp;reasonable and necessary for the prevention or early detection of an illness or disability, (b)&nbsp;recommended with a grade of A or B by
the USPSTF, and (c)&nbsp;appropriate for Medicare beneficiaries under Part A or Part B. CMS establishes coverage through a national coverage determination (&#147;NCD&#148;) process, which generally requires, or is significantly more likely
following, FDA approval. In its discretion, the USPSTF generally waits for FDA authorization before it considers undertaking reviews of novel technology. Galleri and certain other future products could be considered screening tests under Medicare
and, accordingly, are and may not be eligible for traditional Medicare <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> coverage and reimbursement unless we pursue substantial additional measures,
including, but not limited to, securing FDA authorization of Galleri and other future products, followed by obtaining a grade A or B recommendation from the USPSTF, in an effort to enable CMS to issue an NCD. Medicare coverage can also be changed by
statute, and another possible pathway for Medicare reimbursement would be to amend the Medicare statute to cover MCED testing. This process would generally require new legislation to expressly authorize CMS to cover
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> early cancer screening and detection tests. We are working with stakeholders to advance and shape the public reimbursement landscape to reflect that additional scope of coverage. However, even if
we are successful in obtaining an NCD on the basis of the new reimbursement landscape envisioned by this legislation, we intend to seek a USPSTF grade for Galleri. If we receive an NCD for Galleri or our other products and subsequently receive a
USPSTF grade lower than A or B, it is possible that CMS would rescind the NCD. Further, such legislation may never be enacted, may be significantly delayed in being enacted, or may be enacted in a different form, including narrower or less favorable
terms, any of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. Any of these efforts, individually and together, require significant investments and resources, and may
ultimately be unsuccessful or may take several years, if at all, to achieve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the USPSTF does not recommend any of our products with a
grade of A or B, CMS declines to initiate an NCD, CMS decides to rescind a prior NCD, or the decision regarding an NCD is negative, the impacted product would not be eligible for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicare coverage in the absence of a new statutory provision providing for coverage. Even if the USPSTF were to recommend Galleri or other products we
are developing, the USPSTF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review process and the ensuing NCD process by CMS could take several years to complete, and coverage for our products would be delayed while review is ongoing. The Affordable Care Act
(&#147;ACA&#148;) mandates that many private insurance plans cover, among other preventive health services, evidence-based items or services recommended by USPSTF with a grade of A or B, with certain prohibitions on cost-sharing requirements.
Accordingly, if USPSTF does not recommend use of Galleri or other products we are developing or requires a substantial amount of time to review such products, our business and results of our operations would be harmed. Coverage and adequate
reimbursement under Medicare are also uncertain as discussed further in &#147;Business&#151;Government Regulations&#151;Coverage and Reimbursement&#148;, beginning on page&nbsp;163 of this Information Statement. DAC is intended to be a diagnostic
aid, and we believe it could be eligible, with current or additional clinical study data, for Medicare coverage and reimbursement in the next several years, although there can be no assurances that we will be successful in obtaining such coverage,
if and when DAC is launched. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If eligible for reimbursement, laboratory tests including ours are generally classified for reimbursement
purposes under CMS&#146;s Healthcare Common Procedure Coding System (&#147;HCPCS&#148;) and the American Medical Association&#146;s (&#147;AMA&#148;) Current Procedural Terminology (&#147;CPT&#148;) coding systems. We and payors must use those
coding systems to bill and pay for our diagnostic tests, respectively. These HCPCS and CPT codes are associated with the particular product or service that is provided to the individual. Accordingly, without a HCPCS or CPT code applicable to our
products, the submission of claims would be a significant challenge. Once CMS creates an HCPCS code or the AMA establishes a CPT code, CMS establishes payment rates and coverage rules under traditional Medicare, and private payors establish rates
and coverage rules independently. Under Medicare, payment for laboratory tests is generally made under the Clinical Laboratory Fee Schedule (&#147;CLFS&#148;) with payment amounts assigned to specific HCPCS and CPT codes. In addition, effective
January&nbsp;1, 2018, a new Medicare payment methodology went into effect for clinical laboratory tests, under which laboratory-reported private payor rates are used to establish Medicare payment rates for tests reimbursed via the Medicare Clinical
Laboratory Fee Schedule. The new methodology implements Section&nbsp;216 of the Protecting Access to Medicare Act of 2014 (&#147;PAMA&#148;) and requires laboratories that meet certain requirements related to volume and type of Medicare revenues to
report to CMS their private payor payment rates for each test they perform, the volume of tests paid at each rate, and the HCPCS code associated with the test. CMS uses the reported information to set the payment rate for each test at the weighted
median private payor rate. Most affected tests are revalued every three years. A series of legislative amendments delayed the next PAMA reporting period to January&nbsp;1, 2024 through March&nbsp;31, 2024, which will cover the original data
collection period of January&nbsp;1, 2019 through June&nbsp;30, 2019. New CLFS rates for clinical diagnostic laboratory tests (&#147;CDLTs&#148;) will be established based on that data beginning in 2025, subject to
<FONT STYLE="white-space:nowrap">phase-in</FONT> limits. As a result, Medicare payment rates determined by data reported in 2017 will continue through December&nbsp;31, 2024. In addition, under PAMA, as amended, the payment reduction cap will be 15%
per test per year in each of the years 2024 through 2026. PAMA also authorized the adoption of new, temporary billing codes and unique test identifiers for <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> or approved tests, as well as advanced
diagnostic laboratory tests (&#147;ADLTs&#148;). The AMA&#146;s CPT Editorial Panel approved a proposal to create a new section of billing codes called Proprietary Laboratory Analyses (&#147;PLA&#148;) codes, to facilitate implementation of this
section of PAMA. The full impact of the PAMA rate-setting methodology and its applicability to our products remains uncertain at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement by a third-party payor may depend on a number of factors, including a payor&#146;s determination that a product is
appropriate, medically necessary, and cost-effective. Each payor will make its own decision as to whether to establish a policy or enter into a contract to cover our products and the amount it will reimburse for such products. Any determination by a
payor to cover and the amount for which it will reimburse our products would likely be made on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indication-by-indication</FONT></FONT> basis. For example, we may face additional
scrutiny in obtaining coverage and reimbursement from third-party payors given the additional costs of further diagnostic workup in the event the test is deployed at scale, as a result of the false positive rate. As a result, obtaining approvals
from third-party payors to cover our products and establishing adequate coding recognition and reimbursement levels is an unpredictable, challenging, time-consuming, and costly process and we may never be successful. If third-party payors do not
provide adequate coverage and reimbursement for our products, our ability to succeed commercially will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish relationships with payors to provide our products at negotiated rates,
such agreements would not obligate any healthcare providers to order our products or guarantee that we would receive reimbursement for our products from these or any other payors at adequate levels. Thus, these payor relationships may not result in
acceptable levels of coverage and reimbursement for our products, including Galleri and any current or future products, including future versions of Galleri or DAC. We believe it may take several years to achieve coverage and adequate reimbursement
with a majority of third-party payors, including with those payors offering negotiated rates. In addition, we cannot predict whether, under what circumstances, or at what payment levels payors will cover and reimburse our products. Although we do
not expect Galleri to have Medicare or other broad third-party coverage or reimbursement in the near term, we will continue to market our product to health systems, large self-insured employers, life insurance providers, physician directed channels,
health plans, and additional <FONT STYLE="white-space:nowrap">at-risk</FONT> groups such as firefighters. If we fail to establish and maintain coverage and reimbursement for our products, our ability to expand access to our products, generate
increased revenue, and grow our test volume and customer base will be limited and our overall commercial success and growth prospects will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to develop and commercialize new products, including enhanced versions of current products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to expand our research and development efforts to use our proprietary methylation platform and our large clinical and genomic
datasets to develop enhanced versions of our products and future products. The commercialization of any new products, including enhanced versions of current products, will require the completion of certain clinical development activities, regulatory
activities, and the expenditure of additional cash resources. We cannot assure you that we can successfully complete these activities for any such products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating costs to continue to exceed our revenue for the foreseeable future. We also cannot assure you that we will be able to
reduce our expenditures sufficiently, generate sufficient revenue from products that we successfully commercialize or otherwise mitigate the risks associated with our business to raise enough capital to develop and commercialize new products. In
addition, once our development efforts for a product are completed, commercialization efforts, including allocation of resources necessary to comply with applicable laws and regulations, will require significant expenditures. Any failure to develop,
obtain necessary marketing authorizations for, or commercialize new products, and meet and continue compliance with applicable laws and regulations, could have a material adverse effect on our ability to implement our strategy and grow our business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If similar third-party products are developed and do not perform as intended or cause harm or injury to patients, the market for
our products could be impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies are attempting to develop competing cancer detection tests and technologies focused
on improving cancer care with early cancer detection tests and post-diagnostic products. If any of these tests do not perform to expectations or cause harm or injury to patients, it may result in lower clinical and consumer confidence in early
cancer detection and precision medicine in general, which could potentially adversely affect confidence in our products. As a result, the failure of any competing products to perform as expected could significantly adversely affect public perception
about cancer detection tests generally, including our products, and could significantly impair our reputation and operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain additional financing, we may be unable to expand our commercialization efforts with respect to Galleri and any
other products that we successfully develop and commercialize, or to develop additional products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have required
substantial amounts of cash since inception. To date, we have financed our operations primarily through the sale of equity securities and capital contributions from Illumina and, to a lesser extent, revenue derived from Galleri sales and precision
oncology portfolio revenue. Our product development and clinical study activities are expensive, and we expect to continue to spend substantial amounts as we expand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our commercialization efforts with respect to Galleri, including pursuing coverage and reimbursement, prepare for the potential launch and commercialization of DAC, continue to enhance our core
technology platform, broaden the applications of our technology platform, and develop new products. In addition, obtaining any necessary or desirable regulatory approvals, clearances, or certifications, as well as coverage and reimbursement, for our
products will require substantial additional funding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2023, we had $241.6&nbsp;million in cash and cash
equivalents. We believe that our existing cash and cash equivalents, together with the funding obligations of Illumina required by the EC Divestment Decision (as defined in the section titled &#147;The
<FONT STYLE="white-space:nowrap">Spin-Off&#151;Background&#148;</FONT> beginning on page&nbsp;96 of this Information Statement), will be sufficient to fund our projected operations for at least the next 12 months. Our estimate as to how long we
expect our existing cash, cash equivalents, and funding obligations from Illumina to be available to fund our operations is based on assumptions that may prove to be inaccurate, and we could use our available capital resources sooner than we
currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.
We may need to raise additional funds sooner than we anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require additional capital to expand the commercialization of
Galleri and our precision oncology portfolio for the development and potential commercialization of DAC, and for the development of future products. Our future capital requirements depend on many additional factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of development and commercialization activities for our products, including Galleri and our precision
oncology portfolio and our future products, such as DAC, including marketing, sales, and distribution costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost related to continued scaling operations to support demand for our products, including the cost of
operating our laboratory in Durham, North Carolina; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining any required or desired regulatory approvals, clearances, or
certifications for our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope, progress, results, and costs of developing additional products and conducting clinical
studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending, and enforcing patent and
other intellectual property rights and claims, including litigation costs and the outcome of such litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of sales of our products and collection of related receivables; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our products are eligible for coverage and reimbursement from third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the emergence of new technologies, products, or services and other adverse market developments; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other potential adverse developments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional
capital, other than the funds to be committed by Illumina as described above. Furthermore, any additional capital raised through the sale of equity or equity-linked securities will dilute stockholders&#146; ownership interests in us, may require
stockholder approval, may have an adverse effect on the price of our common stock, and holders of these securities may have rights, preferences or privileges senior to those of our then-existing stockholders. Debt financing, if available, may
include restrictive covenants that could limit how we conduct our business and limit our ability to further raise capital, and if available, may be available only on undesirable terms, particularly as we would borrow as an independent company and
not a subsidiary of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Illumina. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back, or
discontinue the commercialization of our products or research and development programs, or be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of
operations, and growth prospects and cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our products result in direct or indirect
participant or patient harm or injury, we could be subject to significant reputational and liability risks, and our reputation, business, financial condition, results of operations, and growth prospects could be materially adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend on the market&#146;s confidence that our products, including Galleri and, if successfully developed and
launched, enhanced versions of Galleri and DAC, and our precision oncology portfolio can provide reliable, high-quality results. We believe that participants, patients, customers, physicians, and regulators are likely to be sensitive to errors in
the use of our products or failure of our products to perform as described, and there can be no guarantee that our products will meet expectations. Galleri is intended to be used to detect a cancer signal in individuals, but its results are not
intended to be diagnostic. If a cancer signal is detected, the product is used to localize the origin of the cancer signal; a &#147;cancer signal detected&#148; test result must be followed up by appropriate diagnostic workup. Because the product
cannot detect all cancer signals, and may not detect signals for all cancer types, a negative test does not rule out the presence of cancer. Additionally, an individual undergoing unnecessary diagnostic tests on the basis of a false positive result
or an erroneous cancer signal origin result could expose us to significant liability and reputational risks. Similarly, an individual who receives a cancer diagnosis shortly following a &#147;no cancer signal detected&#148; test result may create
negative publicity about our product, which would discourage adoption. Performance failures could establish a negative perception of our products among physicians, patients, customers, and regulators, jeopardize our ability to successfully
commercialize our products, impair our ability to obtain marketing authorizations or secure favorable coverage and reimbursement, or otherwise result in reputational harm or enforcement action or inquiry by a regulatory body. These risks may be more
pronounced for certain applications in our precision oncology portfolio, such as companion diagnostic development, as our products would be directly involved with the choice to use certain treatments in a particular case. In addition, we may be
subject to legal claims arising from any errors in the use, manufacture, design, labeling, marketing, or performance of our products, including false positive or false negative results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on Illumina as a sole supplier for our next-generation sequencers and associated reagents, Madison Industries
(&#147;Madison&#148;) (who acquired our blood collection tube manufacturer Streck, Inc. in 2023) as a sole supplier of our blood collection tubes, and Twist Bioscience Corporation (&#147;Twist&#148;) as a sole supplier of our DNA panels.
Additionally, we rely on a limited number of suppliers for some of our laboratory instruments and reagents, and we may not be able to immediately find replacements if necessary. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on Illumina as the sole supplier of the next-generation sequencers and associated Illumina-supplied reagents we use to perform our
genomic tests and as the sole provider of servicing, including maintenance and repair services for these sequencers. Any disruption or interruption in Illumina&#146;s operations or breach of our supply-related agreements would impact our supply
chain and laboratory operations. We also rely on Madison as the sole supplier of our blood collection tubes and Twist as the sole supplier of our DNA panels. We rely on other vendors as sole suppliers, although we believe we are less reliant on
their offerings than the vendors named above, or that there are alternative vendors more readily available. Any disruption or interruption in supply from these vendors would delay our ability to continue laboratory operations, and develop and
commercialize any other future products. Any such disruption or interruption in supply, quality, or servicing would adversely affect our commercial partnerships, our ability to continue supporting clinical studies and conduct new studies, our
reputation, and could impact our timing for regulatory authorization and coverage and reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we are in the process of
submitting a PMA for Galleri to the FDA. We may similarly seek FDA authorization for DAC and other products. For products or components supplied to us by Illumina, we have not negotiated the use of all of their products in any product we intend to
submit for an FDA marketing authorization. We are cooperating with Madison to obtain FDA clearance or approval for their blood collection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tubes for use with our products. In some cases, use of these third-party products in any <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> or approved product we may seek to commercialize will
be conditioned on these suppliers having obtained FDA clearance or approval for their products for the uses of those third-party products as intended with ours. Before we pursue approval for our products that incorporate or use materials supplied to
us by these suppliers, we will need to negotiate and execute agreements with these parties and in some cases may need to ensure these products have obtained the requisite clearances or approvals for the intended uses with our products. Any failures
or delays in negotiating agreements with our suppliers on reasonable terms, or their inability to obtain any required clearances or approvals, may increase our costs or delay or prevent us from obtaining approval of, and thus successfully
commercializing, our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, products supplied to us for use in our LDT products may be currently available to us as RUO
products, which means, among other things, that the third-party supplier intends for the products not to be used for clinical use and that the products must be labeled &#147;For Research Use Only. Not for use in diagnostic procedures.&#148; If the
FDA were to take enforcement action against us or our suppliers for our use of RUO products in connection with our products and future products that we intend to use for clinical purposes, including our launch of LDTs, such action could require us
to seek alternative suppliers and thus materially and adversely affect our ability to provide such products to our customers and could significantly increase our costs of conducting business. Products for FDA-approved or cleared <I>in vitro</I>
diagnostic use generally have significantly higher costs than LDT uses, which, in turn, are more costly than products intended for RUO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current suppliers, including Illumina, Madison, or Twist, may also discontinue or substantially change the specification of products that
we utilize or intend to utilize in our products and future products. We believe there are only a few, if any, other manufacturers that may be capable of supplying and servicing the other equipment and materials necessary for our laboratory
operations, including certain instruments, components, consumables, and reagents. However, qualifying, contracting with, validating, and transitioning to a new supplier for this equipment or these materials could temporarily result in interruptions
in or otherwise affect the performance specifications of our laboratory operations and sample processing or, if we receive FDA authorization for our current or future products, could require that we revalidate such products or submit such changes
for regulatory authorization by the FDA. For example, the products supplied to us by Madison are of a quality and availability on which our business relies, including as a result of our use of Madison products for all of our prior, ongoing, and
planned clinical studies that support product development and validation. Our ability to identify and engage with another supplier who can provide the same products and with the same quality and availability as Madison may be difficult and could
significantly delay our clinical studies and ability to process tests, and materially adversely impact our business. In addition, we purchase certain products on a purchase order basis and cannot guarantee a consistent source of supply. The use of
equipment or materials provided by a replacement supplier could require us to alter our laboratory operations and sample collection and processing and related procedures. In the case of attempting to obtain an alternative supplier for Illumina,
Madison, or Twist, replacement instruments and associated reagents, tubes, and panels that meet our quality control and performance requirements may not be immediately available. If we encounter delays or difficulties in securing, reconfiguring or
revalidating the equipment, reagents, and other materials that we require for our laboratory operations and sample collection and processing, we would likely face significant delays in ongoing clinical studies or conducting new studies,
commercializing our products and our reputation, business, financial condition, results of operations, and growth prospects would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our facilities become inoperable, our ability to provide our products will be significantly impaired and our business will be harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently perform all research and development, and conduct commercial testing work, for our products, including Galleri, in
our laboratories located in Menlo Park, California and Durham, North Carolina. We also have offices in Washington D.C. and the United Kingdom, which is important to our international operations. The facilities may be harmed, rendered inoperable by
physical damage or otherwise become partially or completely unusable due to fire, floods, earthquakes, power loss, telecommunications failures, <FONT STYLE="white-space:nowrap">break-ins,</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accidents, pandemics, and similar events, which may render it difficult or impossible for us to provide our products for some period of time. Our laboratories and the equipment we use to perform
our research and development or commercialization work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming, and expensive to rebuild our facilities, particularly in light of the licensure,
permits, and accreditation requirements for clinical laboratories like ours. For example, the development and commercial test processing activities for Galleri, and future potential commercial launch of DAC, are dependent on the operation of our
Durham, North Carolina laboratory, which received Clinical Laboratory Improvement Amendments of 1988 (&#147;CLIA&#148;) certification to perform high-complexity training, and College of American Pathologists (&#147;CAP&#148;) accreditation. A
disruption at this facility could materially adversely impact our business and operations. Although we carry insurance for damage to our properties and the disruption of our business, this insurance may not be sufficient to cover all of our
potential losses and may not continue to be available to us on acceptable terms, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our operations and business depend on
various third parties, including information technology, sample collection, processing, transfer facilities, and other patient-facing service providers. Any disruption, failure, or interruption at any of these third parties could materially
adversely affect our business, results of operations, financial condition, and growth prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on third parties for
information technology, telecommunication systems, the collection, processing, transport, and storage of sample, and other patient-facing services. Any disruption in these services or operations could materially adversely harm our business and
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on information technology and telecommunications systems, including those provided by third parties and their
vendors, for significant elements of our operations, such as our laboratory information management systems, including test validation, specimen tracking, and quality control; personal information collection, storage, maintenance, and transmission;
our report production systems; and our billing and reimbursement, research and development, scientific, and medical data analysis; and general administrative activities. In connection with becoming a public company, we expect to expand and
strengthen a number of enterprise software systems that affect a broad range of business processes and functions, including, for example, systems handling human resources, financial controls and reporting, customer relationship management,
regulatory compliance, security controls, and other infrastructure operations. These expansions may prove more difficult than we expect and could cause disruptions in our operations or additional expense. Information technology and
telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters. Moreover, despite network security and
<FONT STYLE="white-space:nowrap">back-up</FONT> measures, some of our servers are potentially vulnerable to physical or electronic <FONT STYLE="white-space:nowrap">break-ins,</FONT> computer viruses and similar disruptive events. Any disruption or
loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business, reputation, results of operation, financial condition, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business also depends on our ability to reliably sequence blood samples that we collect, which are transported to our Menlo Park or Durham
facility for analysis. Within the United Kingdom, our samples are initially collected, processed, frozen, and stored at several <FONT STYLE="white-space:nowrap">off-site</FONT> facilities. Any disruption to the operations of these facilities could
compromise the integrity of our samples and impede our ability to access and accurately sequence the data. For example, Event Marketing Solutions Ltd (&#147;EMS&#148;) is responsible for collection of our
<FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial samples and ships those samples to UK Biocentre Ltd (&#147;UKBC&#148;) for, among other things, receipt, storage, and management. If any natural or
<FONT STYLE="white-space:nowrap">man-made</FONT> disaster, accident, or <FONT STYLE="white-space:nowrap">break-in</FONT> were to affect the UKBC facility or EMS&#146; collection or shipping operations, our
<FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> samples could be lost, destroyed, compromised, or otherwise adversely affected. In addition, we maintain samples from our clinical studies for several years. It is possible that the long-term
stability of these samples may not be maintained with the passage of time, which could negatively impact our ability to use such samples to validate our products. Further, interruptions in collection, processing, freezing, or transportation of
samples performed by patient-facing service providers and other third parties, whether due to labor disruptions, bad weather, natural disaster, terrorist acts, threats, or for other reasons could adversely affect the samples and our ability to
process the samples in a timely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner, which could negatively affect our ongoing research studies and harm our business. This is particularly true for transport of our samples, which generally must be delivered to our
facilities for processing within seven days of blood draw. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend on third-party telemedicine providers for certain referrals and
follow up services with patients. Third-party phlebotomists also provide patient-facing services in collecting samples and shipping samples to our facilities for processing. If these telemedicine or phlebotomist vendors fail to perform services, or
if services are performed poorly or perceived to be performed poorly, we may suffer reputational harm, need to replace a provider, limit our ability to reach patients, result in loss of samples, failure to receive samples in a timely manner,
insufficient quality of samples, or other harms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the facilities of any of our third-party collaborators, consultants,
contractors, vendors, suppliers, and service providers could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, tornadoes, hurricanes, fires, extreme weather conditions, medical epidemics, pandemics,
and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations, and policies, or funding shortages. The
occurrence of any of these business disruptions could seriously harm their ability to complete their contracted services to us, which may adversely impact our operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure of, or defects in, our machine learning algorithms, artificial intelligence, and cloud-based computing infrastructure, including
interruptions of service through our key provider, Amazon Web Services, or increased regulation in the machine learning or artificial intelligence space, could impair our ability to process our data, develop products, or provide test results, and
harm our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on technology systems for significant elements of our business operations.
These technology systems support a variety of functions, including manufacturing operations, laboratory operations, data analysis, quality control, partner service and support, billing, research and development activities, and scientific and general
administrative activities. The design, development, maintenance, and operation of our technology over time is expensive and complex, and may involve unforeseen difficulties including performance problems, undetected defects, or errors. Overcoming
technical obstacles and correcting defects or errors could prove to be impossible or impracticable, and the costs incurred may be substantial and adversely affect our results of operations. Additionally, regulation in the machine learning and
artificial intelligence space is constantly evolving and limitations placed on the use of data, including personal information, health data, or genetic/genomic data in such systems may make it difficult for us to continue using our machine learning
algorithms. If our technology does not function reliably, fails to meet expectations in terms of performance, or cannot be fully utilized due to increasing regulation, including regulation by the FDA or comparable regulatory authorities of
artificial intelligence or medical device software, we may be unable to provide, or our customers may stop using, our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently host all of our data on, and conduct a significant portion of our data analysis through, Amazon Web Services (&#147;AWS&#148;) cloud-based hosting facilities. In addition, certain functions of our laboratory operations and business
functions use or leverage AWS. Any technical problems or outages that may arise in connection with AWS, including its data center hosting facilities, could result in operational disruption, loss of data or delayed or ineffective data processing. A
variety of factors, including infrastructure changes, human or software errors, viruses, malware, security attacks, fraud, spikes in customer usage, or denial of service issues could cause interruptions in our service. Such service interruptions may
reduce or inhibit our ability to provide our products, process tests, operate our laboratory, delay our clinical studies, and damage our relationships with our customers. We could also be exposed to potential lawsuits, liability claims, reputational
impact, or regulatory actions, for example if AWS experienced a data privacy breach. If we were required to transfer to another service provider, including the transfer of data to an alternative hosting provider, the transfer and acclimation to the
new provider could result in significant business delays and require additional resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to scale our operations successfully to support demand for our
products, our business could suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As and to the extent test volumes grow, we will need to continue to ramp up laboratory
capacity, including increasing the processing of Galleri in our Durham, North Carolina facility. This includes the transition of operations from 16 hours of operation seven days a week to 24 hours of operation seven days a week. While we have
heavily invested in our scalability, including by expanding our Durham facility laboratory capacity, further buildout of our Durham facility will be needed, as well as further new infrastructure, data processing capabilities, customer service,
billing and systems processes, and expanding our internal quality assurance program and information technology to support testing on a larger scale. We will also need additional equipment, and certified and licensed laboratory personnel to process
higher volumes of tests. Our ability to hire personnel to scale may be more challenging for our 24/7 operations when we will require night shift work. We may face difficulties increasing the scale of our operations, including implementing changes in
infrastructure or programs or acquiring additional equipment or personnel, as well as any additional regulatory, licensing, permitting, or certificate obligations that need to be met at the local, state, or federal level. As we refine our products
and develop additional products, we may need to bring new equipment <FONT STYLE="white-space:nowrap">on-line,</FONT> implement new systems, technology, controls and procedures, and hire personnel with different qualifications, licenses, or
certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of Galleri, our precision oncology portfolio, DAC, and any future products will depend, in part, on our ability
to perform tests and return results to providers on a timely basis and at an appropriate quality standard, and on our reputation for such timeliness and quality. Failure to implement necessary procedures, to transition to new equipment or processes,
or to hire the appropriate, qualified personnel could result in higher costs of processing, longer turnaround times or an inability to meet market demand. There can be no assurance that we will be able to perform tests on a timely basis at a level
consistent with demand, that we will be able to maintain the quality of our test results as we scale our commercial operations, or that we will be successful in responding to the growing complexity of our laboratory operations, including the related
data analysis requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also experience difficulties scaling in international markets in which we are required under law or
contract, or decide to, construct and operate a laboratory in that market. For example, we may be required or decide to build and operate a laboratory in the United Kingdom if and when we have a commercial presence in that country. This may be
challenging due to significant startup costs, difficulty recruiting, and lack of familiarity with the local jurisdiction, among other reasons. If we are unable to build and operate laboratories internationally, our ability to expand internationally
may be limited, and have a negative impact on our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our growth may place a significant
strain on our management, operating and financial systems, research and development, and our sales, marketing, and administrative resources. As a result of our growth, our operating costs may escalate even faster than planned, and some of our
internal systems may need to be enhanced or replaced. If we cannot effectively manage our expanding operations and our costs, we may not be able to grow successfully or we may grow at a slower pace, and our business could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business and results of operations will suffer if we fail to perform effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are market participants in the cancer detection space both in the United States and abroad, including Adela, Inc., DELFI Diagnostics,
Inc., Exact Sciences Corporation, Freenome Inc., Guardant Health, Inc., and Harbinger Health within the United States and AnchorDx, Anpac Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Datar Cancer Genetics, Elypta AB, Gene Solutions
JSC, Singlera Genomics, Inc. and Seekin, Inc. outside of the United States, among others, that have stated that they are attempting to develop tests designed to detect certain types of cancer, including some that will use cell free DNA
(&#147;cfDNA&#148;) analyses. The precision oncology market includes companies such as Roche/Foundation Medicine, Inc., Natera, Inc., Guardant, Inc., Tempus Labs, Inc., Invitae Corp., NeoGenomics Laboratories, Personalis, Inc., Twist Bioscience
Corp. and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Adaptive Biotechnologies Corp., among others. These companies have or may have greater financial, technical, and other resources, such as larger research and development staff, well-established
marketing and sales forces, existing integrated systems connected to health practices&#146; electronic health or medical records to facilitate product ordering and results delivery, or may operate in jurisdictions where lower standards of evidence
are required to bring products to market. These companies may succeed in developing, acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective, have higher performance, or are less costly than our
products. In addition, established medical technology, biotechnology, or pharmaceutical companies may invest to accelerate discovery and development of tests that could make our products less successful than we anticipate. For example, large and
long-tenured healthcare, life sciences, or technology companies may initiate research and development of MCED and bring significant resources and disruption to the cancer detection space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to perform successfully will depend largely on our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully expand commercialization efforts for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrate compelling advantages in the performance and convenience of our products, including on a cost
efficient basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance of our products by healthcare providers and patients, including through our reputation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve adequate coverage and reimbursement by third-party payors for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differentiate our product from future tests and products of and third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract qualified scientific, data science, clinical development, product development, and commercial personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, defend, and enforce patent and other proprietary protection as necessary for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain and maintain any necessary or desirable marketing authorizations or certifications from regulators in the
United States and other jurisdictions, and notified bodies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrate product ordering and results delivery into practices&#146; electronic health or medical records
systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully collaborate with institutions in the discovery, development, and commercialization of our products;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully expand our operations and implement a successful sales and marketing strategy to support
commercialization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to perform effectively if we are unable to accomplish one or more of these or
similar objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we cannot maintain our current collaborations or partnerships and enter into new collaborations or
partnerships in a timely manner and on acceptable terms, our efforts to develop and commercialize our products could be delayed or adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely, and expect to continue to rely, on collaborative partners to help us develop our products and enhance our research and development
efforts. For example, we have collaborated with pharmaceutical companies, research institutions, and academic centers. Additionally, our RUO offering has formed the basis of biopharmaceutical partnerships with several leading oncology companies.
These partnerships leverage our RUO offering to test applications of biomarkers with the goal of optimizing the use of therapeutic interventions. Partnerships may also include development of customized applications to support clinical studies and
companion diagnostic development and commercialization. Our reliance on certain of these third parties reduces our control over our product development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our collaborators or partners were to breach or terminate their agreements with us
or otherwise fail to conduct the contracted activities successfully and in a timely manner, the research and development activities of certain of our products could be delayed or terminated. Further, our collaborators or partners may fail to
properly protect our intellectual property rights, may infringe the intellectual property rights of third parties, may misappropriate our trade secrets, or may use our proprietary information or others&#146; in such a way as to expose us to
litigation and potential liability. Disagreements or disputes with our collaborators or partners, including disagreements over proprietary rights, funding, or contract interpretation, might cause delays or termination of the research, development or
commercialization of our products, might lead to additional responsibilities for us with respect to these products or activities or might result in litigation or arbitration, any of which would divert management attention and resources and be
time-consuming and expensive. We may not be able to renew our current agreements with collaborators or partners or negotiate additional collaboration or partnership agreements on acceptable terms, if at all, and these collaborations and partnerships
may not be successful. Any transition from a current collaborator to a new collaborator could be costly and result in significant product development delays. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we expect to engage in discussions with potential development and/or commercial collaborators that may or may not lead to
collaborations. However, we cannot guarantee that any discussions will result in development or commercial collaborations. Further, once news of discussions regarding possible collaborations are known in the general public, regardless of whether the
news is accurate, failure to announce a collaboration agreement, or the entity&#146;s announcement of a collaboration with an entity other than us, could result in adverse speculation about us, our products, or our technology, resulting in harm to
our reputation and our business. In addition, establishing collaborations is difficult, time-consuming and may require our significant financial investment. Potential collaborators may elect not to work with us based on their assessment of our
financial, regulatory, or intellectual property position. Even if we establish new collaborations, they may not result in the successful development or commercialization of our products or technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. If we
are unable to maintain and expand sales and marketing capabilities in particular, we may not be successful in increasing sales of Galleri or commercializing new products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, we had&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;employees,
substantially all of whom were full-time. As our development plans and strategies develop, and as we transition into operating as a public company, we may require a significant number of additional managerial, operational, financial, and other
personnel. Moreover, despite our progress made in driving commercial implementation to date, we may not be able to market, sell, or distribute Galleri, or any future products that we may develop and commercialize, effectively enough to support our
planned growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize any of our products include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer
service, medical affairs, and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to generate an adequate numbers of customers, including healthcare systems and
healthcare providers, to use our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
gross margin and profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to effectively market to, collaborate with, and secure coverage and reimbursement from third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to comply with applicable regulatory requirements governing the sale, marketing, reimbursement, and
commercialization of our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with maintaining a commercialization organization.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future growth will impose significant added responsibilities on members of management besides
those related to our efforts to commercialize, which will include: managing our internal development efforts effectively, including creating compliant programs and processes, such as a compliant laboratory and manufacturing quality system, and
managing the regulatory requirements for our products, while complying with our contractual obligations to contractors and other third parties, including patient-facing service providers; expanding our operational, financial and management controls,
reporting systems, and procedures; and managing the increasing complexity associated with a larger organization and expanded operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our products will depend, in part, on our ability to effectively manage any
future growth. Our management may also have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to manage these growth
activities. Our ability to successfully manage our expected growth is uncertain given the fact that we have been in operation as a company only since 2016, and have grown significantly in recent years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by hiring new employees, we may not be able to successfully implement the tasks
necessary to commercialize our products, which would have a negative impact on our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are
highly dependent on our key personnel. If we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to perform in the biotechnology industry depends upon our ability to attract, motivate, and retain highly qualified personnel. We
are highly dependent on our executive management team and our scientific, medical, technological, and engineering personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical
advisors, and our inability to find suitable replacements in a timely manner, could result in delays in commercialization of our products and harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are headquartered in Menlo Park, California, a region in which many other healthcare companies, technology companies, and academic and
research institutions are headquartered. In addition, we operate a laboratory facility in Durham, North Carolina, where there is also demand for skilled personnel, especially engineering and laboratory personnel. Competition for personnel is intense
and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of these regions, and doing so may be costly and
difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce valuable employees to join or remain at our company, in addition to salary and periodic cash incentives, we have
generally granted Cash-Based Equity Awards that vest over time. The value to employees of these grants that vest over time may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment
agreements with certain key employees, these employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. If we
are unable to attract and incentivize highly qualified personnel on acceptable terms in a timely manner, or at all, our business and results of operations may suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to economic, political, regulatory, and other risks associated with international operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. For example, some of our suppliers and parties with whom
we have collaborative relationships are located outside the United States, including in the United Kingdom and Israel. Accordingly, our future results could be harmed by a variety of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability, in particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign jurisdictions
that do not respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, import or export controls and licensing requirements (including possible restrictions
on licensing intellectual property to certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons) or other restrictive actions by U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, regulations and customs, tariffs, and trade
barriers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, regulations, and policies related to data
privacy, data protection, and cybersecurity in the transfer or transmittal of data across boundaries and geographies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange rate risk we may face from denominating a portion of our transactions in currencies other than the U.S.
dollar; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political or economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from changes in U.S. national security laws, including those governing <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> investors&#146; ownership of U.S. biotech and other technology companies and U.S. companies&#146; ability to enter into joint ventures with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with staffing and managing international operations, including differing labor relations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability under the Foreign Corrupt Practices Act (&#147;FCPA&#148;) or comparable foreign laws; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, such as recent conflicts in the Middle East, pandemics, or natural disasters, including earthquakes, typhoons, floods, and fires. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in recent years, U.S. administrations have publicly supported potential trade proposals that may affect U.S. trade relations with
other countries. It is unclear at this point how, if at all, such actions or other potential actions would impact our business or operations, but the uncertainty surrounding these matters could create difficulties in our efforts to partner with
certain healthcare providers, suppliers, and insurance carriers. Moreover, future operational expansion into other geographies will subject us to additional political and regulatory regimes that will require us to invest in compliance efforts and
may result in additional risks, including, among others, exposure to various and potentially conflicting regulations, international sanctions and compliance rules, country-specific requirements for testing, approval, and processing of patient
information and biological samples, as well as the risks associated with political and macroeconomic climates in any such geographies. For example, the implementation of a pilot under our agreement with the NHS, and further commercialization of
Galleri with the NHS after that pilot, could be delayed or otherwise impacted if there is a change in the government in the United Kingdom. These and other risks associated with our planned international operations may materially and adversely
affect our business, costs and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to successfully and efficiently conduct any required <FONT
STYLE="white-space:nowrap">in-country</FONT> studies in other countries or regions in which we seek to expand may also be impacted, or may be impossible, due to the regulatory requirements of such countries. Some countries may require that we carry
out testing of our products or future products through government partnerships, which may be difficult to navigate or which may limit our ability to deliver the results we intend. Moreover, the demographics in other countries or regions may differ
vastly, such that study results may not appear as successful, due to, for example, a lower incidence of cancer in the local </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
population. Such outcomes may adversely impact demand for our products in other countries. Finally, our ability to expand internationally may be limited by the availability of international
laboratory space or requirements that will permit us to store, collect, and analyze biological samples required for current or future products, including space that could be made available through potential partners in such countries or regions.
These and other unknown risks make it difficult for us to assess the potential success of our international expansion and the costs associated therewith. We are also subject to a number of risks relating to regulations and legal compliance. For
additional information, see &#147;Risks Relating to Regulation and Legal Compliance&#148; beginning on page&nbsp;53 of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems, or those used by our third-party collaborators or other contractors or consultants, may fail or
suffer security breaches or cyberattacks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collect and maintain information in digital form that is necessary to conduct our
business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store, and transmit large amounts of confidential information, including
intellectual property, proprietary business information, personal, financial, and health information of patients and personal and financial information of our employees and contractors. It is critical that we do so in a secure manner to maintain the
confidentiality and integrity of such confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security and
<FONT STYLE="white-space:nowrap">back-up</FONT> measures, our information technology systems as well as those of our third-party collaborators, consultants, contractors, suppliers, and service providers, may be vulnerable to attack, damage, or
interruption from physical or electronic <FONT STYLE="white-space:nowrap">break-ins,</FONT> computer viruses, malware, malicious code, ransomware, denial or degradation of service, hacking, phishing attacks, and other cyber-attacks, natural
disasters, terrorism, war, telecommunication and electrical failures, instructions and attacks from sophisticated nation-state and nation-state-supported actors (including advanced persistent threat intrusions), or other disruptive incidents that
could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive, and/ or proprietary data, including personal information, protected health information, and other sensitive information, and could subject us to
significant liabilities and regulatory and enforcement actions, and reputational damage. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber
terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased and evolved. If we or our third-party vendors were to experience a significant cybersecurity
breach of our or their information technology systems or data, the costs associated with the investigation, remediation, and potential notification of the breach to counter-parties and data subjects could be material, in addition to any money
required to resolve a ransomware attack. For example, laws in the European Economic Area (&#147;EEA&#148;), the United Kingdom, and all 50&nbsp;U.S. states may require businesses to notify regulators within specific timeframes that a breach
affecting personal information has occurred and/or to provide notice to individuals whose personal information has been impacted as a result of such breach. Complying with such numerous and complex regulations in the event of a data security breach
would be expensive and difficult, and failure to comply could subject us to regulatory scrutiny and additional liability. In addition, our remediation efforts may not be successful. Even if we do allocate and effectively manage the resources
necessary to build and sustain the proper technology and cybersecurity infrastructure, we could nevertheless suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing
inefficiencies, data loss, or the loss of or damage to intellectual property or other proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies with whom we
engage in data sharing, including our service providers, are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident, or security breach to date, we
may nonetheless be a target of such an attack, and if such an event were to occur and cause interruptions in our operations, or any of our third-party collaborators&#146; operations, it could result in a material disruption of our development
programs, reputation, and business operations whether due to a loss, corruption, or unauthorized disclosure of our trade secrets, personal information, financial information, health information, or other proprietary or sensitive information, or
other similar disruptions. For example, the loss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of clinical study data from completed or ongoing clinical studies could result in delays in any regulatory clearance, approval, or certification efforts and significantly increase our costs to
recover or reproduce the data, and subsequently commercialize our products. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the
unauthorized access to or use or disclosure of personal or health information, we may have to notify physicians, patients, partners, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties,
administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on our third-party research institution collaborators and other third parties to conduct clinical studies, and similar
events relating to their computer systems could also have a material adverse effect on our business. It could also expose us to risks, including an inability to provide our services and fulfill contractual demands, and could cause management
distraction and the obligation to devote significant financial and other resources to mitigate such problems, which would increase our future information security costs, including through organizational changes, deploying additional personnel,
reinforcing administrative, physical, and technical safeguards, further training of employees, changing third-party vendor control practices, and engaging third-party subject matter experts and consultants and reduce the demand for our technology
and services. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate or unauthorized access to or disclosure or use of confidential, proprietary, or other sensitive,
personal, or health information, we could incur liability, we could be exposed to the risk of litigation, our market position could be harmed, we could suffer reputational harm, and the development and commercialization of our products could be
delayed. Furthermore, federal, state, and international laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties, fines, and significant legal liability,
if our information technology security efforts fail or if there are material findings regarding data security or data integrity deficiencies by us or our critical partners, vendors, or suppliers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication, and intensity, and are
being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not
recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security incidents that may remain undetected for an extended period. Even if identified,
we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our insurance policies may not be adequate to compensate us for the potential losses arising from such disruptions, failure, or security
breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly,
divert management attention, and harm our reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for product or professional liability, we could face
substantial liabilities that exceed our resources and insurance coverage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual or perceived errors resulting from laboratory or
reporting errors, false positive or false negative test results, or the manufacture, design, marketing, or labeling of our products, could subject us to product liability or professional liability claims. A product liability or professional
liability claim against us could result in substantial damages and be costly and time-consuming to defend. These risks may be more pronounced for certain applications in our precision oncology portfolio, such as companion diagnostic development, as
our products would be directly involved with the choice to use certain treatments in a particular case. Although we maintain liability insurance, including for errors and omissions, our insurance may not fully protect us from the financial impact of
defending against these types of claims or any judgments, fines, or settlement costs arising out of any such claims. Any liability claim brought against us, with or without merit, could increase our </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">insurance rates or prevent us from securing insurance coverage in the future. Additionally, any liability lawsuit
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could damage our reputation or force us to suspend sales of our products. The occurrence of any of these events could have a material adverse effect on our business, financial condition, results
of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our quarterly results of operations may fluctuate significantly or may fall below the
expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our
results of operations to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop, market, and sell our products, including Galleri and our future products,
such as our precision oncology portfolio and DAC, if and when launched; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we are able to sell our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of market developments or our response thereto; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions in our business due to manufacturing, supply, security breaches, outages, or other issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of performing next-generation sequencing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our products are deemed eligible or ineligible for coverage and reimbursement from
third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in coverage and reimbursement or in reimbursement-related laws directly affecting our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval for our products, and the degree of impact of those approvals on
perceptions of our products and market demand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments affecting our products or any future competing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing of investments in our laboratories and other infrastructure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timing of expenditures in connection with our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our international expansion efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-routine</FONT> cash and <FONT STYLE="white-space:nowrap">non-cash</FONT>
expenses and write-offs, whether associated with acquisitions, restructuring activities, litigation, investigations, or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly results of operations fall below the expectations of investors or securities analysts, the price of our common stock could
decline substantially. Furthermore, any quarterly fluctuations in our results of operations, which could be caused by any number of factors including seasonality of prescribing our products, may, in turn, cause the price of our stock to fluctuate
substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions or other strategic transactions may increase our capital requirements, dilute our stockholders, cause us to incur debt or
assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have in the past engaged in and may in the future engage in
acquisitions and strategic partnerships, including licensing or acquiring complementary intellectual property rights, technologies, or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of our equity securities that would result in dilution to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property, and products of an acquired company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with integrating new personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing
such an acquisition or strategic partnership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing or future products and regulatory approvals or certifications, and the validity and enforceability of their intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to consummate acquisitions on which we spend a significant amount of time and resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible write-offs or impairment charges relating to acquired businesses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired intellectual property, technology, or tests sufficient to meet
our objectives or offset the associated transaction costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as our strategy evolves, we may opt to
discontinue, deprioritize, or dispose of assets, technologies, or acquired businesses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Regulation and Legal Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have launched Galleri as an LDT, and plan to launch DAC as an LDT in the United States. If the FDA modifies its current policy of
enforcement discretion on LDTs, as it has recently proposed through rulemaking, or if Congress enacts legislation that changes the current requirements or oversight for LDTs, we may lose the ability to commercialize any LDTs unless we have obtained
FDA marketing authorization, which could require us to incur substantial costs and delays. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we plan to complete our PMA
submission seeking regulatory approval from the FDA for Galleri, we launched Galleri in the United States as an LDT and intend to initially launch DAC in the United States as an LDT. LDTs are <I>in vitro</I> diagnostic (&#147;IVD&#148;) tests that
are intended for clinical use and are designed, manufactured, and used within a single laboratory certified for high complexity testing under CLIA. Although LDTs are classified by the FDA as medical devices and the FDA has asserted statutory
authority to ensure that medical devices, including LDTs, are safe and effective for their intended uses, the FDA has historically exercised enforcement discretion and has not enforced certain otherwise applicable FDA requirements, including
premarket review, with respect to LDTs, with certain exceptions such as in the case of tests for public health emergencies, where the tests are available directly to the consumer, where the tests represented a significant public health concern, or
where the FDA has concerns that a company&#146;s performance claims related to its tests are not sufficiently validated by clinical data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even under its current enforcement discretion policy, the FDA has issued warning letters to and safety communications about IVD device
manufacturers for commercializing laboratory tests that were purported to be LDTs but that the FDA alleged failed to meet the definition of an LDT or otherwise were not subject to the FDA&#146;s enforcement discretion policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has for a number of years stated its intention to modify its enforcement discretion policy with respect to LDTs and impose applicable
medical device requirements to LDTs more broadly. Most recently, the FDA proposed an amendment to its regulations in October 2023 that, if finalized, would clarify the FDA&#146;s historical view that LDTs are medical devices subject to the
requirements applicable to other IVDs, and to phase out its enforcement discretion policy over a period of four years from issuance of the final rule. If this proposed rule or a similar rule is finalized and goes into effect, it would subject our
products currently marketed as LDTs and any future products that we may market as LDTs in the future to the FDA&#146;s standard regulatory requirements applicable to medical devices, including the potential requirement for FDA approval. In such
case, we may be required to cease marketing any products that we market as LDTs if we do not obtain marketing authorization, or have a market authorization pending with the FDA, prior to any relevant effective or enforcement date. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, efforts by the FDA to actively regulate LDTs could create a negative public perception about the validity, safety, effectiveness, or performance of LDTs, including our products, that
could adversely affect patient, provider, and customer perception about, and confidence in, our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, even if the FDA does
not finalize its proposed rule or otherwise modify its current policy of enforcement discretion, the FDA may disagree that we are marketing our LDTs within the scope of its policy of enforcement discretion and may take enforcement action against us
and/or require premarket review and marketing authorizations. The FDA may request that we provide additional analyses and information beyond that which we intend to produce based on the designs of our current and planned clinical studies, or that we
modify or narrow our intended use or product claims. In addition, the FDA may choose not to exercise enforcement discretion with respect to the products we market or intend to market as LDTs. It is possible that the FDA, among other things, may
disagree with our interpretation of data we have relied on to support our LDT launches for our intended uses. If we are required to provide additional analyses or additional data or perform additional clinical studies beyond those we currently
contemplate to support the intended uses of our products or future products, our planned commercial launches may be delayed and we may be required to cease commercialization of any products we currently market as LDTs. A delay in the launch of our
products, or significantly narrowing their intended uses, could negatively impact our financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, Congress has, for over the past decade, considered a number of proposals, which if enacted, would subject LDTs to additional regulatory requirements. For example, in recent years, Congress has worked on legislation to create a novel
regulatory framework governing a new category of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products, referred to as <I>in vitro </I>clinical tests (&#147;IVCTs&#148;), which would govern LDTs and would be separate and distinct from the
existing medical device regulatory framework. For example, most recently, in March 2023, the Verifying Accurate Leading-edge IVCT Development Act of 2023 (the &#147;VALID Act&#148;) was introduced. The bill would have established a risk-based
approach to imposing requirements related to premarket review, quality systems, and labeling requirements on all IVCTs, including LDTs, but would grandfather certain LDTs marketed before the effective date of the bill and exempt them from certain
requirements. It is unclear whether the VALID Act or any other or similar legislative proposals (including any proposals that would, in contrast, reduce FDA oversight of LDTs) will be passed by Congress or signed into law by the President. Depending
on the approach adopted under any potential legislation, certain LDTs (likely those of higher risk) may be required to undergo some form of premarket review, potentially with a transition period for compliance and a grandfathering provision. Any
such legislation could substantially alter our commercial offering and marketing of LDTs and negatively impact our financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA changes its policy of enforcement discretion for LDTs as recently proposed, or because it withdraws its enforcement discretion for
our specific products or for classes of products within which our products fall, or if LDTs become subject to affirmative FDA oversight through legislation, we may be required to obtain marketing authorization for our LDT products from the FDA prior
to initially launching our future products or may be required to cease marketing any commercially marketed products that are marketed as LDTs until such marketing authorization is obtained or the applications are submitted. There can be no assurance
that we will be able to obtain such marketing authorization or that any labeling claims will be consistent with the claims we have made or intend to make for such products when launched as LDTs, or that such claims will be adequate to support
continued adoption of and reimbursement for our products. Even if our products are allowed to remain on the market prior to any required marketing authorization, demand or reimbursement for our products may decline if there is uncertainty about our
products, if we are required by the FDA to label our products as investigational, or if the FDA limits the labeling claims we are permitted to make for our products. As a result, we could experience significantly increased development costs and a
delay in generating additional revenue from our products, or from other future products now in development, which could reduce our revenues or increase our costs and adversely affect our business, results of operations, financial condition, or
growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory clearance, approval, or certification processes of the FDA and
comparable foreign regulatory authorities or notified bodies are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable regulatory approvals, clearances, or certifications, or if such approvals,
clearances, or certifications are significantly delayed, our business will be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet obtained FDA
clearance or approval for any of our products or products in development. We are in the process of seeking PMA approval from the FDA for Galleri, while we market Galleri as an LDT. We may also seek FDA approval or clearance for other products in the
future, such as DAC. The time required and ability to obtain clearance or approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes several years following the commencement of clinical studies, and depends
upon numerous factors, including the type, complexity, and novelty of our products and future products. In addition, policies, laws, regulations, or the type and amount of clinical data necessary to gain clearance or approval may change during the
course of a test&#146;s clinical development and may vary among jurisdictions, which may cause delays in the clearance or approval of, or the decision not to approve, an application. Regulatory authorities have substantial discretion in the
premarket review process and may refuse to accept any application, decide that all or part of our data are unusable or insufficient for clearance or approval, require additional clinical or other data, including analytical validation data, determine
that our manufacturing and quality systems are insufficient or in violation of applicable requirements, or determine that our clinical research program is insufficient or in violation of applicable good clinical practice or other requirements
related to research compliance, human subject protections, or data integrity. Even if we believe our data are sufficient to support marketing authorization, regulatory authorities may disagree, or may require the generation and submission of
additional data or analyses, which could significantly delay or preclude marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before a new medical device can be
marketed in the United States, a company must first submit an application for and receive 510(k) clearance pursuant to a premarket notification submitted under Section&nbsp;510(k) of the FDCA, approval of a PMA application, or grant of a de novo
classification request from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#147;substantially equivalent&#148; to a legally marketed
&#147;predicate&#148; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device), a
device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#147;substantially equivalent,&#148; the proposed device must have the same intended use as the predicate device,
and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes
required to support substantial equivalence. In the process of obtaining PMA approval, which we are pursuing for Galleri, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data,
including, but not limited to, technical, analytical validation, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical trial, manufacturing, and labeling data. The PMA process is typically required for devices that are deemed to pose the
greatest risk, such as life-sustaining, life-supporting or implantable devices. In the de novo classification process, a manufacturer whose novel device under the FDCA would otherwise be automatically classified as Class&nbsp;III and require the
submission and approval of a PMA prior to marketing is able to request down-classification of the device to Class&nbsp;I or Class&nbsp;II on the basis that the device presents a low or moderate risk. If the FDA grants the de novo classification
request, the applicant will receive authorization to market the device. This device type may be used subsequently as a predicate device for future 510(k) submissions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PMA approval, 510(k) clearance and de novo classification processes can be expensive, lengthy and uncertain. The FDA&#146;s 510(k)
clearance process usually takes from three to 12 months, but can take longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the
time the application is submitted to the FDA, including if an Advisory Committee is needed to evaluate a novel technology, which could occur for the review of a PMA for Galleri. In addition, a PMA generally requires the performance of one or more
clinical trials. Despite the time, effort and cost, a device may not obtain marketing authorization by the FDA. Any delay or failure to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary regulatory marketing authorizations could harm our business. Furthermore, even if we are granted such marketing authorizations, they may include significant limitations on the indicated
uses for the test, which may limit the potential commercial market for the test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, any modification to a product for
which we receive clearance or approval may require us to submit a new 510(k) notification and obtain clearance, to submit a PMA and obtain FDA approval, or to submit a de novo request prior to implementing the change. For example, any modification
to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, generally requires a new 510(k) clearance or other marketing authorization.
The FDA requires every manufacturer to make such determinations in the first instance, but the FDA may review any manufacturer&#146;s decision. The FDA may not agree with a manufacturer&#146;s decisions regarding whether new clearances or approvals
are necessary. If we obtain clearances or approvals from the FDA, we may make modifications or add additional features in the future that we believe do not require a new 510(k) clearance, de novo request or approval of a PMA application or
supplement. If the FDA disagrees with our determination and requires us to seek new marketing authorizations for the modifications for which we have concluded that new marketing authorizations are unnecessary, we may be required to cease marketing
and/or to recall the modified product until we obtain such marketing authorization, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future products
or modifications to existing products than we had expected, product introductions or modifications could be delayed or canceled, which could adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are or may become subject to new laws, regulations, and industry standards concerning medical devices proposed and enacted in
various foreign jurisdictions. The EU regulatory landscape concerning IVDs recently evolved. On May&nbsp;26, 2022, the EU In Vitro Diagnostic Medical Devices Regulation (&#147;EU IVDR&#148;) entered into force, which repeals and replaces the EU In
Vitro Diagnostic Medical Devices Directive (&#147;EU IVDD&#148;). Subject to the transitional provisions (i.e., a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully
compliant with the EU IVDR) and in order to sell our products in the EU member states, our products must comply with the general safety and performance requirements of the EU IVDR. Compliance with these requirements is a prerequisite to be able to
affix the European Conformity (&#147;CE&#148;) mark to our products, without which they cannot be sold or marketed in the EU. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in
Annex I to the EU IVDR including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and
must not compromise the clinical condition or safety of patients, or the safety and health of users and &#150; where applicable &#150; other persons, provided that any risks which may be associated with their use constitute acceptable risks when
weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. To demonstrate compliance with the general safety and performance
requirements, manufacturers must undergo a conformity assessment procedure, which varies according to the type of in vitro diagnostic medical device and its (risk) classification. A conformity assessment procedure generally requires the intervention
of a notified body. The notified body would typically audit and examine the technical file and the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">quality system for the manufacture, design and final
inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own
declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us
from selling them within the EU. The aforementioned EU rules are generally applicable in the EEA (which consists of the 27 EU member states plus Iceland, Norway and Liechtenstein). <FONT STYLE="white-space:nowrap">Non-compliance</FONT> with the
above requirements would also prevent us from selling our products in these three countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Brexit, EU laws such as the EU IVDR do not apply directly in Great Britain, however
under the terms of the Protocol on Ireland/Northern Ireland, the EU IVDR does apply in Northern Ireland. Consequently, there are currently different regulations in place in Great Britain as compared to both Northern Ireland and the EU, respectively.
Ongoing compliance with both sets of regulatory requirements may result in increased costs for our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the U.K.
government is currently drafting amendments to the U.K. MDR which is likely to result in further changes to the Great Britain regulations in the near future. For example, subject to transitional periods for validly certified devices, the new Great
Britain regulations are expected to require IVDs placed on the Great Britain market to be &#147;UKCA&#148; certified by a U.K. Approved Body in order to be lawfully placed on the market. The U.K. government has stated that the core elements of the
new regime are likely to apply from July&nbsp;1, 2025 but that IVDs in compliance with either the EU IVDD or EU IVDR can continue to be placed on the Great Britain market until the sooner of certificate expiration or June&nbsp;30, 2030;
understanding and ensuring compliance with any new requirements is likely to lead to further complexity and increased costs to our business. If there is insufficient U.K. approved body capacity, there is a risk that our product certification could
be delayed which might impact our ability to market products in Great Britain after the respective transition periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is currently
unclear to what extent the U.K. government will seek to align its regulations with the EU. The EU laws that have been transposed into U.K. law through secondary legislation remain applicable in Great Britain, however the U.K. government is expected
to introduce changes to the applicable requirements in Great Britain and the full extent of these changes remains uncertain and may cause additional cost to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant political and economic uncertainty remains about how much the relationship between the United Kingdom and EU will differ as a
result of the U.K.&#146;s withdrawal. These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial
markets, and may significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Any of these factors could depress economic activity and restrict our access to capital, which
could have a material adverse effect on our business, financial condition, and results of operations and reduce the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, other regulators or notified bodies can delay, limit, or deny clearance, approval, or certification of a product for many reasons,
including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, comparable foreign regulatory authorities or notified bodies may disagree with the design,
implementation, or results of, or interpretation of the data from, our clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, comparable foreign regulatory authorities or notified bodies may determine that our product has not been
shown to be safe and effective or substantially equivalent to a predicate device, or has other characteristics that preclude us from obtaining marketing authorization or certification, or prevent or limit its commercial use (for example, a narrowed
indication for use claim); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical program may not be sufficiently broad, generalizable, or representative of
the intended target population of our product to assure effectiveness and safety in the population for which we seek approval, clearance, or certification; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, comparable foreign regulatory authorities or notified bodies may disagree with our interpretation of
data from clinical studies or may fail to accept data from clinical studies (or clinical sites), including if we fail to establish the integrity of our data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, comparable foreign regulatory authorities or notified bodies may determine that our clinical studies
otherwise fail to comply with applicable regulations, including good clinical practice requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious or unexpected adverse effects or other performance issues are identified with our existing or future
products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, comparable foreign regulatory authorities or notified bodies may determine that our manufacturing or
quality system fails to comply with applicable regulations or otherwise fails to meet the standards necessary to support approval or certification; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval (or certification) policies or regulations of the FDA or comparable foreign regulatory authorities
may significantly change in a manner rendering our clinical data insufficient for approval or certification. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
engaged in ongoing discussions with the FDA regarding the clinical studies and data that will be needed to support a successful PMA for a multi-cancer test for our planned indications, based on the designs of our current and planned clinical
studies. There can be no assurance that our existing or future products for which we may seek clearance, approval, or certification will be approved, cleared, or certified by the FDA, a comparable foreign regulatory authority or a notified body on a
timely basis, if at all. If our products or future products receive clearance, approval, or certification but there is uncertainty about such products among providers or payors, reimbursement may be adversely affected and we may not be able to sell
our products. Compliance with FDA or comparable foreign regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market
our products, if and when cleared, approved, or certified. The lengthy and unpredictable clearance, approval, and certification processes, as well as the unpredictability of the results of our clinical studies, may result in our failing to obtain
regulatory clearance, approval, or certification to market our products, which would significantly harm our business, results of operations, reputation, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory approval by the FDA or other regulatory authorities is limited to those specific indications and conditions for which
approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions or other enforcement actions if we are determined to be promoting the use of our products for unapproved or &#147;off-label&#148; uses, or in a
manner inconsistent with the approved labeling, resulting in damage to our reputation and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must comply with
requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval from the FDA. When the FDA or other regulatory authorities issue regulatory approval for a product, the regulatory approval is
limited to those specific uses and indications for which a product is approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that labeling claims will be
consistent with our anticipated claims or current claims or marketing statements, including with respect to Galleri as an LDT and its current marketing as an MCED test in its intended use population, or adequate to support adoption of, or
reimbursement for, our products. If the approved, cleared, or certified indication or other labeling claims the FDA or a comparable foreign regulatory authority or notified body allows us to make are more limited than we expect, or are more limited
than current claims made with respect to Galleri, our business, prospects, and growth may be adversely affected and we may be limited in our ability to sell, or unable to sell, our products. If we are not able to obtain FDA approval for desired uses
or indications for our current and future products, we may not market or promote them for those indications and uses, and our business, financial condition, results of operations, stock price and prospects could be materially harmed. We also must
sufficiently substantiate any claims that we make for any products, including claims comparing those products to other companies&#146; products, and must abide by the FDA&#146;s strict requirements regarding the content of promotion and advertising.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our multi-cancer detection tests are a new approach to cancer screening, which present
a number of novel and complex issues for FDA review. Because the FDA has never cleared or approved a multi-cancer detection test, it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a
proposed intended use, or if we will be able to obtain such approval on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our multi-cancer detection tests
represent a new approach to cancer screening, and obtaining FDA approval for Galleri presents a number of novel issues. The FDA has never granted marketing authorization for a multi-cancer detection test. Additionally, in March 2020, the FDA held a
public workshop to discuss the clinical, scientific, and regulatory challenges associated with circulating tumor DNA cancer screening tests, and we expect the FDA to continue to gather input from a variety of industry, academic, and clinical
stakeholders to inform its thinking on how to assess these types of tests, including potentially convening an Advisory Committee meeting during review of a PMA for Galleri (or another company&#146;s PMA for a multi-cancer early detection test,
should it precede ours). In fact, the FDA recently announced a November 29, 2023 meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee to discuss and make recommendations on the design of multi-cancer
detection in vitro diagnostic devices (tests) as well as potential study designs and study outcomes of interest that could inform the assessment of the probable benefits and risks of multi-cancer detection screening tests. The FDA stated that the
committee&#146;s discussion and recommendations from this meeting will help inform future FDA regulatory efforts for these novel tests. As such, the FDA requirements that will govern multi-cancer detection tests, as well as the breadth and nature of
data we must provide the FDA, to support the proposed intended use, may be subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our ongoing discussions with the
FDA regarding the data that will be needed to support a PMA for a multi-cancer detection test based on a proposed intended use, the FDA has provided feedback regarding how it plans to assess the safety and effectiveness of our new version of Galleri
based on potential intended use statements. While we plan to continue discussions with the FDA and provide the FDA with additional information, the FDA may raise additional questions or request additional information in connection with the
submission of a marketing application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the novel nature and complexity of our multi-cancer detection tests, we cannot be certain
whether we will receive FDA approval for Galleri and whether the studies we have conducted, are currently conducting, or plan to conduct, will be sufficient to provide the data that the FDA requires to support a proposed intended use. For example,
we plan on providing evidence from our PATHFINDER 2 study and <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial premarket to support a PMA as our pivotal study data, as well as supplemental data from other clinical studies, and certain
clinical data in the post-approval setting. The FDA may require us to perform new analyses of our clinical data or perform additional clinical trials in addition to those we are contemplating. We may be required to undertake significant efforts to
address the FDA&#146;s requests, which could delay or prevent approval, lead to a more limited intended use statement or approved labeling, and/or lead to significant post-approval limitations or restrictions, if approval is obtained at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our use and disclosure of personal information, including individually identifiable health information, and biologic samples and related
data are subject to federal, state and foreign privacy and security regulations. Data privacy rules are evolving and new legislation concerning privacy and data use may limit our ability to use such data and specimens. Our actual or perceived
failure to comply with privacy and security requirements or to adequately secure such information could result in significant liability, administrative or governmental penalties, and/or reputational harm and, in turn, substantial harm to our
business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global data protection landscape is rapidly evolving and we and our
partners are or may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address data privacy and security). Implementation standards and enforcement practices are likely to remain uncertain
for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in
liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or
regulations, consents and authorizations, our internal or publicly facing policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement
actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We receive, store, process and use personal information as part of our business and as our operations and business grow, we may become subject
to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, numerous state and federal laws and regulations govern the collection,
dissemination, use, disclosure, privacy, confidentiality, security, availability and integrity of personal information, including health related information. We are a covered entity under the Health Insurance Portability and Accountability Act of
1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and the regulations that implement both laws (collectively, &#147;HIPAA&#148;). HIPAA establishes, among other things, a set of national privacy and security
standards relating to the privacy, security, transmission, and breach reporting of individually identifiable health information, by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, the
business associates with whom such covered entities contract for services that involve creating, receiving, maintaining, or transmitting protected health information, and the subcontractors of such business associates. In addition, we may obtain
health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA requires covered entities and business associates to develop and maintain policies with respect to the protection of, use and disclosure
of protected health information (&#147;PHI&#148;), including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a breach of unsecured PHI.
Additionally, under HIPAA, covered entities must report breaches of unsecured PHI to affected individuals without unreasonable delay, not to exceed 60 days following discovery of the breach by a covered entity or its agents. Notification also must
be made to the U.S. Department of Health and Human Services Office for Civil Rights (&#147;OCR&#148;) and, in certain circumstances involving large breaches, to the media. Business associates must report breaches of unsecured PHI to covered entities
within 60 days of discovery of the breach by the business associate or its agents. A <FONT STYLE="white-space:nowrap">non-permitted</FONT> use or disclosure of PHI is presumed to be a breach under HIPAA unless the covered entity or business
associate establishes that there is a low probability the information has been compromised consistent with requirements enumerated in HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an
audit by the U.S. Department of Health and Human Services (&#147;HHS&#148;), may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a
resolution agreement and corrective action plan with HHS to settle allegations of HIPAA <FONT STYLE="white-space:nowrap">non-compliance.</FONT> HIPAA also authorizes state Attorneys General to file suit on behalf of their residents. Courts may award
damages, costs and attorneys&#146; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the
basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain states
have also adopted comparable privacy and security laws and regulations which govern the privacy, processing and protection of health-related and other personal information, such as the California Confidentiality of Medical Information Act; these
laws are not preempted by HIPAA to the extent that they are more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance
issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act (&#147;CCPA&#148;), which went into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect on January&nbsp;1, 2020, creates individual privacy rights for California consumers and increases privacy and security obligations on entities handling certain personal information. The
CCPA provides for fines and penalties for violations, as well as a private right of action for data breaches that is expected to increase the likelihood of, and risks associated with, data breach litigation. Further, the California Privacy Rights
Act (&#147;CPRA&#148;) generally went into effect on January&nbsp;1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on
data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and
information security enforcement. Additional compliance investment and potential business process changes may also be required. Although there are limited exemptions for certain health-related data, including clinical trial data and protected health
information subject to HIPAA, the CCPA (including as amended by CPRA) may increase our compliance costs and potential liability. Other states have passed or are considering similar privacy laws and the federal government may seek to enact a similar
federal privacy law, reflecting a trend toward more stringent privacy legislation in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that there will
continue to be new laws, regulations and industry standards concerning privacy, data protection and information security proposed and enacted in various jurisdictions. For example, Washington State has enacted a broadly applicable law to protect the
privacy of personal health information known as the &#147;My Health My Data Act,&#148; which generally requires affirmative consent for the collection, use, or sharing of any &#147;consumer health data.&#148; Consumer health data is defined to
include personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#146;s past, present, or future physical or mental health status; consumer health data also includes information that is derived or
extrapolated from <FONT STYLE="white-space:nowrap">non-health</FONT> information, such as algorithms and machine learning. Other states, including Connecticut and Nevada, have also passed consumer health data laws, and given the increased focus on
the use of health data by entities that are not subject to HIPAA, additional states are expected to pass consumer health privacy laws. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.
We could be adversely affected if HIPAA, the CCPA (including as amended by CPRA) and other state or federal legislation or regulations applicable to GRAIL require changes in our business practices, our use, receipt, or transfer of health
information, or our privacy policies, or if governing jurisdictions interpret or implement their legislation or regulations in ways that negatively affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Trade Commission (&#147;FTC&#148;) also has authority to initiate enforcement actions against entities that mislead customers
about HIPAA compliance, make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other
unfair practices that harm customers or that may violate Section&nbsp;5 of the Federal Trade Commission Act (&#147;FTC Act&#148;). Even when HIPAA does not apply, according to the FTC, violating consumers&#146; privacy rights or failing to take
appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of the FTC Act. The FTC also expects a company&#146;s data security measures to be reasonable and
appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Personal health information is considered
sensitive data that merits stronger safeguards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to comply with applicable laws, regulations, policies and other legal
obligations relating to privacy, data protection and information security. However, the various regulatory frameworks for privacy and data protection are, and are likely to remain, uncertain for the foreseeable future, and it is possible that these
or other actual or alleged obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules and subject our business practices to uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the actual or perceived compromise of, lax oversight of, irresponsible or
unauthorized use of, or unauthorized access to or release of, patient data or information by GRAIL, our partners, suppliers, contractors, consultants, or vendors, could erode provider, patient, and customer confidence, which could impact our
business, financial condition, and results of operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to utilize biological samples and data from participants in accordance
with applicable law, IRB stipulations, and participant permissions (through consent forms and HIPAA authorizations). If we are unable or significantly restricted in using participant samples and data for secondary research purposes, our ability to
develop additional products and/or improve or refine existing products will be limited, which may impact our business and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we are or may in the future be subject to a range of laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various foreign jurisdictions. In Europe, we are subject
to the United Kingdom General Data Protection Regulation and the Data Protection Act 2018 (&#147;UK GDPR&#148;) and the EU General Data Protection Regulation (&#147;EU GDPR&#148;) (the UK&nbsp;GDPR and EU GDPR together referred to as the
&#147;GDPR&#148;). The GDPR imposes a comprehensive data privacy compliance regime including: maintaining a record of data processing; providing detailed disclosures about how personal information is collected and processed (in a concise,
intelligible and easily accessible form); demonstrating that appropriate legal bases are in place to justify data processing activities; complying with rights for data subjects in regard to their personal information (including data access, erasure
(the right to be &#147;forgotten&#148;) and portability); ensuring appropriate safeguards are in place where personal information is transferred out of the EEA and the UK; and complying with the principal of accountability and the obligation to
demonstrate compliance through policies, procedures, training and audit. The applicability of the specific requirements depends on whether an organization acts as controller or processor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the personal information we process, for example in respect of clinical trial participants, is special category data under the GDPR,
and subject to additional compliance obligations and to local law derogations. We may be subject to diverging requirements under national UK laws and EU member state laws, such as the legal basis we can rely on when processing health data of
clinical trial participants as controller or the roles, responsibilities and liabilities as between CROs. As these laws develop, we may need to make operational changes to adapt to these diverging rules, which could increase our costs and adversely
affect our business. Further, the regulatory landscape of data and digital laws in the UK and EU is under constant development, and in the future we may be required to adapt our processes, or change the way we engage with health data (for example,
if proposed legislation such as the Data Governance Act and the Data Act is enacted and applies to our operations). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other
requirements, the GDPR regulates the transfer of personal information outside of the EEA and the UK. Case law from the Court of Justice of the European Union (&#147;CJEU&#148;) states that reliance on the standard contractual clauses&#150;a standard
form of contract approved by the European Commission as an adequate personal information transfer mechanism&#150;alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. On October&nbsp;7, 2022, President Biden signed an Executive Order on &#145;Enhancing Safeguards for United States Intelligence Activities&#146; which introduced new redress mechanisms and
binding safeguards to address the concerns raised by the CJEU in relation to data transfers from the EEA to the United States and which formed the basis of the new <FONT STYLE="white-space:nowrap">EU-US</FONT> Data Privacy Framework
(&#147;DPF&#148;), as released on December&nbsp;13, 2022. The European Commission adopted its Adequacy Decision in relation to the DPF on July&nbsp;10, 2023, rendering the DPF effective as an EU GDPR transfer mechanism to United States entities
self-certified under the DPF. On October&nbsp;12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to United States entities self-certified under the UK Extension to the DPF.
We currently rely on the EU standard contractual clauses, the UK Addendum to the EU standard contractual clauses, and the UK International Data Transfer Agreement, as relevant, to transfer personal information outside the EEA and the UK, including
to the United States, with respect to both intragroup and third-party transfers. We expect the existing legal complexity and uncertainty regarding international transfers of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personal information to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to
continue to be subject to enhanced scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or
fines; we may have to stop using certain tools and vendors and make certain operational changes, including to implement other/revised relevant documentation for data transfers within required time frames; and/or it could otherwise affect the manner
in which we provide our services, and could adversely affect our business, operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penalties and fines for
failure to comply with the GDPR are significant, including fines of up to &#128;20 million/&pound;17.5&nbsp;million or 4% of a noncompliant company&#146;s global turnover for the preceding year, whichever is higher. Since we are subject to the
supervision of relevant data protection authorities under both the UK GDPR and the EU GDPR, we could be fined under each of those regimes independently in respect of the same <FONT STYLE="white-space:nowrap">non-compliance.</FONT> As we continue to
expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. Noncompliance with applicable foreign privacy laws, such as the GDPR, would also adversely affect
public perception of GRAIL&#146;s data stewardship practices and policies, which could impair our business and prospects with other foreign health systems and governments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our partners fail to comply with federal, state, and foreign laboratory and other applicable licensing and registration
requirements, we could be prevented from performing our tests or experience disruptions to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CLIA is a federal law
that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention, or treatment of disease, or impairment of, or the assessment of the health of, human
beings. CLIA regulations require, among other things, clinical laboratories to obtain a certificate and mandate specific standards in the areas of personnel qualifications, administration, participation in proficiency testing, test management, and
quality assurance. CLIA certification is also required for us to be eligible to bill state and federal healthcare programs, if such reimbursement is otherwise available, as well as many private third-party payors, for our products. To renew these
certifications, we are and will be subject to routine surveys and inspections. Moreover, CLIA inspectors may make random or &#147;for cause&#148; inspections of our clinical laboratories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold CLIA certificates from CMS for our laboratories in Menlo Park, California and Durham, North Carolina to conduct high complexity
testing, subject to inspection to determine compliance with the CLIA regulations. We also hold CAP accreditations for our Menlo Park and Durham facilities. While we have completed validation studies for the version of Galleri currently marketed as
an LDT, we are continuing our validation efforts for the version of Galleri that we intend to submit for PMA approval. We may not successfully complete such validation. Certain product additions to our test menu require notification to the
regulatory and accrediting bodies that regulate our laboratories (e.g., CMS, the California Department of Public Health Laboratory Field Services (&#147;CALFS&#148;) and CAP) that we are adding a new specialty to our assay offerings. At their
discretion, any regulatory or accrediting body may come <FONT STYLE="white-space:nowrap">on-site</FONT> to inspect our laboratories at any time. Any failure to pass inspections, maintain our CLIA certificates, CAP accreditation, or state licenses,
or add new validated products to our laboratory assay offerings could significantly harm our business, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to obtaining federal certification for a laboratory under CLIA, we are also required to obtain and maintain state licenses to
conduct testing in our laboratories. We have obtained a Clinical Laboratory Certificate of Deemed Status from the State of California Department of Public Health for our Menlo Park facility. The California licensure law establishes standards for the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of a clinical laboratory, including the training and skills required of personnel and quality control. In addition, California law mandates
proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory. Further, if we test specimens originating from other states and return patient-specific results, our clinical laboratory must satisfy
such states&#146; licensure laws as well to the extent that such laws regulate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> laboratories that test </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specimens originating in such states. For example, to be able to receive specimens originating from New York, we must maintain a New York State Department of Health clinical laboratory permit and
obtain approval of Galleri, which we achieved. Research testing, however, does not require licensure if patient-specific results are not generated and/or returned for diagnostic purposes. We have obtained New York State Department of Health clinical
laboratory permits for our Menlo Park facility and our Durham facility, which authorize us to accept and generate for diagnosis or treatment purposes patient-specific results on specimens originating from New York at the applicable facility, as well
as having obtained New York State Department of Health approval to offer Galleri to residents of the State of New York. Applicable New York laws and regulations establish standards for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of a clinical laboratory, including training and skill levels required of laboratory personnel, physical requirements of a facility, equipment, and
validation and quality control. There can be no assurance that we will be able to maintain New York clinical laboratory permits or approval of Galleri, or maintain licenses or permits from any other states where we are required to be licensed or
hold a permit. Failure to maintain such licenses or permits could expose us to fines and other penalties, or limit our potential testing population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with CLIA certification and state laboratory licensing and permitting, we remain subject to a number of risks in the event of
noncompliance. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure or permitting, or our failure to renew or maintain a CLIA certificate, a state license or permit, or
accreditation (including CAP), could have a material adverse effect on our business and reputation as certain actions are public. CMS also has the authority to impose a wide range of sanctions, including suspension, limitation, or revocation of the
CLIA certification, termination of Medicare and Medicaid participation, civil money penalties, and a bar on the ownership or operation of a CLIA-certified laboratory by any owners or operators of the deficient laboratory. If we fail to obtain any
required state licensure, or lose CLIA certification, CAP accreditation, or licensure, we would not be able to operate our clinical laboratories and offer our products in full or in particular states, which would adversely impact our business and
results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to state laboratory licensing laws, we may also be subject to state registration and/or licensing requirements that apply to
companies that manufacture medical devices. Certain states require such registrations or licenses before the products are commercialized, including while manufacturers are evaluating the devices in clinical studies. Violations of these laws may
result in the denial, suspension, or revocation of the registration or license, as well as other fines and penalties, including imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Data from our clinical trials that we announce or publish from time to time before our trials are complete may change as more patient
data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which is based on a preliminary analysis of
then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as
part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or
different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data
being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available. Audits, internal or external, including by the
FDA&#146;s Bioresearch Monitoring (&#147;BIMO&#148;) program, of our studies or associated data, can require substantial amounts of time, personnel, and other resources to comply with, and may not be anticipated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may also disclose interim data from our clinical studies. Interim data from these studies that we may complete are
subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available. Adverse differences between interim </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data and <FONT STYLE="white-space:nowrap">top-line,</FONT> preliminary, or final data could significantly harm our business prospects. Further, disclosure of interim data by us or by third
parties could result in volatility in the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, in the United Kingdom, we are working with NHS
England to complete our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial. It is possible that the early preliminary, interim or final data may not be as we expect, may be inconsistent with prior
<FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> data, or with other studies we have conducted, or may be unsuitable to the NHS, any of which could have a significant adverse impact on the success of our commercial efforts for Galleri, our
ability to achieve FDA authorization at all or within our anticipated timelines, our brand and reputation, our business, and our growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, and our ability to receive regulatory clearance or approval or commercialize a particular product and our company in general. In
addition, the information we choose to publicly disclose regarding a particular study or clinical study is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise
appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding our business. If the
data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to commercialize or obtain regulatory clearance or approval for our products may be harmed, which could
harm our reputation, business, operating results, prospects or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Any product for which we obtain a regulatory
certificate, permit, license, clearance, or approval will be subject to extensive ongoing regulatory requirements, and we may be subject to penalties if we or our partners fail to comply with regulatory requirements or if we experience unanticipated
problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product for which we obtain a regulatory certificate, permit or license from a local, state,
federal, or foreign regulatory authority, or notified body, or clearance or approval from the FDA or other comparable regulators, along with the manufacturing processes, post-market surveillance, labeling, packaging, advertising, and promotion,
distribution, storage, import, export, reporting, and recordkeeping for such product, will be subject to continued regulatory review, oversight, requirements, and periodic inspections by the FDA and comparable foreign regulatory authorities, as well
as our laboratory processes and practices will be subject to continued review, oversight, requirements, and inspections by CMS, CALFS, and CAP. These requirements include submissions of safety and other post-marketing information and reports;
registration and listing requirements; requirements relating to quality control, quality assurance, and corresponding maintenance of records and documents; requirements relating to recalls, removals, and corrections; and requirements relating to
product labeling, advertising and promotion, and recordkeeping. The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or
expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA and comparable foreign regulatory authorities enforce regulatory requirements through, among other means, periodic unannounced inspections. We do not know
whether we will be found compliant in connection with any future regulatory inspections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory clearance, approval, or certification
of a test or device may be subject to limitations by the regulatory body or notified body as to the indicated uses for which the product may be marketed or to other conditions of clearance, approval, or certification. In addition, clearance,
approval, or certification may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the test or device. After clearance, approval, or certification, discovery of problems with our product,
suppliers, vendors, or contract manufacturers, or manufacturing processes (including software validation), and/or failure to comply with regulatory requirements, may result in actions such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on operations of our laboratories; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Untitled or Warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal or recall of the product from the market or seizure of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve applications or supplements to approved applications that we may submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension, limitation or withdrawal of regulatory approvals, clearances, or certifications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety communications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our
reputation, business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA may change its clearance or approval policies,
adopt additional regulations or revise existing regulations, or take other actions. For example, on February&nbsp;23, 2022, the FDA issued a proposed rule to amend the Quality System Regulation (&#147;QSR&#148;), which establishes current good
manufacturing practice requirements for medical device manufacturers, to align more closely with the International Organization for Standardization standards. This proposal has not yet been finalized or implemented. Accordingly, it is unclear the
extent to which this or any other proposals, if adopted, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise create market pressure that may negatively affect our business. Such
changes may also occur in foreign jurisdictions where we intend to market our products or future products. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain clearances or approvals,
increase the costs of compliance or restrict our ability to maintain any clearances or approvals we have obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are or
may become subject to new laws, regulations, and industry standards concerning medical devices proposed and enacted in various foreign jurisdictions. The EU regulatory landscape concerning IVDs recently evolved. On May&nbsp;26, 2022, the EU IVDR
became applicable, and repealed and replaced the EU IVDD. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member state laws
implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The EU IVDR, among other things, is intended to establish a uniform, transparent, predictable
and sustainable regulatory framework across the EU for in vitro diagnostic medical devices and ensure a high level of safety and health while supporting innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These modifications may have an effect on the way we intend to develop our business in the EU and the EEA. For example, as a result of the
transition towards the new regime, notified body review times have lengthened, and product introductions could be delayed or canceled, which could adversely affect our ability to grow our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>For any of our products that are approved or cleared by the FDA, we will be required to
report to the FDA certain information about adverse medical events or malfunctions, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, results of operations, and growth prospects.
The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For products for which we obtain FDA clearance or approval or that are otherwise subject to affirmative FDA oversight, we will be subject to
the FDA&#146;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or
contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of
the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if
it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters,
untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our products or delay in clearance or approval of future products. Similar risks exist
in foreign jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in
the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#146;s authority to require a recall must be based on a finding that there is reasonable
probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk
to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the corrective action we take to redress a product&#146;s deficiencies or defects, the FDA or comparable foreign regulatory
authorities may require, or we may decide, that we will need to obtain new clearances, approvals, or certifications for the device before we may market or distribute the corrected device. Seeking such clearances, approvals, or certifications may
delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA or comparable foreign
regulatory authorities warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies are
required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the
FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product
liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from
operating our business and may harm our reputation and financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>To obtain and maintain FDA approvals or clearances, our
products will need to be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we or our partners fail to comply with these regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the FDA to approve or clear a medical device marketing application, the methods used in, and the facilities used for, the manufacture of
our products must comply with the FDA&#146;s QSR, which is a complex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution,
installation, servicing and shipping of medical devices. Furthermore, to obtain FDA clearance or approval, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and
applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Similar state regulations and various
laws and regulations of foreign countries governing manufacturing also apply to our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers may not take
the necessary steps to comply with applicable regulations, which could cause delays in the availability of our products or a delay in obtaining FDA authorization of our marketing application. In addition, the FDA has issued a proposed rule to amend
the QSR to align more closely with the International Organization for Standardization standards. Although this proposal has not yet been finalized or implemented and it is unclear the extent to which this or any other proposals, if adopted, could
impose additional or different regulatory requirements on us or our third-party manufacturers, the amendment could increase the costs of compliance or otherwise create market pressure that may negatively affect our business. Failure to comply with
applicable FDA requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or
withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#146;s refusal to grant pending or future clearances or approvals for
our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers, or our employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these actions could significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be
harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our products may harm our reputation in the marketplace, result
in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any marketing authorization or certification we may receive or obtain for our products by the FDA, comparable foreign regulatory authorities,
or notified bodies will include specified indications for use and approved (or certified) labeling. Upon receipt of FDA authorization, or certification, we will continue to train our marketing personnel and direct sales force to not promote our
authorized (or certified) tests for uses outside of <FONT STYLE="white-space:nowrap">FDA-authorized</FONT> (or certified) indications for use, known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; We cannot, however, prevent a
physician from using our products <FONT STYLE="white-space:nowrap">off-label,</FONT> when in the physician&#146;s independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if
physicians attempt to use our products <FONT STYLE="white-space:nowrap">off-label,</FONT> which could harm our reputation in the marketplace among physicians and patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, after FDA authorization or certification, the FDA or any foreign regulatory body determines that our promotional materials or training
constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an
untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under
other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, which could result in significant penalties, including, but not
limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, physicians may misuse our products or use improper techniques if they are not
adequately trained, potentially leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. As described
above, product liability claims could divert management&#146;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Misleading, untruthful, or unsubstantiated labeling, advertising, marketing, or promotional practices could cause significant harm to our
business, operations, and financial conditions. The FTC has instituted enforcement actions against certain healthcare testing companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in
advertising. These enforcement actions may result in warning letters, consent decrees, and the payment of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or
unsubstantiated, we could be subject to FTC enforcement action and may face significant penalties which may result in a material adverse effect on our reputation, business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The labeling, advertising, marketing, and promotional practices of GRAIL related to our products is governed by numerous state and federal
regulators, including the FDA and the FTC, as well as subject to <FONT STYLE="white-space:nowrap">third-party</FONT> claims. Any statements related to our products that could be construed as misleading, untruthful, or unsubstantiated, could subject
GRAIL to regulatory enforcement action, third-party lawsuits, or plaintiffs&#146; complaints. Any of these actions could significantly and negatively affect our reputation, expose us to liability claims, and we could lose customers and experience
reduced sales and increased costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform and data protection measures, including legislation reforming the U.S.
healthcare system, could cause significant harm to our business, operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare systems are
subject to ongoing reform in the United States and abroad. For example, in the United States, the Affordable Care Act (&#147;ACA&#148;) made a number of substantial changes to the way healthcare is financed both by governmental and private insurers.
The ACA, among other things, included provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse. Since its enactment, there have been executive, judicial and Congressional challenges to
certain aspects of the ACA. Most recently, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by
Congress. Other legislative changes have also been proposed and adopted in the United States since the ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers,
which went into effect in April 2013 and will remain in effect until 2032 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced
Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services are paid under the
CLFS. Under PAMA, certain clinical laboratories are required to periodically report to CMS private payor payment rates and volumes for their tests, and laboratories that fail to report the required payment information may be subject to substantial
civil monetary penalties. Medicare reimbursement for CDLTs is based on the weighted-median of the payments made by private payors for these tests, rendering private payor payment levels even more significant than in the past. As a result, future
Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of diagnostic tests generally and any given test individually. The impact of this payment system on rates for our tests,
including any current or future tests we may develop, is uncertain. For more information, see above and the section entitled &#147;Risks Relating to Our Business and Industry&#151;One of the key elements of our strategy is to expand access to our
tests by pursuing coverage and reimbursement from third-party payors, both private and government payors. If our products do not receive adequate coverage and reimbursement from third-party payors, if at all, our ability to expand access to our
products beyond our existing sales channels will be limited and our overall commercial success will be limited&#148; beginning on page&nbsp;37 of this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether or when these or other recently enacted healthcare initiatives will
be implemented at the federal or state level or in foreign jurisdictions or how any such legislation or regulation may affect us. For instance, the payment reductions imposed by the ACA and the changes to reimbursement amounts paid by Medicare for
tests based on the procedure set forth in PAMA, could limit the prices we will be able to charge or the amount of available reimbursement for our tests, which would reduce our revenue. Additionally, these healthcare policy changes could be amended
or additional healthcare initiatives could be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar developments may occur in the EU. For instance, on
December&nbsp;13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#147;HTA&#148;) amending Directive 2011/24/EU, was adopted. While the regulation entered into force in January 2022, it will only begin to apply from January 2025
onwards, with preparatory and implementation-related steps to take place in the interim. Once the regulation becomes applicable, it will have a phased implementation depending on the concerned products. This regulation intends to boost cooperation
among EU member states in assessing health technologies, including certain high-risk medical devices, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation will permit EU member states
to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific
consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will
continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the impact on our business of the expansion of the federal and state governments&#146; role in the U.S. healthcare industry
generally, including the social, governmental and other pressures to reduce healthcare costs while expanding individual benefits, is uncertain. Any future changes or initiatives could have a materially adverse effect on our business, financial
condition, results of operations and cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory authorization of our products in one
jurisdiction does not mean that we will be successful in obtaining regulatory authorization of our products in other jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory authorization or certification of products in one jurisdiction does not guarantee that we will be able to
obtain or maintain regulatory authorization or certification in any other jurisdiction, but a failure or delay in obtaining regulatory authorization or certification in one jurisdiction may have a negative effect on the regulatory authorization or
certification process in others. For example, even if the FDA or a comparable foreign regulatory authority grants clearance or approval for our products, comparable regulatory authorities or notified bodies in foreign jurisdictions may also need to
authorize or certify the products in those countries. Premarket authorization and certification processes vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including
additional clinical studies, because clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities or notified bodies in other jurisdictions or the data may not be considered applicable to the jurisdiction&#146;s
intended patient population based on demographic, medical practice, genetic, or other differences. In some cases, the price that we intend to charge for our products may also be subject to approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory authorization or certification and maintaining compliance with foreign regulatory requirements could result in
significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in other jurisdictions, or we fail to receive necessary or
desirable marketing authorizations or certification in other jurisdictions, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners, and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that
fails to: comply with applicable rules and regulations of the CMS, the FDA, and other comparable foreign regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing and clinical
laboratory standards; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. For example, in
June 2023, our third-party telemedicine provider experienced a software issue that resulted in erroneous test reports being delivered to patients. Since we began commercializing Galleri in the United States, our potential exposure under such laws
has increased significantly, and our costs associated with compliance with such laws have, and will likely continue to, increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are
subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices, as well as <FONT STYLE="white-space:nowrap">off-label</FONT> product promotion. These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information
obtained in the course of participant recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties,
and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be
in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
significant fines or other sanctions. Even if it is later determined after an action is instituted against us that we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions, and
have to divert significant management resources from other matters. We expect our exposure to and costs associated with compliance with healthcare fraud and abuse laws to increase significantly if we commercialize additional products in the future.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare and other applicable laws and regulations, we could face substantial penalties and our
business, reputation, and operations and financial condition could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to various
U.S. federal and state fraud and abuse laws. In addition, the commercialization of our products outside the United States would also subject us to foreign equivalents of the healthcare laws described below, among other foreign laws. The laws that
may, currently or in the future, impact our operations include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order or recommendation of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation, and many courts have interpreted that statute as being violated if merely one purpose of any arrangement is to induce referrals or
purchases. In 2018, Congress enacted the Eliminating Kickbacks in Recovery Act of 2018 (&#147;EKRA&#148;), which establishes an <FONT STYLE="white-space:nowrap">all-payor</FONT> anti-kickback prohibition for, among other things, knowingly and
willfully paying or offering any remuneration directly or indirectly to induce a referral of an individual to a clinical laboratory. Violations of EKRA may result in fines, imprisonment, or both, for each occurrence; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician self-referral prohibition, commonly known as the Stark Law, which, in the absence of an
applicable exception, prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including clinical laboratory services, if the physician or an immediate family member of the
physician has a financial relationship with the entity providing the designated health services. The Stark Law also prohibits the entity furnishing the designated health services from billing, presenting or causing to be presented a claim for the
designated health services furnished pursuant to the prohibited referral; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, which impose criminal and civil
penalties, including through civil &#147;qui tam&#148; or &#147;whistleblower&#148; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other
third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute or Stark Law constitutes a false or fraudulent claim for
purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">healthcare fraud and false statements laws, which prohibit, among other things, knowingly making a false
statement to improperly avoid, decrease, or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to
violate them in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Civil Monetary Penalties Law, which, subject to certain exceptions, prohibits, among other things,
the offer or transfer of remuneration, including waivers of copayments and deductible amounts (or any part thereof), to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the
beneficiary&#146;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, which
require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to the U.S. Department of Health and Human
Services under the Open Payments Program, information related to payments or other transfers of value made to physicians (as defined by statute), teaching hospitals, and other healthcare practitioners, as well as ownership and investment interests
held by such physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection, and unfair competition laws that may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangement, as well as submitting claims involving healthcare items or services reimbursed
by any third-party payor, including commercial insurers; state laws that require healthcare companies to comply with the medical device industry&#146;s voluntary compliance guidelines, the relevant compliance guidance promulgated by the federal
government that otherwise restricts payments that may be made to healthcare providers, and other potential referral sources or state-specific standards on financial interactions with healthcare providers; state laws that require healthcare companies
to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensation, and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign
laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available and lack of clear guidance, it
is possible that some of our business activities could, despite our efforts to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare and other applicable laws may involve
substantial costs. In the future, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or then-existing statutes, regulations, or case law interpreting applicable fraud
and abuse or other healthcare or applicable laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational
harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations,
we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety
laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, labeling, handling, use, storage, transport, treatment, and disposal of hazardous and regulated materials and wastes; the emission and
discharge of hazardous materials into the ground, air, and water; and employee health and safety. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from
these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources or insurance coverage. Under certain
environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. If
the handling, use, labeling, storage, or transport of hazardous or biohazardous materials by us or our contract manufacturers or suppliers fail to comply with applicable requirements, we could incur significant costs, be subject to civil or criminal
fines and penalties, experience disruption and delays in our operations, and face destruction of any <FONT STYLE="white-space:nowrap">non-compliant</FONT> materials, which could include clinical and biological samples. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may
impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance
to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or
hazardous waste insurance coverage. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical studies or regulatory approvals or
certifications could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding or disruptions at the FDA, other government agencies, and notified bodies caused by funding shortages, global health
concerns, government shutdowns, or other causes could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, certified, or commercialized in a timely
manner or at all, or otherwise prevent those agencies and notified bodies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA, foreign regulatory agencies, and notified bodies to review and clear, approve, or certify new products or changes to
existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#146;s, foreign regulatory agencies&#146;, and notified bodies&#146; ability to hire and
retain key personnel and accept the payment of user fees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government shutdowns, and other events that may otherwise affect the FDA&#146;s foreign regulatory agencies&#146; and notified bodies&#146; ability to perform routine functions. Average review
times at the FDA, foreign regulatory agencies, and notified bodies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political
process, which is inherently fluid and unpredictable. Disruptions at the FDA, other agencies, and notified bodies may also slow the time necessary for new medical devices or modifications to cleared, approved, or certified medical devices to be
reviewed and/or approved, or certified by necessary government agencies or notified bodies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the FDA postponed most inspections of domestic and foreign
manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the
safety of its employees and those of the firms it regulates, and any resurgence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or emergence of new variants may lead to further inspectional delays. If a prolonged government shutdown occurs, or
if global health concerns continue to prevent the FDA, other regulatory authorities, or notified bodies from conducting their regular activities, it could significantly impact the ability of the FDA, other regulatory authorities, or notified bodies
to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, for
example, notified bodies must be officially designated to certify products and services in accordance with the EU IVDR. Only a few notified bodies have been designated so far and the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has
significantly slowed down their designation process. Without EU IVDR designation, notified bodies may not yet start certifying devices in accordance with the EU IVDR. As only a few notified bodies have been EU IVDR-designated, they are facing a
heavy workload and their review times have lengthened. This situation may impact the way we are conducting or intend to conduct our business in the EU and the EEA and the ability of the applicable notified body to timely review and process our
regulatory submissions and perform its audits.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities are subject to the FCPA and similar
anti-bribery and anti-corruption laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business activities are subject to the FCPA and similar anti-bribery or anti-corruption
laws, regulations, or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly
reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, the healthcare providers who administer diagnostic tests are employed by their government, and the purchasers of diagnostics tests are government
entities; therefore, our dealings with these providers and purchasers are subject to regulation under the FCPA. The SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical
companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws.
Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned
countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our
reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property
protection we obtain is not sufficiently broad, third parties could in the future develop and commercialize technology and tests similar or identical to ours, and our ability to successfully commercialize our products may be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to perform successfully will depend in part on our ability to obtain and enforce patent protection for our products, preserve our
trade secrets, and operate without infringing the proprietary rights of third parties. Filing, prosecuting, and defending patents on our products and other technologies in all countries throughout the world would be prohibitively expensive and
time-consuming, and the laws of some foreign countries may not protect our rights to the same extent as the laws of the United States. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patents or patent
applications at a reasonable cost or in a timely manner, or in all jurisdictions. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our products and technologies and each of these provisional patent
applications, or any future provisional patent application on certain aspects of our products and technologies, is not eligible to become an issued patent until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent application within 12 months of the filing date of the applicable provisional patent application. In cases where we have not obtained, or decided not to obtain, patent protection for certain of our inventions, we may not be able to prevent
third parties from practicing our inventions or from selling or importing tests made using our inventions in and into the United States or other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, while we have applied for patents that protect aspects of our technology in the United States and numerous other countries, we
cannot assure you that our intellectual property position, including our owned and exclusively licensed pending and issued patents, will not be challenged or that all patents for which we have applied will be issued on a timely basis or at all, or
that such patents will protect our technology, in whole or in part, or be issued in a form that will provide us with meaningful protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although patents are presumed valid and enforceable upon issuance, a patent may be challenged as to its inventorship, scope, validity, or
enforceability, and certain of our owned or exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents have been, and others in the future may be, challenged in the courts or patent offices in the United States or abroad. For example,
eight of our in-licensed European patents and one of our owned European patents have been subject to oppositions in Europe, as described below. As a result of such challenges, our pending or future patent applications may not result in issued
patents, or the scope of existing or future patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, or our issued patents may be held invalid or unenforceable. It is also
possible that we may fail to identify patentable technologies in a timely fashion, which could impair our ability to obtain patent protection on such technology at all. Third parties may be able to circumvent our owned or exclusively <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents by developing similar or alternative technologies or tests in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Third parties could in the future also set up laboratories outside
the countries in which we have filed patent applications in order to compete without infringing upon our intellectual property, even if they process samples from countries in which we do have patent protection. In addition, to the extent we have
granted, or may grant in the future, licenses or sublicenses of our intellectual property rights to third parties, we cannot provide any assurance that such intellectual property rights will not be used by those third parties in a manner that could
compete with our business or otherwise negatively impact any competitive advantage provided by such intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and
other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending
patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are uncertain. Given the amount of time required
for the development, testing, and regulatory review of new tests, patents protecting such tests might expire before or shortly after such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products are commercialized. As a result, our owned or exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio may not provide us with sufficient rights to exclude others
from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a third party obtains an issued patent on inventions we use in our
products, that party could prevent us from using those inventions, and we may not be able to design around the third party&#146;s patents or obtain a license on commercially reasonable terms, if at all. Third-party patents or other intellectual
property may exist that our current technology, manufacturing methods, products, or future methods or tests infringe or will infringe, which could result in litigation, the imposition of injunctions preventing our use of the foregoing, or require us
to obtain licenses or pay royalties and/or other forms of compensation to third parties, which could be significant and could harm our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to
the U.S. Patent and Trademark Office (&#147;USPTO&#148;) and various government patent agencies outside of the United States over the lifetime of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications. In certain
circumstances, we rely on our licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies and to take the necessary actions to comply with other requirements to maintain such <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents during their term. In some cases, <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete
loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical tests or technology, which could have a material adverse effect on our market position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or
otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreements with Illumina and license agreements with others that provide rights to certain technologies related to assays used in our
products. We may need to obtain additional licenses from others to advance our research or allow commercialization of our products or technology, either globally or in certain geographies, without infringing the intellectual property of third
parties. It is possible that we may be unable to obtain such additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology or to
develop or license replacement technology, any of which may not be feasible on a technical or commercial basis. If we are unable to obtain or maintain applicable licenses, we may be unable to commercialize certain of our products, either globally or
in certain geographies, or continue to utilize our technology, which could harm our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our <FONT STYLE="white-space:nowrap">in-licenses</FONT> impose various development, diligence, commercialization, and other
obligations on us, and we expect that our future license or development agreements will contain similar types of obligations. Certain of our license agreements also require us to meet development timelines, or to exercise commercially reasonable
efforts to develop and commercialize licensed products. Despite our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements or our sublicensees may fail to fulfill their obligations to us
or materially breach our related sublicense agreements, and our licensors might therefore terminate the license agreements or otherwise modify our rights under those agreements, thereby removing or limiting our ability to develop and commercialize
products and technology covered by these license agreements or resulting in litigation. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying patents fail to provide the anticipated market exclusivity,
other third parties may have the freedom to seek regulatory approval of, and to market, tests highly similar to ours or we may be required to cease commercialization of our products or use of our technology. Any of the foregoing could have a
material adverse effect on our position, business, financial condition, results of operations, and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently license or otherwise obtain rights to
intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations, which may lead to disputes between us and our licensor, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our product and technology infringe on intellectual property of the licensor that is not
subject to the license agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right to sublicense patent and other rights under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence and other obligations under the license agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
invention of intellectual property by us and our licensors and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The resolution of any contract
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of
which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. If we are required to engage in litigation to enforce or defend our rights under our license or development agreements,
even if we are successful, such litigation could require significant financial resources, divert the attention of management and harm our business. Moreover, if disputes over intellectual property that we have licensed or otherwise obtained rights
to prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, or at all, we may be unable to successfully commercialize the affected product or technology, which could have a material adverse effect on our
business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our use of open-source software could subject our
proprietary technology to unwanted open-source license conditions that could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A portion of our
technology capabilities incorporates open-source software, and we may incorporate open-source software into other offerings or products in the future. If an author or other third party that distributed such open-source software to us were to allege
that we had not complied with the conditions of one or more of these licenses, we could be required to remediate our open source vulnerabilities or defend against such allegations. In addition, if we combine our proprietary software with open-source
software in a certain manner and make it available to others, under some open-source licenses, we could be required to license or make available the source code of our proprietary software, which could help our third parties develop products that
are similar to ours and harm our business; thus, we could be required to remediate any such open source vulnerabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Developments in patent law could have a negative impact on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress, the USPTO, or applicable authorities in other jurisdictions
may change the standards of patentability and any such changes could have a negative impact on our business. The scope of patent coverage available for medical diagnostics continues to evolve and uncertainty remains around the patentability of
certain diagnostic-based method claims. U.S. Supreme Court and Federal Circuit decisions interpreting and/or limiting the scope of patentable subject matter under 35 U.S.C. &#167; 101, in addition to examination guidelines from the USPTO, have made
it more difficult for patentees to obtain and/or maintain patent claims in the United States that are directed to medical diagnostics, as claims to that subject matter are sometimes perceived to recite or involve laws of nature, natural phenomena,
and/or natural products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several precedential decisions regarding patentable subject matter are of particular relevance to patents in the
medical diagnostics and computer-implemented applications space. The 2012 decision in <I>Mayo Collaborative</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>v. Prometheus Laboratories </I>(<I>Prometheus</I>) concerns patent claims directed to optimizing the amount of drug administered to a specific patient based on certain diagnostic measurements.
The U.S. Supreme Court held that the applicable patent&#146;s claims were directed to a law of nature (i.e., a natural correlation between drug levels and efficacy or toxicity) and failed to incorporate a sufficiently inventive concept above and
beyond routine and conventional method steps to allow the claimed methods of treatment to qualify as patent eligible. The 2013 decision in <I>Association for Molecular Pathology v. Myriad Genetics </I>(<I>Myriad</I>) concerns the patentability of
isolated DNA sequences that were related to methods of diagnosing genetic predisposition to cancer. The U.S. Supreme Court held that isolated fragments of naturally occurring genetic material are not patent eligible, but <FONT
STYLE="white-space:nowrap">non-naturally</FONT> occurring fragments can be patented. The 2014 decision in <I>Alice Corporation Pty. Ltd. v. CLS Bank International </I>(<I>Alice</I>) concerns computer-implemented inventions. The U.S. Supreme Court
held that an abstract idea could not be patented just because it is implemented on a computer, thus providing guidance on the patentability of computer-implemented applications. The 2015 decision in <I>Ariosa v. Sequenom </I>(<I>Sequenom</I>)
concerns the patentability of claims directed to a method of detecting fetal DNA in a mother&#146;s serum or plasma samples. Although the U.S. Supreme Court recognized that the discovery of cell-free fetal DNA present in a mother&#146;s bloodstream
was a scientific breakthrough, it held that the claims were not patent eligible since they were primarily directed to a natural phenomenon. The Federal Circuit&#146;s 2020 decision in <I>Illumina v. Ariosa </I>concerns the patentability of claims
directed to preparing a fraction of DNA enriched in cell-free fetal DNA. The Federal Circuit held the claims were patent eligible and distinguished them from the claims in Sequenom as method of preparation claims, rather than diagnostic claims. The
court further explained that the claimed DNA fragment size thresholds were human-engineered parameters, suggesting that claims based on natural phenomena, but not exclusively directed to such phenomena, may be patent eligible. In short, our efforts
to seek patent protection for our technologies and products may be impacted by the evolving case law and guidelines/procedures issued by the USPTO, or authorities in other jurisdictions based on such changes in the law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot fully predict the impact that the evolving case law on patentable subject matter will have on the ability to obtain or enforce
patents relating to DNA, genes, genomic-related discoveries, or computer-implemented tests, including such tests that use machine learning or rely on software pipelines, in the future, as the contours of whether claims are patent eligible (or
instead recite laws of nature, natural phenomena, natural products, or abstract ideas) are not clear and may take years to develop via interpretation at the USPTO and in the courts. There are many patents claiming nucleic acids and diagnostic
methods based on natural correlations that issued before the court decisions summarized above and, although some of these patents may be invalid under the standards set forth in these decisions, these patents are presumed valid and enforceable until
they are successfully challenged. Thus, third parties holding these patents could allege that we infringe, or request that we obtain a license under, these patents, even if these patents are not likely enforceable under current U.S. laws. Whether
based on patents issued prior to or after these precedential decisions, we could be forced to defend against claims of patent infringement or obtain license rights, if available on commercially reasonable terms or at all, under these patents. In
jurisdictions other than the United States, gene-related patent claims may remain valid and may be enforced against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on
June&nbsp;1, 2023, the European Union Patent Package (&#147;EU Patent Package&#148;) regulations were implemented with the goal of providing a single <FONT STYLE="white-space:nowrap">pan-European</FONT> Unitary Patent and a new European Unified
Patent Court (&#147;UPC&#148;) for litigation involving European patents. As a result, European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. It
is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Our European patent applications, if issued, could be challenged in the UPC. During the first seven years of the UPC&#146;s existence,
the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. We can elect to opt out from the UPC in some of our future European patents, but doing so may preclude us from realizing the potential benefits
of the UPC. Moreover, if we do not meet all of the formalities and requirements for opting out under the UPC, our future European could remain under the jurisdiction of the UPC. The UPC could provide our third parties with a new forum to centrally
revoke our European patents, and allow for the possibility of a third party to obtain a <FONT STYLE="white-space:nowrap">pan-European</FONT> injunction&#151;such a loss of patent protection could have a material adverse impact on our business and
our ability to commercialize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our technology and future products and, resultantly, on our business, financial condition, prospects, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the U.S. Congress has periodically sought to pass bills concerning subject matter eligible for patent protection. We cannot fully
predict the impact that such new laws may have on our ability to obtain patent protection for our products and technologies, and our ability to operate in view of the patents controlled by third parties. These and other substantive changes to U.S.
and foreign patent law could affect our susceptibility to patent infringement claims and our ability to obtain patents and, if obtained, to enforce or defend them, any of which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our position on our products for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan in all jurisdictions around the world. In the United States, if all maintenance fees are timely paid, the
natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is
limited. Even if patents covering our product are obtained, once the patent life has expired for a product, we may be open to competition. Given the amount of time required for the development, testing and regulatory review of new products, patents
protecting such products might expire before or shortly after such products are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing future products similar or identical
to ours for a meaningful amount of time, or at all. Such an inability to exclude third parties from commercializing similar or identical products could have a material adverse impact on our reputation, business, financial condition, results of
operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our products and other technologies could be found invalid or
unenforceable if challenged in court or before administrative bodies in the United States and abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may challenge
the validity or enforceability of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents in court or before administrative bodies in the United States or abroad. If we or one of our licensors initiated legal proceedings against a
third party to enforce a patent, the defendant could counterclaim that our asserted patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of subject matter eligibility, lack of written description, and
<FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a material
misleading statement, during prosecution. Third parties have raised, and in the future may raise, claims challenging the validity or enforceability of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents before administrative
bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes </I>review, interference proceedings, derivation
proceedings, and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover Galleri, DAC,
or our other technologies or products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in 2021, we faced three oppositions in Europe with respect to European patent number
EP 3 363 901 B1 <FONT STYLE="white-space:nowrap">in-licensed</FONT> from the Fred Hutchinson Cancer Center, European patent number EP 3 354 747 B1 <FONT STYLE="white-space:nowrap">in-licensed</FONT> from The Chinese University of Hong Kong, and
European patent number EP 3 478 856 B1 assigned to GRAIL, LLC. The opposition proceeding filed against EP 3 363 901 B1 is still pending and corresponds to technology that is not currently being used in Galleri or DAC. The opposition proceeding filed
against EP 3 354 747 B1 concluded with the patent being revoked. This patent had provided exclusivity relating to one feature used in Galleri and DAC. GRAIL and the licensor elected not to appeal this revocation in favor of strategically pursuing
divisional applications covering the same technology. The opposition proceeding filed against EP 3 478 856 B1 concluded in September 2023 with the claims being maintained as granted. The opponent may file an appeal. These opposition proceedings do
not affect our patents outside Europe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a third party were to prevail on a legal assertion of invalidity or unenforceability, we
would lose at least part, and perhaps all, of the patent protection on our products or other technologies. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations, and growth
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of many countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the
infringement of our or any future licensors&#146; patents or marketing of products in violation of our proprietary rights. Certain countries outside the United States have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner may have limited remedies in certain circumstances, which could
materially diminish the value of such patent. If we or any future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our position may be impaired, and our business, financial condition,
results of operations, and growth prospects may be adversely affected. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain countries outside the United States also have laws that may impact a patent owner&#146;s
right to claim priority or require a patent applicant to obtain a foreign filing license or first file patent applications in a foreign jurisdiction to the extent foreign nationals are involved in the development of the claimed subject matter of the
resulting patent. Our pending and future patent applications may not result in patents being issued that comply with the law of each foreign jurisdiction. Pending applications and issued patents may be challenged in various jurisdictions for failure
to comply with local laws, which could result in the rejection of pending applications or invalidation of issued patents. Further, the standards applied by foreign patent offices in granting patents are not always applied uniformly or predictably.
As such, we do not know the degree of future protection that we will have on our future products. While we will endeavor to try to protect our existing products and products with in development with intellectual property rights, such as patents, as
appropriate, the process of obtaining patents is time consuming, expensive, and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, <FONT
STYLE="white-space:nowrap">geo-political</FONT> actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future
licensors and the maintenance, enforcement, or defense of our issued patents or those of any current or future licensors. For example, the United States and foreign government actions related to Russia&#146;s conflict in Ukraine may limit or prevent
filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications, resulting
in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies
and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing
products made using our inventions in and into Russia. If we are not able to protect our intellectual property rights throughout the world, our position may be impaired, and our business, financial condition, results of operations, and growth
prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that our employees or we have infringed
or misappropriated intellectual property rights, or to assertions by third parties or employees claiming ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our former, current, and future employees may have been previously employed at universities or other biotechnology, diagnostic, laboratory,
technology, or pharmaceutical companies, including, for example, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential competitors and strategic partners. We train our employees not to bring or use proprietary information or technology from former employers to us or use it in their work. Although we try
through such training and other measures to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we have been in the past, and in the future may be,
subject to claims that an employee or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of such employee&#146;s former employer. Litigation, which would be expensive, time-consuming, a
distraction to management, and uncertain of outcome, may be necessary to defend against these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy
to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing or enforcing such an agreement with each
party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may be breached, and we may be forced to bring claims against third parties or current or former employees, or defend claims they may
bring against us, to determine the ownership of what we regard as our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to prevail on any such claims, in
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or be required to obtain a license, which may not be available to us on commercially reasonable terms or at all. Even if we are successful in
prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management, which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and market position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for our products and other technologies, we also rely on trade secrets and confidentiality agreements to protect
our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, data, and other proprietary information, and to maintain our market position. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to
protect. We expect some of our trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and
the movement of personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect these trade secrets and other proprietary technology, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, directors, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
suppliers, service providers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, and remind departing employees when they leave their
employment of their continuing confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our
efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. Some courts outside the United States are less willing or unwilling to protect trade secrets, and the laws of some foreign countries do
not protect proprietary rights to the same extent or in the same manner as the laws within the United States. For example, in China, claims regarding infringement or misappropriation of trade secrets are more difficult to prove, and consequently
plaintiffs are rarely successful in bringing these claims. If any of our trade secrets were to be lawfully obtained or independently developed by a third party, we would have no right to prevent them from using that technology or information. If any
of our trade secrets were to be misappropriated by, disclosed to, or independently developed by a third party, our market position could be materially and adversely harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have and may enter into collaboration, license, contract research, and/or manufacturing relationships with contract organizations that
operate in certain countries that are at heightened risk of theft of technology, data, and intellectual property through direct intrusion by private parties or foreign actors, including those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliated with or controlled by state actors. Accordingly, our efforts to protect and enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license, and we may be at heightened risk of losing our proprietary intellectual property rights around the world, including outside of such countries, to the extent such theft
or intrusion destroys the proprietary nature of our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our success depends on our ability to develop and
commercialize our technology without infringing, misappropriating, or otherwise violating the intellectual property of third parties. Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights,
and if they prevail, could block sales of our products and force us to make large damages and/or royalty payments, which could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success in part depends upon our ability, and the ability of our collaborators, to market, sell, and distribute our products and
use our proprietary technologies without infringing, misappropriating, or otherwise violating the proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology, diagnostic, and
pharmaceutical industries. In addition, there is ongoing intellectual property litigation in the circulating nucleic acid analysis and cancer nucleic acid space, the outcome of which could also impact potential future litigation involving our
intellectual property or our ability to commercialize our products. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products, including interference
proceedings before the USPTO and similar bodies in other jurisdictions. Third parties may assert infringement claims against us based on existing patents or patents that may be issued in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to infringe, misappropriate, or otherwise violate a third party&#146;s intellectual property rights, we could be required to
obtain a license from such third party to continue developing, marketing, selling, and distributing our products, or to cease using the infringing technology. However, we may not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving third parties access to the same technologies licensed to us. In addition, we could be found liable for
monetary damages, including treble damages if we are found to have willfully infringed a patent and attorneys&#146; fees if the court finds the case to be exceptional. A finding of infringement, misappropriation, or other violation could prevent us
from commercializing our products or force us to cease some of our operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative
impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation, or other legal proceedings relating to intellectual property claims
may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some third parties may be able to sustain the costs of such
litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or
other proceedings could have a material adverse effect on our ability to perform in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property
litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs, or intellectual property
could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce or defend our patents, which
could be expensive, time-consuming, and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may infringe our patents or trademarks or misappropriate or
violate our other intellectual property rights. To counter infringement, misappropriation, or unauthorized use of our intellectual property, we or any future licensors may be required to file infringement or misappropriation claims, which can be
expensive and time-consuming and divert the time and attention of our management and scientific personnel. Our or any future licensors&#146; pending patent applications cannot be enforced against third parties practicing the technology claimed in
such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to
counterclaims asserting that our patents or any future licensors&#146; patents are invalid or unenforceable, or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patents and any
patents that we <FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged, narrowed, invalidated, or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our products, other
companies may be better able to develop products that could adversely affect our market position, business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents
or patents licensed to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by us or that are
licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us or that such patents are invalid or unenforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties have initiated, and in the future may initiate, oppositions, <I>inter partes</I> review, post-grant
review, or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being
owned by or licensed to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at our initiation or at the initiation of a third party, the USPTO may initiate an interference between patents
or patent applications owned by or licensed to us and those of third parties, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent
rights; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may seek approval to market products similar to our future approved products prior to expiration of
relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial, legal,
and scientific personnel. There is a risk that a court or administrative body would decide that our owned or exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents are invalid or not infringed by a third party&#146;s activities, or
that the scope of certain issued claims must be limited. An adverse outcome in a litigation or proceeding involving our owned or exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents could limit our ability to assert our patents
against third parties, affect our ability to receive royalties or other licensing consideration from our licensees or sublicensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar products. We
may become more susceptible to these types of lawsuits and proceedings given the proliferation of organizations pursuing intellectual property protections in the cancer detection and cfDNA space. Any of these occurrences could adversely affect our
business position, business, financial condition, results of operations, and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able
to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our registered or
unregistered trademarks or trade names may be challenged, infringed or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we view as valuable to
building name recognition among potential partners and customers in our markets of interest. At times, other third parties have adopted or may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion and/or litigation. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or
unregistered trademarks or trade names. We may also license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of
these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to perform effectively and our business may be adversely affected. Our efforts to enforce, protect, or defend our proprietary rights related to trademarks may be ineffective and could
result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If the Distribution does not qualify as a transaction that is <FONT STYLE="white-space:nowrap">tax-free</FONT> for U.S. federal income
tax purposes, Illumina and its stockholders could be subject to significant tax liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> is conditioned on Illumina&#146;s receipt of a private letter ruling from the IRS and a written opinion of Cravath, Swaine&nbsp;&amp; Moore LLP, each of which shall remain in full force and effect, that,
subject to the limitations specified therein and the accuracy of and compliance with certain representations, warranties, and covenants, the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for
<FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Section&nbsp;355 and 368 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private letter
ruling and the opinion of counsel will not address any U.S. state or local or foreign tax consequences of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> The private letter ruling and the opinion will assume that the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will be completed according to the terms of the Separation and Distribution Agreement and will rely on the facts as stated in the Separation and Distribution Agreement, the Tax Matters Agreement, the other
ancillary agreements, this Information Statement, and certain other documents. In addition, the private letter ruling and the opinion will be based on certain representations as to factual matters from, and certain covenants by, Illumina and us. The
private letter ruling and the opinion cannot be relied on if any of the assumptions, representations, or covenants is incorrect, incomplete or inaccurate or is violated in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion of counsel is not binding on the IRS or the courts, and there can be no assurance that the IRS or a court will not take a contrary
position. Although a private letter ruling from the IRS is generally binding on the IRS, the ruling will be based on certain facts and representations and undertakings from Illumina and us that certain necessary conditions to obtain <FONT
STYLE="white-space:nowrap">tax-free</FONT> treatment under the Code have been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> were determined not to qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Section&nbsp;355 and 368 of the Code, Illumina and its shareholders could be subject
to tax. In this case, each U.S. Holder (as defined in &#147;The Spin-Off&#151;Material U.S. Federal Income Tax Consequences of the Spin-Off&#148;) who receives our common stock in the Distribution would generally, for U.S. federal income tax
purposes, be treated as receiving a distribution in an amount equal to the fair market value of our common stock received, which would generally result in (i)&nbsp;a taxable dividend to the U.S. Holder to the extent of that U.S. Holder&#146;s pro
rata share of Illumina&#146;s current and accumulated earnings and profits; (ii)&nbsp;a reduction in the U.S. Holder&#146;s basis (but not below zero) in Illumina common stock to the extent the amount received exceeds the shareholder&#146;s share of
Illumina&#146;s earnings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and profits; and (iii)&nbsp;a taxable gain from the exchange of Illumina common stock to the extent the amount received exceeds the sum of the U.S. Holder&#146;s share of Illumina&#146;s earnings
and profits and the U.S. Holder&#146;s basis in its Illumina common stock. For more information, see below and the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Material</FONT> U.S. Federal Income Tax Consequences of the <FONT
STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We could have an
indemnification obligation to Illumina if the Distribution were determined not to qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> treatment for U.S. federal tax purposes, which could materially adversely affect our business,
financial condition, and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it were determined that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT>
did not qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Section&nbsp;355 and 368 of the Code, we expect that we could, under certain circumstances, be required to indemnify Illumina for the resulting taxes
and related expenses. Any such expected indemnification obligation could materially adversely affect our business, financial condition, and results of operations. For a description of such indemnification obligation, see &#147;Certain Relationships
and Related Party Transactions&#151;Agreements with Illumina&#151;Tax Matters Agreement&#148; beginning on page&nbsp;203 of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We intend to agree to numerous restrictions to preserve the <FONT STYLE="white-space:nowrap">non-recognition</FONT> treatment of the
Distribution, which may reduce our strategic and operating flexibility. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to agree in the Tax Matters Agreement to certain
covenants and indemnification obligations that address compliance with Section&nbsp;355(e) of the Code. These covenants and indemnification obligations may limit our ability to pursue strategic transactions or engage in new businesses or other
transactions that may otherwise maximize the value of our business, and might discourage or delay a strategic transaction that our shareholders may consider favorable. For more information, see the section entitled &#147;Certain Relationships and
Related Party Transactions&#151;Agreements with Illumina&#151;Tax Matters Agreement&#148; beginning on page&nbsp;203 of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to achieve some or all of the benefits that we expect to achieve from the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> which could materially adversely affect our business, financial condition, and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that, as a separate, publicly traded company, we will be able to, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design and implement corporate strategies and policies that are targeted to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">better focus our financial resources on our specific business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create effective incentives for our management and employees that are more closely tied to our business
performance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more effectively articulate a clear investment proposition to attract a long-term investor base suited to our
business, growth profile, and capital allocation priorities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain a capital structure designed to meet our specific needs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we may not achieve these and other anticipated benefits for a variety of reasons, including, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will require significant amounts of management&#146;s time
and effort, which may divert management&#146;s attention from operating and growing our business and may disrupt our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">due to the application of pushdown accounting, our balance sheet includes goodwill and intangible assets
recognized by Illumina in connection with their acquisition of us that may be subject to additional impairment over time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon closing of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> our obligation to pay to Illumina a royalty
will resume, which was suspended while we were owned by Illumina; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we may be more susceptible to market
fluctuations, the risk of takeover by third parties and other adverse events because our business will be less diversified than Illumina&#146;s businesses prior to the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> may require us to incur significant costs, including
accounting, tax, legal, and other professional services costs and recruiting and relocation costs associated with hiring key senior management personnel who are new to our company, and costs to retain key management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain costs and liabilities that were otherwise less significant to Illumina as a whole will be more
significant for us and Illumina as separate companies after the separation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under the terms of the Tax Matters Agreement that we will enter into with Illumina, we expect to be restricted
from taking certain actions that could cause the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> or other related transactions to fail to qualify as a <FONT STYLE="white-space:nowrap">tax-free</FONT> transaction and these restrictions may limit us
for a period of time from pursuing certain strategic transactions and equity issuances or engaging in other transactions that might increase the value of our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve some or all of the benefits expected to result from the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> or if such
benefits are delayed, our business, financial condition, and results of operations could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have
no history of operating as a separate, publicly traded company, and our historical financial data is not necessarily representative of the results that we would have achieved if we had been a separate, publicly traded company and may not be a
reliable indicator of our future results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January 2016 until our acquisition by Illumina on August&nbsp;18, 2021, we operated
as an independent privately held company. Although we are a wholly owned subsidiary of Illumina, in connection with the legal and regulatory matters described under the section entitled &#147;The Spin Off,&#148; our business is held and operated
separately and independently from Illumina and Illumina must fund our operations and development. We derived the historical financial data included in this Information Statement from our consolidated financial statements and accounting records
prepared as a wholly owned subsidiary of Illumina, and this data does not necessarily reflect the financial condition, results of operations, or cash flows that we would have achieved as a separate, publicly traded company during the periods
presented or those that we will achieve in the future. This is primarily because of the following factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical financial data may not fully reflect the costs associated with the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including the costs related to being an independent public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our historical financial data does not reflect our obligations under the various transitional and other
agreements we will enter into with Illumina in connection with the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">since Illumina acquired us in August 2021, our working capital requirements and capital for our general corporate
purposes, including capital expenditures, have been satisfied by Illumina. Following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will need to obtain additional financing from banks, through public offerings or private placements of debt
or equity securities, strategic relationships, or other arrangements, which may or may not be available or may be available only on less attractive terms than we may have received as a part of Illumina; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we expect that the cost of capital for our
business will be higher than Illumina&#146;s cost of capital prior to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other significant changes may occur in our cost structure, management, financing, and business operations as a result of operating as a
separate, publicly traded company. As such, our historical financial data may not be indicative of our future performance as a separate, publicly traded company. For additional information about our past financial performance and the basis of
presentation of our financial statements, see &#147;Selected Historical Financial Data,&#148; &#147;Unaudited Pro Forma Condensed Consolidated Financial Information,&#148; and &#147;Management&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Discussion and Analysis of Financial Condition and Results of Operations&#148; beginning on pages&nbsp;110,&nbsp;112, and 168, respectively, of this Information Statement and our Consolidated
Financial Statements and the notes thereto included in &#147;Index to Consolidated Financial Statements&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;F-1</FONT> of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our customers, prospective customers, suppliers, or other companies with whom we conduct business may conclude that our financial
stability as a separate, publicly traded company is insufficient to satisfy their requirements for doing or continuing to do business with them. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our customers, prospective customers, suppliers, or other companies with whom we conduct business may conclude that our financial
stability as a separate, publicly traded company is insufficient to satisfy their requirements for doing or continuing to do business with them, or may require us to provide additional credit support, such as letters of credit or other financial
guarantees. Any failure of parties to be satisfied with our financial stability could have a material adverse effect on our business, financial condition, results of operations, and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The unaudited pro forma condensed consolidated financial information included in this Information Statement is presented for
informational purposes only and may not be an indication of our financial condition or results of operations in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
unaudited pro forma condensed consolidated financial information included in this Information Statement is presented for informational purposes only and are not necessarily indicative of what our actual financial condition or results of operations
would have been had the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> been completed on the date indicated. The assumptions used in preparing the pro forma financial information may not prove to be accurate and other factors may affect our
financial condition or results of operations. Accordingly, our financial condition and results of operations in the future may not be evident from or consistent with such pro forma financial information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Until the distribution occurs, the Illumina Board may change the terms of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> in ways
that may be unfavorable to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the Distribution occurs, we will continue to be a wholly owned subsidiary of Illumina.
Accordingly, Illumina has the discretion to determine and change the terms of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including the establishment of the Record Date (as defined below) and the Distribution Date, and these changes could
be unfavorable to us. In addition, the Illumina Board may decide not to proceed with the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> at any time prior to the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>No vote of Illumina shareholders is required in connection with the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> As a result, if
the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> occurs and you do not want to receive our common stock in the Distribution, your sole recourse will be to divest yourself of your Illumina common stock prior to the Record Date or in the <FONT
STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> trading market during the period prior to the Distribution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No vote of
Illumina shareholders is required in connection with the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Accordingly, if the Distribution occurs and you do not want to receive our common stock in the Distribution, your only recourse will be to
divest yourself of your Illumina common stock prior to the Record Date or in the <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> trading market during the period prior to the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>After the distribution, certain of our executive officers may have actual or potential conflicts of interest because of their equity
interests in Illumina. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of their former positions with Illumina, certain of our executive officers own equity interests in
Illumina. Continuing ownership of shares of Illumina common stock and equity awards (assuming such awards do not convert to GRAIL awards) could create, or appear to create, potential conflicts of interest if we and Illumina face decisions that could
have implications for both Illumina and us after the separation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>No market for our common stock currently exists and an active trading market may not develop or be sustained after the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> Following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> our stock price may fluctuate significantly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no public market for our common stock. We intend to apply to list our common stock on Nasdaq. We anticipate that before the
Distribution Date, trading of shares of our common stock will begin on a &#147;when-issued&#148; basis and this trading will continue up to and including the Distribution Date. However, an active trading market for our common stock may not develop
as a result of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> or may not be sustained in the future. The lack of an active market may make it more difficult for shareholders to sell our shares and could lead to our share price being depressed
or volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the prices at which our common stock may trade after the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT>
The market price of our common stock may fluctuate widely, depending on many factors, some of which may be beyond our control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercial success of Galleri and the degree to which it meets the expectations for securities analysts and
investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of launch of our other products, including DAC, and the degree to which the launch and
commercialization thereof meets the expectations for securities analysts and investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and results of clinical studies for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement or termination of collaborations for our product development and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall establishment of the MCED testing field and the success of future third-party tests, services, or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical studies, or regulatory approvals (or certifications) of future diagnostic tests of third
parties, or announcements about new research programs or diagnostic tests of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our research programs or clinical development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in our estimates as to our financial results or development timelines;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our financial results, forecasts, and development timelines meet the expectations of securities analysts
or investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders, Illumina, or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems, including changes that would affect coverage and
reimbursement by third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the healthcare sector; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our business profile and market capitalization may not fit the investment
objectives of some Illumina shareholders and, as a result, these Illumina shareholders may sell their shares of our common stock after the Distribution. See &#147;&#151;Substantial sales of our common stock may occur in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> including the disposition by Illumina of the shares of our common stock that it retains after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> which could cause our stock price to decline&#148;
beginning on page&nbsp;91 of this Information Statement. Low trading volume for our stock, which may occur if an active trading market does not develop, among other reasons, would amplify the effect of the above factors on our stock price
volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in recent years, stock markets in general, and the market for healthcare companies in particular (including
companies in the biotechnology, diagnostics, and related sectors), have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is
experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price
of a company&#146;s securities, securities class action litigation has often been brought against that company. See &#147;&#151;We could be subject to securities class action litigation&#148; beginning on page&nbsp;94 of this Information Statement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock,
the price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will rely in part on the research and reports that
industry or securities analysts publish about us or our business. We do not currently have, and may never obtain, research coverage by industry or securities analysts. If no or few analysts commence coverage of us, the trading price of our stock
could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we
could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital
may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to seek additional capital, and may pursue fundraising paths that could include public and private equity offerings, debt financings,
strategic partnerships, and alliances and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing securities issued in any such transactions. Because our decision to issue debt or equity securities
will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any future financings. To the extent that we raise additional capital through the sale of equity or debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could
involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. Additionally, we may pursue collaborations with third parties that could provide capital in the near term but limit our potential revenues or cash flows in the future. If we raise additional funds through strategic
partnerships, alliances, or licensing arrangements with third parties, we may have to trade valuable rights to our technologies or our products. Certain of the foregoing transactions may require us to obtain stockholder approval, which we may not be
able to obtain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, your ownership interest may be diluted in the future because of the settlement or exercise of equity-based
awards that we expect to grant to our directors, officers, and other employees. Prior to completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we expect to approve an equity incentive plan that will provide for the grant of
equity-based awards to our directors, officers, and other employees, including equity grants that are expected to be made upon completion of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> In addition, each Cash-Based Equity Award outstanding
as of the Distribution Date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may convert into GRAIL RSUs. For more information, see &#147;Executive Compensation&#151;Equity-Linked Compensation&#148; beginning on page&nbsp;192 of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and the information we provide shareholders may be different from information provided by other public
companies, which may result in a less active trading market for our common stock and higher volatility in our stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
an &#147;emerging growth company&#148; as defined by the Jumpstart Our Business Startups Act of 2012. We will continue to be an emerging growth company until the earliest to occur of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which our total annual gross revenues first meet or exceed $1.235&nbsp;billion
(as adjusted for inflation); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which we have, during the prior three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which we (i)&nbsp;have an aggregate worldwide market value of common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700&nbsp;million or more (measured at the end of each fiscal year) as of the last business day of our most recently completed second fiscal quarter and (ii)&nbsp;have been a
reporting company under the Exchange Act for at least one year (and filed at least one annual report under the Exchange Act); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock
pursuant to an effective registration statement under the Securities Act of 1933 (the &#147;Securities Act&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
as long as we are an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of the assessment of our internal control
over financial reporting under Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (&#147;SOX&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from new or revised financial accounting standards applicable to public companies until such standards
are also applicable to private companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements, and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirement of holding a nonbinding advisory vote on executive compensation and shareholder
approval on golden parachute compensation not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some or all of
these reduced burdens. For example, we have taken advantage of the reduced disclosure obligations regarding executive compensation in this Information Statement. For as long as we take advantage of the reduced reporting obligations, the information
we provide shareholders may be different from information provided by other public companies. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less
active trading market for our common stock and higher volatility in our stock price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have elected to not take advantage
of the extended transition period that allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies, which means that the financial statements included in
this Information Statement, as well as financial statements we file in the future, will be subject to all new or revised accounting standards generally applicable to public companies. Our election not to take advantage of the extended transition
period is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Substantial sales of our common stock may occur in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> including the disposition by Illumina of the shares of our common stock that it retains after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> which could cause our stock price to decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina shareholders receiving shares of our common stock in the Distribution generally may sell those shares immediately in the
public market. It is likely that some Illumina shareholders, including some of its larger shareholders, will sell their shares of our common stock received in the Distribution if, for reasons such as our business profile or market capitalization as
an independent company, we do not fit their investment objectives, or, in the case of index funds, we are not a participant in the index in which they are investing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Distribution, Illumina will retain up to a 14.5% ownership interest of our common stock. We expect to enter into a Stockholder
and Registration Rights Agreement with Illumina, pursuant to which we will provide Illumina registration rights with respect to the shares of our common stock it will retain following the Distribution. In addition, Illumina will agree to vote any
shares of our common stock that it retains in proportion to the votes cast by our other stockholders and to grant us a proxy to vote its shares of our common stock in such proportion. Pursuant to the IRS private letter ruling, Illumina expects to be
required to dispose of any such shares of our common stock that it retains as soon as warranted consistent with the business reasons for the retention of such shares, but in no event later than five years after the Distribution. See &#147;Certain
Relationships and Related Party Transactions&#151;Agreements with Illumina&#148; beginning on page&nbsp;202 of this Information Statement.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>We are unable to predict with certainty when Illumina
will dispose of a substantial number of shares of common stock following the Distribution. The sales of significant amounts of our common stock by Illumina or any other significant shareholders, or the perception in the market that this will occur,
may decrease the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay any dividends for the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our
common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility or debt securities may contain terms prohibiting or limiting the amount of
dividends that may be declared or paid on our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public
company. Our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, and other
expenses that we did not incur as a private company. SOX Section&nbsp;404, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Listing Rules, and other applicable U.S. rules and regulations impose various requirements on public
companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our
becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements
will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more
expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We cannot predict or estimate the amount of additional costs we may
incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is
provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to SOX Section&nbsp;404, we will be required to furnish a report by our management
on our internal control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we remain an emerging growth
company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period,
we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside
consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as
documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed time frame or at all, that our
internal control over financial reporting is effective as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the
reliability of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions in our Certificate of Incorporation and Bylaws and Delaware law may
discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several provisions of our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger, acquisition, or other change in
control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or
remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our organizational documents: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish that our board of directors is divided into three classes: Class&nbsp;I, Class&nbsp;II, and
Class&nbsp;III, with each class serving staggered three-year terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate cumulative voting in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of
those shares, including preferences and voting rights, without stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit stockholders to take actions only at a duly called annual or special meeting and not by unanimous written
consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholders from calling a special meeting of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at
stockholder meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors, by a majority vote, to amend certain provisions of the Bylaws; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the affirmative vote of at least &nbsp;&nbsp;&nbsp;&nbsp;% or more of the outstanding shares of common
stock to amend many of the provisions described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the Delaware General
Corporation Law (&#147;DGCL&#148;) prohibits a Delaware corporation from engaging in a business combination with any interested stockholder for a period of three years following the date the person became an interested stockholder, subject to
certain exceptions. In general, Section&nbsp;203 of the DGCL defines an &#147;interested stockholder&#148; as an entity or person who, together with the entity&#146;s or person&#146;s affiliates, beneficially owns, or is an affiliate of the
corporation and within three years prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. A Delaware corporation may &#147;opt out&#148; of these
provisions with an express provision in its certificate of incorporation. We have not opted out of Section&nbsp;203 of the DGCL in our Certificate of Incorporation.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other provisions of our Certificate of Incorporation, Bylaws and Delaware law may discourage, delay, or prevent certain types of
transactions involving an actual or a threatened acquisition or change in control of us including unsolicited takeover attempts, even though the transaction may offer our shareholders the opportunity to sell their shares of our common stock at a
price above the prevailing market price. For more information, see &#147;Description of Our Capital Stock&#151;Certain Provisions of Delaware Law, Our Certificate of Incorporation and Bylaws&#148; beginning on page&nbsp;207 of this Information
Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Certificate of Incorporation will designate the Court of Chancery of the State of Delaware as the sole and exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court of
Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim of breach of a fiduciary duty owed by any current of former directors, officers or
other employees, or stockholders to us or our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim arising pursuant to any provision of the DGCL or our amended and restated
Certificate of Incorporation and Bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for
which the federal courts have exclusive jurisdiction. Furthermore, our Certificate of Incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be
the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received
notice of and consented to the foregoing provisions. This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other
employees or agents, or our other stockholders, which may discourage such lawsuits against us and such other persons. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more
of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The rights associated with our common stock will differ from the rights associated with Illumina common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Distribution, the rights of Illumina shareholders who become our shareholders will be governed by our Certificate of
Incorporation and Bylaws and by Delaware law. The rights associated with Illumina shares are different from the rights associated with our shares. Material differences between the rights of Illumina shareholders and the rights of our shareholders
include differences with respect to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the board of directors is classified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right of shareholders to call special meetings; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voting standard in director elections; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain anti-takeover measures. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information, see &#147;Description of Our Capital Stock&#151;Certain Provisions of Delaware Law, Our Certificate of Incorporation and
Bylaws&#148; beginning on page&nbsp;207 of this Information Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price
of its securities. This risk is especially relevant for us, because healthcare companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of our
management&#146;s attention and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_6"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Information Statement contains forward-looking statements. In some cases, you can identify these statements by forward-looking
words such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;would,&#148; or &#147;will,&#148; the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and
assumptions about us, may include expectations and projections of our future financial performance, future tests or products, technology, clinical studies, regulatory compliance, potential market opportunity, anticipated growth strategies, and
anticipated trends in our business and the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including the expected timing of completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and estimated costs associated with the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements are only predictions based on our current expectations and projections about
future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements,
including those factors discussed under the section entitled &#147;Risk Factors.&#148; You should specifically consider the numerous risks described under the section entitled &#147;Risk Factors.&#148; Moreover, we operate in a dynamic and rapidly
changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause
actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot
guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Except to the extent required
by law, we undertake no obligation to update any of these forward-looking statements after the date of this Information Statement to conform our prior statements to actual results or revised expectations or to reflect new information or the
occurrence of unanticipated events. Given these risks, uncertainties, and assumptions, you are cautioned not to place undue reliance on such forward-looking statements as predictions of future performance or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_7"></A>THE <FONT STYLE="white-space:nowrap">SPIN-OFF</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina completed its
acquisition of us on August&nbsp;18, 2021 (the &#147;Acquisition&#148;). At the same time, Illumina executed binding commitments pursuant to which Illumina would hold GRAIL separately during the European Commission&#146;s review of the Acquisition
(the &#147;Hold Separate Commitments&#148;). In April 2021, the European Commission asserted jurisdiction to review the Acquisition pursuant to Article 22 of Council Regulation (EC) No 139/2004 (the &#147;EU Merger Regulation&#148;). On
July&nbsp;13, 2022, the General Court of the European Union dismissed Illumina&#146;s action for annulment of the European Commission&#146;s jurisdictional claim and ruled in favor of the Commission, holding that the European Commission has
jurisdiction to review the Acquisition under the EU Merger Regulation. Illumina maintains that the European Commission does not have jurisdiction over the Acquisition, and on September&nbsp;22 and 30, 2022, Illumina and GRAIL, respectively, each
filed a separate appeal in the Court of Justice of the European Union, both of which remain pending. On September&nbsp;6, 2022, the European Commission adopted a decision finding that, in its view, Illumina&#146;s acquisition of GRAIL was
incompatible with the internal market in Europe. On November&nbsp;17, 2022, Illumina asked for annulment of this decision before the General Court of the European Union (GRAIL intervened in this procedure in support of Illumina). On July&nbsp;12,
2023, the European Commission adopted a final decision finding that Illumina breached the EU Merger Regulation by, in its view, acquiring the possibility to exert decisive influence over GRAIL and exerting such influence during the pendency of the
European Commission&#146;s review. On September&nbsp;26, 2023, Illumina sought the annulment of this decision. On October&nbsp;29, 2021, the European Commission adopted an order imposing interim measures, (the &#147;Initial Interim Measures
Orders&#148;) which was renewed on October&nbsp;28, 2022 (the &#147;Second Interim Measures Orders&#148;). Illumina and GRAIL both sought the annulment of the initial interim measures, and Illumina&#151;with GRAIL intervening in its
support&#151;also sought the annulment of the renewed interim measures. The European Commission imposed transitional measures on October&nbsp;12, 2023 (the &#147;Transitional Measures&#148;) pursuant to the EC Divestment Decision (as defined below),
which replaced the Initial Interim Measures Orders and Second Interim Measures Orders. Such measures provide, among other things, that (i)&nbsp;Illumina ensure that Illumina and GRAIL continue to operate as independent legal entities that transact
at arm&#146;s length, no integration activity takes place, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of GRAIL remains the sole responsibility of GRAIL&#146;s management and
Illumina&#146;s management has no involvement in or influence over GRAIL and (ii)&nbsp;Illumina take certain supportive measures to preserve GRAIL&#146;s viability, marketability, and competitiveness, including with respect to the provision of
resources to GRAIL and the retention and/or replacement of key personnel of GRAIL. Currently, GRAIL is held and operated separately and independently from Illumina and Illumina must fund GRAIL&#146;s operations and development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;5, 2022, the European Commission issued a Statement of Objections informing Illumina of the order it intended to adopt which
would require Illumina to divest GRAIL (the &#147;EC Divestment Decision&#148;). On October&nbsp;12, 2023, the European Commission announced that it had adopted the EC Divestment Decision, which orders Illumina to, among other things, divest GRAIL,
and imposes the Transitional Measures. The EC Divestment Decision requires Illumina to dispose of GRAIL within 12 months of the date of the EC Divestment Decision (which date can be extended by three months in certain circumstances upon request by
Illumina). The EC Divestment Decision permits Illumina to consider a range of methods of disposal including, but not limited to, a third-party sale or a capital markets transaction. On
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, Illumina applied for the suspension of the execution of certain provisions of the EC Divestment Decision, and sought the annulment of the EC
Divestment Decision. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the European Commission approved a divestment plan (the &#147;Divestment Plan&#148;) submitted by Illumina pursuant to which
Illumina agreed to divest GRAIL on specified terms. The EC Divestment Decision permits Illumina to retain up to a 14.5% ownership interest in GRAIL and to <FONT STYLE="white-space:nowrap">re-establish</FONT> the royalty arrangement it previously had
in place with GRAIL. See the section entitled &#147;Certain Relationships and Related Party Transactions&#151;Ongoing Commercial Agreements&#148; beginning on page&nbsp;204 of this Information Statement for more detail. Assuming the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> is consummated, Illumina is required to, among other things, ensure that GRAIL has sufficient funding to cover a specified period of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, Illumina announced plans for the
separation of GRAIL from Illumina via the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To effect the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina will distribute at
least 85.5% of the shares of GRAIL&#146;s common stock owned by Illumina as of the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, which is the record date for the
Distribution, to Illumina&#146;s stockholders, and GRAIL will become an independent, publicly traded company. Immediately after the Distribution becomes effective, Illumina may retain up to 14.5% of GRAIL&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we intend to enter into a Separation and Distribution Agreement
and several other agreements with Illumina related to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> These agreements will govern the relationship between Illumina and us after completion of the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> and allocate between Illumina and us various assets, liabilities and obligations, including <FONT STYLE="white-space:nowrap">tax-related</FONT> assets and liabilities. See the section entitled
&#147;Certain Relationships and Related Party Transactions&#148; beginning on page&nbsp;202 of this Information Statement for more detail. No approval of Illumina&#146;s stockholders is required in connection with the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> and Illumina&#146;s stockholders will not have any appraisal rights in connection with the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is subject to the satisfaction, or the waiver by Illumina&#146;s board of
directors (the &#147;Illumina Board&#148;), of a number of conditions. If the Illumina Board waives any condition prior to the effectiveness of the Registration Statement on Form&nbsp;10, of which this Information Statement is a part, and the result
of such waiver is material to Illumina stockholders, Illumina will file an amendment to the Registration Statement to revise the disclosure in this Information Statement accordingly. In the event that the Illumina Board waives a condition after the
Registration Statement on Form 10, of which this Information Statement is a part, becomes effective and such waiver is material to Illumina stockholders, Illumina will communicate such change to Illumina stockholders by filing a Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> describing the change. For a complete discussion of the conditions to the Distribution, see the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT
STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;105 of this Information Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Illumina has the
right not to complete the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> if, at any time, the Illumina Board determines, in its sole and absolute discretion, that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not in the best interests of
Illumina or its stockholders or is otherwise not advisable. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, Illumina and GRAIL will have incurred significant costs related to the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> including fees for consultants, financial and legal advisors, accountants and auditors, that will not be recouped. Total <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs associated with
the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> are preliminarily estimated to range from $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> is completed. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, the <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs will generally be limited
to the transaction costs incurred for services rendered as of the date the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is abandoned, which will be less than the range noted above. Our and Illumina&#146;s management will also have devoted
significant time to manage the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> process, which will decrease the time they will have to manage their respective businesses. See the section entitled &#147;The
<FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;105 of this Information Statement for more detail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the EC Divestment Decision and with the goal of enhancing stockholder value, the Illumina Board conducted a process through
which it considered a range of potential divestment transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of this evaluation, Illumina retained outside advisors, and the
Illumina Board considered a number of factors, including the long-term prospects and strategic viability of GRAIL, the strategic clarity and flexibility for Illumina and GRAIL after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the ability
of GRAIL to compete and operate efficiently and effectively (including GRAIL&#146;s ability to retain and attract management talent) after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the financial profile of GRAIL, the expected timing of
completion of each structural alternative, the expected tax impact of each structural alternative, the probability of successful execution of each structural alternative, and the potential reaction of investors. After evaluating these and other
considerations, including the input of various outside advisors, the Illumina Board concluded that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> presented the most attractive alternative for enhancing long-term stockholder value while
complying with the requirements of the EC Divestment Decision and that proceeding with the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> would be in the best interests of Illumina and its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, the Illumina Board considered a number of potential benefits of this approach, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Opportunity for continued ownership of GRAIL by Illumina stockholders.</I></B> The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will provide Illumina stockholders the opportunity to determine whether they wish to continue to own an interest in GRAIL despite GRAIL&#146;s required separation from Illumina. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Distinct and clear financial profiles and compelling investment cases</I></B>. Investment in one or the
other company may appeal to investors with different goals, interests, and expectations. The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will allow investors to make independent investment decisions with respect to Illumina and GRAIL and may
result in greater alignment between the interests of each company&#146;s stockholder base and the characteristics of its respective business, capital structure, and financial results. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Separate capital structures and allocation flexibility</I></B>. The
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> will permit each of Illumina and GRAIL to allocate its financial resources to meet the unique needs of its own businesses, which will allow each company to focus on its distinct strategic priorities
and individual business risk and return profiles. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Creation of independent equity securities and increased strategic opportunities</I></B>. The <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will afford Illumina and GRAIL the ability to offer their independent equity securities to the capital markets and enable each standalone company to use its own industry-focused stock to pursue
portfolio-enhancing acquisitions or other strategic opportunities that are more closely aligned with each company&#146;s strategic goals and expected growth opportunities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Illumina Board also considered a number of potentially negative factors in evaluating the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Risk of failure to achieve the anticipated benefits of the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT></I></B>. Illumina and GRAIL may not achieve the anticipated benefits of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> for a variety of reasons, including, among others: the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will require significant amounts of management&#146;s time and effort, which may divert management&#146;s attention from operating and growing our businesses; there may be
<FONT STYLE="white-space:nowrap">dis-synergy</FONT> costs related to the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> and following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> each company may be more susceptible to certain economic
and market fluctuations and other adverse events than if GRAIL were still a part of Illumina because each company will be less diversified than Illumina prior to the separation. For more information on the specific risks to GRAIL of the failure to
achieve the anticipated benefits of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> see the section entitled &#147;Risk Factors&#151;Risks Relating to the <FONT STYLE="white-space:nowrap">Spin-Off&#151;We</FONT> may be unable to achieve some
or all of the benefits that we expect to achieve from the Spin-Off, which could materially adversely affect our business, financial condition, and results of operations&#148; beginning on page&nbsp;85 of this Information Statement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Limitations on strategic transactions</I></B>. Under the terms of the Tax Matters Agreement that GRAIL will
enter into with Illumina, GRAIL expects to be restricted from taking certain actions that could cause the Distribution or certain related transactions to fail to qualify as <FONT STYLE="white-space:nowrap">tax-free</FONT> transactions under
applicable law. These restrictions may limit for a period of time GRAIL&#146;s ability to pursue certain strategic transactions and equity issuances or engage in other transactions that otherwise might increase the value of our business. For more
information, see the section entitled &#147;Certain Relationships and Related Party Transactions&#151;Agreements with Illumina&#151;Tax Matters Agreement&#148; beginning on page&nbsp;203 of this Information Statement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Disruptions and costs related to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT></I></B>. The actions
required to separate GRAIL from Illumina could disrupt both Illumina&#146;s and GRAIL&#146;s operations. In addition, Illumina and GRAIL will incur substantial costs in connection with the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and
GRAIL&#146;s transition to being a standalone public company, which may include accounting, tax, legal and other professional services costs, and recruiting and relocation costs associated with hiring directors and management who are new to GRAIL.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Uncertainty regarding share prices</I></B>. We cannot predict the effect of the Distribution on the trading
prices of Illumina&#146;s and GRAIL&#146;s common stock or know with certainty whether the combined market value of the shares of GRAIL common stock to be distributed per share of Illumina common stock in the Distribution and Illumina&#146;s common
stock following the Distribution will be less than, equal to, or greater than the market value of the shares of Illumina&#146;s common stock prior to the Distribution. Furthermore, there is the risk of volatility in each company&#146;s stock price
following the Distribution due to sales by certain stockholders whose investment objectives may not be met by each company&#146;s common stock, and it may take time for each company to attract its optimal stockholder base. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding these factors, the anticipated costs of which are not reasonably
quantifiable, and considering the potential benefits discussed above, the Illumina Board determined that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> provided the best opportunity to achieve the above benefits and enhance stockholder value.
For additional information, see the section entitled &#147;Risk Factors&#148; beginning on page&nbsp;28 of this Information Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for
Illumina&#146;s Retention of up to 14.5% of GRAIL Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the Distribution becomes effective, Illumina may
retain up to 14.5% of GRAIL&#146;s common stock. Illumina intends to hold any retained shares for investment purposes. Illumina expects that the IRS private letter ruling will require that all retained shares be sold or otherwise disposed of by
Illumina as soon as warranted consistent with the business reasons for the retention of those shares, but in no event later than five years after the Distribution. Such dispositions could include a sale of its shares for cash, distributions of GRAIL
common stock to Illumina stockholders or securityholders as dividends or in exchange for outstanding shares of Illumina common stock, indebtedness or other securities, or any combination thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When and How You Will Receive GRAIL Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina will distribute to its stockholders, as a pro rata dividend, for every
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of Illumina common stock outstanding as of the close of business on the Record Date,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Distribution, Illumina will deliver at least 85.5% of the issued and outstanding shares of our common stock to the distribution
agent. Computershare Trust Company, N.A. (&#147;Computershare&#148;) will serve as distribution agent in connection with the Distribution and as transfer agent and registrar for our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you own Illumina common stock as of the close of business on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, the shares of our common stock that you are entitled to receive in the Distribution will be issued to your account as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Registered stockholders</I>. If you own your shares of Illumina common stock directly through Illumina&#146;s
transfer agent, Computershare, you are a registered stockholder. In this case, the distribution agent will credit the whole shares of our common stock you receive in the Distribution by way of direct registration in book-entry form to a new account
with our transfer agent. Registration in book-entry form refers to a method of recording share ownership where no physical stock certificates are issued to stockholders, as is the case in the Distribution. You will be able to access information
regarding your book-entry account holding the GRAIL shares at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or by calling
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Commencing on or
shortly after the Distribution Date, the distribution agent will mail to you an account statement that indicates the number of whole shares of our common stock that have been registered in book-entry form in your name. We expect it will take the
distribution agent up to two weeks after the Distribution Date to complete the distribution of the shares of our common stock and mail statements of holding to all registered stockholders. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Street name</I>&#148; <I>or beneficial stockholders</I>. If you own your shares of Illumina common stock
beneficially through a bank, broker, or other nominee, such bank, broker, or other nominee holds the shares in &#147;street name&#148; and records your ownership on its books. If you own your shares of Illumina common stock through a bank, broker,
or other nominee, your bank, broker, or other nominee will credit your account with the whole shares of our common stock that you receive in the Distribution on or shortly after the Distribution Date. We encourage you to contact your bank, broker,
or other nominee if you have any questions concerning the mechanics of having shares held in &#147;street name.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you sell any of your shares of Illumina common stock on or before the Distribution Date, the buyer of those shares may, in some
circumstances, be entitled to receive the shares of our common stock to be distributed in respect of the Illumina shares you sold. For more information, see the section entitled &#147;&#151;Trading Prior to the Distribution Date&#148; beginning on
page&nbsp;105 of this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not asking Illumina stockholders to take any action in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> No stockholder approval of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is required. We are not asking you for a proxy and request that you not send us a proxy. We are also not asking you to make
any payment or surrender or exchange any of your shares of Illumina common stock for shares of our common stock. The number of outstanding shares of Illumina common stock will not change as a result of the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Number of Shares You Will Receive </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Distribution Date, for every &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s]
of Illumina common stock you owned as of the Record Date, you will receive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Fractional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
distribution agent will not distribute any fractional shares of our common stock in connection with the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> Instead, the distribution agent will aggregate all fractional shares into whole shares and sell
the whole shares in the open market at prevailing market prices on behalf of Illumina stockholders entitled to receive a fractional share. The distribution agent will then distribute the aggregate cash proceeds of the sales, net of brokerage fees,
transfer taxes and other costs, pro rata to these holders (net of any required withholding for taxes applicable to each holder). We anticipate that the distribution agent will make these sales in the &#147;when-issued&#148; market, and
&#147;when-issued&#148; trades will generally settle within two trading days following the Distribution Date. For more information regarding &#147;when-issued&#148; trading, see the section entitled &#147;&#151;Trading Prior to the Distribution
Date&#148; beginning on page&nbsp;105 of this Information Statement. The distribution agent will, in its sole discretion, without any influence by Illumina or us, determine when, how, through which broker-dealer, and at what price to sell the whole
shares. The distribution agent is not, and any broker-dealer used by the distribution agent will not be, an affiliate of either Illumina or us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution agent will send to each registered holder of Illumina common stock entitled to a fractional share a check in the cash amount
deliverable in lieu of that holder&#146;s fractional share as soon as practicable following the Distribution Date. We expect the distribution agent to take about two weeks after the Distribution Date to complete the distribution of cash in lieu of
fractional shares to Illumina stockholders. If you hold your shares of GRAIL common stock through a bank, broker, or other nominee, your bank, broker, or nominee will receive, on your behalf, your pro rata share of the aggregate net cash proceeds of
the sales. No interest will be paid on any cash you receive in lieu of a fractional share. The cash you receive in lieu of a fractional share will generally be taxable to you for U.S. federal income tax purposes. For more information, see the
section below entitled &#147;&#151;Material U.S. Federal Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page&nbsp;101 of this Information Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Outstanding Equity Incentive Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that each Illumina equity incentive award outstanding as of the Distribution Date held by directors and employees who will continue
at Illumina will remain outstanding and continue to be subject to the same terms and conditions following the Distribution Date, but with adjustments to the number of shares of Illumina common stock subject to such award in order to preserve its
value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Cash-Based Equity Award outstanding as of the Distribution Date may convert into GRAIL RSUs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Consequences of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consequences to U.S. Holders of Illumina Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences to holders of Illumina common stock in connection with the
Distribution. This summary is based on the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), the Treasury Regulations promulgated under the Code and judicial and administrative interpretations of those laws, in each case as in effect
and available as of the date of this Information Statement and all of which are subject to change at any time, possibly with retroactive effect. Any such change could affect the tax consequences described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to holders of Illumina common stock who hold their Illumina common stock as a capital asset. For purposes of this
summary, a &#147;U.S. Holder&#148; is a beneficial owner of Illumina common stock that is, for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or a resident of the U.S.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or
organized under the laws of the U.S. or any state thereof or the District of Columbia;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if (i)&nbsp;a court within the U.S. is able to exercise primary jurisdiction over its administration and
one or more U.S. persons have the authority to control all of its substantial decisions or (ii)&nbsp;in the case of a trust that was treated as a domestic trust under law in effect before August&nbsp;20, 1996, a valid election is in place under
applicable Treasury Regulations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not discuss all tax considerations that may be relevant to
shareholders in light of their particular circumstances, nor does it address the consequences to shareholders subject to special treatment under the U.S. federal income tax laws, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, regulated investment companies, or grantor trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired Illumina common stock pursuant to the exercise of employee stock options or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholders who own, or are deemed to own, 10% or more, by voting power or value, of Illumina equity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholders owning Illumina common stock as part of a position in a straddle or as part of a hedging,
conversion, or other risk-reduction transaction for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the U.S.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholders who are subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who own Illumina common stock through partnerships or other pass-through entities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold Illumina common stock through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement
plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address any U.S. state or local or foreign tax consequences or any estate, gift, or other <FONT
STYLE="white-space:nowrap">non-income</FONT> tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, or any other entity treated as a partnership for U.S.
federal income tax purposes, holds Illumina common stock, the tax treatment of a partner in that partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner or partnership is urged to consult
its own tax advisor as to its tax consequences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>YOU ARE URGED TO CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE U.S. FEDERAL, STATE, AND
LOCAL, AND FOREIGN TAX CONSEQUENCES OF THE DISTRIBUTION. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>General </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is conditioned upon Illumina&#146;s receipt of a private letter ruling from
the IRS and of a written opinion of Cravath, Swaine&nbsp;&amp; Moore LLP, counsel to Illumina, each of which shall remain in full force and effect, that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT
STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code. The private letter ruling and the opinion will be based on the assumption that, among other things, the representations made, and
information submitted, in connection with them are accurate, and that we and Illumina will comply with certain warranties and covenants specified therein. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> qualifies for this treatment and
subject to the qualifications and limitations set forth herein (including the discussion below relating to the receipt of cash in lieu of fractional shares), for U.S. federal income tax purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no gain or loss will be recognized by, or be includible in the income of, a U.S. Holder as a result of the
Distribution, except with respect to any cash received in lieu of fractional shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate tax basis of the Illumina common stock and our common stock held by each U.S. Holder immediately
after the Distribution will be the same as the aggregate tax basis of the Illumina common stock held by the U.S. Holder immediately before the Distribution, allocated between the Illumina common stock and our common stock in proportion to their
relative fair market values on the date of the Distribution (subject to reduction upon the deemed sale of any fractional shares, as described below); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holding period of our common stock received by each U.S. Holder should include the holding period of its
Illumina common stock.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders who have acquired different
blocks of Illumina common stock at different times or at different prices are urged to consult their tax advisors regarding the allocation of their aggregate adjusted tax basis among, and the holding period of, shares of our common stock distributed
with respect to such blocks of Illumina common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder receives cash in lieu of a fractional share of common stock as
part of the Distribution, the U.S. Holder will be treated as though it first received a distribution of the fractional share in the Distribution and then sold it for the amount of cash actually received. The U.S. Holder will generally recognize
capital gain or loss measured by the difference between the cash received for such fractional share and the U.S. Holder&#146;s tax basis in that fractional share, as determined above. Such capital gain or loss will be long-term capital gain or loss
if the U.S. Holder&#146;s holding period for the Illumina common stock is more than one year on the date of the Distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private
letter ruling and the opinion of counsel will not address any U.S. state or local or foreign tax consequences of the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> The private letter ruling and the opinion will assume that the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will be completed according to the terms of the Separation and Distribution Agreement and will rely on the facts as stated in the Separation and Distribution Agreement, the Tax Matters Agreement, the
Stockholder and Registration Rights Agreement, the other ancillary agreements, this Information Statement, and a number of other documents. In addition, the private letter ruling and the opinion will be based on certain representations as to factual
matters from, and certain covenants by, Illumina and us. The private letter ruling and the opinion cannot be relied on if any of the assumptions, representations or covenants are incorrect, incomplete, or inaccurate, or are violated in any material
respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion of counsel will not be binding on the IRS or the courts, and there can be no assurance that the IRS or a court will
not take a contrary position. Although a private letter ruling from the IRS is generally binding on the IRS, the ruling will be based on certain facts and representations and undertakings from Illumina and us
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that certain necessary conditions to obtain <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under the Code have been satisfied, and the private letter ruling will not address every
requirement for the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> to qualify for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> were determined not to qualify for
<FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code, the above consequences would not apply, and U.S. Holders could be subject to tax. In this case, each U.S. Holder who receives our
common stock in the Distribution would generally be treated as receiving a distribution in an amount equal to the fair market value of our common stock received, which would generally result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a taxable dividend to the U.S. Holder to the extent of that U.S. Holder&#146;s pro rata share of Illumina&#146;s
current and accumulated earnings and profits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a reduction in the U.S. Holder&#146;s basis (but not below zero) in Illumina common stock to the extent the
amount received exceeds the shareholder&#146;s share of Illumina&#146;s earnings and profits; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a taxable gain from the exchange of Illumina common stock to the extent the amount received exceeds the sum of
the U.S. Holder&#146;s share of Illumina&#146;s earnings and profits and the U.S. Holder&#146;s basis in its Illumina common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Backup Withholding and Information Statement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of cash in lieu of a fractional share of our common stock may, under certain circumstances, be subject to &#147;backup
withholding,&#148; unless a U.S. Holder provides proof of an applicable exemption or a correct taxpayer identification number, and otherwise complies with the requirements of the backup withholding rules. Corporations will generally be exempt from
backup withholding, but may be required to provide a certification to establish their entitlement to the exemption. Backup withholding is not an additional tax, and it may be refunded or credited against a U.S. Holder&#146;s U.S. federal income tax
liability if the required information is timely supplied to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treasury Regulations require each Illumina shareholder that,
immediately before the Distribution, owned 5% or more (by vote or value) of the total outstanding stock of Illumina to attach to such shareholder&#146;s U.S. federal income tax return for the year in which the Distribution occurs a statement setting
forth certain information related to the Distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consequences to Illumina </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences to Illumina in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> that may be relevant to holders of Illumina common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above, completion of
the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is conditioned upon Illumina&#146;s receipt of a private letter ruling from the IRS and of a written opinion of Cravath, Swaine&nbsp;&amp; Moore LLP, counsel to Illumina, each of which shall
remain in full force and effect, that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code. If the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> so qualifies, no gain or loss will be recognized by Illumina as a result of the Distribution. The opinion of counsel is subject to the qualifications and limitations as are set forth above under the section
above entitled &#147;&#151;Consequences to U.S. Holders of Illumina Common Stock&#148; beginning on page&nbsp;101 of this Information Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> were determined not to qualify for
<FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code, then Illumina would generally recognize gain equal to the excess of the fair market value of our common stock distributed to
Illumina shareholders over Illumina&#146;s tax basis in our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Obligation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it were determined that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> did not qualify for
<FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code, we expect that we could, under certain circumstances, be required under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tax Matters Agreement to indemnify Illumina for certain taxes resulting from the recognition of gain described above and related expenses. In addition, current tax law generally creates a
presumption that the Distribution would be taxable to Illumina, but not to holders, if we or our shareholders were to engage in transactions that result in a 50% or greater change by vote or value in the ownership of our stock during the four-year
period beginning on the date that begins two years before the date of the Distribution, unless it were established that such transactions and the Distribution were not part of a plan or series of related transactions giving effect to such a change
in ownership. If the Distribution were taxable to Illumina due to such a 50% or greater change in ownership of our stock, Illumina would recognize gain equal to the excess of the fair market value of our common stock distributed to Illumina
shareholders over Illumina&#146;s tax basis in our common stock and we expect that we could, under certain circumstances, be required under the Tax Matters Agreement to indemnify Illumina for some or all of the tax on such gain and related expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will be an independent, publicly traded company. Immediately following the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> we expect to have approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beneficial holders of shares of our common stock and approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding, based in part on the number of Illumina stockholders and shares of Illumina common stock outstanding on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2024. Up to 14.5% of our common stock will be held by Illumina. The actual number of shares of our common stock Illumina will distribute in the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will depend on the actual number of shares of Illumina common stock outstanding on the Record Date, which will reflect any issuance of new shares in respect of settlements or exercises of outstanding
equity-based awards pursuant to Illumina&#146;s equity plans, on or prior to the Record Date. The <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will not affect the number of outstanding shares of Illumina common stock or any rights of Illumina
stockholders, although we expect the trading price of shares of Illumina common stock immediately following the Distribution to be lower than immediately prior to the Distribution because the trading price of Illumina common stock will no longer
reflect the value of GRAIL. Furthermore, until the market has fully analyzed the value of Illumina without GRAIL, the trading price of shares of Illumina common stock may fluctuate and result in a higher volatility in the price of our common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before our separation from Illumina, we intend to enter into a Separation and Distribution Agreement and several other agreements with
Illumina related to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> These agreements will govern the relationship between Illumina and GRAIL after completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and allocate between Illumina
and GRAIL various assets, liabilities, rights, and obligations, including <FONT STYLE="white-space:nowrap">tax-related</FONT> assets and liabilities. We describe these arrangements in greater detail under the section entitled &#147;Certain
Relationships and Related Party Transactions&#151;Agreements with Illumina&#148; beginning on page&nbsp;202 of this Information Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing and
Trading of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this Information Statement, we are a wholly owned subsidiary of Illumina. Accordingly,
no public market for our common stock currently exists, although a &#147;when-issued&#148; market in our common stock may develop prior to the Distribution. For an explanation of a &#147;when-issued market,&#148; see the section below entitled
&#147;&#151;Trading Prior to the Distribution Date&#148; beginning on page&nbsp;105 of this Information Statement. We intend to list our shares of common stock on Nasdaq under the ticker symbol &#147;GRAL.&#148; Following the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina common stock will continue to trade on Nasdaq under the ticker symbol &#147;ILMN.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor Illumina can assure you as to the trading price of Illumina common stock or our common stock after the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> or as to whether the combined trading prices of our common stock and the Illumina common stock after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will be less than, equal to or greater than the
trading prices of Illumina common stock prior to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> The trading price of our common stock may fluctuate significantly following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and result in a
higher volatility in the price of our common stock. For more detail, see the section entitled &#147;Risk Factors&#151;Risks Relating to Our Common Stock&#148; beginning on page&nbsp;88 of this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock distributed to Illumina stockholders will be freely
transferable, except for shares received by individuals who are our affiliates. Individuals who may be considered our affiliates after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> include individuals who control, are controlled by, or are
under common control with us, as those terms generally are interpreted for U.S. federal securities law purposes. These individuals may include some or all of our directors and executives. Individuals who are our affiliates will be permitted to sell
their shares of our common stock only pursuant to an effective registration statement under the Securities Act of 1933 (the &#147;Securities Act&#148;) or an exemption from the registration requirements of the Securities Act, such as those afforded
by Section&nbsp;4(a)(1) of the Securities Act or Rule 144 thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trading Prior to the Distribution Date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect a &#147;when-issued&#148; market in our common stock to develop on or shortly before the Record Date for the Distribution and
continue up to and including the Distribution Date. &#147;When-issued&#148; trading refers to a sale or purchase made conditionally on or before the Distribution Date because the securities of the <FONT STYLE="white-space:nowrap">spun-off</FONT>
entity have not yet been distributed. If you own shares of Illumina common stock at the close of business on the Record Date, you will be entitled to receive shares of our common stock in the Distribution. You may trade this entitlement to receive
shares of our common stock, without the shares of Illumina common stock you own, on the &#147;when-issued&#148; market. We expect &#147;when-issued&#148; trades of our common stock to settle within two trading days after the Distribution Date. On
the first trading day following the Distribution Date, we expect that &#147;when-issued&#148; trading of our common stock will end and <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> trading will begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also anticipate that, on or shortly before the Record Date and continuing up to and including the Distribution Date, there will be two
markets in Illumina common stock: a <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> market and an <FONT STYLE="white-space:nowrap">&#147;ex-distribution&#148;</FONT> market. Shares of Illumina common stock that trade on the <FONT
STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> market will trade with an entitlement to receive shares of our common stock in the Distribution. Shares that trade on the <FONT STYLE="white-space:nowrap">&#147;ex-distribution&#148;</FONT>
market will trade without an entitlement to receive shares of our common stock in the Distribution. Therefore, if you sell shares of Illumina common stock in the <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> market up to and
including the Distribution Date, you will be selling your right to receive shares of our common stock in the Distribution. However, if you own shares of Illumina common stock at the close of business on the Record Date and sell those shares on the <FONT
STYLE="white-space:nowrap">&#147;ex-distribution&#148;</FONT> market up to and including the Distribution Date, you will still receive the shares of our common stock that you would otherwise be entitled to receive in the Distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Distribution Date, we expect shares of our common stock to be listed on Nasdaq under the ticker symbol &#147;GRAL.&#148; If
&#147;when-issued&#148; trading occurs, the listing for our common stock is expected to be under a ticker symbol different from our <FONT STYLE="white-space:nowrap">&#147;regular-way&#148;</FONT> ticker symbol. We will announce our
&#147;when-issued&#148; ticker symbol when and if it becomes available. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> does not occur, all &#147;when-issued&#148; trading will be null and void. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the separation will be effective on the Distribution Date, provided that the following conditions shall have been satisfied or
waived by Illumina: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Illumina Board shall have authorized and approved the Distribution and not withdrawn such authorization and
approval, and shall have declared the dividend of our common stock to Illumina stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ancillary agreements contemplated by the Separation and Distribution Agreement shall have been executed by
each party to those agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock shall have been accepted for listing on Nasdaq or another national securities exchange approved
by Illumina, subject to official notice of issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the SEC shall have declared effective our Registration Statement on Form&nbsp;10, of which this Information
Statement is a part, under the Securities Exchange Act of 1934, and no stop order </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
suspending the effectiveness of the Registration Statement shall be in effect and no proceedings for that purpose shall be pending before or threatened by the SEC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina shall have received a private letter ruling from the IRS and the written opinion of Cravath,
Swaine&nbsp;&amp;&nbsp;Moore LLP, each of which shall remain in full force and effect, that, subject to the limitations specified therein and the accuracy of and compliance with certain representations, warranties, and covenants, the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> will qualify for <FONT STYLE="white-space:nowrap">non-recognition</FONT> of gain and loss under Sections&nbsp;355 and 368 of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Illumina Board shall have received one or more opinions (which have not been withdrawn or adversely modified)
in customary form from one or more nationally recognized valuation, appraisal, or accounting firms or investment banks as to the solvency and financial viability of Illumina prior to the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and each of
Illumina and GRAIL after the consummation of the <FONT STYLE="white-space:nowrap">Spin-Off;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no order, injunction, or decree issued by any governmental authority of competent jurisdiction or other legal
restraint or prohibition preventing consummation of the Distribution shall be in effect, and no other event outside the control of Illumina shall have occurred or failed to occur that prevents the consummation of the Distribution;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no other events or developments shall have occurred prior to the Distribution Date that, in the judgment of the
Illumina Board, would result in the Distribution having a material adverse effect on Illumina or its stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the Distribution Date, notice of Internet availability of this Information Statement or this Information
Statement shall have been mailed to the holders of Illumina common stock as of the Record Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Illumina shall have duly elected the individuals to be listed as members of our post-Distribution Board in this
Information Statement, and such individuals shall be the members of our Board of Directors (the &#147;Board&#148;), immediately after the Distribution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately prior to the Distribution Date, our Certificate of Incorporation and Bylaws, each in substantially
the form filed as an exhibit to the Registration Statement on Form 10, of which this Information Statement is a part, shall be in effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fulfillment of the above conditions will not create any obligation on Illumina&#146;s part to complete the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> If the Illumina Board waives any condition prior to the effectiveness of the Registration Statement on Form&nbsp;10, of which this Information Statement is a part, and the result of such waiver is
material to Illumina stockholders, Illumina will file an amendment to the Registration Statement to revise the disclosure in this Information Statement accordingly. In the event that the Illumina Board waives a condition after the Registration
Statement on Form 10, of which this Information Statement is a part, becomes effective and such waiver is material to Illumina stockholders, Illumina will communicate such change to Illumina stockholders by filing a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> describing the change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Illumina has the right not to complete the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> if, at any time, the Illumina Board determines, in its sole and absolute discretion, that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not in the best interests of Illumina or its stockholders,
or is otherwise not advisable. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, Illumina and GRAIL will have incurred significant costs related to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT>
including fees for consultants, financial and legal advisors, accountants and auditors, that will not be recouped. Total <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs associated with the
<FONT STYLE="white-space:nowrap">Spin-Off</FONT> are preliminarily estimated to range from $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the <FONT STYLE="white-space:nowrap">Spin-Off</FONT>
is completed. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, the <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs will generally be limited to the transaction costs incurred for services
rendered as of the date the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is abandoned, which will be less than the range noted above. Our and Illumina&#146;s management will also have devoted significant time to manage the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> process, which will decrease the time they will have to manage their respective businesses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for Furnishing This Information Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are furnishing this Information Statement solely to provide information to Illumina&#146;s stockholders who will receive shares of our
common stock in the Distribution. Illumina&#146;s stockholders are not required to vote on the Distribution. Therefore, you are not being asked for a proxy and you are not required to send a proxy to Illumina. You do not need to pay any
consideration, exchange or surrender your existing shares of Illumina common stock, or take any other action to receive the shares of our common stock to which you are entitled in the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> You should not
construe this Information Statement as an inducement or encouragement to buy, hold, or sell any of our securities or any securities of Illumina. We believe that the information contained in this Information Statement is accurate as of the date set
forth on the cover. Changes to the information contained in this Information Statement may occur after that date, and neither we nor Illumina undertake any obligation to update the information except in the normal course of our and Illumina&#146;s
public disclosure obligations and practices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate paying any cash dividends in the foreseeable future. We currently anticipate that we will retain all available funds for
use in the operation and expansion of our business. Any future determination to pay dividends on our common stock will be made at the discretion of our Board and will depend upon, among other factors, our financial condition, results from
operations, current and anticipated cash needs, plans for expansion, and other factors that our Board may deem relevant. We cannot assure you that we will pay a dividend in the future or continue to pay any dividend if we do commence paying
dividends. See also &#147;Risk Factors&#151;Risks Relating to Our Common Stock&#151;We do not expect to pay any dividends for the foreseeable future&#148; beginning on page&nbsp;91 of this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the cash, cash equivalents and marketable securities, and capitalization of GRAIL as of December&nbsp;31, 2023:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to our conversion from a limited liability company to a corporation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give effect to the Distribution and other related transactions, as if they
occurred on December&nbsp;31, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information below is not necessarily indicative of what our capitalization
would have been had the conversion to a corporation, the Distribution, and other related transactions been completed as of December&nbsp;31, 2023. In addition, it is not indicative of our future capitalization and may not reflect the capitalization
or financial condition that would have resulted had we operated as an independent, publicly traded company as of the applicable dates presented. You should review the following table in conjunction with the sections entitled &#147;Unaudited Pro
Forma Condensed Consolidated Financial Information&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; beginning on pages&nbsp;112 and&nbsp;168 of this Information Statement, respectively,
and our Consolidated Financial Statements and accompanying notes set forth in the section entitled &#147;Index to Consolidated Financial Statements&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;F-1</FONT> of this Information
Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;as<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total member&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share, no shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, pro forma and pro forma as adjusted; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding pro forma as &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_10"></A>SELECTED HISTORICAL FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present selected historical financial data as of and for each of the fiscal years ended December&nbsp;31, 2023 and
January&nbsp;1, 2023 and for the periods from August&nbsp;19, 2021 to January&nbsp;2, 2022 and January&nbsp;1, 2021 to August&nbsp;18, 2021. We have derived our summary historical statements of operations data for the years ended December&nbsp;31,
2023 and January&nbsp;1, 2023 and for the periods from August&nbsp;19, 2021 to January&nbsp;2, 2022 and January&nbsp;1, 2021 to August&nbsp;18, 2021, and summary historical balance sheet data as of December&nbsp;31, 2023 and January&nbsp;1, 2023, as
set forth below, from our audited historical consolidated financial statements and related notes included elsewhere in this Information Statement. We refer to our audited financial statements as the &#147;Consolidated Financial Statements,&#148;
which are included in this Information Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected historical financial data presented below should be read in conjunction
with our Consolidated Financial Statements and the accompanying notes thereto, the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; beginning on page&nbsp;168 of this Information
Statement, and the section entitled &#147;Unaudited Pro Forma Condensed Consolidated Financial Information&#148; beginning on page&nbsp;112 of this Information Statement. On August&nbsp;18, 2021, we became a wholly owned subsidiary of Illumina.
Although we were held and operated separately and independently from Illumina, the selected historical financial data does not necessarily reflect what our results of operations and financial position would have been if we had operated as an
independent, publicly traded company during the periods presented. In addition, our historical financial data does not reflect changes that we expect to experience in the future as a result of our separation from Illumina, including changes, if any,
in the financing of our business. Accordingly, the historical results should not be relied upon as an indicator of our future performance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended <BR>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021&nbsp;to<BR>January&nbsp;2, 2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,052</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,433</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (exclusive of amortization of <BR>acquired intangible assets)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,288</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,630</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309,781</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">478,071</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,700,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,498,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940,587</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,442,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(928,154</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(337,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(865</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,441,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(929,019</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,399,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(911,542</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(336,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,937,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,955,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,310,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and member&#146;s equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,937,986</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_11"></A>UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, Illumina announced plans
for the separation of GRAIL from Illumina. To effect the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina will distribute at least 85.5% of the shares of GRAIL&#146;s common stock owned by Illumina to Illumina&#146;s stockholders, and
GRAIL will become an independent, publicly traded company. Immediately after the Distribution becomes effective, Illumina may retain up to 14.5% of GRAIL&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed consolidated financial information of GRAIL has been derived from the historical consolidated financial
statements, which we refer to as the &#147;Consolidated Financial Statements,&#148; included in the section entitled &#147;Index to Consolidated Financial Statements&#148; beginning on page <FONT STYLE="white-space:nowrap">F-1</FONT> of this
Information Statement. The unaudited pro forma condensed consolidated statement of operations data for the year ended December&nbsp;31, 2023 has been prepared as though the Distribution occurred on January&nbsp;2, 2023. The unaudited pro forma
condensed consolidated balance sheet data as of December&nbsp;31, 2023 has been prepared as though the Distribution occurred on December&nbsp;31, 2023. The unaudited pro forma condensed consolidated financial information was prepared in accordance
with Article 11 of Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> updated for Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786,</FONT> which became effective January&nbsp;1, 2021. The unaudited pro forma condensed consolidated
financial information has been adjusted to give effect to pro forma adjustments referred to as &#147;Transaction Accounting Adjustments&#148; including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of GRAIL from a limited liability company to a corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed consolidated financial information is presented for illustrative purposes only and is not necessarily
indicative of the operating results or financial position that would have been achieved had the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> occurred on January&nbsp;2, 2023 or December&nbsp;31, 2023, respectively, nor is it indicative of
GRAIL&#146;s future operating results or financial position. The pro forma adjustments are based upon information and assumptions available at the time of the filing of this Information Statement as set forth in the notes to the unaudited pro forma
condensed consolidated financial information. Because this unaudited pro forma condensed consolidated financial information has been prepared based upon preliminary estimates, the impact of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and
the timing thereof could cause material differences from the information presented herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed consolidated
financial information should be read in conjunction with our Consolidated Financial Statements and accompanying notes included under the section entitled &#147;Index to Consolidated Financial Statements&#148; beginning on page <FONT
STYLE="white-space:nowrap">F-1</FONT> of this Information Statement and the sections entitled &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; beginning on
pages&nbsp;109 and&nbsp;168, respectively, of this Information Statement. The unaudited pro forma condensed consolidated financial information constitutes forward-looking information and is subject to certain risks and uncertainties that could cause
actual results to differ materially from those anticipated. For more information, see the sections entitled &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; and &#147;Risk Factors&#148; beginning on pages&nbsp;95 and&nbsp;28,
respectively, of this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our mission is to
detect cancer early, when it can be cured. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative commercial-stage healthcare company focused on saving lives and
shifting the paradigm in early cancer detection. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our Galleri test is a clinically-validated,
commercially available test for early detection of multiple types of cancer, which we termed multi-cancer early detection (&#147;MCED&#148;). Galleri detects a shared cancer signal across more than 50 types of cancer and can predict with high
accuracy the specific organ or tissue type where the cancer signal originated, all from a simple blood draw. We launched Galleri in the United States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold
more than 125,000 commercial tests and established over 100 commercial partnerships, including leading healthcare systems, employers, payors, and life insurance providers. Commercial use of Galleri has detected some of the most aggressive cancers in
early stages including, among others, endometrial, esophageal, gastrointestinal stromal, head and neck, liver, pancreatic, and rectal cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is a major public health crisis. It is the second leading cause of death both in the United States and worldwide. Most cancers that
result in death are diagnosed too late, in advanced stages when they are most challenging to treat. Approximately 67% of cancer deaths result from cancers that have no recommended screening guidelines. In the United States, we consider standard of
care screening for cancer to consist of the grade A and B recommendations published by the United States Preventive Services Task Force (&#147;USPSTF&#148;), which currently recommend broad population screening for only four types of cancer using
single-cancer screening tests (breast, cervical, colorectal, and lung cancer), and prostate cancer screening, which is USPSTF grade C and is widely implemented in the United States. We believe that expanding upon these current guidelines to screen
individuals for many types of cancer with a single test represents a significant opportunity to reduce cancer mortality and the cost of cancer care. Based on our published modeling data, we estimate that adding Galleri to these five standard of care
single-cancer screening tests could detect many more cancers at an earlier stage and potentially avert approximately 100,000 deaths per year in the United States as measured by five-year survival. In addition, a recent analysis demonstrated that
diagnosing cancer early could result in an estimated $26&nbsp;billion in annual cost-savings in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed Galleri to
detect cancer early, when it can be cured. Galleri works by detecting DNA fragments shed into the bloodstream by tumor cells. DNA from cancer has specific methylation patterns that can be used to both identify a general cancer signal and localize
that signal to a specific organ or tissue type. In clinical studies, Galleri identified a shared cancer signal across more than 50 types of cancer, often at an early stage. If a cancer signal is detected, Galleri predicts the tissue type or organ
associated with the cancer signal (the cancer signal origin) with high accuracy. Test results are then used by healthcare providers to guide <FONT STYLE="white-space:nowrap">follow-up</FONT> diagnostic testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an early leader in MCED testing, we have established strong relationships within the cancer and primary care community, including through
partnerships with academic and community medical centers, key opinion leaders, and governmental policy and advocacy partners. We have shared evidence supporting our MCED testing at renowned medical conferences, such as the American Association of
Cancer Research (&#147;AACR&#148;), American Society of Clinical Oncology (&#147;ASCO&#148;), European Society of Medical Oncology (&#147;ESMO&#148;), and American Academy of Family Physicians (&#147;AAFP&#148;). We have also published results from
our studies in leading scientific and medical journals, including <I>The Lancet</I>,<I> Nature</I>,<I> Nature Medicine</I>,<I> Cancer Cell</I>, and<I> The Lancet Oncology</I>. Our industry leadership has been recognized with multiple national
high-profile accolades, including being acknowledged by <I>Time Magazine </I>as one of the Best Inventions of 2022, and<I> The Atlantic</I> as one of the top breakthroughs of 2022 and being named in <I>Fast Company</I> World Changing Ideas of 2022
and in the <I>Fortune</I> Change the World List in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To support broad access for Galleri in the United States, we plan to complete a
premarket approval application (&#147;PMA&#148;) submission with the FDA in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We seek to use data from the
<FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
together with data from our PATHFINDER 2 study, as well as supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States. We believe that
FDA approval could unlock broad coverage by large commercial payors in the United States and we are working with stakeholders to advance and shape the public reimbursement landscape in the United States to enable coverage of <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> MCED tests by Medicare. Following FDA approval, we also expect to pursue inclusion of Galleri in the USPSTF&#146;s guideline recommendation. In the United Kingdom, we are working with NHS England to
complete our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial. Subject to results of an early analysis from the first screening test (the prevalent screening round) representing one year of results out of the
<FONT STYLE="white-space:nowrap">three-year</FONT> trial period, the NHS may commence phased commercial implementation in England, beginning with a two-year pilot, and with the potential for further expansion subject to final results from the trial.
We believe our work with the NHS and the data generated from our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial could facilitate adoption in other single-payor systems around the world and support evidence of clinical utility worldwide.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding, we have undertaken a rigorous approach to identify in a blood sample the most informative markers of cancer through
what we believe is the largest clinical program in genomic medicine to date. We have collected population-scale clinical data from more than 300,000 participants across eight clinical studies, with more than 21,000 of these participants included in
the studies that supported the development and launch of Galleri, and over 165,000 individuals enrolled in interventional studies (NHS Galleri and PATHFINDER 2) to support our PMA submission. These studies include our foundational case-control
Circulating Cell-free Genome Atlas (&#147;CCGA&#148;) study to develop and validate our MCED technology, multiple large-scale observational studies in asymptomatic individuals, and multiple large-scale interventional studies in intended use
populations. Our interventional studies include our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, which is the first and largest randomized controlled trial of an MCED test, and which enrolled more than 140,000 individuals in just over
10 months. Through these studies and our ongoing collection of real-world data, we have built what we believe is an unprecedented longitudinal dataset of high quality, linked clinical and genomic data. Our clinical studies, including our early
discovery work, have demonstrated robust and reproducible test performance. Notably, key results from our interventional PATHFINDER study were generally consistent with data from our case-control CCGA study, which is evidence supporting the
generalizability and robustness of Galleri. We expect to continue to report ongoing and long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> clinical data from these studies over many years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our extensive discovery work, we believe that targeted methylation is the best approach for detecting a cancer signal and identifying
a cancer signal origin. In our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> analyses, methylation exhibited stronger performance when compared to interrogating mutations, chromosomal alterations,
fragment lengths, and other genomic features, either alone or in combination. In contrast to well-established cancer mutations that only affect a handful of genomic locations, there are nearly 30&nbsp;million methylation sites across the human
genome, making them a ubiquitous and rich signal for cancer detection. After comprehensive analysis of whole-genome methylation patterns, we refined and developed a targeted methylation approach focused on highly informative and <FONT
STYLE="white-space:nowrap">low-noise</FONT> methylation regions for cancer signal and cancer signal origin detection. Our targeted methylation approach can detect lower levels of cancer signal in blood compared to other approaches, enabling early
cancer detection in asymptomatic individuals more efficiently compared to whole-genome methylation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary targeted methylation
platform, as well as our growing body of clinical and real-world data, have provided us with unique insights into cancer biology that enable development of products beyond asymptomatic screening. We are leveraging our proprietary platform for
additional applications, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Precision oncology portfolio</I>:<I> </I>We are developing our precision oncology portfolio and launched our
research use only (&#147;RUO&#148;) targeted methylation platform with customizable classifiers in 2023. We have partnered with a number of leading oncology therapeutics companies to test applications of biomarkers with the goal of optimizing the
use of therapeutic interventions. Some of our partnerships also include development of customized applications to support clinical studies and companion diagnostic development and commercialization. Potential applications for our technology in a
precision </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
oncology setting include <FONT STYLE="white-space:nowrap">pre-treatment</FONT> prognosis, post-treatment prognosis or minimal residual disease (&#147;MRD&#148;), biomarker discovery, recurrence,
and clinical monitoring. We believe the research and clinical development settings represent significant opportunities with biopharmaceutical companies given the large number of ongoing oncology studies and the significant need to identify residual
disease or recurrence early and help inform treatment decisions. In addition to companion diagnostic opportunities, we believe that our methylation platform could enable standalone clinical products to support patient care across the cancer care
continuum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Diagnostic aid for cancer test</I>: We are developing our diagnostic aid for cancer (&#147;DAC&#148;) test to
accelerate diagnostic resolution for patients with <FONT STYLE="white-space:nowrap">non-specific</FONT> signs and symptoms, but with a clinical suspicion of cancer. Through a simple blood test, DAC is designed to provide physicians with a powerful
decision-making tool to aid diagnosis, achieve resolution more quickly, and avoid unnecessary workups. Symptomatic detection of cancer is a significant unmet need; we estimate that approximately 16&nbsp;million patients in the United States present
with <FONT STYLE="white-space:nowrap">non-specific</FONT> signs and symptoms each year. Data published in <I>The Lancet Oncology</I> showed that, in a symptomatic patient population, our methylation technology was able to detect many cancer types
and identify where they were located in the body with high accuracy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these products and other future
products in development present significant market opportunities and patient care solutions across the cancer care continuum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our continued growth will be driven by the following strengths: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our clinically-validated, commercially available, MCED test, Galleri.</B> Galleri is a clinically-validated,
commercially available, MCED test that is setting the standard for multi-cancer early detection. From a simple blood draw, Galleri can detect a cancer signal shared by over 50 types of cancer, over 45 of which do not have recommended screening
guidelines. Galleri has demonstrated high positive predictive value (&#147;PPV&#148;) and low false positive rate, improves the opportunity for early detection of cancer in asymptomatic individuals by screening for multiple types of cancer, and
predicts the location of the suspected cancer with high accuracy to help guide an efficient diagnostic evaluation. Further, as Galleri relies on a blood draw, the test can be integrated into existing care pathways, such as annual health checks,
which can enable wide-scale implementation and increase access to cancer screening, thus helping to address well-known disparities in cancer care. Our industry leadership in MCED testing has been recognized with multiple national high profile
accolades, including being acknowledged by <I>Time Magazine </I>as one of the Best Inventions of 2022, and<I> The Atlantic</I> as one of the top breakthroughs of 2022 and being named in <I>Fast Company</I> World Changing Ideas of 2022 and in the
<I>Fortune</I> Change the World List in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our established commercial leadership is driving the development of a significant market.</B> The commercial
opportunity for Galleri is significant, with more than 300&nbsp;million individuals globally over the age of 50 (our intended use population), including more than 100&nbsp;million individuals in the United States. We launched Galleri in the United
States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold more than 125,000 commercial tests and established over 100 commercial partnerships, including leading healthcare systems, employers, payors, and
life insurance providers. In this real-world setting, Galleri is detecting deadly cancers in early stages. As an early leader in MCED testing, we have established strong relationships within the cancer and primary care community, including through
partnerships with academic and community medical centers, key opinion leaders, and governmental policy and advocacy partners. Our partnership with the NHS presents an opportunity to drive further adoption of Galleri, including by payors and health
systems around the world. Subject to the results of an early analysis from the first screening test (the prevalent screening round) in the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, the NHS may commence phased commercial
implementation in England, beginning with a two-year pilot, and with the potential for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
further expansion subject to final results from the trial. Our commercial leadership is further supported by our high-capacity laboratories to enable population screening volumes.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Clinical validation through unprecedented clinical studies and real-world experience.</B> We designed and
executed what we believe is the largest clinical program in genomic medicine to date. We have collected population-scale clinical data from more than 300,000 participants across eight clinical studies, with more than 21,000 of these participants
included in the studies that supported the development and launch of Galleri, and over 165,000 individuals enrolled in interventional studies (NHS Galleri and PATHFINDER 2) to support our PMA submission. These studies include our foundational
case-control CCGA study to develop and validate our MCED technology, multiple large-scale observational studies in asymptomatic individuals, and multiple large-scale interventional studies. Our interventional studies include our <FONT
STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, which is the first and largest randomized controlled trial of an MCED test, and which enrolled more than 140,000 individuals in just over 10 months. Through these studies and our ongoing
collection of real-world data, we have built what we believe is an unprecedented longitudinal dataset of high quality, linked clinical and genomic data. Our clinical studies, including our early discovery work, have demonstrated robust and
reproducible test performance. Notably, key results from our interventional PATHFINDER study were generally consistent with data from our case-control CCGA study, which is evidence supporting the generalizability and robustness of Galleri. Together
with our partners at leading community and academic medical centers in the United States and United Kingdom, we expect to continue to report ongoing and long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> clinical data from these studies
over many years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our highly-differentiated methylation platform, which enables product opportunities across the cancer care
continuum.</B> We have taken a scientifically rigorous approach to develop a deep and comprehensive understanding of cancer biology. We built an atlas to characterize the landscape of cell-free nucleic acids (&#147;cfDNA&#148;) across a broad and
diverse population and in individuals with and without cancer. We then used this atlas and other data to train our machine learning algorithms to recognize methylation patterns indicative of cancer and accurately predict the cancer signal origin.
These efforts supported the development of our proprietary methylation platform on which Galleri is based, and which we will continue to leverage to advance a number of clinical applications across the cancer care continuum. For example, we
developed and launched our post-diagnosis RUO offering and are working closely with biopharmaceutical companies to develop products and services to optimize treatment once a cancer has been diagnosed. Potential applications for our technology in a
post-diagnosis setting include <FONT STYLE="white-space:nowrap">pre-treatment</FONT> prognosis, post-treatment prognosis or MRD, biomarker discovery, detection of recurrence, and clinical monitoring. We are also developing our DAC test to enable
faster diagnosis and care for patients presenting with <FONT STYLE="white-space:nowrap">non-specific</FONT> symptoms that are suspicious for cancer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our intellectual property portfolio.</B> We own or license exclusive worldwide commercial rights to
intellectual property covering Galleri and our products in development. Specifically, we have exclusive licenses to more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;granted patents globally,
and own more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued patents, with more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pending
patent applications covering methylation and other technologies. In addition, our patents, trade secrets, and <FONT STYLE="white-space:nowrap">know-how</FONT> provide broad intellectual property coverage for our products, including chemistry,
bioinformatics, and machine learning algorithms used in Galleri and our product development pipeline. Our patents will begin to expire in 2028. Our patent applications, if issued as patents, would begin to expire in 2037. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our highly experienced and multidisciplinary team.</B> Since our founding, we have built an entrepreneurial
culture driven to improve outcomes for cancer patients. We are led by a multidisciplinary team with extensive experience across biotechnology, life sciences, public health, genomics, computer science, data science, biostatistics, clinical
development, medical affairs, government and regulatory affairs, quality assurance, and laboratory and commercial operations. We believe this confluence of talent from multiple disciplines has enabled us to make significant progress in improving
cancer care and will enable us to remain at the forefront of our industry. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Establishing Galleri as the population multi-cancer screening standard and extending commercial leadership in
large global markets.</B> We believe we have an unprecedented opportunity to establish a new standard of care by adding Galleri to existing single-cancer screenings, and establish and maintain the market-leading position in cancer detection. The
commercial opportunity for Galleri is significant, with more than 300&nbsp;million individuals globally over the age of 50, including over 100&nbsp;million individuals in the United States. Our goal is to address cancer screening globally, beginning
in large markets with established health systems, such as the United States and United Kingdom, and thereafter extending to other markets. We will continue to engage with key opinion leaders, healthcare providers, advocacy organizations, regulators,
and payors to help drive broader scientific and commercial endorsement worldwide. In addition, we believe Galleri&#146;s performance will drive clinical outcomes and high patient and provider satisfaction that will lead to further awareness and
adoption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expanding access to our products by pursuing reimbursement and coverage from payors.</B> Our ability to impact
cancer outcomes will be accelerated in markets where we secure reimbursement for our products. Prior to broad reimbursement in the United States, we will continue our work with clinics and health systems to accelerate utilization, and with
self-insured employers and health insurers to offer and cover Galleri. In the United States, we have established private reimbursement from over 70 self-insured employers and multiple payors and health systems as of September&nbsp;30, 2023. To
support broad access for Galleri in the United States, we plan to complete a PMA submission with the FDA in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We seek to use data from the <FONT
STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, together with data from our PATHFINDER 2 study, as well as supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States. We believe that
FDA approval could unlock large commercial payors in the United States and we are working with stakeholders to advance and shape the public reimbursement landscape in the United States to enable coverage of FDA-approved MCED tests for Medicare.
Following FDA approval, we also expect to pursue inclusion of Galleri in the USPSTF&#146;s guideline recommendation. In the United Kingdom, we are working with NHS England to complete our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial.
Subject to results of an early analysis from the first screening test (the prevalent screening round) representing one year of results out of the three-year trial period, the NHS may commence phased commercial implementation in England, beginning
with a two-year pilot, and with the potential for further expansion subject to final results from the trial. We believe our work with the NHS and the data generated from our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial could facilitate
adoption in other single-payor systems around the world and support evidence of clinical utility worldwide. We will continue to invest in clinical evidence generation and work with regulatory bodies and payors in our target markets to expand
coverage for early cancer screening and to increase access. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Defining, leading, and expanding adoption of MCED.</B> We coined the term &#147;multi-cancer early
detection&#148; and will continue to drive MCED as a solution to one of healthcare&#146;s most important challenges. Since our inception in 2016, we have established and maintained a leading voice regarding the early detection of multiple cancer
types in peer-reviewed literature. As of September&nbsp;30, 2023, we have published more than 45 manuscripts, including in high profile journals like <I>The Lancet</I>, <I>Nature</I>, <I>Nature Medicine</I>, <I>Cancer Cell</I>, and <I>The Lancet
Oncology</I>. We have also presented our data in more than 20 podium and 135 poster presentations at renowned medical conferences, including AACR, ASCO, ESMO, and AAFP. We fund medical education programs for MCED and intend to continue to educate
healthcare providers, as well as key opinion leaders, regulators, professional societies, and policymakers on the clinical benefits and public health impact of MCED. In addition, we believe this market development strategy will drive adoption of our
products and further awareness of the benefits of MCED testing generally. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Driving cutting edge science and technology to continuously improve existing products and develop new
products.</B> Our methylation platform and extensive technological infrastructure, together with expansive ongoing data collection, will continue to drive improvements to Galleri and enable the development of additional products. Our technology has
broad applicability in cancer detection and management, and findings from our SYMPLIFY study demonstrated the potential of our platform to extend beyond asymptomatic screening, into symptomatic detection. We launched our RUO offering, a part of our
precision oncology portfolio, in 2023, which has formed the basis of additional biopharmaceutical partnerships to enable further discovery and execution of new development programs. In addition, these partnerships have generated findings that
support expansion into precision oncology applications, including <FONT STYLE="white-space:nowrap">pre-</FONT> and post-treatment prognosis, recurrence detection, and clinical monitoring. We continually seek to enhance the performance of our
products through a comprehensive, rigorous approach to ongoing classifier training, improvement of features, and reduced processing time and cost. We will continue to improve our technologies and launch innovative products across the cancer care
continuum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leveraging our existing infrastructure to enable and scale our growing business.</B> Over the last several
years, we have made significant investments to build a scalable infrastructure capable of meeting significant demand while satisfying stringent certification parameters. Our high-capacity laboratories are accredited by the College of American
Pathologists (&#147;CAP&#148;) and certified by the Clinical Laboratory Improvement Amendments of 1988 (&#147;CLIA&#148;) and the New York Department of Health, which represents one of the most rigorous levels of validation required for
laboratory-developed tests. Our facilities are able to process a substantial number of tests per year and we expect to be able to meet our anticipated near-term needs. In addition, we engineered custom technology infrastructure and cloud-based tools
to enable scalable data collection and analysis capabilities. Our ability to collect, manage, and integrate high-quality genomic and clinical data is central to our business, and our automated laboratory workflows and processes enable high volumes
of tests and samples to be processed automatically with high efficiency and speed and low failure rates. As demand for our products increases, we expect to leverage the scale efficiencies of our infrastructure and platform technology, which we
believe will positively impact margins over time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Sustaining a patient-first corporate culture that champions diversity.</B> We have built a multi-disciplinary
organization of leading scientists, engineers, and clinicians driven to improve outcomes for cancer patients. We are on an urgent mission to detect cancer early, when it can be cured. In our pursuit to improve cancer care and solve one of
healthcare&#146;s most important challenges, we intend to grow our diversity among employees and will continue to foster an agile and inclusive environment that is a destination for world-class talent. We believe our mission, values, and leadership
attributes all contribute to this vibrant and inclusive culture and serve as a powerful magnet for talent. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Improving Cancer Care
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Burden of Cancer and the Benefits of Earlier Detection </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is the second leading cause of death in both the United States and worldwide, with more than 19&nbsp;million new cases and 10 million
deaths globally in 2020. This burden is expected to grow as the global population ages. According to the American Cancer Society, there will be approximately 1.9&nbsp;million new cancer cases and 610,000 cancer deaths in the United States in 2023.
An analysis published in the AACR&#146;s Cancer Epidemiology, Biomarkers and Prevention Journal estimated that $201&nbsp;billion was spent on cancer care in the United States in 2020, with some of the costliest treatments targeting late-stage
cancers that are highly challenging to treat. The same analysis projected that by 2030, the cost of cancer in the United States would rise to more than $246&nbsp;billion annually, driven by an aging population and rising costs of care. It is
estimated that the global economic cost of cancer from 2020 to 2050 will be approximately $25 trillion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A fundamental driver of cancer
mortality today is that most cancers that result in death are diagnosed too late, in advanced stages when they are most challenging to treat. If cancer is detected early, when it is localized, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it is more amenable to curative treatment. According to 2006 to 2015 data from the Surveillance, Epidemiology, and End Results Program of the U.S. National Cancer Institute (&#147;SEER&#148;),
across all cancers, the five-year cancer-specific survival rate is approximately 89% when localized, compared to 21% when the cancer is metastasized. Historically, a key challenge to early detection is that there has been no mechanism to detect most
cancers while individuals are asymptomatic. Detecting cancers at earlier stages could potentially reduce cancer-related five-year mortality by at least <FONT STYLE="white-space:nowrap">15-24%,</FONT> according to a model published in the AACR&#146;s
<I>Cancer Epidemiology, Biomarkers &amp; Prevention Journal</I> in May 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Treatment costs increase by stage across all cancers, and
treating cancers that are in more advanced stages can be up to two to four times more costly than treating cancers at earlier states. In addition, a recent analysis demonstrated that diagnosing cancer early could result in an estimated
$26&nbsp;billion (approximately 17% of total treatment costs) in annual cancer treatment cost-savings in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cancer
Screening Today and Limitations of the Current Cancer Screening Paradigm </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we consider standard of care
screening for cancer to consist of the grade A and B recommendations published by the USPSTF, which currently recommend broad population screening for only four types of cancer using single-cancer screening tests (breast, cervical, colorectal, and
lung cancer), and prostate cancer screening, which is USPSTF grade C and is widely implemented in the United States. These screening tests have helped to reduce mortality for these specific types of cancer; however, there are a number of limitations
to the current paradigm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">First, existing standard of care screening is limited to a minority of cancers. For the majority of cancer
types, there are no recommended screening guidelines or no screening tests exist. Only 14% of cancers in the United States are diagnosed through screening, according to NORC at the University of Chicago. We estimate that approximately 67% of cancer
deaths result from cancers that have no recommended screening guidelines. Many patients are diagnosed when presenting with symptoms, by which time these cancers may be advanced and harder to treat. Additionally, we estimate that asymptomatic
individuals undertaking a standard of care screening test are many times (2-24x depending on cancer type) more likely to have a different type of cancer than the cancer type for which they are being screened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Second, the existing standard of care screening tests are each for a single cancer type and prioritize high sensitivity, resulting in higher
false positive rates. Even if single-cancer screening tests were available for every cancer type, the administration of many single-cancer screening tests, either as independently administered tests or as a string of individual screens combined into
a single test, would be clinically and economically untenable at population-scale. Screening individuals with multiple single-cancer screening tests adds incrementally to the total number of independent tests conducted and therefore to the
cumulative false positive rate. For example, in the Prostate, Lung, Colorectal and Ovarian (&#147;PLCO&#148;) Cancer Screening Trial, which was a large randomized controlled trial designed and sponsored by the U.S. National Cancer Institute, the
cumulative risk of a false positive after 14 sequential single-cancer screening tests over a three-year period covering only four cancer types was 50% or greater. In addition, we developed a model using SEER data to analyze, among others, the false
positive rate of a hypothetical screening system in which a patient is screened using single-cancer screening tests for the 11 most deadly types of cancer in the United States (excluding prostate) over a
<FONT STYLE="white-space:nowrap">one-year</FONT> period, with each of the 11 single-cancer screening tests having an assumed false positive rate of 11%. Based on this model, we estimate that the cumulative risk of a false positive after these 11
single-cancer screening tests would be approximately 80%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third, single-cancer screening tests are also unlikely to be developed for
detecting less common cancers, which account for a majority of all cancer deaths. In many instances, the incidence of such cancers can be too low to undertake the required clinical studies. Additionally, achieving cost effectiveness for a test for a
less common cancer type would be challenging. Developing single-cancer screening tests for individual cancer types with lower incidence presents significant logistical burdens and expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opportunity for Multi-Cancer Early Detection </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe a population-scale, MCED screening test will help address these limitations of the current cancer screening paradigm and can be a
powerful tool to reduce the burden of cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>How to Measure Performance of a Population Screening Test </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of measures of performance for cancer screening tests. These include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While sensitivity has become an established measure in evaluating the performance of single-cancer
screening tests, we do not believe that sensitivity is the best measure to evaluate MCED tests for two primary reasons. First, sensitivity in blood-based cancer screening tests is largely dependent on the amount of cfDNA in the blood. The levels of
cfDNA are driven by the cancer types (certain cancers shed more circulating tumor DNA (ctDNA) than others) and stage (earlier stage cancers shed less ctDNA than later stage) in the population being tested. This variability can make it challenging to
measure and interpret the overall performance of a test that identifies a shared cancer signal, and is not searching for any particular cancer, and is deployed across broad populations. Second, tests that are optimized for sensitivity often
sacrifice specificity, which results in a higher rate of false positive results. While this tradeoff is generally accepted for single-cancer screening tests, it is critical to retain high specificity for a multi-cancer screening test due to the
substantial resulting impact that false positive results could have across the population if a significant number of individuals are screened. This is particularly relevant when screening the general population for a
<FONT STYLE="white-space:nowrap">low-incidence</FONT> disease, like cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rather than sensitivity, we believe that the two most
appropriate metrics for evaluating the effectiveness of an MCED test screening at population-scale are PPV, which incorporates both sensitivity and specificity, and yield. An MCED that has high PPV and high yield would result in identifying more
cancers earlier. PPV represents the probability that a positive test result is a true positive and directly answers the patient-centric clinical question, &#147;if my patient has a positive test result, what is the likelihood they truly have
cancer?&#148; We believe a high PPV can give clinicians confidence in a positive test result and a sense of urgency to initiate confirmatory diagnostic workups. The ability to detect as many cancer types as possible drives a high yield, enabling
detection of as many cancer cases in a population as possible. We believe that a high yield maximizes the population-scale impact of an MCED test in detecting cancer early. We believe dramatically increasing the yield of a cancer screening program
will be necessary to address the global burden of cancer and provide the potential to significantly improve cancer care. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a condition like cancer that has a low prevalence in the population, PPV is significantly
impacted by prevalence and specificity, such that PPV increases with the prevalence of cancer in the population and with the specificity. This is because in diseases, like cancer, with low prevalence, the population without cancer will be much
larger and therefore small changes in specificity will result in relatively large changes in the number of false positives. The relationship between specificity, prevalence, and PPV is illustrated by the figure below. For example, to illustrate how
prevalence impacts PPV, note the &#147;esophagus&#148; single-cancer screening test data, depicted by purple circles in the figure, which has a significantly lower PPV than the &#147;multi-cancer&#148; screening data, depicted by the gray squares in
the figure. For convenience, these data points are highlighted with two red vertical arrows. The higher PPV of the multi-cancer screening test is due to the aggregate prevalence of multiple cancers using a single test. To illustrate how specificity
impacts PPV, note the three gray squares indicating &#147;multi-cancer&#148; screening data, which are indicated by three black horizontal arrows. The increase in specificity from 95% to 99% results in a significant increase in PPV due to the
reduction in false positives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe another critical metric for measuring the performance of a multi-cancer early detection test is
the yield. Single-cancer screening tests are, by definition, limited in their maximum yield, as they are focused on only one cancer type. By contrast, multi-cancer screening tests increase the yield by detecting multiple cancer types simultaneously
in a population. There is an inverse relationship between aggregate sensitivity and yield; for example, low signal cancer types will drive down aggregate sensitivity but will increase the yield. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Requirements of a Population-Scale MCED Screening Test </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following features are essential for an MCED test to be accepted as a broad-based screening test in asymptomatic populations:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ability to identify a broad range of cancer types</I>:<I></I> An MCED test should identify many cancer types
to maximize the absolute number of clinically significant cancer cases detected in a population and yield. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>High PPV and low false positive rate</I>: An MCED test should have a high PPV and low false positive rate to
help maximize physician confidence in a positive test result, drive a sense of urgency to perform confirmatory diagnostic workups, and minimize the number of unnecessary workups in a population. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ability to predict with high accuracy the cancer signal origin and direct diagnostic workup</I>: An MCED test
should predict the cancer signal origin with high accuracy to facilitate efficient diagnostic workups. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Backed by robust analytical and clinical performance</I>: An MCED test should be rigorously validated to
account for <FONT STYLE="white-space:nowrap">non-cancer</FONT> biological signals and the underlying heterogeneity of populations without cancer. We believe clinical validation should be performed using a locked assay and classifier and should be
analyzed in case-controlled and <FONT STYLE="white-space:nowrap">intended-use</FONT> populations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Ability to limit overdiagnosis of indolent cancers</I>: An MCED test should preferentially detect the cancers
most likely to result in death, which are aggressive and clinically significant cancers warranting treatment, and should not result in overdiagnosis of more indolent cancers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Application to a diverse population</I>: An MCED test should be built on a comprehensive evidence program that
supports implementation in the broad elevated risk population (such as those over the age of 50). To support this, clinical studies should evaluate effectiveness in diverse and high-risk populations, including populations that are diverse in
behaviors (such as smoking), <FONT STYLE="white-space:nowrap">non-cancer</FONT> diseases, environmental exposures, age, gender, race, ethnicity, socio-economic status, and other confounding indications and differences. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Complementary to standard of care screenings</I>: An MCED test should serve as a complement to, not a
replacement for, current standard of care screening tests so as not to discourage adherence to existing USPSTF guidelines. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Simple to implement and access</I>: An MCED test should be easy to implement in clinical practice and reduce
or avoid common barriers to screening such as requirements for access to specialized equipment. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Products: Galleri and Beyond
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Multi-Cancer Early Detection Test: Galleri </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinically-validated, commercially available multi-cancer early detection test, Galleri, is transforming cancer care and has the potential
to unlock substantial improvements in cancer detection and mortality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A fundamental driver of cancer mortality today is that most cancers
that result in death are diagnosed too late, in advanced stages when they are most challenging to treat. If cancer is detected early, when it is localized, it is more amenable to curative treatment. Galleri is designed to complement the
USPSTF&#146;s recommended screenings, be easy to implement in practice, and improve overall population cancer detection. From a simple blood draw, Galleri can detect a cancer signal shared by over 50 types of cancer, over 45 of which do not have
recommended screening guidelines. Galleri improves the opportunity for early detection of cancer in asymptomatic individuals by screening for multiple types of cancer, predicts the location of the suspected cancer with high accuracy to help guide
next steps for diagnosis, and has demonstrated high PPV and low false positive rates. We launched Galleri in the United States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold more than 125,000
commercial tests and established over 100 commercial partnerships. In this real-world setting, Galleri has detected deadly cancers in early stages. Our validated test has been deployed across healthcare systems,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employers, payors, and life insurance providers, and for additional <FONT STYLE="white-space:nowrap">at-risk</FONT> groups such as firefighters, and continues to unlock the promise of early
cancer detection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed Galleri with the following critical features necessary to address the requirements of a population-scale
MCED screening test: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Ability to identify a broad range of cancer types</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galleri is able to detect a cancer signal shared in over 50 types of cancer, including the most deadly types of cancer that do not have
recommended screens. We believe that Galleri can significantly increase the number of cancer types screened for in the population and has the potential to increase yield of cancers in the United States that are diagnosed through screening from 14%
to 49%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>High PPV and low false positive rate</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In clinical studies, Galleri has demonstrated a high PPV of approximately 43% and a low false positive rate of less than 1%. A high PPV, which
is enabled in part by a low false positive rate, is important in clinical practice because it represents the probability that a positive test result is a true positive and can give clinicians high confidence and a sense of urgency to initiate
confirmatory diagnostic workups. A low false positive rate can help to limit unnecessary workups on patients who do not have cancer. The image below sets forth certain key performance information from our PATHFINDER study. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a18.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Galleri is designed to complement the current standard of care screening tests,
Galleri&#146;s high PPV of approximately 43% is significantly higher than the PPV of all of the standard of care single-cancer screening tests. Galleri&#146;s low false positive rate of less than 1% is also significantly lower than the false
positive rate of all of the standard of care single-cancer screening tests. The table below presents the PPV and number of false positives associated with the current standard of care screening tests: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g00a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Ability to predict with high accuracy the cancer signal origin and direct diagnostic workup</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galleri has a high 88% cancer signal origin prediction accuracy for identifying the location of cancer, which supports physician approaches to
diagnostic resolution through well-established workup pathways. Cancer signal origin prediction accuracy represents the extent to which first and second origins identified were correct among true positive tests. In our PATHFINDER study the first
workup based on cancer signal origin facilitated a diagnostic resolution in 25 of the 32 participants who had diagnostic resolution (approximately 80%). Importantly, this group of 32 participants consisted of only those who received a cancer signal
detected result from both Galleri and an earlier version of our MCED test also being studied in our PATHFINDER study. We also found that Galleri&#146;s cancer signal origin prediction generally facilitated diagnosis in less than three months (median
of 79 days) among participants who had a cancer signal detected. Further, Galleri&#146;s cancer signal origin prediction capability enables physicians to limit the use of full body imaging following cancer signal detected results, which can be
expensive, not readily accessible to broad patient populations, exposes patients to radiation, and can lead to false alarms and unnecessary ancillary workups. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Backed by robust analytical and clinical performance</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galleri test performance is validated by extensive clinical studies. We have established a broad population-scale clinical evidence program,
including the more than 21,000 participants included in the studies that supported the development and launch of Galleri. We established clinical validation using a locked assay and classifier in case-controlled and intended-use populations.
Importantly, we were able to translate performance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from our foundational case control CCGA study to our interventional PATHFINDER study. We have shared evidence supporting Galleri&#146;s performance at renowned medical conferences and published
results from our studies in leading scientific and medical journals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Ability to limit overdiagnosis of indolent cancers</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data across our clinical studies suggests that although Galleri detects cancer signals for some of the most aggressive cancers, detection of
cancer signals for indolent cancer types, which people are less likely to die from, is low. Based on the Kaplan-Meier curves in the figure below, which show survival over time, detected cancers have a similar prognosis to that expected based on our
analysis of SEER data, whereas cancers not detected by Galleri had a more favorable prognosis than would be expected. At any given stage, survival was worse for cancers detected by Galleri, as shown in the figure below. More specifically, the blue
curves, which represent detected cancers, are steeper than the purple curves, which represent undetected cancers, meaning that cancers detected by Galleri have a worse prognosis than those cancers that were not detected. These findings were
consistent across stages of cancer. Because this effect could be influenced by the types of cancer being evaluated, we adjusted for the age and cancer type distribution reported in the SEER data, and showed that this result is consistent if our
detection rate were applied to the cancer and age distribution present in the SEER data (represented by the dashed lines in the figure below). This suggests that indolent cancers are unlikely to be detected by Galleri, and Galleri would be unlikely
to contribute to the problem of overdiagnosis, and the associated harms related to treatment of over-diagnosed cancers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">p-values</FONT> shown in the figure above indicate the likelihood that
this result might be due to chance. The smaller the <FONT STYLE="white-space:nowrap">p-value,</FONT> the less likely these results are due to chance (for example, a <FONT STYLE="white-space:nowrap">p-value</FONT> = 0.001 means that there is a 0.1%
probability that the result is purely due to chance). The small <FONT STYLE="white-space:nowrap">p-value</FONT> reflects both the magnitude of the difference as well as the large sample size. We believe these findings are biologically consistent
with evidence suggesting that indolent, less aggressive cancers are less likely to shed DNA into the blood. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Application to a diverse population</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galleri has been validated in population-scale clinical studies to help detect cancer across broad populations that are diverse in behaviors
(such as smoking), <FONT STYLE="white-space:nowrap">non-cancer</FONT> diseases, environmental exposures, age, gender, race, ethnicity, socio-economic status, and other confounding indications and differences. For example, in published data from our
CCGA study, we found no differences in performance across racial subgroups. Understanding the signals associated with population diversity is important to our ability to account for biological noise and develop high-specificity tests for a broad
testing population. The inclusion of confounding conditions in our studies, such as aging and inflammatory conditions, enables us to discriminate true cancer signals from biological noise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to study Galleri in population-scale studies that evaluate the effectiveness of the test in diverse and high-risk populations. For
example, we have worked with clinics, fire departments, municipalities, and unions to test thousands of firefighters, who generally have exposure-related increased risk of cancer. We established a research collaboration with the U.S. Department of
Veterans Affairs (&#147;VA&#148;), the largest healthcare system in the United States, and the Veterans Health Foundation to provide Galleri to 10,000 veterans, many of whom are at high risk for cancer, across multiple participating VA sites over a
three-year clinical study period. In addition, in our SUMMIT study, we are evaluating Galleri in a population of individuals at high risk for lung and other smoking-related cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Complementary to standard of care screenings</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the five standard of care single-cancer screening tests have helped to reduce mortality for these specific types of
cancer. Galleri expands upon the current standard of care guidelines to screen individuals with a single test for many types of cancer, most of which have no recommended screenings. We envision a world where Galleri is broadly accessible and used
routinely alongside current standard of care screenings, potentially annually, to drive significant improvements in patient care and reduce cancer mortality and the cost of cancer care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To estimate the potential impact of early cancer detection and mortality reduction, we developed and published a cancer epidemiology forecast
model. Based on our published modeling data, we estimate that adding Galleri to the five standard of care single-cancer screening tests could detect many more cancers at an earlier stage and potentially avert approximately 100,000 deaths per year in
the United States, or 39% of the five-year deaths expected if not for early detection by Galleri. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we estimate that in a
population of approximately 107 million individuals between the ages of <FONT STYLE="white-space:nowrap">50-79</FONT> in the United States, adding Galleri to the five standard of care single-cancer screening tests could result in the detection of an
additional 460,000 cancer cases. Our model shows that the use of Galleri together with standard of care screenings could lead to the detection of three times as many cancer cases overall as compared to standard of care screenings alone, with only
6.5% more incremental false positives. We estimate that identification of many more cancer cases with a limited number of additional false positives would reduce the cost to diagnose one cancer by approximately 68%. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a21.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Simple to implement and access</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galleri is administered via a simple blood draw that enhances patient access and is easy for healthcare providers to implement. We believe
ease of a blood draw can increase compliance by reducing some of the barriers that have limited the adoption of certain individual cancer screening tests, including the time to obtain the screening test as well as access to specialists and
specialized equipment. The test is available through a wide range of <FONT STYLE="white-space:nowrap">in-person</FONT> and telemedicine care settings in the United States. Galleri is conveniently accessible to patients who can complete the blood
draw at physician offices, reference labs, and mobile phlebotomy labs, among other locations. In addition, Galleri can be easily integrated into routine practice, where healthcare providers can order Galleri as part of an annual examination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Support Services for Physicians that Drive a Positive Patient Experience </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a suite of support services to optimize the test experience for healthcare providers and patients. We believe it is important
that cancer signal detected patients and their healthcare providers are supported as they navigate <FONT STYLE="white-space:nowrap">follow-ups</FONT> such as scheduling a confirmatory diagnostic procedure. For all cancer signal detected results, our
medical science liaisons connect with the ordering provider via email or phone to offer support in clinical decision making. Clinical care documents are shared with the healthcare provider that describe published clinical guidelines to help guide
next steps in the diagnostic <FONT STYLE="white-space:nowrap">work-up.</FONT> Healthcare providers can additionally elect to access a Galleri experience council&#151;a cohort of physicians (including experts from National Cancer Institute designated
cancer centers) with experience with Galleri who can provide <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> consultations. We also operate an early cancer detection board, analogous to a tumor board,
that includes third-party experts across specialties to discuss any challenging cases for which advice is sought. We offer patients a post-cancer signal detected result support center that provides materials they can bring to a referral to ensure
the receiving physician understands the cancer signal detected test result to facilitate urgent care for such patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our
software systems support a positive experience for physicians and their patients. Our physician portal is designed to allow physicians to order our test and obtain patient consent electronically, which is efficient and helps minimize errors and
incomplete user information. We designed our software systems to integrate with third-party electronic medical record systems to streamline test ordering and results delivery. Importantly, for every test we process, we provide a clinically
actionable test report, as depicted in the graphic below, that is delivered through our secure web portal to the ordering healthcare providers to show whether or not a cancer signal is detected, and if so, to predict where in the body the cancer
signal is located. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The image below depicts an illustrative cancer signal detected test report. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g40g40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Investment to Enhance Versions of Tests </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to continually enhance the performance and features of Galleri. Commercial use and ongoing research programs provide valuable data that
we believe can enhance test performance. Real-world evidence is already informing product improvements today. We will leverage even larger datasets to further develop our advanced machine learning algorithms. By further refining and selecting
subsets of highly informative regions for cancer signal origin detection to reduce panel size, we could achieve deeper sequencing coverage and lower sequencing costs. We also aim to further improve the sensitivity of our tests by obtaining deeper
sequencing coverage and a better understanding of noise and leveraging even larger datasets to further develop our advanced machine learning algorithms. We also continue to research and develop technologies that have the potential to complement
methylation through orthogonal biological information, including additional analytes and biofluids such as proteins and urine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Precision Oncology Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The precision oncology market is expected to grow significantly in the coming years, and multiple research studies have indicated that liquid
biopsies and ctDNA detection will play a major part in this growth. Our precision oncology portfolio currently consists of an RUO-targeted methylation-based platform with customizable classifiers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that enables applications for disease prognostication, risk stratification, minimal residual disease (&#147;MRD&#148;) detection and recurrence and relapse monitoring across many cancer types.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated early collaborations with select, leading biopharmaceutical companies beginning in 2020, and the launch of our RUO offering
in early 2023 has unlocked additional partnerships with several leading oncology companies. These partnerships leverage our RUO offering to test applications of biomarkers with the goal of optimizing the use of therapeutic interventions.
Partnerships may also include development of customized applications to support clinical studies and companion diagnostic development and commercialization. Our first companion diagnostic partnership was announced in 2022 with AstraZeneca. We have
published or presented early performance data on MCED testing at multiple academic conferences, including ASCO, AACR and ESMO, across different use cases and indications. These data demonstrate the versatility of the platform across multiple
applications and areas of clinical unmet need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our RUO offering uses our proprietary targeted methylation platform to analyze cfDNA
isolated from peripheral blood for cancer signal interrogation. Our RUO technology estimates tumor burden based on tumor methylation fraction, enabling longitudinal monitoring and surveillance solutions. Data from our studies have demonstrated
analytically validated performance, and robust analytical sensitivity, specificity, and precision. For example, in a recent analytical validation study, cfDNA was analyzed from donors with and without cancer. Analytical sensitivity was assessed in
12 different solid tumor types. Results demonstrated strong median limit of detection (&#147;LoD&#148;) of 0.023% based on measures of the abnormally methylated ctDNA fraction. Analytical specificity was 98.5% and overall precision across all
replicates was 94.6%. The low input requirements support retrospective research studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our biopharmaceutical business,
we believe that our targeted methylation platform could enable clinical products to support patient care across the cancer care continuum. For example, many tests available today for solid tumors require tissue samples and development of
patient-specific assays, which contributes to longer turnaround times and potential delays in treatment decisions. Our multi-cancer, <FONT STYLE="white-space:nowrap">non-invasive</FONT> targeted methylation platform enables cancer detection,
classification and monitoring with limited plasma input and no tumor tissue. Test results can be returned rapidly with a 7-10 day clinical turnaround time. The blood-only liquid biopsy approach eliminates challenges with obtaining tissue samples and
avoids bias due to tumor heterogeneity and disease evolution. The targeted methylation approach is also able to enhance accuracy as compared to mutation-based approaches which are known to be confounded by normal biological processes, such as those
associated with aging. In the clinical monitoring application, the difficulty of obtaining serial tissue samples, particularly in cancer types such as lung and liver, means a blood-based approach is likely to be much more attractive to clinicians
and biopharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we have validated performance of our technology in an MRD setting, with sensitivity on par with
tumor-informed methods. MRD testing is used in pharmaceutical studies and clinical practice to detect the presence or absence of residual disease and inform treatment decisions, including identifying patients who may be eligible for adjuvant
therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Diagnostic Aid for Cancer Test </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To accelerate diagnostic resolution for patients with <FONT STYLE="white-space:nowrap">non-specific</FONT> signs and symptoms, but with a
clinical suspicion of cancer, we are developing our DAC test using the same proprietary platform used to develop Galleri. Through a simple blood draw, DAC is designed to provide physicians with a powerful decision-making tool to aid diagnosis,
achieve resolution more quickly, and avoid unnecessary workups. Data published in <I>The Lancet Oncology </I>showed that, in a symptomatic patient population, our methylation platform was able to detect many cancer types and identify where the
cancer signal origin was located in the body with high accuracy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Symptomatic detection of cancer is a significant unmet need; we estimate
that approximately 16&nbsp;million patients in the United States present with <FONT STYLE="white-space:nowrap">non-specific</FONT> signs and symptoms each year. These patients are subject </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to potentially invasive and time-consuming diagnostic workups. Further, over 70% of patients with <FONT STYLE="white-space:nowrap">non-specific,</FONT> but concerning symptoms, undergo imaging,
scoping, biopsies and other procedures, and over 25% of patients take more than four months to reach a diagnosis once they have already been referred for investigation. There is currently no option for multi-cancer detection for these patients,
meaning they will need to potentially undergo multiple single cancer workups. Only around 4% of these patients are ultimately diagnosed with cancer. As demonstrated through SYMPLIFY and other published studies, primary care physicians frequently
have difficulty determining which investigations and specialists a patient should be referred to having presented with a <FONT STYLE="white-space:nowrap">non-specific</FONT> symptom such as unexplained weight loss. This can sometimes result in a
prolonged diagnostic odyssey for the patient, with multiple investigations over many months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our findings in the SYMPLIFY study
that included more than 6,200 participants and was published in <I>The Lancet Oncology</I>, DAC demonstrated an overall PPV of approximately 76% with an overall NPV of approximately 98%. NPV is an important measurement in a symptomatic population
because we believe it provides a physician with more certainty that a negative test indicates a patient does not have cancer that will go untreated. In addition, the overall cancer signal origin prediction accuracy was approximately 91% (first
origin indicated had a cancer signal origin prediction accuracy of approximately 85%). Test performance was the strongest in patients referred for investigation of a possible upper gastrointestinal cancer, which has historically been more difficult
to diagnose, with a PPV of approximately 66% and an NPV of approximately 99%. The high overall PPV, NPV, and cancer signal origin prediction accuracy results demonstrated in the SYMPLIFY study provide further evidence that our methylation-based
platform can help clinicians in difficult <FONT STYLE="white-space:nowrap">non-specific</FONT> symptomatic situations determine the likelihood that an individual might have cancer, and if a cancer signal is reported, where to direct patients based
on the predicted cancer signal origin. The image below summarizes information from our SYMPLIFY study. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our DAC test has the potential to be reimbursed as a medical benefit, which is an existing, established
coverage pathway in the United States. We anticipate launching our DAC test when we have confirmed eligibility for reimbursement in the United States. In deploying DAC in clinical practice, we expect to leverage our existing commercial salesforce
and infrastructure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Products in Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our rigorous discovery efforts have already enabled us to build unique technologies and develop a powerful platform for early detection. Moving
forward, we will continue to research and develop technologies that have the potential to complement and enhance our capabilities. We have conducted early research and development in areas such as immunology and biofluids such as urine. We also plan
to leverage relationships, including with academic and industry partners, to help expedite bringing potential new applications of our technology to market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Methylation Technology Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Origin Story </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the presence of tumor DNA in the blood was discovered in 1948, it has largely been used as a
<FONT STYLE="white-space:nowrap">non-invasive</FONT> method to select targeted therapies for patients with late-stage cancer. More recently, evidence supported the idea that DNA in the blood could also detect cancer in earlier stages, which raised
the possibility of utilizing cfDNA for early cancer detection (i.e., when patients are asymptomatic). This idea originated in part at Illumina from incidental findings from a study involving a commercial cfDNA-based
<FONT STYLE="white-space:nowrap">non-invasive</FONT> prenatal test. This study leveraged whole-genome sequencing to interrogate copy-number variations to identify fetal chromosomal abnormalities from fetal cfDNA in maternal circulation. From an
overall cohort of 125,426 pregnant women, 10 cases of maternal cancer were identified. In cancer cases that presented with advanced symptoms, the treating clinician noted that earlier detection of the malignancy would have had a positive effect on
their care. This incidental detection of multiple cancer types via cancer-specific chromosomal changes suggested that a cfDNA-based MCED was possible and GRAIL was founded shortly thereafter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Detecting Cancer Signals in the Blood </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Blood contains circulating genomic material, including fragments of tumor DNA in an individual with cancer, which makes it well suited for
detecting cancer signals. The genome is a set of DNA instructions found in a cell that contains information for how an organism and its cells function. Changes to one or more genes, often referred to as mutations, can disrupt a cell&#146;s normal
functioning and cause disease. Genetic mutations can be indicative of cancer, and the reason why cancer is often called a disease of the genome. Although understanding an individual&#146;s genetic mutations can help diagnose and treat cancer (for
example, by selecting a therapy known to target a specific mutation or set of mutations), mutations only provide part of the picture that drives the complex biology of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is well recognized that a hallmark of cancer is abnormally methylated DNA. Methylation is a fundamental biological process active in all
living cells that regulates gene expression (i.e., which sections of the DNA &#147;turn on&#148; or &#147;turn off&#148;) and thus drives cellular function. A methylation site is a location on the genome where a methyl group, made up of one carbon
atom and three hydrogen atoms, is attached to a cytosine base along the DNA strand. An abnormal methylation site is either hyper (normally not methylated but is then methylated) or hypo (normally methylated but is not then methylated).
Hypermethylation can lead to silencing of tumor suppressor genes, transcription factors, and DNA repair mechanisms and therefore increase the likelihood of tumor formation. Hypomethylation can lead to genomic instability and chromosomal
rearrangements. Modifications in methylation patterns can result in changes in protein levels, which can trigger changes in cellular function and lead to disease, including cancer. For example, hypermethylation of the genome&#146;s regulatory region
that activates a tumor suppressor gene can turn off expression and lead to tumor growth. Additionally, because each cell type in the body has a unique methylation pattern, or &#147;fingerprint,&#148; evaluation of methylation patterns can enable the
determination of a cancer signal origin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nucleic acids, including tumor DNA and its methylation patterns, can shed from cells into the
bloodstream. Short DNA fragments in the blood are known as cfDNA and come from nearly all cell types in the body, including normal cells, diseased cells, cancerous cells, microbes such as parasites, bacteria, and viruses, and, in pregnant women, the
placenta. The cfDNA fragments shed into the blood can be sequenced, and their exact sequences and methylation patterns can be used to identify disease and to determine the location from which they originated. When a person has cancer, the DNA from
cancerous cells circulate as part of the blood plasma. Cancerous tumor DNA in the blood is specifically referred to as circulating tumor DNA (&#147;ctDNA&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability to sequence cfDNA from blood allows for a direct interrogation of methylation patterns that are shared by many types of cancer. To
successfully develop cfDNA sequencing technology into an effective, highly-specific MCED test, we had to overcome a number of technical, biological, and clinical challenges. Due to the very small amount of ctDNA present in a blood sample, the
sequencing assay must achieve a sufficiently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
LoD to capture signals that are derived from a tumor versus those from healthy cells in the body, and be able to distinguish this signal from noise in a population of asymptomatic individuals
with other confounding conditions and circulating DNA from normal cells.<I> </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Proprietary Methylation Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a targeted methylation platform, comprising wet lab workflows and machine learning algorithms, to recognize a shared cancer
signal by efficiently interrogating over one million methylation sites on DNA fragments found in blood. We leveraged our methylation platform to produce our first MCED test, Galleri. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We invested heavily to develop our methylation platform and have built what we believe is an unprecedented longitudinal dataset of
high-quality, linked clinical and genomic data. Our proprietary wet lab procedures enable a rich retention of DNA signal in our bisulfite sequencing process, and are designed to optimize the processing of data and improve the quality of our assays.
Investments in scalable data management infrastructure enable collection, management, and integration of data from our population-scale clinical program. Sophisticated machine learning algorithms efficiently analyze these extremely large data sets
and differentiate cancer signal from technical and biological noise. Our algorithms learn from the growing aggregate data set over time and derive biological insights that we believe will enable both product improvements and new product development
over time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Unbiased Discovery Approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To identify the most effective way of detecting cancer signals in the blood, we took a comprehensive and unbiased discovery approach to
evaluate multiple next-generation sequencing (&#147;NGS&#148;) prototype assays. We designed our CCGA study to characterize the range of genomic signals in the blood of people with and without cancer. Our goal was to develop and evaluate
computational models to distinguish cancer cfDNA from <FONT STYLE="white-space:nowrap">non-cancer</FONT> cfDNA and to develop machine learning algorithms to identify and localize the cancer signal within the body. Notably, the <FONT
STYLE="white-space:nowrap">non-cancer</FONT> participants included individuals with varied age, sex, ethnicity, cancer risk factors such as smoking status, and body mass index and comorbid conditions, increasing the generalizability of this study.
This study led to the development, refinement, and clinical validation of our targeted methylation platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed multiple
prototype assays to identify and measure a wide variety of cancer genome signals that are found in cfDNA. Our prototype assays used targeted sequencing to measure single nucleotide variants (&#147;SNV&#148;) and small variants to evaluate
cancer-derived mutations (with and without white blood cell (&#147;WBC&#148;) noise removal); whole-genome (&#147;WG&#148;) sequencing to analyze somatic copy number alterations (&#147;SCNA&#148;) and fragment features such as length and endpoint;
and whole-genome bisulfite sequencing (&#147;WGBS&#148;) to identify methylation patterns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We demonstrated that a WGBS approach to characterizing methylation patterns performed as well
or better than the other approaches we tested, either as standalone or in combination, and showed the most potential for further optimization. We found that the methylation signatures were shared across more than 50 cancer types. Additionally, the
methylation assay performed better to determine the cancer signal origin. After comprehensive analysis of whole-genome methylation patterns, we discovered highly informative and low noise methylation regions for cancer signal detection and
localization. Based on these results, a more efficient version of our methylation technology was advanced into further development, using a targeted methylation approach that had superior performance and lower costs compared to WGBS methylation. The
graphic below shows that our targeted methylation assay had a LoD of approximately 100 parts per million (&#147;PPM&#148;) which is significantly lower than other NGS approaches we assessed. LoD is the tumor fraction (or the estimated fraction of
tumor genomes in a cfDNA sample) at which the probability of detecting the cancer is at least 50%. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the performance advantage of ctDNA methylation is largely due to its biological characteristics,
which make it more robust at the low <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> ratios inherent in cfDNA. In contrast to typical cancer mutations that only affect a handful of genomic locations,
there are nearly 30&nbsp;million methylation sites across the human genome, making them a ubiquitous and rich signal for detecting cancer. When localizing cancer signal origin, methylation signals inherently reflect tissue differentiation and
malignant cancer states which makes them significantly more informative than other approaches we tested. Data describing our CCGA discovery approach was published in <I>Cancer Cell</I> in 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Methylation-based Platform is Highly-Differentiated &#150; Technology Advantages and
Validated Performance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our targeted methylation approach is differentiated from other blood-based detection
technologies. Whole-genome methylation from cfDNA used in our prototype MCED test performed strongly with respect to cancer signal detection and cancer signal origin prediction, without requiring additional sequencing to correct for the high
background noise due to DNA from WBCs. Importantly, subsequent technology improvements led to our development of the targeted methylation approach that has superior performance and lower costs compared to whole-genome methylation. These performance
improvements (specificity, sensitivity, and cancer signal origin prediction accuracy) were recently reported in large-scale clinical validations studies, CCGA and PATHFINDER, which supported the commercial launch of Galleri. We continue to learn
from our clinical studies and apply these learnings to our methylation platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our studies, methylation outperformed WGS and
targeted sequencing in cancer detection and cancer signal origin for a number of reasons. First, methylation is more pervasive compared with the mutation sites&nbsp;typically interrogated in traditional liquid biopsy approaches. Our targeted
methylation approach interrogates approximately one&nbsp;million informative sites of cytosine and guanine separated by a phosphate group (&#147;CpG sites&#148;) out of the roughly 30&nbsp;million CpG sites across the genome.&nbsp;We identified
these 1&nbsp;million CpG sites as the most informative regions for cancer signal detection and cancer signal origin prediction. This allows deeper sequencing of those informative regions compared with WGBS and may overcome expected cost and
efficiency limitations of WGS or WGBS approaches. Second, although WGS detected cancer at high tumor fractions, it had a worse limit of detection than a methylation-based approach.&nbsp;Targeted sequencing for mutation detection was also subject to
highly prevalent mutations present in individuals due to other biological processes and aging.&nbsp;As such, unlike methylation, targeted sequencing required concurrent WBC sequencing to achieve strong performance. Finally, epigenetic signals
inherently reflect tissue differentiation and malignant cancer states; this likely contributes to the strong cancer detection and cancer signal origin classification. Importantly, we found there was little to no value in combining approaches to
improve clinical LoD or sensitivity above WGBS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Clinical Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have built what we believe is one of the largest clinical programs in genomic medicine, which has generated what we believe is an
unprecedented longitudinal dataset of high-quality, linked clinical and genomic data. To date, we have enrolled more than 300,000 participants in numerous population-scale, prospective, multi-center clinical studies, with more than 21,000 of these
participants included in the studies that supported the development and launch of Galleri, and over 165,000 individuals enrolled in interventional studies (NHS Galleri and PATHFINDER 2) to support our PMA submission. Additionally, we announced plans
for a 100,000 individual real world study in the Medicare population. Our studies have supported the development of our methylation platform, Galleri, and are facilitating the development of DAC. These foundational population-scale studies involve
partnerships with numerous leading academic and cancer institutions and large community networks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our studies include the collection of
blood and, as available and as directed by the protocol, tissue samples, demographic data, patient-reported outcomes data, and clinical data from participants. Clinical information, demographics, and medical data relevant to cancer status are
collected from participants at time of enrollment and at regular intervals during a <FONT STYLE="white-space:nowrap">follow-up</FONT> period. We integrate this information with the genomic data created from sequencing the samples and utilize these
data to both train and validate our early cancer detection tests. Importantly, these are longitudinal studies and, in many cases, participant medical data will continue accruing for a number of years, facilitating analyses of longer-term outcomes,
and further performance improvements of our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical studies are summarized in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were the first to invest in and initiate multiple, large clinical validation studies for multi-cancer
early detection. Results from PATHFINDER, our first completed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">return-of-results</FONT></FONT> study, provided critical data to support launch of Galleri and understand how clinicians
implement Galleri into care pathways in clinical practice. We have completed enrollment in five additional studies: <FONT STYLE="white-space:nowrap">NHS-Galleri,</FONT> Circulating Cell-free Genome Atlas (&#147;CCGA&#148;), SUMMIT, STRIVE, and
SYMPLIFY. We are actively enrolling two studies: PATHFINDER 2 and REFLECTION, and will begin enrollment in our Galleri-Medicare Study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have presented data and published results from our clinical studies in leading forums, including multiple major medical conferences, such
as AACR, ASCO, and ESMO, and leading journals, such as <I>The Lancet</I>,<I> Nature</I>,<I> Nature Medicine</I>,<I> Cancer Cell</I>, and<I> The Lancet Oncology</I>. Data from our studies is expected to support regulatory filings as we pursue PMA
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Importantly, our clinical program was designed to enable test development for a diverse population, and enrollment was managed
to enable diversity across multiple characteristics including diversity in behaviors (such as smoking), <FONT STYLE="white-space:nowrap">non-cancer</FONT> diseases, environmental exposures, age, gender, race, ethnicity, socio-economic status, and
other confounding indications and differences. Understanding and cataloging this diversity has enabled us to develop tests with high-specificity, cancer signal detection across many cancer types, and accurate cancer signal origin prediction.
Long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> in the studies we have launched in years past will continue to yield critical data that we believe can help define the standard of care in early cancer detection. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, NHS England selected us to assist with the United Kingdom&#146;s ambitions for early cancer detection and to assess Galleri for
potential population screening on a national scale. In 2021, we initiated the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, a fully enrolled prospective randomized controlled clinical utility trial of approximately 140,000 participants
between the ages of 50 and 77 at the time of enrollment, to evaluate the implementation of Galleri alongside the existing NHS standard of care screenings. The <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial is being conducted pursuant to
an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> investigational device exemption (&#147;IDE&#148;) application. The primary objective of the trial is to assess whether implementation of Galleri can reduce the incidence of late-stage cancers
through early cancer detection. Secondary objectives include collecting outcomes reported by participants with a cancer signal detected test over several timepoints. These outcomes include an assessment of participants&#146; anxiety, satisfaction
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with Galleri, and attitudes regarding standard of care screening. The trial aimed to enroll a representative population sample to promote health equity and was fully enrolled in just over 10
months. Results of an early analysis from the first screening test (the prevalent screening round) representing one year of results out of the three-year trial period are expected to be reviewed by the NHS in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and final results from the trial are expected to be available
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We seek to use data from the <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, together with data from our PATHFINDER 2 study, as well as
supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trial is
designed for participants to provide three blood draws over a two-year period, with the first draw taken at enrollment. As a randomized controlled trial, half of the trial participants will receive the Galleri test, and half will have their blood
sample stored for future analysis. Any participant in the interventional arm with a cancer signal detected result will be sent for further diagnostic workup with the NHS. All other participants and their physicians remain blinded as to which arm of
the study they are in. The second round of blood draws was completed in July 2023, with over 91% retention of participants from the first round. The final round of blood draws commenced in September 2023 and is expected to conclude in July 2024.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial is summarized in the figure below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PATHFINDER 2 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PATHFINDER 2 is a prospective, multi-center, interventional study evaluating the safety and performance of Galleri in a population of
individuals aged 50 years and older who are eligible for guideline-recommended cancer screening in the United States. We began enrolling PATHFINDER 2 in December 2021, and the study is expected to enroll approximately 35,000 participants at up to 40
clinical institutions in North America. PATHFINDER 2 is being conducted pursuant to an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> IDE application. The primary objectives of the study are to evaluate the safety of Galleri based on the
number and type of diagnostic procedures performed in participants who receive a cancer signal detected but do not receive a cancer diagnosis (<I>i.e.</I>, false positive) and to evaluate the performance of Galleri across various measures, including
PPV, NPV, sensitivity, specificity, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancer signal origin prediction accuracy, among others. Participants who receive a cancer signal detected result undergo additional diagnostic testing based on the predicted cancer signal origin
to confirm if the participant does in fact have cancer. Secondary objectives include, among others, collecting outcomes reported by participants over several timepoints, including an assessment of participants&#146; anxiety, satisfaction with
Galleri, and attitudes regarding standard of care screening. Timepoints for collection will include baseline measurement prior to testing, post-results, and post-diagnostic resolution for positive test results. Interim results from the study are
expected to be announced in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We seek to use data from the PATHFINDER 2 study, together with data from the
<FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, as well as supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of our PATHFINDER 2 study is summarized in the figure below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PATHFINDER </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we initiated PATHFINDER, a prospective, multi-center, interventional study evaluating an earlier version of Galleri in
clinical practice. The study enrolled 6,662 participants across several health systems in the United States, and evaluated the safety and performance of this earlier version of Galleri in a population of individuals aged 50 years and older divided
into two cohorts: participants with elevated cancer risk and participants with <FONT STYLE="white-space:nowrap">non-elevated</FONT> cancer risk. PATHFINDER was our first study that returned test results to physicians and participants, and evaluated
how these test results affected diagnostic and care pathways in a screening population. PATHFINDER was conducted pursuant to an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> IDE application involving an earlier version of Galleri. Over the
course of the study, we made refinements to the test to reduce the detection of <FONT STYLE="white-space:nowrap">pre-malignant</FONT> hematologic conditions, which are relatively common. Results for the study are reported for both the earlier and
refined versions of the test. Initial results from the PATHFINDER study were presented at ESMO in 2022, and full results were published in <I>The Lancet</I> in October 2023. These data, in conjunction with the results from our CCGA study, supported
our launch of Galleri as a laboratory developed test (&#147;LDT&#148;) in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the study, when added to current standard
of care screening, Galleri more than doubled the number of cancers detected from screening. Study results showed that 71% (25/35) of participants that received a cancer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signal detected from our MCED test result had types of cancer detected that have no routine cancer screening available. Among participants who received a cancer signal detected result and had a
confirmed new cancer diagnosis (true positive), nearly half (48%) of the <FONT STYLE="white-space:nowrap">non-recurrent</FONT> cancers were detected at an early stage (Stage I or II). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patients with a cancer signal detected result, the predicted cancer signal origin directed diagnostic workups and helped to resolve cancer
diagnosis in less than three months (median 79 days) for most participants (73%), and in less than two months (57 days) for patients with true positive results. As expected, the median time to diagnostic resolution was longer for false positive
results (162 days), with 44% of these participants scheduling <FONT STYLE="white-space:nowrap">follow-up</FONT> imaging or procedures three or more months later, contributing to the longer time to resolution. Notably, approximately 80% of
participants with a cancer signal detected result achieved a diagnostic resolution based on the first cancer signal origin-directed workup. This group of 32 participants consisted of only those who received a cancer signal detected result from both
Galleri and an earlier version of our MCED test also being studied in PATHFINDER. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Study results with the earlier version of the test
showed a high PPV of approximately 38%, high cancer signal origin prediction accuracy of approximately 97%, and the test detected 36 cancer cases in 35 patients out of 6,621 participants with analyzable results. A pre-specified retrospective <FONT
STYLE="white-space:nowrap">re-analysis</FONT> of samples with the refined version of the test showed a higher PPV of approximately 43%, which is consistent with our CCGA study, and high cancer signal origin prediction accuracy of approximately 88%.
Specificity was 99.1% with the earlier version of the test and 99.5% with the refined version of the test, resulting in a false positive rate of less than 1% for both versions of the test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of our PATHFINDER study is summarized in the figure below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Circulating Cell-free Genome Atlas Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CCGA is our foundational observational, case-controlled study with planned five years of longitudinal
<FONT STYLE="white-space:nowrap">follow-up.</FONT> The study was used to discover, train, and validate Galleri, and was used alongside the SYMPLIFY study to analyze performance in the symptomatic patient population to support our DAC offering. The
CCGA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
study enrolled 15,254 participants, 56% of which had newly diagnosed cancer, inclusive of both early- and late-stage disease, and 44% of which did not have a known cancer diagnosis at the time of
enrollment. We completed enrollment of our CCGA study in February 2019, and <FONT STYLE="white-space:nowrap">follow-up</FONT> with participants is ongoing and expected to continue until 2024. The results of CCGA, in conjunction with the results from
our PATHFINDER study, supported our launch of Galleri as an LDT in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The goals of CCGA included the development and
evaluation of classifiers to distinguish cancer cfDNA from <FONT STYLE="white-space:nowrap">non-cancer</FONT> cfDNA and the identification of classifiers for the cfDNA prediction of cancer signal origin. By enrolling people with and without cancer,
we are able to characterize cfDNA profiles by tumor type and tumor stage in participants with cancer, and can compare these signals to participants without cancer. In addition, understanding the signals associated with population diversity is
important to our ability to account for biological noise and develop high-specificity tests. For example, our machine learning algorithms are trained to distinguish patterns of cancer from technical and biological noise, which is necessary to
distinguish cancer cfDNA from other cfDNA signals that are indicative of <FONT STYLE="white-space:nowrap">non-cancerous</FONT> conditions but that may be confused with a cancer signal. As a result, we enrolled participants with confounding
indications across broad populations, and individuals with varied age, sex, cancer risk factors such as smoking status, body mass index and comorbid conditions, to increase the generalizability of this population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluated data from the CCGA study in three <FONT STYLE="white-space:nowrap">pre-specified</FONT>
<FONT STYLE="white-space:nowrap">sub-studies,</FONT> each as described in more detail below. The design of our CCGA study, including the three <FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">sub-studies,</FONT>
is summarized in the figure below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">CCGA-1</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <FONT STYLE="white-space:nowrap">CCGA-1,</FONT> our first CCGA <FONT STYLE="white-space:nowrap">sub-study</FONT> of approximately 2,800
participants, we investigated various comprehensive cfDNA-based approaches for the detection of cancer signals and the prediction of the cancer signal origin, including through targeted sequencing to analyze single nucleotide variants and small
insertions and deletions; WGS to analyze copy number variations, fragment lengths, fragment endpoints, and allelic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
imbalance; and WGBS to analyze methylation patterns. The data demonstrated that WGBS (the methylation-based assay studied) performed as well or better than the other prototype assays we tested,
either alone or in combination, at both cancer signal detection and cancer signal origin prediction. After comprehensive analysis of these whole-genome methylation patterns, we discovered highly informative and low-noise methylation regions for
cancer signal detection and cancer signal origin prediction, suggesting that the methylation-based assay also had the most room for efficiency improvements. Based on these results, our methylation technology was advanced into further development,
ultimately resulting in a targeted methylation approach that had superior performance and lower costs compared to whole-genome methylation. Data from this <FONT STYLE="white-space:nowrap">sub-study</FONT> were shared in several oral and poster
presentations at multiple major medical conferences, including at AACR, ASCO, and ESMO, and were published in <I>Cancer Cell</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">CCGA-2</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of the <FONT STYLE="white-space:nowrap">CCGA-2</FONT> <FONT
STYLE="white-space:nowrap">sub-study</FONT> was to train and validate a classifier for cancer detection versus <FONT STYLE="white-space:nowrap">non-cancer</FONT> detection, and cancer signal origin prediction, utilizing our targeted methylation
assay. This <FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">sub-study</FONT> included approximately 6,700 total participants across training and validation sets, with 4,487 participants from CCGA and 2,202 from
STRIVE. Of the total participants, 2,482 participants had previously untreated cancers and 4,207 participants did not have cancer. More than 50 types of cancer across all clinical stages were represented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from the <FONT STYLE="white-space:nowrap">CCGA-2</FONT> <FONT STYLE="white-space:nowrap">sub-study</FONT> were published in the
<I>Annals of Oncology </I>in March 2020 (and reflected on the cover) and demonstrated that Galleri could detect a shared cancer signal across more than 50 different types of cancer, including many types of cancer that do not have recommended
screenings, from a simple blood draw with very high specificity. Data was evaluated in both training and test sets, and performance was comparable across the two analyses. At greater than 99% specificity, Stage
<FONT STYLE="white-space:nowrap">I-III</FONT> sensitivity for a <FONT STYLE="white-space:nowrap">pre-specified</FONT> set of 12 deadly types of cancer, which together account for approximately 63% of cancer deaths in the United States annually, was
approximately 67% and for all cancers was approximately 55%. The cancer signal origin prediction was correct in more than 90% of true positive test results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">CCGA-3</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CCGA-3,</FONT> our third CCGA <FONT STYLE="white-space:nowrap">sub-study,</FONT> was designed to further
validate a version of the MCED test refined for use as a screening tool (Galleri) in a large cohort of participants with and without cancer. This <FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">sub-study</FONT>
included 4,077 participants in an independent validation set (2,823 had cancer and 1,254 did not have cancer). Specificity, sensitivity, and cancer signal origin prediction accuracy were measured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results of the <FONT STYLE="white-space:nowrap">CCGA-3</FONT> <FONT STYLE="white-space:nowrap">sub-study</FONT> were published in the
<I>Annals of Oncology</I> in June of 2021, and confirmed that Galleri detects a shared cancer signal across more than 50 different types of cancer. Specificity for cancer signal detection was 99.5%. Stage
<FONT STYLE="white-space:nowrap">I-III</FONT> sensitivity for a <FONT STYLE="white-space:nowrap">pre-specified</FONT> set of 12 deadly types of cancer, which together account for approximately 63% of cancer deaths in the United States annually, was
approximately 68% and for all cancers was approximately 41%. The overall sensitivity for cancer signal detection was 52%. As expected, and as previously observed, sensitivity increased with stage (stage I: 16.8%, stage II: 40.4%, stage III: 77.0%,
stage IV: 90.1%). The cancer signal origin prediction was correct in approximately 89% of true positive test results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>STRIVE
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">STRIVE is a prospective, observational, longitudinal cohort study in the United States that enrolled 99,481 women without a known
cancer at the time of enrollment. Samples from a subset of women will be used to help further validate Galleri in an asymptomatic and intended use population. This study was initiated in February 2017 and completed enrollment in November 2018. Each
participant had a blood draw at the time of their regular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
screening mammogram. Participants diagnosed with any type of cancer had additional blood draws. Participants were followed for 30 months and thereafter, if they developed cancer, through state
and national cancer registries. We collected demographic information, such as age, race, and ethnicity, in addition to clinical information, such as cancer diagnoses, treatment, cancer-specific mortality, and overall survival. We utilized 2,202
samples for validation of an earlier version of Galleri and used 4,891 samples in a training set to support the version of Galleri we launched as an LDT. We have not used other samples to analyze or validate performance in an asymptomatic and
intended use population to date, and thus we have not reported any interim findings or results from STRIVE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>SUMMIT </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUMMIT is a prospective, observational, longitudinal cohort study that is being conducted in and around London, United Kingdom. The study is
designed to further validate Galleri as an MCED test, including for lung and other smoking-related cancers, and to assess the feasibility of <FONT STYLE="white-space:nowrap">low-dose</FONT> computed tomography (&#147;LDCT&#148;) lung cancer
screening in the United Kingdom. The study enrolled 13,035 men and women between the ages of 50 and 77 who did not have a cancer diagnosis at the time of enrollment. Participants in the study are individuals at high risk for lung cancer due to
significant smoking history based on validated risk scores. Participants provided three serial (annual) blood draws and are being followed annually for three years and then for a further five years through national health registries as well as
medical records. The primary objective is to measure cancer incidence, which will be used to assess the test performance for sensitivity, specificity, PPV, and NPV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SUMMIT study may also demonstrate the utility of MCED testing in a high-risk population by comparing performance of Galleri in detecting
lung and other smoking-related cancers to that of LDCT. We expect to report interim results from the SUMMIT study in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>REFLECTION </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">REFLECTION is a multi-center, prospective, observational cohort study of patients administered Galleri as part of their medical care in a
real-world setting in the United States that will enroll approximately 17,000 individuals. The purpose of the study is to evaluate and understand the real-world experience with Galleri in clinical settings. The objectives of the study are to
describe cancer signal detection and cancer signal origin prediction within and across sites among participants who opt to receive Galleri in a real-world setting, to assess the feasibility and acceptability of Galleri from the perspective of
participants and patient-reported outcomes, and to assess healthcare resource utilization associated with diagnostic workups for participants that receive a cancer signal detected result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began enrolling the REFLECTION study August 2021 and enrollment is ongoing at all sites. We expect that data will be generated over time as
enrollment increases across sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of our REFLECTION study is summarized in the figure below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>SYMPLIFY </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SYMPLIFY evaluated the performance of MCED in symptomatic patients in the United Kingdom that were referred from the primary care setting due
to clinical suspicion of cancer. This patient population represents a distinct patient population from Galleri&#146;s targeted asymptomatic screening population. The SYMPLIFY study enrolled 6,238 participants aged 18 years and older in England and
Wales. Participants were referred for urgent imaging, endoscopy or other diagnostic modalities to investigate symptoms suspicious for possible gynecological, lung, lower GI or upper GI cancer, or who presented with
<FONT STYLE="white-space:nowrap">non-specific</FONT> symptoms. The most commonly reported symptoms leading to referral were unexpected weight loss (24.1%), change in bowel habit (22.0%), post-menopausal bleeding (16.0%), rectal bleeding (15.7%),
abdominal pain (14.5%), pain (10.6%), difficulty swallowing (8.8%), and anemia (7.1%). In the study, the MCED test&#146;s cancer signal detected and cancer signal origin prediction results were compared with diagnoses results obtained through
standard of care pathways. Data from the study demonstrated strong performance in this symptomatic population, and supported the feasibility of using an MCED test to assist clinicians with decisions regarding referrals from primary care. Data from
the SYMPLIFY study were presented at ASCO in 2023 (in a podium presentation) and published in <I>The Lancet Oncology</I>, and we are using the results to support the development and launch of DAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the study, 368 (6.7%) of the 5,461 evaluable patients were diagnosed with cancer through standard of care pathways. The most common cancer
diagnoses were colorectal (37.2%), lung (22.0%), uterine (8.2%), oesophago-gastric (6.0%) and ovarian (3.8%). Our test detected a cancer signal in 323 participants, and cancer was diagnosed in 244 of these participants. The test demonstrated a high
PPV of approximately 75%, NPV of approximately 98%, sensitivity of approximately 66%, specificity of approximately 98%, and cancer signal origin prediction accuracy of approximately 91%. Among participants in the study, 6.7% of enrolled participants
were eventually diagnosed with cancer, having already been referred by their primary care physician for investigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The design of our SYMPLIFY study is summarized in the figure below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g556103g01a36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Established Commercial Leadership in a <FONT STYLE="white-space:nowrap">Pre-Reimbursement</FONT> Setting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched Galleri in the United States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold more
than 125,000 commercial tests and established over 100 commercial partnerships, including leading healthcare systems, employers, payors, and life insurance providers. We have also established a network of over 8,000 prescribers in the <FONT
STYLE="white-space:nowrap">pre-reimbursement</FONT> setting, with prescribers in private practices across the United States. As of September&nbsp;30, 2023, our commercial organization included 385 personnel supporting our multi-channel strategy. We
continue to build the key components of our commercial infrastructure and capabilities that are required to support rapid, population-scale testing in a post-reimbursement environment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Commercial Strategy in the United States is Focused on Innovative Value-oriented Partnerships </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strong commercial adoption is underpinned by our ability to demonstrate clinical utility and economic value even before obtaining broad
reimbursement coverage. We are driving adoption in the following key channels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Health systems</B>. We have partnered with over 40 health systems as of September&nbsp;30, 2023 that offer
Galleri, typically as part of a comprehensive screening program with patient and physician support services. We believe many of these health systems view Galleri as a key differentiating offering to patients. We have streamlined the implementation
of Galleri for these partners, often connecting the health system&#146;s electronic medical record system with our software systems. This bolsters our position as the partner of choice for establishing early cancer detection programs. Many health
systems are investing in robust programs in population health management and precision medicine, of which Galleri is a key feature, and have developed novel care navigation pathways. With these novel pathways, a positive test result can result in
patients being referred within the health system. We believe our experience with these partners will allow us to rapidly scale upon broad reimbursement for Galleri. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Employers</B>. As of September&nbsp;30, 2023, we have engaged over 70 employers who offer Galleri as a benefit
to eligible employees. We target medium and large self-insured employers with compelling and innovative healthcare offerings that are designed to attract and retain employees and to deepen health equity among employees. Cancer treatment costs now
represent the highest spend category for self-insured employers according to the most recent Business Group on Health&#146;s 2023 Large Employers&#146; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Health Care Strategy and Plan Design Survey. Galleri offers earlier cancer detection to help reduce these costs. Our employer customer base includes large tech companies, large life insurance
companies, professional services companies, major health systems, and educational institutions, among others. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Life insurance providers</B>. We have partnered with several leading life insurance providers to provide
Galleri to their policyholders. Life insurers are committed to helping customers live longer, healthier, better lives and understand that preventative care and early detection are key to that mission. Galleri is offered by these providers as a
preventative health benefit and is not used for underwriting, risk assessment or risk pooling. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Physician-directed channels</B>. We believe Galleri is compelling to physicians whose patients are focused on
preventive health and wellness as well as to concierge and executive health practices. The physician practices we are targeting are known to offer innovative, cutting-edge health offerings, and market research suggests the members are willing to
invest in differentiated healthcare services. We are targeting physicians serving this market segment in all major metropolitan population centers in the United States with our field-based sales team. Concierge medicine has been a key early adopter
of Galleri. As our strategy evolves in the physician-directed channel, we are working to educate physicians and patients on the benefits of annual screening. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Payors</B>. We have announced pilot or benefit programs with leading payors and continue to engage with other
progressive payors. These programs allow for measurement of the clinical utility and economic value of Galleri. These payors include Medicare Advantage plans, which generally must cover all of the services that traditional Medicare covers, but they
have the discretion to offer their enrollees additional or supplemental benefits. This also includes early-adopting commercial payors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Firefighters</B>. We have worked with clinics, fire departments, municipalities, and unions to make Galleri
available to firefighters who generally have exposure-related increased risk of cancer and are actively screening their populations and seeking new approaches. To date, thousands of firefighters have been tested with Galleri across more than 40 fire
departments nationally. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement Landscape for Screening Tests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>United States </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicare generally does not cover screening tests, which are considered preventive services, that are performed in the absence of signs or symptoms of
illness or injury, unless there is a statutory provision that explicitly authorizes coverage of the test. The Medicare Improvements for Patients and Providers Act of 2008 authorizes the Centers for Medicare and Medicaid Services (&#147;CMS&#148;) to
cover additional preventive services that are not expressly covered by the statute if the service is (a)&nbsp;reasonable and necessary for the prevention or early detection of an illness or disability, (b)&nbsp;recommended with a grade of A or B by
the USPSTF, an independent, volunteer panel of experts in the field of prevention, evidence-based medicine and primary care, and (c)&nbsp;appropriate for Medicare beneficiaries under Part A or Part B. CMS establishes coverage through a national
coverage determination (&#147;NCD&#148;) process. In its discretion, the USPSTF generally waits for FDA authorization before it considers undertaking reviews of novel technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because MCED is not expressly authorized for coverage by the Medicare statute, one possible pathway for Medicare reimbursement is to first
obtain FDA approval and then obtain a grade of A or B recommendation from USPSTF, to enable CMS to issue an NCD. The last cancer screening test to receive a recommendation from USPSTF with a grade A/B and obtain Medicare coverage was LDCT to screen
high-risk smokers for lung cancer in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare coverage can also be changed by statute, thus a second possible pathway for Medicare
reimbursement would be to amend the Medicare statute to cover MCED. This process would generally require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
new legislation to expressly authorize CMS to cover <FONT STYLE="white-space:nowrap">FDA-approved</FONT> early cancer screening and detection tests. We are working with stakeholders to advance
and shape the public reimbursement landscape to reflect that additional scope of coverage. Galleri is currently offered as an LDT in our <FONT STYLE="white-space:nowrap">CAP-accredited</FONT> and CLIA-certified laboratories. We have a Breakthrough
Device designation with the FDA and have begun the modular PMA submission process, which we expect to conclude with data from our ongoing pivotal studies. Under our Breakthrough Designation, interactions with the FDA have resulted in a clear
timeline to submission, which we anticipate making in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Following FDA approval and assuming a statutory change in the reimbursement landscape, we plan to
pursue broad reimbursement, for example, through Medicare reimbursement, and subsequently pursue inclusion of Galleri in the USPSTF guideline recommendation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>United Kingdom&#151;Commercial agreement with NHS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, we established a partnership with NHS England. The <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial, which was
undertaken as part of the partnership established by our commercial agreement with NHS England, is a large randomized controlled trial taking place across eight regions in England. The trial aims to assist with the United Kingdom&#146;s ambitions
for early cancer detection and to assess Galleri for potential population screening on a national scale. The primary objective of the trial is to assess whether implementation of Galleri can reduce the incidence of late-stage cancers through early
cancer detection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to results of an early analysis from the first screening test (the prevalent screening round) representing one
year of results out of the three-year trial period, the NHS may commence phased commercial implementation in England, beginning with a two-year pilot, and with the potential for further expansion subject to final results from the trial. In the event
that we proceed with phased commercial implementation following such results, our partnership with the NHS would be our first national system implementation. Given that the NHS has a reputation for high evidence standards for new technologies, we
expect NHS approval and implementation would expand adoption in the United Kingdom and could also facilitate adoption in other single payor systems around the world. The Galleri test is UKCA marked. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Other International </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
intend to explore the launch of Galleri in select other geographies, including through distributors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Significant Investments for Scale </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have made significant investments for scale in our <FONT STYLE="white-space:nowrap">CAP-accredited</FONT> and CLIA-certified laboratory
facilities in Menlo Park, California and Durham, North Carolina and demonstrated execution with more than 350,000 clinical and commercial individual samples processed through September&nbsp;30, 2023. We have an established footprint in the United
States and United Kingdom, with operations in Durham, North Carolina, Washington, D.C., and London, United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In total we have
approximately 65,000 square feet of <FONT STYLE="white-space:nowrap">CAP-accredited,</FONT> CLIA-certified laboratory space and laboratory support with sufficient capacity to support multiple years of growth. We have made significant investments to
our Durham laboratory to improve the automation, including development of a fully automated laboratory testing platform consisting of robotic work cells connected by a central track system to increase efficiencies and reduce costs. Our lab operates
16&nbsp;hours a day, seven days a week, and uses automation and other technology to reduce staff exposure to complicated, dangerous, repetitive, or injury-prone work. We believe that our current facilities are sufficient to meet our current and
anticipated near-term needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Supply Chain and Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our supply chain includes industry leading vendors and we maintain significant supplies on hand of both laboratory consumables and other
materials to avoid work stoppages and material delays. We rely on a limited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of suppliers, or in some cases, sole suppliers, to provide certain materials for our products and services. For example, Illumina, Inc. is our primary supplier of sequencers and certain
laboratory reagents, Madison (who acquired our blood collection tube manufacturer Streck, Inc. in 2023) is our sole supplier of tubes used for sample collection and Twist is the sole supplier of our DNA probes. We rely on standard commercial
carriers for the delivery of samples to our laboratories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our supply strategy is to maintain raw material and released reagent supplies
at levels that ensure our clinical laboratories can maintain continuous operations 365 days a year. We utilize a risk-based approach such that higher risk materials (e.g, sole-sourced or more vulnerable supply chains) have a higher safety stock and
lower risk materials (e.g, multi-sourced) may have lower safety stock levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into supply agreements with various
parties, including Illumina, Madison, and Twist. In January 2016, we entered into a supply and commercialization arrangement with Illumina, which agreement was amended and restated in February 2017 and subsequently further amended (&#147;Supply
Agreement&#148;). Pursuant to the Supply Agreement, Illumina granted us <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights to use certain Illumina <FONT STYLE="white-space:nowrap">know-how</FONT> and technology with Illumina products
purchased under the agreement. Under the terms of the Supply Agreement, regardless of whether our products incorporate any Illumina technology, we were obligated to pay Illumina a high single-digit royalty, subject to certain reductions, in
perpetuity on net sales generated by our products or revenues otherwise generated or received by us, subject to certain exceptions, in the field of oncology. In August 2021, following Illumina&#146;s acquisition of us, the Supply Agreement was
amended to suspend the perpetual royalty obligation to Illumina as long as we are an affiliate of Illumina or as long as any successor to us or any substantial part of our business is held by Illumina or an affiliate of Illumina. In connection with
our separation from Illumina via the Spin-Off, we will no longer be an affiliate of Illumina and the perpetual royalty obligation to Illumina will restart, without retroactive effect. In addition, at the time of the separation we may elect to have
either Illumina&#146;s universal pricing terms applicable to all of its for-profit oncology customers in the United States since March 2021, as updated (the &#147;Open Offer&#148;) or the pricing terms we had prior to Illumina&#146;s acquisition of
us (the &#147;Grandfathered Pricing&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry Participants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are other companies, such as Adela, Inc., DELFI Diagnostics, Inc., Exact Sciences Corporation, Freenome Inc., Guardant Health, Inc., and
Harbinger Health within the United States and AnchorDx, Anpac Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Datar Cancer Genetics, Elypta AB, Gene Solutions JSC, Singlera Genomics, Inc. and Seekin, Inc. outside of the United States,
among others, that are attempting to develop tests to detect certain types of cancer early, including some that will use cfDNA analyses. Some of these companies may have substantially greater financial and other resources than we have, such as
larger research and development staff and well-established marketing and sales forces, or may operate in jurisdictions where lower standards of evidence are required to bring products to market. For example, we are aware that some companies have
conducted large-scale clinical studies for single-cancer early detection tests, including Guardant Health, Inc., Exact Sciences Corporation and Freenome Inc. in colon cancer, as well as AnchorDX in lung cancer (pulmonary nodules). In addition, other
established diagnostic, medical technology, biotechnology, or pharmaceutical companies may decide in the future to invest to accelerate discovery and development of similar tests. If any tests are developed by these companies and do not perform to
expectations or cause harm or injury to patients, it may result in lower confidence in early cancer detection tests in general, which could potentially adversely affect confidence in our products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the numerous and rigorous requirements for a successful cancer detection test, we do not believe many companies would have the financial
resources to invest in population-scale clinical studies and rigorous analytics to compete with our products. Further, among companies pursuing an early-detection product, we believe we are substantially differentiated by our robust intellectual
property portfolio, extensive research, rigorous and objective approach, and multidisciplinary capabilities, which leverage the power of NGS, population-scale clinical studies, and advanced and trained machine learning algorithms and data science.
We believe we are further differentiated by the extent of our investment in our facilities and operational workflows, including our high-capacity laboratories, which we built for rapid, automatic processing of samples and to scale as we grow and
process more tests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, certain of our other products in development, such as DAC, and our precision
oncology offerings, could compete against a number of companies that are working to leverage blood-based technologies to improve cancer care. Many companies such as Roche&nbsp;/&nbsp;Foundation Medicine, Inc., Natera, Inc., Guardant, Inc., Tempus
Labs, Inc., Invitae Corp., NeoGenomics Laboratories, Personalis, Inc., Twist Bioscience Corp. and Adaptive Biotechnologies Corp., among others, currently provide or are developing technologies focused on improving cancer care after a diagnosis of
cancer is made, including enabling selection of therapy, monitoring of therapy, or detection of relapsed disease. Unlike with respect to MCED testing, precision oncology is a very competitive space with many industry participants. However, as DAC
and our precision oncology portfolio leverage our methylation platform, we believe we are differentiated by the extent of the quality of our methylation platform and our investments to develop such platform through our population-scale clinical
studies, rigorous analytics and machine learning expertise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain intellectual property protection for our products and technology, including
by seeking and maintaining patent protection, protecting our trade secrets and other proprietary information, obtaining and maintaining our licenses to use intellectual property owned by third parties, and continually evaluating third-party
technologies for further licensing opportunities. We also seek trademark protection where appropriate to protect the names that identify us as the source of our products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own certain patents, patent applications, and other intellectual property, and also exclusively license certain patents, patent
applications, and other intellectual property from third parties, including the Chinese University of Hong Kong. Our patent portfolio broadly relates to methods, techniques, systems, and chemistry used to generate and analyze data using our
proprietary bioinformatics and classifiers, including, for example, cfNA sequencing, marker panels, methylation signatures, bioinformatics techniques and biologically directed machine learning classifiers, which are incorporated into or used for
Galleri, our precision oncology portfolio, and DAC. We have also entered into certain supply and commercial agreements with various vendors and suppliers, including Illumina, under which we receive rights to their intellectual property for use in
our products. Our material licenses and other agreements are described in more detail below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, we have
exclusive licenses to more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued or granted patents and more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending patent applications globally, including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued U.S. patents and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patents granted in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> and provisional patent applications. We also own or <FONT STYLE="white-space:nowrap">co-own</FONT> more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued or granted patents and more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending patent applications globally, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued U.S.
patents and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patents granted in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> and provisional patent applications. Our patent portfolio includes at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patent families related to sequencing, library preparation and
enrichment (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patent families with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued or granted patents and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending applications), marker panels
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patent families with issued or granted patents and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending applications), methylation profiling (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
patent families with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued or granted patents and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending applications), and bioinformatic techniques and classifiers
(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patent families with &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; issued or granted patents and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pending applications), many of which we believe
cover, or will cover, various aspects of Galleri, DAC and our precision oncology portfolio. Our patent portfolio also includes granted patents and pending patent applications directed to other technologies, including, for example, error correction
for identifying somatic variants and variant based assessment of cancer, sequencing based assessment of copy number aberrations in cancer, fragment length assessment in cancer detection, fragmentation based assessment of cancer, viral based
assessment of cancer, multiomics for diagnostics, and lab platforms and automation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently facing oppositions from anonymous
challengers against two of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> European patents and one of our owned patents. None of these patents relate to aspects of Galleri, DAC or our precision oncology portfolio. The challengers are
asserting that these granted patents are invalid over prior art, among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other arguments. While we believe that these patents are valid as granted, there is a risk that one or more of these patents could be invalidated in its entirety, or certain claims of these
patents could be amended and narrowed in scope. These oppositions are at various stages of the adjudication process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, if issued as patents, expire or would be expected to expire, at the earliest, in 2028, absent any potentially available patent term adjustment and assuming our timely
payment of applicable issue fees, maintenance fees and annuities. The patent applications that we own, if issued as patents, would be expected to expire at the earliest in 2037, absent any potentially available patent term adjustment and assuming
our timely payment of applicable issue fees, maintenance fees and annuities. The term of these patents depends upon the laws of the countries in which they are obtained, and in most countries in which we file, is 20 years from the earliest date of
filing of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. A provisional patent application is not eligible to become an issued patent until, among other things, we file a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of the filing date of the provisional patent application. If we do not timely file <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent
applications, we may lose our priority date with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. In the United States, patent term adjustments may be
available depending upon the time the United States Patent and Trademark Office takes to examine and eventually issue a patent, and the patent term may be shorter than 20 years if we disclaim a portion of the patent term to overcome double patenting
rejections. The protection of patents may vary on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">claim-by-claim</FONT></FONT>
basis, which can vary the scope of protection afforded by such patents. In addition, we must generally pay fees to maintain our patents annually or at other specified intervals, or risk the patent lapsing. We cannot provide any assurance that any of
our current or future owned or licensed patent applications will result in the issuance of patents in any jurisdiction, or that any of our current or future owned or licensed issued patents will effectively protect any of our products or technology
or prevent others from commercializing competitive products or technology. Even if any of our current or future owned or licensed patent applications are granted as issued patents, those patents may be challenged, circumvented or invalidated by
third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreements with the Chinese University of Hong Kong </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into five license agreements with the Chinese University of Hong Kong, each on substantially similar terms and with two dated
April&nbsp;7, 2016 and three dated May&nbsp;29, 2017. Pursuant to these agreements, the Chinese University of Hong Kong has granted exclusive, worldwide intellectual property licenses to us for the use of certain nucleic acid sequencing and analysis
technologies in all fields under one license and in all fields except prenatal diagnostics, prognostications, or analysis under four licenses. The Chinese University of Hong Kong reserves the right to use its technology for internal research and
education purposes and for fulfilling governmental contractual obligations (to the extent they exist). Three of the licenses are subject to certain <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license rights granted by the Chinese
University of Hong Kong to a certain third party, solely for such third party&#146;s internal research purposes in the field of cancer detection, cancer prognostication and other analysis for the screening and management of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our products use the licensed technology, we are required to pay the Chinese University of Hong Kong low single-digit percentage
royalties on net sales of such products, subject to minimum annual guarantees, which began in 2018. In addition, for any sublicense of the licensed technology, we are obligated to pay the Chinese University of Hong Kong a specified portion of the
revenue we receive from sublicensing. Our royalty and sublicense payment obligations with respect to each license for each product containing any licensed technology extends until the expiration or termination of such license, which shall be the
later of a low double-digit number of years from our payment of the license issue fee or expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed patent. We are additionally obligated
to reimburse the Chinese University of Hong Kong for costs and expenses related to the filing, prosecution, maintenance, and defense of the licensed patents and patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these license agreements, we are obligated to use specified efforts to reach milestones relating to the development and sale of products
that use the Chinese University of Hong Kong&#146;s technology, and our failure to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
do so could result in termination of the license agreements. The Chinese University of Hong Kong may also terminate the agreements under certain other circumstances, such as our uncured material
breach of the agreements or cessation of our business. We may terminate the agreements at any time at our convenience, provided we give the Chinese University of Hong Kong a certain period of notice. We can also terminate the agreements for the
Chinese University of Hong Kong&#146;s uncured material breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trade Secrets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on trade secret protection for our confidential and proprietary information. Included in our trade secrets are the data from our
genomics studies, various aspects of the operation of our laboratories, and various aspects of the algorithms used to process our data. Trade secrets are difficult to protect. Although we take steps to protect our proprietary information and trade
secrets, including through contractual means with our employees, contractors, and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or
disclose our technology via unauthorized means, such as hacking by private or state actors. Although state and federal courts in the United States are generally willing to protect trade secrets, some courts inside and outside the United States are
less willing or unwilling to protect trade secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For further discussion of the risks relating to our intellectual property, see
&#147;Risk Factors&#151;Risks Related to Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal office and laboratory is approximately 74,300 square feet and located at 1525&nbsp;O&#146;Brien Drive, Menlo Park, California. We
amended the related lease in June 2017 to add approximately 57,400&nbsp;square feet at 1605&nbsp;Adams Drive, Menlo Park, California. Our lease expires in 2026 and we have an option to extend the lease for an additional five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we entered into an agreement to lease approximately 200,000 square feet of a building in Durham, North Carolina. Our lease
expires in 2033 and we have three separate options to extend the lease, each for an additional five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold CLIA Certificates of
Accreditation Registration from the CMS and accreditations from CAP for our laboratories in Menlo Park, California, and Durham, North Carolina, and a Clinical Laboratory Certificate of Deemed Status from the State of California Department of Public
Health. Our Menlo Park, California laboratory also holds a Clinical and Public Health Laboratory License from the California Department of Public Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our facilities are sufficient to meet our current and anticipated near-term needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023, we had&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full-time employees in the United States. We also engage with contractors, vendors, and consultants. We have invested
substantial time and resources into building our team. Our success depends in large part on our collective effort across our areas of expertise and across sites in Menlo Park, California, Durham, North Carolina, Washington, D.C., and London, United
Kingdom. Therefore, it is crucial that we continue to attract and retain high-performing employees from all demographics by providing competitive compensation and benefits, and fostering a diverse, inclusive, and safe workplace, while making
opportunities for all employees to grow and develop in their careers. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are guided by our mission to detect cancer early, when it can be cured. Since our
founding, we have built an entrepreneurial culture, driven to improve outcomes for cancer patients. We are led by a multidisciplinary team with extensive experience across biotechnology, life sciences, public health, genomics, computer science, data
science, biostatistics, clinical development, medical affairs, government and regulatory affairs, quality assurance, and laboratory and commercial operations. We believe this confluence of talent from multiple disciplines has enabled us to make
significant progress in improving cancer care and will enable us to remain at the forefront of our industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fostering a Culture of
Inclusivity and Belonging </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovation-driven company where diversity, inclusion, and equity are critical drivers to our
success. We embrace talent from all backgrounds, seek out diverse perspectives, and facilitate and invite open and authentic conversations. Our diverse employee pool includes expertise across the specialties that drive our business. As of
December&nbsp;31, 2023, our workforce was&nbsp;&nbsp;&nbsp;&nbsp;% racially/ethnically diverse and &nbsp;&nbsp;&nbsp;&nbsp;% female. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are investing in culture and creating opportunities to build community for our employees. We currently have six employee resource groups (&#147;ERGs&#148;), which are sponsored by members of our executive and senior leadership teams. ERGs are <FONT
STYLE="white-space:nowrap">employee-led</FONT> groups that can help create a more inclusive culture and amplify the voices of employees with shared identities and experiences across the company. We have invested in resources to educate our employees
on building an inclusive culture and on recognizing and managing bias. We also regularly survey employees on how effective our leadership has been in creating an equitable and inclusive workplace to discover new opportunities to build an inclusive
community. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our company culture helps us to achieve our mission and is a core driver of our success. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Embrace Change</U></I>&#151;We operate in a dynamic environment. We need to mirror the external world and
be agile, adaptive, and able to adjust course to move in the direction required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Solve Problems Together</U></I>&#151;Working together allows us to take on increasingly complex problems.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Think BIG</U></I>&#151;We are leading BIG changes that require a long runway, and we&#146;ll succeed by
keeping our mission in sight as we work toward long-term goals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Be Courageous</U></I>&#151;We are going up against entrenched ways of thinking, which requires boldness,
determination, and courage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Bring an Open Mind</U></I>&#151;We seek to improve cancer care, which requires engaging everyone in a
conversation around what&#146;s needed, what&#146;s possible, and how to approach problems in different ways with creative thinking. We&#146;re open-minded, curious, and always learning. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each value has defined behaviors that link to our leadership attributes and our programming to keep our values as the cornerstone for how we
show up with one another and support our customers. These values are embedded in our recruiting and hiring practices and performance management. We believe that our focus on our values helps support a culture of inclusivity and belonging. We operate
from a place of openness, taking initiative to drive our shared success, while seeking input in order to grow ourselves and our customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensating and Supporting Our Colleagues </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to providing equitable compensation opportunities to attract and retain accountable, team-oriented, high-performing colleagues
with the purpose of driving our mission. We consider external market data as well as internal parity considerations when making compensation decisions using data-informed actions to build desirable programs. To incentivize top performance, we aim to
differentiate pay increases and incentive programs in recognition of colleague contributions aligned to the success of the business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We take a holistic approach to supporting employee well-being through providing eligible
colleagues and their eligible dependents with competitive health and wellness benefits, retirement savings plans, and work-life options designed to provide flexibility to thrive. We also provide flexible time off and other opportunities to enable
balance. We are also devoted to investing in the development of our colleagues through learning and development opportunities to help them achieve their personal and professional goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to
complex and frequently changing national, state, and local laws and regulations that govern various aspects of our business. In many jurisdictions, including the United States, the clinical laboratory and medical device industries must operate in
accordance with extensive and complex legal standards, including laws and regulations related to certification, licensing, development, research, testing, manufacturing, laboratory operations, distribution, ordering and billing practices,
advertising, promotion, marketing, sales and pricing practices, <FONT STYLE="white-space:nowrap">anti-markup</FONT> practices, health information privacy and security, and consumer protection and unfair trade practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in some
instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Clinical laboratory tests are regulated under CLIA, as well as by applicable state laws. In addition, the Federal Food, Drug and Cosmetic Act
(&#147;FDC Act&#148;) defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, <I>in vitro</I> reagent, or other similar or related article, including a component part or accessory intended for use in
the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease in man or other animals. The tests we are developing and marketing are considered by the FDA to be subject to regulation as medical
devices. Among other things, pursuant to the FDC Act and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and
sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. The FDA has statutory authority to assure that medical devices are safe and
effective for their intended uses, but the FDA has historically exercised its enforcement discretion and not enforced certain applicable provisions of the FDC Act and regulations with respect to LDTs. However, the FDA recently issued a proposed rule
to phase out its enforcement discretion with respect to LDTs, which, if finalized, would make LDTs subject to the FDA&#146;s medical device authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Laboratory Improvement Amendments of 1988 (CLIA) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to obtain and hold certain federal and state licenses, certificates, permits and accreditations to offer our products in the
United States through our laboratory facilities in Menlo Park, California, and Durham, North Carolina. In 1988, Congress passed CLIA, establishing rigorous quality standards for laboratories in the United States that perform testing on human
specimens for the purpose of providing information for the diagnosis, prevention, or treatment of disease or impairment of, or the assessment of the health of, human beings. Such testing may also include procedures to determine, measure, or
otherwise describe the presence or absence of various substances or organisms in the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CLIA requires such laboratories to be
certified by the federal government and mandates compliance with ongoing requirements intended to ensure the accuracy, reliability, and timeliness of medical test results. CLIA certification is also a prerequisite to be eligible to bill federal and
state healthcare programs, as well as many commercial <FONT STYLE="white-space:nowrap">third-party</FONT> payors, for laboratory testing services. We hold CLIA Certificates of Accreditation from the CMS and accreditations from CAP for our Menlo
Park, California and Durham, North Carolina laboratories, and a Clinical Laboratory Certificate of Deemed Status from the State of California Department of Public Health. Our Menlo Park, California laboratory also holds a Clinical and Public Health
Laboratory License from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
California Department of Public Health. In order to obtain a CLIA certification, a laboratory must validate the test (ensure and document that the test provides accurate and reliable test
results) and add the applicable specialty or subspecialty to the test menu. Before introducing and reporting patient results from an LDT, a laboratory is required to establish the specifications for a variety of performance characteristics,
including accuracy, precision, analytical sensitivity, analytical specificity, reportable range, and reference interval. Such analytical validation is based on, among other things, the specific conditions, staff, and equipment of the particular
laboratory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to offering a new test at our laboratories, we must also satisfy certain notification requirements to change our
testing menu, such as notifications to regulatory and accrediting bodies, CMS, the California Department of Public Health Laboratory Field Services, and CAP. At their discretion, any of these entities may inspect our clinical laboratory at any time.
In connection with a CLIA certification, laboratories are subject to routine survey and inspection every other year, as well as additional random or &#147;for cause&#148; inspections. Under CLIA, a survey is generally conducted every two years by
CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA Certificate of Accreditation, a <FONT STYLE="white-space:nowrap">CMS-approved</FONT> accreditation organization (for example, CAP). The routine biennial survey includes
review of the laboratory&#146;s analytical validation of any LDTs performed by the laboratory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penalties for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with CLIA requirements include a range of enforcement actions, including suspension, limitation or revocation of the laboratory&#146;s CLIA certificate, as well as directed plan of correction, state <FONT
STYLE="white-space:nowrap">on-site</FONT> monitoring, civil monetary penalties, civil injunctive suit or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CLIA
provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. State laws may require that laboratory
personnel meet certain qualifications and obtain licenses, specify certain quality control procedures and facility requirements, or prescribe record maintenance requirements. For more information on state licensing and other requirements, see
&#147;&#151;State Licensing Laws.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>State Licensing Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the federal certification requirement for laboratories under CLIA, many states require licensure for laboratories under state
law. For example, both California and North Carolina require laboratories to maintain <FONT STYLE="white-space:nowrap">in-state</FONT> licenses to conduct testing in the state. In addition to <FONT STYLE="white-space:nowrap">in-state</FONT>
licensing requirements, certain<I> </I>states<I> </I>require licensing of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> laboratories when specimens are collected or received from patients in such
states. The state laboratory licensure requirements establish standards for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operation of a clinical laboratory, including the training and qualifications
required of personnel, quality control, and proficiency testing. Moreover, certain states, such as New York, require state approval of certain tests, including certain tests that have not been cleared or approved by the FDA (such as LDTs), through a
premarket submission containing, among other information, documentation relating to device analytical and clinical performance data. The New York Department of Health also mandates proficiency testing for laboratories granted a permit under New York
State law, regardless of whether or not such laboratories are located in New York. Clinical laboratory licensing laws in certain states, however, do not apply to laboratories operated for research purposes that do not return <FONT
STYLE="white-space:nowrap">patient-specific</FONT> results for the purpose of diagnosis or treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> with state laboratory licensure requirements may cause the state agency to suspend,
restrict, or revoke a license to operate the clinical laboratory, disapprove a licensure application, assess substantial civil money penalties, require onsite monitoring or impose specific corrective action plans. Certain statutory or regulatory
noncompliance may also result in misdemeanor charges under state law. CLIA does not preempt state laws that have established laboratory quality standards that are at least as stringent as the federal law requirements under CLIA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to laboratory licensing, certain states, including California, impose registration and/or licensing requirements on companies that
manufacture medical devices. These laws can apply to a manufacturer before its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products are commercialized, including when a company is evaluating its product candidates in clinical trials. Violations of these laws may result in the denial, suspension, or revocation of the
registration or license, as well as other fines and penalties, including imprisonment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>U.S. Food and Drug Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, laboratory tests, such as Galleri and DAC, are subject to regulation by the FDA under the FDC Act and its implementing
regulations, and other federal and state statutes and regulations. The laws and regulations govern, among other things, medical device development, testing, manufacture, labeling, storage, premarket clearance or approval, advertising and promotion,
export, import, and product sales and distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Laboratory Developed Tests </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDA&#146;s regulatory framework, <I>in vitro </I>diagnostic devices (&#147;IVDs&#148;), such as Galleri and DAC, are a type of
medical device, including tests that can be used in the diagnosis or detection of diseases, such as cancer, or other conditions. The FDA considers LDTs to be a subset of IVDs that are intended for clinical use and are designed, manufactured, and
used within a single laboratory. Although the FDA has statutory authority to assure that medical devices, including IVDs, are safe and effective for their intended uses, the FDA has historically exercised its enforcement discretion and not enforced
certain applicable provisions of the FDC Act and regulations with respect to LDTs, with certain exceptions such as in the case of tests for public health emergencies or where the tests are offered directly to the consumer. Even under its current
enforcement discretion policy, the FDA has issued warning letters to and safety communications about <I>in vitro </I>diagnostic device manufacturers for commercializing laboratory tests that were purported to be LDTs but that the FDA alleged failed
to meet the definition of an LDT or otherwise were not subject to the FDA&#146;s enforcement discretion policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has for a number
of years stated its intention to modify its enforcement discretion policy with respect to LDTs and impose applicable medical device requirements to LDTs more broadly. Most recently, the FDA proposed an amendment to its regulations in October 2023
that, if finalized, would clarify the FDA&#146;s historical view that LDTs are medical devices subject to the requirements applicable to other IVDs, and to phase out its enforcement discretion policy over a period of four years from issuance of the
final rule. In addition, Congress has, for over the past decade, considered a number of proposals, which if enacted, would subject LDTs to additional regulatory requirements. For example, in recent years Congress has worked on legislation to create
a novel regulatory framework governing a new category of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products, referred to as <I>in vitro </I>clinical tests (&#147;IVCTs&#148;), which would govern LDTs and would be separate and distinct
from the existing medical device regulatory framework. For example, most recently, in March 2023, the Verifying Accurate Leading-edge IVCT Development Act of 2023 (the &#147;Valid Act&#148;) was introduced. The bill would establish a risk-based
approach to imposing requirements related to premarket review, quality systems, and labeling requirements on all IVCTs, including LDTs, but would grandfather certain LDTs marketed before the effective date of the bill and exempt them from certain
requirements. Depending on the approach adopted under any potential legislation, certain LDTs (likely those of higher risk) may be required to undergo some form of premarket review, potentially with a transition period for compliance and a
grandfathering provision. Pending the FDA&#146;s issuance of the final rule or Congress&#146;s enactment of legislation governing LDTs, LDTs remain subject to the FDA&#146;s existing policy of enforcement discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>PMA Pathway </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA
categorizes medical devices into one of three classes&#151;class I, II, or III&#151;based on the risks presented by the device and the regulatory controls necessary to provide a reasonable assurance of the device&#146;s safety and effectiveness.
Class&nbsp;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#146;s General Controls for medical devices, which include compliance with the applicable
portions of the Quality System Regulation (&#147;QSR&#148;) facility registration and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product listing, reporting of adverse medical events, and truthful and <FONT STYLE="white-space:nowrap">non-misleading</FONT> labeling, advertising, and promotional materials. Class&nbsp;II
devices are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Special controls are established by the FDA for a specific device type and often
include specific labeling provisions, performance metrics, and other types of controls that mitigate risks of the device (usually incorrect results for an IVD). Devices deemed by the FDA to pose the greatest risks, such as life-sustaining,
life-supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&nbsp;III, requiring approval of a PMA.
Some <FONT STYLE="white-space:nowrap">pre-amendment</FONT> devices are unclassified, but are subject to the FDA&#146;s premarket notification and clearance process in order to be commercially distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;III devices generally require PMA approval before they can be marketed. Obtaining PMA approval requires the submission of
&#147;valid scientific evidence&#148; to the FDA to support a finding of a reasonable assurance of the safety and effectiveness of the device. A PMA must provide complete analytical and clinical performance data and also information about the device
and its components regarding, among other things, device design, manufacturing, and labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the
application for review, it has 180 days under the FDC Act to complete its review of a PMA, although in practice, the FDA&#146;s review often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the
FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#146;s recommendation. As part of the FDA&#146;s review of a PMA, the
FDA will typically inspect the manufacturer&#146;s facilities for compliance with QSR requirements, which impose requirements related to design controls, manufacturing controls, documentation, and other quality assurance procedures. The user fee
costs and the length of the FDA review time for obtaining PMA approval are significantly higher than for a 510(k) notification or a <I>de novo</I> classification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid
scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with <FONT STYLE="white-space:nowrap">post-approval</FONT> conditions intended to ensure the safety
and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of <FONT STYLE="white-space:nowrap">long-term</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> data
from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies <FONT STYLE="white-space:nowrap">post-approval.</FONT> The FDA may condition PMA approval on some form of <FONT
STYLE="white-space:nowrap">post-market</FONT> surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the
manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse
enforcement action, including withdrawal of the approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain changes to an approved device, such as changes in manufacturing
facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the
same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel.
Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a
new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>510(k) Notification Pathway. </I>To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating to the
FDA&#146;s satisfaction that the proposed device is &#147;substantially equivalent&#148; to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
another legally marketed device that itself does not require PMA approval (a predicate device). A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a
device that was legally marketed prior to May&nbsp;28, 1976 <FONT STYLE="white-space:nowrap">(pre-amendments</FONT> device) and for which a PMA is not required, a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or I, or a
device that was found substantially equivalent through the 510(k) process. The FDA&#146;s 510(k) clearance process usually takes from three to 12 months, but often takes longer. The FDA may require additional information, including clinical data, to
make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device establishments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA agrees that the device is substantially equivalent to a lawfully marketed predicate device, it will grant 510(k) clearance to
authorize the device for commercialization. If the FDA determines that the device is &#147;not substantially equivalent&#148; to a previously cleared device, the device is automatically designated as a Class&nbsp;III device. The device sponsor must
then fulfill more rigorous PMA requirements, or can request a <FONT STYLE="white-space:nowrap">risk-based</FONT> classification determination for the device in accordance with the <I>de novo</I> process, which is a route to market for novel medical
devices that are low to moderate risk and are not substantially equivalent to a predicate device. Once a <I>de novo</I> petition is reviewed and approved, it results in the device having a Class&nbsp;II status, and future devices from the company or
a third party may use the company<I> de novo</I><FONT STYLE="white-space:nowrap">-classified</FONT> device as a 510(k) predicate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a
device receives 510(k) clearance or <I>de novo </I>classification, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k)
clearance or, depending on the modification, PMA approval or new <I>de novo </I>classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA
can review any such decision and disagree with a manufacturer&#146;s determination. Modifications that do not rise to the level of requiring a new 510(k) are accomplished through a &#147;letter to file&#148; in which the company documents the
rationale for the change and why a new 510(k) is not required. However, if the FDA disagrees with a manufacturer&#146;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until new
marketing authorization for the change is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased
requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in September 2023, the FDA issued three draft guidance documents to
strengthen and modernize the 510(k) program, and the FDA noted that in light of increasing technical complexity, clinical data are increasingly being required to support substantial equivalence determinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>De Novo Classification Pathway. </I>If no legally marketed predicate can be identified for a new device to enable use of the 510(k)
pathway, the device is automatically classified under the FDC Act into class III, which generally requires PMA approval. However, the FDA can reclassify or use &#147;<I>de novo</I> classification&#148; for a device that meets the FDC Act standards
for a class I or class II device, permitting the device to be marketed without PMA approval. To grant such a reclassification, the FDA must determine that the FDC Act&#146;s general controls alone, or general controls and special controls together,
are sufficient to provide a reasonable assurance of the device&#146;s safety and effectiveness. The <I>de novo</I> classification route is generally less burdensome than the PMA approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investigational Device Exemption Process</I>. Clinical trials are almost always required to support a PMA and are sometimes required to
support a 510(k) submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#146;s investigational device exemption (&#147;IDE&#148;) regulations which govern
investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting, and monitoring responsibilities of study sponsors and study investigators. If the device presents a
&#147;significant risk&#148; to human health, as defined by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that
presents a potential for serious risk to the health, safety, or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise
preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device
in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there
are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (&#147;IRB&#148;) for each
clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may
begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk to the patient, a sponsor may begin the clinical
trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed
consent, and labeling and <FONT STYLE="white-space:nowrap">record-keeping</FONT> requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the
FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor
or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping, and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them.
The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and
comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects
outweigh the anticipated benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expedited Development and Review Programs. </I>The FDA has established programs to support and
expedite the development of devices that meet criteria for Breakthrough Device designation, which can be voluntarily requested by sponsors. The program offers manufacturers of certain devices an opportunity to interact with the FDA more frequently
and efficiently as they develop their products with the goal of expediting commercialization of such products to help patients have more timely access, as well as use of <FONT STYLE="white-space:nowrap">post-market</FONT> data collection, when
scientifically appropriate, to facilitate expedited and efficient development and review of the device, opportunities for efficient and flexible clinical study design, and priority review of premarket submissions. The program is available to medical
devices that meet certain eligibility criteria, including that the device provides more effective treatment or diagnosis of <FONT STYLE="white-space:nowrap">life-threatening</FONT> or irreversibly debilitating diseases or conditions, and constitutes
a device (i)&nbsp;that represents a breakthrough technology, (ii)&nbsp;for which no approved or cleared alternatives exist, (iii)&nbsp;that offer significant advantages over existing approved or cleared alternatives, or (iv)&nbsp;the availability of
which is in the best interest of patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Postmarket Regulation</I>.<I> </I>After a device is cleared or approved by the FDA for
marketing, numerous and pervasive regulatory requirements continue to apply. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration and device listing with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSR requirements, which require manufacturers, including <FONT STYLE="white-space:nowrap">third-party</FONT>
manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling regulations and FDA prohibitions against the promotion of
<FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses of cleared or approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements related to promotional activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of product modifications to <FONT STYLE="white-space:nowrap">510(k)-cleared</FONT> devices
that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to <FONT STYLE="white-space:nowrap">PMA-approved</FONT> devices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets
may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDC Act that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">post-market</FONT> surveillance activities and regulations, which apply when
deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Device manufacturing processes subject to FDA oversight are required to comply with the applicable portions of the QSR, which cover the
methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation, and servicing of finished devices intended for human use. The QSR also
requires, among other things, maintenance of a device master file, device history file, and complaint files. Manufacturers are subject to periodic scheduled or unscheduled inspections by the FDA. A failure to maintain compliance with the QSR
requirements could result in the <FONT STYLE="white-space:nowrap">shut-down</FONT> of, or restrictions on, manufacturing operations and the recall or seizure of products. The discovery of previously unknown problems with products, including
unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or <FONT STYLE="white-space:nowrap">off-label</FONT> by a physician in the practice of
medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>FDA Enforcement Powers. </I>The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has
failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requesting or requiring recalls, withdrawals, or administrative detention or seizure of our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposing operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified
products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawing 510(k) clearances or PMA approvals that have already been granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant export approvals for our products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Federal and State Physician <FONT STYLE="white-space:nowrap">Self-Referral</FONT> Prohibitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the federal physician <FONT STYLE="white-space:nowrap">self-referral</FONT> prohibitions, commonly known as the Stark Law.
The Stark Law generally prohibits us from billing, presenting, or causing to be presented a claim for any clinical laboratory services or other designated health services payable by the Medicare or Medicaid programs when the physician ordering the
service, or any member of such physician&#146;s immediate family, has an ownership interest in, or compensation arrangement with, us, unless the arrangement meets an exception to the prohibition. The Stark Law contains several exceptions, including
an exception for compensation paid to a physician for personal services rendered by the physician provided that several conditions are met, including that the payment is set at fair market value for the services furnished and the terms of the
arrangement be set out in writing and signed by the parties. These prohibitions apply regardless of the reasons for the financial relationship and the referral. The Stark Law is a strict liability statute, and thus no finding of intent is required
for a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sanctions for a violation of the Stark Law include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">denial of payment for the services provided in violation of the prohibition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refunds of amounts collected by an entity in violation of the Stark Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monetary penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusion from federal healthcare programs, including Medicare and Medicaid. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act, which prohibits
knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many states,
including California, also have laws restricting physicians from referring persons for certain services to entities in which the referring physician has a financial interest, which may apply regardless of whether the payor for such claims is
Medicare or Medicaid. For example, we are subject to the California Physician Ownership and Referral Act of 1993 (&#147;PORA&#148;). PORA, which applies regardless of payor type, generally prohibits physicians from referring individuals for certain
services, including laboratory or diagnostic services, if the physician or his or her immediate family has a financial interest in the entity receiving the referral. PORA would generally prohibit us from billing an individual or any governmental or
private payor for any laboratory or diagnostic services when the physician ordering the service, or any member of such physician&#146;s immediate family, has an investment interest in, or compensation arrangement with, us, unless the arrangement
falls under one of the statutory exceptions. Further, certain violations of PORA are a misdemeanor, and violations generally could result in civil penalties, criminal fines, and disciplinary action by the applicable governmental agency. Finally,
other states have <FONT STYLE="white-space:nowrap">self-referral</FONT> restrictions with which we have to comply, which may differ from those imposed by federal and California law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Healthcare Fraud and Abuse </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we commercially launch a product in the United States, our business operations, including any relationship we may form with
physicians, healthcare providers or other potential customers or business partners, will need to comply with various healthcare fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal healthcare program <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute makes it a felony for a person or entity,
including a laboratory, to knowingly and willfully offer, pay, solicit, or receive remuneration, directly or indirectly, in order </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to induce business that is reimbursable under any federal healthcare program, including the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. The <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute contains certain statutory exceptions and regulatory safe harbors that protect certain interactions if
specific requirements are met. If an arrangement meets the provisions of a safe harbor, it is deemed not to violate the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute. An arrangement must fully comply with each element of an
applicable safe harbor in order to qualify for protection. The failure of a transaction or arrangement to fit within a specific safe harbor, however, does not necessarily mean that the transaction or arrangement is illegal or that prosecution under
the federal <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute will be pursued if the arrangement is determined by the government not to be abusive. A violation of the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute may
result in imprisonment, fines and possible exclusion from Medicare, Medicaid, and other federal healthcare programs. Actions that violate the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute or any similar laws may also incur liability
under the Federal False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute applies only to federal
healthcare programs, a number of states have passed statutes substantially similar to the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute. For example, California has enacted the PORA (see &#147;&#151;Federal and State Physician <FONT
STYLE="white-space:nowrap">Self-Referral</FONT> Prohibitions&#148; above) and a <FONT STYLE="white-space:nowrap">Medi-Cal</FONT> <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute, Welfare and Institutions Code Section&nbsp;14107.2, that
prohibit conduct similar to that prohibited by the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute. Violations of PORA and Section&nbsp;14107.2 are both punishable by imprisonment and fines. Many other states have <FONT
STYLE="white-space:nowrap">all-payor</FONT> statutes that extend the provisions of the state <FONT STYLE="white-space:nowrap">anti-kickback</FONT> statute to not only governmental payors, but also private payors and
<FONT STYLE="white-space:nowrap">self-pay</FONT> patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state law enforcement authorities scrutinize arrangements between
healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to induce healthcare referrals or induce the purchase, prescribing or ordering of particular products or services. Law enforcement
authorities and the courts have also demonstrated a willingness to look behind the formalities of a transaction to determine the underlying purpose of any remuneration exchanged between healthcare providers and actual or potential referral sources.
Generally, courts have taken a broad interpretation of the scope of the <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or
purchases. Investigation or challenge under the federal <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute and analogous state laws of any relationship we may form with physicians, healthcare providers or other potential customers or
business partners could lead to sanctions that could have a negative effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other healthcare fraud and
abuse laws could have an effect on our business. For example, in 2018, Congress enacted the Eliminating Kickbacks in Recovery Act of 2018 (&#147;EKRA&#148;), which establishes an <FONT STYLE="white-space:nowrap">all-payor</FONT> <FONT
STYLE="white-space:nowrap">anti-kickback</FONT> prohibition for, among other things, knowingly and willfully paying or offering any remuneration directly or indirectly to induce a referral of an individual to a clinical laboratory. Violations of
EKRA may result in fines, imprisonment, or both. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Civil Monetary Penalties law prohibits, among other things, offering or
transferring remuneration to a federal healthcare program beneficiary that a person knows or should know is likely to influence the beneficiary&#146;s decision to order or receive items or services reimbursable by a federal healthcare program from a
particular provider or supplier. Penalties for violating the Civil Monetary Penalties law may include exclusion from federal healthcare programs and substantial fines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal False Claims Act prohibits a person from knowingly submitting (or causing to be submitted) a claim, making a false record or
statement in order to secure payment, or retaining an overpayment by the federal government. Moreover, the government may assert that a claim including items and services resulting from a violation of the U.S. federal
<FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. In addition to actions initiated by the government itself, the statute authorizes actions to be brought
on behalf of the federal government by a private party known as the &#147;relator&#148; who has knowledge of the alleged fraud. These types of actions are also known as qui tam or &#147;whistleblower&#148; lawsuits. Because the complaint is
initially filed under seal, the action may be pending for some time before the defendant is even </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aware of the action. If the government is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government&#146;s involvement,
then the plaintiff will receive a percentage of the recovery. It is not uncommon for qui tam lawsuits to be filed by employees, third parties or consultants of healthcare providers, including clinical laboratories. Several states have also enacted
similar false claims laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) created two
federal crimes: healthcare fraud and false statements relating to healthcare matters, in addition to the privacy and security regulations described below under &#147;&#151;Privacy Regulation.&#148; The healthcare fraud statute prohibits knowingly
and willfully executing a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from
<FONT STYLE="white-space:nowrap">government-sponsored</FONT> programs. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact, or making any materially false, fictitious, or fraudulent
statement in connection with the delivery of, or payment for, healthcare benefits, items, or services. Similar to the U.S. federal <FONT STYLE="white-space:nowrap">Anti-Kickback</FONT> Statute, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. A violation of this statute is a felony and may result in fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar foreign laws and regulations may apply to us if we offer our products in foreign jurisdictions in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we intend fully to comply with applicable federal and state fraud and abuse laws, and similar laws of other states and countries as we
commercialize products, it is possible that some of our arrangements or arrangements we may enter into in the future could become subject to regulatory scrutiny, and we cannot provide assurance that we will be found to be in compliance with these
laws following any such regulatory review. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Transparency Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sunshine Act was enacted by Congress in 2010 as part of the Affordable Care Act (&#147;ACA&#148;) and was amended in 2018 by the Substance <FONT
STYLE="white-space:nowrap">Use-Disorder</FONT> Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. The Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS certain data on payments and other transfers of value made to
<FONT STYLE="white-space:nowrap">U.S.-licensed</FONT> physicians (as defined by statute), teaching hospitals, and certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners, including physician assistants, nurse practitioners,
clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified <FONT STYLE="white-space:nowrap">nurse-midwives.</FONT> The data are sent to CMS for public disclosure on the Open Payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Additional International Regulation and Product Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may have to obtain or submit approvals, markings, notifications, certifications or satisfy other premarket requirements from regulatory
authorities in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions prior to marketing our products in those countries and territories. The laws and regulations in other jurisdictions vary from those in the United States and may be easier
or more difficult to satisfy, and they are subject to change, in some cases frequently. Certain regulatory authorities regulate LDTs and IVDs differently than the United States, and our products may need to satisfy additional requirements to be
offered commercially within the jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical devices (including IVDs) are subject to extensive regulation, such as premarket review, marketing authorization or certification, by
similar agencies or notified bodies in other countries. Regulatory requirements and approval or certification processes are not harmonized and vary from one country to another. International regulators and notified bodies are independent and not
bound by the findings of the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulation of In Vitro Diagnostic Medical Devices in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are or may become subject to new laws, regulations, and industry standards concerning medical devices proposed and enacted in various
foreign jurisdictions, including the European Union (&#147;EU&#148;). The EU has adopted specific directives and regulations regulating the design, manufacture, clinical investigation, conformity assessment, labeling, and adverse event reporting for
IVDs. Until May&nbsp;25, 2022, IVDs were regulated by Directive 98/79/EC (&#147;EU IVDD&#148;), which has been repealed and replaced by Regulation (EU) No 2017/746 (&#147;EU IVDR&#148;). The EU IVDR became effective on May&nbsp;26, 2022. However, to
prevent disruption in the supply of IVDs on the EU market, a regulation adopted by the European Parliament and the Council on December&nbsp;15, 2021 enacted a &#147;progressive&#148; <FONT STYLE="white-space:nowrap">roll-out</FONT> of the EU IVDR
and provided for a tiered grace period for most devices depending on the risk classification of the device. Galleri currently benefits from the grace period applicable to Class&nbsp;C IVDs, and therefore must only be fully compliant with the EU IVDR
requirements by May&nbsp;26, 2026. Galleri has been assessed in accordance with the EU IVDD whose regime is described below. However, as of May&nbsp;26, 2022 and regardless of the tiered grace period, some of the EU IVDR requirements apply in place
of the corresponding requirements of the EU IVDD with regard to registration of economic operators and of devices, post-market surveillance and vigilance requirements.<B> </B>Pursuing marketing of IVDs in the EU will notably require that our devices
be certified under the new regime set forth in the EU IVDR when our current certificates expire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>In Vitro Diagnostic Medical Devices
Directive</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the EU IVDD, an IVD may be placed on the market only if it conforms the essential requirements set out in the EU IVDD
including the requirement that an IVD must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the
performances intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices. There are also harmonized standards relating to design
and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical matter as it creates a rebuttable presumption that the device satisfies that essential
requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a general rule, demonstration of conformity of IVDs and their manufacturers with the essential requirements must be
based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance
during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of
the device are supported by suitable evidence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>In Vitro Diagnostic Medical Devices Regulation</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory landscape related to IVDs in the EU recently evolved. On April&nbsp;5, 2017, the EU IVDR was adopted with the aim of ensuring
better protection of public health and patient safety. The EU IVDR establishes a uniform, transparent, predictable and sustainable regulatory framework across the EU for IVDs and ensures a high level of safety and health while supporting innovation.
Unlike the EU IVDD, the EU IVDR is directly applicable in EU member states without the need for member states to implement it into national law. This aims at increasing harmonization across the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU IVDR became effective on May&nbsp;26, 2022. IVDs lawfully placed on the market pursuant to the EU IVDD prior to May&nbsp;26, 2022 may
generally continue to be made available on the market or put into service, provided that the requirements of the transitional provisions are fulfilled. However, even in this case, manufacturers must comply with a number of new or reinforced
requirements set forth in the EU IVDR, in particular the obligations described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All manufacturers placing medical devices into the
market in the EU must comply with the EU medical device vigilance system. Under this system, serious incidents and Field Safety Corrective Actions (&#147;FSCAs&#148;) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
must be reported to the relevant authorities of the EU member states. Manufacturers are required to take FSCAs defined as any corrective action for technical or medical reasons to prevent or
reduce a risk of a serious incident associated with the use of a medical device that is made available on the market. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area (&#147;EEA&#148;), which consists of the 27 EU member
states plus Norway, Liechtenstein, and Iceland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulations Related to Clinical Laboratories in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU does not have an overarching law or regulation that governs the legal framework surrounding the operations of clinical laboratories in a
way that would be analogous to CLIA in the United States. However, EU member states&#146; laws may affect how our business as a diagnostic testing service provider is carried out. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other laws and guidelines that impact clinical laboratories&#146; work include the Convention for the Protection of Human Rights and Dignity
of the Human Being with regard to the Application of Biology and Medicine, the Declaration of Helsinki adopted by the World Medical Association and related codes of conduct and guidelines issued by the relevant research ethics committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the EEA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulation of In Vitro Diagnostic Medical Devices in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Brexit, EU laws no longer apply directly in Great Britain. The regulations on IVDs in Great Britain continue to be based largely on
the EU IVDD, which preceded the EU IVDR, as implemented into national law by the Medical Devices Regulation 2002 (&#147;UK MDR&#148;). However, under the terms of the Protocol on Ireland/Northern Ireland, the EU IVDR does apply to Northern Ireland.
Consequently, there are currently different regulations in place in Great Britain as compared to both Northern Ireland and the EU, respectively. The United Kingdom government has passed a new Medicines and Medical Devices Act 2021, which introduces
delegated powers in favor of the Secretary of State or an &#147;appropriate authority&#148; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by
way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the powers granted by the Medicines and Medical Devices Act 2021, the United Kingdom is currently drafting amendments to the UK MDR
which is likely to result in further changes to the Great Britain regulations in the near future. For example, subject to transitional periods for validly certified devices, the new Great Britain regulations are expected to require IVDs placed on
the Great Britain market to be &#147;UKCA&#148; certified by a United Kingdom-approved body in order to be lawfully placed on the market. The United Kingdom has stated that the core elements of the future regime are expected to apply from
July&nbsp;1, 2025, but that IVDs in compliance with either the EU IVDD or IVDR can continue to be placed on the Great Britain market until the sooner of certificate expiration or June&nbsp;30, 2030. Following these transitional periods, it is
expected that all IVDs will require a United Kingdom Conformity Assessment (&#147;UKCA&#148;) mark. Manufacturers may choose to use the UKCA mark on a voluntary basis prior to the regulations coming into force. However, from July 2025, it is
expected that products which do not have existing and valid CE certification will be required to carry the UKCA mark if they are to be sold into the market in Great Britain. UKCA marking will not be recognized in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2021, the Medicines and Healthcare Products Regulatory Agency (&#147;MHRA&#148;) has become the sovereign regulatory
authority responsible for Great Britain. All IVDs are required to be registered with the MHRA, and since January&nbsp;1, 2022, manufacturers based outside the UK have been required to appoint a UK responsible person that has a registered place of
business in the UK to register devices with the MHRA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are pursuing payment for our products through a diverse and broad range of channels, including sales to self-insured employers, integrated
health systems, healthcare providers, life insurance companies, and patients, as well as, where available, through coverage and reimbursement by government health insurance programs and commercial <FONT STYLE="white-space:nowrap">third-party</FONT>
payors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there is no uniform coverage for clinical laboratory tests. The extent of coverage and rate of payment for covered
services varies from payor to payor. Obtaining coverage for tests like ours that involve genomic sequencing can be particularly challenging. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare is the single largest healthcare payor in the United States, and a particularly significant payor for many <FONT
STYLE="white-space:nowrap">cancer-related</FONT> laboratory services given the demographics of the Medicare population, a large portion of which includes elderly individuals. Many other U.S. payors look to the Medicare policies as a benchmark and
model for their own. Medicare provides two main forms of insurance coverage: traditional Medicare <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service,</FONT></FONT> administered by the federal government and its
contractors, and Medicare Advantage, where coverage is provided by private insurers approved by CMS that must follow federal rules and guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, Medicare will not cover screening tests, which are considered preventive services, that are performed in the absence of signs or
symptoms of illness or injury, except if explicitly authorized by statute. CMS, the agency responsible for administering the Medicare program, authorizes certain additional preventive services including certain screening tests that are not expressly
covered by statute if the service is (a)&nbsp;reasonable and necessary for the prevention or early detection of an illness or disability, (b)&nbsp;recommended with a grade of A or B by the USPSTF, an independent, volunteer panel of experts in the
field of prevention, <FONT STYLE="white-space:nowrap">evidence-based</FONT> medicine and primary care, and (c)&nbsp;appropriate for Medicare beneficiaries under Part A or Part B. CMS establishes coverage through an NCD process. In making the NCD
determination, CMS may also consider, among other things, the relationship between predicted outcomes and expenditures for such services, and take into account the results of such an assessment in making such determination. In its discretion, the
USPSTF generally waits for FDA authorization before it considers undertaking review of novel technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Galleri could be considered a
screening test under Medicare and, accordingly, is unlikely to be covered by Medicare without pursuing the CMS <FONT STYLE="white-space:nowrap">NCD-related</FONT> measures described above. These processes may take multiple years to complete as
currently, coverage decisions for preventive services are not made prior to FDA authorization. Even if we pursue these processes, it is possible that Galleri will never become eligible for Medicare coverage and reimbursement. We are evaluating
opportunities for <FONT STYLE="white-space:nowrap">nearer-term</FONT> reimbursement through Medicare Advantage plans, while generating evidence to meet the requirements of the traditional Medicare path. Medicare Advantage plans generally must cover
all of the services that traditional Medicare covers (except hospice care), but they have the discretion to offer their enrollees additional, or supplemental, benefits not otherwise covered under traditional Medicare, including those benefits
referred to as optional supplemental benefits, for which enrollees may elect to pay extra to receive coverage. Obtaining such coverage may, however, involve lengthy negotiations with individual Medicare Advantage plans, and there is no guarantee
that we will receive such coverage. We also intend to pursue coverage and reimbursement from private payors for our products. Many of these private payors must cover certain services required by federal and state laws, such as preventive health
services that have received a rating of A or B by the USPSTF. Like Medicare Advantage plans, private payors have discretion to extend greater coverage than recognized under traditional Medicare, but obtaining coverage from such payors may involve
lengthy negotiations, and there is no guarantee that we will receive such coverage. State Medicaid programs make individual coverage decisions for diagnostic tests and have taken steps to control the cost, utilization and delivery of healthcare
services, meaning that, even if Galleri receives coverage through private payors, there is no guarantee that it will be covered by individual state Medicaid programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DAC is intended to be a diagnostic product, and we believe we could obtain Medicare coverage
and reimbursement of DAC as a medical benefit in the next several years, although there are no assurances that we will be successful in doing so. We may explore Medicare local coverage of DAC by Medicare Administrative Contractors (&#147;MACs&#148;)
by demonstrating utility of our product in a clinical study. MACs administer the Medicare program in their respective designated regions and have some discretion in determining coverage. We may seek FDA clearance or approval, which, if obtained,
would help us obtain coverage and reimbursement for DAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If eligible for reimbursement, laboratory tests such as ours generally are
classified for reimbursement purposes under CMS&#146;s Healthcare Common Procedure Coding System (&#147;HCPCS&#148;) and the American Medical Association&#146;s (&#147;AMA&#148;) Current Procedural Terminology (&#147;CPT&#148;) coding systems. We
and payors must use those coding systems to bill and pay for our diagnostic tests, respectively. These HCPCS and CPT codes are associated with the particular product or service that is provided to the individual. Accordingly, without an HCPCS or CPT
code applicable to our tests, the submission and payment of claims would be a significant challenge. Once CMS creates an HCPCS code or the AMA establishes a CPT code, CMS establishes payment rates and coverage rules under traditional Medicare, and
private payors establish rates and coverage rules independently. Under Medicare, payment for laboratory tests is generally made under the Clinical Laboratory Fee Schedule (&#147;CLFS&#148;) with payment amounts assigned to specific HCPCS and CPT
codes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (&#147;PAMA&#148;), which included substantial
changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA (as amended by the Further Consolidated Appropriations Act, 2020), laboratories that receive the majority of their Medicare revenue from payments made under
the CLFS and Physician Fee Schedule and receive at least $12,500 in Medicare revenues for CLFS services during a data collection period are subject to certain reporting requirements. CMS uses the data reported, which includes certain private payor
payment rates for each test the laboratory performs, the volume of tests paid at each rate, and the HCPCS code associated with the test, to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS
reimbursement rates for clinical diagnostic laboratory tests (&#147;CDLTs&#148;). If the test is an advanced diagnostic laboratory test (&#147;ADLT&#148;), the test will be paid based on an actual list charge for an initial period of three quarters
before being shifted to the weighted median private payor rate reported by the laboratory performing the ADLT. Laboratories offering ADLTs are subject to recoupment if the actual list charge exceeds the weighted median private payor rate by a
certain amount. Accordingly, if our tests receive Medicare coverage in the future, the reimbursement rate we receive for such tests may be affected by payment rates made by private payors for such tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revised reimbursement methodology described above generally results in relatively lower reimbursement amounts under Medicare for clinical
laboratory services than has been historically reimbursed. Any reductions to reimbursement rates resulting from the new methodology are limited to 0% in 2023 and 15% per test per year in each of 2024 through 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, PAMA codified Medicare coverage rules for laboratory tests by requiring any local coverage determination to be made following the
local coverage determination process. PAMA also authorizes CMS to consolidate coverage policies for clinical laboratory tests among one to four <FONT STYLE="white-space:nowrap">laboratory-specific</FONT> MACs. These same contractors may also be
designated to process claims if CMS determines that such a model is appropriate. It is unclear whether CMS will proceed with contractor consolidation under this authorization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General Coverage and Reimbursement Considerations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Across jurisdictions, a decision to provide coverage for a product from a government payor, such as Medicare, or other <FONT
STYLE="white-space:nowrap">third-party</FONT> payor does not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for products, and services that utilize such products, can differ significantly from payor
to payor. As a result, the coverage determination process is often a <FONT STYLE="white-space:nowrap">time-consuming</FONT> and costly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be
applied consistently or obtained in the first instance or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the price and examining
the medical necessity and <FONT STYLE="white-space:nowrap">cost-effectiveness</FONT> of medical products and services, including clinical laboratory tests, in addition to their safety and efficacy. In certain foreign markets, the government controls
the coverage and pricing of many healthcare products, including IVDs and clinical laboratory tests. In order to obtain coverage and reimbursement for any product that might be cleared or approved by regulators for sale (or certified by a notified
body), or for any procedure that utilizes such product, it may be necessary to conduct health economic studies in order to demonstrate the medical necessity and <FONT STYLE="white-space:nowrap">cost-effectiveness</FONT> of the products. The cost of
such studies would be in addition to the costs required to obtain regulatory approvals or certifications. If <FONT STYLE="white-space:nowrap">third-party</FONT> payors do not consider a product to be
<FONT STYLE="white-space:nowrap">cost-effective</FONT> compared to other available products, they may not cover the product after approval (or certification) as a benefit under their plans or, if they do, the level of payment may not be sufficient
to allow a company to sell its products at a profit. Tests such as ours that will cover a large population and could potentially generate a significant number of <FONT STYLE="white-space:nowrap">false-positive</FONT> results on an absolute basis may
face incremental scrutiny in obtaining reimbursement from <FONT STYLE="white-space:nowrap">third-party</FONT> payors given the additional costs of further diagnostic workup. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of Galleri and DAC may suffer if government and <FONT STYLE="white-space:nowrap">third-party</FONT> payors fail to provide
adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased, and we expect will continue to increase the pressure on medical products and services pricing. Coverage policies and <FONT
STYLE="white-space:nowrap">third-party</FONT> reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for our tests, less favorable coverage policies and reimbursement rates may be implemented in
the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare
system. Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our products, decrease our revenue and adversely impact sales of, and pricing of and
reimbursement for, our products. For example, in March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of
provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of the ACA in the United States, for example, has changed healthcare financing and delivery by both governmental and
private insurers substantially, and affected medical device manufacturers significantly. The ACA included, among other things, provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse.
Since its enactment, there have been judicial, U.S. Congressional and executive branch challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several
states without specifically ruling on the constitutionality of the ACA. It is unclear how other healthcare reform measures, if any, will impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget
Control Act of 2011, among other things, resulted in reductions in payments to Medicare providers, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, with
the exception of a temporary suspension from May&nbsp;1, 2020 through March&nbsp;31, 2022, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several
providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, on December&nbsp;13, 2021, Regulation No 2021/2282 on Health Technology Assessment
(&#147;HTA&#148;) amending Directive 2011/24/EU, was adopted. While the regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the
interim. Once the regulation becomes applicable, it will have a phased implementation depending on the concerned products. This regulation intends to boost cooperation among EU member states in assessing health technologies, including certain
high-risk medical devices and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation will permit EU member states to use common HTA tools, methodologies, and procedures across the EU,
working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities,
identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing
<FONT STYLE="white-space:nowrap">non-clinical</FONT> (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that there will continue to be proposals by legislators at both the federal and state levels and in foreign jurisdictions,
regulators and <FONT STYLE="white-space:nowrap">third-party</FONT> payors to reduce costs while expanding individual healthcare benefits. Certain of these proposals to further reform healthcare or reduce healthcare costs may limit coverage of or
lower reimbursement for the procedures associated with the use of our products. Changes in healthcare policy could increase our costs, decrease our revenue and impact sales of and reimbursement for our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of
health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws,
health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy
and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations,
proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. For additional information, see the section entitled &#147;Risk Factors&#148; beginning on page 28 of this Information Statement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not
currently a party to any material legal proceedings. From time to time, we are and may become involved in legal proceedings or investigations. For example, we are currently involved in various lawsuits and claims with respect to employment matters.
Lawsuits or other legal proceedings could have an adverse impact on our reputation, business, financial condition, results of operations, or cash flows, and could divert the attention of our management from the operation of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined by the Jumpstart Our Business Startups Act of 2012. We will continue to be an emerging growth company until the earliest to occur of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which our total annual gross revenues first meet or exceed $1.235&nbsp;billion
(as adjusted for inflation); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which we have, during the prior three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which we (i)&nbsp;have an aggregate worldwide market value of common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of $700&nbsp;million or more (measured at the end of each fiscal year) as of the last business day of our most recently completed second fiscal quarter and (ii)&nbsp;have been a
reporting company under the Securities Exchange Act of 1934, which refer to as the &#147;Exchange Act,&#148; for at least one year (and have filed at least one annual report under the Exchange Act); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock
pursuant to an effective registration statement under the Securities Act of 1933. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For as long as we are an emerging
growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with
the auditor attestation requirements in the assessment of our internal control over financial reporting under Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, exemption from new or revised financial accounting standards applicable to public
companies until such standards are also applicable to private companies, reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, and exemptions from the requirement of
holding a nonbinding advisory vote on executive compensation and stockholder approval on golden parachute compensation not previously approved. We may choose to take advantage of some or all of these reduced burdens. For example, we have taken
advantage of the reduced disclosure obligations regarding executive compensation in this Information Statement. For as long as we take advantage of the reduced reporting obligations, the information we provide stockholders may be different from
information provided by other public companies. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market for our common stock and
higher volatility in the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to not take advantage of the extended transition period that allows
an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies, which means that the financial statements included in this Information Statement, as well as financial
statements we file in the future, will be subject to all new or revised accounting standards generally applicable to public companies. Our election not to take advantage of the extended transition period is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_13"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion of our results of operations and financial condition together with our accompanying consolidated
financial statements, which we refer to as the &#147;Consolidated Financial Statements,&#148; and the notes thereto included under the section entitled &#147;Index to Consolidated Financial Statements&#148; beginning on page F-1 of this Information
Statement, as well as the discussion in the sections entitled &#147;Unaudited Pro Forma Condensed Consolidated Financial Statements&#148; and &#147;Business&#148; beginning on pages 112 and 113, respectively, of this Information Statement. This
discussion contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the midstream
industry and our business and financial results. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed in the sections entitled &#147;Risk
Factors&#148; and &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; beginning on pages 28 and 95, respectively, of this Information Statement. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>GRAIL, LLC, previously named SDG Ops, LLC, was formed in the state of Delaware as a wholly owned subsidiary of Illumina, Inc.
(&#147;Illumina&#148;). SDG Ops, LLC, along with SDG Ops, Inc., a Delaware corporation and wholly owned subsidiary of Illumina, were formed for the purpose of completing a merger transaction between GRAIL, Inc., and Illumina (the
&#147;Acquisition&#148;) in order to carry on the business of GRAIL, Inc. and its subsidiaries. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>On September&nbsp;20, 2020, GRAIL,
Inc., Illumina and its subsidiaries, SDG Ops, LLC, and SDG Ops, Inc., entered into an agreement and plan of merger (the &#147;Merger Agreement&#148;). On August&nbsp;18, 2021 (the &#147;Closing Date&#148;), Illumina completed its acquisition of
GRAIL, Inc. (&#147;predecessor&#148;). According to the terms and conditions of the Merger Agreement, SDG Ops, Inc. and GRAIL, Inc. merged, with GRAIL, Inc. surviving and now a wholly owned subsidiary of Illumina (the &#147;First Merger&#148;).
Immediately following the First Merger and as part of the same overall transaction, GRAIL, Inc., as the surviving corporation, merged with SDG Ops, LLC (the &#147;Second Merger&#148;). According to the terms and conditions of the Merger Agreement,
SDG Ops, LLC became the surviving company and was renamed GRAIL, LLC (&#147;successor&#148;). </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Prior to the Closing Date, and
unless the context otherwise requires, references to &#147;GRAIL,&#148; &#147;we,&#148; and &#147;us&#148; within this Information Statement refer to GRAIL, Inc., and its consolidated subsidiaries, while references to &#147;GRAIL,&#148;
&#147;we,&#148; and &#147;us&#148; on or after the Closing Date refer to GRAIL, LLC and its consolidated subsidiaries unless the context otherwise requires. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative commercial-stage healthcare company focused on saving lives and shifting the paradigm in early cancer detection. We
believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our Galleri test is a clinically-validated, commercially available test for early detection of
multiple types of cancer, which we termed multi-cancer early detection (&#147;MCED&#148;). Galleri detects a shared cancer signal across more than 50 types of cancer and can predict with high accuracy the specific organ or tissue type where the
cancer signal originated from a simple blood draw. We launched Galleri in the United States in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> As of September&nbsp;30, 2023, we have sold more than 125,000 commercial tests and established over 100
commercial partnerships, including leading healthcare systems, employers, payors, and life insurance providers. Commercial use of Galleri has detected some of the most aggressive cancers in early stages including, among others, endometrial,
esophageal, gastrointestinal stromal, head and neck, liver, pancreatic, and rectal cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred net
losses each year. Our net losses were $5.4&nbsp;billion for fiscal year 2022 (which includes $4.7 billion in goodwill impairment), $911.5&nbsp;million for the 2021 successor period and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$336.2&nbsp;million for 2021 predecessor period (see &#147;Basis of Presentation&#148; below for a description of applicable fiscal periods). Adjusted EBITDA was $(500.1)&nbsp;million for fiscal
year 2022, $(158.1)&nbsp;million for the 2021 successor period and $(216.5)&nbsp;million for the 2021 predecessor period. Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. For a reconciliation of Adjusted
EBITDA to the most directly comparable U.S. generally accepted accounting principle (&#147;GAAP&#148;) financial measure, information about why we consider Adjusted EBITDA useful and a discussion of the material risks and limitations of these
measures, please see <FONT STYLE="white-space:nowrap">&#147;Non-GAAP</FONT> Financial Measures&#148; below. Substantially all of our net losses resulted from the application of pushdown accounting, including $4.7 billion goodwill impairment and
amortization of intangible assets, as well as our research and development programs and G&amp;A costs associated with our operations and sales and marketing costs associated with commercializing our products. Additionally, due to the application of
pushdown accounting, our balance sheet includes goodwill and intangible assets recognized by Illumina in connection with their acquisition of us that may be subject to additional impairment over time. We expect to continue to incur operating losses
over at least the next several years as we continue to invest in research and development of new and existing products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Separation
from Illumina </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, Illumina
announced plans for the separation of GRAIL from Illumina via the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To effect the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina will distribute at least 85.5% of the shares of GRAIL&#146;s common stock owned by Illumina to Illumina&#146;s stockholders on a pro rata basis, and GRAIL will become an independent, publicly
traded company. Immediately after the Distribution becomes effective, Illumina may retain up to 14.5% of GRAIL&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we intend to enter into a Separation and Distribution Agreement and several other agreements with Illumina related to the <FONT STYLE="white-space:nowrap">Spin-Off.</FONT> These
agreements will govern the relationship between Illumina and us up to and after completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and allocate between Illumina and us various assets, liabilities, and obligations, including <FONT
STYLE="white-space:nowrap">tax-related</FONT> assets and liabilities. See the section entitled &#147;Certain Relationships and Related Party Transactions&#148; beginning on page 202 of this Information Statement for more detail. No approval of
Illumina&#146;s stockholders is required in connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> and Illumina&#146;s stockholders will not have any appraisal rights in connection with the
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is subject to the
satisfaction, or the waiver by Illumina&#146;s board of directors (the &#147;Illumina Board&#148;) of a number of conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, Illumina has the right not to complete the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> if, at any time, the Illumina Board determines, in its sole and absolute discretion, that the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is
not in the best interests of Illumina or its stockholders or is otherwise not advisable. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, Illumina and GRAIL will have incurred significant costs related to the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> including fees for consultants, financial and legal advisors, accountants, and auditors, that will not be recouped. Total <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs associated with
the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> are preliminarily estimated to range from $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if
the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is completed. If the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is not completed for any reason, the <FONT STYLE="white-space:nowrap">one-time</FONT> transaction costs will generally be
limited to the transaction costs incurred for services rendered as of the date the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> is abandoned, which will be less than the range noted above. Our management will also have devoted significant time
to manage the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> process, which will decrease the time they will have to manage our business. See the section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Conditions</FONT> to the <FONT
STYLE="white-space:nowrap">Spin-Off&#148;</FONT> beginning on page 105 of this Information Statement for more detail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of
Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on a stand-alone basis using the consolidated
financial statements and accounting records of Illumina. These consolidated financial statements reflect GRAIL&#146;s consolidated historical financial position, results of operations and cash flows as historically managed, in accordance with GAAP.
The Consolidated Financial Statements may not be indicative of GRAIL&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future performance and do not necessarily reflect what the financial position, results of operations and cash flows would have been, and may not include all expenses that would have been
incurred, had GRAIL been operated as an independent, publicly traded company during the periods presented. Certain situations require management to make estimates based on judgments and assumptions, which may affect the reported amounts of assets
and respective disclosures at the date of the financial statements. Management&#146;s judgments and assumptions may also affect the reported amounts of net sales and expenses during the reporting periods. Actual results could differ from these
management estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GRAIL&#146;s fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, so the exact year-end date
may change from year to year. Upon the closing of the Spin-Off, GRAIL will have a fiscal year end of December&nbsp;31. References herein to (i)&nbsp;the &#147;2021 predecessor period&#148; refer to the period from January&nbsp;1, 2021 through
August&nbsp;18, 2021 and reflect the <FONT STYLE="white-space:nowrap">pre-Acquisition</FONT> activity of GRAIL, (ii)&nbsp;the &#147;2021 successor period&#148; refer to the period from August&nbsp;19, 2021 through January&nbsp;2, 2022 and reflect
the post-Acquisition activity of GRAIL, and (iii) &#147;fiscal year 2022&#148; refer to the period from January&nbsp;2, 2022 through January&nbsp;1, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Acquisition represented a change of control with respect to GRAIL. Given GRAIL, Inc. merged with SDG Ops, Inc., which then merged with SDG
Ops LLC, authoritative guidance (ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-50-30)</FONT></FONT> required pushdown accounting to be applied for the Second Merger amongst entities under common control. As a result of
the application of pushdown accounting, the separately issued financial statements of GRAIL reflect Illumina&#146;s basis in the assets and liabilities of GRAIL which were remeasured to fair value as of the Closing Date. Acquired intangible assets
included developed technology, in-process research and development, and tradenames, as well as goodwill. There were also various other purchase price adjustment entries made in connection with the Acquisition that impacted the GRAIL standalone
financial statements. We have explained these fluctuations within the section titled &#147;&#151;Results of Operations&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the separation from Illumina, we expect to incur additional costs as a separate public company. These additional costs are
primarily related to certain supporting functions that may differ from and be higher than the costs historically incurred or allocated to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The additional costs we expect to incur as a separate public company are summarized as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Accounting and audit related costs, professional services, and new systems and software to support the
accounting, financial reporting, and audits as a standalone public company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Personnel costs, including compensation-related expenses for additional headcount to enhance our capabilities in
areas such as investor relations, accounting, financial reporting, treasury, risk management, and equity administration, among others; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corporate governance costs, including but not limited to board of directors compensation and expenses, legal and
other professional services fees, annual report and proxy statement costs, SEC filing fees, transfer agent fees, and stock exchange listing fees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These additional costs are expected to increase our general and administrative (&#147;G&amp;A&#148;) expenses. Certain factors could impact
the nature and amount of these separate public company costs, including the finalization of our staffing and infrastructure needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
also expect Illumina to continue providing us with some of the services related to certain functions on a transitional basis. Costs associated with services provided by Illumina on a transitional basis are expected to be immaterial. We also expect
to provide certain services to Illumina on a transitional basis in exchange for agreed-upon fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Key Factors Affecting Performance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of
operations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continued development of the market for MCED testing</I></B>. Multi-cancer early detection is a relatively
novel concept and the market for MCED tests is rapidly evolving. We coined the term &#147;multi-cancer early detection&#148; and continue to drive MCED as a solution to one of healthcare&#146;s most important challenges. Our performance depends on
the extent to which key stakeholders, including current and potential commercial partners, payors and health systems, regulators, policy makers, academic and community medical centers, and key opinion leaders and advocates, understand and support
MCED testing as an effective solution for cancer screening. We make significant efforts to educate these key stakeholders regarding the benefits of MCED and the clinical and economic value of our products, which we believe will continue to drive
awareness of MCED and expand the commercial opportunity for our products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Demand for our products and customer mix</I></B>. A key factor to our future success is and will be our
ability to increase demand for, and sales of, Galleri and our other products from new and existing customers. Our commercial strategy is focused on innovative value-oriented partnerships and targets health systems, employers, payors, and life
insurance providers, as well as other <FONT STYLE="white-space:nowrap">at-risk</FONT> populations. As Galleri is not currently broadly reimbursed, our ability to drive demand from these customers is directly linked to our ability to demonstrate the
clinical and economic value of our test through clinical validation and real-world experience. As of September&nbsp;30, 2023, we have entered into over 100 commercial partnerships, including with leading healthcare systems, employers, payors, and
life insurance providers, and have established a network of over 8,000 prescribers across the United States in a <FONT STYLE="white-space:nowrap">pre-reimbursement</FONT> setting. We believe this commercial network represents a significant
opportunity to drive further demand for Galleri. The mix of customers from which we generate revenue from period to period has an impact on our revenue and gross margin. Test pricing is generally based on our list price or, for certain customers,
such as larger, higher-volume customers, negotiated contractual rates. For certain customers, we also offer rebates or discounts from time to time. Revenue generated from customers with negotiated contractual rates, or with rebates or discounts, is
generally lower margin as compared to revenue generated based on list pricing. In addition, we have entered into a number of biopharmaceutical research partnerships for our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">research-use-only</FONT></FONT> (&#147;RUO&#148;) offering under our precision oncology portfolio. Large customers, such as healthcare systems, employers, and biopharmaceutical
partners, generally begin using our products by initiating pilots involving a limited number of tests. We believe that our ability to convert these initial pilots into long-term customer relationships has the potential to drive substantial long-term
revenue. We also expect to increase demand from new customers through our efforts to further develop the market for MCED testing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Regulatory approval and reimbursement</I></B>. Our performance will be impacted by the extent to which we
can secure reimbursement and coverage for our products. Prior to broad reimbursement in the United States, we will continue our work with clinics and health systems to accelerate utilization, and with self-insured employers and health insurers to
offer and cover Galleri. Galleri is currently available as an LDT in the United States and we have established private reimbursement from a number of self-insured employers and health plans. While FDA approval is currently not required to market our
tests in the United States, we plan to complete a PMA submission with the FDA in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to support broad access for Galleri. We believe that FDA approval, if
obtained, could unlock large commercial payors in the United States and we are working with stakeholders to advance and shape the public reimbursement landscape in the United States to enable coverage of FDA-approved MCED tests by Medicare.
Following FDA approval, we expect to pursue inclusion of Galleri in the USPSTF&#146;s guideline recommendation, which we believe would further increase adoption and market acceptance of our tests. In the United Kingdom, we are working with NHS
England to complete our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial. Subject to results of an early analysis from the first screening test (the prevalent screening round) representing one year of results out of the three-year trial
period, the NHS may commence phased commercial implementation with the potential for further expansion subject to final results from the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
trial. We believe our work with the NHS and data generated from our <FONT STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial could facilitate adoption in other single-payor systems around the
world and support evidence of clinical utility worldwide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Investment in clinical studies and innovation to support our strategy and growth</I></B>. A significant
aspect of our business is our investment in research and development, including the development of new and improved products, and the ongoing evidence generation supporting the clinical utility of Galleri. In particular, we have invested heavily in
clinical studies and designed and executed what we believe is the largest clinical program in genomic medicine to date. These studies include: <FONT STYLE="white-space:nowrap">NHS-Galleri,</FONT> CCGA, SUMMIT, STRIVE, SYMPLIFY, PATHFINDER,
PATHFINDER 2, and REFLECTION. We have established and maintained a leading voice in conversations regarding the early detection of multiple cancer types in the peer-reviewed literature. We have published data from these studies in high-profile
journals and have presented such data at renowned medical conferences. We believe these studies are critical to driving adoption of our tests, as well as favorable coverage decisions, and expect our investments to continue. In addition, we have
invested heavily in the development of our methylation platform and extensive technological infrastructure. We expect to increase our research and development expenses as we continue to develop new technologies and launch innovative products across
the cancer care continuum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leverage our operational infrastructure</I></B>. We have made significant investments to build a scalable
infrastructure capable of meeting significant demand while satisfying stringent certification parameters. Our facilities are able to process a substantial number of tests annually and are <FONT STYLE="white-space:nowrap">CAP-accredited</FONT> and
CLIA-certified. In addition, we engineered custom technology infrastructure and cloud-based tools to enable scalable data collection and analysis capabilities. With this foundational infrastructure in place, we have been able to generate scale
efficiencies as the volume of tests sold has increased. As demand for our products increases, we expect to further leverage the scale efficiencies of our infrastructure and platform technology, which we believe will positively impact margins over
time. In addition, we may invest significant amounts in infrastructure to support new products resulting from our research and development activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>International expansion</I></B>. A component of our long-term growth strategy is to expand our commercial
reach internationally. We have expanded internationally into the United Kingdom, and we expect to launch Galleri in the United Kingdom through our partnership with NHS England. We continue to evaluate international expansion opportunities and expect
to expand into additional select geographies over time, including through distributors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While each of these areas
presents significant opportunities for us, they also pose significant risks and challenges that we must address. See &#147;Risk Factors&#148; for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Components of Results of Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently
derive revenue primarily through the sale of Galleri within the United States and primarily through health systems, employers, payors, and life insurance providers. Galleri is not currently broadly reimbursed. The test price is based on the
negotiated contractual rate with our contracted customers, otherwise our standard list price applies. We identify each sale of our test to our customer as a single performance obligation; therefore, revenue is recognized at the point of time when
the test result report is delivered. For <FONT STYLE="white-space:nowrap">self-pay</FONT> patients, we have concluded that an implied contract exists, however the transaction price for the implied contract represents variable consideration as there
are situations in which we do not expect to collect the full invoiced amounts from <FONT STYLE="white-space:nowrap">self-pay</FONT> patients due to price concessions. We utilize the expected value approach to estimate the transaction price and apply
a constraint for such variable consideration, on a portfolio basis. We monitor the estimated amounts to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also derive revenue through our development services, which consist of research services
we provide to biopharmaceutical and clinical customers including support of ongoing clinical studies, pilot testing, research, and therapy development. We evaluate the terms and conditions included within our development services contracts with
biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. Revenue from pilot and research services
performed is recognized as performance obligations are achieved. We recognize revenue from development service agreements related to regulatory filing to support clinical study and companion diagnostic device development and regulatory submissions
for the developed product(s) using an input method based on costs incurred to measure its progress toward the completion and satisfaction of the performance obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Revenue and Cost of Revenue&#151;Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue represents expenses that are incurred to produce and sell our products and services. For screening revenue, these costs consist
of direct materials, direct labor including salaries and wages, bonus, benefits and stock-based compensation, shipping, royalties, and allocations of overhead and equipment depreciation. For development services, these costs consist of direct
materials and patient sample acquisition, direct labor including salaries and wages, bonus, benefits and stock-based compensation, royalties, and allocations of overhead and equipment depreciation. Cost of revenue&#151;related parties represents the
costs of supplies purchased from related parties used in the generation of revenue from all customers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of
Revenue&#151;Amortization of Intangible Assets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the application of pushdown accounting, intangible assets recognized in
our standalone financial statements relate to our own technology, and consist of developed technologies and in-process research and development that were measured at fair value upon the Acquisition. Our developed technology includes intangible
assets related to Galleri, designed as a cancer screening test for asymptomatic individuals over 50 years of age, as well as DAC that is being designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of
cancer. The cost of identifiable intangible assets with finite lives, such as developed technology assets, are amortized on a straight-line basis over the assets&#146; respective estimated useful lives of 18 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development and Research and Development&#151;Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include costs incurred to develop our technology (prior to establishing technological feasibility), collect
clinical samples, and conduct clinical studies to develop and support our products. These costs consist of personnel costs, including salaries, benefits, and stock-based compensation expense associated with our research and development personnel,
costs associated with setting up and conducting clinical studies at domestic and international sites, laboratory supplies, consulting costs, depreciation, and allocated overhead including facilities and information technology expenses, which we do
not allocate by product. We expense both internal and external research and development costs in the periods in which they are incurred. Research and development&#151;related parties expenses include only those costs incurred with related parties as
further discussed in Note 9 to our audited Consolidated Financial Statements included elsewhere in this Information Statement. Nonrefundable advance payments for goods and services that will be used or rendered in future research and development
activities are deferred and recognized as expense in the period in which the related goods are delivered or services are performed. We expect our research and development expenses to continue to increase in the foreseeable future as we continue our
research and development activities for new products, to enhance existing products, conduct our existing clinical studies and initiate and conduct additional clinical studies to provide the evidence to support our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sales and Marketing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation expense,
consulting costs, allocated overhead including facilities and information technology expenses, and travel associated with our commercial organization. Also included are costs associated with advertising programs that consist of brand and product
awareness activities and trade events and conferences. Sales and marketing expenses in the successor periods also includes amortization of the tradename intangible asset that was recognized upon the Acquisition, which has been recorded in our
financial statements as a result of the application of pushdown accounting. The cost of identifiable intangible assets with finite lives, such as trade names, are amortized on a straight-line basis over the assets&#146; respective estimated useful
lives of 9&nbsp;years. We expect our sales and marketing expenses to continue to increase in the foreseeable future as we continue to invest in building brand awareness of our current products and services, as well as additional product marketing
and sales functions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative and General and Administrative&#151;Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G&amp;A expenses consist of personnel expenses, including salaries, benefits and stock-based compensation expense, for executive, finance and
accounting, legal, human resources, business development, corporate communications, and management information systems personnel. Also included are professional fees, legal costs, including patent and trademark-related expenses. The related party
amount represents allocated audit fees and stock administration expenses from Illumina. We expect our G&amp;A expenses to continue to increase for the foreseeable future as we become a standalone public company and continue to grow our business. We
will incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, director and officer insurance premiums, investor relations activities, and other
expenses related to administrative and professional services. We also expect to increase our administrative headcount as a standalone public company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Goodwill Impairment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
the Acquisition, excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, was recognized by Illumina as goodwill. As a result of the application of pushdown accounting, the separately issued
financial statements of GRAIL reflect the goodwill recorded by Illumina upon the Acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2022, the European General
Court ruled that the European Commission has jurisdiction under the European Union Merger Regulation to review the Acquisition. Additionally, on September&nbsp;6, 2022, the European Commission issued a decision prohibiting the Acquisition. These
decisions constituted substantive changes in circumstances that would more likely than not reduce the fair value of goodwill. We recognized a goodwill impairment for $4.7 billion in 2022. We evaluate goodwill impairment annually or more frequently
if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. See &#147;Note 2&#151;Summary of Significant Accounting Policies&#151;Goodwill and Intangible
Assets&#148; to our Consolidated Financial Statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists primarily of interest income earned on our cash and cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net primarily consists of foreign currency gains and losses as a result of our intercompany agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Benefit from Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the Acquisition, as a wholly owned entity of Illumina, we were no longer subject to U.S. income tax for the successor periods
ended January&nbsp;1, 2023 and January&nbsp;2, 2022 on a standalone basis and U.S. income tax is combined into Illumina&#146;s consolidated income tax return as a division of Illumina. However, for financial statement purposes, we have elected to
compute our income tax provision, including current and deferred taxes, as if we filed a separate income tax return and were not included in Illumina&#146;s consolidated return. Including the provision for income taxes in our standalone financials
is more representative of our financial position as a standalone company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this method, various tax attributes, such as net
operating losses and tax credits, are also presented on a separate return basis. For income tax purposes, since GRAIL is not a separate taxpayer and merely a division of Illumina, these tax attributes, including net operating losses and tax credits,
are the property of Illumina and have either already been utilized by Illumina in its consolidated or combined income tax returns or will be utilized by Illumina in its returns in the future. Accordingly, such tax attributes will not be available to
a standalone GRAIL entity on its income tax returns in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparisons of Fiscal Year 2022 to the 2021 Successor Period and the 2021 Predecessor Period </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for fiscal year 2022, the 2021 successor period and the 2021 predecessor period.
Results between periods presented are not comparable and thus, percentage change has been omitted for presentation purposes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2021 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 54,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 12,052</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,433</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (exclusive of amortization of acquired intangible assets)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,288</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,630</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309,781</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">478,071</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,700,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,498,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940,587</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,442,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(928,154</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(337,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(865</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,441,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(929,019</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,399,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(911,542</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(336,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Fiscal Year 2022, the 2021 Successor Period, and the 2021 Predecessor
Period: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in revenue in fiscal year 2022 as compared to all prior periods presented is a direct result of the commercial launch of Galleri
in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> Revenue increased from $2.2&nbsp;million in the 2021 predecessor period, to $12.4&nbsp;million in the 2021 successor period. The 2021 successor period revenue consisted of $7.4&nbsp;million
related to sales of Galleri and $5.0&nbsp;million related to development services. In fiscal year 2022, total revenue expanded to $55.5&nbsp;million, consisting of $39.8&nbsp;million of Galleri revenue and $15.7&nbsp;million of development services.
The increase in Galleri revenue as compared to prior periods was driven by an increased volume of tests sold and having a full year of commercialized sales compared to seven months of sales in calendar year 2021. The increase in development services
revenue was primarily due to services performed in fiscal year 2022 for a large biopharmaceutical partner, as well as new pilots initiated with other biopharmaceutical partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Revenue (Exclusive of Amortization of Acquired Intangible Assets) and Cost of Revenue&#151;Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in cost of revenue (exclusive of amortization of acquired intangible assets) and cost of revenue&#151;related parties corresponded
to the increase in revenue. Cost of revenue (exclusive of amortization of acquired intangible assets) and cost of revenue&#151;related parties was $5.5&nbsp;million in the 2021 predecessor period, $6.1&nbsp;million in the 2021 successor period and
$38.1&nbsp;million in fiscal year 2022. Cost of revenue (exclusive of amortization of acquired intangible assets) and cost of revenue&#151;related parties as a percent of revenue decreased in fiscal year 2022 primarily due to improved efficiency of
Galleri production process, primarily due to increased volume following the commercial launch of Galleri in mid-2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of
Revenue&#151;Amortization of Intangible Assets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase of the amortization of acquired intangible assets is a result of the
amortization of definite-lived developed technology intangible assets resulting from the Acquisition and the recognition of a full year of amortization as compared to the shorter successor period. Prior to the Acquisition, we did not have intangible
assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development and Research and Development&#151;Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development and research and development&#151;related parties expenses for the predecessor and successor periods were as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,</B><br><B>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2021 to<BR>August&nbsp;18,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256,823</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical studies and research collaboration expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,784</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory supplies and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,523</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cloud computing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,196</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and impairment expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,248</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocated and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,682</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development and research and development&#151;related parties
expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>329,576</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>311,256</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in the compensation expenses from the 2021 predecessor period to the 2021
successor period is primarily due to <FONT STYLE="white-space:nowrap">non-recurring</FONT> compensation of $201.2&nbsp;million incurred as a result of the Acquisition, primarily consisting of accelerated vesting of stock-based compensation expenses
in connection with the Acquisition, which resulted in $615.0&nbsp;million of expense recognized immediately upon closing of the Acquisition in August 2021, of which $177.7&nbsp;million was allocated to research and development, and retention
incentives of $23.5&nbsp;million. The decrease from the 2021 successor period to fiscal year 2022 was a result of no non-recurring transaction related compensation expenses in the 2021 successor period, which was offset by increased headcount year
over year and the introduction of new employee long-term incentive programs in the post transaction period. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies and research
collaboration expenses increased in 2022 as compared to other periods presented, primarily due to increased clinical study activity. The majority of the increase in our clinical studies and research collaboration expenses relate to the <FONT
STYLE="white-space:nowrap">NHS-Galleri</FONT> Trial which enrolled its first patient in August 2021, and the PATHFINDER 2 clinical study, which began enrollment in the fourth quarter of 2021, as a result of active enrollment and a full year of
expenses in 2022. These increases were partially offset by a reduction in expenses related to the SUMMIT and STRIVE clinical studies as enrollment completed in the predecessor period and thus study activity decreased. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in the laboratory supplies and expenses from the 2021 predecessor period to the 2021 successor period is a result of a decrease
in clinical study sample processing, a decrease in general research and development sample processing, and a $0.9 million reduction in expenses due to renegotiation of a previously accrued purchase commitment. The increase of laboratory supplies and
expenses in 2022 as compared to other periods presented is primarily due to increased research and development and clinical study sample processing. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cloud computing expenses remained relatively unchanged period over period. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and impairment expenses increased in 2022 compared to all other periods presented as $20&nbsp;million of equipment was placed
into service at our laboratory locations. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allocated and other expenses increased as a result of higher software, IT, and facilities
expenses being allocated to the research and development function, in addition to increases in the use of contractors and temporary labor. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sales and Marketing </I></P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses in fiscal year 2022 were $122.3&nbsp;million, compared to $100.5&nbsp;million in the 2021 successor period and
$24.8&nbsp;million in the 2021 predecessor period. The increase of sales and marketing expense from the 2021 predecessor period to the 2021 successor period was primarily due to the accelerated vesting of stock-based compensation expenses in
connection with the Acquisition, which resulted in $615&nbsp;million of expense recognized immediately upon closing of the Acquisition in August 2021, $71.8&nbsp;million of which was allocated to sales and marketing. The increase of sales and
marketing expenses in fiscal year 2022 compared to all periods presented was primarily attributable to an increase of compensation expenses, primarily due to increased headcount in our dedicated sales team initially hired to support the commercial
launch of Galleri in 2021. Headcount increased 205% from the end of the 2021 successor period to the end of fiscal year 2022, contributing to higher wages, employer payroll taxes, bonuses, long-term incentive compensation, and other personnel
related costs in 2022 compared to previous periods presented. Additionally, we incurred higher travel expenses in fiscal year 2022 as a result of fewer <FONT STYLE="white-space:nowrap">COVID-19</FONT> related travel restrictions and more sales-based
travel as compared to other periods. Third-party marketing and professional services expenses increased from $6.4 million in the 2021 successor period to $28.0&nbsp;million in fiscal year 2022 to support efforts to market our newly commercialized
product. Additionally, our corporate overhead allocations increased as a result of our increased headcount. Trade name intangible assets amortization expense increased from $1.5&nbsp;million in the 2021 successor period to $4.4&nbsp;million in
fiscal year 2022 as a result of a full year of amortization as compared to the shorter 2021 successor period. These increases from the 2021 successor period to 2022 were offset by the <FONT STYLE="white-space:nowrap">one-time</FONT> stock-based
compensation expense being incurred in the 2021 successor period with no comparable expense in 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 predecessor period includes non-recurring transaction related professional services fees and insurance premiums of $51.0 million and
$4.5 million, respectively. The increase in G&amp;A expense in the 2021 successor period compared to the 2021 predecessor period was primarily due to the accelerated vesting of stock-based compensation expenses in connection with the Acquisition,
which resulted in $615.0&nbsp;million of expense recognized immediately upon closing of the Acquisition in August 2021, $365.5&nbsp;million of which was allocated to G&amp;A. Non-recurring retention bonuses of $12.4&nbsp;million and severance
related costs of $7.2 million were also incurred in the 2021 successor period. The corresponding decrease from the 2021 successor period to fiscal year 2022 was primarily a result of these <FONT STYLE="white-space:nowrap">non-recurring</FONT>
transactions not being incurred in fiscal year 2022 and a reduction in legal expenses. This decrease was partially offset by an increase in facilities expenses in fiscal year 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Goodwill Impairment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
result of an impairment assessment performed, an impairment charge of $4.7&nbsp;billion was recorded in 2022 which represents the amount by which the carrying value of GRAIL exceeded the fair value of GRAIL upon performing a quantitative test. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
decrease in interest income from the 2021 predecessor period to the 2021 successor period was primarily a result of the sale of our marketable securities upon consummation of the transaction. The increase from the 2021 successor period to fiscal
year 2022 was primarily attributable to an increase in interest earned on our money market account primarily due to the increase in length of the period, and higher interest rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in other income (expense), net from the 2021 successor period to fiscal year 2022 primarily related to unrealized foreign currency
gains, offset slightly by losses on asset retirements. The decrease from the 2021 predecessor period to the 2021 successor period was a result of foreign currency gains in the 2021 predecessor period converting to foreign currency losses in the 2021
successor period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our results provided throughout this Information Statement that are determined in accordance with GAAP, this Information
Statement also includes the following <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures for the 2021 predecessor period, 2021 successor period, and fiscal year 2022, which information should be read in conjunction with our audited
Consolidated Financial Statements and the related notes and accompanying notes included elsewhere in this Information Statement: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adjusted Gross Profit/(Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted Gross Profit/(Loss) is a key performance measure that our management uses to assess our operational performance, as it represents the
results of revenues and direct costs, which are key components of our operations. We believe that this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure is useful to investors and other interested parties in analyzing our financial
performance because it reflects the gross profitability of our operations, and excludes the indirect costs associated with our sales and marketing, product development, general and administrative activities, and depreciation and amortization, and
the impact of our financing methods and income taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We calculate Adjusted Gross Profit/(Loss) as gross profit/(loss) (as defined below)
adjusted to exclude amortization of intangible assets and stock-based compensation allocated to cost of revenue. Adjusted Gross Profit/(Loss) should be viewed as a measure of operating performance that is a supplement to, and not a substitute for,
operating income or loss from operations, net earnings or loss and other GAAP measures of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income (loss) or profitability. The following table presents a reconciliation of gross profit, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted Gross
Profit/(Loss). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,</B><br><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2021 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross loss (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(116,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,280</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,630</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Gross Profit/(Loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gross profit/(loss) is calculated as total revenue less cost of revenue (exclusive of amortization of acquired
intangible assets), cost of revenue&#151;related parties, and cost of revenue&#151;amortization of intangible assets. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adjusted EBITDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal
planning and forecasting purposes. We believe that this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable
overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of net income (loss) to Adjusted EBITDA, helps investors make comparisons between our company and other
companies that may have different capital structures, different tax rates, different operational and ownership histories, and/or different forms of employee compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including
managing expenditures. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Period-to-period</FONT></FONT> comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown
solely by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons of net income or income from operations. Our Management recognizes that Adjusted EBITDA has inherent limitations because of the
excluded items, and may not be directly comparable to similarly titled metrics used by other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We calculate Adjusted EBITDA as
net income (loss) adjusted to exclude interest (income) expense, income tax expense (benefit), depreciation, impairment of goodwill, and amortization of intangible assets, which represent acquired intangible assets resulting from pushdown
accounting. We believe that the items subject to these further adjustments are not indicative of our ongoing operations due to their nature, especially considering the impact of certain items as a result of the Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for, operating income or
loss from operations, net earnings or loss and other U.S. GAAP measures of income (loss). Additionally, it is not intended to be a measure of free cash flow for management&#146;s discretionary use, as it does not consider certain cash requirements
such as interest payments, tax payments, and debt service requirements. Further, our definition of Adjusted EBITDA may differ from similarly titled measures used by other companies and therefore may not be comparable among companies. The following
table presents a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reconciliation of net income (loss), the most directly comparable financial measure calculated in accordance with U.S. GAAP, to Adjusted EBITDA on a consolidated basis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2021 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,399,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(911,542</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted to exclude the following:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,740</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,111</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,422</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,700,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Illumina/GRAIL merger legal and professional services costs (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,750</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">650,260</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recurring</FONT> transaction related<BR>compensation
(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,346</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(500,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(158,149</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(216,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents amortization of intangible assets, including developed technology and tradenames.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects impairment of goodwill recognized as a result of the Acquisition. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents legal and professional services costs associated with the Acquisition and corresponding antitrust
litigation, including compliance with the hold separate arrangements imposed by the European Commission. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents all stock-based compensation recognized on our standalone financial statements for the periods
presented. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents various retention bonuses paid out in association with the transaction in accordance with terms of
the Merger Agreement, as well as severance paid to executives who did not continue employment post-transaction in accordance with terms of their employment agreements. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From inception through the Closing Date, we had funded our operations primarily through the sale and issuance of our redeemable convertible
preferred stock and receipt of continuation payments from Illumina. Post-Acquisition, we received funding on a quarterly basis directly from Illumina. As of January&nbsp;1, 2023, our cash and cash equivalents totaled $241.6&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began generating revenue in mid-2021, but we have continued to incur significant losses and negative cash flows from operations. Subsequent
to the Acquisition, we have incurred net losses of $6.3 billion which include charges for impairment of goodwill and amortization of intangible assets. We expect to incur additional losses in the foreseeable future as we conduct and expand our
research and development efforts and seek to achieve broad reimbursement of our current commercialized products. We believe that our existing cash and cash equivalents, in addition to the funding that Illumina is required to provide pursuant to the
EC Divestment Decision, will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months, as of the date of this Information Statement. However, we anticipate that we will need to raise additional
financing in the future to fund our operations. Our future capital requirements will depend on many factors, including the timing and extent of spending to support development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization efforts; the timing of our launch and market acceptance of our products; other expenditures, including marketing activities; and additional costs associated with operating as a
public company. We are subject to all the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, the data of which is needed to support commercial launch of our
products, and other unknown factors that may adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future enter into arrangements to acquire or
invest in complementary businesses, services, technologies, and intellectual property rights. We may be required to seek additional capital through equity or debt financing. In the event that additional financing is required, we may not be able to
raise it on terms acceptable to us or at all. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations, and the existence
of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations. We may also choose to raise funds through collaborations and licensing
arrangements, in which case we may relinquish significant rights or grant licenses on terms that are not favorable to us. If we are unable to raise additional capital when desired, our business, results of operations, and financial condition would
be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2021 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; "></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt"></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(561,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(485,870</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(202,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used by) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,976</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">352,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used by) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">604,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,931</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,134</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(350,050</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>401,275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used by Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2021 predecessor period, net cash used by operating activities consisted of a net loss of $336.2&nbsp;million, adjusted by <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $38.4&nbsp;million, and cash provided by changes in our operating assets and liabilities of $95.5&nbsp;million. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of
stock-based compensation expense of $31.6&nbsp;million, depreciation of $6.9 million, and amortization of premium on marketable securities of $0.5&nbsp;million. Cash provided by operating assets and liabilities was primarily a result of an increase
in accounts payable of $62.5&nbsp;million, an increase in accrued and other liabilities of $13.3&nbsp;million, and an increase in operating lease liabilities which was primarily due to tenant inducements received from our landlord of
$18.2&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2021 successor period, net cash used by operating activities consisted of a net loss of
$911.5&nbsp;million, adjusted by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $684.6&nbsp;million, $185.0 million of cash payments for equity awards and cash used by changes in our operating assets and liabilities of
$74.0&nbsp;million. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges primarily consisted of stock-based compensation expense of $650.3&nbsp;million and depreciation and amortization of $51.5&nbsp;million, which was partially offset by a <FONT
STYLE="white-space:nowrap">non-cash</FONT> benefit of $17.5&nbsp;million relating to deferred income tax. The main driver of changes in our operating assets and liabilities was an increase in accounts receivable of $6.1&nbsp;million, an increase in
supplies and supplies&#151;related parties of $3.7&nbsp;million, and a decrease of accounts payable and accounts payable-related parties of $63.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During fiscal year 2022, net cash used by operating activities consisted of a net loss of
$5.4&nbsp;billion, adjusted by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $4.9&nbsp;billion, $41.0&nbsp;million cash payments for equity awards, and cash used by changes in our operating assets and liabilities of $14.5&nbsp;million.
The <FONT STYLE="white-space:nowrap">non-cash</FONT> adjustments consisted of goodwill impairment of $4.7&nbsp;billion, depreciation and amortization of $154.8&nbsp;million, and stock-based compensation expense of $75.7&nbsp;million, which was
partially offset by a non-cash benefit of $39.1&nbsp;million relating to deferred taxes. The changes in operating assets and liabilities was predominantly driven by increases in accounts receivable of $8.6 million, an increase in prepaids and other
current assets of $11.3&nbsp;million, an increase in supplies and supplies&#151;related parties of $14.1&nbsp;million, partially offset by an increase in accrued and other liabilities of $14.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Provided by Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2021 predecessor period, net cash provided by investing activities consisted of $574.1&nbsp;million in proceeds from the sale of and
the maturities of marketable securities, partially offset by $159.4&nbsp;million in purchases of marketable securities and $62.0&nbsp;million of capital expenditures. Capital expenditures were primarily related to purchases of machinery and
equipment for use in our laboratories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2021 successor period, net cash used by investing activities consisted of
$8.0&nbsp;million for capital expenditures primarily related to purchases of machinery and equipment for use in our laboratories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
fiscal year 2022, net cash used by investing activities primarily consisted of $22.9&nbsp;million for capital expenditures primarily related to purchases of machinery and equipment for use in our laboratories. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Provided by Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2021 predecessor period, net cash provided by financing activities consisted of $245.0&nbsp;million in funding from Illumina and
$6.0&nbsp;million of proceeds from the exercise of stock options and the early exercise of unvested stock options, partially offset by $0.2&nbsp;million of repurchases of early exercised stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2021 successor period, net cash provided by financing activities primarily consisted of $774.0&nbsp;million in funding received
from Illumina, offset by $625.7&nbsp;million cash payments for acquisition consideration on behalf of Illumina, and by $4.3&nbsp;million of taxes paid related to net share settlement of equity awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2022 successor period, net cash provided by financing activities primarily consisted of $609.0&nbsp;million in funding received
from Illumina, offset by $4.2&nbsp;million of taxes paid related to net share settlement of equity awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Cash Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
material cash requirements include the following contractual and other obligations as of December&nbsp;31, 2023: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have entered into operating leases for facilities and equipment used for research and development. Operating
leases have remaining lease terms which range from 1 year to 11 years, and often include one or more options to renew. These renewal terms can extend the lease term from 5 to 15 years and are included in the lease term when it is reasonably certain
that the option will be exercised. The exercise of lease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
renewal and termination options are at the sole discretion of GRAIL. We also have variable lease payments that are primarily comprised of common area maintenance and utility charges. As of
December&nbsp;31, 2023, we had operating lease payment obligations of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; payable within twelve
months of December&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Purchase Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contractual obligations represent future cash commitments and liabilities under agreements with third parties and exclude purchase orders for
goods and services that are cancellable. Our <FONT STYLE="white-space:nowrap">non-cancelable</FONT> purchase orders represent authorizations to purchase rather than binding agreements. The Company&#146;s contractual commitment amounts are associated
with agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum services to be used; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The
purchase commitments primarily relate to contractual commitments for future use of web services, laboratory supplies and marketing events in the normal course of business. As of December&nbsp;31, 2023, we had non-cancelable purchase obligations of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; payable within twelve months of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Minimum Royalties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Minimum royalty commitments are associated with licensing agreements related to research efforts. Minimum annual royalty payments do not
include royalties that would be payable on net sales of Galleri or any future products, pursuant to existing agreements and licenses with Illumina, The Chinese University of Hong Kong, and other third parties in excess of minimum annual royalty
payments. As of December&nbsp;31, 2023, we had minimum royalties of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; payable within twelve
months of December&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion and analysis of our financial condition and results of operations is based on our audited Consolidated Financial Statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these audited Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the audited Consolidated Financial Statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in the notes to our audited Consolidated Financial Statements included elsewhere in this Information Statement, we
believe that the following accounting policies are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
revenue is derived from screening and development services. Screening revenue includes cancer screening testing services provided to patients. Patients obtain tests via their employers, healthcare systems, payors, concierge medicine practices, or
life insurance providers, or they can order the test via telemedicine (collectively referred to as our direct customers). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Screening
Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize screening revenue from the sale of cancer screening testing services for patients. The test price is based on the
negotiated contractual rate with our direct customers, otherwise our standard list price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applies. For each specimen received, testing services are performed and test results are electronically delivered to the ordering physician. We identify each sale of our test to a customer as a
single performance obligation; therefore, revenue is recognized at the point of time when the test result report is delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT
STYLE="white-space:nowrap">self-pay</FONT> patients, we have concluded that an implied contract exists, however the transaction price for the implied contract represents variable consideration as there are situations in which we do not expect to
collect the full invoiced amounts from <FONT STYLE="white-space:nowrap">self-pay</FONT> patients due to price concessions. We utilize the expected value approach to estimate the transaction price and apply a constraint for such variable
consideration, on a portfolio basis. We monitor the estimated amounts to be collected at each reporting period and assess whether a revision to the estimate is required based on the actual cash collections. Both the estimate and any subsequent
revisions are subject to uncertainty and require significant judgment in the estimation and application of the constraint for such variable consideration. We analyze our actual cash collections over the expected collection period and compare it with
the estimated variable consideration for each portfolio. The difference is then recognized as an adjustment to revenue when we do not believe there is a probable revenue reversal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Development Services Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a breakthrough methylation-based technology which is utilized by biopharmaceutical companies in research and clinical
studies, and companion diagnostic development. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone
selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive
pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by
reference to the total transaction price less the sum of the observable standalone selling prices of other performance obligations promised in the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biopharmaceutical partners engage with us to run pilot and research studies by sending patient samples and comparing our test result to their
expected result for evaluation of performance and application. We recognize revenue as performance obligations are completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
favorable results from pilot and research studies, biopharmaceutical partners may enter into development service agreements with us related to clinical study and companion diagnostic device development and regulatory submissions for the developed
product(s). These agreements typically have multiple commitments of services and therefore, have longer performance periods. We use an input method based on costs incurred to measure our progress toward the completion and satisfaction of the
performance obligations. We assess the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognized at each reporting
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Clinical Studies and Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We accrue for estimated costs of research and development activities conducted by third-party service providers, including those conducting
clinical studies. We record the estimated costs of research and development activities based upon the estimated amount of services provided and include these costs in accrued liabilities and accrued liabilities&#151;related parties in our
consolidated balance sheets and within research and development and research and development&#151;related parties expenses in our consolidated statements of operations. These costs are a significant component of our research and development
expenses. We accrue for these costs based on factors such as estimates of the work completed and in accordance with agreements established with our third-party service providers. We make judgments and estimates in determining the accrued liabilities
balance in each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash-Based Equity Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our employees through a long-term incentive program that includes GRAIL cash-based equity incentive awards (&#147;Cash-Based
Equity Awards&#148;). As these awards are indexed to the value of GRAIL and settled in cash, they are accounted for under ASC 718 <I>Compensation </I>- <I>Stock Compensation</I> as a liability-classified award because the substantive terms of the
award require cash settlement on each vesting date. Under ASC 718, we have elected to expense the compensation cost over the life of the award via a straight-line method, recognized in stock-based compensation expense. This method results in the
amount of compensation cost recognized as of any date to be at least equal to the fair value of the awards that is vested as of that date. Given we do not have an actively traded standalone stock, we use independent valuation experts and analyses to
value the awards, which may require various assumptions to be used, such as our long-range financial projections, as well as the discount rate and terminal growth rate. The assumptions used are inherently subject to uncertainty and we note that
small changes in these assumptions could have a significant impact on the concluded value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and Indefinite-Lived Intangible
Impairment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill represents the costs in excess of the fair value of net assets of GRAIL acquired by Illumina. Indefinite-lived
intangible assets consist of GRAIL&#146;s in-process research and development (&#147;IPR&amp;D&#148;) and were measured by Illumina at fair value as of the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We test goodwill and indefinite-lived intangible assets for impairment annually or more frequently if an event occurs or circumstances change
in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. Goodwill and indefinite-lived intangible assets are considered to be impaired when the carrying value of a reporting unit or asset exceeds
its fair value. GRAIL currently has one reporting unit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the evaluation of goodwill for impairment, we first assess qualitative factors
to determine whether it is more likely than not that the fair value of a reporting entity is less than its carrying value. If we determine that it is more likely than not for a reporting unit&#146;s fair value to be greater than its carrying value,
a calculation of the fair value is not performed. If we determine that it is more likely than not for a reporting unit&#146;s fair value to be less than its carrying value, a calculation of the fair value is performed and compared to the carrying
value of that reporting unit. In certain instances, we may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying value of a reporting unit exceeds its fair value, goodwill of that
reporting unit is impaired and an impairment loss is recorded equal to the excess of the carrying value over its fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally,
we measure the fair value of the reporting unit based on a present value of future discounted cash flows. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting
units are expected to generate in the future. Significant estimates in the discounted cash flow models include the weighted average cost of capital, revenue growth rates, long-term rate of growth, and profitability of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discount rates were determined using a weighted average cost of capital for risk factors specific to us and other market and industry data. In
our most recent analysis, we selected a discount rate of 22.0%. The estimates and assumptions used in our assessment represent a Level&nbsp;3 measurement because they are supported by little or no market activity and reflect our own assumptions in
measuring fair value. The assumptions used are inherently subject to uncertainty and we note that small changes in these assumptions could have a significant impact on the concluded value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 13, 2022, the European General Court ruled that the European Commission had jurisdiction under the European Union Merger Regulation to
review the Acquisition. Additionally, on September 6, 2022, the European Commission issued a decision prohibiting the Acquisition. These decisions constituted substantive changes in circumstances and led us to test goodwill for impairment. Based on
our analysis, we concluded that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our reporting unit&#146;s carrying value exceeded its estimated fair value. As a result, we recorded $4.7 billion of goodwill impairment, primarily due to the negative impact of capital market
conditions and a higher discount rate selected for the fair value calculation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2023, Illumina
recorded an impairment to GRAIL goodwill and IPR&amp;D for consolidated financial reporting purposes. We are currently in the process of performing our required goodwill and indefinite-lived impairment test, which may result in impairment charges.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth
company under the Jumpstart our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We
have nonetheless irrevocably elected not to avail ourselves of this exemption and, as a result, upon completion of this offering, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required
for other public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest to occur of the following: (i)&nbsp;the last day
of the fiscal year in which our total annual gross revenues first meet or exceed at least $1.235&nbsp;billion (as adjusted for inflation), (ii) the date on which we have, during the prior three-year period, issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt, (iii)&nbsp;the last day of the fiscal year in which we (a)&nbsp;have an aggregate worldwide market value of common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of
$700&nbsp;million or more (measured at the end of each fiscal year) as of the last business day of our most recently completed second fiscal quarter and (b)&nbsp;have been a reporting company under the Exchange Act for at least one year (and have
filed at least one annual report under the Exchange Act), or (iv)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the
Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 to our audited Consolidated Financial Statements included elsewhere in this Information Statement for details of recent accounting
pronouncements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Sensitivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $241.6&nbsp;million as of
January&nbsp;1, 2023, which consisted primarily of bank deposits and money market funds. The primary objective of our investment activities is to preserve capital to fund our operations. We do not enter into investments for trading or speculative
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investments are subject to interest rate risk and could fall in value if market interest rates increase. Due to the
short-term duration of our investment portfolio and the <FONT STYLE="white-space:nowrap">low-risk</FONT> profile of our investments, a hypothetical 10% relative change in interest rates during any of the periods presented would not have had a
material impact on our Consolidated Financial Statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Sensitivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our transactions occur in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than
the U.S. dollar, primarily the British pound, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against the foreign currencies affects the reported amounts of expenses, assets, and liabilities
associated with certain activities. We do not currently engage in any hedging activity to reduce our potential exposure to currency fluctuations, although we may choose to do so in the future. A hypothetical 10% change in foreign exchange rates
during any of the periods presented would not have had a material impact on our Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_14"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers of GRAIL Following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying narrative present information, as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, regarding the individuals who are expected to serve as executive officers of GRAIL following the completion of the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> including a five-year employment history. We are in the process of identifying any other persons who may be expected to serve as executive officers following the completion of the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> and will include information concerning those persons in an amendment to this Information Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position with GRAIL</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ragusa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Freidin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josh Ofman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors of GRAIL Following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying narrative present information, as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, regarding the individuals who are expected to serve on our Board of Directors (the &#147;Board&#148;) following the completion of the <FONT
STYLE="white-space:nowrap">Spin-Off</FONT> and until their respective successors are duly elected and qualified, including a five-year employment history and any directorships held by our directors in public companies. We are in the process of
identifying the persons who are expected to serve as directors following the completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and will include information concerning those persons in an amendment to this Information Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position with GRAIL</B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nomination Process </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial
Board will be selected through a process involving Illumina and us. The initial directors who will serve after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> are expected to begin their terms at the time of the Distribution, except as noted
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Structure and Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> our Board will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; members. Our board has determined that each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is independent under the applicable Nasdaq Global Select Market rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors will be divided into three classes serving staggered three-year terms. Class&nbsp;I, Class&nbsp;II, and Class&nbsp;III directors
will serve until our annual meetings of stockholders in 2024, 2025, and 2026, respectively. The Class&nbsp;I directors will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . The Class&nbsp;II directors will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The Class&nbsp;III directors will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. At each annual meeting of stockholders, directors
will be elected to succeed the class of directors whose terms have expired. This classification of our Board could have the effect of increasing the length of time necessary to change the composition of a majority of the Board. In general, at least
two annual meetings of stockholders will typically be necessary for stockholders to effect a change in a majority of the members of the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Sessions</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the
independent directors will meet in executive session in which independent directors meet without the presence or participation of management at most regular Board meetings and meet in executive session at other times whenever they believe it
appropriate. We expect that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will chair the executive sessions of the independent directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended January&nbsp;1, 2023, GRAIL did not have a compensation committee (or any other committee serving a similar
function). Decisions as to the compensation of those who served as our executive officers for that fiscal year required agreement with Illumina (including its compensation committee) on a mutually acceptable and workable approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective
immediately prior to the commencement of &#147;when issued&#148; trading, the Board will have a standing Audit Committee, and upon the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> our Board is expected to have three additional
standing committees: the Compensation Committee, the Nominating and Governance committee, and the Science, Medicine, and Technology Committee. Each committee is governed by a charter that will be available on our website following completion of this
<FONT STYLE="white-space:nowrap">Spin-Off.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the members of our Audit Committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairperson of our Audit Committee. The
composition of our Audit Committee meets the requirements for independence under the current listing standards of the Nasdaq Global Select Market and Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act. Each member of our Audit
Committee is financially literate. In addition, our Board has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an &#147;audit committee financial expert&#148; within the meaning of
the SEC rules. This designation does not impose on such directors any duties, obligations, or liabilities that are greater than are generally imposed on members of our Audit Committee and our Board. Our Audit Committee is directly responsible for,
among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, retaining, compensating, and overseeing the work of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing the independence and performance of the independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with our independent registered public accounting firm the scope and results of the firm&#146;s annual
audit of our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the financial reporting process and discussing with management and our independent registered public
accounting firm the financial statements that we will file with the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing policies and practices related to risk assessment and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our accounting and financial reporting policies and practices and accounting controls, as well as
compliance with legal and regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, overseeing, approving, or disapproving any related-person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with our management the scope and results of management&#146;s evaluation of our disclosure controls
and procedures and management&#146;s assessment of our internal control over financial reporting, including the related certifications to be included in the periodic reports we will file with the SEC; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting,
internal controls, or auditing matters, or other ethics or compliance issues. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the members of our Compensation Committee will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairperson of our Compensation
Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined by Rule <FONT STYLE="white-space:nowrap">16B-3</FONT> of the Exchange Act and meet the requirements for independence under the current Nasdaq Global Select Market listing
standards. Our Compensation Committee is directly responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of our executive officers, including reviewing and approving corporate
goals and objectives with respect to compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to act as an administrator of our equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or making recommendations to our Board with respect to, incentive compensation and
equity plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending that our Board approve the compensation for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> board members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and reviewing general policies relating to compensation and benefits of our employees.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the members of our Nominating and Governance Committee will
consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairperson of our Nominating and
Governance Committee. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; meet the requirements for independence under the current Nasdaq Global Select Market listing standards. Our Nominating and Governance Committee is
responsible for, among other thing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and recommending candidates for membership on our Board, including the consideration of nominees
submitted by stockholders, and on each of the Board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending our corporate governance guidelines and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing proposed waivers of the code of business conduct and ethics for directors and executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the process of evaluating the performance of our Board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting our Board on corporate governance matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Science, Medicine, and Technology Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the members of our Science, Medicine, and Technology
Committee will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chairperson of our Science, Medicine,
and Technology Committee. Our Science, Medicine, and Technology Committee is responsible for, among other thing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advising our Board on key scientific, medical, and technological issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating, and advising our Board regarding our performance in achieving long-term strategic goals
and objectives and the quality and direction of our research and development programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting our Board with recruitment and retention of scientific and technological talent to advance our research
and development programs. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will adopt a code of business conduct and ethics that applies to
all of our employees, officers, and directors, including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. Upon completion of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the full text
of our code of business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conduct and ethics will be posted on the investor relations section of our website. We intend to disclose future amendments to our code of business conduct and ethics, or any waivers of such
code, on our website or in public filings if required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently in the process of determining the composition of our Board and of developing the details regarding the compensation packages
of the directors who will comprise our Board. This is an ongoing process and we will include the relevant disclosure in an amendment to this Information Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have a board of directors in 2022 and we have not established a compensation program for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. In connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we expect to approve and implement a compensation program for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors that we expect will consist of annual retainer fees and long-term equity awards. We expect that directors who are also full-time officers or employees of our company will receive no
additional compensation for serving as directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_15"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our named executive officers (NEOs) who are named in
the &#147;2023 Summary Compensation Table&#148; below. In 2023, our NEOs and their positions were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert Ragusa, Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aaron Freidin, Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Josh Ofman, President. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations
regarding future compensation programs and policies. Actual compensation programs and policies that we implement following the completion of the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> may differ materially from the currently planned
programs and policies summarized in this discussion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation awarded to or earned by our NEOs during our fiscal years ended
December&nbsp;31, 2023 and December&nbsp;31, 2022. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2023 SUMMARY COMPENSATION TABLE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ragusa <BR></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Freidin<BR></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josh Ofman<BR></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2023 Salaries </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual base salaries for Robert Ragusa, Aaron Freidin, and Josh Ofman for 2023 were $785,000 (increased from $750,000 in 2022), $560,000
(increased from $535,000 in 2022), and $655,000 (increased from $630,000 in 2022), respectively. Increases in base salary were approved following an analysis of market positioning against peers in alignment with our overall compensation philosophy.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2023 Annual Bonuses <FONT STYLE="white-space:nowrap">(Non-Equity</FONT> Incentive Plan Awards) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our annual Variable Compensation Program (&#147;VCP&#148;) provides the opportunity to eligible employees, including our NEOs, to earn annual
cash bonuses based on the achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> corporate and individual performance goals for the applicable fiscal year. Individual VCP targets are determined by salary grade and expressed as a
percentage of base pay&#151;2023 target bonuses for Messrs. Ragusa, Freidin, and Ofman have not been changed since 2022 and were 100%, 50%, and 50% of applicable base salary, respectively. The payment of any annual bonus, if earned, is contingent
upon the applicable participant&#146;s (i)&nbsp;continued employment or other service with the company through the applicable payment date, (ii)&nbsp;employment start date commencing on or prior to October&nbsp;1 of the applicable fiscal year and
(iii)&nbsp;continued compliance with company policy and applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity-Linked Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our NEOs currently holds Cash-Based Equity Awards representing dollar-denominated, long-term incentive awards which increase or
decrease in value based on corresponding changes in our equity value. The Cash-Based Equity Awards generally vest and are paid out incrementally over a four-year period with twenty-five percent (25%) of the award vesting and paid (based on value as
of the applicable vesting date) on or shortly after each of the first four anniversaries of the vesting commencement date, subject to continued employment through the applicable vesting date. If we experience a &#147;change in control&#148; (as
provided in the Cash-Based Equity Award agreements), the Cash-Based Equity Awards will continue on their terms unless the Cash-Based Equity Awards are not assumed/continued or substituted for in connection with such change in control, in which case
the Cash-Based Equity Awards will vest and be paid upon such change in control. The Cash-Based Equity Awards are generally paid in cash, but may be converted into Illumina restricted stock units at Illumina&#146;s election, in which case the
converted awards would entitle the applicable holder to awards denominated in Illumina common shares and would be valued based on the fluctuation in value of Illumina shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information about these awards, please see the sections titled &#147;&#151;Outstanding Equity Awards at Fiscal Year End&#148;
and &#147;&#151;Executive Compensation Arrangements&#148; below. For information regarding their treatment in connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> see &#147;The Spin-Off&#151;Treatment of Outstanding Equity Incentive
Awards&#148; beginning on page 100 of this Information Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt a 2024 Incentive Award Plan, referred to below as
the 2024 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our NEOs) and consultants of our company and certain of our subsidiaries and to enable our company and certain of our subsidiaries to
obtain and retain services of these individuals following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> which we view as essential to our long-term success. We expect that the 2024 Plan will become effective in connection with the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> subject to approval of such plan by Illumina, in its capacity as our sole stockholder, as required by applicable listing requirements. For additional information about the 2024 Plan, please see the section
titled &#147;&#151;Executive Compensation Arrangements&#151;2024 Equity Incentive Plan&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Elements of Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Retirement Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
maintain a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) retirement savings plan for our employees, including our NEOs, who satisfy certain eligibility requirements. Our NEOs are eligible to participate in the 401(k) plan on the same
terms generally as other eligible, full-time employees. The Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis through contributions to the
401(k) plan. We believe that providing a vehicle for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our
employees, including our NEOs, in accordance with our compensation policies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Health/Welfare Plans. </I>All of our full-time employees, including our NEOs, are eligible to participate in our health and welfare plans,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical, dental, and vision benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical and dependent care flexible spending accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short-term and long-term disability insurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">wellbeing benefits (including mental health, <FONT STYLE="white-space:nowrap">back-up</FONT> care and family
forming benefits); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">life insurance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the benefits described above are <FONT STYLE="white-space:nowrap">in-line</FONT> with market practice and necessary and appropriate
to provide a competitive compensation package to our NEOs. There are no executive perquisites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>No Tax <FONT STYLE="white-space:nowrap">Gross-Ups</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not make <FONT STYLE="white-space:nowrap">gross-up</FONT> payments to cover our NEOs&#146; personal income taxes that may pertain to any
of the compensation or perquisites paid or provided by our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the number of shares of common stock underlying outstanding equity incentive awards for
each NEO as of December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares<BR>or&nbsp;Units&nbsp;of<BR>Stock<BR>That Have<BR>Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares<BR>or Units<BR>of Stock<BR>That<BR>Have<BR>Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number<BR>of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other<BR>Rights<BR>That&nbsp;Have<BR>Not<BR>Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market<BR>or Payout<BR>Value of<BR>Unearned<BR>Shares,<BR>Units or<BR>Other<BR>Rights<BR>That<BR>Have
Not<BR>Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Ragusa</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aaron Freidin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josh Ofman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE COMPENSATION ARRANGEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a description of the material terms of each employment contract, agreement, plan, or arrangement that provides for the employment of,
and payments to, our NEOs (including such payments to be made at, following or in connection with the resignation, retirement, or other termination of an NEO, or following a change in control). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer Letters and Separation and General Release Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Robert Ragusa Offer Letter </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into an employment offer letter with Robert Ragusa, dated October&nbsp;14, 2021, pursuant to which Mr.&nbsp;Ragusa serves as our Chief Executive Officer. Mr.&nbsp;Ragusa&#146;s employment pursuant to the offer letter is <FONT
STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> and is terminable by either party with or without notice or cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to his
offer letter, Mr.&nbsp;Ragusa was entitled to receive an initial base salary of $725,000 (increased to $785,000 in 2023). In addition, pursuant to his offer letter, Mr.&nbsp;Ragusa is eligible to participate in our VCP with a target bonus of 100% of
his base salary. In connection with his entry into his offer letter, Mr.&nbsp;Ragusa was granted a Cash-Based Equity Award with an initial award value of $15,800,000 (subject to adjustment based on changes in our equity value) vesting in annual
increments as to 25% of the award on each of the first four anniversaries of grant, and received a signing bonus in the amount of $4,000,000, of which 50% was subject to clawback in the event of a voluntary resignation or termination by us without
cause within 12 months of commencing employment with us. The offer letter also provides that Mr.&nbsp;Ragusa will be entitled to receive standard benefits in accordance with our policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the offer letter, if Mr.&nbsp;Ragusa&#146;s employment is terminated by us without cause or Mr.&nbsp;Ragusa resigns with good
reason (each as defined in the offer letter), then, in addition to any accrued benefits and subject to his timely execution of an effective separation and release agreement in a form prescribed by us, Mr.&nbsp;Ragusa will be entitled to receive the
following severance payments and benefits: (i)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to the sum of (x) 12 months of base salary and (y) 100% of Mr.&nbsp;Ragusa&#146;s target bonus under the VCP,
(ii)&nbsp;reimbursement for the cost of health benefits under COBRA for up to 12 months, and (iii)&nbsp;accelerated vesting of any outstanding equity award(s) (or portion thereof) that would have vested over 12 months following such termination had
Mr.&nbsp;Ragusa&#146;s service not terminated (with performance-vesting awards being deemed vested at target). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change
in control transaction, if outstanding and unvested equity awards are not assumed by the acquirer or successor, Mr.&nbsp;Ragusa&#146;s outstanding and unvested equity awards shall accelerate in full as of immediately prior to the closing of the
change in control transaction. In addition, pursuant to his offer letter, if Mr.&nbsp;Ragusa&#146;s employment is terminated by us without cause or he resigns for good reason, in either case, within 24 months following or within 3 months preceding a
change in control, then Mr.&nbsp;Ragusa will instead be entitled to receive the following severance payments and benefits (subject to the same separation and release agreement requirements and in lieu of the amounts described above): (i) a <FONT
STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 24 months of base salary, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 200% of Mr.&nbsp;Ragusa&#146;s target bonus under
the VCP, (iii)&nbsp;reimbursement for the cost of health benefits under COBRA for up to 24 months, and (iv)&nbsp;full accelerated vesting of outstanding and unvested equity awards (including equity appreciation awards, and with performance vesting
awards vesting based on target performance). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Aaron Freidin Letter Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a letter agreement with Aaron Freidin, dated July&nbsp;5, 2018, pursuant to which Mr.&nbsp;Freidin&#146;s employment is <FONT
STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> and terminable by either party with or without notice or cause. The letter agreement provides that if Mr.&nbsp;Freidin&#146;s employment is terminated by us without cause or Mr.&nbsp;Freidin
resigns for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
good reason (each as defined in the letter agreement), then, in addition to accrued benefits and subject to his timely execution of an effective separation and release agreement in a form
prescribed by us, Mr.&nbsp;Freidin will be entitled to receive the following severance payments and benefits: (i)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to nine months of base salary and
(ii)&nbsp;reimbursement for the cost of health benefits under COBRA for up to nine months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pursuant to
Mr.&nbsp;Freidin&#146;s letter agreement, if Mr.&nbsp;Freidin&#146;s employment is terminated by us without cause or Mr.&nbsp;Freidin resigns for good reason, in either case, within 12 months following or 3 months preceding a change in control, then
Mr.&nbsp;Freidin will instead be entitled to receive the following severance payments and benefits (subject to the same separation and release agreement requirements and in lieu of the amounts described above): (i) a
<FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 12 months of base salary, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 100% of Mr.&nbsp;Freidin&#146;s target
bonus under the VCP, (iii)&nbsp;reimbursement for the cost of health benefits under COBRA for up to 12 months, and (iv)&nbsp;full accelerated vesting of outstanding and unvested equity awards (with performance vesting awards vesting based on target
performance). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Josh Ofman Offer Letter </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment offer letter with Josh Ofman, dated May&nbsp;13, 2019, pursuant to which Mr.&nbsp;Ofman serves as our
President. Mr.&nbsp;Ofman&#146;s employment under the offer letter is <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> and is terminable by either party with or without notice or cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to his offer letter, Mr.&nbsp;Ofman was entitled to receive an initial base salary of $500,000 (in 2023, Mr.&nbsp;Ofman&#146;s base
salary was $655,000) and is eligible to participate in our VCP with a target bonus of 50% of his base salary. In connection with his entry into the offer letter, Mr.&nbsp;Ofman was granted an option to purchase 2,340,000 shares of Grail common
stock, vesting as to one-fourth (1/4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) of the shares subject thereto on the first anniversary of the vesting commencement date and thereafter as to
<FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> (1/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) of the shares subject thereto on each monthly anniversary of the vesting commencement date, subject to continued service on the
applicable vesting date, and received a signing bonus in the amount of $750,000, subject to clawback in the event of termination by us for cause or resignation by Mr.&nbsp;Ofman without good reason, in either case, within 12 months of commencing
employment with us, and reimbursement for relocation expenses, also subject to clawback in the event of termination by us for cause or resignation by Mr.&nbsp;Ofman without good reason, in either case, within 12 months of the payment date.
Mr.&nbsp;Ofman&#146;s option award was converted into an Illumina equity award in connection with Illumina&#146;s acquisition of GRAIL in 2021, which is now fully vested. The offer letter also provides that Mr.&nbsp;Ofman will be entitled to receive
standard benefits in accordance with our policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the offer letter, in the event that Mr.&nbsp;Ofman&#146;s employment is
terminated by us without cause or Mr.&nbsp;Ofman resigns for good reason (each as defined in the offer letter), then, in addition to accrued benefits and subject to his timely execution of an effective separation and release agreement in a form
prescribed by us, Mr.&nbsp;Ofman will be entitled to receive the following severance payments and benefits: (i)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to nine months of base salary and
(ii)&nbsp;reimbursement for the cost of health benefits under COBRA for up to nine months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the offer letter, in
the event that Mr.&nbsp;Ofman&#146;s employment is terminated by us without cause or Mr.&nbsp;Ofman resigns for good reason, in either case, within 12 months following or 3 months preceding a change in control, then Mr.&nbsp;Ofman will instead be
entitled to receive the following severance payments and benefits (subject to the same separation and release agreement requirements and in lieu of the amounts described above): (i) a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in
an amount equal to 12 months of base salary, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment in an amount equal to 100% of Mr.&nbsp;Ofman&#146;s target bonus under the VCP, (iii)&nbsp;reimbursement for the cost of health
benefits under COBRA for up to 12 months, and (iv)&nbsp;full accelerated vesting of outstanding and unvested equity awards (with performance vesting awards vesting based on target performance). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2024 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt the 2024 Incentive Award Plan, or the 2024 Plan, subject to approval by Illumina, in its capacity as our sole stockholder,
as required by applicable listing requirements, under which we may grant cash and equity incentive awards to eligible service providers in order to attract, motivate, and retain the talent for which we compete. The material terms of the 2024 Plan,
as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing the 2024 Plan and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility and Administration</I>. Our employees, consultants, and directors, and employees, consultants, and directors of our
subsidiaries, will be eligible to receive awards under the 2024 Plan, however, only our employees will be eligible to receive incentive stock options (&#147;ISOs&#148;). Following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> the 2024 Plan
will be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to other participants, each of which may delegate its duties and
responsibilities to committees of our board of directors and/or officers (referred to, collectively, as the plan administrator below), subject to certain limitations that may be imposed under the 2024 Plan, Section&nbsp;16 of the Exchange Act,
and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2024 Plan, subject to
its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2024 Plan, including any vesting and vesting acceleration conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Available</I>. An aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock will be available for issuance under awards granted pursuant to the 2024 Plan, which shares may be authorized but unissued shares or shares purchased in the open market. Notwithstanding anything to the contrary in the 2024
Plan, no more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock may be issued pursuant to the exercise of ISOs under the 2024 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares available for issuance will be increased annually on the first day of each calendar year beginning January&nbsp;1, 2024
and ending on and including January&nbsp;1, 2033, equal to the lesser of (A) &nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;such
smaller number of shares as is determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award under the 2024 Plan expires, lapses, or is terminated,
exchanged for, or settled in cash, surrendered, repurchased, canceled without having been fully exercised, or forfeited, any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used again for new
grants under the 2024 Plan. Further, shares delivered to us to satisfy the applicable exercise or purchase price of an award under the 2024 Plan and/or to satisfy any applicable tax withholding obligations (including shares retained by us from such
award being exercised or purchased and/or creating the tax obligation) will become or again be available for grants under the 2024 Plan. The payment of dividend equivalents in cash in conjunction with any awards under the 2024 Plan will not reduce
the shares available for grant under the 2024 Plan. However, the following shares may not be used again for grant under the 2024 Plan: (i)&nbsp;shares subject to SARs that are not issued in connection with the stock settlement of the stock
appreciation rights (&#147;SAR&#148;) on exercise and (ii)&nbsp;shares purchased on the open market with the cash proceeds from the exercise of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards granted under the 2024 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity
plan maintained by an entity with which we enter into a merger or similar corporate transaction, or the conversion or substitution of the Cash-Based Equity Awards for awards under the 2024 Plan, in each case, will not reduce the shares available for
grant under the 2024 Plan but will count against the maximum number of shares that may be issued upon the exercise of ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 Plan
provides that the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under ASC Topic 718, or any successor thereto) of all awards granted to a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar year may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not exceed the amount equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, increased to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
in the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>. The 2024 Plan provides for the grant of stock options, including ISOs and <FONT STYLE="white-space:nowrap">non-qualified</FONT>
stock options (&#147;NSOs&#148;), SARs, restricted stock, dividend equivalents, restricted stock units (&#147;RSUs&#148;), and other stock- or cash-based awards. Certain awards under the 2024 Plan may constitute or provide for a deferral of
compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2024 Plan will be evidenced by award agreements, which will detail all terms and
conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of common stock, but the plan administrator may provide for
cash settlement of any award. A brief description of each award type follows. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Options and SARs</I>. Stock options provide for the purchase of shares of our common stock in the future
at an exercise price set on the grant date. ISOs, in contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied.
SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The exercise price of a stock option or SAR may not be less than 100%
of the fair market value of the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The
term of a stock option or SAR may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock</I>. Restricted stock is an award of nontransferable shares of our common stock that are
subject to certain vesting conditions and other restrictions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>RSUs</I>. RSUs are contractual promises to deliver shares of our common stock in the future, which may also
remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of common stock prior to the delivery of the underlying shares (i.e., dividend
equivalent rights). The plan administrator may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to RSUs will be determined by the
plan administrator, subject to the conditions and limitations contained in the 2024 Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Stock- or Cash-Based Awards</I>. Other stock- or cash-based awards are awards of cash, fully vested
shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock- or cash-based awards may be granted to participants and may also be available as a payment form
in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Equivalents</I>. Dividend equivalents represent the right to receive the equivalent value of
dividends paid on shares of our common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited as of the dividend record dates during the period between the date an award is granted
and the date such award vests, is exercised, is distributed, or expires, as determined by the plan administrator. Dividend equivalents are only paid out to the extent that the vesting conditions of the underlying award are subsequently satisfied.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions</I>. The plan administrator has broad discretion to take action under the 2024 Plan, as well as
make adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our
common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations, and other corporate transactions. In addition, in the event of certain non-reciprocal transactions with our stockholders known as &#147;equity
restructurings,&#148; the plan administrator will make equitable adjustments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the 2024 Plan and outstanding awards. In the event of a change in control of our Company (as defined in the 2024 Plan), to the extent that the surviving entity declines to continue, convert,
assume, or replace outstanding awards, then all such awards will become fully vested and exercisable in connection with the transaction. If, however, the surviving entity assumes outstanding awards and, on or within 12 months of such change in
control, a participant&#146;s employment or service is involuntarily terminated by the Company (or the surviving entity or its affiliates) other than for cause (as defined in the 2024 Plan) and other than due to death or disability (as defined in
the 2024 Plan), then all such awards will become fully vested and exercisable as of the date of such termination. Awards under the 2024 Plan are generally non-transferrable, except by will or the laws of descent and distribution, or, subject to the
plan administrator&#146;s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Foreign Participants, Claw Back Provisions, Transferability, and Participant Payments</I>. The plan administrator may modify award terms,
establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of the United States.
All awards will be subject to the provisions of any claw back policy implemented by our Company to the extent set forth in such claw back policy and/or in the applicable award agreement. With regard to tax withholding, exercise price, and purchase
price obligations arising in connection with awards under the 2024 Plan, the plan administrator may, in its discretion, accept cash or check, shares of our common stock that meet specified conditions, a &#147;market sell order,&#148; or such other
consideration as it deems suitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment and Termination</I>. The plan administrator may amend or terminate the 2024 Plan at
any time; however, no amendment, other than an amendment that increases the number of shares available under the 2024 Plan, may materially and adversely affect an award outstanding under the 2024 Plan without the consent of the affected participant,
and stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws or to increase the director limit. The plan administrator will have the authority, without the approval of our stockholders, to
&#147;reprice&#148; any stock option or SAR, or cancel any stock option or SAR in exchange for cash or another award when the option or SAR price per share exceeds the fair market value of the underlying shares. The 2024 Plan will remain in effect
until the tenth anniversary of the date the board of directors adopted the 2024 Plan, unless earlier terminated by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2024
Employee Stock Purchase Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we intend to adopt the 2024
Employee Stock Purchase Plan, or the 2024 ESPP, subject to approval of such plan by Illumina, in its capacity as our sole stockholder, as required by applicable listing requirements. The material terms of the 2024 ESPP as it is currently
contemplated are summarized below. Our board of directors is still in the process of developing the 2024 ESPP and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 ESPP is comprised of two distinct components in order to provide increased flexibility to grant options to purchase shares under the
2024 ESPP to our U.S. and non-U.S. employees. Specifically, the 2024 ESPP authorizes (i)&nbsp;the grant of options to U.S. employees that are intended to qualify for favorable U.S. federal tax treatment under Section&nbsp;423 of the Code (the
&#147;Section&nbsp;423 Component&#148;) and (ii)&nbsp;the grant of options that are not intended to be tax qualified under Section&nbsp;423 of the Code to facilitate participation for employees located outside of the U.S. who do not benefit from
favorable U.S. federal tax treatment and to provide flexibility to comply with non-U.S. law and other considerations (the &#147;Non-Section&nbsp;423 Component&#148;). Where permitted under local law and custom, we expect that the
Non-Section&nbsp;423 Component will generally be operated and administered on terms and conditions similar to the Section&nbsp;423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Available for Awards; Administration</I>. A total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will initially be reserved for issuance under the 2024 ESPP. In addition, the number of shares available for issuance under
the 2024 ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2024 and ending in and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including 2033, by an amount equal to the lesser of (A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percent of the shares of our common stock outstanding on the final day of the immediately preceding calendar
year and (B)&nbsp;such smaller number of shares as is determined by our board of directors. Our board of directors or a committee of our board of directors will administer and will have authority to interpret the terms of the 2024 ESPP and determine
the eligibility of participants. We expect that the compensation committee will be the initial administrator of the 2024 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. We expect that our employees and the employees of certain of our subsidiaries participating in the 2024 ESPP from time to
time, or our designated subsidiaries, will be eligible to participate in the 2024 ESPP if they meet the eligibility requirements under the 2024 ESPP established from time to time by the plan administrator, consistent with Section&nbsp;423 of the
Code, as applicable. However, an employee may not be granted rights to purchase stock under our 2024 ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined
voting power or value of all classes of our common or other class of stock. Neither <FONT STYLE="white-space:nowrap">non-employee</FONT> directors nor consultants are eligible to participate in the 2024 ESPP. Employees who choose not to participate,
or who are not eligible to participate at the start of an offering period but who become eligible thereafter, may enroll in any subsequent offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Grant of Rights</I>. Stock will be offered under the 2024 ESPP during offering periods. The length of the offering periods under the 2024
ESPP will be determined by the plan administrator and may be up to twenty-seven months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering period
will be the final trading day in the purchase period (or, if no purchase period is specified, the final day of the offering period). The number of purchase periods within, and purchase dates during, each offering period will be established by the
plan administrator. Offering periods under the 2024 ESPP will commence when determined by the plan administrator. We expect the initial offering period under the 2024 ESPP to commence on the pricing date of our common stock in the <FONT
STYLE="white-space:nowrap">Spin-Off.</FONT> The plan administrator may, in its discretion, modify the terms of future offering periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2024 ESPP will permit participants to purchase shares of our common stock through payroll deductions of up to a specified percentage of
their eligible compensation, which will include a participant&#146;s gross cash compensation for services to us, including prior-week adjustments, overtime payments, compensation paid by the company or an designated subsidiary during any leaves of
absence, commissions, incentive compensation, and bonuses, but excluding education or tuition reimbursements, travel expenses, business and moving reimbursements, income received in connection with any compensatory equity awards, fringe benefits,
other special payments, and all contributions made by the company or any designated subsidiary for the participant&#146;s benefit under any employee benefit plan. In any non-U.S. jurisdictions where participation in the 2024 ESPP through payroll
deductions is prohibited (if any), the plan administrator may provide that an eligible employee may elect to participate through contributions to his or her account under the 2024 ESPP in a form acceptable to the plan administrator in lieu of or in
addition to payroll deductions. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be 20,000
shares. In addition, no participant will be permitted to accrue the right to purchase stock under the Section&nbsp;423 Component at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is
outstanding (based on the fair market value per share of our common stock as of the first day of the offering period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first
trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. The option will be exercised on the applicable purchase date(s) during the offering period, to the extent of the
payroll deductions (or contributions, as applicable) accumulated during the applicable purchase period. The purchase price of the shares, in the absence of a contrary designation by the plan administrator, will be 85% of the lower of the fair market
value of our common stock on the first trading day of the offering period or on the applicable purchase date (which will be the final trading day of the applicable purchase period), whichever is lower. Participants may voluntarily end their
participation in the 2024 ESPP at any time at least two weeks prior to the end of the applicable offering period (or such longer or shorter period specified by the plan administrator in the applicable offering terms), and will be paid their accrued
payroll deductions (and contributions, if applicable) that have not yet been used to purchase shares of common stock. If a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participant withdraws from the 2024 ESPP during an offering period, the participant cannot rejoin until the next offering period. Participation ends automatically upon a participant&#146;s
termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the 2024 ESPP other than by will or the laws of descent
and distribution, and such rights are generally exercisable only by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions</I>. In the event of certain
<FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions or events affecting our common stock, the plan administrator will make equitable adjustments to the 2024 ESPP and outstanding rights. In the event of certain unusual or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> events or transactions, including a change in control, the plan administrator may provide for (i)&nbsp;either the replacement of outstanding rights with other rights or property or termination of
outstanding rights in exchange for cash, (ii)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (iii)&nbsp;the adjustment in the number and type of shares of
stock subject to outstanding rights, (iv)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering
periods, or (v)&nbsp;the termination of all outstanding rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment</I>. The plan administrator may amend, suspend, or
terminate the 2024 ESPP at any time. However, stockholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the 2024 ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_16"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this Information Statement, Illumina beneficially owns all the outstanding shares of our common stock. After the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> Illumina may own up to 14.5% of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide information
regarding the anticipated beneficial ownership of our common stock at the time of the Distribution. Except as otherwise noted below, we based the share amounts on each person&#146;s beneficial ownership of Illumina common stock on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024, giving effect to a distribution ratio pursuant to which, for every
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share[s] of Illumina common stock he, she, or it held, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
share[s] of our common stock will be distributed. Immediately following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we estimate that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our
common stock will be issued and outstanding, based on the approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Illumina common stock outstanding on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024. The actual number of shares of our common stock outstanding following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will be determined on
the Record Date, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent
our directors and executive officers own Illumina common stock at the Record Date of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> they will participate in the Distribution on the same terms as other holders of Illumina common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Ownership Information for Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the number of shares of GRAIL common stock expected to be beneficially owned by our current directors, named
executive officers and directors and executive officers as a group immediately following the Distribution based on the assumptions set forth above. None of these individuals, or the group as a whole, would be expected to beneficially own more than
1&nbsp;percent of our common stock immediately following the Distribution. Except as otherwise noted in the footnotes below, each person or entity identified in the table has sole voting and investment power with respect to the securities he, she,
or it holds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Beneficial Owners </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows all holders known to GRAIL that are expected to be beneficial owners of more than 5&nbsp;percent of the outstanding
shares of GRAIL common stock immediately following the completion of the Distribution based on the assumptions set forth above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_17"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Illumina </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the <FONT
STYLE="white-space:nowrap">Spin-Off,</FONT> we and Illumina will operate independently. Immediately after the Distribution becomes effective, Illumina may retain up to 14.5% of our common stock and we will not have any ownership interest in
Illumina. Illumina expects that the IRS private letter ruling will require that all retained shares be sold or otherwise disposed of by Illumina as soon as warranted consistent with the business reasons for the retention of those shares, but in no
event later than five years after the Distribution. Such dispositions could include a sale of its shares for cash, distributions of GRAIL common stock to Illumina stockholders or securityholders as dividends, or in exchange for outstanding shares of
Illumina common stock, indebtedness, or other securities, or any combination thereof. In order to govern the ongoing relationships between us and Illumina after the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> and to facilitate an orderly
transition, we intend to enter into a series of agreements with Illumina to effect the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> to provide a framework for the relationship between GRAIL and Illumina after the separation and to provide for
various rights and obligations following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> in each case, pursuant to which we and Illumina will agree to indemnify each other against certain liabilities arising from our respective businesses. The
following summarizes the terms of the material agreements we expect to enter into with Illumina. The summaries of these agreements are qualified in their entirety by reference to the full text of the applicable agreements, which will be filed as
exhibits to our Registration Statement on Form 10, of which this Information Statement is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Separation and Distribution
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Illumina intend to enter into a Separation and Distribution Agreement that will set forth our agreements with
Illumina regarding the principal actions to be taken in connection with <FONT STYLE="white-space:nowrap">the&nbsp;Spin-Off.&nbsp;It</FONT> will also set forth other agreements that govern aspects of our relationship with Illumina following <FONT
STYLE="white-space:nowrap">the&nbsp;Spin-Off.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Distribution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Separation and Distribution Agreement will govern Illumina&#146;s and our respective rights and obligations regarding the proposed
Distribution. On or prior to the Distribution, Illumina will deliver at least 85.5% of the issued and outstanding shares of our common stock to the distribution agent. Following the Distribution Date, the distribution agent will electronically
deliver the shares of our common stock to Illumina stockholders based on the distribution ratio. The Illumina Board will have the sole and absolute discretion to determine the terms of, and whether to proceed with, the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Separation and Distribution Agreement will also provide that several conditions must be satisfied or waived by Illumina in its sole and absolute discretion before the Distribution can occur. For further information about these conditions, see the
section entitled <FONT STYLE="white-space:nowrap">&#147;The&nbsp;Spin-Off&#151;Conditions&nbsp;to</FONT> <FONT STYLE="white-space:nowrap">the&nbsp;Spin-Off&#148;&nbsp;beginning</FONT> on page&nbsp;105 of this Information Statement. The Illumina
Board may, in its sole and absolute discretion, determine the Record Date, the Distribution Date and the terms of <FONT STYLE="white-space:nowrap">the&nbsp;Spin-Off&nbsp;and</FONT> may at any time prior to the completion of <FONT
STYLE="white-space:nowrap">the&nbsp;Spin-Off&nbsp;decide</FONT> to abandon or modify <FONT STYLE="white-space:nowrap">the&nbsp;Spin-Off.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Illumina
Board, in its sole and absolute discretion, may terminate the Separation and Distribution Agreement at any time prior to the Distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and
Illumina will each agree to indemnify the other and each of the other&#146;s former and current directors, officers, and employees, and each of the heirs, executors, successors, and assigns of any of them, against certain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities incurred in connection with <FONT STYLE="white-space:nowrap">the&nbsp;Spin-Off&nbsp;and</FONT> our and Illumina&#146;s<B>&nbsp;respective businesses. The amount of either
Illumina&#146;s or our indemnification obligations will be reduced by any insurance proceeds the party being indemnified receives. The Separation and Distribution Agreement will also specify procedures regarding claims subject to indemnification.
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tax Matters Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Illumina intend to enter into a tax matters agreement (the &#147;Tax Matters Agreement&#148;) prior to the Distribution that will govern
the parties&#146; respective rights, responsibilities, and obligations after the Distribution with respect to all tax matters (including tax liabilities, tax attributes, tax returns, and tax contests). The material terms of this agreement will be
described in a subsequent amendment to this Information Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder and Registration Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Illumina intend to enter into a stockholder and registration rights agreement (the &#147;Stockholder and Registration Rights
Agreement&#148;) pursuant to which we will grant to Illumina certain registration rights with respect to the shares of our common stock owned by Illumina. Illumina may transfer these rights in certain limited circumstances, including in connection
with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">equity-for-debt</FONT></FONT> exchange to a third-party lender (a &#147;Permitted Transferee&#148; and, collectively with Illumina, &#147;Holders&#148;), and such Holders will
thereafter be bound by the terms of the Stockholder and Registration Rights Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Demand Registration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders will be able to request registration under the Securities Act of all or any portion of their shares of our common stock covered by the
Stockholder and Registration Rights Agreement, and we will be obligated, subject to limitations on minimum offering size and certain other limited exceptions, to register such shares as requested by such Holders. Holders will be able to designate
the terms of each offering effected pursuant to a demand registration, which may take the form of a shelf registration, and will be able to request that we complete up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
demand registrations in <FONT STYLE="white-space:nowrap">any&nbsp;12-month</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not be required to honor a demand
registration if we have effected a registration within the preceding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days. In addition, if we reasonably determine in good faith that filing a registration statement would be significantly
disadvantageous to us, we may, no more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;during <FONT STYLE="white-space:nowrap">any&nbsp;12-month</FONT> period, delay filing such registration statement until the earlier
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days after we make such determination or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;days after the disadvantageous condition no longer exists. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Piggy-Back Registration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we at any time intend to file on our behalf or on behalf of any of our other security holders a registration statement in connection with a
public offering of any of our securities on a form and in a manner that would permit the registration for offer and sale of shares of our common stock held by Holders, Holders will have the right to include their shares of our common stock in that
offering, subject to certain limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Registration Rights Agreement will contain customary indemnification and contribution provisions by us for the benefit of
Holders and, in limited situations, by Holders for the benefit of us with respect to the information provided by such Holders included in any registration statement, prospectus, or related document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Commercial Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above agreements, we are also currently party to, or intend to enter into, various other agreements with Illumina and its
subsidiaries, including a supply and commercialization agreement and license agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, we entered into a supply and
commercialization agreement with Illumina. The agreement was amended and restated in February 2017, and subsequently amended in September 2017 and December 2019. Under the terms of the agreement, we agreed to pay to Illumina a high single-digit
royalty, subject to certain reductions, on net sales generated by our products or revenues otherwise generated or received by us regardless of whether these products incorporate any Illumina intellectual property, subject to certain exceptions, in
the field of oncology in perpetuity. In August 2021, following Illumina&#146;s acquisition of GRAIL, the agreement was further amended to suspend the royalty as long as GRAIL is an affiliate of Illumina. The Divestment Plan (as defined in the
section entitled &#147;The <FONT STYLE="white-space:nowrap">Spin-Off&#151;Background&#148;</FONT> beginning on page&nbsp;96 of this Information Statement) permits Illumina to maintain the royalty arrangement with GRAIL. In connection with the
separation of GRAIL from Illumina via the Spin-Off, GRAIL will no longer be an affiliate of Illumina and the perpetual royalty obligation to Illumina will restart, without retroactive effect. In addition, at the time of the separation we may elect
to have either the Open Offer or the Grandfathered Pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, Illumina granted us
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights to use certain Illumina <FONT STYLE="white-space:nowrap">know-how</FONT> and technology with Illumina products purchased under the agreement, and we granted Illumina an irrevocable,
perpetual, worldwide, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> and royalty-free license covering improvements to certain Illumina <FONT STYLE="white-space:nowrap">know-how</FONT> and technology. Pursuant to the agreement, we were also
required to develop a small-variant targeted plasma assay and deliver it to Illumina, which we have done. We retain ownership of the intellectual property generated by the development of this assay, and we have granted Illumina an irrevocable,
perpetual, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use any of the intellectual property embodied in this assay, with certain limitations on sublicensing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of the agreement is 10 years, subject to <FONT STYLE="white-space:nowrap">two-year</FONT> automatic renewal periods unless one of the
parties terminates prior to such renewal period; however, the term is limited to a maximum term of 20 years. The agreement may also be terminated by either party for uncured material breach or bankruptcy or insolvency of the other party. Illumina
may terminate the agreement if it is notified by any regulatory authority that our performance under the agreement materially violates an applicable law or due to a change of control of GRAIL involving a competitor of Illumina. Upon the termination
of the agreement for any reason, the licenses granted to us by Illumina under the agreement would terminate but our licenses to Illumina survive the termination of the agreement. Our royalty payment obligations also survive the termination of this
agreement. In February 2019, pursuant to the terms of the supply and commercialization agreement with Illumina, we entered into two separate <FONT STYLE="white-space:nowrap">non-exclusive</FONT> and
<FONT STYLE="white-space:nowrap">non-sublicensable</FONT> license agreements with Illumina. Under these license agreements, Illumina is required to pay us (i)&nbsp;initial aggregate licensing fees of $50,000, (ii)&nbsp;annual minimum aggregate
royalties of $50,000, increasing by $10,000 annually to a maximum of $100,000, and&nbsp;(iii) running royalties in the low percentages of net sales of products utilizing <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology. In addition,
one of the license agreements includes a milestone of $50,000 tied to the first commercial sale of a product covered by a licensed patent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we have had various other arrangements with Illumina, including arrangements
whereby (i)&nbsp;pursuant to the binding Hold Separate Commitments put in place by Illumina and the Transitional Measures imposed by the European Commission, GRAIL has been held and operated separately and independently from Illumina and Illumina
funded GRAIL&#146;s operations and (ii)&nbsp;in connection with Illumina&#146;s acquisition of GRAIL in 2021, Illumina issued contingent value rights (&#147;CVRs&#148;) representing the right to receive future cash payments on a quarterly basis
representing a pro rata portion of certain GRAIL-related revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy and Procedures Governing Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a written Related-Persons Transaction Policy, to be effective upon the completion of the
<FONT STYLE="white-space:nowrap">Spin-Off,</FONT> that applies to our executive officers, directors, director nominees, holders of more than five percent of any class of our voting securities, and any member of the immediate family of, and any
entity affiliated with, any of the foregoing persons. Such persons will not be permitted to enter into a related person transaction with us without the prior consent of our Audit Committee, or other independent members of our Board in the event it
is inappropriate for our Audit Committee to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an executive officer, director, director nominee, principal stockholder, or any of their immediate
family members or affiliates, in which the amount involved exceeds $120,000, must first be presented to our Audit Committee for review, consideration, and approval. In approving or rejecting any such proposal, our Audit Committee will consider the
relevant facts and circumstances available and deemed relevant to our Audit Committee, including, but not limited to, the commercial reasonableness of the terms of the transaction and the materiality and character of the related person&#146;s direct
or indirect interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_18"></A>DESCRIPTION OF OUR CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Distribution Date,
our Board of Directors (the &#147;Board&#148;), will approve and adopt our Certificate of Incorporation and our Bylaws. The following summarizes information concerning our capital stock, including material provisions of our Certificate of
Incorporation and our Bylaws that will be in effect at the time of the Distribution and certain provisions of Delaware law. You are encouraged to read the forms of our Certificate of Incorporation and our Bylaws, which will be filed as exhibits to
our Registration Statement on Form 10, of which this Information Statement is part, for greater detail with respect to these provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized
Capital Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> our authorized capital stock will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.001 per share and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of preferred stock, par value $0.001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Shares Outstanding</I></B><I>. </I>Immediately following the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we estimate that
approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be issued and outstanding, based in part on approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Illumina common stock outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024.<I> </I>The actual number of shares of our common stock outstanding immediately following the <FONT STYLE="white-space:nowrap">Spin-Off</FONT> will depend, in part, on the actual number of shares of Illumina common stock outstanding on the
Record Date, and will reflect any issuance of new shares or exercise of outstanding options pursuant to Illumina&#146;s equity-based incentive compensation plans on or prior to the Record Date. There will be no shares of preferred stock outstanding.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights</I></B>. Holders of shares of our common stock will be entitled to receive dividends when, as and if declared by
our Board at its discretion out of funds legally available for that purpose, subject to the preferential rights of any preferred stock that may be outstanding. See the sections entitled &#147;Dividend Policy&#148; and &#147;Risk Factors&#151;Risks
Relating to Our Common Stock&#151;We do not expect to pay any dividends for the foreseeable future&#148; beginning on pages 108 and 91, respectively, of this Information Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights</I></B><I>. </I>Each share of common stock is entitled to one vote upon any matter submitted to a vote of our
stockholders, including the election of directors. Holders of our common stock will vote as a single class on all matters submitted to a stockholder vote, subject to any voting rights granted to holders of any preferred stock. Holders of the common
stock are not entitled to any cumulative voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation</I></B>. In the event of our liquidation, dissolution, or
winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Rights</I></B>. The holders of our common stock have no preemptive rights or other subscription rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no redemption or sinking fund provisions applicable to our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has the
authority to issue the preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption
prices, liquidation preferences, and the number of shares constituting any series or the designation of such series, without further vote or action by the stockholders. The issuance of preferred stock may have the effect of delaying, deterring, or
preventing a change in control of our company without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. At present, we have no plans to issue any of the preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Provisions of Delaware Law, Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Election and Removal of Directors; Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will consist of between five and fifteen directors. The exact number of directors will be fixed from time to time by resolution of
the Board. Directors will be elected by a plurality of the votes of the shares of our capital stock present in person or represented by proxy at the meeting and entitled to vote on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No director may be removed except for cause, and directors may be removed for cause only by an affirmative vote of shares representing not
less than a majority of the shares then entitled to vote at an election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any vacancy occurring on the Board and any newly
created directorship may be filled only by a majority of the remaining directors in office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately after the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> our Board will be divided into three classes serving staggered
three-year terms. Class&nbsp;I, Class&nbsp;II, and Class&nbsp;III directors will serve until our annual meetings of stockholders in 2024, 2025 and 2026, respectively. At each annual meeting of stockholders, directors will be elected to succeed the
class of directors whose terms have expired. This classification of our Board could have the effect of increasing the length of time necessary to change the composition of a majority of the Board. In general, at least two annual meetings of
stockholders will typically be necessary for stockholders to effect a change in a majority of the members of the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limitation
on Action by Written Consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and our Bylaws provide that holders of our common stock will not be
able to act by written consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and our Bylaws provide that special meetings of our stockholders may be called only by a majority of the
directors. Our Certificate of Incorporation and our Bylaws specifically deny any power of any other person to call a special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of Incorporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of our Certificate of Incorporation described under &#147;&#151;Election and Removal of Directors; Vacancies,&#148;
&#147;&#151;Stockholder Meetings,&#148; &#147;&#151;Limitation on Action by Written Consent,&#148; &#147;&#151;Limitation of Liability of Directors and Officers,&#148; &#147;&#151;Common Stock&#151;Voting Rights,&#148; and &#147;&#151;Forum
Selection&#148; and provisions relating to amendments to our Certificate of Incorporation may be amended only by the affirmative vote of holders of at least 66-2/3% of the voting power of our outstanding shares of voting stock. The affirmative vote
of holders of at least a majority of the voting power of our outstanding shares of stock will generally be required to amend other provisions of our Certificate of Incorporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our Bylaws may generally be altered, amended, or repealed, and new bylaws may be adopted, with the affirmative vote of a
majority of directors present at any regular or special meeting of the Board called for that purpose, provided that any alteration, amendment, or repeal of, or adoption of any bylaw inconsistent with specified provisions of the bylaws, including
those related to special and annual meetings of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders, action of stockholders by written consent, nomination of directors, transfers of capital stock and dividends requires the affirmative vote of at least
<FONT STYLE="white-space:nowrap">66-2/3%</FONT> of all directors in office at a meeting called for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All other provisions of
our Bylaws may generally be altered, amended, or repealed, and new bylaws may be adopted, with the affirmative vote of holders of <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of our outstanding shares of voting stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Limitations on Stockholder Actions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws impose some procedural requirements on stockholders who wish to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make nominations in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose that a director be removed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose any repeal or change in our Bylaws; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose any other business to be brought before an annual or special meeting of stockholders.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these procedural requirements, in order to bring a proposal before a meeting of stockholders, a stockholder must
deliver timely notice of a proposal pertaining to a proper subject for presentation at the meeting to our corporate secretary along with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of the business or nomination to be brought before the meeting and the reasons for conducting such
business at the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stockholder&#146;s name and address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material interest of the stockholder in the proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares beneficially owned by the stockholder and evidence of such ownership; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names and addresses of all persons with whom the stockholder is acting in concert and a description of all
arrangements and understandings with those persons, and the number of shares such persons beneficially own. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be
timely, a stockholder must generally deliver notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with an annual meeting of stockholders, not less than 120 nor more than 150 days prior to the date
on which the annual meeting of stockholders was held in the immediately preceding year, but in the event that the date of the annual meeting is more than 30 days before or more than 70 days after the anniversary date of the preceding annual meeting
of stockholders, a stockholder notice will be timely if received by us not later than the close of business on the later of (1)&nbsp;not less than 70 nor more than 120 days prior to the date of the annual meeting and (2)&nbsp;the 10th day following
the day on which we first publicly announce the date of the annual meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with the election of a director at a special meeting of stockholders, during the period not less
than 120 nor more than 150 days prior to the date of the special meeting, or the 10th day following the day on which a notice of the date of the special meeting was mailed to the stockholders or the public disclosure of that date was made.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to submit a nomination for our Board, a stockholder must also submit all information with respect to the
nominee that would be required to be included in a proxy statement, as well as other information. If a stockholder fails to follow the required procedures, the stockholder&#146;s proposal or nominee will be ineligible and will not be voted on by our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability of Directors and Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation provides that no director will be personally liable to us or our stockholders for monetary damages for breach
of fiduciary duty as a director, except as required by applicable law, as in effect from time to time. Section&nbsp;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a
director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to our company or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or which involved intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, neither we nor our stockholders have the right, through stockholders&#146; derivative suits on our behalf, to recover monetary
damages against a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation also provides that, to the fullest extent permitted by law, we will indemnify any officer or director of our
company against all damages, claims, and liabilities arising out of the fact that the person is or was our director or officer, or served any other enterprise at our request as a director or officer. Amending this provision will not reduce our
indemnification obligations relating to actions taken before an amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Forum Selection </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the
following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on behalf of us; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer,
or other employee of our company to us or our stockholders; (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our Certificate of Incorporation and bylaws; or (iv)&nbsp;any action
asserting a claim governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts
have exclusive jurisdiction. Furthermore, our Certificate of Incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum
for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice
of and have consented to the foregoing forum selection provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exclusive forum provision will not relieve us of our duties to
comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enforceability of similar federal court choice of forum provisions in other companies&#146; certificates of incorporation has been
challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable or unenforceable. If a court were to find either of the choice of forum provisions contained in our Certificate of Incorporation or
Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with the company or its directors, officers or other employees, which may discourage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such lawsuits against the company and its directors, officers, and other employees and result in increased costs for investors to bring a claim. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Business Combination Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to be subject to Section&nbsp;203 of the Delaware General Corporation Law. Section&nbsp;203 prevents an &#147;interested
stockholder,&#148; which is defined generally as a person owning 15% or more of a corporation&#146;s voting stock, or any affiliate or associate of that person, from engaging in a broad range of &#147;business combinations&#148; with the corporation
for three years after becoming an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Board of the corporation had previously approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, that
person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, other than statutorily excluded shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the transaction in which that person became an interested stockholder, the business combination is
approved by the Board of the corporation and holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, the restrictions described above also do not apply to specific business combinations proposed by an interested
stockholder following the announcement or notification of designated extraordinary transactions involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder
with the approval of a majority of the corporation&#146;s directors, if such extraordinary transaction is approved or not opposed by a majority of the directors who were directors prior to any person becoming an interested stockholder during the
previous three years or were recommended for election or elected to succeed such directors by a majority of such directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 may make it more difficult for a person who would be an interested stockholder to effect various business combinations with a
corporation for a three-year period. Section&nbsp;203 also may have the effect of preventing changes in our management and could make it more difficult to accomplish transactions that our stockholders may otherwise deem to be in their best
interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Takeover Effects of Some Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our Certificate of Incorporation and Bylaws could make the following more difficult: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquisition of control of us by means of a proxy contest, tender offer, or otherwise; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">removal of our incumbent officers and directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, as well as our ability to issue preferred stock, are designed to discourage coercive takeover practices and inadequate
takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of increased protection give us the potential ability to negotiate with the
proponent of an unfriendly or unsolicited proposal to acquire or restructure us, and that the benefits of this increased protection outweigh the disadvantages of discouraging those proposals, because negotiation of those proposals could result in an
improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and Illumina intend to enter into a Stockholder and Registration Rights Agreement. For additional information, see &#147;Certain
Relationships and Related Party Transactions&#151;Stockholder and Registration Rights Agreement&#148; beginning on page&nbsp;203 of this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be Computershare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to list
our common stock on the Nasdaq Global Select Market under the ticker symbol &#147;GRAL.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc556103_19"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a Registration Statement on Form&nbsp;10 with the SEC with respect to the shares of our common stock that Illumina&#146;s
stockholders will receive in the Distribution, as contemplated by this Information Statement. This Information Statement is a part of, and does not contain all the information set forth in, the Registration Statement and the other exhibits and
schedules to the Registration Statement. For further information with respect to us and our common stock, please refer to the Registration Statement, including its other exhibits and schedules. Statements we make in this Information Statement
relating to any contract or other document are not necessarily complete, and you should refer to the exhibits attached to the Registration Statement for copies of the actual contract or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">Spin-Off,</FONT> we will become subject to the information and reporting requirements of
the Securities Exchange Act of 1934, which we refer to as the &#147;Exchange Act,&#148; and, in accordance with the Exchange Act, we will file periodic reports, proxy statements, and other information with the SEC. The SEC maintains a website,
www.sec.gov, that contains periodic reports, proxy statements, and information statements and other information regarding issuers, like us, that file electronically with the SEC. The Registration Statement, including its exhibits and schedules, and
the periodic reports, proxy statements, and information statements and other information that we file electronically with the SEC will be available for inspection and copying at the SEC&#146;s website. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can also find a copy of the Registration Statement and our annual report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly
reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports, in each case, filed with or furnished to the SEC pursuant to the Exchange Act, on our
website, https://grail.com, which we will make available free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Information contained on, or connected to, any website we refer to in this Information Statement does not and will not constitute a part of
this Information Statement or the Registration Statement of which this Information Statement is a part. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to furnish holders
of our common stock with annual reports containing financial statements prepared in accordance with GAAP and audited and reported on, with an opinion expressed, by an independent registered public accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this Information Statement or to which this Information Statement has referred you. We
have not authorized any person to provide you with different information or to make any representation not contained in this Information Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc556103_20"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>Page<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_8">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_1">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_2">Consolidated Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_3">Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_4">Consolidated Statements of Member&#146;s Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_5">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin556103_7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_8"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors of Illumina, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the
Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated financial statements of GRAIL, LLC (Successor), which comprise the consolidated
balance sheets as of January 1, 2023 and January 2, 2022, and the related consolidated statements of operations and comprehensive loss, member&#146;s equity and cash flows for the period from August 19, 2021 to January 2, 2022 and for the year ended
January 1, 2023, and the related notes to the financial statements, and the consolidated financial statements of GRAIL, Inc. (Predecessor), which comprise the related consolidated statements of operations and comprehensive loss, redeemable
convertible preferred stock and stockholders&#146; deficit and cash flows for the period from January 1, 2021 to August 18, 2021, and the related notes to the consolidated financial statements, collectively referred to as the consolidated financial
statements. In our opinion the consolidated financial statements present fairly in all material respects, the financial position of the Successor at January 1, 2023 and January 2, 2022, and the results of operations and cash flows of the Successor
for the period from August 19, 2021 to January 2, 2022 and for the year ended January 1, 2023 and of the Predecessor for the period from January 1, 2021 to August 18, 2021 in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basis for Opinion </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Predecessor&#146;s and Successor&#146;s management. Our responsibility is to express an opinion on the Predecessor&#146;s and Successor&#146;s financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Predecessor and Successor in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal
control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in
accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ <I>Ernst &amp; Young LLP</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served
as the Company&#146;s auditor since 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San&nbsp;Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;8, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_1"></A>CONSOLIDATED BALANCE SHEETS (SUCCESSOR) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplies&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,935,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,073,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,497,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,197,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 4,937,986</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,737,919</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and member&#146;s equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incentive plan liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Member&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,955,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,341,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,310,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(911,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total member&#146;s equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,646,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,430,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and member&#146;s equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 4,937,986</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,737,919</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>See accompanying notes to consolidated financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_2"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021&nbsp;to<BR>January&nbsp;2, 2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,052</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,433</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (exclusive of amortization of acquired intangible assets)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,288</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,630</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">310,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309,781</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,475</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">478,071</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,700,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,498,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940,587</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,442,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(928,154</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(337,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(884</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(865</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,441,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(929,019</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,399,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(911,542</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(336,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Class&nbsp;A and Class&nbsp;B common stockholders (Predecessor)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of Class&nbsp;A and Class&nbsp;B common stock used in computing net loss
per share attributable to Class&nbsp;A and Class&nbsp;B common stockholders (Predecessor):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,574,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>See accompanying notes to consolidated financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_3"></A>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021&nbsp;to<BR>January&nbsp;2, 2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,399,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(911,542</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized loss on marketable securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation income (loss) adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,398,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(911,227</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(337,035</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>See accompanying notes to consolidated financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_4"></A>CONSOLIDATED STATEMENTS OF MEMBER&#146;S EQUITY (SUCCESSOR) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Member&#146;s<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Member&#146;s<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of August&nbsp;19, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,745,477</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,745,477</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(911,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(911,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">639,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">639,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distribution to member, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;2, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,341,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>315</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(911,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,430,523</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,399,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,399,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution from member, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">604,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">604,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,955,907</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>894</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,310,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,646,161</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>See accompanying notes to consolidated financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_5"></A>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT (PREDECESSOR)
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><B>Redeemable Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Compre-<BR>hensive<BR>(Loss)<BR>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stock-<BR>Holders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Series C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Series D</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of January 1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>85,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>68,263</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>309,256,591</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,235,404</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>63,144,600</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>299,557</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>76,743,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>391,694</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>121,672,294</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>123</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,989,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>180,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,617,787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,433,082</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of shares upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,775,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchases of early exercised stock&nbsp;options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of early exercised stock&nbsp;options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(336,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Continuation payment received from&nbsp;Illumina&#150;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(802</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at August 18, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>85,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>68,263</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>309,256,591</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,235,404</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>63,144,600</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>299,557</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>76,743,836</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>391,694</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>128,427,897</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>129</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,989,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>464,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,800</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,954,185</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,486,784</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>See accompanying notes to consolidated financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_6"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Successor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Predecessor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1<BR>to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash flows from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,399,098</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(911,542</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(336,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of intangibles assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,111</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,422</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">650,260</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash payments for equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(184,963</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of premium on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,700,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,089</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Supplies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,334</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Supplies&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,409</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,468</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(706</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,267</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,947</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,881</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued and other liabilities&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used by operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(561,313</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(485,870</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(202,260</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash flows from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,158</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchases of property and equipment&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(159,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from sale of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash provided by investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(22,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(7,976</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>352,788</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash flows from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from early exercise of unvested stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from continuation payment received from Illumina&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash funding received from Illumina</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">609,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">774,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash payments for acquisition consideration paid on behalf of Illumina</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(625,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Taxes paid related to net share settlement of equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,320</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>604,817</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>143,931</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>250,811</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(350,050</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">401,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash&#151;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">576,044</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash&#151;end of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>246,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>225,994</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>576,044</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Represented by:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221,155</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>246,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>225,994</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>$576,044</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental cashflow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,261</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating cashflows from operating leases, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,379</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>See accompanying notes to consolidated financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin556103_7"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GRAIL, LLC, a limited liability company (&#147;LLC&#148;), previously named SDG Ops, LLC, was formed in the state of Delaware as a wholly owned
subsidiary of Illumina, Inc. (&#147;Illumina&#148;). SDG Ops, LLC, along with SDG Ops, Inc., a Delaware corporation and wholly owned subsidiary of Illumina, were formed for the purpose of completing a merger transaction between GRAIL, Inc., and
Illumina (the &#147;Acquisition&#148;) in order to carry on the business of GRAIL, Inc. and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2020,
GRAIL, Inc., Illumina and its subsidiaries, SDG Ops, LLC, and SDG Ops, Inc., entered into an agreement and plan of merger (the &#147;Merger Agreement&#148;). On August&nbsp;18, 2021 (the &#147;Closing Date&#148;), Illumina completed its acquisition
of GRAIL, Inc. (the &#147;Predecessor Company&#148; or &#147;Predecessor&#148;). According to the terms and conditions of the Merger Agreement, SDG Ops, Inc. and GRAIL, Inc. merged, with GRAIL, Inc. surviving and becoming a wholly owned subsidiary
of Illumina (the &#147;First Merger&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the First Merger and as part of the same overall transaction, GRAIL,
Inc., as the surviving corporation, merged with SDG Ops, LLC (the &#147;Second Merger&#148;). According to the terms and conditions of the Merger Agreement, SDG Ops, LLC became the surviving corporation and was renamed GRAIL, LLC (the
&#147;Successor Company&#148; or &#147;Successor&#148;). At the effective time of the First Merger (the &#147;Effective Time&#148;), each issued and outstanding share of Predecessor Class&nbsp;A Common Stock, par value $0.001 per share, Class&nbsp;B
Common Stock, par value $0.001 per share, Series A Preferred Stock, par value $0.001 per share, Series B Preferred Stock, par value $0.001 per share, Series C Preferred Stock, par value $0.001 per share, and Series D Preferred Stock, par value
$0.001 per share, of GRAIL (collectively, the &#147;GRAIL Stock,&#148; subject to limited exceptions, including shares with respect to which dissenters&#146; rights were validly exercised in accordance with Delaware law) was converted into each
holder&#146;s elected merger consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing Date, references to the &#147;Company&#148; or &#147;GRAIL&#148; within
these consolidated financial statements refer to GRAIL, Inc., and its consolidated subsidiaries, while references to the &#147;Company&#148; or &#147;GRAIL&#148; on or after the Closing Date refer to GRAIL, LLC and its consolidated subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of the Company as of January 1, 2023 and January 2, 2022, and for the year ended
January 1, 2023 and the period from August 19, 2021 to January 2, 2022 (the &#147;Successor,&#148; or the &#147;Post-Combination&#148; period), reflect the basis applied by Illumina in connection with its accounting for the acquisition of GRAIL as a
business combination (&#147;pushdown accounting&#148;), and for the period from January&nbsp;1, 2021 to August&nbsp;18, 2021 (the &#147;Predecessor&#148; or the &#147;Pre-Combination&#148; period), reflect the activity of the Predecessor Company.
Due to the application of pushdown accounting, the Successor periods have been clearly distinguished from the Predecessor period as these periods are not comparable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GRAIL, headquartered in Menlo Park, California, is an innovative commercial-stage healthcare company focused on saving lives and shifting the
paradigm of early cancer detection. GRAIL&#146;s Galleri blood test screens for various types of cancers before individuals are symptomatic. Illumina is the sole member and 100% owner of GRAIL. Illumina implemented extensive and binding Hold
Separate Commitments upon the Acquisition in order for Illumina and GRAIL to be held and operated as distinct and separate entities. The Hold Separate Commitments also provided for the appointment of a monitoring trustee. Notwithstanding the
foregoing, the European Commission has adopted an order requiring Illumina and GRAIL to be held and operated as distinct and separate entities. Compliance with the order is monitored by an independent monitoring trustee. Refer to note &#147;12.
Legal and Regulatory Proceedings&#148; for additional details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Our Ability to Continue as a Going Concern </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on, among other things, the Company&#146;s ability to manage our net
loss, and to become profitable and operate profitably, to manage our negative cash flows from operations and to generate positive cash flows from operations and our ability to obtain financing to support our working capital requirements. As part of
Illumina, the Company is dependent upon Illumina for its working capital and financing requirements. The Company had $241.6&nbsp;million of cash and cash equivalents as of January&nbsp;1, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our existing cash and cash equivalents, in addition to the funding that Illumina is required to provide, will be sufficient to
meet our working capital and capital expenditure needs for at least the next 12 months, as of the date these consolidated financial statements were filed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fiscal Year </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31. References to 2022 refer to the fiscal year ended January&nbsp;1, 2023, which was 52 weeks. References to 2021 refer either to the Predecessor period from
January&nbsp;1, 2021 to August&nbsp;18, 2021, or the Successor period from August&nbsp;19, 2021 to January&nbsp;2, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2. SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation and Principles of Consolidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements represent the historical operations of the standalone GRAIL legal entity and in the
Successor periods include purchase accounting adjustments and certain tax adjustments as if GRAIL filed a separate income tax return and was not included in Illumina&#146;s consolidated return. All revenues and costs as well as assets and
liabilities directly associated with the business activity of the Company are included in the consolidated financial statements. Assets and liabilities were reflected at fair value under the new basis of accounting established at the Closing Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management considered the need to allocate any shared costs incurred by the parent, Illumina, to the accompanying consolidated financial
statements. As previously discussed, the European Commission has adopted an order requiring Illumina and GRAIL to be held and operated as distinct and separate entities. As no integration has occurred, management has concluded that no material
allocations are required in the Successor periods. However, amounts recognized in the Successor periods by the Company are not necessarily representative of the amounts that would have been reflected in the financial statements had the Company
operated independently of the parent. Related party transactions with Illumina are discussed further in Note &#147;9 Related-Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles (&#147;U.S.
GAAP&#148;) and include the accounts of GRAIL and its wholly owned subsidiaries. All intercompany balances have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the
reported amounts of revenues and expenses in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience and other market-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specific or other relevant assumptions that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, including, but not limited to, those
related to estimation of variable consideration, estimation of credit losses, standalone selling price included in contracts with multiple performance obligations, measure of progress toward the completion and satisfaction of performance
obligations, accrued clinical studies and research and development expenses, stock-based compensation expense, measurement of liability-classified awards, valuation of goodwill and intangible assets, useful lives of intangible assets and property
and equipment, determination of incremental borrowing rate for operating leases, contingencies, and the provision for income taxes, among others. These estimates generally involve complex issues and require judgments, involve the analysis of
historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results could differ from those estimates, and such differences could be material to the
consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash
equivalents. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents to the extent recorded in the consolidated balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2023, the Company had approximately $241.6&nbsp;million of cash deposits and cash equivalents (&#147;Funds&#148;) in
accounts with Silicon Valley Bank (&#147;SVB&#148; or the &#147;Bank&#148;). The majority of the funds held in the SVB accounts were invested in money market securities issued by another large U.S. bank. The SVB accounts served as sweep accounts to
settle end-of-day cash transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;10, 2023, at the direction of the Federal Deposit Insurance Corporation (the
&#147;FDIC&#148;) and in coordination with the California Department of Financial Protection and Innovation, SVB was declared insolvent, was closed and the FDIC was appointed as the receiver of the Bank. The FDIC completed its resolution of SVB in a
manner that fully protected all depositors, and on Monday, March&nbsp;13, 2023, it stated that depositors will have access to all of their funds. The Company had full control and access to these funds as of March&nbsp;13, 2023. There was no impact
to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Company and it did not experience any losses on any deposits processed by SVB. Subsequently, the Company&#146;s management has
outlined a plan that follows a diversified strategy when it comes to deposit and lending institutions, allowing it to reduce risk and ensure ongoing access to its funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies and
institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. As of January&nbsp;1, 2023, the Company had no <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet concentrations of
credit risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to credit risk related to its accounts receivable. Accounts receivable primarily arise from testing
services in the United States and are primarily with biopharmaceutical companies, employers, healthcare organizations, concierge medicine practices, life insurance companies, and individuals. The Company does not require collateral. Accounts
receivable are recorded net of the allowance for credit losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had sales to a single customer that accounted for
approximately 21% and 38% of total sales, for the year ended January&nbsp;1, 2023 and period from August&nbsp;19, 2021 to January&nbsp;2, 2022, respectively. No single customer accounted for more than 10% of net sales for the period from
January&nbsp;1 to August&nbsp;18, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts due from this same single customer represented approximately 45% and 68% of total
accounts receivable as of January&nbsp;1, 2023 and January&nbsp;2, 2022, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risks and Uncertainties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to emerging and commercial-stage healthcare companies, including, but not limited to,
the Company&#146;s operation in a dynamic and highly regulated industry, its ability to successfully commercialize products, its ability to drive industry education and awareness of its products and multi-cancer early detection generally,
difficulties or delays in clinical studies, delays in planned commercial launches, complex regulatory regimes, regulatory implications and issues, including approvals, recommendations, coverage and reimbursement determinations, its ability to
establish and maintain strategic relationships and key third-party vendors and providers, developments involving the Company&#146;s infrastructure and platform, dependence on key personnel, and other factors. Any of these factors and other factors
could negatively impact operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s first commercial product, Galleri, was commercially launched in <FONT
STYLE="white-space:nowrap">mid-2021.</FONT> As a result, the Company has a limited history as a commercial-stage company and this product has not and may not generate revenues sufficient to fund operations. The Company is subject to risks and
uncertainties regarding its need for, and ability to obtain, additional financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Significant Accounting Policies </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash on deposit with banks denominated in U.S. Dollars and British Pounds. To be considered cash
equivalents, all investments purchased must be highly liquid and have an original maturity date of three months or less. As of January&nbsp;1, 2023 and January&nbsp;2, 2022, the Company&#146;s cash equivalents were held in money market funds, a
marketable security, totaling $236.0&nbsp;million and $214.1&nbsp;million, respectively. Cash equivalents held in money market funds were categorized as Level&nbsp;1 investments within the fair value hierarchy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Cash </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash is comprised of cash that is restricted as to withdrawal or use related to letters of credit for the Company&#146;s operating
lease agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accounts Receivable, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable represent unconditional rights to consideration from customers. Accounts receivable are regularly evaluated for
collectability and estimated allowance is determined for potential credit losses based on management&#146;s best estimates. As of January&nbsp;1, 2023, and January&nbsp;2, 2022, the Company had $1.3&nbsp;million and $0.1&nbsp;million of allowance
for credit losses, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Supplies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplies consists of materials and reagents consumed in the performance of testing services. The Company periodically analyzes supply levels
and expiration dates, and writes down supply that has become obsolete or that has a cost basis in excess of expected sales requirements as cost of revenue. The Company records an allowance for excess or obsolete supplies using an estimate based on
historical trends and evaluation of near-term expirations. Cost of revenue&#151;related parties represents the costs of supplies purchased from related parties used in the generation of revenue from all customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Financial Instruments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of financial assets and liabilities is determined using the fair value hierarchy established in Accounting Standards
Codification (&#147;ASC&#148;) Topic 820, Fair Value Measurement (&#147;ASC 820&#148;). ASC 820 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. The hierarchy describes three levels of inputs that may be used to measure fair value, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1
&#151;Observable inputs, such as quoted prices in active markets for identical assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2 &#151;Observable
inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by
observable market data for substantially the full term of the assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3 &#151;Unobservable inputs that are
supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A financial
instrument&#146;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts for financial instruments such as accounts receivable, net, accounts receivable, net&#151;related parties, prepaid
expenses and other current assets, prepaid expenses and other current assets&#151;related parties, accounts payable, accounts payable&#151;related parties, accrued liabilities and accrued liabilities&#151;related parties&#146; approximate fair value
due to their short-term nature. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Property and Equipment, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net is stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the
straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the useful life of the improvements. Repair expenses and maintenance costs
are expensed as incurred. When an item is sold or disposed of, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in the consolidated statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated useful lives of the major classes of property and equipment are generally as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful&nbsp;Life<BR>(in&nbsp;Years)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3 to 5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Lease&nbsp;Term</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Leases </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leases are classified as operating or financing at lease inception and as necessary at modification. Leased assets represent the Company&#146;s
right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating leases are included in operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
(&#147;ROU&#148;) assets and operating lease liabilities in the consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.
When readily </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determinable, the Company uses the rate implicit in the lease to discount lease payments; however, when the rate is not readily determinable, the Company uses the incremental borrowing rate based
on the information available at the commencement date. The incremental borrowing rate is the rate of interest that a company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a
similar economic environment. The Company&#146;s weighted average remaining lease term is approximately 7.8&nbsp;years and 8.3&nbsp;years as of January&nbsp;1, 2023 and<B> </B>January&nbsp;2, 2022, respectively. The Company&#146;s weighted average
discount rate for operating leases is 2.1% and 2.0% as of January&nbsp;1, 2023 and<B> </B>January&nbsp;2, 2022, respectively, which were based on Illumina&#146;s incremental borrowing rate as GRAIL was a wholly owned subsidiary. The operating lease
ROU asset also includes any initial direct costs, lease payments made prior to lease commencement, and lease incentives received. Variable lease payments are expensed as incurred and are not included within the ROU asset and lease liability
calculation. Variable lease payments primarily include reimbursements of costs incurred by lessors for common area maintenance and utilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each lease, the determined lease term is based on a noncancellable period, including any rent-free periods provided by the lessor, and may
include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease cost for lease payments is recognized on a straight-line basis over the lease term. Certain lease agreements contain
lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. The Company accounts for <FONT STYLE="white-space:nowrap">non-lease</FONT> components as part of the lease component to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not recognize ROU assets and lease liabilities for short-term leases, which have a lease term of twelve months or less and do
not include an option to purchase the underlying asset that the Company is reasonably certain to exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Goodwill and Intangible
Assets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets identified in the Acquisition include GRAIL trade names, developed technology, and GRAIL <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development (&#147;IPR&amp;D&#148;) and were measured at fair value as of the Closing Date. Goodwill represents the excess of purchase price paid cost over fair value of the net identifiable
assets acquired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s trade names, GRAIL and Galleri, have brand recognition in the market related to the services GRAIL
provides customers and the research and development activities GRAIL performs. GRAIL&#146;s developed technology includes intangible assets related to Galleri, its multi-cancer early detection test that was launched as a laboratory-developed test
(&#147;LDT&#148;) in 2021, as well as a diagnostic aid for cancer (&#147;DAC&#148;) test. The developed technology underpins both Galleri, designed as a cancer screening test for asymptomatic individuals over 50 years of age, and DAC that is being
designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The cost of identifiable intangible assets with finite lives, such as trade names and developed technology assets, are amortized on a
straight-line basis over the assets&#146; respective estimated useful lives of 9 years and 18 years, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s
IPR&amp;D includes assets related to GRAIL&#146;s development of a minimal residual disease (&#147;MRD&#148;) test, a post-diagnostic test, that is currently under development. IPR&amp;D is considered indefinite lived and therefore is not amortized
until completed and placed into service, at which point it will begin to be amortized over its estimated useful life or expensed upon abandonment of the associated research and development efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While goodwill and IPR&amp;D are not amortized, they are reviewed for impairment at least annually or more frequently if events or
circumstances indicate a potential for impairment. Goodwill and IPR&amp;D are considered impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform our goodwill impairment analysis at the reporting unit level. We have one reporting unit, which aligns with our reporting structure
and availability of discrete financial information. During the goodwill </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than the carrying amount, including goodwill. If
we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, no additional assessment is necessary. If the carrying amount of the reporting unit exceeds its fair value, we record an
impairment loss based on the excess. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Impairment of Long-Lived Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, other than goodwill and IPR&amp;D (as described above), are evaluated for indications of possible impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. Should impairment
exist, the impairment would be measured as the amount by which the carrying amount of the assets exceeds the fair value of those assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Segments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
operates and manages its business as one reportable operating segment which provides multi-cancer early detection testing and services. The chief operating decision maker reviews financial information on an aggregate basis for the purposes of
evaluating financial performance and allocating the company resources. Substantially all of the Company&#146;s long-lived assets are located in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is accounted for in accordance with Topic 606, which provides for a five-step model that includes identifying the contract with a
customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.
Revenues are derived from screening and development services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Screening Revenue </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes screening revenue from the sale of cancer screening testing services for patients. Patients obtain tests via their
employers, healthcare systems, payors, concierge medicine practices, life insurance providers or directly via telemedicine. Patients receive the multi-cancer early detection kit after the order is placed and complete the blood draw. The specimen is
then sent to the Company&#146;s lab, the test is processed, and the result is electronically delivered to the patients&#146; physician. The test price is based on the negotiated contractual rate with the Company&#146;s direct customers, otherwise
the Company&#146;s standard list price applies. The Company identifies each sale of its test to a customer as a single performance obligation; therefore, revenue is recognized at the point of time when the test result report is delivered. Invoices
are generally due within 30 days of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For <FONT STYLE="white-space:nowrap">self-pay</FONT> patients, the Company has concluded
that an implied contract exists, however the transaction price for the implied contract represents variable consideration as there are situations in which the Company is not expected to collect the full invoiced amounts from <FONT
STYLE="white-space:nowrap">self-pay</FONT> patients due to price concessions. The Company utilizes the expected value approach to estimate the transaction price and applies a constraint for such variable consideration, on a portfolio basis. The
Company monitors the estimated amounts to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and
require the use of significant judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. The Company analyzes its actual cash collections over the expected collection period and
compares it with the estimated variable consideration for each portfolio and any difference is recognized as an adjustment to estimated revenue after the expected collection period, subject to assessment of the risk of future revenue reversal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Development Services </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development services revenue includes development activities performed in partnership with biopharmaceutical companies. The Company&#146;s
targeted methylation-based technology enables development of products and services to optimize treatment once a cancer has been diagnosed. Biopharmaceutical partners engage the Company to run pilots and research studies to evaluate and learn about
the technology&#146;s application. The Company evaluates the terms and conditions included within its development services contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are
considered distinct performance obligations. The Company first identifies material promises under the contract and then evaluates whether these promises are capable of being distinct within the context of the contract. In assessing whether a
promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the
research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. For contracts with multiple performance obligations, the transaction price is allocated to
the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as
other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each
performance obligation plus appropriate margin; or by using the residual approach if standalone selling price is not observable, by reference to the total transaction price less the sum of the observable standalone selling prices of other
performance obligations promised in the contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biopharmaceutical partners engage the Company to run pilot and research studies by
sending patient samples and comparing the Company&#146;s test result to their expected result for evaluation of performance and application. The Company recognizes revenue as performance obligations are completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following favorable results from pilot and research studies, biopharmaceutical partners and the Company may enter into development service
agreements related to clinical trial and companion diagnostic device development and regulatory submissions for the developed product(s). These agreements typically have multiple commitments of services and therefore have longer performance periods.
The Company uses an input method based on costs incurred to measure its progress toward the completion and satisfaction of the performance obligations. The Company assesses the changes to the total expected cost estimates as well as any incremental
fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognized at each reporting period. Invoices are generally due within 60 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Deferred Revenue </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred
revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, <FONT STYLE="white-space:nowrap">pre-payments</FONT> received from patients for screening
testing services and development services and other contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company&#146;s performance
of the related development services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is recognized. Deferred revenue was $0.6 million and $1.8 million as of January 1, 2023 and January 2,
2022, respectively, all of which is considered short-term and was recorded within other current liabilities on the accompanying consolidated balance sheets. We did not have deferred revenue prior to the year ended January&nbsp;2, 2022, as we first
began providing services to customers in the year ended January&nbsp;2, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Screening Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of screening revenue generally consists of cost of materials, direct and indirect labor including salaries and wages, bonus, benefits and
stock-based compensation, amortization of GRAIL intangible assets, royalty expenses primarily owed under the supply and commercialization agreement with Illumina in the Predecessor period and the Chinese University of Hong Kong in both the
Predecessor and Successor periods, third-party support services, shipping and logistics costs, depreciation of equipment and allocated overhead expenses associated with processing specimens received from customers. The royalty obligation under the
supply and commercialization agreement with Illumina is currently suspended in the Successor periods. Allocated overhead expenses include rent expenses, amortization of leasehold improvements and information technology costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Cost of Development Services Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of development services revenue generally consists of direct and indirect labor including salaries and wages, bonus, benefits and
stock-based compensation, cost of materials and patient sample acquisition, amortization of GRAIL intangible assets, royalty expenses primarily owed under the supply and commercialization agreement with Illumina in the Predecessor period,
depreciation of equipment, and allocated overhead expenses associated with processing development samples received from biopharmaceutical customers. The royalty obligation under the supply and commercialization agreement with Illumina is currently
suspended in the Successor periods. Allocated overhead expenses include rent expense, amortization of leasehold improvements, and information technology costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accrued Clinical Studies and Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimates of unbilled costs of research and development activities for clinical studies conducted by third-party service providers are accrued.
The estimated costs of research and development activities are recorded based upon the estimated amount of services provided. These costs are included in accrued liabilities and accrued liabilities&#151;related parties in the consolidated balance
sheets and within research and development and research and development&#151;related parties expenses in the consolidated statements of operations. These costs are a significant component of research and development expenses. The costs are accrued
based on factors such as estimates of the work completed and in accordance with agreements established with third-party service providers. The judgments and estimates in determining the accrued liabilities balance are assessed in each reporting
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development and Research and Development&#151;Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development and research and development&#151;related parties expenses include costs incurred to develop the Company&#146;s
technology (prior to establishing technological feasibility), collect clinical samples, and conduct clinical studies to develop and support the Company&#146;s multi-cancer tests. These costs consist of personnel costs, including salaries, benefits,
and stock-based compensation expense associated with the research and development personnel, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies at domestic and international sites, and allocated
overhead expenses including rent, information technology, and equipment depreciation. Both internal and external research and development costs are expensed in the periods in which they are incurred. Research and development&#151;related parties
expenses are further discussed in note &#147;9. Related-Party Transactions.&#148; Nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities are deferred and recognized as
expense in the period in which the related goods are delivered, or services are performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Advertising Costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advertising costs are expensed as incurred. Advertising costs were $24.5&nbsp;million for the year ended January&nbsp;1, 2023 and
$3.0&nbsp;million<B> </B>and<B> </B>$4.6&nbsp;million<B> </B>for the period from August&nbsp;19, 2021 to January&nbsp;2, 2022, and the period from January&nbsp;1, 2021 to August&nbsp;18, 2021, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employee stock-based compensation expense includes expenses related to Cash-Based Equity Awards, restricted stock units, and performance stock
options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Cash-Based Equity Awards are classified as liability awards, as such awards may be settled in cash. The value of the awards
is determined using a calculation and based on advice from independent valuation experts. The fair value of the awards is recorded over the respective vesting periods of the awards, with recognition of a corresponding liability recorded in incentive
plan liabilities in the consolidated balance sheets. The awards are remeasured at each reporting date until the awards are settled, with changes in fair value recognized in stock-based compensation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Acquisition, Illumina issued equity awards to GRAIL employees in exchange for any of their remaining outstanding and
unvested GRAIL equity awards (the &#147;Replacement Awards&#148;). The awards consist of restricted stock units and performance stock options that are issued as shares of Illumina common stock at vesting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of restricted stock is determined by the closing market price of Illumina&#146;s common stock on the date of grant. Stock-based
compensation expense is recognized based on the fair value on a straight-line basis over the requisite service periods of the awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
fair value of performance stock options with service conditions is determined using the Black-Scholes-Merton option-pricing model. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The expected
volatility is generally determined by weighing the historical and implied volatility of Illumina&#146;s common stock. The historical volatility is generally commensurate with the estimated expected term, adjusted for the impact of unusual
fluctuations and other relevant factors. The implied volatility is calculated from the implied market volatility of exchange-traded call options on Illumina&#146;s common stock. The expected term is generally based on historical forfeiture
experience, exercise activity, and on the terms and conditions of the stock awards. Given that Illumina has never declared or paid cash dividends on the Illumina common stock, the expected dividend yield is determined to be 0%. Illumina does not
anticipate paying cash dividends in the near future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the stock-based awards. The fair value of the awards begins to be recognized
when it is probable that the performance-based condition will be met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forfeitures are accounted for, as incurred, as a reversal of
stock-based compensation expense related to awards that will not vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Predecessor period, stock-based compensation expense for
awards containing both performance and market-based conditions was recorded using the accelerated attribution method. Management used the Monte Carlo simulation to determine the fair value at the grant date and recognized stock-based compensation
expense over the derived service period when it became probable that the performance-based condition will be met. Under the Monte Carlo simulation, stock returns were simulated to estimate the payouts established by the vesting conditions of the
awards and an estimated time that the awards will vest. The assumptions used in the Monte Carlo simulation included: the fair value of common stock, estimating the length of time employees will retain their vested stock options before exercising
them (expected term), the estimated volatility of the common stock price over the expected term (expected volatility), the risk-free interest rate and expected dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Defined Contribution Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors a defined contribution plan under Section&nbsp;401(k) (the &#147;401(k) Plan&#148;) of the Internal Revenue Code covering
eligible employees. Employer contributions made to the 401(k) Plan are voluntary and are determined annually by the board of directors on an individual basis subject to the maximum allowable amount under federal tax regulations. The Company has not
made contributions to the 401(k) Plan since inception of the plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Provision for (Benefit from) Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the merger, as a single member limited liability company wholly owned by Illumina, GRAIL, LLC is no longer subject to U.S.
income tax as a separate entity for the Successor periods ended January&nbsp;1, 2023 and January&nbsp;2, 2022 and is combined into Illumina&#146;s consolidated income tax return as an entity disregarded as being separate from Illumina. However, for
financial statement purposes, GRAIL has elected to compute its income tax provision, including current and deferred taxes, as if GRAIL was a corporation filing a separate income tax return and was not included in Illumina&#146;s consolidated return.
Under this method, various tax attributes, such as net operating losses and tax credits, are also presented on a separate return basis. For income tax purposes, since GRAIL, LLC is not a separate taxpayer and merely a disregarded entity of Illumina,
these U.S. tax attributes, including net operating losses and tax credits, are the property of Illumina and have either already been utilized by Illumina in its consolidated or combined income tax returns or will be utilized by Illumina in its
returns in the future. Accordingly, such U.S. tax attributes will not be available to a standalone GRAIL entity on its income tax returns in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are
recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards.
Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in
the provision for income taxes in the period that includes the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets are regularly assessed to determine
the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the
ability to recover deferred tax assets within the jurisdiction in which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> book income for the
past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of <FONT STYLE="white-space:nowrap">pre-tax</FONT> book income over the foreseeable future, and the impact of any feasible
and prudent tax planning strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of a tax position is recognized in the consolidated financial statements only if that
position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense
(benefit). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The functional currencies of foreign subsidiaries are the British Pound and the Hong Kong Dollar. Adjustments resulting from translating the
financial statements of the United Kingdom and Hong Kong subsidiaries into U.S. Dollars are recorded as a component of other comprehensive loss in the consolidated statements of comprehensive loss. Monetary assets and liabilities denominated in a
foreign currency are translated into U.S. Dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the weighted-average exchange rates during the period. Equity transactions are translated using historical
exchange rates. Gains and losses resulting from translation of foreign currency monetary transactions are reported in other income (expense), net in the consolidated statements of operations and comprehensive loss. Gains and losses resulting from
foreign currency transactions that are deemed to be of a long-term investment nature are reported as a separate component of other comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3. GRAIL ACQUISITION, GOODWILL AND INTANGIBLE ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GRAIL Acquisition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
August&nbsp;18, 2021, Illumina completed its acquisition of GRAIL, Inc. The total purchase price consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,861,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,975,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">757,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of previously held investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,149,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of preexisting relationships</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total purchase price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,745,477</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Acquisition accelerated the vesting of certain outstanding and unvested equity awards of GRAIL. Refer to
note &#147;8. Stock Incentive Awards&#148; for further details on the accelerated vesting of the equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair values of GRAIL,
Inc.&#146;s assets acquired and liabilities assumed were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,197,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current and non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability, net&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current and non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(149,376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total net assets acquired</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,745,477</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain adjustments were made to deferred tax liability, net, as a result of
<FONT STYLE="white-space:nowrap">re-calculating</FONT> the provision on a stand-alone basis as compared to Illumina&#146;s consolidated reporting, resulting in an increase in goodwill and an increase in deferred tax liability, net, as compared to
that calculated by Illumina. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transaction costs associated with the Acquisition consisted primarily of legal,
regulatory, and financial advisory fees of approximately $82.3 million, which were expensed as incurred as general and administrative expense in 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Unaudited Pro Forma Financial Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma financial information summarizes the combined results of operations of GRAIL as if the Acquisition had been
completed on January 1, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands) <I></I><I></I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,318,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes revenue&#151;related parties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma financial information is presented for information purposes only and is not indicative of the results of operations
that would have been achieved had the Acquisition been completed on January 1, 2021. In addition, the unaudited pro forma financial information is not a projection of future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results of operations of the Company. The unaudited pro forma financial information includes adjustments to reflect incremental amortization expense of the identifiable intangible assets acquired
and the related tax effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Goodwill and Goodwill Impairment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill represents the excess of purchase price paid over fair value of the net identifiable assets acquired and is primarily attributable to
assembled workforce, expanded market opportunities, and expected synergies to be achieved. Goodwill is not deductible for tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 13, 2022, the European General Court ruled that the European Commission had jurisdiction under the European Union Merger Regulation to
review the Acquisition. Additionally, on September 6, 2022, the European Commission issued a decision prohibiting the Acquisition. These decisions constituted substantive changes in circumstances and led us to test goodwill for impairment. The
assessment was performed using a combination of both an income and a market approach to determine the fair value of goodwill. The income approach utilized the estimated discounted cash flows, while the market approach utilized comparable company
information. Estimates and assumptions used in the income approach included projected cash flows and a discount rate. The discount rate selected at the time of the goodwill impairment assessment was 22.0%. These estimates and assumptions represent a
Level&nbsp;3 measurement because they include unobservable inputs that are supported by little or no market activity and reflect self-determined and judgmental factors for these assumptions in measuring a fair value. The assumptions in the
assessment of an impairment analysis are inherently subjective due to uncertainty and any slight changes in these rates and assumptions could have a significant impact on the concluded value of goodwill. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized a goodwill impairment of $4.7&nbsp;billion as a result of the impairment assessment, primarily due to the negative
impact of capital market conditions and a higher discount rate selected for the fair value calculation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Intangible Assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets recognized as part of the Acquisition include developed technologies, trade name and IPR&amp;D that were measured at fair
value as of the Closing Date. The following roll-forward indicates the fair values assigned to identifiable assets from the Acquisition and the resulting amortization: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Developed<BR>Technologies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Trade&nbsp;Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>In-process<BR>Research&nbsp;and<BR>Development<BR>(IPR&amp;D)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Intangible<BR>Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Beginning balance as of August 19, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross carrying amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ending balance - Intangible assets, net as of January 2, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,365,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>38,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>670,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,073,889</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(133,889</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(138,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ending balance - Intangible assets, net as of January 1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,231,481</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>34,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>670,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,935,556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair values of the developed technologies, trade name and IPR&amp;D were estimated using an income
approach, under which an intangible asset&#146;s fair value is equal to the present value of future economic benefits to be derived from ownership of the asset. The estimated fair values were developed by discounting future net cash flows to their
present value at market-based rates of return and inclusive of an assumption for technology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obsolescence. The useful lives of the intangible assets for amortization purposes were determined by considering the period of expected cash flows used to measure the fair values of the
intangible assets adjusted as appropriate for entity-specific factors including legal, regulatory, contractual, competitive, economic, and other factors that may limit the useful life. The developed technology and trade name assets are amortized on
a straight-line basis over their estimated useful lives. As of January&nbsp;1, 2023, the research and development project had not been completed or abandoned. The IPR&amp;D intangible asset is not currently subject to amortization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the goodwill impairment assessment, the IPR&amp;D intangible asset was evaluated for potential impairment. The evaluation
and assessment for a potential impairment of the IPR&amp;D intangible asset was performed by comparing its carrying value to the assessed estimated fair value, which was determined by the income approach, using a discounted cash flow model.
Estimates and assumptions used in the income approach included projected cash flows and a discount rate. These estimates and assumptions represent a Level&nbsp;3 measurement because they include unobservable inputs that are supported by little or no
market activity and reflect self-determined and judgmental factors for these assumptions in measuring a fair value. Based on our impairment test, the carrying value of the IPR&amp;D intangible asset did not exceed its estimated fair value. As a
result, no impairment for the IPR&amp;D intangible asset was recorded. A recoverability test for the definite-lived intangible assets, which includes developed technology and trade name, was also performed. Based on the assessment performed, no
impairment was noted for the definite-lived intangibles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated future annual amortization of finite-lived intangible assets is
shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Annual<BR>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,573,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,265,556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4. REVENUE RECOGNITION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents our customer revenues disaggregated by revenue source: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021<BR>to<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1<BR>to<BR>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Screening</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,074</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Screening&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,978</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>55,550</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>12,433</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s revenues were generated in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5. BALANCE SHEET COMPONENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present financial information of certain consolidated balance sheets components: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prepaid expenses and other current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid service and maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total prepaid expenses and other current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>18,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction-in-process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total property and equipment, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>91,501</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>90,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment, net&#151;related parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction-in-process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment, net&#151;related parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,515</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,877</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accrued liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal and professional expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical studies expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total accrued liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>64,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>48,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accrued liabilities&#151;related parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued purchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued to Illumina</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total accrued liabilities&#151;related parties</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,517</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6. LEASES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into operating leases for facilities and equipment used for research and development. Operating leases have remaining
lease terms which range from 1 year to 11 years, and often include one or more options to renew. These renewal terms can extend the lease term from 5 to 15 years and are included in the lease term when it is reasonably certain that the option will
be exercised. The exercise of lease renewal and termination options are at the sole discretion of the Company. The Company also has variable lease payments that are primarily comprised of common area maintenance and utility charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost components of lease costs are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021<BR>to<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1<BR>to<BR>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,747</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,328</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total lease cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>26,134</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,075</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,438</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future undiscounted lease payments under operating leases as of January&nbsp;1, 2023 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Successor<BR>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total undiscounted lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Tenant improvement allowance*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,820</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating lease liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>96,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant improvement allowance is estimated to be received as follows: approximately $1.8&nbsp;million in 2023,
$0.9&nbsp;million in 2024, and $9.1&nbsp;million thereafter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future <FONT STYLE="white-space:nowrap">non-lease</FONT> commitments over the next five years and thereafter were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of January&nbsp;1, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum<BR>Royalties</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Purchase<BR>Commitments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,900</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>91,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>100,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Minimum Royalty Commitments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Minimum royalty commitments are associated with licensing agreements related to research efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above includes minimum annual royalty payments but does not include royalties that would be payable on net sales of Galleri, and any
future products, pursuant to existing agreements and licenses with Illumina, the Chinese University of Hong Kong, and other third parties in excess of minimum annual royalty payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Purchase Commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purchase commitments primarily relate to contractual commitments for future use of web services, laboratory supplies and marketing events in the normal course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Intellectual Property </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an agreement with a third party for exclusive option rights to certain intellectual property. The Company exercised
those option rights to license intellectual property in December 2022. Under the terms of the agreement, the Company may be obligated to make future milestone payments if certain milestone events, such as new product launches or expansion into new
regions, are achieved with respect to products covered by the licensed intellectual property. No such milestones were achieved or probable of achievement as of January&nbsp;1, 2023.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is (or was) serving in such capacity. The indemnification period covers all pertinent events and occurrences during the
director&#146;s or officer&#146;s service. The maximum potential amount of future payments the Company could be required to make under the applicable indemnification agreements is not specified in the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company
indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any
third party with respect to the Company&#146;s technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments that the Company could be required
to make under these arrangements is not determinable. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements
is minimal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8. STOCK INCENTIVE AWARDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense, which includes expense for both equity and liability-classified awards, reported in our consolidated
statements of operations was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,&nbsp;2023&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021&nbsp;to<BR>January&nbsp;2,&nbsp;2022&nbsp;(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (exclusive of amortization of acquired intangible assets)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,767</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,419</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384,924</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense, before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">650,260</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related income tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,046</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(155,510</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stock-based compensation expense, net of taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>57,683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>494,750</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>24,040</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes $65.8&nbsp;million related to the Cash-Based Equity Awards and $9.9&nbsp;million related to the
Replacement Awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes $11.1&nbsp;million related to the Cash-Based Equity Awards, $24.1&nbsp;million related to the
Replacement Awards and $615.0&nbsp;million of accelerated equity awards attributable to the Post-Combination period. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liability-Classified Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established following the Acquisition, a cash-based equity incentive award (the &#147;Cash-Based Equity Award&#148;) was adopted to provide
GRAIL, LLC employees with dollar-denominated long-term incentive awards that increase or decrease in value based on corresponding changes in GRAIL&#146;s calculated equity value, similar to a dollar-denominated restricted stock unit award determined
in accordance with the award agreement. The Company uses independent valuation experts and analyses to value the awards, which requires various assumptions to be used, such as long-range financial projections, as well as the discount rate and
terminal growth rate. The awards generally have terms of four years and vest in four equal installments on each anniversary of the grant date, subject to continued employment through the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash-Based Equity Awards activity was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021<BR>to<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Beginning balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>184,532</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40,937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and paid in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>$293,359</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>184,532</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s estimated incentive plan liabilities as of January&nbsp;1, 2023 and January&nbsp;2, 2022
were $35.9&nbsp;million and $11.1&nbsp;million, respectively. As of January&nbsp;1, 2023, approximately $257.4&nbsp;million of total unrecognized compensation cost related to awards issued to date was expected to be recognized over a
weighted-average period of approximately 3.1 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has one performance-based award outstanding for which vesting is based on future
revenues. The award has an aggregate potential value of up to $78.0&nbsp;million and expires, to the extent unvested, in August 2030. One-fourth of the total potential value of the award vests immediately upon the achievement of cumulative net
revenues in any period of four consecutive fiscal quarters of $500.0&nbsp;million, $750.0&nbsp;million, $1.5&nbsp;billion, and $2.0&nbsp;billion. The Company assesses the probability of achieving the performance conditions associated with the award
on a quarterly basis at each reporting period. As of January&nbsp;1, 2023, it was not probable that the performance conditions associated with the award will be achieved and, therefore, no stock-based compensation expense, or corresponding
liability, has been recognized in the consolidated financial statements to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accelerated Awards at Acquisition and Replacement
Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Acquisition, the vesting of certain outstanding and unvested equity awards was accelerated. The fair
value of the accelerated awards attributable to the Post-Combination period and recognized in connection with this event was $615.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illumina issued Replacement Awards to GRAIL employees in exchange for any of their remaining outstanding and unvested GRAIL equity awards as
of the Closing Date. The Replacement Awards, granted under Illumina&#146;s 2015 Stock and Incentive Compensation Plan (the 2015 Stock Plan), consist of restricted stock units and performance stock options that are issued as shares of Illumina common
stock at vesting. RSUs generally vest over a <FONT STYLE="white-space:nowrap">two-year</FONT> period with equal vesting quarterly. The terms of the Replacement Awards are substantially similar to the former GRAIL equity awards for which they were
exchanged. The fair value of the Replacement Awards was $47.5 million, all of which is attributable to Post-Combination service, and will be recognized as stock-based compensation expense over the remaining vesting period subsequent to the
acquisition. The weighted-average acquisition-date fair value of the replacement performance stock options was determined using the Black-Scholes option pricing model with the following assumptions: (i)&nbsp;market price of $510.61 per share, which
was the closing price of Illumina&#146;s common stock on the Closing Date; (ii)&nbsp;weighted-average expected term ranging from 1.6 years to 2.2 years; (iii)&nbsp;weighted-average risk-free interest rate ranging from 0.17% to 0.28%; (iv)
weighted-average annualized volatility ranging from 40% to 43%; and (v)&nbsp;no dividend yield. The weighted-average acquisition-date fair value per share of the replaced performance stock options was $424.39. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2023, approximately $4.3&nbsp;million of total unrecognized compensation cost related to restricted stock and
performance stock options was expected to be recognized over a weighted-average period of approximately 3.1 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Replacement award
activity was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted<BR>Stock&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Grant-Date Fair<BR>Value per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(Units in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSU</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSU</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding at August&nbsp;19, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Awarded</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding at the beginning of January&nbsp;2, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding at January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>510.61</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-tax</FONT> intrinsic value and fair value of vested
restricted stock was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pre-tax intrinsic value of outstanding restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of restricted stock vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Performance Stock Options activity was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(Units in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Performance<BR>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding at August&nbsp;19, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding at the beginning of January&nbsp;2, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Outstanding at January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>85.54</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no outstanding performance stock options exercisable as of January&nbsp;1, 2023. The aggregate
intrinsic value of performance stock options outstanding as of January&nbsp;1, 2023 and January&nbsp;2, 2022 was $3.3&nbsp;million and $6.3&nbsp;million, respectively. The total intrinsic value of performance stock options exercised was
$6.3&nbsp;million in 2021. Outstanding performance stock options, in general, have contractual terms of ten years from the respective grant dates. The performance stock options generally vest monthly over three years upon the achievement of
Company-specified performance targets and subject to continued service through the applicable vesting date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Predecessor Period
Awards</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the Predecessor period, the Company granted awards under the GRAIL, Inc. 2016 Amended Equity Incentive Plan (the
&#147;2016 Plan&#148;) as well as incentive awards not under the 2016 Plan (the <FONT STYLE="white-space:nowrap">&#147;Non-Plan</FONT> Equity Incentive Awards&#148;). The Company&#146;s 2016 Plan allowed for the grant of awards in the form of:
(i)&nbsp;incentive stock options, (ii)&nbsp;nonqualified stock options; (iii)&nbsp;stock appreciation rights; (iv)&nbsp;RSAs; (v) RSUs; and (vi)&nbsp;unrestricted stock. Directors, employees, and consultants were eligible to participate in the 2016
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Acquisition, a portion of the unvested stock options and RSUs under the 2016 Plan and <FONT
STYLE="white-space:nowrap">Non-Plan</FONT> Equity Incentive Awards were accelerated and vested. GRAIL, Inc.&#146;s 2016 Plan and <FONT STYLE="white-space:nowrap">Non-Plan</FONT> Equity Incentive Awards were then cancelled, with any remaining
unvested equity awards replaced with equity awards issued by Illumina. Refer to the Replacement Awards section of this disclosure for a further discussion of these Replacement Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Activity</I></B>&#151;A summary of all stock option activity for the 2016
Plan is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands, except years and per share data)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Underlying<BR>Outstanding<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term (in<BR>Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Awards Authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,262</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of August&nbsp;18, 2021 cancelled in connection with the Acquisition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>77,335</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.91</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8.12</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>506,651</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Unit Activity</I></B>&#151;A summary of all restricted stock unit activity for the 2016
Plan is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands, except per share data)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted<BR>Stock Units<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date Fair<BR>Value&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested balance as of August&nbsp;18, 2021 cancelled in connection with the
Acquisition</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6.25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9. RELATED-PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Illumina Purchases and Sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in note &#147;1. Organization and Description of Business,&#148; GRAIL and Illumina entered into the Merger Agreement on
September&nbsp;20, 2020, and on August&nbsp;18, 2021, Illumina completed its acquisition of GRAIL, Inc. Prior to the Acquisition, Illumina held a 12% stake in the Company. Illumina is both a customer of the Company and a major supplier of the
Company&#146;s reagents and capital equipment. Goods and services transactions with Illumina are invoiced and paid when due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goods and
services transactions with Illumina have been reflected in the consolidated financial statements as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplies&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021&nbsp;to<BR>January 2, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January 1 to<BR>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses&#151;Research and development&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses&#151;General and administrative&#151;related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Merger Agreement, the Company received continuation payments of
$35.0&nbsp;million per month from the signing of the Merger Agreement until Closing, which were recorded as additional paid-in capital. During the Predecessor period from January&nbsp;1, 2021 to August&nbsp;18, 2021, the Company received total
continuation payments from Illumina of $245.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contributions from (Distribution to) Member, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following related party transactions between the Company and Illumina have been included in these consolidated financial statements. As
there is no intercompany loan agreement between Illumina and GRAIL and because these transactions have no history of being settled, the total net effect of these transactions are reflected in the consolidated statements of cash flows as cash
provided by (or used by) financing activity and in the consolidated balance sheets as contribution from (distribution to) member, net, in member&#146;s equity. The following table presents the components of the net transfers to and from Illumina:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash funding received from Illumina</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">609,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash funding received from Illumina at acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payments for acquisition consideration on behalf of Illumina</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(625,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payments for equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(184,963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes paid related to net share settlement of equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,883</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contribution from (distribution to) member, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>604,273</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(42,915</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Klausner Consulting Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective May 2016, the Company entered into a consulting agreement for advisory consulting services with Richard Klausner, M.D., a member of
the board of directors of the Company at that time. The compensation under the consulting agreement consisted of options to purchase Class&nbsp;A common stock and reimbursement of certain out-of-pocket expenses. The Company granted options to
purchase shares of Class A common stock under the consulting agreement in 2016, 2018, and 2020. In accordance with the terms of the Merger Agreement, all awards granted to Dr.&nbsp;Klauser became fully vested upon the closing of the transaction,
which is also when Dr.&nbsp;Klauser stopped providing directorship and consulting services to the Company and ceased to be a related party of the Company. Stock-based compensation expense of $0.4&nbsp;million related to the consulting agreement is
included in research and development&#151;related parties for the Predecessor period from January&nbsp;1, 2021 to August&nbsp;18, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Agilent Relationship</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From June 2019 through October 2021, Mr.&nbsp;Hans Bishop served as the Company&#146;s chief executive officer, during which time
Mr.&nbsp;Bishop also served on the board of directors of Agilent Technologies, Inc. (&#147;Agilent&#148;), a supplier to the Company. Transactions with Agilent during the period of time Mr.&nbsp;Bishop held an officer role at the Company are
reflected in the consolidated financial statements as related party transactions. Related party expenses of $0.1&nbsp;million and $0.2&nbsp;million are included in research and development&#151;related parties in the periods of August&nbsp;19, 2021
to January&nbsp;2, 2022 and January&nbsp;1, 2021 to August&nbsp;19, 2021, respectively. Agilent was no longer a related party as of the year ended January&nbsp;1, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Twist Bioscience Relationship </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Robert Ragusa was appointed as the Company&#146;s chief executive officer in October 2021. Mr.&nbsp;Ragusa also serves on the board of
directors of Twist, a supplier to the Company. Transactions with Twist beginning when Mr.&nbsp;Ragusa became the Company&#146;s chief executive officer are reflected in the consolidated financial statements as related party transactions. Related
party expenses of $0.4&nbsp;million and $0.1&nbsp;million are included in research and development&#151;related parties in the year ended January&nbsp;1, 2023 and the period of August&nbsp;19, 2021 to January&nbsp;2, 2022, respectively. Accrued
liabilities with Twist of $0.1&nbsp;million and $0.1&nbsp;million are included in accrued liabilities&#151;related parties as of January&nbsp;1, 2023 and January&nbsp;2, 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Acquisition, each issued and outstanding share of GRAIL Stock was converted into the elected merger consideration. As
the Successor Company is a single-member limited liability company wholly owned by Illumina, a separate calculation of net loss per share is not included for the year ended January 1, 2023 and for the period ended January 2, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the Predecessor period from January 1, 2021 to August&nbsp;18, 2021, basic and diluted net loss per share attributable to common
stockholders were presented in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. All series of its redeemable convertible preferred stock and early exercised stock options and
restricted stock awards were determined to be participating securities. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss attributable to common stockholders was not allocated to the redeemable convertible preferred
stock as the holders of the redeemable convertible preferred stock did not have a contractual obligation to share in losses. The Company had two classes of common stock, Class A and Class B, with voting rights of 1:1 and 10:1, respectively. The
shares of Class B common stock were convertible into shares of Class A common stock at a ratio of 0.44 shares of Class A common stock to 0.42 shares of Class B common stock, but were otherwise obligated to share in losses equitably. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders was calculated by dividing the net loss adjusted to include deemed dividends paid
to the holders of the preferred stock and accretion to the redemption value of the redeemable common stock awards, to the extent both impact accumulated deficit, by the weighted-average number of shares of common stock outstanding during the period,
less shares subject to repurchase. Diluted net loss per share attributable to common stockholders was the same as basic net loss per share, since the effects of potentially dilutive securities were anti-dilutive given the net loss attributable to
common stockholders for each period presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the calculation of the Predecessor&#146;s basic and diluted net
loss per share attributable to common stockholders: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except share and per share data)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>January&nbsp;1 to August&nbsp;18, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(280,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(280,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic common shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares of common stock&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,584,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,989,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used in earnings per common share&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,584,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,989,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is in a net loss position, whereby the basic net loss per share is the same as diluted net loss
per share because the inclusion of potential shares of common stock would have been anti-dilutive. The following common stock equivalents were therefore excluded from the computation of diluted net loss per share for the period presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (on an if-converted basis)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">534,145,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock and restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,971,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>664,596,071</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 11. TAXES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes summarized by region was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021<BR>to<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,443,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(892,906</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(343,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,113</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before provision for (benefit from) income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,441,388</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(929,019</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(336,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision for (benefit from) income taxes consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021<BR>to<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current income tax expense/(benefit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,862</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,615</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred income tax expense/(benefit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Provision for (Benefit from) income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(42,290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(17,477</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision for (benefit from) income taxes reconciles to the amount computed by applying the federal
statutory rate to income (loss) before income taxes as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,<BR>2021 to<BR>January&nbsp;2,<BR>2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1 to<BR>August&nbsp;18,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,142,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(195,094</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(70,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,718</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,792</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,907</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,072</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,384</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">859</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(310,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of acquisition related items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,179</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">987,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in tax rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total tax provision (benefit from) income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(42,290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(17,477</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of deferred tax assets and liabilities were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">740,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized U.S. research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,056,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">906,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance on deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(392,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(245,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>664,116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>661,383</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(709,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(742,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(735,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(771,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liability, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(71,075</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(110,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of the merger, as a single-member limited liability company wholly owned by Illumina, GRAIL, LLC
is no longer subject to U.S. income tax as a separate entity for the Successor periods ended January&nbsp;1, 2023 and January&nbsp;2, 2022, and is combined into Illumina&#146;s consolidated income tax return as an entity disregarded as being
separate from Illumina. However, for financial statement purposes, GRAIL has elected to compute its income tax provision, including current and deferred taxes, as if GRAIL was a corporation filing a separate income tax return and was not included in
Illumina&#146;s consolidated return. Under this method, the deferred tax assets and liabilities presented above are as if GRAIL, LLC filed a separate return for the Successor periods. For income tax purposes, since GRAIL, LLC is not a separate
taxpayer and merely a disregarded entity of Illumina, several of the U.S. tax attributes shown above, including net operating losses and tax credits, are the property of Illumina and have either already been utilized by Illumina in its consolidated
or combined income tax returns or will be utilized by Illumina in its returns in the future. Accordingly, such U.S. tax attributes will not be available to a standalone GRAIL entity on its income tax returns in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established when it is more likely than not that the future realization of all or some of the deferred tax assets
will not be achieved. The evaluation of the need for a valuation allowance is performed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis and includes a review of all available
positive and negative evidence, including operating results and future reversals of existing taxable temporary differences such as the deferred tax liabilities related to purchased intangibles. Based on the available evidence as of January&nbsp;1,
2023, we were not able to conclude it is more likely than not certain deferred tax assets will be realized. Therefore, a valuation allowance of $392.0&nbsp;million was recorded against certain U.S. and foreign deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;1, 2023, the net operating loss carryforwards for federal and state tax purposes were $3,170.1&nbsp;million and
$1,993.4&nbsp;million, respectively, a portion of which will begin to expire in 2036 unless utilized prior. The federal and state tax credit carryforwards were $78.8&nbsp;million and $56.5&nbsp;million. The federal credits will begin to expire in
2036 unless utilized prior. The state credits do not expire and can be carried </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forward indefinitely. GRAIL&#146;s U.K. subsidiary had $45.1&nbsp;million of U.K. net operating losses that can generally be carried forward provided that the U.K. entity maintains its existing
trade or business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;382 and 383 of the Internal Revenue Code, utilization of net operating losses and credits may
be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the gross amount of uncertain tax positions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Successor)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Predecessor)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;19,&nbsp;2021<BR>to<BR>January&nbsp;2,&nbsp;2022</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1<BR>to<BR>August&nbsp;18,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,683</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at end of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>51,843</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>43,595</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>41,683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Included in the balance of uncertain tax positions as of January&nbsp;1, 2023 and January&nbsp;2, 2022 were
$47.6&nbsp;million and $39.9&nbsp;million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the effective income tax rate in future periods. The Company has not recognized any interest or penalties related to
uncertain tax positions. If interest and penalties are recognized in the future, such amounts will be included in the provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tax years 2016 to 2022 remain subject to future examination by the major tax jurisdictions in which we are subject to tax. It is reasonably
possible that the balance of unrecognized tax benefits could change significantly over the next 12 months. However, due to the number of years remaining that are subject to examination, we are unable to estimate a full range of possible adjustments
to the balance of unrecognized tax benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 12. LEGAL AND REGULATORY PROCEEDINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to various claims, complaints, regulatory proceedings, and legal actions that arise from time to time in the ordinary
course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2021, the U.S. Federal Trade Commission (&#147;FTC&#148;) issued an administrative complaint
seeking to prevent the acquisition of GRAIL, Inc. by Illumina. On September&nbsp;1, 2022, an administrative law judge issued a decision in favor of the transaction and dismissed the FTC&#146;s complaint. The FTC appealed to the FTC Commission. On
March&nbsp;31, 2023, the FTC Commission issued a decision overturning the administrative law judge&#146;s prior ruling. GRAIL and Illumina appealed the Commission&#146;s decision to the U.S. Court of Appeals for the Fifth Circuit. Oral argument in
that appeal occurred on September&nbsp;12, 2023 and a decision has not yet been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;19, 2021, the European Commission
accepted a request for a referral of the GRAIL, Inc. acquisition for European Union merger review, submitted by a Member State of the European Union (France), and joined by several other Member States (Belgium, Greece, Iceland, the Netherlands, and
Norway), under Article 22(1) of Council Regulation (EC) No 139/2004 (the &#147;EU Merger Regulation&#148;). On April&nbsp;28, 2021, Illumina filed an action in the General Court of the European Union (the &#147;EU General Court&#148;) asking for
annulment of the European Commission&#146;s assertion of jurisdiction to review the acquisition under Article 22 of the EU Merger Regulation, as the acquisition does not meet the jurisdictional criteria under the EU Merger
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulation or under the national merger control laws of any Member State of the European Union. On July&nbsp;13, 2022, the EU General Court confirmed the European Commission&#146;s jurisdiction
to examine the Acquisition (&#147;EU General Court Article&nbsp;22 Judgment&#148;). On September&nbsp;22 and 30, 2022, Illumina and the Company each asked for annulment of the EU General Court Article 22 Judgment and their request is currently
pending before the Court of Justice of the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;29, 2021, the European Commission adopted an order imposing
interim measures (the &#147;Initial Interim Measures Order&#148;). As the Initial Interim Measures Order was set to expire in 2022, the European Commission adopted new interim measures on October&nbsp;28, 2022 (the &#147;Second Interim Measures
Order&#148;). The Company and Illumina both sought the annulment of the Initial Interim Measures Order, and Illumina also sought the annulment of the Second Interim Measures Order (the Company intervened in this procedure in support of Illumina).
All requests for annulment were stayed pending the appeal asking for annulment of the EU General Court Article 22 Judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;6, 2022, the European Commission adopted a decision finding Illumina&#146;s acquisition of GRAIL, Inc. incompatible with the internal market in Europe. On November&nbsp;17, 2022, Illumina asked for annulment of this decision before
the EU General Court (the Company intervened in this procedure in support of Illumina). This procedure is currently pending and moving forward. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2023, the European Commission adopted a decision requiring Illumina to divest the Company and to restore the situation
prevailing before the Company&#146;s acquisition by Illumina (the &#147;EC Divestment Decision&#148;). Consistent with the previous interim measures orders, Illumina is required to continue funding the Company until any divestiture. In the instance
of a capital markets transaction, Illumina must capitalize the Company at the time of the transaction. The order also permits Illumina to maintain its royalty arrangement with the Company (which will result in royalty payments restarting if GRAIL is
no longer an affiliate of Illumina). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contingencies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingencies primarily correspond to claims arising in the ordinary course of business. If necessary, these contingencies will be accrued to
the extent believed to be reasonably estimable to resolve the matter. The accrued contingency amounts are included in other current liabilities. Should the Company not be able to secure the terms it expects, these estimates may change and will be
recognized in the period in which they are identified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Matters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal matters include various claims, complaints, and legal actions that arise from time to time. There can be no assurance that existing or
future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company&#146;s business, financial position, results of operations, or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to employment
matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the consolidated financial statements if it is believed to be
probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Litigation is inherently unpredictable and unfavorable resolutions could occur; therefore, assessing contingencies is highly subjective and requires
judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures. We may change our estimates if our assessment of the various factors changes and the amount of
ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows. As of the filing date of this Information Statement, there are no currently pending
litigations with any probable losses that can be reasonably estimated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Treatment Requested by GRAIL, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 17 C.F.R. Section 200.83 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 13. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has reviewed and evaluated subsequent events through December&nbsp;8, 2023, the date these consolidated financial statements were
filed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2023, Illumina recorded an impairment to GRAIL goodwill and IPR&amp;D for consolidated financial reporting
purposes. The Company is currently in the process of performing its required goodwill and indefinite-lived impairment test, which may result in impairment charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g556103g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g00a01.jpg
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M-$%V>(&QM+8E.#E1='>"MR1Q)F%$>9'_Q  < 0$  P$! 0$!
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M23,LBL(K>)"O,D".Q9M5PP ;?;V\ MVN[LR<H2<J**(A7FD #-WF!"QHI&S
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MZ2\I,LQ0?=YZ'A9')-51$631=2:5&A#DHLDR& D) 0>,&BSM+-TDU=K)6WG
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MJ(A'KM-*V&#C,2PSSQOY.GX/D\2E(_)S@BQ,Z0O?<9<("0,+-"(BP!P619&
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MKFV8V76LU22LIGX51D=E"L[LH9F"EB5#-C9@"<!FP-B.IP,YQ4"S$8+$@$D
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MPHW;*+K*(IX9*YWR%W*A"S%%)94+'4,V S!<X!( !(&3@9\*;-@+DZ@DA<G
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M.$,%5\,E4[90>VN8@#);SQAF"J7BD0,QSA06498X. .IP>E536%];A3/9W<
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M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O??B'_X#7=2/_=_0?\
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MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*5[[_P HY_[]\!_V5-2?]2;'KYG\E/\
MTZ?_ )Z?_P <%?$_D%_Z+/\ ]2N?_%;UX$5]-7VU*4I2E28_"IE%$FB\HB4F
MC:+^^=F*Q\"5#I/;IXXYYV:*$6C;!S?##/#+.R-\_!QSQROWK96O>"R1N2$D
M1ROB%96(_: 3C]]5I-%(2(Y8Y"OP@CJY'[0I./WU&:G5E9%4061Q89K"R*.!
M5MB]%Y*LG*>))GF]6&X.V&6:5K/&V9%NNPQ7;W42R>H+-;9W73S3QYLISA@=
M3ANHZ$ $@^1 (.#UP0?"HAE.V&4ZG#8([I #$-UZ$*0V#@X(/@:Z[UD\&O'8
MXBT<L"#!RNR?,7J"K5XR>-5<T'31VU7P37;.6RZ>:*Z"V&"J*N&::F&.>-[6
M @@$$$$ @@Y!!Z@@CH01U!'C700P#*0RL 58$$$$9!!'0@CJ".A%<*::BRB:
M22>:JJN>*:22>.6:BBF>5L<$T\,;7RSSSRO;'''&U\LLKVM:U[WM:N^'C720
M 23@#J2? #S-2"0PZ71'-JG*XK(XPH]Q5S9X2$&3"YN\$;X66R:XDFK;)QBE
M=1.RN25L[)WSPMG>U\L>_!)(Y,\MT?'CHRMC/AG!.*KCEBESRI(Y-<9Y;J^,
M^&=2<9P<9\<5'*G5E9E*.2%=AYU1!&5AEVCU_8DD+?*,+L1KIHR(O?+,$+M_
M)&#U^Q:/7'C/$M73QHW7S35<(X9Q+H#@LH.0,%AG)!(&,YR0"0/$@''A43(@
M;4N@;(&I8;98$J,9SE@K$#Q(!(Z UB,<<L[WMACEE>V.65[8VOE>V.&-\\\K
MVM:_>QQQM?+*_P#1CC:][WM:U[U*I5VB X@)>+#RK!X,?MKX6<,2#5=D\0NH
MG@LG99LYP362OFDHFKA;/#&^2>>&>/?QRQO?@(894A@? @@@_%XCIX]*XK*P
M#*0P/@5((/[".AKIUVNTI2E*4I2O?;^3]_XQ\V/]@'<__5.NZ^9_*?\ V?A_
M_4H/_A+7Q/Y;_P"R<(_ZU:_^.>O FOIJ^VI2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E9YE_FR7_P _XF=4O\(_N_H*N3X(_?\ U-8&KJII2E*4
MI2E*4I2E*4K<0CPAVX&U CMLU(]1!5W6LAVZF6IB^SH\.W0^T^8>(-1.Q&<%
M=9I76#E47+<N,%8E+2PC'UD3[*.+B5D7:F <1@:<P*EPP$QMS.L#FW$ZCO1&
M4#HP/=+8T# J7!KREXQ:O=&U2.Z<"X:S:Y2VD:T6Z0$O;M, <.I!5FUY2N"C
M2!@0*97X^[[:D  ESI#;S<K*P^<ABXQ?6LS2(20 FHS1S. &2@7%R8#X*D1Z
M69,<FY98J/F>%U[9.D+9Z.U6I#,+F A&T<\Z/".<X5CMA6.K=TX/0].AK6+Z
MR*NXO+4K$XCD87$16-SDA'.^$<A6PK$'H>G0UC\=)[FS6G3?#4>SLE]7)9+;
M,0Q@4JR6UTCA@JIFK.D[";YQ%+!-!=3)208C\<<$5<KWMBGG?'O:;?$9Y\.)
MO\D\U,2YZ#E][OY)'P<^-2[7:>\'M5OBY(%L>='_ (@GP$'>]])R,"/;.:):
M3W,OC#\T-1[.6QV&-)&(!DE I4IC.1 9BH4+E8?? 3>TF&BAB2I$D^"W>M6+
M%-1VZ52;X9*6&XMQS,SPCE$++F5/>V8ZJ).]W"6( #8))P.M#>6@YN;JW'(9
M5GS/%[RSL%59>][VS,0JA]26( !-04V#-1DR5CLD$%(_( 1%X(-@C8]V*,AB
MPYPHT("RHQ^BW>CB+%TDJV>,G:"+EJX34172P4PRQM:K*ZJZ,K(P#*RD,K*1
MD,K#(((Z@@D$=15R.DB+)&ZO&ZAT=&#(Z, 5964E65@00P)!!!!Q6+KM2I2E
M*4I2E*4I2E>^_$/_ ,!KNI'_ +OZ#_\ L+35?,WW_N7@_P#R]Q_XKFOBN)_^
M]/R=_P"4OO\ \>\KP(KZ:OM:4I2E*4I6XNJN%\QVWI66;W#;<X^1V'P/R'&:
MC9ILO,#*XJJ:+E0D80-!+ 7EFJTN?AGF$:PL[4\XIW1SRNAXSO8X)^(1P7"6
MS073R2YY;1P[(X559RK;@D1AAOTZ=1UKRKGBT5K=Q63VM])+-MR6AMP\4@1%
M>0H_,&1$KCF9 U.1UJC$M';K7?0@6AI_:2Q/9K%0IK<<EK^6*/M@C$4+.E2,
M(:8"+N)6Q2:Y8N5'8%-^WP0O9;)2R=[95I[3;@2$W$.(3B8\V/$1SC$AVQ&<
M],-@YK:;RT"S,;JW"VS!;AC/%K Q. LQVQ$Q(( <J2>E6U#^%')*7BA\ARUJ
M>BD:?;8<Z25/S(85!M1&R60!62/H^='>;G4@$YLA^"*2[AV&P;W).T!B*BK[
M!V@UHDXC9QDKSE=A!VC6,JQ:(MH&4Y"-DY( ;.H+' P3EEXO81,R=H2606HO
M D3*Y>W+B,2(VPC8%CD /G4%O@X)II]IS;HR.AY@2U7L<?$I"]##0$H?0>3M
M(Z<(R(<@8C[ .;<"TQA-Z=$N6Q0,U9.EUR8YP@]9)KME4U<M N("[1B>$N@8
MN@D0NH4E6+*&RH4@AB0 ""#@UK6ZM6D>);FW:5 [/&LT9D18V*NSH&V4(P*N
M2 %8$'!&*R#S1NVPLVB6O9?KV8:_E,VD Z-1\=L*,GH8HZ)DB3$2E:^!X:S7
M\0W>$F>+Y5-!7R7!?#)3'OYX8Y1%S T<DL<L<J1(7<Q.LF%52W^Z2,D XZC-
M1%Y:O#+/%/%/%#&TDC02), JJSGX#$9*J=1GKCI6UVR^YE\I=2A>4DAF0>(-
M1/$5YK!EM!VSE&#W IGMQ.-KQ): ^+8V^EC:S681EV772\CP&HF65L_&+*^*
MMBBXQ93-9I&SEKX3-""F-1!N).;U[ARC@>.2I^+K7F6_Y0\-NGX:D3RE^*"X
M-N#'@KV4R"03][WHDQ2! <[%&\ ,U08;B5R4-6V39+2FQ1BVH]96W%/V<CBI
MB,D06N%"C ,VD_FP\T'D2#)X]()YL\1C5XLN.9F36"?F4 <(#]37UHO*_P 1
M"PGF[/$4D5PTV"Q3920" .N2,$JOPG4'<_$^'IR,WENPNKCLL!25)%>X"ES'
MLA95*@=[8@!BB$[R(K<VY.)7(+1>S5-3S?64MSDZ\I)0V-N ,;D98'/CXA=!
MJ19:[+8"$4IKFU=.46JV()-VJDY4Q042P4RQQORWOK6YA$\<R!-!(X=T5HE;
M.#*NQY><9&V.E<M>)V-Y;BYAN(N6(EFD#R1J\","09UV/*R 3W\ @9!(K&Z\
MXN;_ -F[50TO&]3SY.?X2.,1J1""L.E _*!.9:8'@Q)+8F.8=1U"@5GA-HH[
M+'6K1LW:YY.+WRQM:V79;VUA@-P\\7*T=U99$;F<M2S+%AL2/A3A5))/2I3\
M1LK>V-W)<P<@QR21NLL;<\1(SNMOW\3/A2 J$DD8JH)3'"4/D\CB)BR%B\6/
M&(X5LU5\>VL2"$' Q]9NOX.'CD+.FJMDE? P\8GX.?@X]_O6T(ZR(DBYUD17
M7(P=6 89'Q'!'2M44BRQQRIG25$D7(P=74,N1\1P1D5@:E4Z4I2E*4I7OO\
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ME*4I2O?;^3]_XQ\V/]@'<_\ U3KNOF?RG_V?A_\ U*#_ .$M?$_EO_LG"/\
MK5K_ ..>O FOIJ^VI2E*4K:'1_%*8[R@6P-GLI]I_6T#UK)85$)')-NS?.&#
M\Y'L!C+"49%C%,!!6[UP[90F0KJ8]Y*R6+2W[<O#_FX[F]CMI8H3%<32RI)(
MJ01B0Z1%%<G++@ R*/C\:\Z\XE%9SP6Y@NKB:XCFECCM81*W+@:)9&;+K@ S
M1@>.<U@(7Q=W;L"3Z_!1F#G'8':.V0&EH+M%8*?;:AD$WDTM2A8=NPV*J(L
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MMZ]>.E<UW3MVZ7S47<N7*ZF:RZZRF:JRN>:BF>6>5[W^A          P !T
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M3UJRG%Y6.T7-P0L%RF!<B8C$Q&SVZ@-9NAHD'IF3A9"W)1QW9!T8? +3H2W
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M+?FX=Y46=XXWG5%SK//+(V @+8>-68DA%))-F!NZAC9>UU.6Y$0*>["V-JN
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ME*4I2E*4I2O??^4<_P#?O@/^RIJ3_J38]?,_DI_Z=/\ \]/_ .."OB?R"_\
M19_^I7/_ (K>O BOIJ^VI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MKWV_D_?^,?-C_8!W/_U3KNOF?RG_ -GX?_U*#_X2U\3^6_\ LG"/^M6O_CGK
MP)KZ:OMJ4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6>9?YLE_\
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MQVA\\T]V^*^F/_!%^'3\YN.>GO\ 4V_X-/J<^YJ^JQ%_SCM#YYI[M\5],?\
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MWU.?<U?58B_YQVA\\UM]V^*^F/\ P1?AUZOYS<<]/?ZFW_!I]3GW-7U6(O\
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MQVA\\T]V^*^F/_!%^'3\YN.>GO\ 4V_X-/J<^YJ^JQ%_SCM#YYI[M\5],?\
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MQVA\\T]V^*^F/_!%^'3\YN.>GO\ 4V_X-/J<^YJ^JQ%_SCM#YYI[M\5],?\
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MJ2#D3R(NN-B#L!@$@(9"F^!KHS^/757$9Z>>Q QX_'5MY;5U?@'RD.6R(#B
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M>)# 8=NX>,FJI(@VQ=O6;:ZKE+1:VTEY<16T6O,E8@%SJB@ LSNV"0J(K,Q
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M1G)M1LDY9V6<X:>(9((Y76;6QQ54\Y_S+YWRQMC;O7[]\K?^=5M;CF(>TVN
M#GW[KU!^+7/T50]O$T\4@XAP[1%8,>TCH6# =-,^)%1#TOX[]RO)/X1/_P!3
MJSD+Z3:_6G[E7\JW^<>'?:?[*>E_'?N5Y)_")_\ J=.0OI-K]:?N4Y5O\X\.
M^T_V4]+^._<KR3^$3_\ 4Z<A?2;7ZT_<IRK?YQX=]I_LIZ7\=^Y7DG\(G_ZG
M3D+Z3:_6G[E.5;_./#OM/]E/2_COW*\D_A$__4Z<A?2;7ZT_<IRK?YQX=]I_
MLIZ7\=^Y7DG\(G_ZG3D+Z3:_6G[E.5;_ #CP[[3_ &4]+^._<KR3^$3_ /4Z
M<A?2;7ZT_<IRK?YQX=]I_LIZ7\=^Y7DG\(G_ .ITY"^DVOUI^Y3E6_SCP[[3
M_93TOX[]RO)/X1/_ -3IR%])M?K3]RG*M_G'AWVG^RGI?QW[E>2?PB?_ *G3
MD+Z3:_6G[E.5;_./#OM/]E/2_COW*\D_A$__ %.G(7TFU^M/W*<JW^<>'?:?
M[*>E_'?N5Y)_")_^ITY"^DVOUI^Y3E6_SCP[[3_93TOX[]RO)/X1/_U.G(7T
MFU^M/W*<JW^<>'?:?[*>E_'?N5Y)_")_^ITY"^DVOUI^Y3E6_P X\.^T_P!E
M/2_COW*\D_A$_P#U.G(7TFU^M/W*<JW^<>'?:?[*>E_'?N5Y)_")_P#J=.0O
MI-K]:?N4Y5O\X\.^T_V4]+^._<KR3^$3_P#4Z<A?2;7ZT_<IRK?YQX=]I_LI
MZ7\=^Y7DG\(G_P"ITY"^DVOUI^Y3E6_SCP[[3_94OFO+@,W+(INM%\FVBEQ[
M;*R3G3S]-2^&2B_@YVQ\Z7[^&5[7M:_?_;?&_P#Y55#; *<W-K\(G_.S\0\E
MJBWMHHH]7XAPX'8G':@>AQC_ '/U?'UJ(>E_'?N5Y)_")_\ J=6\A?2;7ZT_
M<J_E6_SCP[[3_93TOX[]RO)/X1/_ -3IR%])M?K3]RG*M_G'AWVG^RGI?QW[
ME>2?PB?_ *G3D+Z3:_6G[E.5;_./#OM/]E/2_COW*\D_A$__ %.G(7TFU^M/
MW*<JW^<>'?:?[*>E_'?N5Y)_")_^ITY"^DVOUI^Y3E6_SCP[[3_93TOX[]RO
M)/X1/_U.G(7TFU^M/W*<JW^<>'?:?[*>E_'?N5Y)_")_^ITY"^DVOUI^Y3E6
M_P X\.^T_P!E/2_COW*\D_A$_P#U.G(7TFU^M/W*<JW^<>'?:?[*>E_'?N5Y
M)_")_P#J=.0OI-K]:?N4Y5O\X\.^T_V4]+^._<KR3^$3_P#4Z<A?2;7ZT_<I
MRK?YQX=]I_LIZ7\=^Y7DG\(G_P"ITY"^DVOUI^Y3E6_SCP[[3_93TOX[]RO)
M/X1/_P!3IR%])M?K3]RG*M_G'AWVG^RGI?QW[E>2?PB?_J=.0OI-K]:?N4Y5
MO\X\.^T_V4]+^._<KR3^$3_]3IR%])M?K3]RG*M_G'AWVG^RGI?QW[E>2?PB
M?_J=.0OI-K]:?N4Y5O\ ./#OM/\ 93TOX[]RO)/X1/\ ]3IR%])M?K3]RG*M
M_G'AWVG^RGI?QW[E>2?PB?\ ZG3D+Z3:_6G[E.5;_./#OM/]E2^'<N R[HI9
MMHSDVZR3$.5%,6^GGZF2:6*B/A*YV\Z6\%/&][6OE_HO>U5RVX(7%S:]&!_S
ML>&?-15$]O%(J!.(<.)616/^)'@ 0?%/UBHAZ7\=^Y7DG\(G_P"IU9R%])M?
MK3]RK^5;_./#OM/]E/2_COW*\D_A$_\ U.G(7TFU^M/W*<JW^<>'?:?[*>E_
M'?N5Y)_")_\ J=.0OI-K]:?N4Y5O\X\.^T_V4]+^._<KR3^$3_\ 4Z<A?2;7
MZT_<IRK?YQX=]I_LIZ7\=^Y7DG\(G_ZG3D+Z3:_6G[E.5;_./#OM/]E/2_CO
MW*\D_A$__4Z<A?2;7ZT_<IRK?YQX=]I_LIZ7\=^Y7DG\(G_ZG3D+Z3:_6G[E
M.5;_ #CP[[3_ &4]+^._<KR3^$3_ /4Z<A?2;7ZT_<IRK?YQX=]I_LIZ7\=^
MY7DG\(G_ .ITY"^DVOUI^Y3E6_SCP[[3_93TOX[]RO)/X1/_ -3IR%])M?K3
M]RG*M_G'AWVG^RGI?QW[E>2?PB?_ *G3D+Z3:_6G[E.5;_./#OM/]E/2_COW
M*\D_A$__ %.G(7TFU^M/W*<JW^<>'?:?[*>E_'?N5Y)_")_^ITY"^DVOUI^Y
M3E6_SCP[[3_93TOX[]RO)/X1/_U.G(7TFU^M/W*<JW^<>'?:?[*>E_'?N5Y)
M_")_^ITY"^DVOUI^Y3E6_P X\.^T_P!E/2_COW*\D_A$_P#U.G(7TFU^M/W*
M<JW^<>'?:?[*>E_'?N5Y)_")_P#J=.0OI-K]:?N4Y5O\X\.^T_V4]+^._<KR
M3^$3_P#4Z<A?2;7ZT_<IRK?YQX=]I_LKDQY=Q[*UK]"_)&W?_P!%]1D+7_I[
MW65<Y"^D6WUO]M<Y<'SAP_[2/NU(ZP5\C2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*MN._X43O]XB?^;&U _#7]GMJ0^"W_;_6JDJ=1I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E6WN?^];/]P#_ ..]J">!_;_H
M*D_PC^[^@JI*G4:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*MO47]
MHR?_ %2)?QVE0?P'[?\ 0U-/$_L_U%5)4ZA2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*YL/ZMO]_\ QO2E<-*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2K;CO\ A1._WB)_YL;4#\-?V>VI#X+?]O\ 6JDJ=1I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E6WN?^];/]P#_P".]J">
M!_;_ *"I/\(_N_H*J2IU&E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2K;U%_:,G_U2)?QVE0?P'[?]#4T\3^S_ %%5)4ZA2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*YL/ZMO]__ !O2E<-*4I2E*4I2E*4I2E*5Y,\\
MYF:";>$!&NTX]KI)SQPV(7C-ICRMVMQH!WGS>4AF@8P('ZTRS3VC*1R2U[-H
MF;;Y(+M,LD,<KX.E$\OI.#1*]LSFWDGQ?VZR&+AMMQ!N28W+HS7&.SHV/\Q#
MD$9(Z UZ_#T5H&)B:3%U&&TM(;E@A1M@QEZQ(<=64CKU\0#7T;Y;\@ ,?5E"
MV,<"0W+:VK-19.9W!10"70!E(.)<,W\:F^TC,MW5K;7+,Z8G,CPU8B </X>#
M FB3!-N5DIY0?%R_$X;9._+S(\HMKFYQ#,SQ3M'Q26R2*V2*TN)RBP)VDN!,
M[HC'6--I$ZMG;,VO>9Q%+-A)"R2$7;VZI$$ADDU5%YI8!V8#J%7+#IC^>&U'
MLTU"$69P-NYDV>HQ4RBOF)NGDNMLJ)+FLI5&7W2Z\V([CZKI['GP1['M03:%
M-D,R<07V'(9A=3 'UN#VZQ73@S$1=I:*7<D#D2A!'(.S" . LBNKW4,Q.LH@
M2+&_3P^$),V9"%YS(^W@(G"ZN.2(@V P(::-\X?EJGPOK3O*[:VUIGQ]2DFP
M(**:+;K<1*<91$((R@DPRDG'B>2P!$P4P";EG@XFXPE(-ZN*"GL(QL,?FO%<
M99KL:_;,W4G[=<-MK:*]*0S,W9!+#S7;G1<N^@BDEDA>T@908Y &=.9 ??.7
M.P)$?)[2&&.X*12,1 &3=CO'K<1HSE&A0@:L-F4O$>]I(02%];J^:KQZ4I2E
M*4I2E*4I2E*MN._X43O]XB?^;&U _#7]GMJ0^"W_ &_UJI*G4:4I2E*4I6J/
M-A"6/N.TA"P>:2C7<GE$_P!#PT?-H82>B9-'$9KOS6,3*$1;\>L@Z2SP$&7Z
M;E/%7%%RS4<M75LVJZR>7I<),2WT;S11SQQPWDK0S*&CD,-E<2JK@Y!&R+CX
MP<$=0*UV.@N4+HLB*D[E' *MI!*X# ],9 _9XCK6A+GEAMC"<8[R)E3$.CZN
MC".L[P JV<O]?"=KQ'=G&"!;*EST$>F>N(Q@;C>R=M;0U->3RB912.#F6ML"
MC^3-8VY(KN/8'#;;E=C55E?M:W'/4A9VMI;3B,UO&LB0W$FDEO:V]URTBE=F
MN-5C,@4#T!:0Z<@*'83"7F#I(T3P74D2!E21]6CBBET1'8F4@*6 J4 .9/)&
M8Q%4]''.I&:L71.J%UR4!,2!"7>0\I7VD@BK%6)[C< Q+5]!L&LF>/0<CF(L
MB7R0*QTHI&7J+?*N3A=A#+I(+IA)IJ%F1#$6X<MVX;FV@=B)B8PKQPNJ961>
M:I-1:RM4DU82D/J%UD"Z$VHG.=X021)E<%5*C*L"P-2@UR=Y/LUY<)&D=1W?
M:Q?&F1LF0U=,%VTU4:<DL-0B\F0YIM5GE&$;Q!U@3)6Q('U%SS3%ZSR9BG"@
MI*M.'\//+9ENM;A4**MQ$##FP[2VS&V;F>^@JO1,1G!RXV,5M;0Z,PFUE"E0
M)4RFUJ9CDF+#X<:CHO0]<D=>*1\PMV1/Z;"#1K4K*2:W1V/>,,2<*D+![RHE
MD1VG*8B+U3JH9GL7QD=FBL?#1EF2Q9+3]VK)]C14ZU!M8\P( R74X7:2\ED6
MY,<Y@YK++&PX;%+;12M<W+<COPB1Y&4D0#EV\B%S(RNI;*!]&59BDO*V(D4B
MU1X4=I93RN\@9FQGE@+&RY+$$=$ES,W6I*4HN!DNE5)3(L)(@YU\X@\I>2G1
MQAAR_P"._'T(.V+9KLMNK(,G,'V^;DCA&XZ$K$S AJ="+91%^U;VZO"K01&5
MX[L1Q\LB<31B.[1N&7UZ[09MR(\2VJ(.],%1RC@2J2>K90:;,DX52N)=TTG4
MV=S<'E9C[IWA5!U< $JW?K!;$YX;:@<FVF 9E=:2#/7\,W^@LJ2A*0+ 9-=)
MPWSPT.$P(K>LHV.E'3Y<2?<J#I+!H.B>CKH6^U[(I$(8VE$EG!P:VFCMG9;A
M!/-8X"S;EH;N;1D5VLHX.8B,@VCFGTD#K/'&QY<<HN'PR)$V)5YCVQ $FV4G
M?!4,8%CV4,O57<JP(D12=5[$AY&;\,3:0'-=[-UG* NH]/<O)$.F@&(20OJ#
M=377T9X:SD5=I' ^ULV%Y!')5.9EK;*6,)=)&XMFSF(T>T9R%^<;!T=A9+"B
M3V]Q&]S=\+C:)Y8TNK0SOQ:%\N]KG21(8;CE&)"Q,+,3&$+EMK=8U66*5&FF
MLE,;2*)H3(][&>\T6VK(B2Z%%))0DZ:YV[U=O78TXWE(]0E8^''MX(,)SB5F
MT!99))Y!IZTBA'0:095P1S;^7EKO=HQR4$\O*<%CVDSZC4.)9R(==GYES9P0
MV<=TKLQF80QH64XF@:1;TMA0=5Q;21KTPEX@+NT;9Q36\4<"S!F/,(1 67I)
M&76XS@=5&(F0=,+.N22ISN#7EUBI2E*4I2E*4JV]S_WK9_N ?_'>U!/ _M_T
M%2?X1_=_054E3J-*4I2E*4I2E*4K'EGJPT62(MQKTRX8#WCU 0,\DL2*K-6Z
MBZ0T?=^Z9,?+7V:>+5IY8]:-/'JI^4.FZ/AJX24!F52P4%@"S9U4$X+-J"<#
MQ. 3@= 3TKJC+ $A02 6.<#)QDX!.!XG )QX"O/KBUN/9:A?DL]WF-GXB4=(
M<)=1V%RU[%V L:9E6I(L48:5U/CE*,QCM9H[;9M&"RZ@C.7DB%Y<4LP*'BS$
M9[7$;:W"</%H86CY$PDEB65F9([J16N[GWH,,@Y( 81*O*7945G]*[@BUM1
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M2N$08!/>8]!G&!GQ) ^.I*N[!<JN?C<A5'3/4GH/+]M0#4F^()N36[S:\?\
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MRE064X8=1T(.1@^1\CBQ:HJJE*4I2E*4I2K;W/\ WK9_N ?_ !WM03P/[?\
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M*R(J!M"-6<*S!F&[$EC@B'@N!L& 1,-KQIL;8JFNA;"%K.H@O:'Y(%YA M*
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M;D@L/+,W+1R#7L3>ZAYDTG8[7:Y$AN,B5A+(]Q;W6S!I3A%GMHV6(>]ZO*K
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M>H^(::X'Q"J+DQFXN#%CE&:4QX\-"[%<?JUQC]57!66J:MO<_P#>MG^X!_\
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M9)JX8*)YV[V::F..>&5O_++'*U\<K?\ ]7M>U*5]TI2E*MO<_P#>MG^X!_\
M'>U!/ _M_P!!4G^$?W?T%5)4ZC2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I5MZB_M&3_ZI$OX[2H/X#]O^AJ:>)_9_J*J2IU"E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*5S8?U;?[_^-Z4K?KS2*ZL'_@FW9UGK13S2
M*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'
M_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW
M9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3
MS2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI3S2*ZL'_@FW9TI7+BP8
MX)*(8,FF*"M[751Q;(XI*7QO:^-U$[86PSOC>UKVOE:][7M:]OZ+4I7%YI%=
M6#_P3;LZ4IYI%=6#_P $V[.E*>:175@_\$V[.E*>:175@_\ !-NSI2GFD5U8
M/_!-NSI2GFD5U8/_  3;LZ4IYI%=6#_P3;LZ4IYI%=6#_P $V[.E*>:175@_
M\$V[.E*>:175@_\ !-NSI2GFD5U8/_!-NSI2GFD5U8/_  3;LZ4IYI%=6#_P
M3;LZ4IYI%=6#_P $V[.E*>:175@_\$V[.E*>:175@_\ !-NSI2GFD5U8/_!-
MNSI2GFD5U8/_  3;LZ4KE68,7&=E'#)HOG;&V%LUFZ*N=L+7O>V-LL\,KVQM
M>][VQ[_>M>]^];]MZ4KB\TBNK!_X)MV=*4\TBNK!_P"";=G2E/-(KJP?^";=
MG2E/-(KJP?\ @FW9TI3S2*ZL'_@FW9TI3S2*ZL'_ ()MV=*4\TBNK!_X)MV=
M*4\TBNK!_P"";=G2E/-(KJP?^";=G2E/-(KJP?\ @FW9TI3S2*ZL'_@FW9TI
M3S2*ZL'_ ()MV=*4\TBNK!_X)MV=*4\TBNK!_P"";=G2E/-(KJP?^";=G2E/
M-(KJP?\ @FW9TI3S2*ZL'_@FW9TI7*DP8M[Y709-$;YX73SNDV13OFGEWKY8
M97PPQOEA>]K7OC?OXW[UN_;]E*5Q>:175@_\$V[.E*>:175@_P#!-NSI2GFD
M5U8/_!-NSI2GFD5U8/\ P3;LZ4IYI%=6#_P3;LZ4IYI%=6#_ ,$V[.E*>:17
M5@_\$V[.E*>:175@_P#!-NSI2GFD5U8/_!-NSI2GFD5U8/\ P3;LZ4IYI%=6
M#_P3;LZ4IYI%=6#_ ,$V[.E*>:175@_\$V[.E*>:175@_P#!-NSI2GFD5U8/
M_!-NSI2GFD5U8/\ P3;LZ4IYI%=6#_P3;LZ4IYI%=6#_ ,$V[.E*>:175@_\
M$V[.E*R%*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2J2Y)[2)Z1T!N/;X48P,EM:ZZE4S'
M"2F;A,<1> !+D@@S>J-,TW.#9=1"R:N2"F"ML,KWPRMEWJU64"W5Y;6S,56>
M:.(LN"RAV"DC/3(S\=6PQB6:*,D@2.J$CQ 8@9&?+-<6W>0<"TJL20F*9Y3,
M5HW>/(-UYF'-WV-X%Q]RUYA/$TKK/F?AGE+[-C?F$=>V+<C; EY0^8^2I^4+
M>SFN0#'IAKJULQLQ'OUYSN3X ]SWA]V\5[N <]$<+R@%=>LL4/4D=^;?3XCW
M?>VV/B.F >N*0-<^M1QLO*&1^'[8%!(\8V/$ALR6C<><QZ;[ U@J/2/:]AC1
MA+WDM?28CD49X1IP5BX6+G'>3@4UDEC#)\.;:EX1<.J,DENS.L$C1AW#Q0W&
M=)I2T8C5!J=PLC2(!L4T(8W"SD8+AHRS!&*;$,B29P[DJ$"C'> 8L!UUU(-7
M_IW<H[<*,_21ADYU_(-83WHWFL2V"TC;<X*DMX/"-AI8HN(C)YC'"HQS&-@Q
MMVT*B#[YD[S77LW5422P65R7-L;8PGFQ3)/%SHI(2Y5DYLL/421QNK!X7!5D
M! QD=<53+$8M.\CK(FZ,A;!7=T_WE5@=D8$$ CX^O2KBK-55*4I2E*4I2E*4
MI2E*4I2E*4I2E:$\L^;L?XQ;.TE!2"\&LPF#M.1[3=RF6,X^4BNK7<[@VIVI
MV,,'#E#(P;2E^R&<P=-,TUT,M;:QVJX03R,,A6&?K\/X6]_!=2J)=HAI (XR
MZR3B*6X99" =4Y<)B!Z>_P ]N"=2U:[>U:>.5P'[O=CU7*M)HTA#'XAJA4'Y
M;Q@]"35D;SY.L=%;2UQ$#P)X8C\ZUELN2MT@#;RZ9%]@!-S\4]+ZR@D99.GX
MP)DK.Y/R1P&K/3I 6*%NVHP@5-!0*!DBA1:V)N[>>5'"O#/!&=SB-87M>(74
M\KD!G]ZCL=@J*S,"RJCN54PBMS-'(ZG#))&O7HH1HKB61V/4]Q8,X )() !.
M 8"^[H=H@"LN,F(W8L(DK"5P^$&8G(8\(5.!I1)MCO\ 7AL>YSC\D.A'S76B
M#1IL;8QT$8+QP5JHX#FH8O(&K[)LA<.#7;X,30RHT<LJR([:-'' )T(WC1E,
M^3! CJKM<(\3JA&3,64S=4*.I5G#*QP56,.#U4$%\E$# $R H0I'6<*<U=&N
M(J/.1PTK,Y2?-" D2U'%R<.<;:EF4GE7T8AA@;%2<K%-Q46F;=1G, ,KEI:-
MQ[&#$6,D,$1+=11)*KW+NQ(R2)RHT5FDN9%D%O'RX^9*K2+&Q:2(YB>.-7?G
M QJK'&8]EFV(9=%4$M(P81KJNS@L%.60]UE4,VX*@$U46M^Z"1R0 G3^;:TV
M&#> 9O-A&R7(H."5"Z3B=N4VX>-^JBFT<G\P3*YEI*[U01=2QEKIA/\ "'J,
MRQZ08 X<H)+O-$W"'1P(IX7#Q1- &9][J3W/MKZX6#6(KK&+A1&9FAYFRHF\
MNRBR2S92 KH0RJ8\ELRMV>*>01X7&%$@"ERF^0J[/D#ZOW33CKA&3\G61DK-
MJ+V,'U4&:E#VFPRDJFIE*?O< =BAC;3",ZW-"P^L)F=D,5WH>U/,X\-&M<#$
M;9D3(4>0>X=[ND8T):!KABJ73<N)3"-]5MS).C-/$J26B7$3LQU<A6(=@G#!
M>[DH9&P)#JHT&<",F0$R(%:$2HQ/1B 2+&D7+ ?*-0:'G^@T \H)<FY^#UOK
M!Y+E7+:,@2KP-,Y-*2\QQ!+N7#Y.%1[7,WO<("*)HRJ4"QL;'R@8Q-82AG0O
M#VCN;N&\+1BQA::<1@&1U#11QK'L !S7GB[[KF.-FD:-BG+,%MBLLR3946Z&
M20+\)@"BJ$)&!N9$[S#NJ2Q4D:F#[IVIS%U)J]"4N,..:AT5N?6.K7A#*.;#
M?@IV W+M#3^LHI-Q$?0V Q*ZW?QDGL:07DL*,2'8'GC&,,'8B6,&QVV+*VV@
MX;<7!C';>6UM/.!O"KQ/;07$\D3.8668.L*Z2JD.O,(:,E.LHH[:20K[_J8I
M)!WD!0Q1RR,A.A#A@BZN F-CE215N;HY*!^+FNH!(=X63/R*72%M"+YP+&+P
MV.OY;G'C\D4LR>;>V/&XZ";.V,<?-P@<Q/G4AD!A5A'XVT/&G[=EGGM;%K^:
M9+7N1Q(9??N9*ZQ[I&,BV@=W(+KNR0A$7+N40$U7% ;AW6'H%4OW]F8+LJ]1
M&C,Q!89(0*HRS%0":QSCF'#,,YT]'ZVW.<A^OTC;0QL,/$!"\05ET<C(J5&8
M+:[F4-)&%+CV!=%B]DTOCL9UBR/M"8![/FQ8:Z:I]'#I?>09[999BA6%I&$@
MC=V193B,QLK%21'&[SE"KB$JP)Z+5^X#)$K/J0A8[:LQ4/T4A@2,ZJ6D*X8(
M0<U3]NZ9Z.7BJTL$0S:LG9A0&])?.D(@GJF6I:]AG'%;6_2S*SLECNUR4%D0
MP&-VQ"S+!GK.63T^?9/7S,(&?'A)$,WTG@=T).6TMO&6>UBB,AN(S-+>B?L\
M:1R6ZRH6:WE1C/'"B,H+LJ,K&WL$V^A>-23"J;F1-VGYG*4*T8=23$X)D5%4
MX+$ @UZ*VO;*ULK7[]KVM>U[?T7M>W?M>W_[M7C5AK]I2E*4I2E*4I2E*4I2
ME*4I2E*5\J7SQPSR3PLIG;#*^&%\O MGG:U[XX7S[V7@6ROWK7R\&_@]_O\
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MI&Z[L ?(X(/3'?VAPYU;/())(P,&MAAHB3VI+ !4ZYEAD4'G>VASIG(I"['
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MSC/:TCD$PD[8P0UF\SO*Y";'%5#J)Y#5S27O7(<8-;PJ,M)!)#@J-P'!I$Q
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M^KVTZ=0/4Q?VF7;TT/F/7[*;CR/J]M.G4#U,7]IEV]-#YCU^RFX\CZO;3IU
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M*G4:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I5M[G_O6S_< _\
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MX(P<$9!_>""/,=:YZY7*4I2E*4I2E*4I2E*MO47]HR?_ %2)?QVE0?P'[?\
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M[89*8V6;9/&B:G>QRSQPQ50NNG:^6.-LT^_;&U[.V77Z9_I'[_BKO,F !+.
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MD01<J.$$V[(@[;N5LUDL$TLLE,+90-M<AUC-O.)'!*(8I [@9)*J5V8  DD
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M0U3J25#(GL60-(JZ.%]6QT 0*%8XW8F9%MTS/PT8"MFN1RQUFNCGK@^^?D#
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M,9E$4AB!P9 C&,'.,%\:@Y(&,YSTH+:Y:$W"V\YMPVIG$4AA#$A0IE"Z!BQ
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M6$YA5GS"P?"?YS=,@GJ=PI KZ_R6Q\]9FOHB3(!-OR6M^5A>44:9I.87WSD
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M1>QR]H;X>J6))$)<C*\H[EM_"4;;:0W:*S1A:$H18S WL!:5_P#$@W*:2*-
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M<; #3S77 Z80_7J49(GH"\D:9CN?K[SVU1*Y=YGQ!V?"IU*FV+I<,D]M<VQ
M'6T1PMA9/%Z6_P"T[C$'#M;'9+Q!))2X60*1Q(:]/_\ =BDC3IMCNEE,GZEZ
M;8%>K-QF*6X,H2<1E>.#0Z^/%;::&,X#X[C.AE_^E.[L0!68Y,:-VSN/>&V8
MO#HI",8AMKA@AHV0[.G5I TSA6$MGNQ,##^"J"HN<8RN3 !KYE(5H(0,0U$@
M01B)5Q*A:0[#!YRUN(8((7D>3>&^-PL4>I$FD<6!)LZE$8@KS '(!==&VZ1X
M?>6MK9VLDTLW-M>+&\CMH>6W.,4%OHLP:5#%&[*T8G5)BJF51$Q;I3^S> G(
M+92^Q&)";:Z3&FQ7-<)&B-Y-)60]<?R?@&SXM#UG&KHWK:/1*)FHP[ET=OLB
M3K&=E3#9C]H;F[J2L"SMP +W1<1MXA$0DNRFQ9QHA(-I)$SXE>5G=7"-RDUB
M2($1A2N&75;\;L;<0,L-P65N$/(O+C+!N'3VTDH6YDN'ED218G[/&$MXK=2D
M(C90)$] H'J,W!-^;/G(UK$6VMY[K+44:&,!CAX./1Z1:Q?3])9AA'4 -@2D
M:)BIDW<MB:$@;/F;\>LPS +MG&!%'SI)EDMHHR7,L<T[DG!5EF$77;;8,&C.
M1K@@YVSTKQ)[I)[&VA8RFX@N+J1F8!DDCN5@.QD+[B17A(*E"I5@VX(U.@+S
MN?.XY5K2%P&0F]2PY73FMG,-A1#7AF9I7VD1>\B]%\AG=]C+WB4>?P80[=:,
M0B93*/.)Z_)N]@2J=8>;G#9&*D/1'$8$EDD59G$\N\@D6,\E>S7%L.4-V$C
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MI%5D$H!:,(7 YL<988D4AT#1MDZN2#BR]X9/8Q03.\4L5P\T<;Q"=07@$32
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MT7"2:F,XY&BD21#J\;JZ' .&4AE.""#@@=""#X$8JV":2WFBN(6TEAD26-L
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M$1-)!;S1S10,%<0B-'AB4&.))3'&L1D,8*FPGG&#6;Y=ZY7RD?C'Y3CF87\
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MJ%( 4+-N-3LIC-O:&%EG1X66=E=;F2UEEWD>X:X+&2TB97YW,CZA&4! G>]
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M[ML5US-@@J($3$6:R5V%O*X7$4ICBCC:U6!VAFLX<Q8>.,&*Y3=+M9&<%EN
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%I2E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g556103g01a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1LV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &QJ^:3@X0DE-! 0      &@< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   " ?\< E  ($)A:V5R+"!#:')I<W1I;F4@36%R>2 H0TE"
M($E"0RP@' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0
M$%4))950XWCO&Q_FRL#K__HX0DE-!#H      .\    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     8 00!0 $0 +0 R       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'LQ7#         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !4    !
M   "0    D     !   [ @$ .$))300>       $     #A"24T$&@     #
M00    8             !2H   G5    !@!G #  ,0!A #$ -0    $
M                     0             )U0  !2H
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !2H     4F=H=&QO;F<
M  G5    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   4J     %)G:'1L;VYG   )U0    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $    &3A"24T$#      0
M1     $   "@    5    >   )V    0*  8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ 5 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M_P!/=ZECO^+4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1F%WL[2UMC9TLB4F-$)1&34W4G&!0T2AL>'P\?_$ !L! 0$  P$! 0
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M#*=M9JH;@U]:0@EOL/O/1@'=@D-7QFHI!75CU[.# Q)B?L,OL&.7ET6B%")
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M!C9HO5K(,)(M%31")C-B%&[$Y:P# !LC(DR6H8?#X</''S+".=L-:ANM\+M
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M+6&R+[2#%9<K5.+CWI5?L9@J-LV&0Q8/ ][TID4USW7[02PU*-:;#JO7\FW
M:_KW9TQ(@H,ALV-5[UEVC =<34MU6;P)%KIR9+M@)PV6Y;1J>C 62YD?E<T<
MT!O;L+;[&N*K7K23UYM(^L^[#CKK5*JC5LLX%^4-=(N-GH(DH]"C(A9:7 F2
MH9&?"P0RAF-)DM.-OJ#./[-_0]=6VY7[%KDGM J(M>O*V$AGB1IG9()RJ&!
MJN,/2RA8@.??D*CCFX<=Z6W)R[E+D=M3F,8QCW< UNZ6]I+3V%B7P;L</6:Q
M=@WH[8M: 5Q]]W.=(;B 8LFL9)U,D@16BY@Y,*U42]-,+CQ4V6I2IC \9')1
MH+(%^T#8Y*W6O>&9>!46BZSN4&B@I[;,A$T@2#4P%9;X5G37);D1X</+V5%8
MC,QXD5V$1JY[XIV3AYC$<#4/8G;[9X[K3J;96O@="E[>['DIEBTK3K6H@/ L
MZTP%/;3'.VQW!J)*^>KU(%'#2<Z--A0(FQK:(AL0),)+4.:!95[[]]==?ZLT
MQM0[?*J.';PSJN?4@QNU!P)?%6V+:JO7#-J>8GN>-8[7$:QOF;BA#:<P(X,G
M&?<BNMJ6V(VEUM+WGBF[GVIOC:IS7_6#8.JZM1Z-K776PCVVK)2R6W(]SG[9
M5:)5+ 4D.$V#K\<P B@*LX=L%IDF";D_!L4*"P8CC$\D@4GXC:NVJI9.NU8W
M4!I0HGN%F\4([Z+D$YPT?M^I@C5Z R0DXC)PYBG7C7E*O)E HA'?,UDM"#!7
M2IK,B9-: SA.\]@8G8:%3H.GP9+0"J-,,3MHM7)+-BQ;?+><@UZ+6) QIK,O
MSX#T-QJ3/8$.0BPXLNS0YL5ZO2@-:HO;#>LVA;E<)Z_HE&VN([;:WZS:WK1,
MC/MP&M,;.K^CBHZP;%( B0M-G*UN'LTX?.BZC/$"Y;PN+4Q)V0TC-PGO/('@
M@]C.RIO8&>L(\CI4?O<'LR]UVR;6EZ^ND_6<NA4_4NJ=LC;"(U6SM&#8H=C.
MM;IIM5G"9>U9L -,&V(RQ+*QW!P_ <?*_J;@]<MHE]R:9IU_L0P<'LT_-B V
ML<&=DO!6+;1K6=HEK4$<FY5-^22+#6B4D.B8X]+:&O16I+\A]#CS@%W< C+]
M*ILFVPK])J59D7H:'D5T==7P(IVVP*_+D?%R@<*QN1%&(H>3*_QF0,8F-PGI
M'\,XPIS[;F6_-0=:G)5N2DX;SW')+"DXYW7)+@FUE+AD]%;:JW2K+%3*:LE4
MIR5<II84W7G=<TN"DUE+@G@]=F 0[57+!5R+Y**/L@0J G20Y*8&+QX9B!('
M2GQ1<>ZQ/%$FF)*W()*"^S,@RDM2HSK;S2%X1DX2C)8;C)22DE*.4\K,6FI+
MAQ3337!K!*YNNR%D5%RKG&:4XJ<6XM22E"2<91;7K1DFI+*::9\K*W[*O!6U
MZ\G=BNTFTNRU&TQK[9^L]1TZY52B5PX&K.UJ40UO8,7C95<'MV_91!BCE)8J
M%,-/P_#.\HPZTY*P^B1UY[7Q"U:;24Z2S464VWSKG9*,I4V*Z'153DX4IV14
MI);V5ZO!'T5GX1;M=\=#L[3:"[5WZ?4:JVJRZ<)V::Z.HAT.GLDZ]/%W1C*4
M8;V5F&4L8P$#V.VOX^C]JZ1([SO1@7?Z7K76E>-JH.HZ[/I%"UAL*N;"%0W&
MJ54*NJ[6LW-JX@99[M;)<PJ7A08+BV6I$7S'<GMNWTBK41T]495SMME'I+Y*
MRRZJ=4G_ )ED^CA%3DX5PPHMOBT\&4OPGO>KT^KCHZ82HNU&HG!7:J:MNU%-
ME,GFZZWHJH*R4JZJE&,6VLM/A?.T_9ZA-D7+LW>H6X[I33796P:"L1>+ K-$
MLU;%N:#IY&G#*^=J=Y!V6M;!IULB$ES;)7+**PRJ;%@N1)#7P^,KUJ=I2JAI
M:W179'2QU$8N4K(R?I%BL<HSKE"==D&L1E"74WE,T]/MJ=%6@J>EJMAH(:RN
M+E9=7.7IEL;93A93.NRFVIQQ797+J;RGDKK6?LF]1ZSB:4@P=B74A$U/&[9X
M)1L":F"@VF=V^K0VLWE8D)710RN:\"5J(-;73JO5 K04;A>6W&'?X5Q[UMVQ
M?:]0W7!.[T))[TY2@M%-SKWI3<I6SFW_ )D[).3Y)>^H_"35:B6KE*BI/4O9
MN'O6SE7'9=DIT[T[)RLOG8Y/IK+9N<GQ3742W27LV:EJPI0)=OVK:-OC*#U
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M,2TV\PZI#R/>*3B 8$%5S6Q90<26-E+@D40)T:8N!-;_ ,I#FICNN9BRF_\
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M+@B!<*?,40G0QT&+-GJQE*ITN/&:9DS%)SG.4JDO(6]G&<YSC*_=G.<\ R/
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M$PHPX=$;6XMU:(L*&TS&CH4ZXXXI+32$J<6M><94I6<@9'@#@#@#@#@#^/\
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M%DE*^,$0\QRMA>@ GC=A3)(XK\)F:EIC$P)??J?V-JG:*V[GU#K;6FQZ]==
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M3@IK?6^NG:<MHP/U-M=.U%5-8*V#++W/;$#:]@L]L*T16ZINUWP]9USC50:
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M? V/X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M=:;W]/*%Z^>J)\)28EJWH:MU<I(LC#(+.38-GKIT>8C+&PU#8C573%LN1IG
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MP6>&%3Y2HI]^A&I#DPT\8CMBUAY\X,K/Z1[*M6M^T<!&K-8ZHM^SM7=>@>O
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MSIK</#@*>B"!],N . . . . . . . . . . . . . . . . . . . . . .
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M_LQ[)_O<\;^C_,:G];J_@ATFS?T37?M'3_RP>FNV']-/7C^S'LG^]SQOZ/\
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MCH+-Q35D)0A;58DXJRJR*E"6ZV]V23W;(9EN61G#>ENY=D\\CP' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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ML/\ 4(_=?&'VOY> RNQ?/Q'IPC_.^P_U"/W7QA]K^7@,KL7S\1Z<(_SOL/\
M4(_=?&'VOY> RNQ?/Q'IPC_.^P_U"/W7QA]K^7@,KL7S\1Z<(_SOL/\ 4(_=
M?&'VOY> RNQ?/Q'IPC_.^P_U"/W7QA]K^7@,KL7S\1Z<(_SOL/\ 4(_=?&'V
MOY> RNQ?/Q'IPC_.^P_U"/W7QA]K^7@,KL7S\1Z<(_SOL/\ 4(_=?&'VOY>
MRNQ?/Q'IPC_.^P_U"/W7QA]K^7@,KL7S\1Z<(_SOL/\ 4(_=?&'VOY> RNQ?
M/Q.NG,^1'.(4I+SV+*50_*S'BL2)KC'P\=,F9F(Q'0_*4RRTA;ZT9<4AMM&5
M>!M"4LMY3;>."R\X6$\+NRWA>P-MXRWP6$LMX78LMX66WCO9+^4@X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MRX<A"5X2_%E,M2([N%-/M-NH4C 'HX X X X X!%JM_(/_A2;_XZ.1=<O?\
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M1]C:J)$'<(R,EWS9U!T*:77'G4Y,"[3M5WX?PQYR<BE"=.J#L^!OC3)&XEB
M7>XNS;'?['($=5-X [9:8SP6V1BL+=78VX[N(:DO-!)6"17SNL"52IQ#Q3(5
M39H5?K(!H]$A">U]7+CW<<\>1]^>"C@#@#@$6JW\@_\ A2;_ ..CD77+W_9
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M,\<;S6</L)MA[/OQ]'T?Z<?1_P#W^CW?1_IS_P#YY@>)Z,9QG&,X_BSP#]X
MX X X X X X X!%[3_DP7X4 O^;Y'U?&/U15U_"7T9*.4@X X X X X X X
MX X X X X X!%O\ 7;'X+9_ZLGF/Y?\ U^X)3S(#@#@#@#@#@#@#@#@#@#@#
M@#@#@$6JW\@_^%)O_CHY%UR]_P!D"4\H' ' ' ' ' ' ' ' ' ' ' ' ' '
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MRKQ8]X&M6M>YFI-G'M? (0;;50>VU >GZN*[&U+>*36=@)8KDBX*B5FSEQ*
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MP6,*>D.+?DYF3G<8Q'%AX9,V2>BBAD^7' AD7?6L9F\B?7..>6O:PFA,;'F
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MX!^R+%7XD@7$EG0T64;SX0L:03A,R"ZO<G/A%LN/I<(9]RT9]T1+N?<M.?\
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MK%,U->-M>SY)D8,KK8!Z[4ZT5Z@[>VAG;DIW3PB7,D0 @.IE T&R.WU*;.6
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M]F_SH]+_ .XOLC_WUU=YL1_TEW_(TO[O5FY#_;]5_P S0_N-HEL#O_%5F_\
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M3E7:D_49=@[_ ,56;_R->_\ 04YJ>U^Y?61H$HY0. . . . . . . . . .
M. 1>T_Y,%^% +_F^1]7QC]45=?PE]&2CE(. . . . . . . . . . . . .
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M +UE_G@S^\.,+OYOQ ]'5_[UE_G@S^\.,+OYOQ ]'5_[UE_G@S^\.,+OYOQ
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MI.+,GLNLQ"1=(OGV>>[X?%V)"ZA=@1N[*>8K%:B5$(Z6UH:NUJF76AW?7\A
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MC(QCX-ULNI>T/K?L*QO?L[M@AK22J=-"V*^ZXM%$T%2QAZ-ND7KB%4<ZK$0
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M? ' ' ' ' ' ' ' (O:?\F"_"@%_S?(^KXQ^J*NOX2^C)1RD' ' ' ' ' '
M' ' ' ' /Q*4IQ[DIPG'O4KW)QC&/$I65*S[L>['O4K.5*S_ !Y5G.<^_.<\
M 82G"LKPE.%JPE*E8QCQ*2G*LI3E7\><)RI64XSGW8RI6<>[WY]X'[P"+?Z[
M8_!;/_5D\Q_+_P"OW!*>9 < < < < < X>4WYGG>6CS?!Y?F^!/F>#W^+P>/
MW>+P>_Z?#[_=[_I]WOX!SX X X!^*2E:<I4G"DJQG"DJQA258S_'C.,^_&<9
M_P!.,X]W /W@'YA*4^_PIPGWYRK/NQC'O4K/ORK/N_CSG/TYSGZ<Y_CX!^\
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M/(NN7O\ L@2GE X X X X X X X X X X X X X X X X X X X X X X X
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M=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4
MS\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'
MHNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(
M9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1
MQA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?
M4 S\F3QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^
M;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=B
MY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\
MF1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HN
MJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?:^;'HNJ?4 S\F1QA=BY(9?
M:^;'HNJ?4 S\F1QA=BY(9?:^;,U &P!;'PHZ*S#C^-3ODL(PAOS%^["E^''^
7E6$X]^?]F.7"74L$/;P!P!P!P!P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g556103g01a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2@J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    * Z^$"5#A"24T$!       6!P!6@ #&R5'' %:  ,;)4<< @   @'_'
M)0 "!"86ME<BP@0VAR:7-T:6YE($UA<GD@*$-)0B!)0D,L(!P"!0 74&]W97
M)0;VEN="!0<F5S96YT871I;VXX0DE-!"4      ! ' 7D,X=\'AMN]X.O_G_
M9=.$))300Z      #O    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    & $$ 4
M!$ "T ,@      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@
M @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M  #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M    $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M    !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G
M1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M      26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M   %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";"
M @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"
M!5;G1&(U)L=                %)S;'15;G1&(U!X;$!SIRL         "G
M9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M  3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M      4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V
M)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,96
M9T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296
M-T5&]P;&]N9P      .$))30/M       0 3IRL  !  (!.G*P  $  CA"24
MT$)@      #@             _@   .$))30/R       *  #_______\  #
MA"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M         ! #A"24TG$       "@ !          (X0DE- _4      $@ +V
M9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M8       $ -0    $ +0    8       $X0DE- _@      '   /________
M____________________\#Z     #_____________________________ ^
M@     _____________________________P/H     /________________
M____________\#Z   .$))300(       0     0   D    )      #A"24
MT$'@      !      X0DE-!!H      S4    &              6N   &(@
M         !                          $             !B(   6N
M                    $                         $     $
M!N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %
M1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   6N
M   %)G:'1L;VYG   &(@    9S;&EC97-6;$QS     4]B:F,    !
M %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F
M5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F
M]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M    P    "/_         X0DE-!!$       $! #A"24T$%       !
M(X0DE-! P     '5L    !    H    )0   '@  $5@   '3\ &  !_]C_[0
M ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"P
MH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,#
MP,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1#
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M=<R*V>F1?9T[T[KK[JL:IWVC'R?=9?Z.S'?^E_FO4HGZ_8-4Y%U9^R7LH=A
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M7=4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!O '? P$1  (1 0,1 ?_$ !\
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M6>LE\C91B"4)T-E2"=>9+A*IP>3)525KHZD@$KMK=Z)\C?WU\S;<']4<$/\
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M.U@.BSZPTS(LM6='GJI=0,20[IF.1GT^WB@5A_:'G]ICMFXH^2&7*5J'J?\
MJ]*82Y'AN2XED&?B/0+"16^TLJ<CY"VU,Z=@//4L&UYUKS&1B9.*1[]10-^Z
MVU92?G092R[_ $WO])-#.9*TYYO(M]O)7^4$_)I1"ESMA*D5S@7)IU>IL^Q&
M)E5!395<X,Y)F!J](F."!<J0Y.FK?D08;#SRYDI3BU*D.[7['D::E]'\%<M5
M:VOF92O:$46.H?)T'<#LP&AH$D#0U\3KY"J.)P6"J&:VSLP #'36@;.MG0
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M3\G^)_WSVYB8C$1B)2+!_4)O_I!+_LGLV3]]?^DO^\3*_(_B/]\XI_A%X/\
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MS,<V6X[C?@$?6?\ RF5 ?@2'CV%EV7A.0$RUL"[^UJ%F0_V#LWZE5'GXE?\
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MY>B?@X\W >>S]EO4_NTM4?"TD<AS>S+][21W0^SEID5'U<CMVL,-TT]O[?\
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M+9_0WG;9/O8VZ@XQG=TO@VQW%19U^QPR2'DUNQ,Z=J\%;%:U!@-BTPV<\O\
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M?IRUKZ-U/@_I42?FUP)TB7N2LI8:<6 U6V34Q9\J;-FMQXSU:7&:DL!YZ#T
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M'YG7[7/CZ^='C?-%^0.*^[O.4CRX/&R*)2.HW2IV)CT/0^62$.P60(AB'1S
M]! 0&><'!7%W29,#M(B1Z[9*[%A#$"^N_,>E,J_^DLOB<T9[,+;<:FVO\#=?
M\EV)L5P&;ZF K 8[+HVV[6FR^+M?\1;BW>^3W>M6'LO9\EB2X.B?)'4 Z^I6
MV=YR](?"A#+_ !:<X\#>8;\*K=VX[TFJ]KKG0.CL2FAU^ZD-?L*[28N#@2"<
MF!F3J;:7=$-PQAYL&P-KX);4R!%<F:JX7J<KS]W,9]+659-%F+9301VJH956
MM*NS(&*>VH8EE[;=O#$"14\D1GOEWH66Q&K9$^4K/4*%V1LJ%&]D=B2?!,OK
MN7QP^DO>'CCE=;]C=7YWS_WOPOH!CI7'O0?G9@__  E4;''*-2*]M4 F-JA?
M](4'#P2;'H4P.DP3P(-8A#[JAZA<N'%YK"XGDLA^-Q[K^(RZ5Q\G"SBGN6UE
M=/MD+J&5BYK)V"CLC?/8:U9E&+DV-C5N^):@2VF[79E(TWD%AXV>NSH@D'YW
M(QW#P3\YGJRN"O/?KKW!YSJ/G-^>'3TNU^>JZ=A]KZ4""3X\]$%]Q[G-*$B9
M1&1"CNR%BRH84A_>GB0@_$86'F7Z^6]*<>YS..XK-MS0&-%6;8AQ,=V&M@"V
MQG"@G0=6;[*RD]UG7+XNAC=CXMS7:/1+B#4A(()_?<G6]>03KX*GS)R^[?BT
M@>C>2><(GG?J)GSYZ*\4[%R/+?89$@C9'Q#(H6%%OUB]2Y+LHN<%6)NM@WBI
MJ3HN000ANRYHT] )G A?E<3SS861FG,H7,PN4[#D,700/V9F%E(&E1ZR[]%'
M5=$ ,A5&6KBYQILN-U8NIR=^_7X7>R3V3[ KV.AX&CH%2 PUL>EOBK^83W_R
M-^F^Q_8?F]I^C&*J9Y5SCE(2S ^;V2T02\5@[T'K)N/SD8=DEXE/=/CJQ71(
M.8%9-&OW!I8!F-)9*=O"Y_TWQ&3[O&<;G:M2Q,B_)>M[TK9#UIQT]YD"FWHU
MCLX<JG7ZM[6[1G\=AVA\;'N/8$6/8075=$A*U[D:+!2S$[T-:.P1U)0V51XD
M6.O>E*8CL,J4GZ_;M3324;VGZZUOZ;VG>]?76M_3_P ]:SP9\DG\R9PR=DG\
MSN>C,3$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1+!ZL=)U;EW2;,%?3&,5R@W$Z)DK9:D(CDQ%=(D(
M#ZX[Z'&'TM2H[3BF7FUM.Z3M#B%(4I.YL=%LR**V&U>ZI&&R-JSJI&QY&P3Y
M'F;( 70'R"R@C]"0#-97Q.>WCW?/CM\^^A/6_7:#!Z;TTUU<5+L%AE4CFD*P
M/U7KEVJ@>$)$1]  RY44&(%QG&1D/\SZT?J9"7)#[CB^[ZBXI,/FLW"X['N-
M%"X[!$%M[(+,:JQBS'NVB[,=L=#X'@2]GXPJS+J<>MRE8K.AV<J&K5B2?)UL
MD^3X_LFU\B<""!W[N6,"Q8GZ,[_=")")"'?23M*8^_ULEYJ-])"EH2SO\OT=
MVM.F_NVK7U\\JLQZJK,WY*"3X^? !/B4 "3H D_D 2?Y"5!IUI]IM]AQMYEY
MM#K+S2TN-.M.)TMMQMQ&]H<;<1O2D+3O:5)WI2=[UO6\U^/F8G@%F@QMN0\%
M+#"[,26[ ENBY\4@W%G,:0I^%(<B.NI9ELI<;4[&<VEYO3B-K1K2T_79E9==
ME9=@$=@1L'X(W\@_8_$R01K8(V-C8(V/S&_M^LB_[?\ 87-/"/FKHGI3J2)1
M )2HD2,%K Q]A@U=KB;E(&U>H!ER/N;:E%B+R%3)JFGVPX:,4.2([T48^C=[
MB^-OY;.HP<?0>YCV=@2E5:CM9:^O.D4'0\=FZJ""PD^+COE7I37X+'RQ^%4>
M68_P'P/N= >3-.7,:S\^_M6F!_02O4O#O 5/OPUJT\VX2(XH!Z?:H=7)-)EU
MMSH1.]5TU/%SRXQR+.D)8,OSFD2-.2ZM6Y>W <3TM]GI#B[7PQ@9?,V5-[=V
M6^4V/4;%\/["TLH958$#LNCKP[KIST;&XG%<T^Q;ELAZO:;2BEA^\$", 0#L
M?'V\,P\G+_A?WOZYJGLD_P#&A\DP.B.=[72971>#]XYI"6(IG>J<,;F2"/WA
M]QH$2.;U &'24:2-#UUAM58L@0F @D!\&8:K<KQ''6<8G.<(]WX/W11F8F00
MUN':VNOUC9->V5?J9R>Z,'(+!(LK$QVQAFX3/[/<);4_EZ6.M>?.QLJ/)/[R
MD$@G6["Y=$Y_SF%')="O5.H@Z6ZJ/%(7*SA*O"DOITG:F8\HW.@L/.ITI.U-
MMN*7K2D[VGZ;U]?+UTW7$K359:P&RM:-80/S(4$ZG-5'<Z1&<CR0JEB!^>@#
M*I6[16;D(BV"H6(%:@$W2]PCE;+CS@B7IM6T+W%)#)$J%(TA6MI7^)]?VJUO
M6_IO^C,/6];%+$>MQ\JZE6&_C:L 1_:)AE920RE2/D,""/X@^91S/2>=5T,0
ML=@OU*!5X00V(*GC-J!"PPPKK>M;&$"DV>Q!A$-;WK6X4E]J3K>]:VU]=YE:
M;G942JQW8=E1:V9F7_650"2/U U,A') "L21L *22/S  V1^LKE?L5?M@B%8
M:J=#64 2;V\..5\I",B)[*5J;4[")#GY,*4WIQ"V]K8?<3I:%)WO[D[UK5T>
MMBEB,CKX*NI5@?R*L 1_:)@@J2&!4CY!!!'\0?(EOW/I_-><Z@;Z%T.C4315
MQ30O=SMH"KZ).HVG2VH&S9"#^L<1M2=*1'_(I.U)^NM?77UWKHNNW[--MO4;
M;VZWLZC\SU!T/!^9E4=]]$9M?/52VOXZ!U+QB2XD^+&G0)4>;"F,-28DR(\W
M)BRHSZ-.,R(TAE2VGV'FU)<:=:6IMQ"M*0K:=ZWD9!!(((()!!&B"/!!!\@@
M_(FI!!((T1X(/R#^1EC2^M\J@6YGG\[IO/H=\D.,M1Z3+N=<CVY]V0G2V&V:
MV\209=<?1O2F4(A*4XG>E(TK6];R48^0:_>%%QJ&]VBIS7X^?K"]?'W\S?V[
M"O<(Y3Y[=6ZZ_/MK7^V7B4+"@<)TD:)CPXYC;:7R!2;&'PF5/.(99T[*ENLL
M-[=><0TWI;FMK<6A"?JI6M;B568]54L3\!023KY\#9FH!8Z )/Y $G^0E"@W
M^AD[.0I(V[5$A<Q,1F>5J,&R!I=G&09+;;T>80 1YKA6'$D-/,NLR),1MEUM
MUM;:U)6G>]S3:M8M:JP5,=+8485L1\@.1U)'Y [F2CA0Q5@I.@Q4A2?R!UK<
ML/TE<;!SKSMWSH-3EMP+31>+=3N-:GNQ8TYJ%8*Q1CIL-+<A36GX<QN,1@QG
MEQ9;+T:0E&VGVG&EK1N7"J2[,Q*;!NNW)HJ< D$I9:BL-C1&U)&P01\B;4J'
MNJ1AM6LK5A\;#, 1L>1X/VG-QX6L?SS^[?,'.O45)]^>=:16NC/W%@?6K5YW
MI<HX/53;O8J/,5,?$<UD0%ZES:Y(FQOP/*VF+(92[]KNEIU[;ED])<3GW\?;
MP^;:]'M]K$SK C>Y4EPT&MWX6P [UY!UXT9VLI>*Q;WH?%N9DZ[9;6T>RJPU
MNP'P&T9(#DON+Y$_'_O3@GB3Y(Y_%>R4KU9%*PN*>B.0 )-0EL7$=I3# &PA
M4CP Q_;I98<(3&L5F&^.D6P 8A6$K!3-'M5,CBN%Y+B,SE>$&5C6\>4.5A9+
MK:#4Q_SE;[9OW>S ER#[;J44]28;,7#R,6W)PO=K;'(-M-A#?2?])3LGX[$?
M4=]6! \$[_#W2>=56$7)6>_4JN#@$F'"/$#UI!AX02806IN!$+RB$^.P-DSE
MI4B&Q,<9=DK2I+*%[UO6O'I3=855*K'9P2BHC,6"_)4 $L!]R-Z^\Y(1VT%1
MF+;( 4G8'R1H>=??7Q*M-M57'5Y=N(60# JB(#11=GFF!\6O(&/H0XR16:?D
M(&I@/-N-K:E[DZCN(<0I#FTJ3O>!6Y?VPCFSL5Z!27[ Z*]0.W8'P1K>Y@*Q
M/4 EMZZ@'>_RU\[_ $GAI]^HO0QKAF@72IWD.T^J*Z5I]C#V8:W)1K6UQW)P
M69-BH?3K>MJ94[IQ.MZWM.M;S-E5M+=;:[*FUOK8C(VOSTP!U_9,LCH=.K*?
MG3*5.OST0)6!QP(8<G,B# LHZ+DJA$VAQ").<'3$;6E<2<B,\ZJ))2I"TJ8D
M:;=3M"];1K:=_35E9==E9>PVO8$;'YC8\C]1,$$:V"-C8V"-C\Q^8_6))P+#
M(P0\PP+B%RB75#1<DA$8(D4L)4MY4&"Z\B3+2RE"E.[CM.:;2E6U[UK6]Z!6
M(+!6*K^\P!(&_C9UH;_6 "02 2!\D Z'\3]I:UUZKR_FVX6NB](H5!V1TO8_
M5UN%>JVY^F]_:YN%HZ1@?JM(W_0O;'Y/MW_0KZ;S>K'OOW[--MVOGVJWLU_'
MHIU_;-EK=]]$=]?/52VM_&] RN_OXXI6'K'7"HXP.DB)1$27%3(I,9-;1&=<
M8E0YD5Q^),CJ6C6TN-..-+^F]?7>OKFO0JX1U96#!65@58>=$$'1!_B)KHAM
M,"#O1!\$>?((^1-7/PG^J>U^S/ =![OZ"LT*W=+.W;I@4F;'UT#5HSX^MVZ<
M*$,I#UH>+%,JCP66VENM0T.OJ3MQ]3CF]JWW_5/'XO%\Q=AX:-70E5#JK.]A
M#/4K,>SEF.R2=$^/M+W)T58V6]5*E454(!8L=LH)\L2?F;)M]9Y7JX:YYOI?
M/]7_ &O\>J-NY5S^,-K^S;GV:K/[E^];7^/6U_;J%]?LUM7T^W7USA_A[_;]
M[V+O9_\ U?;?V_\ U^O7_;*?MOU[]'Z?ZW4]?_6UK_;+Q*%182"\3-$H @;&
M_'J00*3(\""QMYU##.GI<MQIAK\K[K;+?WN)_(ZXAM/U6M*=Q*K,0JJ68_ 4
M$DZ&SH#9.AY_A-0"3H DGX &S_(2T2G5>7@[,,I9OI%"#W$UJ/L/4REPKP^S
M%M2_I^EV, RR+)2?J3]=?I]Q8KNGOKK\?W9(M%[HUBTVM6N^UBUN477SV< J
M-??9$V%;LI8(Y4?+!25'\2!H?VF7[D4TF/@G6^4V6RS:77.F\]L%Q&[?T1J8
M2Z5LK98&XO\ ]*U-!0"3Y2+N-_\ C]/Q6_P__C/MR9L>]$%KT7)4VNMC5NJ-
MOXTY4*=_;1\S<UV* S(ZJ?ABK '^!(T9>T^?!%PI1(G-B#AT%AV5-GSY+,2%
M#BL(VX])E2I"VV([#*$[6Z\\XAMM&MJ6K6M;WD0!8A5!))T  223\  >23^0
MF@!)T!LGP /DG\I:M,Z5SGHS,Z1SV_TF^1QCR(Y)^F6H%:&1[[FE;;8G.@Y\
MY$1Y>D+VAM]3:U:0K[4[^W?TDLINIT+J;:BPVHLK=.P_,=@-C]1-F1TUW1DW
M\=E*[_AL#<O7(IK*4;/ ZR+EG+(9%5\*/;_-/,&R,,2+A-?=I/Y99">]'B1F
M_N5I/WO/(3]V]:^OUWK-E5G8*BL['X5068_P !)_LF0"Q 4$D_  ))_@!YEN
M4OIW-NDLRY'.^A4>_1X"D(G/TNV ;2S"6Y]?QHEN@R$Y$92_M5]B7E(VKZ;^
MW6_IO-[:+J2!=3;43\"VMZR?X!P-S+(Z:[HR;^.RE=_PV!*]*LE=A29T.:>"
MQ)@L:LT3B2BD&/)'!VOI^0M.8=?0[$&M_77WSY"&XJ/KK[G=9H$<@$(Q#-U4
MA20S?ZH('EOT'F8ZL=$ D$Z!T?)_(?F?T^91Z;T;GO1HTV;SZ]TV]PQLA,0C
M+IMH"6>- E+TM2(TU\).G-19"DH7M++ZVW%:0O>D[TG?TVLINI(%U5E18; L
M1D)'Y@,!L?J)ED=-=T9-_'92N_X; W/9;;K3:"(4?O5MK-+ H?:C+-VT\*K@
MA$E_[MLQU$C$N'#2^]I"]M-;>TXY]BOL3O[=_3%=5ES=*JWM?1/6M&=M#Y/5
M03H?<ZA59SI%9C\Z4%CK\] $S4[V+V/UT'\N_@_R]0;T"F><^^\#['T*YBAX
M>K&T6<Q5*OTDK6BPJYZA2S$2$U)KHA[384NQ FML*2\AYN0]IST&-QN,_IWE
ML^ZIQFX>9BTU,6L7VUM>I;%:K84G3,/J4D;\:(&NA5C5MQV7>ZD74VUHI)8=
M0SU*P*[T?#'Y&Q_9-Q&><G-G/UZ/]?\ O/U'[UZC\>OQVVOF/!(OG&DUJU>A
M/273*W&NY.,8MT$*3$52@U:>..!G5-P3\-EQ9(*Z].(PCOW%@$41%_?O7X7&
M\3@<1C\SS->1EG-NLKPL+'L]E2E3,KV76 JX^I#H*P 4K]+EOHZU./B48E>9
MF+9:;G*TTH>H(4D%G8$'SU/P1X(\'>UP9WKO'R__ !*P:CZ"]0]XY5[Z\COW
MBM5#L&A?* /)>J\X'V>8F%&L@-%1#A1+C/ZO:!T%XK//0Y9>0-#S!HG]W;-0
MK>)B>G/4368>!AY'#\C[5EF*&R7R<:]JUV:W]TE@2/)ZA"%#,"W7H9:JN/Y
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M2["HZ$[4_IV&C;2=;4YI.M;WD+8]ZUBUJ+EJ.M6M6XK._ TY4*=GX\^9H:[
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MO\M_&_TE3S68F*>[_P#N/[+_ (4]$_T@8RQB?^%XO_I%/_M%F]?^<K_Z:_\
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M"79"5K6V0AOK-+6A J&Q-.A8*-H$WY&YN<I\KB<UK0IM1Z [JH7W ;:NA8*
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M_,=P ?GQOY^)CKY./B,\T>"_(L[VIX.B7/SUZ.\D3Z7=A=\$]%NAR9?14JV
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M - MV+2"G">4^VOC8]#^MH1CXHV??I+N/?;AUOFOJ>NV>H,6"4%LQ%V8*!6
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M=BY/$^G<>BY;+L/%OKR:P&!J=FI*JQ90"3U;]TL/$CS;ZK</CZZW#/36ZV*
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M>O(OSN(RE+X>;0M[CY6NS"L6T.Q/A%9=JS?=A6#'#LKO?BV FJY!8?R5J6#
MDG84$'R2/D*/!U-NWQR^6XWC+Q/YY\[[C,1S])H ^5?%L;0M,KI5J<>MG0I&
MGT?_ $EA-N-%HL!Y6U*T,C0F=;TAI"=>=YK//)\IFYNR4NN;V@=^*$^BD:/P
M?;521_K$RAF7G)R;KOLSD)^B+]*?_P!(!/ZDGY,FSG+E6,1&(F..P5&W7WE?
M1*50.@D.3WFTTZP J?TX6+C&R% LI(;(C!+=$"S)$6(7= D7(Y'0N5)CQR&H
M^XCSS;;JEZFQK*Z<BFVZD9%5=J/90S%%N16!:LL 2H==KV )&]@>)O6RI8C.
MGN(K*60G7=002N]'78;&]>-[D!/ WQR%_)M]['Z"[GZ'M7KCU9W*,#K]N[9;
MJU$IZ!-#K7V+$4>HU:(8/L@Q#DIJ),*HCDTPI2Q0-B$+&-#%;F=?E^:3D*L;
M#Q,*OCN/Q"[U8M=C6]K;/W[;+&52[ZV%)&P"VR>WBWEY@R$KIJI7'HJV5J5N
MVW;Y=FTNS\@>-^3LG<VA9PI1C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B0)]<^&!_J
MWMWB?L\SI,RD/^-.R3>O0:]&JS!]KH#\QRK.; RR3IX2NMM-_P ,HU^XLP32
MU?K%;_1I_!K\O6X[E6X_%Y3%% M')XRXS.;"AI"ESW"A&[GZ_@E?CY\^+>/E
M&BK)JZ=OQ-8K+=NO37;R!U/;][XV/CY\^)[9R94C$1B(Q$8B,1&(C$1B(Q$8
MB:<[O\6-^[E[.K7H7TS[%O?9_/O)^LO=HX1Y%D4D97J71+LTO<FNN6&S1C\U
MV[0*C.6M\,W/KT6=N-]!"B#(204&$_25<_5B<99AX/&TXN9DX_X7,Y$6N]MU
M)/UA$*@4FQ0 _5R"?JUV"E>BN>E6,U-.,E=ME?M6Y 8EW7[]1H=2P_>TQ&_.
MM@$;C,\W.=&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*-8SXNIUX]:3DA40)6@Q0^8E(9>DKC"PT
M%\B0D)CQFW9$A3,2,\XEEAIQYW:=-M-K6I*=PY%]>-1?DW,5IQZ;+[6 +%:Z
MD:QV"J"S$*I.E!)UH F7^+XW,YGD^.X?CZQ=G\KGXG&X-+65U+;F9V17BXU;
M6VLE58>ZU%-ECK6@/9V502(7\*^2'R)Z1Z(.Y5R'HQ.QW<M!*DH(N51+R!9=
MB!83A BXHB=KX\<WMF*TMQ+;DE+CN]?8TE:]Z3OS7%^M?3O,YM?'\?FV795J
MV-76V)E5!A4C6/\ 7;2B#2*Q\L-ZT-D@3[O^T/\ R6/VV?LK],97K'UMZ7Q.
M+]/X>1AXN1F4^HO3_(NE^?D+C8JC%X_DLG*<67.JEDJ94![.54$R=.>KGYYC
M$1B(Q$8B,1,4=YN)/GG#NR7X(:JE<-4GE?0;:&L%[=D,T@&7KM3+%QA:X.P]
M*F(JXZ=$8EGE1$JE:%M2OTZ5/?9K=C%K6[*QJF6QUMOIK9*0#:RO8JLM0/@V
M$$A-^.Q&_$DJ4/;6A#$/8BD)KN0S $+OQV.]+OQO4T-C_</J#G'.^T32EP[E
M!O;/C7F73@E8]=\SY-7[4&[%TCJE9Y?(Z+R*-RJGU.M7#CU+W=192[ +++)D
M*X9G4,(0A@I)6Q"4^I/%X-]V,%KQ6I/)7T-9Q]^0]3XU&.]_LY!R+++*LBT5
M,*70*KJ+G'8*C3J?A:'LJ 6HH<EZRV/985-:(S]+#8S,EC]2%*@ CN?.E,VD
M>>+-T^F^H>]>8;YUJW=P TWC'GSME.O'0!-!&W87(ZA8NVT>WU0J_P WIM#K
MI 0DCR(=9JZIVO(*P%6 T-?(31T82U"X>8E%F#B9U6/7BO;DYF+952US5,,=
M,2VNQ1?;<X8C):M]/U/1&"ABQ-*Y:VHIO2M:B]MU3JA<I_5BIU8>XSL"1:0=
M'1Z@@ [WF_MOJCA7G24#B]DN4VG?Q#%ESA\[^"K]80K,&!(CQILTT?JM7. Z
MW#BN2F5/RK$0%,-L?DE*<U%8?>;Y4J20+;B'6T.M+2XVXA+C:T[TI*T+3I2%
MIWK^C:5)WK>MZ_HWK>MXB?O$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B)XR,IR"/GS68C\]Z'"E2FH$7[=R9KD=AQY$2/I6])V_)4C3+/W;TG\B
MT_7>M?7$3G$\]_(S[$]$2 %VY]VCR47OY#HKX<[X%LPB1S/HHRFQ[!*&2&:_
MTV[V00[9KFR'98*I2-BSQS;TG:GX3DJ+)K*$UV3\$?PUY^?X_(_E-I75ODJ\
MR<ANG4N=GG^GV"Z<42%F]3!T/DUXN.Z37C(6&>U;SI00*="0ZH,@D1R2IEPG
MIJ/+G,1&42']/H93.QY^3K6] GYE:Z7\B/F7F\#F$N.=M_3YW8**]U*B5WC=
M"L_1[,0YC%BJF3K_ #PH6#N2#K4!EM_4N09_0RVWH1-A,-;PHFB&C8_^GG_=
M/9;_ )!/,]7Y]QGH@FR6;I47T,F<OBM4Y32+->N@]!2':2[8OVBF"X&C$9=7
M^NV;(V7:&N!YJ'!TI"2"=Q<1L?S^/S/]GS,/G?D"Y_>)'D^S<:ZJ"$4_L7:+
M+S"TUFZ<KOY"]EC-5C#UG>>Q(4),)?.[H)=E)4_+M$24-DLS(3L']2PZT^ZC
M?Q^IU\?EO^7Q(%@OE5[/T,=[$Z3&O7/.+<QXE>-U&@M7?S)VZQ/QA.^ET"I"
M3UWL<$_"1_%AF#8IP\ES1H# LH$C/B')T: &%R6Y2 =D_D/S!!_W_P# &;0N
MV_(=YVX!<"M N$GH=HLU/J(J]=.US'F-NOHSE%.,(86.M'2"(*!(B587.9?1
M-9;?>D$$0'&);T-MB9!<E(V/U_D3_N$P]TSY!0//;[V*PAKI7>F<TI'C -Z6
MJ/-:G0+X[=#_ /$1T5 K%J?Z%#A%*^W2#W[N/A3HZ 3A2IPY4FU'$MAQ,_2$
M;'GS]M_V>?/^R7OY2^1/EOH&O^<PUF9-TKL??Z*9LP2KS*1= E7*%J<&BF;R
M/J5CL ]N&9'AXTI$D>1;FO1S0_:)HY^0AS6M(!!U^O\ P^9*KC?H#F7>U=*W
MS O./1.3],L?(K>2=#DAHM%[J>HN["+#SI\=A@['&_K8FG28M4D<YN0WIF2Y
MO[OM3,S3B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1,1>@?_ '"]M_PBZ3_H
MTUG+YS_Q+S'_ %7R'_NET]K^S7_[Q?0/_P"]?2O_ ,=P)R#?"G_;[Y__ /F7
MTW_1Y#/SO^S7_G?Q_P#YG/\ _<KY_;?_ "]__P -WJ7_ *^])_\ QS&G:MGZ
M<G\$XQ$8B,1&(C$2TK]1:GU"C7'FU]"Q;)1^@5<]3+A7IJGD1#=9LPN4&."I
M*XSK$EMF>-F28JW8S[,AI+NW&'FG4H6F2FVRBVN^EREM-B6UN-;1T8,C#8(V
M& .B"#]P1-D=JW5T)5T8,K#Y#*=@_P!A'W\2)0[X^^$NB;D(Z&5ZMVUNY<=)
M>?E3^O\ 2#-F+UCC9>:,)DZ74"8Y .4&60+@:V8(6]2Y?0"):KUD@0MDJ2!&
M.1^@W+Y7:IJ5Q\7VLE<O6/2J+9DH&5;;%;N'ZJ[JM>A4JV6 5@.V[!R[=J4%
M=76P7:K0 -8 0'8$L#H%@%_< 9@%T3O,'$O.%.X>4NUG'67H?0;YT1BICK=T
M3JMK<M]R*5^A0RD*D5=,Y$(6/A5^KI/6*7 AP1D9V46L9\V7DDC!>;.=K969
M9E+4A2FFJGW#73CU^W4KVE3;9K;$O9T0,2QTJ(JA54 1VW-:%4JB(G8JE:]5
M#/KNVMDEFZJ"2?A5    F.?D-_L+^L_\!>D_Z;G94D,EL&_J<5_TV#_VK6(E
M2Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B4LXP6E!3$8#/CBCD
M@608"E)</]PBC2ST1YL=/DP-N,ZG1X<Q3,AZ'^9K]2VVIG\C?W_=I$YA^\^4
M?6WINHQN;W_XZN?UCURN\C'27O*AW[G=(INQT&WL%'NBO!ZI+'6([.E5MO\
M:U!3#!,VRXXLY$@1#K4<5$30@GQH?]+\O/V^_P#\_P"<R*%G>F 7M3Y8*=PC
MB KT45N5/\_\\L<HKT&J<_(5XX6X?*#A;<2;MSD4?8JP_J38)=D#CB31G]4P
M*9@QWV)DR1"3(^6/\/\ =_\ .>?7QM^G_.1[S;?.=5F[=WDU/R0O@G1JWQ_T
MF_YMMU=NW\;%^C-$A-XE':Q_$/.5%SNP<H%^K0Z^T+;.;$ZEM#F&D==:^2-:
M/G7WV#XU^N_._/W\S,-4\3>B/,SOA;N7(>&5F\VOA%6[/5NJ><*YUY,) QKM
M4LF764H'1.L%Y Z;-!D"LI5BCD3"6)LA6XP-Z1 <W,83.M:U]@?'\='QO]1]
M]3)'0.,^WN[WGP)U'JG'.?50MRGUA<ND7JI<\M5?=8Y9R*<R%9J^K86+VQ3%
M]NWUB$'#\[GL:3#EJ7&7&"Q%_E2I'GQ^A\_R/\)@OHWAWU(=\7_)!R<5RY4O
MH'>?=IWL?)P'\9\^9W:^;S.E\TL$:R:*2+8R%":<$5\O+_:;&1$'4?I/P.#$
MR7XS+R!]_P!3_P !) 67E/L_S9Z<]9]9\]< J_HH-ZVIG)EB)QWI5/IL;DW0
M.;4V32M1+Z$LY000N%(D[FNF]QZC.U/<ALMA4.17G%3VT>1O7W_,_'C\O[!^
MOG])Y+%Y0]1WST9Z.OMPJE/CZ[#\6\_SK_%M7,C8-"=[Z>7_ .LJV#!$3Y*]
M#JS"DR'W89HP+_0K',(VN;^L7J)I!&]_J /]_P#?(F^CH74///QS>1>C]!J@
M/A/J_P )7+G@_F%1/W^CV\MU2O,0@'-[E% -TTR23)$7:&59(DP,21)+P1]7
M4J8ME#Z%Z3'P!^8U_=_M^W\?B;C/C^\_RO-/DGD',S;:]7=8%5SZ9*?5^2;,
MZ1?)+MJN&Y\G?_-+D#B9-8-N2OZJ7"$Q$_\ LH3K29'Q_O\ X_>3+Q,QB(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B8B] _P#N%[;_ (1=)_T::SE\Y_XEYC_J
MOD/_ '2Z>U_9K_\ >+Z!_P#WKZ5_^.X$Y!OA3_M]\_\ _P R^F_Z/(9^=_V:
M_P#._C__ #.?_P"Y7S^V_P#E[_\ X;O4O_7WI/\ ^.8T[5L_3D_@G&(C$1B(
MQ$8B,1&(C$2&_P AO]A?UG_@+TG_ $W.Q$EL&_J<5_TV#_VK6(E-N5J$T2H6
MJ[GW'6@5-K9RU&G66_RO-":\+E%R+C37U3^1U$.&\IMO[D_>K6D_77U^N(G!
MSUS^44^\3W9"EGYH>JO/>9P3KW[)S!-+J-A@O!(LI28\2P6 V$F68A.E1D)2
M4FC3 9MU];KHN*(:4RPQ[3$])K=AUW793UWW5K8B*BFNL.H95?9[,=$=BI4
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M3R>7R+\'-PA@9>39D=\AKEOQUNL:QZS4E3K<:RQ6MA:ON #O[9)(_KA^S?\
M[H;Z&X#]F?"</ZK])^J+?67IO@<'A4IX:OC+.%YNSB\*K"Q<PY^3R&/D<6,M
M**[<VH\=EC%=K/POXI0E8ZPOCX\OE_(7EB@\;LY:$:N4:2?M5UF"ENN!FK/;
MB\DS/%AG7VF'I T(R_%#,376&%DE0'"2HT;<S],U]GXW!KXWC\+CZF9Z\+%H
MQ4=OWG%-:U]V V S]>Q \ G0\ 3^6_K?U5F>N?6/JGUGR%-.-F^JO4'+>H,K
M&Q^QQ\:[ELZ_-?&H+?6U6.;O9K9]V.B!G)<DGUU:E=^Y_P!;] RPU#YG9^=]
MNZ^ OK%GG=:/5RTUP,GC'(N6F6'J4UR0^/*$($SGQ,M 9;NL%@G'F0XKTD8Y
M^9UN[/+?G^I_X ?\)A?E?BOH--L7F?9>Q5AJD4#B?%QO9J\(E$GWK%W/S_ST
M[0>=V"NJD"HL>:!VB[RC9 H12-+-$N3<LW''*;U-3"3,P'6?CCZ[!IXJEV A
M5S&J!1 W-ZS8C77[[;(=P!(Z_P INU@?<H$V@!@G.X)T'SE90R 46Z/^LN$J
M&Q"*0($>65((FZY*4IUI*4Z2G7_EI.M:UKZ[^N_IK7TUKZ[_ *?_ +.(G]Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2DF#P*O1V99\T
M)!Q9,N/ CR3!&&,COSY2MIBPF7IKS#;LN2K6TQXR%*>>5K>FT*WK>L1$\\#%
M2Q< H9$C9QN0N(%A3R,.'++RVT?D7%%QI#S;T^0AO_Q%LQ$.N)1_S;3I/].(
MGU07$N%7@2"@Y9N/":)/AT38RBK Y]Y<=B>\/T[N6W">?;<8:E+92PX\VMI#
MFUI4G2)]X4Z$2CIECID6?$6M]I$J%(9E1UN1GW(LEM+S"W&U+CR67H[Z-*VI
MI]IQES27&U)TB>K$1B(Q$8B,1&(F!.J^I?.G$0]X-]2[/SZI1>:@(=JOD.58
M84^P56MD38JMP#9>JAUD;/'&S3YT,'BRM"%-/D2<**TI3K[:=RUT76E!76[&
MPE4\$!F )(#'2D@ G6_@&6:</*R&K6FBUS:Q2LA2%=@K.55VTA(568CMX )^
M!(PD?D-CW;G5/Z%Y*\O^D_6L"^'[;7:_)K-,B<8K<-^IQJW*V9M5A]"D.9R0
M53L;=E:34[+'!%QYQT18&H^TNBG$+G&'UL9,B^C'*!2W9C:Q[;\**18"RZ^I
M2RE=KOY\6AQIKM>K-R\7"-:HS!W-[D.6'5%QA:&=.NW4LI4,N_GQ?C9?Y"K1
MV2LKB4[R]ROS@EBHD+:FS63H'0O0<W1*K#)]OKH6'6X0+EM=(UNU2B5?AG)1
MFYC3$02V69@MM$FVHVNL-:V^J^R[Z@NE1*1IB%9B2UC KIM (03HGQYCZ\8E
M#;?+NROK"=$JJQAIR*V8N6N<,@#%0M94MUV2#,>@?"_8+95.F5KU%[Q]$]M;
MZ8.KHMYCG$:K>7@U-C5^S0+(M=&:Y+%3;!$H^W!W6[)(F74FHO5YY$:^G3[[
M4R/L<JM6K:C%IJ]LL=OVO+%E*_7[I*$+OLHZ#3 'X\25N0IK>I\3CL6CVBS
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M-P8$X7!,.0HRRL,84?'RB8Z*04UN7'@$90D7)G0V7D1Y;XT>](;<<AQE-HF
M>E=F\I^/*Q),=/Z!Q3SO6C! D=6@X6J5 19#4M:%E2, .A<"99CLQS\:IK@Z
M"1*2W/LV[IU7VY+53=<>M-3V'[A%+:_B0- >/DZ$L8^+DY3=,:BV]ON*JV?6
M_CL0"%'ZL0)BB1[*L5HZ[<^*<9\N>A+R5J(VZM/]BMM01RSS4Y;P%4)F*S7X
MO4;5*T9M ^VV*.)K*;'SVCW,6-080<4Y,'Q7OK*,=16MME]*!BO]6K>Y?U+
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M'U2ITM[:-*DSR)&4I4LD4(/RB)&6M<J=*D/J4YNO9;9<Y>UV=V^68DDZ^/X
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M&NV;H^K#/F5W]TA<@A6-\<!-,&=3]L:=_%:&.%J2^ZQ%1F'6I6#7V)VZNRJ
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M^.!!X+4DO8#*QPV=*B P<$@8GIBNH@P9#B?LS*J6.@-_'Z ;(&R3H*-D DD
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MFKE/"AJ\Y(9G%&]?M@J,' "AXP$.:C"1,.(S#&1(D-IF.VB2)_\ G+_RJ_\
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M8B,1&(C$1B(Q$8B,1&(C$1B(Q$AO\AO]A?UG_@+TG_3<[$26P;^IQ7_38/\
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MG(P,VVJM+Z"UE;TW(156'12GM6AV6RSLR+LG^/[QOT'@Y:_]A[9)KC/3^AA
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M[I0"+(&4$6W7YSBC4-XAMIN,YL7PJW0U56WA>W<9#!%?:Z72TGLH5O)VY[:
M\>9NUG%4V5-11DY84O[HS'6I+-II.J8Y+H%?;^;&+#2D#[?N;\8?GCHE2YK7
M/49GK/L8CS)VUR1=B]#=%-%U&9=O,QCD]5FJM,53*+8H@F1&1"JT Y623%=#
MJ4+A;W'^W[0SKD>QL<5XPLZ@K2@&@@T.K/W=21Y8JP['R8'+9-3VMB+3@B[H
M&7&J5="M2HZ/9[EB%@27*NI=OJ/F8@]N?'#=>X]<Y%V+S=9>'<AL%&I72Z5<
MHESYF9+1[I'O$[ETH66D3:/8:F1DE $7FS(METQ(G_:/EH994E+24H57U>S9
M3D"YU:RNQ36ZJ5*"T$:=7&F]TDZ \C]8Q\RG\+=BYHRK:WMINK--R*:S4MX*
M@6I8H5O?+'J!Y&_SW#NW?$/[.Z*&34;AZ&\Q1*S.-U:>:>K7(^JLG=0J]: ]
MC<;%NE.GS1Z)3ZA*6$*EQ76=:<5]VD[^BTR4WX5%@MKKRBZA^H>VKKMD9/JZ
MU Z^K?@R;&RN+Q+DR*J<]K*P_067XY0EZV3ZNM"MH=M^"#.B*QUROW"OFZI:
MP@JR5BR"IX.PUXY C% QL,4C.PB0HJ-FM/1)X^?$>=C2XDEIQB0PXMIU"D*W
MK?/G&FH#SI\%7Q_\(F]GC&N$\P[36>@]0DW[G\+K5#!7 ]R>ND:^$@2^9B+$
M88F32=4&G!Q,M7UR=-3HT(ND>2<)SH;YHDB27_\ DI?C4_N+>7O_ +3M-_\
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MR)MW08W4;:6J]R+M&"I(;4JI6S0^FUH7^#;ALK#@S$N1QL4@@C?YC^!U_/\
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M'1W99 F3EQX ^#$93M;TF9,E.-1HT=I&MK=>?<0VVG6U+5K6OKF0"2  23X
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MY(WK6_,GQZ'R+5K17;PSO[:AF6JL%[7 )4$J@9@"P!("[V1,6^+>3=FY'P@
M-]'=+G]8[]:R5AOW5[/((RB(019[J=(V9_GM _6[V\-YISO]U56*8)9TQ 9A
MPWY\* -;)J@L29-E5EK&FL5TJ%2M0-$J@"AW_.Q]=G)V=G6SK<ESKJ+LASBU
M"G&0+72F@&9*U"BRW7S;;KO8WD[.B3K9EAE>4XQ$8B,1&(C$1B)3#1L-6A!.
MP6(N,   D&44,FS4^*+$"1D%E<B:1)DISK$.!!B1VW'Y4N4\U'CLH6ZZXA"=
MJUD L0J@DDZ  )))^  /))_(3*JSL%52S,0%5069B?@ #9)/V &Y Y[U3UWM
M'6:-0O*?($W+@EBK8BX73VP8N(&!R./4+-!GMPFN!L0(5ND==Z*/F-;<E020
MT34P4X?L=9)"HY)F2U;_  ]=5;MD6=;E)5<4(QL[*1OWME14A'Y$N=[4>#.C
M^$HHILLS+^F2K%$P%K8W=U(W^))-?L5$;\J6<@@J-C1R%YB\=5KSQ&L1VR=*
MZCZ'[#>SHFV7[L/;;(]9#)&SAA9P.,?I=5;TS2^5@Q RSV,2#!4,**U!!EWQ
M$T@580VO6E^2;M!:ZZ:D!5*JET "03V8[>QB54EG8[(! $BR\YLDJJ54XU%:
MLE5%"!0$9E8BQ_\ .7,S(K,UC-MAV 63"RM*48B,1&(C$1B(Q$^3S[$=*5R'
MFF$+=980MYQ#25OR'4,1V4J7M.E.OON-LLMZWM;KJT-HTI:DZVC1/P-_)_L
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M!4!$&IN--ITS,V1504_ BQ'",KY#D>Y87 [=4'9:E&M*5)?R=M++YE&(U?\
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M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(;_ "&_V%_6?^ O2?\
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M]3!V]RU25V0#HS9+\_?![R5WQ_U**A2IO/:K6=\QO;*E)3+II"Q6F-,IQ63
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MV\JK/(WV?SP^DEK[68U*))W^33;8BQ*);&&)+ZVG&HL,7(ERY;Z-L1F'7O\
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MKQ[5?C,<8A6MJ_=M9<F]RQ4^[VL3I38 N@:4709AL[W)_46ATKF-1KU!YW5
M%(I-3$PP59JM7%0PH$&''M:9ACA@R TQ%BQ8[>OHAMIM.ONVI:ON6M2MU'=K
M&9W8N[$LS,268GY))\DF<VRRRUVLM=K+')9W=BS,Q.R23LDDR[,UFD8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(;_ "&_V%_6?^ O2?\ 3<[$23!"S J5
M09MRM!%@16JE4)-FL):3M6HPL&"#+*%B$C:$J7^&% BR)+OVI4K[&U?:G>_I
MK:)R-]._E05U']<(Q>6^>Z40XT-,/0XRKB2L"+^?%1G]M:(?N(@LR!KLN<VC
M;R86P5D:';<TSN83_'MUWTV/Z6S\C&7(]RFIK$#UTV=PY4C:]V"E4+#1"^2-
M_5H[ ]OB>A.5RL),LW8U%EM8MJQK39[A1AV3W&5&6MG!!"GL5V _0[ WF?%I
MU!7J?G'5/;5@IO,JY</0'4[,$"RJ7!3JXL</Y26)5WCM3ZN;3*>0;N@&%-/D
MERH\06Q^T6$4G4+_ )$NJXF6/;9,8&T?AU*V)8?"9)/]>$'V7LH7Y.RI8'33
MS/(?U+58(-Z_A$*7TW$:JSB=9BUJ!I5%B!?E@Q0L&T1-I&5)SHQ$@]Z6]4=
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M)DR2Z]+GSY3C\XA,>>F39#\EYUU=\DDDD[)\DGY)_,SQ T  !H#P %( 'Y
M>)??\^D!_=D]O?Y6>A_[&)G8_7^1_NC^?2 _NR>WO\K/0_\ 8Q&Q^O\ (_W1
M_/I ?W9/;W^5GH?^QB-C]?Y'^Z/Y](#^[)[>_P K/0_]C$;'Z_R/]T?SZ0']
MV3V]_E9Z'_L8C8_7^1_NC^?2 _NR>WO\K/0_]C$;'Z_R/]T?SZ0']V3V]_E9
MZ'_L8C8_7^1_NC^?2 _NR>WO\K/0_P#8Q&Q^O\C_ '1_/I ?W9/;W^5GH?\
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MK_(_W1_/I ?W9/;W^5GH?^QB-C]?Y'^Z/Y](#^[)[>_RL]#_ -C$;'Z_R/\
M='\^D!_=D]O?Y6>A_P"QB-C]?Y'^Z/Y](#^[)[>_RL]#_P!C$;'Z_P C_='\
M^D!_=D]O?Y6>A_[&(V/U_D?[I0;+\B7/*<,2:M? ?9-<$+* 0:29GS->Q\)1
MBTG1U8K8S4F2AMK<XY8BXL(*C?=^6:4(0X4=*WY#:%(V/U_D?[I7OY](#^[)
M[>_RL]#_ -C$;'Z_R/\ ='\^D!_=D]O?Y6>A_P"QB-C]?Y'^Z/Y](#^[)[>_
MRL]#_P!C$;'Z_P C_='\^D!_=D]O?Y6>A_[&(V/U_D?[H_GT@/[LGM[_ "L]
M#_V,1L?K_(_W1_/I ?W9/;W^5GH?^QB-C]?Y'^Z/Y](#^[)[>_RL]#_V,1L?
MK_(_W1_/I ?W9/;W^5GH?^QB-C]?Y'^Z/Y](#^[)[>_RL]#_ -C$;'Z_R/\
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M@Z/\#L$'X((((V""#+0XWP#F7!XUH;Y\/L:B5W,1#USM5XOU\ZE>K42&B(8
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MHK)VSO96Y"MV*BE"#DV&NH+8_0"WBFWL0C(B;5KK71&6M%)\LS*Q .]>V/\
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H743)V(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g556103g01a18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &J:^:"(X0DE-! 0      &@< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   " ?\< E  ($)A:V5R+"!#:')I<W1I;F4@36%R>2 H0TE"
M($E"0RP@' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0
M$%4))950XWCO&Q_FRL#K__HX0DE-!#H      .\    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     8 00!0 $0 +0 R       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'@I1[         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !H    !
M   "0    D     "___]_P$  &ML 3A"24T$'@      !      X0DE-!!H
M     T$    &              3@   )6@    8 9P P #$ 80 Q #@    !
M                          $             "5H   3@
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   3@     %)G:'1L
M;VYG   )6@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   $X     !29VAT;&]N9P  "5H    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !    "0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MN=:6Y5=0=LN932::6=-L]/!_P_\ .,_2ZG1<3-P^G5T9UQR,AI<7/+P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^NK=&DGL;.Y,ERJQ\Y=BM&HE:(9WJA)Y$*&. :/ID@5^'/;3R1J6DABDS(H
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M.#9-=ZE+/<A1-:.T/$DC3DNY&1@ 5 *J /0NXVM[&"&&6U8.@$BQE7EN7>0
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MS>P_#+=??0[-H-9G'O!]=2J'J-H\17D$3SJSI0J[:G25MQ6*1%JM@)-'A:-
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MGO%W^HI^V_\ "F_.TD7\O*:_+GCQ=T;_ "2_C7'YU/$_HYZ,3WB[_44_;?\
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MJNJ"$%E\XZSN)E.))M(0A%"6/5+#F@(DY.MA\+!/R<G5/AWSML=>F7&K"**
MHCH,WV!9,D.[2WN7NM5$TXE2.\*1IM8%!PT9=A,C!8]C ; O-@7W>5M'IZ)+
M>RW^OBYN1-##J BAC,;J8@((G4(6F=4CV,H,80;I \NX;]@V6/>#UZN)1IY
MA8.]A=FN_!<QWPA ^X34SC[FMQ\D'UZ.E4CKS:%(P%BX<P^1$]2@EK*U)K@H
M$./0X-(6^]!=OC'&NJWN\2L]N81K#:8;=8VXS(9"JR\3B'#J,'8(]K ,<C(
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M\A98YF\+/V[D-+'(R2./)E="O$3R)-R\J7&C:5<</C6<1$=N+- I>)1; Y6
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MXUSXF#C..75GS9.<#^.#[#3]_OVBN/%*<4IQ2G%*<4K],_@_?^J)47_8G/\
MZE3+G]+?_#__ '1TC_[_ /\ V=[7X9TP_P!X]2^^U_\ 96U?S,3TMDT!O([.
M86<)1F7P^U"\FB\C#N=V98#( <K<DA!<:[3SA1L_'/VR#MHOIG&Z2Z6F^O\
MCKCG]-)&DMJD<BAXY($1T895E:,!E(\X()!'97[BD4<]FD,R+)%+;)')&X#(
MZ/$%96!Y$,"01V5D=>]J.R=3')S):OO6U:]/66Z=/Y^5ALW/QUW+B+MV\?J%
M#B@IZUP]+)O2+]VS**8]8#W+UTNP<ME'"NVU9;&SG6-)K:&580%B#QJVQ0
MJY!PN  5ZC@9!JD^FZ?<I#'<65M.EN L"RPI((E "[4W*<(0J@I]E@ &!P*[
M8?VO[-U]!Y)6L'O^WXG 9>N5<R2) ;!DXP&5<GM,I2!RNQ:DDTM'$B0SEO(E
MF^$53S7.6I?9ZWSE/B2QLY9$EDM8'DC"A':)"P"8V#..80@% <A2/)Q42Z9I
MT\T=Q-8VLD\041RO!&SJ$^P Q7.(S@Q@Y"$ K@\ZPB07):\KKR&5+)K%F)^L
MJZ=%'L#@A<^1(1>(.3*JBY12/"'*ZC07AXNNX653:)II86=.U=---W;G971+
M>!)I)TBC6:4 2RJH#N!C&XCF<8'7SY#L%;):6T4\MU'!$EQ.%6:9459)0@ 4
M2. "V  !G)P /,,;5]BO"%7I>T-@U7B93.ZTJ*,4-2U)R.JPECGWT(G2].1E
MK'4I@9!)H!QNB\ERQ'D" 3=F];)KC17I+THH+'N&_%::5;6TDDS)%-.]S<7"
M3-$HDB$[%MBL2Q.S) ?(."< 9.?-T_0K.REFN&CAN+J2]N[N.Y>W19H1=2%^
M$CDNV(\LJN"I(9L*H9@8'+=JNRQZ"0VL#E\VR8KJO'X8G"824G<B?QJ-/HWM
MKM&EA8AT_59HXC6<9Q'$LI;H@--UDQ";--=;7?I6QLUDDE6V@668,LKK&H9P
M_P!L$@9\O^_YV\^:[%TS3TFFN$LK99YU=9I5AC6219 1(&8*#]9GZP@@R'FY
M) K'R5^708?6V2*69+W[^^L)XN9VY,.%5[+PB>:RE+$OWVV\9?"<B8LS.OI'
MC\3]NDXQ_GTQRPM+8" "&,"UYVX"\H<C;Y'^'R>7W5HMC:(+55MX@MEGP0!!
MBWRAC/"_P^02O+S&KN9[/=C9%6 :E#]YVN:J./;#\A:W*3N2/H:.3$;Z*AFK
M<"Y(J#\, JVF%@@[9'9@'7V46&-VJJRN^]5L;-9FN%MH%G;=NE$:ASN&&.X#
M.6')CUD<B354TZPCN7O([.V2ZDW;[A88Q*V_DY+A<[G')VSN<<F) JD*=C+V
M-R6T9D7M:;$95=D:WAUM'W9MRJ3L*+*;A5% ,I=;;>64&;J1P%OLV7SG3.13
M+/B_U&O++:6RI!&L$82V?? H7E$_E>4@\Q\IN?K/;4K86:1VT2VT*QV<G%M4
M" +!(-XWQ@<E;ZQ^8_Q'MKM>]E+](ZGM'MN3MSK**^B542'SAYYXR];P-86X
MAD+>[8WQLJ C*X00J&8^/";)0<UW2\G9+7/*BRM!MQ;Q#9*\ZC:,++)D22 =
M6YP2&/G!(ZC4#3[%=F+6$<.>6Z3"#R;B8,)9@.K?('8,?.&(ZC6?G>]/<F4J
M@UY1V<NN3K1F3PF:QU21V!(3VX.85SNZ5A,H%;%GKO+ _'UGSQ=J6;>;?*KN
MG"[M=PLLIOMFNFZ>F[99VZ;UD1]L:KN27'$0[0,JV!Y)Y# P!6*:-I4>_AZ=
M:1\2.:&3AP1IOBGQQ8VV@;D?:,J>0P-H%17O?-T;"4P6MH3=$4C:SJ]&[1K(
M2#/#6Y'K5!DYLUHLT61<-)HHU;-T?7[95)_IJ@EE-;3=/7;&_@MMNW<",G@"
MV.4!S;@Y$)!!!CS_ '2,5T>!6@??X-"7\&%F28U.;0'(MR""##DD[""O:*SD
M]W'[7RBPXE;,A['727LN!M7#*%3A[8TI5D<59O=-]"30"2R3PN,;&-5%L'$6
MFR29S*[G8OJ]V<KY4R73[%(I(5M+=8I2#)&(DVN5^R6&.97^[_A\V*Q32M,B
M@EM8["T2WG(,T(MXQ'(5^R77;ABF!L)YI@;,8%1W+KIMR?V0G<,YLF:2^TD2
M0@NA/I)(21J4-R$?4;J 5FQ8@X<.6V@3+1KJ(;H;IM1B+9N@R100133UV2W@
MBA-O'%''"593$BA4(<$,"!C.[)W$\SDDG-=$5I:P6YM8;>&*V*NIACC5(R'R
M'RJ@ E\G>3S8DDDDUDCGLSV >.';IU;TZ7</[I2[&O%E#KK91S>R&=\HVNMM
MG;_/-D\J*9T-Y_\ :L>7MXMO\>4%G:C&((_)MS:CR>JV/7#_ .6?\/568TZQ
M  %K" MH;  (!BR/7;?^3_X.JKN#[==HXP,LH+&^P5OQ\1<)H])+/%A)](Q3
M";2"4[*YDYLXT8/T$')62)KK-#[_ %T3=&!ZJ@TBJY8;[-LU:PLG:)GM8&:!
M42$M&I,:1XV*N1]E,>0#D*>:X-4?2].D:W>2QM9&M42.W9X49HHX_P#9HA8$
M[(\913D(WE* W.J2/]JNR45A8*N([>%F"8%%QLV#QN'M9:6UCP$39#!^+G8P
M0*W<;M!["4L2Q9 NT:II(.<%BJF=,*DGJB\O8V;R-,]M$TKLC,Y0;F:,@QL2
M.LH54@GF"!V"IDTS3Y9GN)+.W>:5H6DE,:[W:!E:%F;&6,;(A4G)&U?,HQBP
M.]+EBXB!@8S:$YC8JKI87GE<-H_)"@7:#S,\D.0,RB+N1KAJ[#&R2(D:D[(,
M5T7"NC)#7._BT\7+M;6[M*[PQNTR+'*74-Q(UR51PV0R@DD C&3FM7LK21YW
MDMH9&N8DAN#)&K\:*,L4CD# AT4LQ"D$<S77;=W7!?4E1F-TV9-[2D[8<B(9
MFIQ(R<B>#Q+=159 4-V).%]!HQ)PX<.=6##1NTPZ<N7/F?/N%E%$%M;VJ&.W
MACA0G<5C0*&8\MS8'E'  R<G  ZA2UL[6RC,5I;PVT98L4AC6,,QZV;:!N;
M W-DX &< "HNYO733BE.*4XI3BE.*4XI3BE.*4XI6PO4;_K7=8O_ *A:6_\
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M^?'5]-3BE.*4XI3BE?IG\'[_ -42HO\ L3G_ -2IES^EO_A__NCI'_W_ /\
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M>D7H+5O^7W7Y5/IW1?2VG>^6_P"966#B$\&1MY&&\:E&&:L@$2H<[UCTE1(
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M'<-B=1Z/9M@NIZ9'':NTL4,=U:I$)"C(KE%8#R%>0J!A0S;R"RJ1A7N=DO\
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M$F$.AQ<Q')#&I3'W/I@"4Q:31U\,/QR1!G7C58%A)!JZ3QNLW4V5:.7+=:2
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*S
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MGGU_CE?:;_?Q@=@]@I3SZ_QROM-_OXP.P>P4IY]?XY7VF_W\8'8/8*4\^O\
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M_&!V#V"E//K_ !ROM-_OXP.P>P4IY]?XY7VF_P!_&!V#V"E//K_'*^TW^_C
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MSJ[,D=OFZZRJ0=]JD?UO;,GK)T6+22(T=:UU5LG,H7,XG$;<C]8B'2[\[ Y
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MF+P()<38;[XRXMF:97AL"MP!9E/'"A$LBQK5TUK@V"(-MV1AWJ<1<KLVJIK
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M4)>#Z_ /GA,'"F;ADU15;18.0(/WHP$EOH,8N7CE9LV2W64SLI5 ?HVEI5/
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M%*[B<>*;8EFC5.3:*/A(EHX42/)LF:95)139)YHU0U6TWU2TQA2JB*]=.O\
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M*RL"9HF8&2.0!65-:4>P%IW%)1MMM[J1KW>3%/!RMS,M"-V"45(0Q7OCX0F
ML=%FKP@V$HB28@-#W1=55;T>0Z"$&)#55H]VTTZO!H8$,/@YFVC4RJ,3O#_1
MVERGFH))!9PN/L;B1S%=_@5M:QFV-H9^']/E(W+&191HN@S$@A2Q=6>4)@9C
M+EEYCGO%T_[56O8?9F:5;:=C!):W+"[F/0D97K.H956N@FN+1"1=)<1*H7+T
MKB@)./BSS$!*8A?%<^>/2199U&)FUV".PA3S[RTACM8YHHV0@P*YE,R3$RQ,
M_E(\? D5BI9'MY?)7DZ'<&'D:GIUM!I\5Q;P/&R-:I,TYNHKC=<6[R>7'+$;
M299&0O%+97&$CQQ(2'#K#H_L),:C["WXL'OR(D4'W?X%7Y7J\YC@HY,B$$EU
M1U6I+K'&K($LV)IO!PK<O8#1( RTB.P""2D:]9ORY)9\'W:V2:VM\V[@C3FE
M%V&*H)(YIMD3#'#^L;;$=QW[I(R"%&&ZFL8KJQL@UE*I717G740[)"LT5U<\
M.!LKP#QG*0$R-Q=\T14JJA7B*#>$*[%R,99383<4 ?NR76*+W?$)1:&_7*'B
MHR5-7)6T'PL+9558]IL*\CTMC$\((P41V)/$CH>7L0.TY>-Q#>3)[;R:;:H8
MB8)0!=M;NL/A4A=1#-)Y1FB@:5XWC7BM;*JLA;AC<4KKFT.QC:W+VLRA=0DL
MY8[?P^5I%2UN)CN:YM[8SO#) IG:Q18WB9^"-QCJZO/"!=@7P2MH<*G1@415
M.=B6,]LR0"NG<;,HR:I6]/E0%=M99(;SUZPS8>W 6F]D<BE%='6TBD8F/9&C
M8K"R4;GQ$94:;;AIG,:D!;4Q0JUZP*S\<-(8UMO"T\J$*JR*55FR7D#1AJ+H
MED&N)6B1E"V!@MT;59$,=UX6KSF..R^D(FXELL:1SQE$=]S2RK) K\K@[1VS
M<%7;*6!=U:TF6:CNA9MI1(AM&";BZEK9DE5S24S:&RQ:0NI8_C"TB=&XM"-X
M4Y="F:4%D*DK5D39ZJJ.B"TABF^KMY9U+:BIN&+ 0"%9HT21-@17";7E$@#'
MB)LVG&5KIUM:W!X%G<7:%M:0WK&11:"UCN88X98Q&(EDV!)9N, YXT8C$9 W
M;Y]M;WF<)MP373/L+ ^J\3:4+.[C;V#.X[%#B%A2R,2 :']Q+52;OV(A,#$1
MCE"0S<8 SI-2S.2 O4IF/-V+UP]\^SMTDA:3P:2\<W$</#C9U,2.I/$/#!.Y
MV&V-F^K4JVY7)&/%TVSBFMGG-C-J,IO(;4P0O*A@CD1FXIX*LV^5ALA9\PH8
MWWI(6 76Z/\ :_M=+1J]T$)0!@$>B5L>#JA!Z@U:Y8.5'B?;N-=5\6N&D,N+
M._=4*(0LO?!=U"MQFH]R/(A5&<HTD3!R@S&]3V=I&1 $:1GAU.1;CB$8-DUY
MP2B+Y!$@MU$F[(*ME-I!)]!]-TV-A:".2=Y;;7)DO1.1CZ,?4O!FCB5>&RS+
M9()MVX,KYCX; EL:L.TI=UX[O=K[>"+$C+:S"<.ZR@8JX<NW(9S>A+K-5MA=
M9T<--E-FHM [*D+(A3UVFFAJ[)3D'HZ4VRDAXKQQ)<V%G P"\)7NW< !A;B[
MFBNCG&6*IPI,$\EC;%:0V\5[H^FVSA4-NLNH/(  XLUU"X@U YQEBD1MY0#G
M"POCKQ4>=9H!7R\AI?KWV<,LYQ1T=>^$+%0$';)31U!+1NBO>\4MBSIS+V1Y
MWD/,YC&JU3]:0R.R#!'1FP*S0\''*. JKX5K=2R[9[FT4QSL-,:1H5Q)#!)8
M*XV%!F-'E.V1EQDA%8X;!VU":?9=WVGJT-XZZ$TSVRD36]K<:-#*!$4&Z**2
MXRLSQ[<LL2.V'"MQLQC0LAM_J]$*@4IVUZ. 03O:.CX_M1:DIA].LBL;N?K@
MP=,*RFFL/EV9.%@Y$B>B5:)#VI0 SB>AX2%DOH8)-EO$+7$<-Y)-QX;AI-/+
MFTA1YR'@NB#,A=-AD 5Y2<,9-K,N6)JUL;R.UU&6Z\*MKQY]&9VTZVBENF62
MUU!@UQ#Q8N&\RA)+@L5D,NQGCW.34N,81U1*]@8%&;P&]9@E= .G"Y*- X_9
M34A38&2N+]FFTD>5]+3FL-4>/-/..52A+0:-(LGF7:>^B6&VJN<3+>BWD:W:
M[:1[TJ[-$1.Z^#Q;!*B[\9'V1D@CF*Y&FU);*>2S;4'GDU3;([VY6Z>,64/#
M$\2<4*.K:NYE(Q@G-2&'E%A/O!*]@Y/&+"F39<)77<AU1EH$7Q(O."M'PZ;6
MWBA9/K(";K!L@]/4T'B.P&:.'FQQX->"I=Z6X*K8=+9E(AK-LCQH0TMD+B$
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MV.$I0G(I:Q*.L/\ :1J[L12;#810[[N"*,PQPZ@T*E))-[B&TU/#N[.QW/M
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MX>(QVLC/-)([!KGAM-N;9M>0JJ*%5?,2XN\'93*->2D9:8.F:RMV$W;?-63
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MCN'8R<[5$.BX23240@8BI4+''+Z.O>*2VM87&V%M[W=K" [31M;\2))7*)Q
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M"PW$8+$CR0&(P<CR% 8C^ZH!Y"I62X++LDF+KN9=K.67R KLN#D?5( Q']Q
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MN;A&=DGF5I#ND9975G;GS<A@6/,\V)/,]M4*]*TVZ;"V3FI:S<,P::Z05HO
MXLJV#I.GBI%RD+04%;)#TW!!==\OHTT1U5>+*NE,;+J;[[3QYP21-*"WVCQ'
MR<# SSYX  Y^;E5A=70+$7-P"Y!8B:0%B %!8[LL0H &<X  ZA63N3L/P%*K
M/#$:Q'A;<RT.+.2 O 4<T!YV8R%L5456]!:-P^<;LS*+O*:8_.-F[[5'.,Z<
MH%?<H"MN.TJ #N);FI7SG/6I'7UBLPDN]0%DWL4* *V]B_E(5&,DOR*$?:ZQ
MFJ9M 8&T=@"3.%Q%L_BP_P!5Q9^VC@9%W'!>R>Z?JX Z29ZK"!^4E5$_1!RC
M=ME-3?7S?D[[8S)DD(8%W(<[G!9L,W:PSACZSDU)FF(=3+*5D;=(ID8B1O\
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M$I_JFX)%G'WCW*9#_5HC-$\.?\FB'^&D,DD<\4T?.6.5)(\C<3(CAER/[V6
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M3CHIOA=!OHY2<Z<9^#P!M$9D$C84!G9053>^-S! S[%S@;V."2,;>$R^"^"
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M:"+]]&I6,<JR1^:9#2 G=G'4<)PL]]8AD@2.2WT]<Y81.!;PJX<B0,-K!HB
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MO[$A8XR1CB\@9JR$/O"=3 (=HY+&1"=C&B$?A+LL+%(/7PT=("P@LW:E'J"
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M[>::Z(1UP[.+*P_;+%NZ5:;!]]$.>::%KZRDFDCGCC2U6X:-"8R4/UF4VKO
M_OX7$G,@'=7+=7-LVK:9-=30W<,,6GK>20IF%C$WUP*;$X@'_P#8 @XOE$ [
M^>O;;K9*IG8D0$5Y0UY5#U0+V1UV3LFJY]*2C!>0&P$8[$;6S)WX1C/Y(^UB
M1!B<J6)6"35)I#+1.--':[20-V3@X_Z_"DCBD,MQ;S7BQ7/!FC0':#);<! 3
M$HWJ5F>, 9B4@ KG:O:;^.*"5Y[RSNM26"^X%Q#&K!$>2Q%M&K&",<12ES+
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(Q2G%*<4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g556103g01a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2&F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (8J^A88X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?C&J          IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             (6   "Z\
M         0                         !              NO   (6
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   (6
M  !29VAT;&]N9P  "Z\    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,     !;7     0   *    !R   !X   U<   !:[ !@  ?_8_^T
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M]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))30ZOTO]I54,#VL-%PN
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M-+,-XN=:UHR,H10'3!MM/N]!O]MBO8$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,C9767>1N!DS=7:AMB<H-$)#@K&SP</P_\0 &P$!  ,! 0$!
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M."]8L;%.47*MD*C;*FD5LP-0?GK>K%PZ:<S'K?)4Y*LKO2:CVP2O(U=TL0;
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M$KTU.I=.5U3(P,?I=!QTJ??WJMJ<?G0X3?:L%G,, S%M'>JC*S;V.L=<C&#
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M#5*6OIL>Q$=4L6REJ77GO@X!+*R,01^$&4Z!'GQ29O\ B5]$]FO1B3VDZ_Z
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MBHPP?6.3.2C--%\7Q(DUU\DW5L(_2?)ZIS?V2U<L(_;;G]^Z?9C)M/PA]]8
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M+N5@0#DOQY#7Q"<-!AZACZGS*8\Q_#%[E5ZGS+UL:?A:?AQDO:,UJE4M/O\
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ML( VU?<*$Z'(*&(V9=90E%74$K)X,N#8G+\)5M?F%;YE=ZW\=;]94ZL?B/\
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MV1['0NQ8UL'"J')")S"L44:/$ G7B0:=^"_9;'P]!ZR7C\0CV6L_KYS'-/\
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M=5XQ:O2V.++04;;[F#D5%CAZDXO8?))N3UU9RFH<^J@+"&M"MF6/OCMM8LF
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M&N?SKQL_(_9^N-#YC[?U1]Z<_N@W_B-<_G7C9^1^S]<:'S'V_JC[TY_=!O\
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M:Y_.O&S\C]GZXT/F/M_5'WIS^Z#?^(US^=>-GY'[/UQH?,?;^J/O3G]T&_\
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MJ81G7@*0RT>9DVV'SH)SRN=<7-,[0[19^B>LZ@#O'MKOEW%OO^33SLJOZ/\
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M4H\+6T%+:XVI.ZQC#'H:'^EV]H/T&GAP<("7J0'%T-BEG7M8&E *OW.I!'V
M>* N'VOH>:H-CU(\F0? -EB#'Z3I%#+:UW6UJM)&RM8:Q;0R_@MW%K78/$D$
M&97=;[)U3H3ZK4SN/5KA$)5CBV-A]A_7CGUVYQDJ,-:S7F<Y:>O@_K@U+?#Y
M+,4M*M8R&T3R;3$:@E,0IEG<QWBM4KOCU(2X 7&R;:[->\"+%R3E +X!#J%X
M[][ER'&'+ LH2VW$QJB;5 KPLZ^F_1+*PO7-.>H0Z5EL0*4'E@X;W?/;J_/?
MQ#^A>MM3;_UW.D\NM*BVV) [)Y_Z9>R@5R;3,0)3%11M<K0-KZ:8B!B_*/%8
M8*@%4@BM-!-6933;&TWI46],JRG7V"NY"BL!;G8I0 -Y 9^%7(_Y/,N1L\0/
M3W,6_H>/GVJ>D49-35I8@OZK@-4H4Z8"RPUXX<GR:^XUI&_<"^E7)?1#\6?%
MY1<]_P#NMG6H[%9$\3I7++SCV8AJWTGVXYCO$SONU9Q0T3;0985F9"\LJY[$
M5L*#.NC/8 #%;1U+HO;:S[B4%58JWW[%Y[V![M?+N,OD:9592 2#I21Z8ZU]
M&NR]_P#R8Q>W6_!@+^GFW>U7:T\^^Z$L/OB5LFMD,0&(U.#U$_$YGJEEN^?Q
MH+"NJU0:!IK&VL"WO%9C6,#YX11(9!GZ5>;/I.01#%J4(-.)C:3&=I]<8SG$
MSG](#JGW 0NX+*%>AM@;)\KL>@]"=_DEAZK]'A974/HG4UEJEZU1L*SDH!).
MT9E&@"=$@_DF]UCT[_$B3V[F ;W\;Q#AAT:%38N?UII8;62PZ E-TS.)/7:Z
MY>J"+(.='MKF,8;7;$^/CKMG7;7X>569W2F2TI]'V JY+:ZA=5MO]\P1@NOF
M?J(E-G5N@/5D%?H@W&CFE]B)6!0X\:>Q*V"<3ZD^GKZ&>EW*VWM&'4$JAY^(
MKZ7W.Q<&NEFE]BVN.?DV0I K+UZ.F4I.CLE7L54(%I +N=0-]J;5OFTJQA79
M=,M6\M6)7VKR;1B%V8=,SD7(1?9E%H0,1VF9J@V+86VO([#V@AQX'+:_/9*=
M.-K,G0^K55YE58P4[XK#N/9V=Z V!:7#)R.U>_DM@/%>X#7:&"P]N/"KC,/V
MO]1IUUQVETJ1X7"+/.%:=QR(Q"-:V7CW&F@=[0%30C2X6[E9B(ECAWQK)OKK
MG*4H!8'$S04_#!R$!3QOWA[#M? )\Z\">?V\16L4]-ZGRJUW5.96&JV"1W!]
MRP4V 2.6M@;$V@=)[.$DD!:>POK_ #EB?'!@H/KA;?JA?A^7X_/AW]I3)(,X
M_/K_ /?H_AC\^OQQGXX^,"V(//LV0 ?3>4FOY/\ %!^V_P"2LOT\ 'V'- /H
M6SZM'\Q'3EW.:2B^T\F<_P#ZQ'+X/C_T#>N#+&,?^K'U/=B\_P#V<Y\YSQ/Q
M>[^7)7_=CB<[W3OQ+(/Y\Y?]V&/]WYIQ8Y][2X_;CV3H.V?^G&_KIC.G_LQI
MV"/?&/\ KWSG_P!?G>YB?BUGZ3__ *([W3OQ"_\ 3O\ _E_W"8"W\W]PF-1M
M*RM>RW+P;&QKCP% QF]?&2_Z!V6L*'5&_<!^QL]@?I3I()_K-4[;(OR_GX6'
MYT^EEZEF&'0OC7%0RE@,E3M006!!H&]CQKDN_F/43JOZ6ME;68&2R*Z%U&:K
M<E# L.)Q%WM01QYKO>N2^HC^D<D]^D]I0,;-[0\8;H0N5*ZXW7D\/MC;4SH
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M&5IM@D%]I#O8II(@4IT!8A6NZ):>JNBK)6*]834#FJ&/$BML75[%H'&_KI+
M*$J=&ZC7&,%^K55++N"?@$\T/ZJ"7Z8LB'\DNZ)G_$1XB5, _P#3JM?_ &3.
M??\ ?#TSS>W_ $77_'[O]GHF@_\ -%_C#?\ AI+9^8)GCQ$>(G"0..7#(.5!
M"2/+KG26 B+2:&33/]NLD4FNVF^N?^G7;7.,_P##Q.$!@0P# ^H(!!_.#XFI
ME<ZY\=:4MY-HM.,NU;$W KMQ*K"0BTH09!S Y DM@E!W;*Q-Q&+ 7<8$N"'8
M<XR'.F8R9M=Y<F"E0S!2=E=GB3X\D>A/@?4/E,S8.$^15F/AXKY>.I2C*;'J
M;(I0JZE*KRAMK4K98I5&4%7<:TQ!U>/A_-@T5FKB52YJ:RWGB,WFU&NMXHC.
M0\,O!T1*Y[3K&C>(=Y2/S?7:H6*V-E!),&QT*$FF@W[S;8)(8KX')5;U\>0P
M(/Y-[U\)G'2,!:<BBJNW&KRG6R[V/+R\.PNC\PU=V+?3;02WX8I>L6*2E@9&
M*FK71_PS/4WIP]=7OJE8Q4U<QC:%&NM[B18T+^=(3(U<Z.9'!1CLHB66=B\B
M*&;M99RMV9I>QIF2+5R;DV0PV?B0-C\@UH:'H!K0^ \"?/9_T!^C?44HJOQ;
MUIH\BE,FTI8_+F;;3:;7:]FVSWAUML+.;'?F_*NS'\%_A4J!VD4=T]H5F6$2
M_P"T;[])7_;D!2U BJHTT:9%6ZV(VC_3=;2II-&NY)6P8 \>IVFL,6([!FOL
M$UTG7_T>ODMZDG7DD^ /).]SPW_P5]'-&135UCZ1U]T5FH_=+28[58].*A6J
MFFA;1[/134W>+L4K4*ZZ&NGO^&7[&U<#E=4Y5^(IWBJT+GE<K-9+K[$> V0E
M=7&C/88.L2!GB#5Y</7B@E(2]T-;QXI!(X_AI7P4U=6=]IJ8NSXU;,Q)!]-;
M'DGYG>SL<3OR=G9E?_(#KN-7TW%Z9].^MXN%@T8^.]%BI:6KHL<JN.P9!0@H
M9:E2Y<M1Q T*$JHKL'IZQ>TT5%M](E]N.G'SZ\X+346X:6*BJK 3<]4<(07Z
MI^'!&A:Y"0QP1N2_4/&=P""VBF@E,=8RTUK[M7(,*4'O;8<6("[WX'< /CQH
M@#^3Q/='T?\ I",3)Q#])^I.1@M5B9??P:\ALKLJJ^T'[B6FNEK>6[JK+<E*
M^)'.[=DU&X>OWMKN#7[+CO7LC.\R6C7OJ3SCI7KTZA$"2MRV!#X.PW?@O&E#
M29R']/!*OEKZW,!DLD1N'"2*)='U;*3L=NH  Z9EM&R1X!"VOKS^7T^1\S+D
M]$^DG"G(^[?7VN+4UW8F!G="M5$JM=VN6[+Z)TNJUK4XAD-->G)#=VE0@V!7
MQGV+IC*P5Y)[)^TKZR*.1(8*G;+RDX&\XT_O=86MS)(G&%W.770]5+=FR7+&
M,&BE==RPQ&NV+59"M*^8!$O4VB:Z@"YY!>X'"DCTVX38&R/) ^('F:*^E=<Q
M6NHJ^D'TBNOKZ;2,?*S:>AW=,NR\='8BWM].LS^W;8Z5VJ*Z\IT6TC)N<4NF
M\Q^S?:=*?+>F_&N75*NCN\5TB:]]/]C:(Q@:;"1FX_,CM_I E=2*]H9<:QV&
M%?+7I2(YQ(6LA0Q$,?.TG+B'8G6_=6IAK\ZWD;_)O8^4UCKW5?93F6=,Z=C4
M"[L$YF?UW#L%F@1NG*^B5-W;(/B_M]@G8%A((&W+>[]2EO-7H#BN>K:RR6H
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MINAT:)]"HIMR]LQ(EE_$1XB5-]RO_-ESK_M9>DW_ -MUQ;S?T[]WM_B'4_\
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M;UZ[.Y\WF_0CJ^.N+D?1[Z5]4Q<[!8O4G467-Q,E1B86+[/D)I#VW7#4L2+
M R@5[J0G6N==/_&&YH#?:[U'UQY3WO-?26(:@7VG7RLU&2QO0!UNJ)HW6-;&
MO8,T)LNIV9E\=<JMB)DFFWTDBB%%U-ZR8;%2EKU[(+JREN().P" 1O6O.R!\
M1O<S]/ZC_A1P%S:.I]!Z9UKLU7C!S,+.Q\/VBY%K[+W)=>KM2YY\E&-CW$[U
MX5>?9XG[,_BG+3J$L]@?1D2P 62P,!G5@YO>N?+6P"B-"].B_P#(CF]Q(Z\0
M(8EBVADM-A&!>X81*8&2YJ:EB/658FF->0=@#09&T?(^(!)\'SH>-;T?.N](
M^D'^$9'PJ^N?0U;4R+W6[(P,_ 6Q*Q1<X/8MS%JH*O2-'(R%2WF*A8EKTK99
M3K'NE?>2G*2'GI?[+;U&5%='-@LPT7*['HACJM=(?#[;B\VZ5T/&!S<B3C&;
MMYT<XP^LK!9 [R',%M4E*OZ75;V  >8WLZ_?(OS^6ORB?0=1^E69TUJVN^BO
MT@.,:<JV[(1>FY I&-2;AM,#J&:VGTRDV&H@ M6MW$K,G%^(EZQ?I])8S7'2
M50SRSS5.%6PXCU_6T#,(4+.P9+GJ8M+*LA";817./JW5+&06I>^N)98QH#B@
M^>SV[(TIT-DATUKQ^^Y:^/IO\GK)#Z<_1TT57O=GUK;D'&%=G2.J#(6P4O?R
M.,N(U[5<:RO=KK= W@L KLN>KWO[ZC6%^GJV.SH*]8'T[@=4NN0;FGQ$;I"F
MXQ.LK>PK5Z$*>;"4N<4 YJ,RETW$@W"B.+A#V''N +=LD#6R--ZZ^ ).O(\@
M:_++Z/IG]&;[Z\;[JT4WW-:M=>4MN*&-+VHWWR^NNE234Q5&L6P@J"@=@LS%
M9]Y_3RVB6L]3[)\;B7TEP"BL9[J_UNMB ',H!)0=LRV!@MQ(&5.5LLA.TQD2
M5N$R5Z3;&+RHH^&BX:W4_O#8TI.Q_(#K7J0?(&CZ$2W'^E_T7RDR;*NO]*%>
M':E.2]N=CT+598%[88WO7[KLW;5_P6M5ZP2Z,!M"'VU]8+39&-2KOL)Q=V]5
MKE;4D)9TZE'9W";[$:B2"[BNY="]M<0:;E1CYDW#C.62$XCT9!;3\-5H )K<
M DCRC#TU^3\O^N:*/I+]'LG(?%Q^N=)NOKKKM:NKJ&(YX6[X,O&X\O0%@NRH
M>LMH6(6[T'L_Z^$_J+Y'7:3)^D\7'-@^#>/'V_% PFS;<_MUQ]5A3BP*/VA?
M4X/^K^"SZW(Y7R.=NP:VC>=:]T^=[U]>C]4L7K_17[_'J>&WL_M/>U<ON>R=
MHY&_GV^]7^#OER]SEIM3<(8(P&A, *&-$(CTF'*$GB)&GBETUDCEAGAVWBEC
MDCVUWTWTVVUWTVUVUSG7.,YA/55E=0R,KJP!5E(92"-@@@D$$>00=$3L^)*/
M$3KSAB%0S#E"C$CDZYT(@G@BFAGTSGXYTFBDUVTEUSG]N==]=L9S_P!'G02/
M0D:]-3H)!!!((]"#HC\TUP^B4=IJET9TVJ,=*V5DZNZ'UU09JA-R1"9DQ+J0
M')A65DL<<K) .()<D00SYW^;%IMK(6..6G<<AIM,1R&M:;1\C1(T?@=2:W6K
MSXVV+W!I^+L.8T1I]'WAHD:.QHD?&8??D7)Y&]KL&_,.>;O[VF.KEX>;TJM[
M-[E7FD<43-%:V65F3;$F8Q001G*V\Y@)<<,6A$$FL>F-9=Z[BB]VWC6P:M>X
MW&MAY#(-Z5@?0KHCX&3]IR>-:>T7\*7%E*=VSC4Z[*O6O+5;J22&4 C9T9J9
M'K/ZZDTU3SK?A?)(J"A=$61'2Q.>U4&KI;"7K/H4\4HPE8ZU:W)T))U(8ACP
MES8GFQ++MB3?XR&5DAVL]HN[C+Q9^ZY=E&B%9BVRHT- G7@2P9^<+6O&9E=Y
MT%;VF^TV/6-$(SEBS(-#2DE1H:'B;9GD_.,WTKJ&*>FUZ":MRG,MND&^C@E9
ML'$OR'.1I)KB6' 4$(VN-],[:11Z:Z;:_#&?(=ZWMBKFW;!Y!-^Z#O>P/SDG
M^4ROVF_LC'[K]@-R%1.T#;+; ^!V2?SDS3X/6SBHE)+YT#3-EU..?1V<E0LL
MMN6;;O(1(@8SM&0#X=M!\!8(HLC0'Q![?DQOL/M)G.^;/:K^X+2^W"E=E$/N
MD[(XE2OD_DW+3GY9M%[6\K50UAFKJ;W"2Q'%D*GR3Y()\ZWKQ-GVY!1-K=5[
MS]$^TL=-2#5U!+#>+S IA4B#L!1X&-:ALD=9?SZ0LS,98/U#-C))M!-(7O,&
M'(/#O6<'KVO%V+-][KV22"=-QY*/ \*P&MC6B0:_:;NU93M.%KEW'9I+%B5)
M*V&ON(-J/=1E76P!HD'!P<#Y^*DNB 4WJ8H-^/"96 @7O/=!W8Y:]ANS'S5+
M+#T;2QT$?8J3?4L&B-:V"Q"SA8P'*6ZZB8E[19RK;5.ZP0H./CE2"-'FAJX6
M'7H;%<@^\"#YDSFW%Z7*XQ:A65 <+#*$,O$]VOL=N\Z]&O6QE/O*0WF=Z7C%
M6DGY^1K8.M0[\VC"A1:1=Q[)\AO""0.1%IT >6\RP=1DFW%CT-+Z/':3CA]R
M!BRIH"R8Y>"]P+!QI/=WRWCT;78(^]GM[J]? JX '1 !$B,NP"\<,8C(V7)P
M\7:D@C[P>SO']? H-:@Z( (&LY6N?"5BS6JSCVF_MY;81DDA)9;FZL-922;$
MSE;:55&SGG$K@^=I\PX%6XA&T&C@'CBTBATUQ%K"ZHI2L<!H,J*K-X ]]@ 6
M/CU/G9))D++C9776:Z5%0T'KJ1+'&@/OCJ ;#XWMMG9))V9OWE<ICQ$\BOQ
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M*D'4B"E-:!T-S$$P2/'_ #ZL%6K8@#.AA09*&LR!D?,!AD/TTT,F:39]X@?
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M#MONTM(P'MRI,]TETZ$XDF<<XZ$K91:Y<WDNL5Q=FMLG%6WWI]6#HK'?+>P
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M^W[?M_NEV/$2,>R+GK;F]C7UFI 7EZ3A5A?5VSF1&H921NULLF[@B,Y9ADH
M@CE9-*P2Q! N((<]38F"@.B9XT2N' N+]6H76C;/963HFF[\T6U@:*Q6L%TV
MF+ JO%DR?4X==#/),X 94KHS!WN6\:5M=-:1C*)$&9:^@[F(EW?$2#O8BF6&
M_P#+W=5K"N9BW:ZSC"$!V@6K,4)4ZQD,NLJR9DE>)F1R1M.O,C#;"Q8 CTEL
MJ6?:TH$ A2)K/#Z=>45SZA8;K6?TQ(^E3@ Z++3)8Z]8<)V=H,+N69&+MG8<
M6"R$/=M]X&P:V*MT\&F41;J8-4\GE(EE_$2OOL12+C>ZNG5T=='-8!'PC16\
MWM/Z?UJK8"2(M8W+#W4L-FJ:6:&18_E2%J+LK3'&34IB(Y(U-#1-?]7>;=.Y
MG7[,JZ6UU='FLE967$S()F>_?0JHP[3:-I%JI/#"JL)T QRJ%T.PNFN<F_JA
MZSS]LC"1+1>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$
MH'UWN/;N7]AN8$#"I6#G2+^J40MKD5%9@V.2+V'[M=>3V(8BXXMK *;-44TC
M+T>>*J0[3R/<1%1C0@1SF)SZO4?M^?Y2OL7XH5V&KFSU]ZR *?JJXN=K]]>U
M&2H@)S@?4ZP39O%B8\;304^MKJS[<U"8ZSX$=Z#V.HW%'*LC5CK;.>G?]4W+
MV*]WNK<XTI+^FT14*DAHOK_USH]<=ASVRQXI'2<=FL_14E=855Y&HGL=(I7#
MW8H)Z_+U6T?V15-!H2%&/$P1^W[?M]<C2J_B8]4K_,@7G4N%KF]ZCKW8+4V1
MH;$UIK%A%2;WWU&I04:K&UJY36>.GIN.JYNSV::Q*M*4%<JY90T3N)P.DC1^
MW[?6)L-E]^_8*&_JJFFXKR]:1H1"&?6VW2[2<>\9JNC=(J%HB1V6'FP&FE9'
M2U>K-B++BH%FUIO95Z@NONAG2]D,B2!S[\0)KTZQ)52[FR^JQZ]"X8D9K)[7
MFZ6!E4NWCNEP99.B)* EH;RO,Y4-CF2/'32Q'UI98-Y:VJ"D">>(GIMXB/$1
MXB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1
MXB/$1XB/$1XB/$1XB5L]F;7U6FUVAL^5V&KHC7?6^7<^=XL](/ND4BKI-_K5
M*F9AQ 6^I;@SU\=P6U_WTAD!VT48\N0X]=Y]DX=_#X_9^WI*1*?Q'>EBCK8F
M? %C\<<+,K^RP=%9UHJ64):LL+F173\\SL,'Y1D+"3"R&>WZY9.AH5Y$JL,N
M9J C?K\=;]/L'Y]27*%[MV?JG)B+\KY@-S]EMW_EG'Q@W5I"N> 5EWM-1!<S
MVP!6/7VE.OB5:Z95]E27 V?L=TV41:M; NGWVW3LJ+P[\3'V#L2Y8[ZARVC@
MKQN6U76QD&R6/F=47]3L-[Y_+):GU[/@OF*ER,/DO8.<.3"\5:Q&A669J#,=
MM!'O] G-^GYB?EKT_7YDS8_$:Z6]BK<ZGU\5T9?8W?.?R-.E= ="%)4+3HWJ
M]4NAQ7-")SL2.GL4P'LLLT4,-[ \%@*K5D:.5L<"H90Z1O\ W>OY=?G^?YOR
MS\\@_$3Z': N!U?HO(ZM7+EUL?FBEC;%O0"I$P[?I7-.-79$X1<](I^UQ:D$
M3]4.^]U,$A@FH@U7)GLW2-4I$]@7H_;X_P"KX?[IZ&\ Z*PZ]PSC_4VZZ!0U
MZ+S2E71FM$^;]"&PL==7M38EV9]Y)]UN"2I=ELDV^TTH.P\DNV=]MO$[)=\1
M'B(\1'B(\1'B(\1'B(\1'B(\1'B(\1*\V?VZ]4*38&U3N?L[Z\U&TH3)%[RM
M6?M/-T-@3'Q8QF4%LF:V41BN,CQMKF08P:&;3&V,[:8^./-*8698H>O$R71A
MM72BUE8?,,$((_*#-M?3>HVHME6!FVUN.265XM[HZGT*LM95A^4$B8+^O%Z5
M?WP/5S_$!R?_ -[?)>P9WXEE_HUW_HD_N3U7_P"6=0_0LG_VX_KQ>E7]\#U<
M_P 0')__ 'M\>P9WXEE_HUW_ *(^Y/5?_EG4/T+)_P#;DWV#H50K=$,Z4:Y%
M,IHR."PC-TN^KN)TN.AAE3_IS59DG-@*L.Y00M<$4_53OC3P!%>A,YH^DF4@
MJ2K J02""-$$'1!!\@@^"#YWXF!E9&9'4JRDJRL"K*RG15@=$$$$$$ @C1E=
M7/NSQU,2]%E^XRRHIZ@)OK+8N5HY#3KC6$=Q#'A'M72*^6M%5U]Z.4Z?V0=%
M5QRA&"H-X<W@T!FY.2W44FLT4<NGPSI+'I)KG&VF^,Z[ZXVU^&\>V\>^/AG'
MPVCWWTV_MTVVUSC.432>D=&K'*:>VN]N(*A3*(L;RQ+PY6+,O?.-MOIUZ^#_
M 'Q4ND.DQA.V/RP KA36A\PJT$PN!$B0/VMY268Z!P2?K.I[ CX=#! 36&S%
MK>'E]9<ZUQ#7T%E;V9(F7OTS<@YK<DM8CF1K#'*F-H%#G?*)97Q$T.^=(JW.
M(JQ)9228Y;C=*I0J^&")*<8:_M[P%$O^,,7P^0N#G.T+;,9]HQ@ 8I-]MI"9
M!1242.A_8VHLWJY-7*[<K0*?U&;D6;"H&K<*<:U#UM=<)R=8'=G46%O78ZL:
M58/OU:1/ 9$R5JTAVD U7D,$YO\ O_)\?VU+ ^)V1A?.JI>?O*77V:=^Q.OK
M$Y+7MU.B3$$[X9<2R"1_%P\43$,7$(9F1=5T!XRP8,QQ9B4%>#*<0HFMT3OM
M8O;A!7HZW>*V[L@_0"UHEA2@R ;B\UL@E3L4_P"J*RWLE/G^:Z+S&H'!L)A;
M0$>9O /A3N(:2B3GXB0;U;OU1XV1OBYIK;$IU0NW,=F#6+MJ\2<CJ]MN4U7%
M,.< 3SV FO4E\9#G43[")-JL <O51[Q,,<B=+FGL?0>JV\FE5K67[P#6![.=
MG>T<Q;0CQD_:Y,+H(JG?[(Q;SP"NEA1KE"O:T\')D*TNS0N]]5>4?R?ZOJ]?
M[ORR?_$2OUV['S7GUT?$W"N.U#>N<^?-Q;I)6QI];'7TY]*E=56I$C$S6-Z;
M][NM*""60JM%CNSM-4:$QE85SA> B9;F/?>?]=L%JKM,)*,)J$8>6A$LJ7,7
MSB9)QBA-@ W)KY80M8#$KI_U"G2P,B!BIJ[.[ %),A1)K\1*Q=2]A>/TMM.+
M<%![%US^VU>%9LV7(*T()9[=4[^4 VKEJZ:YIE2TT&J5=O YUDAL(R[33+"O
MB,2V\I:K1$F&E=(JW0#[T!6223-N>6^2CORY!9(0); ,C2/3H5)>V<Q-!5^C
MV!6<8-G,$+P%LL_-M,OFSXB;YXB1QT7HT7.8:X234[59A['94M4CDJ^U5WD7
M-+"U7IU.30K#::\P,'(+/^;/L@$=3+UX3)HR@#7!R$^(DC^(CQ$C>X=/0TBT
M4*K.@G&9NAN9*^E:"PK]E<#KZ6<L-:5@EF*V-*.@$.(UAKRIYNL  .<6#"=(
M-*RU1)(\1'B)I1-^0B]$4<OEC<?J=W3;!>PY<)66$/V*M.JV@8Z;V+<?11LW
M^OM*S:-+ 5.RT#S(<6.*+(%*6B;KXB/$2+EO6ZTTZ8YY8.&\T=)H#LRMYPQ8
MZX8R5*:2_<(@3-3MSY&JM'T6G,Y_GK!EQ4#6>%8P/-2OQ5:)*/B(\1'B(\1'
MB)"W0O9+UUY(]BJ_5N^<6YE99UP[>"N]"ZG1J6]F4ESE#"M(E-C>K3Y%Q) 1
M@XYN@^1IIQ"HHY=I!Y==+Z\7)N7G3CWVILKRKILL7D-$CDJD; ()&]^1\YJH
MP<W)0V8V'E9%88J7HQ[K4#  E2U:,H8 @D;V 0=>1-%_KQ>E7]\#U<_Q <G_
M />WRSV#._$LO]&N_P#1+ON3U7_Y9U#]"R?_ &X_KQ>E7]\#U<_Q <G_ />W
MQ[!G?B67^C7?^B/N3U7_ .6=0_0LG_VY/-*O5)Z36EUSYU<:K?J>WR7A3:Z5
M85%JK33*\XE8?A<]1&'JS<A,@RUY>!BI<C'"DB3?DG@ECUSV5V5.:[4>MUUR
M2Q61UV PVK $;!!&QY!!'@S';3;18U5]5E-JZY5VHU=B\@&7DCA6&U(8; V"
M"/!$@QE[7\\1V;])6!'>:\YT,AV)B=IU($0-8*=5VNA7@[>5_P#G%2%NK;7
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MHV><<-4/0F(=40F4M9BO#N:I 2D'LF^Q"]O6=A#E(M)'LNR-9G7:SC5J(8C
MZ):GQ$TN_7U#S:O;6:QZ-Y%N&:=1\$J5D\*P6\9C*@MYAUH\^0P(R2H]SVIV
MPJQ:-K(2<7!%K^;*)@N>];K72F%C7(PW@4U=P&7K(Y"&%@?5]FXM"!/:T6XI
MQV9D3AO2[0(!]QT6-]M5.QLZD=><K+.1)1\1-'O'0ZYSV*O3V/+32&S6=/4@
M)UZ=@R%&9NI_IQ)W)@D$@:-7K)\-)6;8@07:>0<$?<AB8&&0B8OEG54'6T1C
MY O?*8@#@0BE]D!& 9QZN*Q7KJC-S &<Q'^E<U.V5YV+KDK!HFC'*UP&L=@L
MU82))GB)'O4ND)>2TES?K$"U-1U\>0YOE3A5K*"M&AE*/9EDO&J10&"O#'G)
MFE,:#[D;Z1+EL9S<U>N+1-\'GC*'@*A_/F$F&*>+,D<D,F8YM-9-/SPS:1S1
M;_EVQ^:.7322/;XZ[Z:[8SC")S>(D7=,ZW6N5PK)[ &\/T.@<M2\(@Q3-D55
MK L!MLNCG!9X'RZY5Q2P96VP&6#C?ZT;18G8R;2:1HDH^(CQ$A5_ZV>NMK<L
M;':.!\5LEA<$[FMGK_EE&<.6ADF,8D+8M&*(DXTG?&NN-YR9Y9=L8QC;?/PQ
MY>N5E(H1,F]%4:55NL50/D &  _,)K3/SJT5*\W+K11I43)N5% ] JJX  ^0
M $Q']4SU6_NS^OW_ ":YS_[M^2]MS/QO)_[^W_UR7W2ZC^/YOZ5?_P"Y']4S
MU6_NS^OW_)KG/_NWX]MS/QO)_P"_M_\ 7'W2ZC^/YOZ5?_[DDFT<UH5SJ&M!
MLM20M:;%  ,)6YU@F%"^-3K'JH^V@Z1:C ;)_DP;*LB1Q?;]H(-A?E9BT_+G
M))))))))))V23Y))/DDGR2?68V)<LS$LS$LS,22Q)V2Q/DDGR2?7SN1;+ZO\
MTVA#&'-Z$N&4UC]%H!5?2+DO%KE4)5H$SNO(QAFVD(2>QKZN@T;K<Z2A:FJQ
M7"J!6[TRQSR<D_@ !JP0EBX>(1>N$& !$AU_+"*&'#H.,/%K^W\L4$,>D4>O
MQS\-=<8\1-&Z?R?GO9*Q/4.DU=9:4<N#MH(& ^DDZTM@G9H"&2@K./GK&F$[
MEH!$P$WB)B&/*BUW^7-)KLB1TW]5^*V-[-9;56B;<^PUKS)2UMCEI8CJP-6+
MGGH"FOU8IJ23.CK,=IDF,F2AR:BS@[CHM\?85*1:L1+$^(D:]#X_S?JV:])?
MJDIL154;+G-=/-&CV8)RUUBKEIQH";^7Z@<,]O4T$C8./?4=G N@'+TDCTUQ
MJB8:B\"Y-S-K*UH=/75;.[ QI$L3Z9"1AG&U>I4S<@!/#^0 +>"N4Q2M#^GA
MTP)"0XU@QIAN;B5&M?ZY,?B)H5KYQ7KHXK3=[.^EQ6&2]N(F%L+<&NL&29NO
ML"$UTB%*C7,RD3Y4 V5D30XGA)'Q#+).#+,)(B?BO\QJ-8AY[ H#)ACY?4B*
M34<2'$S["H"@D $\)FTF^VS J0>M*OS&%9D(S+'-+G?,A$N=D20/$2(;/QBN
MVN[;WTY_>0'6U1(I44:.UGI@P$Y4I91,J;Z+$9R%F6=.&<Q9(SEQ+B=%6]'.
MS 1 K&&1.*F\+H]&?#6)1+:C#P];),-$^M[]\M'<W-A$UN=E%5LSB  7UK8P
M_6MR01QA<E$M" 0PIG;N1BB3'XB05:?73FEYL=PL5T!/MFEV6*E39!82H&M>
M$@1#QPII$898<A22161]:V"C7G0B#O7+MU&+ADT*)W3A&_7]OJ_;U^$R7..#
M<WY0QD84E6<LUU5D)UJV5NQ,3H%[$L)D\A0+"9Y!5?ZC;+06[W:#3XG,AM"<
M?*_-+K(G?23'XB13<N.5&\3ORFA-I7%6A>E4/2*U:WE<D8IT8EM7P*2OM)@V
MI"\H"\6,<P:?677,Q(+47(KM*E9KT3GYMQGF/'\V37FE.34T:UL%S-P"C%C!
M7[DJDX2,+ P4.NL D$((,>?D0::1[%3%E;8S,5-MLB2?XB:\ZJZ=^QJ;5G#)
M,92K 19D&VD\D48[<JL6.GRSSQ:9QH5I]CM;F#2&;&T>D\\16N,3#Q;:HFP^
M(CQ$T&U\WKUT<UQR](L$N*TP6-A4PMC<!5M@R1.0;%7SG" 8N-:Q+1/U@+9:
M5)!J1J0-I 3*2!G</9$W[Q$>(FOE5A07:4MQGAEV>H$-EK:V?$\FL,2JV'U9
MDZAD&QGY,TDY=-1;Q3;ZYD'U'FTBVUU)FQLB;!XB/$2-E_**@LZ,WZD+$UQ:
M'0Q4)<<KEC,CB(8+:@F:- T4D^RX5JR44&G+2C(H<;8%1Z?3:CS,G4K)$DGQ
M$>(CQ$>(CQ$BRZ<+XETAO&_Z)QWEE]?0A0K(G=TY[4K2WB6CRD3CKXV3Q0<9
MH%!.45-")K-B"*4DB32/7>:3.UU>1D5+QJONK4G96NUT4DZ!.E8#9  WZ^!\
MIHJS,NA2E&5D4H26*57VUJ6( +%491L@ $ZV0 /A-1_JF>JW]V?U^_Y-<Y_]
MV_)^VYGXWD_]_;_ZY;]TNH_C^;^E7_\ N1_5,]5O[L_K]_R:YS_[M^/;<S\;
MR?\ O[?_ %Q]TNH_C^;^E7_^Y)@JM1JE%1!5>D5BO4ZLK<DY75VJI5M>1+\F
M%SGF9"4*!@UXN2SB23"<P#Q_/+(G(E_/-+)OM0[O8Q>QV=VUMG8LQT !MF))
MT  -GT $RV6V7.UEMCVV-KE98[.[: 4<F8ECI0%&SX  '@"03+ZG\I/AB%L.
MULM@6EY+Z'*%9K(2S'/LAQ(Y9<[;'RH97$4NX0 F,LY2RH48>M5'*BJI;%(;
M&0DJ<YY1S[DB]TIYS6%M34/G?Z@-5*(-!%NC'"9.AUR$'%C6 (:-6B6CQBCZ
M:01_)SMIIC.^WQ1-\)@^I&(&^;/!]1!+!\\:3,),/S8]H_FCS8QG,4\?YOSQ
M28QG.DFNNV,9^'P\1*](/5SEZ+>@;R[6FP[<S9G.:K^I;$2T^2T..$;R,F/P
MC'^[-/OXFED(;G_/;MK#)(X?'-C-1Y($2;*Q65%04:HT<,L"_1@[::QS3R$;
M_66%VQL+/?YLNVV^=96;0R6./X_EACWUACQB./7&$3FLB.&SUY[6R3G"L9^H
M8IB&5?:%)'H$#,28.8M,Y!WC.4M!XYMI0&84D18)6L10TL<\4>^J)7R7U&XZ
M7^FI&0EB9%TRO05VHFROR02*Q$ 4T)2M*_JFC6"IW"##<N!.6O&'B'CP-+,,
M08+ 5HB3S4:HGI%>7UE%H5JN7_5R8E/-)9,3361Q+5LT9L3))2CV;=J::T9&
M3R;2$G%D3;?#\_Y<(G2Z!2%?2*>[I#LQT"HL,$ C*9 SE4,I XC!BYP<&0Z[
MYV 9:#Y7. 9HY@VJ@HY6=#.$81%NB1?%ZS<K#9R6-2 UKUT(1#U\Z^5=M-6+
M<S$&-KAND[5F@C70L2)<U-$&5H6)*"8J"PH+"F6[[BY1K]MF3-6:ZGI]<K]2
MKPGV]!5DBJNHP/GD%?1)T@ ZQ8)]27+.61],$+!#\\J>8B7\GS)Y9)=MM]D3
MBME847:JV:FV"&4A#;:^YK#L>&>06:=0^7$JF4,1,.VLP\LH9<VD<\6VLD.^
MV)(]L;:XSXB1M=. \YOH3X%^(YQI9K87<79"NP-E!IS-ESW3E#860Q>3!/A2
MUYUKM5C%VF^L6H>^I@F16PH+ 5$FG&,8QC&,8QC&/AC&/V8QC']F,8_Z,8\1
M-?LU94VY9&G=PRS@Q.JR_P!-(9Y!]\,JE9%-L22YDBSKOF.!TE GFASGY9$4
M>X\N-HI=]<HD$:>I/%M=T^=U#PD="Z2M5*\RT.RUH(=:GW)K-:@ (+D&BK-=
MGE)PH6QZ:2C!GME&2Y$KMRM/1++^(FIW&D5N^K@U-I ^YK0V<#70/:66*&8F
M <H7$96L6VN9Q9!S28IA]\_+ETD^&V/V8^")$=?]7>4UQVML@<%J,>!FI&#)
MDWN-A:DVHJIX@Q29+=L8;)A_^B,"BXJV"L?^3LCZ;2?4[[S;2HEB/$37[165
M%Q1FUU[#+.K/V#W)BAGD&DVV .&8C?EFAVUDT_*4)!OMC7./SZZYTV^.NV<>
M(FK4/E%0YP=8V-9A:ZDV66#4K[FZ9-HEZP-K87BZOI(#IY8E%?5M[;9C5JL3
M72(/+D@6+; ,  HB))/B)K=HJ:2X@A+GXNQ88#Q'8H(<2[Q:Y95UF,W6;38T
MSCYT&AHL.TXTGQA(BQM#+KM'OMC*)KW,^6U3DJ,JOU+5OD(TX0XF=X[9/V$N
MZVO(JBI@V/:$$$?3*:M6*^B"BQO\<B*X2"]RF)!QQ2)(OB)J-VIBZ^(Y$+1C
M8U8LDWS=BJO86M;8;:[C$A$"S%*R(,E@EA&%#$ FZ$BYS)&9%%$R"7FB(F>4
M*EZ)4L1J!= E29>$J6!19WVC$7KAH@PA8]I=MY-M!QH8HM,R;[[YUTQG?;;;
MXYRB9#Q$C;HO**?U&)7!:X6NT:S[D-G[2Y8I=F:1Z-&'8JLYW73P;,ZQ8Q8!
MH7:<C.1S<"";YSI(/'OA$DGQ$>(E-;WR7W1=7"PM:%[AT6C4X]C*17:BQ]74
M]O.0+=L:XA7$V:?J:>9U+%G&V=CI%@6TOYL8S!K^7]MZO0% :AF8#RPN*[/S
MUP.OS;GRF;TSZ6795]N%]*</#Q7L+48K_1VG*>BOQI&R&ZC4;2/)YFM-[UKQ
M-2_H1]__ ._=SC_!TB_^,GG>YC_B[?\ ?G_T3-]Q_IK_ -<\'_\ 16C^U8_H
M1]__ ._=SC_!TB_^,GCN8_XNW_?G_P!$?<?Z:_\ 7/!__16C^U99OHM6N[[A
M]NJ*VSM-NC'<W9J!+5591Z8R8W'""2'1@HFW)*CJF'+C3X:2#L=248YFVP#D
M0L4=I#0=;.AH;.AO>A\!OXZ^<^PI6Q*:DNL%URUHMMH05"VQ5 >P5@L*P[ L
M$#,$!X@G6Y2_I'*_9%G=6S!0%U-E7/G6[:R#USM457BO(C6B5Y9R0:CC?TCI
M,TZ?E]S&8-KO/)%3,O=="V(<E^G:RKM^?M^W[?/^6R>C26%B.G4CN"8S6\"T
M&%J9#I\N$MC$+%H<3%'^73\D<Y.LLL>GY=?RZ[XU_+K\/AA$U3J:A^_YGT!)
M53FBVS-J995]?.2$1AN!G):<R!;*L+E;(-!3L&;PX&)^_H=X)<ZRQO$\FFK(
M9$I;PKFGM!7.IU5WTDQXRJD<%HTU&*MS#[-4JDQ;]68)*XP3:=EM\KN\K\L^
M<!1;L NA(QJ[&?#)T0UK5JMF%$]#_$2)^XHK39.86-32YG,5BEGKA8D5?+T"
M:,155I2M6Z2(G>X<^_(,_3!,$C'2.\50B9:P+@&?+2)(B8T2-N$47KU69*6'
M2[&^>;3<5YZA9CGV'#%2KNJ9M9Y6XP2[9HU(E:85'J(WEI/8OV-@+BUQ/9VT
M 0>HZ):'Q$KA[/U7IEOH*E9S(A]H7#;13;0OJSG5!9'-9TK]D&B7J&FUVYOJ
M/)!;2JJX88_7%?VE3*F4<<C.7;1&T1.AQ.L=02]"Z,WN2M^G0/*]2X(@6U_8
M7=%)<U3&WRV%U1<M;C9FP2-V V3Z%#MTM&(6QJDJ,)4Z$6;.,(EGO$2O/LC7
M+Y9J6O"YPNM!-M@=CFI65:NDE1A1,Q8I)0C[/%^KZ?"[J<^^FZUQ#G:U&*M3
M87*ZBV@L+02-$_/ 4=S5YZ*?;ZY?*A&YM\A""N7:^!]#S$H$AV$C=!NX+Y=Y
M(#;+)ILX;IX(ZNE1;3@HE"0O*LZR/D2Q'B)6#OU8O]JLW,0*4HZ0*/ R(,=]
M#H]^55X2F#B-:\9$(PIC2\5H2W[V7 DJXY@<@N,=>J>EG&6HRVU@'AV1.]ZN
MU7J52H+<#JI+/=B3:MC*XN=L2&CA-7(ZK5%DXK(LKH_7)=B&5N6VNRZ:_P!(
MMDUU&?09URGQG]/*$2R/B)7SLM8O+!REL56BO%A5*Z/U%6XHU3O8=$V?'MZW
MC2O1@M)F:'(-F.9PZ+DUH);::5#>39F#.HEF-,)1-LX@HLB/F%;76X1^NL.L
MCXQ@JLKF&PM$V6ED<-!46CR&TW3[HH1!FCIZ\819&!TM?!6;,= #OJ%H:)*_
MB)%75:W:K -1Y:FU> %(>F4%ZV#4N(4PK6M!65=FSC.]MMH9F:R)!LRGRET*
MUB83ZPZR"'31#1:HDJ^(CQ$K+U6J=.<=8YXWJVEHD0 2U7/W)/<]$-:JN5M_
M5MNBR76KYL:O>YQWCG,153J^D5=N&4;C6<C>*MQ';N<HEFO$1XB5E<U/IT_L
ME6[0'I9\T0457L:U@N>@M+AK\%.ZHM<U(VA_J..1A:&-Z=\^L\%@Q4"X=U*?
M4:6SA2)!5!R)9KQ$>(E9*[4^G"^R=PM#'2T8H!J]QA>Q*N>IE.+6%5?C8-=K
MRJBXL<\BE^FM5?Z>Y-<[U1=#D.P;8@>LY7I8*U$LWXB/$1XB/$1XB5?['SCV
MEMEK'9\8]FJCQ^I:)0Q"*J]X LZ>:0[B*.D,<ZV,SH-7EA@+%F %T586[Z#;
M@R$8*ER9M'#:C5*"'J+G>P184T-#QH*?CL[W\=?"?/=5P/I%E9*V=)^D&-TK
M&%*HV-=T2OJ+-<'L+7"]\W'*JR-6@J[9"E"W(\R!%']"/O\ _P!^[G'^#I%_
M\9/)]S'_ !=O^_/_ *)YGW'^FO\ USP?_P!%:/[5C^A'W_\ []W./\'2+_XR
M>.YC_B[?]^?_ $1]Q_IK_P!<\'_]%:/[5EN.7H^@UNCI4W4[ZMZ;>A,L<NKL
MHIL'/U[C!#4TE;B"I#.K# KRN4S JY<Z-ROKI@I&.V(-B]AHJ7*EB44HOC2E
MN1'@;][0WL[/IXWJ?3].ISL?#IJZCFU]0S$[G>S*L1<%+>5KM7QQ5MO6KMU%
M*SJUN;(;/=Y<15JM<_[(64<]C ZK1=X.W5=^'2K/UA?9DS:F*BSQ&KAD[%O-
MU8SZ6(4C=P[IX>M:KBK\R),IJ;PVOD6)O&;?V^'U_M]4F3UYK_8JZBN\':B
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MD;<W"R>W9EXF4^0M25V6T9M%"6FO:K8:FZ=>5<IQ5CW&#%>7C>IMWZ4]U/\
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MB7R.(ZV3 DD#NAZ;=NI#<JJ:0^:*&C58H8AC-& @<R)K],]@.6= ? UBJM[
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MH=+%CL>CU%&RJ[54WW'C2K6%Z]<PH+!D' #M'CIE("B7NK:YJH0)UCQ^3:G
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M&LZ!'+SL;A9B$WEL:X<P/9UKRE04MQ8'N=S&N:]2Q4\0U+ !EY[8,O?T&[7
M]NQ$CCEK.LRIS]N<*=*W;$;T!_B.+[7#=K#M:["O;)]IM9\'DHJRE-UCDBV'
M$WVAWUGYNCC6.-H;8[K<T92N_/;7@I4Z] SL-^I$CO$*4CAD*X8>T-W*G1DW
M[QIK[2%6UK0>QQL>3H^,&4Y]C0JBA)%YWQ:PWJ1J9%:5&_8;O5*N"CUDFP P
MKKW/$;:T<-YHL#;%I6B&OA#2;SZPV O6*/::07&+L#9>M>AQ;LUNY;XAE[Z!
M5'P8,Q/^2-Z$PF";7!ORDI"@UM[+598SZ\JZ>UUJB@[ =7<D:)0;T-QP]O\
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MJ&"5X*PA'9D F%'5M_8*98,&K-M=EYHUHI[1%9 BPLZ:ZCDAM8)HX\?*QO\
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M]-GFS<%F"$Z2\6Z@CZW)J Q8BJQ7"I9$@KUK98AG,B);KA:Z3A,MT*82,2Q
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M -+'.B!M(*6C5)=7R@!,2K!=Z@AJI$<,^=FHIS*#ZCRH#;6$X8TPTJJ;U%1
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MUUS7AUFYN9!M'$/4C"OI]8R]TFF\FPD4.RO;WS86\M%"M0KX[UL6=_D3^3M
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MYAD*,P70N-6_#UG*@+V52:B;"E-I[VU/G\'3:XGSZ[4\AZ>/=/CUG>SU!?9
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MB^T LSP[!R*/I!K6O3Y2*653^J.1\U*E6XWN4);!FW""KZ]\D36NRUY.RWQ
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MM1R)T2U_B(\1*F^Y7_FRYU_VLO2;_P"VZXMYOZ=^[V_Q#J?_ )=E31C?AO\
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MDV4@.O)3W =KR9-^!X]Y6&CH^/3TFQ?UJ]/[N7M;_P FY_Y[Y#[G_P"F]/\
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M?^D_\$YV?\[3_/\ [H_K5Z?W<O:W_DW/_/?'W/\ ]-Z?^D_\$=G_ #M/\_\
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M(Q$ *&J.$0M4W!DK,:NVV,;='(LLW$+<MW!(RPD*S("[]>.6SQ2$S$221*&
MY.\\;MI@E.Z_7^WU3J!^AWKRI(Y^>F0O V7*YJ(=0YB+79# E37F-0I-+HS
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M;4MMCMB- >EB9^/C5&NWI>#FL7+"[).8+ "% 0=C*I3B""1M"VV.V(T!#_\
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M<O\ _C9YWLK^,4?79_[<S?\ *_(_ZF?3/^C^E_VS']>:P_W$/??_ )4<O_\
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M='H =C>#!!O8G=KKSH5?'%$)"RJUH;UZ?6/05Y:5^N^V%VFY&BRT61=$3O-
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M"8(ILZYDCA(D$%WGCTVQI-N,/M)KMM#'G5$YO$1XB8^-2JB9D.HEB^-R6)
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M7&GNCZI8A0EP94YTDRHG38?7/R_SHFSU;H=)N["SK*C95-D*IK*%-9<IBXF
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MKF=!$J%=*XUEQHR<=BU<;P%]<O._3Y%%1Z6W'(N?QI$-2"L,-SP7A+6S)W-
M@.>KQD+='K^Q$V+H_5/;^&]](K-3YL*/S\:)@)5[H-1G]ALJ[:!7-& 3"KAN
M:-3:9+&]G5#@%)'.N*^H8$.[$$L(KKM1"B:+4^\>VC'G1\E6YT#8FX]KNVB.
MTLDEG?UIK2DUMTKPS(EJHL31FQ?%& VXK0.NKF.NBP%24EK$JHQ$N;HG>5]2
M]^16)D.>75AO 6JLEAA'L5;=J#H'9-49.%5'5SH["SJ\8=:/TJX_U[ZUA1V<
MQVXK +[=JB9-P$3<V+#VFEYKS>R)LN&-J7=4[0[M"IA3F2*=W2=3>FZ\WD.J
M/ZX#:B*@E<]7;+J*98\FOR1TB$\Q.5))N,B;:EL?M%:>6=896-+'7+ ':DB>
M@KZM68Z[<W?-A-ZJ?:[LLAL]MLRP"\6JKL['K5*HVP/'2[:M&2O#VTT1)$*)
MK@>W3<6H3(XWLWM1](*]_1+H84DU:26/%\>;W?;JF[3&S2.D[57>K0U^/JF"
M77Z9AM\HFVE^DK&(T?M^W]\C2+^N*UKA%+IBV^)KS9T5"BLO1^F7",*N5#HJ
M8%W8N@F*%X]%L8PJ-TV5KZH'I0=[!0#TKI1HI 0,]; R@1+&\*L5\ME\N#^S
MINL4M>96T.Y%,Z,";(NBM16(CVVU5/A4"U9<BJVA6*@M@1,BV5LV#962QP[R
M0*V[=$M=XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB/$1XB
M/$1XB/$1XB/$1XB/$1XB/$1XB5=]L_4OD7MWRJT4'I5(H;^P3TGH%=YO=;E2
ME-S-Y99;O7)$L=SK,#',! C)8;$H;9PM8JR2YDX6F#QI(H9XM>'F785R6U66
M*H>MK4KL:L7(CAC6Y&P0PV/*L!L^#Z'T>F]2RNF9-=^/=<B"ZFR^JJYJAD5T
MV!^U85V"K#DOO*P 8^Z=D'&\N]*?7OE',JMS&J<SHU;3*Y5;6WC4NHHZFIZ/
M9AJ SYXW<W!2$)+HT^^IG3/!D91$Q>WS88Y#YHXM\30R<J_+L-EUMEAVW#N.
M7**S%@BD^@&_0:'Y)7G9^5U"]KLF^ZX\G[8NM:TU5LY<5J6]%7?H !\="=6N
M^EG,:P2H(6VCI4VJ.P5^WKXVCY&VEQ;T)_.R=[,:T85B=XT9/%O+JF@>PLVI
MBHA=">P"6K[0?+8<9YBF<NWJ=1>A&.Y;1:K\8M96W;H*6O:%U&)+3.@8RFS!
M<J]IBG;,3V@NJ;6(<"YLK97,#,W DJ.44_:'1$TP_P!#>*--QM6!=L) TAA'
M8)\YI4*MO%HCY\D)^:.-289$LQN>8U)ON549ZV6 Y#F*23JH)_I=$3)O?2SG
M%HE'+LMNZ"^8Z#+PCCF?]'9&K<(+]>P$",$_]'>M<UA;*NA-$C+"]*!OA>N5
M3+]U[;=TS<HDR\FXS7..B-P:ZVL305IJ@$'BL$R6;[*DJB0:N5E MD4(TLLX
M"9(&*!":\W<6 [6'4AN[8F;2$;HDN^(E.?9[TFXM[/35AW;*+SN6ZHKMRQT=
M=+!04]G?.*-0+VNMCOF\QY.XAL:*X*H7%;+CD*(!&&>&2SK&$6\PD]U5]E6P
MK,%*N.(8J S*5#?G4Z/Y=#R/6?+_ $A^B72/I"<>W*PL!LJG,Z;<V7?@TY-]
MN)@YM>5;@%WXN*,NM;<=P79%6]V-5@)1MV=^K7,C$%;I]1PRY/2*Y3>A<\UI
M7+0JA6ZVRH_4VM><WBN3AE51L0F@<G5P>;+.H%UE^)*<T)#;P&$QDP5,Q8EF
M)8GR23LG\Y,]_$P\7 QZL3!QJ,3%I#"K'QJDIIK#NUC!*ZU5$#.[.0H&V8D^
M29H&_HMQS\S?(K*Y ?="2)8?HMZ7'NK"_5<5\4)AII:3,0S5UN[#!V5-':)K
M 7L4+LM;F-J^Q<IV7)IG:_J1<GRKE0[N[U^GY86\648Y=26K=);3S_\ HSO!
M44:FF@31S76J9V%:1:3X#2$[R%482I22;XRB;-0O5&A<\M%=MB>PW H] U+L
M1 AD=$#6V*TDI+Y6M+*\'KU&12QLA4'1;"LC'0D(TY>/HF#54Q<0S,2$2S_B
M)%O7.(<?[Y6A*;VSFE*ZI4P7(UA#KM[KRZRIQ7H8AX C> !I 0/&P'":,1(2
MM=,2QP'%1:[8TFWQFZG(OQG-F/;92Y4J7K8HQ4D$J2"#HD D?,#Y33BYF5A6
M&[$R+L:TH4-E%C5N48@E2RD$J2JDCT) /PFNP>L?KP+QPGUY'XKS6#A9DF92
MN215%-IS\B3:PQ6S;>:KZBX52;9LT$+[.VPV<Y:Q:&__ '_7&^)'+R3>,DWV
MG('I=S;N^%X?A[Y?@>[Z_@^/23/4,XY8SCEY!S1K64;7[XTG:'WW?/Q7[GK^
M#[OIXGXH?J_ZZ<NH=RY?SGB7,Z1SGHD3*"]TBL5!,GK-NA<I\5]K%8$X0L03
M31BCQA29J7%)B<#'TTGYHO\ 9\6Y>5=8EUN1;9;5KMV.[,R<6Y+Q).QIO>&O
MCYB_J.?DW59&1F9%U]'$TW6VN]E11^:FMV)9>+^\-$:;R/,^<<]7?7+UY+>G
M\+XCS+DAMG'!$L17/Z>FJ\[L59*3,N'9R*A1MC(@I3"I!M)L[ZP[D3;:8QF3
M;X]OS,K*"C(R+;@A)06NS\2VMZV3K>AO7KH3N7U'/S@BYN9DY0K+&L7W/:$+
M !BH<G1( !UZZ$C3H'=NPU.\W!(NY=";3%;6%(EN&%5[<["XC6\*8,+2Z55Q
M P(:(=-NK6L$8.NYE+P5SAI(4;"']\)K6:8I'YWL%["Q>N3?H$_-34W36UKN
M2H&L24B^L#>;JLT2P7"F1-T:ZL-'=H9S- J[2H7$"(5,0^M*XHX#78(U$0B:
MJU]L?9.!R^R)ZZ6V-+3;'9D4X<U4?&-KE"'#= E#%24+G5=&'$+5P>B338V"
M^]*'H=67:#32)+%:43)R>TWL.RA7%!<,:)9@VB(AC62ZAT<UY9$$R)"=\U8Y
MUK&M*1_K*P6+-44:$V%D=5V%=9EGQO5NS4NM(FQ\P]C^W]&O_*$3SDCSG5>=
MMF,MD,:U&X:RO%&M*Z\5^?0N9(=7J<*@LU6I(I\+2T9;MCK(HC%D#@+^U,T3
M%P>W'7SIWNRGBA#Q6L>60)8X5H>I$!.F%=M%TKD'-!98://'K<K$/5ECL.[Y
MDSS-/#91063.3<<,QTB:K)[E=J<\K%LR3C#J9O<*G =4'-9IO3&ZJ!ZZVXCL
M.'\IM28-9]JXKZ5>FF[HN+-0LDG.)]53&;XO%ZA$[4GM-[#.;,T4+N-VQ"DK
M%HF3SGFT*S0,[@+.HZAH!&E,,7L4H/R&-!5."G)0>@Q EL5)ME:N:98Q>(DA
MTCV/[G:2JU*=Q'94H)>UD&SR$JNBJSPQK4YX^C*!5BV&I*)9#^>F=+LVUN;D
MCY1L1^9/)EVZ_8EM%442]'B(\1'B) M6]6_7&D7^3JU/X?S&L]*E-=,9;TEI
MZ5?:9#['&9$_+V<C"1F[$.(F!T;&7,OYRM"R-9L[8EW^-AML9>#6.4&AQ+$C
M0]!K>O'PGC8_T=Z#B9QZEB](Z=C]09[K&S:L6E,DOD!A>YN50_*T.XL.]L&;
M>]F?ECZL>MS;I$?8F?#N8']5B>J[/%T(NG)9K='8DN1,J'6KW<3)^K);D +(
M9>)OG#Y%@^7OK\O7X!;8%X"QPFB./(\='U&O31W./]'.@VYXZK9T?IS]2%U>
M0,YL2DY0OJX]JX7%>?<KX)P?>UXKH^!/O1O5CUNZ_9HKIU+AW+^@VV$$-9%8
M[;3DKQS&O7RSS A:'GB3$:C"3$D200XW_)%O-)MKC&=\_$MMB#BECJI.]!B!
ML^O@?FC/^CG0>J9 R^H]'Z=G92HE:WY6)3=:*T+,B!W4L%5F8J-Z!8D>LVSK
MMR?T*F[/JTAR]/\ O5>5RZY76)P,H7-6XH![XY345;JS,0U0TV\\HZA;/)KM
MG0@V8!7 >Q$KGM3S]1>V_M5)4*\Q/]>+?NWK0"N>X"F4NP:L[R1KQKI#SZ-1
M"O"AT4E6R^5VH$ $84 ;(\V06IDHB#)AB#$3?9/:'V!;@U?<'C9]5+.><\U9
M#-:1T=L>TK#3K>M8M-@72*D9E0KX&*@'DF4%[<)#DN[V)WHP9( 53:RHG)SS
MV?[YT9USH!OQ&Q\I#=6^NP.MGM3N99C-(P&-*L(,,^*X;7ZM^BB8!4S]A8W:
M^9U*P#+4Z)6D3&K"HG,Y]M^OCM;H-7.*$6E77+?T2N@-%*'J1HY9M!M73*TM
MILI*^CFAF6CH<M%5:IWR2=C4*B78?H[85&PQ75]J1.PH]M^GLCUXV>-MS4[^
M4(--::_5>G&*87##HW/JI)7C9C*;"/\ 4I*A8;3?3[3#-)1S04T8ZMT5$L=E
M1(D6K?;/V<;+0%^>.7!04@6+=K&]9\VLXQUF-_HHZX4>,HCPI-5 &G=$J5'(
M7GR)HA XK>J63U\Q6T3MW*),J#V4[N[M585YX;((@./2[6EH4JZ,MG0:O.@<
M@I)M2'U=5%9"PL=#"Z._M-EL@WSZ>Y64H[1'/%IH_+K*)>_Q$>(CQ$>(CQ$>
M(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>
M(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>(CQ$>
M(CQ$>(CQ$T#F/_T'"_\ X9MW_P"=[WQ$<G_\UO-?_P 0*;_^;JWQ$W_Q$>(C
MQ$>(CQ$>(CQ$>(CQ$>(CQ$>(F@<U_P#H=8__ (_]8_[TKEXB=KG/_P! U8__
M  5!_P#UV\1-U\1'B(\1'B(\1'B(\1'B(\1'B(\1'B(\1'B(\1'B(\1'B(\1
&'B(\1/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g556103g01a21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %-2^4S(X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?57&H         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             #K   "UH
M         0                         !              M:   #K
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #K
M  !29VAT;&]N9P  "UH    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,      HA     0   *     T   !X   88    H% !@  ?_8_^T
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MIK;&UN;V-T=79W>'EZ>WQP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MO.%RGHIJG')\MKH[/DN2PL=(3Q, S-MG!! (1.L),ZBB>,N48M F6:Z706<
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M8*[/-+;GUD%">8+R*UE89T!4=ZWX5-*V@90-U/RJK*6IY],%;HN[$6%2=@
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MCD'5'ISL.$FL? 1S(/-8=@8%/"T9(B%5,A*ZAA%W9GD/]80\OA.,N)Y]P[B
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M+88;)^-X:)Q"JSC29&/EX.=1B8F'PKS3'H:ZEUH&0RTI864ZK556U5+=1[
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MY:S"Q;ZLA2K+R.^9=:H!( ?=;*VT+ ;T3L$#69%M=E&&BMMJJK$L&B.5C<[
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M%5,EO'<!\GR=LMXE;F-PS/RK,S(LQ'HYJ[>@R64TU*5%*],UI6H%OH\S5J&
M%7S:&LX>S9+6MCWV-=8U)K]%BA#(B+H5@*551Z?;90 @2=I:!=^]>2_D;2N^
MN7XMS[K'EO>>G]_;AWDWW+$I^'W-)-!IK$87&M*0L @G*Q 6;RNP\T?>SI (
M[BP1%T%QN2(HIY%=0MW".'5\0RL3.LR[\[%R</&Q#BV4MBUY?HVV95KGIL]5
M>T04EQ8Y#;5=ZBA\3&7(MIO:Y[ZK::JNFR&M;>S-:S'1*+V7D+<S=^PWJ/\
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M%RZ+C>KBM@ANKKL5 XK.G5B48E9D.7C.:JV=A4_#*<2UU0DU6UL7#<IT756
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M2KMW(<&ELWB[>K:>$U9F)P],:^UCE\>R<"NQRRU>;K5CLE_FY.DM*V%G .R
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MLFIY[%,4R(!]=<P*?2!@HBU=)CB;)'\?#^/LUXRFWGAEP]\%<19YM>1EHA'
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M$MUQX"4C(F7+2)%J%,KM')%I>.R8O&5[N%F.637*SAP'5<I63RO\%%9/'/\
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MTBI]A[?1V/J'N'C[-ZF^V=K^7G_1[+^_Z/\ -?*_V?-45J/9[>P\1\?R]R=
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MC?O'C]O;V=Q-Q1Q ]M/OW;[_ )/WZ ^GUSYW3RM_X-_/_P"S?W^WW>_V^?\
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M8 Z]_>8,JUJ,;(O4 M31=:H;?*6KK9P#H@Z)&CH@Z\#/-K^/1Z#_ "0:;_\
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MQR1,.[R<2]5C6#,K!$F,>/DG&PQZ[F"M10,P5<R)(<,>ND$0IU7HE ?D1<S
MBT31Q?.7K)[!-B,C8D.+%AS1.5G(Z[B:)\#!1PF0 W[^?&1K"%,VQ9@HX/)V
M=)?"1/D1ZJTJR=NV:<KLKF--$A!)R\$2(*+MA'I&1B,M?@S1<*T$3!"(284[
M!2/&)/C.0HMBD/?7;N7+5-9$^;GKCG]D&=GG4X>H#AV)5P3LI!=AXD1(H& C
M$J+2<P&^2?KD1"V,=FL0,+3@DP:P_P!!E !7 WE8LRLLB20I$4B*1/+QW?XL
MW7'/?6FY-.:[?:\2AD(+@60-,S"DRA/% C#HX;<V=/[DD+N,KOB;J^&5TL/@
M)733\K_ \[[[$X=C78]5CA^9P2=/H=F([#7L$\PX_P"5G%^'<7S,+&;'Z-#5
M"OGHYWT]%5AVW,-^DYUV\-"1&_'F=V?PGJG^;M+]KU(^]6)[+/S_ .Z:?\.>
M._RL3]'_ ,<?CS.[/X3U3_-VE^UZ?>K$]EGY_P#='X<\=_E8GZ/_ (X_'F=V
M?PGJG^;M+]KT^]6)[+/S_P"Z/PYX[_*Q/T?_ !Q^/,[L_A/5/\W:7[7I]ZL3
MV6?G_P!T?ASQW^5B?H_^./QYG=G\)ZI_F[2_:]/O5B>RS\_^Z/PYX[_*Q/T?
M_'/9'%B#@M&8Z5>7PN[)@A!!U=/'X"=W#T>W<KW3P\[_  ,+JJ9?!Q\[_!Q\
MK>=_*N:8:9@/ $@?D,]DJ8O76Y\61&.O#;*"=?E,[VJ2^*1%(BD12(I$4B*1
M%(BD12(I$4B>,E]XXW=+=Z\03):J^+0=.$</A:\2OE\!)7/#'SOZWMYW^#C;
MSOY6\[UTHX5B$#M9X#_/_NGC)\N>.@GTL3Q/_)_\<XOX\SNS^$]4_P W:7[7
MJOWJQ/99^?\ W2GX<\=_E8GZ/_CC\>9W9_">J?YNTOVO3[U8GLL_/_NC\.>.
M_P K$_1_\<?CS.[/X3U3_-VE^UZ?>K$]EGY_]T?ASQW^5B?H_P#CC\>9W9_"
M>J?YNTOVO3[U8GLL_/\ [H_#GCO\K$_1_P#''X\SNS^$]4_S=I?M>GWJQ/99
M^?\ W1^'/'?Y6)^C_P"./QYG=G\)ZI_F[2_:]/O5B>RS\_\ NC\.>._RL3]'
M_P <?CS.[/X3U3_-VE^UZ?>K$]EGY_\ ='X<\=_E8GZ/_CC\>9W9_">J?YNT
MOVO3[U8GLL_/_NC\.>._RL3]'_QQ^/,[L_A/5/\ -VE^UZ?>K$]EGY_]T?AS
MQW^5B?H_^./QYG=G\)ZI_F[2_:]/O5B>RS\_^Z/PYX[_ "L3]'_QQ^/,[L_A
M/5/\W:7[7I]ZL3V6?G_W1^'/'?Y6)^C_ ../QYG=G\)ZI_F[2_:]/O5B>RS\
M_P#NC\.>._RL3]'_ ,<?CS.[/X3U3_-VE^UZ?>K$]EGY_P#='X<\=_E8GZ/_
M (X_'F=V?PGJG^;M+]KT^]6)[+/S_P"Z/PYX[_*Q/T?_ !Q^/,[L_A/5/\W:
M7[7I]ZL3V6?G_P!T?ASQW^5B?H_^.9EO"+[LWSV<]WNANIU$W">O6NNEH[\F
M(Y@ OAG)EII@3],OB\=>E6RQ!,/B+7^!\3>RM_WWQG[W6<1Q*L;I=+F]/GYN
M9M^'+KU#VF=GY(\=S^->?>>FD^;^;]/I5]/_ "G6YN;TFW\A=>&N_MF:JM9.
MTBD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12)1NQ8G>>Z^G<%Q?V
M%932&R>)V*7;7>V&WD81\'L_NSLX:7=V9W>>D7;6=-KKV3^*](1^'\9C?6W(
MZ/K?(ZMK>M\I!UO1UO7CH_1,.35YQCWT<W)UJ;:N;7-R]1&3FY=C>N;>MC>M
M;'C, _XA5[_;2M?YEU?_ /5*W7WY'\W/UH_LYPGX"G_I0?H9_P#^J9_)7#6$
MQAA6%$WYD>S+"L1N9:.DW((\.63Q3R:E0I5IG\>.*#W:*#YBOC\;@FY03LND
MX0^,14T9.R3[3N>@ : 'L 'P&I')AQEKI*0)3$W+MC2R:9S$5.3$K-OH:Q?R
M$X#EFCY:*R*"XG"(S%V[9HXY^@0O+ %'PRST7F>4(N'AHFF89TE9;28\.J2"
M6$6(?8!2/ZBF,J?SO8D<:Y,\SLCDQ*3;+EKW+)9R"=HV\B>P\&H9\S("&PH)
M'QK(W'YB309'&")?#5G*>L-/3A].XAD93?O&TE1P'.T8M@R;.ID4%G)235)"
MXN,E9QZ7,B[D4L)5)#X\#F3+M8NQ!CGV3+!$H4_P[KB2QYC$"\\VL^B 1MB)
MBT0)%(0=B42C23"4C6L>!1B1P$P!\V#*6.FPZ8E1Y39@]N* -6<X0:"44,D3
MN\.--6I1V+QYN;GC;Y&/RYF,F42X2QD7("<UUWL)J?3S4C:@Y=^"EFKXJ1$M
MW8U<0JFF_8&Q9D>^4:XHE-GN#M22AW*B$BDNQC12= Y&*FILH_AC^124C)X=
M(X(^D3B3.X,M(A#II'9%Z((BT9*@M:BL0,90:05-B&1:9HEXMM<]PW<CB#+2
MDD?;(P)W9Z+9C$XLJFX<X$ )%%WZ8>BYTM'3#14 @@QE$%)1&6L&;XJV9'D$
MWN5L$2A@W'FM1B88<^DFR)-%HS%34!BL'D,E8JQ&-0(W&I+$7$2$C!8,4M9J
MD E+X=8\^>/9F_:L0+0W)RK./B&S1$H93P^=(+#F+1=_)U7S!$Z-2.6#ZF;O
M_D])0\3#&0+=@TU<WC0G-VG"8^0QF $ )V2U+H.B32;(.'[RZR4U_';P]GT2
MNI+QQJF5-!;$@0F:* A?::[2S(L)1O\ "V]L939\GP4NJ!7MDFUD*N3<+;&V
M%V@FV+9WD_<VN\NE9;;<O%2TR1,I:UG;Z$.IW#I/K:?&GGHKXJK")5 ]5Z\?
M#A6.09TQ68YAM31]^2%Y-Q)T@<^"Y"SZ(B_6P4\B3XI$4B*1/"/XL'_"$=)_
MWQ1+_HVAE=9P_P#WG1_1;_3:>%>5O_"+B7].C_TE$QWU,G.12(I$4B*1/TG8
M'_N'AG]ZD=_YH9UQ+_+;^DW[3/I.C_(4_P#55_Z"RJZMF6*1%(BD12(I$4B*
M1%(BD12(I$4B?FC%?[*$O[O>?XPI7;KX#Z!^R?-#>)^D_MG JLI%(BD12(I$
M4B*1%(BD12(I$4B*1%(BD3TJ_P"QV_[*=7_W!IK_ !C9E:/C/_$?]Y_[9Z9]
MSO\ YU_\'_\ (GISK1STR*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B
M*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1/"/XL'_  A'2?\ ?%$O
M^C:&5UG#_P#>=']%O]-IX5Y6_P#"+B7].C_TE$QWU,G.21XODW>Y>!:MV.VA
M3A&/;KV@'U%JS @Y;C"<TEIZV>(I42R?YM__ )//7:>8YO(G*K<4L^3721<*
M8-G2J. Y%(>Q"_>JLV6:!(15\=D;](#N5&SKU=QO9)PC/?'Q<D4D5YN4F'BA
MF"-=;8#R%0VOQ3$%182%+ @$@$BXV/!FY_EBC%5I!I]N+7UW(=H8[(6VC'KZ
MM3BD3FJ6N)(LZFJ.:K%D^#SI;",.V3Q-NI8GEA@E=1)5%52SSRKEYM6;YU3D
MY#U.9DZBZ7Q(*>D"-]I*_!_.ZW2-F&$\VLRO.3E5^:]*F\8UI-XVH9+R*V5@
M#S>&QHFT,\YUV% H]'Y8IG'IA&I0>VD"!F]>F+3$:_MI]X$9S$Z@\%M\D,XR
MG>0#70X[@IDR>LE%'5\D4\/WV1+ZW9D[HRK6Q#CE(ZN^4=_\[L05\0>TAY'#
M<G'JKN/3NJMLRZZWQWZRMYFR+?8"HUTASJ5L\&7OV$L16::^?I.P/_</#/[U
M([_S0SKB7^6W])OVF?2='^0I_P"JK_T%E5U;,L4B*1%(BD12(I$4B*1%(BD1
M2(I$_-&*_P!E"7]WO/\ &%*[=? ?0/V3YH;Q/TG]LX%5E(I$4B*1%(EQ]3:J
MENZ9T+U["4Q=S9)F>*J.CI=@ !"0D6 DI1)3ILT3519#1(*/!R99^Y6SOEBW
M:9X()+N,TD%+++%J0N^] @: ))+$*H 'B22 />9)P\2[.O7'H"=1EL<FQUKK
M2NJMK;;'=B J5UHSL?'0.@3H3N9YHG9$ V:.U&\$(269'T(>\B3:"/49FSFP
M_8 H8;A!"'NP5W5CK:3C#(UP*P:I^EJY.L&RK9%WBHAA:EU;UFT'E0<P8N.4
MH4)#AM^'*0=^J7WX&3CY2XC(+;K!2:10PN6]<A5>AJ37OJ"U74IH;.]$ ]I?
M9IP!T8MLF6ZJ>BX8!D\&$:Q(2=>1SR.!8^.*[D:"E];0[&0/'> U[+I4\+MQ
M \8P6<M\B2#WX3[%@T4?5B.90$6P%F5S9R\J$L15OG?E^4%4 DD@=O5LZD]?
M)_B1R;L1EHKMQUQ3:;<BM*U?-"G&IZC'E:VTN$55)',".;0W*5$\7[Y+Z^)[
M%2 A&3$2XDGI$:)2@*RG:H:%R\; 9K+&<04<W+NXK$)F69QX^511R]$?>E9)
MH+M6#UPWN.52'"<Q)(7T@I*;92ZKS>',RC8'LUO6YB3@G$'QVR176%4V@U-:
M@OY*+EQ[K13OF-5-SBNQQX-OL0"19G9^JIKJ*92^$3,5FV)0F:2: %B+/%=U
M'W$EB)%48<9BC-T$FI&S5PE\*]TKV4L@HBJHDG97&U9:[%L574[#JK@'L>5A
ML;'B)"RL2_#NNHN734768[LNS6;:FY75'T VC[.^B"1WEN:OD:*1%(BD12)Z
M5?\ 8[?]E.K_ .X--?XQLRM'QG_B/^\_]L],^YW_ ,Z_^#_^1/3G6CGID4B*
M1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(
MI$4B*1%(BD12(I$4B>$?Q8/^$(Z3_OBB7_1M#*ZSA_\ O.C^BW^FT\*\K?\
MA%Q+^G1_Z2B1BUCT/L'4P)]%XX/UF8C94DN6*!I_IW5>QT"#]5HS:(*N'DXB
M!TK9(=9B@N+9H$$63!WF]<-VV.9,EZ7GLI2P@L; 0- I98FAX^"L!W]?;9[
M^ FKQ>)9&)6U-2XKU,Q=TR,/%R0[$* 2U]-CZ7E!0!@JDL0-LV[XZLZCAT2U
MMK2,SF-'IL7AO9D3Z)/"L<1PV-FH( BS .\BS!ZW?I+BRKAXV6P8C6X)( S8
M9I6P<8IXW85ALQV9W9&5 V,U(/<L'9B>8C7<:\26YB?5ZY/Q.*TTXV-7?59<
M]/&JN).@"I4^/74$:I&# HY8'E45BM5UW_S9+>3>(5JP]L <993WJV,ODM2R
M6"$N@(F%U7%MP/71?<;?:84$[@@:3(1%W#X^P2<1JSME-@1XDY=^MWN&;1JF
M#5CKA6!""F.PZJN*6-C5@"LUEN<CFYF.FURE1K0T>\V]GE%B/D(ZW\5J;S.R
MA^(4UXM.8S/FC*2LT)8*336H-?,MU;L6YB.4<AX.S?$3TSLG3FT]/M];2J"#
MMHFNBI*H8BXN/I'8N1FDR@,WU>&8$6<F#-R,/E!"(/VN\XZH+8,EU2 HP 2,
MK@&K)17A6UVUV<ZN:Q2-,3I@JNEA(*$AE#;J;FWXAM;)%,KRCP<K"RL-<>['
M7*;B-A>M*P]377T7XJ*RVJ&IM:IAG5\B@\RM7SE )ARK9SBY^D[ _P#</#/[
MU([_ ,T,ZXE_EM_2;]IGTG1_D*?^JK_T%E5U;,L4B*1%(BD12(I$4B*1%(BD
M12(I$_-&*_V4)?W>\_QA2NW7P'T#]D^:&\3])_;.!592*1%(BD3[M7&;1RW=
M)X(**-ET7&";E!%TVSS14Q4QP<-7&"C=RAEEC;%5!=-1%9.^2:N&6&66-W\>
MS]DJIY6##1*D$ @$'1WW![$>T'L1V,R Z7[M/ ]HQ"6;A Q%\.CS>88(S/6&
ME-)1/:P P=@4KAL7DP\D(BT4:RFT"=2=0R*A\E(I1HFHV;(D[9^KQ"C"%;B*
M49:BP)*[6RVUJV4.K,IVS%><#191S#9UXG?0X/'[*\NF[-2HI6+@+L7!P:<N
MM[*+::K%=*JA;T#:;%IM;IN0 ^^5"M,=-[6U-O21S/<T:/SH1.03'1,*C2TA
M&1P+(=IK@824!3[:$I&Q<P_8PTYFZC4>5:"(VN0"((D<<%ROK'-/%S=1794J
MU,J%#U7;1)%>V!2L%@.<:8[)]+8\->&/BF7B9]EV;59>F16N!16;%J2W+-=#
M5WY5J5.PI?==>EJ+)INY#'O(R/\ <FB',TEUYK'=L)P0]'N'"C)W&1,17E:,
M]X_B@,2\$N1A.6,Q=HG-G:<@8MCJ1I0J(:YB3"L<=N+. Z>%L2X*O(:RX.4I
MYBW+R9+,P(TI/,NQL:T3L<P'>;&KCN!U[NO7EC'LKX$ZM4E)M&1P>JI61E:T
M+T;V6P"P.70%'-;$L@^ [O[6;F%&S,@B$Z1W"YB^_M:#!@E&/.-<YPWH3>UM
MSFY"^,N3#*0H22*)DY)'AH-".N1IK)8.1<'1/HKAJH.&X90K(:N:JPEM\_/3
M5T@ -$$-Z+<VP1HC1V#">4.*:7LLIO7,-?$<953IG'-'$<\9KV,Y9;.I3S6U
MJG3*OZ+%TURRU/??76O^OCL?E<7CTIAA2+2_;0YC'EF X=#B>O)3-74UB,O6
M%L9.72"[<*N#1=KM2[%J\&R5VS#&DCRJN&;%#)AXSXP96*L&2OTMDL'5>5E!
M*C=8T"FR"H)&O7(?E!Q?&XP]=M5=M+U79:K655:7Q[;FOJN*"UPF6Q=URN4,
MMI5'%A^2,=]39SD4B*1%(BD3TJ_[';_LIU?_ '!IK_&-F5H^,_\ $?\ >?\
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M?]ETZE?SB?G+]L>8YO\ ,\K]'M_J3T9?['[ADPB1+J7*5122QG%\QU!9C>0
MB@:SR[=QL>[BS6Y)JVLXNA99&ZUD?AW2LJE\/X/QF'GI.,,K=#E96US[T0=?
M)]AGH_D!1=3]].M3;5S>:<O5K>OFUYQO7,!O6QO7AN>DZM+/1XI$4B*1%(BD
812(I$4B*1%(BD12(I$4B*1%(BD12)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g556103g01a24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &:J^97 X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?C&J          IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             $Y@  "Z\
M         0                         !              NO   $Y@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $Y@
M  !29VAT;&]N9P  "Z\    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,      [X     0   *    !#   !X   ?:    [< !@  ?_8_^T
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M>VKTPUX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M ?_$ !\  0 " @(# 0$            &!P4("0H" P0+ ?_$ %00  $$ @(
M 00,"0@) @4% 04#! 8' 0( " D1$A,:%!46%QA76):7U-;7"ADA5%56E)C5
M-CATD96SM=(B(S$T-79XLK<W=R0E05&V,T-A=;'1_\0 &P$!  (# 0$
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MX1F9'<+&JD\1VVJT>@QH+AYKGAQP7+VQ(B+/(R[MI10X +;22I8!0"=Q/(^
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M0M<B7%F6&T*"@M\#V+'62.2FX9=)3><&A1<*>YO+X):QW<EE!+8V[Z@UW+$
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M(50D9Y"MA;1\4*9EKKC=)=.*.K>_3ABA*N[&)D+4[+17KE[LH9<2!8A 051
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MX5)#6RQ$6EJIKM=4LUM[!+V-KIHM;FU&\B* K+!+%;J?I$([,\;DQG"L,!B
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MC32(K,(DDED.U2S<- "3DD#=TRW4F./?P8[">UC9@-\DLNXEV4'"*SMR&3M
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M3$ZR*L:OC)W*2"3SZC6T?;CHG;DF,0.*/^B/3[OM14:H2M*N@H%](P_4BQ*
ME\*&/1$E4ADO$Q@\7]YV6X4&%P\(!R=)[#';%1B)1T20T>%*&G:K;QI-(NK:
MEI%W)=SSS.J-J,-Y'*P9!+&TB*;F/NE:5T*RALL0>0TV]W&H=A=W%I*TLDC,
M%-PDRN05WJ6"\1>8+E>Z!R?!7C'ND/=BA:\\*>2!V,8[.VITJFU_+6C#REP/
MXQIK"^P41F,2$!(59-@ARQ ^(H\#(AD=&YD+?0O(AD=8-V:#%NXQ@7F35-+O
M)^R!&,EC;ZI':='D6V5_TMG+%(SRP1.HC-VZ-(P0E8WD.2<9(W-K*]^I+01W
M*0\-A&&[J%D8EHT( ,K*6.#A<G.3U[]^*3UTLGMGT0OCK[434.\L2PD*Y3CK
M8^52""%<QJW(#,2N'A19)9)KC4)'B6Z/G)[>F<:HM\>397&<<C0;V#3]6M;R
MY+"&'C[RB[V_26TT2X7(SW;KGGR&3WJJZ?.EM=PS29V)Q-VT9/=1.@P,C/-A
MG[JWH'1X '5W7$@PXM933T2BPX8R9*J)^=C;T>ZC9!+??3SM==O,VSG7SL8S
MY/+C&><HLS?29F_$D_U-5,D]9)_WKK_]D/#EG0#N'V$[#13H9U+\0F!]G,0B
M1^Y^]I1%J]L6B+(BD180HQN+D<P@<V'2:LY<U%"Y Y$#MV1QB:P^0:H(-TDU
MROK[+6HWTVSLGU?4=&EL.*@:T266&[@EE:9=T<4T)CN(B[(&;*,FW)R#CK0W
MBM;Q0M=W%F\&Y0T2LZ2HS%AE4="KJ3C)R"N._P!5QTIT!NRM[*\,*9$X;USA
MR/7(EW/E5^Q_KS&V]:UG&C/8.N&L<A0BOHIELD\DOM:LV9 Y!)'23%Z56'*G
MG+5!-VFV2JW6KVT\.N1K+>R]-738[1[V0SW#K9S;Y6GDR0A89=$&54$("<9.
MJ6[B=+Y0TS<86RQ&9B\C")]S%VSRSS('/&0HZLU;%Q=$9A>W8OOB4E+U@ I_
MM9T2K[K& D[%ZD^D(>8"REPJ&2R\=\K??+0(E-P)-EE5WHB551<,MMDM==]^
M:+;5H[2RTE8U9[G3]7FOW1AB-XV6U"*'R>;&%U;EW((//JJ$=VL4-H%!,EO=
M/.RD84J>'@9\)VD'ERK6J0=?_$Q[.U%3?2'L/4U!5A34"EE*KWEV6AURO9J_
MNN#4-*8S+1(NL*CS"@IJ!2.>%X;'U#)&7G%!P1#8ILR9+8W;#LW4O-#L+FYU
M2RN+R>YFBNA:6,ML(A:2W<<D;-/<\9EF2%9&V")-SG;N*X)K>LME!))=122R
M2NLO"@:(*(GF5E)DDW,'"!FP%4%N7/K-;C=<.KMK5E&/$J%2EJ#2=]H>UE_6
M[56&1E)XFZAUB4_6T+C:QS?5+3 8@H<C!71XQ5PKNT;:H.-M]M5L:XYM]?V]
MP^B&,OBPT^TMKC*X_2PW,\KA.?=*$D7!Y9.1WLU6FGC=[(KG$%O#')D8[I)'
M9L>$888/?-4*AT;OE/I#X4]#[,8O[X'47L-TLLBXF^)&AD4SC-&J/]IXK'R?
MH/1G7J&'"?M6T131V)>7/H]D_)RVVJVAU7L@O,R<'4;34X;;*=T7N\<$.N3L
M!QW1R=OWUNZ7%TJ_F[K9<07,<?<\]TH 3<,\AX3WJ]W;OI9VSM.Z>[]D=?9P
M(JTS=O1BG:)J2?IRI\$.,K"@UN3J:2X0X<A6RIN*,)%#C^(RSF [*CP4Y.+$
M62>K@9KOEIVJ:?!:Z5!>0M.MIJMU=W$1C5T:&:W@BC8!CMD9)(RYC; 8*%)(
M:L6]S;QQVJ3*7$5U)+(FT$%&C55/,X8AAN*GK QWZTAJGPSKY;]C.F]YQSH/
MULZBC:'O(%([9>#NR<CO^^+.".XA)XX8DF9Z>!-VB$3 KDT2.T3('34LDI-X
MT>J+M, L)O\ J7&N6G0M3M'U>^U$W=HR6ZFR2SLX'6:*1%X*.29'"%>($6.-
M00-V\[;4E[%P;F(W<]P98F$>85BA1MP8+L#$Y;&-P 51GESY;UQ7I+>8CPYO
M$#ZSO&,9Q:'8R:]]3M:M4Y$@H%<L.PD@FI&N=C!C"&$A*KAL<89+I*)*Y%;[
M*Z*94RGG.>5)JEJVM:/?@R<"RCT=9^X[O-BD*S[%SW7.-MG,;ACJS51KF(WE
MI."VR%;4/RYYA"A\#O\ 4<>&L'\'7NGU0N.*=BNM%3UGV'WL7J5077SL#2LI
MMQ*H3@2?T(+)LX?8D&GY"+RB.E8Y[!DAL#(H\\'LR"NS9B5%.'.7:R+&73-,
MO[5[*]GGL^#J-Y>6EU';])1X;PH98981(CJ^8D>-U)7F5<# )EQK6XC:&>22
M'9<32PRK'Q%*2D%D=-RL&RH((..>".7.CK_\/#M];_P:.T%[0/K#W=[ UJ[N
MX=;?5JS6X.-TX[JNX9$SD,-K^H)T1@SQHSE-$["V X3-YW&GQ&7-GY[8H84T
M19MR=NSUG3K;IUA:37^E6=QT1K>_MR[W(GMD9)9KB)9E)CN]S%XHI L95-J=
M>-D5W;1\>")Y[6)Q$8YXRQD$D8*L\BAP2LH))16PI P.>1NGX<G5J;4H;NVS
M)QU5ZF=/4K*7B0B!4MUO# BTFC45C+4AN37MBWP4?BHV>ESIQ_E^($A@38/&
M&2&^-7;UX2738\O6K^.Z6U@BU#4=2X D:6YOG<1O(Y&WHUL\DC0JJ#:S,Y:0
M]X!1FO>3I(L4:3W%P4W%Y9V8*S-C'#C9F* #D26RQ^X GE-YP:H4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME:MS#I!TYL&TT+NG/5RA)?;J#MD0Q8LCJN&%Y8L1&:I:#";TN^$+.2!,9J@W
MU&DG^SE\PU;-L-'".&R'H[\>J:E#;FUBO[R.V((,"7$JQ8;Z2A P 5LG<H #
M9.0<FMZW5RD9B6>58R"-@D8+@YR ,X .3D# .>=;2<H5HIQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J-M8;$F,L,SQE& #.;2
M(*$CA^7-1#!"2'(_&71A]' I<TDAH1)"P+R0GW09B\<+-ABYHJJR31W(.\JS
M,DAC6(NYB1W=(RQ**\@0.RKG"LXC0,0 6"+G.T8EN8J$+':I+!<G:&8 ,0.H
M$A5!/6<#/54DY"HTXI3BE.*5&CL-B,H(Q8O)(P /E(,<4DT+(F1# F]B<C6#
ME(\H?CCEX@LJ&-;@39D-DH/V;O?:LL2887PV>N4E)I))&LBH[HLJ<.4*Q42(
M&5]C@$;EWHK;3D;E4XR!4@S*&"L0'&U@"0&7(;#8ZQN4'!Y9 />J2\A4:<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*U!(7[("ML$XE&'\>"QV,6!'ZX76DL)G9$?,9,[3
M&OI&*2L8-YD4@Y)HS(*"8J,)M#3T]*&.S=\F-8$A2COR$FOSRZM+:6TEO!;V
MVH6^FDW5C?R1WMTXC>YB748<6ME*B2-%;12I,\]U'M<11RQ,_I$TB&/3DN+A
M)I9I[.:] @NK1'M8%,B02&RES<7<;N@DN'C:)8;=]REW20+>MDOYNQ8CMXB4
MB$8'Z+/GLPFTS;JDAD6CXX:X=[.40J1N-ZOW+QYHW;;N71QDQ%,L.WSC1UMH
MBAMW=2DO8XXS:26EM&&=[N]O5,D5I;QQL^X0":VXC.X5=S3HD2;Y&#D!3R;%
M+5W<7,=S<.0B6UK:D1R7$SR*NTRF*?8J*68*L3O(^U%*@DU1 RYK/F@5NG'=
M(A%3,;K'2R9V:D4>.DPSC0D^D36&C0P/$A!$0[67#HJ3E;MP3*D'T=!NA+'9
MH_>OMGS7@Q:SJE["HMQ9VLUMI8U*_FN+>>6%N))<)91PP=(@DA2\CM9;MVEE
MD>W@:)-DCR<1>M)IEA:RL9NDW$4]\;*TBAFBCD!1(6N7DFX,T<K6TEQ'; )&
MB32K(X9%4*WS.[^G1R,2&R(HTC8F'5X)@[F2B#@PD6,RR1R6/QN6'8J$*-30
MAM'_ &@#2D0,:DUQ9_<A)W2K=9BU:C%4W\7U^^GM;C4K1+:*ST^*Q:YAGBEE
MFN[FYM[:[GM8)4FA6WX$%W#&DC17!DNG*F-5B*R972+6*>&QN&GDN;V2[6"2
M)TBBMX8)I[>&XEC:*1IA-+;RNT8DA"0*"'9G!2_IS9K*$EXW'$HS*YA)I8SD
M+\( B34.L\79Q?05N8<NG9\W'Q YNA[<L$TW! DV07<KI,TU-GCAJW<=^^U-
M+*:VMA:W=Y<W:7$D%O:+ 79+41&9G>XGMX8U'&C :215+,$!WLBMR+2P>ZBG
MG,]O;06[0I+-<M*%#7'$$2JL,4TCD\)\A$8@ L1L#,L%,]D(H+BP::,XI/3T
M;)1',W($QXH(.:QH EE?#OVX<2F11UN\-,=V;[5Y&(RM(9&EAFHI@7LBNQ5=
MT9NR.UBM8;U+34+BVEM.G22QQ01K:VXW!^,UU<6ZO/&4</:VQN+D;"PB*E"]
MN+1+B2XEM6N+.&>.YZ(B/)*[3S';MX:V\,[+$^]-L\XA@.\#B;E<+AK.['8B
MPBPL0B!RV:&H3H)%*D4&81M$64KEP4(2A@XDY*R<&7?ID%I,#1?M(^Q?DV&7
M.J;Q%E[*8+N=.I]D8M8=0Z%87E[/9"&(R*D"VB7=Y#!+912M+=032"0W4 D2
MWCDD3< XCWQLVVPT3I$MGTJ[MK6*Z,CA"TK7+6]M+*ET\:QP2Q(4$$I1IG1'
MVY4OM<#,(WLTU?OQS>/S"4R)4ZYCXJ @PD=:R-)W&HO&CDV=JDR4U1C*XP$[
ME T41(NS(INW/*8 C?;E51F\?;AKJ"22);>\NKAIWMX;"W@MDN0UK:VT]ZYD
MEOEMFB@>ZCBDD>:%5G/ CXQ*.^HZ2VQ)#-;00B$327<LL[0%9[B>&U41I:FX
M$DRV\DD:+%(S0CC/P@&5/6Z["1QL[1>:L9@X;.!-:)H1-*'^@DZDCM4F90CP
MS?! TS5;E&#,"^7D AR/01%,MD2>2SE)3*"6'[(;97#B.\96BTP+:"SVW)N=
M5EF6WB_23(5EC2!S<0M&HB0K+QF4D#*Z-.RE=ULK+)?$W!N=T AT](C.XV1.
M&C=ID$,BN2[ IPU(R<NG>PY<$J1:0&Q79UG+"4++PM-A&$38$X)'HEWFIPX\
MEC:O1K'82[8$&)):;>PRJ1%D@+5>/5=FNFT:[&UN94T_47G2[DLIK$1VHGMY
MXHUE<3SO=KI\<?">.1)#>[)1+&L1=SL&HZ3(LH1KNR$36T=U'=;YS%-%(YC7
MA1+;M>2.)%='1;7=&8W,@5!N.%5[,0]46)(@8M/)4L4@A.QMQ80:!2>"8R%)
MJB"JQEV<DH8&S<M7S5^FBBF7<:%?:]U[2JDMO8^J^INR6S,4,D%K?W32V$NH
MF*"*#?#;0RF&8S//<0P(R2*X"B5A+PVX)D.T-M^0[E9)$FN+2W$=W'9"2628
MI)/+&)(Q$L4$LK*R,A8F,&/>O%"<\85SV7:,Y)+U%8E(%8!&XG5SX>>11 MG
M)Z6VD311" 4]RTJ&MA6BS Q'MD5CJ0AJU7V.KFR0MBU$*F-#=DR)<WA:TN#I
M]M::6\=P! C3W>J2@0P S7421 QS6^UIQ$BMQS/+$B0F;:NAL\%L%N(1>3W%
M^CPDS,L5O8(QEE_1V\AEPT4V1"969>"L4<CM*(K;2LT?BO)+89H%*(<RB8Z2
MOSHF4"VJ!I@G%VSIT_4138%'H8TV50;97&OPAU\)*)[IX:DL[94]%UAJ<?R=
M=:C/!=6:6D5S)/%=1(LT8M49Y"H25X)E*KF.2&=X901MEZ\<XV+]-@LHI;>Y
M>Y>!(I()&,3FX950$O&DD3!FVNDL221D'='U9@;;L &8O6\?(@9H7="9-7]?
M2Z7,8^'&1H7,I^/BJH5)=N[E*I#.KM_+!;-^/ )R5W''"V_MMMH.U;E'=!>R
M"%)%MY+>]F>*ZT_3KR[2WABMH;V_BM&A#*]T9,/)=Q(\=N+IK=F/%(C"RO<;
M1Y75IDFM8ED@O+VVMGFDDG>ULWN.*0RVX3*I;NR/,8%G _1]WNC7/7C-9-!P
M$?( =TQ0Q_*&XR8S-6,E)DE!(SN(,/-Y"K&Q#EJ[=I*F&8@&J_54W' TR^YD
MF@LR9*Z<L:Y>W5C;V\EN1%%)=+%>7AM9;T6%J8IG-P;:%E=P9DB@:1B8X!,9
MI59$(K3I5K!=33),#(Z6[26UJ)TMC=SB2)1 )Y%95(B:24(!OE,0B0AG!J"*
M6;8$=KU.Q7IF"SV%@ID.=$YE#D=MFLIIM\R;MBTK:,FA@HV#G847?.'IM)%\
M08$0L7)K-FS!P12;L:!U/4+?3QJ+S6-_907L;2WEFN4NM&DC59;M$2>5(9[*
M:1I)P))(Y+>UE94C:15CM]!LYKTV217=G<S6SK';7)&ZWU)79H[=G:.,RPW4
M:*D3%49);B,,SB,L];V-V3L(7'-+$APP&G!SDKP*@B1D<]7+2>%0Z/2B:V+9
M2F4W[3#($1"1EPRA"&6_IEVV6TC>;+-S#!BAS=1[)-0BMAJ-G% +&>ZX5@)H
MI&EN;.SM[J]U'4FQ(FRWD@MF2Q79N9=MP^Y9HT%VRT.SDG-E<R3&[BM^)=F)
MU$=O=7,UO:V5D,HV^5)9PUV<X5MT*X:)V,\L_L"3BMI-8G'D1CB-1"$6#.+2
M)O&RZZB24:A>\B'A SI)TB@U?CU'L7?R+V2BYSJ,EH#1OA-5TING?U3LADM-
M46TMQ$UM9V6H7VJ2NK,5%M9&YCAA=754DC+VKW!8-B*\MPH#,2*ECH\=QI[7
M,S.)[FZL[2PC5@N3/="!Y905)9'VSI#M(S);S;LA0*A<5OZ4:+5HZ?6E4]F9
MD(IR7L>)0,#YA2O@C&#%I,9D;H^.GLE:,QX(VP9 -M#HAE[<K$TD&2K=_KA+
M-.U[(+D-IC/J>E:D;B)I=2M+"#$NGPQV,MS-<O/'?W*I'!-&EOB>%.,90J%9
M!BK-QH\&+Y4L-1L>#(L=E<7<N4O)7NXX(H%A>S@9GFB=YLQ2-PA&68%.NX=[
M0E 7K)[[TB9CL3/WJ=)ID2V;+IC_ '2E 6I(*#U;;N5'&==B;P>*5U]E>D55
MSOG533.^/-Z_RI=0]C/RO<)'TWY*%[P55A'TF6#B00;2Q;]:\<3=UDG)!&17
M-%A!+KGR="SFV^4#:\1F4OP(YMDLNX*%R(U>0';@#'+E58.[M/KV!-(:_N6K
M*XWA2T0CN69V)+&R$@D9&)!Y!(7K/SYR RW&MWQIN,9-]6[G;"[=TGNYWW2S
MSF-K<YO[VSEUC2].-BUG;%9[1IY+BYDM(;BX=/\ CH-L2O,L<:A6.58%B15]
M-*A%G:W*:9J%\+H7,VZ&X$20PI<20PH^+28%RD1D=MRC#*0H!J7RBZ99!9/(
MZV?BV4IL0]F/N*18CV3H6REK0V/59%MSN^')#4<T@9T,;-3$AHMIHSB+X#E!
M)4F\23<V[K6KNQN;G37BCNM2GX#:)'&CQ1W:31E)3.=TG#2PGAFFO9 P"6DD
M&T-*ZAZ]OI=O=V\%\DCV]E#QEU1W99'MFB<-'PAM3B-=Q2Q16R;<M<K*"0BD
MK9LKL/>L8_"TI2U?3&72<DQBK-E$FP,+@_*<A2!A]D?B728*#$,]VP<DX9MB
MDFPX4QHW'-52)%9)-;IW>HG3+>R%TKWEW=2):HEHL$'2+K@23/P^F74$$*%8
M9619;K<<+&ADD(#4+>RZ?-=&W9+:WMXWN&:X:67@V_%2)-_1H)99'#2QJS1P
M;1W3L(T!(K-QV2U;28OAW!)F.AL:JT/.3[DF%8L9&U.2H^[#1F-;"GDA;.$'
MSQ8&=')-=F2VCXGJV<-R"(;+4@3YC=DNVZF#V%[%9VVEPWUPTL"1W*7%U</#
M;6W">X1E=S!/&%*$/+M82+"4DEOC1-T$>V[M7NI[^6UA$<KO T-O"LL\XD6%
ME**)8I"V\;(]RLAEW)'8LGNB,1DV6C.1LB-R0<XB(YB#!LF"[V1'9HWD3\9'
MPF[XH/99(LP\8)G3:Y9T*$" F$B+HIJCZ?*'1NM:M;6>6U,=S/<QM:1I! D;
M/<3WBW$D5O 9)8TXJ0VTD\QF>&**';(TN-VVC!ID\\4<^^"*!Q<N\LSLJPPV
MIA22:4*CMPVEGCAB$:R22RY18R<9B$ O9.2R:1CI"*(Q<<I)I0$BR1EBS8.!
MVE=1*&D)VC*7R1E^PR\;20\>9CG E1X'=#8X[>($5FWL=T[J:?KRW5S<1W$4
MEI&;FZ@M5G1(WC&G6EG)?BZ<321[UN)YTC:(M$\5L\BR,FUWM7FDF""!X9$G
M<06\LYB=G$AO;FZ2T-NAB1PI@AA9UE"RJ\ZJ4!RJW3#Y0RFL9#2L8T),QA]G
MH2&)EVNK)^L-<;;;#WRC359;9NB39^A(M$E]DW>K-TAAXV:.O3-4>U9W27MM
M#=Q)(D5P@EB$R[)#$Q)CD*98J)4VR(&PX1UWJCY4<NYMWM9Y;>1D:2%C'(8V
M+()%QO0-@!C&V48C*EE;8S+AC).6:T4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE:\[TB13/NEL3'+BO]K&WM_2"
M(QQLD9<SC1XD>;H.9BJ;T17CB,L01DK43D"S(:$4F[1Q)-PZ/L'/GCHD@N&;
MIA;3_E(ZN+%;9!.U\'$ZJUX9@K6RW2K<I%P$D$@5&N3"NRNS\JH85'1MMYT(
M::;LSL8A:%3"2+81$B=K=C TG&:,IEE@$AWUX3*J;#L0?7"IZ=QIB\C#30C*
M(VK!W4BA4EF&4V:C8HY%[2X(JY9QQTBX5 CB2Q!CH\6T+N&ZA%D,688O=)U#
M48].-Q?6T;VJ"2ZMC9-<65S>$(5E:(W<)=+=@Q@CE,B!V$S*9$B,:VU"RLWO
M1%:3NL[%+><7:P74%ME@T:R"VE4-,I59G0(Y0&-6"/('\Y12)V2D3RV;!U&"
MK#BT:BUL,&46UU?29M'TB35RK%2^9!C:%8D XL^$%DEV<IW2&[(Y$.!A-/<F
MMFZT2>YEN&^4!%%J-K;6NK1I:]W=+;B1'-K,;C-ETB.5X90R716,CA-'*#*4
M&J10)".AEY+*XGGT]VN.Y@:8HRBXCX/_ !7!>-)(RK6X+@\17C/#!2A]]SA%
MMI+$T*P+SD/8Q*OD(XDF\=20&@#RQ'[RK!;T>(;[;1P0<7C^(Y[.6>MMF6Y[
MVD64%9'0B9Y%%V%TN6^AU*33UME#O<P+ 4C-T)<=#XUO#.UOT;>SKL,_ )BH
M-7Q$A-N3?Q6DEE'>&<[5@E:7>_ X>3<\.>6(3&?:$;=PN( X^660:RI-=#V3
M1>3)P8?'JO81(0:)1IO*F11S,I$4*3/ T?DV%59& J$6@JP\HZ6=#M'#A5)X
M&,H8W21C=V.I7.M/=6MT+&.WTN.TBFDMENDE:\N99;SAQ\>$I- MK8M'*Y>(
M,[!X)ER%E;W=C!IB6]Q ;MYK][F6))VMVC6V@CCM=[\*4-'*;B[#HH5R%!66
M,X)@1[IV$)).Q Z1"48V\AT8AV/=)!!TPF8EE&VN[59.-3(B7;:@6$IPHL\E
M;1N!5>ORCP@28%A;IUKNASY^PZ"0/#%<0K;/96UGBZL([V]B2V4JPM[V29.!
M'=99[M%@+R2R221RQ,PVW(>R66,K*\$AG6YN+D\"[DMK:5IVW SVR1MQGM\!
M+=C*%2-4C>.15P;4-4LY?QTR)&RI%D4,W"*MYT2(Q[8J/<.@,I"'PL??B&YP
M0N[8,&,; !\.4C#-53VL1>>BTTSECSJS:*TEO-#'=!))M8BU=Y);<RQL\%U!
M<0V[Q+/"S1QI;6\083(3PE? '<5SHM45)HY'MR\<6FR::J)-PW59K>6&69)&
MBD"N[SS2[3$P'$*Y)[NL%M09P4]9GX;8N(]+LK6TD:/OHDB>T?C+<FS2:DM1
MX[8\-T%&XZZ&"&$=*K.2C!-HPUT* 226R2#?0=!GB=)[+4NCW>[5A-/):+<"
M2+5KU+V3AQF>(13VS10QVTK-+&$3$MO*" N[Y7BD1H;JR,]MC3C%"MR8BDFG
M6KVJ;W$+F2*=9)'FC C?<_Z.:,@DQB3TG,L3V*.XO*GV5EIDI8Y&8GPZ!YJ+
M=0>K ]8Q&.'F&I<0ZD*9S8I(C[U9F^"N5'CDHN@X'+(-%E*MUHEZ+^T>UNI,
MM>'4I+VYA6X6)K'2H=+L[:XC$T#W(G,MS<2%)(&:1Y65HV536^#5+;H=PMQ
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M05ZJG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KN^_@N?\U'L3_U"I?\
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M.!NXD*]T$X><MW6[:" #G)X%O'<VFJ-9K=7@$UC.%DO9'D6^O%7<9K8=VD7
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M7CU-[I[95,2E-2C@E:UGX\$T;V5S, LFR,LNY5W*4&&08)'.J<.M27TEFB-
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M7W3SH,'-!XM$<P1;*+H.G[V=K;&V$NZ0RR32<1W*A 3M5 %0$@ *H[Y).3X
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M0CR",^(V\#D%+!>8)', _3!.&)/)2!_/-;.,XE . A95!V,P)91UR*Q"-N(
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M('7DUR)\WU:IQ2G%*<4J?LO]S:?T9#^ZTY1?Z;?O-_4U1?Z;?O-_4U^<7*_
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M_P#2\[;/^J\GY.2VCP=_=_OX:EL0?Y1]+?\ ^_ZWXU7@?JIUZ X,Z"JMC[=
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M$(@^77?1-N'),$8R]77> TV#E9179PTP1M'/&<Y)Y=7,G/+O8ZJ<&(*5V#!
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MFN46*&/-\[&VVT@ ,X[YR?Q__!4PH&<#&XY/WG &?X #_:H(QH>GQD:/0]A
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M8MTNDZ=#=';C1@Y=(8SJBY79ZJ8;K+HZ[9U2643V43QG.--L8SGF<#.<#(Y
MXY@'K&:S@9#8&X# .!D ]8!Z\&LB6EDI/, PH[)3YH7'6VS./C2QDB18 F>_
MF>>U#,WCE9N,;;^CT\Y!DF@EMYFGETSYN/)@*JDE54%CEB  6/A) YGF>9K
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M-!2ZJ;+31&4:$$%AU*1U@X)<MC_88YULAB9&!90,1@#F#MS)(^P8QR52H!
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M(EL5?,0,96T].D940"OE&C(#YN_G;$M,:#DM]LZJ+Z*9SKS*LAY*RX S@$8
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MXYV%N0G.8;)P)Z5,UXRH^'!&K,>="$7@EWHPE!/1H0V<#UQI+'#<;2,\FD)
M8 X8Y!&<C/A_'^&.#(-C8;*O,2$<*V)'W!@3W/(#!'(\SSY8,FJOJY.8:R+^
MGCPX4H3ZJS*M63)Q,DY<]$S6;6C8M@O *DA5#@LN6*6LI$X=/6@IB%0=-\LA
M:6X\<S5VRL; =6/T;+UYYEB<9_WY]X=0R*DD+*&& ,PL@[K=AF=VQDA?K#O8
M'5U $^JQJ3OW5E4$:@P51". ^N;*JRZD D59P@XQF*+<(S4%S69RN'R26:T[
MAF.1W]K*KVU-;DV:SMX()ZZB,M3(_<@#D$"]R54[N^"2"=N .2]??HT<GZ,*
M,*L04E"BD-U$%F4MP\#J3!SS(.!5G]0Z3L"H4=_=TR8,U=^OW5*O,ZLBC8EG
MW3U' #\<F:6=F^<XRT0)OVV&#SR^8_0WRLGC7S-]<2C5EZQCN(UZQUJ&!ZOQ
M%3MXWCSN &8X5ZP><:%6ZN]GJ\-:HTU7UP6E4U/-(I6D(B(^JI5V7FP"?R R
M(, 9X;E(R\Z[!Q=W$F3-0ZD..R.<H&;/T.M41KAE&L(C%3ZQ-ON,UA68+A0-
MID()([HG< ,=?////>'?K1$LCI'M15$9F8,2"')XB!2HY\RV7)Y8'+.>7I1Z
MQ]EY(QG3T^".Y>$NH<RIP.QG-@5:X6S/%I'7YT<%C8"KHM&8-#*_=H@23.,J
M)95=(82QI(&()'1E[)<.0[LCKB*C)7KY' "@ *>]X,=X8IP92'R#SMWC 9T)
M#DJ< (H55..7X<\#%;#/:#L2116ZWJL4& Y/:';WK?>XD<^+!7!,;$*]>=6G
M\E:E"HQ9ZPU,@-*VL%FU:LGSMN\5TUV&.E4#*:JLRC%7Y8+2*P&1U#9GG]V&
M_P#PUL,3E9.Y +W$<H!(R%7A$Y(.,C:PP#S^\&J?E/2FWGYV5; BX@<#83PE
M *ZV2+*(.QG6BZ5K0)W@W1QHGIN--AW]RHH1<;HKC=?6C(%LDLDDOGTL#$V3
MC&,[5Y]4;;M_AYY?P#Z(Q46MWRV",;BB<^J*3?Q.^>8,G(?_ --<5D9QU\[$
M';(59C8]LQ@(;LW3=H@6T:E%80RJU*U@$RK@KNL[B8F()V9++<;AHPZ:$7$S
MD&D>W08-<@2^$V <$IDH^[D.0D5A@J%VJ1CE](M@<]QQX.K%&BF+G PHEC<8
M,:IL1EZQC>S@#_,=IQ@'J G?4Z&:/[IN&1"#P25TS39^9U]U^)@7J1,4BK;Y
ML5<-RLFCYOE0>Y1AA]U&ZW#K#'#M$4SCQF/[.4'38B-:9B'=/@@HI(3',=T=
MS#/W<ARY8J4"YDD((:-"4C(.1W9XCC/_ *20@QU 8))S7(OS?5NG%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*G[+_<VG]&0_NM.47^FW[S?U-47^FW[S?U-?D43C^6D
MO_YHD'^+.^?1$^@O[J_T%?6X_P!7'^XO]HKG\Z$>'1UDLWKCU-L6VZ7['=AI
M'W5[$SBA'LHHR6>YV.]0 \7+#X\/G$P'M(;*4CAA^H^<S)RC+WHN.(0D<\?Z
M-_3"M]3G%O+ZXCGN4CE@A6TA28+*N6NBPW%%)9=H'T1LRQ? [_<^:U+5+N*[
MO8H+BUM4T^UCN0EQ'O:^9U+F)"70JH $8X89S(0,\^YP/5WI[T=:=O;0\/[L
M/2UY6G;5<WQ<4?-7U$+D#5?5\3H>L-5GA&R)D$> BZPUN BX(W*RZF'_ )':
MC\;'V6VS]1OZ>5Q=7AMH[V&:&.)X8F$+1&21II.7#0Y&XEB%'+D 6(P#4KR^
MU$V,.IVMQ;PPRVT#+;20---)<S?1BC8,,EV947ERP6/+-<6)^MZAO?NRSIOJ
M>E)(U3ULWW$ZGI9>P'>QB1M@DQE8>$@C\CWT39J[JOW;[V_4';8T<,&KO06J
MNJLVV<;]%9)8;0RW.UI8H6EE"<E)12Y5>L<@-N>HD9QCE7926>VT\SWNQYX+
M9Y[@185"T:-(RIDD<@-H/42,@ '%<R_?SPTNK76.,8#*]<NZ=* HAV"K:I!'
M<*92"(SBHKMA[T_H MJ;3B/I-0CZC\C4T"ABIGC$.9$3QHT;;;(8;$]5Q_+L
M[^XG;/'M96:&21K5%9)(F W1*C=UQL\A("04)/,D<^%IFK7EX^X75A<-);2S
M-8QJ\<]O(%W01QL2PN=V0LX+*T1[_<D'P["^'=TPB]Q5G(@@I"!TA5;+M3;?
M:.,Q2[=+4WD'6"BK&"1SKA.1LG3-F'<8G/<W8R.A4>&M2C%GL7,('XN!#,A[
MM'.(+Z[:*0$EY9#;16S-#P\7$T;-<)C"ATM<;B2.H;69B<TMM4OW@F1B9+F8
MV4%F[VY@"7ES"SW<;*54/'8;3(Y*DA5*.S%@:ZYLD7:NI"<>,8^E%&#TL0>C
MXP@N4=MX\/>.E73$*V=FW+PR[;#&BJ+-L[*O'9%T@BFN]=.'"BBV_=7(4 MN
M( !; &X@8)P.0R>>!R'>KU"@A5!8N0 "Y"@L0,%B% 4$GF0H !.  *RD+_XL
MK_05O[YORU:?KU_!O[35ZP_:%_=?^E<Q=F]#8K'ZHZH6W7LV.RD=9@*E4^QT
M8>:C<2"HY!=CY[O")"&RU'HIKU[-& T\$!D"#9\L&F,5?"S+YQ[? $%8PZF[
M3WT$L:HT+7/1'&=LZVP'$5LDGBQDJS $!D<%0-K5IM]:E>YU.UGA2-K9[LV$
M@W;+J.T4<:-\L?T\+,CNJE0\4@9%'#<U.95T[ZXU3$II()7#.V%P.V'<WM3U
MLCK6GY5! NHF*]?MJQP!.2E(E2\[5(R*3^^"XU<Y8J 1NVX?;#-@EZ13T>M-
M0NYI(T22Q@#:?9WC&X25LO<B7<J$7$>$3A\L[C@\R:TQ:M?W4L21S:9:!M)T
MW4'-U%,^Z2^%P72,K=P!8X^",9WMAN;<N=:]H>EE>TS';Q5@LIGQF94G+^OI
MN11::L0@DP"ICLA40R9!<2T$.;[KA['J>R7S*KK,U3**BE2TJB^&@@,Y]F(;
M[;+49;E[;B)$L=S'=*CQER&N+68HVQF.&AFA!FBRH8!'!+#&+&FZO/=R6?'B
M@2*\BOD22(NR/=V%TT3\)V.'M[FW5KBWRH?;%+EF&#6LG8FGHY2"E0Q%$D:?
M62;IB%V3< \@JQP,B<ELU-W-8?#Q#-NQ0?-5QM3F( 2DV"KYZZTE)HN/U1'I
M#=6^UVTN'N>D2840K<20P$ [G2'"/(Q)((,PD";0!M4'F371L+M[P74NU!;I
M=S6]JRYW2QV^(996))4AKI)UCV #AHC98L36N7+=7Z<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2N[[^"Y_S4>Q/_ %"I
M?^-X?SY[V8?MMK_I?_-)7R'_ !%_YE8?Z$_]Q+79SYY&OGM.*4XI4>DX=<X*
MW8-U4D5-ET5<;K>?YGD3VSG.,^9KOMY<^7\G^CY/_OY.;(G$;AB"0 >0^\8K
M?;RB&42,"0 1@8SS&._5;^]H6_/QW];GZORUTI/JM_+VUT/E&/Q;_P 5]M/>
MT+?GX[^MS]7XZ4GU6_E[:?*,?BW_ (K[:>]H6_/QW];GZOQTI/JM_+VT^48_
M%O\ Q7VT][0M^?COZW/U?CI2?5;^7MI\HQ^+?^*^VGO:%OS\=_6Y^K\=*3ZK
M?R]M/E&/Q;_Q7VUX:5>22USJD[%IZ[;J*9UTPXTURHKOLHKOG&K;&,[J*;[J
M*;9QYV^^VV^V<[;9SETI/JM_+VT^48QU1..__EZ_#UT3K DBGHDD[%I))Z:I
MIIIX<:)IZ:8QKKIIIJVQKIIKKC&-==<8QC&,8QC&,<=*3ZK?R]M!J,8Y")P/
M -OMKS][0M^?COZW/U?CI2?5;^7MI\HQ^+?^*^VGO:%OS\=_6Y^K\=*3ZK?R
M]M/E&/Q;_P 5]M/>T+?GX[^MS]7XZ4GU6_E[:?*,?BW_ (K[:>]H6_/QW];G
MZOQTI/JM_+VT^48_%O\ Q7VT][0M^?COZW/U?CI2?5;^7MI\HQ^+?^*^VGO:
M%OS\=_6Y^K\=*3ZK?R]M/E&/Q;_Q7VT][0M^?COZW/U?CI2?5;^7MI\HQ^+?
M^*^VGO:%OS\=_6Y^K\=*3ZK?R]M/E&/Q;_Q7VT][0M^?COZW/U?CI2?5;^7M
MI\HQ^+?^*^VO!.L"2.F$TG8M)/7RYUT3PXTTQG;;.VV<:ZML:X\[;.=L^3'Y
M=LYSG\N<\=*3ZK?R]M/E&/Q;_P 5]M>?O:%OS\=_6Y^K\=*3ZK?R]M/E&/Q;
M_P 5]M/>T+?GX[^MS]7XZ4GU6_E[:?*,?BW_ (K[:>]H6_/QW];GZOQTI/JM
M_+VT^48_%O\ Q7VT][0M^?COZW/U?CI2?5;^7MI\HQ^+?^*^VO!.KR2.F$TG
M8M+3&=LXT3PXTTQG?;.^^<:ZML8QG;?;;?;/D\NVVV=L^7.<YXZ4GU6_E[:?
M*,?BW_BOMKS][0M^?COZW/U?CI2?5;^7MI\HQ^+?^*^VGO:%OS\=_6Y^K\=*
M3ZK?R]M/E&/Q;_Q7VT][0M^?COZW/U?CI2?5;^7MI\HQ^+?^*^VGO:%OS\=_
M6Y^K\=*3ZK?R]M/E&/Q;_P 5]M/>T+?GX[^MS]7XZ4GU6_E[:?*,?BW_ (K[
M:>]H6_/QW];GZOQTI/JM_+VT^48_%O\ Q7VT][0M^?COZW/U?CI2?5;^7MI\
MHQ^+?^*^VGO:%OS\=_6Y^K\=*3ZK?R]M/E&/Q;_Q7VT][0M^?COZW/U?CI2?
M5;^7MI\HQ^+?^*^VGO:%OS\=_6Y^K\=*3ZK?R]M/E&/Q;_Q7VT][0M^?COZW
M/U?CI2?5;^7MI\HQ^+?^*^VI,WA[Y)!%+9RTSLDDFGG.,K>3.=--=<YQY4L9
M\F<X_)Y<8SY.5VD4DG!YDGO=\_C5=KM"2=C<R3WN^?QK\?J<?RTE_P#S1(/\
M6=\^D)]!?W5_H*^S1_JX_P!Q?[17,OX:?>_JGU0K5EI:$I[T0BPXA<P^UB,/
MZY60W;4GV5 1](8^C->VS#SLO C(]A"0#$&DE-C Y1:20CV0$=JJ^FPQSR[^
MSN;F0F-;1T:(QAIX_P!+ 3D,\;JC%N1)4%@%?F!D9KA:MIUY>RG@IITD3P&$
M2741-S:.Q(>6&18V+@J>X4L-DN&&!DU4$*\0V,)D?%1N*;1N3LNPW>Z#R6#U
MF\BS041BD$ V[:*4FN, ?-$C8<V/'*09H/C,==A@AMT1W:Y;DT1K951SML>R
M;&G1(RF&S97DW$AG:./;&RJ%92=Q9F!90,\LUODTQ\:-!&Z&UTV1))0Y822O
M!#LMV155E)XA+N&90,]R3C%:E4-9%+4R&"7'IBV5NVU3WS4MD4VR8Z0[-#.H
MI!S;.4&TYZHZSB>ZRK<V+8)@]0./:?9ALX]L,^F]'RU-'+*6B_1"VDADCE)W
M\8,X*C9CN-N#SW'.>JKMS%<7!:#] +*>VGBG)XG20\BE%X6/T6S:QW;NZSC'
M*N6;N/XG'4:R:6[OM*""=G"-N>([*:3E%PQN\74*<5?1.U22)"7.VM8/P)@D
M9E;LL8;ZA KDJ*#)"HGJ.]'[7.!"0ASS;6PNHY;3C-;B*Q658FA#B2;BKM_2
M @!0 <M@G+9ZP=PXMCI-]%<:<;EK,0:4EPD#VXDXUSQTX8,P955 J]VV&8F3
M/7N+#4[J7W-HSJG#.L$?3C)N=>V?:N']A^Z;;VD9:;FH33)_1M2=1134J[1'
MREA'_9DLMXJW*;#A!2<E(B+7=:IQ?#].S<VLUR]P=P3%LT%J<GD\JYFD;'-2
MV%B!&2$#'!W8J[>V%Q>O>,66/;926NGG<>YDN$S<W#[<E"V([=< D1*[8R^*
MA'B:=I*V[26+3!6 2N>VJ2K.CQM<S^][0C+>)3JXY4E/)W+$#9<.G(I4\RVC
M4<E(.%CGQ@TX*.4 .Z6$T1345IF6GV\EM'*'5(Q)*9$AC;<D2[$4@':H[IE+
MD 8&1WR:V:39RV<5PLB1PK+<M+%;0N7B@0QQ(55MB#+NC2$*H W=]BU:"0O_
M (LK_05O[YOSL6GZ]?P;^TUZ&P_:%_=?^E<O, [XB8%<M 37,%?2JLX;UTK+
MKG>M9FW35%M9T4BA!8B:6$N6RRGM82&&4@4SKPRKL@_ 36,!"BFNJ3=5);$N
MEM+;W4?$"327<UW;3*"3"[J%4-D<P5W)*HR&1V'.M<^BM/:7T/&6.XEO[B_L
MKA 2;>650J!@1W2LN^*=!E7AD=>L@CWVUXB4\*PZ2QRA9M=M(O)9W#[7=CI
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MC.N%G6Z2>=L9QC;RXSSJLZ*0&95+'"AF +'P $\S^%=IG12H9U4N<(&8 L?
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M1MER&;NDX>"SX7/7GQ^M6SBYU2;H]K?)+IRC=+/"LVF")'S*L3YDVNWZ1#$
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MVC#6/2]D>]FC3HNSBS;P%V<+C<+@9*J&*!@IZ1NSJW693N6TD:B(X.(S11=
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M3U"07WVC9@M+3'""6P^9V4'H#6C-#>LO4-%1+Y484-;;S=-Z23UW;VXBVP"
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MUI8C9\F>5>U$[>NT8[K 1H)! V&3C%60/Q>E RE!'"9&CX.X(%F%MPB"N)P
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MJ9P"GW(-G'W#L2J.",X<0FZ#DSV;<4Q=$299KN.VWQH8> LML82X961F,37
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M'+6I?MDO_L_L6NEKW_-+G_\ ;_\ MK6\W*-<>G%*<4IQ2G%*U:M#^='U5_\
MZ3L%_P#C,.Y;A_9+S\;;^]ZZ-O\ \NU+]^Q_^Y-4](_SB(A_[+V/_P#G%6<U
M#]G?_K1?V35H7]BE_P!5!_\ 9N*NCFFJM.*4XI3BE.*4XI3BE.*5QQ>'E_L[
M1_\ 4;,?_P#<<Z6H_P#\)_I8_P#YKN:W_P#R[_\ M\/_ ,UR.\YM<.G%*I:1
M?S@JG_\ :B\__P HH3FY?V>7_K0?V7%6X_V&Y_U-G_\ ;O:NGFFJE.*4XI3B
ME4OUR_\ 0*FO_;6'?X$RYONOVF?_ *K_ -QJW?\ [;=?]>3^XU='-%5*<4JH
MH_\ ^N%H_P#MY3O^-7!S:WZB/_JS?V059?\ 9+?_ *]U_9:U;O-55J<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
)IQ2G%*<4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g556103g01a27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a27.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1XL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'A"^=I8X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?:7WT         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T#\@      "@  ________   X
M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             (&@  "WD
M         0                         !              MY   (&@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   (&@
M  !29VAT;&]N9P  "WD    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,     !->     0   *    !Q   !X   T^   !-" !@  ?_8_^T
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M2E-F3\/[U+W> ^]1;,GC@?Q4O=Y)*8Z[/DGUD0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]I=UHIUMK<G.!K_8G<AJ/M*OP;]RN@V*G;^2AY.+DWD,1RM'H3GB5^V:.7!
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M8,+<G(Y]NWV=2P"5!UN?CR"KO7):.GJ+K4MLO:P/V:36]9I=SL-99RXOVQL
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M2F*4P;  QQ$"%'3>X@,<2@)A H#0^IA H"80#KT !$?(&(V/M^X_E!M^:Z(
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M4\1&(C$2:W\Z2/P>._YO,1*6(DN;\SR?P%S^:-D;T/T/X1*F6)ANQ?K?7O\
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MN & &B@@!@!/H;H/E#KUZ#Y0\N"!X\#R?D/D8B4AH@C9(21<<41D8<HB5DW
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MZSU-F+>V6C9)T" !L[T!KP!\!\I\>_Z3]>9F;]99"\F+<590J[)/%1Q.E&]
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M>R(& PCV@[/0T^(^A_$1/8=:5\:-Q\ 9]KQ>\ "^,E.@E\(8]1$WB[R" ]
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M3KT!$H]_E_>YE\:*_NS$2<[6E?#8OK'LP$%W/9 ))00,/@3CJ CXN 2] ZB
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M;\S'Y/>G= 3-2@IP#UXF7PV-'M!S4KJGTY9)H9,G9#1Q1Z** 5,3=?I ,)Q
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MY/R^P_\ S_\ N8E'Q/%>]S/\73_1RZ'R'W")$E8J,*_K12L&A2J3:Y% !!,
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M@9M\5VI.E!T"221ZDF?*9'Z3]:OONN&8]0ML>P55A.%89BP1.2EN* A1R))
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MA$P[8D1%EU_>C!'M $*=9Q 003 0$(1\(" ]GR" ^4,:'R'W")[=4_6NUM^
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MB8W:Z&\I0+T^F[17GY#[_P#Z1.+*K28O:WVF#4HA-+"F 2!S <_T/3P=@P^
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MIT>I0'J/.-N CU /*(?P:?)U_P!&;.QTW^(7_P!W_P#W<V^R=#_C.5_=!_\
M<)^O9N[HE_L$:=_XY&__ -M..QTW^(7_ -W_ /W<>R=#_C.5_=!_]PCV;NZ)
M?[!&G?\ CD;_ /VTX['3?XA?_=__ -W'LG0_XSE?W0?_ '"<!ANWNAP"^[WP
M+T\?J_7,IUYPH$["@D2[1 __ (:S=L"@!1 _TO41'Z4.GE=CIO\ $+_[O_\
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M)C>IBR!CCU"39B4.R+$@" FZ (]H.R B;H;IV1OGY#[S^42UW^6][FGQF?\
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M(G[Z\^1JX/JOU_H8GYERE\'1/V2]L)&%*!^@=H"C-1XB4#=.O9$0 1#KT$0
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M58>""02/'V$S=D8]V+=9CY"&NZEBEE9*DHP]02I*G7V$B;*S7-,8B,1/FWS
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ML#F( %9'H>15*/67EC" !$RAOI1,]$2&ZE .T02F$HF((]@YBC8A[&-@<Q
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MC<S\F;R5"@>9A?\ A0>&/_GG9_\ PO<J?[E<V?JK._V=7_-XG_?F[_)[JO\
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MZ%* F$ &$[^?J/4$?$?,1./8)-J>+5*!7@#X3&C]-&R1 Z%DV9A^F.T*4!Z
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MT;'V_<?RB4?&S3[%]\52G['C8^W[C^429,RC0T3)% KT!,R<@':C)(A>HI&
M.IC-"E*'7^4P@ ?RCD)V#Z^A^!'XB)3\;-/L7WQ5*?L>78^W[C^43#MB2K0=
M?WH *]ZC3K. =8R3*'481\'E,9H!0#_2(B  'E$0#&Q]OW'\HGMU3]:[6WX
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M2B(&+T, =H [0&+U*-B6O 7?OU(_S,1^Z\1'@+OWZD?YF(_=>(CP%W[]2/\
M,Q'[KQ$> N_?J1_F8C]UXB/ 7?OU(_S,1^Z\1)TLR=%8+",Q('#MM_I3(Q0
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M(Q$8B,1&(DV3^I9>DF7YT,1*6(C$1B),C?JI+TFX_-H8B4\1)DI_%L_2<?\
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M9U&"4/J>OE AA_\ H.3XCZ'\1$]AY>-\:-S^%I=D(]X41^GZ=H7#$0#ZGVQ
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MOM 'TO\ )V@Z_P#SB)0\<Q?VXE_3_1Q$FS,O&GB9(A7:0F,R<E* =KJ(BD8
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M-8_-*OPJ,]:,LL2YB(Q$8B,1&(DR8\W+?=MOE2&(E/$1B(Q$FM_.DC\'CO\
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M+%7XE]&1<I.0\;)S:IT(:.D)-DS?2ZZ?9%1&,:.%TW#]4@'()TVB:IR]HO:
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M2 M_ 6MQ4V.J,'6ON$%Q7S5'* @,R(3OB)D+&"N@UI^/(Z!8A2"%Y'R%V%)
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M'@]GV5+EB*IJ^=U)2[M1=K;P#9<W!SFQZQ?EYF096BUO*#K)5T-/C$K%7Z7
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MJ%C%P:M<3G4K?4:TM-&/T_)P:N?#NN<C'RT-KA3P7]OE,W ,W&L!>3,-F&]
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MIR"+5FL=VY;MU>MNAYRX_M ]G<>R)GFA,FELI<-U#B\X_(6FM58%RJMP&R0
M"1L;"O%8L_9M^Q7(*+:AM%+*&YFO8;04[.@=#R?'F=@]G\J^.>G*G>+KL+<E
M#A8#6LQ7J[?%&T\SG9*JV&US+6OUN!FX* /)S<?+S$N\0:-&#F/37[/?W:Q$
MF3-XY0XJ,#,R;*JJ<:UWN1[*@4*"Q*T+V.COQ5E55))!UZ ;) .I*+K&54K<
MEPS)L$!E4<F8$Z! 'DD'Y#U(FT(_8NOI:QO:?%WJG25NC8=I8I&K1]GA'EC8
M5]^F@JQG'L(V?*2;6'>I.6RC237:ILG*;A Z*YRJIB;0U-RH+&JL6MF*+8R,
M$9U_>0.1Q++H[4'8UY$UE'"ABK!22 Q4A21Z@$C1(^(]1-63/*_C=!.M:M'6
MZM>/5=O[&<:DUR>!LD=96MEV*SA)"Q/JNB_KZTDP8OV$1&.%WII1RQ;-EU8Z
M.57+)S$0S?="]/S7%Y&+<!C4C(OY(R&NAF5%L(<*2K,P"\0=C;?NJQ&8HN(<
MBI_V:"Q]J5*H2%#:.B02?&M[\GT!(MTOD%JFZ5O6EB^BF.J"^W6IW- JFP'T
M;3KQ83IKG;JLH^J2[Y*4>R"2A2]]9L$G:Q"*HF,  J3KA9B9%;WIVS8,<ZNL
MI!MJ0$;!:Q05"GYD@>##TV*SKQ+=O]]D!95^TL!H#ZZF;,]CZ\D;0>D1]\IC
M^Z)-Y!VI4&=H@W5H3:1+XT9*N3P"#X\L1O&21#Q\@L9H";)\0S1R9-<HIAJ-
M-RIW358*]J.X48)MAR4<R..V7WE&_(\CQ,"CA>11@O@<BI"[(V!O6O(\CYCR
M/$Z\[CYNZ$T=*WJO6Z6LTG9Z$OJ&&>U:EU&:M]CL-ZWQ(V2.U1JZFQ$,@NZL
MVR;86K24L2KQY#+PU<6C;+8%XF"D6K\_9C=,R\I:GK5!7:,AA998E:)5B"ML
MB^UG("4U]Q5YG]Y]UH&<%9NKQ;;0C*%"OW"&=@H"U!398Q)&D7D!R^+;5=L"
M)^-9\U=3;.\2-F]?VO1YM_?;IK6R5G9^N)JASFM[31*$ILR8)L%*:%-C#P;N
MF^"2T%:8]_+UF;+(LD6,LHMX45M;^F9%'/;X]JK57>CT7I:E]=MPH4T\?>9A
M;M6K*K8G%BRC0W'Q[*R?-;CBKJU;JX=7;@.&O)(;892 RZ.P/CN[V;=,@$28
M=N:Q L]8W5.@C?1]5>DU;F1FQ'M6B1\;=)&QM#O&A'4&S[])MS.FQ56I!72
MW+[-D^]_F]_N(+6_96>[6=ZL;W?"'1TYTIT='Q-?:L\_LW]T!F]QO"GT8^/
M/P)\3A[#WEJ[6-"O.Q[-;X8U>U[7MAV.P)Q$BPEI@R&JZ[*6F]Q<7$M71G<G
M8*_#0T@XD(-L4T@U% Q72*'0QBVG%OONJIKK;G<]*)R!5=Y#K74S,1I4=G4!
MS[IWX)E2I['1%4\G9%78(&[&"J2?@"2//I)\5R,T?*Q4-)CM&D13B;UPRVTV
MKLW9X2*MS;7SVN$MGT32%5<ORSC.,:0!C2+]VHR\':((KG55 B1S!6P\I68=
MBU@MQQRZ5NU9N#]OMJX'$L7]U0#LG6AYE--H)_9N0'-?(*2O,-QXA@-$\O &
M_)F(:VY>:'VV2N2=$N 2M.M^IZEN6M;$=LUH2ARM1N]F?5&O-"3LYXN%G:W,
MVQ,U<5.3:,IQBJX:MG;1%\J9H39?T_+Q^:VU\;*\BW&>D$-:ME*"QSP7>ZPK
M;%BDH=$@Z\FOCVUE@ZZ9+&J9 0SAD7DWA=[4#SR!*GU!UYFSQW/IX("!M@[7
MUJ%6M4J:#J]E&]5?Q!9)LBKA$\/ S/C3Q=,2I%FCM$T?'N7#LJK5PF*('14
MNCV;(YO7[/=W*UYNG:LYHGCWG7CR5?(]X@#R//F8=NS97MOR4;*\&V!\R-;
M\CR?$U9R7Y9:SXKZG'=U^A]C6G6;=DXF)>SZGHLMLIA7*RUB%9M:WV):N]^1
MB:D$>EWPM@<*^+SF6;E(J/?B"/1@]/OS\@8M+4I>2%6O(M6@O87""I.YKE9R
M/[@][0)UX,V48[WV=I"BOZ!;&"%FWKBN_5M_#U]?E,KU3R$H.UZ0G>D$K)KM
MJ*\>B\KFX(-76EUB"3DB>+K#J:JMC6;R<4SM[HH%J+AXFD2QE.F,5X28X%S7
M?AW46FH\+CHD/C.+ZFXJ&<)97M6-8/[0 ^X=AM3&RIJVXGB_KIJSS4Z&V 8>
M"5_M ?N_&7'F]]'QZ[UL_P!RZI8N8Y6/0D&[S8=1;+L%I9^O%Q2+U):8(HU5
MDY-JZCH]-<J9WK]LNS; HX143+B,7*(!&-D$,&*D4V$$* S$$+Y"J0S:] 03
MH&3LVG6JK#O>O<;SH;.O'G0\GY#S,G6V%06]L^@%Q>*>A>AB5)\*6M985*V>
M(D@,*LU]#AWI9CQ2F!#BI(^!^!D AA,L'9'IK%-IK[PJL-7+AW0C&OF?1.>N
M/(_ZN]_9,>#E>81BF^/+B>/+Y<M:WY'C>YZ&&R]=RU>L%LA[U4)JL51)XM9I
M^%L43,1, FPAVUA>^-WT8[=-V!VT"\9S*J3E1-4L6\:/NQX,Y044K4W*Z5M5
M8KV:"(R,K/MB@X@@%MN"OC^T"/4&"C@A2C!F_=!4@G9*C0(\^01]01ZB=0=3
M]TDXN;IU/K+<U%G[8XIVV-]USC76$I6ES,+8&NU+:U))5V,L$#()HOH2-E81
MS&V%I+.B>"JP4Q$21!,B_2ST<CHN?BY%^-<E8MQ\1\VSC:CH:*SQ=D=25=E<
M,A4'8=67U!G39A7U665.%#5U&YM,""BG1*D>"0=J1\P1ZB;OU!RGT;NVC:MO
MU/OD,RCMT-9AWK2$MC^/JUPMB4#+2$++!$565>(S$@HR>QKGOZ;%NY,FAWI9
M0"$5*.<N3@96+;?3;4Q;&*B]JP;*Z^:AEY6*"HV&&MD>?'PFJRBVIK$9"35Q
M[A4%E7D 1M@-#8/QUYC6?*?1FU:O!6V"OD-"Q]JV+LG555971_'U&;M%XU1L
M"P:SN,+7(>9>-WLXNUM5:DD&9(Q-RJ]9BT>I) D[2ZK\#*QW>MZF8UT49%AK
M!L2NG)I2^I[&4$(#78I/(C1VI\@Q91;6Q4H251+&*@L%6Q ZEB!H;5AO?H?'
MPF-\BN7VMN--GU/2+96-MWBZ[K->O8^J&GM:3^S;)+)ZXC8:7MSA2(KQ%';9
MO%QLZQ=G6.F8AD0<'ZE*W..9X?3K\Y,BVM\>JK&[7>LR;TH1>\S+6.5A"DLR
M$:WZZ'QEIQWO6QE:M%JX<VL<5@<R0OEO!V1K4V1"[YU=)0D1+3=JC->2,G51
MN3NE[.D(RAW^L0B$4QFI-2WT^??-9FM+04;),'4^E)()%AT7;=1\HDFLD<^E
M\2]795K:Y5L[8MH!NI=BQ1>W:@*.'92$*D\B#QW,#58"0%+@-QY5@NA.R!Q8
M A@2#HCUT=2H;=>FBP-:M)MMZR+6+G)!#4^QFOM5"!M<N*RC<(JM3 RH1\[)
M"X250!C%N'3H5DU$N]=LABAC[+D\WK]GO[E8Y6)VK.=:_P"LZ\>2#[6 $=JW
M;+V[.2C;+P;:CYL-; ^T^)K*!Y>Z&N%N?T>BV\][L$#O1[QSM[>IQKV20I.T
M8^@NMCO(VT.3IMTV4.C M%68V-J+Z%4LA5ZVD\/,1\JU8;WZ=EU5K;;7VD?$
M&;6;&53;CFX4!JQL[8N=]LZ?A^TUP*DYG'M50SKP#5=Y>1 YU\@FU'DD[.^/
M@A?>.E()VU&;:U7--9Y]#;,U]+,JM,(5VSO(RYUQ^UKE@=.TV#6"GG#6251B
M)AR^529(1D@=N]6=J)MDT#+'*0>=L?(4H&HN4V*70-4X+H!LN@*CDH'DL-@#
MSO4UFNP$ HX+#DH*L"RZWL;'D:\['C7F8FUY$:?D;KK&C0]TA[ ^W)#["E];
M3E<>L[!3[2IJY2#^C.#C[3#N7L0:QQS2<"41A3. =O8R%LSMJ"A:Y+%;9G#R
M5KOM:ID&,U*W*X*65]_GVF-; /P)3B7UH,]8.NXN\C38%=BI7ME X8%67GOB
M2IT=$C6_@2H/[PWNS.::HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$ZJ\T^.<ARHX[VW44#:F
MM(MZL[KV_P! M<C&J3,/#;#U)L.K[2HZM@AT7#5:3K;JRU"-C[$S;N$G:D*\
M?&8G(](W,7OZ9FC S:LEZS;6%NINK5N+-3DT68]P1M$+8*[6*$@@.%V-;F_&
MN%%RV%>:Z='4'1*6(R-H_!@K$KL$; V-3J;;^,7.G?D56'O(79W'YL_JG+7B
M'NVK:SU:PMH:_I5$X]WYG<]A*,KO8JFWOUNO^S3IB+.+GF+"IUSQ/$,&+] '
MLQ*K^A5G=*Q'<8=&819T_J.+9=>:^];;F4M53NI+#5750#Y9";'Y,Q!TJCH6
M_%J+=E+M-CY-3/85Y,]R%$]U3Q5$'J1MFV=CT Z/D[B]MUQI>0HDQ:-$2=W:
M\'-6\::=9W86AX2L;&H_+'8&_I6V1<DYHII6(@7E<LT'&L9&,0).J6"-72<Q
MC>/0;2"WJ'])<<9*VK7EK5^M<C-L0=L%Z+L"G$%;*+>+.'1R0QX<"--LD#J_
M658LYA;0IRK;F4<1R2S'2D*0&T2"I)!\:/KOQ-L6GN7V^T+]>-HUIUQ;V;)V
M/D/SLOD=J[D#%W&RZD/0.8D)J>-B9Z<C653?+.-C4%762S*4K:4<K!6JKVF<
MK[>\0(NCR&<Z=<Q#550XSZ%3#Z54V1B-77DB[IKY#,E;&P 4W=_:V;#UV5HY
MJ?B%FM<ZDHE;"] *<5"])5;.>,;"0I+:X/SV&)VK*&X-K4P^Z=RCY0VWDTMN
M)Y?>.0UAA(;:\0DJ\59=6KEKNS.'%EXX1U?5UQ5:+(5U-6HV>2C9 EEL5WOM
MIFJ0BUAB3$&G7&L/-[*^OX->#[,*<WN,F.'[CID#N4]23-9Q=9:'U8@8<$JI
M1;26*N7+IDN?0M':"7;(0'D19Y3)%V^;,">2@@@*BAO.CLD=T-B<'=EW#BWW
M/O1D?:*,VLW$JS:%FKY*/'4^6"L#;57'J\ZBG$JBJA +R#A=_/6AE(Q(3,?#
M)J1"#I1XHS>E29*^;1U2BK.ZODFNTIU"O+2E0$YH;\RG)0V OH )65;BS:8C
M6QLSGKRD2_+M*N5R%M5!XV.=Z6@MYT-!2#HGR1K8\SHI%=Q>V,O1X*NW27T%
M:9B$TKW+35#:0DVMAETFI.%VS'%LWXW8K2=&,Y0@=H5H6L+6T$TDC6 Z/@-P
M:0<>4JIO6?\ 2:CNN]2Y=:OE_I#DD HI_P#%<<5X9(6W1?'LV]AW[F]U%V\3
MJ;J2<^2BY1W,YR 0-^TIQJWI];1MEO7CZJ29Z+]W%_;ERC=\U]O=-)Q==V-K
M;NA%-H45WJS*1]4D.4G*:B<@=.]\B4Z<DQBXFF1U/-'V<T,*R\%.+-EZLSG$
M$A=E5?I-CUG$<U93/1D=%MM;: V+T[I]V%DCEW"6:TVAD#>'38L*GQ"=2K7L
MGA9RK?$9CM=L**'IL\\MDMRVN_4;Y$>D^B_)[B?M/<T#PZME2A] EOO%ZSFN
M$GH:_!8WG&6W.Y_3]@UA*P;-Y&5!Q-1Z.O'%B5F-56%QKIP=J5@5%U6XI20$
M\=XV!U"C%;J5=C9?:SZNTN73P&;6$R4O5R&L"MW@G#(07#?+8L8+IN*B^NHY
M*L;>%Z\!:G$7J!8M@)VVCSXZL7GYWZG7G5W"3N;<YQ3V_K;8L_/:ZN*=+X;1
M^A',I%PCR/L+78;G>>PMJ3"U6;/8UP$7K: JUU8ZVI1%;$>=;U2N14([CD(]
MJEF[J?6ES\>^E$NK-O4CEA6<,II&+50O<((Y7O96;[3P"FQV<,6)FS*S1D(Z
M .O+)-H!.QP[2(.6CY<E>;^-%B3O<U&T[G5RNG[A9=<72X\>XGBY-]TCL?/U
MQ-5E]L>;WM,-TMMCMRG:P5AI.JUZC5H'$Q'P;2RV-G9)YPS9)R",4U>G537S
MI/6<!*Z[ZJ\QL]>B+TCBXI3%7>-[-9>'6Q[;/<9RB%*_>XEB-:FPYF.%5U6X
MWC"7$ 8(*E/:%36;#,[>.14<5\ZW\9UH/W#W;YM?;MICNWZ(L4T^A$H;4-YL
MDAM%]-W4W\+VJ\FGC[<<:>)6K%36D(FKJ4Z16KT'LV<<S%DLEB96*(AY:5J,
MGVG]*,;NXMBUY:*&+9-:#'"U?^'68(&,P(LL"M9W%#O0@6M*RC,!:N_]:5\Z
MVXV@;)L4=O2;QFH_9'?)M%N0#,B\552I(#+M-?N.^UK)MGD!89_8>M:O6-PQ
M_*^9KMVI\QLQ?9E$LO*O3B6KW5)C:R@C4*4OK_61WL@A#2DO*3KFQU.O42,9
MTRA3<&E/M] _2/'KQ\-$INLLQFZ>KU6K1V+4Z?DG(%C6$VVBV_2\U54".]S-
M;<K<)K'4:UKI 1V:OL!E8)VV%%O<Y;)9PUA + <0'+GDRL5FSH3N<N]5W/&>
MVV&A<"ZO;>/G)/5&QCP>K:7;(.-M^NJ3Q_LVD;')66]/*7XWG]@K/IF#NE'K
MZU-C(*L%I\)77=SEE4&EC8<[=9Q0,^NN[JUB9N#D4<\BVMFKNMS:LM%2E;.*
M4Z1ZKF%K-9W7<5J":SK;,JU<JOELMU#INQU/%VN6U0J!M*@TRL>1+<R0@\J=
M PO<:-]Q6KJMJU>]Z F2VGCUH#0^QM@3C2Z2E[T*IHS=-XVB>[<6'YJTW*K(
MV]K="]_CY]:@FB+M7H2UFE)A!MXGSL;])<5KWO%66O;S,S+IJ0U+5E^UXU5'
M:SUY_NUFKP4[O*JQZ^*$\IN/4JC8UG"T<;[[D0%0EHNK5.%XV?"\?.@VT9ET
M-[G;K5O<W;GK_DW0^0)Y'4Y'4#SCYO\ )2TR<2C+IW.>UGR8UO8J?1:<:2/5
MFQWTW7961B'MCBW\H2OM&T=WZ&DY1TB@B?S;^LUW85N(!D:?I?3,)%8KVTOP
MKZ[;;./<(".JNJ,%YDM[RJ"9SOF*]#TZL.\7&H4'7%7IL5W;7(Z# $ @<CO1
M $QO9_#+<FP>0?*.=I3EA5KW"\J>(O/'C??-@0D[)ZCMTY0M!)\>K/J"ZR4"
M4LBW:LFM*MXR;>%5-8*RRV%3;2R82!3'07VT=2QJL3 2T%ZFZ?U#I.;52R+D
M(MN8<VO)J5]J23;4 6'&PT65DKZRIDUI30K LIQ\C$N1"!8H>[O+8H/CU9=;
M\,4=3J4MO<(^;'(]A0;#O';NBGMWKMDY8ODJK3HVS1&O=<T[=_$._<=J#2*;
M..*D>XWM6,N%K)>KO;+NA%OCMY6895V,(TB8>&<8X_4^F81N3%QLH5.G3P;+
M61KK[,7J-.;=;:@L[=/*NLTU5U%EVJEVVS,%>5C4\UJKM"LN."S$,[M5DI<[
ML.05-JO!$38\ LQ))F+R_<P=AU9'CH?559X;V5.C\/:1Q8V73=[:[F[3K2#G
MX"U4NXV#=NOJI"P38MUL]EDH&0;3L39G% >V0T?3Y:0N#)S%N&2FQ>N4V'-[
M[]23O=1MSZ+,2Y*[W1J[:TQ;K'8]I$5P59!<$W8JUD,#*,Y&[W<;)'+);(K:
MMP'(*NHK=B?="@CB5YA=N.)!FK;QW*OE19;;LN(97[0!=43>U^Z5[<IT@Z?[
M$;; 7EN>^A]C:YA86S12-/?5V+C]<VRYH'DGD3,S+B=KIEY%LV8R<:E"S&^K
MKV B4NU.7[0N/T3'M %)I"])RZ+G>LFP.QOKI/$,JA'TI)4EUV)GT*J$I=W!
M5@U,/<X:Q+J[&(/(,2ZIX! XGQL@['#)W)'D=+<B-8[$N=ZT#.:\H<G3RN48
M]K.P5C?U!IPZ?<9[-5):L16N&D#?'Z$V_7FX^[;!M$W8)VH>!U$"TJ'8#$O*
M/TAPTPKZ*ZLM;[DL 8E71;3U)<ZNQ;&N+TC@H0U4HB+9NW]HQV ZA2*714M#
MN&UL@J&]I[RL&+[0<=#@BJ VV]XG8A1?<<]\.M9Z_H-EG..39"I<4N&7&V<B
MX)U<W=;M#CC'S53Y W"T/VCW7+ %B[-URV_QYLZ9KJK;&EY:/DU%H/\ _%#O
M-OTDQ1??=6F:3;U#JF:C/V@]8ZATSV.NL$7-_H+O0@@=E59=/^S&1ZC5S=@M
MQY7Y-P+<=KW\;LJH][TK?T_] &O/NC4W+7@CN/1,U=;=2]4P6]8W:ML[HNC4
M=90.F=B[9UUKFJ<K(;6#NIRK>#H-4DG](W!'R],>1+([FMLM8R47.3+26VM3
M>P#MYT=/ZKCY:5U6Y#XK4)T8V7ME4X]]S]/;(%BE[K%6W&*W!B!8<A62LICV
M^@V8^55:$5[&J-8PRSM8E;NV.;.0V[ /7I@?WBX*C5;'6OK?8^*^R=E]R:8\
M->_0=/VS8>#],T.Z4LSMR:O5R\H:@@ZA($F7T"SFG)X^-F6KA)RYBF4D8Z:1
ME&J3@!)VOGJL^C'_ $@_66GMQZ^J698[8'-ZO:6L'%7*#DRD$!BODZ.IYR7I
M7G^TZ+5C):WW0.14V%AH$@;(/H2/K.M_(KN=O)38>S]H2>MKAH]'76]$.Y\.
MM@GN[^^,+K6I+A!MA2^NF%/9P56F(.887F/43*WDYF1BW,:]:&CU(L[=^$Q'
M=F#UC"HHQUOKRC=B?K@4]H5&IUZIC"D-87=64U,"2JA@RG88$<3OIS*4K0.M
MO.KVSCQX%2,JL)MML".&O0 [WO?C1T(^[BI<I#7UA@':O'9W;YGB9W0732=B
M=Q<RX4#;O*?D2YVGJ+8+B16H:DD*-!H;E6KS4^5-2R0;M56.J[*4B%#.S=@_
M2>L7(X&8*UZAT;)*!E'^;]/PQ1D4@"T#]M:.XJ;%;  V$, )M'4E#@CO!1?A
MV:!'^CQZ178FN>O?;W@N^)]6()FV);N6.YY7;@RRMSTL:F.>3E-Y:.=MKL;6
MOR70L53T3#ZE/H)M*&AO%"NG9.0B!$TVI947S6CRLK5C45VZ<^-@YEZ[C+C<
M>UD]T8%G3AC@UC!*69;9/M97ER]H4,/<[>C:BV=T <1K]NK%>@MH84-CBL%1
M1Q:XV=TKO?<T?36N8#<]>)O%KP#V=4^Y3UO@)JRPZNUSLB<U%0=/;?V-76TE
M&U^082B5=K?(*X0)VE4++3UQM]&0M$;79&Q1$<X=R<C&N9IY'I-![WSGJ^/9
M^D%G5\BN^^A<J_*QJ'*LX8-99A56;LXK57::S8J,P"A@@;?G7[76V>V78+'0
M6/96AT6!')J5.VT%5N)(4G0! W-&P'<I]X:XW-$2-3W_ !>R=+J<C>'/)B<+
MM1A6ZCL&,NG&^%MNMK3&5FLZ4U%2]7>++-J9+5,7%NS,(B3=3%*6&?7.*PR[
MWJLZ_BWXQ5\-J,D874L%?9VLMI:K->N^MG?*R;<CDF0<AF')EXVC@!KB-C9]
M5E9#U%+>SD4@UEF0K<5=>1ML9]K9W"?) #>!\!I6A]Q=W;5I_CX[G+_IZUQ5
M.J>C:SL/QC/;79OJ.XT;R-V#O)A,Z7"MQM:=S3FS-[HS1\%GYVB-JY<(<L^\
M"Z0SAS6W'3=^DV-8F6%IR*VLLRWITF.1:,O"IQ"N3S+A16:B?<2TO6Y0&I@'
M&U^I5LMP"V*6-I3033=VA*2+-D@<2N]@.64\1P/O3Q:^XN;LL+VL+N+]IZ>8
M/G&^JW<X>?GMK1D=4:IM+F[=^4\%==?J4^-@IR:O:=:MS:N6& 5G=>-4;95Z
MG-1U[>Q\#X-(D_27%0/JG(1E&$]3JE#&U\;I5/3VJN%C.B5&RMK$?A>>W98K
M5 OM2]2J7EI+01V64@5GDU>,E!5PQ8!0REE;3^ZS I[WCZ><NN#T?RSY!<0[
M]<U6#O56@T>00WJMHW"_TFW3KS:50J4)4%:O,Z_=0S\J43+5U9U/).K-#)*L
ME$4DTI0%%VI?"Z?U0]/P^HTU@C(R_8^TYJIMK0466/9S6X,-LK@(0C'>_*^L
MX<?*./5D*NQ9;VN#<$=1P9BW(."/(/@A3Y^7K.N.V.YIW>:>\\)[53W2D1:.
M1%=XETW2<UL.!5OLG5*+H&NU. O%,N,Q<Z9=WD82ZL*\Z8PUHCD+Q+Q4BXB[
MNZ:K6:$8@3MQ^M5(.E)D#):O#?J%N2E+]E;+LMK&JMK6JRH-VBX+(34K*&J!
M".=[Z\U ,1;!8RTMD-:JG@&>XL590K+OCRV5/$$;3]UC.K.N.Y#\E-8(K3*#
MGA]M68F7W*^!>:[W\TV9M?456J?)BXZGOK:Z1+2:JI)JV7^I25"E*U8H:7)7
MV.PZ\\9NSW*J.%W<<W[[OTBPKR%UU''5!T]UOQ&HQ\E[,&K(I-3%7*UTVK<M
MB,O,T.".W: &.]^HTV:'^<5@#&/.KA78S4+:A4D-I48.&4C90@^ZW@S<_P#@
MK-K%V==W\=:M.U.CVCGA:N7#6XT=&Q5K:#2M[%XA;(X^V"J(PK>K*PT=+T:\
MVIA<J!WJY2$>NTF[<]>NH:731;3?,.O8XQZE:O)LMKZ17TXUVE'H+T]3HS4L
M+&P,4MIJ-5O[($%:P RDE-7M]?!-K8SKB#'*L59"R9"7!N6]D,H*O[N]A0-C
MR-6M>X^[MF]:_07:I3C!63UO3'#[CK%P>M(JX,*;MZF\<N2]!W9:]J;G:2-2
M34+L6T5FGR%>K]7:L;;&1\C:;.$G>73"=448;S^D6,E_=K7.LYY/4LQGO:MK
M,>S.P;L6O'QBMFNS79:+'L)J9EK350*#>S]8U"SD!>P:S)N)<KRK:^EJE2O3
M:"*6Y%MJ2%72@KYW[0N%6R=4\G-+1S")B!H3;GOS.YR!.T>-E&=3U]K&]Z!>
M:>J6K9%RXA8B'B[G:KGM,TTK58<[MH]AZ[99=FX=DC7RB/';U.F_"RF9F[K=
M)Z;TOA:P-EM]66N39D* [,U5=6-PYMHAK$4@<A-+9*646DL2YQ<?%TY!9W6[
MNEP-L2B)7QY'6BR^A(GVJSYJ>;&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B2%+! ))3*RLY$)HUU8&U@54DF1$H)P+)I)@A,J&7 D8L,
M:_82 )/10.+)ZT=@7O#E%0^7!_=]UO?\I[I]\;*[7Q[WO KXWY!'J#+HG0 )
M)]/!\^2/'S\@CQ\095,8I"F.<Q2$(43'.80*4I2@(F,8PB %*4 $1$1   !$
M1Z9C)/UB)CUIMU4HT([LMVL]>I]<8=Z\.L%IFHVOPC+ORA44?"Y66<M&#;OJ
MIR))=^7)WQ0Q2$ZF, #G779:X2I'L=O1*U9W/Q\*H)/CY"559B%52S'T"@DG
MZ ;)GNC;-6YGQ9XHL$'*^.X?Z(8;Q;+,'WC> [;1/QY&>"N%?#X?MOV)/&;7
MOK+MO&A>_P#5PB!XR.O+DC+Q;@W)2.+^3Q;8\-H$\3H^#X\&"K#>P1HZ.P1H
M_(_(^#X]?$]D;8(&9!T,/-Q$J#'O?AHQLDR? S[Z4QTO"A:K*^#]](0YT^^]
MCME(8Q>H%$0,CKKDK+OTY*1OZ; W!!'J"/J"/QG+:2,?(1[668/F;V*>LT9%
ME)M'2#F/=Q[E KEN^:O43G;.&;AL<CA%TDH=!5 Y54SF3,!AA!!*D$,"05((
M((.B"#Y!!\$'R#!!!((((.B"/(/IHCUWOX3%:SLS7%U8#*4W8%(ML868&NFD
M:S:X&>8%L!2]LT$+R*?NVX3!2?3#&"IX:!?IA0Z>7-CT75'C93;6W'GIZW0\
M/]?3 'C_ .KT^V5D=3ID93K>F4@Z^>B!X^WTF;9JF,XI'S)1ZO&D>-3R+5JT
M?.F!'"1GK9D_5>MV+Q=J!Q71:O5XV11:.%$RI.56#U-$YSM5RIW1T#HZ)(!U
MX)&B0#Z$@$$CX;&_41HZWKQY&_AL:V/Y;&_J)RLD1B)Q7CYE'I$7?O&K%%5T
MR8I+/'"39)1[)/$(^.9D46.0AW3]^Y;,63<HBJZ>.$&R!%%E4R&H!/@ DZ)T
M!OP 23X^  ))^ !)\"-$^@WZG^0&R?Y#R?LG*R1.&]D&$:B+B1?,V" &2(*[
MURBU1 Z[A!H@055SID[2SMRV:I%[751PX01( J*IE-0"3H D_( D^ 2?3[ 3
M] 3* 3Z GZ?_ #[#/T9\R(]0C3O&I)%RU=/FT>9PB5ZX9,5F;=Z\0:B<%U6K
M->1CT73A-,R+=9\S36.0[E IVCHMH\00"VCH$@D GT!(!('J0#KT,FCK>O'I
MOX;.]#^>C]QG*R1&(G$4?L47C6.6>M$I!\BZ<,F*CE$CQX@Q%N#U=JU,<%W"
M+,7;0'2B1#D;BZ;@L8@K)]JZ)!8 E00"='0)WH$^@)T=;]='7I+HZ)T=#6S\
M!OTV?MT=?2<O))/R!BF$P%,4PD-V3@ @(D,)2G I@ >I3"0Y#]!Z#V3%-TZ&
M 11/U[7MXB856]DZZN3&:DZA?J5:HVMN7+*Q2%;M4%.,8!XS3,L[:33N+?NF
M\4Y:HD.JY0?*(*H)E,=4A2E$0VO3=65%E5M9< H'K9"X/@%0P!8$^ 1L&9,C
MJ0&1E+ %0RD$@^A (&P?AJ*[LG75OB&=@J=^I5H@9&6& CYNNVJ"FHA].@(@
M,*SDHU^Y9NI8!*8!C4%CO.I1_P"Y\@X>FZMBEE-M;JO-E>MU8)_K%6 (7_U$
M:^V"CJ2&1E(&R"I! ^9!&P/M])==6& 8I2CA[.0[-"$6;MII9U)LFZ40X=I-
M%VB$HHJN0C!9T@_8K-TG9DCK)/6BB93$<(F/@$<\0$8E]E=*3R )!*^/>T00
M=;T0?E)H^/!\^G@^=>NOGK1]/E+&8R3$&.P:%)VR4H4;=ZA(7J#:)OYJEL;+
M#.[9#L5N\BD]E*X@]4F(]HJ#AN*;EVS11/W]'LG'OI.UL--RUK<:K!4QTMI1
MA6Q'J%<CB3]@.YD4<*'*L$)T&*GB3\@VM$_SF7YKF,8B<1[(,(U(%Y%\S8("
MH@B"SURBU2%5TZ;L6R0*+G3(*CEZ[:M$"=>TLZ<MVZ8&563(:A68Z4%CY.@"
M3H DG0^0!)^0!/H)0"? !)\^!Y]/)^X>3.7DDC$1B(Q$8B,1.*9\R*]2C#/&
MI9)=JN^1CS.$0>K,FJS9NZ>)-!."ZC5LN\:(+N")BBBLZ;)J'*==(IKHZY:/
M$$ MHZ!() WZ;(!('J0#\I='6]'6];^&_EOY^#.5DDC$3B$D&"CMQ'IOF:C]
MH1LHZ9$<HF=MB/0<&9G<-BG%9$CLK5T9L90A07!LX%(3@BIV;HZ!T='>CHZ.
MM;T?0ZV-_+8^<NCH'1T=Z/P.O71^S8W]9R\DD\&,4A3'.8I"%*)C&,(%*4I0
MZF,8P]  H  B(B(  !U'R8B<9J^9/@7,R>-7A6SIPQ<F:N$G -WK104G3-<4
M3G!)TV5 4W#=3LJHJ )%"%,'3*01K8(V 1L:V#Z$?8?@?C&B/4:^/\OG.5DB
M,1,0+L&@GN*FNR7>H'V DP"55HI;+"FN*<8*950DE*P#T9LC 4CD4!X9B#<4
MS%."G9, CL[-W;[W:L[)/$6\&[?+>N/<UQWOQK>]S+@_'GP;AO7/B>._ERUK
M?V;GI;[*UT\L<[3FE_I3JW5=@:4LU6;VJ"7L==C"E3.:1G8-)^:3B&!2+)&,
M\D&K=N!54S"H '*(TTW!%L-5HK<\4L-;!';_ %5;7%C]@),<'"ABC!6.E;B>
M+'Y ZT3]@F2(S$0X-&D0E8U<\RS4D8<B+YJH:5CT2-E57T:4BIA?,TDWK-11
MRU!5 A';8YC@5=(3X%6'+:L.)TVP?=/GPWR/@^#Y\'Y2:/GP?!T?!\'SX/R/
M@^#\C/9'R<;+M0>Q4@RDV1EW;8'<>[0>M1<L':[!\W!PV452%=D^;.63M(#]
M\;.VZ[98I%DE"%A5E.F!4Z!T00=$ @Z/G1!!!^(((\&""#H@@^#HC1T1L'^8
M((^8\SA)66N+GB$T9^$6/8%'B4"1*58J'FU8Y)9>03B"D7$9)1@@W76>$9@L
M9JD@LHN!")G$M*..6T8<-%]J?=#$!2WCW=D@#>MDC7K'%O/@^-;\'QOTW\M_
M#?K(#C9^M6DI'PCO8=&:S4N<$XF(<6V 1E)-09%U$ 2/CU) KMZ<99B]BP*V
M15,,BS=,@#PENJD3,47E6<4VE%_>85N57P&]Y@-#W2&\GT(/H1,A6Y!(1R!Z
MD*2!XWY.O'CSY^'GTG*D]A4&$M$+2)F\4^(NED2.O7:A)V6%86B>03%4%%H6
M =/4I:423%%8#J,6BY"BDJ!A 4S=(M-KH]JU6-4GA[%1BB'QX=P"J^H]2/42
M!'*EPC%%_>8*2J_5@-#U'J9D[MVU8-7+Y\Y;LV3)NL[>/':R;=JT:MTS+.'+
MEPL8B2#=!(AU5EE3D323(8YS%*41#  D@ $DD  #9)/@  >22?03'U])!J-U
MIM_AD[%0[;6+M7U5UVJ4[49Z*LD,JZ:F CELG*0SMZR.NV.($71*N*B)A JA
M2B(!F5E5E+<+:WJ< $I8C(P!]#Q8 Z/P.O,R9'0\75D;UTRE3H^AT0#,FS"8
MQB)Q D&!G@1Q7S,T@9NJ\*Q!RB+PS1!P5JNZ!J!^_BW1='(V57 G>DW!BHG,
M"A@*-T=;T=; WHZV1L#?ILCR!\O,NCZZ.OG_ /U_#S.7DDC$1B(Q$8B,1.*T
M?,GY5SL7C5Z1LZ<L7)FCA%R5N]9JF1=LUS(G."3IJL4R3ENH)5D%2F35(4X"
M&4@C6P1L C8UL'T(^P_ _&-$>HU\?Y?.<K)$8B<-C(,)1HU?QCYG(L'S1L_9
M/6+E%VT>,7B8+,WK5RW.HBX:.D1!5LX1.=%=,0.D<Q1ZY2"I(8%2"000001X
M((/D$'P0?(^,I!!((((.B#X((]01\")S,DDX;Z081C9=[)/F<>S:H*N7+M\Y
M1:-F[9'LBLX77<'32102 Q1554.5-/M%[1@ZAUH!8@*"23H  DD_( >IE )\
M $GTT!OS\IS,DD8B,1.&$@P%ZO' ^9C(-6S%XY8 Y1%ZV:2:[UK&NEVH'[^B
MVD',;(MV*ZB94G:[!ZB@911JN5.Z.@VCHD@'1T2H!8 ^A(#*2/@""?41HZWK
MQY&_AL:V/Y;&_J)^F+YE)LFDC&O&LA'OVZ+QB_8N$7;)ZT<)E5;NFCIN=1!P
MW72.15%=%0Z2J9BG(8Q3 (B"I*L""#H@@@@CU!!\@CY&"""01HCP0?4'Y&<K
M)$_G[Y-\>.0T/(=THW'I^B7RV*[RVU#ZINVJ&T=*+#M35#SBEQ>K5$W+K".4
M1,G*6+36TQOD1-KPA>\6BCO-EQ#X\E9J)3V+'ZW!S,-QT3&R;:JQBX[7U9!8
M#V?('4<ZRW&O;^S7DX_:90W^CN%#CBEMI;UZ;J2,*JQD7M5%UL)'[.P9&0S5
MN?@MM? C?[KBL^%9S/WR&@N7.SJ3R>UM'->5<K>K/KWN@T'M2NKUJ99Z/DM;
MJ5C927$&&T%-*P2%4F[C9RAJ>%\5ZREY2WR\5+[.:[D;M[!XH\%83=/HMP+F
M. M27](:APZMDBX64'J+9:\BZ5)_G#<KU6M66@XQ*<MRHXZ-0Y]G"+9B&L[4
MVAPR'(-P!Y!1[YVX" A.UXW-HZYL7+ISRQ;)SLQR-1U0>UVU95&0U1MD]9><
M7QT7(/-<R+^4GH2"J,#M!2V#6G\RQAVLGR@1VWX^J5GHB5!<+C!Z+Z^GCIYX
M+A^T=NL KD8_,9WM2BX*J,]CT=OF%9RN <?C97:;@.>#C']G\"D/Q4#3U\AD
M=T=P>"6-?'D%+$4<.+*_+PW9[F=7&5BH_&BQ)(;U00HNR8ZXU_9M*U(ZW39]
M<3;G55TJL/8MM<?)S7]LMMSKD]&6F6K%F-'5*-NU!LTU%6$SZJ@QE96,X>FN
M4MS4WBGNT-4]%N2,5+D&158R49:W5UUNC5K8G*QJK:T9-6;53HQCI[P35[U9
M0HUHJ5UYJQ"7!U12"H9=L5=05TVP#T2HV@^0ERN>C]NT+7OL3[-T=JGE;9M1
MRK375YTGJ[9DG.<HJW+HU'8FK[A(S\QJ.(Y4:]7LLU)Z[GY!W,:WE)AEL2!A
M(V0I<5!QGJ69>)55EXUUW?HRLCIZ9"FZK*OI5,&Q393?6$7(? NX*MR +<JF
MAW9;6=NIK:56VIWYI990MH+);8@%!!>MU"BPT.  X #@&LDAR6XU%U+R2A=3
MZ10HNK=G:_F.:VDI7CCOUN\@74?9>.SQGN*S76M[1N2)"*(UN4K^D-E\A8)M
M..1!&3V STS6TG:Z+^,40RMR,-LC)[N11<G2\E<S$*N#7F XU=5E-1)!L#Y5
M&$W #:TG*<@<6V:R@O;RL1QC6]ZH[\7 UJA1?B0;4I;B/1#:VO!,^I.VJ!5I
M3B5R%U)5:-LZZ51;6^S-9)ZP@U9'7]L?P*E.7K#BC:=E[C#1\8@Q)!J#&:ZE
M6R<G3G;T&Z"$J\9"Y.GX./=8O4,/(LMHKL%]%_?<+=6'[HL%N2M;,Q//WKE.
MK0-[4-H3AK=AD4V,R*W-'YD!U!Y<N5@4DD[\N#IM? >)\TJB3?+.Q2KS4U6O
M=RA2N^/L:ONJ4X<V_B_M9Y&5UAO#_P#+:[TF9K-8K-[2U^A)0TJGLNAZPH45
M6GEM&G'6D3JH-8GV;?92B"^RJM_\\/LJ]1KSL8%VQ=756K98]1M(9>S;?<SB
MON>[Y+=K=D@=PHA_:GM#(6^L%NT>XKAF9.9\<&L8L%Y>!LGW$F>4&L8_3[#;
M%^Y4.=9['UUPEL>]I-NVL4GN;V3[E2.6;C>%+TS'UBN!>6UA2O5/X[O=D:IU
M'#KV:FZZ)9YJO5Z%3D9IZYR*X-S9)QZ< 74W=4KQ 2BXW8JMZ>,2W):RSM%#
M59F"C(R&"6W=M7=RJ@.-%G<-24"RNS)%0)7M=M7Q^TUI=N'$(UW"RP\6?B&+
M>[K1].L_+VY51/=-/<;YFJ]<(G35*V7LMS3+E(;7E]/:\Y1]U59MHI%EI. -
M=GEPK:\MQO2V(PTS$JVZ)IEB6D&+5")D1=FZK*^GUV'%M&(KUOD6T4"VM<=<
MF[!Z"2Q.2_:%3A<WLMDOVVM0 DL-38RXZMVG[/)3:U:!E%0L>C ()[I"<& N
MX&TA2P\G8GTDBVW*"S\2N,4/9+%N2-V39]RTJ&VM8XNN)TK:*&F'MZM":RUJ
M:,0G75/=KZY3K32SV5486U,G*RLZ]1I5M6680WB,<*OJ&:U:8S4UX]C4(S]R
M@Y(J3_1D\!8!<7-=8YUL $!MK]YN,FA<B\J*RBUL:U)Y)W.*_N^@8!^6E\J0
M- LNB>L">S.;M I=WJDM!\GK78)F#MU#TA-L-862W2*;_6?.GD!6FMEO=BC*
MTHR@'L_Q4'3,^QN%Y5C&VSH!D>4K3FP6=X=&1[C3TRVVMU;!K1'KNRE:]*P1
M?TO#?MTHS[<)G^U(U=6^PY"V!*QM=_#%=T(-"J"KV@N%'[3%I8J@)V0N1W5X
MIO@3IN*@&<Z:9;YN<FE V2%Y@V3:+#E+J.R;&BI^GN0XO0U6I'=%]#6?7<YK
MN3<P#9C(,(32,1(SK!]J.7E4V%)CKI,<B!;7-E .$(IQ:QR1NG)0<'(2EDM'
MMS66]'RDN2X!R06R6",N2JDVFI<+=1LW/V2@%3CJG9L"%6_;EFP[5<."V]FT
MZU8/WRJT^X2)JS5EC[H*>J2:VR'_ "<$$8[3YN4+. UAL9*VQ$\MM.'1V^;C
ME)6..($ZJE4!M"#MAQ<@+;3U->%CI?7,O&[2;12,YOR$Z2+%[ PM%LDX)>^@
MHR]ACCC-5&/ =SME3GM78+N2WJV.6*;'7$Y#@*=;L[!:Q.)7MDUF\*=C3<3^
MW96YGBX:O>K+RN<FW%XH6RBQ_**74?5'95%U2K;:3:I2:)J]KS=TA/5,FZ(<
M:JX+4[A*:1)8Y5F]V<A7[K*56J0CFSA[(D+/$#$/A=JZG>"NK*+;Q78BKWST
MS*2WV9NY^TK7*X*107J6RQQ7^Q9) U 5TW0 &1[.+ #F<6T-VR6VRBWB/<VH
M9B%]PB8K8V7,AQ.#>:E%<KW/(2L\>=NU7=4Y;J-8SZ]KE@M'+KAY(;,BN,$@
M-=0CYPTIH.J;+E=9L=7.IQO)157J;BM)+[8;W1-38GZM"]JQL 8=F9CV8JUV
MIWG2OI_4ACG.7F2G'+>A<@Y 0JUE@<C&-1F0./H*QQQ2UM;5!7',@8^0$]H
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M*=8]IGQ[* V5?4*?9NG5&W%S4WE4TV8J'&NZ8SV7574U5V%KJQCH+*>X%<7
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MGLLJ'[&UCSIUWUXJA=FH# VHJET!')1L;S%5A8+P<$LR_N.3M-<QH DE 06
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MD5(:O,6B32:6%TK,SB2L#'&0[XDZGTSP22AI8HLPR/3>HA2YP<M4"NY8X]H
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M)[CUUE:U]6<J/ VPV)AY#C8K8>]8FF5@2]=+7% ./[Q5=*/BQ'H/,WY \C-
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MV"U79U[?M.#;CK6 [*?\W[S,18;O="'8F54@95I8HY#-S>NQN08D<>Y2U84
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M Q<7$J&BJ:W6S$J6+'85=5V1W&K-:FL5;*_Z,$,6Y; JJJ0:TO\ 9))!)8[
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M7<R<(_VIUQ$ K&*32$:CB[TVV=@XV)CILW8UE+6AL1;&+T&M@YK6NL!6%&:
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$B)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g556103g01a28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &U*^:90X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?OMPH         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             %Y@  "_T
M         0                         !              O]   %Y@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   %Y@
M  !29VAT;&]N9P  "_T    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,     !"?     0   *    !/   !X   E"   !"# !@  ?_8_^T
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MM+W-9GN,G:WU<5K=I\-/ZO\ PB6O<);W3L&G%:VRP5-R=IK<Z@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML8;<;4KJ3<%XA UPDL(5K9YTE76I/]WBCG=DP3K0Q2H\;+D.#M6R]E<1EPZ
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M4JQ1+M)),EVJ&/0J@-IDB!MW$ ]J5&Z!L*2'25HP2D'.PJXPS.)0NDJ!@X9
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M<6-5:\<GMP@DM[:<0R)- .7V7E2I&T);^YFW$HEC;1.)0[2A5RX(),(KV2,
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M:^+=H'\:[.1OK6K*_5K&B)7"$6X.(X3-)=*!'!%/*(XQ(0LT4<R"/$PU'1(
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M7>9U;K*,II<?75$86S"DCF5LU&OM*:'S?B'VR TI ].6X4OXMM?M,5&<,/\
MQ-8?6MK]]$O:<&>8YS-*<D,<R/NPT8)WW(Y<>#U&A/HKC&MSU=COGYQZC&#U
MZ]U?U1ZA7<&:^H02%#'!J14!(\='!Q1\ 96@T"% BU@I+-UJ-#BQ833$6/7C
M4^<7!LL-H;$E)LN? 3'ER7G5X:65B6:61B2Y)9V))=0KDDDDEU 5R?G* #D
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M6-4 )TJ-@ %554!5 $Y)Y)=.MOF9TX 4#.,X"@#P ^H  8  K+T.KUD>V^U
MKH*"U)%10,EN&('QFY ."X2>A!GT,QT)=%0WC)=V*.<PJ''<*DG&F4*G2LNZ
MYD<D$NY(8N"6)(<Z<L,G9CI7+=3I7)V%5EF/5B=\[DG<XR?MV&_78>H51,:Q
MULD/\.IU[1TU_ LB#P"Q4P. _N4ND:@L']V8'^Q>ZR: XA)$?ZCV2:D4-3)9
M=Q!BX:ESYM6OG2ZM2MJYCZM2ZM+:LYU+J;2<Y&IL$9-9UOG.MLY!SJ.<C.#G
M.<C)P>HR<=:[);7U"/5:-1SE(J!JE0V($:)3RU:#$:M%C"L-I%QXU?F0GA+#
M W#36(#341+</#3>(Z6\(3VPLTJ2&599%E)),BNPD);YQ+@AB6R<G.^=Z!W#
M:@S!MSJ#$-D]3D'._COO7?>J=6D1W(C]:K[\5Z6$GO1G@PYV.[.K3T&17)KC
M*XRFW)=??%C'PDE2<O"GAT%R MA<2.IO',<$$.X(# '4<@."' .>CAF##HP8
MYSDUC4VW>.P(&YV!SD#ZCDY]>3GK5P<A6*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2H,>DS_F ]6G]"UM_PR.=#A7XRLOSB/]]=CT?_ !UPW\ZC
M_C4YD_+'Z,?W<Y]<>N&2TZ\PZTS)=ANK3X4264,..LY[XSXT(DM/L*SVQV[.
MM+3VSGZ/?MG&&!((#%2>C#!(^L!@1[0:R" 02 P'4'(!^K8@^PU0O<QC[W&/
MZA6_V)RKER?YB3]2'X56:X_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y
M*?K2_P ]/<QC[W&/ZA6_V)QRY/\ ,2?J0_"IKC\E/UI?YZ>YC'WN,?U"M_L3
MCER?YB3]2'X5-<?DI^M+_/3W,8^]QC^H5O\ 8G'+D_S$GZD/PJ:X_)3]:7^>
MGN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_S$GZD
M/PJ:X_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%
M;_8G'+D_S$GZD/PJ:X_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2
M_P ]/<QC[W&/ZA6_V)QRY/\ ,2?J0_"IKC\E/UI?YZ>YC'WN,?U"M_L3CER?
MYB3]2'X5-<?DI^M+_/3W,8^]QC^H5O\ 8G'+D_S$GZD/PJ:X_)3]:7^>GN8Q
M][C']0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_S$GZD/PJ:
MX_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G
M'+D_S$GZD/PJ:X_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_P ]
M/<QC[W&/ZA6_V)QRY/\ ,2?J0_"IKC\E/UI?YZ>YC'WN,?U"M_L3CER?YB3]
M2'X5-<?DI^M+_/3W,8^]QC^H5O\ 8G'+D_S$GZD/PJ:X_)3]:7^>GN8Q][C'
M]0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_S$GZD/PJ:X_)3
M]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_
MS$GZD/PJ:X_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_P ]/<QC
M[W&/ZA6_V)QRY/\ ,2?J0_"IKC\E/UI?YZ>YC'WN,?U"M_L3CER?YB3]2'X5
M-<?DI^M+_/3W,8^]QC^H5O\ 8G'+D_S$GZD/PJ:X_)3]:7^>GN8Q][C']0K?
M[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_S$GZD/PJ:X_)3]:7^
M>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_S$GZ
MD/PJ:X_)3]:7^>GN8Q][C']0K?[$XY<G^8D_4A^%37'Y*?K2_P ]/<QC[W&/
MZA6_V)QRY/\ ,2?J0_"IKC\E/UI?YZ>YC'WN,?U"M_L3CER?YB3]2'X5-<?D
MI^M+_/3W,8^]QC^H5O\ 8G'+D_S$GZD/PJ:X_)3]:7^>GN8Q][C']0K?[$XY
M<G^8D_4A^%37'Y*?K2_ST]S&/O<8_J%;_8G'+D_S$GZD/PJ:X_)3]:7^>NVD
M:12E.,V$BO.$XQE>8@7&59QCME6<)&)3C*L^><)3A.,Y\L8QY<EH?S6/_3'_
M  6HZD\L#_J;^)JL\LJ%.*4XI3BE.*4XI3BE.*4XI3BE.*5C>U[AU;1\N-VJ
M_5</):[^. ^6BO$\=OGV%15OD5=O_EBY\_+YYQR^.VN)?\.&1AZ])"_K'"_M
MK5FO;2#::YAC/T2ZZOU 2WAZOJJ#74[Z5WI5Z6-7V#;5MSLB[5BMR1,0@UKR
MG,RR>7#16(&@K98N!FF15,9(38S3KJYC>$)=PM.%X\N=2Q]'^(<0N$MHN1')
M(&*\Z7"]Q2[#,:R'.D$]#TK'#[ZUXG>QV%I*&FD5V5G5TCQ&A=N\5U9TJ2,*
M<XK3):/X6MTL1''$TSI9Z@#[.%=FG+.;UU4G%I[Y\UM"C=U2WGMX<]DO.^><
MX[^6,J]1'_9UQ$@<V_LD/B$6>3'Z62+->J7@$Y^=/$/^57;]X2L9N?PNK7>'
M<X:Z'KHMCQ9[..;S!MNY3]6<LIUFZC"LX^:</YQC_P![/SY?_P#AQ<?_ !6'
M_P#BO\:I_P"S[_YI?='^>KYKO\+;Z<)+J,6WI*W:%8SE/K'*[<:)9W48SC/C
MRADFJHH<SC/;"<*?:PK'?.<H^7*G_LZOP#R^(VCGP#QS1C])428]AJ#< F_)
MN(B?^)77?[1J]N/T5*N@?PH;T95O?BQ[*GJ#U7A[P8?F775D$K!B*4KPJ]8K
M6]NOL]U*,?2RI@<YG*?DCQ_0YSIO0+CT0)C%G<8Z"*XTLVWASXX1]6[#>J'X
M'>KG3R9/^60@G;_C5!]77]E;.-(>E)]'EU%.PX>I>KO2ILP0RA,"M'K4U0+?
M-6O.,);AT_8;55L\IWOG&%-,"7%H_P"9..<*[X#QFQ!-SPZZC4=76,RQC[98
M>9&/UJTI;&\AR9+>0 =6"ZU'_4FI?VU/5MQMU"7&EH<;6E*T.-J2M"T*QXDK
M2I.<I4E6,XRE6,YQG&>^,YQSD=.M:E?OBE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE08])G_ # >K3^A:V_X9'.APK\967YQ'^^NQZ/_ (ZX;^=1_P :G,GY
M8_1C^[G/KCU_>*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI4$[OM[J97U;*U+K>K#R.I*Y5=-V2X'$:WK-DDQ5WJS[&A6&.7N)SJJU
M.6K$5(6EQ/=<JL:1VY)&NR)I*0/-N(BUYWJQ6]C^#C<3R$7+R7*1)SY$!Y4<
M#(5B7A]PLAURG4)+NV#8"AEW>MM(X.S<QVQ(6E51S&7YBQE<(L$@;O.<ZI8P
M>F5&6K'$[TE56Q% % ^J[/.%/$0XJZ>U3ISABFELL:@1> ;PNH56ZL>]==6#
M<8JE60C:B=)HD6\5:Y5*;>!IX<-@%[5X,^75IT#:6:+ &B50;GE.&DDB.F9;
M9I$$:RRF*2*01,C,RR%DQ+ R+G!*8QAQ\IH.69=G$990H=]+*V@@DC]T;TAP
MV3J)^ZW6HH59Q5[O&O)T,,1A! Y0[5=%Q=]P7A:3! C-CQ"P<N%IC32W9Y!R
MT2,KAPY3<J#!>2\'87 BBD)1H8I@6!9U22[-H0VE5!*LK2]%'+&Y!!-&M#S-
M"MW2JOD@D@&4Q'.  <$%L[#2-R,$U9@+TEQHN>-CU:0G82@M4M<UX/$SM*8:
M=VU,N?5('M,,V+B:<D[*@4QBL]-I$H'F+TZQ;(YN:R).U>)%)9) K7X*JHK=
MJ'S7G=CR HMQ%8-&58W(@,A>]56':3&5&I)"1I:9L@ #S1T9R3RP.6%@*X)D
M$>K5, ?E2I&ZL2,-E39_6W+HCO2?L=0&&&T-N#5MOVMMZ19(,E^^44 ^SID!
MKA GW4;]S>V+V+NFK5VTL.1S49V%,7/&3XK,!;TS7@X8)1?PAB]W;SQV]L(R
M!%*X-R\VK4FK')MI'C.4(( 8'.!6EKJ[0FK,L;K''I(T.WRC/G*YQHB8K\TY
MV(WQ6%=)]8_4ULT1:B5Z.=+NDB>D'";NX*[>0MW=9M'J.I+>6GLPJ[9H^RHN
M=<"1PG4+5=BW*96=KIM>RYQ=$6K!( B,%*[-SPZR@:,1K?7*W07LSQ-$"F;*
MUN<O&8#SG9K@N8E>#EPA<N[,66R6W@C*A1/*)0.64*Y&88I-UT'629,E0T>E
M,9))R*@)ZF^LTI2+7=Y@2DU4.6W-KC4FLK#8])#7Z:G&P^LJA]/*#JYU8ZUK
M!>KNX)I%A,F<##&M]*MD3[428HD.B15 "N6L>&+)%&&ED=;6:YN$CNV$OR/#
M);S1B3A:11:I45=2SW6E,KAB=:C#;!D4%F(B>215E.KN6[2XPULJIEP!D/)@
M9&#\X9K7U*;BK>L=E2B0O6VQ-B:IZM-*]-TVPUV&>H6O;R+VM=>GP;/L84+-
ML>Q2U<+547O*332H]^V6:+%V!23,QYSV+#E;C:@LK=YX0K3PPS\/NKT(Y26:
M(V\5XRHS!(5=9#:B56$:$PRJ!DX<U"&-G3!=$>WEFPV'=3&DQ"D@(&#&(,#I
M7N.,;X)Q9&])X+(4]-Y@Z-O#-8D#ZG=VC9N/?! \9J.W@MEGHEULL;&J)MCA
MRA<?6))FPRZW7;=IZOJ,"YQG=T$1 M1*MWG@;+)RFNHN8&EBT*8F9KB)X$,4
M?RX0AC.I02/%<OH8+:ES&LEG8>]IYR$]Y< H29%*#0OR@&^M<:F60[@1$Z0V
M<(?57=FZ'2#,K6M:*W39G4_OWI\I@6+L!NO5;V/4!;J'FC[,>M1(&4?A^\*?
MH,DB4P-"E%2K"2BO18\(5)=2,UFL(N;*HG<1P6-I>2,8=<F;E;,&-8PZ@Z9+
MM=RXPBG)+#>HP+K8!R%2"*9B4RWR@A!4*",X:4=2, '))&3A"O>E#KEVC@B5
M*TG?9X>]$];5G7TZR8-5!$^W;&O&D:%''VLB0IDFIAA HMO,#*EDJ;:MD&D#
M09E^?5A;LVKL6#:?@;Q%UENH5:(3O,$TR$1PQ74N8U$HD9F%JX"R1P+J=0)"
M Y2TV)7(:5 4UEP-+=U$E<E0'U$D1$894&2,,<,5Z]1](+L$/4-CVW;NJJTN
M+KR^6,=9&Z+;'8TP#63?4=M_IRU&,"CCT22O89IZSZ>,RMA654S7XP>*(Q2U
M<K95Z(7!"\2<)B9X8[>=\RQ(4YL>0\B65O>W+,R'$*A+E1"F)F8@AW7*NQK1
M"RK'(W>0%=:]66&.:4L5/<7$BZ!AR3W6(V8W(9](-:0T$^2>Z?FEPZS"+R"R
ML;9AI=3("=.03JMG1(S2:*YB1E.HS+<%M_*VFW-E8CUC&,59Z7L ?%.$(Y11
M=G,A33_=ST>]>P4D\W;^\+DC?$&9-Y (6B+13I FW8@ <L^,Q@SG4/\ >#/_
M "9;YP"&OR_2 17-KD-25[54PX9('3-<U\7=LI,56;&1K&W:SI2T.GK,]1)%
M9&PP]RM,14MO7QO;!H/"&'15R"U*]CDTJ3 <)(@6X>X"*%5YE"*TB*]O)<II
MC$HD):.,@<Y+=7)1HFDB)E$>R$()&D"@ ,XP"RZHVE4!0^HDJNVL1@DJ5+(=
M8H./21"%4YV^8U*0; 8,:GUO&B.72!*N$S=FWZII&W5^GC:&$ F;=9::.'[W
MK"#-RHXFW6MG(6S38>K9HN**G%Y_@9N;RNT+KTW$V>4PC%M;274;R-*S+''(
M6M)-,<K1Q]Z,&<,6"S[$=6CF#5AW^;A>7&TJEB[,%5CR6TJY4'*C7G($W=);
M01N36P78&*Z4J;Y$A:PI"O&6IK,T<7I=O/4DTA+948#,I@/EJ[-E"O?U?K=A
MR+?AYL%9KAK,\' Y=S!V:9H=:R!1&P=2""LL:2KNK.N0K@-H=TU Z'=<,=66
M/EN4U!L!2&!!!#*'&X+#.&&=+,,YPQ&"<K<HJNG%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2L7;6W7JG1]?59]KWNNT@/G+B8SIJ<EN61>:3A;D4.+9P\4-34H
MSA>80F%,E^#Z?J?!C.<7P6T]R^B")Y6\0HV ];,<*H^MB!6K=WMI8Q\V[N(X
M(_ R-@L?4B#+NW_"BLWU5I:WSZ;05!>F!>G37&3>6_6--WC9&9$ :XO'B1AX
M;3Q4EHG*CK[X=8D%#8:1CP^&0'QXLX3Z.U]&F(#7DVC_ /*APS8]32,-(/U*
MK#_BKQ/$/3F-2R<-MN;C83W.43/K6%"'8=""\D9\"GC6H;;_ %L]46\79*+Y
MN&UK$25+QFL5R9\(U=+*L_0CNA*Y@;%(H:3]%MXO@C+[=\N27%Y4K/H+?AEC
M:XY5O'J'Y;CF2?:&?41GU+@?57CKWCW%K\D3WLH0_P"ZB/)BQZBD6D.!ZWUG
MUDU(;IW/Y.ZO$-NNY=E Y,X))4K/=79A[VJ)C/?.<]DCYD1O&<_\649^OOC&
MM=+IF; P& 8?I&#^T&MVPDYELF3DH60_H.1_W2M8J](+656WHOZAQ2&\.*BT
M"39O"I'C[)I9$=<5KQCZE-(!*<2K_D4G"_\ EYM<%DY?%+)O7.L?O08_WO7J
M_1:;D>D'"WSC5<B'_P#D(\ 'Z3(*\5O/JM?H&G%*<4IQ2G%*F/TY>D&ZU.DN
M;$D=/_4EM*@#X;C3B:FW8G[!0)&6<X\&)NO+2DW29O9&,M87( N.H:4I#3B,
M*SSEWW!>%<1!%Y8V\K'/R@01S GQ$T>B7Z_GXSU%:\UI;7 (FAC?/Y6,/^AU
MPX_0:])?2+_"O+R(D":SUL:*%VX1A+4:9M+1:D@K0PE*L)S.*ZXLI-RO''W4
MJ\<I82U5%AGU:U1 [V7$1T>'XE_9Y&P:3A5VR-U%O=]Y#TV6>-0R^.-<4F<@
M%AC-<6XX"IRUK*5/ER[K]@=1D?5E6^LUZO>D_KXZ1^MVNKL'37NNI[!?B1&I
M9NI)?>!W^LMN>!.<V.B'F1UH%QT/KS%03=&*#S'T+P.(S&\8<S\]XAPCB/"G
MT7UK)!DD)(0&BDQGYDJ%HVV&<!M0'4"N#<6EQ:G$\3)DX#=4;'T7&5/V9R/$
M"I@\YM:].*4XI3BE.*4XI3BE.*4XI3BE.*5!CTF?\P'JT_H6MO\ AD<Z'"OQ
ME9?G$?[Z['H_^.N&_G4?\:G,GY8_1C^[G/KCUB[=E2N]\U5=JAK>ZO:YO)X/
MF%6[O'Q)R]7"&94=WV]O$-;<GQ>H:>8_D5I7V>SGOV[\T^(07%S97$%I<&UN
M)$TQ7 SF)M0.H:2#T!&WKK;L9H(+N":Y@%S!&^J6 XQ(NDC3OMU(._JK57_V
M%?2,_P#Q$3W_ --N_:'/&_[.^E7_ ,T2?_?_ )J]5^'?1O\ ^74_^S]U/^PK
MZ1G_ .(B>_\ IMW[0X_V=]*O_FB3_P"__-3\.^C?_P NI_\ 9^ZMM H'8Q>K
MAM:+EW;-;1U!A@RA[Q+;?L%CB5UN!-+^)]?K$.EB;;LWQ/.>-*Y'=Q?BQE7/
M:I'*EFD,CF:=;98WEZ&658@K/OT+N"VY\=Z\DSQO=-(B"*%K@NL?41QM(6";
M#!"*0NP\-A6L@)TD[TKNC:[2!SX\@=W*/T($VG4X1*PZRJE& ZT#F+A?)UDL
MS-GVH;G7W9!9L=K6V6RE"8K!=EV!*8KP^)$DD6?(Q\$XC%PZ*W0JTE^G#H[V
M%7EM(;>*TC>>X:682WDC75U(%M)I[= '!5A$BJ6KTS\7L)+Z2=@RQV3<0DM9
M62.ZEGDNG2&W6.,Q6J+;VR%KF*&=R4(8&1B0E7O6.GF^&Y.JK'L;7*7-A5+I
MUW91;I9&S+<ML_MFDG-25'2]U:E9(1G)LVSU.LVJR5XD_ BN#HI:?',,"9S^
M8>;XN%W,ALI;JUS=0\*XC;7$HD!$M[;R64'#YP0XU--!%-+$Q5="NPD",=-4
MR<1MT%U';W&+>;B5C/#$4(Y=I.EW->P$:2%6*66*.10S!BBE"ZC-8V,=-'4Q
M9WM8!+5*2<&)HO2.%.3GPL1H+6FZ9-W,Y?05CKZ+\MZXRJ^@]75G"L<@.384
MD(*8K3F1[N6]=^$\6F-K'.PE3LW!(W<QKRXN0U_VF.6(7.9FC$D7,D#H)0Z@
M Z#6RG$^&1+=/$.6_:.+N@#DR2\Y;+L[QR=GQ"LACE$:E6Y95B3WA5W7#I[Z
MA ^X0IC533H\=KXG5C]6G1IL8'1K'+J6C9H:=62%?<-DI@>K7JR9E5&:VG$Z
M2"]^I,QWY:QC<M=L_"^*1WR26646U:&6%E81V\S0</9&A>+F.R0W,N8'^<8^
M9S%+% :IAXAPY[)X[LZFN%DCE4JTD\:RWRR"59 BAY8(L3*>Z).7H(&LK6--
M6:$WX+DTM)75U^%[-C9Z0GP^U'K=7D@:$$H0VL)WH$L+K5WP5,(-!X5CK,D#
M!KQR'8R!..\XZB,VHC'U+/AO$D-N'LKE+L?@0I>&:+EVL=LL/X0CE(N \G,1
M9(C$L4BRE@20HU#9NK_A[B?1=0-:G\,![00R:YWN&D[ \0,&B/ENT<HD,D9C
M5",9.D]6@]-.X)^IZY1">MS-;N4FY:C<N=AL5-J^1;P01;URK7(,EA.ZRI38
ML!F&ZW.FPI NFO3XK#J6\Y?>3'1&UX3?-916SVDD,YGL3<2S6\.@QQS$SEW3
MB#O=* 0S*4MRX&VYP,S\3LUNYIUN4DA$%V((XYI=0=X0(A&CV2K;-D%0P>;#
M'/09J2P77NR:=T8F*"?U9<MA["&76P>/7HJW1800^\[LZ2;'2*Y.3:P+K6DT
MP'8I6#0REB@E7JHRY12[ZI#LF6OKQVMU;\ DM9;.XNKE+B7^[).JQRYO#(AB
M83QD6&@JXMWE5S"#;N226/-DN+>?C*7$=W!;V[01XN'A+/&!:A&$J\EP;[4"
MC7"1,HF(G08 %=X^%V34]3]*]= _QAH,@AUU&M)NF0SEJ7LD?HC9#6M6[HU!
M/VVL)BJL[>5B81"R'PD<ZBH0Y)*=.:BNKE)'=06?!HH^U:XUN%^7T<\W:\.N
M^R"X"RSPZ>:"45I98Q*(%+LP!,4DMI;OBLC]GT2-"YY.OE=F:^MC<F M'#*2
M(_G%8D<Q\Y@JKG&0-:UKJQ<9M,8[M&(*<@6"NS $_8FNZY<U'AYC5>MYEHA9
M9HEDULF - ;'=V%$&,HRQ,2_F,E<N<"@18T[9M8>-$3"2\"%)8FB:ZM8;CFJ
M]G:F88MY;70D=UVH(!A@2,LT:@-KW,O"083':EPT<HD6WN98=#)=W(B.9XKG
M4TEL+8L=UQJV61B5B5LO1.Y;(0WC@/JW:8JI6BW:Z)D0\"]4NP3K4;K%LVR2
M+V:JQ;1L'$,\ L>3M',F(]CET B* -":,*%2HE+Q'3Q;KAM_*W$.79WB033V
MKO&MS;RM-+#/>/)-"LUT%EBFYEO+()FMF2,);)&1!@=>VO[*);'7=VKRQ0W*
MJ[031B))8;14BE:*VU1R1<N=(S&+A7D+3NZF;>^=F4S?6Q ^BQH*@V04?U=7
M8=#L3-;L0\'4Z9NA/_9VL\#9@61,N+4VS:XJ-?B[0J+$['OD_F4LL 6!G)*N
M2WMF[M^)74?#DCMIDDLXEMI1#,L4$%_GA4R7<;-<!YK2");R#7\I+DR1\IM9
M)HMIK"W>_9YXGCNY&N(C+&TDLUE__DHFMI L)6*YFD:UF*]R/ 1^8NG2,+D^
MGSJ<<KEACRJ+L(M#<+L8MU<A;*!QB>Q]F8J'5 .;W""GN7Z&Q%K3=OO/3^9R
MR0(@2T9-+:()K'KZ?%8D<]^&<7,4H-M=.ID'/A%W&'NKOD\707T3&Z 6$37'
M#)"&:.0<C4(28 K;J\1X6)(R)[='T'E2FVD*VUMSN%-V.0=G),G)@XBF45T/
M/T\W$Q(V&],46YP&MRC[3.F$X$#;+<.O$9:Y#C<Z4QJS6*-ERA;CZ4Y6(>W1
M_&2MG*4I3@CDHE*4MI;3CT_"!<*+]9F9U6]"Q,V3J9;.T%VR$XS&;\79&P[Q
M?&V*\[Q0P,;-H556:T)D50!I!N[KLH?!/?%EV4')/=T[YS4H>=BN73BE.*5%
M3:$WHSB;)AV+>,#IT&[.JOPVBNW/;<'5\2W0\Q9+IP W5K%;,8L#&01"6HI&
MQ ?CI$3IZ9\;+3LK+ZM^ <2,)CM6O6@?7KBMS.8SD!7UI'W#K4!3D'4!@YQB
MKXQ<E"L1F*-J++&7*^HZ@NVXV.>O2JIM*7TET>0/@[3':+@'8C%XOU9K-E$4
M-RUSWR<J9;;X>J%<(Q_?!$Q9"P^69.RPT5R?83D=R7-=ED&U.)C +^4$P&Z9
M28HG=&EY8T@1Q)(X.E516"J&("*<#"T07#@F/FD91&92^D8&E S#8!0<#)PH
M.-@:QW'V'T($XD,Z09Z=11:U!3@L2'M [5H>YV@#%R;KQ(-!"E%-%24*?G!\
M'[F6G*9*G"PF3$0Y[QC(N,7%5+*IO&6-D9FC:=HXW.AU9G7*J1E&U9V[K _-
M-3,=V#CY8A2"64R%5.S Y&P(P#D=-CGI5"K6TN@"V!B D %T//:;NJ-26.CQ
MZ7073 DHG9[]5CL6>HL0G9(^J.7^$DK#,D(:0+^78%FC/K;EQ)CDG@XM&P9V
MNUS'VA)3)*%=>0')CD)PTG).DJ#K&&C(R"*%+I3DF4'3K#:F&0(PQPV?G!#@
MC.>JX\*D"FZ=,UTUW,O2;1H^UZIJPR369UM][44Y0J\'4[6R$JO2367Y0 4-
M=>'T^>X)<D,1GG(59EYCK4P)<3J<J]BF$7+NH[AV#K'IE29V[X#A<!V;>0:L
M$C+C/SJJTS*^G3*)&.H+AP['O#.,:B=V&<>+?75A%[WT+3"U0/'K=TI23@>$
M5VC0S9@UJ1TH)@V(P6L!O8%4)SI&90YDZ?8/'"EG$OL8*&(YDG*FOS6)SZ+E
MBXJJR(L=^%8K;RJJW 5BB(JPR*!@E$**L; Z5**  5%3"76& 6XTDA' $F"0
M,!& ZX& %/08&,8JV,0/1RR4[%+8&=%TC!$8-G[8(X&:2=R3$6RQU^PB)-_E
M>SJ40@V.WKJAF NP+?:+6===GL>O++&.YGJXR.2NKB8TEA;KJNNZT2.C"$9V
M,<7,4Z,:8PX.%#"L_P!\&@?WD8)$8S*,%5((0>!5=0..BZATS5W_ ,9O1J%I
MN=7A;)T\S*A!KH^QQ=254GK&4)56)^ ]N%EA]#A3&Q61$I@X$MT&8W 1#D12
M0^P1G'&I4:4Y7R.)-)SW2\$A=D-Q(LX;F M&RM*1JU JT; G((*'&"*CR[EF
MUE9M1)!D8/G(RI!<C.=BI!/@0>E46=<.@!P">+DK)T@N5A%TA%+,4FE--K _
MQ@DAU@GP"IN:^]D>JVS1$*US8Y*:[DL\.@V22A_,:&56U)8N+ZT58^(\SE%4
M4+<Z^2K("J@#/+#&,%1W=108R5S(+=ZE4+<:BA"C$F2@QD*.NGYN0-LZ?JJL
M[+!]'ED-:LIVRB&C\$IU_=W+KVA&S-'AM;!N=QK5RU_\6XI\M]#6P%V&)L ^
MU&GNCRB2=DDCY[+[YB'"6F,+\119Y(1=8$0MII464F&..2.;E\P#,.AHD)&5
MP@88"DU%#<*)&02X"<MW 8Z%5E?3J'S,%!MD87(Z$UP_QI=##TUN^?Q@=*CI
M*PEQ0)JXYLVIED#ARFO5*Q!!:#^9F91(A57FJ*?%1L2WG@:FZD7B)BX0&DXS
MR.*!3%R;\+&K.8^7<!4242(S%,859 948X ?,BG/>%9Y=UC1HG 4$Z=,@ #!
ME8XQL&&M2?RN\-]Q7;NMLZ0J\4HTRV,Z1?F'"UY$ULZZ+HQ)D!B8 VS?=CF"
M)K+3K=5KA!C7NU7KE8)DB&*FV"$?@FI+A21.1F,4?$'641]IPJQ,Z!I5+X>W
MAA54R.8X,UN(T +!2A08"T1;E@^DRX 4L,N-6\:( /RF&N/2NYTXQMBJ+G?'
M165L@RD#K7HZT%K<%G6-$8.JD&!DNNICRM/F#,\FA2A#T**- RM=&4>U2)<4
M(*779T5 F*F,F79.)*C2M'=1K&XC.H2JP?(N%4*>]DLPF78 LP<'))IRKD L
M5E4*<;ZP0<\P #KN2'&V,D-G.]5$/?.AM9\);P%NZ5LVJ_6%8ZO6829U/BQW
M&U/GZ\E<,27B2,%#IUZTR:GA3461*G.GY-;[X40D"O'AHN*:&C>._P"7"F71
MEN-$4>A]V4C2B",2=0 $#_DAJ%+K!4K/I49*D285<,<D=%&G5UP,:O#-9J>T
MYJ*0])D/ZKUP^_,K'P3+?>H]8=>E4S^3_P#5*2ZL6I;]8_D6?_0+JE"OY)O_
M ,)]!/;6%Q<  ">8 /S0!*^!)Y@&K9_^/YWUU5S)/,?YVKYS?.^EU^=]?7ZZ
MO,(#"5D2/ 5L.*KX(3&;A"@H0?$%"1D-K&<-1!XV S'APXS>,YPVQ&9;:1C.
M?"C'*V9G8N[,[L<LS$LS'UEB22?K)J))8DL22=R2223ZR3N:JG(UBG%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*HMBLE?J(0I9;2;$URO X,@F9.G2,,2'$CHC>794\
MF3GO1X4"%';3EQ^5*?:8:1C*G%I3C.>256=@B*S,Q 55!9F)V  &223T &34
MD1Y'6.-&D=R%1$4L[,>BJJ@EB?  $FO*IZ0K^$=!:TZ?U5T&CH5H-LJDC)_4
M+:1V7ZL/?1E;+SNMJ@192JSO-*[YBV:TLQJ_ZYG*XM;LHR1'(9]CPOT5>0+/
MQ(F-=B+5#\HPZ_*N"= (ZHO?WW9",5](X'Z!R2A+GC+-$FS+8QGY5AU GE!Q
M&#XQQY?!W>-@16CK4W5)L[J/(V"7N^_6/8>RHCKI'%CM)-T@0G@IDE2_98Z%
MYPQ"B!ILC,>./'L1!T*#*@1H41EIA2<>I:TAM%5+>-(HN@1!@!@-R?$D]2S$
ML3DDFOD']M?H>O!^(V?'K",IPSB*)9S1 NR6E];Q]P)J)T1W=NG,51UGAN'8
MYD%9RY77PRG%*E_TF'\M%;56'%_0F08IN*G.>V$N07\0IGA\_-;S<Z)G..V<
M^&-W^2<\T+Y.ZC^HE3]A&1[,'VUU^%2;RQ'Q D7[1W6]N5]E2KV75T7C7-_I
M;B<+;M]*M576E6,92I)\%/%*QG&?+MG$O.,]_+FG#)RIHI?+ECDVZ]QPW\*]
M%93&VO+2X!P8+F";/JY4JOG_ +M>!]:%MK6VXE2'&U*0M"\92I"TYRE25)SV
MRE258SC.,X[XSC.,\^Q@@@$;@C(/K!K]+U^>*4XI3BE.*4XI3BE7=1+_ 'G5
MUM"7W6UPLU!NU:F((5^VT\X2KEB#36^^$R1I@3)B3XCN4Y4A>67T8<:4MIS"
MFUJ3FJ:"&XC>&>*.:)QAXY45T8>HJP(/U;;'<;U%E5U*.JNK#!5@"I'U@Y!K
MUH^C?_A/=SJ#H#5'I"!4B]5CUD09!ZB::(CM70(PI26$2MDTP8W&@6V!%0I"
MY1^HQ1UE:B1W'7Z];RLA3^?G/'/0*-]=SP5A$^"QL96)C8]<02MDQD^"2DH2
M=G0#%<"\X(K9DLSH;<F%CW3U/<8[J<[:6ROUJ!@^TW5>VM:;PHM?V;J.\5G8
ME!M4)$\!:ZD6B&0Q*.K'9>&I<1QQ+<J,YXH\Z!(PS/'RVWH<^-&E,NLH^83V
M\]K*\%Q%)!-&2KQRJ4=2/6" <'J"-B,$$@@UYN2-XG*2(R.IP58$$?H/AZCT
M(W&U9$Y34*<4IQ2G%*<4IQ2G%*<4IQ2H,>DS_F ]6G]"UM_PR.=#A7XRLOSB
M/]]=CT?_ !UPW\ZC_C4YD_+'Z,?W<Y]<>O[Q2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*AAN/HMJ&Y;AM"XF+?8!4O:&C=DZ+(1(,
M,6]'%!MET^#32)V N4TMQ94="A8DQ&G\YBN.O.-/H4UGMSHV_$I+:."-8T80
M74%T"2P+-!(TBH<'926P2-]AC>MF.Y:-(T"J1'*DHSG)*,6 /U'._CTKI=07
M0]2>H'8K^PS-OL &26IU%IED%0QP0O"(P=76RY7J@3!J#D69$#D1UHO)F45F
MY@D9<N+'$Y 2:J;'-GERL^*2VD/)6-'"R2R(Q+*5:>.**4-I(+ I$H4:E )8
M.)$.BLPW3PIH"J<,S*22,%U5'!P1D%5&-Q@YSJ!P(PG?1K6J,;:JE&V- AZC
MMI*@&=ID3[L>1=ITC7VS]M;,#CZS7VJ-*@1642]FR1ZR2;V'6^G#$ET7AL62
MA7/>3C2%.9+"3<Q"58 @(B F@MX&9WYH8G$ (7E-C)&KO*8KQ?*1K="95#B,
M*#H&N..,ECK!Z)G&D]3ON"F19/HR*"<KZ*?;]I7D_4A\C:::\)BC*S7Y083N
MW:E;VQLT8LR-'X(E'"AFGUV"")37,RZ[":)9;S.5,AI%T#C4ROS8X(DD/(+L
M2[!FM;=[>!M+-A=*R2,ZC9R5^;I.JL7SJ=2QH&.C426.3'&T:'!.V S$@?.V
MZ8.<P5+HNKM7TAL[3CUTEG7-HG U@-6DI3:8^MJ?6@E'KX/QA'QDA@@I,+7X
M>3-)S9R[%"*2Y\RC'**T.ID6HZ\G$G>Z@N1&%Y"LBQK+*.Z[RNW?# KO,P
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MPMQ\<TKI,$..AV/V^O\ 37YD_MU]$3'-;>E]G%\G-RK'C 11W9E&FRO'QO\
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M5=UYRA:4SG@DMW"2@!BH8 ,&V)(&X)'4':J[6[@O(S+;L60.4)*LO> 4D ,
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M(F"C*DI_B]2) 5&<@G2-=N)S#6%B4L9N5"NER=*R7",S , __9\8!C*LV#J
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ML9<]9BKP!PEB3Z[#6',RHD>(F,^YE++6$O+:]<GU;>/'E+:$IR[O(<N[.0,
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MX[KAO9^6EO:W!FE*B=DUF96=BDQ8O& N(LIS3"$24LPP+#+ DMKRRJI%*7?
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MXY;%ZH=6E&5LY3G';"OH+SC.?+/B[XQW[9[8\7EY9QC/;CQ]8/\ 7V>)_1C
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M9PKS[=\]_P#F_P#MCBE6,8HT.4AS&64^:5=TY1]+.>V,]\*PGRQE7?RSGO\
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M\J[/;^1#[I/Y:LY\_G2^\?[Z?!U1^ZU<_ QG^UX[/;^1#[I/Y:<^?SI?>/\
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M/'GC.,8[>6.^<^><XSGF#[/6?L_KQR.OKJ:GPWVW&/VC'C_ZUXV_X0KT<-8
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MNM3E7T65;CB99)W ^)26(]D*I<2@C$CD8@ML?(L31$- B>%70U$&$A5D9B)
M .4XB*Y8*,M*="[X)!;(0JY@;27<@H0H8DAQCNL$(R<=6.D'H<$YTX)Z6T^N
MR@:PNNU:([5K!8S.KA PA(0*G!8WOJ1D'"L5K;B8)RXB&AU+'6?7J"D]MV;,
MF$K>\-&B)$BN%,9E#PN::*WFYB(EPS*-08Z<.43.D'O2-',54XPL>HL ZTCM
M7D6-M042$@9!.-]*YQXL5<@;;)DGO"L@:XZP=+[5O*=?5 F5EFG"9,.S,?AP
MV@,LE!JHZ]Q8(XRV2?B%IQBD$F[7"&B\S24 1&G9L<,%,B.0^4S<.N8(N=(J
MA=*L0"2X5I&B)9< J%E7EEFPI8C07!!J#V\D:ZV Q@'8G."Q7)&-@&&G)P"<
M:=0WJ4?-&J*<4IQ2G%*<4J ^].HC<VL[]M,C7/XK)FJ](571UEME1/5JU9V-
M>4[5N%NKI6#3;Y!O<6N@SD"( A_"-?(ZULF;98Y3(!\P%049(C^K:6EM/%"K
M]H%Q<R74<<B/'R8N1%%(K2Q&(NR$N>:XF3EQ@OI;25.U%#&Z(#S.9(TJJP9=
M"<M58%DT%B#J.I@ZZ0-6#@@X('>DJ-!81*-LZ@@ZY;:_J7>FW%UX=*+2$;!K
M5<L=,!:"G:YENJ=>E*V2:L\_6EC#R84PL)VJ!F"H#;@.972MCVFX*K,O(E9X
MWN+6WUD*#"[QRO=B8#IR%C$R,"%:W<,<,'5+39AL&-F96DBCR0.X65S,']7+
M"AP=@8V!ZA@+\&^D Q/Z;05ZC!A!;?:+: U_8==0A%Q#UDC:(.[:QJ.X2P12
MT11&:T%LHXTF]:S;OI82376+'42)QAYEZ6ERMN$%;V2(LRVHC>9)BT;.J&UD
MN8@ZQEN8R%.3,859>8D@3<"H]D/.*$D1:2X<E20IB,BY"DY((T/I! 8,!@C;
MOV#TD5/KDZ,,DZCV"6*,E+W4SH2K3JS9#@^_4,_NRJ2ZQ#AP"68BV#5BT<;@
M5PU9B-0:/(LM94'ASY4>X0JG%.#2."1<PJ-,,B-('16AF2UD$A)7.42Z0NJ+
M(5Y<FHJ#$9 LF._,0#",K,&4%'$1U'(SL)5)"AL:6R0-);A_[R_7C4T= =U9
MM@C(@L5^9LKX5J%GLO\ %?!MVR3>L:ZY;(S-;ADZU/\ >E>+';$ V&/U]8@%
M9B*F8%$23\$3+S^!9L,>?;J"7$',ECCYYCA6=^62Y#C2RHKPF9&D(&I5!8.Q
M/@GF1CJ$U,JF0J@=M.6[PP0%9"ZL3U !(J1WJ]W!.TCOO8E.U960UTI;^E&-
M2U6Z'V2XVP?QT!]<D0CMR*5 RZU$]5)OF84QD7)8Q!D0'LQWS0S$(P5BO#[=
M;JUADG=XI!<FX>)"K)V9IE<1+(HSD194L#D$9"-E%PMO'S8D9V*L)3(4&"O*
M,F0H8>(0$9&X.X!V&.A'I ;WM+92:1J6KT@16]A3NG.JZCO^PH]@EPAEAVCK
M/?NTMCG+R%$&0JS,&IYTRK45>I@DO5R\W<;9<$:LT"*['5 N;A,4$'-N'E9X
M1>/<0PE062":T@A6)V1M)D[3VAI6611;%75"0=4S:+&FJ0N2G.:1$P"5C>%$
M"D@Z2PEYA<A@(R"%/C<T?J7ZFR^]@^G B-2G8E<J%#*[+M^K=56_<]8<-V+>
MF_=4FV'3V=]ZM5J;(D7I9B2: E FU2%-MLVW5V84LC5.9FV&)LK%;5[E^T(7
MDF6".>XCMI-"6MI<)W.R3\_4UR0LBM LL8C<*G,PD>3"(C(W,!9G"+)(L3:5
MBBD'=Y,G,R9-B#&&4*P"ZL+>73%U);HV$9T/%VNC51,=U)=/-EW]4D:XK=KJ
M1G72*H1U1&GU2UQ+)>[\S<8,^/ML8B#=QCE+0R4!28+]46DU%>'57UE;0I=&
MWYZM97B6DIF>.19N8+@K)&4BA,9!MVS$W-[K@B3N'5&>&-!+R^8##*L3:V5@
M^H.0RZ4321RSE3JV((;;>PZYZ2=N4U+@FNGG<)&P@X-H<LL?7E;*W,,--0!>
MS;/5:U&L,,?@!((V2NZ]@Q\YF&1LEJRW*O#X8V?";L,^O6OP;&&2\ME1V0(9
MY$B8J3 DCE"VL*CSD[*1HB=BP.@/-K+Q6:/!*XUL%8@E%9M).<*S'. >ZC$G
MYNK.G3SU82M_[/MU/'4= *M576%3N$HR\<3(,1;8;V?N+7Y"IEZ]+ABCP-Z-
M$U<T:;@V,& LPS)%X?9 (B<EB,K5O+ 6D$<C2%GDGDC5=&%,2P6TRR*X+(P)
MN-)*.Z-C*.PR:JFM^4BL6RS.5QC8J(XW#!@2#\_!()4XRI(W,S><VM:G%*<4
MIQ2G%*<4IQ2G%*<4IQ2J.6>PVUVSG.,83G/YN^$J5C.>_?R^CC&?+Y9SCY9S
MQ2O W_"*=E.W+KM$4]N7ZP?K'351#JB)SG*(QJREK%;B#^<9SVP]*$EJZA?A
MPG&6HD?Z/B\6<_2/1*$)PV27&\]RYSZTC5$4?H8/[37V?T MQ%P62?&&N;R5
ML^M(DCB4?8&60C[36A/GJ*]S3BE.*4XI3BE>_'T7_3FWI3I?TU3E0T,&9=:@
MW&WKRC&77;3<_!82[<ASRPZL3F<P#8<SCM[$*C)QWPC'?Y!Q>[-[Q*YFSE.8
MT<8]4<1T)MC;4%U_\SD_77Y_](;\\0XO?76<H)C#"/ 00'E1X]6H*9#UPSL<
M'-;NZP%1"B,I3COE24^><>>$8^>>^,]N_?MXL83CO]?;G.KSYWW_ $U?:4X3
MC"<>6,8[8XI5 >ME5CG6*L_9:^Q9I+7KXU<>,CFSLAC*5+P\P(7)20=:\"5+
M]8W'4CPI4KQ=L9SB8C<H9 CE <%PIT ^HMC /U9J6EB"P5BHZM@X'VGI5P<A
M4:H(VU5@R1)!Q%C E2X=7@+BQI@?.(BE^/U?@)08LAV3!5ZS&4>&4TUGQ_1[
M>+RY(HZJK,C*K;JQ4A6'K4D8/Z,UDJP )4@'H2" ?L/0U67WV8S+LF2\U'CQ
MVG'GWWW$-,LLM)RMUUUUS*4-M-H2I;CBU)2A.,J5G&,9SR(!)P!DG8 =2?56
M*I8*QUZT0LDJR>#6(=AYR/F>"*02\+$AKMZUC,H>_(8P\WXD^L:RYXT>+'B3
MCOCDG1T.ET9&P#AU*G!Z'! .#X&LD%3A@0?400?8:K/(UBJ(>LU;JT5N=9[
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MR]$KKM?H_P .<G+11/;-OG'9I'A3?)_W:(?TU[+ALADLH"3DJI0_5H9D&?\
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MW?;E<_LL3_?'C3<>;#[A_P#44S!Y<OOD^!3V6W?;E<_LL3_?'C3<>;#[A_\
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MJV6_>$D0)B%"3*$1")"5#;;CHW^*^D?%N,1I#>3J8$8.(88UBC9QD!W"]YR
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M+VY8?6 (H\^U#7LN# BR&?&5S]NRK]OAC?U5HBY[6NM3BE.*4XI7=&PGB1&
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M.QW)?KEXULW4XY8$\N%60H [D)%&L:.0 3H2(*BM\U4  (&*K^5?N]]L -I
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M,C5MMD;[XVWJ_N55"G%*<4IQ2L3W_&?=<G&,8SXL*3GOW\L92K/EV^OS[_\
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MQ>%(.SR6\@4PLCR1S*)'9;&\M5"L8#(HD:ZUMS99XXL%8HA&3'5<=VBIH9&
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M)72X?.UX]Q/$J6_9X;2U@MX4M9[E8%YI+++Q"542,%<W,P5WU21J$2+5BW=
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MZF&H>/Y :OIK:[:RT,9[(\.?Y/.<X\6.V?GG'?/S[>>,Y_\ OGGPBO$-U/\
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M1?MB68O;K:?FY3A\D;-2W)DQY+3:4,18R%N>HA0(K;4,?":CP83+$6.RTC]
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M9IVG6=$J9(&%6) QZ&OI3\/2)9'CF:5$BD<.%C*L\<L$;+E)'*G$VHI(%D3
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MXZ&E$AMY,+/'=*!<1(W-CEFE$;/%:)KM6,QUPLO,9E$G.!)%6&_RVHQMLZR
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MQN49E" ;QYY9!'>7EY/+"D! S!, G/=D].^CI<<9$D:MIRXH6 !%B8V!#+;
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M-L7F=X]9G9V=7P5!D@2VET# *B6*-%D&2"02 "S9RCD6.4+R$S$9R)S R+S
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M;;0C&$I0A"<82E*<8QA*4XQC&,8QC';FO6GUZU^^*4XI6U+HBZ:?9FX&ZKU
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ME"AZ+)<HL><+?BLRWW*A/&4MXV#JL$<S=T@Z[IV=DD((QI(6WC<==$9P<D5
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MN&J5)$UT1E(%897/1Y3_ +M/$;%G_)4C+#4NKR.V7![\A^;&#ON#@GU#]I\
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M@J<>4M+BG*Y;JXG14ED+(NG2F%5%"F0J%50H4 RR$   :S47ED<!78E1@@8
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M;LI7L[ZUM84G#R&UYRG'RKB'"[_A<O)OK:2!LD*S#,4F/&.5<QN,;]UB1^4
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M,8\/M$QY*529TK*?)4J:\_)7CMA:U>7/+SW$]S)S;B:29R, NQ; ]2CHJCU
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MGE]RO1#AZB8R=C!X6;+_ +<9)#&#R _:A-S.7VSG#3V/?O$VW(UG55]=4O\
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MNU=C;_UKK2S579!FT6C!S1-DOH]U5ZIY7756@ X-JKVNK&9C$ -LLS0<HV.
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MJ^I9()( TN5S,(XY76(3&1$5BJJ$9E,5N9E\0^%8=]5;(9"F6R,OI5B%YFH
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M\8&W1)29#ON3C85'>%Z*D0V3NY(I9-=%YUFTSL*C!SDK5T=RQ -AW'4^E-7
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M#<Q3#&Q^8L908'Y60,;'*[WHW<9OW\9,<CI5F;(ECB$S7J-.>JU8B$#O6;;
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MQF_U?B$:ENFVL:]M T71[)1M>&(5IE0JYAC:-BO(C7=RJ#A%:)T9T;JJU'8
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M#(4C)RY\F,%@1@+NB$D* JY)7)*@8!)) Z$9-4;'2'T_9#P*Z[2RDJO"H2Q
MP#/V%LL@$'UYX>V)EU*$)G7"0/BTD@*9C#"E)9CHJ94?"@0B(:5&@0FF)?A"
M[U%^:H=CJ+B&$,7#:A(6$8)E#$LLN>8I)(8$G.>T39)UC).20J ELYU$A<E@
M=PWS@<D$$FI(,LLQV6H\=IMAAAM#+##*$M,LLM)PAMIIM&$H;;;0E*$(0G"4
M)QA*<8QC&.:77K5-<G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
><4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g556103g01a30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ',*^<V(X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?C;9$         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             '80  "[$
M         0                         !              NQ   '80
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   '80
M  !29VAT;&]N9P  "[$    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,     !(/     0   *    !E   !X   O6   !'S !@  ?_8_^T
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M6-#I<!>]Q_J[7T-_PFS\Y%;9B%Y ZA<2#.WU9C79_H_WG,:FU/\ ?_X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!=P)2 P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
M       &!P4( P0) @H!"__$ &$0  $$ @(  @4$" X,#0,#!04" P0& 0<
M"!$3"1(4%18755?4&!DAE)68U=@:(C$S-#4W5EATEI>STPHC07)S=7>RM-'6
MUR0E,E%A<7:3I+6VM[@G-C@H4E,F8F6Q\/_$ !P! 0 " P$! 0
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MB>["K$Y%NL;\,FB21"]JD_#@9^3&MKSKA%<F5 I34]WC%OS(&YL?D-+A58Z
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M?2&*UA:9P 6TX"J"< N[$*H/9DC.#C.*W^'\,O\ BDQ@L+:2X=0"^G"I&I.
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MT@T:F:[KTMQ68@*I/4:N6=;L%K&?*\;$</E;'*DIPIQYPDB.IQ3$*,TS]/\
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MT$3>L0$5;B!=>)8\P#*V :DV!,EV&MR)02V,-"9$V<S6LV@A75F;.,XTZ3G
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M7'"_%KFU"3W.HQW+S$<B*.4J"\:9CDPI\DN'9M!<LF"-'Z$X9X#3>!B\-O>
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MI_F1Z8T$A(+A,#.6Z8SCT[CYL]HP;&.!G!/?CL&^]:I3>T^Y$V"7F!J@4@-
M8&'OA\V=-#K,1#+UGO"['H3<J/3)L:++&/4>C04);'3\QK 9R GS,L'AY0;L
MBWBT[R;[C4 "H/,B1206!P=3GJ-AG;3@X%V!]SV XWR1I8G?'9@#IU..T8O+
M6N[K1=+))!DZ ^#"H1<6H5F?)SYY.01JT>EDO*DU9FJCF&1\Z#=4-#Y42Q3)
MLN<"(1<#<8<3*13)$JJ&#@GR<J,;!BP]UJ)R"N^5&,C)[\E8GJN!N,YSN,9!
MVVV/?G(.V-ZBX7?UH#:KLM].B&MB,@-A*J XE4X$FOXM4 R)#(I\T(+>6<5)
MF%K_ &(-0B([#[#E3G2"L8X_((TXSDCD85,JH"4RFHAL-I*DZLD8P BEP=]0
MQ@88 1J.DDX.#C(R,Y&V!ODZB%P.G;T),/=[D6.)@;[PTFY$<GWIBJKC)V,*
ME2F!V2X,21E+9C5YS+%R 8-M$S>MR:AE@9#LOEH#Q$<.L$H%GXJ-\2YPFK/+
M(!.&( RVZG& XR,D @$@&-9VRN,MIZY[0.H!&1G=<@@;],XF-/[,V@\B[H.:
MAD!R-2U&QM6"'!VJ9;"EB3(J@.T-UQJ(BE!W0Y%Y9UH"/R52Q,.F1QQ%>%EX
M80I,BX- H"$2@AI.625TA=R-7NCGID@= 1DC(J0Y.?)W"Z@ <YVSCIMW#O.<
M X.,>([$;!GL[,N+E"%3ZE1Z #)@AE9L<LG&N%E(W[8-8FF1MT+50!$<HD85
M41Q5T_@4RD6-D%"ST(I#]A=3)@0&--9#NY!++C2 B,%* L=9+8QG<X&QS4!B
M<G&0%R,'8G+ G) & %!SW$G?:N")VNM:1TBQ&M)$(E9'>HDG* V_XQ,^#,*D
M$R)8(. U-T/8JRV+N7O048'V7VLM $2UY$09"U16!MUSI$H+'L*Z1U< $ELA
MLKC25V)ZX&:!SC)0Z>T@Y/122 -B,-L0=P*ZDKM/?@@XG+,Z:;:6)-V$-+3)
MNQ%I;Y<1-OV45P'F!K>9',%2K-0BAZ2WER)\7'3(X;EZ Z\Q*FR+="=I>H!]
MP.A">4<R# !;+]=*@G?I4ER/S>\=3U!;8>3N3C8=I..[.0QV;V,^=@@(FCHR
MI)+V2;&E3=@&(D%H,8V;5=7!'YSS6KYBXQA9.R.GS@AIF3%#U<5((1C)B4[B
M UCR$P29<  _F DL$9R!^,&1A=(.V6.,#8F-;9QIZ]N3TU!?>]1G)'8.VL8$
M[97VR$&A(K0JX\Z6.K$F-[]V/%'-QI9VLA[%):.P(-/,6<*+_P",9T2LG7*W
M)A6? 0DMQ(26WD>G(VR $F;(!8;(3G!(&"6"D[>4-65R,9&] [$XTXV4[M[X
M9W !('7!QOC)QTJY^MMD1;-71CC=(K6ND2;5>V6*C68J8$<:/A7(W#"NE1Z1
MHM,0^2!L#29;U(^69LB9@G%6F+.889JG73(5U%\*GE'?)TC."2<@'('=T[,G
M)#E<XQNVW3&YZCO[_/5\\IK*L>5$BCHZ8'-C!YD2085&GBRL.,0'3HR_#UX\
MR%+;>C26%^&/6:>:6VKPQXISX<D$@@@D$="#@CY"*$ [$9'<:YX4*&-AQ1XZ
M)&@0(,9B'!@PF&HL.'$C-)9C18L9A#;,>-'90AIAAE"&FFD);;2E*<8Q!)))
M))).23N23U)/:33]VP^0=!\U=GBE=$:,&AX3(X0/@BA\?+N8\ ;$CP83&7WG
M)#V68L5MIAK+TAUU]WU&T^8\ZXZOQ6M2LB23DDD]YW-*XS 4/81DL*?$C3@>
M>WAJ>),0(I,9-:2XAU+4N!-:?BR6TNMH<PAYI:<.(0O&/63C.)!*D%201T()
M!'R$;T(!V(R.XUVXT:-"C1X<..Q$B1&&HT6+&:;8C1HS#:6F(\=AI*&F6&6D
M);::;2EMMM*4(2E.,8Q!))))R3N2>I/>:5S\4IQ2G%*<4J8Q?V-'_P  S_1I
MYZN#\A#_ '4?^!:Y4GY23]-O\1J-$S0$%'%2#Q06)3/)BP8ITI+BP_;#AIY$
M 6)'JDN-YD$R<AU,6'#CY7)E+7EMIM?Z;'.H#@#?&0!\O3 KLQD"./) \E ,
M]Y   \YZ"LC GPBD&&2&RH\X>0C,3(,V*ZA^-+BR6TO,2&'F\J0ZR\TM+C:T
MYRE258SC/AGDU9UJ%B-F4"REBP 98(<R<'7-3+2_%FQ1\G(@L@&76'*SXD<1
M84 ; MD&== S238$Z['$EEPB3S,9;(_G^=_/W5B'4D@$;=>[KC8]#@['!.#U
MZBI#,M-:'S( ^<?#Q)Q2=)&#XCY&*W(ED(8Z<6EPV6E.X6J1&&#2$Y]KPPIJ
M-#?=7C"6U9XJ2RC8D9)QU'7<_N-=6==:J.F0A\HU$]M(H==B1X_FS5K9CR@<
M.3(<]B;D)CQHKMD".2Y$G+3$6)/00D.-P&I$EI0L!C)Z]/U=WRC?SUEV3 F0
MUAZ.4'/LY8D2<.LSHSK68T16$2I&'$.J1EB,M242'<9\ME2L)<4G.<8XID=X
M[^O9WU"2FW=:A4#G"MQ$0$EZU=+>*]H<>0HC7->(@.74G"1Y.5RD5YDE#D38
M[*5RU1G'),>.]'C27&8) ZG&Q/S#KZ*@NHQD@9#,,[;+C4?FR/YS7R6V]KH(
MQ#?GV1O.23I^.+B0!I@N4+2ZO9A]-/0A <2.G%2T\=9BD$4Y!'0I,QUY_+L9
MEZ*T^^W.0/YR>N.G7J<4+J-R>N<=3G! /3SD"LZY>JFT"8L[AJ.BNR:VNVLF
MU-R<#%UY#,21[?F9Y'D(RXS-C.1X:UIG24K5[/%=RT]AM4ZEQG(QC5GLQWYK
M-MEQ;J6UH(PLX>6PVWC,EE*E.RFV78[/J*6E>'GVI,=;3*DX=6E]K.$9PXCQ
M4R.\;_OJ$#=NZZ,F1 $/9F"Y$\/>+B<"X)4C!EB&&1KZS&"T. \)9$+P6AL1
MRDB<U ESO:QT60]/'$8T6,C;S]/FJ-:$X##<9[<8.-\],;_S@U)2%GJH"$S*
M(&PPR ZZ(8C..3(K3+KUB*Q@P-N.E"_[:HR9G11P[RDJ]MG26F&/7=<PG,].
MNW_SC]NWRT+*!U &WZ^GIS7?9-B7H[,G!",TV^F&I"93F(3Z,D&$R83+\67Y
M$J+)D,JPMN))9:D^'CA36%)5C"IR.\?_ #TKGD$AT13B)4^%&6RPF2\F1*89
M4U&6YEI,AQ+CB<H84[C+2758PWES&485E7W.*G([Q6*G6RNCIZA4HFU[S0!+
MV;W=&:D3IZP8)8MLI.:AP69,A[$=PT*0B.RVN7*7.83#8D*RK"7_ ,_SWU&1
MWCIGYAV_K%9!PR*:8DR%$(BVH;;[DG+#R)"VTQD,N/X\F/EUY;C:9,;Q9;;4
M[G,F.E*,J?:2M3(ZY%8#&PJ/D).LF;6";!C%&D$B3Y&/'CCW*X1>$'VIOGK;
M7%>#%6'AQ-E]#;L*<WF+(0V]X(R[,]F^_9MU]';W4U+@G(P,Y\V#@Y^0[?+6
M;9/!WHJ)N"$=AA<9J9G,U61[K45_+F&7I$:=B/)BH<RT[A&9++6<Y;<QC'BA
M7@ID=<C]G[?D-9;]7]3BIIQ2G%*<4IQ2OAS];<_O%?YN>*ANA^0_LK8"!^P8
M7\4C?T*.<Y>@^0?LK@5Y(=O-)6OL!KXYKRF[:L6F3+]L@%\6ZM-S'I3T47-D
MK?#3&1QFOS7($S+K<G.(Y:-E,V%"<=P\PAUASKV[!4C8JKX3HW3)&QZ']AVS
M\M?%/"_AEQQ8\0L[;B$W#9&X@\GC$ 8L5CG<M&P22)RC9SY,B^6J$Y4%3DW:
M3<Q!G5I41/'6]ZG4&P:_L9*W&R 4R72?EZVDOVY#XZO6)J>8RNB2I$L9(2,8
MF2BJ5I*QDLJPLP.H%0HV88.0 "0=L9Z8K>M=,5GXK+++(RBV//*J[RO;Q2QE
MI<N@#2F76S#5@YPIS5+#.N^W&X((8:W=92$$3/HL=_V*W7L41G5L,:%6BX1W
MC4 S&*9+V$G-N%=C3H\B'EJC1Z:$><Q[!-RJKEMME@1E=LGID$X.<Y/E=, C
M&>VM]KRWRY6UC!82G>.(A79&CCPA0KH11')@@_CC*W1AC'T_5N_(UBN  _8[
M0X)SI<_2ANQ">Q#)(=8+J8K6LQ@(X-I^+,1=!R:I. W.0_9UA0MA-2#DB9*<
MF3)#T^:5'!;/:A4'5G)( &W8!CN'R9S64D]H4C=$CU>,I*85A4,D2O.71I="
MAQ('B CU.BA0!I TBR(&G]B#*[<QC6R#A";9/A>?'41NM[<4V0%7ZQV*SC8!
MQTE,-4H3;Z=, 4?SJAF-FNMPI!<4+5+::1*ST, WE=0-R3V$DY/8,8 QT[NT
MT&YA+1DP( G,&T<6ZM"D<;,H4+*T4H>;$F=98*S8R16\SKENET9*PQO2YMD9
M[^5SH\'9-]'M."F(>M6A%=$F">+5FNY$OUNWKDVR'7I5BLZ#F'+'[9),F76<
M#&V_E;G/YQW&%P.AZ8.<#)VSG)J\7EMJ&;6+2!L3!"3J)G+.R+RP^H/&!&7$
M<>CR  J@RK:NA=A["&LU]K911 :3K"/1S3\NT6T4]-*L@KB+-E2(*LOC*Y95
M7MVP <FII:)'?KK-6\P#"??,*P-R9"V-^BX.2>N#DXZ'.<D['857!=PPG68$
MUB<RKB.-@%+1LJJSAG3DZ'T!20YD\L@(-7>MN@#IK:[NQ -JG5Y$:LBAHI4.
MVW2++:*03M.DN-3!L.<T*E 7 M5?C3A\ER9"LLLLG)\2_P"ZX\IX8R6U @#
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M0PRI((U#O&0,BLLC) (.#@X(/[*DW,:4XI4QB_L:/_@&?Z-//5P?D(?[J/\
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MU:59H6$S%36XLZ2.BQV&<)CFP4!)!T.-R>O9D'O&_7TU?XQ8.6:6*1CRD10
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M  9[.N0C4$G).=CDY[0>N,]F,DDXK,TWK@&I=WH]EB6$L6&4&L$@XF(92/\
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M$ 5_=FTWMS,LU^'4"REO@RQE[0["23(4)^"X&/T,8'BC1\IUD9<::S7#J5S
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MQ $4-""8GF^R"Q$&*-'1?:'W93_L\*$TS&9\Z2\](=\MI/F/NNNK]9QQ:LJ
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M0EAD:@NPK]4^ GA;X/P^"%I;PW$8O.$V*B\L-H;AYFD=2\0DTK/SY/+UQLY
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M'>&5HF>-LH2H8Y4D ]F"" 5.0<$8JCP?<L&1KM=DRM>71%CLM9:*!HL9^CM
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MD%!-XHI@@F)&=R,(>S9"T;45,D> R@E2S'=BI( 7\TC?. ,C)WJ.:,9TMT)
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MS$]H?/L+*8X80*-ORDQAH:>7S*Q#5'BQH#LM;S26\+Y3$&?>(Y\D,&5@!I.
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MHS@LPL0@PXDHM:U2:C&DV6V%')Q&QR)C_@V+AL0X3&8NB&#: 2#D99B!G5D
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MXXUKRS% 0B,S A<D'2">F3V_-V[9KM<,X4EY)$T]U!%$X>0Q+*IN72,D.%C
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M:M'4;?E+#P!OO\Q@6,#$;E[H7+9=F*=4\DJ0-6H%6TD8  . N[;8R=ADL%R
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MEQ<,J11@%FTNYRS!55$34\DCNRI'&BL\CLJ(K,P!MAGNKB5(88XVD<D*#E0
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M5@D-R&9#"4(D5DR7#*<%= 4ERV B@LQ !-8RJ;+IETG2Q8(G+P7@Q6Y\@*;
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MAQ3A?$N!\2ON#\8L;KAG%>&74]CQ#A][#);W=G>6TC13V]Q!*JR12Q2*RNC
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M[/N544WKBDR,.!(P,TF><I+\Q<H$,L^SY4L6):OGP\")XBR3 %8]D(MV>9G
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MM)*9)>82<L:TI4O[V<7JW-JGE%K8-Q;AUN]M$&)BBBB>\CDMDB&%2,)'H &
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MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5![3K>DW2-8XUCKP\CFU!
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M0N$!(.M0RN58D$!B&.%&1.JGV'Z$ C-]W +W1HJK7.[."&ME'+K?0M5V3&<
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MO[K:)#,H_8!#\LG(CQF8;+K[9.?%2IN-'2AEG&&6&\92VG&,YQE7ZN<\5 W
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M4B#'(64T-!07YKC3TAN&S+*28K#LI;$:0\B.AQ3RFF'G$HRAI:DJ5K!TFO\
M1+%H'6%?K]UJ1T] J\R7."![(&)EX45!Z<VN3+&PIK\V-'0Y*C-J>>90VE<A
MA&584\WA2H'0?(*W!XJ:<4K0G;_QC+VA*L=&*TT_*$6_4@V <+[44# :]CXL
M3@:P:^+B!>P*_)KMQO9EYR-6BOP;LR->RQ"'0;G4%!@@]:E*U2S:^SJ(9VZG
M>PNMQMB"V^EU(78#M[T/#>@QQ(;;K]WKLVH!+BQJ^3L>)$MJ6*^,,DH$<I,$
M "UC4-'AICHU4'L/3OS\AZ_/CMK;_0ELV(7V/(>ON[Z+?X@2LRZX9!ARNHF9
ME:LTT+H 6*S-#TITD<$&[%L(;NN*9&S;0:#)*L"QX!J/!2'94J:WDXI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*56.H=AN;1ICEL=$H"K;NVTJA["W,5/3E&N-H
M7'73<_VA4:)G"B[=5267&\G.(2YRH27Y28^)3RE6=Q2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2M2.\W6$-V_P"L&TM($&8F#9P(Z6H!27^D0!V,!0X0IQ7S\8RY&C*)
MMI%EUM>#CP D6A_=1*7C*H(R,?R*\\/0<='RW670MAVSLZLRJ_N?=91UJ2*,
M151S-2UY5YTJ"!!2&'<97#E'BK9&TD,-+PB8/D5=$A&'QF/55"C \YZ_S_/;
M7LAL/8-;U?4RMVMV3;==!QGYI:4!K%DMLJ!!B19$R7/D"JJ*,%4P(D:,\[*F
M8AYCL82G#KB5.-I4K*NBC;>LTQI,F?>*T!<'I!Y,#;07A5<W7WK,WAVOPK*"
M/O#B]<(F$*Q[N&FX4&=+5XH9CK7C*<*5YVUOKU0;-"UV=D;^I\!N9<Z,#FQ8
MTH>KY4KOUH+T_7H/W<3F'X4F<4AGJSLHQ[/ @R235HV.'ER7),JK1W#2E=ZS
M5RHTJNZGDE^S.E&6];D:;JZDYJ(6R5VPV5L.-L&IQ=?G2M5[<C7PW8$&=A#/
M> H-.C5>LOH*2WZ\/C%R<J&J.O;V]AQYNP]]2&;4ZQ';8+%NQ6C)T>*5VA(J
M#PXN)KDH; VIV0J>UKM8IUE*[!.8+S-<2ZKB)7XH^&/:D60>R^8D-S4,)@JF
MM[4[1UFM$)Q&Q:(ILDS8) YQ-NKZD$(]3\_-J?A+P0RF4S6L1I/Q ZQEQ ;V
M=_WBJ-Y3GJJ5DZ=<ZOL "S:*:9B6"O22!X9$,#U*<@395:/$ZR75!D92EN;#
M:,")\>,0BY=@$66D3ATF5 D1Y+JE2?BE.*4XI3BE.*4XI3BE.*4XI3BE:T]2
MOW')'^6CL]_\FMO<4K9;BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*55&D+B9O^L*W
M;#^8N2Q1T^B5F&Q[-&\!MF,BHWELY6YZF?9(+&'/T^?7<]=?W/6\,;%U$L,\
MD:9TKIQDY.Z*QR=NTFK)5"2,HS@8QGKNH/[ZE]VJ0V^TVUT<R[-8$7"NF:R3
M?'.LLD&8!P?(&RW8+TF/+CM2VV)+BH[C\62TAW"%.,.HQE"M>J^M:N7/H]JR
MZFKH>E6?8@8A<C4\_P"T@IU.9GU0D:PK-B>I9TC2"=D!*L+CCCL]W!J5)B^O
M[,$?$P6V8K:E2,_U9!G25-9<N5J9JM;=V_,*B_5K3Q6PKVQM"F;2E 'S,FM/
MOCZR/*UJ7"0^&P,N^8;HSR[DB5&GRR"E8"D='M0400\%'%+N1AO*J3?F%)U9
M;G('4D_0SX 3F>%J8>7)BL*UU71+TR:[*-/!D/QLEDR&Q\N I79K_2S5H+)E
MYX[>3TX^FFH)$3,BGH?<:H-0+T2KM,Q0M+#"HJ!]8)QH"\QQS:Y;P,.2EK>)
MX)S":E8HYT1TZ<+N&'#%Z@NOBH@F3#B2Z@\.?:$"I8VN2L1"M+)IAS:V\0GE
MASHU4)N80EN,GV30A# IE2MF]=42#KBK,U: 6,'6TFK;8I9@_@*DL2,7:W'+
MJ>ERFZZ&KP1G#INPD%1XXP,/BQXODL(9SEO+BU*G'%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*UIZE?N.2/\M'9[_Y-;>XI6RW%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2M(>\O:B?U>JFF< %BXMOWKV!USH6H$;#KK86RZ["-7EZ>I.9U?UQ.#
MF9,]Z,.?;$173P=B5(\Q7M#OLRXZ^GPNP%])<Z@S1VMG/=R*DT,#E(0N</,&
M4 %AJ(1R!C89R-FU@$[29R5BB>5@'1"0N.U\C SN0"1W5)?<'?+Z6>HWXO6Y
M/SG>5Z^%_%K_ .VV_P#H*QS;?!S_ %T?\"GN#OE]+/4;\7K<GYSO&OA?Q:_^
MVV_^@IFV^#G^NC_@4]P=\OI9ZC?B];D_.=XU\+^+7_VVW_T%,VWP<_UT?\"G
MN#OE]+/4;\7K<GYSO&OA?Q:_^VV_^@IFV^#G^NC_ (%/<'?+Z6>HWXO6Y/SG
M>-?"_BU_]MM_]!3-M\'/]='_  *>X.^7TL]1OQ>MR?G.\:^%_%K_ .VV_P#H
M*9MO@Y_KH_X%/<'?+Z6>HWXO6Y/SG>-?"_BU_P#;;?\ T%,VWP<_UT?\"GN#
MOE]+/4;\7K<GYSO&OA?Q:_\ MMO_ *"F;;X.?ZZ/^!3W!WR^EGJ-^+UN3\YW
MC7POXM?_ &VW_P!!3-M\'/\ 71_P*>X.^7TL]1OQ>MR?G.\:^%_%K_[;;_Z"
MF;;X.?ZZ/^!3W!WR^EGJ-^+UN3\YWC7POXM?_;;?_04S;?!S_71_P*>X.^7T
ML]1OQ>MR?G.\:^%_%K_[;;_Z"F;;X.?ZZ/\ @4]P=\OI9ZC?B];D_.=XU\+^
M+7_VVW_T%,VWP<_UT?\  I[@[Y?2SU&_%ZW)^<[QKX7\6O\ [;;_ .@IFV^#
MG^NC_@4]P=\OI9ZC?B];D_.=XU\+^+7_ -MM_P#04S;?!S_71_P*>X.^7TL]
M1OQ>MR?G.\:^%_%K_P"VV_\ H*9MO@Y_KH_X%/<'?+Z6>HWXO6Y/SG>-?"_B
MU_\ ;;?_ $%,VWP<_P!='_ I[@[Y?2SU&_%ZW)^<[QKX7\6O_MMO_H*9MO@Y
M_KH_X%/<'?+Z6>HWXO6Y/SG>-?"_BU_]MM_]!3-M\'/]='_ J%:[U1WCUQ3Q
M--&;EZHSX0A9-;,N=UZV]B4[DH7GF'<.^S]F6F?!MX@XTWZC:?[4A'K>*_65
MFV:XX;/*TK6M\"VG(6]M\>2H7;-@3V9ZUF\EL[%C%."<;":/&P ^ \U37W!W
MR^EGJ-^+UN3\YWE6OA?Q:_\ MMO_ *"L,VWP<_UT?\"GN#OE]+/4;\7K<GYS
MO&OA?Q:_^VV_^@IFV^#G^NC_ (%/<'?+Z6>HWXO6Y/SG>-?"_BU_]MM_]!3-
MM\'/]='_  *>X.^7TL]1OQ>MR?G.\:^%_%K_ .VV_P#H*9MO@Y_KH_X%/<'?
M+Z6>HWXO6Y/SG>-?"_BU_P#;;?\ T%,VWP<_UT?\"GN#OE]+/4;\7K<GYSO&
MOA?Q:_\ MMO_ *"F;;X.?ZZ/^!545#L]L>G]TJ1T[WK>]*66V;*T5?MO5B)K
M#56U:,7'NTZT502/8(S+/?\ 9-?)"+$(EWZ:B6U,#J%SZ/[!*==E&AD5_8DL
M8I.&R\1M8;F.."ZAMI#-<03*>;'(QP$A@=61A$,$-J674,!&(L:!&MGN8TD5
M4E2,ZY(V!U*Q. $1@00G8<AL]A->B'.16I3BE.*4XI3BE.*4XI3BE.*4XI6M
M/4K]QR1_EH[/?_)K;W%*V6XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7&ZZU':=??=;989;6Z\\ZM+;
M333:<K<==<7E*&VVT)RM:UYPE*<94K.,8SGBE5I1-U:DV@VE[7.QZ?=V58)Y
M\^L'8!EE& [%=ED,NO0GGFV<,PK?5B",NJ1B2-L(<E%R_!(1I#BE63[3'SA>
M</LYPVG*UY\U'@A&,8SE:_TWZ5.,*QG*L^&/#.,^/AG'%*K:R;JU-3Q9LU9]
M@U<**KEKAT4[-FE&$,B[D0&C3,&L2_5RI39N6*,"B$<?ZN9#L0A%>2C*'DYR
MH3C>L]&V'0IE9!72+=*M(J-HS6L5NSLGAC@$]FYD((FHI$%4R<PB*K,4)CAH
M%,5YU16?.B1(6'GWVVU*5(IY48+@RRA,C!'#8$:7,G$)TN/$@PH@]EV1/E2Y
M;[C;$>/"CL//RWG7$-QV677'E(0VM6%*ZJK$!2#79LF!OP\V*2<6:Q,84-2'
M7$Q/;)YEI7EGV)R%G$IN1A>6UL9PXA64YQG*E5-O'=XS4'7;9?844,:OPBAZ
MM/[/$B1QAD9'M\$57WCPV)#/9ADV(,8VTAA#17V @W'8D8E)B2L)PRNV"+G3
M10ZM/-D2/5C5IUL%U8R,XSG&1GOK9L[?QNZM[;7R^?-'%KTZM&M@NK3E=6,Y
MQJ&>F1UK7@WL+NP6:@O6/HYUV(L 2<2PC73/<E^4T',"_,5!-PW)O5-:(!$?
MYKJHI%G+4B+YCF6GD>LKQV%6U7.B\N5U*5;3:@:E/53B[W4XW!R#C<5M+#PP
M9"\1NP6!4A>'+N#U!Q?[@]HZ&JZLOI MB:0V?K>G=J^N(;5E"V15;[;L;=U?
MNUW>5;U\#U^5UZ%+VC9XW.I=;SZU06R6S*Q%(W4:Y885:;EK-V:&)J0\Y9 ^
M:64<T<C6UPTDD;(@AEAY+2%Q(P6(B64-)B)L(=)<C2FIRJML1\*ANH)I+"\:
M>:&2&,6T]L+9YFF69EC@;QB97FTP2%8FT-(1HC+2%(W]-XTF--C1YD.0Q+B2
MV&I,65&=;?C28S[:76)$=]I2VGF'FEI<:=;4IMQM25H4I.<9SS^G6N*002""
M"#@@[$$=01V$5S\5%.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*5J-VWNFUJXQU_J&H+J+UU8]R]@A.KR5S*4Z#>_<E>5JO;
M5_F.P*Z2(C($B?*G4$9 2])D^K'B2I:T-J>RVI&U:I$WC#RH9%A@,@0.4RW-
MBC&6 )P!(3@#<@;UT+".!_')+B-IDMK0SK&LABU/XQ;0C+JK$ +,QP!N0.RM
M.^Q$"[]:)M0WUOSOO4:B;4R?U+4;[]A&#M=ECB[$/5LBU5QA5.)V$Y K3@S5
M+EPL4V7&8 #(=/<)DYL-J.M:]N!Q.DEM!:.T9*321>.,J%D)BC<APJE@9BB_
MG$O@ YK>M!#>E[>UX2\F LSQ^R1C79EB1B9512Q>98U )9F<*H)(%0I'?3:/
M4[MN>T/V[V%7ME:<.M:H'TO< ;5\V@6>J6?8L4IA@C8@(%XY6[#JEPS#C5<S
M:1,Y!NA6&8*FGQTJI$BYJHY>)1W5J)[6-HY4,I>)I Z.L>DD*2%990I+!6\F
M100I$@57O]BH;_AZ77#X9(;E#.TMNTXECDCA*Y5'8(Z7 4\Q8V!69 P0B142
M7VRYR*\U3BE.*4XI3BE.*4XI3BE.*5K3U*_<<D?Y:.SW_P FMO<4K9;BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI58[6VK7]1 1A^PQ)LYDQ8(5:'Q8)"J"%.DIT,C/;]H+7:RU&L#HR(@
MN8M3Y,]#2XZEJ+&Q(F2(\=Q3]=5^UV4T);*:W,>VA6ZVU9Z@/*^Q&"()D^+'
M6H6-?AK?$SLE1TF9'AV$-/>CY8,#,P2H@F^F8 ,#Y4Y2O*_9G6>@:VIHV$*W
ME6=B6:39*Y0ZI1"X*1 TVW.,;OZ_C886T5B%+V2H/3RUHZI'*S;*B#%P:(=,
MS[")#B-9B1SLB,J/Y^[_ +]_ZJ[FO^C.F NBXEW-]@M71)Y:MAJA>[N-J-?M
MU'),Q:/UG&S:(J>2D@I]CHS$;KY+L(IY,>N3HHC816WUQRK2AT$\M3]N.O\
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M*5.)O9WO7"BLS<AZA)AJ:RN7,AA DB"+6W.FP)310@DMB#$]VNPE+,2<R5P
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M@2;3VC<>0.9GV O L;M);IS 0JLTH?6%B81$"$X9EFC96SRF5@XDT$,7L;<
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M2G%*<4JJ=[_N'[E_R4[$_P#2!CFQ:?[7:_\ $0_YBUG'^4C_ $U_Q"H)6/\
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M,ESXP<57HTZ3 !08$5^9'  08-B2ZTMYH.&%#&UIA#H;#.O+--.P::629@"
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M-(:4EUE]AQQIUM25MK4G.,Y4KN\4JJ=[_N'[E_R4[$_](&.;%I_M=K_Q$/\
MF+6<?Y2/]-?\0J"5C_[N'?Y#M6?^9W7D'\I+^FW^)JHE]V?G_::C]YZT: V:
M5EF]@ZBHMQ+3S(H_.GV$%$)29A0,%S7(#LI<A*_:(^*_G(28/=PL<3%?\ )Q
M)D;^U<VHKR[A4+%<2QJ$9 $<J K-K8#'0Z_*!&X;<$&LDN)XP DKJ I4 '&
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MSO(L<CZ5>"/4),;BR1Z#XK=2<[FAP;LK$J(ZR"14U2212,693(6"EM*E%)U
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MX#1!",8SC,9<R.E?CXY<QX?=4JAODZ[+_P ):M_S!B/]ON*4^3KLO_"6K?\
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M$L4\MNXC;\]BT8 F(3J0VD*322UDBD6,SG(C>9F\H*'61XVTG.YRN-1P=\G
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MFIN$,EG*Y(0D1C#P=97.2:X#N%1U$,YFJ1F3_;.*5:-7JU9I( 75*;7PM5K
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M)QG'+K<@31Y.!DCNZ@@?K-=#A947T&I@H)9<DXW9& &<CJ3CKVU^67J9!O\
M([7ZAU^*%',#HV[*Q;2H#,5N6Y$C C$2<2,R9C<&.M(^(/@JDJD(\F$MEIE>
M,.+RVM?IKLH+661BI)A9 X)P2ZX &2=R3^D,D'NKZ)Q(PKPZYF9ESXK)&KYP
M#K4JJ@%B,ECC&YR2.^OUS3_W3=7_ /5=O_(&^>0?H/E_<:^7)U/R?O%7GRJK
M:J"8I&=I6=&,->8F@:\4I6%P\O90JQ;2PC#C:(J)Z&L*0YEI<F8_#<6I],&+
M$>:(.S;(^WYOWU7)V?/^ZO.F[>D 'ZUWUM74U^U<^Z) ;(K>N*29 S ,B?8W
M"-*ZW'+%-(1S9D6^9..$NS.O6 6O:D-+V8A5*G=K"U[Q>#M!F^['PDS6L$\,
MPU- \\JN'"IB6]1 "J,%738REY9&1%DDB38-KK<2R,D,4B2;M&SN"& 7#3A1
MD Z1B!\NQ"AF5>AS5+T#TM8.=1!EBO&DS\^VF*Y4;=#K>MY8"7,-9LNH]8W:
M(,JHZUG YRYGH9V[S!AMJNPY[5*J403:[9)&"YN'L[,O '$A6*Y0('EC+S!P
M%Y=U<0ZI#&KK$A2$,AD*\V0M'$'9<5<_#"'*I, N64E\C&F61"6*@JJD("-1
M&MB44$BK'K7I%>M&Z-;M;1FZDV.JCT_;]!#@S]EUQ/S6@ME.7:FL!-@%+A&A
MS*9KL/"HVS-:[K'&+U8:R\=I]QCM &25E#'1 ZF3@][;3& 30\V2VE9DCF =
MT6.4O"L9TRS,98)[5EB1PLD9+E8W1C@UC<12<L2IK>)RP#C45"/J0(2'<ZXY
M(6"*VED.HA2"9+H[TC^L=\%;N$UMJ6Y$CE/U@>V,*$0)^OY9BU,@M7Z3VBS7
MQPL=8WR0IZR#=_U8#4C1J+!K1RPCK7 9*M)'-N3L+K@T]HL3S31*DDZPLQ64
M+&6GNH"[,4 ;0;21Y%0LZHT9*G4<836,D(0O*H#2*A)$@"YDEC))( .DPLS*
M#J"E3C<@0X7Z5+2\FT4AINC6IJE[),ZS#ZSLK@D*/5-![*NVUJ96[OY"CT@R
MNL6J-K]FT5UMFMCTQ*R=@S#A&-++Q!K5C<"NECE/,CYD"SM/&&8Z6@BMY)(L
MZ G,C,QC?RSF1&"@A2QR/#Y=+YD76@D,BDL?*C6-F3W.-2ZRK$L<LI"C )K@
MT=Z4*C;"MVIJ':=;RJT7W22I@6HE1LX$_'?CV[1NAMOCY5EK3!(D9JJ2)#>S
M04?$?EF 24"WTHMD\U+8%RESP26*.>:.976V$K2*P8$<N[N[<A'*A9"!:%V(
M"MY0R@7RJF;A[QK*ZR:A%K+ ANJRS1'2V &P(<DX#;CR< D>L.8D7*LJS&CY
M5G#.,JRRWE6<1E^9'QG/J^.<1U_IV<9S_:E_IF_5S]WG"KFY/>?37RB#";QX
M-PXJ,>*,^"([*<>+6<Y;S]Q&/NMYSG*/_P!F<YRGP\>,GO\ Y/7TTR>\^DU]
M9B1<I]3,:/E.$,M83EEO*<-QUY<CM^'J^'J,+SE;*/#U6EYRI&$Y^[QD]_\
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0\TZIIQ2G%*<4IQ2G%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g556103g01a31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &BR^9P X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?,>!          IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             &N0  "R,
M         0                         !              LC   &N0
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   &N0
M  !29VAT;&]N9P  "R,    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,      ]Y     0   *    !A   !X   M>    ]= !@  ?_8_^T
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M2S[/8'LN]0"RRVST[H<ZCT[:OS/I^I_@O0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^=]J=\\<<_9]O7?6N>=?;O6M?;UUO6M?;O>M:^W?\N]:S!( V2 /Q/@0 3X
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M-9;AD9B4YGK.?0AN3>&+$+189V>,ASP X^?EUK;EC5/M</O<F/-Y@_0=I)O
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M).]:BT.W1)PS!@QKTBZ18-4U'+Q1!NIRW;)J+J[Y23[[YLV_6]"=RX]1J0$
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M((]]>X(W[SGY(JZ^1+S9S3U;TO()C:0287:4G=GR8#W&R\&JNNYA;M3"S-9
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M(Q$8B,1&(C$1B)QK_P (&_ZH?U__ .&U!_Z@*ISK]!_?;$_7=_N]L])]$?\
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M6"H[JC?D[D^9WYR(Q$8B,1&(C$1B(Q$8B,1&(G&O_"!O^J']?_\ R&5#O?\
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MY.]BV<MULA!5EWX*J=D< NE%W+O\Y3:<V=%IK%H3Y\DK""1T0.@'%O$+:?\
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MVXYR\!_V8QV#K.4%=^5WCMHZ_P#/IAX_B>=^-=C1/0&(96 ZN@9>7JK+8=G
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M#JM651V**!6&RVOM?LU5FY!C8=-8;36NK=RBVVQ>XRNU@=F=RQD.1E);7P1
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MD8[#L5=GL<!B]];JV:IUOY&AC6*09;'Z:[NQ":;(Y'AWT84EZB.""LU\15W
MZDHPLY<#Q[>^DGQYP2]89&_29.^A5KBC%B^G3$]@_-V':<-V.]KY:D:*BC![
M(.*$*E:O#+]2:)RMKH1'?R_GG;7LBZ8:<$>WKWB]8MQ;'PEQ&QV6G!%5OPRY
M"TBT9>780GQ:K>P[=E9Y/R]^(.ET*>8]3&@5&LA* C]I;%3GWKF.NZ Y]+*=
MMOWUOQXZ#YR)3C$1B(Q$8B,1,/(C*$=CYV0.M?>; @Y,RYY^_KC[R MDN]6U
M]_K6]<?:FAUK[^];US_+O7V:S*@LRJ/=B /UDZ$V12[J@]W95'S\L0!_7/\
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MV=$$SC&N-0N"@H5YZ#H7X=PT\^V&[G'N@IOCK?Z/,S!3U_YI&'1$83N*&GI
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MZY?/%7X50H6N-](+;64+B)O2I6B.1Y&)D80!14"N6KO5M!5VZ>  VEF.>[D
M5#>E50"=;%5E TJJ 25<> !ME\>^AHM<?#9YY;P]0!&KO+3X2.$3N)#BY! +
M.7;*+3[S7-J<@[,J^='"C9R=B4,N):;C2S%$&P.</0RHZ/@Q#U%566[Z29G=
M#OC+2Y:JPJO*D&RK-JR;2JJBD)9;C"ME)8J0VW9@1-WZE=RY&H(248@;392Y
M;&UH \6:OB0=Z\^2=RQ37Q=4M=5O*_/AB_1PE*S?1%#^CPC0XC$ LLY.U9:5
M E$PC%JJ5:.)&*G$_KR+1I!Y]+IV+(SEH%:]%"S@?I_3/4\BZY,M<1F-&'EX
M3%#8U?#(Q\M2Y/$A&JINL<C>F6DL>*AM0_$V.RVBHMPHNH8CDR\;*[ALG1XE
M4=F]]$)OP =1P#^'2H1',*:]V+(>AT6 U6#)("HP"!/I%W6??K3:AM0FS7[6
M'2"1:]8&NG!9)-R['.88$=(*.%'CC3>:SZ1Y#FT]E.5CY#J2[L$[_P!7^GB?
MO(GU>@X[ 86,#H*-[GJ-A#>A=L;""6) YB@:T?<+V!XWH\B/EYRD6^)"M@S]
M,Y(+)?RR0HP690!H[6KF"  PP87HX!0<-.!XP :LA N91&( =/B,H:I\OY09
M?K\:T! L@P,9A_I!<PXI0M:=ZJX@76LS,N4^7:C6,2S566.0M9VM:C^&Y9VP
MW4'(XJG%>:N1S9B2+&M8%CY*LS>%/W0/<DDF.I9\+5(.XZ1X=6X?AK-BY927
MN0 H_'XHL)W$Z)\Y50(Z>&&3YDNA'!I'S6'L(RSX>L.7B\HDHSA^+U^$:U-7
M])<H,NL=+6(-85V>SEW,K-R&TI!'<9<YJ5.FT*ZVTWW9NO4K=_DU;8X\22V^
M5UUAT""-D7%!X) 53Y]IO=7?&15$?F];2ZOKU4-)5#-ZND4]#-@43EBYNSZM
M*V9/6.MRA\2,RZO$3R'H ^5/1/1DDZ=H/XT;V]^\_-KRB&_KF0]5U=V*%^(J
MO2ERSU\:,A**3]FJI7<5^#15LX* 5==>%%>EF;85=7JUW$L5"69=5V!$^[H*
M_'L@!@!Y##Y +[5I_''2=R6S=8EW?.T9!.$9W8R]9-6$!)3:$F;H%P*)R66F
MGN]ISF00-RTK48A"(Y(--P@$JLYVW)DVP6)C(UBCK.3CX^,PQ 4J-5(O)N%5
MJXK6V5UJ/R26@WL;73;NNMJI:QG5YEM==1%7I3@G/U!6%9=E4#[BN.9Y,/40
M/(!+%LEZS^/N@_;%\1J8F;OV#F$*$P8%W 8<^C;U^["TC)YV<DH(XPX*<DU8
M^^?WU%6DW"KL=,Q^V\*Y>ZX4-LN.\=/ZOF=,Q7K3&Y5VM:_>L5P V4E2HZL5
MX\P,.PU,#LGNZ^X=8Q\N[&J915M7+GDP;6[50*0=:Y 5,48'?EM'P9F(1\:/
M=;5Q*J6@GI2QHY3L^AKT9.X,VB<'<[DLX)^=Q/G8I)59&]'N#K*)DQ8 +/WL
M!:N^5/U\PX<,Y8SC:JT<[TMZUWKZ\JW"H?)JM#56FRWT5+F-F!. 8(; SM2+
M2-=DZ-9LU8,/F\W6QJ4-B,"K\G\(+C<%X[X\@24#Z^X3M2WJGJP;XX9)6(>I
MV]:7/6E:R"G#!4C&3]=^4X%#T2_)ZKW]5FWDT!"Y=R/E<K<AG3=^WE1+KI9$
M@SYT['D&JW:'.UO64O;)-V-=<F4@5TNS[K2I7(7(05.U?*NL.NC6/=3X8'S,
MOFBPV<ZW<6@!@][MK3BP<21M5WX*CW!]P?,OW1=/13SY3584?!E":T1JB#QR
M" '1IRD[,OA\<&-QR9(PZ;MVC9<J2Z0[?DE6K-FT[>N%]M6;5O\ AMT^3E9-
MF9DWY5O'N9%KVN%!"AG8MQ4$DA5WI023H#9)\RI;8UUMEKZY6.SMKV!8DZ'Z
M![#]$E;*\CC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(D'>FX!/;6\Z7I6562KF"V78%33^'0&:=ES(#B*3"
M1Q@D*CLAZ.1UN[/A^1!5TU?;)!6KDHRTA]0Q05<II\;M8-U./F8M^17W:*<B
MFVZKBK]RM+%9TX.0C<E!7BQ"G>CXDM#I7=4]B\T2Q&=- \E5@673>#L C1\'
MYSE?9WQR^MR4WM]Q6/JFTP5?GXC&@M4"5/6%N!'4=9!P=0,G\'DC$Y4]M/G"
M#^3PF?3):U^9N:D1+JP'L7-01\(>R)<UW:.L]/6K&%^!CM<ECMD,.GXS"QF?
M)(N0I?CJ"J6U5C'[2UKV5L6T,$X7DS,<)6'QZRX8FP_#UMR)-I#+JRH#2NBA
M. 4< P;84+@B7@7Y""\6#0DOZ#@1@*6AU9C9V\>7)?[A1N_@M=^DH$;BP\5(
M(U*5IM'YYJVZV-RN4R*21UP6*5PJLX@FDNHZV![+U7I"6-:F':K+;<U0&-B#
M:VW85JN61ZQ4]7P]Z5UHCA5NT+2>9;(R\0/S%+ JSE0*ZAL,]+J20R\2G!U5
M0&T'^^3RW83QEX[M'RC81-L;CL=F<=GDL%2YW849NNRF_P"B5 GEBEZC*##5
M2G! R+2A(U/:Y.=QLBF^)NAL?.C'6AD=_($!J%3J74:,^I2KO6]5;5"FS&I/
M=#=0RLE67(5FLKXTWH'70#.C#D_,F19.37D*""RE%*A&J0EN61;:"+ 2R\4L
M (T 2I\MLF0BX^/'V KZ6<7<G<<15[93 P[:RLO=%\&9-*X*7]T4QZ4:11]
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M3CJS^0:WPHADZXA$4M,XM2HVY5ZS"O2C"WWCB=4O9]YM! 00.#=!$H56Q.*
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MY.7CCCQ9CR QTL)#,A[A4$A5=\7X]=2DK:792-^%"D&RVL:TQ.P*PQ]QY.O
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MJV8[NSW]PY+7U8[4A69@=OL:$# +2MA+KW%Y6+V*RE;!F',-6Q)LY&UK%K*
M$GY]!_/M@SN<?M3&V&.3&'8/.(N&Z8\<-?OB>Y91]16N5C#EPSX1;OE(C(;$
M,QMB^X1_%= !P10@[)%]DB+KDY=-578:EN26U6,#Y]7;RLC'5P#Y L2E7()\
M.S@!5XJ*=R*G;*'8=&._QXVV5AM?+D$#:_$G6AH2Q&4Y#&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FFQ
M6O83!W)YY$8R)CSF4$5RT@6&-M-^BI%R0*%EW3K6M[YZ4[(FBKO[.=<\<JOE
M]\<\\]:YU)9;;:%%CLX10J<COBH"J /T<54?J FS.S:#,3Q&AOY#0&O]0 _T
M3<LCFLP<8C("%QJ/0Z*"68&+Q,&)C,;!CDOP1X8 !8-Q8<2Q1UO>D68X<U;,
MVJ7V[_#01XX^W?V9L[O8[V6,7>QF=W8[9G<EF8GYEB22?Q,RS%F9F)+,2S$^
MY).R3^DD[F<S68C$37#<K"QXG#Q!1PHB^G<C=12-I\-UEN79IG$93.%VZRB7
M'7#1/F.PT\ZTX<;31Z6;)->>]N'*"?:)L>(C$1B(Q$8B,1,2)!!P7)#@..:C
M]%2Q Z3Z;IZY4(&"BWXSXB\5W]JCATOUKA/\17OK:39%NT1_#:MFZ*6S.SZY
M,3Q4(N_DJC04#Y ?H]R23Y),R23K9)T !OY >P'Z)ELUF(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B) MP?](7E;_Z]2+_ -+_ *0Q$GK$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B) MP?](7E;_P"O4B_]+_I#$2>L1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(D"W!_TA>5O_KU(O\ TO\ I#$2>L1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B57N:XKBC=PU?2]+UU6DTD$]K6W[0*%;0L^4UP&"!JIE%+13H>PW%
M*IM)Z7)FGMR,W/.G#40U8M0CG[7#E9TDFG?QL;&?&OR<FZ^I*K\>A5HHKN9F
MOKR;-GN9% 55&,1X+$EAX $GKKK:NRRQW4(]: (BN2;%M;9Y.F@.W^G>_EKS
MH!6XO78*1@H><A'A@-+93I;J,Q8K[!LX=(Y'RW^]MQT""._*"),OI#7'>UMC
MVKC27W.OO_=^[O[)5QNGNCV);U1JZ]<[%Z=0R)OVYL.H%5W\MD;FPKH*E@V2
M57[S#'0JOZR+M#W'O-L_4OO3^97R)_6?N7^Z)D?#I7YSU#^@XW_49KK&_E+_
M -C7_?Q^I?>G\ROD3^L_<O\ =$QPZ5^<]0_H.-_U&-8W\I?^QK_OX_4OO3^9
M7R)_6?N7^Z)CATK\YZA_0<;_ *C&L;^4O_8U_P!_'ZE]Z?S*^1/ZS]R_W1,<
M.E?G/4/Z#C?]1C6-_*7_ +&O^_C]2^]/YE?(G]9^Y?[HF.'2OSGJ']!QO^HQ
MK&_E+_V-?]_'ZE]Z?S*^1/ZS]R_W1,<.E?G/4/Z#C?\ 48UC?RE_[&O^_FC2
MT;[OE9^L#RE4>2&'=93DA-V[7CTE<;KDVJ_K6PZWZ&++]>3F^QR:2%@K&=/>
M$7_2BHA(?MIQP_[?,\%.E[&LG/(WZMX6."!H^0/K [/+B-$@:).]@ M8WC5E
M_OY^QK]M'V^W]]Z_#QO]4WG]2^]/YE?(G]9^Y?[HF9X=*_.>H?T'&_ZC&L;^
M4O\ V-?]_'ZE]Z?S*^1/ZS]R_P!T3'#I7YSU#^@XW_48UC?RE_[&O^_F,)V!
M[;"[':,59XQ$[+DVH03HGZNMMALH9>\J],A [3KR2E]:3=\H+]-6#;\5TXY1
M5VDEWI/O>MEIZ8V^.1U)N*EFXX&.>*CW8ZZAX4;&R? WY,R$QSO3Y!T-G5"'
M0'N3J_P!^)\3S,)O[D*(J.1E2>-R+=)Z1&JN&'JFWGB*1$00<B2S!15OY'43
MX>BRC)X-(M>NM+LB#1RS<II.$%4^,&KI:G39'40= Z.!C@Z8!E/GJ'LRD,#[
M$$$>#!7&'N^0/ /FFL>"-@_E_8@@C\0=S *7'Z[2EZ%?*PGPPE/70_HLVA"G
ML&S>)>X%<<J==DT(UUY0T96'\<I*]=/4V73;GE-3>U=:XZWK?X;IYK-PMZIV
M@W$V_5U';#?Q2_UAQ#?HWN9[='$ORR> .BW83B#^!;O:W^C>YMGZE]Z?S*^1
M/ZS]R_W1,CX=*_.>H?T'&_ZC-=8W\I?^QK_OX_4OO3^97R)_6?N7^Z)CATK\
MYZA_0<;_ *C&L;^4O_8U_P!_/9J^Y+P?7>1I6[*TJF(OMU5JT0)RK;8EUBM7
M;1&7)1-Z)+M);3U6K#7'*SE!XU<,E"J:R>E4E>$.M<==8OQ\48RY.-??8._V
M'2_'KI(/;[@937DWAAX(((77@@F'KK%0MK=V'<-9#UJFO3R!!6Q]_@00);+*
M$@C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$J++?\ /S\_?ZHOL'^V7PWG0K_>K+__ '#IW^[=4DZ_]VN_R^/_ +/*
MF/.TC936Y+*ET? 4I.(I;TFHZ3%"UKN9"YDE;=4_T'3;B(O$6$3*#)>Q'NPG
M<_KY5Q.X!W"K0DT@DWX)3>^>7>5RJ3C4UL^359CUY5:KCA EWQ//;V6&Q6K9
M@XINU5=W,>M$VORV%J=M%+6HU:VJ!7KC9W-^68L"NP>#@(_) %\?*E41\+^S
MNF<O3G?H%URNZKJRM0AN ])W^1: +LD4$AH6%RWZ_J*Q(]U#X]+X\0D7(24D
MK$*-%'NR9!_,#3U\XSIV=4Z;NOM8:Z%U'=+X6(I?%2VU[*^/<L3NO6ZH7K%(
M.N(%:@2PV5C;7A2-<TY[HJ!-2LY9=<F')E8+M> .O 43:Y_XW]@R<:08 [P)
MQ]RK-9(9*&P7INYP1BPFQ1W:2\;DCK@Q64]C]1/8:WED4:,Z]@4>,QPAT#'.
M-2@6G 8,S0TIZETY&!?%#@5UJJM@XSK25&/S0<;Z7R!8:G)NM=77DP[;=VTG
M5,C&4@FH'TJ #16P0@)R7Q8C6!BK$NS!AL^GUOOH%05822KXI)&,TE1.:2Z2
MV?;,S(R$C)I%(>%@DILV7'8$,:-SFT6<<3CU?$(O'W,=C(P7&ACX6Z;B$'33
MA(@ZY&7>E]B&JL5UI1CUA B)IJZ*TM8\-E^=P=P[LSL&!8@^!5M=78%5"J$K
M4  #RJ*&/CRVW#'DQ+$'9\^).659%&(C$1B(Q$8B5D]0^>D?1X&LXH_>)CPL
M4M8?/S#Y!^[%R(9R(@\]#@#\'(M&+W8Z=128R&-2V+$U=M.!!,$F61=Z>L6C
M=Q>P<PX3WV*"7LQS2HT"C<K:6=+02.55E265V+YY*_$C1)$]%W9+L/=JR@&@
M5.V0LK@D;1E#*P^8.M>94RF?)?K*#2N*&)U;<4/J(6,:G$C/PV?VM#@X]L;O
MR\[3FPT/1B E:O9;JYXS8T7#R=28G4W%>E&2_<??2_\ 1<**]7LG/P+:[%JQ
MW3=*5(EE-%C'AB8N/46RBW>K^&LI=D%::N4CF*NY8LGLOQW5@M;+Z JAEK8G
M555:DV[#KVF1BO%?6"-A>3"2?)O/EX-'=W#H$&\^D.+)L&:VW$[7GY6PD;$B
M<R/U+U!@#7L+#H^+)-2D8>-VL7C]HQ>W@$CC%8+)"P\:[*!4>RL->7BD8QN;
M,4TTU8]F/2M)ILK3([KGE:[*5<$N^.^.Z/>"S6<7(71;:CVBYN'!%K:M G!D
M%G)CMF((/WC6U95G]VT?$%5!XI]:Q=[(34YO\N[*L["I8Y5J"-_6_,6$4AT?
MMD!*+H"'62T-KV,2E:85^E*XQ'F)F&$6B>C7(AV_&MUGQ[NUD]2Z?8*UJQ%"
M]G)2\_"8]366OCO7C.I%MSU]JXH[E;5)XE@I("26S)QV"A*0 4M%FZJUY,:R
MM3+ZG9>+\6)# ^-^3XGB#>,_8:,BIXB[O4N"#PAQ%=S0;'?35PGNY7(PCNMU
M9/:[_JQ*KE/!IS8#6,2%J3I?7Z9B 1,B3^FG!56PYDNB;J73N&2JXJ,UHL[9
M?!QU[:N+PE"]G(KX"HV(1D^NQN*[J44UJ<'(QBM@%0);?$M2@X@A^-8*6+H)
MM=6^IVT-J."B2CYOK.1T]>U*UO-9$]E\]BG@,")L*6/I5*IHI*+!:6)&D)M(
MD)%-%5)&^8FI,F3(L/KTF&T6CE%),8-3XY9(5\RY,C&R;JT%=5G57:JL5UUB
MNHU.:TX5C@I5.*G6_(/J;W.MSBRJQU4*K9;%5"JO%"AXCBH"@A= Z^?S/O.E
M&<>4HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1*BRW_/S\_?ZHOL'^V7PWG0K_ 'JR_P#]PZ=_NW5).O\ W:[_ "^/
M_L\J5N]',/892PK1!01O93"L#99BI$G]:CZV4(&BC2*4"DR$R8K*%>) !@*R
MZEUNBIJ+*BY/P9 C6:)I)KV+CLMN8;=.6FE[32;T0AQ<;P%5K,PLU:U^A[@/
MA0JV!J^+L2N^3U6*3C!*V<H7 /,.7T 6NV5"C3/KM:# KHDZ]V74A3_Y,)$)
M--S1:3P4QR5+DUEP44I MP.,#JLO IS#(>^/1%XT(5B^LD72@T0^,@Y!,.A9
M<BBI:I%Z5*)021AT5&4JE=J\0H#V92\E.1BJ++0EH*WBALHL%=*^2J>PH"FT
M1A@@@*PT/!:WR.Y4"6TVPX0VMX*KL#[,:'.(S]3>\922<M"$@O!-B-LZX+"[
MYT_K;EF2UMSZ7F560/AYV'<.2U6\N7M(#FD?=.%'8ER]_*-$QJ@!I^G["Y'2
MZU!"8I+48]/M?M3K"KONUS 7(T,IN8]+:Y<6YGG,MF(H^[5LUU)[/[_9+8^M
M^+-"TEOG[Z(;S,HR1_(WN1'V\F'S$-"]3IXR-JP.-4N>DL7KQD=DS>"$Z7U*
MA+0::*R0(WA3BSV4\U9ZS)H5DKV/JUX;%,XLM79.C=M"C5M;V@5%KY*H]Q1#
M:N5VVVJHYL%!I[&RJ!^\I:P1%</0(XEN((YM8JER%YBS@20%;EVRG;!TH/<!
M+2_'EH-.(YYC\YQZSM&N;)!414(:PN9&]X)2'F<"Z_CS&6:/$4WQ1,@:T>0?
MZ*/>"9'AT^_'7Y?.^5-.%.3G-4^;F/1Q[+Y60U/ <4[37.:^"D*57@1Q'%=#
M0T/85+RINN*:X&VPIQ&EXER5T-#0UK0T-#Y"3OE611B(Q$8B,1&(G/3UIQZE
M[EI5I3C>?-H"9KP(),':Q$UL6G+8]V'O];EF"1L970Y)J_EFJ=$R8BDCV2$
MC*SP*[C^]EY?&NOT_P" X*V2:3:MK,J7M>M13EB>6- +;%?Q+5KOBSJ P?TU
M66Z.QQ!L*\PY(#EPN@:O)X>=A>X5'L6 !!\*8'K/7R1.=CH=*'\M@PGAQ74;
M?&V :HI(XC$39SZO1&Y#$3,HCAE=])S%2]30M8>YKS:Z;6:HJNAK:$(#Q8"7
MV[_J8$VUK7<?MG",V16'=J;FX6(CKJM,GM+3VOAR:O#&TLSU2V?!C;*%8^LZ
M)<<FX.=,%8>D6<53@$]'N6V66.B]7^^)\[*A)=*[R'MYRWJ-W*BH)>K@J(!#
MF3>"Q$Y90QTR J_D*1</'O3YB:1A/AR'7Y8NEFXWAM(>6Q^5+^DU!72O%)J.
M2*U<7OS]'56I-H+#F59\%:W.F&P"=H2DG<Q$XE%J/#N !A82?&64Y D<M%J%
M5O?V\[!(D.,&ODH'HB1CT(;&BAU3TT.>-!0.J"BC1ENL*C4MF41O9ABWWU>H
M6>.K;'1< ?DD@K\AT" L'M9:$/$9H1BL7HIY,KHS'(R6!9\@<CW\@8];\3_W
M5ZAC-8ZHEPYN5OY UKHPPCL[!)>T@DV#SSL[:MHG[(IV^1"A_+$6;VHV?RL^
MD(GTJ($6?(CSB=N*9]$K]<6.1BB5@.A,A]M3:0P),^,B[OL"-*.H 1C;IO'@
M3=@/#CU&PP>%"M&:8EE%GA&PV:A$%0R,,?8K9V0R=-J2THSCD5[RN"[DLS;8
MLQ)8ZY 4TDUJ G=J^X&X C&17T6'(CF&&VV2?)))V>KV<*4(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1.15G_ !;@
MK$^5&G?D#4EQ)K%(57!/J85NF8*(M3]S1=8 )K"3<,$^OHN@WZ?ZZ)2%MRLV
MXW(ZO@2_;,CP3**-O14=>>GH&5T?M*;+;T-5_%>28SAVOKY?>Y<]!#Y]%]PV
M-*#T$SBF!9B<=LSCB^AXJ8$NN]@[Y>%V#Z;'&QH3KKGG9SXQ$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B<JU?BWI)3Y2DODE45'=2?BJ=@OT/VDGI+5S\-DH>VMK
MG6N=)*.^:L_&B^V:O/6^2^D)(GO1)/E?GOCKV6.@GH@Y"HY/<[N_/PVS8<;^
M:<C5F_P]'W=@W_CK?@?@O/'N;Y__ &]\C7_^>F_5X]IU4S@2A&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B55]6^JX[YAB\:TWB4AMNY;1.]PRBJ$@O;/<[M
MJ::;=/'+5AV]ZTSCT0C _71ZPK ,ZXCT'C:*I,EVLZ6&#2-_ P'SK'W8F/C4
M)W,K+NY=G'JWH%N()>RQO132OKML(5=#DRSX^.U[-ZEKKK7G;:_W*U]@3\RS
M'TH@\NQ 'S(YRV]!FHR-C['^7KVL^C+6</MMXCX_\X3J=U-4W'?6N%$X.):5
M?VR],>I96VUTAV5<_F/ 5RZ4[X85^S8:;*]]G'M+.:/H[TL6&I?M>HYE-63D
M'_[K'(Y8/3ZSH\1QY ?>O8^URMB6*=/Q@W#[V3<B6/\ SR; :<=3YT/?\;#[
M2KJ\+^'IQWOAU\37K'0K[OX_5@J>*?0G)?ECKG\;]0=ODW?[8M-N4?\ GFR>
MPOUW+?7U/\G^-EX7?2,>!](<#E_(CJF)PV?' #7POZ.//COQ+'+J.OWPQ]^W
M$9-6MD?=]A4=_ARUL_C+0TG7XQ>-/['^(3V@\EH>%/\ 3>7^//0\_F]JU+VI
MSM3ON#/N+,V0])^5)>YYX=]BW2CMR&1>IH_FM=D!_+KO5'*N86+3](NF"MK5
M':ZCAU58^1K?Y8=C6#U"L;'+0#$?=O4ZD%KGEPZCC\2P]&32B5OY_A_9ZHR$
M_5YU]VP3I!Y7]4Q;T]&)-UQ&I#5UN5>?YA-Z45.=-4I[4<YY:\N^1I333OMF
M>BY]GO\ .H#/@O2L;G4;42+"5^%DR \?QL_ LP;$^T3(Q[T[N)EU;[615O7)
M=^4L0^FZEO72_I8>Q-*^AJ&7R'K<<JK5^[8F];&_((/AE/E6V#^,M+E"01B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D$B/4?F6
M0;F_(#T51)SJLQY O8^A%N5^2W7XH2YVR*DYOIE(5]Q0>,><]-"#T]] V9N>
M=H.54U=;XRTV#FIVN>'E)WR%HY8]R]YF&U6K:#N%AY 39(\B2FB]>/*FT<R
MFZW',GR NQZB1Y &]R==;UO6MZWK>MZUO6];^W6];_?K>MZ_=O6]?R;RK(I_
M<1&(FMF)E$(\Y;,Y!*HV#=O2$?$,VI@X+&.7966D'(F*C&R#UT@JN0DQ5F\&
M1]DESVY,D&CED.2<N4%4^-UJL<$I6[A5=B51F 6L!K&) .E12&<GPH(+$ S8
M*S;TK'0).@3H*-L3KY*""3\@=F;)FDUC$1B(Q$8B,1&(C$1B(Q$8B<.8/>
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M$C!=R&1)*'&I<@7)O^KC?2#-HMQV<56TT7U7&E::*"RUYOQ_92VNGE4AR"S
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M333R9V+N[]I$YNS,26;9&^*Z4!1%=<][<K.&_/W41-EB68G@HV2Q)V=Z]AH
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M(X8UK)F, N-6]?5TQ!3VVI6RO)[*<W+6A@+&3L!"+#%9BUU5WE5LLXUL5N(
MK4KE"GAQ*!A9Q&R2P/J8!->J2C<GJR_HG>-Z5E4?57B^H>UNB=K&;0 V+8;1
M492_F3R-9+0 'CP>U(&TC_<F-707'/G IVV%,>&J4CZ E3S@ST<@QNGXEF+B
MWY'?86'&JXT/320<G.ZC079VHM+\%QE(# L=\.:H%X:5X]+4U66=P\NVND*)
MYLOR$))-;%N(J!&]D_=V!K5=K<^1.^"O?H6&QR94_6+L/5+R<5R3%11A81>)
M-@(JH93*GUA&1_H\=*HZ[91^8R));F:T#5\39:)1,K&;&G.TNF9RWC]'Q5&'
M:]>1>&R.U<K6-0MA9LBNL4*V$U;@O6GFO+OL)6Q;**M[25,.I>TS+8^[.#@L
M:PQ)L"\-T%6!*C16VQMA@U:";6-]NVG!K:2-2BRJL0J!S+I/"R,?DB1]%NW9
M:^3VQO,TFM\?.Y%:9#8\$&@Z,<4X$N&+Z(0Q0Q&QH]T)C*#(2^C/2Z+J"E=&
M0<D5UV*Z<#L_4=.<F,:4H7;M;S'($66!7+!K"6FIQJWJ("6=P*&#+K\Q2Y:R
MBUC9+<O.PS ,3MMF?AO[EM2:V&I+QDQ@9RLS!>M0=>UC$$SXTM-FK3Y4IUY=
MW8L5FHRQFJQYJ7JZ/P]U)A6P1.)&B,E"-WO+.*E'P&1CTNBJD5M7:ERKD-=?
M849:R>A4YPILJ:@\2M[V\&#+8JH^MV*KH^&K5 I5P^K"[MHA/W"E_!D*'6K"
MP!!#  ZVP!&R5I[Y] 6@[KF)Q*4^899(;8;^?BBLPB4(GI>)T(4N,-<):1T]
M94;3NOHM++*A"-:ME6J_ZEJM^4Y4+HR.OH3O0MPYTOZ5BT"Y[*\ZM,<Y:]NR
MVI;,M<9L=4R:'.+QKHM-YV.%X72\+K?5K#XE2<V9;E%?>'%F56M%9K"V(35I
M4?GY'%]>-.VSK<K'O"^K9\Y>,9V!/M8=*)U?I85;("NALS9*V,SJ*#7]*B<.
MA+P78@.31 =81^FFJ+9B[/2I1DF98C3*LJ$L2XR3Z48N+CYG4ZG0V)3AJV.]
MS5D4MDW8=2VVAJ6KM-*9)V0M8)4LO;8JR:)737=D*065:0:RY7T&QJE#."A5
MB@L)\!?;8T2"-'KWWY?MD2.HX!#9UY2GY6W9#0*+BRH'!;!,0>J>[:J7T]9L
MLJN4QGF[U",ALF%(T&"^F(*3*#/'(R:;<2:M(DJB*_-I+NDXE"9%MM6?4N.N
M7JFVVE;<@49&#17>C_"Z2FTY;[ JM4&OT7V#EQW?%J1;'=+T%8M]#.@9^W91
M6KJW: ",;6WZ&&U]+MYFX^@K8])LO::-35]=L&C LC*O)BT*AIR$&RO P1-(
MI[!XG925L0MI14G8  @6KL:X=CV?<09JD&$*&[+#U@)%])(\/'PCTPY%V+<Y
M5,\66K:J\FKLZ;V5K+8]BTN%O8!CW3HVMQ(95KUIKI.,;'J<Z6_DX8 $JV/Q
M"[K8(P#ZV>7@L=>?$=F?D,]--*W/V(W!TNDQA</\U#Y3QS#22J.IO>=PSVJY
M#8'1:;>BZJAT5KB')P'HPQB<NF;+LD[DS(8<MZ,L0S@Z4F3H^$;DI+9.[;,X
MU_:#9KQ,:K(2GC5AY%MEUG>"FRNLA0A9,>QF"#9<6AG5.5FW:XKM@#QJK5U3
M24VLSN6UM5.@NQ62=#4M?*5Z$[)52,_9]4Z7Y\$X,.RBIZE^0=V+]>E9_1O8
M*K3:_M-J&BQIH%A8$T78UP2]CO0TFLF.Q]VR[9-Q):9R?46(!D$W9'H;B%"9
M7/&'P5.5SO3ZL+6(6M=%-XZ:&2AW!V66K;X&G5AYN='6@MI-7V*6[L QB6&W
M*[?X?8K9O?86_OH7U%95-7-%JC P(;,B5MA@A^F6[1B:4>F4:V>2>4^H@\@<
M-B.VC-\$JP;$^ZN?:29H$)Y.!P@DR+(,]H/.3AX-.3CV9#VM4N.S)DDE=*;@
MB8+("NR'R#8+QZBM5192I/BK30EE;6%RHK)%I\:',!:"/'L;"W,?)%)!!G.>
M*?*]=1VNTS9O5&Q8W(G]0KQ\ZHQJ4N$ ]6! ;LG,JKZ1AD?D 91$<?B+.JAR
M[*4V[>OG@V>9%SK;5,,I&!&@9'V;.@8R7%$^*L5!DAE!R%9Q3=BU5W(YZ079
M+#D-M,?%S$0HI^)*.72XV!6'(7NL!W-@&P%@CU*KJ3B<BK=P^FNJX#0/<()(
MWII\BGIB4TDPO(%SYUB81>'^3NW4?E(#OHJI+K_JB+6A)W@61SKTY25:N$ O
M;\G&XI!9-.X>H95?LWG5E.2P-M%IS"W1\*O+;$<YEC"W/ >M]KV\3(LH0,E6
M#E7[;BKV6UU6<=$=@*Q>K4X=*VFHFUF#7CD#H:JL:L;5*+;!O0+,J-K1'  E
MEGVW/55E.:,\"7S74I"L65MVG$E+ "+P<D,3M064\_7)+TJ]C#$E.>G$47GT
MVBX<' U=G)QI22%88Z8/IR*3[&3*KCX% RNK8MU;L<:BSM,+E;X=ER\>LW6,
M*0+!34[-;Z*=(M@(J;U5PUT(+,NIE)*5G@>0/ BZI>;>CU<%8E_">D-L(?*Y
M/SA[9E-B1&[I1+9O0]H!JP\Y5OZ [FU"QZ;(1:)EIN M Y(:;F Q::6@;-RZ
M",H *,.7(=4%*"PB5LDW]819_L4F;US>F)39BUUU9=#7YE^(*LMZC98M3T(F
M16PKH1:[3<R@,&K5JR1>Z\BJ[&5&K55M0O<]7&UDVP4H%L4\:P%8L1YVH*^+
M"-ZI,V^5R^7<%E9-L1\W*D8K/J_&OI:J/K=L.5BLUIN?6$NP 0_7OMQ 9')1
M9:%INU>7_I^(3+J&N273>G7DE$Z&/>E]0X@M12N;Q>FYA6&N)%E.333R>WZH
M%M=;"W0(P+*^X%WDA&V+/P%/)01<.2.>.W)Y)8B;+?"<U4A]#5#+R&S8%.QN
MTN^5*UHT=N/8\+6<K%@Z_1E581J/1IKW(&31PVIQP0FEN/3'HX+,(&P@X:QB
MTXFT1M&EZ/BC< S%#1E^NN^US[B*OH6.Z8W)KT9[C7D.[D(2#D@58P7">JXV
MM2M55E&5E6%RS'$'A!HN#65J+&Q.3\7))T3]H M8%)5^;($5J[+3RWNH: GZ
M'_)U=Z)>ITI+S1+"+F[$,1"4'0:%;S&43@<SGM;Q=L0A4"A/MV4LP*+969E(
M<4W5\[]=RYI-!C%X8KB.#""8WL>B8I7(X?%&Q*5M16[]==1-5SE;;;>EUER>
MT+%[]73JC6Q"W.5+ <*K5A7NEE0,%/-54E7)#.V,"3Z0X[B8Z\=@.3YEF_(/
MMNQKO[]&,IFQ@$IE-21AO,X[$J;&CW0]XP=D[('L8_Q.@UV7!V?+$W,*;B6C
M:;06@+$9E$2_9>GF#;I#EI2ZCTNG%^#-9M2O(L-3V9+,""!22YJ;%QPBJ+2Q
M-5V725*\<ECN0Y&*E79*E@MC%2UA((.D\\6JJT/422C6IK6K-RL$O^3ZQ(W5
M<3D0R[/(<UFTS #)STWA4#)=!*^8NJS)S(M6,O<67ZXJ:!N9R!*(C]*N>[IC
M=@D 73U9MY[37T@KN]7T.I\BQ&Q>HUU5.U6[+5YW$7K6M]?9Z?D6BEEY'QBV
M4JVMYFI,N$C.P->0JJQ3U.-N18%#KPQ[&"D;\=MD#:^VUN;T_P#D,]%H15]<
M@N%U2>@";MK%A%4#8W.%K(-R@A\7S'WVQ(M;$;S=T&VR5F3CJLD8LUJA\2?
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M,M:,2NRQUH D@3*5V/\ =#:8.03L*>*LS>3X)XJ?&_EJ;>1.0-@'4*%C$19
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M D^(,!CYRR2;CEG9;IOWRUY<=ZWK1*;K37I&XV.M26/M:ME@@!L;2* 6 )+
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M.S^)_P!<_7 T<G]#^&P9)_EG'20W[C5#G\O3[1TW[38_=3U])QVAK2/7#?\
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LR$>DH.X&9:%*'7:3LJ5VOG9+_>/I73%OO;V.C.<:4XQ$8B,1&(C$1B)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g556103g01a32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a32.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &AZ^9H8X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q @*QD6         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             ')P  #.0
M         0                         !              SD   ')P
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   ')P
M  !29VAT;&]N9P  #.0    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,      ]L     0   *    !9   !X   IN    ]0 !@  ?_8_^T
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M/]$NWU?IJ[_LUB0%H MZI)8G
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" %) E(# 1$  A$! Q$!_\0 'P !  (" @,! 0
M      <(!@D$!0(#"@$+_\0 <Q   0,$ 0$#!08*$ \*"@L !0,$!@ ! @<(
M"1$2%1,4%I/1&"%3E]76%S%255976':2X@H9(CA!46%Q@9&5EIBAL<$C,C<Y
M<G=X>92TM;:WN-,D*3I(25EHLM37&B4T-394::?"V"<S0D1B8V:"A\?P_\0
M'0$!  (# 0$! 0            $% @,$!@<("?_$ &(1  $# @,$!0<## T*
M P8'  $  @,$$042(1,Q05$&89&AT10B<8&QP? 5(S('%C,T-5)5='64L](V
M0E16<G.3E;*TT^'Q)"53=I*DM<+$U EBHD-$98.$PR9%1F.CI=7_V@ , P$
M A$#$0 _ /NPK?8<AV!<Z4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0
M[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4
ML.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[
M B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L
M.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[ B4L.0[
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MB)1$HB41*(E$2B)1$HB41:ANH[RBW=HK>'#0'J_CT=VX*6V0^F+PJ-:G76)
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M1YR28#C XZW03,1^9BS+*^!$6R7RS8D&JBN*5T%%+H*JIY[Z3&\&H:B*JIL
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MN)/4[96<N#3QWC;#.[=NF@TQ3;X4=36U-4YCII7%L5]A$SYN"F;>X930LM'
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M[%*2*9M&(XZ>HEDS$SO/T0TEC;F[6*QHHW4T=2:B2!@C9Y33VJ:>0FL@;(V
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M0Y(DR1#8KO5GV6>.]*IL7IVT,%,RBHFEKG1-<'OD+#=C7%K(V,C:;.$;6?3
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MQL9GJ/;;0N9SD<-QV().MA3V$-WZ,/7@6+J8JS)\W:1EI'1I,F[*(-V#C+"
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MR ZZ[EK@GGWL68<QZ;BWH].B6/)9N/WYHHNF:6%;IU,32C:YQM(56&Q8>\3
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MM/BGN> GVS^0'QX[!^6*)8=?:?%/<\!/MG\@/CQV#\L42PZ^T^*>YX"?;/Y
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M7*IL;/L@>5I%D4K@33J<V>&W\1UO"6"3W++5)(+*"Q0@<:9CSN]>,>L]A 9
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MH3T9F)*S WEM=NKJ9N8!2>:P91Z\DY"5JM(4^$RXQ"$D'IJ2F72A52*"KY2
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M8H7)X4!./-=MLVBT2=2[ -XJW=LC9R\7S% WELF?J'JOR]&[AU=:9?[N1W6
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M^M_&_P!SC\]H_P#N5M\@K?\ 1_\ \T7]HH5ZX1L5)N .NI(!6R<@Y!R:XA'
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M;DVVPF3("T=8PF!.&2AB<G". -;8A-F$79)3(JX$.T]3J;&IZ 1ULTL&&4$
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M_P#[?_BJ^7>N11%Q%OZ>_P"M:B+Z(OR.+^>4WS_:.1_S]B]>1Z8?:5+^-?\
AV9%48Q]@B_C?^1R^PFOGJ\\E$2B)1$HB41*(E$2B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g556103g01a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'WZ^@&(X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?CP$(         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             '-   "[,
M         0                         !              NS   '-
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   '-
M  !29VAT;&]N9P  "[,    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,     !3+     0   *    !C   !X   N:   !2O !@  ?_8_^T
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M.Z/W6^GL;_QB0L^M<P;/K"!')H<=?'1*X_NQ_E]%< \'+/\ C.^MG_<ZD_\
M6:U<_P#'!^L!B.O88D P[&((]H>]KHJ<SZ7L9[_>F==]?Y&T=8 ALAS+2=T#
MU.&?1]3=L_D*WTFSZ\.S'#*'4S5]GR2/59;M]046G
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% #6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@
M>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R
M,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,RTQ,2TP.50Q
M,CHT,CHQ-2LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM
M<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C,M
M,3$M,#E4,3,Z,C$Z,C0K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @
M(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3$Q+3 Y5#$S.C(Q.C(T*S U.C,P
M/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!0;W=E<E!O:6YT
MPJX@,C Q-CPO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)A:V5R+"!#:')I<W1I;F4@
M36%R>2 H0TE"($E"0RP@55-!*3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY0;W=E<E!O:6YT(%!R97-E;G1A
M=&EO;CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @
M(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO
M9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HP
M,48T-D%%-T0S-T5%13$Q.3(W14%!,3<U.4$V1#-".3PO>&UP34TZ26YS=&%N
M8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#I!1$(V
M,C!$0T0R-T5%13$Q.3(W14%!,3<U.4$V1#-".3PO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED
M.D%$0C8R,$1#1#(W145%,3$Y,C=%04$Q-S4Y039$,T(Y/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I!1$(V,C!$0T0R-T5%13$Q
M.3(W14%!,3<U.4$V1#-".3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,RTQ,2TP.50Q,SHQ-3HP-"LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C P1C0V044W1#,W145%,3$Y,C=%04$Q-S4Y039$,T(Y
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(S+3$Q+3 Y5#$S.C(Q.C(T*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP,48T-D%%-T0S-T5%13$Q
M.3(W14%!,3<U.4$V1#-".3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,RTQ,2TP.50Q,SHR,3HR-"LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HP,$8T-D%%-T0S-T5%13$Q.3(W14%!,3<U.4$V1#-".3PO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#I!1$(V,C!$0T0R-T5%13$Q.3(W14%!,3<U.4$V1#-".3PO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.D%$0C8R,$1#1#(W145%,3$Y,C=%04$Q-S4Y039$
M,T(Y/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP
M34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T
M;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 6X"4@,!
M$0 "$0$#$0'_Q  ?  $  @(" P$!            !@<%" 0) @,* 0O_Q !A
M$  !! ("  $%"P8&$ $(" <% @,$!@$'  @)$1(3%!46%QI55UB4EI?5UQ@9
M(973UB(QD[31U HC,S4V-U%45G)S='61LK5!)3(Y=G=XF+<D)SA"87&2TCI#
M1%.!MKC_Q  = 0$  @,! 0$!             P0! @4&!P@)_\0 6A$  @$#
M @(#"0L&"P8% P0# 0(#  01!1(3(10B,08505%35)&2TQ87(S)587&4T=+4
M,T)2DZ*Q-&)C<G.!E:&CLN(')#5$M,%#5G2S\"5U@@@V@X2UX?'_V@ , P$
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M%K8 $8L4&Y;!=&$8#4W84BH!IR*0#(1"LM$U*)C,6*TTP7=M-,MY;I-%#<W
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M^PV>=&PDNZ&6)J5$C[0L_LVW,C'*B;*5_7,IB[F  4Z0/#ZNY@S)&-P<*>3
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MRZD5$06! (I(9  Q"EH8VC("@=4.&+$Y)WY)+# '9)V,ZX3.R_6<GU^NU_7
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M\8PF<;^(O#.6W.P5RJA6Q@&J!U%MWM7ML_<&/=C9Q-GVROLZFB5=F^Z^D!Q
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M(MDP8L[0QSI9I(K,#*FY7:(2;%)"0K,>J"6D'6P7"HH3:_,L47VO^(3N@-#
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M.K=C2ER5%RMR"R^F">P8]B*XS$?:!S11<JZYZ.)+8?E*#@LR'\C9Q:(Y EC
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MTOA*$F0FYU"WEB:.>*2&8.J:="QW1R.,\0 $Y((R#ICK6[4U5@U'KS%%C#X
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MK[#:2NNVR&E[)K_9 #75KTKL@EL8+(MNN9.T*P6G$]:WS6:V"-:AWW7,I$J
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MQ[2T,89A(\E#W)V-M-</;7-Y;PW:B.Y@@Z)&TT*X MWO$M1J#1A0%XANC=!
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MISY6=9_7RK?>O'1;GS>?]3)]VG#D\F_JM]E/?ITY\K.L_KY5OO7CHMSYO/\
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MD121E_,TT6/'MZIN,:60(28EVWT2[M[NWD>*VO D6FI'=75U*]S8"SB9+B.
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M0AW"5^8I2?.QGS59QY,Y^F1_[0M-2-$-C?'8BKG_ '?GM4#/Y7PXKT:Z];
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M[8D294F0XEIB/'8:M*W7WWW5H:99:0IQQQ24(2I2L8S@Z?IP!)LK(  DDVT
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MQW^HR.@3DQ9%E+*%/)B0 OAQ6'TKN?B57DT_2(T<@([VMFBL6&5"LR ,2.8
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M2Q5T?0(L&'2#U6W67,PSQR^2K&EH+'(D)1F/DR @#Y. C*[JT!D9[@2+(<;
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M0=[7<Y5C/-)JLYF9TU1+1[[4 D<$06Y,9L[4:>"C*6%JTQN2VX;!(46X*J&
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M\4_YO@+[:M)_O_Q[IM'\Y?ZO/[.GNV[G//G^J7?L*?F ?%/^;X"^VK2?[_\
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M'Z]4/]Y./>][K?DU/KUA^)I[LNYWSYOJEY["OH:U8#)5G6.N*V983%,5^AU
M&5C)>9D)CDA-?'P)S"9$=;L=]+,J.ZWAYAQQEW"?/:6M"DJS^A-+@DMM,TZV
MF7;-;V%G!*H(8+)%;QQR+N4E6PRD94D'&02.=?&]0ECN+^^GB.Z*:\N98V(*
MEHY)G="5(!&58'! ([" :BB[.=PM>,$%XQA2L8QZ&-_%C.?)_P#R>=OA1_H_
MWM]M6Q:P$#X/P#\Y_O5X^Z@]\8+_ )&-^QXX4?Z/][?;6>BP>3_:?[U/=0>^
M,%_R,;]CQPH_T?[V^VG18/)_M/\ >I[J#WQ@O^1C?L>.%'^C_>WVTZ+!Y/\
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M =I%F:/#Z'=0-&/0VL@[',BB#.2=B'S(8<G-;(-0/3M'6 1=KV2K.PG;_&(
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M[9)5(.0:D#,-U)X):PM9'!T#1@B#D,MH>$$@4C@\+H2:U"T<L(M?@G:9E7J
M;Y+2*V61E(;X0.CRLVYF)?FS/EC9;4(RK((3M+,P^+VF)(]Q'/K%E+$[B3G)
M);)K%BO##[ A,ZMB"NW-K'U^F$:"0L0!@]?9#9@Z)U)U[IERO\ H5-DR,2WS
M+IJ&]6H.VTY#;D-;>LF)Q6&Z^9CGMVUNU;CEM/B9Y%E5&*1#:K7%Y)'$5554
MQB.YBC;(..CIM4X4IEM0@;>6ME)8. =J#"F6=T0A0H*A944YSCA+@8QCT/\
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M4461%%'&#S/#14R<DY.T#/,D\_"2>TFM7EDDP9)'D(Y#>[/@   #<3C  'T
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M'ALY;DI(0JL^Z6(VX"K&P=P-I9=K]22QM5+ 3MG8[(=\;!2D#RD-A5+9=.&
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M<'"[W4L<$A<D D8J6&/BR;,X 221B!D[8HWE? R,L50A1D98@9JG'][T^1,
M"U5\^0EV-P8V)C-(JLWRR#S$C(IB8I%E<9%22$%,AQ+)-<-U,=3J'DH\V0AO
MD-KEFSP1&">1[@QB%1T63+3JW"5B+DB)Y$#';(4(7=N  :NJNBW(2:3CPQK
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MA# QR)B&G>.XT.%FV(C+()#MEAN'6/<D@B5BQ+_!,REVC.21E2^U365:W7P
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MF)%.P"P/92%(EQMA5<<E)K@R!8MCBH,^!FKKCC CUL4HHVC!"42%+),"H.P
M/9\_AR!V8YX4D'/;CECLY9KBG5[FU++?6P#9M^%M'":1)C<[R42:]C61! 1'
M$;@\3(+/&7"+[8/;-94=,(C-8F):!2)RC3.#C#:X#D,%;K/ZFP^H5F&5F)"T
MZ>U)4-DR!C)^3$#QBDUE3I-O!&,9(YXQGYR!GZ,GT=N*V37#(CNME(>'OX@$
MHZI6*XF*AMFUV$=NP;ALT8E98Q(PR]2:%V9$D1-V)Q*VZE-0N,"J8D$#+0<*
M^V1Q,RR3+FBPZ&BN8:4.EPI,>7%E,)+/"A\<A)]IHD,B",<NT9Y<_'R'C\'S
MX/9X#*FLQO'<R"+ M[A8 6E"1L&W8>25T40X*LI!#+Q"BJ[!PPK@CV,V=!%W
M$KF%KM143*O+%>UVW!L#]H(#@;E]:#V1\BFPM+DBX":K!E61N/5HD=Z*LG@>
M7B2_4(KN<#EVXR 6QRR=N1CP')/YQQRY&JCZO>JEQ)MM.)'TKA6864SND9NN
M%,7XH+1JL"-,!;J"#($D4A09<.['GY5PAUV;1)\"*-NC%7V XD8<FKIB9X*F
M01;DDBS%0,7#GW^QFT0[+)5$"SZ55IA>(VMV5%=<$#&<^#(\&>9SR[<@8R,9
MR0*F76)6N5A:U=5CN1!=D)(_1]T5LJ%G $85KJ:4+,V(WMX&D7FP-2 MV/AP
MS98&,IY S*KDDK[I<,E8C#H@<&L-^#RI"H_JS[CA"6.HN#P@2]ZJLA"L0169
M4:*_Z]G&/G'/L[>WEX<=G/F?!@^$8J=]759)(TMV=H7<2CB*K(D<UU&6VX)+
M,EL)HTY%TFB.0IWU 8?;[*\&GY&OI<AF-@R0%Q1QP?F<\,%Z\JMR]EN9DI;B
MR[?$G'I8RV HSC#M27#<8SDT]'PY-SM.>6,<N9Y8R2,^$D<L@@<Q50=T  D9
MK5B%XKHJ2J7*1VD%QL.0%-P&E*31 J8"I!WE<M)+%VA=K,LF)):R/L% L_(P
MG*DDF8=38E,NRD2',6>4/;0F#(2D7D+,EC8B2CI\4PXW 6Z[EO &3R.?H[>W
M'9V>///E@GLJ>;63 722SD#HVQR9 (006!/%9!U3A.&Q0!S*BG:3RD=>WF9L
M-]@U+-'R"@2A-N,8)%C27);\4*8-@0C,6'#@KB*+$YM5LDV<(P1=]2!-#R<8
MA-6[-AP6.6<_-V$C./'R[.7T\^7AJ:'4I)KM;?HW"1HYI-\DG6*I))%&%55V
MEW:&9F3>=L01PS$LJ5V![<.2AH"87H[RG2<G7(B<Z"()(BD%+P++$G7 TV.W
M,F'%P'8D4+."1AB7PA^.>@3RS\<4N?D5Y]O@/+P\B/!X!VD'P\L=M4XM>W+$
MTEL?A&M(V:-P\8>Y1WS&X#-*5(6-XU3,4HE5Y"L9>O*3V>L9NT!H5%K >;6'
MR% B%BT]^=/DJS;PAHG+BBU"W&X&7!\]L2(F3'WG,"'XIE;HXFZY%B1F!@Y.
M#S 'S@XYGP9&2.7BYUEM8FDFC6VAC:$O:K([%V)$\4KL(RF%RCB-&8YV8D)1
MR5 S=2[0.GZ79+',HSC!&J4ZK6(E"C6"$F(Y..PQ3LQAQ4V/'(#!$=XGF6-*
M+@D%E0D*;-8B8FHBC9N2.>/!DC./$<#^L_3@<N?;C>#6N);33-;8D@MX)G59
MEV;I5C+ LRJR1J9-ROL<O&K,%W;4?'/]OPZ!\TJS22.($:% ()>*&X(%;,>1
M3YER<R7BEHL::&64B0E#:3Z>*\W:B\D?$D.@,3H[BFTYQ\Y'C["!D?-XSX/!
MGGC4Z_'M9Q;/M"H^7D6+ :!ISQ%D56CWJNRVW+\/(R(W!+"LD6[8 Q\\>/B4
M\J3>D-2,D,,E!S&1TZ&\/BS@'E?3AI^SP)!1A^6!6[%FI%P34EG#Y"#&$D<8
MY$GEZ>8.>?9V?]R!\];R:[&CHBV[R%@=Y$B@(R[0\>2NTRJ7!,996V)*1ET$
M;^<_LZ\/];BSZ'-&EAB 3I >HQ!(2)'MFS.BDM@HV$CI)J+%%1')!PPPA#-<
M)%0,5R"79EO.M9V_./F)_P"_BYYQGMP>SLH^M%-X:U97C$99>(K$EYBF(QA3
M(JQJ6ED Q"[Q*4D#9K.5_L,X8O%<H$VE+"'3DF; =;F66$OT$UH'?+#$6,82
M/1*."D0**XR=*1F6$!"1X)#2P20\](:P1R8Y[!GL)\7;V8YGESYX/.I8M6+W
M,-JUOPY)6=.M.O)A'=2KL&P-(FRV(E=0.$\L:X<$L*ZKW</VLT/AKU[*G&\U
M8;8B[ (N^]%AK:U^7OEH@MXGA(CZYD)D,\-KT9O,EH[.FPFI<\-CUAQG)7'A
MY9(Y\NP@>/Y\GGR .,U4AU\R!5-HS2"%)9!%(652+62ZF4;HE)*B,I$!GBNR
MAC'S(R+';%963"&AJ7 >F/6$6$E3\W&%+K_JZ]JO:\,'11*,.0LS5XL,<2(-
M6&)'QZ DZ.'3Q3+&"DT?C;VYY>+D2?BAARY<SD#&?'@]@.XUW>R)';H6,JQL
MYN%,.T7IM))4D"=>$*CN)0O)RB,@&]D)[:*B5ABPEM?RH33XC)B+(FGH0:(1
MBPG+O#*,HQ,8D8@GY,^C3FZ[6/6B,DRT1@Y219RW)4C.WGC(/T9/BQV>#GS/
M@P>VG?PK!QI+0H-F\%Y4B5PK7*/C<#MD+6K\*'+F0.G7'6QN3S6O05NTW_@R
M,_X>,_F[/.7_ .*W\YO^]?5X/X)!_00_Y$K"\DK-:,;;['=0=9;CMVN-N5B.
M,N7N)H%L.6>;I4S:A=L8W!:W-?5.J1#5?JI\E:;98"^G@<+%=1%DNDH]5K#$
M!1)^JOQ*_P!."RU">VCG@?=%Q9HU07*QM&;:,322%7D14C1;ECOR ID<MM$@
M+W(H+J2%9(V)3>ZJO%"[>$N]VPSJ%51*3GES9CRW<XI8^VG0:NVA,<KG7[,_
M5;^S'#1PAK)8F3JN''KMMO-VL$!HW5QYV37[C% 6^0[8J##-"+9.AFW5SI^6
MI[J=TL-5D3JB4K<" *HF#"<EXX84)5RF^,R1@)*5:,%!@945LMM>LIQQ/A.&
M%429XI)5$4[7(RF5&UL%05&!RKBD.VG0*')8%DH5,0(D!8XB"K.FR<P@^0;]
M]33,G6^=>1J7(V'!.B0&M=ATR2 (4^&RBKL2ZTQAR!/]GO["PU4Y93)N#%F/
M25"X/1[D3<8R"%D9IH90ZRGKD.>:[AGHM[@D%LYW'X8 8ZDO$W[]A!9T?<&)
MW=;M&18%0VWT0VW>).N*<C4-XM.UQ@&Q3H\'6*2(38L4!3ZOLD"X0MCU1S4;
M24JM,M-,M3(J8<FFJJ.L-:DO0AJR@S#\,EOJD$0FDZ1%' SHI,VUH2TDD+A8
M^)Q(U>6.6,L$"2-'(,MM;&CQ7L2;WXJ+&649DP4)=HVPN_<H9PZDA0&(89.#
M4+E]M/#?)U6A6\E:-/R:C2[,[0M7F2VL"&!E2F5J"&,2)=#60I*< *'6QP^O
M%)>PJ^B)KD'#A!)DBS1&8\!Q,HL-8$DT82XXLD?&N%6=2T@D9E FVRG?,[,Z
MB%\SN2X$9):MA;7X9T"RAG >11(,ONR!O ?+.Q+ (<N22-O;5M],R.D3^K[=
M:M$!+R)K]FWCN^3<9NR(5KBW"T;/ ;%.4F]6<E)N+L@J2B3R=63%!O)?RP,
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MG$7$5NQ0K/<9BS&,.WZYO09-O*W8NG@IK80S!  )/S), 6?CCX;XYY2I,Y0
MV9!5&;&M<J.%(L2IK!TX)NT!(N!F#Z2;@=G;R/;CPGZ,]O(9SV CF?!DZDC7
M+$6$,EU&'BCE+JDH0%#@MP9)(H'$Y$;AF666*Z78O#Z]NZOV\ W0S< TL T-
M2.F2@[X$Q(C%5&@DEE33BR$7U-([#DB.YC)4 U)+.#8) 9@PN,Z4;B)=F/\
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M-(M4HPXNK66OR'!LPC:2YBC,2Y)96<F:)%/'5D +3#X)HVD#M(3*$"C>CC<
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M?Q#M,R,"L=M)2+%7Y9$>;#@/2V%042+C0FGK,]#'U\P(,CV.8&?!VY!#<QS
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MY4PJP&7UBUEPC!.*W'@S:&(1/FB"+SU<N,1Z<-:KAL>2A,2S#\-;.1 'AR?
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M^K1\/91@(L9%271T&6\Q6?3KI)-@16!XI$G%B$>V%MLC._$V1%"5#K(RLI8
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M*5KTY_='/]=7_5GG0KOKV#Z!^ZO#BLU0?9G1=3[/Z,V'HNVG"( )>HHL<\?
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MT<ZI&D>TJ(94Z#(TMHO2&D5MR*ILW8.@-S77<Q.VQMKD0&LB2JS%D5(%?=E
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MZ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M[0O\
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MH'TC[*>Y6X\[A]1Z>\>5^/!_T>3_ $\=+'Z!](^RGN5N/.X?4>GO'E?CP?\
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MC,4;O@\*(1,&Q/>\(A2N;/BIT8E269,R]*8([%U!&XD%2:UQP]J!&#?"3["
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M"<=[OE\ZD_6/<?X-<>^)I/F>H^I;?B:=_K3R5QZL?M:?!..]WR^=2?K'N/\
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M*,RAH89<@JG6F0R+"@=E,LVT,>%$&D(!(7 S0VLN 57<"B/G('-UW; &(+.
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ME@HP5))9]BG 8G:SX57QL8D88Y%>ZD]S>M.Q+D(U]4MF,D+@<-RJT."3*K>
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MLMHZDVF-2+'?X$:XR[<*HL:KP1IXX>>M1BLQ;K#%I%@A1*9Y&Z;,;MI.?EK
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M:M5R$.Q;^QF.Q\_(L$%?8%PH4*P+D5L8/9;3AD$J.[*DS"3+TJ4EUN269)C
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MM$K4E.$Y3''E)$]K+DB.TRY5MK]K:)HEC5@S3G)8C''LYK-A@#\U9BXY\V4
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M<<[7OS?F3&.T,>'M[-O/.>51\<\/9M'Y%H<Y\!N./N QRP>KCQ<\YJ%[DZ.
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M7*LFM7VO>6QS>F)*]\'Z]4Y8VL+N@?878[4NSM0;)N1;9CL!XA:TJ$;JVM9
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0Q2G%*<4IQ2G%*<4IQ2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g556103g01a35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &BR^9P X0DE-! 0      % < 5H  QLE1QP"   " ?\< E  ($)A:V5R
M+"!#:')I<W1I;F4@36%R>2 H0TE"($E"0RP@' (% !=0;W=E<E!O:6YT(%!R
M97-E;G1A=&EO;CA"24T$)0      $"KB69 ]R^11!L0ZS7B5!\<X0DE-!#H
M     .\    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O
M; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E
M;D)I=&)O;VP     "W!R:6YT97).86UE5$585     8 00!0 $0 +0 R
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0'[4H]         *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           %90  "^L          0                         !
M          OK   %90                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   %90    !29VAT;&]N9P  "^L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !64
M    4F=H=&QO;F<   OK     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    ".$))300,      ^8     0   *    !(   !X
MAP    ]\ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M[:O?L_X-5+=YK=3NMHQS<!Z]1RH83=U$,0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MXUX#_&\K^KM?VJ=/V._Q_M#^IX_]JJE;F^6'Y'? N^]%I_O[S]Y@9M2;8#;
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M8EW++XG8L22S=L^I-9-^7=L\?9-(S,6'0<N6.2Q(ZF<^I/\ M-:Q_0NU1_\
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M"J50:MBX:*XL89C$T!CD"VN]P97F#2_39V 8A2,['N/0$+@&S/E?R<<]N_\
M1[//OG!:?\-<&W;6 *\//W:=TFNW+"AN<@V]+3B*'7!]\DHLWX+V%.5ZEO":
M*O;ZNXP7^JG8ZW1Y#D$XOVQO;UX3.L5S*"BL%<"6WZ74B9@P66/?="01L,=L
MY$%Q<"VY>:9DW"N00#AAM$%V4G(#+G(R/ACMZBP&E_C$V9ICXWMK^0<B_F?;
M.P-G;78ML5%7;&LVT]Y*1<V9^56C+7RKKB-AQ:ZJ2J55ZP73(_Q2.<:\7L3%
MBO8@CFPL4[KG8;KF[?DM;ZVA@MX[<R6UQ&G(R]."2+K23E.F9I2^LITPT0U]
M3FHI+Z.2]CN,3QHD:Q[1NHN'U1EW9\%2S$X;M@J,>M48Z^%?U#]/7UM(_"%W
MC]/7UNOZ*&Z/V]?3^WK^JYX9?YO_ '9X]_\ NRQ[_;UUO\*+'[7[5_[RM/P*
MM>\H/\;R?Z^+]FO6P/\ $-\;F D7B>\0^9)SN(ZEB:G$ZUI5A4Q;&M%T1E&5
MKDMNW7'R7.ILZ4%JU9L15NXXYYYI<<I,O/-[2<X6;7E;\)DZAIR6"Y[!B  6
MQC)  )[@"N>>0O<G%U/C/;+G./AGT[_[*K=\U"0GZU^,X;K_ %^M!4U(3=V>
M15Q555T?7% E\$*WL@5!PH4.J81UZE*I7CPBAABPQQQQQ^GOZ<N^^^[OLQ+)
M/SC33.TLLMKR<DDCL6=W:SG+,S'))))))J?C&9[TN[%F:*X9F)R23&Q))^9-
M>W?/+5RZ<4IQ2G%*<4IQ2G%*<4IQ2O.[Y/\ RQL'V#YACU/KR%9/VZ&VM4;#
M:-8NS>SH*9NY%0FNL<:M/,[DH4R1Q='.5"+K&N5KCKF-(M1&V,NJF4>!&EV>
M!OX>-O\ Q$QD0-;W$,=Q%%'-+:RS1E([F.*0JKM$?XI8$J6P?@;EC.EO.9'V
M ,<B*Z*K-$[J0LBJQ )4_#([$^OH:R_ 1K)<UW\? &_ 1:B&T'O;.V#/H7!S
M8[#(>$;N3&7+3C$!GFMX8W1]<2!UDL0U!]R2S8[@RP(]VIHB$675[VNN'GYA
MP1&MO%;VZV73C$:-:RQBZC< >4EVG<DC SY< J:FY9R]XPPH1(XUAT&%,;+U
M P'YR[$G_9\*]J^>8KFU\I.S_![#N'YOM@G?.,^58-IUQ\A>G=\/K1M-N'P:
M9VBR-!)@>UW6B,"H2C&%CWGI/6ZHOEAQ^>"J+#%<[%XIT&NCQ4'OX.62V]EH
MDO>[W,?)6%I#';1$W5LD:+"\\[$,D=G=S2NC(&9G3 796:N\ET(^,03>LBW$
M$2"-#U8P %9G;NJQ2NS KZLN,9!-?5MSP%<&G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*\2?EGE+Y-&G(91L&(&$"TRT"^,<WWF<O8(#,"HV:7N3NO]A5IU0UJM'C%
MC-U)<M99R9X=X8Q_#_\ I<,QNN&4Q*(%M[LI, V[3-)$)8F;.NJ(D+H-0V7<
MY([#Z=[ "/P_)$.3*9H \>1JL820QN!C.69I58DD81< '.?(7GQ^OH5?N/K+
MO/#K##N3+O/'K&/KK++O/+OOKK'#K''^MWWEW]&/76/];OZ?HZ_;]',CU&!D
MY&!ZY_-@=SFA]#WQ^?Y?GKZ_T"P9MHB5:8AU<0P65-=L'!-3"6.J,+S"*<A(
M?6CFDEFC@I7,IJT6$LLLF$<>..<F>77>7?[#X]IGL+)[F-8;AK2V:>) P6*9
MH4,D:AB6"HY*@,20!@DGO7YWO%B6[NEA=I(5N)A%(V-GC$C!'8@ $LN&)  )
M/8#TK;N7*KU#^UM]ZDTI3CL['=!@*Q9C[EH!<.YB+"2Q^GO#'N@!'1VB<\6<
MG7V75KNMA3PD_JRV(_H[[ZXW+<_Q'"(&Y*]BMV9=HX/-)<2CN!TX(PTK D:[
M:A ?K,*Z-AQ/(<FQ6RMGE"G#R=DA3X^>5RJ X[Z[%B/1357]F;A2-GC @O:N
MH]TZJU]>8*.2EN]@H4E&XD.L>7?:Z?ARKW[QQ0BLRYY5:AXI5B'2]V>JA&#&
MG/8DA\OR?,V/*1P0\MP_-<3QTEPAL^=N42S>QOE_)K@:R23V89CHEQ*JQDMI
M(H0N5[MCQUU822R<?R/&<A>)"WB.+A=KA+JU..M"=D2*X*CS-#&QD&NR'< '
M:6O56R:*D2FVC["/PZD'#L[)VZ-35!.9+@''#KZ:]_8 ^2S9[ZMPY8UI)Q8R
MM=)_;=0Q_7FL8XYV[OB>2CM)&Y7VQN%XB*(M</%9V=E<O;@#RR<A&6;SKY28
MH5DE+:C+-@P0<A9-<(+#V<A/(N^L2R7-S<PK-GZR6;A5RI&P#R%8\9[ 9&,4
M/3B-K5&!Y2Z+VYKG1PRC!64GK\JQ$UK%<ZGQKT#AND.OVF8' 8SEQO16BPR>
MX3RN87)I);%SOO**S]J+#C+&#/ \QQO!11JMG?\ A!+;>&SK'<3I%(]U LW[
MX'FB9Y=Q(Q+2=Y+C@[J]NY@.5XZ\Y5W)N+3KF.?K8R\,3.BP2F( H5C=5B"%
M  J8%MD78R+LT)&Q(#4%:P^??6&5L/<CL=UI>\?K?=K];Z<;8ZWCC^W.G?@K
MVL.O_3BQYZZPY*QY2 7/'W4-W">Q>%PVC8SI(OUHW'Q2158?$"O.W=E=6,IA
MN[>6WD]0LBE=AG&R-]5USZ,A93\#6Z<NU6IQ2G%*<4J$-PUB "RJ;=%X4+LF
MLL6+\;"D2= +@74&:I1@/XC"Q6>J*HL Z84**">BMJJ.(]5+86S='?B<9*GQ
M.862!K3EX@CGC/$=>"22.$36=RB+<=.:4K%'<1M%%+%U72.0(\#/'U1(G5XU
MDF6XXZ0NHO\ H]*5(WE,=S S-#O'&&D>%Q))')TU9TV654?IE&CI>V,&]+MB
MI*B291H&M#PMV8#!>',4PF&3(!=Z75P4LWNH30\35P.8%S#,2IU:)/[K6$KG
M9>K<(DJ/-M^1A]I;NT-@2./XRXBO;B:8&&XFN>@_AK:*U?$Z0J)Q--<RHD<H
M5(K;JJ\DB79K*7@[>X%V,WE_#):PQQD201P"9.O/).F8GD)BZ<4",SQ[-).(
MV6-'A[?&PA_C#>I?TPXRTK^D=[@M6ZMV7C6N5<GW7[PD%VFBA-RHJY2X%MDJ
MK+5?LU]O55*N3=5RZ*#LH$"P#B3+&*]W$OB8.B,B6W$CQ^4E)(V\[HQ4$K("
MI,9/E?.G9M2>9!&UY"MJ@Q-"\LL>>T;I(J=17<^6-EZ897<K&06#LI"Y[WF1
MKD]6;?N>S1.%$-J<1K9CT9I$/V2'7W%E%'G)8;-A/^P!XNU:C29[Q9&5 RAK
M\Q-FW QM R6:Z2^38>@%'%POAXA:G)D+B=VP0H\A5578 MV))8 #/8[$81<H
M+6+P9\TQD6:=L$(A1'2..,D#? D=GD4%&)41EE79I');77/,1AG6W^22=9:F
M!VV.DE 6,14SE89BU]L9UEA PR]$!G5,\2)3!FVSA&HY"+-:D;+@K8[KN_X.
M7E;;V8FN;;D"S6UW<7O(V4L $TVUU-)=7-M<0*>I$$N))##=N!9])UCFFMVC
M\_6CXZ?GHH)[, 3V\-I8W4<N8XL01);V\\,Q!1]H8XQ+;@^(ZJL\4<JOY-W4
M=>6W9&VO:>^ZPZSZ$A(YEQ:V3JDX5E8)HXY#$C*9VMC-0+&85\?&0)&*N,P[
M,S=L5QV5L52IV)^SPD<\9N.3N!$MQR5U%?="*19HK>**W@M[:'KQG6>3HP(\
M\L9T,KNL3-$D;'G\A/&DEK;6Y=H^-C,*RRQF-YIC<2W$TAB;S1QF64I%&^'$
M:*T@61G44$7?>-+S8O!_'SR $-7JC6U)(U%KZBO,P$5JC:D$HDB%0GEA?[M^
M83I;$A05+-IX0WK*!V$E:]L=K\+L6I< 7BGJ7M!._7C9A!+O*^4<R1D%6=,*
MN&_? 8V7LRY(!*$$UD;DM>(2EK(7ED+*3)$<[.B1_6GP3A)(\QX*F9X?-K<C
M7OG0^@>7%#3^;.(*/RJ3I['M,GW.S25"&T(]H9[K*X14/K2W:"5;=[%T94@[
M[FOCEF6#O'&2[6QQ[X/.P/R<$P@9(IEGM+RV:89BZ_'W,%W )P,D1226R+,5
MV9%9F79E!.+>^1.0-P\;F"2*:T=$(,HMI[5[)BA[*9DA?9<X5I%&<*36",;R
M%[]#D]%)U3$4[N8IA5'_ #+WAU@*D >XL@CG< &:T\@S9!7"O<FJKM52EOUX
MK4]>ZV9KT5:Q2S\I-SD//PR\%9H(KV]BGM;\S/&T%E;E3#>/;SJ3%R4H5RML
MMIU%#LKW?APK1GJ1<5)Q$L?*W+&2UM9(;BSZ:.LMU-GJVJS1, ]C'E T[7 4
MZJRVXG+!A=.O!'6@@K1?6^RKPQP1_6R[SR^SBPQCP^MEE]/>67U<>OIR[_;W
MW]/??[>^>U50JJH]% 49[G &!D_'L*\P26)8^I))^'<G)[5S<S6*<4IQ2G%*
M<4IQ2G%*Q#!_U";_ -D$O_!3<ROJ/TC_ (ULGUU_RE_XBO!GXGMF;5U#\%WF
M!]TMH@GZ2V$(&/T0C4@A]5=9W#]<AZ4V10)W.G!RQD!CH@@^Q8+2Q306+%W&
MI]TK1?:S=21]SE(XI>;N8YIQ;QLR;2M&\@7%O&0-$\QV.!V],Y/I7J_:""WN
M/:J_BN;I;*%FBVN&ADG":V4+*.E%YVW8!1@@#.3V%2''\BOR>S8221?"5L"6
M.'KZTN<?M[SSGA%C]'??UI,L0?>.'7T8Y=_3EWUU]'7??^;KOFGN_C?YZB^Y
M7-0^Y^"__4\7^Z[W]JIJ\;;LWAM+;)[K=WQ="?%M*DL%#X[<=G<VA-DWCK+8
M*#:4RM]T00XIGJ7# \B5*SF9)K%+*,78J7OJS7J_><%Y!!%$I@Y+QA+!3$(;
MB+5<$[YDRA ( QV/<$9 .*O(VUI!;IX7G6Y(EU1K86MW $0*2'S,S1D*0JA0
M ?,".P-0K\@'S!-?BW?#?I)%\>,'HK#6GF>EZGV>XC]TJNLJ2=KBPWFD^Y;Z
M$G5,_;.]#;PVEG/B(L3$Y^RT6%0--%5L6>3V'$+>0),]XEOU;DVD2&%Y"\NB
MN!E6 7(;U; &.Y&15KB?9V/DK2.ZFY)++KWQX^"-K:2=I9^FL@&R2($V#$#8
M!1J<L"0*\P-X?,P:V VH>U-Q?$JZ63WC!54O8Z\7B]EIM?!%2-P ^D]3V!<'
M!D6.!GI'Z+/3Z@6I(2A8=<[IVB0>A]VG[ZZ4'$*B/%#RT>MZ[6; V<OTDD3!
MVCRS90J0#MV!&0&.2*[EK[-I%'+!;>T$6G)R2<:ZGC9?I9;9Q+)"&:4F,HT?
M>0%589 9@<'ZUDYD@<5%5;ZM::G5:EP&R5JEC+#.>K <&52<-:?./Z8\YH([
M6,4N4??>&6>.7>/]7OKGE64JS*>Y5BI(],@XKY_(G3D>,D$H[(2/0ZL5R,]\
M''QK8^:UI3BE.*4XI3BE.*5\TOR+;%0]3?)OMO8.S=@;HU8C+OPKEI#S_P"=
M[]$7NQ:C(>WEL12MZY(DL,J%)@L$[]*CA9N=Q015+=K.2Q5QZ^\Q>VX:":XX
M.WAMX;:XF?VGC"0W@+6LA'%RL1.H()0*"2!W) P#Z5W+-'DL(T1(I'/)]DF!
M,38M<D.!W(P"?TXK3?A"*4S6Q_E]*#SGJ%EI7+GG26J<]GQ=0>F",/Z*[!PP
MFVA'CA'CU;QZQ^R6LL<.L<TN-<DQ^GK+KON;VI4I#[.*R6$9"WN4XLYL5/BX
MR1 <GM_C.Y^EZE.3R%X_(@4XE[6W[P/I4[1__P"W_:VJ4/,JKZM=/^CN:,6_
M%9J^#]!$-3#?RS.#8A::V7@-?<A.P\ADER-_^9U%S,IL1L<N,1#N.(<0L1R0
M6QUW*J3IU[Z3CXO;.\?E%#V8NI.H'1I(PYMP(GEC0%Y(DE*,Z+W90>S#*G2=
MK=>8E:Y ,(<[94LH)B 4LH[LH;!('KCT/I4IZJUC[_"?$_M9+]"U/6;AON[L
M(K?U*I:H]*(0?V>OZ5FV*GVDQ88_3&8VRFE7T0)KL1%Q/0C;TYM)L2K5871*
M3QAAM>XGXA_:"WDLVXZ*T$*+<2W%C,W&/=""02R)8Y$JPN^BQ(2 LOTA8KEC
M')):-?QM#X=80@$C20.;9I C;$0=F"$ZA1D88;9([GRHQTE[Z[SQQ[T=_P!(
M+ZQ[[ZZ[R_\ *LZ>^GKKOOZ.^^NLM48X]_1__5GAU_[^^NOV\]!XGB?MOL?_
M +@N?QJO]6T_E\/]PE_$KV;#_#W@1$"B!'Y)?F)!$+PVC<O!+GN"M:MA[EFK
M%-9%6K0[7EH?9L#Y\\ZD\]&S8IS2PY25IYH,L),O,M[1E695X7V<<!B XXO
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MZ'W)Y5_Z/#H;>6AM>T]D;)3M5B?PT24#,;($!"3.Y285D>CZXGRPM1T&CKY
MBS$QX*6*WW6'YVK$L(ZM>EPGO[*VY#VRO+2[G,$$MS)LZLB,S+;AXXD>0&-'
ME<+&K., MC!; ,D\,<_+RQ2OHC.<D%5)(B!5 S J"[ *"W;)P.Y JT7E7Y+'
M4A\;6X/<GKA5#AZ6FV#:E,$QHZJZ("WZ%2E&Z.&:U?M?*.R>I&U;@VT>*U5
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MF%VIZ;\^W]3[H1S'@G7NS?,;0ZEI&9)?#>P/<4M\;=&4-5>0"[9KVHG+.O\
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M-9+5V.JK=V\B7%L2P!*KUHD#'!PI/8^E5>(O$L.1MKJ0%H4=DG4#):"9&AF
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M&63+J""*+K&/'[M%PD"1QHU[RTK(B(TK\K?!Y650#(X2=$#.068(JJ"3JH&
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MT8>4@L[8V#<<;:[M6M;.'B87B=)_%+(+4VD[=*-[618+DM-,L+QK;7!FB5D
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MC001!W%UQ%RH=HY"9%4V=X>JX:5FFC4Y3][A>XM1;M'$CB1X1&S&-%!(EM)
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MBZ<I!;'T:@ Z9^ML@8@=)+<!0(I+J%IX)1 %6, .FJA6QZ84=CCYY7)[JL>
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M,MY69%+/CU<_'UJW^X$#V<JZN1D--9=DOQHG[):\828+8UA=:.O-I'5^V#(
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M/5J+\CO_ /-V_P#>8Z_#!_U";_V02_\ !3<OW7Y-<?YB;^S:J4'[_#_G8_\
MSK6X)/\ H8H_[L /_A53E2Q_(K/_ $6W_L4JU=?E-Q_GYO[1JV?EJH*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2HKV!_I+K3_;C!_PB9Y1N/R[B_P#/77]RGJU%^1W_ /F[?^\QU^&#_J$W
M_L@E_P""FY?NOR:X_P Q-_9M5*#]_A_SL?\ YUK<$G_0Q1_W8 ?_  JIRI8_
MD5G_ *+;_P!BE6KK\IN/\_-_:-6S\M5!3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI71)$QH:C.3,$:(H;5QPRM$"5NO1HUL9),(<,I[=J2*"'
M'.62.+#N23'K*3/##KZ<LL>N]))8X4:2:1(HUQM)(ZHBY(4;.Q"C+$ 9(R2
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MR7$$32,K1HVB2R([*C2H'<+HH+,6UCD*P+;RM&)!TPK,57>6-&8AE4E5=@Q
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M 'Q;((!'>MMZ]P>>.C=@).?<:.5-HE3[ADGJS9@I7J&J^WI=!W.K3.15*H.
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M6_OY:??^7IVS8O?:WLL;,=O<><C%9JR8]UIJ4F:]G#V"R['\A%]<@Y$@!":
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M28PZ7*E0MW:!E:6*%]TDM%N6ED66-C*[?N9G9)%O+<6$R/+<)&)I)5<IK+D
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MGI$RD&AYF%#>(C0WN!F7MAI5,6<6G#L//PJ37<DIA>3Q:R6@,4KZ6L<MBUF
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MS%"'#6\S(4$E\-(@HPLYC-D4D+)G3,DP;KB70R6C)D")9""&S%(5T#3X5%4
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M5NR_*/\ N+O^Z3U6/UGZ+[\UH2ZTUZ"N2*-#;95151M/EEL5G/00GG8-KO\
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MQQDLZ)MSQ9(%1]Q&239M,M;* ?<AGC@SLIPZN<&6>/*"7:2V "H;GP_1<=?
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M'%=2))H9G>-X9ICF##1K#;W$V9=975!(]L\:DG&/-W(*5%X(,BR1NQ5T=^Z
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MXY9(F5T<JR9U/K@'.0 <C!R21C&3GUK99'0AE8@KD+\< YR,'(QW/;%9O)>
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M=F,^O0D<\U4E=N:IV,:'QV:X2""S;7@Y4(-PZ+]%(S1@D.DR07-P82<$;I!
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M,$XF_&HQX+TO=8>;ZP8)3]I<63E:VL(KBUW,QCN&N)H8E*%XY#';B8*S CI
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M4IQ2G%*<4IQ2G%*<4JO33N'0#)KS9)=_OU/T\UT8%C=C0[#2FD'2%DH95Y@
M2V ;<N#KQ>I9L$EPFNEA0\B,)V)Z4P>[:FC[^SMI;W:30K$#UIE9H>C+&Q8>
M='\T;D*0%=75BI #!@*F$<JN@4>=P2FC*Q([J>ZL0#V8$$@^N16&D'^2_:8'
M*0NMZG] !D,Y=$61KDHBF6PFGB8@==O"B:^VBNR:_:+@;P<A+1(#ZG1<38$D
M/LK53*C/S?/(<8^%>XLVE0,#%(T8E168!@\;:NJN&4$$ZL&'8Y%9#7%L?*TD
M)< @JQ78 G!!4X.&!&0>S CL0164==6^7AHL>OO6O]3XT>_U(9PR^7605NU;
MR)IY(;M4H$"_<YR)&4HDDR(YQR&U;,I$.0[HDL9X[<,4FL<]\S%XIKC(Z*,Z
MR, -9%-NK-D*NLH#19(U8;+C!(PLDY)97DSY%+!B/1@8P3G PP!7/H1D>F:P
M&P_*?EQ@H/U$MJ5 63^^.F!;9'A41EP:]E#[<LN(NZ>P9:X"Y-$RXC&5OO5S
M97"Q!T3+$K=SJS:)V<;>\-_?(82MQ,Z6NCI%)*[1*D;Q,$T+@=/:.,%%QV50
M, #&4GG4J1(["+#!&=M=592%UV&5RJ@J/@.V .W8E\3>0;:D'127F71194!3
MF+8T(4U4CW!T-YBHAAK#?ZIR _NOWL[36UR K)C#CC;C7%V//#J, 'PHX')\
MB)&E6^NUD8*"ZW$H8JA9D7.^<(7<J,^4NY'=FR\3<!BXGE#'&2)'!PI)49VS
MA2S8R>VS?,YW%WU1YXB5;^&Q$+5L:;E7:PY'\V@U[$%W#MQR!GW ?8R*0=5.
M\]A/]%<+%8,N_MF!MJAK>?5@M%3SZCBN+SJ PS7'4S&R]-WWS;QLD9&IS]#"
M753Z)&6'92:U1YBPT>3;RD:EMOHU(4]N_D7('R7/PS6P:]TEIW4EYG)ZNU;K
M_7A)TMQWFZ^F*0-;N,EJ&V3OPRFK(FE5F(]PD#9LA#A9SDCBOFB]V/#&T4O2
MV-)KFYN!&L\\TRQ#6,2R.X08 PH8D+D*H./4*H/91C5Y)) H=W<*,*&8L%'8
M=@2<=@ <?(?(5TZ^@M'U*/0RIJ+7%4?C24!V-*LG :];H?K]O+[ 1Z/44-'#
M#JFHO)\XWKM;KK[$0R%R1FCA#?NV)Y,F[NB=C<3%LR-DR.3M-&L,I]?62)$C
M<_QD55.5 %9,TI.3(Y.6.=FSEU".?7U90%;YJ #V KMXZ0T[BCGM9_I>AY:[
M:8ZD+*C2*P:138(:(@* IPF0,E3(82AK@UP (BBN5IH\1P8;3ZQ^[U(8\,>*
MN>JD_7EZT>2DO4;J(2S.2KYV&7=V.#W9F/J33JR%P^[;K]5MCL.Y/8^H[L3^
MDD^IK4HO*7F.&NB5(O/FF<*VL"5TSKN'K6RCW@E%B1VNTD22WUV)[_";Q!II
MTFB[:J?9S6F6C1/SYR%Z56Y%)X^^S,?%W.9U"SGK29E55**LGF\P"$H <X0E
M1Y216>O-ESU9/I!A_.WF&-<-W[@*=0#Z#L.W:M\:=2ZN>86ZNZ:\2VRN_A%Y
M:=X&-;$F8&P I$2Y=5$'X2%2Q&4H+18\:*@:]O&7 02)W+U#J"U/G+W%'<3Q
M&,Q32QF)G>(H[*8WD55D9"I&I=457(QLJ@'(%:K(Z%2KLI0DJ58@J6 #$8/8
ML  <>H&#46W/,?D[LFD@+GG[2V1)>4&0,B5<M6J^?0%.QGFKL@H/:P!]UQ0^
M:R_DLYZ.,]?.W8:V&W7BFE)G)I)Q?<AK*XO+G5Y$:4]>3SR8!1F&^6;$*C;!
MP(T!. HK?KW&&;K2X+*6/4;NW\4GOW.$&#\ H'P%;*W>9_.[\R0N3MH_5+8W
M5P&*K SL"&ME3\2WA0*BL >!>X.EOXBXQ9TT-CI]3_8QT"Y*GAAC7O68Y=([
MV\A0QQ74\<9?J%$E=4+Y5M]00-MD5LXSE5/J!6JS2H-5D=5SM@,P&<@YP#ZY
M4']('RKJF?+7FICNP$F#06GCE^JUV'JM<+ZZ5"-B!QN55RE>98I;8N;*,Q?K
MIZGB0NX]]37\UD!/;RFG$4)*Y;Z]0$)=W* QB(A9I%!C!<A,!@-5,DFJ^B[O
MC&QSD3S*,"60#77 =@-?,=<9]!LV!\-C\S7.J:W\[IVXFTPE(.L5C>+"NR,S
MJ:754&(>C2TXL<V=@H>+4*%<@0H,+8K6KEK*W9EZOGAEHC8QSO9S6)4D]Y);
MQK+-/):H^D2O([1(\: !45B54I&X   U1@!@8%&>9HU#,[1!M5!)*AE4=@"<
M956 _,I ],5^@OF7SJMLJJY -%ZE#-J+3M#TMF&Z_5ZAU3H7+9Z]/37"D(S"
MZ&J]66EGDKP#YJ\=3ID/QU,8(C)+"R:]O'22-[JX:.4AI4::0I(RA5!=2V'.
M$098$G1,YT7!IIF#*TLA5L; NQ#8QW(S@GRKDGU*@GN!7"7\O^<#[D=V(:T3
MJ4H^L]4M28W.Z@K,[0<IGU>1)/52IS,;V2O0'5"7\M&HK%F3 J$BJCK_ %8K
M4ZD<!;Z]2-(5N[A88RI2(32"-"DG50J@;4%9/.I RK9(P2:">8*J"60(I!50
M[:@AMA@9P,-YA\CDCN34B2Z[1)HS\4R>N2Q-38$?&6/,12RP/.JWTL=+[46Q
M[A[ZOGPO24H=#"EGJ2Y3Z60?4$N'0VI]E")I1H1(X,<;Q(0S>2*3J;QKW\J/
MU9-E'8]1\CS'.F[]O,WE4HO<]E;;*CY [-D#L=C\S4?&M0><UJBJWF'7FJ08
M]9LZE3$RX67UNA6!6UICOK^E%E>L6Z\> ^R*:-ADP2"+H9Q2Q%'6^)$0]RG[
M%>U,MQ>2-(%FN':07$DH5W8N'0/=.^"20R0J\S'U6(,QP@(W$DS%L/(2W49\
M,WF!&TA8#U!5 6)^"@GTJ/4T-XJTNS/2>@K>B=7M&F $6Y7X(JK*NHWD-<95
MXP$B?BL0L=1ZH#KBHME@F)+'ON.H %?A7TUQ\=:OW-(W)W,<4DKW<\=R_AHG
MD>203.CJW14L3LPD=6U]2[;=R2:W8W,BHSF5UD;IH69F#LI!U&2<D,0?TGYU
M&IXQ\<#)AK+6+"#\],@H@1$ONNP5[7P4ZGA3/H,M(T BTY#M=MJB29WB>.Y%
M0])CO R.SC):+*C4.7KD.&<RKS,?7F1[Q&4-#,XF=)&6S7ILH&XDE6U5-6*!
MU@5?,445N!>+U'!F! *.=R&(A 4C&VS"(#!(!$8'J *_MW;'QYMB\QV"7>J#
MBH I-ETY?(ZZ(V5R.N\;@6FINDJDK2KV+)66S>,:JT7,!-BY=-O]42>APLEJ
M4-R$+?F(W37Q"2.8P@$X#YBMI(X\@2;*([4R1@L $A+(<*<' 2[5@!U QUP
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MXWAMJS=7R[ NJ5RAI;7UI;65JLI>X[/U; 1QF"0B\$BO/(9-UD6-2(QT7.&
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MX\;\K3.4I@34>H-<41;EYS#[61X">\Q<.#+LLKYVZ]!YZSON%9<MI6M<JHN
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MQ=^5[.ZKFV!1T*4)955M<=Q'1ELS%U)$HV94M/%S3!+76+TH"^B^H6([JMN
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MR5 (&C6P7&6 )(E8=P!YB>^HSJZY\ANTW6-*R#ZFU*JUWDMII"J'7S<# /7
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M/>-)CV)C3U>&8;S)^"5VQE;QX<J:7Q>47<='I6) (6+\_P!F@A931QD*;3+
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M(GU!)!5'&PPP$B+(%89(#*& .#Z]^V<5/'*M14XI3BE5C<O4OF\8GGFN]L-
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M*5 B--(VX"(%8*Q=P^JR*^J,C$2K(40J'90=3!<)G*.NJEV.P 4 C.3G 8'
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MRU]VBB^\3?7U+,WUF9O,S=R3YFQLW<_6; V/J<#).!6"2?4D]R>YSW/J?TG
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MMS0\G,?^KCSJ5_C^AL/=_P#*]1%YQ\.I\-?+6!=./XJ^F/C]G\/\_P"3YO\
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MK!5IM=EAJ8H]"H4I])KJ%@51G??(Z"'.V3EL]CVB^7XBO/T@V87TTM>45W4
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'E.*4XI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g556103g01a36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g01a36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &[Z^<0(X0DE-! 0      %@< 5H  QLE1QP!6@ #&R5'' (   (!_QP"
M4  @0F%K97(L($-H<FES=&EN92!-87)Y("A#24(@24)#+" < @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0!P%Y#.'?!X;;O>#K_Y_V
M73A"24T$.@      [P   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %
M1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q ?:LF\         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             $T@  "W@
M         0                         !              MX   $T@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $T@
M  !29VAT;&]N9P  "W@    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    "
M.$))300,     !$,     0   *    !#   !X   ?:   !#P !@  ?_8_^T
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MNI95>0,BJIS;ZQ8RI]L%V75D_HZ_1>VKU:/?ZGZ5EO\ /?X-.CND,>C9]O2
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( /H"4@,!$0 "$0$#$0'_Q  ?  $
M @(" P$!            !P@&"0,% @0* 0O_Q !2$  !! (" 0," @0'"P@'
M"0 % P0&!P$"  @)$1(3%!46(1<8(C$C-CA!=I>V"B0R459887>8M=<9)3,W
M0E?3U29#4G%YM]948GB!D9:DL<'_Q  < 0$  @,! 0$              P0!
M @4&!PC_Q !2$0 " 00" 0($ P,%"P@) P4! @, !!$2!2$3(C$&%$%1(S)Q
M%3-A4H&1L;(D-$)R<W22DZ&S\$-35&+!T=+3!Q8E5764E=3Q@K3A-41C=L+_
MV@ , P$  A$#$0 _ /OXXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7J/W[(6Q>DR3MNP'#FCE^_?.U=
M$&K-DS1W<.G;E=3.J:+=N@FHLLJIMKHFGIMOMG&NN<\R 6(50220 !V22<
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MI1B15<(I%D(NQK$LK'Q)%VT>9%,G+C;&&Z.VC=5RDE\VW>M'FOXS-8_!UA/
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M(0AO3(BGM Q!3L#WJH_7SQS=YZN&S>O*(@W2[QI0JU_L0^X+8H2<WKV6[ R
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M*%3I)F)&IOC1-F%#L]WS]9NUT=%3!!@)&M]E<*OB3UHQ;:*NG**6ZE=Q^_\
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M8$Q')H.ON,5BAW;5D_\ V6#GT/PFEQ%;V5O=.!R3<,UH)&8?_P!0>P\1'DR
M))9"\*29P)9%;('8R[PR<G?M;86.:6^%G_@@"5I?"J]#4LC!$]M69>P1FN?R
M.3NMIETOE,1CAP'.+![%@6,<ZAC8D3'G#4WO(ILQ,TS-:[6'+N=G3*OY7I'K
M0+S89NH+AT5CS^6D7S<:QW5VZG"PS1\G'(Z/%#9N7Y%I%9%BM5RMS'-L!J9H
M]X%B;#22.(U!9L57LT=;E68%$A):X+ J%B&5E1\XP74M&%."S,% R:LY<2J
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M:A-LFHF!<J):\@T<W-\+#;X:]M);FZNBG9M^-DLKF!DG89*+=7;VAAB;!E>
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M6>&YA169CXV#*2%126P0!?8*Z<?&;Z:U=[6%5CCCD96+.ZABR2H 23J<@D
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MOKQ%5$N9E50 JAS@ >P'\![ ?0=5B?\ R1GC(_S&^N/]7 ;_ ,+DG_K'SO\
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M(!;SOK-.B3$-<!>U9U0%X^@S5[E+<.G[M ;F52('#CY4-'XW)#R -W(!_A,
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M9TNJ,QKN88)$-6[F$V(L,E#'1-%9+=N[=LTD"*"FCMGE1LHFIOO$EQ*@<3W
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M@M'@$JD/'YMT99 A'3XQ8PUY=2(DHL;-[A(Y%#QM.\T%I;F1&!5UCFN4F,;
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MQ8)/JH.A%1PJ=]1:[NEB4G[=.U8);?:2)4=)HVUA]5CJT6$ST+7;B]JO%&9
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M+[?M/D,H?G)R41D7:0L KA5<$-D,65$5BP)*HBDX50,_-7'IS-(=00,L3TP
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M5"_9#^3O?7^I>TO[#G>6+3^^[7_.(?\ >+4D/[V+_*)_:%2)#?XH17^C8/\
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M*QL0",F-U50"/OJV"?TJK%IU_;-I]@(AUL[F*QCK)Y5(NP>2?H)Y+Z6:9B4
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MK\C/_+L__J/'_P#W-8\#_P J'_YBW_\ -I^LS7'^3O8#_9-[4?\ !KCY&?\
MEV?_ -1X_P#^YIX'_E0__,6__FU%UXWY#I32MP1@!$.P9([(ZNL "%')=4.T
M22C\L7B9<>-9)J.*>1;I[NGCA%#3==5)'393&RJFFF-ML36UG*EQ [2685)H
MF8_M"PZ574D]7.>@">NZWCA99(V+0@!T)/S%OT P)/[W[5;6*MUVD7C;5REN
M@Y; 0[=P@KKG11%=$>W3524TSZ9UW34UVTWUSCUUVQG&?SQRA(07<CL%V(/W
M!)JN?<_J?ZZ[[FE8IQ2G%*<4IQ2N@E,ICD(CQB6RXV-CD: ,E2)DV7=),APY
MDCC'O7<N%MM=-<9VSJFEICW*KK;IH(Z*+*)I[;QQO*ZQQJSNYU55!+,3] !_
MP!V>JRJL[!5!9B<  9)/\!6NP#U"ZVW!#YX"A%UWFRK@O*IBR0JL;--8R!IV
MQ9=8\8O^68'5U+(2B;8RMW+6@B9AH[<(Z8LXG'9,YS 0$=BLIQH[[#<C>VTL
M3R6UJ9ECC)G:+R/<PQPR6:;31RE3&(R\3O;-$9'0>9Y)(\BX;B>-E+1Q%PJ^
MLIL9$1&A7UJV"NN59HRI9E];%EZR*1^/3K]9<Z3LJY9W8-XRE< 'C9UW/3-;
MM1LKCL;A79ZM& TZ$KROH,%^G;QCN!98U9P'8B'>7;:$O=G6I 4\7,Z)R]W!
M$8+:*&UC#O(@B68M'))+Q\S,C332MDR<;;L Q8 &4 88!<"[F1=(E6(9+*$#
MY4EX),J7=S^:V0]D_P"&/8]=% O&;URJP1%T:ZL&X(A+8DA$"$(M!A/(R]L
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M(07*[PN=*UQ'9]+ C221:O)3;J$;5JR,6!(P)$45"PH],!\D(-#0#+<;NI(
MB9"%>.O'MQ<K$#&4>55\L7F>&-BDDR6Y?SO"CAE:5(S&"KY;T/KJ+>9H_(%!
M4JS@;('**2&=8RV[("""P4J"K=^DXC%/R/\ 4MP*T+LIE.B"9#:&*Q(>RHZ\
M%CMF![#D>D2A4MJ&/_H\U,VY")%(5FPUA-*X8R:,;*/ABZI1)J6%KO+'[%Y
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MX9P)HOPDMID@D:5BX1%,LB(AV(<LNI.PSL;2?4-JI&)"<.GI$;A&+'; &S
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MSM9O, [B/,(J6.DI?"%X.G,8+%Q >=0<T1F<T!@(BT"3.)F%SF@R2!G3V/\
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MG!!%</Z[$G>O"3.*=>3ED;Q2FXW>$WVK:V:FDZ+&)RN;7'#P["&$E#XP!/Y
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MZ8F$5&6M>\X^XLB/*%*,VJR(Z,"VB2:LJL7B8HZLJRJC,I#J"IS4<UO)#@L
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M#+&/?56@+-0Y@1J 0Y-DQHL<=M5K#0I5X_9I#"#O+E'WR_LR]RP$(;4 @K-
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MMPFD<9:.031L2^5E6Z%TI.&&5VV1EZRK9#!@#6$O'CQJJY5MU/?3"42@]$9
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M/=R,5(Z*21R*2[R$&,$+DR,Q/9+$=#). !72AO'C%8RUK8G&;?LD79E7LFI
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MMMQ(&7IF,]>R/Q!*_D4LTJ2"3.XI'7X07,9;'#KMD>AL?N8S!1\L=L29=^(
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M3DG(AHH0]CDG;5E!J6L.2Q^$N])!J\.2=0!?E?Z!1RH]@V-%%#HUB_47 O\
MV1)QERZ0.#&#<2PPJC,P=#/+=0H\@TPL8>TFW8$E5"DC#"M1;2%4;TC=D4*=
M@R[M*BLPUP%S$^3DD#!([%9I77:&JK*&/3XI\_!1H31U8=@3\GE^@R/1^-0>
MU&DX(BFDC)N2JB(61QL9 #9.<CGWQ-(PP7%.'1%35[GX8IK&>%@K .[74]HB
M1[.[RVYB5BBA<LCM,HB(R7(8!1@9U>!T.#@L99(0JY+%HRH) QV"7 4^Y((Q
MU7>3OLMUXK!-=2Q;RJ6$X:O4ASC23V!%@ZZ+Y8$PE6C11L]*(N-5\18H.E"J
M>4O<A&GK:0+83$*ZO,Z165Y/CPVMQ+D;#QPR,,!S'G(4C'D5DSG\X*?F&*U6
M&9_R12-D9&J,>LE<]#VV!7/W!'O7&GV;ZY*R220]*^*@4D\.CQ:62T'I8L2V
M(1F- &3,F>-GD<%O42.!"R0TJ:<OLH)B11,:3(9;L"#-POGY*\"))\I<Z2NL
M<;>&3$DCDA$0Z^IF9650N2S*RC)! SX9@H8Q2:LP53HV&8G  Z[)(( 'N00.
MP:\([V>ZYRUQ"V<8O*JC[ZQB)T1 QPF=1UZ3EI.+_0_B5B"&($-WY!S'\E!.
MII)!OML+W,!TWOP;EAVKD]C>1B0R6MP@A5&E9HG58UDSXR[%< /JVF3ZM6US
MJV!@F78M%( @!<E& 4-G78XP-L''?>#C.#6%E>U(UO/)-$HS35WV-'(#-0%=
MV-:<" PLK"(3+SK://E13@0_GHFTI>G&6$KCSR8DJUKB;"HUH^=MG[W4A'Y0
MS"2K8,8DD>YM87FB::&"5Y5EEC4N P98F@C+F-A&L\T3/@$#5T+;" ZJS21(
MSHSHCLP9E7;O(0QKL58*'=2<# PRDR_5EIQNWH^<DD60+-Q\?LFV:L?:&6K=
MHYWDE,V;*ZHEB[=-J\?)J"7$FAQ5<*ZW52</!"C)TZ9L'*RK)"M/ ]NZHY4E
MH;><:DD:7,$=Q&#D#U".50PQ@-D D#)CDC:,A6QDI'(,=^F1%D7Z#O5AG['(
MR:K]'.[$#,6%$ZVD%:W56IR>D1*<*<6/$@$?9'8X>&V$[!S9TU:R\H?B 0H3
MKMW%D04_"1.PV\EDL09OX0S9EUR#"X_&2K#),D]M,L(;RB&1W9'1H0\0)C5)
M&59A(7A:2$HDA64E=3*ULX1G#QN%SL$8L0P*93\H#$!]LH60JKX8D8./1KR%
MT3+8;54Y!C;$<A[:-%QPE!2.B6Q.-!0MLUI4#F<31DXD:?V6&*F+@K>3MB*"
MI$AO!94PDB@I+7"[1':3B+J.6XB=H0UNJECNQ5V:WGN!%$0GJDUMYHRIP/+&
M4#'HULUI*K2(Q0&,#/9PQ9'D"J=>VQ&ZX.!NI7-9]"^X]23Z0O8O'6TP6,M.
MR4LZNIMG(9DU^OG4*ADJG9^2#MMR^<N*[1"0:7I-9/G5-5^3CQ$>S&+*ZHY6
MBEXZXA0.YCU-E'?$AB=8I98XD1O3U,6EC)C[PKJ2WOC1K:1 &.N#"L_1]D9E
M4 ]?GRZ97Z!@2??'F\[5#]IO((S%Z7O"P8C#)^*J^<6]" 4'*0.*S1^L&;$1
MVX9Y8 VV94RB+H^*:S8] *REP*,N=BJ#XC\L6EV@$+!O$CO<VL4DL33Q6\KR
MK-)&H8JVPA:WC,@1C$DT\;R#4JOXD>X0'56:2)&9"Z1N7#LHS@YT,:[:G4.Z
MENB!AES,]7V9'K;C#Z61A$H@,'SZUZY73+MF[1WD_3EIS*H96JFDV=O4]AKB
M4P8RN%<;+:KO ZC!VZ:L7*ZS%O6G@>W<1R:[&*WF&I)&ES!'<1@D@>H1RJ&'
ML&R 2 "8W1HV"MC)2-^N_3)&LB_SZN,_8Y'?O5?(IW5@<BG,<KTU6UTUN?EY
M*()1C2R(B#CVA&-6 )M-_")P^9MI84-1,)(R=1R*)(1Z;B8S90R5E(N-/P(0
MW,X>M[<G&RI$\RS6TR1B3<PR.^)(6MUEB!,:K(Z+<)(7B9X&C61DE;7!F:V=
M49P\3JH;;1B<,AC#)VH#%1(&RI9"H8JY(P<:CWD,HB4Q:N)<$'6&[&67)# 4
M:EM'A2#Z/A ]H5?5VUARMNO(T]1< (.;IJV:C3#94@_7KR9B9*J(0VRY8(;O
MQ%U')-&S0AH$5F.[$.[07$_AC(0EI@+6>)EP%$T;1[>Q.3:2AG4E,H 3ZCAB
M4=]%Z[<>.12#@;J5S[$Y[$.X]23B5DH9'VTP7/#^QDCZRZ-G 9DVU)S6)P^8
MS.0247MN7]SBO6#*N[ $YDBFB#AS(88>%LQ3C9!LJZBDXVXBC$KF,(;-+[(8
MG6*22.)$;T]3$S0MX^\)*C%AD@:-;R*H8E<&$3^YZ5F5 #UTY+*<>V&!SW6=
M;]G^MZ4X,UFM?5/M["CKI%@;A3FQ8FVDPU\N4" ]&+D,N53?:/=#<EC89=IA
M'9PU+R$$,<II/3 Y!S%\C>^)9Q:7)A<$K*(9#&P"L^0^NN-$=P<X*H[#(5B-
M?!-H'\4A0^S!&*GHG.<8QA6(/U"L1T#CG,=ENN\?EPJ &[SJ07.39QO&A4/>
MV#%49*]/NS[B)M0Z078I@C@@ZEC5>*-VRC?11>4:8CJ6-S*B;+<ME>/&TR6M
MPT2J7:00R% @02%MM=2!&1(2#U'ZSZ>Z"&9E+"*0J%+%M&U"@;$YQC 7U9_D
M]^W==7OVOZQILIN1V[ 4_P#15L28AIXXUL*,;Z14L4..HP+&F,:$MMFSXI*&
M!"+C6V=<K$),/(1]GHL88NV2.?D+W,0^4N,SJ6A'A?\ $55#LR^GL*A$C'V"
M$.<*02\$V4'BDS(,H-&]0 R2.NP 0Q^RD$]'-=,;[D]81#1]NSNZLY280K<E
M:PN*1&<Q,[*93#!\-(V"F_B@I SI@TH5API](PR2#C34B$05,I*8$(KOTMUX
MV^9@#:SQJ9UMVDDBD2..5I1#K(Q7"ZR$(V?9O3C8@'(MYR0#$ZC?QEF1@JML
M$(8XZPQ"G['KWZKMQ?:[K:4VD[;6[ZN8DX+$E9Q/0I*=Q=F7@D99M!CPN4E[
M/<KG[&VCR9H0G(UG6^$03@H-0)*M]R+'#C1K"]70_*SE99/%$RQ2%99"2%6,
MZ^HOJV@';!6*YU.!MYAK^$^&;1"%;#MW@*<=YP<8]P#CV->@CV^ZUNA6\I9W
M75;R!MQ)<D0L!M9E>*Q<4[#2>,0YW'B&OXJQ($9!B22\$$W9I@56[,V_8QXF
M\82,N"$%=CQ]Z&\9M;@2EE40F";R,'C>0.OX>A32-W!WR4!=0R*[*-O.#J8I
M Y( 0QN&.59@1Z<8U4G.>U!894$CKSG=/JR&&[O&UZ5C)2"\"+V2"C44G,4-
M266Q@1&C\MRK%AB1A/!5Z2!1:0OA#/#A'<@@%*KI;8:C"*[79.,OW;'RLZ*)
ME@=Y(I%2.1I$BQ(Q7TA7D16.#J64'M@#D6TY/[J11L$+,C!5)8+ZCCH L 3]
M,C[BK#1B0,9;&H]*A>CC0;)@8F0#M'B>B3O1B98-R+31TDFJLFFXU;N4\+II
MK*Z:*XVUT54UQC?-.1#&[QMC9'9#CL94E3CVZR.NA4+*59E/NI*G'MD'!KO.
M:5BG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*A^
MV:ZE4HJJ;0:FYRQHN82OZE5C80N&MI%L!(&3:125&4X\U-Q++P[(6RIA'<TF
M='E618KF1HNU";1/*EBWFC2>*6YB-U''@&%I2FX5"L:[E9,(A"G70J573 4]
M21NJR(\BF55QE"Q&P PHSAL ==8((&N,56H3TB0RZZN/I),HRAMUN-S-Z\ 5
MM7IJ&PZS@TC(!Y@&'24=+[/M*3Y-@K9B,%MLE,"\SDYF5S2/OR13X7DC(O-;
MK<F<7P2-S\ZD8#S3))) R!HV*&*""/1[>26V$2Q1K'$X5>D45,;GJ<*K?C!1
MEW#,A *DJ5CC7!C9XPH4!5( _*!6)LO'!"6=(UA2N+$D*C*NKX8VP[D6P=EJ
M2F<&&-G\&8TK($=7OLVBNM"?AFDG9'5=1P^#1$2=78?78PT1D/,RFYGN?"@:
M:T-N$#-K%*Q64W2==2?-[W07V5Y&4''=;&\8RO)H,O$8P,G"L2',HZ_-YLRX
M/0+$9QW4P0WJ#'X7%>U<982XBZQV<D5F%</W@IMLK70*R&)QVM#PZ2;S3!8&
M"G4TL6<#-'"K#;5U-R O75!JU07VKR<@\DEA(8P/D4@74,<3- 4 D;KT,T,4
M$)P#U$K=DD5&UPS- VH'@"#&3ZRA'J/V)544X_DY^M5N)>-%X330CJ]\J?HZ
M&%C\E#1?-7L5#"4DF,'B$.E;DO*-YGE(J(45B.I6."&T?$JA]3AD>8*2C34.
MZ$W%YH*=Q:?C%41I/.0I2.222,*GB]+?B:NQ=@VB%5C.P:<7P&6\/K("EO(<
M:J[,N%UZ/JPQR<X! 7L&-NWG2.^3YFX%>O;H<55[5QRZ('9QB0MXMN)@\=M,
M+3<>:M=A)T^'(M6S'2 &3+N>Q3>8',)O5(_M4A9\K'YI$)N.Y.U1;<7@*BP>
MVF@53)M*\#W+D@HC*2?,JB*3QJ2-_F$&\4NUO<Q 1B;($#1O&%VRQ1I&SD @
MY+@:-H.LB0>I6V,3Z&7Q8=3V9#!=H1JGIY(I&98P2Q8I$2LF4C->8DC7<;J1
M"O9> =+S0M$$'XD@<!R0%D*1*)'8_JP(#6R>G'BDM8;B&1H)+B)$4RPR2*F\
MVA#%66-P(EE(94='V5='R&-5$:))$8QF5% +HS!=GU.<$*?2&P0"IR!AL@FH
M0!](!>I7K&8E<CB"N.NB%F#W<4KVN2L-@%F"YTTVP&1E 2765:4C6*1609_&
MRYXU,I,2DTU=%I$240?%W>^;3<FVM\J))_=A@8233++- T)]1C>."! LB?A:
M+&BI$%1<A0*D-T<3!0P\VF&=PSH5(SJ52, ,HT"A5"IA1T!6/@?'C$PE,]>:
MA4L>1D]J)NL7;9&9/!+38_9XH:?(%U*ZEOJ_WUS'"@W2(1LJKE9[N^$0@,DN
MUWQG;5+=^8D:YO+D0HOS5LUNL88Z0,R!?-'U^=3Y'4=8:5B"*R;MC)+)H!Y8
MC&%!Z0X W7K\P.S?3MCW4DPCIG$(=5?:*I\RHV2"=GI/<!4F^PS9LW\%B]J@
M%(VU@L6]V[U#(."CG#S\-:.$]4$UGCG?9BGJLIIO!+R4DD]C<>-%:QCMU49)
M65X'W,LF,':5@-\=D =_6M&N&9X9-0&A6,#W(=HSG9O8Y;K;!^GO5;7723L4
M*M".3D'?,0)RB1D)JZG\]>TF,TCL;%N:*KFDP0B/UL\LQR1=O28R#X,[&MYD
M[T'R95=4B,(1%RI$5[PY.R:"2)[201HL0AA%TWD=A=3W+L\X@"@!IBFHB7,>
M K"4>6IQ<PF,H8F"J%"()3LQ\KRDE_'@8+8QKVN,$-ZJPX'XOWLF@LXI6P;)
M* J0!2*?ITF!CH81^D-A]^I0-2 .>RFR$BRZ<B191;!QPE"GL0%.59 YR_-G
MB0AJ!!B9'YP)+%<PP*]TZ1?-.[-X6TN6NFB2 J-"9 H\JR,-!A45B[-DWH5E
MD5 TI"^5F)T.)3*45,>G+8]08C7H+DDFS?7'I&A0]DHVN0L%&72UP M@.?U8
MQ@Z(&$G%FJ]=$$G[5U,+%LV9Z?80O7*.#MDY%,Y6Z(JEW&6I *## HXRHWO)
M_-PF!83''O;LF9$9E$ O#@B*&"+UO>R-E(HPH495G9W:&:Y\J% FHVC([4D!
M/-T0B1IV9B<JJCH9!)+'H;;Z+%;((SH&,M*+!*DLFSV]PG(S(*A6F%DP:>N1
M8</*3-(6DC9<9&5^M)4 ^27S2>M[)>A#QV2OA+Q$>^'!P^]ORBPK$S02-<0P
M&V5TN!%#+#LS(EU!X':8(6P0DT(=$0,"P+-M'="/1BC&1$,8*R:HZ9)42IHQ
M?!..G3*A0>QDV%IBHY92[HG%QL@!2"NI'..REMFG+X.]'R]I.[QOPS<(,,,W
M0,.Q*T6C@R;R\ 47=-$RA1X/CA1KNP2<$AJ5.YN([D"1E=)DBLK=0&!C,5K:
M);,S94-Y':*-U .J@NIR=34,LBRX8@AU2&,8(*ZQ1",D]9V8JI&.@-@<]&JM
MK=#[*E=;7E"K1[#Q^3S.YB$4D&+QBU-GXE;("202:H3"#[;$3EY3V-[0Z%X1
M4#Q6OH=&J_C0E E("?PN#4ID[\Q>_:L,<UK)!9O'%;"1/E7N4DMW26(QR]+:
MQ2>63(9YI9)G8JB])&BK.+I%DB>.$JL09?$T@9"&35ORQ(VS>[.S.3@#\JJ!
M(NW1*!IG.RKX?)" P#?U3AZOCT7:B6>K*F\MH %KZ022%N?J<*KO),Q@E3%5
MV:R;1-@:K8:0;N%')%TJE#^U)=+(&-6:TN&G=RQS<_C/,B2C&,(TMPH/>5F8
M$8 !T^:;6 :@F&0R%LG\3UEU##Z:EY!GO(<CK%>[4G2>.51:E86@WFY<ZXKO
MKP#IAZ#>B&;9E+9P&($W*E[DETG:JS6>%A\IG@8HDEHND[93%YA9ZI]"TUYB
MXY)Y[>> Q*@FO'N0P8DQQ.%'RJC&#$ICB9<^QC& ,FL27+21R1Z@!YC+D$^E
M2 /$.OR JA'V*^W=819O1(M/2,F #[2B8FGY=;;FZG$;.T\O*K3@4V/OV!6=
M.::MI*SHZ(A"$M,,WIG*DDJ^P280E))+@:2U&.0PP%+!RBPA',$IN([<6P=+
MD1P2Q("L0N8# [2F-2J^B>%66-,KL&9]TN@@4E&,BQ^/99-4=0"$$D?C);4$
M# =0P5<C.2;(4S54MIO+^',3P$[79*47]9KEX[$/F$N1G=W]A)Q="0MOE$PZ
M$K1>-C9\4CRVZK9 F2=C1I5)9LD\=C65*YN([DB0HZ3+':0 !@8S%:VD5ML<
MJ&$CF%7]RH#%<9 +022+)AB"&"PQX!!76*%(L^V=F* _4#)&.@35O]1>T)%4
MUWP*R.Q8 ]8%OE8C*V]_1"F3<.M8#-8)+6\LAQ9\Z-W=/0#^.P]1BR%0Z!Q$
M-7D7CHY0YENT6>24TZ=7OVI EQ:RPV;K#;+)&;22Y62!HIHS'*JA;6)UDD#$
MR32-,[D)DXC0"Q\U&)(G2%@D89?"TH:,JZE6 Q$I!;)+LQ=FZ!Z4 9WIT+KI
MF3[#*B#Q$3'[QI:/T\"C;<:URVJ; RO@];&I5$G>7&JJQ*11^ TRHLT52:)L
M"53A7S9SNN_<;-X_VK,5L]D5GM;E[EY"QS<;3-.L<@P>D>6YP>R1<,".N]/F
MG(BR,M%*9"V3F3+EU5A]E9Y>^\B0@CKOWJ?Z2QRIK+JJS]9R9DQ>NNOP^GC+
M4B*:MFTYG;(V:-.+U)[IO5U&$X*;SFU&A)NCATBZ:V(1T4?;8'M-=];CDWN(
M9X/$D:S7;7*%6),411$^57H!H@(K<@D @P@X]1QB2Y:1)$U"AY3(,'\J8 \0
MZ&4&D>/;M!UW5*"W4'L0_L&W Y>"I':$# .]CBM(V/DD!9S.62GN-9(B>ZK!
M;'=&F1)HJ.,NY-*-5I7"X$O5KI(3'A9V\5V J9,.F.0L_#;LLI2[9^+$\C),
MT4:<; \(V@"%3LHCC.DLWG!9V2U!:-K(N(@B,'Q,3:AV*OJJVR%,,@!!!4(O
MI=MQDE8NU-H(CT,^BA;)E*;%V>3DW!NMS2QY TCC==*06?4'9&7=JK*GC?.S
MUAG36WK1G<DW=#]6K1*/H*(/6^'NVN@]"C)RN9"8X<1++?&%2Y&D%S91V$,1
MZ/\ >\$* -D[D$''N8&NLL2$](:;09QJDD*P(GL?W:*N#DYQCKWJ,8!XNTJN
M)@I%#+M43D]5N@6*%*R2"G)<VBHD*3-+;BK+'';5<XGZ1$":WCKC2OG5'#$?
MH1\C:B$92VT,<GFYPW =);;*3A_FU25(S(S!<-"R6X,6KKN/,+INRA;0E3(]
M]Y%*M%Z7SY0K*A8D#M"L8TP1MZ_*3DJ3J2*R\]X])#*1\KC4E["N2T1GTA_2
MC-6N*DBHB2$[LTH)E0"$E%'8\9#AP-=HA1 61_HY;1-<YN7&Y&[65^&WSX,O
M&G+I&T<D=F%DA3P1'YB1D6U^;-V8V1U9GF+LZ>8R!0C9\.ZAAJ+M5(*P@,HT
M3\1BHB\OEU*L"6?)(WV P<Z; &L+GGCRE@ZO2 J)V,M.F]:O[&L:@(#F.@88
M9&6K9-O1Z\I"0F%@$21T7.@K&=!7BD0AA".PP4Z#E%(Q.Y85SJ.F0"2+EXVF
M5I(?$9Q#!=S!VD5K>&W>U58H55#$QA8>20/*VR[Q1J"T3[I>*7RT>ODT29@S
M,#&D;1 *H *G4C9@S'(RJCM3U=6]#[DE"?Z9;7L$77U^;VI85J1YBS@@(Y&@
M)@_9E:2^/;RN*!+ )"GC+8/6>!1B)!+'-/6K>3_5,[6>2@&G)7>T_*VT9^6M
MX6FM/!# Y,KJ[JEO/$_CD>%6!VG++(T" F, VXC;0'NXU_#C0O#XT0^LAB D
MBL%8J#G,F0Q0 ZX,>IUKN++\:,VMN2IR&=]J3AK*RFQ9\SS7;L6-:R!W!I1!
MR;:*Q*/V<&K"/0]5O*WQEHB[KL]:NY5%OI)+DE SY!^^L'-16Z:Q6"+@X4^8
M,Q02QRKY)'@:=Y 8PI(F2WU)TMHV]582]6,82W4?3.^25V5ALQ0R%AJ!^<1X
M_+$I -;/H7&](=#HG$$W>S].*QD#&TWVZ.&^[W0&+:C-7>[?5175#9SJUPML
MCJJKA+.^=,*;XU]V>'*_DDDD(P9'=\9SC=BV,_7&<9JD[;NS8QLS-C[;$G'^
MVLFYI6M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*5KK4$793W5*VYN;<2B)S.&SIA>V8UM:<EN'5E7%9OH!*Y?6X.93!Z7DI89.
M(1")8#.?<MVZY24RZ3R$2'C34P,"">P&MKB_@B4))%+$UH'\"6Q,TXECBF:.
M,+&K12RQNNN0L<:(S.59FN9BDGC4:LK)XMA&(_6^ZJY50 "C,K#'LJJI+$%C
M30'V-[$/G,B;$YK)W3([6%L^2J-_+LH(1:]9Y%5-D1>L>NVQ08BQ?#]HI8;R
MMIH05;N=#^V$72>SG1%;/Q=)K*S 0K$@*7%OPCGILWR7$,D]YJVRGR0B:)1@
MIC!QU5@PQ>D!5!$D=DQ S^.LB%YL'((9 Z@'KVSG-8UOV_[=AY'9DO$6G4TB
M;4W57D.MHQ7<BA4B>,%H90KSIQ)*\@19 !9 <FQGBL9G,B:!++*+.6[,5+WA
MM[ 95N00VTW''<>Z0QM!<(;F?AK=9DE0$2W:\DDTJEX65HMXHR\"@$M&%$R8
M.=OE[<A4,<BF26SC#JR_FE%RKL-D.5V090>Y3&RXJPVO=&]&\KGB$:&UMK"*
MSL\*VF#26L9Q(Y?)@=A=[;0ZQ(B8H?0FPD7#EP4<B*4I9.R "6"TGR6D;:1Y
MH*=(O@],\;:F.(N9_+-;R-&8S$D:-!Q-O?EI$\3-)N\OC(5XV(_$+E@0T/RT
M6%V+[NC:E=%52EJD^6&I+99M2 5./46R,&3>R]LDX1VGHX?%;\<-C+JP*0BT
MPZ[ZR46+,/H#9TID\/WE<-JY[#E'=R)&RKO).Q97I.Q?Z#H%5!J7@&+UZA(P
MQJ"RMQ+873/:900W+QWGC9E66!$D\<DXD MBJC6&/Q-\U+<+&Y T9-(8PT$I
M:+K21EFU) = K:LX<"/ Z1=#Y7<*<#!'86UV+[(LNPRE3U<O2 2+[VK7-.MR
M4^@T\EYY,O85'3VWU)>MF/6A!1ZPZ,J0?43I%-&Z#F3Z&]E,RR*[!L;F5O9V
M1L_F)Q=,XMYKDB*6&--8;N&V\8W@E;+B;;?.(RGY)-\)B.&$P^1_*6\;R81D
M4865(PO:,<MOG;/IQ^5L]55 ^4*V3,4"3A4=1; D^@\/(;=?U$I.I<)O,FZ5
ML.T3Z\(\1_&Z6F:5!RUX0KY87O '_P HR*24FO:;"3M-X>WO-P<"R-%FZ91-
M(OS8\?RZ:<FU@+5QXS_=+QJLP;RC!D1?ES&?*9S8QABN92 S?BY41J!<^ 1$
M:_O2N'SL/S+B,J=JC[LKW4[=1\'8\;>6/4,!*PZH[QDNQN#0V0 5)*3/=&)'
M>E7 0#B5V%)'@J7U[+!AI;4TT6>HS5$8-,:PV.Z#WXE26QXWCW>!_!<S++<6
MJ:2RH^BIRL=K<,XCA0-'-&RC4X\19E\KY#5O#;6Y:,Z2/M+$NK,K:A;I8I"V
MJ*"KJ1UUJ21N<@U+MX^07L)U]S)@LU6H!V[K.XSD.G,L&1MRPV-PYG0G7^[V
M&\/JJ;=D89)2Q1AK<Y.-R<A!9A:\YRG' Y^)4#)]9"5#Q*"TXBSO-&B^; GM
MEEBC9P=9#=W=J?)<1V4B*K?+*Z"6.WA&[++=QZ*TD<5I#, RF4;QAD4G.&,L
ML7KD2%E /C##98T]15I5P"UD>S/<*;4Y<^(& )5 ('AH92$N'0BPF9U2SNQI
M"WK;EM;EX+1BS.91IL+DE>LHT))D=MXE9SA^5G<7%F D-&K-CY6E9<='<VWE
M=;ABTEU&TL+)X;,6]O',LMT#'(6CF:0JOXD 58G97E;*+##;K)'NPD;+2J60
MC2$1QJX:7TME7+$#U)@(Q!8@@09IV=[ T#TAC%PR$H,N*TK1[-2N'D9879!P
MT(KH&>LZ<QX<]6"61>U51!C&0;:(CHE&@12\JS#.#<C M-CJAATKH=M_(6EW
MRDEL@:V@M[&.41J7:69D@A=E#06MQ*TCF0R.ZVL[!4<Z!!Z)O!#+=-$H,:1P
M*P4$LSD(C'N.&1B26+$B)R%4]8&1S5EWU[$SK$(EI2)TV"A.\DHR%RZ/L_=+
M9))WEUO)V$83.&V! +AFE9 @#1:,Q^7,0K%S;:!4)(W<=TG*#T,E)"^)^)LX
MO+&LER\NEU+&Y_#C06PB9HI(I;>*=W(=XRY%OJZ!_$0Q1</:PJ74-(S!965O
MRJ/$%.K(\2N2=BI)\>"NVN#J.L@_?V^GN:/6G)3K@P+V9$>FLV3J4?&IL%LB
MS@_;Z6)ARF*;7*VP6RNSZ\ W*I>72%2)2YO-<QJ3.B@JG Z+8CS,O$VH%UXE
MO2L$G)1?,,\30P-QT99?F L"^J\<!8T\D?CW0*UPV167M(AY=!,0C7">0LA1
M#;J2/+B/HS-@*-EUV&#(>J@*I>]/:4!1\BDC _#9Z=BO6\IV3//[=&2,ZJ1$
MTIX_/'=;LCA$?VBLDB?V0C9TYOF<%GDI(8/-HX6++FM8T>22V!/+ESQ5@UTB
M%)8D>\6R46S(FK7/+\O;I*_D23<016L2B-="ZJ$W3\XD>U@,@!#H#,(0(R!@
MR7=Y&&.P;(1(D 4$; 8V'O4E7CY(NSE&3245>_A%.S*45[,+"'$Y>UUAM70F
MQ4HQ5_6>T(] 8ZWO3MI6^T0E9-KV$6!%I&$DMXG&OX:82,129=H<>BH]!:<+
M97<23B6XBCFCA98CY;B6'R3WT#S.;3CYO+&IL]PC1VJGR%&N5*!GUALX)E5P
M\BAU0A3N[+EYT9SXK>390800K"(>H@RC4$]W=O=3M,+"EGPB1TA6T=D5BWY'
M(F>>PF3$#%>@NL/>VI.N4B,V$8*66WC,@%SB"RV1DSVHH3"\PK[=L]8R)]A[
MJX :6O&V+,BLEU.ZPVCR()459GON*N;U%A58"Z-%+&BILTOEVP47&&Q%;6Y8
M K*Y6.)G&Z@.9K628! (RP*.%"Y+;=@J/KL5[-V*O#Z0*7'$I@DW#4_-XE-[
M"*@WJ#\=O6E<V,,;=A!)3#39UJKD'7;"PM7P_P!WU8R1!$DG&B;P>JCCCV4(
MDNEMI(R7N(I(H58%3YYH6-FRYQC>9H<'V9'ZZ(-4X$VE$3+DRJR(",'=TS"1
MG[N4P?JIZ]ZU#27L9VT9US:46(SV7@;( 4':'?=B47U19YB\$MNI(\'J>DC+
MIJQ]?M<+O"<7"E'=-4E7J8RA@WU*[M9KOL\]#'9\>9K>188WA>\M^)91D[S6
M]PS7%T@)P6EM8K8OV%VNWQC(QT%AMRZ,$!0RI:$>^SQR%I)!D^[1+%MCK,IQ
MC/4H7SY'NR]$G#M=O8A3<IET$F-R"#D]U1AM8UW-DZZKKKM9<:AX<?>O;FK-
M(5(I$+OM4<8,C+ ND^*1A3J3A*?DXXF1'Q:"TX:RND682W$<<L5LR1?BSS1^
M::\@>1FM>/N/(B-:!E5H;9&\HC:XC8*TFD5G#*H?>159(R%.[LN[S(S$Q6\F
MRJ8<@%(U.P4R*<9]BWO(SV6KN+AI<A#JB:"YO:7<.,QS)QM# 0^&B.IMIF*P
M;1"<3"XNW/7Z#&YO:>1[R5-RT2D67\2!1*6KB*JLMBT?EH]BWX>RFD>(R7!>
M*#CG<+Y7,K<A;K<&6*.UX^]E2*W#",K)'B5I(]KB!B$='9PNS(6DRB6S'&Y+
MFXC$A9%BMIV"QYUPP]19<O&?2;.W1V:MZ.6'1T8@H.*1J47+ *TW50GRQV8Q
MV"F+#LN*Q@HH^ P^51<?+G45:%WF[=0<>$9-KL]6*$@&C7VSQ*C;65N\-R\K
MR21V\L_<(6-Y5@@=UPTD;F,2$#\RMH"249ABJ\<,965F+,L;O^3"%PB,1@LK
M%=B![J<9[!(Q4)E_(K><5B[%F]J.*SFS#42M650\9"V,J8B9VWZO'.P0KLAH
M,&.2T@)AE/6HJS80ENL4,[BY+V+@8,FI)_M#MT7M+PUK(Y(N)(H%DMXY6E,9
M:'Y]+-[+9@J*W]\3F4A5#)92NHCV $@M(F;(D94#1JQ?7*?,+$8<D  _O)"V
M ,K"Q&N>H+?^5B_A=2;S]^(Z_-F@J>8'EIFB?HJ2-"L6S56MANQ\;KV!]_YB
M+?' *N[=8PN,O:0V,\AY,9)8OUYD"F[X<PM#@;4W/A#79)BV6(I=H5D\YA!>
M:7B(F"OV%VM$A$B.DEXG3&;Y"+R! 93E,A=9@0?(4[=[-2 ?IF$1A@0TRC!.
M6A>]EVQ^7V>QD$^JPENE<UK0P/+Y>#D,=A%#P1?LC1M:P\I;\-;3H"H_0C4.
ML'8RV=E2=?F"OW2/,RI\(Q+%Y"K&_%6SQP%(9P#;6\C1QLCRW<PLKJ>5;:0Q
M-J7DAU( E5=7(1F58ZPUK$50JCC\*-F4,"TK>"61_&VC8RT9&!NH[P#J!76#
M?*U9;Z2T-'F;^@92I.[9C]8REU$AJ.H25BI;WAM?J7'[(K@G+^QT6DN\>(1R
MNTK'%"ZZK_LJY=J8,-983KN+IL9>KL>!ATNW(NX_#;O/&)"2R-'Q=OR#PS+'
M9O'NK3&%FFGLP/28UFDS'0V" 2L1,H2(R+MG(*VD=R4?2%USERA+O" ,$!VR
MM<M3=\[K2 5D(F]O4"'D4T@=1K37L7:0TVVI>''R^G<,P8"&80/M>(!A4U>.
MZ3#0531.?Q%+8VB?=/6;AR# 0;?%QQ5MO.T5O=LD<USXK.!D-U)&O[-5'64P
M2,T0%TTH_!D.A4 X9Y1B2UB+2E(Y2J/($AC(,K &W (;QL2H$A?\C=:C."6K
M/@OD)[)FHJVM-:&4C&8D4)9@#& 2MO-PQ\1.G'C*0[[-93*;0?29J($0=E*M
M'=<E KFKFQA"**HS!S(1Q)DZCZT3<19+)X!)=/(%\S31F)D:+]MGBBD< 0LT
MABQ.KB<J9 8A&RD/6IM( VFTI8#8N-"I7Y[Y74(!DMKAP=\%AKK@[#,Q7;NV
M[EZ,SBT8](8P"N2+7U4]6;EX\ 8"H@V)F+?I)NNQV_!EU7_$Y&$>QJ?:BCA:
MO;NF(P@R=OV6A*.R9N7CX&)N/M[;E(H'1WMGM;B?5W+2%5M[K!_$M;21&#P[
M(LUK&RD ZO&5=]3;QQW2(0S1M%))@DEB!'+@^J*)E.4R \2D'&01@F&[L\G]
MRTBD*!ETJ4-3:)3ZPXS8C1M&?PN-G(*(7WI5 HU"FUA=E8>3ARI4*D\<O!,.
M_6FEXN0ZMMG\*91QV.)$K5MP=M=;NOS*1210/"3(9#$TEI\PZRF&QD60*Q4!
MI?D(F3.)2X*K+%8QRG(,@5D1DRVQ0M%N0Q2%@V#[%A I7V?((%D^JO:"P[V[
M++CI%8=8.@>U(6)(7E)P!,BA*Z9D82[0T-:1>ZL$99(MGMCB1K5^/>D&P>!M
M\$,R(:E$\-1S,P3HW]C#:V09(9PWS,*+<S$&.Y1K9Y#);8C3$+,00"TIP$)D
MR2BP3P)%!D(^?*@$K8UE4Q%BT>%7"$X(!+GVRV<@10.[]=@4!L%4FKSKG"&5
MS1:EII'++-1F;LJ\H8!94FM8 ^5MW0E:X_$ZU>N8!&H_%GXV45$Q_'%@B8Z_
MV=-VZ!0G8/$V9,OB6]E:WDN8G@22(S7;P);N/E\6[>+ F=Y%,=PWBA9Q@DJL
MAM(LN%\S&)I4*!E+RE%1AX\1G7 9BPUD.J%ACL#*: [8W/=!CL(5DLP@0P$*
MZ>QRPJYC,-$N6V29P=;G;ZL2%Y0$X4D#\F5KRQV-1PZ< -73(JS91F55RW:&
M<ND2IF;:7?'VULMFJ1RLS<B\,TDC X1K?CIUM9D5%5)H#<2Q/@J6>.8E0-5B
MTEMXXQ$ KDFX*.S'V!BMY!$P"@!T,C*Q!!+*_6,!:Z,_)G>D5JROFC U0]VD
MC(SKXD2OJ&:19M7$**6345SSF2UM86+;[5TO!R]NQEU4$?R5>/KVJQ9^-MH
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MD2,5(1CR#WA.XG &CR54A1)@F9H-UEJ[+QT]+.P*$I[NRVC9(TH8S7=[V-
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MW'E"&!)%18[=I(9E):,CO06D.RAO,ID>! A9-HFF$O[PE 3KXU8*$0LCCM<
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MKO('Q5]@-&3!^#6%IR\=Y-X[CD8X+>(!)[N"UFX^&&6$F&78,MY),[I%(C)
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B99.,9./MGKH8'^SK].J9/W/_ .!@?[.OTKV^8K%.*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g556103g40g40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556103g40g40.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'P 6\# 1$  A$! Q$!_\0 'P
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M@Y 4@+5@?@:"(=I.'71$+5C+]00:@+9+L9AP7F6-"Y\A'7\N(XQ8;AWCW3.
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M[7?*J)0M4&MY8IZ_2%YU=MBNM7E/5)8<NJA$[3N2JH8^%C(^:^97=Z<RMI^
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M>W=L>SMU>3#4YDAH%"=-91&6TM;*G9#"DMV]C:V*21QPS.1VVSPR%N%^)KK
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M%4VF=E:759QLM2-1G&)>4=*FU%U*'6E.+2[R>Y P3CN]VUD4"%4[H%^AAL=
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MH,4V\4\TA$DV-ZI/O-N,E#+;+C33(::04H;;9>4^D-@J405.K6I945$ZQ L
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M1@V91[Q@I9-L:D!E::XQ-EMIIMG8> 7?;7W_  [>\[WZ8#WVBWW(BQA!O8X
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M!3"-1UY"\?7:6:4F:3.(A=A8L231';>[Z7W;[2?$/M/%(*=:P ))-A87-SD
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M?,=\,#U,1%N.-\;^G^EMUN%_UQ^T(2I2-/\ L'ZMXF#"+;'_ &?]6X@F^/\
M4/VL\^OSOEQPXU*O@,MIW_)Y^;/(E-L3GL&[Y?-SY6H]8XR0>D(;UN_VJ6?_
M  >=?Z-)]7;_ %QO]^G_ &A&]2_9*G?;TI^4-Q"_B)_8K>./\"'+_P"1J?UN
M57V3J'V[-?CEQVSNH?LD:>_QPTC_ *VFXUQ>VM_<>XW_  E,_P"2YOKL.AWU
M7.?:Z/Q@CWKYDC_&K2K^+\O_ %BS%!)+;6%G/N2")>J^9Z?'Y#TS1JKXF06Z
MYT,4BA(@MY.LS#HBKZ'[&3(/!;!@EL"E!))!#)B':7.N>;Y)Q3\VI<K1U_X:
MM*%SH2B8(61R(.K+KUM< EHJ5KK%[7 $>U)IE1F*YI.[-Z-]R::_XXS<M+3&
ME[;4I7G&YU:%TMO58H<QRW?C:5KICCK[DU.A*U@K";B>/8F_NE]Q_P !JQ_I
M\KUIZ8_4TG_GW/Q8CIGS77L#H=_"]2_(F8V\]>_LH_$#_P H#_F\6>NIROL;
M5.>1_'+CY>T8_8[[J/\ W)_KR8BV'KC(\UB(N[=FJGC_ ,JMW5[EOOLIJR_Y
MT"^"330UXW*DT$3(5_QXVU^L;,9AQ-)=M=HA(MYCB?A$%(DTVY&3=GYIJ59^
MF=58J(NEM Q6XK@A()M<%1LD8D".SZ':*5/3;22EZ-4E([ZJ3^HIY:269.6;
M279N=?U;'D9670XZI((4XI*66[NN(2?'EY">1?3?):^G7KI#J8K;,I$=?K@T
MLVE=J*F23XHE"!?OOM&/%IIK%@LW?&[!I/'@MD201GX\>L2%/EJ<PEB70!@"
MXX0.4=7M6M69)-[)^E2/%2 (_4W0;0+1[N?45FCT&42WXJ%3U0<2DS]4FDIL
MJ9G'P-91*BHM,)(8ED*Y-AM"+WESPT\+[+YB/+NO3W)12%=#6*#&K5BL)=$3
MF6"=C$G!#6#EK_CCEU3LI2S)#H\":PPZZ0$[D8Q'JU>KMTE#*ELK>4^I:4I2
MH( " DK45$*RUD@"V-SB+1UGNK]UFG]RN3H[\U2IJL3%:F)IJ6EF)AN40AJ1
M1+JFGG9AQI^RDF:ETM-)95RI6HE;81<UGZ=0&_*NB7?FK^8,ES1;0ZJS(I=)
M)( 64E/G!D+"WECBFR(5\G! ^)X89]8I--9X8I<;QZ\A+/HFI=F90"$/M(=2
M%6UDA:0K558D7%[&Q(N,"1'H.CM;E=):#1]())#K<I6:=*5%AI\)2^TW-LH>
M#3P2I2.4;UBA>HI2"I)*%*203L?]G/YX6+B=R0<>Z8](9\5M# =0NG:D[S;<
MS<,)M80F2XF?;;(U3)+DTB?JMM]0EVLV[\' \T#(=MU_2"B-SC*YN60$SC22
MM02+=\(2+E*@!BZ /U-6:K:BK@I*? N[QW%Y#2RE3NE>CTFW+Z64YAR:F6Y9
ML(3I!*LI*WF7VT !=3;:2I<G,@%V8U1)O<H%RZY;U#^O-H_.V,1A&7* =$OF
MT'/D#)C"(EU^.. O>'?4::33W;?%I%-G3??7W9^+77./=GW^[U*;!0*A=-Q<
M# D7Q%]EQ&5DM)>:4\A3C*76RZA)U5+:"@7$)-Q92D7 -Q8F]XTO>*?8O%+C
M/C9;>7>26:U6NM(WM^%[U3KX@W96^].R[ W*%*T')!))N>C!"0J#7R"2$Z1[
MQ?-SO%#)HP)[?5)2J3=0:FJ?RCDJMMA4D\PO5:8;#:002% -%*PHJO:][8_2
MCZP[I.BO=)TKT^IFD6@(J%0T8G).BN:%U6BSHEZ71I-J1E6G&2XV\VW23+SK
M<RZ^ET-J.MJV4L%AMR=9Z\!GL8U-V\@W_B%PZJ>.]4Z)PT2MHEM)$N[%EJ1O
MKHP3V6O_ !G"(((!%.O,/H0SC=8-H@A1"<F;38Y244)0NB0;JLZ[/NR\X7%J
M>+"4V^E6VOQ2X25&8*BD7N21:VAHSHN]\ZKE53H/)=U#3"I:=U*A:8.S\Y,5
MARD,,:@*F9JG3UF79Y:W9HZ1%YUEHK"G7'$<D$M#E]X[AW!9X)4LWO?3*;^5
MOF/?'/1+/4SED5H?ST^QS?9=]3V2U@.&8-'! '&PB#V(A!^H@AS')/\ .CRS
M3,G)+K;J9&6>[UF)!$NTZE1:0'F_'\5*DD@DDZNL 56)P%CRND5'T/T/F.[)
M5FM"]'ZK\[.D>A<G0J=4V9E5.DFZI()[[269>88<=:<4I;JF5.A"GM1:]9*"
MA2<#Y!];<\Q\:*ATKO%AYE2+/UKO7.^J^12[52FLNT/,22-.>)C+*:$6IK!]
MJWQ.(2\F'Q.1HJU**((T'<[FV5(2J)FH.R\BB9>;E9*8E:>HJ4U>9 [X6&P4
MK=2U@4H!L-:P )1;.]H/HS*Z0]T"J:/Z&2.D-8I^C.A5=T:T$?,S-4_7TA;;
M579MJGM/-3518IH*'6Y-"RA!F>3;0@KE0UF=K[;<E,OCW0J9Y+VJU<@L=2Z*
MXF[L-TOF_)'5ZMU<LABT>M,>H6&KDUD..G!Z#:RKI X&-K^JUV,,+(E FBB3
MDF5]_OO4]IJ;;=ETB1,O,3:&&G&PLN)E6W Z>5-[*"BEJU@!90.'1+1"E32-
M.:U5>Y_3J;I3(52@RJ=#'*!7])I2C4N?D&IAR?E]'9&HMU!U55=+A2^'5L4S
MDR&6FVTO)4YT-J\A^NM_"OG-F[V\J$_3.>=O8WFZ<7?5@S>Y@4PP.2I-PW X
M#)*&[F71B0MRPA/FBG;.(-8 YY]XAL:VI"415YAN10Z)>8DTLLSC;HY%3R3R
MJ"@J2LH"BHH"C8C4)N!<\=.4[0;1>5[K->I^A4I5$:/UW1"7HU)TLDZBT*2]
M5F7A5)5Z5<?8FW91#Y=5*M/.V<9$HM2W4H"G+=^<%1Y>Z\:MZGUWJIG-DFCZ
MC"*>C,E4]HVBMZ\V+"4FPIX(OA=!GR0$S.M2-PQ-(\SL)RAM!OB]<51G9E%1
MY65E1,++;Y7+H4&KLJ!UPVLFZ"FX"+:RKV2 28\Q[D%4TBE.Z FIZ+Z--:03
MADZP[,T&7F44X*I;[*^^VY&:6L&4=82MM,H6PZZ5:C*&G%.6BE5,\D>ER/>Y
M4#>_<6[W^'_$_IMT5=_XY4X4+JF%)DQNRJOV8H&#>NXT,.#$.@2K=MM(#= )
M]\YQ#*)!S#U.E@B2?Y";D>4JDLRN0FW2XAX+6G7<;2H\I@%%)6K-.L-H)]9J
M^@.CZ)+0^M"BZ6Z%=^]TK1^D3.A.E535.RE6;FIIH3,]3FW5IGR6F77&7)N8
M *VB\A-BI+JTPGN5K--\=D?6O)6[>.E!F\-^=]/KMPK(:^.7IG5C 0M'4+D\
MQ$W"=QK(<03243033=IB73 _R)6@V99$DT$U!<K3F:@^*M,2SC3A5_@\J%*U
M"@!Q!1K&XY>_BV-R0DVV&]#Z:RUIW.:,=S^DZ=UMONK5[1V>I=0=F%)T?T;:
M?>,FN499G95V4,POE$"LJ<4F6*#RFNF77;[RSH/<NVUOV?M0+[UTFI2]FKGE
M(3T:VU@M7%:7\5#L1<E?SJ6R6L! S0Q0XUPAVH<DP(DLV1\8G^"75,L24FNN
M.IDI=T2CE,$NTZE2FD<NTGE+A*DD@E141K *4!?#"&DE#T/T1J'=NJC6A= J
M:=%)_N<MT&EU%J9739)5:D$)G@6Y>8EW767772^ZR74I>=0C7\362<?3OO7B
M>9\+H_0^\63GU)9^1/<N1=2\C@]%:JUC)N:_')0%9UA)#)6(6%O)V*!)L,H^
M)884^AC"<H:%Q]=/>,J)B<?EY)M]X4^2FY:GG64T5S-@^H-A04M+(LH-@V)6
M0FQU+9#H5HNWI#IC5Z%H9(5RK2^@FAVE&CF@3IF9FFN3>D&HFM3#,BVZW,3L
MO2F^3>1(I7JK5-%IA#:U2W(M&7HSZ^<\MP!W8G?<*Q2O/SQ]K-#O#K8+:4^L
MCFA[0;P[KA @2M9)<;_.9B#QC.9]-V\&N(S=?67O=MAY"DRB)-QZ@S[C[*-:
MR7"#<$*4I0(^M)N@>(<4QR::#)4:N4MYG164T/J-7[B>G%0K5'E \$LU!;+X
M6%)F'7GFB$VU)9UQ3DH@IE5DJ9)B\/M'FR1#5?%IY92P@*XE\U.'MK <QSKA
M>$D7!70QJ6?G?7;3 0P$,\Q6=]=M?D:2?%KG'OQZX?1]"W':FAL%3BZ/.H;2
MGZ92U*9"0GB5$ <8\@[@TM-SM2[H\G3VG7Y^;[D>F,M(LRX)?>FWWJ0U+-,A
M)!+KCRT(; (.N4V(,1#:KWRKM/F5XT.O%35/;K)SH;H3GKURHRS8&OCT,ZN?
M1)ZW9G\(0H#*=PSP8 F'WD,RL,.^+&(MBMLQ[3;,U)TFHHJFNTW,&71*M/+U
MG"^ES64XV@J*DA*;*618* VVCL].HVDFB7<I[H,IW2#-4N0KSE#E-%Z56)A+
MT\Y6F)_EIJ?I\DMYQZ71*RW)O3;B4M<NTU;QPV :\>-W?O(WJ'4.:SL>Q&0V
M/H5RN]3ZISA_UCF8,:--KLY&VQ0.+2* KU1;%10Q<-0#&)3.2Q%*\:8S-'.6
M$7OU"1I\M+3(3*#DY=IEV5F&Y2945K\0_J\X%J8?;?)U5!(2&PK> H=YT^T)
MT$T=T>T@0QHJTJGT.E4BI:-U^2T9TA>5.39$HX#6]+$S3U&K,A677#+/-,-2
MZ9!N9OXJD-.M?.$6=GQ&D^8$]6[Q<6W=:->?(R&O<.?LD9NKZ9+E;.1V%A4]
MDVC!S810AV#THN&7",[=23#]NWBC(BQ$ZVF<>I279%E$D^S3]>>;2L% 6"!*
M)>URE#940V ?'3K ZU[&)TSI\OI?5^Y8BI:&4J4T-K%&T"5/:824O.M&23.!
M]"-%6*GWVJ7E9%QUQF2;:6DSC F6U]\!10J$_F'9N\/:;U,M3T#7M:_/C0[Z
M276K;UKG?4[E6.EKM191;?6*W4@5EAJ*4'ZN: KGK0<HE=)O (UE(R6-ILG9
M"0*Y9MR7[T)J*)<.,RDQ*M+EU$W;6X\I3;JR0"E]!"5"^J+ Q@TRT#T"?G-'
MZ=5='SHHI?= DJ U4*7HS7='*9.T-XN)7(3E2JCTS)5&?7R:5LUV5<;:F$!U
M;* A#UHL@7+[-R^\@H_*FR]1L5@XIBYLZXM8IB)UI^X&QK1?J#LKW9H8]R]<
MU-O5MI(IQQ3999OFX8)RH.-?;=E9MGE:<B6:1-EIMU2%@+0%62J^MJK4$GE
MO$72 , 0?+:_2:CHGI91_"7<WD:!2I72Y5+IU8>EYQMF>ED/I:EWRZ)@2\T\
MVTH5)F=LM"G6D!LZC4PEUFT_M]NY%X\5&3DW;+2?-8F?+Z]TW0%^BC-Y=7&
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M*2VHE386+'4)P-SA>T=4[L;4XUW-^YJJH:)RNA,Z_5=+7YB@2;3\M+2ZG')
M)?:DIEUYZ0$TA*7C*+7XA45I"4N #;)ZZM'S/!Z0@](0>D(/2$'I"$.QUQ3:
ME)25T-J2$3K_ .#68>;7&?E%"R^[.828<YSF.3&,X]V=HY-=XMY(]Y!(-Q$$
M BQB$:#P8.MOBG#\D=SH"5G-?'Q'MB+X-?AWB8,(M\?#DR+.?@B&US)!#+'L
M1\R7;,/RK*7<6&&_U<T4",<<0,N//ZO1G8KU2,D'I"#TA#>MW^U2S_X/.O\
M1I/J[?ZXW^_3_M"-ZE^R5.^WI3\H;B%_$3^Q6\<?X$.7_P C4_K<JOLG4/MV
M:_'+CMG=0_9(T]_CAI'_ %M-QKB]M;^X]QO^$IG_ "7-]=AT.^JYS[71^,$>
M]?,D?XU:5?Q?E_ZQ9BH'*2''O\?KA)2+09U2E5'DO.N=X5=A$1<>:P]15=#:
M\ZGN]1FI1]E'A-!I3^7HB) ZRFM!BT:1A*-L],TSRDT$?X>R'FQ+/.S4Q,:T
MH5S:>]U,(F R[RR6R4J>;$NM:-=I*CJW" (]/TF1*_\ 'BE)J].:T;J]4TFK
MM<,SHL[.Z52J]'9FARU=11ZFFKR\@M;3]8DDT&=G97ONFM3#@82X)-HA^>Q-
M_=+[C_@-6/\ 3Y7K%IC]32?^?<_%B.'^:Z]@=#OX7J7Y$S&WGKW]E'X@?^4!
M_P WBSUU.5]C:ISR/XY<?+VC'['?=1_[D_UY,1;#UQD>:QH@]MC?V ZKAW+Q
M9]XUC,VU7EU!C;;&A!:>%:BKNV<8SC&V!XW%DSMC?&<8VEBVUQC.OO\ 7=M#
MF$E4[,D#62&F$': HJ6YUZK?5'V7\R-1&')O3#2)Q"53$JQ3:/*+(!+;<XN8
MG)ZQ(P*S*2 !%C8+!P,>?[UWJ/MV-\7L0?\ \Y>2?_\ 0\F__P CHWKI.F7T
ME/\ WTUYF(^,?FO_ *GT _SVDW^Q08U<^:7]EGY$_P +EU_TR3Z[)1_8J0^U
M6?\ 9$?1?<E_8RT$_BQ2?R1N*Q^N2CT./:'X7] 8=/\ %CAUS;3R%MCJ* K:
MF3;;;SG,ZM.55&# C?;.<[D'EI)C)]_U;33;[:XQKG&,>0U=A,M4YUE  0E]
M2D@9)2X Z$C@D+L. VYQ^3'=7HC&CO=&TPI,L@-2S%9F'Y9I( 0S+5!**BPR
M@#)#+,VAI S"4"^,67))'#'(,,(A%$%AE)**)EC@'&'@TVEG((GEVTBAAABU
MVDEEDVUCCTUVWWVQKC.<<;'GT1]&#R*^NX7,(?.+I9$<(A,#6,>LV-VG'EG*
MC!(A.UT,/7PR%!FZ"2Z2PZ;SBE:P[9D@EQKE2\\A!;0ZZA"KZR$N*2A5\[I!
M -]MQ'(R]8JTI*NR4I5*C*R3^MR\I+SLRS*O:PU5<K+MNI:<UDX*UT*N,#A"
MW:55%.V2EW5;4S-PFPL5=)M(:<C81Z;+I$%&EF;1[Y@;%S:1QBZ [:&$2Z::
M18WVUUQBJ'7&PH-N+;"QJK"%J2%)QP5JD:PQ.!N,3&*4J-0D$S")&?G))$VW
MR,TF4FGY=,RUC^I3"65H#S?C*\1P*3XQPQ,8THO.JJ37H9QZ56S!=)P*I%+"
MB3DCQM&2U84%7H]]1I8=&+AVH7SCK<:ZELFRT2320H\6.4IUQ6MK.+5KD%>L
MM1URGZ4JN?&*=A-[;(EVHU&8$P'Y^=>$XMMR;#LT^X)I; LRN8"UJ#ZV4BS:
MG=8M@620([FM<H,""9([0T^&K,60D)"AJK2QH#G#MJ.(#%, 7!A<2R;NS1!A
M--XMRF#4L>&'$I<\6N\AYT+#@=<#@%@L+4%@6M8*!U@+86!M;"+-U6J-3;<^
MU4I]N>:0EMJ<;G)A$VTVA')I0W,)<#R$);\1*4K"4H\4 )PCY+4J!9*VN2S5
MFGOZA!I!*I4RIDK6MPZ08VU&D7 ;C3JX](<;;ZP;C18Q'C;;$><8SGU*7GDK
M+B7G4N*OK.)<6%JOG=8.L;[;G&+,5>K2TX[4):J5&7GWM?EIYB=F6IQWE""Y
MRLRVZEYS7(!7K+.L0"J]A"S'7T,,ZLJ%(HB)1B2@)2(UH4<Z<&:/2&8-7+K#
MB1>)-#%'%*.)M##)''IIOIG737&*\HLA0*UD+.LL:QLM5[ZRA>RC<DW-S?&,
M"IZ=4B8;5.32FYQQ+TVVJ8=*)IY"BM#LPDK*7W$J4I25NA2DJ)(())CDRRC-
MVUKS?*HO9R(;MHC99$GV:@AY&T8[:K"OCR<(+L:'J;G$$L,&2QM9\Z9GBQO5
M*E)(4DE*@;A22001D01B#Q$867GI=U#[#KC#S2@MMYE:FG6UC)2'$%*T*&Q2
M2"-AA+34>E5Q<>GKU/JR)0UUEU:*DU?4JUS+6>+>&;4\$$2 8S6:&22*7!$4
MF)(I-X]\9TVVQG(MYYQ25K>=6M%BE2W%J4D@W!2HDD6(!%B,<8W9JKU:>F&9
MJ>JE1G)J7*3+S,U.S,Q,,%"@M!9>>=6XT4K2E22A22E0"A8@&()[/XZ.NGE5
M[:I]GN?(E*)+HBTK-2K]&9(=!XI9MH6B0=]7S"ZO9!AIL+Q':4T>4$,4/0"
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MTPQF&(!WPI^D(Q-& $IY*N,T21F$($>8NT)AW/$!93'CKC20]=\D0",)U32
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MPP! SM?"VUJ.?!+O#Z2VRTORYDJR8ZO]!4ZQUR\=?F_)ZRN54ZKO .%-#T;
MSC#2#J'-'K.R7:-E<DXG(Z:[K+.)F^RX6SJG8H=9POCAGG>^..1B M(P*,B#
MB!C8C.XV6(L,#<@X18!_P;R+EJ'".7\J[S;P*,EO'D5:)^G0];ZOL11*MTB[
M,[/PUNOPGZ2LL75GG(JJZ4JZBGN36S4-V34Q-;*%]J*#E@*22!;'/;LS ZH)
M6 5$C, 6L,Q:YM:PN1C:QQSB0S?9#]F[-7;:[OOF#IT[-LSY*05)K+>^[N:_
M5$_9*ES4%:-79A.GKR\(UG1^3PM+)2'S"TA?:+98Q)WC:UI0; 9CQQ[=?81F
M"A86W"YL,<3Z#GPRQ)B26OLH?)*S2]CTM'F_TMNBO%IZ=:Z&CGZ-UO[11B+'
MS3R0K?+OHHQ;, U@%Y58>O\ +/EK27[U?:5/":ZT9ZPE$ID54"XR)B-9)M=
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MS;:1YQJG+92TJ3_F<.GQHUT:67()T8T0(!!(-&-CPPF@<<C8@@9$&T6]!\2
MU@@X"_R%\I0@A8\1#BC=;UA@ACU]_NUCCTKF-=<>_.=LY]WOVVSG;;.=LYSG
M)X4_ZOIAXF4N?QD<\.Z,$@ :!]S>P%A?1@DX;R9\DG>222<2;QE?FK?^,?Y6
M?QP?^[OIX4_ZNI?O3_W(GZ(__8/N;_>O_P#.@_-6_P#&/\K/XX/_ '=]/"G_
M %=2_>G_ +D/HC_]@^YO]Z__ ,Z#\U;_ ,8_RL_C@_\ =WT\*?\ 5U+]Z?\
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M$XI/D3Y23#DPRCSPR=8@VTEAFTVCECWU_#/Z=)--MM=L?V\9SCU(J=B"*?3
M000>]3F,O^5BR.Z.IM:'&]!NYTA;:DK0M.C2PI*T$*2H'PA@4D @[Q$_T"E)
MN;4:G\]KF3,H*164E42Y83ZE'Y5H%PZL#)A.D4&DY61AH\SS:0PZR2_%OK'I
MC.-<:#[RYAYY]RVN\XMU>J+)UG%%2K DV%R;"YL-L=*K=6FZ_6*K7)_DN_:Q
M4)RIS?((+;/?,],.3+W)-E2RAOE'%:B"M12FP*C:\:A_;6_N/<;_ (2F?\ES
M?7:]#OJN<^UT?C!'U#\R1_C5I5_%^7_K%F/.+Z] C[TC=O[$W]TON/\ @-6/
M]/E>NG:8_4TG_GW/Q8CY"^:Z]@=#OX7J7Y$S&Z?N_1W=0_!E4K3ZNTUM>3;#
M*RZ#;M!I:[SND4Q 38[C;B133  #F PT8*Q0.R,'4#&M=7#?8A8I+ ,Z=)2Z
M'>5=<;<>0R&PEAHD.3#SS@;99!"5*"5'64LI25D)U$66M*A\EZ&T&4JGA6I5
M"2GZK+4=F13+T.F%Q,]7:O59YN0I=,;<9:>>98<<4],33DNTY-.-2QE94(F)
MEIYJ%*IUJW5;I@*6'I=D[GR\J\I>4V>Y6>L<_3_8.D6)<Y- $H]CYZHJ*RU@
MHV"U>BO:DNK%90EVA5D&W$GHK*A'W795IV6*^]FY*9#+DTVTTZ^O7EVB@*+S
M<PMU;16E2EL+#HY0-KUF@%MK/;:EHS2ZCH^]-JT?I^AVD3='F]):=2J?4:W-
M=^T&1?E&GG:Q(5R:JDQ37IR7F'YVC3+=1:[]:ITSRM,;8G:?.KD7KOE"NY V
MZ:D;TUDT9TSG%,O]/#7LH\D])FN5R,YZ/654&%\LBYJ%<=J\JE_0TVECLRTK
M4?3]K#-KRE-5-IEUH>2A+LP\P\5)-I<-,B8+JCK *2ID.*'TMBTH$[1P6C'<
M[?THEM'YR6JLO+2U6KU6HE5>?84&Z BDTIFN+J$RLO)2_+/4KOZ93C+A*J=,
M-E:L5(CIKYUU -;6K$NJLS&I,JGX^6NT6*5]J*/3(O("Z[5A<K.%'2L9SFM8
M5 N[(T%B^GW)T70+-,#2G?5#;"**Z5.-J=U74NS[338;N7C(,\JI227$A*7%
ME#23B!K%5R$V/.RW<=J;K\_(OU)#%38J>G%,IT@F3+BZJK0BD"I/S++BYMA#
M,K4)AZ4D)=U7*!M3ZYA7*)9Y-R9&GEGXYIJ]7K4RZO7!D5I#>L4IGP-)I)0:
MR=LKL!9H(Z^5@G@3MM<J#Y'(H&H[?.JO?.&&^@^VFFEU!;CC295PK;*$K'BV
MUG$ZZ E15JK*D>.-0JNGQOI<8ZK+]S/3N;GIZFR^C4^Y.4YV38FFKRZ4I>J#
M(F9%IEY;Z6)M<U*D33"91U\N2MYE/Z@"X%3G_D7S+IG1K_RZK'LY[1SN<6)K
M]4I+&6LX9U:=E.:E/SKO',,!(Z%6DX/U7%3&QD2KACE>(6,U7Z?,RTNQ,NI2
M&I@'5LL%22%+2$K3L*@@J&J5 )(UBE1U8UJWH+I#H_0J)I%46)=%.KJ'%2W)
M33;DQ+K1,33"&9MC!2''DRCDPWR)F&TLJ;2^XS,%4NB&S/.[C^R?#]+JT,5K
MNVA\;M4S<1BFD2:EF64&.W@0#K',CX R>M$;*4@^!'I<9,$9PBHW:,.7;31)
MO7+:]1*E2:IMH)4E>N4I;465$J1J* =&LLW;!!U5+ )':FNXWI2)HR4V99J8
M?T1=TJIJ)5UB;3-\DU(/&F/K<F)1,D^TB?0)F;<Y62:4VM3+LRR"\F0\^4_+
M=6/UV]FK.W.2.>56\J;N([+/8-R;9=G5'7(@Z8(CE;2RRMU. A=X"B&A3J0I
M'LA')732R8/!DSJVY-SO@3#C"F2@)2@-LH>4LO%80!JJN;@)" %ZY"@(X/Z'
M.D18#(I]0%>17:E1YFD.RC3+$JW3*1*5A^<=JKLXF62E,K,EYT.-MRS4HEN<
M[]6V^A*9 L'<.652D(^C6*VCJ*=930UJ)L8N=1R,V3",R0%:.JPMV<Y8EX +
MU'!W7Z%2S0Y@TAS/O''O@;DIIUY<NVT5O-I4I:$J00E*;:RBO6U-4:PNK6L
M;WM>.$D=$-(ZE5YRA2%,<FJK3VG9B<EFGY129>784TEZ8<F>7$KR#1?:*W@^
M6DI7KE6H%*#?SY-\%T.LBV7IU<&+J*5F_L.IFYH4("U&."4]]Q18D(AC!%$R
M P\3 3E.$TQ@XS, 4F36+-_!T]JMJ[V<(=6EM! !UE+*@C $D)64JU%J 0H
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M6D^C\DU*.RFE$LU+S#LRAQ;\@4,3LF\_3E)=0AE^;I]1G)"96M#@<E7E(L+
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M76]3[UR:Q= \E?(?Q[M]TL7<8ZZ0JUX0D$Y;4NJG= $YE ?3N8DV>S-T#C>
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M33QZG*H-#/N;P*T4_H/*VX-ACWZ##M7IB-7CL!RWD=8%X0ZK[4#LO>+QX_\
M*^+\HX_0+MV>+H7P,NE=//Z773]T_*?,9I4+3ST/G2>N%WGBD72?'BBQ7CJ^
MK=$Q4AWI?0=.?#V>R 6)&AJ@7)O86X;KWZ#@-_-C:+R.\R>J^*-;HT5UX]6^
ML6XOC?4.K=(<T2W.:)1*OKSV_<.YR/&!FP5>Z,M*\4[[TA?6NPO3ET5)YS3>
M@7>0=Y,G$K1R( OEOL+\;^7#KBLL7MED*\IE^->%9IJI=0N97J5@3UU,[^E
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M&Z7@:STZ=#S*QWI15D^ZWG5AK?1%;9U7M*PVLZ6Q+FU7">U^SET@Z%L&JE1
M -[FV6-C;$VQ.S?CNV1FTOVEW6[YY.^/_CF?P6J<L96SI-OK'5R&G2;#<C3E
M%:7^7BS!?$PY.5T7%QJ:U_X]4QI>^C6":J;TS?J%&INM%>SW .SKT-7 F^[R
MVSQXX;[''"(<1^UP[SSXVR).[^-57=-('/D/8E<O-KU<EQHG,^7W7RD3)6D5
M6?<G-FL-2J:OQC)6=8ZOBP)ADUAZMQF4.B[0W_=?6T24BP()M@#>V9 )VX9X
M Y@''"')9O:^MSP;06#XHXL?(RBK-4$G0ORPM1%S<W1E?H$EPL(\/$6(56XE
M/2Z(=?;AU(1W96=+2&#S@T6UCPR'^F1B-4$8DY96V9$9YXX#;AE>*<1>>M^I
ME%\:7MMY0!9+1W!M<L%SU.S.4RH01)VNL<T0C<SP73&I71;"0BN@/1M F&]!
MB.YE2;_?X2A=4^J#;+K8 D7O?#IM@,;YY1A*!=8O]+;,<";G=E;(XD#.+9\@
M]LM8KX^XI1^F>)9%(CZ,XG2=%M17803:Q5J_+RCC75]+'6XK'S6G2](,2U'L
M@C3K=/%CKY= 7UBT%)#NA0#"8+QG [LB.%\1&75N#C?9EGB1LN!<@V\MHD+I
M70BU7EA^32GUEFPX@RI8.HU_BIU[E7A]F9U_3J$%)@O.5VU (13<=('M D.[
M/6RQG29#G&V&TT(ER)42;'=UG]$8E(LG6&_+# <=N=@.UY>K]@:U=L*Y3%;"
MG"[>_7;'OVBFBVSCYHQ,7OQK,--KCX98MOT9Q[MM<ZR:Z;ZV(![=NW'&,8-L
M1$S]W\S N.\$,Z^LJB6Q.UUHI%4:I;9=2N=TBK[7&Q H-K?>^@AT^_EU.@JL
MEY(+L4-,?[1E;@K"!!]B]S!L*A;MVZ-_#$#.@ZV&W<,>KMZ+TVJ_M*.]+>$=
M?\D.G\'IU<J^>]\_YWR"DV>XW+F\U"H]LXI2>F&./(V[%\RN4E8<",K'M5OC
MK-*? 2=&:J><:Z0:1XMQT1?5%P+[+X8[;88CSC"YX1&]L]KJUN9?<J4K\/9K
MDKX]<7"YZ?KUYZH*DI]56=J8V5O"K*X/,YK_ %Q3OQ%U FY>V$'5O8[91&\?
M1X*O:1V^9!L;C9VL8% (%R,1?B#A;;ECGC@#@;14>V>T;LM9M=)0P^.!C@&[
M=7LO/,'!=.R,74(D+RBILUJXCO>;HUPGD"%#>=+!:>%*V[.9#5ZU9G0EW=X
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M.'6;\,<X!(22 ;C9AQ4!?'"X3QO<8B\;D?&_L=C[U0&CR]\V7<Y=!F5Q>PK
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M7&6$?\>T7]^E3_QC3_\ MGI"#\>T7]^E3_QC3_\ MGI"#\>T7]^E3_QC3_\
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ML,NF?=G7;&?T9QG'NVTWUSG3?3.N^FVVFVNV<H((N(Q19?C?9/H_I:E;2O\
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M8=7EV\\=NGL^*IF>RF6.YJF0C"DW>G"#P\[7A0XS;--ACNG6_)5@:XMO;G"
MMS6^B=,CC0RWU 2O63)$HJXF)HB=;S@]5\!M QWX;,X9(O@MRD^U<Z%H'5J2
MI2H+ZL['CGB>A(]XV\U#ZM6;>S/4[H;4B,0&Q)2Z[R2Q%3#ME!-/:+5-EK33
M4:O"JD1<G&U^/1;Y><8;86:EX249&5RNH(.OU28OF1B1F$A I"OZL9?R\+QF
MJ;0NH!A7'.M&LTA_#5"FXV*(=OC9?U6[5Z5,)*X',T0OGQ^7?SYQA]6\,^84
MCQ3>\3<=MI7(.>-;)4RYK-;:PB4UD$X#A];X_F!:+BXT_9-8WEIKF_7Q'=?L
MRAUK>S2LDY<"D.<N$+D\?+?&^._$QED>SY3V:*^.574:AE;U&ZW#H 9*;E89
M"[(_1K)WJX?C+<@>_;C6/L->_+W+KSGL\>P6E?AIE5*Q4FNOSM-D ;8\V?"W
MJMS1,%&\/MJMUZK]:>WI1;S:,=80Z8";S[$!R*GO/RFSX7Q/2[>WFCN&IG0A
MHF=P6A*ES9&AV3_@\&1G&Q5(CMYO5Y3%?^C^$O :0K68MO7J!R UZL<<OJCZ
M1'5Z"4T4.M/*6>.E0ES69:8X':[^1H[2[)E3!>/;F//HF> T>[V'\-HM>^\W
MSQONRXX<?)$V@^'-39T+DR=9:4NTO.*MVBJI[&)4#3=0E_9GJYY8-Z'A_<G;
MRC85,T*U0K$ULCT$>G:L*E$-"',L)3HB^[#+R<UN>(4<^SS0JUZY<R[4AK<)
M[SJ"%"Q'YQ$&\"U[91ZY1V">LLG/0&L$MQL$]?+:O[4\ LCP_P"Z2(:%'S=$
M%"%LAK'S<V&71P%M\371?#(ZN]MI/=;5TP6VVNKYOQ!HP53LE97;FWF[]ZN,
ML56&_*B[&KZ../NI"ANEL(UY^]ZTBI,XSE)Z\?<5"_5^B_7:+U>D1!Z0CSL?
MLC']P#Q]_AA<?R*9>O6.Y+[*U7^#T?E+<47D.?T&(:X)7.\+/%7DUK2:=%9_
MA#F?%NA0MJEX/<@[!/;U> NBKJ#4N6VTY-!9I.C<A6LB!S;Y;K"0!4%]YL9"
MX<+ZC[?8.1JCU,76YYAPRB!,3E1E"W,:2S]/3+K*I1<V_/,)<+(E)]Q *967
M:2J85+,A:E6UVJ@&V>XCQ0;[AAM PN=_28Y_8Y'[L/DI_!K3/Y4'>MONM^Q]
M'^W)C\0F",SS>D1Z)KO_ &:WC?\ \&_R^_YP_#3UX7&;8><>944YZ[[/OQ&\
MG^R^3_:/(FLV%JVHUNKE>V:J;?:4@X--K?CWR"U[Z[*Z^3'@N<<I\[)VEC'F
M-GTEC'TQ)B*&/'>)32ZMT"ETJ3IK[+3#LK,3*TN2[3RB\NIU!I2M9:20-1EL
M:M[ @G,F*:H)-QMX[A% N$>,7L(O):5G%S5WT=+NHYLJ[')CJA/D%P@9KR-X
MR"3J^HUL_N58HX%KH)39FL6?BJKF-$L!C13"45#LU6Y+S#NEZ5C.9E3SR3'H
M BQ:M@4\,#?$;,";'A%L"?9 >RI".K:PPV41E<8U4U07D]_(@.M43[ZG*.6M
MB2N-"'D;G 1GVK=9&5JQ^D)^CS-\B7X)^B7I5]D2GO)F*Z@^M/ECMD]CQ[+"
M(ZRK)9RHF5+RMUN*^3O1>AU3V=;QQI];*)LVQ.BRVDFBC6X:1BY/WECU%^;M
MOKC+Z)>E7V1*>\F8:B=WE/KCFL]CI[+1TT$1I]S6SIA6A;F G6=X-/:'4\WX
M/HK6(O%:REDUHOYD?TKV&'=61\S3Y16_QZ^]]$O2K[(E/>3,-1.[RGUPV&GL
MEO94_@4RZHK. ,DG/GK*>Z2^0T<U2WN&V=X!:]EU([V3S-I#-<#;J<%;'_'G
M;32#YNN,8Q/=T729]!;<?E"DD$VDV@00;@@[#LX@D;8G5U3=(LH99Y\W&*X2
M^RU\2X9)(9:M<(Y8M]XI8][L[QMI)IMG7?3;&=_T;:[8SKMC/ZLXSCU@^?2O
M>WL>]FO5%>67PZHM9S7V+OL];O4E[F6CWS[AI\8+:.+IUHTUC8B_#B7;&F"/
M='H3%M"9'ICWXTT(UTQG]KGUNGNE:5IP[YE#89F39N>)X[XA(21>W XGUQ:#
MQ3\*^#>&7?+DDX4E>I@+UR!.TL.CRR,K').8EN9P@&X\K+??8732$XC$D<6<
M:R;;:[;?IUQZXZN:15/2&ER[E3<:<5+3ZT-<DRAD!+DNE2KA'TQ)2,3E;"+@
M 9;8RN1=6$HJ7R'6K<Q%V@SRL[SL/!M[MX5D,EA'QJ<;K^K.V?TY%%S^F;;'
MS)/=!K[I.II3?$Y#RQ"U6  SMU8F->\Q/FX9T:P3(4FW0!+1T2-<"'<&-"]P
MRECT6[$:6.O[U\].Z'JB[F4M*!;PV*=W<MK (1(GJ^18&)[:QUAS7R-LKG*V
M-@.K=813Q3;''IQ-A@;[;WRL-YW65J/ /,,NB7Z"X:$K^D6+EY.W-2!PN5!U
M:D])&%ZKB."SX N-O+WP<2%S/Y1H\ER1ZX;C$[K8,:6M8DKKGAV[>2+:@PYQ
M?B,,-G'G)P($53LW,?:15PQ8J852=11Q5%].WN3%]S5S9I39S;;'SI.^/K!V
MZH0X16R0Z.XHU)H.Q*=3)':6I4+YB^!1.VV>9 QQMNX7YMQ,04I )-[X97M;
M;B?)<C/FB.%AOM$50J_:&NU)\;L!R=/G:W&TX6.(E?#9?RHO+ %7+=+KM$P8
ML1-%9==:RLID:BHE2(]&^UL636\?ALSZ=WHSPXB(\3CMRZ+9^GCCE$F5WLOM
M/J2+--7(U]BU$5] ^TU^^:<YE$(C;]@0$4S+/"KHDV!K@EYOH^'PG4-1:**D
M^DFS9#[<5*E'J4J.S'H&T>6VS+;>]XL%)&1W;SL-P+@87MQOAEC&\+@%BZW9
MJ)(Q[16!JS;]K)9-A8UV5VJ=A5B'!9E1*5CBMVS*#0:ND+EC#-@U6M2VX+ _
M[:,"4'C-2+$C=%@;X]NW:\3?ZB)@](0>D(/2$19V'EBCL-1!J;G55\E=?.87
MX21PA%L@6K'F71JOT$,>187.+IMJTWK>4LY,1,) @K(B>',FVGR94(U\K_9S
M,6!4@CZ[+T:LVKRJMK>F#F<=KJ48=TM6U*K?,>F3_8L48.G<;AY=QMW9M*^Z
M;]'IU2- =C ,F)5B,18F^S?Y0+GG)N>&S*):-\#D)/"JUQ0.T(DH:.VW*T;R
M@4ITQJ@$MVKEFJY1E'IUMZ/9RJ3:JV-8]K)2+)%:W ];OHY-IT1&1M3U&Z(O
MC?;GTWX0Z[EX8URR\_K-!76!:G'26OIUG,8%4A<WVD9=7;NV[JZ5T.-JJCK/
M9JO.YDFYWUC,K@ZJG[L39D3C#68>)"_H\F'5;,;8KI:O9ZOC+K54U3,Y:LYN
M#6YI+'>']'$?]&8/#:9T^G6*FP*X\+1-.978J^#W2WH-7L+%S;CK?:P[)7;-
M*M-*1-^O8+89@[3NPRRL(G;B/@Y6^)%;.4MQW*M4G/7/.9+-%5%\3+",[G?"
MZ$C"P2[8V8\]-3]N)PO*\AL+!Z%"5:F8Y.Y'RIRF2()OLVW/6?7OV1"R+V8B
M-*O7+]>A5Z086LW.L%@1<S<0*)55OS<BS*^F$FZL8=4JB>[N$KJP@UEJNM94
MH/VRI7BC)&C=:8B;\,C<8\W"VS=MAU!^SQ#%V^HFZ#57!$5<IB;01WQE0377
M/X1BX<./7;L@!MRV&U\G"@X<NDJG-]B5DU896VTMYK:\/($E&1%\^.?'/U[+
M89YPG6SV:Z&X' ;M^E#G*0J/T2G?0L>;K)S/_A#YAT[FI\T18%C5+9D>F.AK
MK+-5'2)VKA<T6NRU>2I2EO26:%\;]._CMO&#:O9D56QJ^N+X[I7X=NM6.SNV
M.KGG;BU)!8+<K[4NGUFJCGJ&]<F>TC':F47)+"E75O:C*JM5E!ZZU0ASS3H7
MRX=!PX]&V\3YT_PW0]-Z_IUDCH-M0[ZGT-GM5U.@NJB8VJ$?6V+8B;.VA) U
M_-I_!"7XTWQZ"[\&JVJS8?5Y8/J4+FUNW;/K,,2I>SWYY5&=,<1-E)#>A6H6
MVUU[%04@=CC:S7?Q\O%G/+=Z'3$[NK5+PTJKLW06H!,U-N>Z(^-E]DD*>H7\
MULSN(]-_-:%6R^!//;+9'=GV;"HFYW0+7T%)8*U3TZFZ5IM>^E<BZ3<#U]MT
M(E,TL[B7F)M3WM(0RXS>GV,92Q%9Y12SO$ ;<V[9VOCS[H4N=^''Y)^:4.H\
M^NR1#:>;]3,ZO5W$M,LK>B:.F/+W_'6(1M ;]3-<QKSZ;9G#(L=!T2OBR7XG
M>V:"QC%-$#%#S='GMY;1%!?LU:L];W%C;[^%:(;:L7@$Z$<OK*F4LM)RCK/+
MZR_L"M(Q H!E@J,?4]G%795>@TK99BKI0I-"RH]' Z%\A;+B>'J\N4+%L]GB
M@N#!D8VNZV6$[I#B^_+BI+5.R+D?.^A.R6UBL54Z)67UBZA6\]"*3<ZZ.0>,
M-2T"A>#BG."YF#$M"_FPX6P';IS ,2;:?#X9AS#GG-Z9>HZ))19+7)FT+:A'
M&\G-NTDY%AM:)C7+#4GM>O,QA)A&YI#U]2+-HV=A=.Y[T1><.*O0OGQBO\WL
M_6[/M(A;XJ@/.0C?AVQLWCVOQN^FV9D@M'%'.O+SM"H(U4/(&4/)SYSZN7*V
MB@>6EW8="&.UB)1U]"^?'8,!MZ<+^C=#VJ7L_(*9T1'T%/U.&,NIU2EU>LB:
M<^B$SB"B(N7J:YI9]P;>*NLJ]&3S68M!'E.L?JE]Q?5R2SGH@:V(E0)X;;[/
M)A?RQL5&T(C&'T*FC(*T@BT)(BAR-%.1K'KB::,?,Q&1XY9,;;Z0YGGS%KMB
M/,TF=?CV1$=WI"#TA'G8_9&/[@'C[_#"X_D4R]>L=R7V5JO\'H_*6XHO(<_H
M,:CY;EX5W7Q,IW*Y^QT#E=^3T_F; 9F-X_\ 1C+^IZ.OGMD_6M;1TVLU[<ZY
MHKA Y2 IDY+8] @UKR_=:,'@?&TG>Q+Z12U=F)X2$U.RKC\ZA39JLHF4<E%A
M@2!9DWG=67=ERTXIQP-I==+R]<JUK"GBVM<#+9C?&]R!MOVSBXO['(_=A\E/
MX-:9_*@[UP'=;]CZ/]N3'XA,2C,\WI$>B:[_ -FMXW_\&_R^_P"</PT]>%QF
MV'G'F5'.OI3;8Q\VZD#*- 78+\.D!G+S+H-"8]\5N(K892]X8YY=1HY9(MY=
MH8)9=8\;YTCEV^'3/)SX_P #HIVFG/CJJ]3MYS%1FKG] C3)_P!!DF2^(',*
M+RJZTCKWF+S:E>-_(NJ67NG8[7U7GE=I?*#:S;>A<?X/OTWF_<47CRC<6]&L
ML%-G&\?#RDHJQ5%I7T\OT9BKC.W;MG&77NHDBPN2+;"=IL1<\";=9B'@/8T6
MRI\Y4U3J'1O$;3K-$\6?'3FO-+'8K0X*:\R;<P]HYT[R*L-HJ3^R<\ LU;J[
MB@='IO*D5B3 KCF5T@VJAP"Y)*O/-1.OC< VNH[KW2!LW6N>$.U[[*#I-@Y?
MY*TUH9X 2T-Z\ZK]=Y0DGWC;N785UM\[.?>3EU2^3EEAKT-0KP]!J]'>\[:+
M3#.K3,[" @Q&QYPG ;!SH@+LH$!5[6M?"^J4X<]P1:UM@Q%G1<?8N]<(\O>P
M=OY78^!+.:V^'HECXXP;;D1G<_\ Q+X?E^-E!XF?R5)QZ1&_X15B]P,2)=>S
M8I!?+8OPJ/QW1U (_P!4-<6%[WV\?&UKWOGLO:_'&*QI_8D>4AW,NATC=_X?
M.[]^6"G= DH075'6B[GAY'C 9Q-DZV(4>)@G(EI-ETW460OG=E\/7U;L="EQ
M7$[NKM5(UQ>(G7%[W.5LO\K6M;6O:_\ E;-QL-G_ #-'V:O!&I.D*>:E4BM)
M^5U+DW4N4S*H*?V@1%Q7G&.DWQ+6DS Y?3D>_6"KBFKM=@C A$4*X,""R 8%
M-*RH-Q;=&JX """?&N3?8;G"]A?"Q.&WH%S/'RW?9;3+7BI?A LNFL</Q9]V
MD3877?<3./?GW:_519F%SC&/BEFV$USGW:8]%BXON\W;TP0;&V_S[(5.K=,C
MHO?)(UN(2WY?$M!AX\[1R1+-I+O)+J6;%C;X\[?+Q\8H^VN,3;>[>3.(<>Z3
M>38TK5OCX1UB.'>UN;.+J5889GR=KQKR\;=7%F-[7C7!;=TW\FNQ9_\ C3%&
M%D/H,YSG/]O.<YSG;.?ACCTQG.<Z1Z9SC138!7[X]NV7-&-6.K^]'IC;QRKE
M05$"PP88A,M!D.,%%8QC>)=%OC&=@ -LX_5^K!).,8V(VQ\.OPP:ZZ[44J_;
MMAY\SL NE-L3GYNW;C,7JL7CYG&-L9UVQC;7;&<;:YQC.,XSCW9QG&?T9QG'
MZ,XS^C./2$0_;>(TFS_-('$S7F6_OV^L4::102;Y]^?>2NSC DF,[9SMOM!J
M+/)MGW[$9]6"B-M^>*E /#F]7JM#1H' QZX[E;V0P-W@*;79*-#%)J/MMKC&
MVIS"&?7./GQ;_HA$TWG@TWU^=O-+M\&NDE=\L-_R>OS14(L<;'AZXL?ZI&2#
MTA!Z0@](0>D(:-YOU*YG6SKAT&SIJ=5EF,;,;!8#H5JD#3;&VWS##2-M8!HL
M:Z;[[RS;Z1Z::;;[[:ZZYSA".RL7BH7-5N[JMC4/5,<^1I#UYD4PT<^NV-,Q
M2;^_'R]_CVQIC7?&N=M_?KCW[8SC"$+9[0!9IB0TG2'&T@D6-<:R2RYV..&6
MC9Q!#I)-F/<TL>#:;Y?RH<RXWFWCCUWWU0C*^?!\4>OSHOBEVVTBU^9I\4F^
MFF9-](\?%[]]M8]=M]M=??G737.V<8UQG/I"$)S;:W7B403EP&";9K!!5$ <
MF^TA3:Q$JV#R-0&-#K)-(7A(I:.9M?@QJ,I7',B=X@A9I]$(Z5-VI[YPR0)+
M,C;NDX\931<L9B'$@0R/;15_>3H-+)B+>*R4JW(2H=L_.#;UQPO*CA*!GBT0
MC,+LU?!/1JS'*X=A9LEXKXDI46LKC(,$91>%^/B]Q.8!Y8Y=_EYS^TDTSK[_
M (L>]"%?6>#?/NTFBWS\S>'W:R:;9^=%[_F1>[&<_P"J1_#M\>G_ %VGNS\6
M,>[/I"/NTT6NT>NTL>NTV^8X==M]<;2[XCVFSI'C.<9WWQ%IO+G77&<XCTVW
M]WPZYSA"$A;9:^X+<@*W"X\ROM]4+H88J*65:ZV1J;+A85IKM[]#/L#U.VS#
MCW[:A,1IML8UD_0A&$[NU/K<D,3ZSHE,\\B:*$<YF) 3OFQ/0ZPCWP/O+B?Y
M#2PGA)A"<QX'E8DQ"XE^;M\.$(6S&2Y>,<:>>$"&L#D8,BS"H!AEX$,4L\IQ
MT\TFD0@<4,$\TA)&\<.D4,LFV^-(]\X0B(EWD?P-O-7!UO8>=F$6YI.DK<$-
MK49F;-AYDP^R\>+).)-2IB+'6APHIM8MF$]EK<(/U,K]/J:B;'<8=]$Z?SGI
MZHUYSJ\5:[)UQF%YS.LNP' 0I<@(C0>.<@*>:/34U2P7.%TV=OD,DS%<W D)
M6GB%3(B'I@D;.=<8(@SG:;<?7&)8\YV(C^+YD&O[;],T?P;_ !Q8]^^OP;?%
MKCX<^Y"/FQ8FF)-MRA]-88MIY<[31ZXBATVWTWFDSG;&-(M-X]]=I-O=IKMI
MOKG.,ZYQA"/NY(T?S?C(@T^1C3:;XY8]?DZR>_Y>TOOVQ\O$GPY^#._NQM[L
M_#[_ '9](1B .D[3$N5C9:QQ"<R639 /%+Q"R3E;A-U\OT\LGRSE1L<@C(3?
MW$ E1[CE1Q2Z[:80A*4W:H/F[!"CLR-PX5!0,&2]8S$.(##(=V6M1SSZC2RX
MTQK8:;:DDVN=OF#-:^U )TB)#FCU0AR1R1S1QS0R:2Q2Z:R12Q[Z[QR1[ZXV
MTWCWUSG7?3?7.-M=M<YUVUSC.,YQGTA'/TA!Z0CSL?LC']P#Q]_AA<?R*9>O
M6.Y+[*U7^#T?E+<47D.?T&/(MZ]XC%'HW_8Z10P76?)HLR>$44;F-/F(((DT
MA@ABTLY^V\DLLF==---<8SG;;;.,8Q^O/KR/NM^Q]'^W)C\2F+HS/-Z1&X_M
MO>M<^8W ,T;37;8#@/E:ORY.ASM#-AA>?$V3>4$+?.N<XAV7:?*F-UVTD^9O
M[P_=KI)MX<$8BYV$X<+>N+%?BFVQ21?H5ZOT17.QMNG74+S%7U6V, ;]8V9@
M55;;'RA0+[B=XZ\X6UMKM@?,< ^5['"V3$T<6N88A8\:^[6+7&.2F_J6F 7P
MDG@G'*]1GS87R!)OAM).9)BE\4E6(S/\HW\@MU1Y\N0UWR/XE5K*_P#'[Q)[
MMPA_7/%3C?+NQ77GU.Z5RWN=M[=CKO,H^D.L6 23J*;R+$W!_*Q=6'6N;\4L
MW25U--$0T^V@L6\D:[C;&V"3D <#?/';CSVX1L$I*AK+"O'44W(*0G5-L/%U
M,=4 %03?,80_/E>=W::YN^[OS?MO0KCIXQR\@ M=GY_9%UP9)ZQ[5CA_4*5
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M3C=7A-W'B!N91BR/-LX]9Z )M8ADF3[6?79 L$5=G-90MA&B=2=<+3;TDMU
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M_#"X_D4R]>L=R7V5JO\ !Z/REN*+R'/Z#'DW&U^""+'_ /!C;/\ O[?ML_\
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MKO=K-]V83JZRED:M([-86\3!Q]KJ"$/1N7I,RAC@.VA*CD=.]V*%^W;+/*)
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M^+3&1_%*2,K^B-R=PNEOV\J^!1;6A_G2#@WE -#[VQV=XAB+IXL9G'TD^?\
M,U@E^G@^9%C;$>V(H\9U]VN,8\MU1<8#(^C9TQA!.H<3],D9[++PCS_>T6&4
MLO.9T'9#Y5R(_3EXSYIIO[I@5)2))$T/UDV',]THH>\Y&N^PI7NWTQG(\_\
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M,E,L&FD+!:\')Q#J-EU,+7W;-U_7&,O$FY2/VUQ<Y*"1T6U;@]8C=5[.SQ1
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M?1J[7%^TVD&63IEXJ<3$&@S+O[]8!HI2H9#2M\9T'@S[_=O+O%%)RL\+RE%
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M8QCUBC-'?Z0B%,_V1FO\"DG\NH_7)?\ 0_\ K+_=80P_%C_8_D'_ ,*?M/\
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M@!&&Y"6,P4(K1!X#\>C^_P $]CZ,:J:K;4H2HYV%.'6T8"[(>Y(;/!4=UM(
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MR([=L(8AOB=U4C9UO#Y:]1S)8H=-&N3PIYM<33(TZ-@2HPJM"/>O_-PF$9B
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M:%^ RMVMMYX8['Q-ZLS4E)I_+WL6138I<3R:2,!3=29G:)E+.,Q66I>QA'D
M3[J-EFQ<JZ*$J7(@XH;&UK;2A?@.KME^F\=CSQ;[4S)5R@>7G0UD2:4Z4'3=
M,Q+GDWG43)@IF4T-[ A:$A $8#D^K$V",T6*G>X$-[,NETN:(/;Y(=;'Q_[
M=?'=JT\H+L/6F;MFQ!Y]HBDA2*EIS-:<*IC9K;6M>;_:8PM]0B135X\A&@0Y
MJXJL%7*K71#MY.-^V5HQ:-XY=9ILZZ8CR?O%FC30J=EH3Q2<6"0>$S@*82V3
M0FY%%64)JMV<JYX33(VLLK\EVS>-G:2H&UQ$W&[?T;NKCY,;K"OQ[OB>VR/
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MQ^"8^"BIJL^3<O\ X)GX./GYLO$/WD_YR6[^?_3PO4?LC\$Q\%%34YTFY?\
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M(C^FALPA\2P[)DAQ:C&^HXGU+ )##;?,=6WIW1 :&Q^<N13-'5#Y+H9^*#I
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M@,[_ "<T2S9?'^XV:R.7DG>>C(@W.V8]DU7;VI$(L$^Q I]8DT UTV5+"L2
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M;%AI51MI* RSUI(_*JKB!_6R&ZX4Z9(Z%SC89FMD(CDV$,@DTBFBEBSKMH1
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0&,8QC&,8QC'NQCW>D1'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
